0001193125-19-014339.txt : 20190123 0001193125-19-014339.hdr.sgml : 20190123 20190123060722 ACCESSION NUMBER: 0001193125-19-014339 CONFORMED SUBMISSION TYPE: F-10 PUBLIC DOCUMENT COUNT: 73 FILED AS OF DATE: 20190123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Green Growth Brands Inc. CENTRAL INDEX KEY: 0001739376 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: F-10 SEC ACT: 1933 Act SEC FILE NUMBER: 333-229329 FILM NUMBER: 19536463 BUSINESS ADDRESS: STREET 1: 2100 BLOOR ST. WEST, SUITE 6339 CITY: TORONTO STATE: A6 ZIP: M6S 5A5 BUSINESS PHONE: 647-341-8033 MAIL ADDRESS: STREET 1: 2100 BLOOR ST. WEST, SUITE 6339 CITY: TORONTO STATE: A6 ZIP: M6S 5A5 FORMER COMPANY: FORMER CONFORMED NAME: Xanthic Biopharma Inc. DATE OF NAME CHANGE: 20180502 F-10 1 d692201df10.htm F-10 F-10

As filed with the Securities and Exchange Commission on January 22, 2019

No. 333-                    

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM F-10

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Green Growth Brands Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Ontario, Canada   Not Applicable   Not Applicable

(Province or other jurisdiction of

incorporation or organization)

  (Primary Standard Industrial
Classification Code Number (if applicable))
 

(I.R.S. Employer

Identification Number (if applicable)

Green Growth Brands Inc.

5300 Commerce Court West

199 Bay Street

Toronto, ON M5L 1B9 Canada

647-495-8798

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

CT Corporation System

28 Liberty Street

New York, NY 10011

(617) 531-5824

(Name, address (including zip code) and telephone number (including area code) of agent for service in the United States)

 

 

Copies of all communications, including communications sent to agent for service, should be sent to:

Kent Kiffner

General Counsel

Green Growth Brands Inc.

5300 Commerce Court West

199 Bay Street

Toronto, ON M5L 1B9 Canada

Approximate date of commencement of proposed sale to the public: From time to time after the effectiveness of this Registration Statement.

Province of Ontario, Canada

(Principal jurisdiction regulating this offering (if applicable))

It is proposed that this filing shall become effective (check appropriate box):

 

A. ☐    upon filing with the Commission, pursuant to Rule 467(a) (if in connection with an offering being made contemporaneously in the United States and Canada)
B.     at some future date (check the appropriate box below)
      1. ☐    pursuant to Rule 467(b) on (date) at (time) (designate a time not sooner than 7 calendar days after filing).
      2. ☐    pursuant to Rule 467(b) on (date) at (time) (designate a time 7 calendar days or sooner after filing) because the securities regulatory authority in the review jurisdiction has issued a receipt or notification of clearance on (date).
      3. ☐    pursuant to Rule 467(b) as soon as practicable after notification of the Commission by the Registrant or the Canadian securities regulatory authority of the review jurisdiction that a receipt or notification of clearance has been issued with respect hereto.
      4.     after the filing of the next amendment to this Form (if preliminary material is being filed).

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to the home jurisdiction’s shelf prospectus offering procedures, check the following box.  ☐

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Each Class of

Securities to be Registered

 

Amount

to be

Registered (1)

 

Proposed

Maximum

Aggregate

Offering Price(2)

 

Amount of

Registration Fee

Common Shares, without par value

  402,313,865   US$ 1,710,230,760.92   US$ 207,279.97

 

 

(1)

Represents the maximum number of common shares of Green Growth Brands Inc. (formerly known as Xanthic Biopharma, Inc.) (“Green Growth” or the “Registrant”), a corporation under the laws of the Province of Ontario, issuable upon consummation of the exchange offer for all of the issued and outstanding common shares (the “Common Shares”) of Aphria Inc. (“Aphria”) on a fully-diluted basis, other than any Common Shares owned directly or indirectly by Green Growth and its affiliates, calculated as the product of (a) 256,022,569, which is the estimated number of Common Shares of Aphria outstanding on a fully-diluted basis as of January 16, 2019, other than any Common Shares owned directly or indirectly by Green Growth and its affiliates and (b) the exchange ratio of 1.5714 common shares of the Registrant for each Common Share of Aphria.

(2)

Estimated solely for the purpose of calculating the registration fee in accordance with General Instruction II.H to Form F-10. The proposed maximum offering price is equal to the product of (i) Cdn$ 8.85 (US$ 6.68), which is the market value per Common Share of Aphria (based upon the average of the high and low sales prices reported for such Common Shares on the Toronto Stock Exchange on January 16, 2019), and (ii) 256,022,569, which is the estimated number of Common Shares of Aphria on a fully-diluted basis as of January 16, 2019, other than any Common Shares owned directly or indirectly by Green Growth and its affiliates. For purposes of this calculation, Cdn$ 1.00 = US$ 0.7548, which is the inverse of the exchange rate for Canadian dollars published by the Bank of Canada on January 16, 2019 (US$ 1.00 = Cdn$ 1.3248).

If, as a result of stock splits, stock dividends or similar transactions, the number of securities purported to be registered on this Registration Statement changes, the provisions of Rule 416 shall apply to this Registration Statement.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registration Statement shall become effective as provided in Rule 467 under the Securities Act or on such date as the Commission, acting pursuant to Section 8(a) of the Securities Act, may determine.

 

 

 

 


PART I

INFORMATION REQUIRED TO BE DELIVERED TO OFFEREES OR PURCHASERS

Item 1. Home Jurisdiction Document.

This registration statement on Form F-10 (this “Registration Statement”) is filed by Green Growth.

This Registration Statement relates to the offer to purchase (the “Offer”) by Green Growth for all of the issued and outstanding common shares (the “Common Shares”) of Aphria Inc. (assuming full conversion of all outstanding convertible and exercisable securities for Common Shares), other than any Common Shares owned directly or indirectly by Green Growth and its affiliates. The Offer is subject to the terms and conditions set forth in Green Growth’s Offer to Purchase and Take-Over Bid Circular dated January 22, 2019 (the “Offer and Circular”), a copy of which is attached hereto as Exhibit 1.1.

The information set forth in the Offer and Circular, including all schedules, exhibits and annexes thereto, is hereby expressly incorporated herein by reference in response to all items of information required to be included in, or covered by, a Registration Statement on Form F-10, and is supplemented by the information specifically provided herein.

Item 2. Additional Information.

See the financial statements included or incorporated by reference in the Offer and Circular.

Item 3. Informational Legends.

See “Notice to Holders in the United States” in the Offer and Circular.

Item 4. Incorporation of Certain Information by Reference.

See “Documents Incorporated by Reference and Further Information” in the Offer and Circular. As required by this Item, the Offer and Circular provides that copies of the documents incorporated therein by reference may be obtained on request without charge from the Corporate Secretary of Green Growth at 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario M5L 1B9 or may be obtained on SEDAR at www.sedar.com.

Item 5. List of Documents filed with the Commission.

See “Documents Filed as Part of the Registration Statement” in the Offer and Circular.    

Information contained herein is subject to completion or amendment. A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This prospectus shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

 

iii


PART II

INFORMATION NOT REQUIRED TO BE DELIVERED TO OFFEREES OR PURCHASERS

Indemnification of Directors or Officers.

The directors of Green Growth are indemnified by Green Growth in accordance with applicable laws and regulations.

Under the Business Corporations Act (Ontario) (the “OBCA”), a corporation may indemnify a director or officer of the corporation, a former director or officer of the corporation or another individual who acts or acted at the corporation’s request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the corporation or other entity, if the individual acted honestly and in good faith with a view to the best interests of the corporation or, as the case may be, to the best interests of the other entity for which the individual acted as a director or officer or in a similar capacity at the corporation’s request, and, in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, such individual had reasonable grounds for believing that his or her conduct was lawful. Any such individual is entitled to indemnification from a corporation as a matter of right in respect of all costs, charges and expenses reasonably incurred by the individual in connection with the defence of any civil, criminal, administrative, investigative or other proceeding to which the individual is subject because of the individual’s association with the corporation or other entity if the individual was not judged by a court or other competent authority to have committed any fault or omitted to do anything that he or she ought to have done and fulfilled the conditions set forth above.

Pursuant to its by-laws, Green Growth is required to indemnify the individuals referred to above and the heirs and legal representatives of such individuals in substantially the manner set out in the OBCA.

Green Growth maintains, at its expense, a directors’ and officers’ liability insurance policy that provides protection for its directors and officers against liability incurred by them in their capacities as such, and also reimburses the Registrant for payments made pursuant to the indemnity provisions under the by-laws of Green Growth.

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”) may be permitted for directors, officers or persons controlling Green Growth pursuant to the foregoing provisions, Green Growth has been informed that, in the opinion of the U.S. Securities and Exchange Commission, such indemnification is against public policy in the United States, as expressed in the Securities Act, and is therefore unenforceable.

 

II-1


EXHIBITS

 

Exhibit
No.
  

Description

1.1    Offer and Circular.*
1.2    Form of Letter of Transmittal.*
1.3    Form of Notice of Guaranteed Delivery.*
2.1    Press release, dated December  27, 2018 relating to Green Growth Brands Inc.’s intention to make an offer for all outstanding common shares of Aphria.**
2.2    Press release, dated December  31, 2018 relating to Green Growth Brands Inc.’s reaffirmation of its commitment to launch a takeover bid for Aphria.**
2.3    Press release, dated January 22, 2019, titled “Green Growth Brands Files Offer and Circular for Aphria Inc.; Formal Take-over Bid to Commence on January  23, 2019; Receives Commitment for $150 Million Equity Investment.”*
3.1    The Annual Information Form of Xanthic Biopharma, Inc. (“Xanthic”), dated November 26, 2018, in respect of the financial year ended June 30, 2018.*
3.2    The Audited Consolidated Financial Statements of Xanthic for the year ended June  30, 2018 and related notes together with the independent auditors report thereon, and the management’s discussion and analysis in connection therewith.*
3.3    The Unaudited Condensed Interim Consolidated Financial Statements of Xanthic for the three months ended September  30, 2018 and related notes, and the interim management’s discussion and analysis in connection therewith.*
3.4    The Material Change Report of Xanthic, dated July 17, 2018, in respect of the entering into of the arm’s length business combination agreement, dated July  13, 2018, between Xanthic and Green Growth Brands Ltd.*
3.5    The Material Change Report of Xanthic, dated November 16, 2018, in respect of the completed business combination of Xanthic and Green Growth Brands Ltd.*
3.6    The Material Change Report of Xanthic, dated December 12, 2018, in respect of Xanthic’s entering into of a membership interest purchase agreement, dated December  10, 2018, in connection with the purchase by Xanthic of all of the issued and outstanding membership interests of Just Healthy LLC.*
3.7    The Material Change Report of Xanthic, dated December 18, 2018, in respect of the entering into on December  12, 2018 by Xanthic of definitive agreements to acquire a cultivation facility operated by Wellness Orchards of Nevada LLC and Panorama WON LLC located in Pahrump, Nevada.*
3.8    The Material Change Report of Xanthic, dated December  18, 2018, in respect of Xanthic’s agreement to accept an irrevocable option (“Henderson Option”) to acquire all of the membership interests of Henderson Organic Remedies, LLC (“Henderson Organic”) together with the right to all of Henderson Organic’s free cash flow until exercise of the Henderson Option.*
3.9    The Business Acquisition Report of Xanthic, dated September 24, 2018, in respect of the entering into of a binding letter agreement with management of Green Growth Brands Ltd. concerning (i)  an arm’s length business combination; and (ii) the acquisition by GGB Nevada LLC of 100% of the outstanding membership interests of Nevada Organic Remedies LLC.*
3.10    The Management Information Circular of Aurquest Resources Inc., dated January 11, 2018, in respect of the annual and special meeting of shareholders of Aurquest Resources Inc. held on February  16, 2018.*
3.11    The Management Information Circular of Xanthic, dated October 12, 2018, in respect of the annual and special meeting of shareholders of Xanthic held on November 2, 2018.*
4.1    Consent of MNP LLP*
4.2    Consent of MNP SENCRL SRL*
4.3    Consent of Norton Rose Fulbright Canada LLP*
5.1    Power of Attorney of certain officers and directors of the Registrant (included on signature pages)

 

*

Filed herewith.

**

Incorporated herein by reference to Form 425 previously filed with the SEC on January 3, 2019.

 

II-2


PART III

UNDERTAKING AND CONSENT TO SERVICE OF PROCESS

Item 1. Undertaking

The Registrant undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the U.S. Securities and Exchange Commission (the “Commission”) staff, and to furnish promptly, when requested to do so by the SEC staff, information relating to the securities registered pursuant to Form F-10 or to transactions in said securities.

Item 2. Consent to Service of Process

Concurrently with the filing of this Registration Statement on Form F-10, the Registrant is filing with the SEC a written irrevocable consent and power of attorney on Form F-X. Any change to the name and address of the agent for service of the Registrant will be communicated promptly to the SEC by amendment to Form F-X referencing the file number of this Registration Statement on Form F-10.

 

III-1


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-10 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Columbus, Ohio, United States on January 22, 2019.

 

Green Growth Brands Inc.

/s/ Peter Horvath

Peter Horvath
Chief Executive Officer and Director

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Peter Horvath and David Bhumgara, and each of them, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for such person and in each person’s name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this Registration Statement and registration statements filed pursuant to Rule 429 under the Securities Act, and to file the same, with all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, each acting alone, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

/s/ Peter Horvath

Peter Horvath

  

Chief Executive Officer and Director

(Principal Executive Officer)

   January 22, 2019

/s/ David Bhumgara

David Bhumgara

  

Chief Financial Officer

(Principal Financial Officer)

   January 22, 2019

/s/ David Bhumgara

David Bhumgara

  

Controller

(Principal Accounting Officer)

   January 22, 2019

/s/ Tim Moore

Tim Moore

   Director    January 22, 2019

/s/ Carli Posner

Carli Posner

   Director    January 22, 2019

 

III-2


AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

 

/s/ Peter Horvath

Peter Horvath

   Authorized Representative in the United States    January 22, 2019

 

III-3

EX-1.1 2 d692201dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

The information in this Offer to Purchase and Circular may change. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”). The Offeror may not complete the Offer and issue the securities issuable hereunder until the registration statement filed with the SEC is effective. Shareholders in the United States should read the “Notice to Shareholders in the United States” beginning on page viii herein. This document shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in the United States in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

No securities tendered to this bid will be taken up until (a) more than 50% of the outstanding securities of the class sought (excluding those securities beneficially owned, or over which control or direction is exercised, by the Offeror or any person acting jointly or in concert with the Offeror) have been tendered to the bid, (b) the minimum deposit period required under applicable securities laws has elapsed, and (c) any and all other conditions of the bid have been complied with or waived, as applicable. If these criteria are met, the Offeror will take up securities deposited under the bid in accordance with applicable securities laws and extend its bid for an additional minimum period of 10 days to allow for further deposits of securities.

This document is important and requires your immediate attention. If you are in doubt as to how to deal with it, you should consult your investment advisor, broker, bank manager, lawyer or other professional advisor. Additionally, if you have questions, please contact Kingsdale Advisors, the depositary and information agent under the Offer, by telephone at 1-866-851-3214 (toll free in North America), or 416-867-2272 (collect calls outside North America), or by email at contactus@kingsdaleadvisors.com. Additional contact details for the depositary and information agent are set out on the back page of this document.

This Offer has not been approved by any securities regulatory authority nor has any securities regulatory authority passed upon the fairness or merits of the Offer or upon the adequacy of the information contained in this document. Any representation to the contrary is an offence.

Information has been incorporated by reference in this Offer to Purchase and Circular from documents filed with securities commissions or similar authorities in Canada. Copies of the documents incorporated herein by reference may be obtained on request without charge from the Corporate Secretary of Green Growth Brands Inc. at 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario M5L 1B9 or by telephone at 647-495-8798. Those documents are also available electronically on SEDAR at www.sedar.com.

January 22, 2019

 

LOGO

GREEN GROWTH BRANDS INC.

OFFER TO PURCHASE

ALL OF THE COMMON SHARES OF

APHRIA INC.

on the basis of 1.5714 common shares of Green Growth Brands Inc. for each common share of Aphria Inc., subject to the terms and conditions as provided herein

 

THE OFFER IS OPEN FOR ACCEPTANCE UNTIL 5:00 P.M. (TORONTO TIME) ON MAY 9, 2019

UNLESS THE OFFER IS ACCELERATED OR EXTENDED BY THE OFFEROR,

OR WITHDRAWN BY THE OFFEROR


This offer (the “Offer” or “Offer to Purchase”) by Green Growth Brands Inc. (formerly known as Xanthic Biopharma Inc.) (the “Offeror” or “GGB”) to purchase all of the issued and outstanding common shares (the “Aphria Shares”) of Aphria Inc. (“Aphria”), including any Aphria Shares that may become issued and outstanding after the date of the Offer but prior to 5:00 p.m. (Toronto time) on May 9, 2019 (the “Expiry Time”) upon the conversion, exchange or exercise of any Convertible Securities, in accordance with the terms and subject to the conditions contained herein, will be open for acceptance until the Expiry Time, unless the deposit period for the Offer is accelerated or extended by the Offeror, or the Offer is withdrawn by the Offeror. The Offer is subject to certain conditions set forth in Section 4 of the Offer to Purchase, “Conditions of the Offer”.

The Offer Consideration

Pursuant to the Offer, Aphria Shareholders who tender their Aphria Shares to the Offer (including any Aphria Shares that may become issued and outstanding after the date of the Offer but before the Expiry Time upon the conversion, exchange or exercise of any Convertible Securities) will receive 1.5714 common shares of the Offeror (each whole common share, a “GGB Share”) in exchange for each Aphria Share (the “Offer Consideration”). The GGB Shares are listed on the Canadian Securities Exchange (the “CSE”) under the symbol “GGB” and on the OTCQB Venture Market (the “OTCQB”) under the symbol “GGBXF”.

Based on the closing price of $5.99 per GGB Share on the CSE as of January 21, 2019, the last trading day prior to the date of this Offer to Purchase and Circular, the implied Offer Consideration would be $9.41 per Aphria Share (being a 24.5% premium over the Aphria Shares’ closing price of $7.56 on the Toronto Stock Exchange (the “TSX”) on December 24, 2018, the last trading day prior to GGB’s public announcement of its intention to launch the Offer, and 24.9% over the volume weighted average price of $7.5328 of the Aphria Shares on the TSX for the last ten (10) trading days ended December 24, 2018). Based on the closing price of $4.25 per GGB Share on the CSE on December 24, 2018, the implied Offer Consideration would be $6.68 per Aphria Share.

The number of GGB Shares to be issued in exchange for each Aphria Share under the Offer will not be adjusted to reflect any change in the market value of GGB Shares that may occur prior to the time of the take up of Aphria Shares under the Offer. Accordingly, there can be no assurance of what the value of a GGB Share will be at the time of the take up of the Aphria Shares under the Offer.

Financing

The Offer is not subject to any financing condition. The Offeror, however, intends to complete, immediately following the take up of Aphria Shares under the Offer, a third-party equity financing at a share price equal to $7.00 per GGB Share for aggregate gross proceeds of $300 million (the “Financing”). As a backstop to the Financing, the Offeror has entered into a commitment letter (the “Commitment Letter”) with All Js Greenspace LLC (the “Backstop Investor”) pursuant to which the Backstop Investor has agreed, subject to the terms and conditions set forth in the Commitment Letter, to subscribe for and purchase up to $150 million of newly-issued GGB Shares for $7.00 per share (or the equivalent value of PV Shares) (the “Commitment”). The Commitment is conditional upon the successful completion of the Offer and the take up of Aphria Shares at the Expiry Time on the terms and conditions set forth in the Offer to Purchase, without any amendment or waiver. The Commitment is also subject to certain terms which the Offeror believes are customary, including the entering into of a definitive purchase agreement in respect of the Commitment (and satisfaction of the conditions set out therein), GGB not taking any steps to change its capital structure or capitalization, and no material events occurring with respect to GGB or its business, assets, liabilities, prospects or results of operations. To induce the Backstop Investor to provide the Commitment, the Offeror has agreed to pay the Backstop Investor a commitment fee equal to $7,500,000, payable by issuing 2,504 PV Shares to the Backstop Investor, and to indemnify and reimburse the Backstop Investor for certain liabilities, costs and expenses. GGB will also be obligated to sell to the Backstop Investor up to $150 million of GGB Shares for $7.00 per share (or the equivalent value of PV Shares) even if the Offer has not been completed (any such sales shall reduce the Commitment on a dollar-for-dollar basis).

The Backstop Investor’s commitment under the Commitment Letter terminates on the earliest of (a) the termination, withdrawal or expiration of the Offer, (b) the execution of the definitive purchase agreement in respect of the Commitment, (c) any amendment or waiver of any term or condition of or contained in this Offer to Purchase and

 

ii


Circular without obtaining the prior written consent of the Backstop Investor, and (d) May 13, 2019. The Offeror’s obligation to sell up to $150 million in GGB Shares or PV Shares to the Backstop Investor shall not terminate or expire until May 23, 2019.

The foregoing is a summary only of certain terms and conditions of the Commitment Letter and is qualified in its entirety by the actual terms of the Commitment Letter. A copy of the Commitment Letter has been filed with the applicable securities regulatory authorities and is available for review under the Offeror’s profile on SEDAR.

If the Offer and the Financing are completed, the Offeror expects to use the net proceeds of the Financing to fund the business growth of the combined company, including for working capital and general corporate purposes.

There can be no assurance that the Financing will be completed (or on which terms it would be completed), or what the value of a GGB Share will be at the time of the take up of Aphria Shares under the Offer, which could be substantially less or more than $7.00 per GGB Share. Accordingly, Aphria Shareholders should be aware that the Financing may not be completed, or may be completed on terms that are different than the terms currently expected and set forth in this Offer to Purchase and Circular. See Section 9 of the Circular, “Financing” and Section 29 of the Circular, “Risk Factors”, in particular “Risk Factors – The Offeror may not be able to complete the Financing on the terms currently contemplated, or at all”.

The Offer Conditions

The Offer is subject to certain conditions described in Section 4 of the Offer to Purchase, “Conditions of the Offer”, including, without limitation:

 

  (a)

more than 6623% of the Aphria Shares (calculated on a Fully-Diluted Basis) held by Aphria Shareholders who are not Interested Aphria Shareholders, having been validly tendered to the Offer and not validly withdrawn (the “Minimum Tender Condition”);

 

  (b)

the Regulatory Approvals and all other third party approvals, licenses, permits, authorizations and clearances considered necessary or reasonably appropriate by the Offeror in relation to the Offer and the operation of the combined company having been obtained on terms satisfactory to the Offeror in its sole judgment;

 

  (c)

there being no legal prohibition against GGB making the Offer or taking up and paying for the Aphria Shares under the Offer or completing any Compulsory Acquisition or Subsequent Acquisition Transaction in respect of any Aphria Shares not acquired under the Offer;

 

  (d)

the Registration Statement having become effective under the U.S. Securities Act and not becoming subject to a stop order or a proceeding seeking a stop order;

 

  (e)

Aphria having not adopted or implemented a shareholder rights plan or taken any other action that provides rights to the Aphria Shareholders to purchase any securities of Aphria as a result of the Offer or any Compulsory Acquisition or Subsequent Acquisition Transaction;

 

  (f)

except to the extent publicly disclosed in a filing with a Securities Regulatory Authority prior to December 28, 2018, neither Aphria nor its subsidiaries having amended, or proposed or authorized any amendment to, their respective articles or bylaws (or other similar organizational documents);

 

  (g)

neither Aphria, nor any of its affiliates or subsidiaries, nor any other person having taken any action or authorized, recommended, proposed or announced an intention to take any action: (i) that has had or could have the effect (as determined by the Offeror in its sole judgment) of impairing the ability of the Offeror to acquire Aphria Shares, diminishing in any respect the expected economic value to the Offeror of the acquisition of Aphria, or making the acquisition of Aphria more costly in any material respect to the Offeror, or (ii) that would (as determined by the Offeror in its sole judgement) make it inadvisable for the Offeror to proceed with the Offer, to take up and

 

iii


  pay for Aphria Shares deposited under the Offer or to complete any Compulsory Acquisition or Subsequent Acquisition Transaction in respect of any Aphria Shares not acquired under the Offer;

 

  (h)

there not existing and not having occurred or been publicly disclosed since December 28, 2018 (in the sole judgment of the Offeror) any material adverse change in respect of Aphria;

 

  (i)

Aphria and its affiliates having conducted their respective businesses in the ordinary course of business consistent with past practice at all times on or after December 28, 2018 and prior to the Expiry Time;

 

  (j)

the Offeror not becoming aware of any untrue statement of a material fact, or an omission to state a material fact that is required to be stated or that is necessary to make a statement made not misleading in the light of the circumstances in which it was made and at the date it was made (after giving effect to all subsequent filings prior to the date of the Offer in relation to all matters covered in earlier filings), in any document filed by or on behalf of Aphria or any of its subsidiaries with any of the Securities Regulatory Authorities or a similar securities regulatory authority in the United States or elsewhere or with any other Governmental Entity anywhere in the world;

 

  (k)

the Offeror having obtained the approval of its shareholders to issue the GGB Shares pursuant to the Offer in accordance with the policies of the CSE;

 

  (l)

the Offeror not becoming aware of any information corroborating in any material respect the statements contained in the December 3, 2018 report of Hindenburg Research and Quintessential Capital Management entitled “Aphria: A Shell Game with a Cannabis Business on the Side”; and

 

  (m)

the statutory minimum condition of 50% of the Aphria Shares having been tendered to the Offer, excluding Aphria Shares beneficially owned or over which control or direction is exercised by the Offeror or by any person acting jointly or in concert with the Offeror (which condition cannot be waived) (the “Statutory Minimum Condition”).

The consummation of the Financing on the terms set forth herein is not a condition to the Offer, and there is no other financing condition to the Offer. See Section 4 of the Offer to Purchase “Conditions of the Offer” for additional conditions of the Offer, as well as a more detailed description of the conditions of the Offer.

GGB intends to seek to obtain, in accordance with the policies of the CSE, approval of its shareholders for the issuance of the GGB Shares in connection with the Offer prior to the Expiry Time, but there can be no assurance that such approval will be obtained. Subject to applicable Canadian Securities Laws, the Offeror reserves the right to withdraw or extend the Offer and to not take up and pay for any deposited Aphria Shares unless each of the conditions of the Offer is satisfied or waived by the Offeror (other than the Statutory Minimum Condition, which cannot be waived) prior to the Expiry Time.

The minimum statutory deposit period under the Offer may be shortened by the Offeror in certain circumstances, in accordance with applicable Securities Laws (including applicable orders of the relevant Securities Regulatory Authorities), as a result of actions of Aphria, including where Aphria enters into an Alternative Transaction (as defined in NI 62-104).

How to Accept the Offer

Registered Aphria Shareholders who hold their Aphria Shares in certificated form or DRS Statement(s) who wish to accept the Offer must properly complete and duly execute the accompanying Letter of Transmittal (printed on yellow paper) or a manually signed facsimile thereof and deposit the originally signed Letter of Transmittal, together with certificate(s) or DRS statement(s) representing their Aphria Shares, in accordance with the instructions in the Letter of Transmittal. Alternatively, Registered Aphria Shareholders may follow the procedure for Book-based Transfer set forth in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Book-based

 

iv


Transfer (CDS and DTC)” or the procedure for guaranteed delivery set forth in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery” using the accompanying Notice of Guaranteed Delivery (printed on green paper) or a facsimile thereof.

Non-registered Aphria Shareholders whose Aphria Shares are held on their behalf, or for their account, by an investment advisor, broker, bank, trust company or other intermediary, should contact their intermediary directly if they wish to accept the Offer. Intermediaries will likely establish tendering cut-off times that are prior to the Expiry Time. As a result, Aphria Shareholders who wish to tender their Aphria Shares to the Offer and whose Aphria Shares are held through an intermediary should promptly and carefully follow the instructions provided to them by their investment advisor, broker, bank, trust company or other intermediary.

The Offer is made only for Aphria Shares and is not made for any Convertible Securities, which term includes options and warrants. Any holder of Convertible Securities who wishes to accept the Offer must exercise such rights in order to obtain certificate(s) or DRS Statement(s) representing Aphria Shares and then deposit those Aphria Shares under the Offer. Any such exercise must be made sufficiently in advance of the Expiry Time to ensure that Aphria Shares will be available for deposit at or prior to the Expiry Time or in sufficient time to comply with the procedures referred to in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”. If any holder of Convertible Securities does not exercise such Convertible Securities prior to the Expiry Time, such Convertible Securities may remain outstanding following the Expiry Time in accordance with their terms and conditions, including with respect to time of expiry, vesting schedule, exercise price, and rights following a takeover bid (such as the Offer). The tax consequences to holders of Convertible Securities of exercising or not exercising their Convertibles Securities are not described in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations” or Section 19 of the Circular, “Certain United States Federal Income Tax Considerations”. Holders of Convertible Securities should consult with their own tax advisors for advice with respect to potential income tax consequences to them in connection with the decision to exercise or not exercise their Convertible Securities.

The Offeror intends to submit an application to list the GGB Shares that may be distributed to Aphria Shareholders in connection with the Offer on the CSE. Listing of the GGB Shares will be subject to the Offeror fulfilling all of the applicable listing requirements of the CSE, and the CSE’s approval of the Offer and the transactions contemplated thereby.

The Aphria Shares trade on the TSX and on the New York Stock Exchange (the “NYSE”) under the symbol “APHA”.

Shareholder Questions

Questions and requests for assistance may be directed to Kingsdale Advisors (“Kingsdale” or the “Depositary and Information Agent”). Additional copies of this document, the Letter of Transmittal and the Notice of Guaranteed Delivery may also be obtained without charge from Kingsdale. Contact details may be found on the back page of this document. Copies of this document and related materials may also be found on GGB’s website at www.greengrowthbrands.com or on SEDAR at www.sedar.com under GGB’s profile. The SEDAR and GGB website addresses are provided for informational purposes only and no information contained on, or accessible from, such websites is incorporated by reference in this document unless otherwise expressly noted herein.

Other Important Information

This document does not constitute an offer or a solicitation to any person in any jurisdiction in which such offer or solicitation is unlawful. The Offer is not being made to, nor will deposits be accepted from or on behalf of, Aphria Shareholders in any jurisdiction in which the making or acceptance of the Offer would not be in compliance with the Laws of such jurisdiction. However, the Offeror may, in its sole discretion, take such action as it may deem necessary to extend the Offer to Aphria Shareholders in any such jurisdiction.

The purpose of the Offer is to enable the Offeror to acquire all of the outstanding Aphria Shares. Provided the Minimum Tender Condition is met, the Offeror will have a sufficient number of Aphria Shares to acquire all of the

 

v


Aphria Shares not tendered to the Offer pursuant to a Subsequent Acquisition Transaction or, if a sufficient number of Aphria Shares are tendered to the Offer, a Compulsory Acquisition. See Section 16 of the Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer”.

No broker, investment dealer or other person has been authorized to give any information or to make any representation or warranty on behalf of the Offeror or any of its affiliates in connection with the Offer other than as contained in the Offer, and, if any such information, representation or warranty is given or made, it must not be relied upon as having been authorized. No broker, investment dealer or other person shall be deemed to be the agent of the Offeror or any of its affiliates, or the Depositary and Information Agent for the purposes of the Offer.

The information contained in this document speaks only as of the date hereof, unless otherwise stated. The Offeror does not undertake to update any such information except as required by applicable Law. Information in this Offer to Purchase and Circular related to Aphria has been compiled from public sources, as described herein.

Aphria Shareholders will not be required to pay any fee or commission if they accept the Offer by depositing their Aphria Shares directly with the Depositary and Information Agent (including through a book-entry transfer) or if they make use of the services of a Soliciting Dealer, if any, to accept the Offer. However, an investment advisor, broker, bank, trust company or other intermediary through whom you own your Aphria Shares may charge a fee to tender any such Aphria Shares on your behalf. You should consult your investment advisor, broker, bank, trust company or other intermediary to determine whether other charges will apply.

Aphria Shareholders reading this Offer to Purchase and Circular are cautioned that the financial statements incorporated by reference herein do not include unaudited interim consolidated financial statements (and notes thereto) of GGB, prepared in accordance with International Financial Reporting Standards applicable to Canadian public companies formulated by the International Accounting Standards Board (“IFRS”), nor any related management’s discussion and analysis, for any period following completion of the Business Combination. See Section 17 of the Circular, “Unaudited Condensed Consolidated Pro Forma Financial Statements”, Section 29 of the Circular, “Risk Factors”, and the Unaudited Condensed Consolidated Pro Forma Financial Statements of the combined company attached hereto as Annex A.

Peter Horvath, Marc Lehmann, Jean Schottenstein, and Steven Stoute, four of GGB’s directors, reside outside of Canada and have appointed GGB, at 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario M5L 1B9, as agent for service of process. Investors are advised that it may not be possible for investors to enforce judgements obtained in Canada against any person or company that is incorporated, continued or otherwise organized under the Laws of a foreign jurisdiction or resides outside of Canada, even if the party has appointed an agent for service of process.

Various capitalized terms used in this document (including in these cover pages) are defined in the Glossary of this document.

 

vi


QUESTIONS AND REQUESTS FOR ASSISTANCE MAY BE DIRECTED TO

THE DEPOSITARY AND INFORMATION AGENT FOR THE OFFER

 

LOGO

130 King St West, Suite 2950

Toronto, ON M5X 1K6

North American Toll Free Phone:

1-866-851-3214

Outside of North America:

416-867-2272

Facsimile:

416-867-2271

E-mail:

contactus@kingsdaleadvisors.com

 

vii


NOTICE TO SHAREHOLDERS IN THE UNITED STATES

The Offeror is a Canadian issuer that is a “foreign private issuer”, as such term is defined in Rule 405 promulgated under the U.S. Securities Act of 1933, as amended, (together with the rules and regulations promulgated thereunder, the “U.S. Securities Act”). The Offeror is permitted, under a multi-jurisdictional disclosure system adopted by the United States, to prepare this Offer to Purchase and Circular in accordance with the disclosure requirements of Canada, which are different from those of the United States. The financial statements included and incorporated by reference herein have been prepared in accordance with IFRS and are subject to Canadian auditing standards and auditor independence rules, and may not be comparable to the financial statements of United States companies.

This Offer to Purchase and Circular are subject to applicable disclosure requirements with Canadian provincial and federal corporate and takeover bid rules. Aphria Shareholders resident in the United States should be aware that such requirements are different from those of the United States applicable to prospectuses and circulars for tender offers of United States domestic issuers registered under the U.S. Securities Act and under the United States Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act”), and the respective rules and regulations promulgated thereunder.

GGB has filed with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form F-10 under the U.S. Securities Act (the “Registration Statement”) pursuant to the multi-jurisdictional disclosure system adopted by the United States, a Tender Offer Statement on Schedule 14D-1F (the “Tender Offer Statement”) under the U.S. Exchange Act and other documents and information, and expects to mail this Offer to Purchase and Circular to Aphria Shareholders. SHAREHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE TENDER OFFER STATEMENT AND THIS OFFER TO PURCHASE AND CIRCULAR AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and Aphria Shareholders will be able to obtain the documents free of charge at the SEC’s website, www.sec.gov. In addition, documents filed with the SEC by GGB will be available free of charge from GGB. You should direct requests for documents to Kingsdale, 130 King St West, Suite 2950, Toronto, ON M5X 1K6, Toronto, North American Toll Free Phone: 1-866-851-3214, outside North America Phone: 416-867-2272. To obtain timely delivery, such documents should be requested no later than five (5) business days before the Expiry Time.

THIS TRANSACTION HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY U.S. STATE SECURITIES COMMISSION NOR HAS THE SEC OR ANY U.S. STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS OFFER TO PURCHASE AND CIRCULAR. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

THESE SECURITIES HAVE NOT BEEN REGISTERED OR OTHERWISE QUALIFIED FOR OFFER AND SALE IN CERTAIN U.S. STATES WHERE HOLDERS OF APHRIA SHARES RESIDE AND NO SUCH OFFER TO SELL OR SALE, OR SOLICITATION OF AN OFFER TO BUY MAY BE MADE IN SUCH U.S. STATES.

No Offer to Sell or Solicitation of an Offer in Certain States

All references to “$” and “dollars” in this subsection “No Offer to Sell or Solicitation of an Offer in Certain States” are stated in lawful currency of the United States of America.

THE OFFER DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY STATE IN THE UNITED STATES IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. THE OFFER IS NOT BEING MADE OR DIRECTED TO, NOR IS THIS DOCUMENT BEING MAILED TO, NOR WILL DEPOSITS OF APHRIA SHARES BE ACCEPTED FROM OR ON BEHALF OF, SHAREHOLDERS IN ANY STATE IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE MAKING OR ACCEPTANCE OF THE OFFER WOULD NOT BE IN COMPLIANCE WITH THE LAWS AND REGULATIONS OF SUCH STATE OR OTHER JURISDICTION.

 

viii


No offer to sell or solicitation of an offer to buy Aphria Shares pursuant to the Offer is being made in the state of New York or to Aphria Shareholders resident in the state of New York. However, prior to the Expiry Time, the Offeror intends to take steps to enable Aphria Shareholders resident in the state of New York to acquire GGB Shares in exchange for Aphria Shares. Upon taking such steps, the Offeror will provide notice thereof to Aphria Shareholders as required by applicable Law.

In addition, no offer to sell or solicitation of an offer to buy GGB Shares pursuant to the Offer is made in the U.S. states, districts and territories of Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Guam, Illinois, Kentucky, Louisiana, Maryland, Massachusetts, Minnesota, Montana, Nebraska, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wyoming (collectively, the “Restricted States”), except only to a person who qualifies as an “exempt institutional investor” in the applicable Restricted State.

Any Aphria Shareholders who reside in one of the Restricted States and who wish to tender their Aphria Shares in exchange for GGB Shares must qualify as an “exempt institutional investor” in such jurisdiction. The criteria that must be satisfied to qualify as an exempt institutional investor in each of the Restricted States are generally set out below, and unless otherwise specified, the term “investment company” means an investment company as defined in the Investment Company Act of 1940:

Alabama    Any dealer, bank, savings institution, credit union, trust company, insurance company, investment the relevant statute contains an exemption for sales to “other institutional buyers,” the Supreme Court of Alabama has held that institutional buyers not specified in the exemption must be of the same type as those institutions specified in the preceding sentence.

Arizona     Any dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust or other financial institution or institutional buyer.

Arkansas    Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust or other financial institution or institutional buyer.

California    Any broker-dealer, bank, savings and loan association, trust company, insurance company, investment company registered under the Investment Company Act of 1940, pension or profit-sharing trust (other than a pension or profit sharing trust of the issuer, - if non-exempt a self-employed individual retirement plan or individual retirement account), any organization described in Section 501(c)(3) of the Internal Revenue Code as amended to December 29, 1981, which has total assets (including endowment, annuity and life income contracts) of not less than $5,000,000 according to its most recent audited financial statement, any wholly-owned subsidiary of any of the foregoing, the federal government, any agency or instrumentality of or any corporation wholly owned by the federal government, any state, city, city and county, county or any agency or instrumentality thereof, any state university or state college, and any retirement system for the benefit of the employees of any of such governmental units, agencies, instrumentalities, corporations or educational institutions, or any other institutional investor or governmental agency or instrumentality designated by rule of the California Department of Business Oversight provided purchaser represents that it is purchasing for investment and not with a view to or for sale in connection with any distribution of the securities. This is limited to corporations only.

Colorado    Any broker-dealer, depository institution, insurance company or separate account of an insurance company, investment company registered under the Investment Company Act of 1940, business development company as defined in the Investment Company Act of 1940, private business development company as defined in the Investment Advisers Act of 1940, employee pension, profit sharing, or benefit plan if (i) the plan has total assets in excess of $5,000,000 or (ii) investment decisions are made by a named fiduciary, as defined in the Employee Retirement Income Security Act of 1974, that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, a depository institution or an insurance company, an entity a substantial part of whose business activities consist of investing, purchasing, selling or trading in securities of more than one issuer and not of its own issue and that has total assets in excess of $5,000,000 as of the end of its latest fiscal year, a small business investment company licensed under the Small Business Investment Act of 1958 or any other institutional buyer.

 

ix


Connecticut    Any broker-dealer, bank and trust company, national banking association, savings bank, savings and loan association, credit union, trust company, insurance company, investment company, pension or profit-sharing trust or other financial institution or institutional buyer (including any qualified institutional buyer).

Delaware     Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust, accredited investor as defined in Rule 501(a)(1)-(4), (7)-(8) promulgated under the U.S. Securities Act (other than a self-directed employee benefit plan with investment decisions made solely by persons that are accredited investors as defined in Rule 501(a)(5)-(6)), qualified institutional buyer, corporation, partnership, trust, estate, or other entity (excluding individuals) not formed for the purpose of acquiring the securities having a net worth of at least $5,000,000 and any wholly-owned subsidiary of such an entity, or other financial institution or institutional buyer.

District of Columbia    Any broker-dealer, depository institution, insurance company or separate account of an insurance company; investment company or business development company as defined in the Investment Company Act of 1940; employee pension, profit-sharing, or benefit plan if (i) the plan has total assets in excess of $5 million or (ii) it investment decisions are made by a named fiduciary, as defined in the U.S. Employee Retirement Income Security Act of 1974, as amended (“ERISA”), that is either a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, a depository institution, or an insurance company, qualified institutional buyer, accredited investor as defined in SEC Rule 501(a) or limited liability company with net assets of at least $500,000.

Florida     Any dealer, bank, trust company, savings institution, insurance company, investment company, pension or profit-sharing trust or qualified institutional buyer.

Guam     Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust or other financial institution or institutional buyer.

Illinois     Any dealer, corporation, bank, savings bank, savings institution, trust company, insurance company, savings and loan association, building and loan association, pension fund or pension trust, employees’ profit-sharing trust, other financial institution or institutional investor, any government or political subdivision or instrumentality thereof, any partnership or other association engaged as a substantial part of its business or operations in purchasing or holding securities, any trust in respect of which a bank or trust company is trustee or co-trustee, or to any employee benefit plan within the meaning of Title I of ERISA if (i) the investment decision is made by a plan fiduciary as defined in Section 3(21) of ERISA and such plan fiduciary is either a bank, savings and loan association, insurance company, or an investment adviser registered under the Investment Advisers Act of 1940 or applicable Illinois securities Laws, or (ii) the plan has total assets in excess of $5,000,000, any plan established and maintained by, and for the employees of, any state or political subdivision or agency or instrumentality thereof if such plan has total assets in excess of $5,000,000, any organization described in Section 501(c)(3) of the Internal Revenue Code, any Massachusetts or similar business trust, any partnership, if such organization, trust or partnership has total assets in excess of $5,000,000, any entity ninety percent of the equity of which is owned by any of the foregoing, or any investment company, university or other organization whose primary purpose is to invest its own assets or those held in trust by it for others.

Kentucky    Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust or other financial institution or institutional buyer.

Louisiana    Any dealer, bank, savings institution, trust company, insurance company, investment company, real estate investment trust, small business investment corporation, pension or profit-sharing plan or trust or other financial institution.

Maryland    Any broker-dealer, bank, savings and loan association, trust company, insurance company, investment company, investment adviser with assets under management of not less than $1,000,000, employee benefit plan with assets of not less than $1,000,000, government agency or instrumentality, institutional accredited investor as defined in SEC Rule 501(a)(1)-(3), (7)-(8), qualified institutional buyer, or any other institutional investor designated by rule or order of the Securities Commissioner of Maryland.

 

x


Massachusetts    Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust, small business investment company licensed under the Small Business Investment Act of 1958, private business development company as defined in the Investment Advisers Act of 1940, business development company as defined in the Investment Company Act of 1940, any corporation, Massachusetts or similar business trust, partnership, limited liability company or limited liability partnership not formed for the specific purpose of acquiring the securities, a substantial part of whose business consists of investing, purchasing, selling or trading in securities issued by another person if (a) investment decisions are made by persons who are reasonably believed to have such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of the investment and (b) having total assets in excess of $5,000,000, any organization described in Section 501(c)(3) of the Internal Revenue Code with total assets in excess of $5,000,000, qualified institutional buyer or other financial institution or institutional buyer.

Minnesota    Any broker-dealer registered under the U.S. Exchange Act, banking institution organized under the laws of the United States, member bank of the Federal Reserve System, or any other banking institution doing business under the laws of a state or of the United States, a substantial portion of the business of which consists of receiving deposits or exercising fiduciary powers similar to those permitted to be exercised by national banks under the authority of the Comptroller of the Currency pursuant to Section 1 of Public Law 87-722, and which is supervised and examined by a state or federal agency having supervision over banks, and which is not operated for the purpose of evading the Minnesota Uniform Securities Act (2002); a receiver, conservator, or other liquidating agent of any of the foregoing; a savings institution, trust company, credit union, or similar institution organized or chartered under the laws of a state or of the United States, authorized to receive deposits, and supervised and examined by an official or agency of a state or the United States whose deposits or share accounts are insured to the maximum amount authorized by statute by the Federal Deposit Insurance Corporation, the National Credit Union Share Insurance Fund, or a successor authorized by federal law (other than a Morris Plan bank or an industrial loan company which is not an “insured depositary institution” as defined in Section 3(c)(2) of the Federal Deposit Insurance Act); an international financial institution of which the United States is a member and whose securities are exempt from registration under the U.S. Securities Act; an insurance company or separate account of an insurance company; an investment company; an employee pension, profit-sharing, or benefit plan if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a named fiduciary, as defined in ERISA, that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, an investment adviser registered in Minnesota, a depository institution, or an insurance company; a plan established and maintained by a state, a political subdivision of a state, or an agency or instrumentality of a state or a political subdivision of a state for the benefit of its employees, if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a duly designated public official or by a named fiduciary, as defined in ERISA, that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, an investment adviser registered in Minnesota, a depository institution, or an insurance company; a trust (except a trust that includes as participants self-directed individual retirement accounts or similar self-directed plans) with total assets in excess of $10,000,000 if its trustee is a depository institution, and its participants are exclusively employee pension, profit sharing, or benefit or governmental plans described above regardless of the size of their assets; an organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts trust or similar business trust, limited liability company, or partnership, not formed for the specific purpose of acquiring the securities, with total assets in excess of $10,000,000; a small business investment company licensed under Section 301(c) of the Small Business Investment Act of 1958 with total assets in excess of $10,000,000; a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940 with total assets in excess of $10,000,000; a person registered under the Investment Advisers Act of 1940 acting for its own account; a qualified institutional buyer as defined in Rule 144A(a)(1), other than Rule 144A(a)(1)(i)(H), adopted under the U.S. Securities Act; a “major U.S. institutional investor” as defined in Rule 15a-6(b)(4)(i) adopted under the U.S. Exchange Act; or any other person, other than an individual, of institutional character with total assets in excess of $10,000,000 not organized for the specific purpose of evading the Minnesota Uniform Securities Act (2002); and any accredited investor as defined in Rule 501(a) under the U.S. Securities Act.

Montana    Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust or other financial institution or institutional buyer.

 

xi


Nebraska    Any bank, savings institution, credit union, trust company, or other financial institution; insurance company; investment company; pension or profit-sharing trust; broker-dealer; corporation, Massachusetts or similar business trust or partnership with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities; trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities, whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he or she is capable of evaluating the merits and risks of the prospective investment; individual accredited investor, or an entity in which all of the equity owners are individual accredited investors; or any other institutional buyer as may be defined by the Director of Banking and Finance of the State of Nebraska by rule and regulation or order.

New Jersey    Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust, qualified institutional buyer, or other financial institution or institutional buyer.

North Carolina    Any dealer, entity having a net worth in excess of $1,000,000, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust or other financial institution or institutional buyer.

North Dakota    Any broker-dealer registered under the U.S. Exchange Act; banking institution organized under the laws of the United States, member bank of the Federal Reserve System, or any other banking institution doing business under the laws of a state or of the United States, a substantial portion of the business of which consists of receiving deposits or exercising fiduciary powers similar to those permitted to be exercised by national banks under the authority of the Comptroller of the Currency pursuant to Section 1 of Public Law 87-722, and which is supervised and examined by a state or federal agency having supervision over banks, and which is not operated for the purpose of evading the North Dakota Securities Act of 1951; a receiver, conservator, or other liquidating agent of any of the foregoing; a savings institution, trust company, credit union, or similar institution organized or chartered under the laws of a state or of the United States, authorized to receive deposits, and supervised and examined by an official or agency of a state or the United States whose deposits or share accounts are insured to the maximum amount authorized by statute by the Federal Deposit Insurance Corporation, the National Credit Union Share Insurance Fund, or a successor authorized by federal law (other than a Morris plan bank or industrial loan company); an international financial institution of which the United States is a member and whose securities are exempt from registration under the U.S. Securities Act; an insurance company or a separate account of an insurance company; an investment company; an employee pension, profit-sharing, or benefit plan if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a named fiduciary, as defined in ERISA, that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, an investment adviser registered in this State, a depository institution, or an insurance company; a plan established and maintained by a state, a political subdivision of a state, or an agency or instrumentality of a state or a political subdivision of a state for the benefit of its employees, if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a duly designated public official or by a named fiduciary, as defined in ERISA, that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, an investment adviser registered in this State, a depository institution, or an insurance company; a trust (except a trust that includes as participants self-directed individual retirement accounts or similar self-directed plans) with total assets in excess of $10,000,000 ifs its trustee is a depository institution, and its participants are exclusively employee pension, profit-sharing, or benefit or governmental plans described above regardless of the size of their assets; an organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts trust or similar business trust, limited liability company, or partnership, not formed for the specific purpose of acquiring the securities, with total assets in excess of $10,000,000; a small business investment company licensed under Section 301(c) of the Small Business Investment Act of 1958 with total assets in excess of $10,000,000; a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940 with total assets in excess of $10,000,000; a federal covered investment adviser acting for its own account; a qualified institutional buyer as defined in Rule 144A(a)(1), other than rule 144(a)(1)(i)(H), adopted under the U.S. Securities Act; a “major United States institutional investor” as defined in Rule 15a-6(b)(4)(i) adopted under the U.S. Exchange Act; or any other

 

xii


person, other than an individual, of institutional character with total assets in excess of $10,000,000 not organized for the specific purpose of evading the North Dakota Securities Act of 1951.

Ohio     Any dealer, bank, trust company, savings and loan association, savings bank, credit union incorporated or organized under the laws of a state, the United States, Canada or any province of Canada that is subject to regulation or supervision by that country, state, or province, or any international banking institution; any insurance company or separate account of an insurance company; an investment company; broker-dealer registered under the U.S. Exchange Act, or licensed by the Ohio Division of Securities as a dealer; an employee pension, profit-sharing, or benefit plan if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a named fiduciary, as defined in ERISA that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, or an investment adviser registered under the Ohio Securities Act, a bank, or an insurance company; a plan established and maintained by a state, a political subdivision of a state, or an agency or instrumentality of a state or a political subdivision of a state for the benefit of its employees, if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a duly designated public official or by a named fiduciary, as defined in ERISA that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, or an investment adviser registered under the Ohio Securities Act, a bank, or an insurance company; a trust (except a trust that includes as participants self-directed individual retirement accounts or similar self-directed plans) with total assets in excess of $10,000,000 if its trustee is a depository institution, and its participants are exclusively employee pension, profit sharing, or benefit or governmental plans described above regardless of the size of their assets; an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, corporation, Massachusetts trust or similar business trust, limited liability company, or partnership, not formed for the specific purpose of acquiring the securities, with total assets in excess of $10,000,000; a small business investment company licensed under Section 301(c) of the Small Business Investment Act of 1958 with total assets in excess of $10,000,000; a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940 with total assets in excess of $10,000,000; a federal covered investment adviser acting for its own account; a qualified institutional buyer as defined in Rule 144A(a)(1), other than Rule 144A(a)(1)(i)(H), adopted under the U.S. Securities Act; a “major United States institutional investor” as defined in Rule 15a-6(b)(4)(i) adopted under the U.S. Exchange Act; or any other person, other than an individual, of institutional character with total assets in excess of $10,000,000 not organized for the specific purpose of evading the Ohio Securities Act.

Oklahoma    Any broker-dealer registered under the U.S. Exchange Act, banking institution organized under the laws of the United States, member bank of the Federal Reserve System, or any other banking institution doing business under the laws of a state or of the United States, a substantial portion of the business of which consists of receiving deposits or exercising fiduciary powers similar to those permitted to be exercised by national banks under the authority of the Comptroller of the Currency pursuant to Section 1 of Public Law 87-722, and which is supervised and examined by a state or federal agency having supervision over banks, and which is not operated for the purpose of evading the Oklahoma Uniform Securities Act of 2004; a receiver, conservator, or other liquidating agent of any of the foregoing; a savings institution, trust company, credit union, or similar institution organized or chartered under the laws of a state or of the United States, authorized to receive deposits, and supervised and examined by an official or agency of a state or the United States whose deposits or share accounts are insured to the maximum amount authorized by statute by the Federal Deposit Insurance Corporation, the National Credit Union Share Insurance Fund, or a successor authorized by federal law (other than a Morris Plan bank or an industrial loan company); a trust company organized or chartered under the laws of this State; an international financial institution of which the United States is a member and whose securities are exempt from registration under the U.S. Securities Act; an insurance company or separate account of an insurance company; an investment company; an employee pension, profit-sharing, or benefit plan if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a named fiduciary, as defined in ERISA, that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, an investment adviser registered in this State, a depository institution, or an insurance company; a plan established and maintained by a state, a political subdivision of a state, or an agency or instrumentality of a state or a political subdivision of a state for the benefit of its employees, if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a duly designated public official or by a named fiduciary, as defined in ERISA,

 

xiii


that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, an investment adviser registered in this State, a depository institution, or an insurance company; a trust (except a trust that includes as participants self-directed individual retirement accounts or similar self-directed plans) with total assets in excess of $10,000,000 if its trustee is a depository institution, and its participants are exclusively employee pension, profit-sharing, or benefit or governmental plans described above regardless of the size of their assets; an organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts trust or similar business trust, limited liability company, or partnership, not formed for the specific purpose of acquiring the securities, with total assets in excess of $10,000,000; a small business investment company licensed under Section 301(c) of the Small Business Investment Act of 1958 with total assets in excess of $10,000,000; a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940 with acting for its own account; a qualified institutional buyer as defined in Rule 144A(a)(1), other than Rule 144A(a)(1)(i)(H), adopted under the U.S. Securities Act; a “major U.S. institutional investor” as defined in Rule 15a-6(b)(4)(i) adopted under the U.S. Exchange Act; or any other person, other than an individual, of institutional character with total assets in excess of $10,000,000 not organized for the specific purpose of evading the Oklahoma Uniform Securities Act of 2004.

Oregon     Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, mortgage broker or mortgage banker, pension or profit-sharing trust or other financial institution or institutional buyer.

Pennsylvania    Any broker-dealer, bank, savings bank, savings institution, savings and loan association, thrift institution, trust company or similar organization which is organized or chartered under the laws of a state or of the United States, is authorized to and receives deposits and is supervised and examined by an official or agency of a state or by the United States if its deposits are insured by the Federal Deposit Insurance Corporation or a successor authorized by federal law, any agency, branch or representative office of a foreign bank that is subject to the same degree of regulation and supervision as a domestic bank, any wholly owned subsidiary of one of the foregoing, insurance company, pension or profit sharing plan or trust (other than a municipal pension plan or system), a college, university or other public or private institution which has received exempt status under Section 501(c)(3) of the Internal Revenue Code of 1954 and which has a total endowment or trust funds, including annuity and life income funds, of $5,000,000 or more according to its most recent audited financial statements; provided that the aggregate dollar amount of securities being sold to the person may not exceed 5% of the endowment or trust funds, a qualified pension and profit sharing and stock bonus plan under Section 401 of the Internal Revenue Code of 1986 (“KEOGH”), an individual retirement account under Section 408 of the Internal Revenue Code of 1986 (“IRA”) and a simplified employee pension under Section 408(k) of the Internal Revenue Code of 1986 (“SEP”) if the KEOGH, IRA or SEP has one of the following: (1) plan assets of $5 million or more, or (2) has retained, on an ongoing basis, the services of a person knowledgeable and experienced in financial and business matters to render professional investment management advice and has investments of $500,000 or more in securities, investment company, or any entity which controls any of the foregoing, the federal government, a state or any agency or political subdivision thereof except public school districts of this State, a corporation or business trust or a wholly owned subsidiary thereof which has been in existence for eighteen months and which has a tangible net worth on a consolidated basis, as reflected on its most recent audited financial statements, of $10,000,000 or more, a small business investment company as defined in the Small Business Investment Act of 1958 which (a) has total capital of at least $1,000,000 or (b) is controlled by one of the foregoing institutions, a seed capital fund as defined and authorized in the Small Business Incubators Act, a business development credit company as authorized in the Business Development Credit Corporation Law, qualified institutional buyer, a person whose security holders consist solely of any of the foregoing, or any other person designated by regulation of the Pennsylvania Department of Banking and Securities.

Puerto Rico    Any broker-dealer, bank, savings institution, trust company, insurance company, investment company as defined in the Investment Company Act of Puerto Rico, pension or profit-sharing trust or other financial institution or institutional buyer.

Tennessee    Any broker-dealer, bank (other than a bank is acting as a broker-dealer as such term is defined in Tennessee Securities Act of 1980), trust company, insurance company, investment company registered under

 

xiv


the Investment Company Act of 1940, a holding company which controls any of the foregoing, a trust or fund over which any of the foregoing has or shares investment discretion, a pension or profit sharing plan, an institutional buyer as defined by rule by the Commissioner of Commerce and Insurance, or any other person (other than a broker-dealer) engaged as a substantial part of its business in investing in securities, in each case having a net worth in excess of $1,000,000.

Texas     Any registered dealer actually engaged in buying and selling securities as a business, bank, trust company, building and loan association, insurance company, surety or guaranty company, savings institution, federally chartered credit union, savings and loan association, federal savings bank, credit union chartered under the laws of any state, investment company, small business investment company as defined in the Small Business Investment Act of 1958, qualified institutional buyer, accredited investor as defined in Rule 501(a)(1)-(4) and (7)-(8) (other than a self-directed employee benefit plan with investment decisions made solely by persons that are accredited investors as defined in Rule 501(a)(5)-(6)) promulgated under the U.S. Securities Act, any corporation, partnership, trust, estate or other entity (other than an individual) not formed for the purpose of acquiring the securities having a net worth of not less than $5,000,000 and any wholly-owned subsidiary of such an entity, such securities being purchased by such institution for its own account or as a bona fide trustee of a trust organized and existing other than for the purpose of acquiring the securities.

Utah     Any broker-dealer, bank, savings and loan association, savings bank, industrial bank, credit union or other institution that holds or receives deposits, savings, or share accounts, issues certificates of deposit, or provides to its customers other depository accounts that are subject to withdrawal by checks, drafts, or other instruments or by electronic means to effect third party payments, trust company, insurance company, investment company, pension or profit-sharing trust, qualified institutional buyer or other financial institution or institutional investor.

Virginia     Any broker-dealer, corporation, investment company or pension or profit-sharing trust.

Washington    Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, or any wholly owned subsidiary of one of the foregoing, pension or profit-sharing trust (other than a self-directed pension plan), corporation, business trust or partnership, or any wholly owned subsidiary of such an entity, which has been operating for at least 12 months and which has a net worth on a consolidated basis of at least $10,000,000 as determined by the entity’s most recent audited financial statements (which are dated within the past 16 months), entity which has been granted exempt status under Section 501(c)(3) of the Internal Revenue Code with a total endowment or trust fund of at least $5,000,000 according to its most recent audited financial statements (which are dated within the past 16 months), or other financial institution or institutional buyer.

West Virginia    Any broker-dealer, bank, savings institution, trust company, insurance company, investment company, pension or profit-sharing trust or other financial institution; any corporation, business trust, partnership, limited liability company, limited liability partnership or wholly owned subsidiary of any of the aforementioned entities or an entity which has been granted exempt status under Section 501(c)(3) of the Internal Revenue Code, as amended, which has been operating on a continuing basis for at least twelve months and which has a net worth of at least $5,000,000, a substantial part of whose business activities consists of investing, purchasing, selling or trading in securities issued by others and whose investment decisions are made by persons who are reasonably believed by the seller to have such knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of investment; a small business investment company licensed by the United States Small Business Administration under the Small Business Investment Act of 1958, as amended; a private business development company as defined by the Investment Advisors Act of 1940, as amended; a business development company as defined in the Investment Company Act of 1940, as amended; a wholly owned subsidiary of a bank, savings institution, insurance company, or investment company; or a qualified institutional buyer as defined in Rule 144A(a) adopted under the U.S. Securities Act.

Wyoming    Any banking institution organized under the laws of the United States, member bank of the Federal Reserve System, or any other banking institution doing business under the laws of a state or of the United States, a substantial portion of the business of which consists of receiving deposits or exercising fiduciary powers similar to those permitted to be exercised by national banks under the authority of the Comptroller of the Currency

 

xv


pursuant to Section 1 of Public Law 87-722, and which is supervised and examined by a state or federal agency having supervision over banks, and which is not operated for the purpose of evading the Wyoming Uniform Securities Act, or a receiver, conservator, or other liquidating agent of any of the foregoing; a savings institution, trust company, credit union, or similar institution organized or chartered under the laws of a state or of the United States, authorized to receive deposits, and supervised and examined by an official or agency of a state or the United States if its deposits or share accounts are insured to the maximum amount authorized by statute by the Federal Deposit Insurance Corporation, the National Credit Union Share Insurance Fund, or a successor authorized by federal law (other than a Morris Plan bank or an industrial loan company); an international financial institution of which the United States is a member and whose securities are exempt from registration under the U.S. Securities Act; an insurance company or separate account of an insurance company; an investment company; an employee pension, profit-sharing, or benefit plan if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a named fiduciary, as defined in ERISA, that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, an investment adviser registered in Wyoming, a depository institution, or an insurance company; a plan established and maintained by a state, a political subdivision of a state, or an agency or instrumentality of a state or a political subdivision of a state for the benefit of its employees, if the plan has total assets in excess of $10,000,000 or its investment decisions are made by a duly designated public official or by a named fiduciary, as defined in ERISA, that is a broker-dealer registered under the U.S. Exchange Act, an investment adviser registered or exempt from registration under the Investment Advisers Act of 1940, an investment adviser registered in Wyoming, a depository institution, or an insurance company; a trust (except a trust that includes as participants self-directed individual retirement accounts or similar self-directed plans) with total assets in excess of $10,000,000 if its trustee is a depository institution, and its participants are exclusively employee pension, profit sharing, or benefit or governmental plans described above regardless of the size of their assets; an organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts trust or similar business trust, limited liability company, or partnership, not formed for the specific purpose of acquiring the securities, with total assets in excess of $10,000,000; a small business investment company licensed under Section 301(c) of the Small Business Investment Act of 1958 with total assets in excess of $10,000,000; a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940 with total assets in excess of $10,000,000; a person registered under the Investment Advisers Act of 1940 acting for its own account; a qualified institutional buyer as defined in Rule 144A(a)(1), other than Rule 144A(a)(1)(i)(H), adopted under the U.S. Securities Act; a “major U.S. institutional investor” as defined in Rule 15a-6(b)(4)(i) adopted under the U.S. Exchange Act; or any other person, other than an individual, of institutional character with total assets in excess of $10,000,000 not organized for the specific purpose of evading the Wyoming Uniform Securities Act.

If you reside in one of the Restricted States, you may accept the Offer and receive GGB Shares under the Offer for any Aphria Shares that you tender to the Offer if and only if you are an “exempt institutional investor” under the laws of your state of residence. If you are an “exempt institutional investor” under the laws of your state of residence, and wish to tender Aphria Shares and receive GGB Shares, you may be required to certify your status as an “exempt institutional investor” to the Offeror and the Depositary and Information Agent and should contact the Depositary and Information Agent for additional information in that regard.

GGB or its agents may, in its or their sole discretion, take such action as it or they may deem desirable to extend the Offer to Aphria Shareholders in any such state or other jurisdiction. Notwithstanding the foregoing, GGB or its agents may elect not to complete such action in any given instance. Accordingly, GGB cannot at this time assure Aphria Shareholders that otherwise valid tenders can or will be accepted from holders resident in all states in the United States and all other jurisdictions.

Certain Federal Income Tax Considerations

Aphria Shareholders should be aware that the disposition of their Aphria Shares and the acquisition of GGB Shares by them as described herein may have tax consequences both in the United States and in Canada. Such consequences for investors who are resident in, or citizens of, the United States may not be described fully herein and such Aphria Shareholders are encouraged to consult their tax advisors. See also Section 18 of the Circular,

 

xvi


“Certain Canadian Federal Income Tax Considerations” and Section 19 of the Circular, “Certain United States Federal Income Tax Considerations”.

Enforcement of Civil Liabilities

The enforcement by Aphria Shareholders of civil liabilities under U.S. federal securities Laws may be affected adversely by the fact that the Offeror was amalgamated under the Laws of Ontario, and Aphria was amalgamated under the Laws of Ontario, that some or all of their respective officers and directors may be residents of a foreign country, that some or all of the experts named herein may be residents of a foreign country and that all or a substantial portion of the assets of the Offeror and Aphria and said persons may be located outside the United States. Aphria Shareholders may not be able to sue the Offeror or Aphria or their officers or directors in a foreign court for violations of U.S. securities Laws. It may be difficult to compel the Offeror or Aphria or their respective affiliates to subject themselves to a U.S. court’s judgment.

Purchases Outside the Offer

Aphria Shareholders in the United States should be aware that, during the period of the Offer, the Offeror or its affiliates, directly or indirectly, may bid for or make purchases of the securities to be distributed or to be exchanged, or certain related securities, as permitted by applicable Laws of Canada or its provinces or territories and as permitted by the U.S. federal securities Laws. If any such purchases are made, the Offeror will issue a news release immediately after the close of business on the day of any such purchase, containing disclosure of the number of Aphria Shares purchased and certain other information as required by applicable Law. See Section 12 of the Offer to Purchase, “Market Purchases and Sales of Aphria Shares”.

Reporting Following the Completion of the Offer

Following the effectiveness of the Registration Statement, the Offeror will become subject to the reporting requirements of the U.S. Exchange Act and in accordance therewith will file reports and other information with the SEC. Under a multi-jurisdictional disclosure system adopted by U.S. and Canadian securities regulators, such reports and other information may be prepared in accordance with the disclosure requirements of Canada, which requirements are different from those of the United States. The Offeror will be exempt from the rules under the U.S. Exchange Act prescribing the furnishing and content of proxy statements, and its officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the U.S. Exchange Act. Reports and other information filed by the Offeror may be inspected and copied at the public reference facilities maintained by the SEC at Room 1580, 100 F Street, NE, Washington, D.C. 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the SEC at 100 F Street, NE, Washington, D.C. 20549. Prospective investors may call the SEC at 1-800-SEC-0330 for further information regarding the public reference facilities or visit the SEC’s website at www.sec.gov. The Registration Statement filed with the SEC concerning the Offer, including the exhibits, and the Offeror’s reports and other information filed under the U.S. Exchange Act are available to the public free of charge at the SEC’s website at www.sec.gov.

If, as a result of the completion of the Offer and any subsequent transaction, the number of Aphria Shareholders is sufficiently reduced, Aphria may become eligible to cease to be a reporting issuer (or equivalent) in Canada and a registrant with the SEC. To the extent permitted under applicable Law, the Offeror intends to cause Aphria to apply to the TSX and the NYSE to delist the Aphria Shares from both stock exchanges as soon as practicable after completion of the Offer or a Compulsory Acquisition or Subsequent Acquisition Transaction and, subject to applicable Law, to cause Aphria to cease to be a reporting issuer (or equivalent) in Canada and a registrant with the SEC. The rules and regulations of the TSX and NYSE could also, upon the consummation of the Offer and/or a subsequent transaction, lead to the delisting of the Aphria Shares from such exchanges.

 

xvii


FORWARD-LOOKING STATEMENTS AND INFORMATION

This document includes or incorporates by reference information, statements, beliefs and opinions which constitute forward-looking statements or “forward-looking information” within the meaning of applicable Securities Laws, including “future-oriented financial information” with respect to prospective financial performance, financial position, EBITDA, cash flows and other financial metrics that are presented either as a forecast or a projection. Wherever possible, forward-looking statements or forward-looking information can be identified by the expressions “seeks”, “expects”, “intends”, “believes”, “estimates”, “will”, “plans”, “may”, “anticipates,” and similar expressions (or the negative of such expressions). The forward-looking statements or forward-looking information are not historical facts, but reflect the current expectations of the Offeror regarding future results or events and are based on information currently available to it. Future-oriented financial information is forward-looking information about prospective results of operations, financial position or cash flows, based on assumptions about future economic conditions and courses of action, and presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows. Similarly, a “financial outlook” is forward-looking information about prospective financial performance, financial position or cash flows that is based on assumptions about future economic conditions and courses of action that is not presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows. Future-oriented financial information and financial outlook are made as of the date hereof, subject to the same assumptions, risk factors and other qualifications as all other forward-looking statements or forward-looking information, and presented solely for the purpose of conveying the current anticipated expectations of the Offeror and may not be appropriate for any other purposes.

Statements and information contained in the accompanying Circular under “Background to the Offer”, “Reasons to Accept the Offer”, “Purpose of the Offer and Plans for Aphria” and “Effect of the Offer” and the pro forma financial statements accompanying the Circular, as well as statements relating to:

 

   

the satisfaction of the conditions of the Offer;

 

   

the anticipated successful completion of the Offer;

 

   

the expected completion of the Financing, including the timing and terms thereof;

 

   

the satisfaction of the conditions of the Commitment;

 

   

the process and timing for obtaining the Regulatory Approvals applicable to the Offer and other approvals, including the approval of the shareholders of the Offeror;

 

   

the expected Expiry Time;

 

   

the estimated expenses of the Offer;

 

   

the completion of a Compulsory Acquisition or a Subsequent Acquisition Transaction;

 

   

the tax treatment of Aphria Shareholders;

 

   

the anticipated effect of the Offer;

 

   

the Offeror’s plans for Aphria if the Offer is successful;

 

   

expected benefits to Aphria Shareholders of tendering Aphria Shares to the Offer;

 

   

Aphria Shareholders’ entitlement to dividends and the timing thereof; and

 

   

the Offeror’s capitalization strength following successful completion of the Offer and the Financing;

 

   

the use of proceeds of the Financing; and

 

xviii


   

other statements that are not historical facts, in addition to certain statements and information contained elsewhere in this document and in the documents incorporated by reference concerning the business, operations and financial performance and condition of the Offeror and Aphria that are not historical facts;

are forward-looking statements or forward-looking information within the meaning of applicable Securities Laws. It is important to know that:

 

   

unless otherwise indicated, forward-looking statements in this document describe the Offeror’s expectations as of January 22, 2019 and, accordingly, are subject to change after such date;

 

   

forward-looking statements in the documents incorporated by reference herein are as of the dates specified in the applicable documents and are expressly qualified by the statements made therein;

 

   

historical statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In particular, historical results of the Offeror should not be taken as a representation that such trends will be replicated in the future. No statement in this document is intended to be nor may be construed as a profit forecast; and

 

   

the Offeror’s actual results and events could differ materially from those expressed or implied in the forward-looking statements or forward-looking information in this document or documents incorporated by reference herein, if known or unknown risks affect the business of the Offeror, or if its estimates or assumptions turn out to be inaccurate. As a result, the Offeror cannot guarantee that the results or events expressed or implied in any forward-looking statements or forward-looking information will materialize, and accordingly, you are cautioned against relying on these forward-looking statements or forward-looking information.

Forward-looking statements or forward-looking information are based upon, among other things, current assumptions, estimates, opinions, expectations and projections of management of the Offeror as of the effective date of such statements and, in some cases, information supplied by third parties. Although the Offeror believes the opinions and expectations reflected in such forward-looking statements or forward-looking information are based upon reasonable assumptions and that information received from third parties is reliable, it can give no assurance that those opinions and expectations will prove to have been correct or that the actual results or developments will be realized by certain specified dates or at all.

The Offeror made a number of assumptions in making forward-looking statements in the Offer to Purchase and the Circular, including the documents incorporated by reference. In particular, in making these statements, the Offeror has assumed, among other things, that the Offeror will receive the Regulatory Approvals applicable to the Offer on the timelines and in the manner currently anticipated and that the other conditions of the Offer will be satisfied on a timely basis in accordance with their terms.

Forward-looking information respecting the Offer, various terms of the Offer and the anticipated timing of certain steps or events associated with the Offer is based upon various assumptions and factors, including but not limited to, (i) the current business conditions and expectations of future business conditions and trends affecting the Offeror and Aphria, including the U.S. and Canadian economy, the cannabis and cannabidiol industry in Canada, the U.S. and elsewhere, and capital markets, and (ii) that there have been no material changes in the business, affairs, capital, prospects or assets of the Aphria. All forward-looking statements or forward-looking information in this document are qualified by these cautionary statements.

Forward-looking information concerning possible synergies and efficiencies that may be achieved upon a combination of the businesses of the Offeror and Aphria and other benefits of a combination of the businesses of the Offeror and Aphria is based upon various assumptions and factors, including (in addition to assumptions and factors noted above and elsewhere in this document), the financial information of Aphria available through publicly filed documents and the Offeror’s general industry knowledge and experience. Forward-looking information concerning the business and geographical diversification that may be achieved upon a combination of the businesses of the Offeror and Aphria is based upon various assumptions and factors, including (in addition to assumptions and factors noted above and elsewhere in this document) the current business conditions and expectations of future business

 

xix


conditions and trends affecting the Offeror and Aphria, such as the United States and Canadian economy, the cannabis industry in Canada, the United States and elsewhere, and capital markets, publicly available information concerning the location and size of various operating facilities of Aphria and the Offeror’s general industry knowledge and experience. Forward-looking information concerning the anticipated market capitalization of the Offeror following successful completion of the Offer is based upon various assumptions and factors including the current market capitalization of both the Offeror and Aphria, advice from the Offeror’s financial advisor, the absence of market disruptions that would affect the trading price of GGB Shares and/or the Aphria Shares, and the absence of material adverse changes or developments affecting the Offeror or Aphria.

Forward-looking statements or forward-looking information are subject to a number of risks, uncertainties and assumptions that could cause actual results or events to vary materially from those expressed or implied by the forward-looking statements or forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition to risks noted elsewhere in this document, material risks include, but are not limited to:

 

   

the risk that the conditions of the Offer will not be met, or met on a timely basis, or that the transaction will not be consummated for any other reason;

 

   

the risk that the Financing will not be completed, or will be completed on terms that are different than the terms set forth in this Offer to Purchase and Circular;

 

   

changes in general economic conditions in Canada, the United States and elsewhere;

 

   

changes in operating conditions (including changes in the regulatory environment) affecting the cannabis industry;

 

   

fluctuations in currency and interest rates, availability of materials and personnel; and

 

   

the Offeror’s ability to successfully integrate the operations of the Offeror and Aphria following completion of the Offer, including the ability to retain key Aphria personnel and renegotiate certain contracts to obtain economies of scale or other synergies.

Even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking statements or forward-looking information contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. You should not place undue reliance on forward-looking statements or forward-looking information, which are based on the information available as of the date of this Offer to Purchase and Circular.

Additional risk factors could cause actual results or events to differ materially from the results or outcomes expressed or implied by the forward-looking statements or forward-looking information in this document and various documents incorporated by reference herein. For a discussion regarding such risks, see, in particular, the sections of the Circular entitled “Purpose of the Offer and Plans for Aphria”, “Certain Information Concerning Securities of the Offeror”, “Regulatory Matters” and “Risk Factors”, as well as the information contained under the heading “Risk Factors” in each of the documents incorporated by reference herein.

The Offeror cautions you that the risks described or referenced in this section are not the only ones that could affect the Offer or the Offeror. Additional risks and uncertainties not presently known by the Offeror or that the Offeror currently believes are not material may also materially and adversely affect the receipt of the Regulatory Approvals, the satisfaction or waiver by the Offeror of any of the conditions of the Offer, the successful completion of the Offer or the business, operations, financial condition, financial performance, cash flows, reputation or prospects of the Offeror. Except as otherwise indicated by the Offeror, forward-looking statements or forward-looking information do not reflect the potential impact of any special initiatives or of any dispositions, monetizations, mergers, acquisitions, other business combinations or other transactions that may be announced or that may occur after January 22, 2019. The financial impact of any such special initiatives or transactions may be complex and will depend on the facts particular to each of them. The Offeror, therefore, cannot describe the expected effects in a

 

xx


meaningful way or in the same way it presents known risks affecting its business. Forward-looking statements are presented herein for the purpose of providing information about the Offeror and the Offer and its anticipated impacts.

The Offeror disclaims any intention and assumes no obligation to update or revise any forward-looking statements or forward-looking information, even if new information becomes available, as a result of future events or for any other reason, except to the extent required by applicable Securities Laws.

CURRENCY

All currency amounts expressed herein, unless indicated otherwise, are expressed in Canadian Dollars. On January 21, 2019 the exchange rate published by the Bank of Canada was USD$1.00 = $1.3297. The foregoing rate may differ from the actual rates used in the preparation of the financial statements and other financial data appearing in this Offer to Purchase and Circular. The inclusion of this exchange rate is not meant to suggest that the Canadian dollar amounts actually represent such U.S. dollar amounts or that such amounts could have been converted into U.S. dollars at any particular rate, if at all.

AVAILABILITY OF DISCLOSURE DOCUMENTS

The Offeror is a reporting issuer or the equivalent in the provinces of British Columbia, Alberta, Ontario, Québec, and Nova Scotia, and files its continuous disclosure documents with applicable Securities Regulatory Authorities therein. Such documents are available on SEDAR under the Offeror’s profile at www.sedar.com.

NON-IFRS MEASURES

This Offer to Purchase, Circular, and the documents incorporated by reference herein contain references to certain financial measures that are not defined under the generally accepted accounting principles applicable to the Offeror, being IFRS.

These non-IFRS financial measures are “EBITDA”, “TEV / EBITDA”, and “TEV / 2020E EBITDA”.

The Offeror uses these non-IFRS financial measures to provide investors with supplemental measures of its operating and financial performance (or expected operating and financial performance), as they highlight trends in the Offeror’s core business that may not otherwise be apparent when one relies solely on IFRS measures. The Offeror believes certain investors may also use this information to assess the Offeror’s performance and determine the Offeror’s ability to generate cash flow.

The Offeror defines these non-IFRS financial measures as follows:

 

   

“EBITDA” is defined as net income (loss), plus (minus) income taxes (recovery) plus (minus) finance income, net, plus amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on sale of inventory and on growth of biological assets, plus impairment of intangible assets, plus transaction costs, plus (minus) loss (gain) on disposal of capital assets, plus (minus) loss (gain) on foreign exchange, plus (minus) loss (gain) on marketable securities, plus (minus) loss (gain) from equity investee, minus deferred gain on sale of intellectual property, plus (minus) loss (gain) on dilution of ownership in equity investee, plus (minus) unrealized loss (gain) on convertible notes receivable, plus (minus) loss (gain) on long-term investments and certain one-time non-operating expenses, as determined by management. The Offeror believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash generated by operations.

 

   

“TEV / EBITDA” is defined as total enterprise value divided by EBITDA for the period stated, where total enterprise value is calculated as of the stated date, and where EBITDA is calculated in accordance with the following: (i) for GGB, the definition of EBITDA herein; and (ii) for all other companies, analysts’ consensus estimates.

 

xxi


   

TEV / 2020E EBITDA” is defined as total enterprise value divided by EBITDA in the year 2020, where total enterprise value is calculated as of the stated date, and where EBITDA is calculated in accordance with the following: (i) for GGB, the definition of EBITDA herein; and (ii) for all other companies, analysts’ consensus estimates.

These non-IFRS financial measures do not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. As such, non-IFRS financial measures should not be considered in isolation or as a substitute for measures prepared in accordance with IFRS. Non-IFRS financial measures are not necessarily indicative of, and should not be construed as alternatives to, other earnings measures determined in accordance with IFRS.

NOTICE REGARDING APHRIA INFORMATION

Except as otherwise indicated herein, the information concerning Aphria contained in this document has been taken from, or is based upon, publicly available information filed by Aphria with various Securities Regulatory Authorities in Canada and other public sources available as of January 21, 2019. As of the date of this Offer to Purchase and Circular, the Offeror has not had access to the non-public books and records of Aphria and the Offeror is not in a position to independently assess or verify certain of the information in Aphria’s publicly filed documents, including its financial statements. Aphria has not reviewed this document and has not confirmed the accuracy and completeness of the information concerning Aphria contained herein. While the Offeror has no reason to believe that such information is inaccurate or incomplete, the Offeror has no means of verifying the accuracy or completeness of any information contained herein that is derived from publicly available information regarding Aphria or whether there has been any failure by Aphria to disclose events or facts that may have occurred or may affect the significance or accuracy of any such information. Neither the Offeror, nor any of the directors or officers of the Offeror, assumes any responsibility for the accuracy or completeness of such information or any failure by Aphria to disclose events or facts which may have occurred or which may affect the significance or accuracy of any such information, but which are unknown to the Offeror or such persons.

 

xxii


TABLE OF CONTENTS

 

NOTICE REGARDING APHRIA INFORMATION

     xxii  

SUMMARY

     1  

OFFER TO PURCHASE

     9  

1.  THE OFFER

     9  

2.  TIME FOR ACCEPTANCE

     10  

3.  MANNER OF ACCEPTANCE

     10  

4.  CONDITIONS OF THE OFFER

     15  

5.  ACCELERATION, EXTENSION AND VARIATION OF THE OFFER

     20  

6.  WITHDRAWAL OF DEPOSITED APHRIA SHARES

     23  

7.  PAYMENT FOR DEPOSITED APHRIA SHARES

     24  

8.  RETURN OF DEPOSITED APHRIA SHARES

     25  

9.  MAIL SERVICE INTERRUPTION

     25  

10.  CHANGES IN CAPITALIZATION, DIVIDENDS AND DISTRIBUTIONS

     26  

11.  NOTICES AND DELIVERY

     26  

12.  MARKET PURCHASES AND SALES OF APHRIA SHARES

     27  

13.  OTHER TERMS OF THE OFFER

     28  

TAKE-OVER BID CIRCULAR

     29  

1.  THE OFFEROR

     29  

2.  CERTAIN INFORMATION CONCERNING SECURITIES OF THE OFFEROR

     29  

3.  DOCUMENTS INCORPORATED BY REFERENCE AND FURTHER INFORMATION

     32  

4.  APHRIA INC.

     34  

5.  CERTAIN INFORMATION CONCERNING SECURITIES OF APHRIA

     35  

6.  BACKGROUND TO THE OFFER

     36  

7.  REASONS TO ACCEPT THE OFFER

     40  

8.  PURPOSE OF THE OFFER AND PLANS FOR APHRIA

     43  

9.  FINANCING

     44  

10.  TREATMENT OF CONVERTIBLE SECURITIES

     45  

11.  FRACTIONAL SHARES

     45  

12.  BENEFICIAL OWNERSHIP OF AND TRADING IN SECURITIES OF APHRIA

     45  

13.  COMMITMENTS TO ACQUIRE APHRIA SHARES

     47  

14.  ARRANGEMENTS, AGREEMENTS OR UNDERSTANDINGS; OTHER BENEFITS TO INSIDERS, AFFILIATES AND ASSOCIATES

     47  

15.  EFFECT OF THE OFFER

     47  

16.  ACQUISITION OF APHRIA SHARES NOT DEPOSITED UNDER THE OFFER

     47  

17.  UNAUDITED CONDENSED CONSOLIDATED PRO FORMA FINANCIAL STATEMENTS

     51  

18.  CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS

     51  

 

xxiii


19.  CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

     59  

20.  OFFEREES’ STATUTORY RIGHTS

     67  

21.  MATERIAL CHANGES AND OTHER INFORMATION

     67  

22.  REGULATORY MATTERS

     67  

23.  DEPOSITARY AND INFORMATION AGENT

     69  

24.  FINANCIAL ADVISOR, DEALER MANAGER AND SOLICITING DEALER GROUP

     69  

25.  EXPENSES OF THE OFFER

     70  

26.  BENEFITS FROM THE OFFER

     70  

27.  EXPERTS

     70  

28.  LEGAL MATTERS

     70  

29.  RISK FACTORS

     70  

30.  DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT

     76  

31.  EXEMPTION FROM NATIONAL INSTRUMENTS

     76  

32.  DIRECTORS’ APPROVAL

     77  

GLOSSARY

     78  

CONSENT OF NORTON ROSE FULBRIGHT CANADA LLP

     87  

CERTIFICATE OF GREEN GROWTH BRANDS INC.

     88  
ANNEX A – UNAUDITED CONDENSED CONSOLIDATED PRO FORMAFINANCIAL STATEMENTS      A-1  

 

xxiv


SUMMARY

The following are some of the questions you, as an Aphria Shareholder, may have about the Offer and the Offeror’s answers to those questions. The following is a summary only and is qualified by the detailed provisions contained elsewhere in this Offer to Purchase and Circular. Certain capitalized words and terms used in this Summary are defined in the Glossary. Aphria Shareholders are urged to read this Offer to Purchase and Circular in their entirety.

Who is offering to buy the Aphria Shares?

The Offeror, Green Growth Brands Inc., is making the Offer to purchase the Aphria Shares. See Section 1 of the Circular, “The Offeror”.

The GGB Shares trade on the CSE under the symbol “GGB” and on the OTCQB under the symbol “GGBXF”.

What is the Offer?

Pursuant to the Offer, Aphria Shareholders who tender their Aphria Shares to the Offer (including any Aphria Shares that may become issued and outstanding after the date of the Offer but before 5:00 p.m. (Toronto time) on May 9, 2019 (the “Expiry Time”) upon the conversion, exchange or exercise of any Convertible Securities) will receive 1.5714 GGB Shares in exchange for each Aphria Share (the “Offer Consideration”).

Why should I accept the Offer?

The Offeror believes that the consideration offered for your Aphria Shares is a full and fair price and provides a unique opportunity for the Aphria Shareholders to retain equity exposure to the cannabis industry through an ownership interest in the Offeror. While Aphria Shareholders may be discouraged by recent events and have seen their investment significantly impacted, they should be aware of the immediate benefits of the Offer and reasons to tender:

 

   

Based on the closing price of $5.99 per GGB Share on the CSE as of January 21, 2019, the last trading day prior to the date of this Offer to Purchase and Circular, the implied Offer Consideration would be $9.41 per Aphria Share (being a 24.5% premium over the Aphria Shares’ closing price of $7.56 on the TSX on December 24, 2018, the last trading day prior to GGB’s public announcement of its intention to launch the Offer, and 24.9% over the volume weighted average price of $7.5328 of the Aphria Shares on the TSX for the last ten (10) trading days ended December 24, 2018). Based on the closing price of $4.25 per GGB Share on the CSE on December 24, 2018, the implied Offer Consideration would be $6.68 per Aphria Share. See Section 29 of the Circular, “Risk Factors”.

 

   

Aphria Shareholders will have a meaningful ownership position of approximately 60% in the combined company.

 

   

Aphria Shareholders will be part of an organization which is poised for further growth in the significantly larger U.S. market, with much greater long-term value potential.

 

   

There is potential for further downward pressure on the market price of the Aphria Shares if the Offer is not accepted.

See Section 7 of the Circular, “Reasons to Accept the Offer”.

What is the strategic rationale for the combination?

The Offeror believes that the combination of the two companies is extremely compelling, in the best interest of all shareholders, and is the fastest way to create significant value for shareholders of both companies. The combined company is expected to:



 


   

Create an Unparalleled North American Player with a Developing International Presence. Aphria has a large market position in Canada and supply agreements with all provinces and Yukon territory, as well as strong strategic partnerships establishing wholesale supply agreements. Aphria has established operations in federally-legalized foreign jurisdictions, including Australia, Argentina, Colombia, Denmark, Germany, Italy, Jamaica, Lesotho, Malta, and Paraguay, and maintains an option for entry into Brazil. GGB operates vertically integrated cannabis operations including cultivation, manufacturing and retail assets in Nevada, was recently awarded seven incremental provisional retail cannabis dispensary licenses in Nevada, and has agreed to acquire Just Healthy LLC, which holds provisional certificates of registration for a registered medical marijuana dispensary and will, as a condition of closing, own an option to purchase land for a cultivation and processing site in Northampton, Massachusetts. GGB also holds an irrevocable option to purchase Henderson Organic Remedies LLC (“Henderson Organic”), which operates a second The+Source location in Henderson, Nevada, subject to certain local regulatory changes and approvals. Further, through its consumer-focused line of cannabidiol (“CBD”) products, GGB’s long term goal is to establish a presence in each U.S. state where the sale of cannabis and CBD is not inconsistent with applicable Law. Together, the combined company is expected to have a strong foundation, extensive retail relationships and infrastructure to capture significant future growth as international markets evolve.

 

   

Increase Scale and Footprint, While Creating the Preeminent U.S. Consolidator. The combined company will be one of the largest U.S. cannabis operators by market capitalization and the only North American-wide cannabis operator at significant scale. Given the combined company’s increased size, both Aphria and GGB shareholders should benefit from a trading multiple expansion. The benefits of scale are expected in both Canada and the U.S. when examining trading metrics for comparable companies with similar market capitalization.

 

   

Combine Aphria’s Cultivation and Production Capacity with GGB’s Retail Strength. The combined company will marry Aphria’s low-cost cultivation and near-term production capacity with GGB’s vast retail know-how to capture market share. Aphria’s current cash cost per gram is $1.76 and it projects annual capacity of over 250,000 kg by early 2019. GGB’s strong management team has a proven track record of delivering at the retail level and already operates or has licensing agreements in place with dispensaries in Nevada. In addition, GGB was recently awarded seven incremental provisional retail cannabis dispensary licenses in Nevada. Following expected receipt of regulatory approvals for the proposed acquisitions of Just Healthy LLC and Henderson Organic, as well as a cultivation facility in Pahrump, Nevada, and when such acquisitions are combined with GGB’s current operations, GGB is expected to generate total revenue from the cannabis business of over USD$300 million by the end of 2020.

 

   

Benefit from Transformational Cannabis-Related Regulatory Changes in the World’s Largest Cannabis Market. GGB is in the process of rolling out a consumer-focused line of CBD-infused personal care products, including topicals and balms, and is well positioned to benefit from further expected pro-cannabis U.S. regulation. On January 10, 2019, GGB announced an agreement with DSW, Inc. (“DSW”) to sell CBD-infused personal care products at 96 U.S.-based DSW stores, with an initial agreement for approximately 55,000 units. GGB is also partnering with additional retailers to sell CBD personal care products in U.S. states where the sale of cannabis and CBD is not inconsistent with applicable Law. Further, GGB is working with multiple large developers who represent a network of malls to launch kiosks in prime locations throughout the U.S. in states where the sale of cannabis and CBD is not inconsistent with applicable Law. By leveraging its CBD business in these prime locations, as well as through e-commerce, GGB expects to generate revenue from the CBD business of over USD$200 million by the end of 2020.

 

   

Unite Best-in-Class Management Teams: Aphria’s Pharmaceutical and Greenhouse Operational Experience and GGB’s Proven Retail Expertise. Aphria’s team, many of whom the Offeror hopes to retain following the successful completion of the Offer, is comprised of veterans in the greenhouse industry and proven operators of large pharmaceutical companies. GGB’s management has held senior positions at a number of well-known retailers including DSW, American Eagle Outfitters, and Bath & Body Works.

See also Section 7 of the Circular, “Reasons to Accept the Offer”.



 

2


How long do I have to accept the Offer?

The Offer is open for acceptance until the Expiry Time, being 5:00 p.m. (Toronto time) on May 9, 2019, unless the deposit period for the Offer is accelerated or extended by the Offeror, or the Offer is withdrawn by the Offeror. See Section 2 of the Offer to Purchase, “Time for Acceptance”. The deposit period under the Offer may be shortened in certain circumstances, in accordance with applicable Securities Laws, at the election of the Offeror as a result of actions that may be taken by Aphria. See Section 5 of the Offer to Purchase, “Acceleration, Extension and Variation of the Offer”.

How do I deposit my Aphria Shares?

You can deposit your Aphria Shares in one of the following three ways:

 

  (a)

If you are an Aphria Shareholder who holds physical certificate(s) or DRS Statement(s) for Aphria Shares in your name (a “Registered Aphria Shareholder”), then in order to accept the Offer, you must deposit the certificate(s) representing your Aphria Shares, together with the originally signed Letter of Transmittal (printed on yellow paper or use a copy of the form), and deposit the originally signed Letter of Transmittal, properly completed and duly executed, at or prior to the Expiry Time, at the office of the Depositary and Information Agent specified in the Letter of Transmittal. Instructions are contained in the Letter of Transmittal which accompanies this Offer to Purchase and Circular;

 

  (b)

If you hold Aphria Shares in nominee form (e.g. in a brokerage account), you should contact your investment advisor, broker, bank, trust company or other nominee to deposit your Aphria Shares if you wish to accept the Offer. Shares held in nominee form may be deposited pursuant to the procedure for Book-based Transfer if applicable. Nominees will likely establish tendering cut-off times that are prior to the Expiry Time. Please contact your nominee to ensure your instructions are received prior to their deadline; and

 

  (c)

If you are unable to deliver any required document or instrument to the Depositary and Information Agent by the Expiry Time, you may obtain additional time to do so by having a broker, a bank or other fiduciary that is an Eligible Institution guarantee that the missing items will be received by the Depositary and Information Agent by 5:00 p.m. (Toronto time) on the second trading day on the CSE after the Expiry Time. You may use the Notice of Guaranteed Delivery (printed on green paper), which has been enclosed with the Offer for this purpose. Brokers, nominees and CDS or DTC participants may also follow LOG options. For the deposit to be valid, however, the Depositary and Information Agent must receive the missing items by 5:00 p.m. (Toronto time) on the second trading day on the CSE after the Expiry Time, either through physical means or LOG guaranteed delivery procedures. The procedures for guaranteed delivery are set forth in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”.

Participants of CDS or DTC should contact the Depositary and Information Agent with respect to the deposit of their Aphria Shares under the Offer. CDS and DTC will be issuing instructions to their participants as to the method of depositing such Aphria Shares under the terms of the Offer.

See Section 3 of the Offer to Purchase, “Manner of Acceptance” for more details on how to deposit Aphria Shares.

What securities are being sought in the Offer?

The Offer is made only for Aphria Shares and is not made for any Convertible Securities, which term includes stock options and warrants.



 

3


I hold options or warrants. Can I deposit these options or warrants to the Offer?

No. If you hold options, warrants or other Convertible Securities and wish to accept the Offer, you should exercise your rights to acquire Aphria Shares and deposit the resulting Aphria Shares in response to the Offer. Any such exercise must be made sufficiently in advance of the Expiry Time to ensure that Aphria Shares will be available for deposit at or prior to the Expiry Time or in sufficient time to comply with the procedures referred to in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”.

Will fractional shares be issued in the Offer?

No. In no event will any Aphria Shareholder be entitled to a fractional GGB Share. Where the aggregate number of GGB Shares to be issued to an Aphria Shareholder as consideration under the Offer would result in a fraction of GGB Shares being issuable, the number of GGB Shares to be received by such Aphria Shareholder shall be either rounded up (if the fractional interest is equal to or exceeds 0.5) or down (if the fractional interest is less than 0.5) to the nearest whole number of GGB Shares without any additional payment in lieu thereof.

What does the board of directors of Aphria think of the Offer?

Under Canadian Securities Laws, a directors’ circular must be prepared by the board of directors of Aphria and sent to Aphria Shareholders no later than 15 days from the date of commencement of the Offer. The directors’ circular must include either: (i) a recommendation to accept or reject the Offer, and the reasons for the board of directors’ recommendation, or a statement that the board of directors is unable to make or is not making a recommendation, (ii) if no recommendation is made, the reasons for not making a recommendation; or (iii) a statement that the board of directors is considering the Offer and advising Aphria Shareholders not to deposit their Aphria Shares under the Offer until they receive further information from the board, provided that the board of directors must communicate to Aphria Shareholders a recommendation to accept or reject the Offer or the decision that it is unable to make, or is not making, a recommendation, together with the reasons for the recommendation or decision, at least seven (7) days before the scheduled expiry of the initial deposit period. See Section 6 of the Circular, “Background to the Offer” for a description of the proposals made by the Offeror to the board of directors of Aphria and the lack of action by the board of Aphria with respect to such proposals.

What are the most significant conditions of the Offer?

The Offer is subject to certain conditions, including, among other things:

 

  (a)

more than 6623% of the Aphria Shares (calculated on a Fully-Diluted Basis) held by Aphria Shareholders who are not Interested Aphria Shareholders, having been validly tendered to the Offer and not validly withdrawn (the “Minimum Tender Condition”);

 

  (b)

the Regulatory Approvals and all other third party approvals, licenses, permits, authorizations and clearances considered necessary or reasonably appropriate by the Offeror in relation to the Offer and the operation of the combined company having been obtained on terms satisfactory to the Offeror in its sole judgment;

 

  (c)

there being no legal prohibition against GGB making the Offer or taking up and paying for the Aphria Shares under the Offer or completing any Compulsory Acquisition or Subsequent Acquisition Transaction in respect of any Aphria Shares not acquired under the Offer;

 

  (d)

the Registration Statement having become effective under the U.S. Securities Act and not becoming subject to a stop order or a proceeding seeking a stop order;

 

  (e)

Aphria having not adopted or implemented a shareholder rights plan or taken any other action that provides rights to the Aphria Shareholders to purchase any securities of Aphria as a result of the Offer or any Compulsory Acquisition or Subsequent Acquisition Transaction;



 

4


  (f)

except to the extent publicly disclosed in a filing with a Securities Regulatory Authority prior to December 28, 2018, neither Aphria nor its subsidiaries having amended, or proposed or authorized any amendment to, their respective articles or bylaws (or other similar organizational documents);

 

  (g)

neither Aphria, nor any of its affiliates or subsidiaries, nor any other person having taken any action or authorized, recommended, proposed or announced an intention to take any action: (i) that has had or could have the effect (as determined by the Offeror in its sole judgment) of impairing the ability of the Offeror to acquire Aphria Shares, diminishing in any respect the expected economic value to the Offeror of the acquisition of Aphria, or making the acquisition of Aphria more costly in any material respect to the Offeror, or (ii) that would (as determined by the Offeror in its sole judgement) make it inadvisable for the Offeror to proceed with the Offer, to take up and pay for Aphria Shares deposited under the Offer or to complete any Compulsory Acquisition or Subsequent Acquisition Transaction in respect of any Aphria Shares not acquired under the Offer;

 

  (h)

there not existing and not having occurred or been publicly disclosed since December 28, 2018 (in the sole judgment of the Offeror) any material adverse change in respect of Aphria;

 

  (i)

Aphria and its affiliates having conducted their respective businesses in the ordinary course of business consistent with past practice at all times on or after December 28, 2018 and prior to the Expiry Time;

 

  (j)

the Offeror not becoming aware of any untrue statement of a material fact, or an omission to state a material fact that is required to be stated or that is necessary to make a statement made not misleading in the light of the circumstances in which it was made and at the date it was made (after giving effect to all subsequent filings prior to the date of the Offer in relation to all matters covered in earlier filings), in any document filed by or on behalf of Aphria or any of its subsidiaries with any of the Securities Regulatory Authorities or a similar securities regulatory authority in the United States or elsewhere or with any other Governmental Entity anywhere in the world;

 

  (k)

the Offeror having obtained the approval of its shareholders to issue the GGB Shares pursuant to the Offer in accordance with the policies of the CSE;

 

  (l)

the Offeror not becoming aware of any information corroborating in any material respect the statements contained in the December 3, 2018 report of Hindenburg Research and Quintessential Capital Management entitled “Aphria: A Shell Game with a Cannabis Business on the Side” (the “Report”); and

 

  (m)

the statutory minimum condition of 50% of the Aphria Shares having been validly tendered to the Offer and not validly withdrawn, excluding Aphria Shares held by or over which control or direction is exercised by GGB or any person acting jointly or in concert with GGB (which condition cannot be waived) (the “Statutory Minimum Condition”).

The consummation of the Financing on the terms set forth herein is not a condition to the Offer, and there is no other financing condition to the Offer. See Section 4 of the Offer to Purchase, “Conditions of the Offer” for additional conditions of the Offer, as well as a more detailed description of the conditions of the Offer.

Does the Offeror own any Aphria Shares?

Yes, the Offeror has purchased 3,000,000 Aphria Shares in the open market and may purchase up to an additional 5% of the Aphria Shares in the aggregate. Aphria Shareholders should thus be aware that during the period of the Offer, the Offeror or any of its affiliates may, directly or indirectly, bid for and make purchases of Aphria Shares as permitted by applicable Law. For details and conditions and regarding such purchases, please see Section 12 of the Offer to Purchase, “Market Purchases and Sales of Aphria Shares”.



 

5


What will happen if the conditions of the Offer are not satisfied?

If the conditions of the Offer are not satisfied or waived by the Offeror, the Offeror will not be obligated to take up, accept for payment or pay for any Aphria Shares tendered to the Offer, and may terminate and withdraw the Offer prior to the Expiry Time if the conditions of the Offer become incapable of being satisfied.

Do I have dissent or appraisal rights in connection with the Offer?

No. Aphria Shareholders will not have dissent or appraisal rights in connection with the Offer. However, Aphria Shareholders who do not tender their Aphria Shares to the Offer may have rights of dissent in the event the Offeror acquires their Aphria Shares by way of a Compulsory Acquisition or Subsequent Acquisition Transaction.

Will I have to pay any fees or commissions to deposit my Aphria Shares?

No. Aphria Shareholders will not be required to pay any fee or commission if they accept the Offer by depositing their Aphria Shares directly with the Depositary and Information Agent (including through a book-entry transfer) or if they make use of the services of a Soliciting Dealer, if any, to accept the Offer. However, an investment advisor, broker, bank, trust company or other intermediary through whom you own your Aphria Shares may charge a fee to tender any such Aphria Shares on your behalf. You should consult your investment advisor, broker, bank, trust company or other intermediary to determine whether other charges will apply.

How long do I have to withdraw any previously deposited Aphria Shares?

Aphria Shares deposited under the Offer may be withdrawn at any time if the Aphria Shares have not been taken up by the Offeror and in the other circumstances described in Section 6 of the Offer to Purchase, “Withdrawal of Deposited Aphria Shares”.

Can the Offeror extend the Offer?

Yes. The Offeror may elect, in its sole discretion, to extend the Offer from time to time.

In accordance with applicable Law, if the Offeror is obligated to take up the Aphria Shares deposited at the expiry of the initial deposit period, it will extend the period during which Aphria Shares may be deposited under the Offer for a 10-day Mandatory Extension Period following the expiry of the initial deposit period and may extend the deposit period after such 10-day Mandatory Extension Period for one or more Optional Extension Periods. If the Offeror extends the Offer, it will notify the Depositary and Information Agent and publicly announce such extension and, if required by applicable Law, mail you a copy of the notice of variation. See Section 5 of the Offer to Purchase, “Acceleration, Extension and Variation of the Offer”.

When will the Offeror take up and pay for Aphria Shares deposited under the Offer?

Assuming all of the conditions of the Offer (including the Statutory Minimum Condition) are either met or, if applicable, waived at or prior to the Expiry Time, the Offeror will promptly take up Aphria Shares validly deposited under the Offer and not validly withdrawn. Any Aphria Shares will be taken up immediately after the initial deposit period for the Offer, and the Offeror will issue GGB Shares as consideration for Aphria Shares taken up as soon as possible but in any event not later than three (3) business days after taking up such Aphria Shares. The Offeror will take up and pay for Aphria Shares deposited under the Offer during the Mandatory Extension Period and any Optional Extension Period not later than ten (10) days after such deposit. In each case, share certificates, DRS Statements or other evidence of the GGB Shares issued as consideration for the Aphria Shares will be provided as soon as practicable thereafter. See Section 7 of the Offer to Purchase, “Payment for Deposited Aphria Shares”.

How will Aphria Shareholders be taxed for Canadian federal income tax purposes?

Subject to the qualifications noted in the Circular, if you are a resident of Canada and hold your Aphria Shares as capital property and you exchange your Aphria Shares under the Offer, you generally will not realize a capital gain



 

6


(or capital loss) in respect of the exchange unless you choose to report the gain (or loss) in your Canadian tax return for the year in which the exchange occurred.

Similarly, if you are not a resident of Canada and hold your Aphria Shares as capital property and you exchange such Aphria Shares under the Offer, you generally will not realize a capital gain (or capital loss) in respect of the exchange unless you choose to report such gain (or loss) in a Canadian tax return for the year in which the exchange occurred. In addition, if you are not a resident of Canada, you generally will not be subject to tax under the Tax Act on any capital gain realized on a disposition of your Aphria Shares under the Offer unless your Aphria Shares are held or deemed to be held as “taxable Canadian property”.

The foregoing is a brief summary of certain Canadian federal income tax consequences only, and is qualified by the description of Canadian federal income tax considerations set out in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”. Aphria Shareholders are urged to consult their own tax advisors to determine the particular tax consequences to them of a sale of Aphria Shares under the Offer or a disposition of Aphria Shares pursuant to any Compulsory Acquisition or Subsequent Acquisition Transaction. Holders of options, warrants or other Convertible Securities are not addressed in this summary or in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”, and all such holders should also consult their own tax advisors.

How will U.S. Holders of Aphria Shares be taxed for U.S. federal income tax purposes?

Subject to the qualifications noted in the Circular and to the passive foreign investment company rules discussed below, a U.S. Holder (as defined in Section 19 of the Circular, “Certain United States Federal Income Tax Considerations”) who holds Aphria Shares as a capital asset will not recognize gain or loss on the exchange of its Aphria Shares for GGB Shares pursuant to the Offer if the exchange constitutes a tax-deferred reorganization under Section 368(a) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). Instead, the U.S. Holder will carry over its tax basis and its holding period in the Aphria Shares surrendered to the GGB Shares received.

If the exchange does not qualify as a tax-deferred reorganization, then, subject to the passive foreign investment company rules discussed below, a U.S. Holder will recognize a capital gain or loss on the exchange, equal to the difference between the U.S. Holder’s tax basis in the Aphria Shares surrendered and the fair market value of the GGB Shares received. The gain or loss will be long-term gain (and subject to a reduced tax rate) or long-term loss if the Aphria Shares have been held for more than one year at the time of the closing of the Offer; otherwise it will be short-term gain (taxable as ordinary income) or short-term loss.

If Aphria were to constitute a passive foreign investment company for any taxable year during which a U.S. Holder held Aphria Shares, then special rules will apply to U.S. Holders. Under these rules, U.S. Holders may recognize a gain on the exchange even if the exchange qualifies as a tax-deferred reorganization, and that gain will be taxed at ordinary income tax rates and may be subject to interest, as well. A U.S. Holder that realizes a loss on the exchange would only be able to recognize that loss if the exchange does not qualify as a tax-deferred reorganization.

The foregoing is a brief summary of certain U.S. federal income tax consequences only, and is qualified by the description of United States federal income tax considerations set out in Section 19 of the Circular, “Certain United States Federal Income Tax Considerations”. Aphria Shareholders are urged to consult their own tax advisors to determine the particular tax consequences to them of a sale of Aphria Shares under the Offer or a disposition of Aphria Shares pursuant to any Compulsory Acquisition or Subsequent Acquisition Transaction. Holders of options, warrants or other Convertible Securities are not addressed in this summary or in Section 19 of the Circular, “Certain United States Federal Income Tax Considerations”, and all such holders should also consult their own tax advisors.

Is GGB’s financial condition relevant to my decision to tender my Aphria Shares to the Offer?

Yes. As GGB Shares will be issued to Aphria Shareholders who validly tender their Aphria Shares, you should consider GGB’s financial condition before you decide to tender your Aphria Shares to the Offer. In considering GGB’s financial condition, you should review the documents included and incorporated by reference in this Offer to Purchase and Circular as they contain detailed business, financial and other information about the Offeror. See also Section 17 of the Circular, “Unaudited Condensed Consolidated Pro Forma Financial Statements”, Section 29 of the



 

7


Circular, “Risk Factors”, and the Unaudited Condensed Consolidated Pro Forma Financial Statements of the combined company attached hereto as Annex A.

Will Aphria continue as a public company?

If, as a result of the Offer and any subsequent transaction, the number of Aphria Shareholders is sufficiently reduced, then to the extent permitted under applicable Law, the Offeror intends to cause Aphria to apply to the TSX and the NYSE to delist the Aphria Shares from both stock exchanges as soon as practicable after completion of the Offer or a Compulsory Acquisition or Subsequent Acquisition Transaction and, subject to applicable Law, to cause Aphria to cease to be a reporting issuer (or equivalent) in Canada and the United States. The rules and regulations of the TSX and NYSE could also, upon the consummation of the Offer and/or a subsequent transaction, lead to the delisting of the Aphria Shares from such exchanges. See Section 8 of the Circular, “Purpose of the Offer and Plans for Aphria” and Section 15 of the Circular, “Effect of the Offer”.

What will Aphria’s representation be in the combined company?

Upon completion of the Offer and a Compulsory Acquisition or Subsequent Acquisition Transaction, and assuming completion of the Financing, Aphria Shareholders will have a meaningful ownership position of approximately 60% in the combined company, and GGB shareholders will represent approximately 40%. In the event the Financing is not completed, Aphria Shareholders will have an ownership position of approximately 64% in the combined company, and GGB shareholders will represent approximately 36%. See Section 9 of the Circular, “Financing” and Section 29 of the Circular, “Risk Factors”.

If the Offer is successful, it is anticipated that the board of directors of Aphria will promptly be replaced by nominees of the Offeror. Management of the Offeror would look to engage with Aphria management (which may include its directors) in an effort to retain those members of the Aphria management team who are aligned with the culture and strategy of the Offeror to assist with the future growth and development of the combined company. See Section 8 of the Circular, “Purpose of the Offer and Plans for Aphria”.

Who can I talk to if I have questions about the Offer?

Questions and requests for assistance concerning the Offer should be made directly to Kingsdale at 1-866-851-3214 (Toll Free in North America) or 416-867-2272 (Collect Outside North America) or by email at contactus@kingsdaleadvisors.com, or using the additional contact details on the back page of this document.



 

8


OFFER TO PURCHASE

The accompanying Circular is incorporated into and forms part of this Offer to Purchase and contains important information that should be read carefully before making a decision with respect to the Offer. Capitalized terms used in this Offer to Purchase and not otherwise defined herein, have the respective meanings ascribed to them in the Glossary of this document unless the context otherwise requires.

January 22, 2019

TO: THE HOLDERS OF COMMON SHARES OF APHRIA INC.

 

1.

The Offer

Pursuant to the Offer, Aphria Shareholders who tender their Aphria Shares to the Offer (including any Aphria Shares that may become issued and outstanding after the date of the Offer but before the Expiry Time, being 5:00 p.m. (Toronto time) on May 9, 2019, upon the conversion, exchange or exercise of any Convertible Securities) will receive 1.5714 GGB Shares in exchange for each Aphria Share.

Based on the closing price of $5.99 per GGB Share on the CSE as of January 21, 2019, the last trading day prior to the date of this Offer to Purchase and Circular, the implied Offer Consideration would be $9.41 per Aphria Share (being a 24.5% premium over the Aphria Shares’ closing price of $7.56 on the TSX on December 24, 2018, the last trading day prior to GGB’s public announcement of its intention to launch the Offer, and 24.9% over the volume weighted average price of $7.5328 of the Aphria Shares on the TSX for the last ten (10) trading days ended December 24, 2018). Based on the closing price of $4.25 per GGB Share on the CSE on December 24, 2018, the implied Offer Consideration would be $6.68 per Aphria Share. See Section 29 of the Circular, “Risk Factors”.

The number of GGB Shares to be issued in exchange for each Aphria Share under the Offer will not be adjusted to reflect any change in the market value of GGB Shares that may occur prior to the time of the take up of Aphria Shares under the Offer. Accordingly, there can be no assurance of what the value of a GGB Share will be at the time of the take up of the Aphria Shares under the Offer.

The Offer is made only for Aphria Shares and is not made for any Convertible Securities, which term includes options and warrants. Any holder of Convertible Securities who wishes to accept the Offer must exercise such rights in order to obtain certificate(s) or DRS Statement(s) representing Aphria Shares and then deposit those Aphria Shares under the Offer. Any such exercise must be made sufficiently in advance of the Expiry Time to ensure that Aphria Shares will be available for deposit at or prior to the Expiry Time or in sufficient time to comply with the procedures referred to in Section 3 of this Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”. If any holder of Convertible Securities does not exercise such Convertible Securities prior to the Expiry Time, such Convertible Securities may remain outstanding following the Expiry Time in accordance with their terms and conditions, including with respect to time of expiry, vesting schedule, exercise price, and rights following a takeover bid (such as the Offer). The tax consequences to holders of Convertible Securities of exercising or not exercising their Convertibles Securities are not described in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations” or Section 19 of the Circular, “Certain United States Federal Income Tax Considerations”. Holders of Convertible Securities should consult with their own tax advisors for advice with respect to potential income tax consequences to them in connection with the decision to exercise or not exercise their Convertible Securities.

The Offeror intends to submit an application to list the GGB Shares that may be distributed to Aphria Shareholders in connection with the Offer on the CSE. Listing of the GGB Shares will be subject to the Offeror fulfilling all of the applicable listing requirements of the CSE, and the CSE’s approval of the Offer and the transactions contemplated thereby.

The obligation of the Offeror to take up and pay for Aphria Shares pursuant to the Offer is subject to certain conditions. See Section 4 of this Offer to Purchase, “Conditions of the Offer”.


This document does not constitute an offer or a solicitation to any person in any jurisdiction in which such offer or solicitation is unlawful. The Offer is not being made to, nor will deposits be accepted from or on behalf of, Aphria Shareholders in any jurisdiction in which the making or acceptance of the Offer would not be in compliance with Laws of such jurisdiction. However, the Offeror may, in its sole discretion, take such action as it may deem necessary to extend the Offer to Aphria Shareholders in any such jurisdiction.

The accompanying Circular, Letter of Transmittal and Notice of Guaranteed Delivery, all of which are incorporated into and form part of this Offer, contain important information that should be read carefully before making a decision with respect to the Offer.

 

2.

Time for Acceptance

The Offer is open for acceptance until the Expiry Time, being 5:00 p.m. (Toronto time) on May 9, 2019, unless the deposit period for the Offer is accelerated or extended by the Offeror, or withdrawn by the Offeror. The deposit period under the Offer may be shortened in certain circumstances, in accordance with applicable Securities Laws, at the election of the Offeror as a result of actions that may be taken by Aphria. The Offeror will not amend the Offer to cause the Expiry Time to occur earlier than 35 days or 20 business days, whichever is longer, following the date of the Offer. In connection with the Offer, the Offeror obtained an exemption from the Autorité des marchés financiers (the “AMF”) to permit the Offeror to file French versions of the documents incorporated by reference into the Circular as soon as possible following the filing of the Circular but by no later than January 28, 2019. The Offeror expects to file French versions of all documents incorporated by reference within such time period.

If the Statutory Minimum Condition is satisfied and the other conditions of the Offer are satisfied or waived by the Offeror at the expiry of the initial deposit period under the Offer and the Offeror takes up the Aphria Shares deposited under the Offer, the Offeror will make a public announcement confirming those matters and extend the period during which Aphria Shares may be deposited and tendered to the Offer for a period of not less than ten (10) calendar days after the date of such announcement. See Section 5 of this Offer to Purchase, “Acceleration, Extension and Variation of the Offer”.

 

3.

Manner of Acceptance

Letter of Transmittal

The Offer may be accepted by registered holders of the Aphria Shares by delivering the following documents to the Depositary and Information Agent at the office listed in the Letter of Transmittal accompanying the Offer so as to arrive there not later than the Expiry Time:

 

  (a)

the certificate(s) or DRS Statement(s) representing the Aphria Shares, in respect of which the Offer is being accepted;

 

  (b)

a Letter of Transmittal (printed on yellow paper) in the form accompanying this Offer to Purchase and Circular or a manually executed facsimile thereof, properly completed and duly executed as required by the instructions set out in the Letter of Transmittal including signature guaranteed if required; and

 

  (c)

any other document required by the terms of the Offer and instructions set out in the Letter of Transmittal.

The Offer will be deemed to be accepted only if the Depositary and Information Agent has actually received these documents prior to the Expiry Time at the address for the Depositary and Information Agent noted on the Letter of Transmittal.

 

10


Signature Guarantees

Except as otherwise provided in the instructions set out in the Letter of Transmittal or as may be permitted by the Offeror, the signature on the Letter of Transmittal must be guaranteed by an Eligible Institution. If a Letter of Transmittal is executed by a person other than the registered holder of the Aphria Shares represented by the certificate(s) or DRS Statement(s) deposited therewith, then the certificate(s) or DRS Statement(s) must be endorsed or be accompanied by an appropriate share transfer power of attorney duly and properly completed by the registered holder, with the signature on the endorsement panel or share transfer power of attorney medallion guaranteed by an Eligible Institution.

Registered Aphria Shareholders who cannot comply on a timely basis with these procedures for deposit of the certificate(s) or DRS Statement(s) representing their Aphria Shares prior to the Expiry Time may utilize the procedure for guaranteed delivery described below.

Aphria Shareholders will not be required to pay any fee or commission if they accept the Offer by depositing their Aphria Shares directly with the Depositary and Information Agent (including through a book-entry transfer) or if they make use of the services of a Soliciting Dealer, if any, to accept the Offer. However, an investment advisor, broker, bank, trust company or other intermediary through whom you own your Aphria Shares may charge a fee to tender any such Aphria Shares on your behalf. You should consult your investment advisor, broker, bank, trust company or other intermediary to determine whether other charges will apply.

Lost Certificates or DRS Statements

If an Aphria Shareholder has lost his/her/its certificate(s) or DRS Statement(s) representing Aphria Shares, but wishes to tender his/her/its Aphria Shares to the Offer, such Shareholder should complete the Letter of Transmittal to the extent possible and deliver it together with a letter describing the circumstances surrounding the loss to the Depositary and Information Agent. The Depositary and Information Agent and/or the transfer agent will advise the Aphria Shareholder of the steps that the Aphria Shareholder must take to obtain a replacement certificate(s) or DRS Statement(s) for his/her/its Aphria Shares. The foregoing action must be taken sufficiently in advance of the Expiry Time in order to obtain a replacement certificate(s) or DRS Statement(s) in sufficient time to permit the Aphria Shares represented by the replacement certificate(s) or DRS Statement(s) to be deposited under the Offer at or prior to the Expiry Time.

Procedure for Book-based Transfer (CDS and DTC)

An Aphria Shareholder whose Aphria Shares are registered in the name of a bank, broker, trust company investment dealer, or other intermediary (a “Non-registered Aphria Shareholder”) need not and should not complete a Letter of Transmittal. Non-registered Aphria Shareholders should contact such intermediary directly if they wish to tender Aphria Shares to the Offer.

Certain Non-registered Aphria Shareholders whose Aphria Shares are held in the name of The Canadian Depositary for Securities Limited (“CDS”) may also accept the Offer in Canada by following the procedures for a book-based transfer (“Book-based Transfer”) established by CDS, provided that a continuation of the Book-based Transfer of such Aphria Shares through CDSX into the Depositary and Information Agent’s account at CDS is received by the Depositary and Information Agent prior to the Expiry Time. The Depositary and Information Agent has established an account at CDS for the purposes of the Offer. Any financial institution that is a participant in CDS may cause CDS to make a Book-based Transfer of an Aphria Shareholder’s Aphria Shares by means of a Book-based Transfer that will constitute a valid tender under the Offer.

Aphria Shareholders, through their respective CDS participants, who utilize CDSX to accept the Offer through a Book-based Transfer of their holding into the Depositary and Information Agent’s account with CDS shall be deemed to have completed and submitted a Letter of Transmittal and to be bound by the terms thereof and therefore such instructions received by the Depositary and Information Agent are considered as a valid tender in accordance with the terms of the Offer.

 

11


Aphria Shareholders may also accept the Offer by following the procedures for book-entry transfer established by The Depository Trust Company (“DTC”) through the ATOP system, provided that a book-entry confirmation, together with an Agent’s Message (as described below) in respect thereof or a properly completed and executed Letter of Transmittal (including signature guarantee, if required) and all other required documents, are received by the Depositary and Information Agent at its office in Toronto, Ontario specified in the Letter of Transmittal at or prior to the Expiry Time. The Depositary and Information Agent has established an account at DTC for the purpose of the Offer. Any financial institution that is a participant in DTC may cause DTC to make a book-entry transfer of an Aphria Shareholder’s Aphria Shares by their intermediary into the Depositary and Information Agent’s account in accordance with DTC’s procedures for such transfer. However, although delivery of Aphria Shares may be effected through book-entry transfer at DTC, either an Agent’s Message in respect thereof, or a Letter of Transmittal, properly completed and duly executed (including signature guarantee if required), and all other required documents, must, in any case, be received by the Depositary and Information Agent, at its office in Toronto, Ontario at or prior to the Expiry Time. Delivery of documents to DTC in accordance with its procedures does not constitute delivery to the Depositary and Information Agent. Such documents or Agent’s Message should be sent to the Depositary and Information Agent.

The term “Agent’s Message” means a message, transmitted by DTC to, and received by, the Depositary and Information Agent and forming part of a Book-Entry Confirmation, which states that DTC has received an express acknowledgement from the participant in DTC depositing the Aphria Shares which are the subject of such Book-Entry Confirmation that such participant has received and agrees to be bound by the terms of the Letter of Transmittal as if executed by such participant or intermediary and that the Offeror may enforce such agreement against such participant.

Intermediaries will likely establish tendering cut-off times that are prior to the Expiry Time. As a result, Non-registered Aphria Shareholders who wish to tender their Aphria Shares to the Offer and whose Aphria Shares are held through an intermediary should promptly and carefully follow the instructions provided to them by their investment advisor, broker, bank, trust company or other intermediary.

Aphria Shareholders who cannot comply on a timely basis with these procedures for Book-based Transfer prior to the Expiry Time may utilize the procedure for guaranteed delivery described in this Section 3.

CDS and DTC will be issuing instructions to their participants as to the method of depositing such Aphria Shares under the terms of the Offer. Participants of CDS or DTC may also contact the Depositary and Information Agent with respect to the deposit of their Aphria Shares under the Offer.

In addition, Aphria Shares may be deposited in compliance with the procedures set forth below for guaranteed delivery not later than the Expiry Time.

Procedure for Guaranteed Delivery

If an Aphria Shareholder wishes to deposit Aphria Shares pursuant to the Offer and the certificate(s) or DRS Statement(s) representing the Aphria Shares are not immediately available or the Aphria Shareholder is not able to deliver the certificate(s) or DRS Statement(s) and all other required documents to the Depositary and Information Agent at or prior to the Expiry Time, those Aphria Shares may nevertheless be deposited under the Offer provided that all of the following conditions are met:

 

  (a)

the deposit is made by or through an Eligible Institution;

 

  (b)

a Notice of Guaranteed Delivery (printed on green paper) in the form accompanying this Offer to Purchase and Circular or a facsimile thereof, properly completed and duly executed, including a guarantee by an Eligible Institution in the form specified in the Notice of Guaranteed Delivery, is received by the Depositary and Information Agent at its office in Toronto, Ontario as set out in the Notice of Guaranteed Delivery, at or prior to the Expiry Time; and

 

12


  (c)

the certificate(s) or DRS Statement(s) representing deposited Aphria Shares, in proper form for transfer, together with a Letter of Transmittal in the form accompanying this Offer to Purchase and Circular or a manually executed facsimile thereof, properly completed and duly executed, with any required signature guarantees and all other documents required by the Letter of Transmittal, are received by the Depositary and Information Agent at its office in Toronto, Ontario as set out in the Notice of Guaranteed Delivery prior to 5:00 p.m. (Toronto time) on the second trading day on the CSE after the Expiry Time.

Aphria Shareholders through their respective CDS or DTC participants, who utilize CDS or DTC through a book-entry transfer (see “Procedures for Book-based Transfer” above), may also have the option of tendering the Notice of Guaranteed Delivery through CDSX or ATOP Online Letter of Guarantee (“LOG”) option (the “LOG option”). Participants tendering through LOG options in CDSX or ATOP are deemed to have completed the Notice of Guaranteed Delivery and such instructions are considered valid with the terms of the Offer.

If the securities are not available in the CDS or DTC participant’s account, by the second trading day on the CSE after the Expiry Time or as specified on the LOG option, the CDS or DTC participant may be liable for failure of delivery for the value of the full tender or parts thereof.

THE NOTICE OF GUARANTEED DELIVERY MUST BE DELIVERED BY LOG OPTION, HAND OR COURIER OR TRANSMITTED BY FACSIMILE OR MAILED TO THE DEPOSITARY AND INFORMATION AGENT AT ITS OFFICE SPECIFIED IN THE NOTICE OF GUARANTEED DELIVERY AT OR PRIOR TO THE EXPIRY TIME AND MUST INCLUDE A GUARANTEE BY AN ELIGIBLE INSTITUTION IN THE FORM SET OUT IN THE NOTICE OF GUARANTEED DELIVERY. DELIVERY OF THE NOTICE OF GUARANTEED DELIVERY AND THE LETTER OF TRANSMITTAL AND ACCOMPANYING CERTIFICATE(S) OR DRS STATEMENT(S) REPRESENTING APHRIA SHARES AND ALL OTHER REQUIRED DOCUMENTS TO AN ADDRESS OR TRANSMISSION BY FACSIMILE TO A FACSIMILE NUMBER OTHER THAN THOSE SPECIFIED IN THE NOTICE OF GUARANTEED DELIVERY DOES NOT CONSTITUTE DELIVERY FOR PURPOSES OF SATISFYING A GUARANTEED DELIVERY.

General

In all cases, payment for Aphria Shares deposited and taken up by the Offeror will be made only after timely receipt by the Depositary and Information Agent of the certificate(s) or DRS Statement(s) representing the Aphria Shares or Book-based Transfer of the Aphria Shares, a Letter of Transmittal or a facsimile thereof, properly completed and duly executed, covering those Aphria Shares with the signatures guaranteed, if required, in accordance with the instructions set out in the Letter of Transmittal and any other required documents.

The method of delivery of certificate(s) or DRS Statement(s) representing Aphria Shares, the Letter of Transmittal and all other required documents is at the option and risk of the person depositing same. The Offeror recommends that all such documents be delivered by hand to the Depositary and Information Agent and a receipt obtained or, if mailed, that registered mail, with return receipt requested, be used and that proper insurance be obtained.

All questions as to the validity, form, eligibility (including timely receipt) and acceptance of any Aphria Shares deposited pursuant to the Offer will be determined by the Offeror in its sole discretion. Depositing Aphria Shareholders agree that such determination shall be final and binding. The Offeror reserves the absolute right to reject any and all deposits which it determines not to be in proper form or which it may be unlawful to accept under the Laws of any jurisdiction. The Offeror reserves the absolute right to waive any defects or irregularities in the deposit of any Aphria Shares. There shall be no duty or obligation on the part of the Offeror or the Depositary and Information Agent or any other person to give notice of any defects or irregularities in any deposit and no liability shall be incurred by any of them for failure to give any such notice. The Offeror’s interpretation of the terms and conditions of this Offer to Purchase, the Circular, the Letter of Transmittal and the Notice of Guaranteed Delivery will be final and binding.

The Offeror also reserves the right to permit the Offer to be accepted in a manner other than that set out above.

 

13


Under no circumstance will interest accrue or any amount be paid by the Offeror or the Depositary and Information Agent by reason of any delay in making payments for Aphria Shares to any person on account of Aphria Shares accepted for payment under the Offer.

Dividends and Distributions

Subject to the terms and conditions of the Offer by accepting the Offer pursuant to the procedures set forth above, an Aphria Shareholder deposits, sells, assigns and transfers to the Offeror all right, title and interest in and to the Aphria Shares covered by the Letter of Transmittal delivered to the Depositary and Information Agent (the “Deposited Securities”) and in and to all rights and benefits arising from such Deposited Securities, including any and all dividends, distributions, payments, securities, property or other interests which may be declared, paid, accrued, issued, distributed, made or transferred on or in respect of the Deposited Securities or any of them on and after the date of the Offer, other than any cash dividend, distribution or payment in respect of which a reduction in the price of the Offer is made pursuant to Section 10 of this Offer to Purchase, “Changes in Capitalization, Dividends and Distributions”, but including any dividends, distributions or payments on such dividends, distributions, payments, securities, property or other interests (collectively, “Distributions”).

If, notwithstanding such assignment, any Distributions are received by or made payable to or to the order of an Aphria Shareholder, then: (a) the Offeror will be entitled to all rights and privileges as the owner of any such Distribution and such Distribution shall be received and held by such Aphria Shareholder for the account of the Offeror and shall be promptly remitted and transferred by the Aphria Shareholder to the Depositary and Information Agent for the account of the Offeror, accompanied by appropriate documentation of transfer (in form and substance satisfactory to the Offeror); or (b) in its sole discretion, the Offeror may, in lieu of such remittance or transfer, reduce the amount of the consideration payable to such Aphria Shareholder under the Offer by deducting from the number of GGB Shares otherwise issuable by the Offeror to the Aphria Shareholder pursuant to the Offer a number of GGB Shares equal in value to the amount or value of such Distribution, as determined by the Offeror in its sole discretion.

The declaration or payment of any such Distribution or the distribution or issuance of any such securities, rights or other interests with respect to the Aphria Shares, may have tax consequences not discussed in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations” or Section 19 of the Circular, “Certain United States Federal Income Tax Considerations”. Aphria Shareholders should consult their own tax advisors in respect of any such Distribution.

Power of Attorney

An executed Letter of Transmittal (or in the case of Aphria Shares deposited by Book-based Transfer by the making of a Book-based Transfer) irrevocably appoints, effective on and after the date that the Offeror takes up and pays for the Deposited Securities covered by the Letter of Transmittal or Book-based Transfer (which securities upon being taken up and paid for are, together with any Distributions thereon, hereinafter referred to as the “Purchased Securities”), certain officers of the Offeror and any other person designated by the Offeror in writing (each an “Appointee”) as the true and lawful agents, attorneys and attorneys-in-fact and proxies, with full power of substitution, of the depositing Aphria Shareholder. The Letter of Transmittal or the making of a Book-based Transfer irrevocably authorizes all Appointees, effective on and after the date the Offeror takes up and pays for such Deposited Securities, in the name and on behalf of such Aphria Shareholder: (a) to register or record the transfer and/or cancellation of such Purchased Securities (to the extent consisting of securities) on the appropriate register maintained by or on behalf of Aphria; (b) for so long as the Purchased Securities are registered or recorded in the name of such Aphria Shareholder, to exercise any and all rights of such Aphria Shareholder, including, without limitation, in connection with any meeting or meetings (whether annual, special or otherwise or any adjournment thereof) of holders of relevant securities of Aphria, to vote any or all Purchased Securities, to execute, deliver or revoke any and all instruments of proxy, authorizations or consents in form and on terms satisfactory to the Offeror in respect of any or all Purchased Securities, revoke any such instruments, authorization or consent and to designate in such instrument, authorization or consent any person or persons as the proxy of such Aphria Shareholder in respect of the Purchased Securities for all purposes including, without limitation, in connection with any meeting or meetings (whether annual, special or otherwise or any adjournment thereof) of holders of relevant securities of

 

14


Aphria; (c) to execute, endorse and negotiate, for and in the name of and on behalf of such Aphria Shareholder, any and all cheques or other instruments representing any Distribution payable to or to the order of, or endorsed in favour of, such Aphria Shareholder; and (d) to exercise any other rights of an Aphria Shareholder of Purchased Securities.

An Aphria Shareholder accepting the Offer under the terms of the Letter of Transmittal revokes any and all other authority, whether as agent, attorney-in-fact, attorney, proxy or otherwise, previously conferred or agreed to be conferred by the Aphria Shareholder at any time with respect to the Deposited Securities or any Distributions. The Aphria Shareholder accepting the Offer agrees that no subsequent authority, whether as agent, attorney-in-fact, attorney, proxy or otherwise will be granted with respect to the Deposited Securities or any Distributions by or on behalf of the depositing Aphria Shareholder, unless the Deposited Securities are not taken up and paid for under the Offer. An Aphria Shareholder accepting the Offer also agrees not to vote any of the Purchased Securities at any meeting (whether annual, special or otherwise or any adjournment thereof) of holders of relevant securities of Aphria and not to exercise any of the other rights or privileges attached to the Purchased Securities, and agrees to execute and deliver to the Offeror any and all instruments of proxy, authorizations or consents in respect of all or any of the Purchased Securities, and to appoint in any such instruments of proxy, authorizations or consents, the person or persons specified by the Offeror as the proxy of the holder of the Purchased Securities. Upon such appointment, all prior proxies and other authorizations (including, without limitation, all appointments of any agent, attorney or attorney-in-fact) or consents given by the holder of such Purchased Securities with respect thereto will be revoked and no subsequent proxies or other authorizations or consents may be given by such person with respect thereto.

Further Assurances

An Aphria Shareholder accepting the Offer (including an Aphria Shareholder accepting the Offer by making a Book-based Transfer) covenants under the terms of the Letter of Transmittal to execute, upon request of the Offeror, any additional documents, transfers and other assurances as may be necessary or desirable to complete the sale, assignment and transfer of the Purchased Securities to the Offeror and acknowledges that all authority therein conferred or agreed to be conferred may be exercised during any subsequent legal incapacity of such Aphria Shareholder and shall, to the extent permitted by law, survive the death or incapacity, bankruptcy or insolvency of the Aphria Shareholder, and all obligations of the Aphria Shareholder therein shall be binding upon the heirs, personal representatives, successors and assigns of such Aphria Shareholder.

Depositing Aphria Shareholders’ Representations and Warranties

The acceptance of the Offer pursuant to the procedures set forth above constitutes an agreement between a depositing Aphria Shareholder and the Offeror in accordance with the terms and conditions of the Offer. This agreement includes a representation and warranty by the depositing Aphria Shareholder that (a) the person signing the Letter of Transmittal or on whose behalf a Book-based Transfer is made has full power and authority to deposit, sell, assign and transfer the Deposited Securities and any Distributions being deposited to the Offer; (b) the Deposited Securities and Distributions have not been sold, assigned or transferred, nor has any agreement been entered into to sell, assign or transfer any of the Deposited Securities and Distributions, to any other person; (c) the deposit of the Deposited Securities and Distributions complies with applicable Laws; (d) when the Deposited Securities and Distributions are taken up and paid for by the Offeror, the Offeror will acquire good title thereof, free and clear of all liens, restrictions, charges, encumbrances, claims and rights of others; and (e) the Aphria Shareholder is not acting for the account or benefit of a person from any jurisdiction in which the acceptance of the Offer would not be in compliance with the Laws of such jurisdiction and is not in, or delivering the Letter of Transmittal, from, such a jurisdiction.

 

4.

Conditions of the Offer

Notwithstanding any other provision of the Offer, subject to applicable Law, and in addition to (and not in limitation of) the Offeror’s right to vary or change the Offer pursuant to Section 5 of this Offer to Purchase, “Acceleration, Extension and Variation of the Offer”, the Offeror will not take up, purchase or pay for any Aphria Shares unless, at the Expiry Time, being 5:00 p.m. (Toronto time) on May 9, 2019, or such earlier or later time following the expiry

 

15


of the minimum statutory deposit period during which Aphria Shares may be deposited under the Offer, excluding the Mandatory Extension Period or any extension after the Mandatory Extension Period, there shall have been validly deposited under the Offer and not validly withdrawn that number of Aphria Shares that constitutes more than 50% of the outstanding Aphria Shares, excluding any Aphria Shares beneficially owned, or over which control or direction is exercised, by the Offeror or by any person acting jointly or in concert with the Offeror. In the event the Statutory Minimum Condition is not satisfied, the Offeror will have the right to withdraw or terminate the Offer or to extend the period of time during which the Offer is open for acceptance. The Statutory Minimum Condition cannot be waived by the Offeror.

In addition, notwithstanding any other provision of the Offer and in addition to (and not in limitation of) the Offeror’s right to vary or change the Offer pursuant to Section 5 of this Offer to Purchase, “Acceleration, Extension and Variation of the Offer”, the Offeror shall have the right to terminate the Offer and withdraw the Offer and/or not take up, purchase or pay for any Aphria Shares tendered to the Offer, unless all of the following conditions are satisfied or waived by the Offeror prior to the Expiry Time or such earlier or later time during which Aphria Shares may be deposited under the Offer, excluding the Mandatory Extension Period or any extension after the Mandatory Extension Period:

 

  (a)

the Minimum Tender Condition;

 

  (b)

the Regulatory Approvals and all other third party approvals, licenses, permits, authorizations and clearances considered necessary by the Offeror in relation to the Offer, including those considered necessary or reasonably appropriate by the Offeror to operate the business of the combined company following completion of the Offer in compliance with applicable Laws, having been obtained on terms satisfactory to the Offeror in its sole judgment;

 

  (c)

there is not any prohibition at Law existing against the Offeror making the Offer or taking up and paying for Aphria Shares under the Offer or completing any Compulsory Acquisition or Subsequent Acquisition Transaction in respect of any Aphria Shares not acquired under the Offer;

 

  (d)

the Registration Statement having become effective under the U.S. Securities Act and not becoming subject to a stop order or a proceeding seeking a stop order;

 

  (e)

Aphria having not adopted or implemented a shareholder rights plan or taken any other action that provides rights to the Aphria Shareholders to purchase any securities of Aphria as a result of the Offer or any Compulsory Acquisition or Subsequent Acquisition Transaction;

 

  (f)

except to the extent publicly disclosed in a filing with a Securities Regulatory Authority prior to December 28, 2018, neither Aphria nor its subsidiaries having declared, paid, or made, or resolved to recommend, declare, pay or make, any bonus issue, dividend or other distribution (whether in cash or otherwise) on any of its securities (including any Aphria Shares);

 

  (g)

except to the extent publicly disclosed in a filing with a Securities Regulatory Authority prior to December 28, 2018, neither Aphria nor its subsidiaries having purchased, redeemed or repaid, or proposed to purchase, redeem or repay any of its securities (including any Aphria Shares);

 

  (h)

except to the extent publicly disclosed in a filing with a Securities Regulatory Authority prior to December 28, 2018, neither Aphria nor its subsidiaries having amended, or proposed or authorized any amendment to, their respective articles or bylaws (or other similar organizational documents);

 

  (i)

neither Aphria, nor any of its affiliates or subsidiaries, nor any other person having taken any action or authorized, recommended, proposed or announced an intention to take any action: (i) that has had or could have the effect (as determined by the Offeror in its sole judgment) of impairing the ability of the Offeror to acquire Aphria Shares, diminishing in any respect the expected economic value to the Offeror of the acquisition of Aphria, or making the acquisition of Aphria more costly in any material respect to the Offeror, or (ii) that would (as determined by the Offeror

 

16


  in its sole judgement) make it inadvisable for the Offeror to proceed with the Offer, to take up and pay for Aphria Shares deposited under the Offer or to complete any Compulsory Acquisition or Subsequent Acquisition Transaction in respect of any Aphria Shares not acquired under the Offer, including, without limitation, any of the following:

 

  (i)

any sale, disposition or other dealing (or entry into any agreement with respect thereto) relating to any of the assets of Aphria or any of its affiliates, other than any sales of Aphria’s products in the ordinary course of business consistent with past practice;

 

  (ii)

the incurrence or issuance of any debt obligations, debt securities or other liabilities, any amendment to any debt or other similar agreements, or taking any steps in the furtherance of the foregoing (including entry into any agreements relating to the foregoing), other than incurrence of immaterial debt obligations in the ordinary course of business consistent with past practice;

 

  (iii)

the making of or committing to make any capital expenditure by Aphria or any of its affiliates, other than immaterial capital expenditures incurred in the ordinary course of business consistent with past practice;

 

  (iv)

any change to the capitalization of Aphria or any of its subsidiaries, including, without limitation, any issuance, authorization, or proposal regarding the issuance or sale of any Aphria Shares, other securities of Aphria or Convertible Securities (other than in connection with the exercise of any Convertible Securities outstanding as of December 28, 2018, in accordance with their terms existing as of December 28, 2018);

 

  (v)

any acquisition from a third party of material assets or securities by Aphria or any of its affiliates, any reorganization of Aphria and its affiliates, or any takeover bid (other than the Offer), merger, amalgamation, statutory arrangement, recapitalization, business combination, share exchange, joint venture or similar transaction involving Aphria or any of its subsidiaries or affiliates;

 

  (vi)

undertaking any transaction that would prevent the Offeror obtaining, if otherwise available, a “bump” in the tax cost of the property of Aphria in accordance with paragraph 88(1)(d) of the Tax Act, or any transaction that would reduce the amount of the “bump”, if otherwise available;

 

  (vii)

the waiving, releasing, granting, transferring or amending of any rights or liabilities under (A) any existing material contract, including those with respect to any joint ventures or material properties or projects, or (B) any other material license, lease, permit, authorization, concession, contract, agreement, instrument or other document; or

 

  (viii)

except as may be required by Law, adopting any new, or materially amending, varying, modifying any existing, bonus, profit sharing, incentive, salary or other compensation, equity based award, pension, retirement, deferred compensation, severance, change in control, employment or other employee benefit plan, agreement, trust, fund or arrangement for the benefit or welfare of any officer, director or employee, or similar rights or other benefits, whether or not as a result of or in connection with the transactions contemplated by the Offer and the Circular;

 

  (j)

the Offeror having determined, in its sole judgment, that no act, action, suit or proceeding shall have been taken, commenced or threatened before or by, and no judgement or order shall have been issued by, any Governmental Entity or by any elected or appointed public official or private person (including any individual, corporation, firm, group or other entity) in Canada or elsewhere, whether or not having the force of Law, and no Law shall have been proposed, enacted, promulgated or applied, in any case:

 

17


  (i)

challenging the validity of the Offer or the Offeror’s ability to maintain or complete the Offer or operate the business of the combined company as the Offeror deems appropriate, in its sole discretion, after completion of the Offer;

 

  (ii)

to cease trade, enjoin, prohibit or impose material and adverse limitations, damages or conditions on the purchase by or the sale to the Offeror of the Aphria Shares or the right of the Offeror to own or exercise full rights of ownership of the Aphria Shares following completion of the Offer;

 

  (iii)

which, if the Offer (or any Compulsory Acquisition or Subsequent Acquisition Transaction with respect to the Aphria Shares) were consummated, could, individually or in the aggregate, give rise to a material adverse change in respect of Aphria or the Offeror; or

 

  (iv)

seeking to prohibit or limit the ownership or operation by the Offeror of any material portion of the business or assets of Aphria or any of its subsidiaries or to compel the Offeror or any of its subsidiaries to dispose of or hold separate any material portion of the business or assets of Aphria or any of its subsidiaries following completion of the Offer (or any Compulsory Acquisition or Subsequent Acquisition Transaction);

 

  (k)

the Offeror having determined, in its sole judgment, that there does not exist and there shall not have occurred or been publicly disclosed since December 28, 2018 any event, effect, change, circumstance, development or occurrence that, individually or in the aggregate, constitutes a material adverse change or could give rise to a material adverse change in respect of Aphria;

 

  (l)

each of Aphria and its subsidiaries having carried on their respective businesses in the ordinary course of business consistent with past practice at all times on or after December 28, 2018 and prior to the Expiry Time;

 

  (m)

the Offeror not becoming aware of any untrue statement of a material fact, or an omission to state a material fact that is required to be stated or that is necessary to make a statement made not misleading in the light of the circumstances in which it was made and at the date it was made (after giving effect to all subsequent filings prior to the date of the Offer in relation to all matters covered in earlier filings), in any document filed by or on behalf of Aphria or any of its subsidiaries with any of the Securities Regulatory Authorities or a similar securities regulatory authority in the United States or elsewhere or with any other Governmental Entity anywhere in the world;

 

  (n)

the Offeror having determined, in its sole judgment, that:

 

  (i)

no material license, right, permit, franchise, indenture, instrument or agreement to which Aphria or any of its subsidiaries or affiliates is a party or by which Aphria or any of its subsidiaries or affiliates is bound would, if the Offer, a Compulsory Acquisition or a Subsequent Acquisition Transaction were consummated, be impaired or adversely affected (including as a result of any vesting or acceleration of an obligation or the performance an obligation becoming due prior to a stated date (in each case, either immediately, or after notice or passage of time or both)), if such impairment or effect, individually or in the aggregate, could constitute a material adverse change or otherwise materially reduce the value to the Offeror of the Aphria Shares it proposes to acquire under the Offer; and

 

  (ii)

no covenant, term or condition (individually or in the aggregate) exists in any material license, right, permit, franchise, indenture, instrument or agreement to which Aphria or any of its subsidiaries or affiliates is a party or by which Aphria or any of its subsidiaries

 

18


  or affiliates is bound which, if the Offer, a Compulsory Acquisition or a Subsequent Acquisition Transaction were consummated could:

 

  (A)

result in the creation or acceleration of any material liability or obligation of the Offeror, Aphria or any of their respective affiliates;

 

  (B)

result in any default under or cause the suspension or termination of, or give rise to any right of any person to suspend or terminate, any such license, right, permit, franchise, indenture, instrument or agreement;

 

  (C)

limit or otherwise adversely affect any material right or benefit of Aphria or any of its affiliates under, or reduce the value, in any material respect, of any such license, right, permit, franchise, indenture, instrument or agreement; or

 

  (D)

adversely impact the ability of the Offeror to acquire, redeem or defease any Convertible Securities that have not been converted into, exchanged for or otherwise become Aphria Shares at the Expiry Time or, to complete the Offer, a Compulsory Acquisition or a Subsequent Acquisition Transaction;

 

  (o)

the Offeror having obtained the approval of its shareholders to issue the GGB Shares pursuant to the Offer in accordance with the policies of the CSE;

 

  (p)

neither the Offeror nor any of its affiliates having entered into a definitive agreement or an agreement in principle with Aphria providing for a plan of arrangement, amalgamation, merger, acquisition of assets or other business combination with Aphria or for the acquisition of securities of Aphria or for the commencement of a new offer for the Aphria Shares, pursuant to which the Offeror has determined that this Offer will be terminated;

 

  (q)

the Offeror having determined, in its sole judgment, that none of the following events or circumstances have occurred: (i) any general suspension of trading in, or limitation on prices for, securities on any national securities exchange or in the over-the-counter market in Canada or the United States, (ii) a declaration of a banking moratorium or any suspension of payments in respect of banks by federal, provincial, territorial, or state authorities in Canada or the United States, (iii) any limitation (whether or not mandatory) by any Governmental Entity on, or other event which, in the sole judgment of the Offeror, might materially affect, the extension of credit by banks or other lending institutions, (iv) commencement of a war, armed hostilities or the occurrence of any other national or international calamity directly or indirectly involving Canada or the United States or any attack on, or outbreak or act of terrorism involving, Canada or the United States, (v) a material change in the Canadian dollar, the United States dollar or any other currency exchange rates or a suspension of, or limitation on, the markets therefor, (vi) any change in the general political, capital market, economic or financial conditions in Canada, the United States or other jurisdictions in which Aphria or its affiliates do business (including any major stock exchange indices in Canada or the United States), that could, in the sole judgment of the Offeror, have a material and negative effect on the business, properties, assets, liabilities, capitalization, shareholders’ equity, condition (financial or otherwise), operations, licenses, franchises, results of operations or prospects of Aphria or any of its affiliates or the trading in, or value of, Aphria Shares, (vii) in the case of any of the foregoing existing at the time of commencement of the Offer, a material acceleration or worsening thereof, or (viii) any decline in the S&P/TSX Composite Index, the Dow Jones Industrial Average, the S&P Index of 500 Industrial Companies, or any other stock market index on which either Aphria or the Offeror are listed or traded at the time of the commencement of the Offer by a material amount measured from the close of business at the time of commencement of the Offer;

 

  (r)

the Offeror having been provided with, or been given access to, in a timely manner, all non-public information relating to Aphria and its subsidiaries and affiliates, including access to management

 

19


  of Aphria, as has been, or may on or after the date of the Offer, be given, provided or made available by Aphria or any of its subsidiaries or affiliates to any other potential acquiror which has commenced a takeover bid or entered into a definitive agreement with Aphria or any of its subsidiaries or affiliates relating to any merger, amalgamation, statutory arrangement, recapitalization, business combination, share exchange, joint venture or similar transaction involving Aphria or any of its subsidiaries or affiliates on terms and conditions which are more favourable to Aphria Shareholders from a financial point of view than the terms and conditions of the Offer, on substantially the same terms and conditions as have been imposed on or as may be imposed on any such other potential acquiror, provided that no such term or condition shall be imposed on the Offeror that would be inconsistent with, or would render the Offeror unable to make, the Offer or a revised offer, to take up and pay for any Aphria Shares deposited under the Offer or a revised offer or to complete the acquisition of the Aphria Shares pursuant to the terms of the Offer or to effect a Compulsory Acquisition or a Subsequent Acquisition Transaction; and

 

  (s)

the Offeror not becoming aware of any information corroborating in any material respect the statements contained in the Report, including, but not limited to, statements relating to Aphria’s business practices, operations, and financial condition, which would lead the Offeror to reasonably conclude that the statements made in the Report are materially accurate.

The foregoing conditions (other than the Statutory Minimum Condition) are for the exclusive benefit of the Offeror and may be asserted by the Offeror, at any time, regardless of the circumstances giving rise to any such condition. Except as otherwise provided below in this Section 4, the Offeror may, in the Offeror’s sole discretion, waive any of the foregoing conditions (other than the Statutory Minimum Condition), in whole or in part, at any time and from time to time, both before and after the Expiry Time, without prejudice to any other rights the Offeror may have. The failure by the Offeror at any time to exercise any of the foregoing rights will not be deemed to be a waiver of any such right and each such right shall be considered an ongoing right which may be asserted at any time and from time to time. If any of the conditions described above became incapable of being satisfied, whether through actions by Aphria or otherwise, the Offeror will have the right to terminate and withdraw at the Offer in its sole discretion.

Any waiver of a condition or the withdrawal of the Offer shall be effective upon written notice, or other communication confirmed in writing by the Offeror to that effect, having been given to the Depositary and Information Agent at its principal office in Toronto, Ontario. The Offeror, forthwith after giving any such notice, will make a public announcement of such waiver or withdrawal and provide a copy of such notice to the CSE and the Securities Regulatory Authorities, as applicable, and to the extent required by applicable Law, cause the Depositary and Information Agent as soon as is practicable thereafter to notify the Aphria Shareholders in the manner set out in Section 11 of this Offer to Purchase, “Notices and Delivery”. If the Offer is withdrawn, the Offeror will not be obligated to take up, accept for payment or pay for any Aphria Shares tendered to the Offer.

Any determination by the Offeror concerning any event or other matter described in the conditions set out above in this Section 4 will be final and binding on all parties.

The consummation of the Financing on the terms set forth herein is not a condition to the Offer, and there is no other financing condition to the Offer. See Section 29 of the Circular, “Risk Factors”, in particular “Risk Factors – The Offeror may not be able to complete the Financing on the terms currently contemplated, or at all”.

 

5.

Acceleration, Extension and Variation of the Offer

The Offer is open for acceptance from the date of the Offer until the Expiry Time (as accelerated or extended by the Offeror, if applicable), subject to variation in the Offeror’s sole discretion or as set out below, unless the Offer is withdrawn by the Offeror. In addition, if the Offeror takes up any Aphria Shares under the Offer, the Offer will be extended and remain open for the deposit of Aphria Shares for not less than ten (10) days from the date on which the Aphria Shares are first taken up (the “Mandatory Extension Period”).

Subject to the limitations set out below, the Offeror reserves the right, in its sole discretion, at any time and from time to time while the Offer is open for acceptance (or at any other time if permitted by applicable Law) to vary the

 

20


terms of the Offer (including, without limitation, by extending or shortening the period during which Aphria Shares may be deposited under the Offer where permitted or required by applicable Law).

Under applicable Law, the Offeror is required to allow Aphria Shares to be deposited under the Offer for a minimum statutory deposit period of at least 105 days. The minimum statutory deposit period under the Offer may be shortened in the following circumstances, subject to a minimum deposit period of at least 35 days or 20 business days, whichever is longer, from the date of the Offer: (i) if Aphria issues a deposit period news release in respect of either the Offer or another offeror’s takeover bid that stipulates a deposit period of less than 105 days, the Offeror may vary the terms of the Offer to shorten the initial deposit period to at least the number of days from the date of the Offer as stated in the deposit period news release; (ii) if Aphria issues a news release announcing that it has agreed to enter into, or determined to effect, an Alternative Transaction; or (iii) if permitted by an order of the applicable Securities Regulatory Authorities. In these circumstances, the Offeror may vary the terms of the Offer to shorten the initial deposit period to at least 35 days from the date of the Offer. In any case, the Offeror intends to vary the terms of the Offer by shortening the minimum statutory deposit period to the shortest possible period permitted by applicable Law. In connection with the Offer, the Offeror obtained an exemption from the AMF to permit the Offeror to file French versions of the documents incorporated by reference into the Circular as soon as possible following the filing of the Circular but by no later than January 28, 2019. The Offeror expects to file French versions of all documents incorporated by reference within such time period.

If, before the Expiry Time or after the Expiry Time but before the expiry of all rights of withdrawal with respect to the Offer, the terms of the Offer are varied (other than a variation in the terms of the Offer consisting solely of the waiver of a condition of the Offer and any extension of the Offer, other than an extension in respect of the Mandatory Extension Period, resulting from the waiver), including any reduction of the period during which securities may be deposited under the Offer pursuant to applicable Law, or any extension of the period during which securities may be deposited under the Offer pursuant to applicable Canadian Securities Laws, and whether or not such variation results from the exercise of any right contained in the Offer, the Offeror will promptly (a) issue and file a news release to the extent and in the manner required by applicable Law, and (b) send a notice of variation in the manner set out in Section 11 of this Offer to Purchase, “Notices and Delivery”, to every person to whom the Offer is required to be sent under applicable Law and whose Aphria Shares were not taken up before the date of the variation. If there is a variation, the period during which Aphria Shares may be deposited under the Offer must not expire before ten (10) days after the date of the notice of variation. If the Offeror is required to send a notice of variation before the expiry of the initial deposit period, the initial deposit period for the Offer must not expire before ten (10) days after the date of the notice of variation, unless otherwise permitted by applicable Law, and the Offeror must not take up Aphria Shares deposited under the Offer before ten (10) days after the date of the notice of variation. In addition, the Offeror will file a copy of such notice, as required by the Securities Regulatory Authorities and the SEC, and will provide a copy of such notice in the manner required by applicable Law as soon as practicable thereafter to Aphria and the CSE. Any notice of variation of the Offer will be deemed to have been given and to be effective on the day on which it is delivered or otherwise communicated to the Depositary and Information Agent at its principal office in Toronto, Ontario. If the variation consists solely of a waiver of a condition, the Offeror will promptly issue and file a news release announcing the waiver.

In addition, notwithstanding the foregoing, if the Offeror makes a material change in the terms of the Offer or the information concerning the Offer, or if it waives a material condition of the Offer, the Offeror will disseminate additional offer materials and extend the Offer to the extent required by Rule 14e–1 under the U.S. Exchange Act. Under the U.S. Exchange Act, the minimum period during which an offer must remain open following material changes in the terms of such offer, other than a change in consideration offered, percentage of securities sought or inclusion of or changes to a dealer’s soliciting fee, will depend upon the facts and circumstances, including the materiality, of the changes. Generally, in the SEC’s view, an offer should remain open for a minimum of five (5) U.S. business days from the date the material change is first published, sent or given to shareholders and, if material changes are made with respect to information that approaches the significance of the consideration offered, percentage of securities sought or a dealer’s soliciting fee, a minimum of ten (10) business days in the U.S. is required to allow for adequate dissemination of information to shareholders and investor response.

 

21


Accordingly, if, prior to the Expiry Time, the Offeror decreases the number of Aphria Shares being sought, increases or decreases the consideration offered pursuant to the Offer or increases or decreases a dealer’s soliciting fee, and if the Offer is scheduled to expire at any time earlier than the tenth U.S. business day from the date that notice of such increase or decrease is first published, sent or given to Aphria Shareholders, the Offer will be extended at least until the expiration of such tenth business day in the United States. The requirement to extend the Offer will not apply to the extent that the number of business days in the United States remaining between the occurrence of the change and the then scheduled Expiry Time equals or exceeds the minimum extension period that would be required because of such amendment.

If, before the Expiry Time or after the Expiry Time but before the expiry of all rights of withdrawal with respect to the Offer, a change occurs in the information contained in the Offer or the Circular or any notice of change or notice of variation that, in either case, would reasonably be expected to affect the decision of an Aphria Shareholder to accept or reject the Offer (other than a change that is not within the control of the Offeror or of an affiliate of the Offeror unless it is a change in a material fact relating to the GGB Shares), the Offeror will promptly (a) issue and file a news release setting out information concerning the change to the extent and in the manner required by applicable Law, and (b) send a notice of the change in the manner set out in Section 11 of this Offer to Purchase, “Notices and Delivery”, to every person to whom the Offer was required to be sent and whose Aphria Shares were not taken up before the date of the change. If the Offeror is required to send a notice of change before the expiry of the initial deposit period, the initial deposit period for the Offer must not expire before ten (10) days after the date of the notice of change, and the Offeror must not take up Aphria Shares deposited under the Offer before ten (10) days after the date of the notice of change. In addition, the Offeror will file a copy of such notice as required by the Securities Regulatory Authorities and the SEC and will provide a copy of such notice in the manner required by applicable Law as soon as practicable thereafter to Aphria and the CSE. Any notice of change in information will be deemed to have been given and to be effective on the day on which it is delivered or otherwise communicated to the Depositary and Information Agent at its principal office in Toronto, Ontario.

During any extension or in the event of any variation of the Offer or change in information, all Aphria Shares previously deposited and not taken up or withdrawn will remain subject to the Offer and may be taken up by the Offeror in accordance with the terms hereof. An extension of the Expiry Time, a variation of the Offer or a change in information does not, unless otherwise expressly stated, constitute a waiver by the Offeror of its rights under Section 4 of this Offer to Purchase, “Conditions of the Offer”. Notwithstanding the foregoing, but subject to applicable Law, the Offeror may not make a variation in the terms of the Offer, other than a variation to extend the time during which Aphria Shares may be deposited under the Offer or a variation to increase the consideration for the Aphria Shares, after the Offeror becomes obligated to take up Aphria Shares deposited under the Offer. If the consideration being offered for the Aphria Shares under the Offer is increased, the increased consideration will be paid to all depositing Aphria Shareholders whose Aphria Shares are taken up under the Offer, whether or not such Aphria Shares were taken up before the increase.

Mandatory Extension Period

If the conditions of the Offer are satisfied or waived by the Offeror and the Offeror takes up the Aphria Shares deposited under the Offer, the Offeror will issue and file a news release announcing those matters and extend the period during which Aphria Shares may be deposited and tendered to the Offer for a period of not less than ten (10) calendar days after the date of such announcement. The Offeror will not amend the Offer to shorten or eliminate such Mandatory Extension Period.

A Mandatory Extension Period will constitute an extension of the Offer under Canadian Securities Laws. The Offeror’s news release (with respect to the Mandatory Extension Period), will include disclosure that the Minimum Tender Condition has been satisfied, the number of Aphria Shares validly deposited and not validly withdrawn as of the expiry of the initial deposit period and the period during which the Offer will be open for acceptance; such news release will be provided to the Depositary and Information Agent and the Offeror will cause the Depositary and Information Agent to provide, as soon as practicable thereafter, a copy of such news release in the manner set out in Section 11 of this Offer to Purchase, “Notices and Delivery” to all Aphria Shareholders that have not had their Aphria Shares taken up pursuant to the Offer at the date of the extension. The same form and amount of consideration will be paid to Aphria Shareholders depositing Aphria Shares during the Mandatory Extension Period as was paid prior to the commencement of such period. The Offeror will permit the withdrawal of Aphria Shares deposited during the Mandatory Extension Period, at any time prior to the expiration of such Mandatory Extension Period; provided, however, that this right of withdrawal will not apply in respect of Aphria Shares which have been taken up and paid for by the Offeror. Subject to the foregoing sentence, the expiration time with respect to a subsequent Offer shall be 5:00 p.m. (Toronto time) on the last day of the Mandatory Extension Period, or any extension thereof.

 

22


6.

Withdrawal of Deposited Aphria Shares

Unless otherwise required or permitted by applicable Law, any Aphria Shares deposited in acceptance of the Offer may be withdrawn by or on behalf of the depositing Aphria Shareholder:

 

  (a)

at any time before such Aphria Shares have been taken up by the Offeror pursuant to the Offer;

 

  (b)

at any time before the expiration of ten (10) calendar days from the date upon which either:

 

  (i)

a notice of change relating to a change which has occurred in the information contained in the Offer, which change is one that would reasonably be expected to affect the decision of an Aphria Shareholder to accept or reject the Offer (other than a change that is not within the control of the Offeror or of an affiliate of the Offeror) in the event that such change occurs before the Expiry Time or after the Expiry Time but before the expiry of all rights of withdrawal in respect of the Offer; or

 

  (ii)

a notice of variation concerning a variation in the terms of the Offer (other than a variation consisting solely of an increase in the consideration offered for the Aphria Shares pursuant to the Offer where the time for deposit is not extended for a period greater than ten (10) calendar days or a variation consisting solely of a waiver of a condition of the Offer),

is mailed, delivered or otherwise properly communicated, but only if such deposited Aphria Shares have not been taken up by the Offeror at the time of the notice and subject to abridgement of that period pursuant to such order or orders as may be granted by Canadian courts or Securities Regulatory Authorities, or

 

  (c)

at any time after three (3) business days from the date the Offeror takes up the Aphria Shares, if such Aphria Shares have not been paid for by the Offeror.

Withdrawals of Aphria Shares deposited under the Offer must be effected by notice of withdrawal made by or on behalf of the depositing Aphria Shareholder and must be actually received by the Depositary and Information Agent at the place of deposit of the applicable Aphria Shares within the time limits indicated above. Notice of withdrawal must (i) be an originally signed notice (no faxes or emails) that provides the Depositary and Information Agent with a written or printed copy, (ii) be signed by the person who signed the Letter of Transmittal accompanying, or the Notice of Guaranteed Delivery in respect of, the Aphria Shares which are to be withdrawn, and (iii) specify such person’s name, the number of Aphria Shares to be withdrawn, the name of the registered holder and the certificate number shown on each certificate representing the Aphria Shares to be withdrawn. Any signature on the notice of withdrawal must be guaranteed by an Eligible Institution in the same manner in a Letter of Transmittal (as described in the instructions set out in such letter), except in the case of Aphria Shares deposited for the account of an Eligible Institution. None of the Offeror, the Depositary and Information Agent or any other person will be under any duty to give notice of any defect or irregularity in any notice of withdrawal or shall incur any liability for failure to give such notice. The withdrawal, if duly completed, will take effect upon actual receipt by the Depositary and Information Agent of the properly completed and executed written or facsimile notice of withdrawal.

Alternatively, if Aphria Shares have been deposited pursuant to the procedures for Book-based Transfer, any notice of withdrawal must specify the name and number of the account at CDS or DTC to be credited with the withdrawn Aphria Shares and otherwise comply with the procedures of CDS or DTC.

 

23


A withdrawal of Aphria Shares tendered to the Offer can only be accomplished in accordance with the procedures described above in this Section 6. The withdrawal, if duly completed, will take effect only upon actual receipt by the Depositary and Information Agent of the properly completed and executed written or facsimile notice of withdrawal.

Investment advisors, brokers, banks, trust companies or other intermediaries may set deadlines for the withdrawal of Aphria Shares deposited under the Offer that are earlier than those noted above in this Section 6. Aphria Shareholders should contact their intermediary for assistance.

All questions as to form and validity (including time of receipt) of notices of withdrawal will be determined by the Offeror in its sole discretion and such determination will be final and binding on all parties. There will be no duty or obligation on the Offeror, the Depositary and Information Agent or any other person to give notice of any defect or irregularity in any notice of withdrawal, and no liability will be incurred by any of them for failure to give such notice.

Withdrawals may not be rescinded and any Aphria Shares withdrawn will thereafter be deemed not validly deposited for purposes of the Offer. However, withdrawn Aphria Shares may be redeposited at any time at or prior to the Expiry Time by again following one of the procedures described in Section 3 of this Offer to Purchase, “Manner of Acceptance”.

If the Offeror is delayed in taking up or paying for Aphria Shares or is unable to take up or pay for Aphria Shares for any reason, then, without prejudice to the Offeror’s other rights, Aphria Shares may not be withdrawn except to the extent that depositing Aphria Shareholders are entitled to withdrawal rights as set forth in this Section 6 or pursuant to applicable Laws.

In addition to the foregoing rights of withdrawal, holders of Aphria Shares in certain provinces of Canada are entitled to statutory rights of rescission or to damages, or both, in certain circumstances. See Section 20 of the Circular, “Offerees’ Statutory Rights”. All questions as to the validity (including timely receipt) and form of notices of withdrawal will be determined by the Offeror in its sole discretion, and such determination will be final and binding.

 

7.

Payment for Deposited Aphria Shares

If, at the expiry of the initial deposit period, the Statutory Minimum Condition has been satisfied and all of the other conditions described in Section 4 of this Offer to Purchase, “Conditions of the Offer” have been satisfied or waived by the Offeror, the Offeror will immediately take up the Aphria Shares validly deposited under the Offer and not validly withdrawn. The Offeror will pay for Aphria Shares taken up under the Offer as soon as possible but in any event not later than three (3) business days after taking up such Aphria Shares. In accordance with applicable Law, if the Offeror is obligated to take up such Aphria Shares, the Offeror will extend the period during which Aphria Shares may be deposited under the Offer for the Mandatory Extension Period and may extend the deposit period after expiration of the mandatory 10-day extension period (“Optional Extension Periods”).

The Offeror will take up and pay for Aphria Shares deposited under the Offer during the Mandatory Extension Period and any Optional Extension Period not later than ten (10) days after such deposit. In each case, share certificates, DRS Statements or other evidence of the GGB Shares issued as consideration for the Aphria Shares will be provided as soon as practicable thereafter.

Subject to applicable Law, the Offeror expressly reserves the right in its sole discretion to delay or otherwise refrain from taking up and paying for any Aphria Shares or to terminate the Offer and not take up or pay for any Aphria Shares if any condition specified in Section 4 of this Offer to Purchase, “Conditions of the Offer”, is not satisfied or waived by the Offeror, by giving written notice thereof, or other communication confirmed in writing, to the Depositary and Information Agent at its principal office in Toronto, Ontario. The Offeror also expressly reserves the right, in its sole discretion and notwithstanding any other condition of the Offer, to delay taking up and paying for Aphria Shares in order to comply, in whole or in part, with any applicable Law. The Offeror will not, however, take

 

24


up and pay for any Aphria Shares deposited under the Offer unless it simultaneously takes up and pays for all Aphria Shares then validly deposited under the Offer and not validly withdrawn.

The Offeror will be deemed to have taken up Aphria Shares validly deposited under the Offer and not validly withdrawn if, as and when the Offeror gives written notice or other communication confirmed in writing to the Depositary and Information Agent to that effect.

The Offeror will pay for Aphria Shares validly deposited under the Offer and not validly withdrawn by causing Offeror’s transfer agent to issue a sufficient number of GGB Shares for transmittal to depositing Aphria Shareholders.

Settlement will be made by the Depositary and Information Agent causing the issuance of GGB Shares in the amount to which the person depositing Aphria Shares is entitled. Unless otherwise directed in the Letter of Transmittal, the GGB Shares will be issued in the name of the registered holder of the deposited Aphria Shares. Unless the person depositing Aphria Shares instructs the Depositary and Information Agent to hold the GGB Shares for pick-up by checking the appropriate box in the Letter of Transmittal, the GGB Shares will be forwarded by first class mail, postage prepaid, to such person at the address specified in the Letter of Transmittal, or if no address is specified, the GGB Shares issuable in respect of registered Aphria Shares will be forwarded to the address of the holder as shown on the share register maintained by or on behalf of Aphria. GGB Shares mailed in accordance with this paragraph will be deemed to have been delivered at the time of mailing.

Depositing Aphria Shareholders will not be obligated to pay any brokerage fee or commission if they accept the Offer by depositing their Aphria Shares directly with the Depositary and Information Agent. If an Aphria Shareholder owns Aphria Shares through a broker, dealer or other nominee and such nominee deposits the Aphria Shares on the Aphria Shareholder’s behalf, the nominee may charge a fee for performing this service.

No GGB Shares will be delivered to any person who is, or appears to the Offeror or the Depositary and Information Agent to be, a resident of any other foreign country unless such GGB Shares may be lawfully delivered to persons resident in such foreign country without further action by the Offeror. The Offeror may, in its sole discretion, take such action as it may deem necessary to make the Offer in any such jurisdiction and extend the Offer to Aphria Shareholders in any such jurisdiction. If the GGB Shares cannot be lawfully delivered to a person resident in a foreign country without further action, such GGB Shares will be delivered by the Depositary and Information Agent to a broker retained for the purpose of effecting a sale on behalf of such person.

 

8.

Return of Deposited Aphria Shares

If any deposited Aphria Shares are not taken up and paid for pursuant to the terms and conditions of the Offer for any reason, certificate(s) or DRS Statement(s) for Aphria Shares that are not purchased will be returned at the Offeror’s expense as soon as practicable after the Expiry Time or withdrawal and early termination of the Offer, as the case may be, by sending certificate(s) or DRS Statement(s) representing Aphria Shares not purchased back to the respective Aphria Shareholders or in the case of Aphria Shares deposited by Book-based Transfer such Aphria Shares will be credited to the depositing Aphria Shareholder’s account maintained with CDS or DTC, as applicable. Certificate(s) or DRS Statement(s) (and other relevant documents) will be forwarded by first class mail in the name of, and to the address specified by, the Aphria Shareholder in the Letter of Transmittal or, if such name or address is not so specified, in such name and to such address as shown on the share register maintained by or on behalf of Aphria. Under no circumstances will interest accrue or be paid by GGB or the Depositary and Information Agent to persons depositing Aphria Shares which are not purchased by the Offeror and returned to the applicable Aphria Shareholder.

 

9.

Mail Service Interruption

Notwithstanding the provisions of this Offer to Purchase, the Circular, the Letter of Transmittal or the Notice of Guaranteed Delivery, cheques, share certificate(s) or DRS Statement(s) and any other relevant documents will not be mailed if the Offeror determines that delivery thereof by mail may be delayed. persons entitled to cheques, share certificate(s) or DRS Statement(s) and any other relevant documents which are not mailed for the foregoing reason

 

25


may take delivery thereof at the office of the Depositary and Information Agent to which the deposited certificate(s) or DRS Statement(s) for Aphria Shares were delivered until such time as the Offeror has determined that delivery by mail will longer be delayed. The Offeror will provide notice of any determination not to mail under this Section 9 as soon as reasonably practicable after the making of such determination and in accordance with Section 11 of this Offer to Purchase, “Notices and Delivery”. Notwithstanding Section 7 of this Offer to Purchase, “Payment for Deposited Aphria Shares”, cheques, certificate(s) or DRS Statement(s) or other relevant documents not mailed for the foregoing reason will be conclusively deemed to have been mailed on the first day upon which they are available for delivery to the depositing Aphria Shareholder at the appropriate office of the Depositary and Information Agent.

 

10.

Changes in Capitalization, Dividends and Distributions

If, on or after the date of the Offer, Aphria should divide, combine, reclassify, consolidate, convert or otherwise change any of the Aphria Shares or its capitalization, issue any Aphria Shares, or issue, grant or sell any securities convertible into Aphria Shares, or should disclose that it has taken or intends to take any such action, then the Offeror may, in its sole discretion and without prejudice to its rights under Section 4 of this Offer to Purchase, “Conditions of the Offer”, make such adjustments as it deems appropriate to the terms of the Offer (including, without limitation, the type of securities offered to be purchased and the consideration payable therefore) to reflect such division, combination, reclassification, consolidation, conversion, issuance, grant, sale or other change.

Aphria Shares acquired pursuant to the Offer shall be transferred by the Aphria Shareholder and acquired by the Offeror free and clear of all liens, charges, encumbrances, claims and equities and together with all rights and benefits arising therefrom, including, without limitation and except as provided below, the right to any and all dividends, distributions, payments, securities, property or other interests which may be declared, paid, accrued, issued, distributed, made or transferred on or in respect of the Deposited Securities or any of them on and after the date of the Offer, other than as provided in this Section 10 of this Offer to Purchase.

If, on or after the date of the Offer, Aphria should declare, make or pay any other Distribution in respect of Aphria Shares which is payable or distributable to the Aphria Shareholders on a record date which is prior to the date of transfer of such Aphria Shares into the name of the Offeror or its nominees or transferees and the share register maintained by or on behalf of Aphria, then without prejudice to the Offeror’s rights under Section 4 of this Offer to Purchase, “Conditions of the Offer”, the whole of any such Distribution will be received and held by the depositing Aphria Shareholder for the account of and for the benefit of the Offeror and will be promptly remitted and transferred by the depositing Aphria Shareholder to the Depositary and Information Agent for the account of the Offeror, accompanied by appropriate documentation of transfer. Pending such remittance, the Offeror will be entitled to all rights and privileges as owner of any such Distribution and may withhold the entire purchase price payable by the Offeror pursuant to the Offer or deduct from the purchase price payable by the Offeror pursuant to the Offer the amount or value of the Distribution, as determined by the Offeror in its sole discretion. The declaration or payment of any such dividend or distribution may have tax consequences not discussed under Section 18, “Certain Canadian Federal Income Tax Considerations” and Section 19, “Certain United States Federal Income Tax Considerations” of the Circular.

 

11.

Notices and Delivery

Without limiting any other lawful means of giving notice and unless otherwise specified by applicable Laws, any notice to be given by the Offeror to the Depositary and Information Agent pursuant to the Offer will be deemed to have been properly given to Registered Aphria Shareholders if it is in writing and is mailed by first class mail, postage prepaid, to such Registered Aphria Shareholders at their respective addresses as shown on the share register maintained by or on behalf of Aphria in respect of the Aphria Shares and, unless otherwise specified by applicable Laws, will be deemed to have been received on the first business day following the date of mailing. For this purpose, “business day” means any day other than a Saturday, Sunday or statutory holiday in the jurisdiction to which the notice is mailed. These provisions apply notwithstanding any accidental omission to give notice to any one or more Aphria Shareholders and notwithstanding any interruption of mail services in Canada or the United States following mailing. Except as otherwise required or permitted by Law, in the event of any interruption of or delay in mail services, following mailing, the Offeror intends to make reasonable efforts to disseminate the notice by other means,

 

26


such as publication. Except as otherwise required or permitted by Law, if post offices in Canada are not open for the deposit of mail, any notice which the Offeror or the Depositary and Information Agent may give or cause to be given under the Offer will be deemed to have been properly given and to have been received by Aphria Shareholders if it is published once in (i) the National Edition of The Globe and Mail or The National Post, and (ii) Le Devoir, or (iii) it is given to the Canada NewsWire Service for dissemination through its facilities.

This Offer to Purchase, the Circular, the Letter of Transmittal and the Notice of Guaranteed Delivery will be mailed to registered holders of Aphria Shares (and to registered holders of securities exercisable for or convertible into Aphria Shares) or made in such other manner as is permitted by applicable regulatory authorities and the Offeror will use its reasonable efforts to furnish such documents to brokers, banks and similar persons whose names, or the names of those nominees, appear on the securityholder lists or, if applicable, who are listed as participants in a clearing agency’s security position listing, for subsequent transmission to beneficial owners of Aphria Shares (and securities exercisable for or convertible into Aphria Shares) when such list or listing is received.

Whenever the Offer calls for documents to be delivered to the Depositary and Information Agent, such documents will not be considered delivered unless and until they have been physically received at one of the addresses listed for the Depositary and Information Agent in the Letter of Transmittal or the Notice of Guaranteed Delivery, as applicable. Whenever the Offer calls for documents to be delivered to a particular office of the Depositary and Information Agent, such documents will not be considered delivered unless and until they have been physically received at that particular office at the address listed in the Letter of Transmittal or the Notice of Guaranteed Delivery, as applicable.

 

12.

Market Purchases and Sales of Aphria Shares

The Offeror reserves the right to acquire or to cause an affiliate to acquire beneficial ownership of Aphria Shares by making purchases through the facilities of the TSX at any time, and from time to time, prior to the Expiry Time subject to and in accordance with applicable Law. In no event, however, will the Offeror (or its affiliates) make any such purchases of Aphria Shares until the third business day following the date of the Offer and the Offeror shall comply with the following requirements under Section 2.2(3) of NI 62-104, in the event it decides to make any such purchases:

 

  (a)

the aggregate number of Aphria Shares beneficially acquired shall not exceed 5% of the outstanding Aphria Shares as of the date of the Offer, calculated in accordance with applicable Law;

 

  (b)

the purchases shall be made in the normal course through the facilities of the TSX (and not the NYSE), and no purchases will in any case be pre-arranged with a buyer that resides in the U.S.;

 

  (c)

the Offeror shall issue and file a news release containing the information required under Canadian Securities Laws immediately after the close of business of the TSX on each day on which Aphria Shares have been purchased; and

 

  (d)

the broker involved in such trades shall provide only customary broker services and receive only customary fees or commissions, and no solicitation for the sale or purchase of Aphria Shares shall be made by the Offeror or its agents (other than under the Offer) or the seller or its agents.

Purchases pursuant to Section 2.2(3) of NI 62-104 will not be counted in any determination as to whether the Statutory Minimum Condition has been fulfilled, but will be counted in determining whether the Minimum Tender Condition has been satisfied.

Although the Offeror has no present intention to sell Aphria Shares taken up under the Offer, the Offeror reserves the right to make or enter into agreements, commitments or understandings prior to the Expiry Time to sell any of such Aphria Shares after the Expiry Time, subject to applicable Law and to compliance with Section 2.7(2) of NI 62-104. Solely for the purposes of this Section 12, the “Offeror” includes any person acting jointly or in concert with the Offeror.

 

27


13.

Other Terms of the Offer

The Offeror reserves the right to transfer or assign, in whole or from time to time in part, to one or more persons designated by or affiliated with the Offeror, the right to purchase all or any portion of the Aphria Shares deposited pursuant to the Offer, but any such transfer will not relieve the Offeror of its obligations under the Offer or prejudice the rights of persons depositing Aphria Shares to receive payment for Aphria Shares validly deposited and accepted for payment pursuant to the Offer.

No investment advisor, broker, or other person has been authorized to give any information or to make any representation or warranty on behalf of the Offeror or any of its affiliates in connection with the Offer other than as contained in the Offer, and, if any such information, representation or warranty is given or made, it must not be relied upon as having been authorized. No investment advisor, broker, or other person shall be deemed to be the agent of the Offeror or any of its affiliates, or the Depositary and Information Agent for the purposes of the Offer.

The Offer and all contracts resulting from the acceptance of the Offer shall be governed by and construed in accordance with the Laws of the Province of Ontario and the federal Laws of Canada applicable therein. Each party to any agreement resulting from the acceptance of the Offer unconditionally and irrevocably attorns to the non-exclusive jurisdiction of the courts of the Province of Ontario.

The Offer is not being made to (nor will deposits of Aphria Shares be accepted from or on behalf of) Aphria Shareholders residing in any jurisdiction in which the making of the Offer or the acceptance thereof would not be in compliance with the Laws of such jurisdiction. The Offeror may, in its sole discretion, take such action as it may deem necessary to make the Offer in any such jurisdiction and extend the Offer to Aphria Shareholders in any such jurisdiction.

The Offeror in its sole discretion shall be entitled to make a final and binding determination of all questions relating to this Offer to Purchase, the Circular, the Letter of Transmittal and the Notice of Guaranteed Delivery, the interpretation of the foregoing, the validity of any acceptance of the Offer, and the validity of any withdrawal of Aphria Shares.

The provisions of the Circular, the Letter of Transmittal and the Notice of Guaranteed Delivery accompanying this Offer to Purchase, including the instructions contained therein, form part of the terms and conditions of the Offer.

This Offer to Purchase and the accompanying Circular together constitute the takeover bid circular required under Canadian Securities Laws with respect to the Offer. Aphria Shareholders are urged to refer to the accompanying Circular for additional information relating to the Offer.

 

DATED: January 22, 2019
GREEN GROWTH BRANDS INC.
(signed) “Peter Horvath”
Chief Executive Officer

 

28


TAKE-OVER BID CIRCULAR

This Circular is furnished in connection with the Offer to Purchase dated January 22, 2019 by the Offeror to purchase any and all of the issued and outstanding Aphria Shares (including any Aphria Shares which may become outstanding after the date of the Offer upon the exercise of any Convertible Securities, on the basis of 1.5714 GGB Shares for one (1) Aphria Share. The terms and provisions of the Offer to Purchase, the Letter of Transmittal and the Notice of Guaranteed Delivery are incorporated into and form part of this Circular. Aphria Shareholders should refer to the Offer to Purchase for details of its terms and conditions, including details as to payment and withdrawal rights. Defined terms used in the Offer to Purchase are used in this Circular with the same meaning unless the context otherwise requires.

Except as otherwise indicated, the information concerning Aphria contained in the Offer to Purchase and this Circular has been taken from or based upon publicly available documents and records on file with the Securities Regulatory Authorities, and other public sources. Although the Offeror has no knowledge that would indicate that any statements contained herein relating to Aphria taken from or based upon such documents and records are untrue or incomplete, none of the Offeror and its affiliates or any of its respective officers or directors assumes any responsibility for the accuracy or completeness of the information relating to Aphria taken from or based upon such documents and records, or for any failure by Aphria to disclose events which may have occurred or may affect the significance or accuracy of any such information but which are unknown to the Offeror.

 

1.

The Offeror

GGB is in the business of cultivating, processing and retailing cannabis and CBD-infused consumer products. The Offeror’s business strategy is to continue to develop a premium cannabinoid brand offering, focusing on certain states in the United States where the sale of cannabis and CBD is not inconsistent with applicable Law.

The Offeror intends to expand its retail and wholesale cannabis businesses as well as its CBD consumer products business through a combination of strategic partnerships, merger and acquisition activity, and organic license capture. The Offeror’s objectives are to establish top-tier retail and medical cannabis locations, offer CBD-infused personal care products at retail via an expansive network of kiosks and brick-and-mortar locations, and distribute such CBD products at wholesale to larger national retailers.

The Offeror’s registered office is 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario M5L 1B9. The GGB Shares trade on the CSE under the symbol “GGB” and on the OTCQB under the symbol “GGBXF”.

 

2.

Certain Information Concerning Securities of the Offeror

GGB’s authorized share capital consists of an unlimited number of GGB Shares and an unlimited number of proportionate voting shares (the “PV Shares”). At January 21, 2019, there were 183,020,397 GGB Shares and 38,194 PV Shares issued and outstanding.

As of January 21, 2019, the dilutive securities are summarized as follows:

 

Security Type

   GGB
Shares
Issuable (#)
     Exercise price
(average) ($)
     Cash proceeds
if exercised ($)
 

Warrants

     26,739,218        1.36        58,583,947  

Options

     475,000        1.73        820,325  

 

29


GGB Shares

The holders of the GGB Shares are entitled to vote at all meetings of holders of GGB Shares, other than at meetings of the holders of other share classes meeting separately as a class, and at all such meetings each such holder is entitled to one (1) vote for each GGB Share held. Subject to the rights and conditions of the holders of PV Shares, the holders of GGB Shares are entitled to receive dividends if, as and when declared by the board of directors of GGB. In the event of the liquidation, dissolution or winding up of GGB or other distribution of assets or property of GGB, the holders of the GGB Shares are, subject to the rights, privileges, restrictions and conditions of the holders of any other class of shares, equally entitled to receive all property and assets properly distributable to GGB’s shareholders. A holder of GGB Shares may at any time have the option to convert 500 GGB Shares for one (1) PV Share.

Proportionate Voting Shares

The holders of PV Shares are entitled to receive notice and vote at all meetings of GGB shareholders, other than at meetings of the holders of other share classes meeting separately as a class, and at all such meetings each such holder shall have 500 votes for each PV Share held. The holders of PV Shares are entitled to receive dividends if, as and when declared by the board of directors of GGB. All dividends which are declared at the discretion of the directors on the PV Share shall be declared and paid on the GGB Shares at the time outstanding, and vice versa, in the proportion hereinafter provided for. If, as and when dividends are declared by the directors, each PV Share is entitled to 500 times the amount paid or distributed per GGB Share. In the event of the liquidation, dissolution or winding up of GGB or other distribution of assets or property of GGB, the holders of PV Shares will be entitled to receive all property and assets properly distributable to GGB shareholders on the basis that each PV Share will be entitled to 500 times the amount distributed per GGB Share, but otherwise there is no preference or distinction among or between PV Shares and GGB Shares. A holder of PV Shares may at any time have the option to convert one (1) PV Share held into 500 GGB Shares.

GGB shall use commercially reasonable efforts to maintain its status as a “foreign private issuer” (as determined in accordance with Rule 3b-4 under the U.S. Exchange Act. Accordingly, GGB shall not give effect to any voluntary conversion of PV Shares, and the PV Shares conversion rights will not apply, to the extent that after giving effect to all permitted issuance after such conversion of PV Shares, the aggregate number of GGB Shares and PV Shares (calculated on the basis that each GGB Share and PV Share is counted once, without regard to the number of votes carried by each share) held of record, directly or indirectly, by residents of the United States, as determined in accordance with Rules 3b-4 and 12g3-2(a) under the U.S. Exchange Act, would exceed 40% (the “40% Threshold”) of the aggregate number of GGB Shares and PV Shares (calculated on the same basis) issued and outstanding as calculated herein. The directors may by resolution increase the 40% Threshold to a number not to exceed 50%, and if any such resolution is adopted, all references to the 40% Threshold shall refer instead to the amended percentage threshold set by the directors in such resolution.

Consolidated Capitalization

The following table sets out information concerning the consolidated capitalization of the Offeror as of September 30, 2018, before and after giving effect to the issuance by the Offeror of the GGB Shares as consideration under the Offer and in connection with the Financing, the completion of which is conditional upon, among other things, the successful completion of the Offer. This table should be read in conjunction with: (a) audited consolidated financial statement of GGB for the year ended June 30, 2018 and the notes and the auditors’ report in respect thereof; (b) unaudited condensed interim consolidated financial statements of GGB for the three months ended September 30, 2018; (c) unaudited condensed interim consolidated financial statements of GGB for the three months ended August 31, 2018; and (d) pro forma condensed consolidated financial statements as of October 31, 2018 attached hereto as Annex A. See also Section 9 of this Circular, “Financing” and Section 29 of this Circular, “Risk Factors”.

 

30



Unaudited (expressed in thousands)
  

GGB
October 31,
2018
    

Aphria
August 31,
2018
    


Pro Forma
Adjustments
    GGB Pro
Forma
(assuming no
Financing)
    


Financing (1)
     GGB Pro
Forma
(assuming
Financing
completed)
 
     (USD$)      (CAD$)      (USD$)     (USD$)      (USD$)      (USD$)  

Statement of Financial Position

                

Current Assets

     66,154        418,181        (110,539     373,796        218,307        592,103  

Total Assets

     161,001        1,625,710        225,554       2,012,265        218,307        2,230,572  

Current Liabilities

     41,265        54,936        (11,319     84,882        —          84,882  

Total Liabilities

     41,265        165,273        1,641       208,179        —          208,179  

Shareholders’ Equity

     119,736        1,460,437        223,914       1,804,087        218,307        2,022,394  

 

(1) 

Represents net proceeds from the Financing.

Dividends

GGB has not paid any dividends on its shares since incorporation and does not anticipate paying any dividends on its shares or other securities in the foreseeable future.

Price Range and Trading Volumes of GGB Shares

The GGB Shares trade on the CSE under the symbol “GGB” and on the OTCQB under the symbol “GGBXF”. The following table sets forth the reported intraday high and low prices and monthly trading volumes of the GGB Shares on the CSE from November 13, 2018 (the first day of trading on the CSE following completion of the business combination between Xanthic Biopharma Inc. (“Xanthic”), Green Growth Brands Ltd. (“GGB Ltd.”), and a wholly owned subsidiary of GGB Ltd., on November 9, 2018 (the “Business Combination”), and the 4:1 share consolidation completed in conjunction therewith) until January 21, 2019:

 

Month

   High ($)      Low ($)      Volume Traded  

November 13-30 2018(2)

     4.25        2.30        10,039,707  

December 2018

     5.27        2.48        9,479,162  

January 2 – 21, 2019

     6.40        4.09        16,976,075  

On December 27, 2018, GGB announced that it had submitted the Proposal to Aphria. On December 24, 2018, the last trading day prior to such announcement, the closing price of GGB Shares on the CSE was $4.25.

On January 21, 2019, the last trading day prior to the date of this Offer to Purchase and Circular, the closing price of the GGB Shares on the CSE was $5.99.

The following table sets forth the reported intraday high and low prices and monthly trading volumes of the GGB Shares on the CSE (then being the common shares of Xanthic and trading on the CSE under the symbol “xTHC”) from April 19, 2018 (the first day of trading on the CSE) until July 13, 2018 (the date on which trading on the CSE was halted as result of the announcement of the Business Combination):

 

Month

   High ($)      Low ($)      Volume Traded  

April 19-30, 2018(1)

     0.57        0.250        3,226,869  

May 2018

     0.325        0.145        6,781,251  

June 2018

     0.30        0.18        10,220,140  

July 1-13, 2018(2)

     0.28        0.225        1,828,005  

 

31


Prior Sales

Prior sales for the 12-month period before the date of this Offer to Purchase and Circular, GGB issued the following GGB Shares and securities convertible into GGB Shares:

 

Date of Issuance(1)

  

Class of Securities
Issued

   Number of Securities
Issued or Issuable
   Issue, Exercise or
Conversion Price
 

January 16, 2018(2)

   GGB Shares    12,000,000(3)    $ 0.125  

February 28, 2018(4)

   Options    577,000 GGB Shares(5)    $ 0.50  

April 19, 2018(4)(6)

   GGB Shares    284,000(5)(7)    $ 2.00  

April 19, 2018(4)(6)

   Warrant    139,000 GGB Shares(5)(7)    $ 3.00  

April 19, 2018(4)

   Options    100,000 GGB Shares(5)    $ 2.40  

April 20, 2018(4)

   Options    125,000 GGB Shares(5)    $ 1.60  

May 28, 2018(4)

   Options    250,000 GGB Shares(5)    $ 0.64  

July 26, 2018(4)

   GGB Shares(8)    175,000(5)    $ 0.64  

September 18, 2018(4)

   GGB Shares(8)    50,000(5)    $ 0.50  

November 9, 2018(4)

   GGB Shares    14,099,582(9)    $ 2.00  

November 13, 2018(4)

   Options    150,000 GGB Shares    $ 3.05  

November 13, 2018(4)

   GGB Shares(8)    277,000    $ 0.50  

November 20, 2018(4)

   GGB Shares(10)    17,361    $ 1.80  

November 21, 2018(4)

   GGB Shares(8)    50,000    $ 0.50  

November 22, 2018(4)

   GGB Shares(10)    17,361    $ 1.80  

December 5, 2018(4)

   GGB Shares(10)    10,416    $ 1.80  

December 7, 2018(4)

   GGB Shares(10)    26,040    $ 1.80  

December 13, 2018(4)

   GGB Shares    426,992    $ 3.13  

December 14, 2018(4)

   Warrant    1 warrant exercisable for
7,609,746 GGB Shares
   $ 3.16  

December 21, 2018(4)

   GGB Shares(10)    34,722    $ 1.803  

December 28, 2018(11)

   GGB Shares(10)    3,204,860    $ 1.80  

December 31, 2018(11)

   GGB Shares(10)    31,000    $ 3.00  

January 3, 2019(11)

   GGB Shares(10)    25,000    $ 3.00  

January 8, 2019(11)

   GGB Shares(10)    48,609    $ 1.80  

January 9, 2019(11)

   GGB Shares(10)    34,722    $ 1.80  

January 10, 2019(11)

   GGB Shares(10)    17,361    $ 1.80  

January 11, 2019(11)

   GGB Shares(10)    123,263    $ 1.80  

January 15, 2019(11)

   GGB Shares(10)    69,444    $ 1.80  

January 17, 2019(11)

   GGB Shares(10)    434,027    $ 1.80  

 

(1) 

1,480,057 GGB Shares are issuable in connection with the Offeror’s proposed acquisition of Just Healthy LLC, the completion of which is subject to receipt of all necessary regulatory approvals.

(2) 

Issued by Aurquest Resources Inc., which changed its name to “Xanthic Biopharma Inc.” on February 22, 2018.

(3) 

Adjusted for the 8:1 share consolidation completed by Aurquest Resources Inc. on February 22, 2018 and the 4:1 share consolidation completed in conjunction with the Business Combination.

(4) 

Issued by Xanthic, which changed its name to “Green Growth Brands Inc.” on December 28, 2018.

(5) 

Adjusted for the 4:1 share consolidation completed in conjunction with the Business Combination.

(6) 

Units consisting of one GGB Share and one half warrant exercisable at a price of $0.75.

(7) 

Includes the issuance of 6,000 compensation options consisting of one GGB Share and one half warrant, with each whole warrant being exercisable at a price of $0.75 per GGB Share (adjusted for the 4:1 share consolidation completed in conjunction with the Business Combination).

(8) 

Issued pursuant to the exercise of options.

(9) 

Includes 12,228,960 GGB Shares issued pursuant to the exercise of warrants.

(10) 

Issued pursuant to the exercise of warrants.

(11) 

Issued by GGB.

 

3.

Documents Incorporated by Reference and Further Information

The following documents of GGB filed with the CSE are specifically incorporated by reference into, and except where herein otherwise provided, form an integral part of, the Offer to Purchase and this Circular:

 

32


  (a)

the annual information form of Xanthic dated November 26, 2018 in respect of the financial year ended June 30, 2018;

 

  (b)

the audited consolidated financial statements of Xanthic for the year ended June 30, 2018 and related notes together with the independent auditors report thereon, and the management’s discussion and analysis in connection therewith;

 

  (c)

the unaudited condensed interim consolidated financial statements of Xanthic for the three months ended September 30, 2018 and related notes, and the interim management’s discussion and analysis in connection therewith;

 

  (d)

the material change report of Xanthic dated July 17, 2018 in respect of the entering into of the arm’s length business combination agreement dated July 13, 2018 between Xanthic and Green GGB Ltd.;

 

  (e)

the material change report of Xanthic dated November 16, 2018 in respect of the completed business combination of Xanthic and GGB Ltd.;

 

  (f)

the material change report of Xanthic dated December 12, 2018 in respect of Xanthic’s entering into of a membership interest purchase agreement dated December 10, 2018 in connection with the purchase by Xanthic of all of the issued and outstanding membership interests of Just Healthy LLC;

 

  (g)

the material change report of Xanthic dated December 18, 2018 in respect of the entering into on December 12, 2018 by Xanthic of definitive agreements to acquire a cultivation facility operated by Wellness Orchards of Nevada LLC and Panorama WON LLC located in Pahrump, Nevada;

 

  (h)

the material change report of Xanthic dated December 18, 2018 in respect of Xanthic’s agreement to accept an irrevocable option (“Henderson Option”) to acquire all of the membership interests of Henderson Organic together with the right to all of Henderson Organic’s free cash flow until exercise of the Henderson Option;

 

  (i)

the business acquisition report of Xanthic dated September 24, 2018 in respect of the entering into of a binding letter agreement with management of Green Growth Brands Ltd. concerning

 

  (i)

an arm’s length business combination; and

 

  (ii)

the acquisition by GGB Nevada LLC of 100% of the outstanding membership interests of Nevada Organic Remedies LLC;

 

  (j)

the management information circular of Aurquest Resources Inc. dated as of January 11, 2018 in respect of the annual and special meeting of shareholders of Aurquest Resources Inc. held on February 16, 2018; and

 

  (k)

the management information circular of Xanthic dated as of October 12, 2018 in respect of the annual and special meeting of shareholders of Xanthic held on November 2, 2018.

Information has been incorporated by reference in the Offer to Purchase and this Circular from documents filed with certain securities commissions or similar regulatory authorities in certain provinces of Canada. Copies of these documents may be obtained on request without charge from the Corporate Secretary of GGB at 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario M5L 1B9 or may be obtained on SEDAR at www.sedar.com under the Offeror’s profile.

All material change reports (excluding confidential reports), financial statements (including any report of the auditor, where applicable), management’s discussion and analysis, annual information forms, information circulars and business acquisition reports filed by GGB with the securities commission or similar regulatory authority in

 

33


certain provinces of Canada after the date of this Circular and before the Expiry Time will also be deemed to be incorporated by reference into this Circular.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for the purposes of this Circular to the extent that a statement contained herein or in any other subsequently filed document that is also incorporated or is deemed to be incorporated by reference herein modifies or supersedes such statement. The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement will not be deemed an admission for any purpose that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this Circular.

Information contained in or otherwise accessed through GGB’s website, www.greengrowthbrands.com or any other website does not form part of this Circular. All such references to GGB’s website are inactive textual references only.

 

4.

Aphria Inc.

Aphria was incorporated under the Business Corporations Act (Alberta) on June 22, 2011 as Black Sparrow Capital Corp. (“Black Sparrow”), a capital pool company listed on the TSX Venture Exchange (the “TSXV”). 2427745 Ontario Inc. (“Subco”), a wholly-owned subsidiary of Black Sparrow, was incorporated on July 24, 2014 in order to effect a business combination with Pure Natures Wellness Inc. d.b.a Aphria (“Pure Natures”) whereby Black Sparrow would acquire all of the issued and outstanding shares of Pure Natures pursuant to a court-approved plan of arrangement. Pure Natures amalgamated with Subco under the OBCA to form a wholly owned subsidiary of Black Sparrow, and together with Black Sparrow, was continued in Ontario on December 1, 2014 as “Aphria Inc.” under the OBCA. On March 22, 2017, Aphria graduated from the TSXV to the TSX. The Aphria Shares trade on the TSX and on the NYSE under the symbol “APHA”.

Aphria is a global cannabis company with its head office located at 245 Talbot Street West, Suite 103, Leamington, Ontario and its registered office is located at 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario.

Aphria is licensed to produce and sell medical cannabis in Canada under the Cannabis Act (Canada) (the “Cannabis Act”). Aphria obtained its license to produce and sell medical cannabis on November 26, 2014, followed by its license to sell cannabis extracts on August 18, 2016. Both of these licenses were issued pursuant to regulations made under the Controlled Drugs and Substances Act (Canada) and have transitioned to licenses under the Cannabis Act.

Cannabis Industry and Other Relationships

While certain overlapping relationships between GGB and Aphria, and their respective insiders, may exist due, in large part, to the nature of the nascent cannabis industry in Canada and the United States, such overlapping relationships, to the extent they exist, have played no role in GGB’s decision-making process relating to the Offer. See Section 6 of this Circular, “Background to the Offer”.

As previously disclosed by GGB, GA Opportunities Corp. (“GA”) is the beneficial owner of approximately 13% of the outstanding GGB Shares, which were acquired pursuant to the terms of a subscription agreement entered into between GGB and GA on October 12, 2018. Under the terms of the subscription agreement and the Business Combination, GGB has issued to GA an aggregate of 27.5 million GGB Shares (collectively, the “GA Common Shares”) for cash consideration at a price equal to $2.00 per share.

In connection therewith, and pursuant to the terms of an amended and restated nomination rights agreement between among others, GGB and GA, dated November 9, 2018 (the “Nomination Rights Agreement”), GA has the right to nominate one director of GGB so long as it beneficially owns, directly or indirectly, and in the aggregate, more than 5% of the issued and outstanding GGB Shares (on a non-diluted basis). To date, none of the parties to the Nomination Rights Agreement has

 

34


exercised any rights under the agreement. In addition, GGB understands that GA has granted Aphria an option to acquire, from GA, the GA Common Shares. Based on Aphria’s publicly available information, GGB believes the option is subject to the following conditions: (1) cannabis becoming legalized federally in the United States; and one or more of the following conditions having been satisfied: (2) the TSX has provided its approval for the purchase of the U.S. cannabis assets; (3) the TSX revises its rules such that it no longer has a prohibition against its listed companies having an interest in US assets which are involved in the cannabis business; (4) the Aphria Shares are voluntarily or involuntarily delisted from the TSX; and/or (5) Aphria is acquired by another entity, provided that the Aphria Shares will be delisted from the TSX upon the change of control. GGB further understands that the option may only be exercised on at least 60 days’ notice and is restricted such that Aphria may only exercise the option to the extent that such exercise does not result in it receiving equal to or greater than an aggregate of five percent of the issued and outstanding securities of GGB (on a non-diluted basis). As a result of such arrangements, and in order to address certain U.S. regulatory matters, GGB Ltd. sought and obtained a letter from GA. pursuant to which GA acknowledged and agreed that it would not, without the prior written consent of GGB Ltd., cause or permit any amendment to the terms of such option.

Between the time of incorporation of GGB Ltd. and the completion of the Business Combination, Green Acre Capital Fund I LP or its affiliate subscribed for securities of GGB Ltd., which securities would currently represent approximately 3% of the issued and outstanding GGB Shares on a partially diluted basis. Based on information contained on the Green Acre Capital (“Green Acre”) website, Green Acre is a private investment fund dedicated to the Canadian medical and recreational cannabis industry and Aphria’s director Shawn Dym is listed, and GGB understands that Aphria’s director and departing CEO, Vic Neufeld was listed, as a member of the advisory board to Green Acre. While GGB does not have direct knowledge, it understands from Aphria’s public disclosure, that Aphria invested $2,000,000 in Green Acre Capital Fund I LP and, according to Green Acre’s website, Green Acre Capital Fund I LP raised approximately $25,000,000, made its first investments in 2017 and was fully deployed by 2018. GGB has no direct knowledge of the current holdings in GGB of Green Acre Capital Fund I LP or its affiliates.

 

5.

Certain Information Concerning Securities of Aphria

Authorized and Outstanding Share Capital

Based on publicly available information, the authorized share capital of Aphria consists of an unlimited number of common shares, of which 250,233,273 were issued and outstanding as of January 10, 2019, the effective date of Aphria’s management’s discussion and analysis for the three (3) and six (6) months ended November 30, 2018, as filed on SEDAR on January 11, 2019.

The holders of the Aphria Shares are entitled to one (1) vote per share at all meetings of the shareholders. The holders of Aphria Shares are also entitled to dividends, if and when declared by the board of directors and the distribution of the residual assets in the event of a liquidation, dissolution or winding up of Aphria.

For further information regarding Aphria, refer to the Aphria’s filings with applicable Securities Regulatory Authorities in Canada, which may be obtained through SEDAR at www.sedar.com under the Offeror’s profile.

Price Range and Trading Volume of Aphria Shares

The Aphria Shares trade on the TSX and the NYSE under the symbol “APHA”. The following table sets forth the reported intraday high and low prices and monthly trading volumes of the Aphria Shares on the TSX and the NYSE for the six-month period preceding the date of this Offer to Purchase and Circular, according to published sources:

TSX

 

Month

   High ($)      Low ($)      Volume Traded  

July 2018

     12.22        10.11        58,388,603  

August 2018

     16.98        8.62        182,204,472  

September 2018

     22.00        15.76        251,553,947  

October 2018

     20.96        12.37        281,296,060  

 

35


November 2018

     17.60        10.15        126,085,247  

December 2018

     9.12        4.76        322,181,036  

January 2-21, 2019

     10.06        7.44        109,027,678  

NYSE

 

Month

   High (USD$)      Low (USD$)      Volume Traded  

November 2-30, 2018(1)

     13.45        7.63        8,562,024  

December 2018

     6.91        3.75        35,401,954  

January 2-18, 2019(2)

     7.20        5.45        10,338,518  

 

(1) 

Aphria Shares commenced trading on the NYSE on November 2, 2018.

(2) 

Aphria Shares did not trade on the NYSE on January 21, 2019, being a federal holiday in the United States (Martin Luther King Jr. Day).

The intention to make the Offer was announced by press release on December 27, 2018. The closing prices of the Aphria Shares on the TSX on December 24, 2018 and on the NYSE on December 26, 2018, the last respective trading days prior to the public disclosure of GGB’s intention to pursue a combination with Aphria, were $7.56 and USD$5.82, respectively.

Dividend Policy of Aphria

According to publicly available information, Aphria has no current intention to declare dividends on the Aphria Shares in the foreseeable future.

 

6.

Background to the Offer

The cannabis and CBD industries are undergoing rapid development and change in Canada, in the United States and globally. As part of the implementation of its business strategy, management of the Offeror, along with its board of directors and their advisors, are constantly evaluating opportunities for enhancing shareholder value, including investment, acquisition, consolidation and divestiture opportunities. As part of this continuing process, GGB (and historically GGB Ltd.) has from time to time considered possible business opportunities, including joint ventures and investments, with other companies in the cannabis and CBD industries, including Aphria. In light of the foregoing, GGB was familiar with Aphria and certain of its management and board members.1

During the week of December 3, 2018, management became aware of the Report and its unfavourable presentation of certain information about Aphria. Following the issuance of the Report, the price of the Aphria Shares on the TSX and NYSE fell by approximately 40%. At a weekly strategic discussion, members of management of the Offeror discussed whether the issuance of the Report and the subsequent decrease in market value of Aphria shares presented a potential opportunity for the Offeror, and whether they should be considering the possibility of a strategic transaction involving Aphria. GGB’s management was of the view that this could represent a potential opportunity and, accordingly, determined to undertake a preliminary assessment of Aphria to investigate whether a strategic transaction would be appropriate at that time.

On December 5, 2018, certain members of GGB’s management team held a call with Canaccord Genuity Corp. (“Canaccord”), to discuss the details of the Report, the recent decline in the price of the Aphria Shares, and the Aphria business generally. During the call, the parties discussed potential benefits and drawbacks of a transaction with Aphria, as well as general transaction considerations.

Over the following days, management of GGB, together with their advisors, continued to assess the viability of the proposed combination of GGB and Aphria, which assessment included an evaluation of the credibility of the claims alleged in the Report, based on publicly available information, a careful evaluation of the strategic and financial rationale of the combination and the management team of Aphria, and the range of potential exchange ratios. GGB’s management considered the possibility of approaching the management or the board of directors of Aphria to

 

1 

Shawn Dym was a director on the board of GGB Ltd. prior to the Business Combination and is on the board of directors of Aphria.

 

36


determine if it might be possible to negotiate a friendly transaction. GGB’s management also reviewed the possibility of completing a financing of GGB at a premium to its then share price given the potential financial profile of GGB, the upside potential of the combined company and recent trends in the industry, as well as a potential investment in Aphria by GGB.

GGB’s management’s assessment confirmed that the combination of the two companies could yield strategic benefits to both GGB and Aphria shareholders, that Aphria could be successfully integrated into GGB, and that a combination could better position GGB for future potential growth within the industry. GGB’s management, however, also believed that further analysis was required.

On December 10, 2018, GGB contacted Norton Rose Fulbright Canada LLP (“Norton Rose Fulbright”) with respect to acting as legal counsel on the potential transaction.

On December 13, 2018, GGB requested that Canaccord prepare a presentation for GGB’s management to consider the opportunity and document their verbal analysis of the potential combination.

On December 14, 2018, GGB formally engaged Norton Rose Fulbright.

Over the course of the weekend of December 15 and 16, 2018, management of GGB considered a range of exchange ratios for the transaction, which ratios remained subject to further analysis regarding the combination of the two companies and the advice of its financial advisors.

At a board meeting held on December 16, 2018, the GGB board of directors reviewed with GGB management the proposed transaction, including the proposed exchange ratio, and the GGB board of directors was provided with an overview of the financial analysis being conducted by Canaccord. At the meeting, the board of directors authorized management to formally approach the board of directors of Aphria with a written proposal to combine the two companies and to evaluate opportunities for the proposed equity financing.

Following this meeting, management of GGB and its advisors engaged in discussions with All Js Greenspace LLC (GGB’s largest shareholder) and other potential investors with respect to participating in the proposed GGB financing. Through these discussions, representatives of All Js Greenspace LLC and other investors indicated that they would be prepared to participate in and backstop the proposed financing. Additionally, GGB engaged in discussions with, and received verbal preliminary expressions of interest and support from, certain Aphria Shareholders about the possibility of locking up support for a potential business combination transaction with Aphria. A draft form of lock-up agreement was shared with certain Aphria Shareholders for their consideration. As of the date of this Offer to Purchase and Circular, the terms of formal lock-up agreements have not been agreed to by the parties.

On December 18, 2018, Canaccord, acting on behalf of GGB, delivered a formal letter to the board of directors of Aphria outlining a proposed business combination transaction involving the two companies at the Offer Consideration (the “Proposal”). The Proposal indicated that as a condition to the completion of the Proposal, GGB would complete a brokered financing of $300 million at a per share price of $7.00 and that certain significant shareholders of GGB were expected to have a substantial participation in the financing. The Proposal also stipulated that GGB was prepared to work with Aphria to finalize a transaction on an expedited basis and that the management of GGB was available to meet with the Aphria management team at any time prior to December 31, 2018. The Proposal also indicated that if the companies were not in a position to announce the Proposal at the start of the new year, GGB was prepared to publicly announce the Proposal and to pursue an offer for Aphria without the support of the board of directors of Aphria. Norton Rose Fulbright met with counsel to Aphria later that day to further outline the Proposal. Counsel to Aphria indicated that its client was in receipt of the Proposal and that it would be considered by the Aphria board of directors.

On December 19, 2018, Canaccord provided an analysis relating to a possible combination of GGB and Aphria to GGB’s management. This analysis outlined the strategic, financial, and capital markets implications of the possible combination, along with analysis surrounding a proposed $300 million concurrent equity financing at $7.00 per GGB Share. The analysis also outlined the expected benefits to each of Aphria and GGB in respect of a possible

 

37


combination, as well as a range of potential exchange ratios for the combination, including 1.5714 GGB Shares for each Aphria Share, and the resulting financial implications of such exchange ratios.

On December 19, 2018, in order to allow GGB to provide additional information about GGB that could assist Aphria in evaluating the Proposal, Norton Rose Fulbright provided counsel to Aphria with a draft one-way non-disclosure agreement. Aphria did not execute, or indicate any intention to negotiate the terms of, the draft non-disclosure agreement.

On December 20, 2018, counsel to Aphria advised Norton Rose Fulbright that the board of directors of Aphria had established an independent committee to consider the Proposal and was in the process of retaining financial advisors to assist in that review. Later in the day on December 20, 2018, select members of GGB’s board of directors and management team, as well as representatives of Canaccord, visited Aphria’s headquarters in Leamington, Ontario, at the invitation of Aphria management. Although GGB was given a guided tour of Aphria’s cultivation facility, it became clear to the GGB attendees that Aphria management had been instructed not to answer any specific questions. Counsel to Aphria contacted Norton Rose Fulbright at that time to request, on behalf of the board of directors of Aphria, that the GGB attendees leave the premises. Norton Rose Fulbright informed counsel to Aphria that the GGB attendees had visited the headquarters at the invitation of Aphria management.

On December 22, 2018, Canaccord provided GGB’s management with a written presentation which updated its previous analysis provided to GGB’s management on December 19, 2018.

At the request of GGB, during a call between a representative of All Js Greenspace LLC and a director of Aphria held on December 23, 2018, the representative of All Js Greenspace LLC suggested that Aphria enter into a limited exclusivity period with GGB to facilitate the parties’ continuing discussions regarding the Proposal. On the same day, Norton Rose Fulbright contacted counsel to Aphria to request the opportunity for GGB to present the Proposal directly to Aphria’s board of directors on December 27, 2018.

On December 24, 2018, counsel to Aphria confirmed to Norton Rose Fulbright that GGB could make a presentation to the board of directors of Aphria on December 27, 2018. On December 24, 2018, a draft exclusivity agreement was provided by Norton Rose Fulbright to counsel to Aphria for the Aphria board of directors’ consideration after GGB’s presentation on December 27th. The agreement proposed a short exclusivity period until 9:00 am (Toronto time) on January 7, 2019. During this period, GGB would not be permitted to make any announcement relating to a business combination and Aphria would not engage with any third parties on an alternative transaction. Norton Rose Fulbright reiterated to counsel to Aphria that GGB was prepared to make the Proposal public and pursue an offer without the support of the board of directors of Aphria if the board of directors of Aphria was not willing to enter into an exclusivity period for purposes of evaluating a friendly business combination.

On December 26, 2018, GGB’s board of directors had a conference call with GGB’s management team, Norton Rose Fulbright and Canaccord during which Canaccord provided an update regarding the status of discussions with Aphria since December 16, 2018, and previewed the presentation that would be made to Aphria’s board of directors the following day. During this call, GGB’s board of directors was advised by management and the advisors that discussions were continuing on the potential $300 million equity financing and backstop.

During the morning of December 27, 2018, GGB management along with Canaccord and Norton Rose Fulbright presented to the board of directors of Aphria regarding, among other things, GGB’s current and projected business plans, the merits of the Proposal, and the benefits and impact of the potential combination transaction. GGB also described the proposed $300 million financing. In the course of its presentation, GGB reiterated that the Proposal included a very short exclusivity period to allow both parties to seriously consider the combination, a full “go-shop” provision in favour of Aphria, the preservation of Aphria’s management team following completion of the transaction and a commitment to board representation at the combined company. In addition, GGB stated it would be willing to invest $50 million in equity at a valuation of $11.00 per Aphria share in connection with a friendly transaction.

 

38


Towards the conclusion of the presentation, members of the board of directors of Aphria asked questions, which were addressed by GGB’s management and its advisors. Aphria and its legal counsel then advised GGB that they would review the Proposal but did not specify a timeline within which they would respond. GGB made clear its desire to enter into an exclusivity agreement with Aphria quickly in light of the uncertainty in the market and made clear that it would be ready to proceed in other ways if it did not hear back by the end of the day on whether or not Aphria would agree to such exclusivity period. Counsel to Aphria asked several follow-up questions of Norton Rose Fulbright relating to GGB’s presentation, but there was no formal response from Aphria with respect to the Proposal by the end of the day.

Given that Aphria had been considering the Proposal for in excess of a week without any formal response, that Aphria had declined to agree to an exclusivity period or enter into discussions regarding a non-disclosure agreement, the lack of engagement from Aphria’s board of directors (despite the value that could be realized by Aphria Shareholders), and the compelling strategic rationale for the combination of the two companies, on December 27, 2018, following the close of markets, GGB issued a press release announcing its intention to make the Offer to the holders of Aphria Shares.

On December 28, 2018, Aphria issued a press release responding to GGB’s announcement of its intention to make the Offer and indicating that the proposal significantly undervalued Aphria. Aphria also announced that it held a passive investment in Green Acre Capital Fund II, which it understood had invested in numerous emerging cannabis companies, including GGB.

On December 31, 2018, GGB issued a press release reaffirming its commitment to launch the Offer and addressing certain statements that had been made in the media relating to GGB and the Offer.

During the week of January 7 to 11, 2019, Canaccord and members of management of GGB met with potential investors regarding GGB and the proposed Offer. During this time, GGB and its advisors negotiated with All Js Greenspace LLC and its counsel regarding the terms relating to the Commitment.

On January 11, 2019, Aphria announced its second quarter results and the decisions by its Chief Executive Officer, Vic Neufeld, and Co-Founder Cole Cacciavillani, to transition out of their current executive roles in the coming months.

On January 13, 2019, the board of directors of GGB met to approve the launch of the Offer, subject to the finalization of certain matters, and entry into the Commitment, and matters related to the Offer and the Commitment. At the board meeting, Canaccord made another presentation advising as to the relative values of GGB and Aphria. Canaccord indicated that the Offer Consideration would be appropriate, given the relative values and growth prospects of GGB and Aphria, as well as the expected benefits to each of the potential combination.

From January 13 to January 21, 2019, the terms of the Commitment were finalized and early in the day on January 22, 2019, GGB and All Js Greenspace LLC entered into the Commitment. All Js Greenspace LLC was prepared to commit up to $200 million; however, GGB reduced this amount to $150 million in order to avail itself of certain exemptions under MI 61-101 relating to minority approval which would be very costly to obtain. See Section 9 of this Circular, “Financing”.

Since announcing the intention to make the Offer, members of the independent committee of the Aphria board of directors have had limited informal discussions with GGB management, GGB’s financial advisor as well as representatives of All Js Greenspace LLC about the terms of the Offer. These discussions have been introductory in nature and have not resulted in support for the bid by Aphria. During these discussions, members of GGB management have offered to enter into a standstill agreement in order to facilitate due diligence and a negotiated transaction.

On January 22, 2019, GGB filed this Offer to Purchase and Circular.

 

39


7.

Reasons to Accept the Offer

The Offeror believes that the consideration offered for your Aphria Shares is a full and fair price and provides a unique opportunity for Aphria Shareholders to retain equity exposure to the cannabis industry through an ownership interest in the Offeror. While Aphria Shareholders may be discouraged by recent events and may have seen their investment significantly impacted, they should be aware of the immediate benefits of the Offer and reasons to tender:

 

   

Based on the closing price of $5.99 per GGB Share on the CSE as of January 21, 2019, the last trading day prior to the date of this Offer to Purchase and Circular, the implied Offer Consideration would be $9.41 per Aphria Share (being a 24.5% premium over the Aphria Shares’ closing price of $7.56 on the TSX on December 24, 2018, the last trading day prior to GGB’s public announcement of its intention to launch the Offer, and 24.9% over the volume weighted average price of $7.5328 of the Aphria Shares on the TSX for the last ten (10) trading days ended December 24, 2018). Based on the closing price of $4.25 per GGB Share on the CSE on December 24, 2018, the implied Offer Consideration would be $6.68 per Aphria Share. See Section 29 of this Circular, “Risk Factors”.

 

   

Aphria Shareholders will have a meaningful ownership position of approximately 60% in the combined company.

 

   

Aphria Shareholders will be part of an organization which is poised for further growth in the significantly larger U.S. market, with much greater long-term value potential.

 

   

There is potential for further downward pressure on the market price of the Aphria Shares if the Offer is not accepted.

The Offeror believes that the combination of the two companies is extremely compelling, in the best interest of all shareholders, and is the fastest way to create significant value for shareholders of both companies. The combined company is expected to:

 

   

Create an Unparalleled North American Player with a Developing International Presence. Aphria has a large market position in Canada and supply agreements with all provinces and Yukon territory, as well as strong strategic partnerships establishing wholesale supply agreements. Aphria has established operations in federally-legalized foreign jurisdictions, including Australia, Argentina, Colombia, Denmark, Germany, Italy, Jamaica, Lesotho, Malta, and Paraguay, and maintains an option for entry into Brazil. GGB operates vertically integrated cannabis operations including cultivation, manufacturing and retail assets in Nevada, was recently awarded seven incremental provisional retail cannabis dispensary licenses in Nevada, and has agreed to acquire Just Healthy LLC, which holds provisional certificates of registration for a registered medical marijuana dispensary and will, as a condition of closing, own an option to purchase land for a cultivation and processing site in Northampton, Massachusetts. GGB also holds an irrevocable option to purchase Henderson Organic, which operates a second The+Source location in Henderson, Nevada, subject to certain local regulatory changes and approvals. Further, through its consumer-focused line of CBD products, GGB’s long term goal is to establish a presence in each U.S. state where the sale of cannabis and CBD is not inconsistent with applicable Law. Together, the combined company is expected to have a strong foundation, extensive retail relationships and infrastructure to capture significant future growth as international markets evolve.

 

   

Increase Scale and Footprint, While Creating the Preeminent U.S. Consolidator. The combined company will be one of the largest U.S. cannabis operators by market capitalization and the only North American-wide cannabis operator at significant scale. Given the combined company’s increased size, both Aphria and GGB shareholders should benefit from a trading multiple expansion. The benefits of scale are expected in both Canada and the U.S. when examining trading metrics for comparable companies with similar market capitalization.

 

   

Combine Aphria’s Cultivation and Production Capacity with GGB’s Retail Strength. The combined company will marry Aphria’s low-cost cultivation and near-term production capacity with GGB’s vast

 

40


 

retail know-how to capture market share. Aphria’s current cash cost per gram is $1.76 and it projects annual capacity of over 250,000 kg by early 2019. GGB’s strong management team has a proven track record of delivering at the retail level and already operates or has licensing agreements in place with dispensaries in Nevada. In addition, GGB was recently awarded seven incremental provisional retail cannabis dispensary licenses in Nevada. Following expected receipt of regulatory approvals for the proposed acquisitions of Just Healthy LLC and Henderson Organic, as well as a cultivation facility in Pahrump, Nevada, and when such acquisitions are combined with GGB’s current operations, GGB is expected to generate total revenue from the cannabis business of over USD$300 million by the end of 2020.

 

   

Benefit from Transformational Cannabis-Related Regulatory Changes in the World’s Largest Cannabis Market. GGB is in the process of rolling out a consumer-focused line of CBD-infused personal care products, including topicals and balms, and is well positioned to benefit from further expected pro-cannabis U.S. regulation. On January 10, 2019, GGB announced an agreement with DSW to sell CBD-infused personal care products at 96 U.S.-based DSW stores, with an initial agreement for approximately 55,000 units. GGB is also partnering with additional retailers to sell CBD personal care products in U.S. states where the sale of cannabis and CBD is not inconsistent with applicable Law. Further, GGB is working with multiple large developers who represent a network of malls to launch kiosks in prime locations throughout the U.S. in states where the sale of cannabis and CBD is not inconsistent with applicable Law. By leveraging its CBD business in these prime locations, as well as through e-commerce, GGB expects to generate revenue from the CBD business of over USD$200 million by the end of 2020.

 

   

Unite Best-in-Class Management Teams: Aphria’s Pharmaceutical and Greenhouse Operational Experience and GGB’s Proven Retail Expertise. Aphria’s team, many of whom the Offeror hopes to retain following the successful completion of the Offer, is comprised of veterans in the greenhouse industry and proven operators of large pharmaceutical companies. GGB’s management has held senior positions at a number of well-known retailers including DSW, American Eagle Outfitters, and Bath & Body Works.

If the shares of the combined company trade in-line with North American cannabis companies having a market capitalization greater than $300 million, which on average trade at 12.7x TEV / 2020E EBITDA, the pro forma market capitalization would be approximately $6.0 billion, making it the largest U.S. cannabis operator by market capitalization, the fifth largest cannabis operator in North America by market capitalization, and the only North American-wide cannabis operator at significant scale. If the shares of the combined company trade in-line with U.S. cannabis companies with a market capitalization of over $1 billion, which on average trade at 11.4x TEV / 2020E EBITDA, the pro forma market capitalization would be approximately $5.4 billion.

 

41


The following chart outlines the pro forma market capitalization of the combined company as compared to industry competitors:

Pro Forma Market Capitalization ($ millions)

LOGO

Note: Assumes $300 million financing is completed and the combined company trades in-line with U.S. cannabis operators > $1 billion at 11.4x TEV / 2020E EBITDA or North American cannabis operators >$300 million at 12.7x TEV / 2020E EBITDA.

Note: Adjusted for subsequent events from most recent filings.

Note: Adjusted average excludes outliers.

Note: Analyst consensus estimates, aside from GGB, which are management estimates.

Source: Company filings, Bloomberg, Capital IQ, public disclosure, as of January 21, 2019.

The benefits of scale appear evident in both Canada and the U.S. when examining comparable company trading metrics. The largest four Canadian licensed producers trade at an adjusted average of 50.8x TEV / 2020E EBITDA. Canadian licensed producers with market capitalizations of $250-$3,000 million trade at an average of 8.2x TEV / 2020E EBITDA and the remainder of Canadian licensed producers with market capitalization under $250 million trade at an average of 2.5x TEV / 2020E EBITDA.

U.S. licensed cannabis operators with market capitalization greater than $1.0 billion trade at an average of 11.4x TEV / 2020E EBITDA while U.S. licensed cannabis operators with market capitalization less than $1.0 billion trade at an average of 4.5x TEV / 2020E EBITDA. The combined company will have significantly larger scale and is therefore expected to benefit from multiple expansion, trading in-line with North American cannabis companies having a market capitalization greater than $300 million, at 12.7x TEV / 2020E EBITDA.

The following tables outline the locations of operations that are expected to be owned, operated and/or licensed by the combined company following the successful completion of the Offer, which are in addition to Aphria’s supply agreements with all Canadian provinces and Yukon territory, Aphria’s international operations, and GGB’s long-term goal of establishing a presence in each U.S. state where the sale of cannabis and CBD is not inconsistent with applicable Law.

 

42


Aphria Facilities Overview

LOGO

GGB Operations Overview

LOGO

Note: Aphria owns 51% of Aphria Diamond, a strategic relationship with Double Diamond Farms, with all production from the facility to be sold to Aphria at an agreed upon transfer price.

Note: Aphria currently has 300,000 sq. ft. operational at “Aphria One”, its original campus in Leamington, Ontario.Note: Wellness Orchards/Panorama Cultivation, Henderson Organic, and Just Healthy LLC transactions remain subject to the satisfaction of conditions of closing as of the date hereof.

Source: Public disclosure.

GGB’s retail strategy is expected to result in an unparalleled U.S. reach and its long-term goal is to establish a presence in each U.S. state where the sale of cannabis and CBD is not inconsistent with applicable Law. Together with Aphria’s low cost production and distribution capabilities in Canada, as well as its international reach, GGB’s U.S. capabilities will help position the combined company as a leader in the global cannabis space. The combined platform will allow for revenue diversification, cross-selling opportunities and access to additional growth markets, including the significantly larger U.S. market, with much greater long-term value potential.

GGB’s management team has developed and executed strategies that led to top tier retail outcomes in several product categories. Upon completion of the Offer, they intend to focus on executing GGB’s retail growth strategy for the combined company.

 

8.

Purpose of the Offer and Plans for Aphria

Purpose of the Offer

The purpose of the Offer is to enable the Offeror to acquire all of the outstanding Aphria Shares in exchange for the Offer Consideration. The Offer is open for acceptance from the date of the Offer until 5:00 p.m. (Toronto time) on May 9, 2019 (as accelerated or extended by the Offeror, if applicable), subject to variation in the Offeror’s sole discretion or as set out in Section 5 of the Offer to Purchase, “Acceleration, Extension and Variation of the Offer”, unless the Offer is withdrawn by the Offeror.

If, by the Expiry Time or within 120 days after the date of the Offer, whichever period is shorter, the Offeror takes up and pays for 90% or more of the outstanding Aphria Shares under the Offer, other than Aphria Shares held at the date of the Offer by or on behalf of the Offeror, or an affiliate or associate of the Offeror (as those terms are defined in the OBCA), then the Offeror intends to acquire the remainder of the Aphria Shares by way of a Compulsory Acquisition for consideration per Aphria Share not less than, and in the same form as, the Offer Consideration. If the Offeror acquires less than 90% of the Aphria Shares under the Offer, the right of Compulsory Acquisition is not

 

43


available for any reason, or the Offeror chooses not to avail itself of such statutory right, the Offeror intends to pursue a Subsequent Acquisition Transaction. If the Offeror were to proceed with a Subsequent Acquisition Transaction, it is the Offeror’s current intention that the consideration to be paid to Aphria Shareholders pursuant to any such Subsequent Acquisition Transaction would be equal in amount to and in the same form as the Offer Consideration. See Section 16 of this Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer”.

If, for some reason, the Offeror is unable to effect a Compulsory Acquisition or a Subsequent Acquisition Transaction, the Offeror will evaluate other available alternatives. These alternatives could include, to the extent permitted by applicable Law, purchasing additional Aphria Shares: (a) in the open market; (b) in privately negotiated transactions; or (c) in another takeover bid or exchange offer or otherwise. Any additional purchases of Aphria Shares could be at a price greater than, equal to or less than the price to be paid for Aphria Shares under the Offer and could be for cash or securities or other consideration. Alternatively, the Offeror may decide not to pursue completion of the privatization of Aphria and sell or otherwise dispose of any or all Aphria Shares acquired pursuant to the Offer. These transactions may be completed on terms and at prices then determined by the Offeror, which may vary from the terms and the price paid for Aphria Shares under the Offer.

Plans for Aphria Following the Successful Completion of the Offer

If the Offer is successful, it is anticipated that the board of directors of Aphria will promptly be replaced by nominees of the Offeror. Management of the Offeror would look to engage with Aphria management (which may include directors) in an effort to retain those members of the Aphria management team who are aligned with the culture and strategy of the Offeror to assist with the future growth and development of the combined entity. Upon the successful completion of the Offer, the Offeror also intends to conduct a detailed review of Aphria and its affiliates and its corporate and capital structure to determine what changes, if any, would be desirable in light of such review and the circumstances which then exist.

With the exception of the foregoing, the GGB has not developed any specific proposals with respect to Aphria or its operations, or any changes in its assets, business strategies, management or personnel following the acquisition of the Aphria Shares pursuant to the Offer.

 

9.

Financing

The Offer is not subject to any financing condition. The Offeror, however, intends to complete, immediately following the take up of Aphria Shares under the Offer, a third-party equity financing at a share price equal to $7.00 per GGB Share for aggregate gross proceeds of $300 million (the “Financing”). As a backstop to the Financing, the Offeror has entered into a commitment letter (the “Commitment Letter”) with All Js Greenspace LLC (the “Backstop Investor”) pursuant to which the Backstop Investor has agreed, subject to the terms and conditions set forth in the Commitment Letter, to subscribe for and purchase up to $150 million of newly-issued GGB Shares for $7.00 per share (or the equivalent value of PV Shares) (the “Commitment”). The Commitment is conditional upon the successful completion of the Offer and the take up of Aphria Shares at the Expiry Time on the terms and conditions set forth in the Offer to Purchase, without any amendment or waiver. The Commitment is also subject to certain terms which the Offeror believes are customary, including the entering into of a definitive purchase agreement in respect of the Commitment (and satisfaction of the conditions set out therein), GGB not taking any steps to change its capital structure or capitalization, and no material events occurring with respect to GGB or its business, assets, liabilities, prospects or results of operations. To induce the Backstop Investor to provide the Commitment, the Offeror has agreed to pay the Backstop Investor a commitment fee equal to $7,500,000, payable by issuing 2,504 PV Shares to the Backstop Investor, and to indemnify and reimburse the Backstop Investor for certain liabilities, costs and expenses. GGB will also be obligated to sell to the Backstop Investor up to $150 million of GGB Shares for $7.00 per share (or the equivalent value of PV Shares) even if the Offer has not been completed (any such sales shall reduce the Commitment on a dollar-for-dollar basis).

The Backstop Investor’s commitment under the Commitment Letter terminates on the earliest of (a) the termination, withdrawal or expiration of the Offer, (b) the execution of the definitive purchase agreement in respect of the Commitment, (c) any amendment or waiver of any term or condition of or contained in this Offer to Purchase and Circular without obtaining the prior written consent of the Backstop Investor, and (d) May 13, 2019. The Offeror’s

 

44


obligation to sell up to $150 million in GGB Shares or PV Shares to the Backstop Investor shall not terminate or expire until May 23, 2019.

The foregoing is a summary only of certain terms and conditions of the Commitment Letter and is qualified in its entirety by the actual terms of the Commitment Letter. A copy of the Commitment Letter has been filed with the applicable securities regulatory authorities and is available for review under the Offeror’s profile on SEDAR.

If the Offer and the Financing are completed, the Offeror expects to use the net proceeds of the Financing to fund the business growth of the combined company, including for working capital and general corporate purposes.

There can be no assurance that the Financing will be completed (or on which terms it would be completed), or what the value of a GGB Share will be at the time of the take up of Aphria Shares under the Offer, which could be substantially less or more than $7.00 per GGB Share. Accordingly, Aphria Shareholders should be aware that the Financing may not be completed, or may be completed on terms that are different than the terms currently expected and set forth in this Offer to Purchase and Circular. See Section 29 of this Circular, “Risk Factors”.

 

10.

Treatment of Convertible Securities

The Offer is made only for Aphria Shares and is not made for any Convertible Securities, which term includes options and warrants. Any holder of Convertible Securities who wishes to accept the Offer must exercise such rights in order to obtain DRS Statement(s) or certificate(s) representing Aphria Shares and then deposit those Aphria Shares under the Offer. Any such exercise must be made sufficiently in advance of the Expiry Time to ensure that Aphria Shares will be available for deposit at or prior to the Expiry Time or in sufficient time to comply with the procedures referred to in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”. If any holder of Convertible Securities does not exercise such Convertible Securities prior to the Expiry Time, such Convertible Securities may remain outstanding following the Expiry Time in accordance with their terms and conditions, including with respect to time of expiry, vesting schedule, exercise price, and rights following a takeover bid (such as the Offer).

The tax consequences to holders of Convertible Securities of exercising or not exercising their Convertibles Securities are not described in Section 18 of this Circular, “Certain Canadian Federal Income Tax Considerations” or Section 19 of this Circular, “Certain United States Federal Income Tax Considerations”. Holders of Convertible Securities should consult with their own tax advisors for advice with respect to potential income tax consequences to them in connection with the decision to exercise or not exercise their Convertible Securities.

 

11.

Fractional Shares

In no event will any Aphria Shareholder be entitled to a fractional GGB Share. Where the aggregate number of GGB Shares to be issued to an Aphria Shareholder as the consideration under the Offer would result in a fraction of GGB Shares being issuable, the number of GGB Shares to be received by such Aphria Shareholder shall be either rounded up (if the fractional interest is equal to or exceeds 0.5) or down (if the fractional interest is less than 0.5) to the nearest whole number of GGB Shares without any additional payment in lieu thereof.

 

12.

Beneficial Ownership of and Trading in Securities of Aphria

The Offeror beneficially owns 3,000,000 Aphria Shares, representing 1.2% of the total number of issued and outstanding Aphria Shares as of the date hereof. Such Aphria Shares were acquired by the Offeror on December 19, 2018 at a price of $7.62 per Aphria Share.

Igor Galitsky, a director of the Offeror, beneficially owns 3,000 Aphria Shares, representing less than 1% of the total number of issued and outstanding Aphria Shares as of the date hereof. Mr. Galitsky purchased 1,000 Aphria Shares on October 22, 2018 at a price of $16.20 per Aphria Share and 2,000 Aphria Shares on December 3, 2018 at a price of $7.50 per Aphria Share.

 

45


Marc Lehmann, a director of the Offeror, beneficially owns 110,000 Aphria Shares, representing less than 1% of the total number of issued and outstanding Aphria Shares as of the date hereof. Mr. Lehmann completed the following trades of Aphria Shares in the six (6) months prior to the date of this Offer to Purchase and Circular:

 

Number and Type of Securities

   Sold/Bought    Average Price ($)      Date

5,000 Aphria Shares

   Sold      10.77      August 24, 2018

8,400 Aphria Shares

   Sold      12.12      August 27, 2018

10,000 Aphria Shares

   Sold      11.77      August 29, 2018

10,000 Aphria Shares

   Sold      12.63      August 31, 2018

40,000 Aphria Shares

   Bought      14.92      September 20, 2018

20,000 Aphria Shares

   Sold      12.78      October 8, 2018

11,100 Aphria Shares

   Sold      15.04      October 10, 2018

10,000 Aphria Shares

   Sold      15.24      October 11, 2018

40,000 Aphria Shares

   Bought      14.95      October 11, 2018

31,100 Aphria Shares

   Bought      14.93      October 12, 2018

10,000 Aphria Shares

   Sold      15.29      October 15, 2018

25,000 Aphria Shares

   Bought      14.92      October 16, 2018

40,000 Aphria Shares

   Sold      13.92      October 17, 2018

40,000 Aphria Shares

   Bought      13.51      October 17, 2018

15,000 Aphria Shares

   Sold      15.56      October 18, 2018

12,600 Aphria Shares

   Bought      13.99      October 19, 2018

10,000 Aphria Shares

   Bought      12.88      October 22, 2018

87,400 Aphria Shares

   Bought      11.96      October 26, 2018

5,000 Aphria Shares

   Bought      9.82      October 29, 2018

5,000 Aphria Shares

   Sold      10.33      October 30, 2018

5,000 Aphria Shares

   Sold      12.41      November 1, 2018

10,000 Aphria Shares

   Bought      11.47      November 1, 2018

5,000 Aphria Shares

   Sold      12.22      November 5, 2018

15,000 Aphria Shares

   Bought      11.75      November 5, 2018

5,000 Aphria Shares

   Sold      12.90      November 6, 2018

10,000 Aphria Shares

   Bought      12.35      November 7, 2018

20,000 Aphria Shares

   Sold      9.88      November 14, 2018

10,000 Aphria Shares

   Sold      9.86      November 16, 2018

19,800 Aphria Shares

   Sold      7.93      November 27, 2018

10,000 Aphria Shares

   Sold      8.26      November 28, 2018

15,000 Aphria Shares

   Sold      6.07      December 3, 2018

10,000 Aphria Shares

   Sold      4.66      December 4, 2018

5,200 Aphria Shares

   Sold      5.64      December 10, 2018

No other officer or director of the Offeror, beneficially owns, directly or indirectly, or exercises control or direction over any Aphria Shares, Convertible Securities or any other securities of Aphria.

To the knowledge of the Offeror, after reasonable enquiry, no Aphria Shares, Convertible Securities or other securities of Aphria are beneficially owned, directly or indirectly, nor is control or direction exercised over any such securities, by any insider of the Offeror (other than directors or officers of the Offeror) or any associate or affiliate of any insider of the Offeror or any party acting jointly or in concert with the Offeror.

Other than as set forth herein, to the knowledge of the Offeror after reasonable enquiry, none of the Offeror or its officers and directors, nor any insider of the Offeror (other than directors or officers of the Offeror) or any associate or affiliate of any insider of the Offeror or any party acting jointly or in concert with the Offeror, has traded in any securities of Aphria during the six (6) months preceding the date hereof.

None of the Offeror nor, to the knowledge of the Offeror, after reasonable enquiry, any of its directors or officers, any associate or affiliate of an insider of the Offeror, any insider of the Offeror other than a director or officer of the

 

46


Offeror or any person acting jointly or in concert with the Offeror, has entered into any agreements, commitments or understandings to acquire any securities of Aphria.

 

13.

Commitments to Acquire Aphria Shares

Except pursuant to the Offer, neither the Offeror, nor, to the knowledge of the Offeror after reasonable enquiry, any associate of any director or senior officer of the Offeror, any person or company holding more than 10% of any class of equity securities of the Offeror, or any person or company acting jointly or in concert with the Offeror, has entered into any agreements, commitments or understandings to acquire any securities of Aphria.

 

14.

Arrangements, Agreements or Understandings; Other Benefits to Insiders, Affiliates and Associates

There are no agreements, commitments or understandings made or proposed to be made between the Offeror and any of the directors or officers of Aphria and no payments or other benefits are proposed to be made or given by the Offeror by way of compensation for loss of office or as to such directors or officers remaining in or retiring from office if the Offer is successful.

There is no agreement, commitment or understanding made between the Offeror and Aphria relating to the Offer.

There is no agreement, commitment or understanding of which the Offeror is aware that could affect control of Aphria that the Offeror has access to and can reasonably be regarded as material to an Aphria Shareholder in deciding whether to deposit its Aphria Shares under the Offer.

 

15.

Effect of the Offer

If, as a result of the Offer and any subsequent transaction, the number of Aphria Shareholders is sufficiently reduced, to the extent permitted under applicable Law, the Offeror intends to cause Aphria to apply to the TSX and the NYSE to delist the Aphria Shares from both stock exchanges as soon as practicable after completion of the Offer or a Compulsory Acquisition or Subsequent Acquisition Transaction and, subject to applicable Law, to cause Aphria to cease to be a reporting issuer (or equivalent) in Canada and the United States. The rules and regulations of the TSX and NYSE could also, upon the consummation of the Offer and/or a subsequent transaction, lead to the delisting of the Aphria Shares from such exchanges. See Section 8 of the Circular, “Purpose of the Offer and Plans for Aphria”.

Even if the Compulsory Acquisition or Subsequent Acquisition Transaction cannot be completed as quickly as intended, the purchase of Aphria Shares by the Offeror pursuant to the Offer will reduce the number of Aphria Shares that might otherwise trade publicly, as well as the number of Aphria Shareholders, and would likely adversely affect the liquidity and market value of the remaining Aphria Shares held by the public.

 

16.

Acquisition of Aphria Shares Not Deposited Under the Offer

If sufficient Aphria Shares are deposited under the Offer, the Offeror intends to acquire the remaining Aphria Shares pursuant to the right of Compulsory Acquisition provided in the OBCA. If the Offeror acquires less than 90% of the Aphria Shares subject to the Offer, or the right of Compulsory Acquisition is not available for any reason, or the Offeror chooses not to avail itself of such statutory right, the Offeror may, at its option, pursue other means of acquiring the remaining Aphria Shares not deposited under the Offer pursuant to a Subsequent Acquisition Transaction. The Offer is conditional upon, among other things, the Statutory Minimum Condition. These and other conditions of the Offer are described in Section 4 of the Offer to Purchase, “Conditions of the Offer”.

There is no assurance that either a Compulsory Acquisition or a Subsequent Acquisition Transaction will be completed, and the Offeror expressly reserves the right not to propose a Compulsory Acquisition or a Subsequent Acquisition Transaction, in which case the Offer will reduce the number of Aphria Shares that might otherwise trade publicly, as well as the number of Aphria Shareholders, and would likely adversely affect the liquidity and market value of the remaining Aphria Shares held by the public.

 

47


Compulsory Acquisition

If, by the Expiry Time or within 120 days after the date of the Offer, whichever period is the shorter, the Offeror takes up and pays for 90% or more of the outstanding Aphria Shares under the Offer, other than Aphria Shares held at the date of the Offer by or on behalf of the Offeror, or an affiliate or associate of the Offeror (as those terms are defined in the OBCA), then the Offeror intends to acquire the remainder of the Aphria Shares by way of a compulsory acquisition pursuant to Part 15 of the OBCA (a “Compulsory Acquisition”) for consideration per Aphria Share not less than, and in the same form as, the consideration under the Offer.

To exercise its statutory right of Compulsory Acquisition, the Offeror must send a notice (the “Offeror’s Notice”) to each Aphria Shareholder who did not accept the Offer (and each person who subsequently acquires any such Aphria Shares) (in each case, a “Dissenting Offeree”) of such proposed acquisition within 60 days after the date of the termination of the Offer and in any event within 180 days after the date of the Offer. Within 20 days after the Offeror sends the Offeror’s Notice, the Offeror must pay or transfer to Aphria the consideration the Offeror would have to pay or transfer to the Dissenting Offerees if they had elected to accept the Offer, to be held in trust for the Dissenting Offerees. In accordance with subsection 188(4) of the OBCA, within 20 days after receipt of the Offeror’s Notice, each Dissenting Offeree must send the certificate(s), if any, representing the Aphria Shares held by such Dissenting Offeree to Aphria and must elect either to transfer such Aphria Shares to the Offeror on the terms of the Offer or to demand payment of the fair value of such Aphria Shares held by such holder by so notifying the Offeror within 20 days after the Dissenting Offeree receives the Offeror’s Notice. A Dissenting Offeree who does not, within 20 days after the Dissenting Offeree received the Offeror’s Notice, notify the Offeror that the Dissenting Offeree is electing to demand payment of the fair value of the Dissenting Offeree’s Aphria Shares is deemed to have elected to transfer such Aphria Shares to the Offeror on the same terms that the Offeror acquired Aphria Shares from the Aphria Shareholders who accepted the Offer. If a Dissenting Offeree has elected to demand payment of the fair value of such Aphria Shares, the Offeror may apply to the Court to hear an application to fix the fair value of such Aphria Shares of such Dissenting Offeree. If the Offeror fails to apply to the Court within 20 days after it made the payment or transferred the consideration to Aphria referred to above, the Dissenting Offeree may then apply to the Court within a further period of 20 days to have the Court fix the fair value. If there is no such application made by the Dissenting Offeree within such period, the Dissenting Offeree will be deemed to have elected to transfer such Aphria Shares to the Offeror on the terms that the Offeror acquired Aphria Shares from the Aphria Shareholders who accepted the Offer. Any judicial determination of the fair value of the Aphria Shares could be less or more than the amount paid pursuant to the Offer.

If all of the requirements of Part 15 of the OBCA are not fulfilled within 120 days after the date of the Offer, the Offeror may apply to a court having jurisdiction for an extension of such period pursuant to Section 188(21) of the OBCA.

The foregoing is a summary only of the right of Compulsory Acquisition which may become available to the Offeror and the dissent rights that may be available to a Dissenting Offeree, and is qualified in its entirety by the provisions of Part 15 of the OBCA. The provisions of Part 15 of the OBCA are complex and may require strict adherence to notice and timing provisions, failing which a Dissenting Offeree’s rights may be lost or altered. Aphria Shareholders should refer to Part 15 of the OBCA for the full text of the relevant statutory provisions, and those who wish to be better informed about the provisions of the OBCA should consult their legal advisors. There can be no assurance that the Offeror will pursue a Compulsory Acquisition.

Please also see Section 18 of this Circular, “Certain Canadian Federal Income Tax Considerations” and Section 19 of this Circular, “Certain United States Federal Income Tax Considerations” for a discussion of certain tax consequences to Aphria Shareholders in the event of a Compulsory Acquisition.

Subsequent Acquisition Transaction

If the Offeror acquires less than 90% of the Aphria Shares under the Offer, the right of Compulsory Acquisition described above is not available for any reason, or the Offeror chooses not to avail itself of such statutory right, the Offeror intends to pursue other means of acquiring the remaining Aphria Shares not deposited under the Offer, including, without limitation, causing one or more special meetings to be called of the then Aphria Shareholders to

 

48


consider an amalgamation, statutory arrangement, capital reorganization, amendment to its articles, consolidation or other transaction involving the Offeror and/or an affiliate of the Offeror and Aphria and/or the Aphria Shareholders for the purpose of Aphria becoming, directly or indirectly, a wholly-owned subsidiary or affiliate of the Offeror (a “Subsequent Acquisition Transaction”). If the Offeror were to proceed with a Subsequent Acquisition Transaction, it is the Offeror’s current intention that the consideration to be paid to Aphria Shareholders pursuant to any such Subsequent Acquisition Transaction would be equal in amount to and in the same form as that payable under the Offer.

The timing and details of a Subsequent Acquisition Transaction, if any, will necessarily depend on a variety of factors, including, without limitation, the number of Aphria Shares acquired pursuant to the Offer. If after taking up Aphria Shares under the Offer the Offeror owns more than 6623% of the outstanding Aphria Shares and sufficient votes are cast by “minority” holders to constitute a majority of the “minority” pursuant to MI 61-101, as discussed below, the Offeror should own sufficient Aphria Shares to be able to effect a Subsequent Acquisition Transaction. There can be no assurance that the Offeror will pursue a Subsequent Acquisition Transaction.

MI 61-101 may deem a Subsequent Acquisition Transaction to be a “business combination” if such Subsequent Acquisition Transaction would result in the interest of a holder of Aphria Shares being terminated without the consent of the holder, irrespective of the nature of the consideration provided in substitution therefor. The Offeror expects that any Subsequent Acquisition Transaction relating to Aphria Shares will be a “business combination” under MI 61-101.

In certain circumstances, the provisions of MI 61-101 may also deem certain types of Subsequent Acquisition Transactions to be “related party transactions”. However, if the Subsequent Acquisition Transaction is a “business combination” carried out in accordance with MI 61-101 or an exemption under MI 61-101, the “related party transaction” provisions therein do not apply to such transaction. Following completion of the Offer, the Offeror may be a “related party” of Aphria for the purposes of MI 61-101, but the Offeror expects that any Subsequent Acquisition Transaction would be a “business combination” for purposes of MI 61-101 and that therefore the “related party transaction” provisions of MI 61-101 would not apply to the Subsequent Acquisition Transaction. The Offeror intends to carry out any such Subsequent Acquisition Transaction in accordance with MI 61-101, or any successor provisions, or an exemption under MI 61-101, such that the “related party transaction” provisions of MI 61-101 would not apply to such Subsequent Acquisition Transaction.

MI 61-101 provides that, unless exempted, a corporation proposing to carry out a business combination is required to prepare a valuation of the affected securities (and, subject to certain exceptions, any non-cash consideration being offered therefor) and provide to the holders of the affected securities a summary of such valuation. The Offeror currently intends to rely on available exemptions (or, if such exemptions are not available, to seek exemptions pursuant to MI 61-101 exempting Aphria and the Offeror or one or more of its affiliates, as appropriate) from the valuation requirements of MI 61-101. An exemption is available under MI 61-101 for certain business combinations completed within 120 days after the date of expiry of a formal takeover bid where the consideration per security under the business combination is at least equal in value to and is in the same form as the consideration that depositing security holders were entitled to receive in the takeover bid, provided that certain disclosure is given in the takeover bid disclosure documents. The Offeror has provided such disclosure and currently expects that these exemptions will be available.

Depending on the nature and terms of the Subsequent Acquisition Transaction, the provisions of the OBCA and Aphria’s constating documents may require the approval of at least 6623% of the votes cast by holders of the outstanding Aphria Shares at a meeting duly called and held for the purpose of approving the Subsequent Acquisition Transaction. MI 61-101 would also require that, in addition to any other required security holder approval, in order to complete a business combination (such as a Subsequent Acquisition Transaction), the approval of a majority of the votes cast by “minority” shareholders of each class of affected securities must be obtained unless an exemption is available or discretionary relief is granted by applicable Securities Regulatory Authorities. If, however, following the Offer, the Offeror and its affiliates are the registered holders of 90% or more of the Aphria Shares at the time the Subsequent Acquisition Transaction is initiated, the requirement for minority approval would

 

49


not apply to the transaction if an enforceable appraisal right or substantially equivalent right is made available to minority shareholders.

In relation to the Offer and any subsequent business combination, the “minority” shareholders will be, unless an exemption is available or discretionary relief is granted by applicable Securities Regulatory Authorities, all Aphria Shareholders other than (i) the Offeror (other than in respect of Aphria Shares acquired pursuant to the Offer as described below), (ii) any “interested party” (within the meaning of MI 61-101), (iii) certain “related parties” of the Offeror or of any other “interested party” (in each case within the meaning of MI 61-101) including any director or senior officer of the Offeror, affiliate or insider of the Offeror or any of their directors or senior officers, and (iv) any “joint actor” (within the meaning of MI 61-101) with any of the foregoing persons. MI 61-101 also provides that the Offeror may treat Aphria Shares acquired under the Offer as “minority” shares and to vote them, or to consider them voted, in favour of such business combination if, among other things: (a) the business combination is completed not later than 120 days after the Expiry Time; (b) the consideration per security in the business combination is at least equal in value to and in the same form as the consideration paid under the Offer; and (c) the Aphria Shareholder who tendered such Aphria Shares to the Offer was not (i) a “joint actor” (within the meaning of MI 61-101) with the Offeror in respect of the Offer, (ii) a direct or indirect party to any “connected transaction” (within the meaning of MI 61-101) to the Offer, or (iii) entitled to receive, directly or indirectly, in connection with the Offer, a “collateral benefit” (within the meaning of MI 61-101) or consideration per Aphria Share that is not identical in amount and form to the entitlement of the general body of holders in Canada of Aphria Shares. The Offeror currently intends that the consideration offered for Aphria Shares under any Subsequent Acquisition Transaction proposed by it would be equal in value to, and in the same form as, the consideration paid to Aphria Shareholders under the Offer and that such Subsequent Acquisition Transaction will be completed no later than 120 days after the Expiry Time and, accordingly, the Offeror intends to cause Aphria Shares acquired under the Offer to be voted in favour of any such transaction and, where permitted by MI 61-101, to be counted as part of any minority approval required in connection with any such transaction. To the knowledge of the Offeror, after reasonable enquiry, only the votes attached to Aphria Shares held by the Offeror would be required to be excluded in determining whether “minority” approval for a Subsequent Acquisition Transaction has been obtained for the purposes of MI 61-101. See Section 12 of this Circular, “Beneficial Ownership of and Trading in Securities of Aphria”.

Any such Subsequent Acquisition Transaction may also result in Aphria Shareholders having the right to dissent in respect thereof and demand payment of the fair value of their Aphria Shares. The exercise of such right of dissent, if certain procedures are complied with by the holder, could lead to a judicial determination of fair value required to be paid to such Dissenting Offeree for its Aphria Shares. The fair value so determined could be more or less than the amount paid per Aphria Share pursuant to such transaction or pursuant to the Offer. The exact terms and procedures of the rights of dissent available to Aphria Shareholders will depend on the structure of the Subsequent Acquisition Transaction and will be fully described in the proxy circular or other disclosure document provided to Aphria Shareholders in connection with the Subsequent Acquisition Transaction.

Whether or not a Subsequent Acquisition Transaction will be proposed, and the details of any such Subsequent Acquisition Transaction, including, without limitation, the timing of its implementation and the consideration to be received by the minority holders of Aphria Shares, will necessarily be subject to a number of considerations, including, without limitation, the number of Aphria Shares acquired pursuant to the Offer. Although the Offeror may propose a Compulsory Acquisition or a Subsequent Acquisition Transaction on the same terms as the Offer, it is possible that, as a result of the number of Aphria Shares acquired under the Offer, delays in the Offeror’s ability to effect such a transaction, information hereafter obtained by the Offeror, changes in general economic, industry, regulatory or market conditions or in the business of Aphria, or other currently unforeseen circumstances, such a transaction may not be so proposed or may be delayed or abandoned. The Offeror expressly reserves the right to propose other means of acquiring, directly or indirectly, all of the outstanding Aphria Shares in accordance with applicable Law, including, without limitation, a Subsequent Acquisition Transaction on terms not described in this Circular.

If the Offeror is unable to, or determines at its option not to, effect a Compulsory Acquisition or propose a Subsequent Acquisition Transaction, or proposes a Subsequent Acquisition Transaction but cannot obtain any required approvals or exemptions promptly, the Offeror will evaluate its other alternatives. Such alternatives could

 

50


include, to the extent permitted by applicable Law, purchasing additional Aphria Shares in the open market, in privately negotiated transactions, in another takeover bid or exchange offer or otherwise, or from Aphria. Subject to applicable Law, any additional purchases of Aphria Shares could be at a price greater than, equal to, or less than the price to be paid for Aphria Shares under the Offer and could be for cash, securities and/or other consideration. Alternatively, the Offeror may take no action to acquire additional Aphria Shares, or, subject to applicable Law, may either sell or otherwise dispose of any or all Aphria Shares acquired under the Offer, on terms and at prices then determined by the Offeror, which may vary from the price paid for Aphria Shares under the Offer. See Section 12 of the Offer to Purchase, “Market Purchases and Sales of Aphria Shares”.

The tax consequences to an Aphria Shareholder of a Subsequent Acquisition Transaction may differ from the tax consequences to such Aphria Shareholder of accepting the Offer. Please also see Section 18 of this Circular, “Certain Canadian Federal Income Tax Considerations” and Section 19 of this Circular, “Certain United States Federal Income Tax Considerations”.

Aphria Shareholders should consult their legal advisors for a determination of their legal rights and the tax consequences to them, having regard to their own particular circumstances with respect to a Subsequent Acquisition Transaction.

 

17.

Unaudited Condensed Consolidated Pro Forma Financial Statements

Aphria Shareholders should refer to Annex A to this document, which sets out the unaudited pro forma condensed consolidated statement of financial position of the Offeror as of October 31, 2018, the unaudited pro forma condensed consolidated statement of net income (loss) and comprehensive income (loss) of the Offeror for the three months ended August 31, 2018, September 30, 2018 and October 31, 2018, and the twelve months ended May 31, 2018, June 30, 2018 and October 31, 2018, after giving effect to the proposed acquisition of all of the Aphria Shares under the Offer and the Financing, the completion of which is conditional upon, among other things, the successful completion of the Offer. Such unaudited pro forma consolidated financial statements have been prepared using certain of the Offeror’s and Aphria’s financial statements as more particularly described in the notes to the unaudited pro forma consolidated financial statements. In preparing the unaudited pro forma consolidated financial statements, management of the Offeror has made certain assumptions that affect the amounts reported in the unaudited pro forma consolidated financial statements. Such unaudited pro forma consolidated financial statements are not intended to be indicative of the results that would have actually occurred, had the events reflected therein occurred on the dates indicated, and do not purport to project the future financial position of the Offeror. Actual amounts recorded upon consummation of the Offer and the Financing will differ from such unaudited pro forma consolidated financial statements. Any potential synergies that may be realized following consummation of the Offer have been excluded from such unaudited pro forma consolidated financial statements. Aphria Shareholders are cautioned not to put undue reliance on such unaudited pro forma consolidated financial statements. See Section 9 of this Circular, “Financing” and Section 29 of this Circular, “Risk Factors”.

 

18.

Certain Canadian Federal Income Tax Considerations

In the opinion of Norton Rose Fulbright Canada LLP, counsel to the Offeror, the following is a summary of the principal Canadian federal income tax considerations under the Income Tax Act (Canada) and the regulations thereunder, (collectively, the “Tax Act”) as of the date hereof, generally applicable to an Aphria Shareholder who, for purposes of the Tax Act and at all relevant times, holds Aphria Shares and will hold any GGB Shares acquired pursuant to the Offer as capital property, deals at arm’s length with Aphria and the Offeror, is not affiliated with Aphria or the Offeror, and who disposes of Aphria Shares to the Offeror in exchange for GGB Shares pursuant to the Offer or (to the extent addressed in this summary) otherwise disposes of Aphria Shares pursuant to certain transactions described in Section 16 of this Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer”. An Aphria Shareholder who meets all of the foregoing requirements is referred to as a “Holder” for purposes of this summary, and this summary only addresses Holders as so defined.

Aphria Shares and GGB Shares generally will be considered capital property to a Holder for purposes of the Tax Act unless the Holder holds such shares in the course of carrying on a business of buying and selling securities or the

 

51


Holder has acquired or holds them in a transaction or transactions considered to be an adventure or concern in the nature of trade.

This summary is based on the current provisions of the Tax Act in force as of the date hereof and counsel’s understanding of the current published administrative policies and assessing practices of the Canada Revenue Agency (“CRA”) publicly available prior to the date hereof. This summary takes into account all specific proposals to amend the Tax Act that have been publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the “Tax Proposals”) and assumes that any such Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in the form proposed, or at all. This summary does not otherwise take into account or anticipate any other changes in law, whether by judicial, governmental or legislative decision or action, or changes in the administrative policies or assessing practices of the CRA, nor does it take into account provincial, territorial or foreign income tax legislation or considerations, which may differ materially from those described in this summary.

This summary does not address holders of options, warrants or other Convertible Securities, and all such holders should consult their own tax advisors.

This summary is not applicable to Holders who acquired Aphria Shares pursuant to employee stock options or other employee compensation plans. In addition, this summary does not apply to a Holder: (a) that is a “financial institution” for the purposes of the mark-to-market rules in the Tax Act, (b) an interest in which is a “tax shelter investment” as defined in the Tax Act, (c) that is a “specified financial institution” as defined in the Tax Act, (d) that has made a “functional currency” election under Section 261 of the Tax Act, (e) that has entered into, or will enter into, with respect to Aphria Shares or GGB Shares, a “derivative forward agreement” or a “synthetic disposition arrangement”, as each of those terms are defined in the Tax Act, (f) that is exempt from tax under Part I of the Tax Act, or (g) that is a partnership for Canadian tax purposes. All such Holders should consult their own tax advisors. In addition, this summary is not applicable to a Holder where the Holder, or persons with whom the Holder did not deal at “arm’s length” (as defined for purposes of the Tax Act), or the Holder together with such persons, control the Offeror or beneficially own shares of the Offeror having a fair market value of more than 50% of the fair market value of all of the outstanding shares of the Offeror, immediately after the exchange of Aphria Shares for GGB Shares. All such Holders should also consult their own tax advisors.

Further, this summary is not applicable to a Holder that (i) is a corporation resident in Canada, and (ii) is, or becomes as part of a transaction or event or series of transactions or events that includes the acquisition of the GGB Shares, controlled by a non-resident corporation for the purposes of the foreign affiliate dumping rules in Section 212.3 of the Tax Act. Any such Holder should also consult its own tax advisor.

This summary is of a general nature only and is not, and is not intended to be, nor should it be construed to be, legal or tax advice or representations to any particular person (including a Holder). This summary is not exhaustive of all Canadian federal income tax considerations. Accordingly, all Aphria Shareholders (including Holders as defined above) and holders of other Aphria securities are urged to consult their own legal and tax advisors with respect to the tax consequences to them having regard to their particular circumstances, including with respect to the application and effect of the income and other tax Laws of any country, province or other jurisdiction that may be applicable.

Aphria Shareholders Resident in Canada

This part of the summary is applicable only to a Holder who, for purposes of the Tax Act and any applicable income tax treaty or convention, and at all relevant times, is resident or is deemed to be resident in Canada (a “Resident Holder”). Certain Resident Holders whose Aphria Shares might not otherwise constitute capital property may be eligible to make an irrevocable election in accordance with subsection 39(4) of the Tax Act to have their Aphria Shares and every other “Canadian security” (as defined in the Tax Act) owned by such Resident Holder in the taxation year in which the election is made and in all subsequent taxation years, be deemed to be capital property. Resident Holders contemplating such an election should first consult their own tax advisors.

 

52


Disposition of Aphria Shares Pursuant to the Offer

Resident Holders who tender and deposit their Aphria Shares and whose Aphria Shares are taken up pursuant to the Offer will directly exchange their Aphria Shares with the Offeror for GGB Shares (a “Direct Exchange”).

A Resident Holder who exchanges Aphria Shares for GGB Shares in a Direct Exchange will, in general terms, be deemed to have disposed of such Aphria Shares under a tax-deferred share-for-share exchange pursuant to Section 85.1 of the Tax Act as described in paragraph (a) below, unless such Resident Holder chooses to recognize a capital gain (or capital loss) on the Direct Exchange as described in paragraph (b) below.

 

  (a)

Where a Resident Holder does not include, in computing income for the year in which the exchange occurred (in the Resident Holder’s Canadian income tax return for such year), any portion of the gain or loss otherwise determined from the exchange, the Resident Holder will be deemed to have disposed of the Aphria Shares for proceeds of disposition equal to the aggregate adjusted cost base of the Aphria Shares to the Resident Holder, determined immediately before the exchange, and the Resident Holder will be deemed to have acquired the GGB Shares at an aggregate cost equal to such adjusted cost base of the Aphria Shares. This cost will be averaged with the adjusted cost base of all other GGB Shares held by the Resident Holder as capital property for the purpose of determining the adjusted cost base of each GGB Share held by the Resident Holder as capital property.

 

  (b)

A Resident Holder may choose to recognize all of a capital gain (or capital loss) in respect of the exchange of Aphria Shares for GGB Shares by including any portion of the capital gain (or capital loss) in computing the Resident Holder’s income for the taxation year in which the Direct Exchange takes place. In such circumstances, the Resident Holder will realize a capital gain (or a capital loss) equal to the amount, if any, by which the fair market value of the GGB Shares received, net of any reasonable costs of disposition, exceeds (or is less than) the aggregate of the adjusted cost base of the Aphria Shares to the Resident Holder, determined immediately before the exchange. It is not possible for a Resident Holder to elect such treatment on only a portion of the capital gain (or loss) otherwise realized on the disposition of Aphria Shares. For a description of the tax treatment of capital gains and capital losses, see “Aphria Shareholders Resident in Canada – Taxation of Capital Gains and Capital Losses” below. The cost of the GGB Shares acquired on such an exchange will be equal to the fair market value thereof. This cost will be averaged with the adjusted cost base of all other GGB Shares held by the Resident Holder as capital property for the purpose of determining the adjusted cost base of each GGB Share held by the Resident Holder as capital property.

Taxation of Capital Gains and Capital Losses

Generally, a Resident Holder will be required to include in computing income for a taxation year one-half of the amount of any capital gain (a “taxable capital gain”) realized in that year. A Resident Holder will be required to deduct one-half of the amount of any capital loss (an “allowable capital loss”) realized in a taxation year from taxable capital gains realized by the Resident Holder in that year. Allowable capital losses in excess of taxable capital gains realized in a taxation year may be carried back to any of the three preceding taxation years or carried forward to any subsequent taxation year and deducted against net taxable capital gains realized in such years, subject to and in accordance with the detailed rules contained in the Tax Act.

The amount of any capital loss realized on the disposition of an Aphria Share or an GGB Share by a Resident Holder that is a corporation may, to the extent and under the circumstances specified in the Tax Act, be reduced by the amount of any dividends received or deemed to have been received by the corporation on such share (or on a share for which such share is substituted or exchanged). Similar rules may apply where shares are owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary. Resident Holders to whom these rules may be relevant should consult their own tax advisors.

 

53


A Resident Holder that is throughout the year a “Canadian-controlled private corporation”, as defined in the Tax Act, may be liable to pay an additional tax (refundable in certain circumstances) on certain investment income, including taxable capital gains realized, interest and certain dividends.

Capital gains realized by a Resident Holder who is an individual or a trust, other than certain specified trusts, will be taken into account in determining liability for alternative minimum tax under the Tax Act.

Disposition of Aphria Shares Pursuant to a Compulsory Acquisition

As described in Section 16 of this Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer – Compulsory Acquisition”, the Offeror may, in certain circumstances, acquire Aphria Shares not deposited pursuant to the process described therein. The income tax consequences to a Resident Holder of a disposition of Aphria Shares in exchange for GGB Shares in such circumstances generally will be as described above under the heading “Aphria Shareholders Resident in Canada – Disposition of Aphria Shares Pursuant to the Offer”.

A Resident Holder who dissents and obtains an order from a court of competent jurisdiction in respect of a Compulsory Acquisition and receives a cash payment from the Offeror for such holder’s Aphria Shares will be considered to have disposed of such Aphria Shares for proceeds of disposition equal to the amount received (not including the amount of any interest awarded by the court). As a result, such dissenting Resident Holder will realize a capital gain (or a capital loss) equal to the amount, if any, by which the amount of cash received (not including the amount of any interest awarded by the court), net of any reasonable costs of disposition, exceeds (or is less than) the adjusted cost base of the Aphria Shares to the Resident Holder, determined immediately before the time at which the Aphria Shares are taken up by the Offeror. For a description of the tax treatment of capital gains and capital losses, see “Aphria Shareholders Resident in Canada – Taxation of Capital Gains and Capital Losses” above.

Any interest awarded to a dissenting Resident Holder by the court in connection with a Compulsory Acquisition must be included in computing such Resident Holder’s income for purposes of the Tax Act.

Resident Holders should consult their own tax advisors with respect to the potential income tax consequences to them of having their Aphria Shares acquired pursuant to a Compulsory Acquisition.

Disposition of Aphria Shares Pursuant to a Subsequent Acquisition Transaction

As described in Section 16 of this, “Acquisition of Aphria Shares Not Deposited Under the Offer – Subsequent Acquisition Transaction”, if the Offeror does not acquire all of the Aphria Shares pursuant to the Offer or by means of a Compulsory Acquisition, the Offeror may propose other means of acquiring the remaining issued and outstanding Aphria Shares.

The income tax treatment of a Subsequent Acquisition Transaction to a Resident Holder will depend on the exact manner in which the transaction is carried out and the consideration offered. It is not possible to comment substantively as to the tax treatment of such a transaction until the form of such transaction is determined. However, the income tax consequences of such a transaction may differ from those arising on the disposition of Aphria Shares under the Offer and will depend on the particular form and circumstances of the transaction. Depending on the form of the transaction, a Resident Holder may, among other potential impacts, realize a capital gain (or loss) and/or be deemed to receive a dividend. No opinion is expressed herein as to the income tax consequences of any such transaction to a Resident Holder.

Resident Holders should consult their own tax advisors with respect to the potential income tax consequences to them of having their Aphria Shares acquired pursuant to a Subsequent Acquisition Transaction.

Potential Delisting

As described in Section 15 of this Circular, “Effect of the Offer”, the Aphria Shares may cease to be listed on the TSX and the NYSE in the circumstances described therein. Resident Holders who do not exchange their Aphria Shares under the Offer are cautioned that, if the Aphria Shares are no longer listed on a “designated stock exchange” (which currently includes the TSX and the NYSE) and Aphria ceases to be a “public corporation” for purposes of

 

54


the Tax Act for any reason, the Aphria Shares will not be qualified investments for trusts governed by registered retirement savings plans (“RRSPs”), registered retirement income funds (“RRIFs”), registered education savings plans (“RESPs”), registered disability savings plans (“RDSPs”), deferred profit sharing plans or tax-free savings accounts (“TFSAs”) (collectively, “Deferred Income Plans”). Resident Holders should consult their own tax advisors with respect to the potential income tax consequences to them in this regard.

Holding and Disposing of GGB Shares

Dividends on GGB Shares

Dividends on GGB Shares (if any) will be included in the recipient’s income for the purposes of the Tax Act. Such dividends received by a Resident Holder who is an individual will be subject to the gross-up and dividend tax credit rules in the Tax Act normally applicable to taxable dividends received from taxable Canadian corporations. Provided that appropriate designations are made by the Offeror, such dividend may be treated as an eligible dividend for the purposes of the Tax Act and a Resident Holder who is an individual may be entitled to an enhanced dividend tax credit in respect of such dividend. GGB’s ability to pay dividends, if any, as eligible dividends for the purposes of the Tax Act may be subject to limitations under the Tax Act, and GGB has made no commitments in this regard. Dividends received by an individual (including certain trusts) may give rise to a liability for alternative minimum tax.

In the case of a Resident Holder of GGB Shares that is a corporation, dividends received on the GGB Shares will be required to be included in computing the corporation’s income for the taxation year in which such dividends are received and will generally be deductible in computing the corporation’s taxable income, subject to the rules and limitations in the Tax Act. A Resident Holder of GGB Shares that is a “private corporation” (as defined in the Tax Act), or any other corporation resident in Canada and controlled, whether because of a beneficial interest in one or more trusts or otherwise, by or for the benefit of an individual (other than a trust) or a related group of individuals (other than trusts) may also be liable under Part IV of the Tax Act to pay a special tax (refundable in certain circumstances) on dividends received on the GGB Shares to the extent that such dividends are deductible in computing the Resident Holder’s taxable income.

In certain circumstances, subsection 55(2) of the Tax Act will recharacterize a dividend into a capital gain or additional proceeds of disposition. Corporate Resident Holders should consult with their own tax advisors in this regard.

Disposition of GGB Shares

A disposition or deemed disposition of a GGB Share by a Resident Holder (other than a disposition to the Offeror in circumstances other than a purchase by the Offeror in the open market in the manner in which shares are normally purchased by a member of the public in the open market) will generally result in a capital gain (or a capital loss) to the extent that the proceeds of disposition, net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base to the holder of the GGB Share immediately before the disposition. For a description of the tax treatment of capital gains and capital losses, see “Aphria Shareholders Resident in Canada – Taxation of Capital Gains and Capital Losses” above.

Eligibility for Investment

Based on the current provisions of the Tax Act, the GGB Shares will be qualified investments under the Tax Act for Deferred Income Plans at any particular time, provided that, at that time, the GGB Shares are listed on a “designated stock exchange” (which currently includes the CSE) as defined in the Tax Act.

Notwithstanding that GGB Shares may be qualified investments for a trust governed by a RRSP, RRIF, RESP, RDSP or TFSA, the annuitant under an RRSP or RRIF, subscriber of an RESP or the holder of a TFSA or RDSP, will be subject to a penalty tax on such shares if such shares are a “prohibited investment” (as defined in the Tax Act). The GGB Shares will generally not be a “prohibited investment” for a relevant Deferred Income Plan, provided that (i) the holder of the TFSA or RDSP, the subscriber of the RESP or the annuitant under the RRSP or

 

55


the RRIF, as the case may be, deals at arm’s length with GGB for purposes of the Tax Act and does not have a “significant interest” (as defined in the Tax Act) in GGB or (ii) GGB Shares are “excluded property” (as defined in subsection 207.01(1) of the Tax Act) for the TFSA, RRSP, RESP, RDSP or RRIF. Holders should consult their own tax advisors to ensure that the GGB Shares would not be a prohibited investment for a trust governed by a Deferred Income Plan in their particular circumstances.

Aphria Shareholders Not Resident in Canada

This part of the summary is generally applicable to a Holder who, for purposes of the Tax Act and any applicable income tax treaty or convention, and at all relevant times, is neither resident nor deemed to be resident in Canada, and does not use or hold, and is not deemed to use or hold, Aphria Shares or GGB Shares in connection with carrying on a business in Canada (a “Non-Resident Holder”). This part of the summary is not applicable to Non-Resident Holders that are insurers carrying on an insurance business in Canada and elsewhere. Such Non-Resident Holders should consult their own tax advisors.

Disposition of Aphria Shares Pursuant to the Offer

A Non-Resident Holder will not be subject to tax under the Tax Act on any capital gain realized on a disposition of Aphria Shares pursuant to the Offer unless (i) those Aphria Shares constitute “taxable Canadian property” and, (ii) are not “treaty-protected property” as defined in the Tax Act (“treaty-protected property”). A Non-Resident Holder’s Aphria Shares would constitute treaty-protected property at a particular time if gains on the disposition of such shares would be, at that time, exempt from Canadian federal income tax under an income tax treaty or convention between Canada and the jurisdiction of residence of the Non-Resident Holder.

Generally, an Aphria Share will not be “taxable Canadian property” of a Non-Resident Holder at a particular time provided that such share is listed on a designated stock exchange (which includes the TSX and the NYSE) at that time, unless at any time during the 60-month period immediately preceding the particular time (a) the Non-Resident Holder, persons with whom the Non-Resident Holder did not deal at arm’s length, a partnership in which the Non-Resident Holder or a non-arm’s length person holds a membership interest directly or indirectly through one or more partnerships, or the Non-Resident Holder together with such persons or partnerships, owned 25% or more of the issued shares of any class or series of shares of Aphria, and (b) more than 50% of the fair market value of the Aphria Share was derived directly or indirectly from one or any combination of real or immovable property situated in Canada, “Canadian resource properties” or “timber resource properties” (as defined in the Tax Act), and options in respect of, or interests in, or for civil law rights in, any such properties (whether or not such property exists). As noted below under “Aphria Shareholders Not Resident in Canada – Potential Delisting”, in certain circumstances Aphria Shares may cease to be listed on a designated stock exchange, impacting the potential status of the Aphria Shares as taxable Canadian property for purposes of the Tax Act.

Aphria Shares may also be deemed to be taxable Canadian property to the Non-Resident Holder in other circumstances for the purposes of the Tax Act. Non-Resident Holders whose Aphria Shares may constitute taxable Canadian property should consult their own tax advisors for advice having regard to their particular circumstances.

In the event that the Aphria Shares are considered to be taxable Canadian property and not treaty-protected property, such Non-Resident Holder will realize a capital gain (or capital loss) generally in the circumstances and computed in the manner described above under “Aphria Shareholders Resident in Canada – Disposition of Aphria Shares Pursuant to the Offer” as if the Non-Resident Holder were a Resident Holder thereunder. Such Non-Resident Holder may be subject to the tax deferral provisions of Section 85.1 of the Tax Act as described above if such Non-Resident Holder satisfies the conditions above under the heading “Aphria Shareholders Resident in Canada – Disposition of Aphria Shares Pursuant to the Offer” and provided that such Non-Resident Holder is, in general terms, not a foreign affiliate of a taxpayer resident in Canada that has included the gain or loss otherwise determined in its foreign accrual property income. In general terms, if Section 85.1 of the Tax Act applies, the GGB Shares received in exchange for Aphria Shares that constituted taxable Canadian property to such Non-Resident Holder may be deemed to be taxable Canadian property to such Non-Resident Holder. Any capital gain (or loss) realized by a Non-Resident Holder will generally be computed in the manner described above under “Aphria Shareholders Resident in Canada –

 

56


Taxation of Capital Gains and Capital Losses”. Non-Resident Holders whose Aphria Shares may be held as taxable Canadian property should consult their own tax advisors for advice having regard to their particular circumstances.

Disposition of Aphria Shares Pursuant to a Compulsory Acquisition

As described in Section 16 of this Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer – Compulsory Acquisition”, the Offeror may, in certain circumstances, acquire Aphria Shares not deposited pursuant to the Offer pursuant to the process described therein.

A Non-Resident Holder whose Aphria Shares do not constitute taxable Canadian property will not be subject to tax under the Tax Act in respect of any capital gain realized on the disposition of Aphria Shares by way of a Compulsory Acquisition. Whether an Aphria Share is considered to be taxable Canadian property at the time of a disposition by way of a Compulsory Acquisition will generally be determined as described above (see “Aphria Shareholders Not Resident in Canada – Disposition of Aphria Shares Pursuant to the Offer”), except that more stringent rules may be applied where the Aphria Shares cease to be listed on a designated stock exchange (see “Aphria Shareholders Not Resident in Canada – Potential Delisting” below).

A Non-Resident Holder whose Aphria Shares are taxable Canadian property for purposes of the Tax Act and not treaty-protected property may be subject to tax under the Tax Act in respect of any capital gain realized on the disposition of Aphria Shares by way of a Compulsory Acquisition. If such Non-Resident Holder receives only GGB Shares as consideration for Aphria Shares of the Non-Resident Holder, the Non-Resident may be subject to the tax deferral provisions of Section 85.1 of the Tax Act generally as described above under “Aphria Shareholders Not Resident in Canada – Disposition of Aphria Shares Pursuant to the Offer”.

Generally, interest paid or credited to a Non-Resident Holder in connection with a Compulsory Acquisition will not be subject to Canadian withholding tax under the Tax Act.

Non-Resident Holders should consult their own tax advisors with respect to the potential income tax consequences to them of having their Aphria Shares acquired pursuant to a Compulsory Acquisition.

Disposition of Aphria Shares Pursuant to a Subsequent Acquisition Transaction

As described in Section 16 of this Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer –Subsequent Acquisition Transaction”, if the Offeror does not acquire all of the Aphria Shares pursuant to the Offer or by means of a Compulsory Acquisition, the Offeror may propose other means of acquiring the remaining issued and outstanding Aphria Shares.

The income tax treatment to a Non-Resident Holder of a Subsequent Acquisition Transaction will depend on the exact manner in which the transaction is carried out and the consideration offered. It is not possible to comment substantively as to the tax treatment of such a transaction until the form of such transaction is determined. However, the income tax consequences of such a transaction may differ from those arising on the disposition of Aphria Shares under the Offer and will depend on the particular form and circumstances of the transaction.

Depending on the form of the transaction, a Non-Resident Holder may (among other potential impacts) realize a capital gain (or loss) and/or be deemed to receive a dividend. Whether or not a Non-Resident Holder would be subject to tax under the Tax Act on any such capital gain generally would depend in part on whether the Aphria Shares are “taxable Canadian property” of the Non-Resident Holder for the purposes of the Tax Act at the time of the disposition and whether such Aphria Shares constitute treaty-protected property. Whether an Aphria Share is considered to be taxable Canadian property at the time of a disposition by way of a Subsequent Acquisition Transaction will generally be determined as described above (see “Aphria Shareholders Not Resident in Canada – Disposition of Aphria Shares Pursuant to the Offer”), except that more stringent rules may be applied where the Aphria Shares cease to be listed on a designated stock exchange (see “Aphria Shareholders Not Resident in Canada – Potential Delisting” below).

 

57


Dividends paid or credited or deemed to be paid or credited to a Non-Resident Holder, if any, will be subject to Canadian withholding tax at a rate of 25%, subject to any reduction pursuant to an applicable income tax treaty or convention.

Generally, interest paid or credited to a Non-Resident Holder in connection with a Subsequent Acquisition Transaction will not be subject to Canadian withholding tax under the Tax Act.

Non-Resident Holders should consult their own tax advisors with respect to the potential income tax consequences to them of having their Aphria Shares acquired pursuant to a Subsequent Acquisition Transaction.

Potential Delisting

As described in Section 15 of this Circular, “Effect of the Offer”, the Aphria Shares may cease to be listed on the TSX and the NYSE in the circumstances described therein.

Non-Resident Holders who do not exchange their Aphria Shares pursuant to the Offer are cautioned that Aphria Shares that are not listed on a designated stock exchange at the time of their disposition will be considered taxable Canadian property of the Non-Resident Holder if, at any time within the 60-month period immediately preceding the disposition, more than 50% of the fair market value of the Aphria Shares was derived directly or indirectly from one or any combination of real or immovable property situated in Canada, “Canadian resource properties” (as defined in the Tax Act), “timber resource properties” (as defined in the Tax Act), and options in respect of, or interests in, or for civil law rights in, any such properties (whether or not such property exists). Notwithstanding the foregoing, in certain other circumstances set out in the Tax Act, Aphria Shares may also be deemed to be taxable Canadian property.

If the Aphria Shares are taxable Canadian property of the Non-Resident Holder at the time of their disposition but are not treaty-protected property, the Non-Resident Holder may be subject to tax under the Tax Act in respect of any capital gain realized on disposition. In addition, if such Aphria Shares constitute taxable Canadian property and are not listed on a recognized stock exchange (which includes the TSX and the NYSE) at the time of their disposition, the notification and withholding provisions of Section 116 of the Tax Act will apply to the Non-Resident Holder, in which case the Offeror (or a successor thereof, as applicable) may deduct and withhold 25% from any payment made to the Non-Resident Holder and remit such amount to the Receiver General of Canada on account of the Non-Resident Holder’s liability for tax under the Tax Act, and the Non-Resident Holder may be subject to certain Canadian federal income tax filing obligations. Holders should consult their own tax advisors in this regard.

Holding and Disposing of GGB Shares

Dividends on GGB Shares

Any dividends paid or deemed to be paid in respect of GGB Shares to a Non-Resident Holder will be subject to Canadian withholding tax at the rate of 25%, subject to any reduction pursuant to an applicable income tax treaty or convention.

Disposition of GGB Shares

Any capital gain realized on the disposition or deemed disposition of a GGB Share by a Non-Resident Holder (other than to the Offeror) will not be subject to tax under the Tax Act unless such share constitutes taxable Canadian property other than treaty-protected property to that Non-Resident Holder. See also the discussion regarding taxable Canadian property and treaty-protected property above in “Aphria Shareholders Not Resident in Canada – Disposition of Aphria Shares Pursuant to the Offer”. Non-Resident Holders who hold GGB Shares that are or may be “taxable Canadian property” should consult their own advisors as to the Canadian income tax consequences of disposing of their GGB Shares.

 

58


19.

Certain United States Federal Income Tax Considerations

The following is a general summary of certain U.S. federal income tax considerations applicable to a U.S. Holder with respect to the Offer and the acquisition, ownership and disposition of GGB Shares received pursuant to the Offer. This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder as a result of the Offer or as a result of the acquisition, ownership and disposition of GGB Shares received pursuant to the Offer. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder, including specific tax consequences to a U.S. Holder under an applicable tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. Except as discussed below, this summary does not discuss applicable income tax reporting requirements. This summary does not address the U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the Offer or the acquisition, ownership, and disposition of Aphria Shares or GGB Shares. Each U.S. Holder should consult its own tax advisors regarding the U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences of the Offer and the acquisition, ownership, and disposition of Aphria Shares and GGB Shares.

No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the “IRS”) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the Offer and the acquisition, ownership and disposition of GGB Shares received pursuant to the Offer. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the positions taken in this summary.

Scope of This Disclosure

Authorities

This summary is based on the Code, U.S. Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the “Canada-U.S. Tax Convention”), and U.S. court decisions that are applicable and, in each case, as in effect and available, as of the date of this Circular. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive or prospective basis, which could affect the U.S. federal income tax considerations described in this summary. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.

U.S. Holders

For purposes of this summary, the term “U.S. Holder” means a beneficial owner of Aphria Shares participating in the Offer (or after the Offer, GGB Shares) that is for U.S. federal income tax purposes:

 

   

an individual who is a citizen or resident of the U.S.;

 

   

a corporation (or other entity classified as a corporation for U.S. federal income tax purposes) organized under the Laws of the U.S., any state thereof or the District of Columbia;

 

   

an estate whose income is subject to U.S. federal income taxation regardless of its source; or

 

   

a trust that (a) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (b) has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.

 

59


Non-U.S. Holders

For purposes of this summary, a “non-U.S. Holder” is a beneficial owner of Aphria Shares participating in the Offer that is not a U.S. Holder and is not a partnership. This summary does not address the U.S. federal, state or local tax consequences applicable to non-U.S. Holders arising from the Offer or the acquisition, ownership and disposition of GGB Shares received pursuant to the Offer. Accordingly, a non-U.S. Holder should consult its own tax advisors regarding the U.S. federal income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences (including the potential application of and operation of any income tax treaties) relating to the Offer and the acquisition, ownership and disposition of GGB Shares received pursuant to the Offer.

Transactions Not Addressed

This summary does not address the U.S. federal income tax consequences of transactions effected prior or subsequent to, or concurrently with, the Offer (whether or not any such transactions are undertaken in connection with the Offer), and does not address the following: (a) any conversion into Aphria Shares or GGB Shares of any notes, debentures or other debt instruments; (b) any vesting, conversion, assumption, disposition, exercise, exchange, or other transaction involving any options, warrants or other rights to acquire Aphria Shares or GGB Shares; and (c) any transaction, other than the Offer, in which Aphria Shares or GGB Shares are acquired.

U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed

This summary does not address the U.S. federal income tax considerations of the Offer to U.S. Holders that are subject to special provisions under the Code, including U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a “functional currency” other than the U.S. dollar; (e) own Aphria Shares (or after the Offer, GGB Shares) as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) acquired Aphria Shares (or after the Offer, GGB Shares) in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Aphria Shares (or after the Offer, GGB Shares) other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) own, directly, indirectly, or by attribution, 5% or more, by voting power or value, of the outstanding Aphria Shares (or after the Offer, GGB Shares); (i) are resident outside of the U.S.; or (j) are subject to the alternative minimum tax provisions of the Code. This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Tax Act; (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold Aphria Shares (or after the Offer, GGB Shares) in connection with carrying on a business in Canada; (d) persons whose Aphria Shares (or after the Offer, GGB Shares) constitute “taxable Canadian property” under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions under the Code, including U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the Offer and the acquisition ownership and disposition of GGB Shares received pursuant to the Offer.

If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds Aphria Shares (or after the Offer, GGB Shares), the U.S. federal income tax consequences to such partnership and the partners of such partnership of participating in the Offer and the ownership of GGB Shares received pursuant to the Offer generally will depend in part on the activities of the partnership and the status of such partners. Partners of entities that are classified as partnerships for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences of the Offer and the acquisition, ownership and disposition of GGB Shares received pursuant to the Offer.

 

60


Certain U.S. Federal Income Tax Consequences of the Offer

Consequences of Exchanging the Aphria Shares Pursuant to the Offer

In considering the tax consequences of the Offer, U.S. Holders must take into account the discussion under “Tax Consequences if Aphria is Classified as a PFIC” below.

The determination of whether the Offer will qualify as a tax-deferred “reorganization” within the meaning of Section 368(a) of the Code (a “Reorganization”) depends on the resolution of complex issues and facts, some of which will not be known until the closing of the Offer and any Compulsory Acquisition or Subsequent Acquisition Transaction, and as a result, it is uncertain as to whether the Offer will qualify as a Reorganization or a fully taxable transaction. GGB has not determined how any Subsequent Acquisition Transaction will be structured, and as of the date of this Circular, GGB does not expect that the U.S. federal income tax consequences to U.S. Holders will be a significant factor in determining the structure of any such Subsequent Acquisition Transaction. As described in detail below, even if the Offer qualifies as a Reorganization, the PFIC rules may require a U.S. Holder to fully recognize gain (but not loss) if Aphria is considered a PFIC with respect to a particular U.S. Holder. All U.S. Holders of Aphria Shares should consult their own tax advisors regarding the specific U.S. federal income tax consequences of the Offer that are applicable to them.

Tax Consequences if the Offer Qualifies as a Reorganization

If the Offer qualifies as a Reorganization, subject to the PFIC rules discussed below, then the following U.S. federal income tax consequences will result for U.S. Holders:

 

  (a)

no gain or loss will be recognized by a U.S. Holder on the exchange of Aphria Shares for GGB Shares pursuant to the Offer;

 

  (b)

the tax basis of a U.S. Holder in the GGB Shares acquired in exchange for Aphria Shares pursuant to the Offer will be equal to such U.S. Holder’s tax basis in the Aphria Shares exchanged;

 

  (c)

the holding period of a U.S. Holder for the GGB Shares acquired in exchange for Aphria Shares pursuant to the Offer will include such U.S. Holder’s holding period for Aphria Shares; and

 

  (d)

U.S. Holders who exchange Aphria Shares for GGB Shares pursuant to the Offer generally will be required to report certain information to the IRS on their U.S. federal income tax returns for the tax year in which the exchange occurs, and to retain certain records related to the Offer.

If a U.S. Holder acquired different blocks of Aphria Shares at different times or at different prices, the U.S. Holder’s tax basis and holding period in the GGB Shares received will be determined separately for each block of Aphria Shares. U.S. Holders that hold Aphria Shares with differing bases or holding periods are urged to consult their tax advisors as to the determination of the bases and holding periods of the GGB Shares received pursuant to the Offer.

Treatment of the Offer as a Taxable Transaction

If the Offer does not qualify as a Reorganization for U.S. federal income tax purposes, subject to the PFIC rules discussed below, then the following U.S. federal income tax consequences will result for U.S. Holders:

 

  (a)

a U.S. Holder will recognize gain or loss in an amount equal to the difference, if any, between (i) the fair market value (expressed in U.S. dollars) of the GGB Shares received in exchange for Aphria Shares pursuant to the Offer and (ii) the adjusted tax basis (expressed in U.S. dollars) of such U.S. Holder in the Aphria Shares exchanged;

 

  (b)

the tax basis of a U.S. Holder in the GGB Shares received in exchange for Aphria Shares pursuant to the Offer would be equal to the fair market value of such GGB Shares on the date of receipt; and

 

61


  (c)

the holding period of a U.S. Holder for the GGB Shares received in exchange for Aphria Shares pursuant to the Offer will begin on the day after the date of receipt.

If Aphria is not classified as a PFIC for any tax year in which a U.S. Holder held Aphria Shares, any gain or loss described in clause (a) immediately above generally would be capital gain or loss, which will be long-term capital gain or loss if such Aphria Shares were held for more than one year. Preferential tax rates apply to long-term capital gains of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gains of a U.S. Holder that is a corporation. Deductions for capital losses are subject to complex limitations under the Code.

Tax Consequences if Aphria is Classified as a PFIC

A U.S. Holder of Aphria Shares would be subject to special, potentially adverse tax rules in respect of the Offer if Aphria was classified as a “passive foreign investment company” under Section 1297 of the Code (a “PFIC”) for any tax year during which such U.S. Holder holds or held Aphria Shares.

A non-U.S. corporation is classified as a PFIC for each tax year in which: (i) 75% or more of its gross income is passive income (as defined for U.S. federal income tax purposes); or (ii) on the quarterly average for such tax year, 50% or more (by value) of its assets either produce or are held for the production of passive income. For purposes of the PFIC provisions, “passive income” generally includes dividends, interest, royalties, rents, and gains from commodities or securities transactions. In determining whether or not it is classified as a PFIC, a non-U.S. corporation is required to take into account its pro rata portion of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest.

GGB does not know whether Aphria was classified as a PFIC during one or more prior tax years or will be classified as a PFIC for its current tax year.

Under proposed U.S. Treasury Regulations, absent application of the “PFIC-for-PFIC Exception” discussed below, if Aphria is classified as a PFIC for any tax year during which a U.S. Holder holds or has held Aphria Shares, special rules may increase such U.S. Holder’s U.S. federal income tax liability with respect to the Offer. Under the PFIC rules, the following tax consequences would result with regard to such U.S. Holder’s U.S. federal income tax liability with respect to the exchange of Aphria Shares pursuant to Offer:

 

   

the acquisition of Aphria Shares pursuant to the Offer may be treated as a taxable exchange even if such transaction qualifies as a Reorganization as discussed above;

 

   

any gain on the exchange of Aphria Shares will be allocated rateably over such U.S. Holder’s holding period;

 

   

the amount allocated to the current tax year and to any tax year prior to the first year in which Aphria was classified as a PFIC will be taxed as ordinary income in the current year;

 

   

the amounts allocated to each of the other tax years will be subject to tax as ordinary income at the highest rate of tax in effect for the applicable class of taxpayer for that year;

 

   

an interest charge for a deemed deferral benefit will be imposed with respect to the resulting tax attributable to each of the other tax years, which interest charge is not deductible by non-corporate U.S. Holders; and

 

   

any loss realized would generally not be recognized if the Offer qualifies as a Reorganization.

A U.S. Holder that has made a “Mark-to-Market Election” under Section 1296 of the Code or a timely and effective election to treat Aphria as a “qualified electing fund” (a “QEF”) under Section 1295 of the Code (a “QEF Election”) generally may mitigate the PFIC consequences described above with respect to the Offer. In order to make a “Mark-to-Market Election”, Aphria Shares must be “regularly traded” on a “qualified exchange” within the meaning of applicable U.S. Treasury Regulations. Also, in order to make the QEF Election, Aphria must track and make certain information available to its shareholders.

 

62


U.S. Holders should be aware that there can be no assurances that Aphria has or will satisfy the record keeping requirements that apply to a QEF, or that Aphria has or will supply U.S. Holders with information that such U.S. Holders require to report under the QEF rules, in the event that Aphria is a PFIC during its current tax year or was a PFIC during any prior tax year. Thus, U.S. Holders may not be able to make a QEF Election with respect to their Aphria Shares. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a QEF Election. U.S. Holders should consult with their own tax advisors regarding the potential application of the PFIC rules or any Mark-to-Market Election or QEF Election. A shareholder of PFIC stock who does not make a timely QEF Election is referred to for purposes of this summary as a “Non-Electing Shareholder”.

Under certain proposed U.S. Treasury Regulations:

 

   

a Non-Electing Shareholder does not recognize gain in a Reorganization where the Non-Electing Shareholder transfers stock in a PFIC so long as such Non-Electing Shareholder receives in exchange stock of another corporation that qualifies as a PFIC for its tax year that includes the day after the date of transfer (for purposes of this summary, this exception will be referred to as the “PFIC-for-PFIC Exception”); and

 

   

a Non-Electing Shareholder generally does recognize gain (but not loss) in a Reorganization where the Non-Electing Shareholder transfers stock in a PFIC and receives in exchange stock of another corporation that does not qualify as a PFIC for its tax year that includes the day after the date of transfer.

As discussed below, based on current business plans and financial expectations, GGB anticipates that it should not be a PFIC for its current tax year ending June 30, 2019, and for the foreseeable future. Accordingly, if the proposed U.S. Treasury Regulations were finalized and made applicable to the Offer (even if this occurs after the Effective Date of the Offer), it is likely that the PFIC-for-PFIC Exception will not be available to U.S. Holders with respect to the Offer. PFIC classification is factual in nature, and generally cannot be determined until the close of the tax year in question. Additionally, the analysis depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. Consequently, there can be no assurances regarding the PFIC status of GGB during the tax year which includes the day after the Effective Date of the Offer or the availability of the PFIC-for-PFIC Exception.

Each U.S. Holder should consult its own tax advisors regarding the potential application of the PFIC rules to the exchange of Aphria Shares for GGB Shares pursuant to the Offer, and the information reporting responsibilities in connection with the Offer.

Transfer of Aphria Shares Not Exchanged Pursuant to the Offer

As described under Section 16 of this Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer”, GGB may, in certain circumstances, acquire Aphria Shares not deposited under the Offer pursuant to a Compulsory Acquisition or a Subsequent Acquisition Transaction. A U.S. Holder whose Aphria Shares are acquired in exchange for GGB Shares pursuant to a Compulsory Acquisition should be subject to tax consequences generally similar to those described above under “Consequences of Exchanging the Aphria Shares Pursuant to the Offer”. The tax treatment of a Subsequent Acquisition Transaction to a U.S. Holder will depend upon the exact manner in which the Subsequent Acquisition Transaction is carried out and may be substantially the same or materially different than the tax consequences described above. GGB does not expect that the U.S. federal income tax consequences to U.S. Holders will be a significant factor in determining the structure of any such Subsequent Acquisition Transaction. U.S. Holders should consult their own tax advisors for advice with respect to the income tax consequences of having their Aphria Shares acquired pursuant to a Compulsory Acquisition or a Subsequent Acquisition Transaction, including the consequences of exercising dissent rights pursuant to a Compulsory Acquisition or a Subsequent Acquisition Transaction.

A U.S. Holder that exercises dissent rights in any Compulsory Acquisition or Subsequent Acquisition Transaction and is paid cash in exchange for all of such U.S. Holder’s Aphria Shares generally will recognize gain or loss in an amount equal to the difference, if any, between (a) the U.S. dollar amount of cash received by such U.S. Holder in exchange for Aphria Shares (other than amounts, if any, that are or are deemed to be interest for U.S. federal income tax purposes, which amounts will be taxed as ordinary income) and (b) the tax basis of such U.S. Holder in such

 

63


Aphria Shares surrendered. Subject to the PFIC rules discussed in this summary, such gain or loss generally will be capital gain or loss, which will be long-term capital gain or loss if such Aphria Shares have been held for more than one year. Preferential tax rates apply to long-term capital gains of a U.S. Holder that is an individual, estate, or trust. Deductions for capital losses are subject to complex limitations under the Code.

Ownership of GGB Shares

The following discussion is subject to the PFIC rules discussed below under “Passive Foreign Investment Company Rules Relating to the Ownership of GGB Shares”.

Distributions with Respect to GGB Shares

A U.S. Holder that receives a distribution (including a constructive distribution, but excluding certain pro rata distributions of stock described in Code Section 305) with respect to the GGB Shares will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current or accumulated “earnings and profits” of GGB, as determined under U.S. federal income tax rules. To the extent that a distribution exceeds the current and accumulated “earnings and profits” of GGB, such distribution will be treated: (a) first, as a tax-free return of capital to the extent of a U.S. Holder’s tax basis in the GGB Shares; and (b) thereafter, as gain from the sale or exchange of such shares (see more detailed discussion below under the heading “Disposition of GGB Shares”). GGB may not maintain the calculations of earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder therefore may have to assume that any distribution by GGB with respect to GGB Shares will constitute ordinary dividend income. Dividends paid on the GGB Shares generally will not be eligible for the “dividends received deduction” generally available to U.S. corporate shareholders receiving dividends from U.S. corporations. Subject to applicable limitations and provided GGB is eligible for the benefits of the Canada-U.S. Tax Convention or the GGB Shares are readily tradable on a United States securities market, dividends paid by GGB to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that GGB not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.

Dispositions of GGB Shares

A U.S. Holder will recognize gain or loss on the sale or other taxable disposition of GGB Shares in an amount equal to the difference, if any, between: (a) the U.S. dollar amount of cash plus the fair market value of any property received; and (b) such U.S. Holder’s tax basis in the GGB Shares sold or otherwise disposed of. Subject to the PFIC rules discussed below, any such gain or loss generally will be capital gain or loss, which will be long-term capital gain or loss if the GGB Shares are held for longer than one year. Preferential tax rates apply to long-term capital gains of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gains of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.

Passive Foreign Investment Company Rules Relating to the Ownership of GGB Shares

If GGB is or becomes a PFIC, the preceding section of this summary may not describe the U.S. federal income tax consequences to U.S. Holders of the acquisition, ownership and disposition of GGB Shares. The U.S. federal income tax consequences of owning and disposing of GGB Shares if GGB is or becomes a PFIC are described below.

If GGB were to constitute a PFIC for any tax year during a U.S. Holder’s holding period, then certain potentially adverse rules may affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of GGB Shares.

Based on current business plans and financial expectations, GGB expects that it will not be a PFIC for its current tax year and for the foreseeable future. No opinion of legal counsel or ruling from the IRS concerning the status of GGB

 

64


as a PFIC has been obtained or is currently planned to be requested. The determination of whether any non-U.S. corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any non-U.S. corporation is a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this Circular. Accordingly, there can be no assurance that GGB will or will not be a PFIC for the current tax year or any future tax year or that the IRS will not challenge any determination made by GGB (or any subsidiary of GGB) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of GGB and any subsidiary of GGB, the application of the PFIC rules to the GGB Shares and the consequences of being treated as the owner of subsidiary PFICs.

In any tax year in which GGB is a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as U.S. Treasury Regulations and other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621.

If GGB were a PFIC in any tax year during which a U.S. Holder held GGB Shares, such holder generally would be subject to special rules with respect to any “excess distribution” made by GGB on the GGB Shares and with respect to gain from the disposition of the GGB Shares. An “excess distribution” generally is defined as the excess of distributions with respect to the GGB Shares received by a U.S. Holder in any tax year over 125% of the average annual distributions such U.S. Holder has received from GGB during the shorter of the three preceding tax years, or such U.S. Holder’s holding period for the GGB Shares. Generally, a U.S. Holder would be required to allocate any excess distribution or gain from the disposition of the GGB Shares rateably over its holding period for the GGB Shares. Such amounts allocated to the tax year of the disposition or excess distribution and to any tax year prior to the first year in which GGB was a PFIC would be taxed as ordinary income, and amounts allocated to all other tax years would be taxed as ordinary income at the highest tax rate in effect for each such tax year and an interest charge at a rate applicable to underpayments of tax would apply. Any loss realized on the disposition of GGB Shares would generally not be recognized.

While there are U.S. federal income tax elections that sometimes can be made to mitigate these adverse tax consequences (including the “QEF Election” under Section 1295 of the Code and the “Mark-to-Market Election” under Section 1296 of the Code), such elections are available in limited circumstances and must be made in a timely manner.

U.S. Holders should be aware that, for each tax year, if any, that GGB is a PFIC, GGB can provide no assurances that it will satisfy the record keeping requirements or make available to U.S. Holders the information such U.S. Holders require to make a QEF Election with respect to GGB or any subsidiary of GGB that also is classified as a PFIC. In addition, no assurance can be provided that GGB Shares will be “regularly traded” on a “qualified exchange” within the meaning of applicable U.S. Treasury Regulations, which is required in order to make the “Mark-to-Market Election”. U.S. Holders should consult their own tax advisors regarding the potential application of the PFIC rules to the acquisition, ownership and disposition of GGB Shares, and the availability of certain U.S. tax elections under the PFIC rules for GGB and any subsidiary of GGB that is also a PFIC.

Other Considerations

Foreign Tax Credit

A U.S. Holder that pays (whether directly or through withholding) Canadian income tax in connection with the Offer or in connection with the ownership or disposition of GGB Shares may be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax paid. Generally, a credit will reduce a U.S. Holder’s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder’s income subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year.

 

65


Complex limitations apply to the foreign tax credit, including the general limitation that the credit cannot exceed the proportionate share of a U.S. Holder’s U.S. federal income tax liability that such U.S. Holder’s “foreign source” taxable income bears to such U.S. Holder’s worldwide taxable income. In applying this limitation, a U.S. Holder’s various items of income and deduction must be classified, under complex rules, as either “foreign source” or “U.S. source”. Generally, dividends paid by a foreign corporation should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign corporation by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an applicable income tax treaty, and if an election is properly made under the Code. However, the amount of a distribution with respect to the GGB Shares that is treated as a “dividend” may be lower for U.S. federal income tax purposes than it is for Canadian federal income tax purposes, resulting in a reduced foreign tax credit allowance to a U.S. Holder. In addition, this limitation is calculated separately with respect to specific categories of income. The foreign tax credit rules are complex, and each U.S. Holder should consult its own tax advisors regarding the foreign tax credit rules.

Foreign Currency

The amount of any distribution or proceeds paid in Canadian dollars to a U.S. Holder in connection with the ownership of GGB Shares, or on the sale, exchange or other taxable disposition of GGB Shares, or any Canadian dollars received as a result of Aphria Shareholders exercising dissent rights under a Compulsory Acquisition or Subsequent Acquisition Transaction, generally will be equal to the U.S. dollar value of such Canadian dollars based on the exchange rate applicable on the date of receipt (regardless of whether such Canadian dollars are converted into U.S. dollars at that time). A U.S. Holder that receives Canadian dollars and converts such Canadian dollars into U.S. dollars at a conversion rate other than the rate in effect on the date of receipt may have a foreign currency exchange gain or loss, which generally would be treated as U.S. source ordinary income or loss for foreign tax credit purposes.

Taxable dividends with respect to GGB Shares that are paid in Canadian dollars will be included in the gross income of a U.S. Holder as translated into U.S. dollars calculated by reference to the exchange rate prevailing on the date of actual or constructive receipt of the dividend, regardless of whether the Canadian dollars are converted into U.S. dollars at that time. If the Canadian dollars received are not converted into U.S. dollars on the date of receipt, a U.S. Holder will have a basis in the Canadian dollars equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who receives payment in Canadian dollars and engages in a subsequent conversion or other disposition of the Canadian dollars may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes.

Different rules apply to U.S. Holders who use the accrual method. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of Canadian dollars.

Additional Tax on Passive Income

Certain U.S. Holders that are individuals, estates or trusts (other than trusts that are exempt from tax) will be subject to a 3.8% tax on all or a portion of their “net investment income,” which includes dividends on the Aphria Shares or GGB Shares and net gains from the disposition of the Aphria Shares or GGB Shares. Further, certain complex rules apply if Aphria and/or GGB were treated as a PFIC. U.S. Holders that are individuals, estates or trusts should consult their own tax advisors regarding the applicability of this tax to any of their income or gains in respect of the Aphria Shares or GGB Shares.

Information Reporting; Backup Withholding Tax

Under U.S. federal income tax law and U.S. Treasury Regulations, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a non-U.S. corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain threshold amounts. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial

 

66


instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a non-U.S. entity. Penalties for failure to file certain of these information returns are substantial. A US Holder may also be required specifically to report a sale or other taxable disposition of the GGB Shares to the IRS if it recognises a foreign currency or other loss from a single transaction that exceeds, in the case of an individual or trust, USD$50,000 in a single taxable year or, in other cases, various higher thresholds. U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.

Payments made within the U.S. or by a U.S. payor or U.S. middleman, of: (a) distributions on the GGB Shares; (b) proceeds arising from the sale or other taxable disposition of GGB Shares; or (c) any payments received in connection with a Compulsory Acquisition or Subsequent Acquisition Transaction generally may be subject to information reporting and backup withholding tax, at the rate of 24%, if a U.S. Holder: (i) fails to furnish such U.S. Holder’s correct U.S. taxpayer identification number (generally on IRS Form W-9); (ii) furnishes an incorrect U.S. taxpayer identification number; (iii) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax; or (iv) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder’s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner.

The discussion of reporting requirements set forth above is not intended to constitute an exhaustive description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.

 

20.

Offerees’ Statutory Rights

Securities legislation in certain of the provinces and territories of Canada provides securityholders of Aphria with, in addition to any other rights they may have at law, one or more rights of rescission, price revision or to damages if there is a misrepresentation in a circular or notice that is required to be delivered to such securityholders. However, such rights must be exercised within prescribed time limits. Aphria Shareholders should refer to the applicable provisions of the securities legislation of their province or territory for the particulars of those rights or consult with a lawyer.

 

21.

Material Changes and Other Information

Except as disclosed elsewhere in this Circular or as publicly disclosed by Aphria, the Offeror has no information which indicates any material change in the affairs of Aphria since the date of the last published financial statements of Aphria, and the Offeror has no knowledge of any other matter that has not previously been generally disclosed but that would reasonably be expected to affect the decision of the Aphria Shareholders to accept or reject the Offer.

 

22.

Regulatory Matters

Competition Act

Part IX of the Competition Act requires that the parties to certain classes of transactions provide prescribed information to the Commissioner where the applicable thresholds set out in Sections 109 and 110 of the Competition Act are exceeded and no exemption applies (each, a “Notifiable Transaction”).

Subject to certain limited exceptions, a Notifiable Transaction cannot be completed until the parties to the transaction have each submitted the information prescribed pursuant to subsection 114(1) of the Competition Act (a “Notification”) to the Commissioner and the applicable waiting period has expired or been waived or terminated

 

67


early by the Commissioner. If a proposed transaction is an unsolicited offer to acquire the shares of a corporation and the Commissioner receives the offeror’s Notification, the Commissioner is required under subsection 114(3) of the Competition Act to immediately notify the corporation whose shares the offeror proposes to acquire that the Commissioner has received the offeror’s Notification, and such corporation must supply its Notification within ten (10) days thereafter.

The waiting period is 30 days after the day on which the parties to the transaction each submits a Notification, except in the case of an unsolicited offer where, pursuant to subsection 123(3) of the Competition Act, the period begins on the date on which the offeror submits its Notification. The parties are, or the offeror in an unsolicited offer is, entitled to complete the Notifiable Transaction at the end of the 30-day period, unless the Commissioner notifies the parties (or the offeror in an unsolicited offer), pursuant to subsection 114(2) of the Competition Act, that he requires additional information that is relevant to the Commissioner’s assessment of the transaction (a “Supplementary Information Request”). If the Commissioner provides the parties with a Supplementary Information Request, the Notifiable Transaction cannot be completed until 30 days after compliance with such Supplementary Information Request, provided that there is no order issued by the Competition Tribunal (the “Tribunal”) as established by subsection 3(1) of the Competition Tribunal Act (Canada) in effect prohibiting completion at the relevant time. In the case of an unsolicited offer, the 30-day period following compliance with the Supplementary Information Request begins on the day after the offeror’s compliance with the Supplementary Information Request.

The parties to a transaction are legally entitled to complete their transaction: (a) upon expiry of the applicable statutory waiting period; (b) upon the Commissioner’s issuance of an advance ruling certificate pursuant to Section 102 of the Competition Act (an “ARC”); or (c) upon the Commissioner’s issuance of a letter indicating that he does not, at that time, intend to challenge the transaction by making an application to the Tribunal under Section 92 of the Competition Act while reserving the Commissioner’s statutory right to challenge the transaction before the Tribunal at any time within one year of the transaction being completed (a “No-Action Letter”) together with either (i) expiry of the applicable statutory waiting period; or (ii) waiver of the Notification requirement and, accordingly, the applicable waiting period.

At any time before a “merger” (as defined in the Competition Act) is completed, even where the Commissioner has been notified under subsection 114(1) of the Competition Act and the applicable waiting period has expired, the Commissioner may apply to the Tribunal for an interim order under subsection 100(1) of the Competition Act forbidding any person named in the application from doing any act or thing where it appears to the Tribunal that such act or thing may constitute or be directed toward the completion or implementation of a proposed merger. The Tribunal may issue such an order for up to 30 days where (a) the Commissioner has certified that an inquiry is being made under paragraph 10(1)(b) of the Competition Act and that, in his opinion, more time is required to complete the inquiry, and (b) the Tribunal finds that, in the absence of an interim order, a party to the proposed merger or any other person is likely to take an action that would substantially impair the ability of the Tribunal to remedy the effect of the proposed merger on competition under Section 92 of the Competition Act because that action would be difficult to reverse. The duration of such interim order may be extended for a period of up to an additional 30 days where the Tribunal finds, on application made by the Commissioner, that the Commissioner is unable to complete the inquiry within the period specified in the order because of circumstances beyond the control of the Commissioner.

Whether or not a merger is subject to notification under Part IX of the Competition Act, the Commissioner can apply to the Tribunal for a remedial order under Section 92 of the Competition Act at any time before the merger has been completed or, if completed, within one year after it was substantially completed, provided that the Commissioner did not issue an ARC in respect of the merger, or, if the Commissioner did issue an ARC in respect of the merger, provided that (a) the merger was completed within one year after the ARC was issued and (b) the grounds upon which the Commissioner intends to apply to the Tribunal for a remedial order are not the same or substantially the same as the information on the basis of which the ARC was issued. On application by the Commissioner under Section 92 of the Competition Act, the Tribunal may, where it finds that the merger prevents or lessens, or is likely to prevent or lessen, competition substantially, order that the merger not proceed or, if completed, order its dissolution or the disposition of assets or shares involved in such merger; in addition to, or in

 

68


lieu thereof, with the consent of the person against whom the order is directed and the Commissioner, the Tribunal may order a person to take any other action. The Tribunal is prohibited from issuing a remedial order where it finds that the merger or proposed merger has brought or is likely to bring about gains in efficiency that will be greater than, and will offset, the effects of any prevention or lessening of competition that will result or is likely to result from the merger and that the gains in efficiency would not likely be attained if the order were made.

The transactions contemplated by the Offer constitute a “merger” and based on the publicly available financial information regarding Aphria, most notably its most recently completed audited annual financial statements, the Offeror believes the transactions constitute a Notifiable Transaction. The obligation of the Offeror to complete the Offer is, among other things, subject to the condition that, either (i) the Offeror receives an ARC; or (ii) the Offeror receives a No-Action Letter and there is an expiry, termination or waiver of the waiting period under Part IX of the Competition Act, in either case on terms satisfactory to the Offeror, exercising its sole judgement (“Competition Act Approval”). See Section 4 of the Offer to Purchase, “Conditions of the Offer”.

Cannabis Act

The Cannabis Act requires that all activities undertaken with cannabis (including but not limited to: possession, cultivation, processing, testing, packaging and sale) be undertaken in accordance with one or more active licences, permits, authorizations and/or clearances issued by Health Canada. In addition, the Cannabis Act requires the identification and security clearance of certain individuals associated with the licence holder.

The transactions contemplated by the Offer will require the transfer and/or issuance of licences, permits, authorizations and clearances by Health Canada in order for the Offeror to be able to operate the business of the combined company following completion of the Offer in compliance with applicable Laws.

 

23.

Depositary and Information Agent

The Offeror has engaged Kingsdale to act as Depositary for the receipt of certificate(s) or DRS Statement(s) in respect of Aphria Shares and related Letters of Transmittal and Notices of Guaranteed Delivery deposited under the Offer, and as Information Agent to provide information to holders of Aphria Shares in connection with the Offer. Kingsdale will receive reasonable and customary compensation from the Offeror for its services relating to the Offer and will be reimbursed for certain out-of-pocket expenses. The Offeror has also agreed to indemnify Kingsdale against certain liabilities and expenses in connection with the Offer, including certain liabilities under applicable Canadian Securities Laws.

No fee or commission is payable by any Aphria Shareholder who transmits its Aphria Shares directly to the Depositary and Information Agent. If you hold Aphria Shares through a broker or other nominee and such broker or nominee deposits the Aphria Shares on your behalf, the broker or nominee may charge a fee for performing this service. Questions and requests for assistance concerning the Offer should be made directly to the Depositary and Information Agent.

Kingsdale can be contacted by telephone at 1-866-851-3214 (North American Toll Free Number) or 416-867-2272 (outside North America) or by email at contactus@kingsdaleadvisors.com.

 

24.

Financial Advisor, Dealer Manager and Soliciting Dealer Group

The Offeror may, in its sole discretion, also retain the services of one or more dealer manager(s) as it determines, to form and manage a soliciting dealer group (the “Soliciting Dealer Group”) comprised of members of the Investment Industry Regulatory Organization of Canada and members of the TSX to solicit acceptances of the Offer from persons who are resident in Canada on terms and conditions, including the payment of fees and reimbursement of expenses, as are customary in a retainer agreement for such services. Each member of the Soliciting Dealer Group is referred to herein as a “Soliciting Dealer”.

The Offeror expects that if a dealer manager is engaged and/or a Soliciting Dealer Group is formed, then the Offeror will provide notice of such event by press release and/or such other means as the Offeror may determine. Investment advisors or registered representatives employed by soliciting dealers, if any, may solicit their clients to deposit or

 

69


tender their Aphria Shares to the Offer. Soliciting Dealers may pay an investment advisor or registered representative a portion of the solicitation fee, if any, for each Aphria Share deposited or tendered to the Offer by clients of or served by the investment advisor or registered representative.

Holders of Aphria Shares will not be required to pay any fee or commission if they accept the Offer by depositing their Aphria Shares directly with the Depositary and Information Agent or if they make use of the services of a Soliciting Dealer, if any, to accept the Offer. However, an investment advisor, broker, bank, trust company or other intermediary through whom Aphria Shareholders own Aphria Shares may charge a fee to tender any such Aphria Shares on their behalf. Aphria Shareholders should contact the Depositary and Information Agent or a broker or dealer for assistance in accepting the Offer and depositing their Aphria Shares with the Depositary and Information Agent.

Except as set out herein, the Offeror has not agreed to pay any fees or commissions to any stockbroker, dealer or other person for soliciting tenders of Aphria Shares under the Offer; provided that the Offeror may make other arrangements with soliciting dealers, dealer managers or information agents, either within or outside Canada, for customary compensation during the Offer period if it considers it appropriate to do so.

 

25.

Expenses of the Offer

The Offeror estimates that if it acquires any and all of the Aphria Shares, including any Aphria Shares issued following the date hereof pursuant to the exercise of Convertible Securities, pursuant to the Offer, the total cash amount of related fees and expenses, including legal, financial advising, accounting, filing and printing costs, the cost of preparation and mailing the Offer, will be approximately $20,000,000 in expenses.

 

26.

Benefits from the Offer

Other than as disclosed elsewhere in this Circular, no person named in Section 12 of this Circular, “Beneficial Ownership of and Trading in Securities of Aphria”, will receive any direct or indirect benefit from accepting or refusing to accept the Offer, other than the consideration available to any Aphria Shareholder who deposits Aphria Shares to the Offer.

 

27.

Experts

The audited consolidated financial statements of the Offeror for the year ended June 30, 2018 incorporated by reference in this Offer to Purchase and Circular have been audited by MNP LLP, chartered professional accountants, as stated in its report in respect thereof dated September 13, 2018, which is incorporated by reference into this Offer to Purchase and Circular. The audited consolidated financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. MNP LLP has confirmed that it is independent of the Offeror within the meaning of the relevant rules and related interpretations prescribed by the relevant professional bodies in Canada and any applicable legislation or regulations.

 

28.

Legal Matters

Legal matters on behalf of the Offeror will be passed upon by, and the opinion contained in Section 18 of this Circular, “Certain Canadian Federal Income Tax Considerations”, has been provided by, Norton Rose Fulbright Canada LLP, counsel to the Offeror. As of the date of this Circular, the partners and associates of Norton Rose Fulbright Canada LLP beneficially owned, directly or indirectly, less than 1% of the outstanding securities of any class of the Offeror or of Aphria.

 

29.

Risk Factors

Aphria Shareholders should carefully consider the following risk factors related to the Offer and the Offeror and the risks set out in the documents incorporated by reference in this Offer to Purchase and Circular. Such risks may not be the only risks applicable to the Offer or the Offeror. Additional risks and uncertainties not presently known by the Offeror or that the Offeror currently believes are not material may also materially and adversely affect the successful

 

70


completion of the Offer or the business, operations, prospects, financial condition, financial performance, cash flows or reputation of the Offeror.

Risk Factors Related to the Offer and the Offeror

The Offer may not be completed for a variety of reasons

In addition to various risks identified under the heading “Forward-Looking Statements and Information”, completion of the Offer is subject to satisfaction or waiver of a number of conditions, certain of which are outside the control of the Offeror, including, but not limited to Aphria Shareholders tendering a sufficient number of Aphria Shares to the Offer, and the Offeror obtaining the Regulatory Approvals, as needed. There is no certainty, nor can the Offeror provide any assurance, that the conditions of the Offer will be satisfied.

If the Offer is completed, the market for Aphria Shares may be adversely affected, Aphria Shares may be delisted and Aphria may cease to be a reporting issuer.

The purchase of any Aphria Shares under the Offer will reduce the number of Aphria Shares that might otherwise trade publicly, as well as the number of Aphria Shareholders, and, depending on the number of Aphria Shareholders participating in the Offer and the number of Aphria Shares deposited by such Aphria Shareholders under the Offer, successful completion of the Offer would likely adversely affect the liquidity and market value of the remaining Aphria Shares held by the public.

After the purchase of the Aphria Shares under the Offer, the Offeror may be able to cause Aphria to eliminate any public reporting obligations of Aphria under applicable Securities Laws. The rules and regulations of the TSX and the NYSE establish certain criteria that, if not met, could lead to the delisting of the Aphria Shares from the TSX and the NYSE. Although it is possible that the Aphria Shares could be traded on other securities exchanges or in the over-the-counter market, and price quotations would be reported by such exchanges or by other sources, there can be no assurance that any such trading or quotations will occur. In addition, the extent of the public market for the Aphria Shares and the availability of such quotations would depend upon the number of holders and/or the aggregate market value of the Aphria Shares remaining at such time and the interest in maintaining a market in the Aphria Shares on the part of securities firms. The Offeror intends to cause Aphria to apply to delist the Aphria Shares from the TSX and the NYSE as soon as practicable after the completion of the Offer or any Compulsory Acquisition or Subsequent Acquisition Transaction. If the Aphria Shares are delisted and if Aphria ceases to be a “public corporation” for the purposes of the Tax Act of any reason, Aphria Shares may cease to be qualified investments for trusts governed by RRSPs, RRIFs, RESPs, RDSPs, deferred profit sharing plans and TFSAs. Delisting can also have adverse tax consequences to non-resident Aphria Shareholders, as described in Section 18 of this Circular, “Certain Canadian Federal Income Tax Considerations”.

Because the market price of GGB Shares will fluctuate, Aphria Shareholders cannot be sure of the market price of the GGB Shares they will receive, and such value may be materially different than expected.

Pursuant to the Offer, Aphria Shareholders who tender their Aphria Shares to the Offer (including any Aphria Shares that may become issued and outstanding after the date of the Offer but before the Expiry Time upon the conversion, exchange or exercise of any Convertible Securities) will receive 1.5714 GGB Shares in exchange for each Aphria Share. The number of GGB Shares per Aphria Share will not be adjusted to reflect any change in the market value of GGB Shares that may occur prior to the time of take up of Aphria Shares under the Offer. The market price of GGB Shares will continue to fluctuate after the date of the Offer and may vary significantly from the market prices on the dates referenced in this Offer to Purchase and Circular or the offering price established for the purposes of completing the Financing. Accordingly, Aphria Shareholders will not know or be able to determine the market price of the GGB Shares they will receive upon completion of the Offer, the Compulsory Acquisition or a Subsequent Acquisition Transaction until their Aphria Shares are taken up and paid for. Thereafter, the market price of the GGB Shares will also continue to fluctuate. It is possible that, at the time of the completion of the Offer or the Compulsory Acquisition or a Subsequent Acquisition Transaction, the Aphria Shares held by Aphria Shareholders may have a greater market price than the GGB Shares for which they are exchanged. The market price of GGB Shares on the date of this Offer to Purchase and Circular or at any time after or the price that is contemplated in the

 

71


Financing may not be indicative of the market price of GGB Shares that Aphria Shareholders will receive upon completion of the Offer or the Compulsory Acquisition or a Subsequent Acquisition Transaction. The market prices of GGB Shares and Aphria Shares are subject to general price fluctuations in the market for publicly traded equity securities and have experienced significant volatility in the past. Share price changes may result from a variety of factors, including general market and economic conditions and changes in the respective businesses, operations and prospects, and regulatory considerations of GGB and Aphria. Market assessments of the benefits of the Offer and the likelihood that the Offer will be completed, as well as general and industry-specific market and economic conditions, may also impact market prices of GGB Shares and Aphria Shares. Many of these factors are beyond the Offeror’s control. You should obtain current market quotations for GGB Shares and for Aphria Shares. See also Section 9 of this Circular, “Financing”.

The Offeror may not be able to complete the Financing on the terms currently contemplated, or at all.

The Financing has not been completed, and there can be no assurance that the Financing will be completed or, if completed, what the terms of the Financing would be. Completion of the Financing is conditional upon the successful completion of the Offer and the Financing is not contemplated to be consummated until following the date on which the Offeror takes-up the Aphria Shares under the Offer. The Financing may not be completed due to a variety of factors that are beyond the Offeror’s control. If completed, the Financing may have terms, including, but not limited to, the issuance price per GGB Share, that are different than the terms currently expected and set forth in this Offer to Purchase and Circular. Conditions to the completion of the Financing may fail to be satisfied following the time at which the Offeror takes up and pays for any Aphria Shares that are validly tendered to the Offer and not validly withdrawn, and such former Aphria Shareholders will neither be entitled to any notice that the Financing will not be completed nor have any ability to withdraw such Aphria Shares.

Former Aphria Shareholders who tendered Aphria Shares to the Offer and did not validly withdraw such Aphria Shares will not have any ability to withdraw such Aphria Shares following the take up of Aphria Shares under the Offer in the event that, following the date that the Offeror takes-up the Aphria Shares under the Offer, the Financing is not completed or is not completed on the terms set forth herein.

The issuance of GGB Shares as consideration under the Offer could adversely affect the market price of GGB Shares after the take up of Aphria Shares under the Offer.

If the fully diluted Aphria Shares are tendered to the Offer, a significant number of additional GGB Shares will be available for trading in the public market. The overall increase in the number of GGB Shares may lead to sales of such shares or the perception that such sales may occur, either of which may adversely affect the market for, and consequently the market price of, GGB Shares. The perceived risk of substantial sales of GGB Shares, as well as any actual sales of such GGB Shares in the public market, could adversely affect the market price of GGB Shares.

The acquisition of all of the outstanding Aphria Shares might not be successfully completed without the possibility of Aphria Shareholders exercising dissent and appraisal rights in connection with a Compulsory Acquisition or a Subsequent Acquisition Transaction.

In order for the Offeror to acquire all of the issued and outstanding Aphria Shares, it will likely be necessary, following consummation of the Offer, to effect a Compulsory Acquisition or Subsequent Acquisition Transaction. A Compulsory Acquisition or Subsequent Acquisition Transaction may result in Aphria Shareholders having the right to dissent and demand payment of the fair value of their Aphria Shares. If the statutory procedures governing dissent rights are available and are complied with, this right could lead to a judicial determination of the fair value required to be paid to such dissenting Aphria Shareholders for their Aphria Shares that is different from the consideration to be paid under the Offer. There is no assurance that a Compulsory Acquisition or Subsequent Acquisition Transaction can be completed without Aphria Shareholders exercising dissent rights in respect of a substantial number of Aphria Shares, which could result in the requirement to make a substantial cash payment that could have an adverse effect on the Offeror’s financial position and liquidity.

The tax consequences to an Aphria Shareholder under the Offer may differ materially from the tax consequences to an Aphria Shareholder under a Compulsory Acquisition or Subsequent Acquisition Transaction.

 

72


Following the completion of the Offer and prior to the completion of any Compulsory Acquisition or Subsequent Acquisition Transaction or if a Compulsory Acquisition or Subsequent Acquisition Transaction cannot be completed, the trading liquidity for Aphria Shares not deposited under the Offer will be reduced, which might affect the price of the Aphria Shares and the ability of an Aphria Shareholder to dispose of its Aphria Shares.

If the Offer is completed, the liquidity and market value of any remaining Aphria Shares, prior to the completion of any Compulsory Acquisition or Subsequent Acquisition Transaction, held by the public could be adversely affected by the fact that they will be held by a smaller number of holders. The purchase of any Aphria Shares by the Offeror pursuant to the Offer will reduce the number of Aphria Shares that might otherwise trade publicly, as well as the number of Aphria Shareholders, and, depending on the number of Aphria Shareholders depositing and the number of Aphria Shares purchased under the Offer, successful completion of the Offer would likely adversely affect the liquidity and market value of the remaining Aphria Shares held by the public. In addition, if the Offeror is unable to complete a Compulsory Acquisition or Subsequent Acquisition Transaction, the liquidity and market value of the Aphria Shares held by the public will likely be adversely affected. After the purchase of the Aphria Shares under the Offer, it may be possible for Aphria to take steps towards the elimination of any applicable public reporting requirements under applicable securities legislation in any province of Canada. If such requirements are eliminated, Aphria will cease filing periodic reports with the Canadian Securities Administrators and or the SEC, which may further impact the value of the Aphria Shares.

The rules and regulations of the TSX and the NYSE establish certain criteria that, if not met, could lead to the delisting of the Aphria Shares from such exchanges. Among such criteria are the number of shareholders, the number of Aphria Shares publicly held and the aggregate market value of the Aphria Shares publicly held. Depending on the number of Aphria Shares purchased under the Offer, it is possible that Aphria would fail to meet the criteria for continued listing on the TSX or the NYSE. If this were to happen, the Aphria Shares could be delisted and this could, in turn, adversely affect the market or result in a lack of an established market for the Aphria Shares. The Offeror intends to cause Aphria to apply to delist the Aphria Shares from the TSX and the NYSE as soon as practicable after the completion of the Offer or any Compulsory Acquisition or Subsequent Acquisition Transaction. If the Aphria Shares are delisted and Aphria ceases to be a “public corporation” for the purposes of the Tax Act, Aphria Shares would cease to be qualified investments for trusts governed by RRSPs, RESPs, RRIFs, TFSAs, and deferred profit sharing plans. Delisting can also have adverse tax consequences to non-resident Aphria Shareholders, as described under “Certain Canadian Federal Income Tax Considerations” in Section 18 of this Circular.

After consummation of the Offer, Aphria could be a majority-owned subsidiary of the Offeror and the Offeror’s interest could differ from that of the remaining minority Aphria Shareholders.

After consummation of the Offer (which may result in the Offeror holding less than 100% of the issued and outstanding Aphria Shares), the Offeror would have the ability to elect the directors of Aphria, appoint new management or approve certain actions requiring the approval of Aphria Shareholders, including, in the event the Offeror acquires at least 66 2/3% of the issued and outstanding Aphria Shares, adopting certain amendments to Aphria’s constating documents and approving mergers or sales of Aphria’s assets. In particular, after the consummation of the Offer, the Offeror intends to exercise its statutory right of Compulsory Acquisition, if available, to acquire all of the Aphria Shares not deposited under the Offer or, if such statutory right of acquisition is not available or the Offeror elects not to pursue such right, to integrate Aphria and the Offeror, by a Subsequent Acquisition Transaction for the purpose of enabling the Offeror or an affiliate to acquire all Aphria Shares not acquired under the Offer. In any of these contexts, the Offeror’s interests with respect to Aphria may differ from, and conflict with, those of any remaining minority Aphria Shareholders.

Change of control provisions in Aphria’s agreements triggered upon the acquisition of Aphria may lead to adverse consequences.

Aphria may be a party to agreements that contain change of control provisions that may be triggered following successful completion of the Offer, since the Offeror would then hold Aphria Shares representing a majority of the voting rights of Aphria. The operation of these change of control provisions, if triggered, could result in unanticipated expenses and/or cash payments following the consummation of the Offer or adversely affect Aphria’s

 

73


results of operations and financial condition or, following the completion of any Compulsory Acquisition or Subsequent Acquisition Transaction, the results of operations and financial condition of Aphria and the Offeror on a combined basis. Unless these change of control provisions are waived by the other party to any such agreements, the operation of any of these provisions could adversely affect the results of operations and financial condition of Aphria or, following the completion of any Compulsory Acquisition or Subsequent Acquisition Transaction, the results of operations and financial condition of Aphria and the Offeror on a combined basis.

The Offeror has been unable to independently verify the accuracy and completeness of Aphria information in this Offer to Purchase and Circular.

The Offeror has not had access to Aphria’s detailed accounting records or other non-public books and records. The Offeror has not been able to independently assess or verify the information in Aphria’s publicly filed documents, including its financial statements. As a result, all historical information regarding Aphria contained herein, including all of Aphria’s financial information and all pro forma financial information reflecting the pro forma effects of a combination of Aphria and the Offeror derived in part from Aphria’s financial information, has been derived, by necessity, from Aphria’s public reports and securities filings. Although the Offeror has no reason to doubt the accuracy of Aphria’s publicly disclosed information, any inaccuracy or material omission in Aphria’s publicly available information, including the information about or relating to Aphria contained in the Offer, could result in unanticipated liabilities or expenses, increase the cost of integrating the two companies, or adversely affect the operational plans of the combined company and its results of operations and financial condition.

The Offeror may not realize all of the anticipated benefits and synergies from the completion of the transaction.

The Offer has been made with the expectation that its successful completion will result in certain synergies and costs savings. These anticipated benefits will depend in part on whether the operations of Aphria and the Offeror can be integrated in an efficient and effective manner and the timing and manner of completion of a Compulsory Acquisition or Subsequent Acquisition Transaction, if any. The integration of the two companies may present challenges to management of the Offeror, and the Offeror may encounter unanticipated delays, liabilities and costs. If the Offeror does not acquire at least 6623% of the Aphria Shares and cannot or does not complete a Compulsory Acquisition or Subsequent Acquisition Transaction, it will not be able to fully and efficiently integrate Aphria into its business. In addition, many operational and strategic decisions regarding the integration have not yet been made, including decisions about the integration of the assets, systems and personnel of the two companies, as well as risks relating to possible unanticipated liabilities, unanticipated costs and the loss of key employees. There can be no assurance that the operational or other synergies that the Offeror expects to realize in the combined company will be ultimately realized, or that the integration of the operations of both companies will be timely or effectively accomplished, or will ultimately result in cost reductions.

The Offeror may have difficulty accessing banks and financial services

The Offeror may have difficulty accessing the services of banks, which may make it difficult for the Offeror to operate. Since the use of cannabis is illegal under U.S. federal Law, and in light of concerns in the banking industry regarding money laundering and other federal financial crime related to cannabis, U.S. banks have been reluctant to accept deposit funds from businesses involved with the cannabis industry. Consequently, businesses involved in the cannabis industry often have difficulty finding a bank willing to accept their business. Likewise, cannabis businesses have limited, if any, access to credit card processing services. As a result, cannabis businesses in the U.S. may be cash-only. This complicates the implementation of financial controls and increases security issues. The inability to open or maintain bank accounts or take credit cards may make it difficult for the Offeror to operate. The lack of banking and financial services presents unique and significant challenges to businesses in the cannabis industry. The potential lack of a secure place in which pay creditors through the issuance of cheques and the inability to secure traditional forms of operational financing, such as lines of credit, are some of the many challenges presented by the unavailability of traditional banking and financial services.

 

74


The Offeror is an early stage company that lacks an established operating history

The Offeror’s business has only recently been established and has no history of earnings. The Offeror’s lack of operating history may make it difficult for investors to evaluate the Offeror’s prospects for success. There is no assurance that the Offeror will be successful and the likelihood of success must be considered in light of its relatively early stage of operations. The Offeror’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Offeror’s revenue, EBITDA and expenses may differ materially from the revenue, EBITDA and expenses profits provided in this presentation. Such information is presented for illustrative purposes only. The process for estimating the Offeror’s revenue, EBITDA and expense requires the use of judgment in determining the appropriate assumptions and estimates. These estimates and assumptions may be revised as additional information becomes available and as additional analyses are performed. In addition, the assumptions used in preparing this presentation may not prove to be accurate, and other factors may affect the Offeror’s financial condition or results of operations. Any potential decline in the Offeror’s financial condition or results of operations may negatively impact the ability to pay amounts on its issued and outstanding convertible debentures and the Offeror’s ability to complete a business combination. Some of the financial information on which the information in this presentation is based has been provided by third parties, which financial information management believes to be reliable but there can be no assurances that such information is accurate. The development of the business of the Offeror and its ability to execute on the acquisition opportunities described herein will depend, in part, upon the amount of additional financing available. Failure to obtain sufficient financing may result in delaying, scaling back, eliminating or indefinitely postponing the acquisitions and the business of the Offeror’s current or future operations. There can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be acceptable. Part of the Offeror’s business strategy includes acquiring and integrating complementary businesses, products, or other assets, and forming strategic alliances, joint ventures and other business combinations, to help drive future growth. Acquisitions or similar arrangements may be complex, time consuming and expensive. In particular, there can be no assurance that any acquisition opportunities will be completed or, if completed, will be completed within the proposed timeframe or on terms that are exactly the same as or similar to those disclosed in this presentation. There can be no assurance that future acquisition opportunities may arise and, if they do, that the Offeror will be able to consummate such acquisition opportunities. The Offeror may not be able to consummate negotiations for acquisitions or other arrangements, which could result in significant diversion of management and other employee time, as well as substantial out-of-pocket costs. In addition, there are a number of legal, financial and reputational risks relating to closing transactions. If such transactions are not completed for any reasons, the Offeror will be subject to such risks and uncertainties.

Additional financing presents a risk of dilution to existing shareholders

The Offeror will require equity and/or debt financing to support on-going operations, to undertake capital expenditures or to undertake acquisitions or other business combination transactions. The Offeror’s inability to raise financing of fund capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon future profitability. If additional funds are raised through further issuances of equity or convertible debt securities (for example, the Financing, if completed), existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences and privileges superior to holders of GGB Shares. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the Offeror to obtain additional capital and to pursue business opportunities.

Fluctuation in the exchange rates of foreign currencies may negatively impact the Offeror’s business, financial condition and results of operations.

The Offeror has operations in the United States which generate a significant portion of its sales, and incurs a significant portion of its expenses in currencies other than the Canadian dollar. To the extent that the Offeror is unable to match revenues received in foreign currencies with costs paid in the same currency, exchange rate fluctuations in any such currency could have an adverse effect on the Offeror’s financial results. In particular, currency fluctuations between the Canadian dollar and the U.S. dollar affect the Offeror’s results as reported in Canadian dollars. These fluctuations could adversely affect the Offeror’s revenues and results of operations.

 

75


30.

Documents Filed as Part of the Registration Statement

The following documents have been filed with the SEC as part of the Registration Statement and the Tender Offer Statement: (i) this Offer to Purchase and Circular; (ii) the Letter of Transmittal; (iii) the Notice of Guaranteed Delivery; (iv) press releases related to the Offer, dated December 27, 2018, December 31, 2018 and January 22, 2019; (v) the documents listed in Section 3 of this Circular, “Documents Incorporated by Reference and Further Information”; (vi) powers of attorney pursuant to which the Registration Statement was, or amendments to the Registration Statement may be, signed; and (vii) consents of legal counsel and auditors.

 

31.

Exemption from National Instruments

The Offeror has been exempted from the restricted security requirements under National Instrument 41-101General Prospectus Requirements (“NI 41-101”) (Sections 12.2 and 12.3) and Form 41-101F1Information Required in a Prospectus (Sections 1.13 and 10.6), including that the GGB Shares be referred to using a term or a defined term that includes a restricted security term. As a condition of obtaining the requested exemption, the Offeror is required to make the following disclosure related to characteristics of the PV Shares and GGB Shares:

 

   

The PV Shares constitute subject securities (as defined in NI 41-101, National Instrument 51-102Continuous Disclosure Obligations and Ontario Securities Commission Rule 56-501Restricted Shares) and the Offeror’s only issued and outstanding subject securities are the PV Shares.

 

   

The Offeror’s authorized share capital consists of (i) an unlimited number of GGB Shares; and (ii) an unlimited number of PV Shares.

 

   

The GGB Shares may at any time, at the option of the holder thereof, be converted into PV Shares on the basis of 500 GGB Shares for one PV Share.

 

   

The PV Shares may at any time, at the option of the holder thereof, be converted into GGB Shares on the basis of 500 GGB Shares for one PV Share.

 

   

Each PV Share is entitled to dividends if, as and when dividends are declared by the board of directors of GGB, with each PV Share being entitled to 500 times the amount paid or distributed per GGB Share.

 

   

In the event of the liquidation, dissolution or winding-up of the Offeror, the holders of PV Shares are entitled to participate in the distribution of the remaining property and assets of the Offeror, with each PV Share being entitled to 500 times the amount distributed per GGB Share, and otherwise without preference or distinction among or between the shares.

 

   

The holders of the GGB Shares and PV Shares are entitled to receive notice of, attend and vote at any meeting of shareholders of the Offeror, except those meetings at which holders of a specific class of shares are entitled to vote separately as a class under the OBCA.

 

   

The GGB Shares will carry one vote per share and the PV Shares will carry 500 votes per share.

 

   

The rights, privileges, conditions and restrictions attaching to the GGB Shares and PV Shares may be modified if the amendment is authorized by not less than 6623% of the votes cast at a meeting of holders of the GGB Shares and PV Shares duly held for that purpose. However, if the holders of PV Shares, as a class, or the holders of GGB Shares, as a class, are to be affected in a manner materially different from such other class of shares, the amendment must, in addition, be authorized by not less than 6623% of the votes cast at a meeting of the holders of the class of such shares which is affected differently.

 

   

No subdivision or consolidation of the GGB Shares or PV Shares may be carried out unless, at the same time, the GGB Shares or PV Shares, as the case may be, are subdivided or consolidated in the same manner and on the same basis, so as to preserve the relative rights of the holders of each class of shares.

 

76


See also Section 2 of this Circular, “Certain Information Concerning Securities of the Offeror – GGB Shares” and “Certain Information Concerning Securities of the Offeror – Proportionate Voting Shares”.

 

32.

Directors’ Approval

The contents of the Offer to Purchase and this Circular have been approved, and the sending thereof to the Aphria Shareholders has been authorized by the board of directors of the Offeror.

 

77


GLOSSARY

In this Offer to Purchase and Circular, unless the subject matter or context is inconsistent therewith, the following terms have the meanings set forth below:

 

“affiliate”

   unless otherwise indicated, has the meaning ascribed thereto in the Securities Act (Ontario);

“Agent’s Message”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Book-based Transfer (CDS and DTC)”;

“Alternative Transaction”

   has the meaning ascribed thereto in NI 62-104;

“AMF”

   means the Québec Autorité des marchés financiers;

“Aphria”

   means Aphria Inc., a company amalgamated under the laws of Ontario;

“Aphria Shareholders”

   means holders of Aphria Shares;

“Aphria Shares”

   means common shares in the capital of Aphria as constituted on the date hereof, together with any Aphria Shares that are issued subsequent to the date hereof but prior to the Expiry Time upon the conversion, exchange or exercise of any Convertible Securities;

“Appointee”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Power of Attorney”;

“ARC”

   has the meaning ascribed thereto in Section 22 of the Circular, “Regulatory Matters – Competition Act”;

“associate”

   unless otherwise indicated, has the meaning ascribed thereto in the Securities Act (Ontario);

“ATOP”

   means the Automated Tender Offer Program system operated by DTC;

“Backstop Investor”

   has the meaning ascribed thereto in Section 9 of the Circular, “Financing”;

“Black Sparrow”

   means Black Sparrow Capital Corp.;

“Book-based Transfer”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Book-based Transfer (CDS and DTC)”;

“Business Combination”

   has the meaning ascribed thereto in Section 2 of the Circular, “Certain Information Concerning Securities of the Offeror – Price Range and Trading Volumes of GGB Shares”;

“business day”

   means any day other than a Saturday, Sunday or day that is observed as a statutory or civic holiday in Toronto, Ontario;

“Canaccord”

   means Canaccord Genuity Corp.;

 

78


“Canada-U.S. Tax Convention”

   has the meaning ascribed thereto in Section 19 of the Circular “Certain United States Federal Income Tax Considerations – Scope of This Disclosure”;

“Canadian Securities Laws”

   means the securities legislation of each of the provinces and territories of Canada, as amended from time to time, and includes all regulations, rules, policy statements, notices and blanket orders or rulings thereunder;

“Cannabis Act”

   means the Cannabis Act (Canada), and the regulations made thereunder, as amended;

“CBD”

   means cannabidiol;

“CDS”

   means The Canadian Depository for Securities Limited;

“CDSX”

   means CDS on-line tendering system;

“Circular”

   means the takeover bid circular accompanying the Offer to Purchase and forming part of the Offer;

“Code”

   means the U.S. Internal Revenue Code of 1986, as amended;

“Commissioner”

   means the Commissioner of Competition under subsection 7(1) of the Competition Act or any person duly authorized to perform duties on behalf of the Commissioner of Competition;

“Commitment”

   has the meaning ascribed thereto in Section 9 of the Circular, “Financing”;

“Commitment Letter”

   has the meaning ascribed thereto in Section 9 of the Circular, “Financing”;

“Competition Act”

   means the Competition Act (Canada), and the regulations made thereunder, as amended;

“Competition Act Approval”

   has the meaning ascribed thereto in Section 22 of the Circular, “Regulatory Matters – Competition Act”;

“Compulsory Acquisition”

   has the meaning ascribed thereto in Section 16 of the Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer – Compulsory Acquisition”;

“Convertible Securities”

   means any existing or future rights, warrants or options to purchase, convert into, exchange into, exercise for or otherwise acquire Aphria Shares;

“Court”

   means the Ontario Superior Court of Justice (Commercial List);

“CRA”

   means the Canada Revenue Agency;

“CSE”

   means the Canadian Securities Exchange;

“Deferred Income Plans”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations – Potential Delisting”;

 

79


“Depositary and Information Agent”

   means Kingsdale Advisors;

“Deposited Securities”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Dividends and Distributions”;

“Direct Exchange”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations – Disposition of Aphria Shares Pursuant to the Offer”;

“Dissenting Offeree”

   has the meaning ascribed thereto in Section 16 of the Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer – Compulsory Acquisition”;

“Distributions”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Dividends and Distributions”;

“DRS Statement”

   means a statement evidencing Aphria Shares issued under the name of the applicable shareholder and registered electronically in Aphria’s records;

“DSW”

   means DSW, Inc. (Designer Shoe Warehouse);

“DTC”

   means The Depository Trust Corporation, or its nominee, which at the date hereof is Cede & Co.;

“EBITDA”

   has the meaning ascribed thereto on the cover pages to this Offer to Purchase and Circular under the heading “Non-IFRS Measures”;

“Effective Date”

   means the first date on which the Offeror has taken up and paid for Aphria Shares under the Offer;

“Eligible Institution”

   means a Canadian Schedule I chartered bank, a member of the Securities Transfer Agents Medallion Program (STAMP), a member of the Stock Exchange Medallion Program (SEMP) or a member of the New York Stock Exchange, Inc. Medallion Signature Program (MSP). Members of these programs are usually members of a recognized stock exchange in Canada or the United States, members of the Investment Dealers Association of Canada, members of the National Association of Securities Dealers or banks and trust corporations in the United States;

“ERISA”

   means the U.S. Employee Retirement Income Security Act of 1974, as amended;

“Expiry Time”

   means 5:00 p.m. (Toronto time) on May 9, 2019, or such earlier or later time and date as may be fixed by the Offeror, from time to time, pursuant to Section 5 of the Offer to Purchase, “Acceleration, Extension and Variation of the Offer”;

“Financing”

   has the meaning ascribed thereto in Section 9 of the Circular, “Financing”;

“Fully-Diluted Basis”

   means, with respect to the number of outstanding Aphria Shares, such number of outstanding Aphria Shares calculated on the assumption that all Convertible Securities, warrants or other rights to purchase or acquire Aphria Shares are exercised in full;

 

80


“GA”

   means GA Opportunities Corp.;

“GA Common Shares”

   has the meaning ascribed thereto in Section 4 of the Circular; “Aphria Inc. – Cannabis Industry Relationships”;

“GGB”

   means Green Growth Brands Inc. (formerly known as Xanthic Biopharma Inc.), a company amalgamated under the laws of the Province of Ontario;

“GGB Ltd.”

   means Green Growth Brands Ltd., a wholly-owned subsidiary of the Offeror;

“GGB Shares”

   means common shares in the capital of GGB;

“Governmental Entity”

   means any (i) multinational, federal, provincial, territorial, state, municipal, local or other governmental or public department, central bank, court, commission, commissioner, tribunal, board, bureau, agency or instrumentality, whether domestic or foreign, (ii) any stock exchange or Over-the-Counter Bulletin Board; (iii) any subdivision or authority of any of the foregoing, (iv) any quasi-governmental or private body exercising any regulatory, expropriation or taxing authority under or for the account of any of the above;

“Green Acre”

   means Green Acre Capital;

“Henderson Option”

   has the meaning ascribed thereto in Section 3 of the Circular, “Documents Incorporated by Reference and Further Information”.

“Henderson Organic”

   has the meaning ascribed thereto in Section 3 of the Circular, “Documents Incorporated by Reference and Further Information”.

“IFRS”

   means International Financial Reporting Standards applicable to Canadian public companies formulated by the International Accounting Standards Board;

“Interested Aphria Shareholders”

   means any Aphria Shareholder who would be excluded from voting as part of the minority in any Subsequent Acquisition Transaction relating to the Aphria Shares pursuant to Part 8 of MI 61-101;

“IRS”

   means the U.S. Internal Revenue Service;

“Kingsdale”

   means Kingsdale Advisors, the Depositary and Information Agent under the Offer;

“Law”

   means all laws, statutes, rulings, ordinances, rules, regulations, judgments, orders, injunctions, decrees, awards, agency requirements, license or permit of any Governmental Entity.

“Letter of Transmittal”

   means the letter of acceptance and transmittal in the form printed on yellow paper accompanying this Offer to Purchase and Circular;

“LOG”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”;

 

81


“LOG option”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”.

“Mandatory Extension Period”

   has the meaning as ascribed thereto in Section 5 of the Offer to Purchase, “Acceleration, Extension and Variation of the Offer”;

“material adverse change”

   means any change, circumstance, development, state of facts, event or effect (i) that, individually or in the aggregate with any other changes, circumstances, developments, state of facts, events or effects, has had or would reasonably be expected to have a material adverse change or effect (taken alone or in the aggregate with any other adverse change or effect) in or with respect to the business, properties, assets, condition (financial or otherwise), liabilities (contingent or otherwise), results of operations or future prospects of Aphria and its affiliates, or (ii) that would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the consummation by the Offeror of the transactions contemplated by the Offer;

“material adverse effect”

   means any change or effect having a material adverse effect on the conduct of the business, results of operations or financial condition, earnings or prospects of Aphria and any of its affiliates, on a consolidated basis;

“MI 61-101”

   means Multilateral Instrument 61-101Protection of Minority Security Holders in Special Transactions;

“Minimum Tender Condition”

   has the meaning ascribed thereto in Section 4 of the Offer to Purchase, “Conditions of the Offer”;

“NI 41-101”

   means National Instrument 41-101General Prospectus Requirements;

“NI 62-104”

   means National Instrument 62-104Take-Over Bids and Issuer Bids;

“No-Action Letter”

   has the meaning ascribed thereto in Section 22 of the Circular, “Regulatory Matters – Competition Act”;

“Non-registered Aphria Shareholder”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Book-based Transfer (CDS and DTC)”;

“Non-Resident Holder”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations – Aphria Shareholders Not Resident in Canada”;

“Nomination Rights Agreement”

   has the meaning ascribed thereto in Section 4 of the Circular; “Aphria Inc. – Cannabis Industry Relationships”;

“Norton Rose Fulbright”

   means Norton Rose Fulbright Canada LLP;

“Notice of Guaranteed Delivery”

   means the notice of guaranteed delivery in the form printed on green paper accompanying this Offer to Purchase and Circular;

“Notifiable Transaction”

   has the meaning ascribed thereto in Section 22 of the Circular, “Regulatory Matters – Competition Act”;

 

82


“Notification”

   has the meaning ascribed thereto in Section 22 of the Circular, “Regulatory Matters – Competition Act”;

“NYSE”

   means the New York Stock Exchange;

“OBCA”

   means the Business Corporations Act (Ontario);

“Offer” or “Offer to Purchase”

   means the offer to purchase Aphria Shares made hereby to Aphria Shareholders, the terms and conditions of which are set forth in the Offer to Purchase, the Circular, the Letter of Transmittal and the Notice of Guaranteed Delivery;

“Offer Consideration”

   has the meaning ascribed thereto in Section 1 of the Offer to Purchase, “The Offer”;

“Offer to Purchase and Circular”

   means, collectively, the Offer to Purchase and the Circular, including, without limitation, the cover pages, summary, and glossary;

“Offeror’s Notice”

   has the meaning ascribed thereto in Section 16 of the Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer – Compulsory Acquisition”;

“Offeror”

   means Green Growth Brands Inc. (formerly known as Xanthic Biopharma Inc.), a company amalgamated under the laws of Ontario;

“Optional Extension Periods”

   has the meaning ascribed thereto in Section 7 of the Offer to Purchase, “Payment for Deposited Aphria Shares”;

“OTCQB”

   means the OTCQB Venture Market;

“person”

   includes any natural person, body corporate, trust, limited partnership, Governmental Entity or other juridical entity;

“PFIC”

   has the meaning ascribed thereto in Section 19 of the Circular “Certain United States Federal Income Tax Considerations – Certain U.S. Federal Income Tax Consequences of the Offer”;

“PFIC-for-PFIC Exception”

   has the meaning ascribed thereto in Section 19 of the Circular “Certain United States Federal Income Tax Considerations – Certain U.S. Federal Income Tax Consequences of the Offer”;

“Proposal”

   has the meaning ascribed thereto in Section 6 of the Circular, “Background to the Offer”;

“Purchased Securities”

   has the meaning ascribed thereto in Section 3 of the Offer to Purchase, “Manner of Acceptance – Power of Attorney”;

“Pure Natures”

   means Pure Natures Wellness Inc. d.b.a Aphria;

“PV Shares”

   has the meaning ascribed thereto in Section 2 of the Circular, “Certain Information Concerning Securities of the Offeror”;

 

83


“QEF”

   has the meaning ascribed thereto in Section 19 of the Circular “Certain United States Federal Income Tax Considerations – Certain U.S. Federal Income Tax Consequences of the Offer”;

“QEF Election”

   has the meaning ascribed thereto in Section 19 of the Circular “Certain United States Federal Income Tax Considerations – Certain U.S. Federal Income Tax Consequences of the Offer”;

“RDSPs”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations – Aphria Shareholders Resident in Canada”;

“Registered Aphria Shareholder”

   has the meaning ascribed thereto in the Summary of this Offer to Purchase and Circular under “How do I deposit my Aphria Shares?”;

“Registration Statement”

   means the registration statement on Form F-10, filed under with the SEC the U.S. Securities Act by GGB with the SEC on January 22, 2019;

“Regulatory Approvals”

   means (i) Competition Act Approval, (ii) the approval of the CSE to list the GGB Shares and approval of the transactions contemplated by the Offer, (iii) all licences, permits, clearances and authorizations required under the Cannabis Act and/or the Food and Drugs Act (Canada); and (iv) such other sanctions, rulings, consents, orders, exemptions, permits and other approvals (including the lapse, without objection, of a prescribed time under a statute or regulation that states that a transaction may be implemented if a prescribed time lapses following the giving of notice without an objection being made) of Governmental Entities (domestic or foreign) that the Offeror determines are required in connection with the commencement of the Offer or the consummation of the Offer, a Compulsory Acquisition or any Subsequent Acquisition Transaction;

“Reorganization”

   has the meaning ascribed thereto in Section 19 of the Circular “Certain United States Federal Income Tax Considerations – Certain U.S. Federal Income Tax Consequences of the Offer”;

“Report”

   means the December 3, 2018 report of Hindenburg Research and Quintessential Capital Management entitled “Aphria: A Shell Game with a Cannabis Business on the Side”;

“Resident Holder”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations – Aphria Shareholders Resident in Canada”;

“RESPs”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”;

“Restricted States”

   has the meaning ascribed thereto under “Notice to Shareholders in the United States – No Offer to Sell or Solicitation of an Offer in Certain States”;

“RRIFs”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”;

“RRSPs”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”;

 

84


“SEC”

   means the U.S. Securities and Exchange Commission;

“Securities Laws”

   means Canadian Securities Laws, the U.S. Exchange Act, the U.S. Securities Act and any other applicable United States state securities Laws;

“Securities Regulatory Authorities”

   means each of the securities commission or similar regulatory authority in each of the provinces and territories of Canada;

“SEDAR”

   means the System for Electronic Document Analysis and Retrieval of the Canadian Securities Administrators;

“Soliciting Dealer”

   has the meaning ascribed thereto in Section 24 of the Circular, “Financial Advisor, Dealer Manager and Soliciting Dealer Group”;

“Soliciting Dealer Group”

   has the meaning ascribed thereto in Section 24 of the Circular, “Financial Advisor, Dealer Manager and Soliciting Dealer Group”;

“Statutory Minimum Condition”

   has the meaning ascribed thereto in Section 4 of the Offer to Purchase, “Conditions of the Offer”;

“Subco”

   means 2427745 Ontario Inc.;

“Subsequent Acquisition Transaction”

   has the meaning ascribed thereto in Section 16 of the Circular, “Acquisition of Aphria Shares Not Deposited Under the Offer – Subsequent Acquisition Transaction”;

“subsidiary”

   means a company the voting shares of which are controlled by its parent company to the extent that the board of directors of the subsidiary is determined by the parent company;

“Supplementary Information Request”

   has the meaning ascribed thereto in Section 22 of the Circular, “Regulatory Matters – Competition Act”;

“Tax Act”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”;

“Tax Proposals”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”;

“Tender Offer Statement”

   means the tender offer statement on Schedule 14D-1F filed under the U.S. Exchange Act by GGB on January 22, 2019;

“TEV / EBITDA”

   has the meaning ascribed thereto on the cover pages to this Offer to Purchase and Circular under the heading “Non-IFRS Measures”;

“TEV / 2020E EBITDA”

   has the meaning ascribed thereto on the cover pages to this Offer to Purchase and Circular under the heading “Non-IFRS Measures”;

“TFSAs”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”;

 

85


“treaty-protected property”

   has the meaning ascribed thereto in Section 18 of the Circular, “Certain Canadian Federal Income Tax Considerations”;

“Tribunal”

   means the Competition Tribunal as established by subsection 3(1) of the Competition Tribunal Act (Canada);

“TSX”

   means the Toronto Stock Exchange;

“TSXV”

   means the TSX Venture Exchange;

“U.S. Exchange Act”

   means the U.S. Securities Exchange Act of 1934, as amended;

“U.S. Registration Approval”

   means the Registration Statement having been declared effective by the SEC and no stop order suspending the effectiveness of the Registration Statement having been issued, and no proceedings for that purpose having been initiated by the SEC that have not been withdrawn;

“U.S. Securities Act”

   means the U.S. Securities Act of 1933, as amended, together with the rules and regulations promulgated thereunder;

“Xanthic”

   means the predecessor to the Offeror, Xanthic Biopharma Inc.; and

“40% Threshold”

   has the meaning ascribed thereto in Section 2 of the Circular, “Certain Information Concerning Securities of the Offeror – Proportionate Voting Shares”.

 

86


CONSENT OF NORTON ROSE FULBRIGHT CANADA LLP

TO: The Directors of the Offeror

We hereby consent to the reference to our opinion contained under “Certain Canadian Federal Income Tax Considerations” in the Circular accompanying the Offer to Purchase dated January 22, 2019 made by the Offeror to the holders of Aphria Shares.

DATED: January 22, 2019

(signed) “NORTON ROSE FULBRIGHT CANADA LLP”

 

87


CERTIFICATE OF GREEN GROWTH BRANDS INC.

DATED: January 22, 2019

The foregoing contains no untrue statement of a material fact and does not omit to state a material fact that is required to be stated or that is necessary to make a statement not misleading in the light of the circumstances in which it was made.

 

(signed) “Peter Horvath”
Chief Executive Officer
   (signed) “David Bhumgara”
Chief Financial Officer
On behalf of the Board of Directors of
Green Growth Brands Inc.
(signed) “Tim Moore”
Director
   (signed) “Carli Posner”
Director

 

88


ANNEX A

 

LOGO

Green Growth Brands Inc. (formerly Xanthic Biopharma Inc.)

Pro Forma Consolidated Financial statements of the Combined Company

As at October 31, 2018

(In United States Dollars)

 

A-1


INDEX TO PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS

 

  1.

Pro Forma Consolidated Statement of Financial Position

 

  2.

Pro Forma Consolidated Statement of Net Loss and Comprehensive Loss

 

  3.

Notes to Pro Forma Consolidated Financial Statements

 

A-2


GREEN GROWTH BRANDS INC. (formerly Xanthic Biopharma Inc.)

Pro Forma Condensed Consolidated Statement of Financial Position

As at October 31, 2018

(unaudited – in thousands)

 

    Reverse Take Over by Green Growth Brands Ltd.     Business acquisition of Aphria Inc.  
    Xanthic
Biopharma
Inc.
30-Sep-18
    Green
Growth
Brands
Ltd.
31-Oct-18
   

Notes

  Pro forma
Adjustments
    Pro forma
Consolidated
    Aphria
Inc.
31-Aug-18
   

Notes

  Pro forma
Adjustments
    Pro forma
Consolidated
(pre-financing)
   

Notes

  Concurrent
Financing
    Pro Forma
Consolidated
(post-financing)
 
    (USD)     (USD)         (USD)     (USD)     (CAD)         (USD)     (USD)         (USD)     (USD)  

Assets

                       

Current Assets

                       

Cash and cash equivalents

  $ 1,521     $ 54,605     2 e) g)   $ 5,887     $ 62,012     $ 273,087     2 i) j) n)   $ (77,156   $ 257,943     2 o)   $ 218,307     $ 476,250  

Marketable securities

    —         —           —         —         40,895     2 i)     (9,570     31,325         —         31,325  

Receivables

    422       303         —         725       3,237     2 i) j)     (320     3,643         —         3,643  

Inventory

    1,382       —       2 h)     228       1,610       34,752     2 i) j)     (8,082     28,280         —         28,280  

Biological assets

    660       —           —         660       6,633     2 i)     (1,552     5,741         —         5,741  

Prepaids expenses

    80       1,035     2 h)     13       1,127       —           —         1,127         —         1,127  

Loan receivable

    —         32,348     2 a)     (32,348     —         —           —         —           —         —    

Other current assets

    —         —       2 h)     19       19       16,657     2 i) j)     (3,817     12,859         —         12,859  

Assets held for sale

    —         —           —         —         16,496     2 i)     (3,860     12,636         —         12,636  

Current portion of convertible notes receivable

    —         —           —         —         26,424     2 i)     (6,183     20,241         —         20,241  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
    4,066       88,290         (26,201     66,154       418,181         (110,539     373,796         218,307       592,103  

Non-Current Assets

                       

Property and equipment

    710       —       2 g)     13,595       14,305       360,864     2 i) j)     (84,068     291,101         —         291,101  

Interest in equity investees

    839       —           —         839       10,187     2 i)     (2,384     8,642         —         8,642  

Long-term investments

    —         —           —         —         76,675     2 i)     (17,943     58,732         —         58,732  

Intangible assets

    32,235       —       2 f) g) h)     25,323       57,558       235,291     2 i) j)     91,295       384,144         —         384,144  

Goodwill

    22,145       —           —         22,145       524,512     2 i) j) l) m)     349,193       895,850         —         895,850  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
  $ 59,994     $ 88,290       $ 12,717     $ 161,001     $ 1,625,710       $ 225,554     $ 2,012,265       $ 218,307     $ 2,230,572  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Liabilities

                       

Current Liabilities

                       

Accounts payable and accrued liabilities

  $ 1,736     $ 914     2 f)   $ 847     $ 3,497     $ 35,134     2 i) j)   $ (6,701   $ 31,930       $ —          $ 31,930  

Income taxes payable

    —         —           —         —         3,396     2 i) j)     (780     2,616         —         2,616  

Deferred revenue

    —         —           —         —         2,096     2 i)     (490     1,606         —         1,606  

Due to related parties

    66       —       2 h)     352       418       —           —         418         —         418  

Current portion of derivative liability

    —         —           —         —         10,376     2 i)     (2,428     7,948         —         7,948  

Other financial liabilities

    3,138       —       2 b)     (2,838     300       —           —         300         —         300  

Interest bearing loans

    53,913       —       2 a) h)     (16,863     37,050       3,934     2 i)     (921     40,063         —         40,063  

Convertible debenture

    —         47,938     2 d)     (47,938     —         —           —         —           —         —    
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
    58,852       48,853         (66,439     41,265       54,936         (11,319     84,882         —         84,882  

Long-term liabilities

                       

Long-term interest bearing loans

    —         —           —         —         52,015     2 i)     (12,172     39,843         —         39,843  

Deferred tax liability

    —         —           —         —         58,322     2 i) j)     25,132       83,454         —         83,454  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
    —         —           —         —         110,337         12,960       123,297         —         123,297  

Shareholders’ Deficiency

                       

Share Capital

    3,321       27,468     2 c) d) e) f)     67,365       98,154       1,370,477     2 i) j) k) l)     (898,684     569,947     2 o)     218,307       788,254  

Reserve for share based payments

    432       7     2 c)     (432     7       21,726     2 i) k)     (21,726     7         —         7  

Reserve for warrants

    141       19,314     2 c) h)     5,492       24,947       1,375     2 i) k)     (1,375     24,947         —         24,947  

Reserve for changes in equity of subsidiary

    (2,838     —       2 b)     2,838       —         —           —         —           —         —    

Deficit

    (2,771     (7,916   2 c)     3,895       (6,791     48,839     2 i) k) m) n)     1,149,302       1,191,349         —         1,191,349  

Accumulated other comprehensive loss

    —         564         —         564       (801   2 i) k)     801       564         —         564  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
    (1,713     39,437         79,157       116,881       1,441,616         228,318       1,786,815         218,307       2,005,122  

Non-controlling interest

    2,855       —             2,855       18,821     2 i)     (4,404     17,272         —         17,272  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Total equity

    1,142       39,437         79,157       119,736       1,460,437         223,914       1,804,087         218,307       2,022,394  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
  $ 59,994     $ 88,290       $ 12,718     $ 161,001     $ 1,625,710       $ 225,554     $ 2,012,265       $ 218,307     $ 2,230,572  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

The accompanying notes are an integral part of these pro forma consolidated financial statements.

 

A-3


GREEN GROWTH BRANDS INC. (formerly Xanthic Biopharma Inc.)

Pro Forma Condensed Consolidated Statement of Net Income (Loss) and Comprehensive Income (Loss)

For the three months ended August 31, 2018, September 30, 2018 and October 31, 2018

(unaudited – in thousands)

 

    Reverse Take Over by Green Growth Brands Ltd.     Business acquisition of Aphria Inc.  
    Xanthic
Biopharma
Inc.
30-Sep-18
    Green
Growth
Brands Ltd.
31-Oct-18
   

Notes

  Pro forma
Adjustments
    Pro forma
Consolidated
    Aphria Inc.
31-Aug-18
   

Notes

  Pro forma
Adjustments
    Pro forma
Consolidated
(pre-financing)
    Notes     Concurrent
Financing
    Pro Forma
Consolidated
(post-financing)
 
    (USD)     (USD)         (USD)     (USD)     (CAD)         (USD)     (USD)           (USD)     (USD)  

Revenues

  $ 1,771     $ 22         $ 1,793     $ 13,292     2 i)   $ (3,145   $ 11,940       $ —       $ 11,940  

Production costs

    876       66         —         942       4,441     2 i)     (1,051     4,332         —         4,332  

Other costs of sales

    —         —           —         —         393     2 i)     (93     300         —         300  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Gross Profit before fair value adjustments

    894       (44       —         851       8,458         (2,001     7,308         —         7,308  

Fair value adjustments on biological assets

    (333     —           —         (333     (5,306   2 i)     1,255       (4,384       —         (4,384
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Gross Profit

    1,227       (44       —         1,183       13,764         (3,256     11,691         —         11,691  

Expenses

                       

General and Administration

    992       2,813         —         3,805       8,851     2 i)     (2,094     10,562         —         10,562  

Legal and professional fees

    151       2,415         —         2,566       —           —         2,566         —         2,566  

Stock based compensation

    139       7         —         146       6,122     2 i)     (1,448     4,820         —         4,820  

Advertising and promotion

    31       594         —         626       4,741     2 i)     (1,122     4,245         —         4,245  

Depreciation and amortization

    13       —           —         13       3,274     2 i)     (775     2,512         —         2,512  

Loss (gain) on equity investment

    16       —           —         16       247     2 i)     (58     205         —         205  

Research and development

    —         —           —         —         262     2 i)     (62     200         —         200  

Exchange loss on translating foreign operations

    —         —           —         —         59     2 i)     (14     45         —         45  

Gain on dilution of ownership in equity investee

    —         —           —         —         (2,210   2 i)     523       (1,687       —         (1,687

Loss on marketable securities

    —         —           —         —         167     2 i)     (40     127         —         127  

Gain on sale of equity investee

    —         —           —         —         (9,880   2 i)     2,337       (7,543       —         (7,543

Deferred gain on sale of intellectual property

    —         —           —         —         (233   2 i)     55       (178       —         (178

Finance income, net

    —         —           —         —         (1,059   2 i)     251       (808       —         (808

Unrealized gain on convertible note receivable

    —         —           —         —         (295   2 i)     70       (225       —         (225

Gain on long-term investments

    —         —           —         —         (22,700   2 i)     5,370       (17,330       —         (17,330

Unrealized loss on derivative liability

    —         —           —         —         415     2 i)     (98     317         —         317  

Interest and bank charges

    408       110         —         517       —           —         517         —         517  

Foreign exchange loss (income)

    (7     (564       —         (571     —           —         (571       —         (571
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Total Expenses

    1,743       5,374         —         7,117       (12,239       2,895       (2,227       —         (2,227

Listing and transaction fees

      488     2 c)     (3,895     (3,407     865     2 i) k) m) n)     (1,160,936     (1,163,477       —         (1,163,477
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Net Income (Loss) before income taxes

    (516     (5,906       3,895       (2,528     25,138         1,154,785       1,177,395         —         1,177,395  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Income taxes

    —         —           —         —         3,962         (937     3,025         —         3,025  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
    (516     (5,906       3,895       (2,528     21,176         1,155,722       1,174,370         —         1,174,370  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Other comprehensive Income (Loss)

                       

Other comprehensive loss from equity investee

    —         —           —         —         —       2 k)     (614     (614       —         (614
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Comprehensive Income (Loss) for the period

    (516     (5,906       3,895       (2,528     21,176         1,156,336       1,174,984         —         1,174,984  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Net Loss and comprehensive loss attributable to:

                       

Owners of the parent

    (534     (5,906       3,895       (2,545     21,387         1,156,336       1,175,177         —         1,175,177  

Non-controlling interest

    18       —             18       (211         (193       —         (193
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
    (516     (5,906       3,895       (2,528     21,176     —       1,156,336       1,174,984         —         1,174,984  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Net Income (loss) per common share

                       

Basic

    (0.01     (0.08         (0.01     0.09           2.05         —         1.91  

Diluted

    (0.01     (0.08         (0.01     0.09           2.05         —         1.91  

Weighted average number of shares outstanding

                       

Basic

    57,422,634       76,084,384           179,669,722       225,659,684           572,146,183           615,003,326  

Diluted

    57,422,634       76,084,384           179,669,722       230,366,310           572,146,183           615,003,326  
 

 

 

   

 

 

       

 

 

   

 

 

       

 

 

       

 

 

 

The accompanying notes are an integral part of these pro forma consolidated financial statements.

 

A-4


GREEN GROWTH BRANDS INC. (formerly Xanthic Biopharma Inc.)

Pro Forma Condensed Consolidated Statement of Net Income (Loss) and Comprehensive Income (Loss)

For the twelve months ended May 31, 2018, June 30, 2018 and October 31, 2018

(unaudited – in thousands)

 

    Reverse Take Over by Green Growth Brands Ltd.     Business acquisition of Aphria Inc.  
    Xanthic
Biopharma
Inc.
30-Jun-18
    Green
Growth
Brands Ltd.
31-Oct-18
   

Notes

  Pro forma
Adjustments
    Pro forma
Consolidated
    Aphria Inc.
31-May-18
   

Notes

  Pro forma
Adjustments
    Pro forma
Consolidated
(pre-financing)
   

Notes

  Concurrent
Financing
    Pro Forma
Consolidated
(post-financing)
 
    (CAD)     (USD)         (USD)     (USD)     (CAD)         (USD)     (USD)         (USD)     (USD)  

Revenues

  $ —        $ 22         $ 22     $ 36,917     2 i)   $ (8,734   $ 28,205       $ —         28,205  

Production costs

    —         66         —         66       8,692     2 i)     (2,056     6,702         —         6,702  

Other costs of sales

    —         —           —         —         313     2 i)     (74     239         —         239  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Gross Profit before fair value adjustments

    —         (44       —         (44     27,912         (6,604     21,264         —         21,264  

Fair value adjustments on biological assets

    —         —           —         —         (12,975   2 i)     3,070       (9,905       —         (9,905
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Gross Profit

    —         (44       —         (44     40,887         (9,674     31,169         —         31,169  

Expenses

                       

General and Administration

    914       3,540     2 p)     (194     4,260       13,901     2 i)     (3,289     14,872         —         14,872  

Legal and professional fees

    375       3,133     2 p)     (80     3,428       —           —         3,428         —         3,428  

Stock based compensation

    386       7     2 p)     (82     311       17,874     2 i)     (4,229     13,956         —         13,956  

Advertising and promotion

    174       594     2 p)     (37     731       11,873     2 i)     (2,809     9,795         —         9,795  

Depreciation and amortization

    —         —           —         —         3,985     2 i)     (943     3,042         —         3,042  

Loss (gain) on equity investment

    58       —       2 p)     (12     46       9,295     2 i)     (2,199     7,142         —         7,142  

Research and development

    —         —           —         —         490     2 i)     (116     374         —         374  

Deferred gain recognized

    —         —           —         —         (1,304   2 i)     309       (995       —         (995

Gain on dilution of ownership in equity investee

    —         —           —         —         (7,535   2 i)     1,783       (5,752       —         (5,752

Loss on marketable securities

    —         —           —         —         2,155     2 i)     (510     1,645         —         1,645  

Gain on sale of equity investee

    —         —           —         —         (26,347   2 i)     6,233       (20,114       —         (20,114

Loss on sale of capital assets

    —         —           —         —         191     2 i)     (45     146         —         146  

Finance income, net

    —         —           —         —         (5,012   2 i)     1,186       (3,826       —         (3,826

Unrealized gain on embedded derivatives

    —         —           —         —         (4,135   2 i)     978       (3,157       —         (3,157

Gain on long-term investments

    —         —           —         —         (26,675   2 i)     6,311       (20,364       —         (20,364

Unrealized loss on derivative liability

    —         —           —         —         12,451     2 i)     (2,946     9,505         —         9,505  

Other income

    —         —           —         —         (1,244   2 i)     294       (950       —         (950

Interest and bank charges

    4       110     2 p)     (1     113       —           —         113         —         113  

Foreign exchange loss (income)

    —         (564       —         (564     (124   2 i)     29       (659       —         (659
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Total Expenses

    1,911       6,819         (406     8,324       (161       37       8,200         —         8,200  

Listing and transaction fees

    918       488     2 c) p)     (4,090     (2,684     5,192     2 i) k) m) n)     (1,161,959     (1,159,450       —         (1,159,450
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Net Income (Loss) before income taxes

    (2,829     (7,351       4,496       (5,684     35,856         1,152,248       1,182,419         —         1,182,419  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Income taxes

    —         —           —         —         6,408         (1,516     4,892         —         4,892  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
    (2,829     (7,351       4,496       (5,684     29,448         1,153,764       1,177,527         —         1,177,527  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Other comprehensive Income (Loss)

                       

Other comprehensive loss from equity investee

    14       —       2 o)     (14     —         801     2 i) k)     (804     (3       —         (3
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Comprehensive Income (Loss) for the period

    (2,843     (7,351       4,510       (5,684     28,647         1,154,568       1,177,530         —         1,177,530  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Net Loss and comprehensive loss attributable to:

                       

Owners of the parent

    (2,843     (7,351       4,510       (5,684     28,867         1,154,568       1,177,750         —         1,177,750  

Non-controlling interest

    —         —             —         (220         (220       —         (220
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 
    (2,843     (7,351       4,510       (5,684     28,647     —       1,154,568       1,177,530         —         1,177,530  
 

 

 

   

 

 

     

 

 

   

 

 

   

 

 

     

 

 

   

 

 

     

 

 

   

 

 

 

Net Income (loss) per common share

                       

Basic

    (0.08     (0.10         (0.03     0.18           2.72           2.48  

Diluted

    (0.08     (0.10         (0.03     0.18           2.67           2.44  

Weighted average number of shares outstanding

                       

Basic

    34,472,257       76,084,384           179,669,722       161,026,463           432,706,706           475,563,849  

Diluted

    34,472,257       76,084,384           179,669,722       165,914,000           440,386,982           483,244,124  
 

 

 

   

 

 

       

 

 

   

 

 

       

 

 

       

 

 

 

The accompanying notes are an integral part of these pro forma consolidated financial statements.

 

A-5


GREEN GROWTH BRANDS INC.

Notes to the Pro Forma Condensed Consolidated Financial Statements

 

1.

Background and basis of presentation

Background

On November 9, 2018, the company announced it had completed the previously announced business combination between Xanthic Biopharma Inc. (“Xanthic”) and Green Growth Brands Ltd. (“GGB”, and collectively with Xanthic the “Company”). The Company received listing approval on November 7, 2018 and commenced trading on the Canadian Securities Exchange (the “CSE”) on November 13, 2018 under the symbol “GGB”. For more information on this business combination and the subsequent listing on CSE see the Company’s listing statement as filed on www.sedar.com.

Description of the Transaction

On December 27, 2018, the Company formally announced its intention to make an offer (the “Offer”) to purchase all of the issued and outstanding common shares (the “Aphria Shares”) of Aphria Inc. (“Aphria”) (TSX: APHA and NYSE: APHA) which it does not already own.

The Offer will provide Aphria shareholders with 1.5714 common shares of the Company (the “Green Growth Shares”) for each Aphria Share.

Concurrent with the Offer, the Company expects to complete a brokered financing of C$300 million, at a price per share of C$7.00.

The Company’s registered office is 5300 Commerce Court West, 199 Bay Street, Toronto, ON, M5L 1B9 and its principal place of business is 4300 E. Fifth Avenue, Columbus, OH 43219.

Basis of presentation

The accompanying unaudited pro forma condensed consolidated statement of financial position as at October 31, 2018, the unaudited pro forma condensed interim consolidated statement of comprehensive income (loss) for the three months ended October 31, 2018, and the unaudited condensed consolidated statement of comprehensive income (loss) for the twelve months ended October 31, 2018 of the Company were prepared in compliance with National instrument 62-104F1 Takeover Bid Circular to reflect the Company’s proposal to purchase all of Aphria issued and outstanding common shares.

The unaudited pro forma condensed consolidated statement of financial position and the unaudited pro forma condensed consolidated statements of comprehensive income (loss) of the Company are comprised of information from:

 

   

the unaudited condensed interim consolidated statement of financial position of Xanthic as at September 30, 2018;

 

   

the unaudited condensed interim consolidated statement of financial position of GGB as at October 31, 2018;

 

   

the unaudited condensed interim consolidated statement of financial position of Aphria as at August 31, 2018;

 

   

the unaudited condensed interim consolidated statement of comprehensive income (loss) of Xanthic for the three months ended September 30, 2018;

 

   

the unaudited condensed interim consolidated statement of comprehensive income (loss) of GGB for the three months ended October 31, 2018

 

   

the unaudited condensed interim consolidated statement of comprehensive income (loss) of Aphria for the three months ended August 31, 2018

 

   

the audited consolidated statement of comprehensive income (loss) of Xanthic for the twelve months ended June 30, 2018

 

A-6


GREEN GROWTH BRANDS INC.

Notes to the Pro Forma Condensed Consolidated Financial Statements

 

   

the unaudited consolidated statement of comprehensive income (loss) of GGB for the period ended October 31, 2018

 

   

the audited consolidated statement of comprehensive income (loss) of Aphria for the twelve months ended May 31, 2018

The unaudited pro forma condensed consolidated financial statements do not include all of the information disclosures required by International Financial Reporting Standards (“IFRS”) and should be read in conjunction with the Company’s unaudited condensed interim consolidated financial statements as at and for the three months ended September 30, 2018, the audited consolidated financial statements of the Company for the year ended June 30, 2018, the unaudited condensed interim consolidated financial statements of Aphria as at and for the three months ended August 31, 2018, and the audited consolidated financial statements of Aphria for the year ended May 31, 2018.

The unaudited pro forma condensed consolidated statement of financial position gives effect to the proposed acquisition of Aphria as if it had occurred on October 31, 2018. The unaudited pro forma condensed consolidated statements of comprehensive loss for the three months ended September 30, 2018 and the twelve months ended June 30, 2018 give effect to the proposed acquisition as if it had occurred at July 1, 2017.

The accounting policies used in the preparation of the unaudited pro forma condensed consolidated financial statements are consistent with those described in the audited consolidated financial statements of the Company for the year ended June 30, 2018. Certain historical Aphria amounts have been reclassified to conform to the Company’s presentation.

The unaudited pro forma condensed consolidated financial statements are not necessarily indicative of the results of operations that would have occurred had the acquisition of Aphria been affected on the dates indicated, nor are the unaudited pro forma condensed consolidated financial statements indicative of future periods. Actual amounts recorded upon consummation of the proposed acquisition will differ from such unaudited pro forma condensed consolidated financial statements. Since the pro forma condensed consolidated financial statements have been developed to retroactively show the effect of a transaction that is expected to occur at a later date (even though this was accomplished by following generally accepted practice and using reasonable assumptions), there are limitations inherent in the very nature of such pro forma data.

As of the date of these pro forma consolidated financial statements, the Company has not had access to the nonpublic books and records of Aphria and the Company is not in a position to independently assess or verify certain of the information in Aphria’s publicly filed documents, including its financial statements.

Aphria has not reviewed these pro forma consolidated financial statements and has not confirmed the accuracy and completeness of the information in respect of Aphria contained herein. As a result, all pro forma financial information regarding Aphria included herein has been derived, by necessity, from Aphria’s public reports and securities filings as of January 21, 2019. While the Company has no reason to believe that such publicly filed information is inaccurate or incomplete, the Company does not assume any responsibility for the accuracy or completeness of any such information.

 

2.

Pro Forma Adjustments and Assumptions

The unaudited pro forma condensed interim consolidated statement of financial position of the Company as at October 31, 2018 has been adjusted to reflect the following transactions as if the acquisition of Aphria had been completed on October 31, 2018:

 

  a)

On closing of the GGB business combination on November 9, 2018, the Company would eliminate the intercompany loan of $32,348,000 from GGB to Xanthic to complete the Nevada Organic Remedies (“NOR”) acquisition that was completed on September 5, 2018. For further information on the NOR acquisition see the business acquisition report as filed on www.sedar.com.

 

  b)

On completion of the NOR acquisition, 5% of the NOR purchase price will be settled for shares. This amounts to US$2,837,500 or 7,482,488 common shares of the Company.

 

A-7


GREEN GROWTH BRANDS INC.

Notes to the Pro Forma Condensed Consolidated Financial Statements

Reverse Takeover Adjustments:

 

  c)

The acquisition of GGB by Xanthic constituted a reverse takeover transaction (“RTO”) and Xanthic is considered to meets the definition of a business, as defined in IFRS 3—Business Combinations due to its productive operating potential. Accordingly, as a result of the RTO, the pro forma consolidated statement of financial position has been adjusted for the elimination of Xanthic’s share capital of US$3,321,229, reserves for share based payments of US$432,142, reserves for warrants of US$141,482, accumulated deficit of US$2,770,510 within shareholders’ (deficiency) equity.

 

  d)

On completion of the business combination on November 9, 2018, the Debentures converted into common shares of the combined company and a portion converted into GGB proportionate shares and GGB proportionate warrants. Further, as outlined in the listing statement available on www.sedar.com, the Company completed a 4:1 share consolidation on closing of the business combination.

 

  e)

Further on completion of the business combination on November 9, 2018 with GGB, 12,228,960 warrants were exercised at C$2.0 for gross proceeds of US$18,998,000 (C$24,458,000).

Other Adjustments announced by the Company

 

  f)

On December 11, 2018 the Company announced it had executed a definitive agreement to acquire 100% of the membership interest of Just Healthy LLC. Just Healthy holds provisional certificates of registration for registered cannabis dispensary in Northampton Massachusetts, and a cultivation and processing site also in Northampton. The Consideration to be paid was US$3,750,000 in 1,480,057 common shares of the Company and the assumption of US$455,000 in corporate debt. The transaction is expected to close in January 2019 at which time the assumed debt will be settled.

 

  g)

On December 13, 2018 the Company announced it entered into a definitive agreement to acquire Pahrump, Nevada cultivation facility operated by Wellness Orchards of Nevada LLC (“WON”) and Panorama WON LLC (“Panorama”) for a total purchase price of US$13,372,162. The transaction is expected to close in early 2019.

 

  h)

On December 14, 2018, the Company announced it had agreed to accept an irrevocable option to acquire all the membership interests in Henderson Organic Remedies, LLC (“HOR”) from HOR Holdings LLC. As consideration the Company would issue i) a secured loan in the principal amount of US$15,485,000 with an interest rate of 6% and expires on May 4, 2019 and ii) purchase warrant exercisable for 7,609,746 common shares of the Company at an exercise price of C$3.16 per share, for a total purchase price of US$33,444,000 The Company issued a payment/performance guarantee for third-party HOR Holdings LLC, the purchaser. The Company via NOR also has a license fee of all the net cash flow of HOR. The transaction is expected to close in the first half of 2019 once state and municipal regulatory approvals are granted.

Aphria business combination

 

  i)

The Company’s functional and presentation currency presented in its unaudited condensed interim consolidated financial statements are reflected in United States dollars. Aphria’s reporting currency is Canadian dollars in its unaudited condensed interim consolidated financial statements. To complete unaudited pro forma condensed consolidated statement of financial position the Company must translate Aphria’s statement of financial position into United States dollars.

 

  j)

Aphria announced subsequent to the August 31, 2018 condensed consolidated financial statements that it had acquired LATAM holdings Inc. (“LATAM”). The transaction was funded by the assumption of US$1.5 million in LATAM debt and issuance of 15,678,310 common shares at a deemed price of C$17.47 per share.

 

A-8


GREEN GROWTH BRANDS INC.

Notes to the Pro Forma Condensed Consolidated Financial Statements

 

  k)

The acquisition of Aphria will be accounted for as a business combination under IFRS 3 in which the Company is viewed as the acquirer. As such the pro forma consolidated statement of financial position has been adjusted for the elimination of Aphria’s share capital US$1,259,577,000, reserves for share based payments of US$16,642,000, reserve for warrants of US$1,053,000, accumulated deficit of US$1,276,658,000 and accumulated other comprehensive loss of US$614,000 within shareholders’ equity.

 

  l)

The Aphria business combination will be accounted for as a business combination under IFRS 3. The estimated fair value of net assets acquired, and consideration paid for 100% ownership of Aphria is allocated as follows:

 

     US$  

Cash and cash equivalents

   $ 211,251  

Marketable securities

     31,325  

Receivables

     2,917  

Inventory

     26,670  

Biological assets

     5,081  

Other current assets

     45,717  

Property and equipment

     276,796  

Interest in equity investees

     7,803  

Long-term investments

     58,732  

Intangible assets

     326,586  

Goodwill

     502,519  
  

 

 

 

Total assets

     1,495,398  

Accounts payable and accrued liabilities

     28,433  

Other current liabilities

     15,183  

Long-term liabilities

     123,297  
  

 

 

 

Total liabilities

     166,913  
  

 

 

 

Net assets acquired

     1,328,485  
  

 

 

 

Consideration paid

     1,800,278  
  

 

 

 

Goodwill

   $ 471,793  
  

 

 

 

 

  m)

Due to timing of the announcement of the acquisition of Aphria, the Company has not yet obtained sufficient information to accurately determine the fair market value of Aphria’s net assets by category and has therefore allocated the book values of the net assets acquired as a proxy of fair value as at September 30, 2018. Furthermore, the Company has deducted from Goodwill US$100,607,000 for the fair value per common share paid to the Aphria shareholders. This represents an estimated difference between C$9.41 per issued and outstanding common share (based on the closing price of C$5.99 per share on January 21, 2019) compared to the last trading day price before the announcement of the Company’s intention to purchase the Aphria’s shares on December 24, 2018, which closed at C$7.56 per common share.

 

  n)

GGB has assumed US$15,320,000 (C$20 million) in transaction costs in connection with the Offer. These costs include legal, financial advising, accounting, filing and printing costs.

 

  o)

Concurrent with the Offer, the Company expects to complete a brokered financing for gross proceeds C$300 million at a price per share of C$7.00. Net proceeds are expected to be C$285 million (US$218.3 million) after commissions, a 5% backstop fee to be settled in common shares and other financing related costs.

 

  p)

For the twelve months ended June 30, 2018, Xanthic’s reporting currency was Canadian dollars. In order to complete the pro forma consolidated statement of comprehensive income (loss) for the twelve months ended June 30, 2018 the Company converted the Xanthic audited consolidated statement of comprehensive income (loss) to United States dollars.

 

A-9


GREEN GROWTH BRANDS INC.

Notes to the Pro Forma Condensed Consolidated Financial Statements

 

3.

Pro Forma Shareholders’ equity

 

(Expressed in thousands United States dollars)

                                                                         
                          Reserves                                
    Note                                                                                    
        Common
Shares
    Proportionate
Shares
    Share
Capital
    Share based
Payments
    Warrants     Proportionate
Warrants
    Changes in
Equity of
subsidiaries
    Earnings
(Deficit)
    Non-
controlling
Interest
    Accumulated
Other
Comprehensive
loss
    Total  
        #     $     #     $     #     $  

Xanthic’s Balance at September 30, 2018

      57,746,547       —       $ 3,321       2,608,000     $ 432       568,000     $ 141       —       $ —       $ (2,838   $ (2,771   $ 2,855     $ —       $ 1,142  

GGB Consolidation

  2 d)     598,613,786       152,777       75,406       —         7       141,170,003       19,314       76,388       —         —         (7,916     —         564       87,375  

Business Combination

  2 c)     —         —         (3,321     —         (432     —         (141     —         —         —         3,895       —         —         0  

Share Consolidation (4:1)

  2 d)     (497,882,116     (114,583     —         (1,956,000     —         (106,303,503     —         (57,291     —         —         —         —         —         —    

NOR Acquisition

  2 b)     7,482,488       —         —         —         —         —         —         —         —         2,838       —         —         —         2,838  

Warrant exercise

  2 e)     12,228,960       —         18,998       —         —         (12,228,960     —         —         —         —         —         —         —         18,998  

Just Healthy acquisition

  2 f)     1,480,057       —         3,750       —         —         —         —         —         —         —         —         —         —         3,750  

HOR acquisition

  2 h)     —         —         —         —         —         7,609,746       5,633       —         —         —         —         —         —         5,633  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance after GGB RTO

      179,669,722       38,194       98,154       652,000       7       30,815,286       24,947       19,097       —         —         (6,791     2,855       564       119,736  

Foreign exchange translation

  2 i)     —         —         (320,705     —         (5,084     —         (322     —         —         —         (11,429     (4,404     187       (341,757

LATAM acquisition

  2 j)     —         —         209,805       —         —         —         —         —         —         —         —         —         —         209,805  

Aphria Consolidation

  2 k)     392,476,461       —         1,370,477       14,679,249       21,726       4,451,993       1,375       —         —         —         48,839       18,821       (801     1,460,437  

Business Combination

  2 k) l)     —         —         (787,783     —         (16,642     —         (1,053     —         —         —         1,176,051       —         614       371,186  

Transaction Costs

  2 m)     —         —         —         —         —         —         —         —         —         —         (15,320     —         —         (15,320
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance post Aphria acquisition (pre-financing)

      572,146,183       38,194       569,947       15,331,249       7       35,267,279       24,947       19,097       —         —         1,191,349       17,272       564       1,804,087  

GGB Brokered financing

  2 o)     42,857,143       —         218,307       —         —         —         —         —         —         —         —         —         —         218,307  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance post Aphria acquisition (post-financing)

      615,003,326       38,194     $ 788,254       15,331,249     $ 7       35,267,279     $ 24,947       19,097     $ —       $ —       $ 1,191,349     $ 17,272     $ 564     $ 2,022,394  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

A-10


QUESTIONS?

NEED HELP

TENDERING?

CONTACT US:

 

 

North American Toll Free Phone:

1-866-851-3214

 

 

 

LOGO      E-mail: contactus@kingsdaleadvisors.com
LOGO    Fax: 416-867-2271
   Toll Free Fax: 1-866-545-5580
LOGO   

Outside North America, Banks and Brokers

Call Collect: 416-867-2272

 

LOGO

EX-1.2 3 d692201dex12.htm EX-1.2 EX-1.2

Exhibit 1.2

THIS LETTER OF TRANSMITTAL IS FOR USE BY PERSONS WHO WISH TO ACCEPT THE OFFER (AS DEFINED HEREIN) BY GREEN GROWTH BRANDS INC. TO PURCHASE ALL OF THE ISSUED AND OUTSTANDING COMMON SHARES OF APHRIA INC., INCLUDING ANY COMMON SHARES THAT MAY BECOME ISSUED AND OUTSTANDING (INCLUDING UPON THE EXERCISE, EXCHANGE OR CONVERSION OF ANY CONVERTIBLE SECURITIES) AFTER THE DATE OF THE OFFER, BUT BEFORE THE EXPIRY TIME (AS DEFINED HEREIN).

THIS LETTER OF TRANSMITTAL MUST BE VALIDLY COMPLETED, DULY EXECUTED AND RETURNED WITH PHYSICAL CERTIFICATES OR DRS STATEMENTS REPRESENTING COMMON SHARES OF APHRIA TO THE DEPOSITARY, KINGSDALE ADVISORS. IT IS IMPORTANT THAT YOU VALIDLY COMPLETE, DULY EXECUTE AND RETURN THIS LETTER OF TRANSMITTAL ON A TIMELY BASIS IN ACCORDANCE WITH THE INSTRUCTIONS CONTAINED HEREIN.

PLEASE READ THE ACCOMPANYING OFFER TO PURCHASE AND CIRCULAR (AS DEFINED HEREIN) BEFORE COMPLETING THIS LETTER OF TRANSMITTAL.

SHAREHOLDERS WHOSE COMMON SHARES ARE REGISTERED IN THE NAME OF A BROKER, INVESTMENT DEALER, BANK, TRUST COMPANY OR OTHER NOMINEE SHOULD CONTACT THAT NOMINEE FOR INSTRUCTIONS AND ASSISTANCE IN DELIVERING THOSE COMMON SHARES.

IF YOU NEED ASSISTANCE IN COMPLETING THIS LETTER OF TRANSMITTAL, PLEASE CONTACT KINGSDALE ADVISORS AT 1-866-851-3214 (TOLL FREE IN NORTH AMERICA) OR AT +1-416-867-2272 (OUTSIDE NORTH AMERICA) OR BY EMAIL AT CONTACTUS@KINGSDALEADVISORS.COM, OR CONTACT YOUR PROFESSIONAL ADVISOR.

LETTER OF TRANSMITTAL

TO DEPOSIT COMMON SHARES OF

APHRIA INC.

Pursuant to the offer, dated January 22, 2019 made by

GREEN GROWTH BRANDS INC.

 

THE OFFER WILL BE OPEN FOR ACCEPTANCE UNTIL 5:00 PM (TORONTO TIME) ON MAY 8, 2019 (THE “EXPIRY TIME”) UNLESS THE OFFER IS ACCELERATED, EXTENDED, OR WITHDRAWN BY THE OFFEROR.

 

  USE THIS LETTER OF TRANSMITTAL IF:

 

  1

YOU WISH TO ACCEPT THE OFFER AND ARE DEPOSITING A PHYSICAL SHARE CERTIFICATE(S) OR DRS STATEMENT(S); OR

 

  2

YOU PREVIOUSLY DEPOSITED APHRIA SHARES PURSUANT TO A NOTICE OF GUARANTEED DELIVERY (IN THE FORM ACCOMPANYING THE OFFER TO PURCHASE AND CIRCULAR).


APHRIA SHAREHOLDERS WHO HAVE ACCEPTED THE OFFER THROUGH A BOOK-ENTRY TRANSFER WILL BE DEEMED TO HAVE COMPLETED AND SUBMITTED A LETTER OF TRANSMITTAL (IN THE FORM HEREOF) AND WILL BE BOUND BY THE TERMS HEREOF.

This letter of transmittal (the “Letter of Transmittal”) is to be used by registered shareholders (the “Aphria Shareholders”) of common shares (the “Aphria Shares”) of Aphria Inc. (“Aphria” or the “Company”) to accept the offer (the “Offer”) made by Green Growth Brands Inc. (the “Offeror” or “GGB”) to purchase, upon and subject to the terms and conditions of the Offer, all of the issued and outstanding Aphria Shares (including any Aphria Shares that may become issued and outstanding upon exercise of convertible securities after the date of the Offer but before the Expiry Time), as set out in the Offer to Purchase and accompanying Take-Over Bid Circular of GGB dated January 22, 2019 (together, the “Offer to Purchase and Circular”), and to facilitate the deposit of Aphria Shares pursuant to the Offer.

The terms and conditions of the Offer to Purchase and Circular are incorporated by reference in this Letter of Transmittal and capitalized terms used but not defined in this Letter of Transmittal have the respective meanings set out in the Offer to Purchase and Circular.

This Letter of Transmittal is to be used by registered Aphria Shareholders only and is NOT to be used by beneficial holders of Aphria Shares (each, a “Beneficial Shareholder”). A Beneficial Shareholder does not have Aphria Shares registered in his, her or its name; rather, such Aphria Shares are held by an intermediary or clearing agency such as CDS & Co. (each, an “Intermediary”). If you are a Beneficial Shareholder, you should contact your Intermediary immediately for instructions and assistance in accepting the Offer and receiving the consideration for your Aphria Shares.

On the Effective Date, Aphria Shareholders who tender their Aphria Shares to the Offer will be entitled to receive 1.5714 common shares of the Offeror (the “GGB Shares”) in exchange for each Aphria Share (The GGB Shares issuable in exchange for Aphria Shares pursuant to the Offer are sometimes collectively referred to herein as the “Consideration”). Aphria Shareholders are not entitled to receive fractional GGB Shares in connection with the Offer and the number of GGB Shares issuable to each Aphria Shareholder pursuant to the Offer will be either rounded down to the nearest whole number (if the fractional interest is less than 0.5) without any additional payment in lieu thereof, or up to the nearest whole number (if the fractional interest is 0.5 or higher). The Consideration will be paid in the manner described herein and in the Circular.

Notwithstanding the foregoing, GGB and the Depositary and Information Agent (as defined herein) will be entitled to deduct and withhold from any amount otherwise payable under the Offer to any Aphria Shareholder such amounts as GGB or the Depositary and Information Agent is required to deduct or withhold with respect to such payment under any provision of applicable Laws. To the extent that amounts are so withheld, deducted and remitted, such amounts will be treated for all purposes of the Offer as having been paid to the Aphria Shareholder in respect of which such deduction and withholding was made.

The Offer is subject to, among other things, the receipt of more than 6623% of the Aphria Shares (calculated on a fully diluted basis) held by Aphria Shareholders who are not Interested Aphria Shareholders (as defined in the Circular), having been validly tendered to the Offer and not validly withdrawn. The conditions of the Offer may be waived by GGB in its absolute discretion, other than the Statutory Minimum Condition (as defined in the Circular), which may not be waived.

Aphria Shareholders who wish to accept the Offer must, prior to the Expiry Time, complete and execute this Letter of Transmittal and deliver it, or a manually executed facsimile thereof, together with the certificate(s) or DRS Statement(s) representing the Aphria Shares and any other documents required by this Letter of Transmittal, to Kingsdale Advisors, the Depositary and Information Agent for the Offer (in such capacity, the “Depositary and Information Agent”), at the offices of the Depositary and Information


Agent set out on the back page of this Letter of Transmittal. Detailed rules and instructions are set out below in this Letter of Transmittal. Alternatively, the Aphria Shareholders may accept the Offer by:

 

  (a)

following the procedures for book-entry transfer of the Aphria Shares described in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Book-based Transfer”; or

 

  (b)

following the procedures for guaranteed delivery described in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”, using the accompanying Notice of Guaranteed Delivery (printed on green paper) or a manually executed facsimile thereof.

Aphria Shareholders who wish to accept the Offer will not be required to pay any fee or commission if they tender their Aphria Shares directly to the Depositary and Information Agent. However, an Intermediary through which an Aphria Shareholder owns Aphria Shares may charge a fee to tender any such Aphria Shares on behalf of the Aphria Shareholder. Aphria Shareholders should consult such Intermediary to determine whether any charge will apply. See Section 3 of the Offer to Purchase, “Manner of Acceptance”.

GGB will pay for Aphria Shares validly deposited under the Offer and not validly withdrawn by providing a treasury direction to the Offeror’s transfer agent, Capital Transfer Agency Inc. (“Capital”), to issue a sufficient number of GGB Shares for transmittal to depositing Aphria Shareholders. Under no circumstances will interest accrue or be paid by GGB or the Depositary and Information Agent to persons depositing Aphria Shares on the purchase price of Aphria Shares purchased by GGB, regardless of any delay in making such payment. The Depositary and Information Agent will act as the agent of persons who have deposited Aphria Shares in acceptance of the Offer for the purposes of receiving payment from GGB and transmitting payment to such persons, and receipt of payment by the Depositary and Information Agent shall be deemed to constitute receipt thereof by persons depositing Aphria Shares.

PLEASE READ THE OFFER TO PURCHASE AND CIRCULAR, AND THE INSTRUCTIONS SET OUT BELOW CAREFULLY BEFORE COMPLETING THIS LETTER OF TRANSMITTAL. DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN THE ADDRESS AS SET FORTH HEREIN WILL NOT CONSTITUTE A VALID DELIVERY. IF SHARES ARE REGISTERED IN DIFFERENT NAMES, A SEPARATE LETTER OF TRANSMITTAL MUST BE SUBMITTED FOR EACH DIFFERENT REGISTERED OWNER. SEE INSTRUCTION #9.

NOTICE TO U.S. SHAREHOLDERS

The Offer is made for the securities of a company formed outside of the United States. The Offer is subject to disclosure requirements of Canada which are different from those of the United States. Financial statements included or incorporated by reference in the Offer to Purchase and Circular have been prepared in accordance with Canadian accounting standards and may not be comparable to the financial statements of United States companies.

It may be difficult for you to enforce your rights and any claim you may have arising under the U.S. federal Securities Laws, since the Offeror is located in Canada, and some or all of its officers or directors may be residents of Canada or another country outside of the United States. You may not be able to sue a Canadian company or its officers or directors in a court in Canada or elsewhere outside of the United States for violations of U.S. Securities Laws. It may be difficult to compel a Canadian company and its affiliates to subject themselves to the jurisdiction of a court in the United States or to enforce a judgment obtained from a court of the United States.

You should be aware that Offeror may purchase securities other than under the Offer, such as in open market or privately negotiated purchases.


THESE SECURITIES HAVE NOT BEEN REGISTERED OR OTHERWISE QUALIFIED FOR OFFER AND SALE IN CERTAIN U.S. STATES WHERE HOLDERS OF APHRIA SHARES RESIDE AND NO SUCH OFFER TO SELL OR SALE, OR SOLICITATION OF AN OFFER TO BUY MAY BE MADE IN SUCH U.S. STATES.

LETTER OF TRANSMITTAL

TO:             GREEN GROWTH BRANDS INC.

AND TO:    KINGSDALE ADVISORS

DEPOSIT OF COMMON SHARE CERTIFICATES

The undersigned certifies that the undersigned has read the instructions set out herein before completing this Letter of Transmittal and upon the terms and subject to the conditions set forth in the Offer, the undersigned hereby deposits with the Depositary and Information Agent for transfer in exchange for the Consideration, the enclosed certificate(s) or DRS Statement(s) (if applicable) representing Aphria Shares, details of which are as follows: (Please print or type)

 

 

Box 1

 

 

DESCRIPTION OF COMMON SHARE CERTIFICATES DEPOSITED

 

Certificate Number(s) (if applicable)*

 

  

 

Name in which Aphria Shares are
Registered
(Please fill in exactly as
name(s) appear on certificate(s))**

 

  

Number of Aphria Shares Represented
by Certificate OR DRS Statement***

 

           
           
           
   TOTAL:       

 

(1)

If space is not sufficient, please attach a list in the above form.

(2)

The total of the numbers filled in above must equal the number of Aphria Shares represented by the physical certificate(s) or DRS statement(s) enclosed with this Letter of Transmittal.

Some or all of my Aphria Share certificates have been lost, stolen or destroyed. Please review Instruction #6 for the procedure to replace lost or destroyed certificates. (Check box if applicable.)

 

*

A certificate number does not need to be provided if the Aphria Shares are represented by a DRS Statement. (See Instruction 8.)

 

**

If Aphria Shares are registered in different names, a separate Letter of Transmittal must be submitted for each different registered Aphria Shareholder. See Instructions 2 and 9 of this Letter of Transmittal.

 

***

The total number of Aphria Shares evidenced by all certificates or DRS Statements delivered will be deemed to have been deposited.

It is understood that, upon receipt of this Letter of Transmittal validly completed and duly signed, the certificate(s) / Direct Registration System (the “DRS”) Statement(s) representing the Aphria Shares deposited herewith (the “Deposited Aphria Shares”) and any other required documentation, and following the Effective Date, the Depositary and Information Agent will deliver to the undersigned, in accordance with the delivery instructions provided in Box “A” or “B” below, a DRS Statement in respect of the GGB Shares that the undersigned is entitled to receive under the Offer or hold such DRS Statement in respect of the GGB Shares for pick-up in accordance with the instructions set out below, and the certificate(s) / DRS Statement(s) representing the Deposited Aphria Shares will forthwith be transferred to GGB and cancelled.


The undersigned holder of Aphria Shares hereby:

 

1.

acknowledges receipt of the Offer to Purchase and Circular, and acknowledges entering into a binding agreement between the undersigned and GGB in accordance with the terms and conditions of the Offer;

 

2.

transmits herewith the certificate(s) or DRS Statement(s) representing the Deposited Aphria Shares described above for transfer under the Offer;

 

3.

surrenders to GGB, effective on and after the date that GGB takes up and pays for the Aphria Shares, all right, title and interest in and to all of the Deposited Aphria Shares evidenced by the certificate(s) or DRS Statement(s) transmitted herewith and irrevocably approves, constitutes and appoints each officer of GGB and any other Person designated by GGB in writing (each an “Appointee”) as the true and lawful agents, attorneys and attorneys-in-fact and proxies, with full power of substitution and re-substitution (such power of attorney being deemed to be an irrevocable power coupled with an interest), of the undersigned with respect to the Deposited Aphria Shares:

 

  (a)

to register or record the transfer and / or cancellation of the Deposited Aphria Shares on the appropriate register maintained by or on behalf of the Company;

 

  (b)

for so long as any Deposited Aphria Shares are registered or recorded in the name of such Aphria Shareholder (whether or not they are now so registered or recorded), to exercise any and all rights of such Aphria Shareholder, including the right to vote, to execute and deliver any and all instruments of proxy, authorizations or consents (in form and on terms satisfactory to GGB) in respect of any or all Deposited Aphria Shares, to revoke any such instrument, authorization or consent, and to designate in such instrument, authorization or consent any Person or Persons as the proxy of such Aphria Shareholder in respect of the Deposited Aphria Shares for all purposes, including in connection with any meeting or meetings of holders of relevant securities of the Company (whether annual, special or otherwise or any adjournment or postponement thereof, including any meeting to consider a Subsequent Acquisition Transaction);

 

  (c)

to execute, endorse and negotiate, for and in the name of and on behalf of such Aphria Shareholder, any and all cheques or other instruments representing any Distribution (as defined below) payable to or to the order of, or endorsed in favour of, such Aphria Shareholder; and (d) to exercise any other rights of a holder of the Aphria Shares;

 

4

acknowledges that the delivery of the Deposited Aphria Shares shall be effected, and the risk of loss to such Deposited Aphria Shares shall pass, only upon proper receipt thereof by the Depositary and Information Agent;

 

5

revokes any and all authority, other than as granted in this Letter of Transmittal, whether as agent, attorney, attorney-in-fact, proxy or otherwise, previously conferred or agreed to be conferred by the undersigned at any time with respect to the Deposited Aphria Shares and agrees that no subsequent authority, whether as agent, attorney, attorney-in-fact, proxy or otherwise will be granted with respect to the Deposited Aphria Shares;

 

6

agrees not to vote any of the Deposited Aphria Shares taken up and paid for under the Offer at any meeting of holders of Aphria Shares (whether annual, special or otherwise or any adjournment or postponement thereof) and not to exercise any other rights or privileges attached to such Deposited Aphria Shares, or otherwise act with respect thereto. The undersigned agrees to execute and deliver to GGB, at any time, and from time to time, as and when requested by, and at the expense of, GGB, any and all instruments of proxy, authorizations or consents, in form and on terms satisfactory to GGB, in respect of any such Deposited Aphria Shares. The undersigned further agrees to designate in any such instruments of proxy, the Person or Persons specified by GGB as the proxyholder of the undersigned in respect of all or any such Deposited Aphria Shares;

 

7

acknowledges and agrees that, subject to the terms and conditions of the Offer (as such terms may be varied by the Offeror (see Section 5 of the Offer, “Acceleration, Extension and Variation of the Offer”), except for the Deposited Aphria Shares that are validly withdrawn by or on behalf of the undersigned Aphria Shareholder, and except as provided below, by accepting the Offer using the procedures set out in the Offer,


  the undersigned Aphria Shareholder irrevocably assigns to GGB, and GGB will thereby acquire, free and clear of all liens, restrictions, charges, encumbrances, claims, adverse interests, equities and rights of others, all of the rights and benefits of such Aphria Shareholder in and to the Deposited Aphria Shares tendered to the Depositary and Information Agent under the Offer and in and to all rights and benefits arising from such Deposited Aphria Shares, including any and all dividends, distributions, payments, securities, property and other interests (collectively, “Distributions” and each individually a “Distribution”), which may be declared, paid, accrued, issued, distributed, made or transferred on or in respect of the Deposited Aphria Shares, or any of them, on or after January 22, 2019 (being the date of the Offer), including any dividends, distributions or payments on such Distributions; if, notwithstanding such assignment, any Distributions are received by or made payable to or to the order of the undersigned Aphria Shareholder, then:

 

  (a)

GGB will be entitled to all rights and privileges as the holder of any such Distribution and such Distribution shall be received and held by such Aphria Shareholder for the account of GGB and shall be promptly remitted and transferred by the Aphria Shareholder to the Depositary and Information Agent for the account of GGB, accompanied by appropriate documentation of transfer (in form and substance satisfactory to GGB); or

 

  (b)

in its sole discretion, GGB may, in lieu of such remittance or transfer, reduce the amount of the consideration payable to such Aphria Shareholder under the Offer by deducting from the number of GGB Shares otherwise issuable by GGB to the undersigned Aphria Shareholder pursuant to the Offer a number of GGB Shares equal in value to the amount or value of such Distribution, as determined by GGB, in its sole discretion;

 

8

represents and warrants that:

 

  (a)

the undersigned is the registered owner of the Deposited Aphria Shares and has full power and authority to execute and deliver this Letter of Transmittal or cause the book-entry transfer to be made (as applicable) and to deposit, sell, assign and transfer the Deposited Aphria Shares (and any associated Distributions);

 

  (b)

the Deposited Aphria Shares and associated Distributions have not been sold, assigned or transferred, nor has any agreement been entered into to sell, assign or transfer any such Deposited Aphria Shares or associated Distributions to any other person, other than under the Offer;

 

  (c)

the deposit of the undersigned’s Deposited Aphria Shares and associated Distributions complies with applicable Laws;

 

  (d)

all information provided by the undersigned in this Letter of Transmittal is complete, true and accurate;

 

  (e)

when the Deposited Aphria Shares are taken up and paid for by GGB in accordance with the terms of the Offer, GGB will acquire good title thereto (and to any associated Distributions), free and clear of all liens, restrictions, charges, encumbrances, claims and rights of others;

 

  (f)

the undersigned is not acting for the account or benefit of a person from any jurisdiction in which the acceptance of the Offer would not be in compliance with the Laws of such jurisdiction and is not in, or delivering this Letter of Transmittal from, such a jurisdiction;

 

  (g)

the undersigned is, and will immediately prior to the Effective Date be, the legal owner and registered holder of the Deposited Aphria Shares;

 

  (h)

the undersigned has, and will immediately prior to the Effective Date have, good title to the rights represented by the above mentioned certificate(s) or DRS Statement free and clear of all liens, charges, encumbrances, claims security interests and equities, together with all rights and benefits;

 

  (i)

the undersigned will execute and deliver any additional documents necessary or desirable to complete the surrender of the Deposited Aphria Shares; and


  (j)

the foregoing representations and warranties shall survive the completion of the Offer and the delivery to the Depositary and Information Agent of the Deposited Aphria Shares and any associated Distributions;

 

9

will, upon request, execute any signature guarantees or additional documents, transfers and other assurances as GGB may reasonably request to complete the sale, assignment and transfer of the Deposited Aphria Shares (including, as applicable, Distributions) to GGB;

 

10

understands and acknowledges that a physical certificate(s) for GGB Shares may not be issued to Aphria Shareholders upon take-up and payment for the Deposited Aphria Shares; rather, a DRS Statement may be delivered by the Depositary and Information Agent and GGB Shares will be held in the name of the applicable Aphria Shareholder and registered electronically in GGB’s records;

 

11

instructs GGB and the Depositary and Information Agent, following receipt of this Letter of Transmittal (and the certificate(s) or DRS Statement representing the Deposited Aphria Shares) and the completion of the Offer, to send a DRS Statement representing GGB Shares issued in exchange for the Deposited Aphria Shares, by first class mail, postage prepaid, or to hold such DRS Statement representing those GGB Shares for pick-up, in accordance with the instructions set out below. DRS Statements mailed in accordance with this paragraph will be deemed to have been delivered at the time of mailing;

 

12

acknowledges that the Depositary and Information Agent will act as the agent of the undersigned for the purposes of receiving a DRS Statement for GGB Shares from GGB and receipt thereof by the Depositary and Information Agent will constitute receipt thereof by the undersigned;

 

13

acknowledges that all authority conferred or agreed to be conferred, by the undersigned in this Letter of Transmittal (including deemed submission in the case of book-entry transfers) is irrevocable and may be exercised during any subsequent legal incapacity of such Aphria Shareholder and shall, to the extent permitted by Law, survive the death or incapacity, bankruptcy or insolvency of such Aphria Shareholder and all obligations of the Aphria Shareholder herein will be binding upon the heirs, executors, administrators, attorneys, personal representatives, successors and assigns of such Aphria Shareholder;

 

14

acknowledges that if any Deposited Aphria Shares are not taken-up and paid for under the Offer for any reason, or if certificates or DRS Statements are submitted for more Aphria Shares than are tendered, a certificate or certificates for Aphria Shares that are not taken up and paid for will be returned (or, where applicable, a new DRS Statement will be issued), at GGB’s expense, to the undersigned Aphria Shareholder following the Expiry Time or the termination of the Offer. Unless otherwise directed in accordance with the instructions set out in Box “B” below, certificates or DRS Statements representing Aphria Shares not taken-up and paid for will be forwarded to the address of the registered Aphria Shareholder as shown on the list of Aphria Shareholders provided to GGB by the Company;

 

15

understands and acknowledges that the undersigned will not receive the Consideration in respect of the Deposited Aphria Shares until after the Offer is completed, the Deposited Aphria Shares are taken-up and paid for by GGB and the certificate(s) or DRS Statement representing the Deposited Aphria Shares, in proper form for transfer, together with a duly signed Letter of Transmittal (or a manually signed facsimile thereof) is (are) received by the Depositary and Information Agent at the address set out on the back page of this Letter of Transmittal, together with such additional documents as the Depositary and Information Agent may require, and until such certificate(s) or DRS Statement is (are) processed for payment by the Depositary and Information Agent. It is further understood that under no circumstances will any amount be payable or paid by GGB or the Depositary and Information Agent by reason of any delay in exchanging any Aphria Shares or in issuing GGB Shares to any person on account of Aphria Shares taken up under the Offer. Aphria Shareholders who wish to accept the Offer will not be required to pay any fee or commission if they tender their Aphria Shares directly to the Depositary and Information Agent. See Section 7 of the Offer, “Payment for Deposited Aphria Shares”;

 

16

acknowledges that the Offer is not being made to, nor will deposits be accepted from or on behalf of, Aphria Shareholders in any jurisdiction in which the making or acceptance thereof would not be in compliance with the Laws of such jurisdiction;


17

acknowledges that GGB and the Depositary and Information Agent may be required to disclose personal information in respect of the undersigned and consents to disclosure of personal information in respect of the undersigned to (i) stock exchanges or securities regulatory authorities, (ii) the Depositary and Information Agent, (iii) any of the parties to the Offer and (iv) legal counsel to any of the parties to the Offer;

 

18

warrants that the certificate(s) or DRS Statement described above are enclosed and the Aphria Shareholder irrevocably deposits the above-mentioned certificates or DRS Statement in exchange for the Consideration to which such holder is entitled pursuant to the Offer; and

 

19

transmits the certificate(s) or DRS Statement(s) described above representing the Deposited Aphria Shares to be dealt with in accordance with this Letter of Transmittal;

This Letter of Transmittal will be construed in accordance with and governed by the Laws of the Province of Ontario and the federal Laws of Canada applicable therein. The Aphria Shareholder covered by this Letter of Transmittal irrevocably attorns and submits to the exclusive jurisdiction of the Ontario courts situated in the City of Toronto, and waives objection to the venue of any proceedings in such court or that such court provides an inconvenient forum.

Beneficial Shareholders should contact their Intermediary (i.e. broker, investment dealer, trust company, bank or other registered holder) for instructions and assistance in submitting their Aphria Shares receiving the Consideration for their Aphria Shares.

By reason of the use by the undersigned of an English language form of Letter of Transmittal, the undersigned shall be deemed to have required that any contract evidenced by the Offer as accepted through this Letter of Transmittal, as well as all documents related thereto, be drawn exclusively in the English language. En raison de l’usage d’une lettre d’envoi en langue anglaise par le soussigné, le soussigné est réputé avoir requis que tout contrat attesté par l’offre et son acceptation par cette lettre d’envoi, de même que tous les documents qui s’y rapportent,soient rédigés exclusivement en langue anglaise.


PLEASE COMPLETE BOX A, AND IF APPLICABLE, BOX B OR BOX C. SEE INSTRUCTION 5 BELOW.

 

BOX A

ISSUANCE INSTRUCTIONS

 

To be completed by all Aphria Shareholders

 

☐ Issue GGB Shares in the name of:

 

(Please print or type)

    

BOX B

SPECIAL DELIVERY INSTRUCTIONS

 

To be completed ONLY if the GGB Shares to which the undersigned is entitled pursuant to the Offer are to be sent to someone other than the address shown in Box A or Box C is checked

 

(Please print or type)

 

 

(Name)

 

    

 

(Name)

 

 

(Street Address and Number)

 

    

 

(Street Address and Number)

 

        

 

(City and Province or State)

 

    

 

(City and Province or State)

 

(Country and Postal (or Zip) Code)

 

    

 

(Country and Postal (or Zip) Code)

 

** The delivery instructions given in

Box A or Box B

will also be used to return certificate(s) representing Aphria Shares if required for any reason. See Instruction 7.

 

(Email Address)

 

 

 

(Telephone - Business Hours)

 

 

 

(Taxpayer Identification or Social Insurance Number)

 

 

 

 

BOX C

SPECIAL PICK-UP INSTRUCTIONS

To be completed ONLY if the GGB Shares to which the undersigned is entitled pursuant to the Offer are to be picked-up at an office of the Depositary and Information Agent

 

  ☐

HOLD FOR PICK-UP AT THE OFFICE OF THE DEPOSITARY AND INFORMATION AGENT WHERE THE APHRIA SHARES WERE DEPOSITED


BOX D

To be completed by all Aphria Shareholders by selecting one box below.

  Indicate whether you are a resident of Canada for tax purposes:

 

  ☐

The owner signing below represents that it is a resident of Canada for tax purposes;

OR

 

  ☐

The owner signing below represents that it is NOT a resident of Canada for tax purposes.

 

BOX E

SIGNATURE GUARANTEE

 

Signature guaranteed by

(if required under Instruction 3):

 

Authorized Signature of Guarantor

 

Name of Guarantor (Please print or type)

 

Address of Guarantor (Please print or type)

 

Area Code and Telephone Number

    

BOX F

SIGNATURE

 

Date:                                                                           

 

Signature of Aphria Shareholder or Authorized Representative - See Instruction 4

 

Name of Aphria Shareholder or Authorized Representative (Please print or type)

 

Taxpayer Identification, Social Insurance Number or Social Security Number of Aphria Shareholder (Please print or type)

 

Name of Authorized Representative, if applicable (Please print or type)

 

Daytime telephone number of Aphria Shareholder or Authorized Representative

 

Daytime facsimile number of Aphria Shareholder or Authorized Representative

 

Email Address of Aphria Shareholder or Authorized Representative (Please print or type)

    

 


BOX G

DEPOSIT PURSUANT TO NOTICE OF GUARANTEED DELIVERY

☐ CHECK HERE IF APHRIA SHARES ARE BEING DEPOSITED PURSUANT TO A NOTICE OF GUARANTEED DELIVERY PREVIOUSLY SENT TO THE DEPOSITARY AND INFORMATION AGENT AND COMPLETE THE FOLLOWING:

(Please print or type)

Name of Registered Holder:

 

                                                                                              

Date of Execution of Notice of Guaranteed Delivery:

 

                                                                                              

Window Ticket Number (if any):

 

                                                                                              

Name of Institution which Guaranteed Delivery:

 

                                                                                              


INSTRUCTIONS

 

1

Use of Letter of Transmittal

 

  (a)

Aphria Shareholders should read the accompanying Circular prior to completing this Letter of Transmittal. The terms and conditions of the Offer to Purchase and Circular are incorporated by reference in this Letter of Transmittal and capitalized terms used but not defined in this Letter of Transmittal have the meanings set out in the Offer to Purchase and Circular.

 

  (b)

This Letter of Transmittal duly completed and signed (or an originally signed facsimile copy thereof) together with accompanying certificate(s) / DRS Statement(s) representing the Deposited Aphria Shares and all other required documents must be sent or delivered to the Depositary and Information Agent at the address set out on the back of this Letter of Transmittal. In order to receive the GGB Shares under the Offer for the Deposited Aphria Shares, it is recommended that the foregoing documents be received by the Depositary and Information Agent at the address set out on the back of this Letter of Transmittal as soon as possible.

 

  (c)

The method used to deliver this Letter of Transmittal and any accompanying certificate(s)/DRS Statement(s) representing Deposited Aphria Shares and all other required documents is at the option and risk of the Aphria Shareholder and delivery will be deemed effective only when such documents are actually received. GGB and the Depositary and Information Agent recommend that the necessary documentation be hand delivered to the Depositary and Information Agent at the address set out on the back of this Letter of Transmittal, and a receipt obtained; otherwise the use of registered mail with return receipt requested, properly insured, is recommended. Holders of Aphria Shares whose Aphria Shares are registered in the name of a broker, investment dealer, bank, trust company or other nominee should contact that nominee for assistance in depositing those Aphria Shares. Delivery to an office other than to the specified office in this Letter of Transmittal does not constitute delivery for this purpose.

 

  (d)

GGB reserves the right, if it so elects in its absolute discretion, to instruct the Depositary and Information Agent to waive any defect or irregularity contained in any Letter of Transmittal and / or accompanying documents received by it.

 

  (e)

If the DRS Statement in respect of the GGB Shares is to be issued in the name of a person other than the person(s) signing this Letter of Transmittal or if the DRS Statement in respect of the GGB Shares is to be mailed to someone other than the person(s) signing this Letter of Transmittal or to the person(s) signing this Letter of Transmittal at an address other than that shown above, the appropriate boxes in this Letter of Transmittal should be completed (Box A and Box B).

 

2

Signatures

This Letter of Transmittal must be completed and signed by the registered holder of Aphria Shares or by such registered holder’s duly authorized representative (in accordance with Instruction 4 below).

 

  (a)

If this Letter of Transmittal is signed by the registered holder(s) of the certificate(s) (if applicable) representing Aphria Shares, such signature(s) on this Letter of Transmittal must correspond with the name(s) as registered or as written on the face of such certificate(s) or DRS Statement(s) without any change whatsoever, and the certificate(s) or DRS Statement(s) need not be endorsed. If such deposited certificate(s) or DRS Statement(s) are owned of record by two or more joint owners, all such owners must sign this Letter of Transmittal.

 

  (b)

If this Letter of Transmittal is signed by a person other than the registered holder(s) of the certificate(s) / DRS Statement(s) representing Aphria Shares and / or the share certificate(s) / DRS Statement(s) representing GGB Shares are to be issued to a person other than the registered holder(s):

 

  (i)

such deposited certificate(s) / DRS Statement must be endorsed or be accompanied by appropriate share transfer power(s) of attorney duly and properly completed by the registered holder(s); and


  (ii)

the signature(s) on such endorsement or share transfer power(s) of attorney must correspond exactly to the name(s) of the registered holder(s) as registered or as appearing on the certificate(s) / DRS Statement(s) and must be guaranteed as noted in Instruction 3 below.

 

  (c)

If any of the Deposited Aphria Shares are registered in different names on several certificate(s) / DRS Statement(s), it will be necessary to complete, sign and submit as many separate Letters of Transmittal as there are different registrations of such Deposited Aphria Shares.

 

3

Guarantee of Signatures

If this Letter of Transmittal is signed by a person other than the registered holder(s) of the Deposited Aphria Shares or if the GGB Shares are to be issued in a name other than the registered holder(s) of the Aphria Shares, such signature must be guaranteed by an Eligible Institution (as defined below), or in some other manner satisfactory to the Depositary and Information Agent (except that no guarantee is required if the signature is that of an Eligible Institution). An “Eligible Institution” means a Canadian Schedule I chartered bank, a member of the Securities Transfer Agent Medallion Program (STAMP), a member of the Stock Exchange Medallion Program (SEMP) or a member of the New York Stock Exchange, Inc. Medallion Signature Program (MSP). Members of these programs are usually members of a recognized stock exchange in Canada or the United States, members of the Investment Industry Regulatory Organization of Canada, members of the Financial Industry Regulatory Authority, Inc. (FINRA) or banks and trust companies in the United States.

 

4

Fiduciaries, Representatives and Authorizations

Where this Letter of Transmittal or any share transfer power(s) of attorney is executed by a person as an executor, administrator, trustee or guardian, or on behalf of a corporation, partnership or association or is executed by any other person acting in a representative capacity, such person should indicate such capacity when signing and this Letter of Transmittal must be accompanied by satisfactory evidence of the authority to act. GGB or the Depositary and Information Agent, at their discretion, may require additional evidence of authority or additional documentation.

 

5

Delivery Instructions

The GGB Shares to be issued in exchange for the Deposited Aphria Shares will be issued in the name of the person indicated in Box A and delivered to the address indicated in Box A (unless another address has been provided in Box B). If any DRS Statement in respect of GGB Shares is to be held for pick-up at the offices of the Depositary and Information Agent, complete Box C. If neither Box A nor Box B is completed, any GGB Shares issued in exchange for the Deposited Aphria Shares will be issued in the name of the registered holder of the Deposited Aphria Shares and will be mailed to the address of the registered holder of the Deposited Aphria Shares as it appears on the register of Aphria Shares. Any DRS Statement mailed in accordance with this Letter of Transmittal will be deemed to be delivered at the time of mailing.

 

6

Lost Certificates

If a certificate representing Aphria Shares has been lost, stolen or destroyed, this Letter of Transmittal should be completed to the extent possible and deliver it together with a letter describing the circumstances surrounding the loss to the Depositary and Information Agent. The Depositary and Information Agent and/or the transfer agent will advise the Aphria Shareholder of the steps that the Aphria Shareholder must take to obtain a replacement certificate(s) or DRS Statement(s) for his/her/its Aphria Shares. The foregoing action must be taken sufficiently in advance of the Expiry Time in order to obtain a replacement certificate(s) or DRS Statement(s) in sufficient time to permit the Aphria Shares represented by the replacement certificate(s) or DRS Statement(s) to be deposited under the Offer at or prior to the Expiry Time.


7

Return of Certificates

If the Offer does not proceed for any reason, any certificate(s) representing Aphria Shares received by the Depositary and Information Agent will be returned to you forthwith in accordance with your delivery instructions in Box “A” or Box “B”.

 

8

Direct Registration System

GGB Shares issuable under the Offer may be issued in the Direct Registration System, or DRS. The DRS is a system that allows you to hold your GGB Shares in “book-entry” form without having a physical share certificate issued as evidence of ownership. Instead, your GGB Shares will be held in your name and registered electronically in GGB’s records, which will be maintained by its transfer agent, Capital. The Direct Registration System eliminates the need for shareholders to safeguard and store certificates, it avoids the significant cost of a surety bond for the replacement of, and the effort involved in replacing, physical certificate(s) that might be lost, stolen or destroyed and it permits / enables electronic share transactions.

Upon completion of the Offer you may receive an initial DRS Statement acknowledging the number of GGB Shares you hold in your DRS account. Each time you have any movement of shares into or out of your DRS account, you will be mailed an updated DRS Statement. You may request a statement at any time by contacting Capital at 1-416-350-5007 or info@capitaltransferagency.com.

At any time you may request a share certificate for all or a portion of the GGB Shares held in your DRS account. Simply contact Capital with your request. A share certificate for the requested number of GGB Shares will be sent to you by first class mail upon receipt of your instructions, at no cost to you.

For more information about DRS, please contact Capital at 1-844-499-4482 (toll free within Canada and the U.S.) or +1-416-350-5007 (outside of Canada and the U.S.) or visit on-line at www.capitaltransferagency.com.

 

9

Miscellaneous

 

  (a)

If the space on this Letter of Transmittal is insufficient to list all certificate(s) / DRS Statement(s) for Aphria Shares, additional certificates / DRS Statement(s) for Aphria Shares may be listed (in the same form as above) on a separate signed list affixed to this Letter of Transmittal.

 

  (b)

If Aphria Shares are registered in different forms (e.g. “John Doe” and “J. Doe”), a separate Letter of Transmittal should be signed for each different registration.

 

  (c)

No alternative, conditional or contingent deposits of Aphria Shares will be accepted and no fractional GGB Shares will be issued.

 

  (d)

Additional copies of this Letter of Transmittal may be obtained from the Depositary and Information Agent at the office specified on the last page of this Letter of Transmittal.

 

  (e)

Under no circumstances will any amount or interest be paid by GGB or the Depositary and Information Agent by reason of any delay in exchanging any Aphria Shares accepted for exchange pursuant to the Offer.

 

  (f)

This Letter of Transmittal will be construed in accordance with and governed by the laws of the Province of Ontario and the federal laws of Canada applicable therein. The holder of the Aphria Shares covered by this Letter of Transmittal hereby unconditionally and irrevocably attorns to the exclusive jurisdiction of the courts of the Province of Ontario and the courts of appeal therefrom.

 

10

Representations

The representations made by the undersigned Aphria Shareholder in this Letter of Transmittal will survive the completion of the Offer.


The Depositary and Information Agent is:

 

LOGO

130 King St West, Suite 2950

Toronto, ON M5X 1K6

North American Toll Free Phone:

1-866-851-3214

Outside of North America:

+1-416-867-2272

By Registered Mail:

Attn: Corporate Actions

130 King St West, Suite 2950 P.O. Box 361,

Toronto, ON M5X 1K6

By Hand or Courier:

Attn: Corporate Actions

130 King St West, Suite 2950,

Toronto, ON M5X 1K6

Facsimile:

1-416-867-2271

E-mail:

contactus@kingsdaleadvisors.com

Any questions or requests for assistance or additional copies of this Letter of Transmittal and the Offer to Purchase and Circular may be directed by Aphria Shareholders to the Depositary and Information Agent at the telephone numbers and location set out above. You may also contact your broker or other intermediary for assistance concerning the Offer.

EX-1.3 4 d692201dex13.htm EX-1.3 EX-1.3

Exhibit 1.3

THIS IS NOT A LETTER OF TRANSMITTAL. THIS NOTICE OF GUARANTEED DELIVERY IS FOR USE (IN THE CIRCUMSTANCES DESCRIBED BELOW) BY PERSONS WHO WISH TO ACCEPT THE OFFER (AS DEFINED HEREIN) BY GREEN GROWTH BRANDS INC. TO PURCHASE ALL OF THE ISSUED AND OUTSTANDING COMMON SHARES OF APHRIA INC., INCLUDING ANY COMMON SHARES THAT MAY BECOME ISSUED AND OUTSTANDING (INCLUDING UPON THE EXERCISE, EXCHANGE OR CONVERSION OF ANY CONVERTIBLE SECURITIES) AFTER THE DATE OF THE OFFER, BUT BEFORE THE EXPIRY TIME (AS DEFINED HEREIN).

PLEASE READ THE ACCOMPANYING OFFER TO PURCHASE AND CIRCULAR (AS DEFINED HEREIN) BEFORE COMPLETING THIS NOTICE OF GUARANTEED DELIVERY.

NOTICE OF GUARANTEED DELIVERY

TO DEPOSIT COMMON SHARES OF

APHRIA INC.

Pursuant to the offer, dated January 22, 2019 made by

GREEN GROWTH BRANDS INC.

 

THE OFFER WILL BE OPEN FOR ACCEPTANCE UNTIL 5:00 PM (TORONTO TIME) ON MAY 8, 2019 UNLESS THE OFFER IS ACCELERATED OR EXTENDED BY THE OFFEROR, OR WITHDRAWN BY THE OFFEROR.

 

USE THIS NOTICE OF GUARANTEED DELIVERY IF YOU WISH TO ACCEPT THE OFFER BUT:

1. YOUR PHYSICAL SHARE CERTIFICATE(S) OR DRS STATEMENT(S) REPRESENTING APHRIA SHARES (AS DEFINED HEREIN) IS (ARE) NOT IMMEDIATELY AVAILABLE;

2. YOU CANNOT COMPLETE THE PROCEDURE FOR BOOK-ENTRY TRANSFER OF YOUR APHRIA SHARES ON A TIMELY BASIS; OR

3. YOUR PHYSICAL SHARE CERTIFICATE(S) OR DRS STATEMENT(S) REPRESENTING APHRIA SHARES AND ALL OTHER REQUIRED DOCUMENTS CANNOT BE DELIVERED TO THE DEPOSITARY AND INFORMATION AGENT PRIOR TO THE EXPIRY TIME.

This Notice of Guaranteed Delivery (the “Notice of Guaranteed Delivery”) is to be used by holders (“Aphria Shareholders”) of common shares (the “Aphria Shares”) of Aphria Inc. (“Aphria”) to accept the offer (the “Offer”) made by Green Growth Brands Inc. (the “Offeror” or “GGB”) to purchase, upon and subject to the terms and conditions of the Offer, all of the issued and outstanding Aphria Shares (including any Aphria Shares that may become issued and outstanding upon exercise, exchange or conversion of convertible securities after the date of the Offer but before the Expiry Time), as set out in the Offer to Purchase and accompanying Take-Over Bid Circular of GGB dated January 22, 2019 (together, the “Offer to Purchase and Circular”), only if:

 

  (a)

The certificate(s) or Direct Registration System (“DRS”) Statement representing such Aphria Shareholder’s Aphria Shares is (are) not immediately available;

 

  (b)

Such Aphria Shareholder cannot complete the procedure for book-entry transfer of the Aphria Shares on a timely basis; or


  (c)

Such Aphria Shareholder cannot deliver the certificate(s) or DRS Statement for the applicable Aphria Shares, the Letter of Transmittal and all other required documents (if any) to Kingsdale Advisors, the depositary and information agent for the Offer (in such capacity, the “Depositary and Information Agent”), prior to the Expiry Time.

The terms and conditions of the Offer are incorporated by reference into this Notice of Guaranteed Delivery. Capitalized terms used but not defined in this Notice of Guaranteed Delivery that are defined in the Offer to Purchase and Circular shall have the respective meanings set out in the Offer to Purchase and Circular.

The Depositary and Information Agent or your broker or other financial advisor can assist you in completing this Notice of Guaranteed Delivery.

This Notice of Guaranteed Delivery is to be used by registered Aphria Shareholders only and is NOT to be used by beneficial holders of Aphria Shares (“Beneficial Shareholders”). A Beneficial Shareholder does not have Aphria Shares registered in his, her or its name; rather, such Aphria Shares are held by an intermediary or clearing agency such as CDS & Co. (each, an “Intermediary”). If you are a Beneficial Shareholder, you should contact your Intermediary for instructions and assistance in receiving the consideration for your Aphria Shares.

Aphria Shareholders, through their respective CDS participants, who utilize CDSX through a book-entry transfer of their holdings into the Depositary and Information Agent’s account with CDS may also have the option of tendering this Notice of Guaranteed Delivery through CDSX Online Letter of Guarantee (LOG) option (the “LOG option”). Participants tendering through LOG options in CDSX are deemed to have completed this Notice of Guaranteed Delivery and such instructions are considered valid under and in accordance with the terms of the Offer. CDS Participants must comply with the CDS instructions regarding the deadline to deposit using this LOG option.

Aphria Shareholders and CDS participants are advised that the last date for fulfillment of the LOG option as described in the Offer to Purchase and this Notice of Guaranteed Delivery is before 5:00 p.m. (Toronto Time) on the second trading day on the TSX after the Expiry Time. If the Aphria Shares are not available in participants’ account as specified on the LOG Option, participant participants may be liable to the Offeror for failure of delivery for the value of the full tender or part thereof.

On the Effective Date, Aphria Shareholders who tender their Aphria Shares to the Offer will be entitled to receive 1.5714 common shares of the Offeror (the “GGB Shares”) in exchange for each Aphria Share. (The GGB Shares issuable in exchange for Aphria Shares pursuant to the Offer are sometimes collectively referred to herein as the “Consideration”). Aphria Shareholders are not entitled to receive fractional GGB Shares in connection with the Offer and the number of GGB Shares issuable to each Aphria Shareholder pursuant to the Offer will be either be rounded down to the nearest whole number (if the fractional interest is less than 0.5) without any additional payment in lieu thereof, or up to the nearest whole number (if the fractional interest is 0.5 or higher). The Consideration will be paid in the manner described herein and in the Circular.

Notwithstanding the foregoing, GGB and the Depositary and Information Agent will be entitled to deduct and withhold from any amount otherwise payable under the Offer to any Aphria Shareholder such amounts as GGB or the Depositary and Information Agent is required to deduct or withhold with respect to such payment under any provision of applicable Laws. To the extent that amounts are so withheld, deducted and remitted, such amounts will be treated for all purposes of the Offer as having been paid to the Aphria Shareholder in respect of which such deduction and withholding was made.

The Offer is subject to, among other things, the receipt of more than 6623% of the Aphria Shares (calculated on a fully diluted basis) held by Aphria Shareholders who are not Interested Aphria Shareholders (as defined in the Circular), having been validly tendered to the Offer and not validly withdrawn. The conditions of the Offer may be waived by GGB in its absolute discretion, other than the Statutory Minimum Condition (as defined in the Circular), which may not be waived.

 

- 2 -


As set forth in Section 3 of the Offer to Purchase, “Manner of Acceptance – Procedure for Guaranteed Delivery”, if an Aphria Shareholder wishes to deposit Aphria Shares pursuant to the Offer and (i) the certificate(s) or DRS Statement(s) representing such shares are not immediately available, or (ii) the certificate(s) or DRS Statement(s) and all other required documents cannot be delivered to the Depositary and Information Agent prior to the Expiry Time, those Aphria Shares may nevertheless be deposited validly under the Offer by utilizing the procedures contemplated by the Notice of Guaranteed Delivery, provided that all of the following conditions are met:

 

  (a)

such deposit is made by or through an Eligible Institution;

 

  (b)

a properly completed and duly executed Notice of Guaranteed Delivery (or a manually signed facsimile copy thereof), including a guarantee to deliver by an Eligible Institution in the form set out in this Notice of Guaranteed Delivery, is received by the Depositary and Information Agent at its principal office in Toronto, Ontario prior to the Expiry Time; and

 

  (c)

the certificate(s) or DRS Statement(s) representing the deposited Aphria Shares, in proper form for transfer, together with a properly completed and duly signed Letter of Transmittal (or a manually executed facsimile copy thereof) and all other documents required by such Letter of Transmittal, including signature guarantee if required, or, in the case of a book-entry transfer, a Book-Entry Confirmation with respect to such Aphria Shares, are received at the Toronto, Ontario office of the Depositary and Information Agent by 5:00 p.m. (Toronto Time) on the second trading day on the TSX after the date on which the Expiry Time occurs.

An “Eligible Institution” means a Canadian Schedule I chartered bank, a major trust company in Canada, a member of the Securities Transfer Agents Medallion Program (STAMP), a member of the Stock Exchange Medallion Program (SEMP) or a member of the New York Stock Exchange, Inc. Medallion Signature Program (MSP). Members of these programs are usually members of a recognized stock exchange in Canada or the United States, members of the Investment Dealers Association of Canada, members of the Financial Industry Regulatory Authority, Inc. (FINRA) or banks or trust companies in the United States.

THIS NOTICE OF GUARANTEED DELIVERY MAY BE DELIVERED BY HAND, COURIERED, TRANSMITTED BY ELECTRONIC FACSIMILE OR MAILED TO THE DEPOSITARY AND INFORMATION AGENT ONLY AT ITS PRINCIPAL OFFICE IN TORONTO, ONTARIO AS SPECIFIED BELOW AND MUST INCLUDE A SIGNATURE GUARANTEE BY AN ELIGIBLE INSTITUTION IN THE FORM SET FORTH HEREIN. DELIVERY OF THIS NOTICE OF GUARANTEED DELIVERY TO ANY OFFICE OTHER THAN THE TORONTO OFFICE OF THE DEPOSITARY AND INFORMATION AGENT AS SET OUT BELOW SHALL NOT CONSTITUTE DELIVERY FOR THE PURPOSES OF SATISFYING A GUARANTEED DELIVERY.

THIS NOTICE OF GUARANTEED DELIVERY IS NOT TO BE USED TO GUARANTEE SIGNATURES ON THE LETTER OF ACCEPTANCE AND TRANSMITTAL. IF A SIGNATURE ON THE LETTER OF TRANSMITTAL IS REQUIRED TO BE GUARANTEED BY AN ELIGIBLE INSTITUTION UNDER THE INSTRUCTIONS THERETO, SUCH SIGNATURE MUST APPEAR IN THE APPLICABLE SPACE IN THE LETTER OF TRANSMITTAL.

DO NOT SEND CERTIFICATES FOR APHRIA SHARES WITH THIS NOTICE OF GUARANTEED DELIVERY. CERTIFICATES FOR APHRIA SHARES SHOULD BE SENT WITH YOUR LETTER OF TRANSMITTAL.

TO CONSTITUTE DELIVERY FOR THE PURPOSE OF SATISFYING GUARANTEED DELIVERY, UPON RECEIPT OF THE CERTIFICATE(S) TO WHICH THIS NOTICE OF GUARANTEED DELIVERY APPLIES, THE LETTER OF TRANSMITTAL, ACCOMPANYING CERTIFICATE(S) AND ALL OTHER REQUIRED DOCUMENTS MUST BE DELIVERED TO THE SAME OFFICE OF THE DEPOSITARY AND INFORMATION AGENT IN TORONTO, ONTARIO WHERE THIS NOTICE OF GUARANTEED DELIVERY IS DELIVERED.

 

- 3 -


The undersigned understands and acknowledges that payment for Aphria Shares deposited and taken up by GGB will be made only after timely receipt by the Depositary and Information Agent, at its office in Toronto, Ontario specified above, of: (i) the certificate(s) or DRS Statement(s) representing the Aphria Shares; (ii) the Letter of Transmittal (or a manually executed facsimile copy thereof), properly completed and duly executed, with any signatures guaranteed, if so required, and (iii) all other documents required by the Letter of Transmittal before 5:00 p.m. (Toronto Time) on the second trading day on the TSX after the date on which the Expiry Time occurs. The undersigned also understands and acknowledges that under no circumstances will interest or other amounts accrue or be paid by GGB or the Depositary and Information Agent to persons depositing Aphria Shares on the purchase price of Aphria Shares purchased by GGB, regardless of any delay in making such payment, and that the consideration for the Aphria Shares tendered pursuant to the guaranteed delivery procedures will be the same as that for the Aphria Shares delivered to the Depositary and Information Agent before the Expiry Time, even if the Aphria Shares to be delivered pursuant to the guaranteed delivery procedures are not so delivered to the Depositary and Information Agent, and therefore payment by the Depositary and Information Agent on account of such Aphria Shares is not made until after the take-up and payment for the Aphria Shares under the Offer.

All authority conferred, or agreed to be conferred, by this Notice of Guaranteed Delivery is, to the extent permitted by all applicable laws, irrevocable and may be exercised during any subsequent legal incapacity of the undersigned and shall, to the extent permitted by law, survive the death or incapacity, bankruptcy or insolvency of the undersigned and all obligations of the undersigned under this Notice of Guaranteed Delivery shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned.

NOTICE TO U.S. APHRIA SHAREHOLDERS

The Offer is made for the securities of a company formed outside of the United States. The Offer is subject to disclosure requirements of Canada that are different from those of the United States. Financial statements included or incorporated by reference in the Offer to Purchase and Circular have been prepared in accordance with Canadian accounting standards and may not be comparable to the financial statements of United States companies.

It may be difficult for you to enforce your rights and any claim you may have arising under the U.S. federal Securities Laws, since the Offeror is located in Canada, and some or all of its officers or directors may be residents of Canada or another country outside of the United States. You may not be able to sue a Canadian company or its officers or directors in a court in Canada or elsewhere outside of the United States for violations of U.S. Securities Laws. It may be difficult to compel a Canadian company and its affiliates to subject themselves to the jurisdiction of a court in the United States or to enforce a judgement obtained from a court of the United States.

You should be aware that Offeror may purchase securities other than under the Offer, such as in open market or privately negotiated purchases.

THESE SECURITIES HAVE NOT BEEN REGISTERED OR OTHERWISE QUALIFIED FOR OFFER AND SALE IN CERTAIN U.S. STATES WHERE HOLDERS OF APHRIA SHARES RESIDE AND NO SUCH OFFER TO SELL OR SALE, OR SOLICITATION OF AN OFFER TO BUY MAY BE MADE IN SUCH U.S. STATES.

Questions and requests for assistance in accepting the Offer and in depositing Aphria Shares with the Depositary and Information Agent may be directed to the Depositary and Information Agent at 1-866-851-3214 toll free in North America or at +1-416-867-2272 collect outside of North America or by e-mail at corpaction@kingsdaleadvisors.com. Shareholders may also contact their brokers or other intermediaries for assistance concerning the Offer.

 

- 4 -


NOTICE OF GUARANTEED DELIVERY

TO:                  GREEN GROWTH BRANDS INC.

AND TO:         KINGSDALE ADVISORS, AS DEPOSITARY AND INFORMATION AGENT

 

By Mail:

130 King St West, Suite 2950, PO Box 261

Toronto, ON
M5X 1K6

  

By Email or Fax:

E-mail: corpaction@kingsdaleadvisors.com

Facsimile: 416-867-2271

By Registered Mail, Hand or Courier:

130 King St West, Suite 2950
Toronto, ON
M5X 1K6

  

The undersigned hereby deposits with the Depositary and Information Agent, upon the terms and subject to the conditions set forth in the Offer to Purchase and the Letter of Transmittal, receipt of which is hereby acknowledged, the Aphria Shares described below, pursuant to the guaranteed delivery procedures set forth in Section 3 of the Offer, “Manner of Acceptance – Procedure for Guaranteed Delivery”.

 

 

DESCRIPTION OF COMMON SHARE CERTIFICATES DEPOSITED

 

Certificate Number(s) (if
applicable)

 

  

 

Name and Address in which
Aphria Shares are Registered

(Please fill in exactly as

name(s) appear on

certificate(s) or DRS

Statement(s)**)

 

  

Number of Aphria

Shares Represented by

Certificate or DRS

Statement**

 

  

Number of

Aphria Shares Deposited ***

 

                
                
                
                
   TOTAL:          

 

(1)

If space is not sufficient, please attach a list in the above form.

(2)

The total of the numbers filled in above must equal the number of Aphria Shares represented by the physical certificate(s) or DRS statement(s) enclosed with the Letter of Transmittal.

 

*

A certificate number does not need to be provided if the Aphria Shares are represented by a DRS Statement.

**

If Aphria Shares are registered in different names, a separate Letter of Transmittal must be submitted for each different registered Shareholder.

***

Total number of Aphria Shares evidenced by all certificate(s) or DRS Statement(s) delivered will be deemed to have been deposited.

 

- 5 -


SHAREHOLDER SIGNATURE(S)

 

        
Signature(s) of Shareholder(s)      Address(es)
   
        
Name (please print or type)       
   
        
SIN/SSN      Postal Code/Zip Code
   
        
Date      Daytime Telephone Number
   
        
        

Email

 

GUARANTEE OF DELIVERY

 

(Not to be used for signature guarantee)

 

The undersigned, an Eligible Institution, guarantees delivery to the Depositary and Information Agent, at
its address set forth herein, of the certificate(s) or DRS Statement(s) representing the Shares deposited hereby,
in proper form for transfer with a properly completed and duly executed Letter of Transmittal in the form
enclosed herewith or a manually signed facsimile copy thereof, with any required signature guarantee (or in the
case of a book-entry transfer of Aphria shares, a Book-Entry Confirmation with respect to all Aphria Shares
deposited hereby) , and all other documents required by the Letter of Transmittal, all on or before 5:00 p.m.
(Toronto Time) on the second trading day on the TSX after the date on which the Expiry Time occurs.

 

Name of Firm:                                                                               

   Authorized Signature:                                                             
   

Address of Firm:                                                                          

   Name:                                                                                            
   

 

   Title:                                                                                              
   

Telephone Number:                                                                     

   Dated:                                                                                            
      

 

- 6 -


The Depositary and Information Agent is:

 

LOGO

130 King St West, Suite 2950

Toronto, ON M5X 1K6

North American Toll Free Phone:

1-866-851-3214

Outside of North America:

+1-416-867-2272

By Registered Mail:

Corporate Actions

130 King St West, Suite 2950 P.O. Box 361,

Toronto, ON M5X 1K6

By Hand or Courier:

Corporate Actions

130 King St West, Suite 2950,

Toronto, ON M5X 1K6

Facsimile:

1-416-867-2271

E-mail:

corpaction@kingsdaleadvisors.com

Any questions or requests for assistance or additional copies of this Notice of Guaranteed Delivery and the Offer to Purchase and Circular may be directed by Aphria Shareholders to the Depositary and Information Agent at the telephone numbers and location set out above. You may also contact your broker or other intermediary for assistance concerning the Offer.

 

- 7 -

EX-2.3 5 d692201dex23.htm EX-2.3 EX-2.3

Exhibit 2.3

Green Growth Brands Files Offer to Purchase and Circular for Aphria Inc.;

Formal Take-over Bid to Commence on January 23, 2019;

Receives Commitment for C$150 Million Equity Investment

 

   

Formal Offer will commence on January 23, 2019 and will remain open until 5:00 p.m. (Toronto time) on May 9, 2019

 

   

Combined Green Growth Brands / Aphria expected to be North America’s preeminent cannabis company

 

   

Aphria shareholders can tender their shares by contacting Kingsdale Advisors at 1-866-851-3214 or by email at contactus@kingsdaleadvisors.com

COLUMBUS, OH, January 22, 2019 – Green Growth Brands Inc. (“Green Growth” or the “Company”) (CSE: GGB) today announced that it has filed its Offer to Purchase and Circular and related documents with the applicable securities regulatory authorities in Canada and the United States and will formally commence its offer (the “Offer”) to acquire all of the issued and outstanding common shares (the “Aphria Shares”) of Aphria Inc. (“Aphria”) (TSX: APHA and NYSE: APHA) on Wednesday, January 23, 2019.

The Company also announced that it has entered into a commitment letter (the “Commitment Letter”) with All Js Greenspace LLC (the “Investor”), pursuant to which the Investor has agreed, subject to the terms and conditions set forth in the Commitment Letter, to subscribe for and purchase up to $150 million of Green Growth shares (the “Commitment”) as a backstop to the Company’s previously announced intention to complete a $300 million equity financing in connection with the completion of the Offer.

About the Offer

The Offer provides Aphria shareholders with 1.5714 common shares of Green Growth (the “Green Growth Shares”) for each Aphria Share (the “Offer Consideration”), including Aphria Shares that may become issued and outstanding after the date hereof but prior to 5:00 p.m. (Toronto time) on May 9, 2019 (the “Expiry Time”) upon the exercise, conversion or exchange of any securities of Aphria that are exercisable for, convertible into or exchangeable for Aphria Shares.

The notice and advertisement of the Offer will appear in the Wednesday, January 23, 2019 editions of The Globe and Mail and Le Devoir. The Offer to Purchase and Circular and related documents will be mailed to Aphria shareholders in the coming days and are available under Aphria’s profile at www.sedar.com.

THE OFFER WILL BE OPEN FOR ACCEPTANCE UNTIL 5:00 P.M. (TORONTO TIME) ON MAY 9, 2019, UNLESS THE OFFER IS ACCELERATED, EXTENDED OR WITHDRAWN.

“We are pleased to officially launch our bid for Aphria. This is an exciting opportunity for shareholders of both Green Growth and Aphria to build value and create the preeminent cannabis operator in North America,” said Peter Horvath, CEO of Green Growth. “The combination of Aphria’s Canadian supply and wholesale agreements with Green Growth’s vertically integrated operations and rapidly growing retail footprint in the United States best positions us to capitalize on the massive growth opportunities in North America and beyond. I encourage Aphria shareholders to tender their shares to our offer.”


Reasons to Accept the Offer

Green Growth believes that the combination of the two companies is extremely compelling and that its Offer represents an unparalleled value-enhancing opportunity and is a superior alternative to the status quo at Aphria.

Green Growth invites Aphria shareholders to join Green Growth Brands in an exciting value-enhancing opportunity to create the only large-scale cannabis company to bridge U.S. and Canadian markets. The combined company is expected to:

Create an Unparalleled North American Player with a Developing International Presence. Aphria has a large market position in Canada and supply agreements with all provinces and Yukon territory, as well as strong strategic partnerships establishing wholesale supply agreements. Aphria has established operations in federally-legalized foreign jurisdictions, including Australia, Argentina, Colombia, Denmark, Germany, Italy, Jamaica, Lesotho, Malta and Paraguay, and maintains an option for entry into Brazil. Green Growth operates vertically integrated cannabis operations including cultivation, manufacturing and retail assets in Nevada, was recently awarded seven incremental provisional retail cannabis dispensary licenses in Nevada, and has agreed to acquire Just Healthy LLC, which holds provisional certificates of registration for a registered medical marijuana dispensary and will, as a condition of closing, own an option to purchase land for a cultivation and processing site in Northampton, Massachusetts. Green Growth also holds an irrevocable option to purchase Henderson Organic Remedies LLC, which operates a second The+Source location in Henderson, Nevada, subject to certain local regulatory changes and approvals. Further, through its consumer-focused line of cannabidiol (“CBD”) products, Green Growth’s long-term goal is to establish a presence in each U.S. state where the sale of cannabis and CBD is not inconsistent with applicable law. Together, the combined company is expected to have a strong foundation, extensive retail relationships and infrastructure to capture significant future growth as international markets evolve.

Increase Scale and Footprint, While Creating the Preeminent U.S. Consolidator. The combined company will be one of the largest U.S. cannabis operators by market capitalization and the only North American-wide cannabis operator at significant scale. Given the combined company’s increased size, both Aphria and Green Growth shareholders should benefit from a trading multiple expansion. The benefits of scale are expected in both Canada and the U.S. when examining trading metrics for comparable companies with similar market capitalization.

Combine Aphria’s Cultivation and Production Capacity with Green Growth’s Retail Strength. The combined company will marry Aphria’s low-cost cultivation and near-term production capacity with Green Growth’s vast retail know-how to capture market share. Aphria’s current cash cost per gram is $1.76 and it projects annual capacity of over 250,000 kg by early 2019. Green Growth’s strong management team has a proven track record of delivering at the retail level and already operates or has licensing agreements in place with dispensaries in Nevada. In addition, Green Growth was recently awarded seven incremental provisional retail cannabis dispensary licenses in Nevada.


Benefit from Transformational Cannabis-Related Regulatory Changes in the World’s Largest Cannabis Market. Green Growth is in the process of rolling out a consumer-focused line of CBD-infused personal care products, including topicals and balms, and is well positioned to benefit from further expected pro-cannabis U.S. regulation. On January 10, 2019, Green Growth announced an agreement with DSW, Inc. to sell CBD-infused personal care products at 96 U.S.-based DSW stores, with an initial agreement for approximately 55,000 units. Green Growth is also partnering with additional retailers to sell CBD personal care products in U.S. states where the sale of cannabis and CBD is not inconsistent with applicable law. Further, Green Growth is working with multiple large developers who represent a network of malls to launch kiosks in prime locations throughout the U.S. in states where the sale of cannabis and CBD is not inconsistent with applicable law.

Unite Best-in-Class Management Teams: Aphria’s Pharmaceutical and Greenhouse Operational Experience and Green Growth’s Proven Retail Expertise. Aphria’s team, many of whom Green Growth hopes to retain following the successful completion of the Offer, is comprised of veterans in the greenhouse industry and proven operators of large pharmaceutical companies. Green Growth’s management has held senior positions at a number of well-known retailers including DSW, American Eagle Outfitters, and Bath & Body Works.

About the Financing

While the Offer is not subject to any financing condition, Green Growth intends to complete, immediately following the take up of Aphria Shares under the Offer, a third-party equity financing of $300 million (the “Financing”) at a share price equal to $7.00 per Green Growth share, as disclosed in the Company’s December 28, 2018 press release. The Commitment provides significant support as a backstop to the Financing. The Commitment is conditional upon the successful completion of the Offer and the take up of Aphria Shares, among other conditions outlined in the Circular. To induce the Investor to provide the Commitment, Green Growth has agreed to pay the Investor a commitment fee equal to $7.5 million, payable by issuing 2,504 Green Growth proportionate voting shares to the Investor, and to indemnify and reimburse the Investor for certain liabilities, costs and expenses. A copy of the Commitment Letter has been filed with the applicable securities regulatory authorities and is available for review under Green Growth’s profile on SEDAR.

If the Offer and the Financing are completed, Green Growth expects to use the net proceeds of the Financing to fund the business growth of the combined company, including for working capital and general corporate purposes. There can be no assurance that the Financing will be completed or what the value of a Green Growth share will be at the time of take up of Aphria Shares under the Offer, which could be substantially less or more than $7.00 per Green Growth share.

If the Offer and the Financing are completed, it is anticipated that the Investor would own approximately 12.5% of the voting rights associated with the issued and outstanding common shares and proportionate voting shares of the combined company (or 9.8% of such voting rights if the Offer is completed but the Financing is not completed).

As the Investor is a related party of Green Growth, the Commitment is deemed to be a “related party transaction” as defined under Multilateral Instrument 61-101—Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Commitment is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 (pursuant to subsections 5.5(a) and 5.7(a)) as neither the fair market value of the subject matter, nor the fair market value of the consideration for the Commitment exceeds 25% of Green Growth’s market capitalization. Green Growth did not file a material change report at least 21 days prior to entering into the Commitment as the value of the participation of the Investor had not been confirmed at that time.


CEO Appointment

Green Growth is also announcing the formal appointment of Peter Horvath, current Chief Executive Officer of Green Growth Brands LLC, the Company’s operating subsidiary, as Chief Executive Officer of the Company.

The Time to Act is Now. Tender Your Shares to the Offer

Consider the benefits and take the simple steps needed to tender your Aphria Shares to the Offer. The Offer expires at 5:00 p.m. (Toronto time) on May 9, 2019.

If you have any questions or require assistance, please contact Kingsdale Advisors, our Depositary and Information Agent, the information agent and depositary for the Offer, at 1-866-851-3214 (North American Toll-Free Number) or 1-416-867-2272 (Outside North America) or via email at contactus@kingsdaleadvisors.com.

Conditions of the Offer

The Offer is conditional upon the specified conditions being satisfied, or where permitted, waived at the Expiry Time or such earlier or later time during which Aphria Shares may be deposited under the Offer, including, among others, (i) there shall have been properly and validly deposited under the Offer and not validly withdrawn at the Expiry Time that number of Aphria Shares which represents as of the Expiry Time more than 50% of the outstanding Aphria Shares, excluding any Aphria Shares beneficially owned, or over which control or direction is exercised, by Green Growth or by any person acting jointly or in concert with Green Growth; (ii) more than 6623% of the Aphria Shares (calculated on a fully-diluted basis) held by Aphria shareholders who are not Interested Aphria Shareholders (as defined in the Circular) shall have been validly tendered under the Offer and not validly withdrawn; (iii) all governmental, regulatory and third party approvals that the Company considers necessary or reasonably appropriate in connection with the Offer and the operation of the combined company shall have been received on terms satisfactory to the Company; (iv) there being no legal prohibition against Green Growth making the Offer or taking up and paying for the Aphria Shares; (v) the Registration Statement (as defined in the Circular) filed with the U.S. Securities and Exchange Commission (the “SEC”) shall have become effective for the purposes of United States securities laws; (vi) Aphria and its affiliates shall not have taken certain actions that could impair the ability of Green Growth to acquire Aphria Shares, diminish the economic value to Green Growth of the acquisition of Aphria, or make the acquisition of Aphria more costly in any material respect to Green Growth or that would (as determined by Green Growth in its sole judgement) make it inadvisable for Green Growth to proceed with the Offer; (vii) no material adverse change in respect of Aphria shall have occurred since December 28, 2018; (viii) Aphria and its affiliates having conducted their respective businesses in the ordinary course of business consistent with past practice at all times on or after December 28, 2018 and prior to the Expiry Time; (ix) Green Growth not becoming aware of any untrue statement of a material fact, or an omission to state a material fact that is required to be stated or that is necessary to make a statement made not misleading in the light of the circumstances in which it was made, in any document filed by or on behalf of Aphria or any of its subsidiaries with any regulatory authorities; (x) the shareholders of Green Growth shall have approved the issue of Green Growth Shares pursuant to the Offer in accordance with the policies of the CSE; and (xi) Green Growth not becoming aware of any information corroborating in any material respect the claims made in a December 3, 2018 report regarding Aphria’s business practices, operations, and financial condition. These conditions are described in more detail in the above referenced Circular.


The Offer is subject to certain other conditions in addition to those listed above. A more detailed discussion of the conditions to the consummation of the Offer can be found in the Offer to Purchase and Circular.

Subject to the terms and conditions of the Offer, Green Growth will take up Aphria Shares immediately following the Expiry Time and pay for the Aphria Shares deposited under the Offer as soon as possible, but in any event not later than three business days after taking up such Aphria Shares.

Subject to applicable law, Green Growth reserves the right to withdraw, vary the terms of, extend, or terminate the Offer and to not take up and pay for any Aphria Shares deposited to the Offer unless each of the conditions of the Offer is satisfied or waived, as applicable, at or prior to the Expiry Time.

Advisors

Green Growth Brands has retained Canaccord Genuity as its financial advisor, Norton Rose Fulbright Canada LLP as its legal advisor, and Kingsdale Advisors as its strategic shareholder and communications advisor and depositary.

About Green Growth Brands

Green Growth Brands expects to dominate the cannabis and CBD market with a portfolio of emotion-driven brands that people love. Led by renowned retailer Peter Horvath, the Green Growth team is full of retail renegades with decades of experience building successful brands. Join the movement at GreenGrowthBrands.com.

Media Contact:

Ian Robertson

Executive Vice President, Communication Strategy

Kingsdale Advisors

Direct: 416-867-2333

Cell: 647-621-2646

Email: irobertson@kingsdaleadvisors.com

Investor Contact:

Peter Horvath

CEO, Green Growth Brands Inc.

Phone: 614-508-4222

Cautionary Statement in Forward-Looking Information

This press release contains certain statements and information which constitute forward-looking statements or “forward-looking information” within the meaning of applicable securities laws, including “future-oriented financial information” with respect to prospective financial performance, financial position, cash flows and other financial metrics that are presented either as a forecast or a projection.


Wherever possible, forward-looking information can be identified by the expressions “seeks”, “expects”, “intends”, “believes”, “estimates”, “will”, “plans”, “may”, “anticipates,” “target” and similar expressions (or the negative of such expressions). The forward-looking statements or forward-looking information are not historical facts, but reflect the current expectations of Green Growth regarding future results or events and are based on information currently available to it. The forward-looking events and circumstances discussed in this release include, but are not limited to, (i) the satisfaction of the conditions of the Offer; (ii) the anticipated successful completion of the Offer; (iii) the expected completion of the proposed $300 million financing, including the timing and terms thereof; (iv) the satisfaction of the conditions of the Commitment; (v) the process and timing for obtaining the Regulatory Approvals (as defined in the Circular) applicable to the Offer and other approvals, including the approval of the shareholders of Green Growth; (vi) the expected Expiry Time; (vii) the anticipated effect of the Offer; (viii) the Company’s plans for Aphria if the Offer is successful; and (ix) expected benefits to Aphria shareholders of tendering Aphria Shares to the Offer. All material assumptions used in making forward-looking statements are based on Green Growth’s knowledge of its business and the business of Aphria, and, in some cases, information supplied by third parties, including the public disclosure made by the Company. Certain material factors or assumptions include, but are not limited to, (i) the current business conditions and expectations of future business conditions and trends affecting Green Growth and Aphria, including the U.S. and Canadian economies, the cannabis industry in Canada, the United States and elsewhere, and capital markets, and (ii) that there have been no material changes in the business, affairs, capital, prospects or assets of the Company, except as publicly disclosed by the Company before the date hereof. All forward-looking statements and forward-looking information in this press release are qualified by these cautionary statements. Green Growth believes that the expectations reflected in forward-looking statements and forward-looking information are based upon reasonable assumptions; however, Green Growth can give no assurance that the actual results or developments will be realized by certain specified dates or at all. Forward-looking statements and forward-looking information are subject to a number of risks and uncertainties that could cause actual results or events to vary materially from current expectations. In addition to risks noted elsewhere in this news release, material risks include, but are not limited to, (i) the risk that the Offer will not be commenced or that the conditions to the Offer will not be met, or met on a timely basis, or that the transaction will not be consummated for any other reason, (ii) changes in general economic conditions in Canada, the United States and elsewhere, (iii) changes in operating conditions (including changes in the regulatory environment) affecting the cannabis industry, (iv) fluctuations in currency and interest rates, availability materials and personnel, and (v) Green Growth’s ability to successfully integrate the operations of Green Growth and Aphria following completion of the Offer, including ability to retain key Aphria personnel and renegotiate certain contracts to obtain economies of scale or other synergies. Readers, therefore, should not place undue reliance on any such forward-looking information. Further, forward-looking statements and forward-looking information speaks only as of the date hereof. Green Growth disclaims any intention and assumes no obligation to update or revise any forward-looking statements or forward-looking information, even if new information becomes available, as a result of future events or for any other reason, except to the extent required by applicable securities laws.


No Offer or Solicitation

This press release is for informational purposes only and does not constitute an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities. The offer to acquire Aphria Shares and to issue securities of the Green Growth will be made solely by, and subject to the terms and conditions set out in, the Offer to Purchase and Circular and accompanying letter of transmittal and notice of guaranteed delivery.

Notice to U.S. Holders Aphria Shares

Green Growth intends to make the offer and sale of the Green Growth’s shares in the acquisition subject to a registration statement covering such offer and sale to be filed with the United States Securities and Exchange Commission (the “SEC”) under the U.S. Securities Act of 1933, as amended. Such registration statement covering such offer and sale will include various documents related to such offer and sale. THE COMPANY URGES INVESTORS AND SHAREHOLDERS OF APHRIA TO READ SUCH REGISTRATION STATEMENT AND ANY AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH SUCH OFFER AND SALE OF GREEN GROWTH’S SHARES AS THOSE DOCUMENTS BECOME AVAILABLE, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.

Investors and shareholders of Aphria will be able to obtain the registration statement, as well as other relevant filings regarding Green Growth or the Offer, free of charge at the SEC’s website, www.sec.gov. In addition, documents filed with the SEC by Green Growth will be available free of charge from Green Growth. You should direct requests for documents to Kingsdale, 130 King St West, Suite 2950, Toronto, ON M5X 1K6, Toronto, North American Toll Free Phone: 1-866-851-3214, outside North America Phone: 416-867-2272. To obtain timely delivery, such documents should be requested no later than five (5) business days before the Expiry Time.

Green Growth is a foreign private issuer and permitted to prepare the offer to purchase and takeover bid circular and related documents in accordance with Canadian disclosure requirements, which are different from those of the United States. Green Growth prepares its financial statements in accordance with International Financial Reporting Standards applicable to Canadian public companies formulated by the International Accounting Standards Board, and they may be subject to Canadian auditing and auditor independence standards. These financial statements may not be comparable to the financial statements of United States companies.

Shareholders of Aphria should be aware that owning the Company’s shares may subject them to tax consequences both in the United States and in Canada. The Offer to Purchase and Circular may not describe these tax consequences fully. Aphria shareholders should read any tax discussion in the Offer to Purchase and Circular, and are also urged to consult their tax advisors.

The enforcement by Aphria Shareholders of civil liabilities under U.S. federal securities laws may be affected adversely by the fact that Green Growth was amalgamated under the Laws of Ontario, and Aphria was amalgamated under the Laws of Ontario, that some or all of their respective officers and directors may be residents of a foreign country, that some or all of the experts named herein may be residents of a foreign country and that all or a substantial portion of the assets of Green Growth and Aphria and said persons may be located outside the United States. Aphria Shareholders may not be able to sue Green Growth or Aphria or their officers or directors in a foreign court for violations of U.S. securities laws. It may be difficult to compel Green Growth or Aphria or their respective affiliates to subject themselves to the jurisdiction of a court in the United States or to enforce a judgment obtained from a court of the United States.


NEITHER THE SEC NOR ANY STATE SECURITIES REGULATOR HAS OR WILL HAVE APPROVED OR DISAPPROVED GREEN GROWTH’S SHARES OFFERED IN THE OFFERING DOCUMENTS, OR HAS OR WILL HAVE DETERMINED IF ANY OFFERING DOCUMENTS ARE TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

GREEN GROWTH’S SHARES HAVE NOT BEEN REGISTERED OR OTHERWISE QUALIFIED FOR OFFER AND SALE IN CERTAIN U.S. STATES WHERE HOLDERS OF APHRIA SHARES RESIDE AND NO SUCH OFFER TO SELL OR SALE, OR SOLICITATION OF AN OFFER TO BUY MAY BE MADE IN SUCH U.S. STATES.

Aphria shareholders should be aware that, during the period of the Offer, Green Growth or its affiliates, directly or indirectly, may bid for or make purchases of the securities to be distributed or to be exchanged, or certain related securities, as permitted by applicable laws or regulations of Canada or its provinces or territories.

EX-3.1 6 d692201dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

XANTHIC BIOPHARMA INC.

ANNUAL INFORMATION FORM

FOR THE FINANCIAL YEAR ENDED JUNE 30, 2018

DATED: November 26, 2018


TABLE OF CONTENTS

 

     Page  

ANNUAL INFORMATION FORM

     1  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

     1  

CORPORATE STRUCTURE

     2  

GENERAL DEVELOPMENT OF THE BUSINESS

     3  

DESCRIPTION OF THE BUSINESS

     7  

ISSUERS WITH U.S. CANNABIS-RELATED ASSETS

     15  

RISK FACTORS

     21  

DIVIDENDS AND DISTRIBUTIONS

     40  

DESCRIPTION OF CAPITAL STRUCTURE

     41  

MARKET FOR SECURITIES

     44  

ESCROWED SECURITIES AND SECURITIES SUBJECT TO CONTRACTUAL RESTRICTION ON TRANSFER

     45  

DIRECTORS AND OFFICERS

     46  

LEGAL PROCEEDINGS AND REGULATORY ACTIONS

     51  

INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS

     51  

TRANSFER AGENT AND REGISTRARS

     51  

MATERIAL CONTRACTS

     51  

INTERESTS OF EXPERTS

     52  

AUDIT COMMITTEE DISCLOSURE

     52  

ADDITIONAL INFORMATION

     54  

SCHEDULE “A”

     A-1  

 

- i -


ANNUAL INFORMATION FORM

In this Annual Information Form (the “AIF”), Xanthic Biopharma Inc. and its subsidiaries are collectively referred to as the “Company” or “Xanthic”, unless specifically identified otherwise.

All financial information in this AIF is prepared in Canadian dollars and using International Financial Reporting Standards. This AIF applies to the business activities and operations of the Company for the year ended June 30, 2018, unless otherwise stated.

Statistical information and other data relating to the medical cannabis industry and the cannabis industry in general included in this AIF are derived from industry reports published by industry analysts, industry associations and/or independent consulting and data compilation organizations. Market data and industry forecasts used throughout this AIF were obtained from various publicly available sources. Although we believe that these independent sources are generally reliable, the accuracy and completeness of such information is not guaranteed and has not been independently verified.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This AIF contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs. Such statements can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, or “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Such forward-looking statements are made as of the date of this AIF. Forward-looking statements in this AIF include, but are not limited to, statements with respect to:

 

   

the performance of the Company’s business and operations;

 

   

the intention to grow the business, operations and potential activities of the Company;

 

   

the ongoing and proposed expansion of the Company’s facilities;

 

   

the expected growth in the number of individuals using the Company’s cannabis, cannabis oil extracts and other cannabis related products;

 

   

the expected growth in the Company’s capacity to grow and cultivate cannabis, cannabis oil extracts, and other cannabis-related products for both medical and recreational use;

 

   

the competitive conditions of the industry;

 

   

the applicable laws, regulations and any amendments thereof;

 

   

the competitive business strategies of the Company;

 

   

the grant and impact of any license or supplemental license to conduct activities with cannabis and/or cannabis oil extracts or any amendments thereof;

 

   

the anticipated future gross revenues and profit margins of the Company’s operations;

 

   

the proposed and anticipated changes to Canadian federal laws and provincial regulations regarding the adult-use recreational market and the business impacts on the Company; and

 

   

the proposed and anticipated changes to U.S. federal, state, and local laws regarding the adult-use recreational market and the business impacts on the Company.

Certain of the forward-looking statements contained herein and incorporated by reference concerning the medical cannabis and cannabis oil extracts industry, the anticipated adult-use recreational market, the general expectations of the Company related thereto, and the Company’s business and operations are based on estimates prepared by the Company using data from publicly available governmental


sources, as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While the Company is not aware of any misstatement regarding any industry or government data presented herein, the current medical cannabis and cannabis oil extracts industry and the future anticipated adult-use recreational market in Canada and the U.S. involves risk and uncertainty and is subject to change based on various factors.

Readers are cautioned that the above list of cautionary statements is not exhaustive. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward-looking statements. The factors identified above are not intended to represent a complete list of the factors that could affect the Company. Additional factors are noted under “Risk Factors” in this AIF. The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. You should not place undue reliance on forward-looking statements contained in this AIF. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this AIF are expressly qualified in their entirety by this cautionary statement.

CORPORATE STRUCTURE

Name, Address and Incorporation

Xanthic Biopharma Inc. was formed by articles of incorporation under the Business Corporations Act (British Columbia) on November 18, 1968, under the name “Rampart Mines Limited” (“Rampart Mines”). On May 28, 1984, Rampart Mines changed its name to “Rampart Resources Limited” (“Rampart Resources”). On July 23, 1987, Rampart Resources changed its name to “Trans-Rampart Industries Ltd” (“Trans-Rampart”). On May 3, 1993, Trans-Rampart changed its name to “Rampart Mercantile Inc.” (“Rampart Mercantile”). On October 6, 1999, Rampart Mercantile amended its Memorandum of Association, consolidating its outstanding capital on the basis of one (1) post-consolidated common share for each ten (10) pre-consolidated common shares and increasing its outstanding capital to 100,000,000 common shares. On November 24, 1999, Rampart Mercantile continued out of the province of British Columbia into the province of Ontario. On November 1, 2000, Rampart Mercantile amalgamated with North American Store Finance Ltd. On April 14, 2011, Rampart Mercantile changed its name to “Aurquest Resources Inc.” (“Aurquest”). On December 15, 2017, pursuant to a reverse takeover involving Aurquest and a privately held Ontario corporation, Xanthic Biopharma Limited (the “Acquisition”), Aurquest changed its name to “Xanthic Biopharma Inc.”. On November 8, 2018, the Company amended its articles, to, among other things, authorize the issuance of an unlimited number of proportionate voting shares (“PVS”) in the capital of the company. Immediately following the completion of the Business Combination (as defined below), the Company consolidated its outstanding capital on the basis of one (1) post-consolidated common share for each four (4) pre-consolidated common shares.

Xanthic’s head and registered office is 77 King Street West, Suite 2905, Toronto, Ontario M5K 1A2.

 

2


GENERAL DEVELOPMENT OF THE BUSINESS

History of the Business

On October 17, 2017, Xanthic Biopharma Limited and Capital Transfer Agency ULC (“CTA”) entered into a services agreement (the “Services Agreement”) pursuant to which Xanthic Biopharma Limited appointed CTA as the transfer agent and registrar for Xanthic Biopharma Limited’s common shares.

On December 13, 2017, Aurquest and Xanthic Biopharma Limited entered into a definitive agreement (the “Definitive Agreement”) pursuant to which Aurquest and Xanthic Biopharma Limited agreed to complete the Acquisition on the terms and conditions set forth therein.

On December 15, 2017, Xanthic was formed pursuant to a reverse takeover involving Aurquest and a privately held Ontario corporation, Xanthic Biopharma Limited. The Company was founded with the objective of becoming a leader in developing innovative, non-combustible alternative delivery methods for cannabis-infused products.

On January 16, 2018, Xanthic completed a non-brokered private placement of 96,000,000 common shares of Xanthic (the “Common Shares”) for gross proceeds of C$1,500,000.

On February 16, 2018, the Company consolidated its Common Shares on basis of one (1) post-consolidation Common Share for every eight (8) pre-consolidation Common Shares, resulting in a total of 55,710,547 Common Shares outstanding at the time of the consolidation. Concurrently, the Company changed its name from “Aurquest Resources Inc.” to “Xanthic Biopharma Inc.”.

On March 22, 2018, Xanthic entered into a licensing and strategic partnership agreement (the “Xanthic Beverages Agreement”) with Xanthic Beverages USA, LLC (formerly Avitas CBD Water, LLC) (“Xanthic Beverages”), a company based in Portland, Oregon. Pursuant to the Xanthic Beverages Agreement, Xanthic Beverages agreed to produce cannabidiol (“CBD”) infused water for distribution to over 500 retail locations, including grocery retailers and convenience stores, across Eastern Washington and Northeast Oregon. The Company also acquired a 45% ownership position in Xanthic Beverages in exchange for a cash payment of US$600,000 and the issuance of up to 600,000 Common Shares, with an aggregate value of US$300,000 at US$0.50 per Common Share, subject to certain performance milestones over the 12 months following the closing of the Xanthic Beverages Agreement.

On March 29, 2018, Xanthic, CTA, and certain security holders of the Company (the “Security Holders”) entered into an escrow agreement (the “Escrow Agreement”) pursuant to which the Common Shares of the Security Holders were held in escrow by CTA on the terms set out therein.

On April 19, 2018, the Common Shares commenced trading on the Canadian Securities Exchange (the “CSE”) under the symbol “xTHC”. Concurrently, the Company completed a non-brokered private placement of 1,112,000 units (“Units”) at a price of $0.50 per Unit to raise aggregate gross proceeds of $556,000. Each Unit is comprised of one Common Share and one-half of one Xanthic common share purchase warrant (the “Common Warrants”). Each Common Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.75 per Common Share until April 19, 2020. In connection with the private placement, Xanthic paid an aggregate finder’s fee of C$18,000 and an aggregate of 24,000 compensation options.

 

3


On April 20, 2018, Xanthic signed a binding letter of intent with Green Mile Solutions LLC (“GMS”) to develop plans to manufacture and distribute Xanthic-branded cannabis-infused products in the U.S. states of Oregon, Nevada and Ohio. GMS facilitates the manufacturing of cannabis-infused powders in licensed facilities using the proprietary Xanthic process to create water soluble tetrahydrocannabinol (“THC”) and CBD. GMS procures sales of the finished products into the local licensed dispensary networks through existing sales and distribution channels.

On May 1, 2018, Xanthic signed a letter of intent with Pasaverde Labs LLC to commercialize the Company’s existing patent-pending powder process in the state of California.

On May 7, 2018, Xanthic also signed a binding letter of intent with Nutritional High International Inc. for the production and distribution of Xanthic-branded, water-soluble cannabis-infused powders in the state of California.

On June 11, 2018, Xanthic signed a letter of intent with ABH Pharma Inc. (“ABH”), a leading FDA-registered and GMP-certified manufacturer of in-house branded and private label dietary supplements in the United States. Through its partnership with the Company, ABH was to offer “Xanthic Powered” CBD-infused products to customers across its broad range of dietary supplements, which would be sold by various brick-and-mortar retailers and e-commerce websites. On July 3, 2018, Xanthic terminated its letter of intent with ABH due to the parties’ inability to reach agreement on key business terms.

On June 26, 2018, Dr. Gunther Hintz resigned from the Company’s board of directors (the “Board”).

Subsequent to the Year Ended June 30, 2018

On July 13, 2018, GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic, entered into a membership interest purchase agreement (the “NOR Agreement”) with inter alios, Andrew Jolley and Stephen Byrne (together, the “NOR Sellers”), pursuant to which GGB Nevada acquired 95% of the issued and outstanding membership interests of Nevada Organic Remedies (“NOR”) and the obligation to acquire the remaining 5% of the issued and outstanding membership interests of NOR (the “NOR Acquisition”) for a total purchase price of US$56,750,000, plus all accrued interest pursuant to a secured promissory note for US$21,565,000 as payment of deferred purchase price consideration. The NOR Acquisition was completed on September 4, 2018. For the current fiscal year, the NOR Acquisition will be immediately accretive to Xanthic’s net income.

On July 13, 2018, Xanthic and Green Growth Brands Ltd. (“GGB”) entered into a transaction agreement, as amended on August 30, 2018, and as amended and restated on October 30, 2018 (the “Transaction Agreement”) to combine Xanthic and GGB by way of amalgamation between GGB and a wholly-owned subsidiary of Xanthic, 2657013 Ontario Inc., to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

On July 13, 2018, in connection with the Business Combination, the Board was reconstituted to include existing Board members Carli Posner as Chair, Tim Moore, Igor “Gary” Galitsky and new GGB nominees Jean Schottenstein, Peter Horvath, Steve Stoute and Marc Lehmann.

On August 30, 2018, Xanthic, GGB, All Js Greenspace LLC, Chiron Ventures Inc., and WMBGG Resources LLC entered into a nomination rights agreement (the “Nomination Rights Agreement”) setting out certain Xanthic director nomination rights of All JS Greenspace LLC, Chiron Ventures Inc., and WMBGG Resources LLC. The Nomination Rights Agreement was amended and restated on

 

4


November 9, 2018 in order to include GA Opportunities Corp. as a party thereto and to provide nomination rights to GA Opportunities Corp.

On August 30, 2018, Xanthic, GGB, and CTA, as warrant trustee, entered into a warrant indenture, as amended on November 9, 2018 (the “Warrant Indenture”) pursuant to which the GGB CS Warrants, the Xanthic New CS Warrants and the Xanthic New Warrants Replacement Warrants, as such terms are defined in the amalgamation agreement dated November 9, 2018 between 2657013 Ontario Inc. and GGB Subco Ltd., were created and issued.

On September 4, 2018, NOR, as an indirect subsidiary of Xanthic, entered into an intellectual property license agreement (the “HOR Licensing Agreement”) with Henderson Organic Remedies LLC (“HOR”), whereby NOR licensed certain of its intellectual property to HOR, allowing it to operate a retail marijuana store using “The Source” intangible property.

On September 17, 2018, NOR submitted an application for eight additional retail marijuana store facilities in Nevada. Xanthic anticipates that its Nevada operations will drive profitability in the near and long term. If NOR is successful in obtaining all eight of its license applications, it will operate nearly 30,000 square feet of medical and retail marijuana space.

On November 8, 2018, the Company amended its articles in order to, among other things, authorize the issuance of an unlimited number of PVS in the capital of Xanthic.

On November 9, 2018, Xanthic entered into a registration rights agreement (the “Registration Rights Agreement”) with All Js Greenspace LLC, which sets out certain registration rights and indemnification rights owed to All Js Greenspace LLC by the Company following the completion of the Business Combination.

On November 9, 2018, Xanthic entered into a coattail agreement (the “Coattail Agreement”) with All Js Greenspace LLC and CTA.

On November 9, 2018, Xanthic and GGB completed the Business Combination. Immediately following the completion of the Business Combination, Xanthic consolidated its outstanding capital on the basis of one (1) post-consolidated Common Share for each four (4) pre-consolidated Common Shares.

On November 13, 2018, Xanthic resumed trading on the facilities of the CSE under the ticker symbol “GGB”.

Recent Developments

The NOR Acquisition and the Business Combination

In June 2018, representatives of Xanthic and GGB discussed at arm’s length the merits of a potential business combination. On July 13, 2018, GGB Nevada entered into an agreement with NOR, which provided for the acquisition by GGB Nevada of substantially all of the outstanding membership interests of NOR, a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada, for aggregate consideration of US$56,750,000, which agreement has been filed by Xanthic with the Canadian securities regulatory authorities and is available on SEDAR at www.sedar.com. Immediately following the execution of the NOR Agreement, Xanthic and GGB entered into the Transaction Agreement.

 

5


To complete the NOR Acquisition, GGB Nevada was required to make a payment of a US$2 million deposit (the “NOR Deposit”) upon the execution of the NOR Agreement and an initial cash payment of US$30 million (the “NOR Closing Payment”) on closing of the NOR Acquisition. To satisfy the NOR Deposit, Xanthic issued a promissory note in favour of GGB in the principal amount of US$2 million (the “Deposit Promissory Note”). To satisfy the NOR Closing Payment, Xanthic and GGB entered into a loan agreement (the “Loan Agreement”) pursuant to which GGB loaned US$30,347,500 to Xanthic (the “Loan”). In addition, on closing of the NOR Acquisition, GGB Nevada was required to deliver to NOR a secured promissory note in the principal amount of US$21,565,000. The initial closing occurred on September 4, 2018. In connection with the closing of the NOR Acquisition, Xanthic issued to the NOR Sellers on November 9, 2018 an aggregate principal amount of US$2,837,500 of Common Shares in the capital of Xanthic.

On November 9, 2018, Xanthic and GGB completed the Business Combination.

The Company now carries on the business of NOR, while retaining certain aspects of the Company’s and GGB’s former businesses.

Intercorporate Relationships

The following table sets out the corporate structure of the Company, prior to the completion of the Business Combination, including the governing jurisdiction of the various entities:

 

LOGO

 

6


Following the completion of the Business Combination, the corporate structure of the Company is as follows:

 

LOGO

DESCRIPTION OF THE BUSINESS

General

Xanthic is a Canadian company based in Toronto, Ontario that is engaged in technology and consulting services used in the cannabis industry. The Company’s objective is to work with strategic partners (“Licensed Partners”) to create premium cannabis-infused beverages and consumables that have the potential to become some of the first national brands in this emerging category in the United States. Over the next 12 months, the Company intends to assist its Licensed Partners in their development of a line of cannabis-infused functional beverages and other edible products that are designed to help with vitality, sleep and cognitive health. To management’s knowledge, the Company is the only entity assisting Licensed Partners produce these kinds of products on a large-scale. As such, the Company intends to assist its Licensed Partners pursue an aggressive distribution plan to place Xanthic-branded products in more stores than any known competitor to reinforce the Company’s early-mover advantage.

NOR, an indirect, wholly-owned subsidiary of Xanthic, is a vertically-integrated cannabis company operating in the State of Nevada, which holds licenses for dispensing, cultivating, producing and distributing cannabis to both medical and retail marijuana customers. Through its cultivation and production operations, NOR produces high quality medical and retail marijuana products that are sold through its retail location and sold wholesale to various other dispensaries. NOR’s Las Vegas area dispensary is considered a premier dispensary, receiving top ratings by multiple local publications. NOR operates its dispensary under the brand “The Source” and offers a comprehensive line of medicinal and retail marijuana, edibles, concentrates, CBD, and topicals. Since July 1, 2017, with expanded legalization in Nevada, NOR’s customer base has expanded to include “adult-use” or retail customers, who do not require a prior medical diagnosis and applicable registration in order to legally purchase cannabis.

 

7


NOR also operates 12,000 square feet of cultivation and production space. NOR’s cultivation capabilities include the use of energy-efficient LED lights during cultivation, integrated pest management practices that reduce the need for pesticides, and use of CO2 as a more environmentally conscious extraction method. NOR also utilizes rockwool as a growing medium, providing a more efficient use of space and reducing the waste of thousands of pounds of soil and soil amendments in the cultivation process.

Upon completion of the Business Combination, Xanthic combined its business with the businesses of GGB and NOR. The Company is now engaged, directly and indirectly, in the business of cultivation, processing, and retailing of cannabis and cannabis-infused products augmented by new and existing intellectual property.

Principal Products

Over the next twelve months, Xanthic intends to expand its retail and wholesale cannabis businesses, as well as its CBD consumer products businesses through a combination of strategic partnerships, merger and acquisition activity, and organic license capture. The Company’s objective is to establish retail cannabis locations, or otherwise apply for such licenses, in various states within that timeframe, pursuant to U.S. state laws. The Company’s principle markets are those U.S. states where cannabis has been legalized for medical and/or recreational use.

Retail Cannabis

Organic License Capture

Xanthic will target expansion into markets with open licensing application processes for dispensaries where it believes it can gain market share against local competition through superior retail experience.

On August 31, 2018, pursuant to a request for applications issued by the New Jersey Department of Health, Xanthic submitted a proposal to operate a single, fully integrated cannabis facility in New Jersey. Should the Company be awarded such license, it will be one of just 12 license holders in the state. The state is expected to make an announcement regarding the successful applications in late 2018 or early 2019. If Xanthic is successful in being awarded a license, it is expected that operations would commence within 12 months thereafter.

On September 17, 2018, NOR submitted an application for eight retail marijuana store facilities in Nevada. Xanthic hopes to receive multiple retail marijuana store awards when the State of Nevada makes its announcement of the successful applications in December 2018. Should the Company’s Nevada applications be successful, the build-out cost for each dispensary awarded is estimated at approximately US$1,500,000. Based on current experience and the number of licenses awarded to date, cultivation and processing capacity would need to be expanded in Nevada.

Xanthic has already incurred expenses for these license applications. Future expenses related to the captured licenses would be associated with dispensary build-outs as well as cultivation and processing build-outs. Should the Company’s New Jersey dispensary application be successful, estimated expenses to build a dispensary facility in New Jersey are approximately US$1,000,000, with an additional expected expense of approximately US$8,000,000 to US$10,000,000 in order to build out the cultivation and processing facility.

 

8


Mergers and Acquisitions

Management is continually evaluating acquisitions and strategic investments that are significant to the Company in both Canada and the United States. In identifying acquisition targets, companies that are well positioned in their markets and will enhance Xanthic’s portfolio of products are key targets. Given the increasingly competitive environment and the capital resources required to produce many of the product offerings, Xanthic will continue to seek out cannabis retailers, CBD manufacturers and cannabis cultivators and processors as prime targets for acquisition. The Company also is actively seeking strategic joint ventures and business relationships to position its current portfolio in existing distribution platforms.

The selection of states for acquisition activity is based upon the Company’s assessment of the regulatory market under the various state-level and local governments, profitability per location when compared to other cannabis-permissive states, and the perceived potential for medical-only states to move to recreational use in the near future. In selecting specific locations for expansion, the Company will continue to seek out real estate in premium locations with significant foot traffic and proximity to popular attractions, such as restaurants, malls, sports arenas and hotels. The Company focuses on retail spaces with a footprint of 3,500 to 5,000 square feet, depending on the market and available real estate.

Wholesale Cannabis

Xanthic, through NOR, its wholly-owned subsidiary, owns a warehouse of approximately 12,000 square feet located in Clark County, Nevada, where cultivation, production, and distribution take place. NOR operates a perpetual harvest that ensures constant production of flower product.

The NOR and HOR dispensaries combined purchase flower each month from NOR cultivation and NOR production. NOR cultivation sells trim and flower each month to NOR production for extraction. Additionally, NOR cultivates fresh frozen product each month that is sold wholesale to licensed production facilities in Nevada to produce additional concentrate and extraction products. NOR production sells wholesale vaporizer cartridges, disposable vaporizers, tinctures, capsules, and concentrates to licensed dispensaries in Nevada. When available, NOR production may sell wholesale oil to licensed production facilities in Nevada. NOR cultivation and production also employ a wholesale sales team to sell finished products to other dispensaries.

NOR cultivation and production also employ a wholesale sales team to sell finished products to other dispensaries. NOR has entered into supplier agreements to provide flower and disposable/cartridge units beginning September 2018 through the end of 2018. The remaining product is sold wholesale as available.

Cannabidiol (“CBD”) Consumer Products

Xanthic anticipates a robust CBD consumer products industry in 2019. The Company will benefit from GGB’s previous investments of more than US$150,000 for research, development, and safety testing relating to proprietary CBD-infused products, including topical body care, face care, and ingestible agents. Research for body-care products is currently being finalized, with an expected limited launch of such products in the United States in the first quarter of 2019. Xanthic expects to finalize research and development for proprietary face care and ingestible products in November 2018, with a launch of those products also in the first quarter of 2019.

 

9


The Company began testing of CBD consumer products in October 2018. The test results of consumer acceptance of the CBD consumer products will dictate the number of expanded distribution points throughout 2019. Expenses will be incurred in the production and manufacturing of the product, along with support associates in merchandising, planning and allocation. Further, Xanthic is currently exploring opportunities in Canada and outside of North America, though the timeline for commercialization in these locations is unknown at this time.

In marketing its CBD consumer products, Xanthic intends to use consistent branding and messaging across all of its locations. The Company has dedicated merchandising and marketing teams, through whom it intends to provide a retail experience unmatched in the CBD space.

In addition, Xanthic intends to commercialize the Company’s existing patent-pending powder process with partners in multiple states. The cost per new location would be approximately US$100,000, which includes equipment and make-ready items such as packaging artwork. To achieve this goal, Xanthic has executed a letter of intent with Pasaverde Labs LLC, based in California. The Company estimates that first production in California will occur in the fourth quarter of 2018. The NOR Acquisition, moreover, provides access to the Nevada market, with estimated first production in that state occurring in the fourth quarter of 2018.

Finally, Xanthic plans to exercise an option to acquire a further 6% of Xanthic Beverages, giving Xanthic control over this business. The cost of this exercise is US$300,000 in Common Shares at the 60-day average stock price at the time of exercise.

E-Commerce

Xanthic expects to create e-commerce-capable websites for its various brands in the fourth quarter of 2018. Product sales are anticipated to begin in early 2019, and the Company expects to begin its product sales at that time. GGB’s e-commerce websites will sell proprietary CBD-infused consumer products, branded apparel, and proprietary branded accessory products.

Xanthic intends to use a third party provider to handle all orders, processing, packaging, unit storage, distribution, delivery, returns and customer-service call centers. No contract or estimated expenses are available at this time and will be dependent on the unit velocity and the terms of the applicable service agreements.

Method of Distribution

Retail Cannabis

NOR operates a retail cannabis store in Las Vegas, Nevada called “The Source”. As of August 2018, this location served an average of over 900 customers per day. The Source also maintains impeccable reviews and ratings, and, in February 2018, was named “Best of the City” by Nevada Public Radio’s Desert Companion Magazine. According to the figures released by the Nevada Department of Taxation (the “DOT”) on August 28, 2018, medical and retail marijuana sales for the fiscal year 2017-2018 totaled approximately US$529,000,000 via 64 dispensary/retail stores. This equates to roughly US$8,200,000 per location. However, NOR’s location, “The Source”, outperformed the state average by over 200%.

This outstanding performance starts not just with quality product, but with a quality experience. NOR elected to take a customer-centric approach to designing its first store. A LEED-certified architect and a top national retail interior designer, specializing in high-traffic retail stores, were hired to create and

 

10


implement the design. Elements from the most successful retailers in the country were incorporated into the store design, such as:

 

   

An open, spacious entrance with abundant natural light;

 

   

Modern, organic design that incorporates reclaimed wood, natural concrete floors, white walls, and special plants to warm up the environment;

 

   

Greeters stationed in the entrance to open the door and personally welcome customers;

 

   

Open ceilings with solar tubes to allow natural light to fill the entire retail area;

 

   

Secure, but unobtrusive, bulletproof safety glass surrounding areas with product or cash;

 

   

Open retail floor with highly trained roaming customer advisors to assist customers;

 

   

Highly efficient and flexible check-out process staffed with friendly cashiers and pick-up options;

 

   

Flexible customer experience with no lines where customers choose how to shop and with whom they interact;

 

   

Prompt service with very few lines and very little waiting;

 

   

Clean, uncluttered, minimalistic merchandising that focuses on education, experience, and the right product selection; and

 

   

Soft background music that appeals to customers from all walks of life.

NOR’s design was instantly accepted and appreciated by customers for an “everyday” approach to the marijuana retail experience. Through the many unique challenges of the industry, NOR focused on operating a compliant retail marijuana store while delivering a familiar and sought-after retail experience.

The size and layout of the proposed retail marijuana store is centered on creating the optimal customer experience. Unlike the vast majority of retail marijuana stores, customers dictate their shopping experience, rather than being assigned to a specific budtender.    

When designing the space, NOR contemplated a myriad of operational considerations, including customer counts, shopper flow, product popularity, orders per hour, online orders/pickup, average wait times (i.e. queue monitoring), and employee roles. In order to deliver optimal customer experience, the store was designed to handle peak traffic flow, including variations in days of the week.

Like the brick-and-mortar retail experience, NOR’s online order and in-store pick up process has been designed around safety, convenience, and efficiency. NOR processes more than 100 orders per day through online order and pick up. As the marijuana market matures and customers become more familiar with the product offering, a growing number of customers choose to place orders online. NOR’s store layout has been designed to accommodate those customers.

Wholesale Cannabis

NOR is a vertically integrated, dual-licensed cannabis operator in Nevada. Through its cultivation, production, distribution, and dispensary licenses, NOR is able to control its entire supply chain, from growth and extraction, to transportation and customer sales.

 

11


For the two facilities that NOR directly supplies, it provides flower each month from NOR cultivation. Each month, the facilities also purchase units from NOR production. NOR cultivation sells trim and flower each month to NOR production for extraction. NOR produces fresh frozen product each month in addition to what it ultimately sells in its own retail locations. NOR sells this product wholesale to licensed production facilities in Nevada to produce additional concentrate and extraction products. NOR production also sells wholesale vaporizer cartridges, disposable vaporizers, tinctures, capsules, and concentrates to licensed dispensaries in Nevada. When available, NOR production may also wholesale oil to licensed production facilities in Nevada as well.

Additionally, NOR employs a wholesale sales team to sell finished products to other dispensaries. NOR has, for example, entered into supplier agreements to provide flower and disposable cartridge units beginning September 2018 through the end of 2018. The remaining product is sold wholesale as available to other dispensaries in the state. NOR’s distribution license allows it deliver wholesale orders, a unique competitive advantage given that (1) the majority of licensees in the State of Nevada do not have distribution licenses, and (2) the state will shortly award an additional 60 recreational dispensary licenses.

CBD Consumer Products

The Company intends to distribute its CBD-infused personal care products to all jurisdictions where CBD sales comply with existing local law through (i) partnerships with specialty retailers; (ii) a robust e-commerce platform; (iii) the creation of kiosk establishments in targeted retail locations; and (iv) the creation of brick-and-mortar store locations.

Distribution of the Company’s CBD-infused water occurs through the licensing of intellectual property to licensed producers in specific, targeted jurisdictions. Production and distribution then follows pursuant to the granted license using the infrastructure of the licensee. At this time, the principal markets for the Company’s CBD-infused water are Oregon and Washington, with anticipated expansion to Nevada via the acquisition of NOR and potential expansion to other locations including California and Colorado.

E-Commerce

The Company expects to create e-commerce-capable websites for its various brands in the fourth quarter of 2018. Product sales are anticipated to begin in early 2019, and the Company expects to begin its product sales at that time. The Company’s e-commerce websites will sell proprietary CBD-infused consumer products, branded apparel, and proprietary branded accessory products subject to governmental approvals, if necessary.

Specialized Skills and Knowledge

The cannabis industry is one that requires management and employees with a broad range of skills and knowledge in order to be successful in the long-term. Xanthic’s founders have the knowledge behind a patent-pending process to convert THC and CBD into water-soluble powder. Xanthic’s proprietary formulations are developed utilizing the most recent developments in cannabis science and are overseen by medical doctors and scientists. This knowledge is unique within the emerging CBD industry. With respect to Xanthic’s leadership, Igor Galitsky, who serves as President, has been a pioneer in the areas of cannabis extracts and products in Canada for over seven years. Mr. Galitsky is a board member of Platinex Inc., which focuses on development of an online community and portal by publishing timely and informative articles in respect of the cannabis industry.

 

12


Competitive Conditions

Retail Cannabis

Nevada has a heavily regulated and restricted retail and medical marijuana framework, where licenses are not only difficult to obtain, but are subject to a competitive application process that favours existing licensees such as NOR.

As one of the first five dispensaries to open in the State of Nevada, NOR opened its doors to medical patients on December 10, 2015 and began retail sales on July 1, 2017. During this time, NOR has distinguished itself as one of the leading dispensaries and retail cannabis stores in Nevada for customer service, compliance, and financial success.

Nevada’s competitive landscape is one of the healthiest among the states that have legalized cannabis in some form. There are more than sixty dispensaries in the entire state, although NOR, through its leadership, skill, and knowledge, has outperformed state revenue averages by approximately 200%. NOR, as discussed above, has recently submitted an application for an additional 8 recreational dispensary licenses in the State of Nevada. In all, the state is anticipating awarding 64 new recreational licenses as part of this application process. The market continues to grow, and NOR is in good position to further bolster its position as a leading cannabis retailer in the state.

Wholesale Cannabis

As to cultivation, the State of Nevada has issued approximately 200 such licenses, though only approximately 120 such licenses are currently active. Cultivators in the state are expanding. Pricing is competitive, with prices decreasing on medium-low quality product, while, for high quality product, the demand and pricing remains higher than average.

The State of Nevada issued approximately 100 production licenses, but only about 60 are currently active. Wholesale prices on edibles and cartridges are competitive and falling. CO2 concentrates are more competitively priced. Low-to-medium quality concentrates are competitive, and prices are falling. High quality concentrates and cartridges are maintaining higher prices and can be more difficult to find. Live resins and rosins are top of the market. Live resin cartridges are extremely popular with consumers and are difficult to keep in stock, even at higher prices.

CBD Consumer Products

The CBD consumer product market is nascent but will grow during the remainder of 2018 and through 2019 as legalization of CBD consumer products continues in the United States, Canada, and Europe. Xanthic anticipates establishing a footprint of operations in all United States locations where such sales are permitted, as well as in Canada and Europe.

Components

Retail and Wholesale Cannabis

NOR’s dispensary purchases finished products and wholesale accessories from a variety of production and cultivation licensees and other sources in the State of Nevada that are readily available and easy to source. It also purchases wholesale CBD products from a variety of sources whose availability has increased as CBD popularity has grown.

 

13


With respect to cultivation, the raw materials are as follows: nutrients, rockwool, packaging, CO2, and cocoa/peat. The nutrients, rockwool and cocoa/peat are purchased from an industry leader in commercial sales and large-scale grow design. These items are readily available. Pricing is very competitive for all products. Additional sources, should the need ever arise, are also readily available.

With respect to packaging, wholesale bags are purchased from a Las Vegas packaging supplier and are readily available and easy to source. Retail packaging is custom-made and available through multiple vendors.

CBD Consumer Products

The sources, pricing and availability of raw materials and component parts for Xanthic’s CBD finished products come from various suppliers, distributors and contract manufacturing companies based in the United States (under the 2014 Farm Bill), Europe and Asia. The Company has sourced raw materials and components from multiple distributors, and its contract manufacturer has several available manufacturing facilities. There are no material issues with the pricing or availability of any of the raw materials or component parts that comprise the finished CBD products.

Intellectual Property Protection

The Company considers its interest in patents to be an important contributor to the future growth profile of its business and therefore devotes resources to maintaining and augmenting its patent portfolio. The Company’s patent strategy is to pursue the broadest possible patent protection on the Company’s proprietary products and technology in selected jurisdictions (the United States and Canada) and to achieve the maximum duration of patent protection available. Where appropriate, and consistent with management’s objectives, patents are pursued once concepts have been validated through appropriate laboratory work. To that end, patents will continue to be sought in relation to those components or concepts that management of the Company perceives to be important. In general, the Company’s strategic approach is to build a portfolio which provides broad protection of the Company’s technology.

In addition to the Company’s patent portfolio, the Company relies upon trade secrets, know-how and continuing technological innovations to develop its competitive position. It is the Company’s policy to require its directors, employees, consultants, members of its advisory board and parties to collaborative agreements to execute confidentiality agreements upon the commencement of employment, consulting or collaborative relationships with the Company. In the case of employees and consultants, the agreements provide that all inventions resulting from work performed for the Company utilizing the Company’s property or relating to the Company’s business and conceived of or completed by the individual during employment are the Company’s exclusive property.

Xanthic has filed a patent application for “Powdered Cannabis Products, Products Containing Powdered Cannabis, and Process of Making Same”. This process, once approved, will provide patent protection for Xanthic’s CBD-infused water products.

Following the completion of the Business Combination, Xanthic’s current intangible properties include the following: CAMP, Seventh Sense, Meri+Jayne, Green Lily, The Source, 8/Fold, and Xanthic Biopharma. For the CAMP, Seventh Sense, Meri+Jayne and Green Lily marks, protection has been sought for each with the United States Patent and Trademark Office and the Canadian Intellectual Property Office. Additionally, the “The Source” mark has been submitted to the United States Patent and Trademark Office. In the case of the Xanthic Biopharma mark, protection has been sought only in the State of Oregon.

 

14


Employees

As of the date of this AIF, Xanthic has three employees.

As of August 31, 2018, NOR had 127 employees, split between its cultivation and dispensary locations.

ISSUERS WITH U.S. CANNABIS-RELATED ASSETS

On February 8, 2018, the Canadian Securities Administrators revised their previously released Staff Notice 51-352 Issuers with U.S. Marijuana-Related Activities (the “Staff Notice”) which provides specific disclosure expectations for issuers that currently have, or are in the process of developing, cannabis-related activities in the United States as permitted within a particular state’s regulatory framework. All issuers with United States cannabis-related activities are expected to clearly and prominently disclose certain prescribed information in prospectus filings and other required disclosure documents.

As a result of the Company’s existing operations and recent acquisitions in the United States, Xanthic is properly subject to the Staff Notice and accordingly provides the following disclosure:

Nature of Involvement in the U.S. Marijuana Industry

Nevada

The Company, through its wholly-owned subsidiary, NOR, is licensed to possess, cultivate, process, dispense and sell medical and recreational cannabis in the State of Nevada. NOR operates a facility which is approximately 12,000 square feet located in Clark County, Nevada, where cultivation, production, and distribution take place.

Washington and Oregon

On March 22, 2018, the Company entered into the Xanthic Beverages Agreement with Xanthic Beverages. Pursuant to the Xanthic Beverages Agreement, Xanthic Beverages agreed to produce CBD infused water for distribution to over 500 retail locations, including grocery retailers and convenience stores, across Eastern Washington and Northeast Oregon.

Status of Medical and Recreational Cannabis under United States Federal Law

Ownership, investment, or control of, or engaging in transactions with entities which manufacture, distribute, dispense, or possess cannabis may create a risk of criminal or civil liability. Cannabis is illegal under federal law and the laws of some states and territories in the United States. Thirty-one states and territories in the United States have legalized medical or recreational cannabis, but the legal and regulatory frameworks in each of these jurisdictions vary and impose substantial restrictions on the manufacture, distribution, dispensation, or possession of cannabis, and on related business activities, including employment, advertising, and finance within the state and territory. Federal criminal laws continue to apply in those states and territories which have legalized cannabis.

Although the Company’s activities are compliant with applicable state and local law in the United States, strict compliance with state and local laws may not act as a shield to federal criminal liability.

 

15


The risk of federal enforcement and other risks associated with Xanthic’s business are described under the heading “Risk Factors” below.

Ability to Access Public and Private Capital

While the Company is not able to obtain bank financing in the United States or financing from other federally regulated entities, the Company’s executive team and board of directors have relationships with potential sources of private capital (such as funds and high net worth individuals).

While there has been an increase in the amount of private financing available over the last several years, there is neither a broad nor deep pool of institutional capital that is available to participants in the United States cannabis industry. There can be no assurance that additional financing will be available to the Company when needed or on acceptable terms. The Company’s inability to raise financing to fund its ongoing operations, capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon future profitability and operations.

Nevada Regulatory Framework

Nevada Revised Statutes Chapter 453D (“Chapter 453D”) provides a regulatory framework that outlines the function of the DOT’s marijuana program. Chapter 453D also outlines licensing and enforcement guidelines which guide the DOT.

Licensing Requirements

Licenses issued by the DOT can be renewed annually so long as the licensee continues to demonstrate compliance with local and state law and pays the renewal fee. The DOT places license caps on all license classifications, which are reassessed annually.

Applicants must demonstrate (and license holders must maintain) that: (i) they are registered with the Nevada Secretary of State to do business in Nevada, (ii) that they have contributed to the advancement of the State of Nevada through regular tax payments, (iii) that they do not have interests in the casino or alcohol industries, (iv) they have the operational expertise required by the individual license type, demonstrated by submission of an operation plan, (v) they have the ability to secure the premises, resources, and personnel necessary to operate the license, (vi) they have the ability to maintain accountability of all cannabis and cannabinoid products and by-products through the state mandated seed-to- sale software to prevent diversion or unlawful access to these materials, (vii) they have the financial ability to maintain operations for the duration of the license, (viii) all owners have passed background screening, inclusive of fingerprinting, and (ix) that all local land use, zoning, and planning notices have been followed in the development of the licensed site.

Security Requirements

In terms of security requirements, a licensee must maintain a fully operational alarm and video monitoring system at all times. The alarm system must secure all points of ingress and egress and be equipped with motion detectors. The 24-hour video surveillance system must record at a high-resolution format approved by the DOT and have camera coverage which covers all areas of the facility without any blind spots. Video footage must be backed-up for a minimum of 30 days in hard-form.

 

16


Cultivation and product manufacturing sites are not open to the public. Any vendor or contractor that needs access to the premises must be fully identified and sign into a vendor log. There is no access to non-employees unless there is an employee present.

Transportation and Storage Requirements

Cannabis and cannabis goods must be stored in a lockable safe or vault at any time that employees are not on location. Any storage container that is large enough to allow an employee to walk into it must have cameras placed inside. Goods to be transported to another licensee must be fully manifested through the state mandated seed-to-sale tracking system prior to being transported.

Department Inspections

The DOT conducts announced and unannounced inspections of all licensed facilities to determine compliance with laws and rules. The DOT will inspect a licensee in the event of a complaint indicating that the licensee has or is actively violating existing statute. The DOT will also inspect at the time of any premises modification, as well as at the time of annual renewal.

Oregon Regulatory Summary

Oregon Revised Statutes Chapter 475 B (Cannabis Regulation) provides the regulatory framework for both the recreational and medical cannabis industries in Oregon. The Oregon Liquor Control Commission’s (“OLCC”) implementation of the recreational cannabis statutes are found in Oregon Administrative Rules Chapter 845, Division 25. The Oregon Medical Marijuana Program’s (the “OMMP”) implementation of the medical cannabis statutes are found in Oregon Administrative Rules Chapter 333, Division 8. Chapter 333, Division 7 provides the packaging, labelling and dosage limits for both programs, and Chapter 333, Division 64 governs the accreditation of laboratories for testing.

Both the OLCC and the OMMP rules include licensing requirements and materials, as well as criteria for denial or approval of license applications.

Licensing Requirements

Licenses issued by the OLCC may be renewed annually so long as the licensee meets the requirements of the law and pays the renewal fee. There is no maximum number of licenses per owner, except for cultivation licenses located at the same address.

Applicants must demonstrate (and license holders must maintain) that: (i) they are registered with the Oregon Secretary of State to do business in Oregon, (ii) they have the operational expertise required by the individual license type, demonstrated by submission of an operation plan, (iii) they have the ability to secure the premises, resources, and personnel necessary to operate the license, (iv) they have the ability to maintain accountability of all cannabis and cannabinoid products and by-products through the state mandated seed-to-sale software to prevent diversion or unlawful access to these materials, (v) they have the financial ability to maintain operations for the duration of the license, (vi) all owners have passed background screening, inclusive of fingerprinting, and (vii) that all local land use, zoning, and planning notices have been followed in the development of the licensed site.

 

17


Security Requirements

A licensee must maintain a fully operational alarm and video monitoring system at all times. Commercial grade, non-residential door locks are required on every external door. The alarm system must secure all entry points and be equipped with motion detectors and pressure activated panic alarms. The 24-hour video surveillance system must record at a high-resolution format approved by the OLCC and have camera coverage which covers all areas of the facility without any blackout areas. Video footage must be backed-up for a minimum of 30 days in hard form, with a minimum of 90 days available on request. Additionally, the camera system must have the ability to print still photos.

Dispensaries are the only facilities permitted to allow public access. These facilities must include a waiting area with sufficient space and seating to accommodate customers. This waiting area is separated from the consumer sales area by a locked door that is controlled by an employee within the secured area. All other facilities require signage advising that there is no public entry. Any vendors or contractors that must be on site have to be fully checked in through a visitor log and must be accompanied at all times by an employee.

Transportation and Storage Requirements

Recreational and medicinal cannabis and cannabis products must be stored in a secured, locked room or vault. Vaults that are large enough to allow a person to walk in must have cameras inside so that there is no blind spot. Smaller safes must be bolted to the floor. When products are transferred between licensees, they must first be fully manifested through the state mandated ‘seed-to-sale’ system. This written manifest must include: (i) departure date and time, (ii) name, address, and license number of the originating licensee, (iii) name, address, and license number of the recipient, (iv) quantity and form of any cannabis or cannabis delivery device being transported, (v) arrival date and time, (vi) delivery vehicle make and model and license plate number, and (vii) name and signature of the employee delivering the product. A copy of this manifest is provided to the receiving licensee for their verification. Upon receiving the transfer, the licensee must immediately verify the shipment versus the manifest and accept it electronically within the ‘seed-to-sale’ system. This completes the inventory transfer. The OLCC licensees must maintain these records for a minimum of 3 years. During transport, all product is packaged individually by order, and maintained within a locked receptacle within the vehicle. All deliveries must be completed within 24 hours.

Department Inspections

The OLCC conducts announced and unannounced inspections of all licensed facilities to determine compliance with laws and rules. The OLCC will inspect a licensee upon receiving a complaint or notice that the licensee has violated any existing rules. The OLCC will also conduct an annual license renewal inspection at the time of application approval. Inspections can cover all records, personnel, equipment, security, and operational methodologies.

Washington State Regulations

Washington has authorized the cultivation, possession, processing, wholesaling, and retail sale of marijuana by certain licensed Washington businesses. The Washington State Liquor and Cannabis Board (“WSLCB”) regulates Washington’s marijuana regulatory program.

 

18


Application and Licensing

Every individual with an ownership or equity interest, with a right to receive a percentage of gross or net profits, or who exercises control over a licensed marijuana operator must apply for licensing with the WSLCB and be approved. Each applicant must be over 21 years of age and a Washington resident.

An applicant must provide the WSLCB with the following information:

 

  1.

the applicant’s organizational and operational documents, including the entity’s operating agreement and a detailed operating plan, in order to verify that the proposed business meets the minimum requirements for licensing;

 

  2.

the applicant’s financial statements to verify the source of funds for the business, including any acquisition agreements and any agreements for the development of an operating marijuana business, as well as financial documents verifying the source of funds for all purchases of and material changes to the business.

 

  3.

the name(s) of any financier(s) which provide funds to be used by the marijuana business; and

 

  4.

the applicant’s and the applicant’s spouse’s personal and criminal history, including fingerprints for the submission of a criminal records background check with the Washington State Patrol and the U.S. Federal Bureau of Investigation.

Any change in the initial ownership of a cannabis entity must receive prior approval through the WSLCB and undergoes a review of the same rigor and breadth as an initial application.

Security Requirements

The WSLCB requires all licensed operators, employees, and non-employee visitors other than retail customers to display an identification badge at all times on the premises. Each licensed operator must keep a log of all visitors other than retail customers to the premises.

All premises must have a security alarm system on all perimeter entry points and perimeter windows. All premises must have a complete video surveillance system with minimum required camera resolution and a surveillance system storage device or internet protocol storage compatibility that: (a) records continuously for 24 hour per day, (b) has cameras in fixed places that allow for the clear identification of persons and activities in the controlled areas of the premises, including grow rooms, processing rooms, storage rooms, disposal rooms/areas and point of sale rooms, (c) has the capability of recording clear images and displays the time and date of the recording, (d) demonstrates a plan for retention of recordings for at least 45 days, and (e) provides outdoor lighting for outdoor cultivation.

Transportation and Traceability

Washington requires use of a seed-to-sale tracking system. Licensed operators must use an inventory control system that identifies and tracks the plant from the time it reaches a height of six inches through harvest, processing, packaging, wholesale, and retail sale. Licensed operators must also manifest and quarantine all marijuana to be delivered to another licensed operator or destroyed as waste for a period of at least 24 hours in order to allow for inspection by WSLCB enforcement officers. Vehicles transporting marijuana must have: (i) a vehicle security system, including separate, secure, locking compartment to store any marijuana product; and (ii) a transportation manifest reported through the seed-to-sale tracking system, including (a) the departure time, (b) name, location, address and license number of the originating licensed operator, (c) quantity and form of product to be

 

19


delivered, (d) estimated time of arrival, and (e) name of the employee and identification of the vehicle delivering the product. Licensed operators must retain traceability records for three years and make records available upon request for inspection by the WSLCB or other law enforcement.

The WSLCB currently has in place a contingency traceability plan that requires licensed operators to report all changes in traceability records weekly. Beginning February 1, 2018, Washington will transition to a new online traceability reporting system using MJ Platform’s Leaf Database System. Licensed operators will provide all traceability records to the WSLCB at the time of transition.

Inspections

The WSLCB sends an enforcement officer to inspect each proposed marijuana facility prior to granting approval to be authorized to begin cultivation, processing, or dispensing. Licensed operators must permit WSLCB enforcement officers to inspect the premises, vehicles, records, and marijuana products at any time, and random inspections are conducted frequently by enforcement officers.

Compliance of Nevada Operations

NOR, a wholly-owned subsidiary of Xanthic, is in compliance with Nevada state law and the related licensing framework. NOR uses reasonable commercial efforts to confirm, through the advice of its legal counsel, through the monitoring and review of its business practices, and through regular monitoring of changes to U.S. Federal enforcement priorities, that its business is in compliance with applicable licensing requirements and the regulatory frameworks enacted by Nevada. NOR has not received any noncompliance orders, citations or notices of violation that may have an impact on its licenses, business activities or operations.

On-Going Compliance Procedures

NOR has a full time Compliance Officer on staff in Nevada whose responsibilities are to monitor the day-to-day activities of staff, including ensuring that the established standard operating procedures are being adhered to at each stage of the cultivation, processing and distribution cycle, to identify any non-compliance matters and to put in place the necessary modifications to ensure compliance. The Compliance Officer performs monthly, unannounced audits against NOR’s established standard operating procedures and state regulations. Each employee is provided with an employee handbook outlining the standard operating procedures and state regulations upon hiring, and is then provided with quality and regulatory training by the Compliance Officer. The Company has 24 hour surveillance of every room in which marijuana is cultivated, processed, and stored. This footage is kept for at least 45 days as per the requirements of the Department. Security officers also perform a walk through every four hours to check each room and look for unusual activity. The Company also utilizes state approved software for tracking marijuana inventory from seed to sale. The Compliance Officer’s duties also include ongoing education of staff on the state regulations. State inspections to date have not resulted in any non-compliance issues.

NOR has worked with its legal advisors to implement measures designed to ensure compliance with applicable state laws in the United States on an ongoing basis, including:

 

   

weekly correspondence and updates with advisors;

 

   

development of standard operating procedures with respect to cultivation, processing and distribution;

 

   

ongoing monitoring of compliance with operating procedures and regulations by on-site management;

 

20


   

appropriate employee training for all standard operating procedures; and

 

   

subscription to monitoring programs to ensure compliance with the FCEN Memo.

Compliance of Oregon and Washington Operations

To the knowledge of management of the Company, Xanthic Beverages, in which NOR holds a minority ownership interest, is in compliance with applicable licensing requirements and the regulatory framework enacted by the applicable regulatory bodies in Oregon and Washington.

Foreign Operations

See below under the heading “Risk Factors”.

Bankruptcy and Similar Procedures

There have been no bankruptcy, receivership or similar proceedings against the Company or any of its subsidiaries, or any voluntary bankruptcy, receivership or similar proceedings by the Company or any of its subsidiaries, within the three most recently completed financial years or during or proposed for the current financial year.

Reorganizations

On December 15, 2017, Xanthic was formed pursuant to a reverse takeover involving Aurquest and a privately held Ontario corporation, Xanthic Biopharma Limited, with the objective of becoming a leader in developing innovative, non-combustible alternative delivery methods for cannabis-infused products.

On November 9, 2018, Xanthic and GGB combined by way of amalgamation between GGB and a wholly-owned subsidiary of Xanthic, 2657013 Ontario Inc., to form one company as a wholly-owned subsidiary of Xanthic.

RISK FACTORS

Management of the Company defines risk as the evaluation of probability that an event might happen in the future that could negatively affect the financial condition and/or results of operations of the Company. The following section describes specific and general risks that could affect the Company. The following descriptions of risk do not include all possible risks as there may be other risks of which management is currently unaware. Moreover, the likelihood that a risk will occur or the nature and extent of its consequences if it does occur, is not possible to predict with certainty, and the actual effect of any risk or its consequences on the business could be materially different from those described below and elsewhere in this AIF.

Risks Specifically Related to Operating under the United States Regulatory System

The cannabis business in the United States is subject to additional risk

Xanthic will be engaged in the medical and adult-use marijuana industry in the United States in compliance with local and state law. While the cannabis industry in all markets is highly regulated and rapidly evolving, presenting challenges to management to operate effectively and accurately predict financial results contained in any forward looking statements, Xanthic is subject to additional risks in its United States operations. Investors are cautioned that in the United States, cannabis is

 

21


illegal under United States federal law. Notwithstanding the more permissive regulatory environment of cannabis at the state level, cannabis continues to be categorized as a controlled substance under the Controlled Substance Act and as such, cultivation, distribution, sale and possession of cannabis violates federal law in the United States. To management’s knowledge, there are to date a total of 31 states, and the District of Columbia, Puerto Rico, the U.S. Virgin Islands and Guam that have legalized cannabis in some form, including Nevada where Xanthic operates.

The United States Congress has passed appropriations bills each of the last four years that have expressly not appropriated funds for prosecution of cannabis offenses of persons who are in compliance with state medical cannabis laws. Courts in the United States have construed these appropriations bills to prevent the federal government from prosecuting persons when those persons comply with applicable state medical cannabis law. However, because this conduct continues to violate federal law, U.S. courts have observed that should United States Congress at any time choose to appropriate funds to fully prosecute offences under the Controlled Substances Act of 1970 (the “CSA”), any individual or business—even those that have fully complied with state law—could be prosecuted for violations of federal law. If United States Congress restores funding, the government will have the authority to prosecute individuals for violations of the law during the time it lacked funding, subject to the CSA’s five-year statute of limitations.

Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, judgments or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, criminal convictions, disgorgement of profits, cessation of business activities, divestiture or civil asset forfeiture. This could have a material adverse effect on Xanthic, including its reputation and ability to conduct business, its holding (directly or indirectly) of medical and adult-use cannabis licenses in the United States, the listing of its securities on the CSE, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for management to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial.

The Company will derive a significant portion of its revenue from the cannabis industry in certain states of the United States, which industry is illegal under United States federal law. While the Company’s business activities are compliant with applicable state and local law, such activities remain illegal under United States federal law. The enforcement of relevant laws is a significant risk.

Approach to the enforcement of cannabis laws is subject to change

As a result of the conflicting views between state legislatures and the federal government regarding cannabis, investments in cannabis businesses in the United States are subject to inconsistent legislation and regulation. The response to this inconsistency was addressed in the United States Department of Justice memorandum drafted by former Deputy Attorney General James Michael Cole in 2013 (the “Cole Memorandum”), acknowledging that notwithstanding the designation of cannabis as a controlled substance at the federal level in the United States, several states have enacted laws relating to cannabis for medical purposes.

The Cole Memorandum outlined certain priorities for the Department of Justice relating to the prosecution of cannabis offenses. In particular, the Cole Memorandum noted that in jurisdictions that

 

22


have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. Notably, however, the Department of Justice did not provide specific guidelines for what regulatory and enforcement systems it deemed sufficient under the Cole Memorandum standard.

In light of limited investigative and prosecutorial resources, the Cole Memorandum concluded that the Department of Justice should be focused on addressing only the most significant threats related to cannabis. States where cannabis had been legalized were not characterized as a high priority. In March 2017, newly appointed Attorney General Jeff Sessions again noted limited federal resources and acknowledged that much of the Cole Memorandum had merit; however, he disagreed that it had been implemented effectively and, on January 4, 2018, Mr. Sessions issued the Sessions Memorandum, which rescinded the Cole Memorandum. The Sessions Memorandum rescinded previous nationwide guidance specific to the prosecutorial authority of United States Attorneys relative to cannabis enforcement on the basis that they are unnecessary, given the well-established principles governing federal prosecution that are already in place. Those principals are included in chapter 9.27.000 of the United States Attorneys’ Manual and require federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community.

Following the issuance of the Sessions Memorandum, Annette Hayes, U.S. Attorney for the Western District of Washington, released a statement on January 4, 2018 affirming that her office will continue to investigate and prosecute “cases involving organized crime, violent and gun threats, and financial crimes related to marijuana” and that “enforcement efforts with our federal, State, local and tribal partners focus on those who pose the greatest safety risk to the people and communities we serve”.

In Oregon, the United States Attorney for the District of Oregon Billy J. Williams released an official statement on May 18, 2018 (“Williams Memo”), which clarified his office’s position with regards to the priorities in enforcement of federal laws involving marijuana in the District of Oregon. The priorities set out in the Williams Memo are as follows:

 

  1.

Priority 1: Overproduction and Interstate Trafficking. Prioritizing enforcement of federal marijuana violations that have national or interstate implications, particularly when the Oregon-based criminal activity adversely affects states that have not legalized marijuana, which will remain a top priority until overproduction that feeds exportation of marijuana across Oregon’s borders stops.

 

  2.

Priority 2: Protecting Oregon’s Children. Prioritizing enforcement of federal marijuana violations that threaten public health, with particular emphasis on the access to marijuana by minors.

 

  3.

Priority 3: Violence, Firearms, or other Public Safety Threats. Prioritizing enforcement of federal marijuana violations that involve or pose a substantial risk of violence or other threats to public safety in our communities, especially those involving firearms and illegal manufacture of butane hash oil that has potential to result in dangerous explosions and fires.

 

23


  4.

Priority 4: Organized Crime. Prioritizing enforcement of federal marijuana violations that serve to fuel other criminal activity, especially through racketeering and the involvement of organized crime. This includes not only violent crimes, but also non-violent criminal activity, such as federal income tax evasion or systematic money laundering to evade detection of illegal proceeds.

 

  5.

Priority 5: Protecting Federal Lands, Natural Resources, & Oregon’s Environment. Prioritizing enforcement of federal marijuana violations that have serious adverse effects on federal land or natural resources, including water, air, and listed species. Examples falling within this priority include cultivating marijuana on federally managed lands, using unlawful pesticides that pose a threat to human health, wildlife, and our environment, or using large amounts of water for grow operations without proper authorization.

To the knowledge of management of the Company, there have not been any additional statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action in Washington, Oregon, or Nevada.

As a result of the Sessions Memorandum, federal prosecutors will now be free to utilize their prosecutorial discretion to decide whether to prosecute cannabis activities despite the existence of state-level laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memorandum as to the priority they should ascribe to such cannabis activities, and resultantly it is uncertain how active federal prosecutors will be in relation to such activities. Furthermore, the Sessions Memorandum did not discuss the treatment of medical cannabis by federal prosecutors. Medical cannabis is currently protected against enforcement by enacted legislation from United States Congress in the form of the Leahy Amendment to H.R.1625 – a vehicle for the Consolidated Appropriations Act of 2018 which similarly prevents federal prosecutors from using federal funds to impede the implementation of medical cannabis laws enacted at the state level, subject to United States Congress restoring such funding. Due to the ambiguity of the Sessions Memorandum, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law.

Such potential proceedings could involve significant restrictions being imposed upon the Company or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on the Company’s business, revenues, operating results and financial condition as well as the Company’s reputation and prospects, even if such proceedings were concluded successfully in favour of the Company. In the extreme case, such proceedings could ultimately involve the prosecution of key executives of the Company or the seizure of corporate assets.

The Leahy Amendment must be renewed to protect the medical cannabis industry

The Leahy Amendment, as discussed above, prohibits the Department of Justice from spending funds appropriated by United States Congress to enforce the tenets of the CSA against the medical cannabis industry in states which have legalized such activity. This amendment has historically been passed as an amendment to omnibus appropriations bills, which by their nature expire at the end of a fiscal year or other defined term. The Leahy Amendment expired on September 30, 2018. As a result, it may or may not be included in the next omnibus appropriations package or a continuing budget resolution, and its inclusion or non-inclusion, as applicable, is subject to political changes.

 

24


Anti-money laundering laws and regulation

The Company will be subject to a variety of laws and regulations domestically and in the United States that involve money laundering, financial recordkeeping and proceeds of crime, including the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), Sections 1956 and 1957 of U.S.C. Title 18 (the Money Laundering Control Act), the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), as amended and the rules and regulations thereunder, the Criminal Code (Canada) and any related or similar rules, regulations or guidelines, issued, administered or enforced by governmental authorities in the United States and Canada.

Banks often refuse to provide banking services to businesses involved in the marijuana industry due to the present state of the laws and regulations governing financial institutions in the United States. The lack of banking and financial services presents unique and significant challenges to businesses in the marijuana industry. The potential lack of a secure place in which to deposit and store cash, the inability to pay creditors through the issuance of checks and the inability to secure traditional forms of operational financing, such as lines of credit, are some of the many challenges presented by the unavailability of traditional banking and financial services.

In February 2014, the Department of the Treasury Financial Crimes Enforcement Network issued a memo (the “FinCEN Memo”) providing instructions to banks seeking to provide services to cannabis-related businesses. The FinCEN Memo states that in some circumstances, it is permissible for banks to provide services to cannabis-related businesses without risking prosecution for violation of federal money laundering laws. It refers to supplementary guidance that former Deputy Attorney General James M. Cole issued to federal prosecutors relating to the prosecution of money laundering offenses predicated on cannabis-related violations of the CSA. While the FinCEN Memo has not been rescinded by the Department of Justice at this time, it remains unclear whether the current administration will follow its guidelines. Overall, the Department of Justice continues to have the right and power to prosecute crimes committed by banks and financial institutions, such as money laundering and violations of the Bank Secrecy Act, that occur in any state, including in states that have legalized the applicable conduct and the Department of Justice’s current enforcement priorities could change for any number of reasons, including a change in the opinions of the President of the United States or the United States Attorney General. A change in the Department of Justice’s enforcement priorities could result in the Department of Justice prosecuting banks and financial institutions for crimes that previously were not prosecuted.

In the event that any of the Company’s operations, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such operations in the United States were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under one or more of the statutes noted above or any other applicable legislation. This could restrict or otherwise jeopardize the ability of the Company to declare or pay dividends, affect other distributions or subsequently repatriate such funds back to Canada. Furthermore, while there are no current intentions to declare or pay dividends on the Common Shares in the foreseeable future, in the event that a determination was made that the Company’s proceeds from operations (or any future operations or investments in the United States) could reasonably be shown to constitute proceeds of crime, the Company may decide or be required to suspend declaring or paying dividends without advance notice for an indefinite period of time.

 

25


The illegality of cannabis in the United States presents additional legal and operational challenges

Because the use of cannabis is illegal under federal law, many judges and courts have denied cannabis businesses bankruptcy protections, enforcement of contracts, and protection of intellectual property – all of which may have a materially adversely effect on the Company’s results of operations and its investors return on investment. Without bankruptcy protections, it would be very difficult for lenders to recoup their investments in the cannabis industry in the event of a bankruptcy. In addition, there remains doubt and uncertainty that the Company will be able to legally enforce its contracts. The Company cannot be assured that it will have a remedy for breach of contract, which may have a material adverse effect on its business. Similarly, the benefit of federal laws and protections which are otherwise available to most businesses, such as federal trademark and patent protection regarding the intellectual property of a business, may not be available to the Company. The Company’s strategy is highly focused on creating brand equity and identity in its markets, by building strong brand awareness. The Company’s intellectual property may never be adequately or sufficiently protected against the use or misappropriation by third-parties. While many states do offer the ability to protect trademarks independent of the federal government, patent protection is wholly unavailable on a state level, and state-registered trademarks provide a lower degree of protection than would federally-registered marks. This position may prevent the Company from effectively marketing and selling its cannabis-infused and CBD-infused consumable products using technology that management believes should otherwise be afforded patent protection. As a result of the United States regulatory position on cannabis businesses, the Company may not be able to effectively prevent competitors from using its technology to market similar products in the markets in which it operates.

Restriction of entry into the United States

In the past, U.S. Customs and Border Protection (the “U.S. CBP”) was given the discretion to question Canadians entering the U.S. about their marijuana use and whether to use their response as a barrier to entry. Recently, the U.S. CBP has been focusing on the whole cannabis industry, including investors. Several highly publicized instances of U.S. CBP detaining and even banning Canadian investors from the United States have occurred in recent months. The restriction of travel to the United States of the Company’s executives and investors would seriously impair the ability of the Company to conduct business and could materially impact the Company’s results of operations.

Risks Related to the Cannabis Industry

Heightened scrutiny by regulatory authorities

For the reasons set forth above, the Company’s operations and investments in the United States may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, the Company may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Company’s ability to operate or invest in the United States or any other jurisdiction, in addition to those described herein.

It had been reported in Canada that the Canadian Depository for Securities Limited is considering a policy shift that would see its subsidiary, Clearing and Depository Services Inc. (“CDS”), refuse to settle trades for cannabis issuers that have investments in the United States. CDS is Canada’s central securities depository, clearing and settling trades in the Canadian equity, fixed income and money markets. The TMX Group, the owner and operator of CDS, subsequently issued a statement on August 17, 2017 reaffirming that there is no CDS ban on the clearing of securities of issuers with

 

26


cannabis-related activities in the United States, despite media reports to the contrary and that the TMX Group was working with regulators to arrive at a solution that will clarify this matter, which would be communicated at a later time.

On February 8, 2018, following discussions with the Canadian Securities Administrators and recognized Canadian securities exchanges, the TMX Group announced the signing of the memorandum of understanding among the TMX Group, Aequitas NEO Exchange Inc., the CSE, the TSX and the TSX Venture Exchange (“TMX MOU”). The TMX MOU outlines the parties’ understanding of Canada’s regulatory framework applicable to the rules, procedures, and regulatory oversight of the exchanges and CDS as it relates to issuers with cannabis-related activities in the United States. The TMX MOU confirms, with respect to the clearing of listed securities, that CDS relies on the exchanges to review the conduct of listed issuers. As a result, there is no CDS ban on the clearing of securities of issuers with cannabis-related activities in the United States. However, there can be no guarantee that this approach to regulation will continue in the future. If such a ban were to be implemented at a time when the Common Shares are listed on a stock exchange, it would have a material adverse effect on the ability of holders of the Common Shares to make and settle trades. In particular, the Common Shares would become highly illiquid as until an alternative was implemented, investors would have no ability to effect a trade of the Common Shares through the facilities of the applicable stock exchange.

Risk of legal, regulatory or political change

The success of the business strategy of the Company depends on the legality of the marijuana industry. The political environment surrounding the marijuana industry in general can be volatile and the regulatory framework remains in flux. To management’s knowledge, there are to date a total of 31 states, and the District of Columbia, Puerto Rico, the U.S. Virgin Islands and Guam that have legalized cannabis in some form and additional states have pending legislation regarding the same; however, the risk remains that a shift in the regulatory or political realm could occur and have a drastic impact on the industry as a whole, adversely impacting the Company’s business, results of operations, financial condition or prospects.

Delays in enactment of new state or federal regulations could restrict the ability of the Company to reach strategic growth targets and lower return on investor capital. The strategic growth strategy of the Company is reliant upon certain federal and state regulations being enacted to facilitate the legalization of medical and adult-use marijuana. If such regulations are not enacted, or enacted but subsequently repealed or amended, or enacted with prolonged phase-in periods, the growth targets of the Company, and thus, the effect on the return of investor capital, could be detrimental. Management is unable to predict with certainty when and how the outcome of these complex regulatory and legislative proceedings will affect its business and growth.

Further, there is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. If the federal government begins to enforce federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing applicable state laws are repealed or curtailed, the Company’s business, results of operations, financial condition and prospects would be materially adversely affected. It is also important to note that local and city ordinances may strictly limit and/or restrict disbursement of marijuana in a manner that will make it extremely difficult or impossible to transact business that is necessary for the continued operation of the marijuana industry. Federal actions against individuals or

 

27


entities engaged in the marijuana industry or a repeal of applicable marijuana related legislation could adversely affect the Company and its business, results of operations, financial condition and prospects.

The Company is aware that multiple states are considering special taxes or fees on businesses in the marijuana industry. It is a potential yet unknown risk at this time that other states are in the process of reviewing such additional fees and taxation. This could have a material adverse effect upon the Company’s business, results of operations, financial condition or prospects.

Overall, the medical and adult-use marijuana industry is subject to significant regulatory change at both the state and federal level. The inability of the Company to respond to the changing regulatory landscape may cause it to not be successful in capturing significant market share and could otherwise harm its business, results of operations, financial condition or prospects.

Public opinion and perception

Government policy changes or public opinion may also result in a significant influence over the regulation of the cannabis industry in Canada, the United States or elsewhere. Public opinion and support for medical and adult-use marijuana has traditionally been inconsistent and varies from jurisdiction to jurisdiction. While public opinion and support appears to be rising for legalizing medical and adult-use marijuana, it remains a controversial issue subject to differing opinions surrounding the level of legalization (for example, legalization of medical marijuana as opposed to recreational use). A negative shift in the public’s perception of cannabis in the United States or any other applicable jurisdiction could affect future legislation or regulation. Among other things, such a shift could cause state jurisdictions to abandon initiatives or proposals to legalize medical and/or adult-use cannabis, thereby limiting the number of new state jurisdictions into which the Company could expand. Any inability to fully implement the Company’s expansion strategy may have a material adverse effect on the Company’s business, results of operations or prospects.

General regulatory risks; risks related to licensure

The Company’s business is subject to a variety of laws, regulations and guidelines relating to the manufacture, management, transportation, storage and disposal of marijuana, including laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. Achievement of the Company’s business objectives is contingent, in part, upon compliance with applicable regulatory requirements and obtaining all requisite regulatory approvals. Changes to such laws, regulations and guidelines due to matters beyond the control of the Company may cause material adverse effects to the Company.

The Company is required to obtain or renew further government permits and licenses for its current and contemplated operations. Obtaining, amending or renewing the necessary governmental permits and licenses can be a time-consuming process potentially involving numerous regulatory agencies, involving public hearings and costly undertakings on the Company’s part. The duration and success of the Company’s efforts to obtain, amend and renew permits and licenses are contingent upon many variables not within its control, including the interpretation of applicable requirements implemented by the relevant permitting or licensing authority. The Company may not be able to obtain, amend or renew permits or licenses that are necessary to its operations. Any unexpected delays or costs associated with the permitting and licensing process could impede the ongoing or proposed operations of the Company. To the extent necessary permits or licenses are not obtained, amended or renewed, or are subsequently suspended or revoked, the Company may be curtailed or prohibited from proceeding

 

28


with its ongoing operations or planned development and commercialization activities. Such curtailment or prohibition may result in a material adverse effect on the Company’s business, financial condition, results of operations or prospects.

In Nevada, all marijuana establishments must register with the DOT and be issued a medical marijuana or retail marijuana establishment registration certificate. In a local governmental jurisdiction that issues business licenses, the issuance by DOT of a medical marijuana or retail marijuana establishment registration certificate is considered provisional until the local government has issued a business license for operation and the establishment is in compliance with all applicable local governmental ordinances. Final registration certificates are valid for a period of one year and are subject to annual renewals after required fees are paid and the business remains in good standing. It is important to note provisional licenses do not permit the operation of any commercial or medical cannabis activity. Only after a provisional licensee has gone through necessary state and local inspections, if applicable, and has received a final registration certificate from DOT may an entity engage in cannabis business operation. There is no assurance that the Company will be issued final registration certificates in respect of any provisional licenses awarded in the future.

While the Company’s compliance controls have been developed to mitigate the risk of any material violations of any license it holds arising, there is no assurance that the Company’s licenses will be renewed by each applicable regulatory authority in the future in a timely manner. Any unexpected delays or costs associated with the licensing renewal process for any of the licenses held by the Company could impede the ongoing or planned operations of the Company and have a material adverse effect on the Company’s business, financial condition, results of operations or prospects.

The Company may become involved in a number of government or agency proceedings, investigations and audits. The outcome of any regulatory or agency proceedings, investigations, audits, and other contingencies could harm the Company’s reputation, require the Company to take, or refrain from taking, actions that could harm its operations or require the Company to pay substantial amounts of money, harming its financial condition. There can be no assurance that any pending or future regulatory or agency proceedings, investigations and audits will not result in substantial costs or a diversion of management’s attention and resources or have a material adverse impact on the Company’s business, financial condition, results of operations or prospects.

Environmental risk and regulation

The Company’s operations are subject to environmental regulation in the various jurisdictions in which it operates. These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors (or the equivalent thereof) and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Company’s operations.

Government approvals and permits are currently, and may in the future, be required in connection with the Company’s operations. To the extent such approvals are required and not obtained, the Company may be curtailed or prohibited from proceeding with the development of its operations as currently proposed.

 

29


Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.

Amendments to current laws, regulations and permits governing the production of medical or retail marijuana, or more stringent implementation thereof, could have a material adverse impact on the Company and cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development.

Service providers

As a result of any adverse change to the approach in enforcement of United States cannabis laws, adverse regulatory or political change, additional scrutiny by regulatory authorities, adverse change in public perception in respect of the consumption of marijuana or otherwise, third party service providers to the Company could suspend or withdraw their services, which may have a material adverse effect on the Company’s business, revenues, operating results, financial condition or prospects.

Limited operating history

Xanthic has limited financial reporting history. Consequently, the Company’s financial results for 2018 are not comparable with prior years, and the financial information in this AIF may not be indicative of its future performance. The Company does not have a history of profitability, with the exception of the NOR business. As such the Company has limited prospects of generating profit from its intended operations. The Company is therefore subject to many of the risks common to early-stage enterprises, including under-capitalization, cash shortages, limitations with respect to personnel, financial, and other resources and lack of revenues. There is no assurance that the Company will be successful in achieving a return on shareholders’ investment and the likelihood of success must be considered in light of the early stage of operations.

If the Company is unable to successfully execute any material part of its growth strategy, its future growth and ability to make profitable investments in its business would be harmed

The Company’s success depends on its ability to expand its business while maintaining profitability. The Company may not be able to sustain its growth or profitability on a quarterly or annual basis in future periods. The Company’s future growth and profitability will depend upon a number of factors, including, without limitation:

 

   

The level of competition in the cannabis industry;

 

   

The Company’s ability to identify, acquire and integrate strategic acquisitions;

 

   

The Company’s ability to win new licenses as cannabis is legalized at the state level;

 

   

The Company’s ability to achieve brand loyalty;

 

   

The Company’s ability to offer new products and to extend existing brands and products into new markets, both in the United States and internationally markets;

 

   

The Company’s ability to remain competitive in its pricing;

 

   

The Company’s ability to leverage its vertically integrated business model to increase profitability;

 

30


   

The Company’s ability to maintain efficient, timely and cost-effective production and delivery of its products;

 

   

The efficiency and effectiveness of the Company’s sales and marketing efforts in building product and brand awareness and cross-marketing its brands;

 

   

The Company’s ability to identify and respond successfully to emerging trends in the cannabis industry;

 

   

The level of consumer acceptance of the Company’s products; and

 

   

The general economic and political conditions and consumer confidence.

The Company may not be successful in executing its growth strategy, and even if the Company achieves targeted growth, it may not be able to sustain profitability. Failure to successfully execute any material part of the Company’s growth strategy would significantly impair the Company’s future growth and its ability to make profitable investments in its business.

Future acquisitions

The Company is continually evaluating acquisitions and strategic investments that are significant to its business both in the United States and internationally. Management may not be able to identify suitable acquisition candidates, or complete such acquisitions, joint ventures and strategic investments on acceptable terms and conditions, and these acquisitions, joint ventures and strategic investments may not be successfully integrated into the Company’s operations. The costs of unsuccessful acquisition, joint venture and strategic investment efforts may adversely affect results of operations, financial condition or prospects. Material acquisitions and other strategic transactions involve a number of risks, including: (i) potential disruption of the Company’s ongoing business; (ii) distraction of management; (iii) the Company may become financially leveraged; (iv) the anticipated benefits and cost savings of those transactions may not be realized fully or at all or may take longer to realize than expected; (v) increasing the scope and complexity of the Company’s operations; (vi) impairment of relationships with customers and (vii) loss or reduction of control over certain of the Company’s assets. Additionally, the Company may issue additional Common Shares in connection with such transactions, which would dilute a shareholder’s holdings in the Company.

The presence of one or more material liabilities of an acquired company that are unknown to the Company at the time of acquisition could have a material adverse effect on the business, results of operations, prospects and financial condition of the Company. A strategic transaction may result in a significant change in the nature of the Company’s business, operations and strategy. In addition, the Company may encounter unforeseen obstacles or costs in implementing a strategic transaction or integrating any acquired business into the Company’s operations reducing its operating cash flow.

Well-capitalized entrants may develop large-scale operations

Currently, the marijuana industry generally is comprised of individuals and small to medium-sized entities, however, the risk remains that large conglomerates and companies who also recognize the potential for financial success through investment in this industry could strategically purchase or assume control of larger dispensaries and cultivation facilities. Larger companies in related business with similar customer bases may position themselves to enter into joint ventures and strategic partnerships in order to capitalize on their existing global distribution channels, which would restrict the Company’s ability to gain market penetration. In doing so, these larger competitors could establish price setting and cost controls which would effectively “price out” many of the individuals and small to medium-sized entities who currently make up the bulk of the participants in the varied businesses

 

31


operating within and in support of the medical and adult-use marijuana industry. While the trend in most state laws and regulations seemingly deters this type of takeover, this industry remains quite nascent, so what the landscape will be in the future remains largely unknown, which in itself is a risk.

The Company’s proposed business plan is subject to all business risks associated with new business enterprises, including the absence of any significant operating history upon which to evaluate an investment. The likelihood of the Company’s success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with the formation of a new business, the development of new strategy and the competitive environment in which the Company will operate. It is possible that the Company will incur losses in the future. There is no guarantee that the Company will be profitable.

Competition

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience than the Company. Increased competition by larger and better-financed competitors could materially and adversely affect the business, financial condition, results of operations or prospects of the Company.

Because of the early stage of the industry in which the Company operates, the Company expects to face additional competition from new entrants. To become and remain competitive, the Company will require research and development, marketing, sales and support. The Company may not have sufficient resources to maintain research and development, marketing, sales and support efforts on a competitive basis which could materially and adversely affect the business, financial condition, results of operations or prospects of the Company.

If the Business Combination’s benefits do not meet the expectations of investors or securities analysts, the market price of the Company’s securities may decline.

If the benefits of the Business Combination do not meet the expectations of investors or securities analysts, the market price of the Common Shares may decline and could contribute to the loss of all or part of your investment. If an active market for the Company’s securities develops and continues, the trading price of the Company’s securities could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond the Company’s control. In such circumstances, the trading price of the Company’s securities may not recover and may experience a further decline.

Warrants will become exercisable for Common Shares, which would increase the number of Common Shares eligible for future resale in the public market and result in dilution to the Company’s stockholders.

Outstanding warrants to purchase an aggregate of 34,207,764 Common Shares will become exercisable for a like number of Common Shares in accordance with the terms of the warrant agreements governing those securities. To the extent Common Warrants are exercised, additional Common Shares will be issued, which will result in dilution to Xanthic shareholders (“Shareholders”) and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such Common Shares in the public market could adversely affect the market price of the Common Shares.

 

32


Additional Financing

The Company has obligations under the NOR transaction that will require future funding. There is also additional funding required to implement the strategic plan, including additional acquisitions. Therefore, the Company may require equity or debt financing to support its strategic plan. There can be no assurance that additional financing will be available on acceptable terms when required. The Company’s inability to raise additional financing could severely limit its growth and ability to make strategic capital expenditures, both of which may have a material adverse effect on the Company’s business, results of operations, financial condition or prospects.

Conflicts of interest

Certain of the directors and officers of the Company are, or may become, directors and officers of other companies, and conflicts of interest may arise between their duties as directors and officers of the Company and as directors and officers of such other companies.

Reliance on management

The success of the Company depends on its ability to attract, develop and retain talented employees, including executives and other key managers. The loss of certain key officers and employees, or the failure to attract and develop talented new executives and managers, could have an adverse effect on the Company’s business. The Company’s ability to attract and retain employees with the requisite experience and skills depends on several factors, including, but not limited to the Company’s ability to offer competitive wages, benefits and professional growth opportunities. Effective succession planning is also important to its long-term success. Failure to ensure effective transfer of knowledge and smooth transitions involving key employees could hinder the Company’s strategic planning and execution. The Company’s success is also dependent upon the ability, expertise, judgment, discretion and good faith of its senior management. Any loss of the services of key management could have a material adverse effect on the Company’s business, operating results, financial condition or prospects.

Enforcement of Legal Rights and Difficulty in Enforcement of Judgments

Although the Company is incorporated in the Province of Ontario, some of the Company’s directors and officers reside in the United Stated and substantially all of the assets of these persons are located outside of Canada. It may not be possible for Shareholders to effect service of process against certain of the Company’s directors or officers who are not resident in Canada. In the event a judgment is obtained in a Canadian court or securities commission, predicated on the civil liability provisions of Canadian securities legislation or otherwise, against one or more directors or officers for violations of Canadian securities laws, it may not be possible to enforce such judgment against that director or officer. Courts in the United States may refuse to hear a claim based on a violation of Canadian securities laws on the grounds that such jurisdiction is not the most appropriate forum to bring such a claim. Even if a United States court agrees to hear a claim, it may determine that the local law, and not Canadian law, is applicable to the claim. If Canadian law is found to be applicable, the content of applicable Canadian law must be proven as a fact, which can be a time-consuming and costly process.

Management of growth

The Company may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Company to deal with this growth may have

 

33


a material adverse effect on the Company’s business, financial condition, results of operations or prospects.

Risks inherent in an agricultural business

Adult-use and medical marijuana are agricultural products. There are risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Although the products are usually grown indoors under climate-controlled conditions, with conditions monitored, there can be no assurance that natural elements will not have a material adverse effect on the production of the Company’s products.

Vulnerability to rising energy costs

Adult-use and medical marijuana growing operations consume considerable energy, making the Company potentially vulnerable to rising energy costs. Rising or volatile energy costs may adversely impact the business, results of operations, financial condition or prospects of the Company.

Unfavorable publicity or consumer perception

The Company believes the adult-use and medical marijuana industries are highly dependent upon consumer perception regarding the safety, efficacy and quality of the marijuana produced. Consumer perception can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of marijuana products. There can be no assurance that future scientific research or findings, regulatory investigations, litigation, media attention or other publicity will be favorable to the marijuana market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory investigations, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or other publicity could have a material adverse effect on the demand for adult-use or medical marijuana and on the business, results of operations, financial condition, cash flows or prospects of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of marijuana in general, or associating the consumption of adult-use and medical marijuana with illness or other negative effects or events, could have such a material adverse effect. There is no assurance that such adverse publicity reports or other media attention will not arise.

Results of future clinical research

Research in Canada, the U.S. and internationally regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in early stages. There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC). Although management believes that the articles, reports and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Given these risks, uncertainties and assumptions, prospective purchasers of Common Shares should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions to those stated in this AIF or reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to cannabis, which could have a material adverse effect on the demand for the Company’s products with the

 

34


potential to lead to a material adverse effect on the Company’s business, financial condition, results of operations or prospects.

Product liability

As a manufacturer and distributor of products designed to be ingested by humans, the Company faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury. In addition, the manufacture and sale of marijuana involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of marijuana alone or in combination with other medications or substances could occur. As a manufacturer, distributor and retailer of adult-use and medical marijuana, or in its role as an investor in or service provider to an entity that is a manufacturer, distributor and/or retailer of adult-use or medical marijuana, the Company may be subject to various product liability claims, including, among others, that the marijuana product caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against the Company could result in increased costs, could adversely affect the Company’s reputation with its clients and consumers generally, and could have a material adverse effect on the business, results of operations, financial condition or prospects of the Company. There can be no assurances that the Company will be able to maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to maintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Company’s potential products or otherwise have a material adverse effect on the business, results of operations, financial condition or prospects of the Company.

Product recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. Such recalls cause unexpected expenses of the recall and any legal proceedings that might arise in connection with the recall. This can cause loss of a significant amount of sales. In addition, a product recall may require significant management attention. Although the Company has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if one of the Company’s brands were subject to recall, the image of that brand and the Company could be harmed. Additionally, product recalls can lead to increased scrutiny of operations by applicable regulatory agencies, requiring further management attention and potential legal fees and other expenses.

Reliance on key inputs

The marijuana business is dependent on a number of key inputs and their related costs including raw materials and supplies related to growing operations, as well as electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition, results of operations or prospects of the Company. Some of these inputs may only be available from a single supplier or a

 

35


limited group of suppliers. If a sole source supplier was to go out of business, the Company might be unable to find a replacement for such source in a timely manner or at all. If a sole source supplier were to be acquired by a competitor, that competitor may elect not to sell to the Company in the future. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition, results of operations or prospects of the Company.

Dependence on suppliers and skilled labour

The ability of the Company to compete and grow will be dependent on it having access, at a reasonable cost and in a timely manner, to skilled labour, equipment, parts and components. No assurances can be given that the Company will be successful in maintaining its required supply of skilled labour, equipment, parts and components. It is also possible that the final costs of the major equipment contemplated by the Company’s capital expenditure plans may be significantly greater than anticipated by the Company’s management, and may be greater than funds available to the Company, in which circumstance the Company may curtail, or extend the timeframes for completing, its capital expenditure plans. This could have an adverse effect on the business, financial condition, results of operations or prospects of the Company.

Co-investment risk

The Company may co-invest in one or more investments with certain strategic investors and/or other third parties through joint ventures or other entities, which parties in certain cases may have different interests or superior rights to those of the Company, although it is the general intent of the Company to retain superior rights associated with its investments. Although it is the Company’s intent to retain control and other superior rights over the Company’s investments, under certain circumstances it may be possible that the Company relinquishes such rights over certain of its investments and, therefore, may have a limited ability to protect its position therein. In addition, even when the Company does maintain a control position with respect to its investments, the Company’s investments may be subject to typical risks associated with third-party involvement, including the possibility that a third-party may have financial difficulties resulting in a negative impact on such investment, may have economic or business interests or goals that are inconsistent with those of the Company, or may be in a position to take (or block) action in a manner contrary to the Company’s objectives. The Company may also, in certain circumstances, be liable for the actions of its third-party partners or co-investors. Co-investments by third parties may or may not be on substantially the same terms and conditions as the Company, and such different terms may be disadvantageous to the Company.

Difficulty to forecast

The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the industry. A failure in the demand for its products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations, financial condition or prospects of the Company.

Reliable data on the medical and adult-use marijuana industry is not available

As a result of recent and ongoing regulatory and policy changes in the medical and adult-use marijuana industry, the market data available is limited and unreliable. Federal and state laws prevent widespread participation and hinder market research. Therefore, market research and projections by

 

36


management of estimated total retail sales, demographics, demand, and similar consumer research, are based on assumptions from limited and unreliable market data, and generally represent the personal opinions of the Company’s management team as of the date of this AIF.

Litigation

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company becomes involved be determined against the Company, such a decision could adversely affect the Company’s ability to continue operating and the market price for the Common Shares. Even if the Company is involved in litigation and wins, litigation can redirect significant company resources.

Intellectual property risks

The Company may have certain proprietary intellectual property, including but not limited to brands, trademarks, trade names, patents and proprietary processes. The Company will rely on this intellectual property, know-how and other proprietary information, and require employees, consultants and suppliers to sign confidentiality agreements. However, these confidentiality agreements may be breached, and the Company may not have adequate remedies for such breaches. Third parties may independently develop substantially equivalent proprietary information without infringing upon any proprietary technology. Third parties may otherwise gain access to the Company’s proprietary information and adopt it in a competitive manner. Any loss of intellectual property protection may have a material adverse effect on the Company’s business, results of operations or prospects.

The risks associated with protecting intellectual property in the United States are discussed above.

Competition from synthetic production and technological advances

The pharmaceutical industry may attempt to dominate the marijuana industry, and in particular, legal marijuana, through the development and distribution of synthetic products which emulate the effects and treatment of organic marijuana. If they are successful, the widespread popularity of such synthetic products could change the demand, volume and profitability of the marijuana industry. This could adversely affect the ability of the Company to secure long-term profitability and success through the sustainable and profitable operation of its business. There may be unknown additional regulatory fees and taxes that may be assessed in the future.

Constraints on marketing products

The development of the Company’s business and operating results may be hindered by applicable restrictions on sales and marketing activities imposed by government regulatory bodies. The regulatory environment in the United States limits companies’ abilities to compete for market share in a manner similar to other industries. If the Company is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, the Company’s sales and results of operations could be adversely affected.

Fraudulent or illegal activity by employees, contractors and consultants

The Company is exposed to the risk that its employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to the Company that

 

37


violates: (i) government regulations; (ii) manufacturing standards; (iii) federal and provincial healthcare fraud and abuse laws and regulations; or (iv) laws that require the true, complete and accurate reporting of financial information or data. It may not always be possible for the Company to identify and deter misconduct by its employees and other third parties, and the precautions taken by the Company to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting the Company from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against the Company, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on the Company’s business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of the Company’s operations, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations or prospects.

Information technology systems and cyber-attacks

The Company’s operations depend, in part, on how well it and its suppliers protect networks, equipment, information technology (“IT”) systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism and theft. The Company’s operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, IT systems and software, as well as pre-emptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays and/or increase in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact the Company’s reputation and results of operations.

There can be no assurance that the Company will not incur material losses relating to cyber-attacks or other information security breaches in the future. The Company’s risk and exposure to these matters cannot be fully mitigated because of, among other things, the evolving nature of these threats. As a result, cyber security and the continued development and enhancement of controls, processes and practices designed to protect systems, computers, software, data and networks from attack, damage or unauthorized access is a priority. As cyber threats continue to evolve, the Company may be required to expend additional resources to continue to modify or enhance protective measures or to investigate and remediate any security vulnerabilities.

Security breaches

Given the nature of the Company’s product and its lack of legal availability outside of channels approved by the Government of the United States, as well as the concentration of inventory in its facilities, despite meeting or exceeding all legislative security requirements, there remains a risk of shrinkage as well as theft. A security breach at one of the Company’s facilities could expose the Company to additional liability and to potentially costly litigation, increase expenses relating to the resolution and future prevention of these breaches and may deter potential patients from choosing the Company’s products.

In addition, the Company collects and stores personal information about its patients and is responsible for protecting that information from privacy breaches. A privacy breach may occur through procedural or process failure, information technology malfunction, or deliberate unauthorized

 

38


intrusions. Theft of data for competitive purposes, particularly patient lists and preferences, is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such theft or privacy breach would have a material adverse effect on the Company’s business, financial condition and results of operations.

Costs of being a public company

As a public issuer, the Company is subject to the reporting requirements and rules and regulations under the applicable Canadian securities laws and rules of any stock exchange on which the Company’s securities may be listed from time to time. Additional or new regulatory requirements may be adopted in the future. The requirements of existing and potential future rules and regulations will increase the Company’s legal, accounting and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on its personnel, systems and resources, which could adversely affect its business and financial condition.

In particular, the Company is subject to reporting and other obligations under applicable Canadian securities laws, including National Instrument 52-109Certification of Disclosure in Issuers’ Annual and Interim Filings, which requires annual management assessment of the effectiveness of the Company’s internal controls over financial reporting. Effective internal controls, including financial reporting and disclosure controls and procedures, are necessary for the Company to provide reliable financial reports, to effectively reduce the risk of fraud and to operate successfully as a public company. These reporting and other obligations place significant demands on the Company as well as on the Company’s management, administrative, operational and accounting resources.

Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company’s results of operations or cause it to fail to meet its reporting obligations. If the Company or its auditors discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market’s confidence in the Company’s consolidated financial statements and materially adversely affect the trading price of the Common Shares.

Market price volatility risks

The market price of the Common Shares may be subject to wide fluctuations in response to many factors, including variations in the operating results of the Company, divergence in financial results from analysts’ expectations, changes in earnings estimates by stock market analysts, changes in the business prospects for the Company, general economic conditions, legislative changes, and other events and factors outside of the Company’s control. In addition, stock markets have from time to time experienced extreme price and volume fluctuations, which, as well as general economic and political conditions, could adversely affect the market price for the Common Shares.

Dividends

The Company has no earnings or dividend record, and does not anticipate paying any dividends on its Common Shares in the foreseeable future. Dividends paid by the Company would be subject to tax and, potentially, withholdings.

 

39


Limited market for securities

Notwithstanding that the Common Shares are listed on the CSE, there can be no assurance that an active and liquid market for the Common Shares will develop or be maintained and a Shareholder may find it difficult to resell any of its Common Shares.

Fluctuations in currency exchange rates could have an adverse effect on revenues and results of operations.

Xanthic has operations in the United States, which accounted for 8% of the Company’s operating expenses up until June 30, 2018. To the extent that the Company is unable to match revenues received in foreign currencies with costs paid in the same currency, exchange rate fluctuations in any such currency could have an adverse effect on the Company’s financial results. Currency fluctuations between the Canadian dollar and the U.S. dollar affect the Company’s results as reported in Canadian dollars. These fluctuations could adversely affect the Company’s revenues and results of operations.

Global financial conditions

Following the onset of the credit crisis in 2008, global financial conditions were characterized by extreme volatility and several major financial institutions either went into bankruptcy or were rescued by governmental authorities. While global financial conditions subsequently stabilized, there remains considerable risk in the system given the extraordinary measures adopted by government authorities to achieve that stability. Global financial conditions could suddenly and rapidly destabilize in response to future economic shocks, as government authorities may have limited resources to respond to future crises.

Future economic shocks may be precipitated by a number of causes, including a rise in the price of oil, geopolitical instability and natural disasters. Any sudden or rapid destabilization of global economic conditions could impact the Company’s ability to obtain equity or debt financing in the future on terms favourable to the Company. Additionally, any such occurrence could cause decreases in asset values that are deemed to be other than temporary, which may result in impairment losses. Further, in such an event, the Company’s operations and financial condition could be adversely impacted.

Furthermore, general market, political and economic conditions, including, for example, inflation, interest and currency exchange rates, structural changes in the cannabis industry, supply and demand for commodities, political developments, legislative or regulatory changes, social or labour unrest and stock market trends will affect the Company’s operating environment and its operating costs, profit margins and share price. Any negative events in the global economy could have a material adverse effect on the Company’s business, financial condition, results of operations or prospects.

DIVIDENDS AND DISTRIBUTIONS

Xanthic has not paid any dividends on its shares since incorporation.

Other than statutory rules provided by the Business Corporation Act (Ontario), there are no restrictions in Xanthic’s articles of incorporation that prevent the declaration of dividends.

 

40


The payment of dividends, if any, will rest within the sole discretion of the directors of Xanthic. The decision to declare and pay dividends depends upon earnings, capital requirements and financial condition, as well as other relevant factors. Xanthic does not anticipate paying any dividends on its shares or other securities in the foreseeable future.

DESCRIPTION OF CAPITAL STRUCTURE

AS AT YEAR ENDED JUNE 30, 2018

The following table sets out the capitalization of Xanthic as at June 30, 2018, and prior to the Business Combination:

 

Designation of Security

  

Authorized Amount

   Amount Outstanding
as at June 30, 2018
     Amount
Outstanding
prior to the
Business
Combination
 

Common Shares

   Unlimited      56,846,547        57,746,547  

Options

   10% of the issued and outstanding Common Shares      3,508,000        2,608,000  

Common Warrants

   Unlimited      568,000        568,000  

As at June 30, 2018, the authorized capital of the Company consisted of an unlimited number of Common Shares without par value and an unlimited number of first preferred shares (“First Preferred Shares”) issuable in series without par value. As at June 30, 2018, no First Preferred Shares were issued and outstanding.

SUBSEQUENT TO YEAR ENDED JUNE 30, 2018

The following table sets out the capitalization of the Company after giving effect to the Business Combination:

 

Designation of Security

  

Authorized Amount

   Amount Outstanding as at
November 26, 2018
 

Common Shares

   Unlimited      166,304,982  

 

41


Common Shares reserved for issuance upon exercise of Common Warrants

   Unlimited      35,690,403  

Common Shares reserved upon exercise of broker warrants

   Unlimited      1,226,736  

Common Shares reserved for issuance upon exercise of options

   10% of the issued and outstanding Common Shares      475,000  

Proportionate Shares

   Unlimited      38,194  

Proportionate Shares reserved for issuance upon exercise of proportionate warrants

   Unlimited      19,097  

Capital Structure Following the Completion of the Business Combination

Upon completion of the Business Combination, the authorized share capital of Xanthic now consists of: (i) an unlimited number of Common Shares, without par value and (ii) an unlimited number of PVS. Other securities to be outstanding include: common warrants, proportionate warrants, broker warrants, and options. The class of First Preferred Shares have been eliminated.

Common Shares

The rights, privileges, restrictions and conditions attaching to the Common Shares are as follows:

Voting Rights

 

  (a)

The holders of the Common Shares shall be entitled to vote at all meetings of the Shareholders, other than at meetings of the holders of other share classes meeting separately as a class, and at all such meetings each such holder shall have one vote for each Common Share held. The holders of the Common Shares will not have cumulative voting rights.

Dividend Rights

 

  (b)

Subject to the rights and conditions of the holders of PVS, the holders of the Common Shares shall be entitled to receive dividends if, as and when declared by the board of directors of the Company out of the assets of the Company properly applicable to the payment of dividends in such amounts and payable at such times and at such place or places in Canada as the board of directors may from time to time determine.

Liquidation Rights

 

  (c)

In the event of the liquidation, dissolution or winding up of the Company or other distribution of assets or property of the Company amongst the Shareholders for the purpose of winding up its affairs, the holders of the Common Shares shall, subject to the rights, privileges, restrictions and conditions of the holders of any other class of shares of the Company, be equally entitled to receive all property and assets of the Company properly distributable to the Shareholders.

 

42


Conversion Rights

 

  (d)

A holder of the Common Shares may at any time have the option to convert 500 (five hundred) Common Shares for 1 (one) PVS.

Pre-emptive, Subscription or Redemption Rights

 

  (e)

The Common Shares will not carry any pre-emptive, subscription or redemption rights, nor will they contain any sinking or purchase fund provisions.

Proportionate Voting Shares

The rights, privileges, restrictions and conditions attaching to the PVS are as follows:

Voting Rights

 

  (a)

The holders of PVS are entitled to receive notice and vote at all meetings of the Shareholders, other than at meetings of the holders of other share classes meeting separately as a class, and at all such meetings each such holder shall have 500 votes for each PVS held.

Dividend Rights

 

  (b)

The holders of PVS shall be entitled to receive dividends if, as and when declared by the board of directors of the Company out of the assets of the Company properly applicable to the payment of dividends in such amount and payable at such times and at such place or places in Canada as the board of directors may from time to time determine. All dividends which are declared at the discretion of the directors on the PVS shall be declared and paid on the Common Shares at the time outstanding, and vice versa, in the proportion hereinafter provided for. If, as and when dividends are declared by the directors, each PVS is entitled to 500 times the amount paid or distributed per Common Share.

Liquidation Rights

 

  (c)

In the event of the liquidation, dissolution or winding up of the Company or other distribution of assets or property of the Company amongst the Shareholders for the purpose of winding up its affairs, whether voluntary or involuntary, the holders of PVS will be entitled to receive all property and assets of the Company properly distributable to the Shareholders on the basis that each PVS will be entitled to 500 times the amount distributed per Common Share, but otherwise there is no preference or distinction among or between PVS and Common Shares.

Conversion Rights

 

  (d)

A holder of PVS may at any time have the option to convert 1 (one) PVS held into 500 (five hundred) Common Shares.

Foreign Private Issuer Status

 

  (e)

The Company shall use commercially reasonable efforts to maintain its status as a “foreign private issuer” (as determined in accordance with Rule 3b-4 under the Securities Exchange

 

43


 

Act of 1934, as amended (the Exchange Act”). Accordingly, the Company shall not give effect to any voluntary conversion of PVS pursuant to this Article or otherwise, and the PVS conversion rights will not apply, to the extent that after giving effect to all permitted issuance after such conversion of PVS, the aggregate number of Common Shares and PVS (calculated on the basis that each Common Share and PVS is counted once, without regard to the number of votes carried by each share) held of record, directly or indirectly, by residents of the United States (as determined in accordance with Rules 3b-4 and 12g3-2(a) under the Exchange Act (“U.S. Residents”) would exceed forty percent (40%) (the 40% Threshold) of the aggregate number of Common Shares and PVS (calculated on the same basis) issued and outstanding (the FPI Restriction) as calculated herein. The directors may by resolution increase the 40% Threshold to a number not to exceed fifty percent (50%), and if any such resolution is adopted, all references to the 40% Threshold herein shall refer instead to the amended percentage threshold set by the directors in such resolution.

MARKET FOR SECURITIES

The Common Shares were previously listed on the CSE under the trading symbol “xTHC”. Upon completion of the Business Combination, the Common Shares are now listed on the CSE under the trading symbol “GGB”.

Prior Sales

The following table summarizes the issuances of securities of Xanthic within 12 months prior to the date of this AIF:

 

Date of Issue

  

Description

  

Number of

Securities

   Price per
Security
(C$)
     Total Issue Price
(C$)
 

November 7, 2017

   Private Placement    20,000,000 Common Shares    $ 0.02      $ 400,000  

December 13, 2017

   Private Placement    10,252,000 Common Shares    $ 0.125      $ 1,281,500  

January 17, 2018

   Private Placement    96,000,000 Common Shares    $ 0.015625      $ 1,500,000  

April 19, 2018

   Private Placement    1,112,000 Units(1)    $ 0.50      $ 556,000  

November 9, 2018

   Private Placement    1,870,622    $ 2.00      $ 3,741,244  

November 13, 2018

   Grant of options    150,000    $ 3.05      $ 457,500  

 

44


November 13, 2018

   Exercise of options    277,000    $ 0.50      $ 138,500  

November 21, 2018

   Exercise of options    50,000    $ 0.50      $ 25,000  

November 22, 2018

   Exercise of warrants    17,361    $ 1.80      $ 31,249.80  

Notes:

 

(1)

Each Unit consisted of one Common Share and one-half of one common share purchase warrant. Each whole warrant entitles the holder thereof to purchase one Common Share at an exercise price of C$0.75 per Common Share for a period of 24 months from the date of closing, being April 19, 2018.

Trading Price and Volume

The following table sets forth the high and low sale prices and trading volumes of the Common Shares on the CSE for each of the months indicated.

 

Period

   High (C$)      Low (C$)      Volume  

July 2018(2)

     0.280        0.225        1,828,005  

June 2018

     0.300        0.180        10,220,140  

May 2018

     0.325        0.145        6,781,251  

April 2018(1)

     0.570        0.250        3,226,869  

Notes:

 

(1)

Trading of the Common Shares commenced on April 19, 2018.

(2)

Trading of the Common Shares was halted on July 13, 2018 pending the announcement of the Business Combination and remained halted pending the completion of the Business Combination. Trading of the Common Shares resumed on November 13, 2018.

ESCROWED SECURITIES AND SECURITIES SUBJECT TO CONTRACTUAL RESTRICTION ON TRANSFER

AS AT YEAR ENDED JUNE 30, 2018

The following table includes the balance of escrowed securities as at June 30, 2018:

 

Designation of Class

   Number of Securities held in
Escrow
     Percentage
of Class
 

Common Shares

     5,448,001        9.6

Options

     Nil        0

Warrants

     Nil        0

Note:

 

(1)

Xanthic is an exempt issuer pursuant to Section 3.2 of National Policy 46-201 – Escrow for Initial Public Offerings (NP 46-201”) due to the fact that, following the completion of the Business Combination, Xanthic had a market capitalization of over C$100 million. As a result, no Common Shares are escrowed pursuant to NP 46-201.

 

45


SUBSEQUENT TO YEAR ENDED JUNE 30, 2018

The following table includes the balance of securities subject to lock-up agreements:

 

Designation of Class

   Number of Securities held in
Escrow
     Percentage of Class  

Common Shares

     88,255,322        9.6

Note:

 

(1)

Depositary is CTA. Each month following the closing of the Business Combination, 1/12 of securities subject to lock-up agreements will be released pursuant to the terms of such lock-up agreements.

DIRECTORS AND OFFICERS

On July 13, 2018, in connection with the Business Combination, the Board was reconstituted to include existing Board members Carli Posner as Chair, Tim Moore, Igor “Gary” Galitsky and new GGB nominees Jean Schottenstein, Peter Horvath, Steve Stoute and Marc Lehmann.

The Board and its executive officers consist of the following individuals as at the date of this AIF:

 

Name, place of

residence and

position with the

Company                        

  

Principal occupation

during past five years

  

Periods During

Which Each

Proposed Director

Has Served as a

Director and when

his or her term of

office will expire

   Number of
Common Shares
   Percentage of
Common
Shares
 

Tim Moore

 

Chief Executive
Officer and
Director

 

Unionville,
Ontario, Canada

   CEO of Xanthic; Managing Director of Brita GmbH North America    December 15, 2017 – until the next annual meeting of the Shareholders or until his successor is elected or appointed    387,500      0.19

David Bhumgara

 

Chief Financial
Officer

 

Toronto, Ontario,
Canada

   CFO of Xanthic; CFO of Dundee Energy Limited    N/A    168,750      0.08

Igor Galitsky (1)

 

President and
Director

 

Thornhill, Ontario,
Canada

   President of Xanthic; Entrepreneur and consultant to the cannabis industry    December 15, 2017 – until the next annual meeting of the Shareholders or until his successor is elected or appointed    957,083      0.47

Jean Schottenstein

 

Director

 

Columbus, Ohio,
United States of

   Trustee, Columbus Museum of Art; Founder, Beit Ohr Community Domestic    July 11, 2018 – until the next annual meeting of the Shareholders or until his successor is elected    Nil      0

 

46


America    Violence Program    or appointed      

Peter Horvath

 

Director

 

New Albany, Ohio,

United States of America

   CEO of GGB; CEO of Mission Essential Personnel    July 11, 2018 – until the next annual meeting of the Shareholders or until his successor is elected or appointed    5,500,064      2.72

Steve Stoute (1)

 

Independent

Director

 

New York City,

New York, United

States of America

   Founder and CEO of Translation    July 11, 2018 – until the next annual meeting of the Shareholders or until his successor is elected or appointed    Nil      0

Carli Posner (1) (2)

 

Independent

Director

 

Toronto, Ontario,

Canada

   Film producer at Notable Life    February 16, 2018 – until the next annual meeting of the Shareholders or until her successor is elected or appointed    50,000      0.02

Marc Lehmann

 

Independent

Director

 

Miami, Florida,

United States of America

   Managing Member of Flamingo Drive Partners, LLC; General Partner at Riverloft Capital Management    July 11, 2018 – until the next annual meeting of the Shareholders or until his successor is elected or appointed    347,222      0.17

Notes:

 

(1)

Member of the Audit Committee.

(2)

Chair of the Audit Committee.

(3)

No directors or executive officers of the Company hold Xanthic Proportionate Shares.

The following sets out additional information with respect to the education, experience and employment history of each of the directors and officers referred to above during the past five years:

Tim Moore (Age 60), Chief Executive Officer & Director

Mr. Moore has been the Chief Executive Officer of Xanthic since December 2017. Mr. Moore has over 30 years of experience in various consumer products companies, including 18 years with The Clorox Company, a NYSE-listed company. Prior to working with The Clorox Company, Mr. Moore was the Managing Director, North America, for Brita GmbH, a privately held German manufacturer of water filters. Previous to Brita, Mr. Moore was the Chief Operating Officer for Synnex, a NYSE-listed electronics distribution company. Mr. Moore holds a Bachelor of Arts (Economics) from

 

47


Western University and a Master of Business Administration from the Richard Ivey School of Business.

David Bhumgara (Age 49), Chief Financial Officer

Mr. Bhumgara has been the Chief Financial Officer of Xanthic since December 2017. Mr. Bhumgara has over 20 years of finance experience across various industries and capacities. Prior to working with Xanthic, Mr. Bhumgara was the Chief Financial Officer of Dundee Energy Limited, a TSX-listed company, from September 2009 to December 2016. Previous to that, Mr. Bhumgara was a financial consultant from February 2009 to September 2009. From August 2007 to February 2009, Mr. Bhumgara was a corporate controller for Strategic Resource Acquisition Corporation, a TSX-listed mining company. Mr. Bhumgara is a Chartered Professional Accountant and holds a Bachelor of Commerce Honours degree in Accounting from the University of Ottawa.

Igor Galitsky (Age 46), President & Director

Mr. Galitsky has been President of Xanthic since December 2017. Mr. Galitsky was one of the first applicants to receive a license under the Marijuana Medical Access Regulations for both personal and designated production in Canada. Mr. Galitsky has developed and refined over the last seven years the production and extraction processes for cannabis. In addition, Mr. Galitsky has been consulting varies licensed producers in Canada on scaling and refining their extraction and secondary processes.

Jean Schottenstein (Age 62), Director

Mrs. Schottenstein will serve as a director on Xanthic’s Board. Mrs. Schottenstein serves on the Board of Trustees of the Columbus Museum of Art, is Co-Chair of Congregation Torat Emet/Main Street Synagogue, and is Chair of “Defining Moments,” a group dedicated to leadership development. She is also on the Board of Trustees of Nishmat – the Jerusalem Center for Advanced Torah Study for Women and has co-chaired the recently completed Columbus Community Mikvah Capital Campaign. She has previously served on the Boards of Trustees of Central Ohio State of Israel Bonds and Columbus Torah Academy; Chairperson of the Columbus Jewish Federation’s Women’s Division for their annual appeal; and the Board of Trustees of “I know I can”. Mrs. Schottenstein is deeply committed to issues relating to women’s health, education and increasing awareness of domestic violence. To that end, she created “Beit Ohr”, a community program designed to help meet the needs of victims of domestic violence within the Jewish community and serves as Honorary Chair of the National Council of Jewish Women’s “Women of Valor” program. Mrs. Schottenstein attended Indiana University and is a graduate of Ohio State University with a Bachelor of Science in Accounting and a Master of Science in Psychology from the University of Phoenix.

Peter Horvath (Age 61), Director

Mr. Horvath will serve as a director on Xanthic’s Board. Mr. Horvath currently serves as the Chief Executive Officer of Green Growth Brands Ltd., a lifestyle oriented, consumer products company that celebrates health, wellness and happiness. Mr. Horvath has 35 years of executive management experience with specialty brand retailers such as American Eagle Outfitters®, DSW®, Victoria’s Secret®, and L Brands®. From 2012 to 2015, Mr. Horvath served as Chief Executive Officer of Mission Essential Personnel, a defense contractor focusing on intelligence solutions. Mr. Horvath received his Bachelor of Business Administration, Business, Management, Marketing, and Related Support Services from Boston University, School of Management.

 

48


Marc Lehmann (Age 46), Independent Director

Mr. Lehmann will serve as an independent director on Xanthic’s Board. Mr. Lehman is currently the Managing Member of Flamingo Drive Partners, LLC, an investment firm involved in public markets, real estate and start-up investing. Prior to that, Mr. Lehmann was the General Partner at Riverloft Capital Management from 2011 to 2016. From 2002 to 2010, Mr. Lehmann was a Partner and Director of Research at JANA Partners, a hedge fund. Earlier in his career, he was an Analyst at Appaloosa Management, from 1999 to 2002, sourcing and analyzing distressed special situations investments for the opportunistic hedge fund portfolio and began his career as an Analyst at Morgan Stanley and Lehman Brothers. Mr. Lehmann completed his Master of Business Administration at The Wharton Business at the University of Pennsylvania. Mr. Lehmann has a Bachelor of Science in Finance and International Business from New York University.

Steve Stoute (Age 48), Independent Director

Mr. Stoute will serve as an independent director on Xanthic’s Board. Mr. Stoute is the founder and Chief Executive Officer of Translation, a marketing agency. In 2017, Mr. Stoute joined United Masters, a data-driven digital distribution company helping music artist grow and manage their fan bases. In 2009, the American Advertising Federation inducted Mr. Stoute into the Advertising Hall of Achievement, and he was named “Executive of the Year” by Advertising Age in 2013.

Carli Posner (Age 35), Independent Director

Ms. Posner has served as an independent director on the Board since February 2018. Ms. Posner is the Co-CEO and Principal of Notable Life, a media company that reaches over 1.2 million high-earning millennials across Canada. Prior to Notable, she was the executive producer of the hit show, Hockey Wives, overseeing many departments including premium sponsors and media strategy. Ms. Posner has spent a significant portion of her career in Los Angeles, working in film finance and production. She is the leading talent packager in our country and has worked with top stars including George Clooney, Coldplay, Drew Barrymore, Jamie Oliver and Wayne Gretzky, to name a few. During Ms. Posner’s career, she has generated over C$100 million dollars of sponsorships and endorsements in the Canadian marketplace with top brands including MasterCard®, Corvette®, Scotiabank®, BMW® and LG®.

Cease Trade Orders, Bankruptcies, Penalties or Sanctions

Cease Trade Orders

To the Company’s knowledge, no director or executive officer of the Company is, at the date of this AIF, or was within ten years before the date of this AIF, a director, chief executive officer or chief financial officer of any company, including the Company that:

 

   

was subject to an order that was issued while the director or executive officer was acting in the capacity as director, chief executive officer or chief financial officer, or

 

   

was subject to an order that was issued after the director or executive officer ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer.

 

49


For purposes of this section, order means (a) a cease trade order; (b) an order similar to a cease trade order; or (c) an order that denied the relevant company access to any exemption under securities legislation that was in effect for a period of more than 30 consecutive days.

Bankruptcies

To the Company’s knowledge, no director or executive officer of the Company, and no Shareholder holding a sufficient number of securities of the Company to affect materially the control of the Company:

 

   

is, or has been within the ten years before the date of this AIF, a director or executive officer of any company that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or

 

   

has, within the ten years before the date of this AIF become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director, executive officer or Shareholder.

Penalties or Sanctions

To the Company’s knowledge, no director or executive officer of the Company or a Shareholder holding a sufficient number of securities of the Company to affect materially the control of the Company, has been subject to any penalties or sanctions imposed by a court relating to Canadian securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority or has been subject to any other penalties or sanctions imposed by a court, or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.

Conflicts of Interest

To the best of the Company’s knowledge, there are no known existing or potential conflicts of interest among the Company, proposed directors, executive officers or other members of management of the Company as a result of their outside business interests other than the lease agreement dated as of July 10, 2018, as amended, between GGB and Schottenstein Property Group and certain product testing agreements with DSW®, except that certain proposed directors and officers may serve as directors and officers of other companies, and therefore it is possible that a conflict may arise between their duties to the Company and their duties as a director or officer of such other companies.

Promoters

During the two years immediately preceding the date of this AIF, the promoters of Xanthic or its subsidiaries are as follows:

 

Name

  

Type of Securities

Held

   Number of Securities
Held
     % of Outstanding Class
 

Igor Galitsky

   Common Shares      957,083        0.47

 

50


All Js Greenspace LLC

   Common Shares      37,464,236        22.57

Chiron Ventures Inc.

   Common Shares      11,227,676        6.77

All Js Greenspace LLC

   Proportionate Shares      38,194        100

LEGAL PROCEEDINGS AND REGULATORY ACTIONS

The Company is not, and was not during the most recently completed financial year, or from the end of the most recently completed financial year to the date of this AIF, a party to, nor was any of its property the subject of, any legal proceedings or regulatory actions material to the Company, and no such proceedings or actions are known to be contemplated.

INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS

GGB entered into a lease agreement (the “Lease”) dated as of July 10, 2018 with Schottenstein Property Group with respect to its corporate office at 4300 East Fifth Avenue, Columbus, Ohio 43219. The term of the Lease is for a period of three years, commencing on May 1, 2018 and concluding on April 30, 2021. There are no options for renewal, and the Lease is in good standing. On August 13, 2018, the Lease was amended in order to generate a model for its brick-and-mortar retail stores. Schottenstein Property Group is owned by the Schottenstein family.

TRANSFER AGENT AND REGISTRARS

The transfer agent and registrar for the Common Shares and PVS of the Company is Capital Transfer Agency, which is located at 390 Bay Street, Suite 920, Toronto, Ontario MSH 2Y2.

MATERIAL CONTRACTS

Xanthic Material Contracts

Except for contracts entered into by Xanthic in the ordinary course of business, the only material contracts entered into by Xanthic in the previous two years are the following:

 

  1.

Escrow Agreement. See “General Development of the Business – History of the Business for further details.

 

  2.

Services Agreement. See “General Development of the Business – History of the Business for further details.

 

  3.

Definitive Agreement. See “General Development of the Business – History of the Business for further details.

 

  4.

The Transaction Agreement. See “General Development of the Business – History of the Business for further details.

 

  5.

The NOR Agreement. See “General Development of the Business – History of the Business for further details.

 

51


  6.

The Registration Rights Agreement. See “General Development of the Business – History of the Business for further details.

 

  7.

The Nomination Rights Agreement. See “General Development of the Business – History of the Business for further details.

 

  8.

The Coattail Agreement. See “General Development of the Business – History of the Business for further details.

 

  9.

Warrant Indenture. See “General Development of the Business – History of the Business for further details.

INTERESTS OF EXPERTS

There is no person or company whose profession or business gives authority to a statement made by such person or company and who is named as having prepared or certified a statement, report or valuation described or included in a filing, or referred to in a filing, made under National Instrument 51-102Continuous Disclosure Obligations by the Company during, or related to, the Company’s most recently completed financial year other than MNP LLP, Chartered Accountants (“MNP”), the Company’s auditors for the most recently completed financial year. MNP is independent in accordance with the auditor’s rules of professional conduct of the Institute of Chartered Accountants of Ontario.

AUDIT COMMITTEE DISCLOSURE

Under National Instrument 52-110Audit Committees, the Company is required to include in this AIF the disclosure required under Form 52-110F1 with respect to the audit committee of the Board (the Audit Committee”). The Audit Committee is responsible for the Company’s financial reporting process and the quality of its financial reporting. The Audit Committee is charged with the mandate of providing independent review and oversight of the Company’s financial reporting process, the system of internal control and management of financial risks, and the audit process, including the selection, oversight and compensation of the Company’s external auditors. In performing its duties, the Audit Committee maintains effective working relationships with the Board, management, and the external auditors and monitors the independence of those auditors.

The full text of the charter of the Company’s Audit Committee is attached hereto as Schedule “A”.

Composition of the Audit Committee

The following are the members of the Audit Committee:

 

Name

  

Independent/Not Independent (1)

  

Financial History (1)

Carli Posner (2)    Independent    Financially literate
Steve Stoute    Independent    Financially literate
Igor Galitsky    Not Independent (President)    Financially literate

Notes:

 

(1)

Terms have their respective meanings ascribed in NI 52-110.

(2)

Chair of the Audit Committee.

 

52


Relevant Education and Experience

The education and experience of each Audit Committee member that is relevant to the performance of his or her responsibilities as an audit committee member is as follows:

 

Carli Posner

  

Ms. Posner has served as an independent director on the Board since February 2018 and is the Co-CEO and Principal of Notable Life, a media company that reaches over 1.2 million high-earning millennials across Canada. Prior to Notable, she was the executive producer of the hit show, Hockey Wives, overseeing many departments including premium sponsors and media strategy. Ms. Posner has spent a significant portion of her career in Los Angeles, working in film finance and production. She is the leading talent packager in Canada and has worked with top stars including George Clooney, Coldplay, Drew Barrymore, Jamie Oliver and Wayne Gretzky, to name a few. During Ms. Posner’s career, she has generated over C$100 million dollars of sponsorships and endorsements in the Canadian marketplace with top brands including MasterCard®, Corvette®, Scotiabank®, BMW® and LG®.

Steve Stoute

  

Mr. Stoute will serve as an independent director on the Board and is the founder and Chief Executive Officer of Translation, a marketing agency. In 2017, Mr. Stoute joined United Masters, a data-driven digital distribution company helping music artist grow and manage their fan bases. In 2009 the American Advertising Federation inducted Mr. Stoute into the Advertising Hall of Achievement, and he was named “Executive of the Year” by Advertising Age in 2013.

Igor Galitsky

  

Mr. Galitsky has been President of Xanthic since December 2017 and was one of the first applicants to receive a license under the Marijuana Medical Access Regulations for both personal and designated production in Canada. Mr. Galitsky has developed and refined over the last seven years the production and extraction processes for cannabis. In addition, Mr. Galitsky has been consulting varies licensed producers in Canada on scaling and refining their extraction and secondary processes.

Audit Committee Oversight

At no time since the commencement of the Company’s financial year ended June 30, 2018 was a recommendation of the Audit Committee to nominate or compensate an external auditor not adopted by the Board.

Reliance on Certain Exemptions

At no time since the commencement of the Company’s financial year ended June 30, 2018 has the Company relied on the exemption provided under section 2.4 of NI 52-110 (De Minimis Non-Audit Services) or an exemption from NI 52-110, in whole or in part, granted under Part 8 of NI 52-110.

Pre-Approval Policies and Procedures

The Audit Committee has adopted specific policies and procedures for the engagement of non-audit services as described in the Audit Committee’s charter attached hereto as Schedule “A”.

 

53


External Auditor Service Fees (By Category)

The following table sets forth, by category, the fees for all services rendered by the Company’s current external auditor, MNP LLP, for the financial year ended June 30, 2018:

 

     Fiscal Year Ended June
30, 2018
($)

Audit Fees (1)

   $37,450

Audit-related Fees(2)

   $21,000

Tax Fees (3)

   $Nil

All Other Fees (4)

   $Nil

Notes:

(1)

“Audit fees” include fees rendered by the Company’s external auditor for professional services necessary to perform the annual audit and any quarterly reviews of the Company’s financial statements. This includes fees for the review of tax provisions and for accounting consultations on matters reflected in the financial statements.

(2)

“Audit-related fees” include fees for assurance and related services that are reasonably related to the performance of the audit or review of the Company’s financial statements and that are not included in the “Audit Fees” category.

(3)

“Tax fees” include fees for professional services rendered by the Company’s external auditor for tax compliance, tax advice and tax planning.

(4)

“All other fees” include fees for products and services provided by the Company’s external auditor, other than services reported under the table headings “Audit Fees”, “Audit-Related Fees” or “Tax Fees”.

ADDITIONAL INFORMATION

Additional information relating to the Company is available through the internet on the Canadian System for Electronic Document Analysis and Retrieval (SEDAR) which can be accessed at www.sedar.com. Financial information on the Company is provided in the comparative financial statements and management discussion and analysis of the Company for its most recently completed financial year which can also be accessed at www.sedar.com or which may be obtained upon request to the Company’s Corporate Secretary at 77 King Street West, Suite 2905, Toronto, ON M5K 1A2.

Additional financial information is provided in the Company’s financial statements and MD&A for its most recently completed financial year.

Additional information, including directors’ and officers’ remuneration, principal holders of the Company’s securities, and securities authorized for issuance under equity compensation plans, is contained in the Company’s information circular for its most recent annual general meeting of security holders that involved the election of directors.

 

54


SCHEDULE “A”

XANTHIC BIOPHARMA INC.

(the “Corporation”)

AUDIT COMMITTEE CHARTER

 

1.

PURPOSE

The audit committee (the “Committee”) assists the Board of Directors of the Corporation (the “Board”) in fulfilling its responsibilities. The Committee reviews the financial reporting process, the system of internal control and management of financial risks, the audit process, and the Corporation’s process for monitoring compliance with laws and regulations and its own code of business conduct as it relates to financial reporting and disclosure. In performing its duties, the Committee maintains effective working relationships with the Board, management, and the external auditors and monitors the independence of those auditors. The Committee is also responsible for reviewing the Corporation’s financial strategies, its financing plans and its use of the equity and debt markets.

Each Committee member has obtained an understanding of the responsibilities of committee membership as well as the Corporation’s business, operations, and risks.

 

2.

COMMITTEE MEMBERSHIP

The Committee shall consist of no fewer than three members, a majority of whom shall not be officers or employees of the Corporation or any of its affiliates and who shall meet the independence requirements of Canadian securities laws and any stock exchange on which the Common Shares of the Corporation are listed from time to time. The members and chair of the Committee (the “Chair”) shall be appointed and removed by the Board.

 

3.

COMMITTEE MEETINGS

The Committee shall meet quarterly each year. The Chairman will schedule regular meetings, and additional meetings may be held at the request of two or more members of the Committee, the CEO, or the Chairman of the Board. External auditors may convene a special meeting if they consider that it is necessary.

The Committee may invite such other persons (e.g. the CEO and/or CFO) to its meetings, as it deems appropriate. The external auditors should be present at each quarterly audit committee meeting and should be expected to comment on the financial statements in accordance with best practices.

The Committee shall keep adequate minutes of all its proceedings, and the Chair will report its actions to the next meeting of the Board. Committee members will be furnished with copies of the minutes of each Committee meeting and any action taken by unanimous consent.

 

4.

COMMITTEE AUTHORITY AND RESPONSIBILITIES

In carrying out its responsibilities, the Committee will:

4.01 Gain an understanding of whether internal control recommendations made by external auditors have been implemented by management.

 

A-1


4.02 Gain an understanding of the current areas of greatest financial risk and whether management is managing these effectively.

4.03 Review the Corporation’s strategic and financing plans to assist the Board’s understanding of the underlying financial risks and the financing alternatives.

4.04 Review management’s plans to access the equity and debt markets and to provide the Board with advice and commentary.

4.05 Review significant accounting and reporting issues, including recent professional and regulatory pronouncements, and understand their impact on the financial statements.

4.06 Review any legal matters which could significantly impact the financial statements as reported on by the general counsel and meet with outside counsel whenever deemed appropriate.

4.07 Review the annual and quarterly financial statements including Management’s Discussion and Analysis and determine whether they are complete and consistent with the information known to committee members; determine that the auditors are satisfied that the financial statements have been prepared in accordance with International Financial Reporting Standards, stock exchange requirements and governmental regulations.

4.08 Pay particular attention to complex and/or unusual transactions such as those involving derivative instruments and consider the adequacy of disclosure thereof.

4.09 Focus on judgmental areas, for example those involving valuation of assets and liabilities and other commitments and contingencies.

4.10 Review audit issues related to the Corporation’s material associated and affiliated companies that may have a significant impact on the Corporation’s equity investment.

4.11 Meet with management and the external auditors to review the annual financial statements and the results of the audit.

4.12 Assess the fairness of the interim financial statements and disclosures, and obtain explanations from management on whether:

 

  (a)

actual financial results for the interim period varied significantly from budgeted or projected results;

 

  (b)

generally accepted accounting principles have been consistently applied;

 

  (c)

there are any actual or proposed changes in accounting or financial reporting practices; and

 

  (d)

there are any significant or unusual events or transactions which require disclosure and, if so, consider the adequacy of that disclosure.

4.13 Review the external auditors’ proposed audit scope and approach and ensure no unjustifiable restriction or limitations have been placed on the scope.

 

A-2


4.14 Review the performance of the external auditors and approve in advance provision of services other than auditing.

4.15 Consider the independence of the external auditors, including reviewing the range of services provided in the context of all consulting services bought by the Corporation.

4.16 Make recommendations to the Board regarding the reappointment of the external auditors.

4.17 Meet separately with the external auditors to discuss any matters that the committee or auditors believe should be discussed privately.

4.18 Endeavour to cause the receipt and discussion on a timely basis of any significant findings and recommendations made by the external auditors.

4.19 Obtain regular updates from management and the Corporation’s legal counsel regarding compliance matters, as well as certificates from the CFO as to required statutory payments and bank covenant compliance and from senior operating personnel as to permit compliance.

4.20 Ensure that the Board is aware of matters which may significantly impact the financial condition or affairs of the business.

4.21 Perform other functions as requested by the full Board.

4.22 If necessary, institute special investigations and, if appropriate, hire special counsel or experts to assist.

4.23 Review and update the charter; receive approval of changes from the Board.

 

A-3

EX-3.2 7 d692201dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

 

LOGO

Xanthic Biopharma Inc.

Consolidated Financial Statements

For the year ended

June 30, 2018

(In Canadian Dollars)


MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL REPORTING

The accompanying consolidated financial statements of Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) are the responsibility of the management and Board of Directors of the Company.

The consolidated financial statements have been prepared by management, on behalf of the Board of Directors, in accordance with the accounting policies disclosed in the notes to the consolidated financial statements. Where necessary, management has made informed judgments and estimates in accounting for transactions which were not complete at the date of the consolidated statements of financial position. In the opinion of management, the consolidated financial statements have been prepared within acceptable limits of materiality and are in accordance with International Financial Reporting Standards using accounting policies consistent with International Financial Reporting Standards appropriate in the circumstances.

Management has established systems of internal control over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors is responsible for reviewing and approving the consolidated financial statements together with other financial information of the Company and for ensuring that management fulfills its financial reporting responsibilities. An Audit Committee assists the Board of Directors in fulfilling this responsibility. The Audit Committee meets with management to review the financial reporting process and the consolidated financial statements together with other financial information of the Company. The Audit Committee reports its findings to the Board of Directors for its consideration in approving the consolidated financial statements together with other financial information of the Company for issuance to the shareholders.

Management recognizes its responsibility for conducting the Company’s affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

 

“Tim Moore”

     

“David Bhumgara”

Tim Moore       David Bhumgara
Chief Executive Officer       Chief Financial Officer


To the Board of Directors and Shareholders of Xanthic Biopharma Inc.:

We have audited the accompanying financial statements of Xanthic Biopharma Inc., which comprise the statement of financial position as at June 30, 2018 and 2017, and the consolidated statement of loss and comprehensive loss, changes in shareholders’ deficiency and cash flows for the year ended June 30, 2018 and the period from the date of incorporation March 15, 2017 to June 30, 2017, and a summary of significant accounting policies and other explanatory information.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Xanthic Biopharma Inc. as at June 30, 2018 and 2017, and its financial performance and its cash flows for the periods then ended in accordance with International Financial Reporting Standards.

Emphasis of Matter

Without qualifying our opinion, we draw attention to Note 1 in the financial statements which indicates the existence of a material uncertainty that may cast significant doubt on the ability of Xanthic Biopharma Inc, Inc. to continue as a going concern.

 

   LOGO
Toronto, Ontario    Chartered Professional Accountants
September 13, 2018    Licensed Public Accountants


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Consolidated Statement of Financial Position

For the periods ended June 30, 2017 and June 30, 2018

 

(Expressed in Canadian dollars)

 
     Note      June 30, 2018     June 30, 2017  

Assets

       

Current Assets

       

Cash and cash equivalents

      $ 1,037,049     $ 24,096  

Prepaid expenses

        249,915       —    

Inventory

     5        181,096       —    

Other receivable

        157,982       12,428  
     

 

 

   

 

 

 
        1,626,042       36,524  

Non-Current Assets

       

Equipment

     6        56,597       —    

Equity investment in Xanthic Beverages USA, LLC

     7        1,126,865       —    
     

 

 

   

 

 

 
      $ 2,809,504     $ 36,524  
     

 

 

   

 

 

 

Liabilities

       

Current Liabilities

       

Accounts payable and accrued liabilities

     14        156,368       111,643  

Contingent consideration payable

     8        790,080       —    
     

 

 

   

 

 

 
        946,448       111,643  

Shareholders’ Equity (Deficiency)

       

Share capital

     9        4,236,395       26,422  

Reserve for share based payments

     11        385,542       —    

Reserve for warrants

     10        186,304       —    

Deficit

        (2,930,766     (101,541

Accumulated other comprehensive loss

        (14,419     —    
     

 

 

   

 

 

 
        1,863,056       (75,119
     

 

 

   

 

 

 
      $ 2,809,504     $ 36,524  
     

 

 

   

 

 

 

The comparative figures at June 30, 2017 represent those of Xanthic Biopharma Limited.

Nature of operations (note 1)

Subsequent events (note 18)

Approved on behalf of the Board of Directors:

 

“Tim Moore”

     

“Carli Posner”

CEO and Director      

Director

The accompanying notes are an integral part of these consolidated financial statements.

 

1


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Consolidated Statements of Net Loss and Comprehensive Loss

For the periods ended June 30, 2018 and from the date of incorporation March 15, 2017 to June 30, 2017

 

(Expressed in Canadian dollars)

 
     Note      June 30, 2018      June 30, 2017  

Expenses

        

Consulting fees

     13      $ 827,658      $ 60,000  

Stock based compensation

     11        385,542        —    

Advertising and promotion

        174,289        13,496  

Legal and professional fees

        375,023        27,968  

General and administration

        86,569        61  

Loss on equity investment in Xanthic Beverages USA, LLC

     7        58,255        —    

Interest and bank charges

        3,835        16  
     

 

 

    

 

 

 

Loss before transaction related expenses

        1,911,171        101,541  

Listing fees

     4        918,054        —    
     

 

 

    

 

 

 

Net loss from operations

      $ 2,829,225      $ 101,541  
     

 

 

    

 

 

 

Other comprehensive loss

        

Exchange loss on translating foreign operations

        14,419        —    
     

 

 

    

 

 

 

Comprehensive Loss for the period

      $ 2,843,644      $ 101,541  
     

 

 

    

 

 

 

Net Loss per Common Share

        

Basic and Diluted

      $ 0.08      $ 0.04  

Weighted average common shares outstanding

        34,472,257        2,373,953  
     

 

 

    

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Consolidated Statement of Changes in Shareholders’ Equity (Deficiency)

For the periods ended June 30, 2018 and from the date of incorporation March 15, 2017 to June 30, 2017

 

(Expressed in Canadian dollars)

 
                         Reserves            Accumulated
Other
       
     Note      Common
Shares
     Share
Capital
    Share based
Payments
     Warrants      Deficit     Comprehensive
loss
    Total  

Balance at incorporation March 15, 2017

        —        $ —       $ —        $ —        $ —       $ —       $ —    

Shares issued for cash, net of issuance costs

        7,000,000        26,422       —          —          —         —         26,422  

Deficit

                   (101,541       (101,541
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at June 30, 2017

        7,000,000        26,422       —          —          (101,541     —         (75,119

Shares issued for cash, net of issuance costs

     9        43,388,000        3,588,962       —          —          —         —         3,588,962  

Issuance of shares on RTO

     4        6,458,547        807,315       —          —          —         —         807,315  

Warrants issued on private placement

     10        —          (186,304     —          186,304        —         —         —    

Stock based compensation

     11        —          —         385,542        —          —         —         385,542  

Deficit

        —          —         —          —          (2,829,225     —         (2,829,225

Exchange loss on translating foreign operations

        —          —         —          —          —         (14,419     (14,419
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at June 30, 2018

        56,846,547      $ 4,236,395     $ 385,542      $ 186,304      $ (2,930,766   $ (14,419   $ 1,863,056  
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Consolidated Statement of Cash flow

For the periods ended June 30, 2018 and from the date of incorporation March 15, 2017 to June 30, 2017

 

(Expressed in Canadian dollars)

 
     Note      June 30, 2018     June 30, 2017  

Cash flow from Operating Activities

       

Net loss for the period

      $ (2,829,225   $ (101,541

Adjustments for:

       

Listing fees

     4        894,054       —    

Stock based compensation

     11        385,542       —    

Loss on equity investment in Xanthic Beverages USA, LLC

     7        58,255       —    

Changes in non-cash working capital balances

       

Other receivable

        (145,554     (12,428

Prepaid expenses

        (249,915     —    

Inventory

        (195,515     —    

Accounts payable and accrued liabilities

        (42,014     111,643  
     

 

 

   

 

 

 
        (2,124,372     (2,326

Cash flow from Investing Activities

       

Purchase of equipment

     6        (56,597     —    

Investment in Xanthic Beverages USA, LLC

     7        (395,040     —    
     

 

 

   

 

 

 
        (451,637     —    

Cash flow from Financing Activities

       

Private placement of shares, net of issuance costs

     9        3,588,962       26,422  
     

 

 

   

 

 

 
        3,588,962       26,422  

Increase in cash and cash equivalents

        1,012,953       24,096  
     

 

 

   

 

 

 

Cash and cash equivalents, beginning of period

        24,096       —    
     

 

 

   

 

 

 

Cash and cash equivalents, end of the period

      $ 1,037,049     $ 24,096  
     

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

1. Nature of operations

Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Company”) was incorporated under Ontario Business Corporations Act. The Company was acquired by Xanthic Biopharma Limited (“Xanthic”) in a reverse takeover transaction (see Note 4) completed on December 15, 2017. The Company’s principal business activity is the licensing of non-combustible medical cannabis products. The Company is in the development stage and has not yet earned any revenues. As Xanthic has been identified as the accounting acquirer, these financial statements are considered a continuation of Xanthic and any comparative information provided prior to the reverse takeover are those of Xanthic.

2. Basis of presentation and going concern

(a) Statement of compliance

The Company’s consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The accounting policies set out below were consistently applied to all periods presented unless otherwise noted.

These consolidated financial statements were reviewed, approved and authorized by the Company’s Board of Directors on September 13, 2018.

(b) Basis of measurement

These consolidated financial statements have been prepared in accordance with IFRS, on the historical cost basis except for certain financial instruments, which are measured at fair value, as explained in the accounting policies set out in Note 3.

(c) Basis of consolidation

These consolidated financial statements include the accounts of the Company and its subsidiaries, Xanthic Biopharma Limited, Xanthic US Hold Co., Xanthic Biopharma Oregon LLC, Xanthic Biopharma California LLC, Xanthic Biopharma Nevada LLC and Xanthic Colorado LLC. All significant intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement and has the ability to affect those returns through its power to direct the relevant activities of the entity.

(d) Functional and presentation currency

All figures presented in the consolidated financial statements are reflected in Canadian dollars, which is the functional currency of the Company. The functional currency of the Company’s wholly owned subsidiaries, Xanthic US Hold Co., Xanthic Biopharma Oregon LLC, Xanthic Biopharma California LLC, Xanthic Biopharma Nevada LLC and Xanthic Colorado LLC is United States dollars. Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. The assets and liabilities of foreign operations, are translated in Canadian dollars at year-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in equity.

 

5


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

(e) Use of estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant estimates include but are not limited to the following:

 

  (I)

Inputs when Black-Scholes valuation model

The estimates used in determining the stock option fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes valuation model. Inputs are subject to estimates include volatility, forfeiture rates, estimated lives and market rates.

 

  (II)

Functional and presentation currency

In determining the functional currency of the parent and its subsidiary companies, management considered the currency that mainly influences sales and the cost of providing goods and services in each jurisdiction in each the Company operates. The Company also considered secondary indicators including the currency in which each funds from financing activities are denominated, the currency in which funds are retained and whether the activities of the subsidiaries are carried out as an extension of the Company or if they are carried out with a degree of autonomy.

 

  (III)

Contingent Consideration

The valuation of the contingent consideration payable to former owners of Xanthic Beverages USA, LLC is subject to estimates surrounding the probability of milestones being made.

(f) Going Concern

These consolidated financial statements have been prepared using accounting principles applicable to a going concern. The going concern basis assumes that the Company will continue its operations for the foreseeable future, and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. As at June 30, 2018, the Company had working capital of $679,594 and during the year ended, it incurred a net loss from operations of $2,829,225. The uncertainty on the Company’s ability to raise additional finances to fund its operations casts significant doubt upon the Company’s ability to continue as a going concern and the ultimate appropriateness of using accounting principles applicable to a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is not able to continue as a going concern, the Company may be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in these consolidated financial statements. These differences could be material.

3. Significant accounting policies

A summary of the significant accounting policies, which have been applied consistently to all periods presented in the accompanying consolidated financial statements are set out below:

Cash

Cash comprises bank balances held in Canadian chartered banks.

 

6


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

Inventory

Inventory is recorded at the lower of cost and net realizable value. Cost is determined using the standard cost method, which is updated regularly to reflect current conditions and approximate cost based on the weighted average formula. Cost of inventory includes cost of purchase (purchase price, transport, handling, and other costs directly attributable to the acquisition of inventories), cost of conversion, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

All inventories are reviewed for impairment due to slow moving and obsolete inventory. The provisions for obsolete, slow moving or defective inventories are recognized in profit or loss. Previous write downs to net realizable value are reversed to the extent there is a subsequent increase in the net realizable value of the inventory.

Capital assets

Capital assets are carried at cost less any residual value, accumulated depreciation and impairment losses. Cost includes the acquisition costs or construction costs, as well as the costs directly attributable to bringing the asset to the location and condition necessary for its use in operations. When capital assets include significant components with different useful lives, they are recorded and amortized separately. Depreciation is computed using the straight-line method based on the estimated useful life of the assets. The residual value, useful life and depreciation methods are reviewed at the end of each reporting period. Such a review takes into consideration the nature of the asset, the intended use and impact of technological changes. Where parts of an item of capital assets have different useful lives, they are accounted for as separate items of capital assets. Subsequent costs are included in the asset carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

Impairment of non-financial assets

At each date of the statement of financial position, the Company reviews the carrying amounts of its tangible assets to determine whether there is an indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash generating unit to which the assets belong. Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

If the recoverable amount of an asset (or cash generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in the statement of comprehensive loss.

Equity Accounted Investments

Equity accounted investments are investments over which the Company has significant influence, but not control. The financial results of the Company’s equity accounted investments are included in the Company’s consolidated financial statements using the equity method whereby the Company recognizes its proportionate share of income or loss and other comprehensive income or loss of the equity accounted investment in its own operations or comprehensive income or loss, as applicable.

Dilution gains and losses arising from changes in the Company’s interest in equity accounted investments are recognized in net operations. If the Company’s investment is reduced to zero, additional losses are not provided for, and a liability is not recognized, unless the Company has incurred legal or constructive obligations, or made payments on behalf of the equity accounted investment.

 

7


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

Financial instruments

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation specified in the contract is discharged, cancelled or expires.

A derivative is a financial instrument whose value changes in response to a specified variable, requires little or no net investment and is settled at a future date.

At initial recognition, the Company classifies its financial instruments in the following categories:

 

(i)

Financial assets and liabilities at fair value through profit or loss: a financial asset or liability is classified in this category if acquired principally for the purpose of selling or repurchasing in the short-term. Derivatives are also included in this category unless they are designated as hedges. Financial instruments in this category are recognized initially and subsequently at fair value. Gains and losses arising from changes in fair value are presented in the statements of net loss and comprehensive loss within other expense (income) in the period in which they arise. Cash and contingent consideration payable are included in this category.

 

(ii)

Loans and receivables: Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at the amount expected to be received, less, when material, a discount to reduce the loans and receivables to fair value. Subsequently, loans and receivables are measured at amortized cost using the effective interest method less a provision for impairment. Other receivable is included in this category.

 

(iii)

Available for sale financial assets: Available for sale assets are non-derivative financial assets that are designated as available for sale and are not categorized into any of the other categories described above. They are initially recognized at fair value including direct and incremental transaction costs. They are subsequently recognized at fair value. Gains and losses arising from changes in fair value are included as a separate component of equity until sale, when the cumulative gain or loss is transferred to the statements of loss and comprehensive loss. Interest is determined using the effective interest method, and impairment losses and translation differences on monetary items are recognized in the statements of net loss and comprehensive loss. The Company does not have any available for sale assets.

 

(iv)

Financial liabilities at amortized cost: Financial liabilities at amortized cost are composed of accounts payable and the promissory note payable. Trade payables, accrued liabilities and promissory note payable are initially recognized at the amount required to be paid, less, when material, a discount to reduce payables to fair value. Subsequently, accounts payables are measured at amortized cost using the effective interest method. These are classified as current liabilities if payment is due within 12 months. Otherwise, they are presented as non-current liabilities.

Impairment of financial assets carried at amortized cost

At each statement of financial position date, the Company assesses whether there is objective evidence a financial asset or group of financial assets is impaired. A financial asset or group of financial assets is impaired and impairment losses are incurred if, and only if, there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a loss event), and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

The amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows (excluding future credit losses) discounted at the financial asset’s original effective interest rate. The asset’s carrying amount is reduced and the amount of the loss is recognized in the statements of loss and comprehensive loss. If a loan has a variable interest rate, the discount rate for measuring any impairment loss is the

 

8


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

current effective interest rate determined under the contract. For practical reasons, the Company may measure impairment on the basis of an instrument’s fair value using an observable market price.

Stock based compensation

The Company issues stock based compensation awards to directors, employees and consultants. These arrangements include stock options. The Company expects that these stock based awards will be settled in equity of the Company. The Company uses a fair value method to account for stock based compensation. The fair value of stock based compensation, as at the date of grant, is measured using an option-pricing model and is recognized over the applicable vesting period as compensation expense, based on the number of stock based awards expected to vest, with a corresponding increase in contributed surplus. When stock options are exercised, the proceeds received, together with any amount in contributed surplus, are included in share capital. The expected number of stock based awards expected to vest is reviewed at least annually, with any impact being recognized immediately.

Share capital

In situations where the Company issues units, the value of units is bifurcated, and the value of warrants is included as a separate reserve of the Company’s equity. On expiry, the fair value of the warrants is transferred to share capital.

Share issuance costs

Costs incurred in connection with the issuance of share capital are netted against the proceeds received. Costs related to the issuance of share capital and incurred prior to issuance are recorded as deferred share issuance costs and subsequently netted against proceeds when they are received.

Loss per common share, basic and diluted

Basic loss per share is calculated by dividing the net loss for the period attributable to equity owners of the Company by the weighted average number of common shares outstanding during the period. Contingently issuable shares (including shares held in escrow) are not considered outstanding common shares and consequently are not included in the loss per share calculations.

Diluted loss per share is calculated by adjusting the weighted average number of common shares outstanding for dilutive instruments. The number of shares included with respect to options, warrants and similar instruments is computed using the treasury stock method.

For the periods presented, all options and warrants were anti-dilutive.

Income taxes

Income tax comprises current and deferred tax. Income tax is recognized in the statements of loss and comprehensive loss except to the extent that it relates to items recognized directly in shareholders’ equity, in which case the income tax is also recognized directly in shareholders’ equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect of previous years.

In general, deferred tax is recognized in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively enacted at the statements of financial position dates and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are recognized to the extent that it is probable the assets can be recovered.

Deferred income tax assets and liabilities are presented as non-current.

 

9


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

Provisions

A provision is recognized when the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable an outflow of economic benefits will be required to settle the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation.

New standards, amendments and interpretations not yet adopted

A number of new standards and amendments to standards and interpretations have been issued but have not yet been applied in preparing these consolidated financial statements, as set out below:

 

   

IFRS 9, Financial Instruments, addresses the classification, measurement and recognition of financial assets and financial liabilities. The complete version of IFRS 9 was issued in July 2014. It replaces the guidance in IAS 39 that relates to the classification and measurement of financial instruments. IFRS 9 retains but simplifies the mixed measurement model and establishes three primary measurement categories for financial assets: amortized cost, fair value through other comprehensive income (OCI) and fair value through profit or loss. The basis of classification depends on the entity’s business model and the contractual cash flow characteristics of the financial asset. Investments in equity instruments are required to be measured at fair value through profit or loss with the irrevocable option at inception to present changes in fair value in OCI not recycling. There is now a new expected credit losses model that replaces the incurred loss impairment model used in IAS 39. For financial liabilities, there were no changes to classification and measurement except for the recognition of changes in own credit risk in other comprehensive income, for liabilities designated at fair value through profit or loss. The standard is effective for accounting periods beginning on or after January 1, 2018 and earlier adoption is permitted. The Company does not expect this standard to have a significant impact on the Company’s financial statements at this time.

 

   

IFRS 15, Revenue from Contracts with Customers, deals with revenue recognition and establishes principles for reporting useful information to users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. Revenue is recognized when a customer obtains control of goods or services and thus has the ability to direct the use and obtain the benefits from the goods or services. The standard replaces IAS 18, Revenue, and IAS 11, Construction Contracts, and related interpretations. The standard is effective for annual periods beginning on or after January 1, 2018 and earlier adoption is permitted. The Company does not expect this standard to have a significant impact on the Company’s financial statements at this time.

 

   

In January 2016, the IASB issued IFRS 16, Leases, which will replace IAS 17, Leases. Under IFRS 16, a contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Under IAS 17, lessees were required to make a distinction between a finance lease and an operating lease. IFRS 16 now requires lessees to recognize a lease liability reflecting future lease payments and a right-of-use asset for virtually all lease contracts. There is an optional exemption for certain short-term leases and leases of low value assets; however, this exemption can only be applied by lessees. The standard is effective for annual periods beginning on or after January 1, 2019, with earlier application if IFRS 15 is also applied. The Company has yet to assess the impact of this standard.

 

   

IFRIC 22, Foreign Currency Transactions and Advance Consideration, was issued on December 8, 2016 and clarifies which date should be used for translation when a foreign currency transaction involves an advance payment or receipt and is applicable for annual periods beginning on or after January 1, 2018. The Company does not expect this standard to have a significant impact on the Company’s financial statements at this time.

 

   

IFRIC 23, Uncertainty over Income Tax Treatments, was issued in June 2017 and clarifies the accounting for uncertainties in income taxes. The interpretation committee concluded that an entity shall consider whether it is probable that a taxation authority will accept an uncertain tax treatment. If an entity concludes it is probable that the taxation authority will accept an uncertain tax treatment, then the entity shall determine

 

10


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

 

taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates consistently with the tax treatment used or planned to be used in its income tax filings. If an entity concludes it is not probable that the taxation authority will accept an uncertain tax treatment, the entity shall reflect the effect of uncertainty in determining the related taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates. IFRIC 23 is effective for annual periods beginning on or after January 1, 2019. Earlier adoption is permitted. The Company has yet to assess the impact of this standard.

4. Xanthic’s Biopharma Limited Reverse Take Over (“RTO”)

On December 15, 2017, the Company entered into a definitive agreement with Xanthic Biopharma Limited (“Xanthic”). Pursuant to the definitive agreement the Company acquired all the issued and outstanding common shares of Xanthic (the “Xanthic Shares”) from the Xanthic shareholders. At the date of closing on the definitive agreement there were 37,252,000 Xanthic Shares issued and outstanding, inclusive of 10,252,000 Xanthic Shares issued at a price of $0.125 per Xanthic Share pursuant to a non-brokered private placement. In exchange for the Xanthic Shares, the Company issued 298,016,000 common shares in the Company at a ratio of eight Company shares for each Xanthic Share at a deemed price of $0.015625 per Company share, resulting in a reverse takeover of the Company by Xanthic shareholders.

The Company had 51,668,184 common shares outstanding prior to the completion of the RTO. On closing of the RTO there was 349,684,184 common shares outstanding of which 51,668,184 represented the original shareholders of the Company who retained 14.8% and Xanthic shareholders obtained 85.2% of the Company.

Since the Company did not meet the definition of a business under IFRS 3 – Business Combinations, the acquisition was accounted for as a purchase of the Company’s assets. The consideration paid was determined as equity-settled share based payments under IFRS 2, at the fair value of the equity of the Company retained by the shareholders of the Company based on the fair value of the Xanthic common shares on the date of closing of the RTO, which was determined to be $0.125 per common share based on the most recent equity raise completed just prior to the RTO. The Company recorded a listing fees of $918,054 in the consolidated financial statements of net loss and comprehensive loss. The details of the listing fees are as follows:

 

Fair value of consideration paid:

  

51,668,184 common shares of Xanthic at $0.015625 per share

   $ 807,315  

Net liabilities of Aurquest acquired by Xanthic

     86,739  
  

 

 

 
     894,054  

Other Transaction Costs:

  

Professional fees

     24,000  
  

 

 

 

Listing fees

   $ 918,054  
  

 

 

 

The net liabilities of the Company were included at their carrying value of $86,739, which approximates their fair value as follows:

 

Cash

   $ 2,141  

Prepaid expenses

     500  

Accounts payable and accrued liabilities

     (44,380

Shareholder loans

     (45,000
  

 

 

 
   $ (86,739
  

 

 

 

For accounting purposes, these consolidated financial statements reflect a continuation of the financial position, operating results and cash flows of the Company’s legal subsidiary, Xanthic Biopharma Limited.

 

11


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

5. Inventory

As at June 30, 2018, the Company purchased certain raw materials which includes packaging, flavoring and other ingredients that will be resold to licensed producers who the Company has partnered with in each jurisdiction. Inventory is recorded at their carrying amount.

6. Capital assets

As at June 30, 2018, the Company purchased certain equipment totaling $56,597 for use in the first jurisdiction it plans to license its technology. The equipment was not in use as at June 30, 2018 and was still undergoing testing and calibration. Once the equipment is in use it will be amortized using the declining balance method at rates from 25% to 40%.

7. Equity investment in Xanthic Beverages USA, LLC (formerly Avitas CBD Water, LLC)

On March 22, 2018, the Company completed the investment in Xanthic Beverages USA, LLC (formerly Avitas CBD Water, LLC) (“Xanthic Beverages”). Xanthic Beverages is based in Portland, Oregon, and will be producing and distributing CBD-infused water, co-branded with the Company. Under the terms of the Agreement, the Company acquired a 45% ownership position in exchange for a cash payment of USD$300,000 and a contingent consideration payable of US$300,000 (see Note 8) on achieving certain performance milestones over the next 12 months.

Further, at the Company option, if Xanthic Beverages achieves certain milestones on sales, the Company may issue 600,000 common shares in the Company or a one time cash payment of up to USD$300,000.

Finally, at the Company’s option, the Company can acquire a further 6% interest in Xanthic Beverages for a one time payment in shares of US$300,000 at the then 60 day average price of the Company’s common shares.

 

For year ended June 30,

   2018  

Opening Investment in Xanthic Beverages USA, LLC

   $ —    

Initial investment

     1,185,120  

Xanthic share of operating loss

     (58,255
  

 

 

 

Closing balance in Xanthic Beverages USA, LLC

   $  1,126,865  
  

 

 

 

The Company picks up its share of the loss of Xanthic Beverages USA, LLC for the period ended June 30, 2018 which was $58,255.

The following table summarizes certain financial information of Xanthic Beverages USA, LLC for the period noted below:

(Expressed in United States dollars)

 

     2018  

Total Current Assets

   $ 498,435  

Total Non-current assets

     —    

Total Current Liabilities

     —    

Revenue

     1,620  

Net loss from operations

   $  (101,665
  

 

 

 

 

12


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

8. Contingent consideration payable

In connection with the Company’s equity investment in Xanthic Beverages, the Company has a contingent consideration payable of USD$300,000 (see Note 7) if Xanthic Beverages issues a second purchase order for a second production run over the next 12 months. The Company has assigned a 100% probability that Xanthic Beverages would be meet this performance milestone. The USD$300,000 payable on the second purchase order is subject to interest at the average US applicable federal rate of 1.76%.

In addition, the Company has accounted for the contingent consideration payable of paying up to USD$300,000 or issuing 600,000 common shares of the Company (see Note 7) if Xanthic Beverages achieves certain additional milestones. The Company has assigned a 100% probability that Xanthic Beverages would achieve either these milestones.

Subsequent to year end, on July 23, 2018, the Company paid the contingent payable of USD$300,000 along with accrued interest of USD$1,735.32 on the issuance of the second purchase order by Xanthic Beverages.

9. Shareholders’ equity

Authorized share capital

Common Share – voting – unlimited

All historical references to share transactions or balances prior to this date have been recast on an eight for one basis unless otherwise stated.

Outstanding share capital

 

     Common Shares      Amount  

Outstanding at June 30, 2017

     7,000,000      $ 26,422  

Common Shares issued for cash

     43,388,000        3,551,196  

Issuance Costs

     —          (148,538

Issuance of shares in RTO

     6,458,547        807,315  
  

 

 

    

 

 

 

Outstanding at June 30, 2018

     56,846,547      $ 4,236,395  
  

 

 

    

 

 

 

On November 21, 2017, Xanthic completed a non-brokered private placement by issuing 160,000,000 (20,000,000 common shares before the share split of 1 for 8) common shares for gross proceeds of $400,000.

On December 13, 2017, prior to the completion of the RTO transaction noted above Xanthic completed a non-brokered private placement by issuing 82,016,000 (10,252,000 common shares before the share split of 1 for 8) common shares for net proceeds of $1,194,144 net of issue costs of $87,356.

On December 15, 2017, the Company completed the previously discussed (see Note 4) RTO by issuing 51,668,184 (6,458,547 common shares after the share consolidation of 8 for 1) common shares to Xanthic shareholders.

On January 16, 2018, the Company completed a non-brokered private placement by issuing 96,000,000 common (12,000,000 common shares after the consolidation of 8 for 1) shares for gross proceeds of $1,500,000.

On February 26, 2018, the Company completed an 8 for 1 consolidation of the common shares outstanding, after receiving shareholder approval at its annual general and special shareholder meeting.

 

13


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

On April 19, 2018, the Company closed a non-brokered private placement for gross proceeds of $556,000. The Company issued 1,112,000 units (the “Units”) at a price of $0.50 per Unit. Each Unit will be comprised of one common share in the Company and one-half of one (1/2) common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one common share at an exercise price of $0.75 per common share for a period of 24 months from the closing date of the private placement. The Company paid to certain finders an aggregate finder’s fee of $18,000 and 24,000 Units comprised of 24,000 common shares and 12,000 Warrants, having the same attributes as the Units.

10. Warrants

The following table reflects the continuity of warrants for the periods presented:

 

            Weighted  
     Number of      Average  
     Warrants      Exercise Price  

Balance outstanding, July 1, 2017

     —        $ —    

Issued

     568,000        0.750  

Expired

     —          —    
  

 

 

    

 

 

 

Balance outstanding, June 30, 2018

     568,000      $  0.750  
  

 

 

    

 

 

 

On April 19, 2018, in conjunction with the non-brokered private placement, the Company issued 556,000 warrants at an exercise price of $0.75 per share, exercisable until April 18, 2020. There were 12,000 finders’ warrants granted in connection with this private placement.

The fair value of these warrants was valued using the Black-Scholes Option Pricing Model with the following assumptions:

 

     2018  

Risk free interest rate

     1.88

Expected dividend yield

     0.00

Expected volatility1

     150

Expected life of the warrants

     2 years  

 

(1)

Expected volatility is based on historical volatility of comparable companies.

11. Stock based compensation

Stock Option Plan

The shareholders of the Company have approved a stock option plan (the “SOP”) pursuant to which the Company may issue up to 5,684,654 common shares of the Company to employees, directors and officers. The exercise price of each option issued pursuant to the terms of the SOP shall be established at the grant date by the directors of the Company and in all cases shall not be less than the closing price of the common shares of the Company on the trading day immediately preceding the grant date. Options are generally issued with a five year term from the date of grant and are subject to vesting conditions whereby one third of the options granted vest immediately, with the remaining two thirds vesting over a two-year period.

During the year ended June 30, 2018, the Company granted 4,208,000 stock option awards at an exercise prices ranging from $0.125 to $0.60 per option. The fair value of the options granted was estimated at the grant date using an option pricing model with the following assumptions:

 

14


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

     May 28,     April 19,     February 28,  
     2018     2018     2018  

Number of options granted

     1,000,000       900,000       2,308,000  

Exercise price

   $ 0.160     $ 0.40 to $0.60     $ 0.125  

Risk free interest rate

     1.88     2.12     2.01

Expected dividend yield

     0.00     0.00     0.00

Expected volatility1

     150     150     150

Expected life of the options

     1 year       1 to 5 years       3 to 5 years  

 

(1)

Expected volatility is based on historical volatility of comparable companies.

A summary of the status of the stock option component of the Company’s SOP as at and for the year ended June 30, 2018, is as follows:

 

            Weighted  
            Average  
     Stock Options      Exercise Price  

Options outstanding, July 1, 2017

     —        $ —    

Options granted

     4,208,000        0.189  

Forfeited

     (700,000      0.321  
  

 

 

    

 

 

 

Options outstanding, June 30, 2018

     3,508,000      $  0.189  
  

 

 

    

 

 

 

Exercisable options

     1,702,661      $ 0.146  
  

 

 

    

 

 

 

 

                   Weighted Avg         
            Weighted      Remaining         
Option    Options      Average      Contractual      Options  

price

   Outstanding      Exercise Price      Life (Yrs.)      Exercisable  

At $ 0.125

     2,108,000      $ 0.125        4.67        702,661  

At $ 0.16

     1,000,000      $ 0.160        0.91        1,000,000  

At $ 0.60

     400,000      $ 0.600        4.80        —    
  

 

 

    

 

 

    

 

 

    

 

 

 

During the year ended June 30, 2018, the Company recognized stock based compensation expense of $385,542 in respect of outstanding stock options.

A summary of the vesting schedule of stock options are as follows:

 

Vesting Schedule

  

Immediate

     1,702,661  

1 year

     400,000  

2 years

     1,405,339  
  

 

 

 

Subsequent to year end, 700,000 stock options were exercised.

 

15


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

12. Income taxes

The reconciliation of the combined Canadian federal and provincial corporate income taxes at a statutory rate 26.5% to the Company’s effective income tax expense is as follows:

 

For year ended June 30,

   2018     2017  

Loss before income taxes

   $  2,829,225     $ 101,541  

Statutory rate

     26.5     26.5
  

 

 

   

 

 

 

Expected income tax recovery at combined basic federal and provincial tax rates

     749,745       26,908  

Effect on income taxes of:

    

Non-deductible expenses

     (417,608     —    

Changes in tax benefits not recognized

     (332,137     (26,908
  

 

 

   

 

 

 

Income tax recovery

   $ —       $ —    
  

 

 

   

 

 

 

Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities.

Deferred tax assets have not been recognized in respect of the following temporary differences:

 

     As at      As at  
     June 30, 2018      June 30, 2017  

Non-capital loss carryforward

   $  2,930,766      $ 101,541  

Deductible share issuance costs

     157,117        8,578  
  

 

 

    

 

 

 

As at June 30, 2018, the Company had Canadian non-capital loss carry forwards which may be available to offset future year’s taxable income. The losses expire as follows:

 

     2018      2017  

2037

   $ 110,119      $ 110,119  

2038

     2,977,764        —    
  

 

 

    

 

 

 
   $ 3,087,883      $ 110,119  
  

 

 

    

 

 

 

13. Related parties

Related parties include the Board of Directors and key management, close family members and entities that are controlled by these individuals, as well as certain persons performing similar functions. At June 30, 2018 there was $25,366 indebtedness to shareholders of the Company.

 

16


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

Management compensation

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling activities of the entity, directly or indirectly including the Chief Executive Officer, President, and Chief Financial Officer and equivalent, and Directors. For the year ended June 30, 2018, the Company’s expenses included $470,942 respectively for salary or consulting fees paid to key management personnel, include in consulting fees. In addition, included in stock based compensation expense is $115,075 in connection with stock awards to management and Directors.

14. Capital management

The Company’s objective in managing capital is to ensure a sufficient liquidity position to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. In order to achieve this objective, the Company prepares budgets and capital requirements to manage its capital structure. The Company defines capital as equity and borrowings, comprised of issued share capital, share-based payments, accumulated deficit, as well as due to related parties.

Since inception, the Company has primarily financed its liquidity needs through issuance of shares.

The Company is not subject to externally imposed capital requirements.

15. Financial instruments and risk management

Financial instruments

The Company has classified its cash and contingent consideration payable as fair value through profit and loss (“FVTPL”), and other receivable as current assets, accounts payable and accrued liabilities and contingent consideration payable as current liabilities.

The carrying values of cash, other receivable, accounts payable and accrued liabilities and contingent consideration payable approximate their fair values due to their short periods to maturity.

Fair value hierarchy

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The hierarchy is summarized as follows:

Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities

Level 2 – inputs that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices) from observable market data

Level 3 – inputs for assets and liabilities not based upon observable market data

 

            Fair value as at June 30, 2018  
            Quoted prices in                
            Active Markets for      Significant Other      Significant  
     Carrying value as at      Identical Assets      Observable Inputs      Unobservable Inputs  
     June 30, 2018      (Level 1)      (Level 2)      (Level 3)  

Financial Assets

           

Cash

   $ 1,037,049      $ 1,037,049      $ —        $ —    

Financial Liabilities

           

Contingent consideration payable

     790,080        —          —          790,080  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

17


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

Contingent consideration payable has a sensitivity of US$75,000 depending on the probability that Xanthic Beverages would achieve certain sales milestones (see Note 8).

Financial risk factors

The Company’s risk exposure and the impact on the Company’s financial instruments are summarized below:

(a) Credit risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and other receivables. The Company’s cash is held at a major Canadian bank and in trust with lawyers. The Company’s other receivables is with Revenue Canada in connection with input tax credits. The Company regularly monitors the credit risk exposure and takes steps to mitigate the likelihood of these exposures resulting in actual loss.

(b) Liquidity risk

The Company is exposed to liquidity risk or the risk of not meeting its financial obligations as they come due as discussed in Note 2 (e) above. The Company constantly monitors and manages its cash flows to assess the liquidity necessary to fund operations. All of the Company’s financial liabilities are due within one year.

(c) Interest rate risk

The Company is not subject to any significant interest rate risk from its liabilities other than noted in connection with the promissory note (Note 8), which are all non-interest bearing instruments.

16. Accounts payable and accrued liabilities

 

     June 30, 2018      June 30, 2017  

Trade payables

   $ 63,303      $ 97,143  

Accrued liabilities

     93,065        14,500  
  

 

 

    

 

 

 
   $ 156,368      $ 111,643  
  

 

 

    

 

 

 

 

18


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

 

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

17. Segmented information

The Company operates in one reportable operating segment, being the licensing of its technology and wholesale distribution of non-cannabis ingredients in North America. The Company is currently still in its development stage has no revenue for the fiscal year ended June 30, 2018.

18. Subsequent event

On July 16, 2018, the Company announced that they entered into an arm’s length business combination agreement (the “Definitive Agreement”) dated July 13, 2018 to combine Xanthic and Green Growth Brands (GGB”) by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

Following completion of the Business Combination, current shareholders of GGB will hold approximately 86% of the common shares (the “Resulting Issuer Shares”) of the resulting issuer (the “Resulting Issuer”). It is anticipated that the Resulting Issuer may operate under the name “Green Growth Brands Ltd.” after effecting a name change (the “Name Change”) with the Resulting Issuer Shares listed and posted for trading on the Canadian Securities Exchange (the “Exchange” or the “CSE”). Xanthic anticipates filing a management information circular or listing statement (the “Disclosure Document”) detailing certain matters relating to the Business Combination and other related matters to be mailed to Xanthic shareholders.

Xanthic and GGB also announced that GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic has entered into a purchase agreement (the “NOR Agreement”) dated July 13, 2018 with Nevada Organic Remedies LLC (“NOR”) and its members pursuant to which it will acquire (the “NOR Acquisition”) 100% of the outstanding membership interests of NOR for aggregate consideration of US$56,750,000 with 5% in common shares and the balance in cash. On July 17, 2018, GGB Nevada made a payment of US$2,000,000 to NOR as a deposit on the NOR Agreement. GGB Nevada secured such funds by signing a promissory note with GGB. NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada holding four Nevada marijuana licenses (dispensary, cultivation, production and distribution). Additionally, NOR produces a line of high quality medical and recreational products under the name 8| fold.

As of July 13, 2018, Xanthic had 57,046,547 Xanthic Shares outstanding together with Xanthic convertible securities entitling the holders thereof to acquire a further 3,876,000 Xanthic Shares. Based on the foregoing, Xanthic will, subject to the receipt of all regulatory approvals, including the approval of its shareholders to certain items of special business and the Exchange, (i) combine with GGB pursuant to the Definitive Agreement such that all of the issued and outstanding GGB Shares will be acquired, and as consideration, Xanthic will issue to holders of GGB Shares, on a 3.394-for-one basis, 346,150,835 Xanthic Shares (the “Consideration Shares”) , in exchange for the then issued and outstanding GGB Shares (which for greater certainty excludes the GGB Shares to be issued under the Subscription Receipt Private Placement and the Debenture Private Placement (as such terms are defined below)); and (ii) reorganize its share structure and consolidate all of the issued and outstanding Xanthic Shares (including the Consideration Shares) on the basis of approximately 4.07 pre-consolidation Xanthic Shares for one (1) post-consolidation Resulting Issuer Share (the “Consolidation”).

In the event that GGB terminates the Definitive Agreement, other than as a result of a breach of representation or warranty or non-performance by Xanthic, GGB shall pay Xanthic a break fee in the aggregate amount of $250,000 and reimburse Xanthic for the full extent of its US legal fees, a portion of its Canadian legal fees, travel costs and other reasonable expenses incurred in connection with the Business Combination.

Further, on September 5, 2018, the Company signed a loan agreement for US$30,347,500 with GGB in connection with the NOR Agreement which closed on the same day. The loan agreement is for a period of 180 days from September 5, 2018 and bears interest at 12% annum. The proceeds of the loan from GGB were used to make the initial payment on closing of the NOR Agreement. In addition, on closing of the NOR Acquisition, GGB Nevada provided to the NOR Members a secured promissory note in the principal amount of US$21,565,000.

 

19


LOGO

XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

MANAGEMENT DISCUSSION AND ANALYSIS

FOR THE YEAR ENDED JUNE 30, 2018


MANAGEMENT DISCUSSION AND ANALYSIS

Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company” or the “Corporation”) was incorporated under Ontario Business Corporations Act. Xanthic was acquired by Xanthic Biopharma Limited in a reverse takeover transaction completed on December 15, 2017. The Company’s principal business activity is the licensing of technology to produce non-combustible medical cannabis products. The Company is in the development stage and has not yet earned any revenues and is focused on developing innovative non-combustible alternative delivery methods of cannabis infused products. Xanthic is a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary methods. The Corporation’s registered office is 77 King St. West Suite 2905, Toronto, Ontario, M5K 1H1.

This Management’s Discussion and Analysis (“MD&A”) has been prepared with an effective date of September 13, 2018 and provides an update on matters discussed in, and should be read in conjunction with the Corporation’s audited financial statements, including the notes thereto, as at and for year ended June 30, 2018 (the “2018 Audited Consolidated Financial Statements”), which have been prepared using International Financial Reporting Standards (“IFRS”). All amounts are in Canadian dollars unless otherwise specified. Tabular dollar amounts, unless otherwise specified, are in dollars, except for per unit or per share amounts. This MD&A contains forward looking statements that are based on certain estimates and assumptions and involve risks and uncertainties. Actual results may vary materially from management’s expectations. See the “Caution Concerning Forward Looking Statements” section in this MD&A.

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements in this MD&A may contain “forward-looking information,” within the meaning of applicable securities laws, including the “safe harbour provisions” of the Securities Act (Ontario) with respect to the Company. Such statements include, but are not limited to, statements with respect to expectations, projections, or other characterizations of future events or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to our plans and objectives, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities. These statements are subject to certain risks, assumptions and uncertainties that could cause actual results to differ materially from those included in the forward-looking statements. The words “believe”, “plan”, “intend”, “estimate”, “expect”, or “anticipate”, and similar expressions, as well as future or conditional verbs such as “will”, “should”, “would”, and “could” often identify forward-looking statements. We have based these forward-looking statements on our current views with respect to future events and financial performance. With respect to forward looking statements contained in this MD&A, the Corporation has made assumptions and applied certain factors regarding, among other things: future product pricing; costs of inputs; its ability to market products successfully to its anticipated clients; reliance on key personnel; the regulatory requirements; the application of federal and state environmental laws; and the impact of increasing competition. These forward-looking statements are also subject to the risks and uncertainties discussed in the “Risks Factors” section of the CSE listing Statement as filed on SEDAR and elsewhere in this MD&A and other risks detailed from time to time in the publicly filed disclosure documents of the Corporation which are available at www.sedar.com. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which could cause actual results to differ materially from the conclusions, forecasts, or projections anticipated in these forward-looking statements. Because of these risks, uncertainties, and assumptions, the reader should not place undue reliance on these forward-looking statements. The Corporation’s forward-looking statements are made only as of the date of this MD&A, and except as required by applicable law, the Corporation undertakes no obligation to update or revise these forward-looking statements to reflect new information, future events or circumstances.


GOING CONCERN ASSUMPTION AND EARLY STAGE CORPORATION

The Corporation was incorporated March 15, 2017. The Corporation’s ability to continue as a going concern is dependent upon the ability to raise the necessary capital to finance development the Corporation’s business strategy of a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary non-combustible methods. The 2018 Audited Consolidated Financial Statements do not give effect to any adjustments which would be necessary should the Corporation be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business. The amounts the Corporation may realize on the disposition of its assets or the discharging of its liabilities in other than the normal course of its business may be significantly different than the carrying value of these assets and liabilities as reflected in the 2018 Audited Consolidated Financial Statements.

OVERVIEW OF THE CORPORATION

Description of Business

Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis and cannabis-infused products. Using a proprietary process, Xanthic empowers its strategic partners to deliver superior cannabinoid solubility, improved bioavailability, accurate micro-dosing, and greater consistency versus competitive infused products. Through its investment in Xanthic Beverages, Xanthic has access to non-cannabis derived CBD-infused products that qualify for distribution outside of the cannabis dispensary network and into mainstream retail. Both business streams are capital-light, utilizing the existing infrastructure of strategic partners to reduce the capital investment required by Xanthic.

Recent Developments

Subsequent to June 30, 2018, on July 16, 2018 Xanthic and Green Growth Brands Ltd. (“GGB”) announced they have entered into an arm’s length business combination agreement (as amended by agreement between Xanthic and GGB dated August 30, 2018, the “Definitive Agreement”) dated July 13, 2018 to combine Xanthic and GGB by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

GGB is a lifestyle oriented, consumer products company that celebrates health, wellness and happiness. GGB is focused on the medicinal and recreational cannabis sector in both the United States and Canada and is the parent company of the CAMP brand. GGB is led by the widely-renowned retailer Peter Horvath. The Business Combination represents the initial step in GGB’s strategy to grow its international footprint, through partnerships with cannabis cultivators and processors across Canada and the United States. While GGB’s principal focus will be to build a retail network, it will leverage Xanthic’s expertise in the science of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”), the two key active ingredients in cannabis.

Following completion of the Business Combination, current shareholders of GGB will hold approximately 86% of the common shares (the “Resulting Issuer Shares”) of the resulting issuer (the “Resulting Issuer”) (excluding any Resulting Issuer Shares that become issuable pursuant to the terms of GGB’s private placement of convertible debentures (the “Debenture Private Placement”) and any subsequent GGB private placement of subscription receipts (the “Subscription Receipt Private Placement”). It is anticipated that the Resulting Issuer may operate under the name “Green Growth Brands Ltd.” after effecting a name change (the “Name Change”) with the Resulting Issuer Shares listed and posted for trading on the Canadian Securities Exchange (the “Exchange” or the “CSE”). Xanthic anticipates filing a management information circular or listing statement (the “Disclosure Document”) detailing certain matters relating to the Business Combination and other related matters to be mailed to Xanthic shareholders. Trading in the common shares of Xanthic (the “Xanthic Shares”) will be halted as a result of this announcement and will remain halted until the resumption of trading is approved by the Exchange. If completed, the Business Combination will constitute a fundamental change of Xanthic (as such term is defined in the CSE’s policies and procedures manual).


Assuming the satisfaction of customary closing conditions, including the approval of Xanthic’s shareholders, the Business Combination is expected to close in the fourth quarter of this year.

Xanthic and GGB also announced that GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic has entered into a purchase agreement (the “NOR Agreement”) dated July 13, 2018 with Nevada Organic Remedies LLC (“NOR”) and its members (“NOR Members”) pursuant to which it will acquire (the “NOR Acquisition”) 100% of the outstanding membership interests of NOR for aggregate consideration of US$56,750,000 payable by a combination of cash and a promissory note. On July 16, 2018, Xanthic borrowed US$2,000,000 from GGB pursuant to a promissory note with a due date of December 1, 2018 and bears interest at a rate of 6% per annum and on July 17, 2018, Xanthic advanced the proceeds of the loan to GGB Nevada which in turn made a payment of US$2,000,000 to NOR as a deposit on the NOR Agreement. NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada holding four Nevada marijuana licenses (dispensary, cultivation, production and distribution). Additionally, NOR produces a line of high quality medical and recreational products under the name 8|fold.

Further, on September 5, 2018, Xanthic borrowed an additional US$30,347,500 from GGB pursuant to the terms of a loan agreement (the “Loan Agreement”) dated August 30, 2018. The proceeds of the loan were subsequently advanced by Xanthic to GGB Nevada, which in turn used the proceeds to make the initial cash payment required pursuant to the NOR Agreement in connection with the closing of the NOR Acquisition. In addition, on closing of the NOR Acquisition, GGB Nevada delivered to the NOR Members a secured promissory note (the “Purchase Note”) in the principal amount of US$21,565,000. The Purchase Note matures on March 3, 2019 and bears interest at 6% per annum and is fully secured by general security interest over the assets of NOR. The Loan Agreement matures on the date that is 180 days from September 5, 2018, bears interest at 12% per annum and has been secured by a pledge over the shares of GGB Nevada. The balance of US$2,715,000 owing to the NOR Members will be satisfied by the issuance of common shares of the resulting issuer following completion of the Business Combination.

The Business Combination

Subject to the terms of the Definitive Agreement, Subco and GGB will complete the Amalgamation and the amalgamated corporation (“Amalco”) will continue under the name “Green Growth Brands (Ontario) Ltd.”. Amalco will be a direct wholly-owned subsidiary of the Resulting Issuer. All of the property and assets of each of Subco and GGB will become the property and assets of Amalco and Amalco will be liable for all of the liabilities and obligations of each of Subco and GGB.

As of the July 16, 2018, Xanthic had 57,046,547 Xanthic Shares outstanding together with Xanthic convertible securities entitling the holders thereof to acquire a further 3,876,000 Xanthic Shares. As of the July 16, 2018, GGB had 92,000,002 GGB common shares (“GGB Shares”) outstanding and no outstanding convertible securities. Pursuant to the terms of the Definitive Agreement, GGB may issue up to an additional 9,200,000 GGB Shares (or convertible securities, or the equivalent) prior to closing of the Business Combination. Based on the foregoing, Xanthic will, subject to the receipt of all regulatory approvals, including the approval of its shareholders to certain items of special business and the Exchange, (i) combine with GGB pursuant to the Definitive Agreement such that all of the issued and outstanding GGB Shares will be acquired, and as consideration, Xanthic will issue to holders of GGB Shares, on a 3.394-for-one basis, 346,150,835 Xanthic Shares (the “Consideration Shares”) , in exchange for the then issued and outstanding GGB Shares (which for greater certainty excludes the GGB Shares to be issued under the Subscription Receipt Private Placement and the Debenture Private Placement (as such terms are defined below)); and (ii) reorganize its share structure and consolidate all of the issued and outstanding Xanthic Shares (including the Consideration Shares) on the basis of approximately 4.07 pre-consolidation Xanthic Shares for one (1) post-consolidation Resulting Issuer Share (the “Consolidation”).

In the event that GGB terminates the Definitive Agreement, other than as a result of a breach of representation or warranty or non-performance by Xanthic, GGB shall pay Xanthic a break fee in the aggregate amount of $250,000 and reimburse Xanthic for the full extent of its US legal fees, a portion of its Canadian legal fees, travel costs and other reasonable expenses incurred in connection with the Business Combination.


Resulting Issuer

The following table sets forth the pro forma capitalization of the Resulting Issuer after giving effect to the Business Combination and the Consolidation but prior to giving effect to the Subscription Receipt Private Placement and the Debenture Private Placement:

 

Equity

(Resulting Issuer Shares)

  

Shares(1)

(#)

    

Shares(2)

(%)

 

Held by current GGB Shareholders

     85,034,014        85.9

Held by current Xanthic Shareholders that are insiders of Xanthic

     1,487,036        1.5

Held by current Xanthic Shareholders that are not insiders of Xanthic

     12,526,788        12.6
  

 

 

    

 

 

 

Total

     99,047,838        100
  

 

 

    

 

 

 

 

(1)

Does not give effect to exercise and/or conversion of issued and outstanding Xanthic convertible securities.

(2)

Expressed on a non-diluted basis.

To the knowledge of the prospective directors and executive officers of the Resulting Issuer, no person or company beneficially will own, or control or direct, directly or indirectly, Resulting Issuer Shares carrying in excess of 10% of the voting rights attached to all outstanding Resulting Issuer Shares, other than All Js Greenspace LLC, a company controlled by three individual family trusts, which is expected to own 33,971,923 Resulting Issuer Shares, representing a 34.3% ownership stake in the Resulting Issuer prior to giving effect to the Subscription Receipt Private Placement and the Debenture Private Placement.

Board of Directors and Management

Subject to Exchange approval, the board of directors and management of Xanthic was reconstituted on July 16, 2018 with the following individuals:

 

   

Jean Schottenstein (Director)

 

   

Peter Horvath (Director)

 

   

Steve Stoute (Director)

 

   

Carli Posner (Director)

 

   

Marc Lehmann (Director)

 

   

Tim Moore (Director and Chief Executive Officer)

 

   

Gary Galitsky (Director and President)

 

   

David Bhumgara (Chief Financial Officer)

It is currently expected that the board of directors and management of the Resulting Issuer will be the aforementioned individuals.

Conditions of Completion

Completion of the Business Combination is subject to a number of conditions, including, but not limited to, Exchange acceptance. Where applicable, the Business Combination cannot close until the required shareholder approval is obtained. There can be no assurance that the Business Combination will be completed as proposed, or at all.

The remaining conditions to completion of the Business Combination include, but are not limited to:


   

The approval of GGB shareholders of the Amalgamation, the approval of Xanthic shareholders of the Amalgamation, the Name Change and the Consolidation, and other matters to be more fully described in the Disclosure Document, and the approval and acceptance of the Exchange;

 

   

Xanthic will have at least $400,000 of working capital (net of expenses relating to the completion of the Amalgamation); and

 

   

The Resulting Issuer being in compliance with the initial listing requirements of the Exchange.

Background

Aurquest Resources Inc. which was formed by an amalgamation of Rampart Mercantile Inc. and North American Store Finance Ltd. back in November 1, 2000. Previous to the amalgamation, the Corporation was initially incorporated in province of British Columbia on November 18, 1968, then continued into Ontario on November 24, 1999 prior to amalgamation with North American Store Finance Ltd. on November 1, 2000.

On December 15, 2017 Xanthic Biopharma Limited acquired via a reverse takeover transaction Aurquest Resources Inc. Pursuant to the Definitive Agreement, Aurquest acquired all of the issued and outstanding common shares of Xanthic Biopharma Limited from the Xanthic Shareholders. As of the date of closing, there was 37,252,000 issued and outstanding Xanthic Shares, inclusive of 10,252,000 Xanthic Shares issued at a price of $0.125 per share pursuant to a non-brokered private placement of Xanthic (the “Xanthic Private Placement”) which closed December 13, 2017. In exchange for the Xanthic Shares, Aurquest issued a total of 298,016,000 Aurquest Shares at a ratio of eight (8) Aurquest Shares for each one (1) Xanthic Share (the “Exchange Ratio”) at a deemed price of $0.01563 per Aurquest Share, resulting in a reverse take-over of Xanthic by Aurquest (the “RTO Transaction”). Aurquest had 51,668,184 shares outstanding. The RTO Transaction resulted in the Company having approximately 349,684,184 common shares. On closing of the RTO Transaction, the Aurquest shareholders had 51,668,184 shares (14.78%), the existing Xanthic shareholders hold 216,000,000 Aurquest shares (61.77%), and the purchasers in the Xanthic Private Placement hold 82,016,000 Aurquest shares (23.45%).

On February 16, 2018, the shareholders of Aurquest Resources Inc. voted in favour of the following: 1) consolidation of the common shares of the Corporation on an eight for one basis; 2) name change from Aurquest Resources Inc. to Xanthic Biopharma Inc.; 3) the election of directors, 4) appointment of auditors, 5) approving a 10% rolling stock option plan; and 6) adoption of new bylaws. The Corporation effected the name change and share consolidation on February 26, 2018, at which time the outstanding common shares were reduced to 55,710,547. Subsequent to the quarter end of March 31, 2018, on April 19, 2018 the Corporation’s common shares commenced trading on the Canadian Securities Exchange (“CSE”) under the stock ticker symbol XTHC.

On March 21, 2018, the Corporation completed its purchase of 45% interest in Xanthic Beverages USA LLC (previously Avitas CBD Water LLC “Xanthic Beverages”) for USD$600,000, USD$300,000 was due on signing and balance due when Xanthic Beverages issues its second purchase order for bottling with a co-packer. In addition, if Xanthic Beverages achieves a minimum market penetration of 100 retailers or sales throughput of 380,000 units, at the option of the Corporation, the Corporation has a contingent consideration payable of USD$150,000 or 600,000 common shares of the Corporation. The Corporation has assigned a 50% probability at June 30, 2018 that the contingent consideration payable will occur. Xanthic Beverages uses CBD isolate derived from non-hemp, non-cannabis source for use in water beverages sold both within and outside the licensed dispensary universe.

Further, the Corporation has an option for 24 months to acquire a further 6% interest in Xanthic Beverages bringing its ownership to 51% and therefore control for an additional $300,000 worth of shares in the Corporation based on the 60 day average price at the time of the exercise.

Corporate Outlook and Strategy

The Corporation is in its infancy, as previously noted, however the Corporation’s business strategy is to be a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary non-combustible methods.


The Corporation’s strategy will be focused initially in certain states in the United States where cannabis has been legalized for recreational or medical use. The Corporation will partner with local licensed cannabis producers in each state in order to facilitate its roll out and minimize capital needs.

The Corporation’s product offering will initially include cannabis infused powder beverage mixes such as a fruit drink, a rescue drink, an energy drink, hot chocolate and a protein drink, with first production planned in the third calendar quarter of 2018.

Through its equity investment in Xanthic Beverages, the Corporation plans to assist Xanthic Beverages with branding and distribution of the Xanthic CBD Water broadly through an extensive retail network using third party bottler’s distribution network, independent local grocery and other retail locations in the states of Oregon, Washington and California.

Overall Financial Performance

As previously discussed, the Corporation incorporated March 15, 2017 and has no revenue from operations. Below is a summary of the Corporation financial performance for the year ended June 30, 2018. During the year ended June 30, 2018 the Corporation had a net loss from operations of $2,829,225. Included in yearend results from operations are listing fees in connection with the RTO completed with Aurquest Resources Inc. of $918,054.

 

For the year ended

   June 30, 2018      June 30, 2017  

Revenue

   $ —        $ —    

Net loss from operations

     2,829,225        101,541  

Net Loss per share

   $ 0.08      $ 0.04  

RTO Transaction

On December 15, 2017, the Company entered into a definitive agreement with Xanthic Biopharma Limited (“Xanthic”). Pursuant to the definitive agreement the Company acquired all the issued and outstanding common shares of Xanthic (the “Xanthic Shares”) from the Xanthic shareholders. At the date of closing on the definitive agreement there were 37,252,000 Xanthic Shares issued and outstanding, inclusive of 10,252,000 Xanthic Shares issued at a price of $0.125 per Xanthic Share pursuant to a non-brokered private placement. In exchange for the Xanthic Shares, the Company issued 298,016,000 common shares in the Company at a ratio of eight Company shares for each Xanthic Share at a deemed price of $0.015625 per Company share, resulting in a reverse takeover of the Company by Xanthic shareholders.

The Company had 51,668,184 common shares outstanding prior to the completion of the RTO. On closing of the RTO there are 349,684,184 common shares outstanding of which 51,668,184 represented the original shareholders of the Company who retained 14.8% and Xanthic shareholders obtained 85.2% of the Company.

Since the Company did not meet the definition of a business under IFRS 3 – Business Combinations, the acquisition was accounted for as a purchase of the Company’s assets. The consideration paid was determined as equity-settled share based payments under IFRS 2, at the fair value of the equity of the Company retained by the shareholders of the Company based on the fair value of the Xanthic common shares on the date of closing of the RTO, which was determined to be $0.125 per common share based on the most recent equity raise completed just prior to the RTO.

The Company recorded listing fees of $918,054 in the 2018 Audited Consolidated Financial Statements of net loss and comprehensive loss. The details of the listing fees are as follows:


Fair value of consideration paid:

  

51,668,184 common shares of Xanthic at $0.015625 per share

   $ 807,315  

Net liabilities of Aurquest acquired by Xanthic

     86,739  
  

 

 

 
     894,054  

Other Transaction Costs:

  

Professional fees

     24,000  
  

 

 

 

Listing fees

   $ 918,054  
  

 

 

 

The net liabilities of the Company were included at their carrying value of $86,739, which approximates their fair value as follows:

 

Cash

   $ 2,141  

Prepaid expenses

     500  

Accounts payable and accrued liabilities

     (44,380

Shareholder loans

     (45,000
  

 

 

 
   $ (86,739
  

 

 

 

Review of Operations for the year ended June 30, 2018 compared to year ended June 30, 2017

During the year ended June 30, 2018 (“Fiscal 2018”), the Corporation incurred a net loss $2,829,225 or $0.08 per share, as compared to a net loss from operations of $101,541 or $0.04 per share for the year ended June 30, 2017 (“Fiscal 2017”). During Fiscal 2018 the Corporation completed three private placements which allowed the Corporation to commence execution on its business plan. In addition, the significant increase in net loss was primarily the result of first full year of operations compared to Fiscal 2017. The Corporation was formed March 2017 so Fiscal 2017 represented less than 4 months of activity.

During Fiscal 2018, the Corporation incurred management, consulting fees of $827,658, compared with $60,000 in Fiscal 2017. The increase is primarily due to the retaining of management and consultants to help establish and capitalize the Corporation. The Corporation also incurred $375,023 in legal costs in Fiscal 2018 compared with $27,968 in Fiscal 2017. The increase in legal costs reflects the increase in business activity and the establishment of agreements, patent filings, financing activities, general counsel and listing application fees with the CSE during Fiscal 2018. In addition, the Corporation incurred $174,289 in advertising and promotion compared with $13,496 in Fiscal 2017. The increase relates to web development, investor presentations, packaging and brand building in Fiscal 2018.

During Fiscal 2018, the Corporation adopted its share-based compensation plan and issued stock options which resulted in stock based compensation expense of $385,542 compared to nil in Fiscal 2017.

Review of Operations for the three months ended June 30, 2018 compared to three months ended June 30, 2017

 

For the quarter ended

   June 30, 2018      June 30, 2017  

Consulting fees

   $ 231,614      $ 60,000  

Stock based compensaton

     287,081        —    

Legal and professional fees

     181,297        27,968  

Advertising and promotion

     77,287        13,496  

Loss from equity accounted investment

     58,255        —    

General and administration

     47,761        61  

Interest and bank charges

     2,709        16  
  

 

 

    

 

 

 
     886,004        101,541  

Net Loss per share

   $ 0.02      $ 0.04  
  

 

 

    

 

 

 

During the three months ended June 30, 2018, the Corporation incurred $231,614 in consulting fees to senior management, accounting, corporate finance work and strategic advisory services compared to $60,000 in the same


period of the prior year. The Corporation consulting fees related to finance work to assist developing the business plan and strategy and product development. The Corporation had for the three months ended June 30, 2018 $181,297 in legal and professional fees associated with investor relations and legal activities this compares to $27,968 in the same period of the prior year. The increase in legal and professional relates to work to complete the CSE listing application with the Corporation first day of trading commencing April 19, 2018.

The Corporation incurred during the fourth quarter 2018 $77,287 in advertising and promotion compared to $13,496 in the same period of the prior year. The Corporation incurred expenses in developing its brand, packaging and artistic elements in anticipation of its product launch in later half of 2018.

The Corporation recorded a $58,255 loss on its share of its equity accounted investment in Xanthic Beverages. Xanthic Beverages commenced operations in March 2018 with the Corporations investment of the initial USD$300,000. The loss represents startup costs for Xanthic Beverages.

The Corporation incurred in the fourth quarter of 2018, $47,761 in general and administrative costs compared to $61 in the same period of the prior year. The increase represents the increased activity in the Corporation compared to the prior year.

On February 28, 2018, the Corporation’s board approved the stock option plan. As a result of grants during the year the Corporation incurred stock based compensation costs of $287,081 compared to nil in the same period of the prior year.

SELECTED QUATERLY FINANCIAL INFORMATION

 

For the three months ended,

   June 30, 2018      March 30, 2018      December 31, 2017      September 30, 2017      June 30, 2017  

Current Assets

   $ 1,626,042      $ 1,810,722      $ 1,236,139      $ 62,553      $ 36,524  

Current Liabilities

     650,168        804,766        314,663        138,168        111,643  

Net Loss from Operations

     860,004        566,047        1,328,678        74,496        101,541  

Net Loss per share

   $ 0.02      $ 0.01      $ 0.01      $ 0.01      $ 0.04  

 

   

The Corporation current assets represent cash, prepaids, inventory and HST receivable. Current assets at June 30, 2018 include cash of $1,037,049.

 

   

The Corporation’s current liabilities represent start up consulting fees, legal and audit fees since inception and include contingent consideration payable in connection with Xanthic Beverages purchase of $493,800 (see 2018 Audited Consolidated Financial Statements Note 8).

 

   

June 30, 2018 quarterly loss includes stock based compensation expense of $287,081.

 

   

December 31, 2017 net loss and comprehensive loss includes listing fees of $944,054.

LIQUIDITY AND CAPITAL RESOURCES

The Corporation has cash of $1,037,049, prepaids of $249,915, inventory of $181,096, and other receivable of $157,982 and current liabilities of $946,448 as at June 30, 2018. The Corporation therefore has a working capital of $679,594. Despite the positive working capital, the Corporation does not have sufficient liquidity and capital resources at June 30, 2018 to meet all its planned expenditures over the next twelve months.

The Corporation plans to complete further financings over the next twelve months in order to fund its ongoing expenditures and execute on its business plan to get to break even cashflow. However, there is no assurance that the Corporation will be successful in these endeavors.


Outstanding Share Data

At June 30, 2018, the Corporation had 56,846,547 common shares outstanding, 568,000 warrants outstanding and 3,508,000 stock options outstanding and on September 13, 2018, the Corporation had 57,546,547 common shares outstanding, 568,000 warrants outstanding and 2,808,000 stock options outstanding.


OFF BALANCE SHEET ARRANGEMENTS

In the normal course of business, the Corporation has entered into arrangements with several third-party goods and services providers. In certain instances, the Corporation, directly and through its subsidiaries, has provided indemnities and/or guarantees to these third parties for the payment of goods or services provided, or otherwise. Generally, there are no pre-determined amounts or limits included in these arrangements, and the occurrence of an event that would trigger the Corporation’s obligations pursuant to these arrangements is difficult to predict. Therefore, the Corporation’s potential future liability cannot be reasonably estimated.

COMMITMENT AND CONTINGENCIES

Commitments and contingencies are detailed in Note 8 to the 2018 Audited Consolidated Financial Statements. The following table summarizes payments due for the next five years and thereafter in respect of the Corporation’s contractual obligations and the obligations of its subsidiaries.

 

     Expected Payments Schedule  
     2019      2020 to 2021      2022 to 2023      Thereafter      Total  

Accounts payable and accured liabilities

   $ 156,368      $ —        $ —        $ —        $ 156,368  

Contingent consideration payable

     790,080        —          —          —          790,080  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 946,448      $ —        $ —        $ —        $ 946,448  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

RELATED PARTY TRANSACTIONS

The Corporation has not entered into any transactions with related parties, other than as disclosed in Note 13 to the 2018 Audited Consolidated Financial Statements.

ACCOUNTING POLICIES, CRITICAL JUDGMENTS AND ESTIMATES

The preparation of the Corporation’s financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and other items in net earnings or loss, and the related disclosure of contingent assets and liabilities, if any. Critical judgments and estimates represent estimates made by management that are, by their very nature, uncertain. The Corporation evaluates its estimates on an ongoing basis. Such estimates are based on historical experience and on various other assumptions that the Corporation believes are reasonable under the circumstances, and these estimates form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and other items in net earnings or loss that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Summaries of the significant accounting policies applied, and significant judgments, estimates and assumptions made by management in the preparation of its financial statements are provided in Notes 2 and 3 to the 2018 Audited Consolidated Financial Statements.

CONTROLS AND PROCEDURES

During 2018, the Chief Executive Officer and the Chief Financial Officer of the Corporation were responsible for establishing and maintaining disclosure controls and procedures and internal control over financial reporting, as defined in the Canadian Securities Administrators National Instrument 52-109,Certification of Disclosure in Issuers’ Annual and Interim Filings”.

Internal Control over financial reporting (“ICFR”) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with applicable IFRS. Disclosure controls and procedures are designed to ensure that information required to be disclosed by the Corporation in the reports it files or submits under securities legislation is recorded, processed, summarized and reported on a timely basis and that such information is accumulated and reported to management, including the Corporation’s Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow required disclosures to be made in a timely fashion. Based on their evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that, as at June 30, 2018, the Corporation’s disclosure controls and procedures were effective.


BUSINESS RISKS

There are numerous and varied risks, known and unknown, that may prevent the Corporation from achieving its goals. If any of these risks occur, the Corporation’s business, financial condition or results of operation may be adversely affected. In such case, the trading price of the Corporation’s common shares could decline, and investors could lose all or part of their investment. The following is a summary of risks that could be applicable to the business of the Corporation:

The Company Relies on Securing and Maintaining Agreements with Licensed Partners

In most U.S. States, the Company is not eligible to obtain a license to grow, store and sell cannabis products. Accordingly, the Company must secure royalty agreements with Licensed Partners that have been able to obtain the requisite licenses with the appropriate regulatory authorities in the targeted jurisdictions. The failure of a Licensed Partner to comply with the requirements of their license or to maintain their license would have a material adverse impact on the business, financial condition and operating results of the Company. There can be no guarantee that the applicable licenses will be maintained by Licensed Operators or granted to other prospective Licensed Operators in the future.

Limited Operating History

Having been founded in late 2017, the Company has a limited operating history which can make it difficult for investors to evaluate the Company’s operations and prospects and may increase the risks associated with an investment in the Company. The Company will be subject to all of the business risks and uncertainties associated with any new business enterprise, such as under-capitalization, cash shortages, limitations with respect to personnel, financial and other resources, achieving market acceptance of existing and future solutions, competing against companies with greater financial and technical resources, and lack of revenues. There is no assurance that the Company will be successful in achieving a return for investors and the likelihood of success must be considered in light of the early stage of operations. Because the Company has a limited operating history in emerging area of business, investors should consider and evaluate its operating prospects in light of the risks and uncertainties frequently encountered by early-stage companies in rapidly evolving markets. These risks may include:

 

   

risks that it may not have sufficient capital to achieve its growth strategy;

 

   

risks that it may not develop its product and service offerings in a manner that enables it to be profitable and meet its customers’ requirements;

 

   

risks that its growth strategy may not be successful;

 

   

risks that fluctuations in its operating results will be significant relative to its revenues; and

 

   

risks relating to an evolving regulatory regime.

The Company’s future growth will depend substantially on its ability to address these and the other risks described in this section. If it does not successfully address these risks, its business may be significantly harmed.

Operating in the United States

The Company will initially focus its operations in the United States, specifically in states that have already passed legislation legalizing the recreational sale and use of cannabis. Currently, the states of California, Nevada, Massachusetts, Maine, Washington, Oregon, Colorado and Alaska, and the District of Columbia, have legalized the recreational use of cannabis. However, the U.S. federal government has not enacted similar legislation and the cultivation, sale and use of cannabis remains illegal under federal law pursuant to the U.S. Controlled Substance Act of 1970. While the Department of Justice under the previous U.S. presidential administration stated its intention not to enforce federal laws relating to cannabis where the conduct at issue is legal under applicable state law, pursuant to the Cole Memorandum, there can be no assurance that the current administration will not enforce such laws in the future. This risk is further compounded by the political and policy variability of the Donald Trump presidential administration, and the conservative, anti-cannabis stances of Attorney General Jeff Sessions. Mr. Trump’s positions regarding marijuana are difficult to discern; however, Attorney General Sessions has been a consistent opponent of marijuana legalization efforts throughout his political career. On January 4, 2018, Attorney General Sessions


rescinded the Cole Memorandum, shifting federal policy from a hands-off approach to unleashing federal prosecutors across the country to decide individually how to crack down on possession, distribution and cultivation of cannabis, including in states in which cannabis is legal. With the Cole Memorandum rescinded, U.S. federal prosecutors no longer have guidance relating to the exercise of their discretion in determining whether to prosecute cannabis related violations of U.S. federal law. It is possible that further developments could significantly adversely affect the business, financial condition and results of businesses involved in U.S. cannabis related activities and in the cannabis industry generally. There can be no assurance that the U.S. federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with applicable state law. If the federal government begins to enforce federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing state laws are repealed or curtailed, the Company would be materially and adversely affected notwithstanding the fact that the Company is not directly engaged in the sale or distribution of cannabis. The consequences of such enforcement would be materially adverse to the Company and the Company’s business and could result in the forfeiture or seizure of all or substantially all of the Company’s assets.

The Products Provided by the Company to Licensed Partners May Become Subject to Regulation Governing Food and Related Products

Should the U.S. federal government legalize cannabis for medical or recreational use nation-wide, there is a risk that the U.S. Food and Drug Administration (the “FDA”) would seek to regulate the products under the Food, Drug and Cosmetics Act of 1938. The FDA may issue rules and regulations including certified good manufacturing practices related to the growth, cultivation, harvesting and processing of cannabis and cannabis-infused products. Clinical trials may be needed to verify the efficacy and safety of cannabis. It is also possible that the FDA would require that facilities where cannabis is cultivated be registered with the applicable government agencies and comply with certain federal regulations. Compliance with such rules and regulations may be unduly costly and may have an adverse effect on the Company. If the Company or its Licensed Partners are unable to comply with the regulations prescribed by the FDA, the Company and/or its Licensed Partners may be unable to continue to operate.

Banking Regulation May Hinder the Company’s Ability to Establish and Maintain Bank Accounts

The U.S. federal prohibitions on the sale of cannabis may prevent the Company’s Licensed Partners from accessing the U.S. banking system and they may be unable to deposit funds in federally-insured and federally-licensed banking institutions. While the Company does not anticipate dealing with banking restrictions directly relating to its business, such restrictions could nevertheless be imposed due to the Company’s banking institutions not accepting payments from its Licensed Partners. Licensed Partners at times do not have deposit services and are at risk that any bank accounts they have could be closed at any time. Such risks increase costs to the Company and to its Licensed Partners. The inability of the Company’s Licensed Partners to access banking services can make it difficult to structure royalty agreements in a manner acceptable to the Company.

In the event financial service providers do not accept accounts or transactions related to the cannabis industry, it is possible that the Company’s Licensed Partners may seek alternative payment solutions, including but not limited to, cryptocurrencies such as Bitcoin. There are risks inherent in cryptocurrencies, most notably its volatility and security issues. If the industry was to move towards alternative payment solutions and accept payments in cryptocurrency the Company would have to adopt policies and protocols to manage its volatility and exchange rate risk exposures. The Company’s inability to manage such risks may adversely affect the Company’s operations and financial performance.

Managing Growth

In order to manage growth and change in strategy effectively, the Company must: (a) maintain adequate systems to meet customer demand; (b) expand sales and marketing, distribution capabilities and administrative functions; (c) expand the skills and capabilities of its current management team; and (d) attract and retain qualified employees. The inability of the Company to deal with this growth may have a material adverse effect on its business, financial condition, results of operations and prospects.


Competition

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience than the Company. Currently, the cannabis, nutraceuticals and pharmaceuticals industry generally is comprised of individuals and small to medium-sized entities, however, the risk remains that large conglomerates and companies that also recognize the potential for financial success through investment in this industry could strategically purchase or assume control of larger dispensaries and cultivation facilities. In doing so, these larger competitors could establish price setting and cost controls which would effectively “price out” many of the individuals and small to medium-sized entities that currently make up the bulk of the participants in the varied businesses operating within, and in support of, the medical and recreational cannabis industry. While most U.S. states seemingly deter this type of arrangement, the cannabis industry is still relatively new for public entities, so the future competitive environment remains largely unknown.

Because of the early stage of the industry in which the Company will operate, the Company expects to face additional competition from new entrants. To become and remain competitive, the Company will require research and development, marketing, sales and support. The Company may not have sufficient resources to maintain research and development, marketing, sales and support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of operations of the Company.

Retention, Acquisition and Integration of Skilled Personnel

The loss of any member of the Company’s management team could have a material adverse effect on its business and results of operations. In addition, the inability to hire new personnel and the increased costs of hiring new personnel could have a material adverse effect on the Company’s business and operating results. At present and for the near future, the Company will depend upon a relatively small number of employees to develop, market, sell and support its products. The expansion of marketing and sales of its products will require the Company to find, hire and retain additional capable employees who can understand, explain, market and sell its products. There is intense competition for capable personnel and the Company may not be successful in attracting, training, integrating, motivating, or retaining new personnel, vendors, or subcontractors for these required functions. New employees often require significant training and, in many cases, take significant time before they achieve full productivity. As a result, the Company may incur significant costs to attract and retain employees, including significant expenditures related to salaries and benefits and compensation expenses related to equity awards, and may lose new employees to its competitors or other companies before it realizes the benefit of its investment in recruiting and training them. In addition, as the Company moves into new jurisdictions, it will need to attract and recruit skilled employees in those areas.

Legal Proceedings

From time to time, the Company may be a party to legal and regulatory proceedings, including matters involving governmental agencies, entities with whom it does business and other proceedings arising in the ordinary course of business. The Company will evaluate its exposure to these legal and regulatory proceedings and establish reserves for the estimated liabilities in accordance with International Financial Reporting Standards. Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management’s evaluations or predictions and accompanying changes in established reserves, could have an adverse impact on the Company’s financial results.


Regulatory Compliance Risks

Achievement of the Company’s business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. The Company may not be able to obtain or maintain the necessary licenses, permits, authorizations or accreditations, or may only be able to do so at great cost, to operate its business. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by local governmental authorities. The impact of the compliance regime, any delays in obtaining, or failure to obtain or keep the regulatory approvals may significantly delay or impact the development of markets, products and sales initiatives and could have a material adverse effect on the business, results of operations and financial condition of the Company.

The Company will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company’s operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

Change of Cannabis Laws, Regulations and Guidelines

Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require the Company to incur substantial costs associated with compliance or alter certain aspects of its business plan. It is also possible that regulations may be enacted in the future that will be directly applicable to certain aspects of the Company’s businesses. The Company cannot predict the nature of any future laws, regulations, interpretations or applications, nor can it determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on the Company’s business. Management expects that the legislative and regulatory environment in the cannabis industry in Canada and internationally will continue to be dynamic and will require innovative solutions to try to comply with this changing legal landscape in this nascent industry for the foreseeable future. Compliance with any such legislation may have a material adverse effect on the Company’s business, financial condition and results of operations.

Unfavourable Publicity or Consumer Perception

Management of the Company believes the cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the cannabis produced. Consumer perception of the Company’s proposed products may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company’s proposed products and the business, results of operations, financial condition and cash flows of the Company. The Company’s dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for the Company’s proposed products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis in general, or the Company’s proposed products specifically, or associating the consumption of cannabis with illness or other negative effects or events, could have such a material adverse


effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers’ failure to consume such products appropriately or as directed.

Liability, Enforcement, Complaints, etc.

The Company’s participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by third parties, other companies and/or various governmental authorities against the Company. Litigation, complaints, and enforcement actions involving the Company could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on the Company’s future cash flows, earnings, results of operations and financial condition.

Product Liability

As a distributor of products designed to be ingested or inhaled by humans, the Company faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused damages, loss or injury. In addition, the sale of the Company’s products involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Adverse reactions resulting from human consumption of the Company’s products alone or in combination with other medications or substances could occur. The Company may be subject to various product liability claims, including, among others, that the Company’s products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning health risks, possible side effects or interactions with other substances. A product liability claims or regulatory action against the Company could: i) result in increased costs; ii) adversely affect the Company’s reputation with its Licensed Partners and consumers generally; and iii) have a material adverse effect on the results of operations and financial condition of the Company. There can be no assurances that the Company will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Company’s potential products.

Insurance Coverage

The Company’s production is, in general, subject to different risks and hazards, including adverse weather conditions, fires, plant diseases and pest infestations, other natural phenomena, industrial accidents, labour disputes, changes in the legal and regulatory framework applicable to the Company and environmental contingencies. Although management of the Company believes that the events and amounts of liability covered by its insurance policies will be reasonable, taking into account the risks relevant to its business, and the fact that agreements with users contain limitations of liability, there can be no assurance that such coverage will be available or sufficient to cover claims to which the Company may become subject. If insurance coverage is unavailable or insufficient to cover any such claims, the Company’s financial resources, results of operations and prospects could be adversely affected.

Product Recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of the Company’s products are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Company may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although the Company has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if the Company is subject to recall, the image of the Company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the Company’s products and could have a material adverse effect on the results of operations and financial condition of the Company. Additionally, product recalls may lead to


increased scrutiny of the Company’s operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses and potential legal fees and other expenses.

Limited Avenues to Market and Promote Products

To be successful, the Company’s business must be successfully marketed. The market for the Company’s products and services has and is expected to grow significantly and may require substantial sales and marketing capability. The Company will be dependent on independent parties to market its products and services. There can be no assurance that the Company can continue to market or can enter into satisfactory arrangements with third parties to continue to market its products and services in a manner that would assure its growth and acceptance in the market place.

Supply of Cannabis Extract

If for any reason the supply of cannabis extract from licensed producers is ceased or delayed, the Company would have to seek alternate suppliers and obtain all necessary authorization for the new cannabis extract. If replacement cannabis extract cannot be obtained at comparable prices, or at all, or if the necessary authorizations are not obtained, the Company’s business, financial condition and results of operations would be materially and adversely affected.

Global Economy

Financial markets are influenced by the economic and market conditions in other countries, including the United States and other global markets. Although economic conditions in these countries may differ significantly from economic conditions in Canada, investor reactions to developments in these other countries may substantially affect the capital flows into and the market value of securities of issuers with operations in the United States and Canada.

Consumer Acceptance of Premium Pricing

The Company branding, and pricing strategy is to offer a premium product at higher than existing market prices of competitive products. The Company assumes that it will be successful in establishing the brand as a premium brand and therefore is relying on pricing its products consistent with its brand image. There can be no assurance that the Company will be successful and that the marketplace will accept a premium price when there is no direct competitive, comparable product.

Access to Capital

In executing its business plan, the Company makes, and will continue to make, substantial investments and other expenditures related to acquisitions, research and development and marketing initiatives. Since its incorporation, the Company has financed these expenditures through offerings of its equity securities and debt financing. The Company will have further capital requirements and other expenditures as it proceeds to expand its business or take advantage of opportunities for acquisitions or other business opportunities that may be presented to it. The Company may incur major unanticipated liabilities or expenses. The Company can provide no assurance that it will be able to obtain financing to meet the growth needs of the Company.

Foreign Sales and Currency Risks

The Company’s functional currency is denominated in Canadian dollars. The Company currently expects that sales will be denominated in U.S. dollars and may, in the future, have sales denominated in the currencies of additional countries in which it establishes sales offices. In addition, the Company incurs the majority of its operating expenses in Canadian dollars. In the future, the proportion of the Company’s sales that are international may increase. Such sales may be subject to unexpected regulatory requirements and other barriers. Any fluctuation in the exchange rates of foreign currencies may negatively impact the Company’s business, financial condition and results of operations. The Company has not previously engaged in foreign currency hedging. If the Company decides to hedge its foreign currency exposure, it may not be able to hedge effectively due to lack of experience, unreasonable costs or illiquid


markets. In addition, those activities may be limited in the protection they provide the Company from foreign currency fluctuations and can themselves result in losses.

Estimates or Judgments Relating to Critical Accounting Policies

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided in the notes to the Company’s Financial Statements, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. The Company’s operating results may be adversely affected if the assumptions change or if actual circumstances differ from those in the assumptions, which could cause the Company’s operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the share price of the Company. Significant assumptions and estimates used in preparing the financial statements include those related to the credit quality of accounts receivable, income tax credits receivable, share based payments, impairment of non-financial assets, as well as revenue and cost recognition.

Tax Risks

The Company will operate and will be subject to income tax and other forms of taxation (which are not based upon income) in multiple tax jurisdictions. Taxation laws and rates which determine taxation expenses may vary significantly in different jurisdictions, and legislation governing taxation laws and rates is also subject to change. Therefore, the Company’s earnings may be impacted by changes in the proportion of earnings taxed in different jurisdictions, changes in taxation rates, changes in estimates of liabilities and changes in the amount of other forms of taxation. The Company may have exposure to greater than anticipated tax liabilities or expenses. The Company will be subject to income taxes and non-income taxes in a variety of jurisdictions and its tax structure is subject to review by both domestic and foreign taxation authorities and the determination of the Company’s provision for income taxes and other tax liabilities will require significant judgment.

Repatriation of Profits

As a holding company with no material assets other than the stock of the Company’s operating subsidiaries and intellectual property, nearly all of the Company’s funds generated from operations are generated by the Company’s operating subsidiaries. The Company’s subsidiaries are subject to requirements of various regulatory bodies, both domestically and internationally. Accordingly, if the Company’s operating subsidiaries are unable, due to regulatory restrictions or otherwise, to pay the Company’s dividends and make other payments to the Company when needed, the Company may be unable to satisfy the Company’s obligations when they arise.

Limited market for securities

There can be no assurance that an active and liquid market for the Company’s shares will develop or be maintained and an investor may find it difficult to resell any securities of the Company.

Stock Market Volatility

The market price of the Company’s Common Shares could be subject to significant fluctuations in response to various factors, many of which are beyond the Company’s control. In addition, the stock markets have experienced significant price and volume fluctuations that have particularly affected the market prices of equity securities of many companies and that often have been unrelated to the operating performance of such companies. These broad market fluctuations may adversely affect the market price of the Common Shares. There can be no assurance that the holders or purchasers of the Company’s Common Shares will be able to resell their shares at prices equal to or greater than their cost.

No History of Payment of Cash Dividends


The Company has never declared or paid cash dividends on its Common Shares. The Company intends to retain future earnings to finance the operation, development and expansion of the business. The Company does not anticipate paying cash dividends on its Common Shares in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of the Board and will depend on the Company’s financial condition, results of operations, contractual restrictions, capital requirements, business prospects and other factors that the Board considers relevant.

Analyst Coverage

The trading market for the Company’s Common Shares will, to some extent, depend on the research and reports that securities or industry analysts publish about the Company or its business. The Company will not have any control over these analysts. If one or more of the analysts who covers the Company should downgrade the Company’s Common Shares or change their opinion of the Company’s business prospects, the Company’s share price would likely decline. If one or more of these analysts ceases coverage of the Company or fails to regularly publish reports on the Company, the Company could lose visibility in the financial markets, which could cause the Company’s share price or trading volume to decline.

Tax Issues

There may be income tax consequences in relation to the Company’s Common Shares, which will vary according to circumstances of each investor. Prospective investors should seek independent advice from their own tax and legal advisers.

INFORMATION CONCERNING XANTHIC BIOPHARMA INC.

Additional information relating to the Corporation, may be accessed through the SEDAR website at www.sedar.com under Xanthic Biopharma Inc. and the Corporation’s website at www.xanthicbiopharma.com.

Toronto, Ontario

September 13, 2018

EX-3.3 8 d692201dex33.htm EX-3.3 EX-3.3

Exhibit 3.3

 

LOGO

Xanthic Biopharma Inc.

Condensed Interim Consolidated Financial Statements

For the three months ended

September 30, 2018

(unaudited)

(In United States Dollars)


XANTHIC BIOPHARMA INC.

Condensed Interim Consolidated Statement of Financial Position

As at June 30, 2018 and September 30, 2018

(Expressed in United States dollars)

 

     Note      September 30, 2018     June 30, 2018  
            (unaudited)     (audited)  

Assets

       

Current Assets

       

Cash and cash equivalents

      $ 1,520,552     $ 787,551  

Receivables

        422,460       119,974  

Inventory

     5        1,382,471       137,527  

Biological assets

     6        660,292       —    

Prepaid expenses

        79,734       189,790  
     

 

 

   

 

 

 
        4,065,509       1,234,842  

Property and equipment

     7        709,929       42,981  

Equity investment in Xanthic Beverages USA, LLC

     8        838,688       854,250  

Intangible assets

     9        32,235,000       —    

Goodwill

     9        22,144,742       —    
     

 

 

   

 

 

 

Total assets

      $ 59,993,868     $ 2,132,073  
     

 

 

   

 

 

 

Liabilities

       

Current Liabilities

       

Accounts payable and accrued liabilities

     19        1,735,541       117,238  

Due to related parties

     15        66,441       —    

Other financial liabilities

     10        3,137,500       600,000  

Interest bearing loans

     11        53,912,500       —    
     

 

 

   

 

 

 
        58,851,982       717,238  

Shareholders’ Equity (Deficiency)

       

Share capital

     12        3,321,229       3,217,189  

Reserve for share based payments

     14        432,142       292,787  

Reserve for warrants

     13        141,482       141,482  

Reserve for changes in equity of subsidiary

        (2,837,500     —    

Deficit

        (2,770,510     (2,236,623
     

 

 

   

 

 

 

Total equity attributable to shareholders of Xanthic

        (1,713,157     1,414,835  

Non-controlling interest

        2,855,043       —    
     

 

 

   

 

 

 

Total equity

        1,141,886       1,414,835  
     

 

 

   

 

 

 

Total liabilities and equity

      $ 59,993,868     $ 2,132,073  
     

 

 

   

 

 

 

Nature of operations (note 1)

Subsequent events (note 21)

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

 

2


XANTHIC BIOPHARMA INC.

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

For the three months ended September 30, 2018 and September 30, 2017

(unaudited)

(Expressed in United States dollars)

 

     Note      September 30, 2018     September 30, 2017  

Sales

       

Revenue

      $ 1,770,595     $ —    

Production Costs

        876,267       —    
     

 

 

   

 

 

 

Gross profit before fair value adjustments

        894,328       —    

Fair value adjustment on biological assets

        (332,616     —    
     

 

 

   

 

 

 

Gross profit

        1,226,944       —    

Expenses

       

General and administration

        992,242       49,488  

Legal and professional fees

        150,882       1,762  

Stock based compensaton

     14        139,355       —    

Advertising and promotion

        31,399       8,140  

Depreciation and amortization

     7        12,553       —    

Loss on equity investment in Xanthic Beverages USA, LLC

     8        15,562       —    

Interest and bank charges

        407,846       40  

Foreign exchange loss (income)

        (6,551     143  
     

 

 

   

 

 

 

Total Expenses

        1,743,288       59,573  
     

 

 

   

 

 

 

Net loss and comprehensive loss

      $ (516,344   $ (59,573
     

 

 

   

 

 

 

Net loss and comprehensive loss attributable to:

       

Owners of the parent

        (533,887     (59,573

Non-controlling interest

        17,543       —    
     

 

 

   

 

 

 
        (516,344     (59,573

Net Income (Loss) per Common Share

       

Basic and Diluted

      $ (0.01   $ (0.01

Weighted average common shares

        57,422,634       7,442,391  
     

 

 

   

 

 

 

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

 

3


XANTHIC BIOPHARMA INC.

Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity (Deficiency)

(unaudited)

(Expressed in United States dollars)

 

                         Reserves               
                                       Changes in               
            Common      Share     Share based             Equity of     Non-controlling         
     Note      Shares      Capital     Payments      Warrants      subsidiaries     Deficit     Interest      Total  

Balance at June 30, 2017

        7,000,000      $ 20,065     $ —        $ —        $ —       $ (77,112   $ —        $ (57,047

For the three months ended September 30, 2017

                       

Shares issued for cash, net of issuance costs

        3,700,000        59,176       —          —          —         —         —          59,176  

Deficit

                   —         (59,573     —          (59,573
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Balance at September 30, 2017

        10,700,000        79,241       —          —          —         (136,685     —          (57,444

From October 1, 2017 to June 30, 2018

                       

Shares issued for cash, net of issuance costs

     12        39,688,000        2,666,341       —          —          —         —         —          2,666,341  

Issurance of shares on RTO

        6,458,547        613,089       —          —          —         —         —          613,089  

Warrants issued on private placement

     12        —          (141,482     —          141,482        —         —         —          —    

Stock based compensation

     14        —          —         292,787        —          —         —         —          292,787  

Deficit

        —          —         —          —          —         (2,099,938     —          (2,099,938

Exchange loss on translating foreign operations

        —          —         —          —          —         —         —          —    
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Balance at June 30, 2018

        56,846,547      $ 3,217,189     $ 292,787      $ 141,482      $ —       $ (2,236,623   $ —        $ 1,414,835  

For the three months ended September 30, 2018

                       

Shares issued on stock option exercise

     14        900,000        104,040       —          —          —         —         —          104,040  

Stock based compensation

     14        —          —         139,355        —          —         —         —          139,355  

Non-controlling interest in subsidiary

        —          —         —          —          (2,837,500     —         2,837,500        —    

Deficit

        —          —         —          —            (533,887     17,543        (516,344
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Balance at September 30, 2018

        57,746,547      $ 3,321,229     $ 432,142      $ 141,482      $ (2,837,500   $ (2,770,510   $ 2,855,043      $ 1,141,886  
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

 

4


XANTHIC BIOPHARMA INC.

Condensed Consolidated Statement of Cashflow

For the three months ended September 30, 2018 and September 30, 2017

(Expressed in United States dollars)

 

     Note      September 30, 2018     September 30, 2017  

Cashflow from Operating Activities

       

Net loss for the period

      $ (516,344   $ (59,573

Adjustments for:

       

Stock based compensation

     14        139,355       —    

Loss on equity investment in Xanthic Beverages USA, LLC

     8        15,562       —    

Fair value adjustment on growth of biological assets

        (332,616     —    

Changes in non-cash working capital balances

       

Receivables

        (300,976     (7,532

Prepaid expenses

        110,056       —    

Inventory

        (1,244,944     —    

Biological assets

        (327,676     —    

Accounts payable and accrued liabilities

        1,683,234       21,161  
     

 

 

   

 

 

 
        (774,349     (45,944

Cashflow from Investing Activities

       

Purchase of equipment

     6        (275,841     —    

Purchase of NOR property & equipment, intangibles, and goodwill

     4        (54,770,849     —    

Investment in Xanthic Beverages USA, LLC

     8        (300,000     —    
     

 

 

   

 

 

 
        (55,346,690     —    

Cashflow from Financing Activities

       

Share capital issued on warrants and options exercised

     14        104,040       —    

Promissory note and loan payable in connection with NOR

     11        56,750,000       —    

Private placement of shares, net of issuance costs

     12        —         59,035  
     

 

 

   

 

 

 
        56,854,040       59,035  

Increase in cash and cash equivalents

        733,001       13,091  
     

 

 

   

 

 

 

Cash and cash equivalents, beginning of period

        787,551       19,443  
     

 

 

   

 

 

 

Cash and cash equivalents, end of the period

      $ 1,520,552     $ 32,534  
     

 

 

   

 

 

 

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

 

5


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

1.

Nature of operations

Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Company”) was incorporated under Ontario Business Corporations Act. The Company was acquired by Xanthic Biopharma Limited (“Xanthic”) in a reverse takeover transaction completed on December 15, 2017. As Xanthic has been identified as the accounting acquirer, these financial statements are considered a continuation of Xanthic and any comparative information provided prior to the reverse takeover are those of Xanthic.

On September 4, 2018, the Company completed the acquisition of Nevada Organic Remedies LLC (“NOR”) for aggregate consideration of $56.8 million (see Note 4). NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada and holds four Nevada marijuana licenses including dispensary, cultivation, production and distribution.    

The Company’s common shares were listed for trading on Canadian Securities Exchange (“CSE”) under the symbol xTHC. The Company’s common shares were halted July 17, 2018 with the announcement of the business combination agreement (“Business Combination”) with Green Growth Brands Ltd. (“GGB”) (see Note 20—“Subsequent Events.”).

 

2.

Basis of presentation and going concern

 

(a)

Statement of compliance

The Company’s unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The accounting policies set out below were consistently applied to all periods presented unless otherwise noted.

These unaudited condensed interim consolidated financial statements were reviewed, approved and authorized by the Company’s Board of Directors on November 26, 2018.

 

(b)

Basis of measurement

These unaudited condensed interim consolidated financial statements have been prepared in accordance with IFRS, on the historical cost basis except for certain financial instruments, which are measured at fair value, as explained in the accounting policies set out in Note 3.

 

(c)

Basis of consolidation

These unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement and has the ability to affect those returns through its power to direct the relevant activities of the entity.

 

6


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

 

Subsidiaries

   Jurisdiction of incorporation      Ownership interest  

Xanthic Biopharma Limited

     Ontario, Canada        100

GGB Nevada Pahrump LLC

     Nevada , United States        100

Xanthic Biopharma US Hold Co.

     Nevada , United States        100

GGB Nevada LLC

     Nevada , United States        100

GGB New Jersey LLC

     New Jersey, United States        100

Xanthic Biopharma Nevada LLC

     Nevada , United States        100

Xanthic Colorado LLC

     Nevada , United States        100

Xanthic Biopharma Oregon LLC

     Oregon, United States        100

Xanthic Biopharma California LLC

     California, United States        100

Nevada Organic Remedies LLC

     Nevada , United States        95

 

(d)

Functional and presentation currency

All figures presented in the unaudited condensed interim consolidated financial statements are reflected in United States dollars, which is the reporting currency of the Company. The functional currency of all the Company’s wholly owned subsidiaries is United States dollars with the exception of Xanthic Biopharma Limited. Foreign currency transactions are translated into United States dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the statement of financial position date are translated to United States dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.

 

(e)

Use of estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant estimates include but are not limited to the following:

 

  (I)

Inputs when Black-Scholes valuation model

The estimates used in determining the stock option fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes valuation model. Inputs are subject to estimates include volatility, forfeiture rates, estimated lives and market rates.

 

  (II)

Functional and presentation currency

In determining the functional currency of the parent and its subsidiary companies, management considered the currency that mainly influences sales and the cost of providing goods and services in each jurisdiction in each the Company operates. The Company also considered secondary indicators including the currency in which each funds from financing activities are denominated, the currency in which funds are retained and whether the activities of the subsidiaries are carried out as an extension of the Company or if they are carried out with a degree of autonomy.

 

  (III)

Contingent Consideration

The valuation of the contingent consideration payable to former owners of Xanthic Beverages USA, LLC is subject to estimates surrounding the probability of milestones being made.

 

7


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

  (IV)

Biological Assets

The calculation of the fair value of biological assets takes into consideration various assumptions which require a high degree of judgment. Any changes in these assumptions, would have an impact on the discounted cash flow result, resulting in an appreciation or devaluation of these assets (Note 6).

The main assumptions used by Management to calculate the fair value of the biological assets and the correlation between changes in such premises and the fair value of the biological assets, are described as follows:

 

Assumptions used

  

Impact on fair value of the biological assets

Actual planted area (sq feet)

   Increase of premise, increase of fair value

Average annual growth cycle

   Increase of premise, increase of fair value

Net average sale price

   Increase of premise, increase of fair value

Plant mortality rate

   Decrease of premise, increase of fair value

Average yield per plant

   Increase of premise, increase of fair value

Discount rate

   Increase of premise, increase of fair value

The assumption regarding the “net average sale price” of biological assets (measured in $/gram of dry bud) is supported only in market prices research, in order to maximize the usage of external and independent data to measure the fair value of the biological assets.

 

  (f)

Going Concern

These unaudited condensed interim consolidated financial statements have been prepared using accounting principles applicable to a going concern. The going concern basis assumes that the Company will continue its operations for the foreseeable future, and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. As at September 30, 2018, the Company had negative working capital of $54,786,473 and during the three months ended, it incurred a net loss from operations of $516,344. The uncertainty on the Company’s ability to raise additional finances to fund its operations casts significant doubt upon the Company’s ability to continue as a going concern and the ultimate appropriateness of using accounting principles applicable to a going concern. These unaudited condensed interim consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is not able to continue as a going concern, the Company may be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in these unaudited condensed interim consolidated financial statements. These differences could be material.

 

3.

Significant accounting policies

These unaudited condensed interim consolidated financial statements have been prepared following the same accounting policies used in the preparation of the audited financial statements of the Company for the year ended June 30, 2018 with the exception of the following new accounting policies applied as set out below:

Inventory

Inventory is valued at the lower of cost and net realizable value. Cost is determined using the weighted average method. Inventories of harvested cannabis are transferred from biological assets into inventory at their fair value at harvest less costs to sell, which is deemed to be their cost. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less estimated costs to sell. Packaging and supplies are initially valued at cost.

 

8


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

All inventories are reviewed for impairment due to slow moving and obsolete inventory. The provisions for obsolete, slow moving or defective inventories are recognized in profit or loss. Previous write downs to net realizable value are reversed to the extent there is a subsequent increase in the net realizable value of the inventory.

Biological assets

The Company’s biological assets consist of cannabis plants which are not yet harvested. These biological assets are measured at fair value less costs to sell. The Company capitalizes all related direct and indirect costs of production to the biological assets to fair value less costs to sell at each reporting date. At the point of harvest, the biological assets are transferred to inventory at their fair value less costs to sell.

Gains or losses arising from changes in fair value less cost to sell are included in the results of operations of the related period.

Capital assets

Capital assets are carried at cost less any residual value, accumulated depreciation and impairment losses. Cost includes the acquisition costs or construction costs, as well as the costs directly attributable to bringing the asset to the location and condition necessary for its use in operations. When capital assets include significant components with different useful lives, they are recorded and amortized separately. Depreciation is computed using the straight-line method based on the estimated useful life of the assets.

Amortization is calculated using the following terms and methods:

 

Asset Type

  

Amortization method

  

Amortization term

Furniture and Equipment    Depreciated over the estimated useful life of the asset    5 years
Vehicles    Depreciated over the estimated useful life of the asset    3 years
Manufacturing equipment    Depreciated over the estimated useful life of the asset    3 years
Leasehold Improvements    Amortized over the life of lease or estimated useful    10 years
   life, whichever is less   

The residual value, useful life and depreciation methods are reviewed at the end of each reporting period. Such a review takes into consideration the nature of the asset, the intended use and impact of technological changes. Where parts of an item of capital assets have different useful lives, they are accounted for as separate items of capital assets. Subsequent costs are included in the asset carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

Intangible assets

Intangible assets are stated at cost, net of accumulated amortization and accumulated impairment losses, if any.

Amortization is calculated using the following terms and methods:

 

Asset Type

  

Amortization method

  

Amortization term

Customer relationships    Straight-line    15 years
Developed technology    Straight-line    4 years
Market related intangible assets    Straight-line    4 years
License, permits & applications    Straight-line    Indefinite

 

9


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

The estimated success of applications, useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

Following initial recognition, intangible assets with indefinite useful lives are carried at cost less any accumulated impairment losses.

Goodwill

Goodwill represents the excess of the purchase price paid for the acquisition of subsidiaries over the fair value of the net tangible and intangible assets acquired. Following initial recognition, goodwill is measured at cost less any accumulated impairment losses.

Revenue

Revenue is recognized at the fair value of consideration received or receivable. Revenue from the sale of goods is recognized in accordance with IFRS 15 Revenue from Contracts with Customers which specifies how and when to recognize revenue, based on a five-step model as follows:

 

   

Identify the contract(s) with the customer;

 

   

Identify the performance obligations in the contract;

 

   

Determine the transaction price;

 

   

Allocate the transaction price to the performance obligations in the contract;

 

   

Recognize revenue when or as the Company satisfies performance obligations.

Revenue from the sale of cannabis and CBD-infused products are generally recognized at a point in time when control over the goods have been transferred to the customer. Payment is typically due prior to shipment and is recognized into revenue upon the satisfaction of the performance obligation. The Company satisfies its performance obligation and transfers control upon delivery and acceptance by the customer.

Amounts disclosed as revenue are net of allowances, discounts and rebates.

Reclassified June 30, 2018 Comparative Amounts

Certain items on the consolidated statement of financial position as at June 30, 2018 have been reclassified to conform to the September 30, 2018 presentation. The Company does not believe that these reclassifications had a material effect on the unaudited condensed interim consolidated financial statements, from either a quantitative or a qualitative perspective.

New Accounting Standards Adopted

The following new standards were adopted during the three months ended September 30, 2018:

 

  a)

Revenue

The Company has adopted IFRS 15 Revenue from Contracts with Customers (“IFRS 15”) commencing the be beginning of the period. On adoption of IFRS 15, the Company adopted and implemented the following accounting policy:    

The Company’s revenue is derived from one performance obligation which is to deliver the Company’s product to its customers, either directly through its own dispensary or being each individual dispensary of the Company’s product (the “Customer”). Revenue is recognized when control of the Company’s product is transferred to the Customer and when the Customer obtains control of the Company’s product. The Company considers control to have passed at the point of shipment as all risk of loss or damage to the Company’s product passes to the Customer at this point.

 

10


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

In each period, the Company recognizes revenue, net of any variable consideration, including the right of return. The estimate of expected returns reflects the amount that the Company expects to repay or credit its Customers, using the expected value method. Revenue includes amounts subject to returns only if it is highly probable that there will be no significant reversal of cumulative revenue if the estimate of expected returns changes.

The Company records an adjustment to cost of sales and inventories representing the Company’s right to receive goods back from the Customers. The adjustment to inventories is initially measured at the carrying amount of the products at the time of sale, less any expected costs to recover the product and any expected reduction in value. In subsequent periods, the Company updates its expected level of returns, adjusting the measurement of the returns liability and inventories.

As the Company previously had no revenue there was no retrospective adjustments to the comparative periods.

 

  b)

Financial Instruments

The Company has adopted IFRS 9 Financial Instruments (“IFRS 9”) on July 1, 2018. On adoption of IFRS 9, the Company adopted and implemented the following accounting policy:

Classification

The Company classifies its financial instruments in the following categories: at fair value through profit or loss (“FVTPL”), at fair value through other comprehensive income (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading including all equity derivative instruments are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election on an instrument by instrument basis to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL or the Company has opted to measure them at FVTPL. The Company completed a detailed assessment of its financial assets and liabilities as at July 1, 2018. The following table shows the original classification under IAS 39 Financial Instruments: Recognition and Measurements (“IAS 39”) and the new classification under IFRS 9:

 

Financial Instrument

  

Classification

  

Measurement

Financial assets

     

Cash and cash equivalents

  

Loans and receivables

   Amortized cost

Trade and other receivables

  

Loans and receivables

   Amortized cost

Financial liabilities

     

Accounts payable and accrued liabilities

  

Other Liabilities

   Amortized cost

Other financial liabilities

  

Other Liabilities

   Amortized cost

Inerest bearing loans

  

Other Liabilities

   Amortized cost

Measurement

Financial assets and liabilities at amortized cost:

Financial assets and liabilities at amortized cost are initially recognized at fair value, and subsequently carried at amortized cost less any impairment.

 

11


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

Impairment of financial assets at amortized cost

The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to twelve month expected credit losses. Impairment losses on financial assets carried at amortized cost are reversed in subsequent periods if the amount of the loss decreases and the decrease can be objectively related to an event occurring after the impairment was recognized.

Derecognition

Financial assets

The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are generally recognized in the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss.

Financial liabilities

The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled or expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss.

New standards, amendments and interpretations not yet adopted

A number of new standards and amendments to standards and interpretations have been issued but have not yet been applied in preparing these unaudited condensed interim consolidated financial statements, as set out below:

 

   

In January 2016, the IASB issued IFRS 16, Leases, which will replace IAS 17, Leases. Under IFRS 16, a contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Under IAS 17, lessees were required to make a distinction between a finance lease and an operating lease. IFRS 16 now requires lessees to recognize a lease liability reflecting future lease payments and a right-of-use asset for virtually all lease contracts. There is an optional exemption for certain short-term leases and leases of low value assets; however, this exemption can only be applied by lessees. The standard is effective for annual periods beginning on or after January 1, 2019, with earlier application if IFRS 15 is also applied. The Company has yet to assess the impact of this standard.

 

   

IFRIC 23, Uncertainty over Income Tax Treatments, was issued in June 2017 and clarifies the accounting for uncertainties in income taxes. The interpretation committee concluded that an entity shall consider whether it is probable that a taxation authority will accept an uncertain tax treatment. If an entity concludes it is probable that the taxation authority will accept an uncertain tax treatment, then the entity shall determine taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates consistently with the tax treatment used or planned to be used in its income tax filings. If an entity concludes it is not probable that the taxation authority will accept an uncertain tax treatment, the entity shall reflect the effect of uncertainty in determining the related taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates. IFRIC 23 is effective for annual periods beginning on or after January 1, 2019. Earlier adoption is permitted. The Company has yet to assess the impact of this standard.

 

12


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

 

13


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

4.

Acquisition of Nevada Organic Remedies LLC

On September 4, 2018, the Company acquired 95% of the outstanding membership interest of Nevada Organic Remedies LLC (“NOR” and “NOR Agreement”) through GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of the Company.

The agreed purchase price of $56,750,000 reflects 100% of the membership interest in NOR, which terms provided that the Company acquired 95% on the acquisition date, and that the remaining 5% interest transfer to the Company upon settlement of the promissory note included in the purchase consideration. The aggregate purchase consideration is comprised of $53,912,500 payable in cash in the amount of $32,347,500 and a promissory note in the amount of $21,565,000 with the balance of 5% or $2,837,500 payable in common shares.

On July 17, 2018, GGB Nevada made a payment of US$2,000,000 to NOR as a deposit on the NOR Agreement. On closing the Company signed a loan agreement for US$30,347,500 with Green Growth Brands Ltd. (“GGB”) in connection with the NOR Agreement which closed on the same day. The loan agreement is for a period of 180 days from September 5, 2018 and bears interest at 12% annum. The proceeds of the loan from GGB were used to make the initial payment on closing of the NOR Agreement. In addition, on closing of the NOR Acquisition, GGB Nevada provided to the NOR Members a secured promissory note in the principal amount of US$21,565,000. The acquisition has been accounted for as a business acquisition and includes the operating results of NOR for the 26-day period from the acquisition date.

Below is a preliminary breakdown of the purchase price allocated to the assets acquired. Remeasurement may be made up to September 3, 2019 (one year after the transaction per IFRS 3.45).

 

Fair value of consideration paid:

  

Cash

   $ 32,347,500  

Promissory note

     21,565,000  

Common Shares

     2,837,500  
  

 

 

 
     56,750,000  
  

 

 

 

Cash

   $ 877,027  

Accounts receivable

     276,449  

Other receivables

     58,777  

Inventory

     1,624,095  

Property, plant and equipment

     347,704  

Intangible assets

     32,235,000  

Goodwill

     22,144,742  

Accounts payable and accrued liabilities

     (813,794
  

 

 

 
   $ 56,750,000  
  

 

 

 

Purchase price allocation:

  

Net Identifiable assets acquired

   $ 34,605,258  

Goodwill

     22,144,742  
  

 

 

 

Total acquired

   $ 56,750,000  

Non-controlling interest

     (2,837,500
  

 

 

 

Total attributed

   $ 53,912,500  
  

 

 

 

From the date of acquisition, NOR has contributed $1,700,595 of revenue and contributed $722,734 in earnings towards the Company’s net income for the period ended September 30, 2018.

 

14


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

5.

Inventory

As at September 30, 2018 and June 30, 2018, Inventory is comprised of:

 

     September 30, 2018      June 30, 2018  

Cannabis harvested

   $ 1,135,376      $ —    

Cannabis oil

     69,431        —    

Packaging and supplies

     177,664        137,527  
  

 

 

    

 

 

 
   $ 1,382,471      $ 137,527  
  

 

 

    

 

 

 

 

6.

Biological assets

As at September 30, 2018, Biological assets are comprised of:

 

Balance at June 30, 2018

   $ —    

Production costs capitalized

     966,317  

Changes in fair value less costs to sell due to biological transformation

     371,881  

Transferred to inventory

     (677,906
  

 

 

 

Balance at September 30, 2018

   $ 660,292  
  

 

 

 

 

7.

Property and equipment

As at September 30, 2018 and June 30, 2018, capital assets consisted of:

 

     September 30, 2018      June 30, 2018  

Furniture and fixtures

   $ 97,816      $ —    

Manufacturing equipment

     494,625        42,981  

Vehicles

     26,688        —    

Leasehold Improvements

     302,024        —    
  

 

 

    

 

 

 

Total property, plant and equipment

     921,153        42,981  

Less: Accumulated depreciation and amortization

     211,224        —    
  

 

 

    

 

 

 
   $ 709,929      $ 42,981  
  

 

 

    

 

 

 

Depreciation expense for the three months ended September 30, 2018 was $12,553 (2017 – nil).

 

8.

Equity investment in Xanthic Beverages USA, LLC (formerly Avitas CBD Water, LLC)

On March 22, 2018, the Company completed the investment in Xanthic Beverages USA, LLC (formerly Avitas CBD Water, LLC) (“Xanthic Beverages”). Xanthic Beverages is based in Portland, Oregon, and will be producing and distributing CBD-infused water, co-branded with the Company. Under the terms of the Agreement, the Company acquired a 45% ownership position in exchange for a cash payment of USD$600,000 and a contingent consideration payable of US$300,000 (see Note 9) on achieving certain performance milestones over the next 12 months.

Further, at the Company option, if Xanthic Beverages achieves certain milestones on sales, the Company may issue 600,000 common shares in the Company or a one-time cash payment of up to USD$300,000.

 

15


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

Finally, at the Company’s option, the Company can acquire a further 6% interest in Xanthic Beverages for a one time payment in shares of US$300,000 at the then 60 day average price of the Company’s common shares.

 

     Amount  

Opening Investment in Xanthic Beverages USA, LLC, June 30, 2017 and September 30, 2017

   $ —    

Initial investment

     900,000  

Xanthic share of operating loss

     (45,750
  

 

 

 

Closing balance in Xanthic Beverages USA, LLC at June 30, 2018

     854,250  

investment

     —    

Xanthic share of operating loss

     (15,562
  

 

 

 

Closing balance in Xanthic Beverages USA, LLC at September 30, 2018

   $ 838,688  
  

 

 

 

The Company picks up its share of the loss of Xanthic Beverages USA, LLC for the three months ended September 30, 2018 which was $15,562.

 

9.

Intangible assets and goodwill

As at September 30, 2018 and June 30, 2018, intangible assets consisted of:

 

     September 30, 2018      June 30, 2018  

Customer relationships

   $ 10,680,000      $ —    

Developed technology

     60,000        —    

Market related intangible assets

     380,000        —    

License, permits & applications

     21,115,000        —    
  

 

 

    

 

 

 
   $ 32,235,000      $ —    
  

 

 

    

 

 

 

Goodwill recognized on the purchase of NOR (see Note 4) was $22,144,742.

 

10.

Other financial liabilities

In connection with the Company’s equity investment in Xanthic Beverages, the Company has accounted for the contingent consideration payable of paying up to USD$300,000 or issuing 600,000 common shares of the Company (see Note 8) if Xanthic Beverages achieves certain additional milestones. The Company has assigned a 100% probability that Xanthic Beverages would achieve either of these milestones.

In connection with the Company’s acquisition of NOR, the Company will settle $2,837,500 of the purchase price (see Note 4) in common shares of the Company upon closing of the Business Combination with Green Growth Brands Ltd. (“GGB”).

 

11.

Interest bearing loans

 

     September 30, 2018      June 30, 2018  

Promissory note to NOR members

   $ 21,565,000      $ —    

Promissory note to GGB

     2,000,000        —    

Loan payable to GGB

     30,347,500        —    
  

 

 

    

 

 

 
   $ 53,912,500      $ —    
  

 

 

    

 

 

 

 

16


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

The promissory note is in connection with the purchase of NOR. As a condition of closing on the NOR business acquisition the Company issued a secured promissory note in favour of the members of NOR for $21,565,000. This promissory note bears interest at 6% per annum. The promissory note becomes due and payable six months from the closing date of the business acquisition on September 4, 2018. Interest accrued to September 30, 2018 in connection with NOR promissory note was $107,825.

The Company also has a promissory note obligation to GGB. This promissory note was incurred in connection with the Company’s initial $2,000,000 deposit required to purchase NOR. The promissory note bears interest at 10% if not repaid on or before December 1, 2018 and is unsecured.

On August 30, 2018, the Company also secured a loan from GGB in connection with the closing payment of $30,347,500 to the NOR members. The loan payable to GGB bears interest at 12% per annum. The loan expires 180 days from August 30, 2018 and is secured by shares of its subsidiary GGB Nevada LLC. Interest accrued to September 30, 2018 in connection with the loan payable was $303,475.

 

12.

Shareholder Capital

Authorized share capital

Common Share – voting – unlimited

All historical references to share transactions or balances prior to this date have been recast on an eight for one basis unless otherwise stated.

Outstanding share capital

 

     Common Shares      Amount  

Outstanding at June 30, 2017

     7,000,000      $ 20,065  

For the three months ended September 30, 2017

     

Common Shares issued for cash

     3,700,000        59,176  
  

 

 

    

 

 

 

Outstanding at September 30, 2017

     10,700,000        79,241  

Transactions from October 1, 2017 to June 30, 2018

     

Common Shares issued for cash

     39,688,000        2,641,833  

Issuance Costs

     —          (116,974

Issuance of shares in RTO

     6,458,547        613,089  
  

 

 

    

 

 

 

Outstanding at June 30, 2018

     56,846,547        3,217,189  

For the three months ended September 30, 2018

     

Common Shares issued for cash

     900,000        104,040  
  

 

 

    

 

 

 

Outstanding at September 30, 2018

     57,746,547      $ 3,321,229  
  

 

 

    

 

 

 

On November 21, 2017, Xanthic completed a non-brokered private placement by issuing 160,000,000 (20,000,000 common shares before the share split of 1 for 8) common shares for gross proceeds of $400,000.

On December 13, 2017, prior to the completion of the RTO transaction noted above Xanthic completed a non-brokered private placement by issuing 82,016,000 (10,252,000 common shares before the share split of 1 for 8) common shares for net proceeds of $1,194,144 net of issue costs of $87,356.

On December 15, 2017, the Company completed the previously discussed (see Note 4) RTO by issuing 51,668,184 (6,458,547 common shares after the share consolidation of 8 for 1) common shares to Xanthic shareholders.

On January 16, 2018, the Company completed a non-brokered private placement by issuing 96,000,000 common (12,000,000 common shares after the consolidation of 8 for 1) shares for gross proceeds of $1,500,000.

 

17


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

On February 26, 2018, the Company completed an 8 for 1 consolidation of the common shares outstanding, after receiving shareholder approval at its annual general and special shareholder meeting.

On April 19, 2018, the Company closed a non-brokered private placement for gross proceeds of $556,000. The Company issued 1,112,000 units (the “Units”) at a price of $0.50 per Unit. Each Unit will be comprised of one common share in the Company and one-half of one (1/2) common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one common share at an exercise price of $0.75 per common share for a period of 24 months from the closing date of the private placement. The Company paid to certain finders an aggregate finder’s fee of $18,000 and 24,000 Units comprised of 24,000 common shares and 12,000 Warrants, having the same attributes as the Units.

 

13.

Warrants

The following table reflects the continuity of warrants for the periods presented:

 

     Number of
Warrants
     Weighted
Average
Exercise Price
 

Balance outstanding, July 1, 2018

     568,000      $ 0.75  

Issued

     —          —    

Expired

     —          —    
  

 

 

    

 

 

 

Balance outstanding, September 30, 2018

     568,000      $  0.750  
  

 

 

    

 

 

 

On April 19, 2018, in conjunction with the non-brokered private placement, the Company issued 556,000 warrants at an exercise price of $0.75 per share, exercisable until April 18, 2020. There were 12,000 finders’ warrants granted in connection with this private placement.

 

14.

Stock based compensation

Stock Option Plan

The shareholders of the Company have approved a stock option plan (the “SOP”) pursuant to which the Company may issue up to 5,774,654 common shares of the Company to employees, directors and officers. The exercise price of each option issued pursuant to the terms of the SOP shall be established at the grant date by the directors of the Company and in all cases shall not be less than the closing price of the common shares of the Company on the trading day immediately preceding the grant date. Options are generally issued with a five-year term from the date of grant and are subject to vesting conditions whereby one third of the options granted vest immediately, with the remaining two thirds vesting over a two-year period. In connection with the Business Combination (see “Note 4”) the board approved the immediate vesting of all outstanding stock options.

During the year ended June 30, 2018, the Company granted 4,208,000 stock option awards at an exercise prices ranging from $0.125 to $0.60 per option. The fair value of the options granted was estimated at the grant date using an option pricing model.

A summary of the status of the stock option component of the Company’s SOP as at and for the period ended September 30, 2018, is as follows:

 

18


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

     Stock Options      Weighted
Average
Exercise Price
 

Options outstanding, July 1, 2018

     3,508,000      $  0.189  

Options granted

     —          —    

Exercised

     (900,000      0.117  

Forfeited

     —          —    
  

 

 

    

 

 

 

Options outstanding, September 30, 2018

     2,608,000      $ 0.202  
  

 

 

    

 

 

 

Exercisable options

     2,608,000      $ 0.202  
  

 

 

    

 

 

 

 

Option price

   Options
Outstanding
     Weighted
Average
Exercise Price
     Weighted Ang
Remaining
Contractual
Life (Yrs.)
     Options
Exercisable
 

At $ 0.125

     1,908,000      $ 0.125        4.41        1,908,000  

At $ 0.16

     300,000      $ 0.160        0.65        300,000  

At $ 0.60

     400,000      $ 0.600        4.55        400,000  

During the three months ended September 30, 2018, the Company recognized stock-based compensation expense of $139,355 in respect of outstanding stock options.

A summary of the vesting schedule of stock options are as follows:

 

Vesting Schedule

      

Immediate

     2,208,000  

1 year

     400,000  

2 years

     —    

Subsequent to September 30, 2018, 1,308,000 stock options were exercised.

 

15.

Related parties

Related parties include the Board of Directors and key management, close family members and entities that are controlled by these individuals, as well as certain persons performing similar functions. At September 30, 2018 there were receivables from related parties of $112,296 and payables due to related parties of $178,737 for a net amount due to related parties of $66,441, which was indebtedness to key members of management of the Company.

NOR, through its cultivation and production operations sells cannabis products to dispensaries owned by members of NOR. During the three months ended September 30, 2018 NOR sold $219,895 to related parties. The balance due from related parties are netted in due from related parties and amount to $4,103.

 

19


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

Management compensation

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling activities of the entity, directly or indirectly including the Chief Executive Officer, President, and Chief Financial Officer and equivalent, and Directors. For the three months ended September 30, 2018, the Company’s expenses included $108,639 respectively for salary or consulting fees paid to key management personnel, included in consulting fees. In addition, included in stock-based compensation expense is $85,589 in connection with stock awards to management and Directors.

 

16.

Income taxes

 

For the three months ended September 30,

   2018     2017  

Loss before income taxes

   $ (516,344   $ (59,573

Statutory rate

     26.5     26.5
  

 

 

   

 

 

 

Expected income tax recovery at combined basic federal and provincial tax rates

     (136,831     (15,787

Effect on income taxes of:

    

Non-deductible expenses

     37,459       —    

Non-taxable fair value adjustment on biological assets

     (88,143  

Deductible purchase interest

     —      

Changes in tax benefits not recognized

     187,515       15,787  
  

 

 

   

 

 

 

Income tax expense

   $ —       $ —    
  

 

 

   

 

 

 

 

17.

Capital management

The Company’s objective in managing capital is to ensure a sufficient liquidity position to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. In order to achieve this objective, the Company prepares budgets and capital requirements to manage its capital structure. The Company defines capital as equity and borrowings, comprised of issued share capital, share-based payments, accumulated deficit, as well as due to related parties.

Since inception, the Company has primarily financed its liquidity needs through issuance of shares.

The Company is not subject to externally imposed capital requirements.

 

18.

Financial instruments and risk management

Financial instruments

The Company has classified its cash and contingent consideration payable as fair value through profit and loss (“FVTPL”), and accounts receivable, other receivable as current assets, accounts payable and accrued liabilities, due to related parties and promissory note and loan payable as current liabilities.

The carrying values of cash, accounts receivable, other receivable, accounts payable and accrued liabilities, due to related parties, contingent consideration payable and promissory note and loan payable approximate their fair values due to their short periods to maturity.

 

20


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

Fair value hierarchy

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The hierarchy is summarized as follows:

Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities

Level 2 – inputs that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices) from observable market data Level 3 – inputs for assets and liabilities not based upon observable market data

 

            Fair value as at September 30, 2018  
     Carrying value as at
September 30, 2018
     Quoted prices in
Active Markets for
Identical Assets
(Level 1)
     Significant Other
Observable Inputs
(Level 2)
     Significant
Unobservable Inputs
(Level 3)
 

Financial Assets

           

Cash

   $ 1,520,552      $ 1,520,552      $ —        $ —    

Financial Liabilities

           

Other financial liabilities

     3,137,500        —          —          3,137,500  

Financial risk factors

The Company’s risk exposure and the impact on the Company’s financial instruments are summarized below:

 

(a)

Credit risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and other receivables. The Company’s cash is held at a major Canadian bank and in trust with lawyers. The Company’s other receivables is with Revenue Canada in connection with input tax credits. The Company regularly monitors the credit risk exposure and takes steps to mitigate the likelihood of these exposures resulting in actual loss.

 

(b)

Liquidity risk

The Company is exposed to liquidity risk or the risk of not meeting its financial obligations as they come due as discussed in Note 2 (e) above. The Company constantly monitors and manages its cash flows to assess the liquidity necessary to fund operations. All of the Company’s financial liabilities are due within one year.

 

(c)

Interest rate risk

The Company is not subject to any significant interest rate risk from its liabilities other than noted in connection with the promissory note (Note 11), which are all non-interest bearing instruments.

 

19.

Accounts payable and accrued liabilities

 

     September 30, 2018      June 30, 2018  

Trade payables

   $ 888,986      $ 46,563  

Accrued liabilities

     846,555        70,675  
  

 

 

    

 

 

 
   $ 1,735,541      $ 117,238  
  

 

 

    

 

 

 

 

21


XANTHIC BIOPHARMA INC.

Notes to the unaudited Condensed Interim Consolidated Financial Statements

For the three months ended September 30, 2018 and September 30, 2017

 

20.

Segmented information

The Company operates in one reportable operating segment, being the operations in Nevada through its subsidiary NOR.

 

21.

Subsequent event

On November 9, 2018 the Company closed the previously announced Business Combination with GGB following the Company receiving shareholder approval on November 2, 2018 at its annual and special meeting.

Following the close of the Business Combination on November 9, 2018 all of the issued and outstanding GGB Shares were acquired by the Company, and as consideration, the Company issued to the GGB shareholders, on a 3.43522878-for-one basis, 414,105,455 common shares in exchange for the then issued and outstanding GGB shares (which for greater certainty excluded the GGB shares and GGB warrants issued in connection with the conversion of the GGB convertible debentures). In addition, the Company reorganized its share structure and consolidated all of the issued and outstanding shares on the basis of four (4) pre-Consolidation shares for one (1) post-Consolidation share.

Following the completion of the Business Combination, previous GGB shareholders hold approximately 103,526,364 shares (excluding any shares and warrants ultimately issuable upon conversion of the GGB convertible debentures), representing approximately 62.4% of the Company’s shares issued and outstanding on a non-diluted basis. A deemed value of C$0.36 per share was placed on the Company’s shares issued in connection with the Business Combination, resulting in total consideration paid to the holders of GGB shares of approximately C$149 million. The Company’s shareholders that are insiders of the Company own 1,513,333 shares and the existing Company shareholders that are not insiders of the Company own 12,923,303 shares, representing 0.91% and 7.79% of the Company’s shares issued and outstanding, respectively, on a non-diluted basis.

The Business Combination will constitute a reverse takeover transaction by GGB and the Company is considered to have met the definition of a business, as defined in IFRS 3 – Business Combinations due to its productive operating potential.

The Company resumed trading on the CSE on November 13, 2018 under the stock symbol GGB following the final approval from the CSE.

 

22


LOGO

XANTHIC BIOPHARMA INC.

MANAGEMENT DISCUSSION AND ANALYSIS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2018


MANAGEMENT DISCUSSION AND ANALYSIS

Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company” or the “Corporation”) was incorporated under the Ontario Business Corporations Act. Xanthic was acquired by Xanthic Biopharma Limited in a reverse takeover transaction completed on December 15, 2017. Xanthic is in the business of cultivation, processing and retailing of cannabis, tetrahydrocannabinol, cannabidiol (“CBD”), and cannabis-infused consumer products. Over the next 12 months, the Company intends to expand its retail and wholesale cannabis businesses as well as its CBD consumer products business through a combination of strategic partnerships, merger and acquisition activity, and organic license capture. The Company’s objectives are to establish retail cannabis locations, or otherwise apply for such licenses, in various states within that timeframe, pursuant to state laws. Such activity will focus on those certain states where cannabis has been legalized for medical and/or recreational use at the state level.

The Corporation’s registered office is 77 King St. West Suite 2905, Toronto, Ontario, M5K 1H1.

This Management’s Discussion and Analysis (“MD&A”) has been prepared with an effective date of November 26, 2018 and provides an update on matters discussed in, and should be read in conjunction with, the Corporation’s audited financial statements, including the notes thereto, as at and for year ended June 30, 2018 (the “2018 Audited Consolidated Financial Statements”) and the unaudited condensed interim consolidated financial statements for the three months ended September 30, 2018 (the “September 2018 Interim Financial Statements”), which have been prepared using International Financial Reporting Standards (“IFRS”).

All amounts are in United States dollars unless otherwise specified. Tabular dollar amounts, unless otherwise specified, are in dollars, except for per unit or per share amounts. This MD&A contains forward looking statements that are based on certain estimates and assumptions and involve risks and uncertainties. Actual results may vary materially from management’s expectations. See the “Caution Concerning Forward Looking Statements” section in this MD&A.

In this MD&A, reference is made to gram equivalents, “all-in” cost of sales, gross profit before fair value adjustments, adjusted gross margin, adjusted EBITDA, capital and intangible asset expenditures – wholly owned subs which are not measures of financial performance under IFRS. The Corporation calculates each as follows:

“Gram equivalents” include both grams of dried cannabis as well as grams of cannabis oil as derived using the an ‘equivalency factor’ of 1 gram per 4.5 mL of cannabis oil, prior period ‘equivalency factor’ of 1 gram per 4.5 mL of cannabis oil. Management believes this measure provides useful information as a benchmark of the Corporation against its competitors.

“All-in” cost of sales of dried cannabis per gram is equal to production costs less the costs of accessories less cannabis oil conversion costs (“cost of sales of dried cannabis”) plus (minus) increase (decrease) in plant inventory divided by gram equivalents of cannabis sold in the quarter. This measure provides the cost per gram of dry cannabis and gram equivalent of oil sold before the packaging and post harvesting processing costs to create oil or other ancillary products.

Gross profit before fair value adjustments is equal to gross profit less the non-cash increase (plus the non-cash decrease) in the fair value adjustments on sale of inventory and on growth of biological assets, if any. Management believes this measure provides useful information as it removes fair value metrics tied to increasing stock levels (decreasing stock levels) required by IFRS.

Adjusted gross margin is gross profit before fair value adjustments divided by revenue. Management believes this measure provides useful information as it represents the gross profit based on the Corporation’s cost to produce inventory sold and removes fair value metrics tied to increasing stock levels (decreasing stock levels) required by IFRS.


Adjusted EBITDA is net income (loss), plus (minus) income taxes (recovery) plus (minus) finance income, net, plus amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on sale of inventory and on growth of biological assets, plus impairment of intangible assets, plus transaction costs, plus (minus) loss (gain) on disposal of capital assets, plus (minus) loss (gain) on foreign exchange, plus (minus) loss (gain) on marketable securities, plus (minus) loss (gain) from equity investee, minus deferred gain on sale of intellectual property, plus (minus) loss (gain) on dilution of ownership in equity investee, plus (minus) unrealized loss (gain) on convertible notes receivable, plus (minus) loss (gain) on long-term investments and certain one-time non-operating expenses, as determined by management. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash generated by operations.

These measures are not necessarily comparable to similarly titled measures used by other companies.

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements in this MD&A may contain “forward-looking information,” within the meaning of applicable securities laws, including the “safe harbour provisions” of the Securities Act (Ontario) with respect to the Corporation. Such statements include, but are not limited to, statements with respect to expectations, projections, or other characterizations of future events or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to our plans and objectives, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities. These statements are subject to certain risks, assumptions and uncertainties that could cause actual results to differ materially from those included in the forward-looking statements. The words “believe”, “plan”, “intend”, “estimate”, “expect”, or “anticipate”, and similar expressions, as well as future or conditional verbs such as “will”, “should”, “would”, and “could” often identify forward-looking statements. We have based these forward-looking statements on our current views with respect to future events and financial performance. With respect to forward looking statements contained in this MD&A, the Corporation has made assumptions and applied certain factors regarding, among other things: future product pricing; costs of inputs; its ability to market products successfully to its anticipated clients; reliance on key personnel; the regulatory requirements; the application of federal and state environmental laws; and the impact of increasing competition. These forward-looking statements are also subject to the risks and uncertainties discussed in the “Risks Factors” section of the CSE listing Statement as filed on SEDAR and elsewhere in this MD&A and other risks detailed from time to time in the publicly filed disclosure documents of the Corporation which are available at www.sedar.com. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which could cause actual results to differ materially from the conclusions, forecasts, or projections anticipated in these forward-looking statements. Because of these risks, uncertainties, and assumptions, the reader should not place undue reliance on these forward-looking statements. The Corporation’s forward-looking statements are made only as of the date of this MD&A, and except as required by applicable law, the Corporation undertakes no obligation to update or revise these forward-looking statements to reflect new information, future events or circumstances.

GOING CONCERN ASSUMPTION AND EARLY STAGE CORPORATION

The Corporation was incorporated March 15, 2017. The Corporation’s ability to continue as a going concern is dependent upon the ability to raise the necessary capital to finance development the Corporation’s business strategy of a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary non-combustible methods and expansion of its Nevada Organic Remedies LLC (“NOR”) business activities in Nevada. The 2018 Audited Consolidated Financial Statements do not give effect to any adjustments which would be necessary should the Corporation be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business. The amounts the Corporation may realize on the disposition of its assets or the discharging of its liabilities in other than the normal course of its


business may be significantly different than the carrying value of these assets and liabilities as reflected in the 2018 Audited Consolidated Financial Statements.

OVERVIEW OF THE CORPORATION

Description of Business

Xanthic is in the business of cultivation, processing and retailing of cannabis, tetrahydrocannabinol, cannabidiol (“CBD”), and cannabis-infused consumer products. Over the next 12 months, the Company intends to expand its retail and wholesale cannabis businesses as well as its CBD consumer products business through a combination of strategic partnerships, merger and acquisition activity, and organic license capture. The Company’s objectives are to establish retail cannabis locations, or otherwise apply for such licenses, in various states within that timeframe, pursuant to state laws. Such activity will focus on those certain states where cannabis has been legalized for medical and/or recreational use at the state level.

With the NOR acquisition completed on September 4, 2018, the Corporation has a vertically-integrated cannabis company operating in the State of Nevada, which holds licenses for dispensing, cultivating, producing and distributing cannabis to both medical and retail marijuana customers. Through its cultivation and production operations, NOR produces high quality medical and retail marijuana products that are sold through its retail location and sold wholesale to various other dispensaries. NOR’s Las Vegas area dispensary is considered a premier dispensary, receiving top ratings by multiple local publications. NOR operates its dispensary under the brand “The Source” and offers a comprehensive line of medicinal and retail marijuana, edibles, concentrates, CBD, and topicals. Since July 1, 2017, with expanded legalization in Nevada, NOR’s customer base has expanded to include “adult-use” or retail customers, who do not require a prior medical diagnosis and applicable registration in order to legally purchase cannabis. Additionally, NOR produces a line of high quality medical and recreational products under the name 8|fold.

Recent Developments

On September 4, 2018, the Corporation through GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary, completed the previously announced purchase of NOR from its members (“NOR Members”) pursuant to which it acquired (the “NOR Acquisition”) 95% of the outstanding membership interests of NOR for aggregate consideration of $56,750,000 payable by a combination of cash, and a promissory note. On July 16, 2018, Xanthic borrowed $2,000,000 from Green Growth Brands Ltd. (“GGB”) pursuant to a promissory note with a due date of December 1, 2018 and bears interest at a rate of 6% per annum and on July 17, 2018, Xanthic advanced the proceeds of the loan to GGB Nevada which in turn made a payment of $2,000,000 to NOR as a deposit on the NOR Agreement. Further, Xanthic borrowed an additional $30,347,500 from GGB pursuant to the terms of a loan agreement (the “Loan Agreement”) dated August 30, 2018. The proceeds were used to make the initial cash payment required pursuant to the NOR Agreement in connection with the closing of the NOR Acquisition. In addition, on closing of the NOR Acquisition, GGB Nevada delivered to the NOR Members a secured promissory note (the “Purchase Note”) in the principal amount of $21,565,000. The Purchase Note matures on March 3, 2019 and bears interest at 6% per annum and is fully secured by general security interest over the assets of NOR. The Loan Agreement matures on the date that is 180 days from September 5, 2018, bears interest at 12% per annum and has been secured by a pledge over the shares of GGB Nevada. The balance of the 5% or $2,837,500 to the NOR Members was satisfied by the issuance of common shares of the resulting issuer following completion of the business combination with GGB, which was completed November 9, 2018, subsequent to September 30, 2018.

On November 2, 2018, the Xanthic shareholders overwhelming approved the business combination agreement with GGB, which was previously announced, and through which Xanthic entered into an arm’s length business combination agreement, dated July 13, 2018 (as amended by agreement between Xanthic and GGB dated August 30, 2018, the “Definitive Agreement”) to combine Xanthic and GGB by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).


GGB is a lifestyle-oriented, consumer products company that celebrates health, wellness and happiness. GGB is focused on the medicinal and recreational cannabis sector in both the United States and Canada and is the parent company of the CAMP brand. GGB is led by the widely-renowned retailer Peter Horvath. The Business Combination represents the initial step in GGB’s strategy to grow its international footprint, through partnerships with cannabis cultivators and processors across Canada and the United States. While GGB’s principal focus will be to build a retail network, it will leverage Xanthic’s expertise in the science of tetrahydrocannabinol (“THC”) and CBD, the two key active ingredients in cannabis.

Following completion of the Business Combination, shareholders of GGB hold approximately 86% of the common shares (the “Resulting Issuer Shares”) of the resulting issuer (the “Resulting Issuer”) (excluding any Resulting Issuer Shares that become issuable pursuant to the terms of GGB’s private placement of convertible debentures (the “Debenture Private Placement”) and subsequent GGB private placement of subscription receipts (the “Subscription Receipt Private Placement”). It is anticipated that the Resulting Issuer will operate under the name “Green Growth Brands Ltd.” after effecting a name change (the “Name Change”) with the Resulting Issuer Shares listed and posted for trading on the Canadian Securities Exchange (the “Exchange” or the “CSE”).    The Corporation resumed trading on the CSE on November 13, 2018.

Resulting Issuer

The following table sets forth the pro forma capitalization of the Resulting Issuer after giving effect to the Business Combination and the 4 for 1 share consolidation but prior to giving effect to the Subscription Receipt Private Placement and the Debenture Private Placement:

 

Equity    Shares(1)      Shares(2)  

(Resulting Issuer Shares)

   (#)      (%)  

Held by current GGB Shareholders

     103,526,364        87.8

Held by current Xanthic Shareholders that are insiders of Xanthic

     1,513,333        1.3

Held by current Xanthic Shareholders that are not insiders of Xanthic

     12,923,303        10.9
  

 

 

    

 

 

 

Total

     117,963,000        100
  

 

 

    

 

 

 

 

(1)

Does not give effect to exercise and/or conversion of issued and outstanding Xanthic convertible securities.

(2)

Expressed on a non-diluted basis.

Corporate Outlook and Strategy

The Corporation is in its startup phase, as previously noted, and, following the Business Combination with GGB the Corporation’s business strategy is to be a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary non-combustible methods.    

The Corporation’s strategy will be focused initially in certain states in the United States where cannabis has been legalized for recreational or medical use. Over the next twelve months, the Corporation intends to expand its retail and wholesale cannabis businesses, as well as its CBD consumer products businesses through a combination of strategic partnerships, merger and acquisition activity, and organic license capture. Its objectives are to establish retail cannabis locations, or otherwise apply for such licenses, in various states within that timeframe, pursuant to state laws as fully outlined in the Corporation’s CSE Listing Statement as can be found on SEDAR.

NOR Acquisition Accounting

On September 4, 2018, as previously mentioned the Corporation completed the acquisition of NOR, a cultivator, processor, and retailer of cannabis and cannabis-infused products. The Corporation purchased through GGB Nevada, a wholly-owned subsidiary of the Corporation 95% of the outstanding membership interests of NOR for aggregate consideration of $56,750,000 payable by a combination of cash, and a promissory note. On July 16, 2018,


Xanthic borrowed $2,000,000 from GGB pursuant to a promissory note with a due date of December 1, 2018 and bears interest at a rate of 6% per annum. On July 17, 2018, Xanthic advanced the proceeds of the loan to GGB Nevada which in turn made a payment of $2,000,000 to NOR as a deposit on the NOR Agreement. Further, Xanthic borrowed an additional $30,347,500 from GGB pursuant to the terms of a Loan Agreement dated August 30, 2018. The proceeds were used to make the initial cash payment required pursuant to the NOR Agreement in connection with the closing of the NOR Acquisition. In addition, on closing of the NOR Acquisition, GGB Nevada delivered to the NOR Members a secured promissory note in the principal amount of $21,565,000. The promissory note matures on March 3, 2019 and bears interest at 6% per annum and is fully secured by general security interest over the assets of NOR. The Loan Agreement matures on the date that is 180 days from September 5, 2018, bears interest at 12% per annum, and has been secured by a pledge over the shares of GGB Nevada. The balance of 5% or $2,837,500 to the NOR Members was satisfied by the issuance of common shares of the resulting issuer following completion of the business combination with GGB, which was completed November 9, 2018, subsequent to September 30, 2018.    

The acquisition has been accounted for as a business acquisition and includes the operating results of NOR for the 26 -day period from the acquisition date.    

Below is a preliminary breakdown of the purchase price allocated to the assets acquired. Remeasurement may be made up to September 3, 2019 (one year after the transaction per IFRS 3.45).

 

Fair value of consideration paid:

  

Cash

   $ 32,347,500  

Promissory note

     21,565,000  

Common Shares

     2,837,500  
  

 

 

 
     56,750,000  
  

 

 

 

Cash

   $ 877,027  

Accounts receivable

     276,449  

Other receivables

     58,777  

Inventory

     1,624,095  

Property, plant and equipment

     347,704  

Intangible assets

     32,235,000  

Goodwill

     22,144,742  
  

 

 

 

Accounts payable and accrued liabilities

     (813,794
  

 

 

 
   $ 56,750,000  
  

 

 

 

Purchase price allocation:

  

Net Identifiable assets acquired

   $ 34,605,258  

Goodwill

     22,144,742  

Total acquired

   $ 56,750,000  

Non-controlling interest

     (2,837,500
  

 

 

 

Total attributed

   $ 53,912,500  
  

 

 

 

OVERALL FINANCIAL PERFORMANCE AND HIGHLIGHTS

 

For the three months ended September 30,

   2018     2017  

Revenue

   $ 1,770,595     $ —    

Revenue per sq ft. (annualized)

     11,277       —    

Grams equivalent sold

     230,694       —    

Production costs

     876,267       —    

“All-in” cost of sales of dried cannabis / gram 1

     3.80       —    

Adjusted gross margin

     51     —    

Adjusted EBITDA

     (688,041     (59,573

Cash and cash equivalents

     1,520,552       787,551  

Working capital

   $ (54,786,473   $ 517,604  
  

 

 

   

 

 

 

 

1

- Non-GAAP measure


 

Revenue reflects revenue from NOR operations from September 4, 2018 to close of the period at September 30, 2018.

 

 

NOR continues to enjoy one of the highest sales per sq. ft. in the industry in Nevada as evidenced by its annualized $11,277 per sq. ft. rate.

 

 

NOR’s “All in” cost of sales of dried cannabis is $3.80 for the period since the acquisition date to the end of the period.

 

 

The Corporation’s adjusted gross margin percentage for the period ended September 30, 2018 was 51%. This is consistent with management’s expectations.

 

 

The Corporation’s negative working capital at September 30, 2018 is a result of the funds borrowed from GGB in connection with the acquisition of NOR. The loans were subsequently settled and eliminated on the closing of the Business Combination, which occurred on November 9, 2018.

Below is a summary of the Corporation financial performance for the three months ended September 30, 2018. During the three months ended September 30, 2018 the Corporation had a net loss from operations of $533,887. This compares to a net loss of $59,573 in the same period of the prior year.

 

For the three months ended September 30,

   2018      2017  

Revenue

   $ 1,770,595      $ —    

Net loss from operations

     (533,887      (59,573

Net Loss per share

   $ (0.01    $ (0.01
  

 

 

    

 

 

 

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Corporation calculates adjusted EBITDA from operations as net income (loss), plus (minus) income taxes (recovery), plus (minus) finance income, net, plus amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on sale of inventory and on growth of biological assets, plus impairment of intangible assets, plus transaction costs, plus (minus) loss (gain) on disposal of capital assets, plus (minus) loss (gain) on foreign exchange, plus (minus) loss (gain) on marketable securities, plus (minus) loss (gain) from equity investee, minus deferred gain on sale of intellectual property, plus (minus) loss (gain) on dilution of ownership in equity investee, plus (minus) unrealized loss (gain) on convertible notes receivable, plus (minus) loss (gain) on long-term investments and certain one-time non-operating expenses, as determined by management, all as follows:

 

For the three months ended September 30,

   2018      2017  

Sales and marketing

   $ 31,399      $ 8,140  

Legal and professional

     150,882        1,762  

General and administration

     992,242        49,488  

Interest and bank charges

     407,846        40  
  

 

 

    

 

 

 
     1,582,369        59,430  

Adjusted EBITDA

     (688,041      (59,430
  

 

 

    

 

 

 

During the three months ended September 30, 2018 the Corporation had an adjusted EBITDA loss of $688,041 compared with $59,430 in the same period of the prior year. During the three months ended of the prior year the Corporation had just been formed and was formulating its team and business strategy.

NOR Operating Results

NOR produces high quality medical and retail marijuana products that are sold through its retail location and sold wholesale to various other dispensaries. NOR’s Las Vegas area dispensary is considered a premier dispensary, receiving top ratings by multiple local publications. NOR operates its dispensary under the brand “The Source” and offers a comprehensive line of medicinal and retail marijuana, edibles, concentrates, CBD, and topicals.


NOR also operates 12,000 square feet of cultivation and production space. NOR’s cultivation capabilities include the use of energy-efficient LED lights during cultivation, integrated pest management practices that reduce the need for pesticides, and use of CO2 as a more environmentally conscious extraction method. NOR also utilizes rockwool as a growing medium, providing a more efficient use of space and reducing the waste of thousands of pounds of soil and soil amendments in the cultivation process.

Revenue

As previously indicated the Corporation completed the acquisition of NOR on September 4, 2018 and the following operating results of NOR reflect approximately one month of operating results of NOR since the acquisition date.    Below is breakdown of revenue from NOR between its direct to consumer business and its wholesale business. NOR sells excess production capacity to other dispensaries in the state of Nevada.    

 

For the three months ended September 30,

   2018      2017      2018     2017  
                   (Percentages)  

Direct to Consumer

   $ 1,304,645      $ —          74     0

Wholesale

     465,950        —          26     0
  

 

 

    

 

 

    

 

 

   

 

 

 
     1,770,595        —          100     0
  

 

 

    

 

 

    

 

 

   

 

 

 

Gross profit

 

For the three months ended September 30,

   2018     2017      2018     2017  
                  (Percentages)  

Revenue

   $ 1,770,595     $ —          100     0

Cost of Sales

         

Production costs

     (779,089     —          -44     0

Other cost of sales

     (97,178     —          -5     0
  

 

 

   

 

 

    

 

 

   

 

 

 

Gross profit before fair value adjustments

     894,328       —          51     0

Gross margin

     51       
         

Gross profit by sales channel

 

For the three months ended September 30,

   2018      2017      2018     2017  
                   (Percentages)  

Direct to Consumer

   $ 744,041      $ —          57     0

Wholesale

     150,287        —          32     0
  

 

 

    

 

 

    

 

 

   

 

 

 
     894,328        —          51     0
  

 

 

    

 

 

    

 

 

   

 

 

 

NOR operates its own dispensary called “The Source” and sells direct to medical and recreational customers from this one location. In addition, NOR sells its excess cultivation and production to other licensed dispensaries in the state. As noted above, NOR has a 57% margin on its direct to customer sales channel and 32% margin on its wholesale sales channel for an overall average of 51% gross margin.

NOR liquidity and capital resources

Cash flow generated from NOR operations since the acquisition date of September 4, 2018 was $84,790. NOR maintains and operates its own cash flow and capital resources to fund its operations. As at September 30, 2018 $1,083,000 in cash and cash equivalents and a positive working capital of $2,495,000.

Fair value measurements

In accordance with IFRS, the Corporation is required to record its biological assets at fair value. During the main growth phase, the cost of each plant is accumulated on a weekly basis. This occurs from the date of clipping from a mother plant up to the end of the twelfth week of growth. For the remainder of the growing period, the cost of each plant continues to be accumulated on a weekly basis but also includes an allocation of the fair value of the plant. At the time of harvest, the Corporation increases the carrying value of the harvested produce to its full fair value less costs to sell.    

At September 30, 2018, the Corporation’s inventory and biological assets consists of the following:


Inventory

 

     September 30, 2018      June 30, 2018  

Cannabis harvested

   $ 1,135,376      $ —    

Cannabis oil

     69,431        —    

Packaging and supplies

     177,664        137,527  
  

 

 

    

 

 

 
   $ 1,382,471      $ 137,527  
  

 

 

    

 

 

 

Biological assets

     

Balance at June 30, 2018

      $ —    

Production costs capitalized

        966,317  

Changes in fair value less costs to sell due to biological transformation

        371,881  

Transferred to inventory

        (677,906
     

 

 

 

Balance at September 30, 2018

      $ 660,292  
     

 

 

 
Corporate Expenses      

For the three months ended September 30,

   2018      2017  

General and administration

   $ 992,242      $ 49,488  

Legal and professional fees

     150,882        1,762  

Stock based compensaton

     139,355        —    

Advertising and promotion

     31,399        8,140  

Depreciation and amortization

     12,553        —    

Loss on equity investment in Xanthic Beverages USA, LLC

     15,562        —    

Interest and bank charges

     407,846        40  

Foreign exchange loss (income)

     (6,551      143  
  

 

 

    

 

 

 
     1,743,288        59,573  

Net loss per share

   $ (0.01    $ (0.01
  

 

 

    

 

 

 

During the three months ended September 30, 2018, the Corporation incurred $992,242 in general and administration costs which include salaries and consulting fees to senior management, accounting, corporate finance work and strategic advisory services. This compares to $49,488 in the same period of the prior year. The Corporation, for the three months ended September 30, 2018 had $150,882 in legal and professional fees associated with investor relations and legal activities this compares to $1,762 in the same period of the prior year. The increase in legal and professional relates to general legal general legal work on corporate governance and licensing the Corporation’s product.

The Corporation incurred during the three months ended September 30, 2018 stock-based compensation expense of $139,355 in connection with stock options granted. This compares to nil in the same period of the prior year. The Corporation incurred expenses in developing its brand, packaging and artistic elements in anticipation of its product launch in the latter half of 2018 of $31,399 compared with $8,140 in the same period of the prior year.

The Corporation incurred interest and bank charges of $407,846 during the three months ended September 30, 2018 compared with $40 in the same period of the prior year. The interest relates to interest due on the loan payable to GGB. Interest on this loan arrangements amounted to $411,300.

The Corporation recorded a loss of $15,562 on its share of its equity accounted investment in Xanthic Beverages for the three months ended September 30, 2018. Xanthic Beverages commenced operations in March 2018 with the Corporation’s investment of the initial USD$600,000. The loss represents startup costs for Xanthic Beverages.


SELECTED QUATERLY FINANCIAL INFORMATION

 

For the three months ended,

   September 30, 2018     June 30, 2018     March 30, 2018     December 31, 2017     September 30, 2017     June 30, 2017  

Current Assets

   $ 4,065,509     $ 1,234,842     $ 1,410,659     $ 1,005,563     $ 48,517     $ 29,254  

Current Liabilities

     58,851,982       717,238       626,960       255,969       107,165       89,422  

Net loss from Operations

     (533,887     (313,318     (446,967     (1,040,205     (59,573     (81,203

Net Loss per share

   $ (0.01   $ 0.01     $ (0.01   $ (0.01   $ (0.01   $ (0.04

 

 

The Corporation current assets represent cash, accounts receivable, prepaids, inventory, biological assets and other receivables. Current assets at September 30, 2018 include cash of $1,520,552.

 

 

The Corporation’s current liabilities include accounts payable, accrued liabilities, due to related parties, other financial liabilities in connection with the Xanthic Beverages purchase of $300,000 (see September 2018 Interim Financial Statements Note 10), $2,837,500 in connection with settling the additional 5% interest in NOR (see September 2018 Interim Financial Statements Note 10) and interest-bearing loans of $53,912,500 (see September 2018 Interim Financial Statements Note 11).

 

 

June 30, 2018 quarterly loss includes stock-based compensation expense of $225,033.

 

 

December 31, 2017 net loss and comprehensive loss includes listing fees of $747,025.

LIQUIDITY AND CAPITAL RESOURCES

The Corporation has cash of $1,520,552, accounts receivable of $422,460, prepaids of $79,734, inventory of $1,382,471, biological assets of $660,292 and current liabilities of $58,851,982 as at September 30, 2018. The Corporation’s, current liabilities include $53,912,500 in interest-bearing loans in connection with the purchase of NOR. These facilities were secured by the pledge of the Corporation’s shares in its wholly owned subsidiary GGB Nevada. Subsequent to September 30, 2018, on November 9, 2018 the Corporation closed the Business Combination with GGB. GGB had raised in excess of $100 million in convertible debentures and a private placement. On closing of the Business Combination, the Corporation settled the promissory notes and loan payable to the NOR Members and GGB.

At September 30, 2018 the Corporation therefore has negative working capital of $54,786,473, however as indicated above on the closing of the Business Combination with GGB, the Company settled all outstanding interest-bearing loans.

The Corporation plans to complete further financings over the next twelve months in order to fund its ongoing expenditures and execute on its business plan to get to break even cashflow. However, there is no assurance that the Corporation will be successful in these endeavors.

Outstanding Share Data

At September 30, 2018, the Corporation had 57,746,547 common shares outstanding, 568,000 warrants outstanding and 2,608,000 stock options outstanding.

On November 26, 2018, the Corporation had; post Business Combination and post share consolidation of the shareholder approved 4 for 1 share consolidation; 166,304,982 common shares outstanding, 38,194 proportionate voting shares outstanding, 19,097 proportionate voting warrants, 36,917,139 warrants outstanding and 475,000 stock options outstanding.


OFF BALANCE SHEET ARRANGEMENTS

In the normal course of business, the Corporation has entered into arrangements with several third-party goods and services providers. In certain instances, the Corporation, directly and through its subsidiaries, has provided indemnities and/or guarantees to these third parties for the payment of goods or services provided, or otherwise. Generally, there are no pre-determined amounts or limits included in these arrangements, and the occurrence of an event that would trigger the Corporation’s obligations pursuant to these arrangements is difficult to predict. Therefore, the Corporation’s potential future liability cannot be reasonably estimated.

COMMITMENT AND CONTINGENCIES

The Corporation has the following outstanding commitments or contingencies:

 

     Expected Payments Schedule  
     2019      2020 to 2021      2022 to 2023      Thereafter      Total  

Accounts payable and accrued liabilities

   $ 1,735,541      $ —        $ —        $ —        $ 1,735,541  

Due to related parties

     66,441        —          —          —          66,441  

Other financial liabilities

     3,137,500        —          —          —          3,137,500  

Interest bearing loans

     53,912,500        —          —          —          53,912,500  

Minimum lease payments

     350,516        934,708        934,708        804,630        3,024,562  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 59,202,498      $ 934,708      $ 934,708      $ 804,630      $ 61,876,544  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

 

The Corporation’s other financial liabilities are in connection with its equity investment with Xanthic Beverages. As a condition in connection with the investment in Xanthic Beverages, the Corporation is obligated to pay either $300,000 or 600,000 in common shares of the Corporation if Xanthic Beverages achieves certain performance milestones. The Corporation has assigned a 100% probability to Xanthic Beverages achieving these milestones. In addition, included in other financial liabilities is $2,837,500 of the purchase price of NOR which will be settled in common shares for the remaining 5% on closing of the Business Combination with GGB.

 

 

The Corporation’s interest-bearing loans are in connection with its purchase of NOR (see September 2018 Interim Financial Statements Note 11). Subsequent to September 30, 2018, on November 9, 2018 on the close of the Business Combination with GGB these promissory notes and loan payable were settled as outlined in the September 2018 Interim Financial Statements.

 

 

NOR has leases on certain premises as part of its operations in Nevada from related parties under operating leases agreements that specify minimum rentals and a percent of net revenues. The leases run through to December 2025 and contain certain renewal provisions.

Contingencies

The Corporation, through its NOR operations are subject to a variety of local and state regulation. Failure to comply with one or more of those regulations could result in fines, restrictions on its consolidated operations, or losses of permits that could result in the NOR ceasing operations. While management of the Corporation believes that the Corporation is in compliance with applicable local and state regulation as of September 30, 2018, cannabis regulations continue to evolve and area subject to differing interpretations. As a result, NOR may be subject to regulatory fines, penalties or restrictions in the future.

From time to time, the Corporation may be involved in litigation relating to claims arising out of operations in the normal course of business. As at September 30, 2018 there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Corporation’s consolidated operations. There are no proceedings in which any of the Corporation’s directors, officers, or affiliates is an adverse party or has a material interest adverse to the Corporation’s interest.


RELATED PARTY TRANSACTIONS

Other than as described in Note 15 to the September 2018 Interim Financial Statements, there are no significant changes in the nature and scope of related party transactions to those described in Note 13 to the 2018 Audited Consolidated Financial Statements and the accompanying MD&A.

BUSINESS RISKS

There are a number of inherent risks associated with the Corporation’s activities. These risks are described in the Corporation’s Canadian Securities Exchange listing statement filed on www.sedar.com under “Business Risks”. At September 30, 2018 the Corporation had not identified any material changes to the risk factors affecting its business, and its approach to managing those risks, from those discussed in the document referred to above. These business risks should be considered by interested parties when evaluating the Corporation’s performance and outlook.

ACCOUNTING POLICIES, CRITICAL JUDGMENTS AND ESTIMATES

The preparation of the Corporation’s financial statements in conformity with IFRS requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenues and other items in net earnings or loss, and the related disclosure of contingent assets and liabilities, if any. Critical judgments and estimates represent estimates made by management that are, by their very nature, uncertain. The Corporation evaluates its estimates on an ongoing basis. Such estimates are based on historical experience and on various other assumptions that the Corporation believes are reasonable under the circumstances, and these estimates form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and other items in net earnings or loss that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Summaries of the significant accounting policies applied, and significant judgments, estimates and assumptions made by management in the preparation of its financial statements are provided in Notes 2 and 3 to the 2018 Audited Consolidated Financial Statements and Notes 2 and 3 to the September 2018 Interim Financial Statements.

CONTROLS AND PROCEDURES

Internal Control over financial reporting (“ICFR”) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with applicable IFRS. Disclosure controls and procedures are designed to ensure that information required to be disclosed by the Corporation in the reports it files or submits under securities legislation is recorded, processed, summarized and reported on a timely basis and that such information is accumulated and reported to management, including the Corporation’s Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow required disclosures to be made in a timely fashion. Based on their evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that, as at September 30, 2018, the Corporation’s disclosure controls and procedures were effective.

The Chief Executive Officer and the Chief Financial Officer of the Corporation have also evaluated whether there were changes to the Corporation’s internal control over financial reporting during the three months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect the Corporation’s internal control over financial reporting. There were no changes identified during their evaluation.


INFORMATION CONCERNING XANTHIC BIOPHARMA INC.

Additional information relating to the Corporation, may be accessed through the SEDAR website at www.sedar.com under Xanthic Biopharma Inc. and the Corporation’s website at www.xanthicbiopharma.com.

Toronto, Ontario

November 26, 2018

EX-3.4 9 d692201dex34.htm EX-3.4 EX-3.4

Exhibit 3.4

FORM 51-102F3

MATERIAL CHANGE REPORT

 

ITEM 1.

  

Reporting Issuer

  

Xanthic Biopharma Inc.

  

2100 Bloor St West, Suite 6339

  

Toronto, Ontario M6S 5A5

ITEM 2.

  

Date of Material Change

  

July 13, 2018

ITEM 3.

  

Press Releases

   A press release in the form of Schedule A attached hereto was disseminated on July 17, 2018 via Cision news service.

ITEM 4.

  

Summary of Material Change

  

Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company”) (CSE: xTHC) and Green Growth Brands Ltd. (“GGB”) have announced they have entered into an arm’s length business combination agreement (the “Definitive Agreement”) dated July 13, 2018 to combine Xanthic and GGB by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

  

Xanthic has also announced that GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic, has entered into a purchase agreement (the “NOR Agreement”) dated July 13, 2018 with Nevada Organic Remedies LLC (“NOR”) and its members pursuant to which it will acquire (the “NOR Acquisition”) 100% of the outstanding membership interests of NOR for aggregate consideration of US$56.75 million. NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada holding four Nevada marijuana licenses (dispensary, cultivation, production and distribution).

 

Xanthic anticipates filing a management information circular or listing statement (the “Disclosure Document”) detailing certain matters relating to the Business Combination and other related matters to be mailed to Xanthic shareholders.

ITEM 5.

  

Full Description of Material Change

  

5.1

  

Full Description of Material Change

  

See Schedule A attached.

  

5.2

  

Disclosure for Restructuring Transactions

   Subject to the terms of the Definitive Agreement, Subco and GGB will complete the Amalgamation and the amalgamated corporation (“Amalco”) will continue under the name “Green Growth Brands (Ontario) Ltd.”. Amalco will be a direct wholly-owned subsidiary of the Resulting Issuer. All of the property and assets of each of Subco and GGB will become the property and assets of Amalco and Amalco will be liable for all of the liabilities and obligations of each of Subco and GGB.

ITEM 6.

  

Reliance on subsection 7.1(2) of National Instrument 51-102

  

Not applicable.


ITEM 7.

  

Omitted Information

  

Not applicable.

ITEM 8.

  

Executive Officer

  

The following Officer of the Company may be contacted for further information:

  

Tim Moore, Chief Executive Officer

  

Telephone

  

(877) 564-5440 ext. 200

  

Email

  

timm@xanthicbiopharma.com

ITEM 9.

  

Date of Report

  

This report is dated this 17th day of July, 2018.

 

Page 2


Schedule A

GREEN GROWTH BRANDS TO ACQUIRE XANTHIC BIOPHARMA

Lifestyle Oriented Consumer Branding Company to Acquire Cannabis Industry Participant Xanthic together with Nevada-based Cultivator, Producer and Retailer of Recreational and Medical Cannabis Products

Toronto, Ontario, July 17, 2018 – Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company”) (CSE: xTHC) and Green Growth Brands Ltd. (“GGB”) are pleased to announce they have entered into an arm’s length business combination agreement (the “Definitive Agreement”) dated July 13, 2018 to combine Xanthic and GGB by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

GGB is a lifestyle oriented, consumer products company that celebrates health, wellness and happiness. GGB is focused on the medicinal and recreational cannabis sector in both the United States and Canada and is the parent company of the CAMP brand. GGB is led by the widely-renowned retailer Peter Horvath. The Business Combination represents the initial step in GGB’s strategy to grow its international footprint, through partnerships with cannabis cultivators and processors across Canada and the United States. While GGB’s principal focus will be to build a retail network, it will leverage Xanthic’s expertise in the science of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”), the two key active ingredients in cannabis.

Following completion of the Business Combination, current shareholders of GGB will hold approximately 86% of the common shares (the “Resulting Issuer Shares”) of the resulting issuer (the “Resulting Issuer”) (excluding any Resulting Issuer Shares that become issuable pursuant to the terms of the Debenture Private Placement and the Subscription Receipt Private Placement (as such terms are defined below)). It is anticipated that the Resulting Issuer may operate under the name “Green Growth Brands Ltd.” after effecting a name change (the “Name Change”) with the Resulting Issuer Shares listed and posted for trading on the Canadian Securities Exchange (the “Exchange” or the “CSE”). Xanthic anticipates filing a management information circular or listing statement (the “Disclosure Document”) detailing certain matters relating to the Business Combination and other related matters to be mailed to Xanthic shareholders. Trading in the common shares of Xanthic (the “Xanthic Shares”) will be halted as a result of this announcement and will remain halted until the resumption of trading is approved by the Exchange. If completed, the Business Combination will constitute a fundamental change of Xanthic (as such term is defined in the CSE’s policies and procedures manual).

Assuming the satisfaction of customary closing conditions, including the approval of Xanthic’s shareholders, the Business Combination is expected to close in the fourth quarter of this year.

Xanthic and GGB are also pleased to announce that GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic has entered into a purchase agreement (the “NOR Agreement”) dated July 13, 2018 with Nevada Organic Remedies LLC (“NOR”) and its members pursuant to which it will acquire (the “NOR Acquisition”) 100% of the outstanding membership interests of NOR for aggregate consideration of US$56.75 million. NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada holding four Nevada marijuana licenses (dispensary, cultivation, production and distribution). Additionally, NOR produces a line of high quality medical and recreational products under the name 8|fold. Assuming satisfaction of customary closing conditions, including completion of due diligence investigations to the satisfaction of GGB Nevada and regulatory approval in Nevada, the NOR Acquisition is expected to be completed on or about September 7, 2018.

Peter Horvath, GGB’s Chief Executive Officer who will serve as a Director of Xanthic, commented, “With this strategic business combination, GGB is positioned to launch our retail and branding expertise into this fast growing marketplace. In addition the NOR acquisition launches our entry into the highly productive Las Vegas


market where we will now expand our footprint, where we can go head to head with the best brands and retail concepts in the cannabis space.”

The Business Combination

Subject to the terms of the Definitive Agreement, Subco and GGB will complete the Amalgamation and the amalgamated corporation (“Amalco”) will continue under the name “Green Growth Brands (Ontario) Ltd.”. Amalco will be a direct wholly-owned subsidiary of the Resulting Issuer. All of the property and assets of each of Subco and GGB will become the property and assets of Amalco and Amalco will be liable for all of the liabilities and obligations of each of Subco and GGB.

As of the date hereof, Xanthic has 57,046,547 Xanthic Shares outstanding together with Xanthic convertible securities entitling the holders thereof to acquire a further 3,876,000 Xanthic Shares. As of the date hereof, GGB has 92,000,002 GGB common shares (“GGB Shares”) outstanding and no outstanding convertible securities. Pursuant to the terms of the Definitive Agreement, GGB may issue up to an additional 10,000,000 GGB Shares (or convertible securities, or the equivalent) prior to closing of the Business Combination. Based on the foregoing, Xanthic will, subject to the receipt of all regulatory approvals, including the approval of its shareholders to certain items of special business and the Exchange, (i) combine with GGB pursuant to the Definitive Agreement such that all of the issued and outstanding GGB Shares will be acquired, and as consideration, Xanthic will issue to holders of GGB Shares, on a 3.394-for-one basis, 346,150,835 Xanthic Shares (the “Consideration Shares”)1, in exchange for the then issued and outstanding GGB Shares (which for greater certainty excludes the GGB Shares to be issued under the Subscription Receipt Private Placement and the Debenture Private Placement (as such terms are defined below)); and (ii) reorganize its share structure and consolidate all of the issued and outstanding Xanthic Shares (including the Consideration Shares) on the basis of 4.07 pre-consolidation Xanthic Shares for one (1) post-consolidation Resulting Issuer Share (the “Consolidation”). The Business Combination values Xanthic at $0.36 per share which represents a 56% premium based on the 20-day volume weighted average price of the Xanthic Shares as of July 11, 2018.

In the event that GGB terminates the Definitive Agreement, other than as a result of a breach of representation or warranty or non-performance by Xanthic, GGB shall pay Xanthic a break fee in the aggregate amount of $250,000 and reimburse Xanthic for the full extent of its US legal fees, a portion of its Canadian legal fees, travel costs and other reasonable expenses incurred in connection with the Business Combination.

Resulting Issuer

The following table sets forth the pro forma capitalization of the Resulting Issuer after giving effect to the Business Combination and the Consolidation but prior to giving effect to the Subscription Receipt Private Placement and the Debenture Private Placement:

 

Equity

(Resulting Issuer Shares)

  

Shares(1)

(#)

    

Shares(2)

(%)

 

Held by current GGB Shareholders

     85,034,014        85.9

Held by current Xanthic Shareholders that are insiders of Xanthic

     1,487,036        1.5

Held by current Xanthic Shareholders that are not insiders of Xanthic

     12,526,788        12.6
  

 

 

    

 

 

 

Total

     99,047,838        100
  

 

 

    

 

 

 

 

(1)

Does not give effect to exercise and/or conversion of issued and outstanding Xanthic convertible securities.

(2)

Expressed on a non-diluted basis.

 

 

1

The number of Consideration Shares issuable to holders of GGB Shares has been fixed at 346,150,835. In the event GGB issues additional GGB Shares or convertible securities convertible into GGB Shares prior to closing of the Business Combination, the 3.394-for-one exchange ratio shall be adjusted downward to accommodate the issuance of such securities.

 

Page A2


To the knowledge of the prospective directors and executive officers of the Resulting Issuer, no person or company beneficially will own, or control or direct, directly or indirectly, Resulting Issuer Shares carrying in excess of 10% of the voting rights attached to all outstanding Resulting Issuer Shares, other than All Js Greenspace LLC, a company controlled by three individual family trusts, which is expected to own 33,971,923 Resulting Issuer Shares, representing a 34.3% ownership stake in the Resulting Issuer prior to giving effect to the Subscription Receipt Private Placement and the Debenture Private Placement.

Board of Directors and Management

Subject to Exchange approval, the board of directors and management of Xanthic will be reconstituted today with the following individuals:

 

   

Jean Schottenstein (Director)

 

   

Peter Horvath (Director)

 

   

Steve Stoute (Director)

 

   

Carli Posner (Director)

 

   

Marc Lehmann (Director)

 

   

Tim Moore (Director and Chief Executive Officer)

 

   

Gary Galitsky (Director and President)

 

   

David Bhumgara (Chief Financial Officer)

It is currently expected that the board of directors and management of the Resulting Issuer will be the aforementioned individuals.    

Conditions of Completion

Completion of the Business Combination is subject to a number of conditions, including, but not limited to, Exchange acceptance. Where applicable, the Business Combination cannot close until the required shareholder approval is obtained. There can be no assurance that the Business Combination will be completed as proposed, or at all.

Other conditions to completion of the Business Combination include, but are not limited to:

 

   

The approval of GGB shareholders of the Amalgamation, the approval of Xanthic shareholders of the Amalgamation, the Name Change and the Consolidation, and other matters to be more fully described in the Disclosure Document, and the approval and acceptance of the Exchange;

 

   

Completion of the NOR Acquisition, the Subscription Receipt Private Placement, the Debenture Private Placement and the Loan Agreement;

 

   

Xanthic will have at least $400,000 of working capital (net of expenses relating to the completion of the Amalgamation); and

 

   

The Resulting Issuer being in compliance with the initial listing requirements of the Exchange.

 

Page A3


Subscription Receipt Private Placement

GGB intends to complete a brokered private placement equity financing (the “Subscription Receipt Private Placement”) of subscription receipts (the “Subscription Receipts”) of GGB for gross proceeds of up to C$60 million less the gross amount of the Proposed Debenture Private Placement (after first deducting the amount of the Debenture Cash Repayment (see “The NOR Acquisition – Debenture Financing and Loan Agreement” below). It is expected that each Subscription Receipt issued under the Subscription Receipt Private Placement will entitle the holder thereof, upon deemed exercise following satisfaction of the Escrow Release Conditions (as defined below) to receive one common share (a “Subscription Share”) of GGB and, upon completion of the Business Combination, and for no additional consideration, one Resulting Issuer Share.

The gross proceeds from the Subscription Receipt Private Placement will be held in escrow pending the satisfaction of, among other things: (i) all conditions precedent to the Business Combination being satisfied or waived in accordance with the terms of the Definitive Agreement; and (ii) the acceptance from the Exchange to list the Resulting Issuer Shares on the Exchange (collectively, the “Escrow Release Conditions”).

Upon satisfaction of the Escrow Release Conditions, the Subscription Receipts will be deemed to be exercised, for no additional consideration, for the Subscription Shares of GGB and, upon completion of the Business Combination, and for no additional consideration, a Resulting Issuer Share. In the event the Business Combination does not occur on or before December 31, 2018, it is expected that the gross proceeds of the Subscription Receipt Private Placement plus any interest accrued thereon will be returned to the holders of Subscription Receipts pro rata without any deduction or interest and the Subscription Receipts will be automatically cancelled without any further action by the holders thereof.

Upon satisfaction of the Escrow Release Conditions, the net proceeds of the Subscription Receipt Private Placement (after deducting the agent’s commission, fees, and estimated costs and expenses in respect of the Subscription Receipt Private Placement) will be released to the Resulting Issuer and used to satisfy the listing requirements of the CSE and for general corporate and working capital purposes.

The NOR Acquisition

Pursuant to the terms of the NOR Agreement, GGB Nevada is required to make payment of a US$2 million deposit (the “NOR Deposit”) on or before July 17, 2018 and an initial cash payment of approximately US$32 million (the “NOR Closing Payment”) on closing of the NOR Acquisition. In addition, on closing of the NOR Acquisition, GGB Nevada will be required to deliver to the NOR Members a secured promissory note in the principal amount of US$21,565,000. It is expected that the members of NOR who are selling their membership interests to GGB Nevada in the NOR Acquisition (collectively, the “NOR Members”) will retain, in the aggregate, 5% of the membership interests of NOR immediately following closing of the NOR Acquisition. GGB has agreed to advance to Xanthic or GGB Nevada, as the case may be, the funds required to satisfy GGB Nevada’s obligation to pay the NOR Deposit and the NOR Closing Payment (see “- Debenture Private Placement and Loan Agreement” below).

Debenture Private Placement and Loan Agreement

GGB intends to complete a non-brokered private placement financing (the “Debenture Private Placement”) of up to 32,000 convertible debentures (the “Debentures”) of GGB at a price of US$1,000 per Debenture for gross proceeds of US$32 million. The net proceeds of the Debenture Private Placement will be loaned to Xanthic pursuant to a loan agreement (the “Loan Agreement”) to be entered into among Xanthic, GGB Nevada and GGB. The funds advanced to Xanthic or GGB Nevada, as the case may be, pursuant to the Loan Agreement will be used to satisfy the NOR Deposit and the NOR Closing Payment.

It is expected that each Debenture issued under the Debenture Private Placement will entitle the holder thereof to a cash repayment of the principal amount thereof, plus accrued but unpaid interest thereon, on the Maturity Date (as defined below). The maturity date is expected to be 270 days from the date the Debentures are issued (the

 

Page A4


Maturity Date”). If the Debenture Conversion Conditions (as defined below) are satisfied prior to the Maturity Date, the Maturity Date of the Debentures will accelerate and the Debentures will be repayable in (i) cash equal to the principal amount thereof plus all accrued but unpaid interest thereon (the “Cash Repayment Option”), (ii) common shares of GGB (the “Conversion Shares”) and, upon completion of the Business Combination, and for no additional consideration, Resulting Issuer Shares at a to-be-determined exchange ratio (the “Share Repayment Option”) or (iii) a combination of the Cash Repayment Option and the Share Repayment Option, in each case as elected by the holder at the time of subscription.

The Cash Repayment Option and the Share Repayment Option will be available to holders of the Debentures upon the satisfaction of certain conditions, including: (i) all conditions precedent to the Business Combination being satisfied or waived in accordance with the terms of the Definitive Agreement; and (ii) the acceptance from the Exchange to list the Resulting Issuer Shares on the Exchange (collectively, the “Debenture Conversion Conditions”).

The net proceeds from the Debenture Private Placement shall be loaned to Xanthic on commercially reasonable terms pursuant to the Loan Agreement to be entered into between Xanthic, GGB Nevada and GGB prior to the completion of the Business Combination and shall be used to satisfy the initial cash consideration for the NOR Acquisition. The Loan Agreement will have, among other things, a maturity date of 180 days from the date of the initial advance, bear interest at a commercially reasonable rate, contain no prepayment privilege and include customary events of default, which shall include the failure to complete the Business Combination prior to the maturity date of the Loan Agreement. As security for the amounts loaned pursuant to the Loan Agreement, GGB shall be granted, among other things, an irrevocable option from Xanthic to elect to satisfy Xanthic’s obligations under the Loan Agreement by acquiring GGB Nevada from Xanthic and assuming Xanthic and GGB Nevada’s obligations under the NOR Agreement.

About the Parties:

Xanthic

Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis and cannabis-infused products. Xanthic is a developer of a patent-pending proprietary process to make THC and CBD, the two key active ingredients in cannabis, water soluble, and its operation will continue to be run by current management. Subject to completion of the Business Combination, Xanthic will combine its business with GGB and thereafter be engaged in the business of cultivation, processing, and retailing of cannabis and cannabis-infused products augmented by Xanthic intellectual property.

Green Growth Brands

Green Growth Brands is a lifestyle oriented, consumer products company that celebrates health, wellness and happiness. GGB is focused on the medicinal and recreational cannabis sector in both the United States and Canada and is the parent company of the CAMP brand. GGB is led by the widely-renowned retailer Peter Horvath. The Business Combination represents the initial step in GGB’s strategy to grow its international footprint, through partnerships with cannabis cultivators and processors across Canada and the United States.

Nevada Organic Remedies LLC

Nevada Organic Remedies LLC is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada and holds four Nevada marijuana licenses including dispensary, cultivation, production and distribution. NOR’s dispensary, The + Source, was voted “Best of the City” for Las Vegas in 2018 by NPR’s Desert Companion magazine. Additionally, NOR produces a line of high quality medical and recreational products under the name 8|fold. More information can be found at www.thesourcenv.com.

 

Page A5


Further Information:

Further details about the Business Combination and the Resulting Issuer will be provided in the disclosure document to be prepared and filed in respect of the Business Combination.

Completion of the transaction is subject to a number of conditions, including but not limited to, Exchange acceptance. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the Disclosure Document to be prepared in connection with the Business Combination, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Xanthic will remain halted until further notice.

The Exchange has in no way passed upon the merits of the Business Combination and has neither approved nor disapproved the contents of this press release.

Xanthic Biopharma Inc.

Tim Moore

Chief Executive Officer

(877) 564-5440 ext. 200

timm@xanthicbiopharma.com

Green Growth Brands Ltd.    

Peter Horvath

Chief Executive Officer

+1 (614) 272-3271

phorvath@greengrowthbrands.com

Cautionary Statements:

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to, among other things, the completion of the Business Combination, the number of securities of Xanthic that may be issued in connection with the Business Combination, the ownership of Xanthic following the Business Combination, the Subscription Receipt Private Placement, the Debenture Private Placement, the Loan Agreement, the Consolidation, , the Name Change the NOR Acquisition, the expected composition of the board of directors of the Resulting Issuer, shareholder approval and the parties’ ability to satisfy closing conditions and receive necessary approvals. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the Business Combination will occur, or that if the Business Combination does occur, it will be completed on the terms described above.

The forward-looking information contained in this release is made as of the date hereof and neither the Company nor GGB is obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United

 

Page A6


States, or in any other jurisdiction in which such an offer would be illegal.    

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

This document may not be distributed or released in the United States or through U.S. Newswire Services.

 

Page A7

EX-3.5 10 d692201dex35.htm EX-3.5 EX-3.5

Exhibit 3.5

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Xanthic Biopharma Inc. (“Xanthic”)

77 King Street West, Suite 2905 Toronto, Ontario

M5K 1A2

Item 2 Date of Material Change

November 9, 2018.

Item 3 News Release

A news release with respect to the material change referred to in this report was issued through Cision on November 9, 2018, a copy of which was filed on SEDAR.

Item 4 Summary of Material Change

On November 9, 2018, pursuant to the terms of an amended and restated transaction agreement (the “Definitive Agreement”) dated October 30, 2018 between Xanthic and Green Growth Brands Ltd. (“GGB”), Xanthic completed a business combination with GGB by way of a three-cornered amalgamation pursuant to which GGB amalgamated with a wholly-owned subsidiary of Xanthic to form one company as a wholly-owned subsidiary of

Xanthic (the “Business Combination”).

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

On November 2, 2018, Xanthic held an annual and special meeting of shareholders of Xanthic (the “Xanthic Shareholders”), where Xanthic Shareholders approved, among other things, a name change, the Business Combination, an amendment to Xanthic’s articles of incorporation to create a new class of proportionate voting shares and the consolidation of the common shares of Xanthic immediately following closing of the Business Combination.

On November 9, 2018, pursuant to the Definitive Agreement, Xanthic completed the Business Combination.

As part of the Business Combination, each of the common shares, proportionate voting shares, common share purchase warrants and proportionate voting share warrants of GGB (collectively, the “GGB Securities”) were cancelled and former GGB securityholders received 3.43522878 common shares, proportionate voting shares, common share purchase warrants, and proportionate voting share warrants of Xanthic, as applicable, for each GGB


Security so cancelled (collectively, the “Consideration Securities”). The common shares of Xanthic (including the Consideration Securities) have also been consolidated on the basis of four (4) pre-consolidation shares for one (1) post-consolidation Resulting Issuer common share.

Additional information on the Business Combination is included in the management information circular of Xanthic dated October 12, 2018 and available on SEDAR at www.sedar.com.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

This material change report is not being filed on a confidential basis.

Item 7 Omitted Information

None.

Item 8 Executive Officer

Further information regarding the matters described in this report may be obtained from David Bhumgara, Chief Financial Officer, who is knowledgeable about the details of the material change and may be contacted at 647-495-8798.

Item 9 Date of Report

November 16, 2018.

 

- 2 -

EX-3.6 11 d692201dex36.htm EX-3.6 EX-3.6

Exhibit 3.6

FORM 51-102F3

MATERIAL CHANGE REPORT

 

Item 1

Name and Address of Company

Xanthic Biopharma Inc. (“Xanthic”)

77 King Street West, Suite 2905

Toronto, Ontario

M5K 1A2

 

Item 2

Date of Material Change

December 10, 2018

 

Item 3

News Release

A news release with respect to the material change referred to in this report was issued through Canada NewsWire on December 11, 2018, a copy of which was filed on SEDAR.

 

Item 4

Summary of Material Change

Xanthic has entered into a membership interest purchase agreement dated December 10, 2018 in connection with the purchase by Xanthic of all the issued and outstanding membership interests of Just Healthy LLC (“Just Healthy”), a Massachusetts limited liability company. Just Healthy is the registered owner of provisional certificates of registration issued by the Department of Public Health Bureau of Health Care Safety and Quality for the Commonwealth of Massachusetts.

 

Item 5

Full Description of Material Change

 

5.1

Full Description of Material Change

See press release attached hereto as Appendix “A”

 

5.2

Disclosure for Restructuring Transactions

Not applicable.

 

Item 6

Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

 

Item 7

Omitted Information

Not applicable.


Item 8

Executive Officer

Further information regarding the matters described in this report may be obtained from David Bhumgara, Chief Financial Officer, who is knowledgeable about the details of the material change and may be contacted at 416-574-4603.

 

Item 9

Date of Report

December 12, 2018.

 

- 2 -


Appendix “A”

See attached.

 

- 3 -


LOGO

Press release

Green Growth Brands Announces the Acquisition of Just Healthy LLC

Just Healthy to provide Green Growth Brands a medical marijuana dispensary license and option to acquire real

estate in Massachusetts’ expanding cannabis market

COLUMBUS, OH December 11, 2018 – Xanthic Biopharma, Inc. d/b/a Green Growth Brands (CSE: GGB) (GGB or the Company) announced that it has executed a definitive agreement, yesterday, December 10, 2018, to acquire 100% of the membership interests of Just Healthy LLC (Just Healthy). Just Healthy holds provisional certificates of registration for a registered marijuana dispensary in Northampton, Massachusetts, and a cultivation and processing site, also located in Northampton. The license allows for up to three medical dispensaries with preferred treatment for future adult use.

Peter Horvath, CEO, “Massachusetts has been on our radar for some time, it is a leading consumer market. We’ve previously competed for, and won, consumer loyalty in this market in other product categories, and by teaming up with Just Healthy, we are excited to bring exceptional consumer experiences to Massachusetts.”

This transaction introduces GGB to its first locations outside of Nevada, where the Company is building towards a leading market position, operating the premier Cannabis store, The+Source, in Las Vegas, NV and a grow and production facility. Last week, the Nevada Department of Taxation awarded GGB an additional seven retail cannabis dispensary licenses. The acquisition gives GGB the opportunity to extend its production and retail operations into the northeastern United States, bringing the region’s consumers access to the Company’s premier brands, products, and services.

Neil Phelan, co-founder and member, Just Healthy LLC, “Over the last year we have developed a close working relationship with the people of Northampton. We are excited to merge our efforts with Green Growth Brands and make significant investments in the Northampton community. Working closely with Mayor David Narkewicz, Councilor Marianne LaBarge, and the entire leadership team of the city of Northampton, we have developed a careful plan to headquarter and grow the business of Just Healthy in Northampton. We are proud to be residents of Northampton and to be creating career opportunities in this high growth industry for the people of Massachusetts. Northampton is playing a leading role in the development of the cannabis industry in Massachusetts and we are thrilled to be part of it.”

As consideration for the membership interests of Just Healthy GGB will issue to the holders of such membership interests an aggregate of US$3,750,000 (CAD$5,01,8850) in common shares of GGB and assume US$455,000 (CAD$608,954) of Just Healthy corporate debt. Completion of the acquisition of Just Healthy, which is expected to occur in early January, 2019, remains subject to regulatory approval and customary conditions of closing.


LOGO

 

As part of the same transaction, GGB will also gain the rights to acquire the real estate necessary for the development of a cultivation facility in Northampton, Massachusetts, currently held by Turnberry Partners LP.

About Green Growth Brands

Green Growth brands expects to dominate the cannabis and CBD market with a portfolio of emotion-driven brands that people love. Led by Peter Horvath, the GGB team is full of retail and consumer packaged goods experts with decades of experience building successful brands. Join the movement at GreenGrowthBrands.com.

For investor relations inquiries, please contact:

Julia Fulton, Investor & Public Relations

(614) 505-9880

jfulton@greengrowthbrands.com

or

Eric Wright

416-640-2963

ewright@greengrowthbrands.com

For media enquiries or interviews, please contact:

Wynn Theriault, Thirty Dash Communications

416-710-3370

wynn@thirtydash.ca

Cautionary Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except


LOGO

 

as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

EX-3.7 12 d692201dex37.htm EX-3.7 EX-3.7

Exhibit 3.7

FORM 51-102F3

MATERIAL CHANGE REPORT

 

Item 1

Name and Address of Company

Xanthic Biopharma Inc. d.b.a. Green Growth Brands (“Xanthic”)

77 King Street West, Suite 2905

Toronto, Ontario

M5K 1A2

 

Item 2

Date of Material Change

December 12, 2018

 

Item 3

News Release

A news release with respect to the material change referred to in this report was issued through CISION on December 13, 2018, a copy of which was filed on SEDAR.

 

Item 4

Summary of Material Change

Xanthic entered into definitive agreements on December 12, 2018 to acquire a Pahrump, Nevada cultivation facility operated by Wellness Orchards of Nevada LLC (“WON”) and Panorama WON LLC (“Panorama”) for a total purchase price of USD$13,372,162 (CAD$16,749,970). WON currently operates a 12,000 square feet cannabis cultivation facility in Pahrump, while Panorama owns the real property and assets upon which the cultivation facility operates.

 

Item 5

Full Description of Material Change

 

5.1

Full Description of Material Change

See press release attached hereto as Appendix “A”

 

5.2

Disclosure for Restructuring Transactions

Not applicable.

 

Item 6

Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

 

Item 7

Omitted Information

Not applicable.


Item 8

Executive Officer

Further information regarding the matters described in this report may be obtained from David Bhumgara, Chief Financial Officer, who is knowledgeable about the details of the material change and may be contacted at 416-574-4603.

 

Item 9

Date of Report

December 18, 2018.

 

- 2 -


Appendix “A”

See attached.

 

- 3 -


LOGO

Press release

Green Growth Brands Acquires Second Nevada Grow Facility

Grow Facility to be Expanded to Support Retail and Wholesale Operations

COLUMBUS, OH, Dec.13, 2018 /CNW/ - Xanthic Biopharma, Inc. d/b/a Green Growth Brands (CSE: GGB) (GGB or the Company) today announced it entered into definitive agreements on December 12, 2018 to acquire a Pahrump, Nevada cultivation facility operated by Wellness Orchards of Nevada LLC (WON) and Panorama WON LLC (Panorama) for a total purchase price of USD$13,372,162 (CAD$16,749,970). Through this acquisition, GGB expects to expand its current Nevada footprint to two cultivation facilities in 2019. This expansion, along with the eight retail cannabis dispensaries GGB plans to operate, positions the Company to be one of the largest vertically integrated operators in the state.

WON currently operates a 12,000 square feet cannabis cultivation facility in Pahrump, while Panorama owns the real property and assets upon which the cultivation facility operates. The transaction is expected to close in early 2019 and remains subject to regulatory approvals and other customary closing conditions. Following closing, GGB intends to phase an expansion of the current WON cultivation space to nearly 150,000 square feet, with the total cost estimated at USD$13,000,000 (CAD$17,421,763). The first phase is expected to be completed by Q3 of 2019. This expansion will provide GGB, which last week announced that it had received seven retail dispensary licenses from the Nevada Department of Taxation, with the support necessary for its growing retail and wholesale operations.

“The acquisition of this facility allows us to provide high quality products at the increased volumes now necessary to support our newly expanded retail footprint, while also allowing us to continue a strong trajectory of growth for our wholesale business.” said Peter Horvath, Chief Executive Officer.

GGB currently operates The+Source, the premier Cannabis store in Las Vegas, NV, as well as a cultivation and production facility in Las Vegas. The Company recently announced an acquisition regarding expanding its operations into Massachusetts.

About Green Growth Brands

Green Growth Brands expects to dominate the cannabis and CBD market with a portfolio of emotion-driven brands that people love. Led by Peter Horvath, the GGB team is full of retail and consumer packaged goods experts with decades of experience building successful brands. Join the movement at GreenGrowthBrands.com.

Cautionary Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital


LOGO

 

from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018 which is available on the Company’s issuer profile on SEDAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

SOURCE Green Growth Brands

For further information: For inquiries, please contact: Julia Fulton, Investor & Public Relations, (614) 505-9880, jfulton@greengrowthbrands.com or Peter Horvath, CEO, (614) 508-4222; For media enquiries or interviews, please contact: Wynn Theriault, Thirty Dash Communications, 416-710-3370, wynn@thirtydash.ca; For investor relations inquiries, please contact: Eric Wright, 416-640-2963, ewright@greengrowthbrands.com

EX-3.8 13 d692201dex38.htm EX-3.8 EX-3.8

Exhibit 3.8

FORM 51-102F3

MATERIAL CHANGE REPORT

 

Item 1

Name and Address of Company

Xanthic Biopharma Inc. d.b.a. Green Growth Brands (“Xanthic”)

77 King Street West, Suite 2905

Toronto, Ontario

M5K 1A2

 

Item 2

Date of Material Change

December 14, 2018

 

Item 3

News Release

A news release with respect to the material change referred to in this report was issued through CISION on December 14, 2018, a copy of which was filed on SEDAR.

 

Item 4

Summary of Material Change

Xanthic announced on December 14, 2018 that it has agreed to accept an irrevocable option (“Henderson Option”) to acquire all of the membership interests of Henderson Organic Remedies, LLC (“Henderson Organic”) together with the right to all of Henderson Organic’s free cash flow until exercise of the Henderson Option in consideration of the issuance of (i) a secured loan in the principal amount of USD$15,485,000 (CAD$20,752,000) and (ii) a common share purchase warrant exercisable for 7,609,746 common shares of Xanthic in the aggregate.

Henderson Organic operates a 2,693 square foot medical and retail marijuana dispensary facility located in Henderson, NV. In connection with these transactions, HOR Holdings LLC is expected to acquire all of the membership interests of Henderson Organic.

 

Item 5

Full Description of Material Change

 

5.1

Full Description of Material Change

See press release attached hereto as Appendix “A”

 

5.2

Disclosure for Restructuring Transactions

Not applicable.

 

Item 6

Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.


Item 7

Omitted Information

Not applicable.

 

Item 8

Executive Officer

Further information regarding the matters described in this report may be obtained from David Bhumgara, Chief Financial Officer, who is knowledgeable about the details of the material change and may be contacted at 416-574-4603.

 

Item 9

Date of Report

December 18, 2018.

 

- 2 -


Appendix “A”

See attached.

 

- 3 -


LOGO

Press release

Green Growth Brands to Acquire Option for Medical and Retail Dispensary in Henderson, Nevada

Potential Acquisition Would Add to GGB’s Expanding Nevada Operations

COLUMBUS, OH, Dec. 14, 2018 /CNW/ - Xanthic Biopharma, Inc. d/b/a Green Growth Brands (CSE: GGB) (GGB or the Company) announced today that it has agreed to accept an irrevocable option (the Henderson Option) to acquire all of the membership interests of Henderson Organic Remedies, LLC (Henderson Organic) together with the right to all of Henderson Organic’s free cash flow until exercise of the Henderson Option in consideration of the issuance of (i) a secured loan (the Loan) in the principal amount of USD$15,485,000 (CAD$20,752,000) and (ii) a common share purchase warrant (the Warrant) exercisable for 7,609,746 common shares of GGB in the aggregate. Henderson Organic operates a 2,693 square foot medical and retail marijuana dispensary facility located in Henderson, NV. In connection with these transactions, HOR Holdings LLC (HOR Holdings) is expected to acquire (the Henderson Acquisition) all of the membership interests of Henderson Organic.

The completion of the Henderson Acquisition and the exercise of the Warrant (which is intended to be satisfied by the issuance of the Henderson Option to GGB) are expected to occur in the first half of 2019 and remain subject to state and municipal regulatory approval and customary conditions of closing. The proposed transactions have been structured to comply with both local and state laws and GGB anticipates exercising the Henderson Option immediately following the later of (i) a change in applicable laws and (ii) the completion of the Henderson Acquisition. The Loan, which was issued on December 13, 2018 to certain members of Henderson Organic, has a maturity date of May 4, 2019, bears interest at a simple annual rate of 6% and is secured against (i) a portion of the payment obligation of Nevada Organic Remedies LLC (NOR), a GGB subsidiary, in favor of the borrowers under the Loan (which portion is equal to the principal amount and accrued interest under the Loan) and (ii) all membership interests of HOR held by the borrowers under the Loan. The Warrant, which was issued to HOR Holdings LLC on December 13, 2018, expires on December 31, 2019 and vests only upon completion of Henderson Acquisition. Once vested, the Warrant is exercisable for an aggregate of 7,609,746 common shares of GGB at an exercise price of CAD$3.16 per share (reflecting the GGB price per share as of the close of trading on December 12, 2018).

GGB currently operates The+Source, the premier Cannabis store in Las Vegas, NV, as well a cultivation and production facility in Las Vegas. The Nevada Department of Taxation awarded GGB seven retail cannabis dispensary licenses on December 5, and the Company recently announced an acquisition regarding expanding its operations into Massachusetts and the acquisition of a cultivation facility in Pahrump, Nevada.

About Green Growth Brands

Green Growth Brands expects to dominate the cannabis and CBD market with a portfolio of emotion-driven brands that people love. Led by Peter Horvath, the GGB team is full of retail and consumer packaged goods experts with decades of experience building successful brands. Join the movement at GreenGrowthBrands.com.


LOGO

 

Cautionary Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018 which is available on the Company’s issuer profile on SEDAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

SOURCE Green Growth Brands

For further information: For investor relations inquiries, please contact: Julia Fulton, Investor & Public Relations, (614) 505-9880, jfulton@greengrowthbrands.com or Peter Horvath, (614) 508-4222; For media enquiries or interviews, please contact: Wynn Theriault, Thirty Dash Communications, 416-710-3370, wynn@thirtydash.ca or For investor relations inquiries, please contact: Eric Wright, 416-640-2963, ewright@greengrowthbrands.com

EX-3.9 14 d692201dex39.htm EX-3.9 EX-3.9

Exhibit 3.9

FORM 51-102F4

BUSINESS ACQUISITION REPORT

 

Item 1

Identity of Company

 

  1.1

Name and Address of Company

Xanthic Biopharma Inc. (“Xanthic” or the “Company”)

77 King Street West, Suite 2905

Toronto, Ontario, M5K 1A2

 

  1.2

Executive Officer

Tim Moore

Chief Executive Officer

647-966-6536

 

Item 2

Details of Acquisition

 

  2.1

Nature of Business Acquired

On July 9, 2018, Xanthic entered into a binding letter agreement (the “LOI”) with management of Green Growth Brands Ltd. (“GGB”), a corporation incorporated pursuant to the laws of Ontario, concerning an arm’s length business combination (the “Business Combination Agreement”). The LOI also provided for the acquisition by GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic, of 100% of the outstanding membership interests of Nevada Organic Remedies LLC (“NOR”), for aggregate consideration of USD$56.75 million (the “NOR Acquisition”). Xanthic entered into an agreement with NOR on July 13, 2018, and completed the NOR Acquisition on September 7, 2018.

NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada holding four Nevada marijuana licenses (dispensary, cultivation, production and distribution). Additionally, NOR produces a line of high quality medical and recreational products under the name 8|fold.

Further information about the Business Combination Agreement and the NOR Acquisition can be found in Xanthic’s news releases dated July 17, 2018 and September 7, 2018 (the “Acquisition News Releases”), copies of which have been filed under Xanthic’s profile on SEDAR at www.sedar.com.

 

  2.2

Date of Acquisition

The effective date of the NOR Acquisition is September 4, 2018.


  2.3

Consideration

Under the terms of the NOR Acquisition, GGB Nevada acquired 100% of the outstanding membership interests of NOR for aggregate consideration of USD$56.75 million.

To complete the NOR Acquisition, GGB Nevada was required to make a payment of a USD$2 million deposit (the “NOR Deposit”) and an initial cash payment of approximately USD$30.3 million (the “NOR Closing Payment”) on closing of the NOR Acquisition. To satisfy the NOR Deposit, Xanthic issued a promissory note in favour of GGB in the principal amount of USD$2 million (the “Deposit Promissory Note”). To satisfy the NOR Closing Payment, Xanthic and GGB entered into a loan agreement (the “Loan Agreement”) pursuant to which GGB loaned approximately USD$30.3 million to the Xanthic (the “Loan”). The proceeds of the Loan were sourced from a brokered and non-brokered debenture financing completed by GGB on August 30, 2018. In addition, on closing of the NOR Acquisition, GGB Nevada was required to deliver the NOR Members a secured promissory note in the principal amount of USD$21,565,000. The balance of consideration (5%) will be settled with the issuance of Xanthic shares delivered on closing of the Business Combination.

 

  2.4

Effect on Financial Position

Except as disclosed in this business acquisition report, or publicly disclosed and in the ordinary course of business, Xanthic does not have any current plans or proposals for material changes in the Company’s business affairs, which may have a significant effect on the operations and financial position of the Company, including any proposal to liquidate the business of NOR, or to sell, lease or exchange all or a substantial part of its assets. NOR will continue to be managed by the current management team that is in place.

 

  2.5

Prior Valuations

To the knowledge of the Company, there has not been any valuation opinion within the last twelve months by Xanthic required by securities legislation or a Canadian exchange or market to support the consideration paid by Xanthic in connection with the NOR Acquisition.

 

2


  2.6

Parties to Transaction

The NOR Acquisition was not with an informed person, associate or affiliate of the Company as defined in Section 1.1 of National Instrument 51-102 Continuous Disclosure Obligations.

 

  2.7

Date of Report

September 24, 2018

 

Item 3

Financial Statements

The following financial statements attached as Schedule “A” hereto are included in this Business Acquisition Report:

 

3


SCHEDULE “A”

Financial Statements

See attached.


LOGO

NEVADA ORGANIC REMEDIES LLC

Consolidated Financial Statements

As of and for the Years Ended

June 30, 2018 (Audited), 2017 (Unaudited)

 

 

 

 

 

 

   LOGO   

Certified

Public

Accountants

 


NEVADA ORGANIC REMEDIES LLC

INDEX TO FINANCIAL STATEMENTS

 

 

     Page  

INDEPENDENT AUDITOR’S REPORT

     1  

FINANCIAL STATEMENTS:

  

Consolidated Balance Sheets

     2  

Consolidated Statements of Operations and Changes in Members’ Equity

     3  

Consolidated Statements of Cash Flows

     4  

Notes to the Consolidated Financial Statements

     5-12  


LOGO   

Certified

Public

Accountants

Independent Auditor’s Report

To the Board of Directors

of Nevada Organic Remedies LLC

We have audited the accompanying consolidated financial statements of Nevada Organic Remedies LLC (the “Company”), which comprise the consolidated balance sheet as of June 30, 2018, and the related consolidated statements of operations and changes in members’ equity, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2018, and the results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Prior Period Financial Statements

The accompanying consolidated balance sheet for the Company as of June 30, 2017 and the related consolidated statements of operations and changes in members’ equity, and cash flows for the year then ended, and the related notes to the consolidated financial statements were not audited by us and accordingly we do not express an opinion or other form of assurance on them.

 

LOGO

San Diego, California

September 21, 2018

 

 

Macias Gini & O’Connell LLP

12264 El Camino Real, Suite 402

San Diego, CA 92130

   1   

www.mgocpa.com


NEVADA ORGANIC REMEDIES LLC

CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

 

     2018
(Audited)
     2017
(Unaudited)
 

ASSETS

     

Current Assets:

 

Cash and Cash Equivalents

   $ 601,010      $ 316,281  

Accounts Receivable

     336,762        —    

Inventory

     1,857,445        532,694  

Prepaid Expenses and Other Current Assets

     124,418        16,677  

Due from Related Party

     212,467        —    
  

 

 

    

 

 

 

Total Current Assets

     3,132,102        865,652  

Property and Equipment, Net

     390,003        124,946  

Other Assets

     2,100        2,100  
  

 

 

    

 

 

 

TOTAL ASSETS

   $ 3,524,205      $ 992,698  
  

 

 

    

 

 

 

LIABILITIES AND MEMBERS’ EQUITY

     

Current Liabilities:

 

Accounts Payable

   $ 677,537      $ 154,721  

Accrued Liabilities

     261,887        436,502  

Notes Payable

     85        405,188  

Due to Related Party

     —          389,984  
  

 

 

    

 

 

 

TOTAL LIABILITIES

     939,509        1,386,395  
  

 

 

    

 

 

 

MEMBERS’ EQUITY (DEFICIT)

     2,584,696        (393,697
  

 

 

    

 

 

 

TOTAL LIABILITIES AND MEMBERS’ EQUITY

   $ 3,524,205      $ 992,698  
  

 

 

    

 

 

 

See Accompanying Notes to the Consolidated Financial Statements.

 

2


NEVADA ORGANIC REMEDIES LLC

CONSOLIDATED STATEMENT OF OPERATIONS AND CHANGES IN MEMBERS’ EQUITY

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

 

 

     2018
(Audited)
    2017
(Unaudited)
 

Revenues

   $ 18,991,307     $ 5,644,805  

Cost of Goods Sold

     9,533,001       3,641,979  
  

 

 

   

 

 

 

Gross Profit

     9,458,306       2,002,826  
  

 

 

   

 

 

 

Operating Expenses:

 

General and Administrative

     4,504,593       1,767,261  

Sales and Marketing

     334,215       172,369  

Depreciation

     26,126       12,780  
  

 

 

   

 

 

 

Total Operating Expenses

     4,864,934       1,952,410  
  

 

 

   

 

 

 

Income from Operations

     4,593,372       50,416  
  

 

 

   

 

 

 

Other Income (Expense):

 

Interest Expense, Net

     (34,737     (1,217

Other Income (Expense)

     3,856       (123,010
  

 

 

   

 

 

 

Total Other Income (Expense)

     (30,881     (124,227
  

 

 

   

 

 

 

Net Income (Loss)

   $ 4,562,491     $ (73,811
  

 

 

   

 

 

 

Members’ Deficit - Beginning of Period

   $ (393,697   $ (806,510

Net Income (Loss)

     4,562,491       (73,811

Contributions from Members

     —         738,817  

Distributions to Members

     (1,584,098     (252,193
  

 

 

   

 

 

 

Members’ Equity (Deficit) - End of Period

   $ 2,584,696     $ (393,697
  

 

 

   

 

 

 

See Accompanying Notes to the Consolidated Financial Statements.

 

3


NEVADA ORGANIC REMEDIES LLC

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

 

 

     2018
(Audited)
    2017
(Unaudited)
 

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net Income (Loss)

   $ 4,562,491     $ (73,811

Adjustments to Reconcile Net Income (Loss) to Net Cash Provided By Operating Activities:

    

Depreciation

     63,170       52,132  

Changes in Operating Assets and Liabilities:

    

Accounts Receivable

     (336,762     —    

Inventory

     (1,324,751     (189,132

Prepaid Expenses and Other Current Assets

     (107,741     (5,133

Other Assets

     —         325  

Due from Related Parties

     (212,467     —    

Accounts Payable and Accrued Liabilities

     348,201       (15,094

Due to Related Parties

     (389,984     (71,262
  

 

 

   

 

 

 

NET CASH PROVIDED BY OPERATING ACTIVITIES

     2,602,157       (301,975
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Purchases of Property and Equipment

     (328,227     (4,695
  

 

 

   

 

 

 

NET CASH USED IN INVESTING ACTIVITIES

     (328,227     (4,695
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Contributions from Members

     —         738,817  

Distributions to Members

     (1,584,098     (252,193

Principal Repayments of Notes Payable

     (405,103     (4,201
  

 

 

   

 

 

 

NET CASH USED IN FINANCING ACTIVITIES

     (1,989,201     482,423  
  

 

 

   

 

 

 

NET INCREASE IN CASH AND CASH EQUIVALENTS

     284,729       175,753  

CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR

     316,281       140,528  
  

 

 

   

 

 

 

CASH AND CASH EQUIVALENTS, END OF YEAR

   $ 601,010     $ 316,281  
  

 

 

   

 

 

 

CASH PAID DURING THE YEAR FOR:

    

Interest

   $ 612     $ 1,217  
  

 

 

   

 

 

 

See Accompanying Notes to the Consolidated Financial Statements.

 

4


NEVADA ORGANIC REMEDIES LLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

 

1.

NATURE OF OPERATIONS

 

The Company and its wholly owned subsidiaries, are a vertically integrated cultivation, production and retail medical and recreational marijuana company based in Las Vegas, Nevada holding four Nevada cannabis licenses (dispensary, cultivation, production and distribution). Through its cultivation and production operations, the Company produces high quality medical and recreational products which are sold through the Company’s dispensary and sold wholesale to various dispensaries. The dispensary is located one facility and the cultivation and production facility in a second facility, all located in Las Vegas, Nevada.

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Preparation

The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All significant intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents

Cash and cash equivalents consists of cash on hand and cash deposits in financial institutions and other deposits that are readily convertible into cash.

Accounts Receivable

Accounts receivable are stated at an amount management expects to collect from outstanding balances and are recorded when invoices are issued. Management provides from probable uncollectible amounts through a charge to earnings and a credit to a valuation allowance based on its assessment of the current status of individual accounts. The allowance for doubtful account was zero at June 30, 2018 and 2017. The Company had zero bad debt expenses for the years ended June 30, 2018 and 2017.

Inventory

Inventory includes cannabis and cannabis-related products and is valued at the lower of cost and net realizable value. Cost is determined using the average method for cultivation, production and retail inventory. Net realizable value is determined as the estimated selling price in the ordinary course of business less estimated costs to sell. Packaging and supplies are initially valued at cost. The Company reviews inventory for obsolete, redundant and slow-moving goods and any such inventory is written-down to net realizable value. As of June 30, 2018 (audited) and 2017 (unaudited), the Company determined that no reserve was necessary.

 

5


NEVADA ORGANIC REMEDIES LLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

 

Property and Equipment

Property and equipment is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method using the following methods and estimated useful lives:

 

Category

  

Depreciation Method

  

Estimated

Useful

Life

Leasehold Improvements    Amortized Over the Life of the Lease or the Estimated Useful Life of the Improvement, Whichever is Less    10 Years
Furniture and Fixtures    Depreciated Over the Estimated Useful Life of the Asset    5 Years
Manufacturing Equipment    Depreciated Over the Estimated Useful Life of the Asset    3 Years
Automobiles    Depreciated Over the Estimated Useful Life of the Asset    3 Years

The assets’ residual values, useful lives and methods of depreciation are reviewed at each financial year-end and adjusted prospectively if appropriate. An item of equipment is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying value of the asset) is included in the Statement of Operations and Changes in Members’ Equity in the year the asset is derecognized.

Repairs and maintenance that do not improve efficiency or extend economic life are charged to expense as incurred.

Impairment of Long-Lived Assets

Long-lived assets such as property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, but no less frequently than annually. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows (undiscounted and without interest charges) expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. There were no impairments recorded during the years ended June 30, 2018 (audited) and 2017 (unaudited).

 

6


NEVADA ORGANIC REMEDIES LLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

 

Income Taxes

The Company is a limited liability company that has elected to be treated as a partnership for federal income tax purposes. Under federal law, the taxable income or loss of a limited liability company is allocated to its members. Accordingly, no provision has been made for federal income taxes.

FASB ASC Topic No. 740, “Accounting for Uncertainty in Income Taxes” (“ASC 740”), clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company did not recognize any tax benefits from uncertain tax positions during the year ended June 30, 2018 (audited) and 2017 (unaudited). The Company is no longer subject to state examinations by tax authorities for the years before June 30, 2014.

Revenue Recognition

Revenue is recognized at the fair value of consideration received or receivable. Revenue from the sale of goods is recognized when all the following conditions have been satisfied, which are generally met once the products are received by customers:

 

   

The Company has transferred the significant risks and rewards of ownership of the goods to the purchaser;

 

   

The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;

 

   

The amount of revenue can be measured reliably;

 

   

It is probable that the economic benefits associated with the transaction will flow to the entity; and

 

   

The costs incurred or to be incurred in respect of the transaction can be measured reliably.

Cost of Goods Sold

Cost of goods sold includes the costs directly attributable to product sales and includes amounts paid for finished goods, such as flower, edibles and concentrates, as well as packaging and other supplies, fees for services and processing, and other expenses for services.

Advertising Costs

Advertising costs are charged to expense when incurred. Advertising expense for the year ended June 30, 2018 and 2017 was $287,458 (audited) and $152,167 (unaudited), respectively.

 

7


NEVADA ORGANIC REMEDIES LLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

 

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, accounts receivables, accounts payables and accrued liabilities, and notes payable. The carrying values of these financial instruments approximate their fair values as of June 30, 2018 and 2017, respectively.

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three levels of hierarchy are:

 

  Level

1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

 

  Level

2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and

 

  Level

3 – Inputs for the asset or liability that are not based on observable market data.

There have been no transfers between fair value levels during the year.

Use of Estimates

Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Accordingly, actual results could differ from those estimates.

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), a new standard on revenue recognition. Further, the FASB has issued a number of additional ASUs regarding the new revenue recognition standard. The new standard, as amended, will supersede existing revenue recognition guidance and apply to all entities that enter into contracts to provide goods or services to customers. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers — Deferral of the Effective Date, which amends ASU 2014-09 to defer the effective date by one year. The new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Entities are allowed to use either the full or modified retrospective approach when transitioning to the ASU. The Company expects to implement the provisions of ASU 2014-09 as of July 1, 2019 and has not yet selected a transition method. The adoption of this ASU is not expected to have a material effect on the Company’s consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10)—Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 is intended to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. ASU 2016-01 is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods beginning after December 15, 2019. The adoption of this ASU is not expected to have a material effect on the consolidated financial statements.

 

8


NEVADA ORGANIC REMEDIES LLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

 

In February 2016, the FASB issued ASU 2016-02, Leases, which supersedes the current accounting for leases and while retaining two distinct types of leases, finance and operating, (1) requires lessees to record a right of use asset and a related liability for the rights and obligations associated with a lease, regardless of lease classification, and recognize lease expense in a manner similar to current accounting, (2) eliminates most real estate specific lease provisions, and, (3) aligns many of the underlying lessor model principles with those in the new revenue standard. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2019. Entities are required to use a modified retrospective approach when transitioning to the ASU for leases that exist as of or are entered into after the beginning of the earliest comparative period presented in the financial statements. The Company expects to implement the provisions of ASU 2016-02 as of July 1, 2020. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.

 

3.

SIGNIFICANT CONCENTRATIONS OF CREDIT RISK

 

The Company places its cash with high quality financial institutions and may be redeemed upon demand. The Federal Deposit Insurance Corporation (“FDIC”) provides coverage of at least $250,000 available to depositors under the FDIC’s general deposit insurance rules. From time to time the Company has account balances with its financial institutions that are in excess of the insured amounts, and, therefore, those excess account balances are uninsured. There were approximately $16,000 (audited) in excess of the FDIC insurance limit at June 30, 2018. At June 30, 2017, the Company had no amounts in excess of the FDIC insurance limit (unaudited).

The Company grants unsecured credit to its customers for purchase of its cultivation and production products. As of June 30, 2018, there was one customer, who is a related party, see Note 9, which accounted for 51 percent (audited) of the total accounts receivable as of June 30, 2018. As of June 30, 2017, the Company had no accounts receivable (unaudited).

 

4.

INVENTORY

 

As of June 30, 2018 (audited) and 2017 (unaudited), inventory consisted of:

 

     2018
(Audited)
     2017
(Unaudited)
 

Work-in-Progress

   $ 744,577      $  335,818  

Finished Goods

     1,112,868        196,876  
  

 

 

    

 

 

 

Total Inventory

   $  1,857,445      $ 532,694  
  

 

 

    

 

 

 

 

9


NEVADA ORGANIC REMEDIES LLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

 

5.

PROPERTY AND EQUIPMENT

 

As of June 30, 2018 (audited) and 2017 (unaudited), property and equipment consisted of the following:

 

     2018
(Audited)
     2017
(Unaudited)
 

Furnitures and Fixtures

   $ 94,063      $ 94,063  

Leasehold Improvements

     304,890        26,898  

Manufacturing Equipment

     91,197        40,962  

Automobiles

     26,688        26,688  
  

 

 

    

 

 

 

Total Property and Equipment, Gross

     516,838        188,611  

Less: Accumulated Depreciation

     (126,835      (63,665
  

 

 

    

 

 

 

Property and Equipment, Net

   $ 390,003      $  124,946  
  

 

 

    

 

 

 

Depreciation expense of $63,170 (audited) and $52,132 (unaudited) was recorded for the year ended June 30, 2018 and 2017, respectively, of which $37,044 (audited) and $39,352 (unaudited), respectively, is included in cost of goods sold.

 

6.

NOTES PAYABLE

 

As of June 30, 2018 (audited) and 2017 (unaudited) notes payable consisted of the following:

 

     2018
(Audited)
     2017
(Unaudited)
 

Automobile Loan - Secured promissory note dated June 01, 2016, which matures on September 1, 2018, and bears-interest at 4.47%.

   $ 85      $ 17,070  

Note payable due to a member. The note payable bears interest at 5% and matured March 31, 2017 and due on demand anytime after thereof.

     —          200,000  

Note payable due to a member. The note payable bears interest at 5% and due on demand anytime after thereof.

     —          188,118  
  

 

 

    

 

 

 

Total Notes Payable

   $  85      $  405,188  
  

 

 

    

 

 

 

During the year ended June 30, 2018 (audited), the notes payables to the members matured and were paid in full by the Company.

 

10


NEVADA ORGANIC REMEDIES LLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

 

7.

MEMBERS’ EQUITY (DEFICIT)

 

The Company formed Nevada limited liability companies on April 16, 2014. Allocations of profits and losses are allocated pro rata in proportion to the member’s capital interest. There are no members units. No member has the right to transfer any or part of their membership interest without the express written permission of a vote of members.

During the year ended June 30, 2017, the members of the Company forgave amounts due from related parties of $738,817 (unaudited). The amount was recorded as a contribution. No contributions were made during the year ended June 30, 2018.

During the year ended June 30, 2017, the Company distributed $252,193 (unaudited) in cash to its members. During the year ended June 30, 2018, the Company distributed $875,000 (audited) in cash to its members and forgave $709,098 (audited) of amounts due from related parties. The amounts forgiven was recorded as a distribution to its members.

 

8.

COMMITMENTS AND CONTINGENCIES

 

Office and Operating Leases

The Company leases all of its business facilities from a related party under operating lease agreements that specify minimum rentals and a percent of net revenues. The leases expire through December 2025 and contain certain renewal provisions. The Company’s rent expense for the years ended June 30, 2018 and 2017 was $1,393,452 (audited) and $638,715 (unaudited), respectively, of which $441,506 (audited) and $330,248 (unaudited), respectively, is included in cost of goods sold. Percentage rent was $1,034,270 (audited) and $332,715 (unaudited), respectively, of which $201,506 (audited) and $90,248 (unaudited), respectively, is included in cost of goods sold.

Future minimum lease payments for the next five years and thereafter are as follows:

 

Year Ending June 30,

   Scheduled
Payments
 

2019

   $ 467,354  

2020

     467,354  

2021

     467,354  

2022

     467,354  

2023

     467,354  

Thereafter

     804,630  
  

 

 

 

Total Future Minimum Lease Payments

   $  3,141,400  
  

 

 

 

Contingencies

The Company’s operations are subject to a variety of local and state regulation. Failure to comply with one or more of those regulations could result in fines, restrictions on its consolidated operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulation as of June 30, 2018, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future.

 

11


NEVADA ORGANIC REMEDIES LLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, 2018 (AUDITED) and 2017 (UNAUDITED)

 

 

8.

COMMITMENTS AND CONTINGENCIES (Continued)

 

 

Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2018 (audited) and 2017 (unaudited), there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s consolidated operations. There are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party or has a material interest adverse to the Company’s interest.

 

9.

RELATED PARTY TRANSACTIONS

 

From time to time, the Company enters into transactions with companies owned by members of the Company. During the year ended June 30, 2017, the Company was advanced amounts from an entity owned by members of the Company. The amount due under this advance as of June 30, 2017 was $389,984 (unaudited). During the year ended June 30, 2018, this advance was paid in full. During the year ended June 30, 2018, the Company advanced funds to entities that are owned by members of the Company. As of June 30, 2018, the amount due from these entities was $212,467 (audited).

The Company, through its cultivation and production operations sells cannabis products to dispensaries owned by members of the Company. During the years ended June 30, 2018 and 2017, the Company sold $969,611 (audited) and $563,058 (unaudited), respectively, to related parties. The balance due from the related parties in accounts receivable as of June 30, 2018 was $173,223 (audited). There were no amounts due from related parties in accounts receivable as of June 30, 2017 (unaudited).

 

10.

SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through September 21, 2018, which is the date these consolidated financial statements were issued. All subsequent events requiring recognition as of June 30, 2018 and 2017 have been incorporated into these consolidated financial statements.

In September 2018, the members of the Company sold 100% of their membership interest to GGB Nevada LLC in an arm’s length arrangement. The Company has yet to assess the impact of this transaction on its consolidated financial statements.

 

12

EX-3.10 15 d692201dex310.htm EX-3.10 EX-3.10

Exhibit 3.10

AURQUEST RESOURCES INC.

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

AND

MANAGEMENT INFORMATION CIRCULAR

IN RESPECT OF THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS OF

AURQUEST RESOURCES INC. TO BE HELD ON FEBRUARY 16, 2018

Dated as of January 11, 2018


AURQUEST RESOURCES INC.

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that an Annual and Special Meeting (the “Meeting”) of the holders of common shares (the “Shareholders”) of Aurquest Resources Inc. (the “Corporation” or “Aurquest”) will be held at the offices of Fogler, Rubinoff LLP, 77 King Street West, Suite 3000, Toronto, Ontario, M5K 1G8, on Friday, February 16, 2018, at 10:00 a.m. (Toronto time), for the following purposes:

 

1.

TO RECEIVE the audited consolidated financial statements of Aurquest for the financial year ended October 31, 2017, together with the auditor’s report thereon;

 

2.

TO CONSIDER, and if deemed advisable, to pass a special resolution, the full text of which is set forth in the Information Circular, to fix the number of directors of the Corporation at seven;

 

3.

TO ELECT the directors of the Corporation;

 

4.

TO CONSIDER and if deemed advisable, to pass a special resolution, the full text of which is set forth in the Information Circular, empowering the directors of the Corporation to determine from time to time the number of directors of the Corporation to be elected at an annual meeting;

 

5.

TO APPOINT MNP LLP, Chartered Accountants as the auditor of the Corporation and authorize the board of directors of the Corporation to fix the remuneration of the auditor;

 

6.

TO CONSIDER, and if deemed advisable, to pass an ordinary resolution, the full text of which is set forth in the accompanying management information circular (the “Information Circular”), approving the Corporation’s 10% rolling stock option plan;

 

7.

TO CONSIDER and, if deemed advisable, to pass a special resolution, the full text of which is set forth in the Information Circular, with or without variation, approving the proposed consolidation of the common shares of the Corporation;

 

8.

TO CONSIDER, and if deemed advisable, to pass a special resolution, the full text of which is set forth in the Information Circular, with or without variation, amending the Corporation’s articles of incorporation to change the name of the Corporation to “Xanthic Biopharma Inc.” or such other name as may be determined by the board of directors;

 

9.

TO CONSIDER, and if deemed advisable, to approve a special resolution, the full text of which is set forth in the Information Circular, to change the municipality in which the Corporation’s registered office is located, from the Town of North York to the City of Toronto, Ontario;

 

10.

TO CONSIDER, and if deemed advisable, to approve a special resolution, the full text of which is set forth in the Information Circular, to confirm, ratify and approve the by-laws of the Corporation; and

 

11.

TO TRANSACT such other business as may properly come before the Meeting or any adjournments or postponements thereof.

Accompanying this Notice of Meeting are, among other things: (1) the Information Circular; (2) a form of proxy, which includes a supplemental mailing list request form for use by shareholders who wish to receive the Company’s financial statements. The Information Circular provides further information respecting proxies and the matters to be considered at the Meeting and is deemed to form part of this Notice of Meeting.


Shareholders who are unable to attend the Meeting in person and who wish to ensure that their common shares will be voted at the Meeting, must complete, date and execute the enclosed form of proxy, or another suitable form of proxy, and deliver it in accordance with the instructions set out in the form of proxy and in the Information Circular.

Beneficial shareholders who plan to attend the Meeting must follow the instructions set out in the form of proxy and in the Information Circular to ensure that their shares will be voted at the Meeting. If you hold your common shares in a brokerage account, you are not a registered shareholder.

DATED this 11th day of January 2018.

BY ORDER OF THE BOARD OF DIRECTORS

Tim Moore

Tim Moore

Chief Executive Officer

 

ii


AURQUEST RESOURCES INC.

(the Corporation”)

MANAGEMENT INFORMATION CIRCULAR

January 11, 2018

GENERAL INFORMATION RESPECTING THE MEETING

This Management Information Circular (“Information Circular”) is furnished in connection with the solicitation of proxies by the management of the Corporation for use at the annual and special meeting (the “Meeting”) of the holders of Common Shares of the Corporation (“Shareholders”) to be held on February 16, 2018, at 10:00 a.m. (Toronto time) at the offices of Fogler, Rubinoff LLP 77 King Street West, Suite 3000, Toronto, Ontario, M5K 1G8, and at any adjournment(s) thereof, for the purposes set forth in the accompanying Notice of Meeting.

In this Information Circular, references to the “Corporation”, “we” and “our” refer to Aurquest Resources Inc., and “Common Shares” means common shares without par value in the capital of the Corporation.

GENERAL PROXY INFORMATION

Solicitation of Proxies

The cost of solicitation by or on behalf of management will be borne by the Corporation. The Corporation may reimburse brokers, custodians, nominees and other fiduciaries for their reasonable charges and expenses incurred in forwarding the proxy material to beneficial owners of shares. It is expected that such solicitation will be primarily by mail. In addition to solicitation by mail, certain officers, directors, and employees of the Corporation may solicit proxies by telephone or personally. These persons will receive no compensation for such solicitation other than their regular salaries.

Appointment of Proxy holders

The Common Shares represented by the accompanying form of proxy (if the same is properly executed in favour of the management nominees, Tim Moore, or failing him, Igor Galitsky, and is received at the offices of Capital Transfer Agency (“Capital Transfer”) not later than 10:00 a.m. (Toronto time) February 14, 2018, or, if the Meeting is adjourned, not later than 48 hours, excluding Saturdays, Sundays and holidays, preceding the time of such adjourned Meeting) will be voted at the Meeting, and where a choice is specified in respect of any matter to be acted upon, will be voted in accordance with the specifications made. In the absence of such a specification, such Common Shares will be voted in favour of such matter. The form of proxy sets out specific instructions for completing and returning the proxy in order to be properly counted at the Meeting.

The accompanying form of proxy confers discretionary authority upon the persons named therein with respect to amendments or variations to matters identified in the annexed notice of Meeting, and with respect to other matters which may properly come before the Meeting. At the date hereof, management of the Corporation knows of no such amendments, variations or other matters.

Each Shareholder has the right to appoint a person other than the persons named in the accompanying form of proxy, who need not be a Shareholder, to attend and act for him and on his behalf at the Meeting. Any Shareholder wishing to exercise such right may do so by inserting in the blank space provided in the accompanying form of proxy the name of the person whom such Shareholder


wishes to appoint as proxy and by duly depositing such proxy, or by duly completing and depositing another proper form of proxy.

In addition to revocation in any other manner permitted by law, only a registered shareholder (“Registered Shareholder”) who has given a proxy may revoke it by:

 

  (a)

executing a proxy bearing a later date or by executing a valid notice of revocation, either of the foregoing to be executed by the Registered Shareholder or the Registered Shareholder’s authorized attorney in writing, or, if the shareholder is a corporation, under its corporate seal by an officer or attorney duly authorized, and by delivering the proxy bearing a later date to Capital Transfer at 920-390 Bay Street, Toronto ON, M5H 2Y2, at any time up to and including the last business day that precedes the day of the Meeting or, if the Meeting is adjourned, the last business day that precedes any reconvening thereof, or to the chairman of the Meeting on the day of the Meeting or any reconvening thereof, or in any other manner provided by law, or

 

  (b)

personally attending the Meeting and voting the Registered Shareholder’s Common Shares.

A revocation of a proxy will not affect a matter on which a vote is taken before the revocation.

Registered Shareholders

Registered Shareholders may wish to vote by proxy whether or not they are able to attend the Meeting in person. Registered Shareholders electing to submit a proxy may do so by completing, dating and signing the enclosed proxy and returning it to the Corporation’s transfer agent, Capital Transfer, 920-390 Bay Street, Toronto ON, M5H 2Y2; or (ii) by facsimile at (416) 350-5007; or (iii) via email to investor@capitaltransferagency.com; (iv) by internet at www.voteproxyonline.com ; or (v) hand delivery to 920-390 Bay Street, Toronto ON M5H 2Y2 not less than forty-eight (48) hours, excluding Saturdays, Sundays or statutory holidays in the Province of Ontario, before the time set for the holding of the Meeting or any adjournment(s) thereof.    

Beneficial Shareholders

The information set forth in this section is of significant importance to shareholders who do not hold Common Shares in their own name (“Beneficial Shareholders”). A Shareholder is a Beneficial Shareholder if (i) an intermediary (such as a bank, trust company, securities dealer or broker, trustee or administrator of a registered retirement savings plan, registered retirement income fund, deferred profit sharing plan, registered education savings plan, registered disability savings plan or tax-free savings account), or (ii) a clearing agency (such as CDS Clearing and Depository Services Inc. or Depository Trust and Clearing Corporation), of which the intermediary is a participant (in each case, an “Intermediary”), holds the Shareholder’s Common Shares on behalf of that shareholder.

Beneficial Shareholders should note that the only proxies that can be recognized and acted upon at the Meeting are those deposited by Registered Shareholders (those whose names appear on the records of the Corporation as the registered holders of Common Shares).

In accordance with National Instrument 54-101Communication with Beneficial Owners of Securities of a Reporting Issuer (“NI 54-101”), the Corporation is distributing copies of a voting instruction form in lieu of a proxy provided by the Corporation, to Intermediaries for distribution to Beneficial Shareholders and such Intermediaries are to forward a voting instruction form in lieu of a proxy provided by the Corporation, to each Beneficial Shareholders (unless the Beneficial Shareholders has declined to receive such materials). Applicable regulatory policy requires Intermediaries to seek voting instructions from

 

2


Beneficial Shareholders in advance of shareholders’ meetings. Every Intermediary has its own mailing procedures and provides its own return instructions, which should be carefully followed by Beneficial Shareholders in order to ensure that their Common Shares are voted at the Meeting. Often, the form of proxy supplied to a Beneficial Shareholder by its Intermediary is identical to the form of proxy provided to registered Shareholders. However, its purpose is limited to instructing the registered Shareholders how to vote on behalf of the Beneficial Shareholder.    

Such Intermediaries often use a service company, such as Broadridge Financial Solutions Inc. (“Broadridge”), to permit the Beneficial Shareholders to direct the voting of the Common Shares held by the Intermediary on behalf of the Beneficial Shareholder. The Corporation is paying Broadridge to deliver, on behalf of the Intermediaries, a copy of a voting instruction form in lieu of a Proxy provided by the Corporation, to each “non-objecting beneficial owner” and each “objecting beneficial owner” (as those terms are defined in NI 54-101). Broadridge typically applies a decal to the proxy forms, mails those forms to the Beneficial Shareholders, and asks Beneficial Shareholders to return the proxy forms to Broadridge.    Broadridge then tabulates the results of all instructions received and provides appropriate instructions respecting the voting of Common Shares to be represented at the Meeting. A Beneficial Shareholder receiving a proxy with a Broadridge decal on it cannot use that proxy to vote Common Shares directly at the Meeting. The proxy must be returned to Broadridge well in advance of the Meeting in order to have the shares voted.

Since the Corporation only has access to the names of its Registered Shareholders, if a Beneficial Shareholder attends the Meeting, the Corporation will have no record of the Beneficial Shareholder’s shareholdings or of its entitlement to vote unless the Beneficial Shareholder’s nominee has appointed the Beneficial Shareholder as proxyholder. Therefore, a Beneficial Shareholder who wishes to vote in person at the Meeting must insert its own name in the space provided on the voting instruction form sent to the Beneficial Shareholder by its nominee, and sign and return the voting instruction form in accordance with its nominee’s instructions. By doing so, the Beneficial Shareholder will be instructing its nominee to appoint the Beneficial Shareholder as proxyholder. The Beneficial Shareholder should not otherwise complete the voting instruction form as its vote will be taken at the Meeting.

INTEREST OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON

Other than as disclosed herein, no director or executive officer of the Corporation who has held such position at any time since the beginning of the Corporation’s last financial year and associates or affiliates of the foregoing persons, has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matters to be acted upon at the Meeting.

VOTING SECURITIES AND PRINCIPAL HOLDERS OF VOTING SECURITIES

Each holder of Common Shares of record at the close of business on January 11, 2018, (the “Record Date”), is entitled to vote at the Meeting or at any adjournment thereof, either in person or by proxy.

As of the Record Date, the Corporation had 349,684,184 Common Shares issued and outstanding. Each Common Share carries the right to one vote.    

To the knowledge of the directors and senior officers of the Corporation, no person or Corporation beneficially owns, or controls or directs, directly or indirectly, 10% or more of any class of voting securities of the Corporation, on a non-diluted basis except for the following.

 

Shareholder Name

   Number of Common
Shares Held
     % of Class on undiluted
and fully diluted basis
 

Igor Galitsky

     40,000,000        11.44

 

3


MATTERS TO BE ACTED ON AT THE MEETING

A. Number of Directors

The articles of incorporation of the Corporation provide that the board of directors of the Corporation (the “Board”) shall consist of a minimum of one and a maximum of fifteen directors. Currently, the Corporation’s Board is set to have seven directors. The Corporation wishes to fix the number of directors at seven.

At the Meeting, Shareholders will be asked to approve a special resolution fixing the number of directors at seven (the “Resolution Fixing the Number of Directors”) in the form set out below. The approval of the special resolution requires the affirmative vote of 2/3 of the votes cast by Shareholders present in person or represented by proxy at the Meeting.

BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

  (a)

the number of directors of the Corporation be fixed at seven; and

 

  (b)

any director or officer of the Corporation be and each of them is hereby authorized to do such things and to execute and deliver all such documents that such director or officer may, in his discretion, determine to be necessary or useful in order to give full effect to the intent and purpose of this resolution.”

Based on the foregoing, the Board unanimously recommends that Shareholders vote FOR the Resolution Fixing the Number of Directors set out above.

Common Shares represented by proxies in favour of management nominees will be voted FOR the Resolution Fixing the Number of Director unless a Shareholder has specified in his, her or its proxy that such Common Shares are to be voted against such resolution.

B. Election of Directors

The articles of incorporation of the Corporation provide that the Board shall consist of a minimum of one and a maximum of fifteen directors. Provided that Shareholders shall have approved the Resolution Fixing the Number of Directors at the Meeting, the directors have determined that there will be seven persons elected to the Board at the Meeting.

Management proposes that each of the persons named below be nominated at the Meeting for re-election or election, as the case may be, as directors of the Corporation to serve, until the next annual meeting of Shareholders or until his or her successor is elected or appointed. Management does not contemplate that any of the nominees will be unable to serve as a director. However, if a nominee should be unable to so serve for any reason prior to the Meeting, the persons named in the enclosed form of proxy reserve the right to vote for another nominee in their discretion. Common Shares represented by proxies in favour of management nominees will be voted FOR the election of all of the nominees whose names are set forth below, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting on the election of directors.

The following table and the notes thereto state the names of all persons to be nominated for election as directors, all other positions or offices with the Corporation now held by them, their principal occupations of employment, the year in which they became directors for the Corporation, the approximate number of Common Shares beneficially owned, or controlled or directed, directly or indirectly, by each of them, as

 

4


of the date hereof, and the number of options to acquire Common Shares held by each of them as of the date hereof.

Common Shares represented by proxies in favour of the management nominees will be voted FOR the appointment of each of the nominees as a director of the Corporation, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting for any or all of the nominees.

 

Name and

Province of Residence

  

Principal Occupation and

Present Offices Held

   Year first became
director
   Number of Common
Shares / Options
Beneficially Owned, or
Controlled or Directed,
Directly or Indirectly

Tim Moore

  

CEO of Xanthic Biopharma Inc.

   December 15, 2017    12,400,000/Nil

Ontario, Canada

        

Igor Galitsky (1)

  

President of Xanthic Biopharma Inc.

   December 15, 2017    40,000,000/Nil

Ontario, Canada

        

Dr. Shafik Dharamshi

  

Medical Doctor - Scarborough Rouge Hospital.

   December 15, 2017    Nil/Nil

Ontario, Canada

        

Dr. Gunther Hintz

  

Medical Doctor - Medicorps

   Nominee    Nil/Nil

Ontario, Canada

        

Carli Posner

  

Co-CEO and Principal of Notable Life

   Nominee    Nil/Nil

Ontario, Canada

        

David Lubotta(1)

  

Chairman of CoolSafe Enterprises Inc.

   Nominee    Nil/Nil

Ontario, Canada

        

Peter Schwartz(2)

New York, U.S.A.

  

Business Economics Consultant – Anderson Economic Group

   Nominee    Nil/Nil

Notes:

 

(1)

Members or proposed members of the Audit Committee of the Board

(2)

Proposed Chairman of the Audit Committee

Director Biographies

Set forth below is a description of principal occupations of each nominee during the past five years:

Tim Moore – CEO and Director

Mr. Moore has been Chief Executive Officer of Xanthic Biopharma Inc. (“Xanthic”) since July 2017. Tim has over 30 years’ experience in various consumer products companies, including 18 years with The Clorox Company, a NYSE listed company. Previous to Xanthic, Tim was the Managing Director, North America, for Brita GmbH, a privately held German manufacturer of water filters. Previous to Brita, Tim was Chief Operating Officer for Synnex, a NYSE listed electronics distribution company. Tim Moore holds a Bachelor of Arts (Economics) from Western University and a Master of Business Administration from the Richard Ivey School of Business.

 

5


Igor Galitsky - Director

Mr. Galitsky has been consultant for a number of licensed medical cannabis producers to develop both scaled plant production growth strategy as well as extraction and secondary processes. Mr. Galitsky has been producing craft cannabis for designated use for seven years and was one of the earliest applicants to receive a license under the Marijuana Medical Access Regulations for both personal and designated production.

Dr. Shafik Dharamshi, MD, CCFP, CPI, CIME – Director

Dr. Shafik Dharamshi is a physician registered with the College of Physicians and Surgeons of Ontario and is certified by the Canadian College of Family Physicians. He studied Biochemistry at McMaster University and received his Medical Degree from the University of Toronto. He has been practicing Emergency Medicine for the past 28 years and is currently a Staff Physician in the Emergency Department of the Scarborough Rouge Hospital. He has spent over ten years actively involved in senior roles in Phase 1, Phase 4 research and Biotechnology companies in Ontario. He has also been practicing Insurance and Medical Legal consulting for the past 22 years. Dr. Dharamshi has been appointed as a Lecturer, University of Toronto, Faculty of Medicine, Department of Family and Community Medicine, Division of Emergency Medicine.

Dr. Gunter Hintz, MD – Director to be nominated

German-born Dr. Gunther Hintz spent most of his adult life in the US as a physician following his education in Germany and residency in Sweden and Denmark. In Hawaii, following a time as a private practitioner, he founded a multi-physician group of plastic and reconstructive surgeons which he left in 1986 to dedicate himself exclusively to charitable work overseas with Medicorps, an international volunteer organization aiming to improve health-care globally and reduce poverty in disadvantaged countries.

Carli Posner - Director to be nominated

Ms. Posner is the Co-CEO and Principal of Notable Life, a media company that reaches over 1.2 million high-earning millennials across Canada. Prior to Notable, she was the Executive Producer of the hit show Hockey Wives, overseeing many departments including premium sponsors and media strategy. Ms. Posner has spent a significant portion of her career in Los Angeles, working in film finance and production. She is the leading talent packager in our country and has worked with top stars including George Clooney, Coldplay, Drew Barrymore, Jamie Oliver and Wayne Gretzky, to name a few. During Ms. Posner’s career, she has generated over $100 million dollars of sponsorships and endorsements in the Canadian marketplace with top brands including Mastercard, Corvette, Scotiabank, BMW and LG.

David Lubotta - Director to be nominated

Mr. Lubotta has a solid track record of innovative and entrepreneurial accomplishments. With over 20 years of experience in business, Mr. Lubotta brings an admirable depth of leadership. Mr. Lubotta is a Principal in Red Team Wins (RTW is a leader in the agency sector of the vastly growing E-gaming/E-sports industry). Mr. Lubotta is also the founder and current Co-Chairman of CoolSafe Enterprises (an innovative product for the Resort and Hotel Industry). In addition to this Mr. Lubotta recently founded Block Rock Capital, a merchant bank focusing on investing, acquiring and partnering with companies in the BlockChain and Crypto currency industry. Mr. Lubotta is currently a special advisor to the International WELL Building Institute (IWBI) and the Canadian partner of DELOS. Mr. Lubotta co-founded and remains a partner in Sygnus Ventures with Leonard Asper. Sygnus Ventures was established in 2011 in order to make investments in early stage technology and new media companies. Mr. Lubotta has recently been involved as a corporate advisor and partner to Creative Wealth Media (a film/content development and finance fund), RYU (a leader in the active wear and apparel industry), and Anthem Media (a specialty media company focusing on Sports and

 

6


Entertainment). Mr. Lubotta also held the position of Executive Vice President of Northern Citadel Bancorp, where he oversaw the mortgage trust and investment operations of the organization. Preceding Northern Citadel, Mr. Lubotta held the position of Senior Corporate Advisor to the CEO of CanWest Global Communications Corp. He was also the Managing Director at Karl Prince von Thurn and Taxis LLC, a merchant bank based in New York and Central Europe. Mr. Lubotta brings with him an impressive background in the real estate industry where he worked some of North America’s most active developers in joint ventures, acquisitions of real estate assets. He holds a Masters of Business Administration from Kellogg at the University of Northwestern.

Peter Schwartz - Director to be nominated

Mr. Schwartz is a business economics consultant. Currently, he directs Anderson Economic Group’s 40 Wall Street office in New York City and works within that firm’s Strategy and Business Valuation practice area. Mr. Schwartz’s work has focused on commercial damages and franchising matters, including in the automotive and food and beverage industries; he also leads the firm’s coverage of the cannabis industry, and compiles reports for expert testimony. An authority in sports-related business, Mr. Schwartz covered that industry extensively as a journalist and has worked as executive management at sports-focused technology and venture capital firms. Mr. Schwartz has authored more than 100 published works as a reporter and staff writer at Forbes and Bloomberg News, where he specialized in compiling data-driven franchise valuations. His value reports have included analysis of professional sports teams across more than a dozen leagues worldwide. Additionally, Mr. Schwartz has written about hedge, mutual, and private equity funds; municipal bonds; and billionaires—and has been a frequent columnist in Forbes Magazine’s “Makers and Breakers” section, providing statistically-based stock market investment advice to readers. Mr. Schwartz previously wrote for Former U.S. President Bill Clinton and New York City’s bid for the Olympic Games. He is co-author of Baseball as a Road to God: Seeing Beyond the Game (Penguin Group, 2013), a New York Times bestselling book (non-fiction). Mr. Schwartz served as Presidential Research Scholar at New York University for five years, where he lectured and previously was the inaugural Lisa Goldberg Fellow in Law. He has earned degrees from the institution in the study of law (MA) and journalism/sports business management (BA). Prior to that, he was a visiting student at Yale University and a graduate of Upper Canada College.

Corporate Cease Trade Orders, Penalties and Bankruptcies

Other than as described below, to the knowledge of the Corporation, as of the date hereof, no director nominee:

 

  (a)

is, or has been, within 10 years before the date hereof, a director, chief executive officer or chief financial officer of any company (including the Corporation) that:

 

  (i)

was subject to an order that was issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer, or

 

  (ii)

was subject to an order that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer;

 

  (b)

is, or has been, within 10 years before the date hereof, a director or executive officer of any company (including the Corporation) that, while such Nominee was acting in that capacity, or within a year of such Nominee ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or

 

7


  (c)

has, within 10 years before the date hereof, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangements, or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of such director nominee.

For the purposes of the above section, the term “order” means:

 

  (a)

a cease trade order, including a management cease trade order;

 

  (b)

an order similar to a cease trade order; or

 

  (c)

an order that denied the relevant company access to any exemption under securities legislation,

that was in effect for a period of more than 30 consecutive days.

Other than as described below, to the knowledge of the Corporation, as of the date hereof, no director nominee has been subject to:

 

  (a)

any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or

 

  (b)

any other penalties or sanctions imposed by a court or regulatory body.

C. Authorizing the Board to Fix Director Number

At the Meeting, Shareholders will be asked to consider and, if deemed advisable, to pass a special resolution approving and authorizing the Board to fix the number of directors of the Corporation as it deems appropriate between the minimum and maximum number set out in the Corporation’s articles (the “Resolution Authorizing the Board re Director Numbers”). Pursuant to section 125(3) of the Business Corporations Act (Ontario) (the “OBCA”), if the Articles of a corporation provide for a minimum and maximum number of directors, the directors may, if a special resolution of shareholders so provides, fix the number of directors and the number of directors to be elected at an annual meeting. The articles of incorporation of the Corporation provide that the Board shall consist of a minimum of one and a maximum of fifteen directors. Section 124(2) of the OBCA further provides that where a special resolution empowers directors to fix the number of directors in accordance with section 125(3) of the OBCA, the directors may appoint one or more directors between annual meetings, provided that the total number of directors of the Corporation does not exceed one and one-third times the number of directors elected at the previous meeting.

From time to time, the Board identifies individuals who could make a valuable contribution to the Corporation as a director. By adopting the proposed Resolution Authorizing Board re Director Numbers, this will allow the Board, subsequent to the next annual general meeting, to change the number of directors and appoint additional directors to augment the Board with different skills and expertise, with a view to enhancing value for the Shareholders.

At the Meeting, the Shareholders will be asked to pass the Resolution Authorizing the Board re Director Numbers, in the form set out below. The approval of the Resolution Authorizing the Board re Director Numbers will require the affirmative vote of 2/3 of the votes cast by the Shareholders present in person or represented by proxy at the Meeting.

 

8


BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

  (a)

in accordance with section 125(3) of the Business Corporations Act (Ontario) (the “OBCA”), the directors shall be empowered and authorized to determine the number of directors of the Corporation and the number of directors of the Corporation to be elected at an annual meeting, within the minimum and maximum numbers provided for in the articles of the Corporation, by a resolution of the directors, subject to the provisions of the OBCA; and

 

  (b)

any director or officer of the Corporation be and each of them is hereby authorized to do such things and to execute and deliver all such documents that such director or officer may, in his or her discretion, determine to be necessary or useful in order to give full effect to the intent and purpose of this resolution.”

Based on the foregoing, the Board unanimously recommends that Shareholders vote FOR the Resolution Authorizing Board re Director Numbers set out above.

Common Shares represented by proxies in favour of management nominees will be voted FOR the Resolution Authorizing Board re Director Numbers unless a Shareholder has specified in his, her or its proxy that his, her or its Common Shares are to be voted against the Resolution Authorizing Board re Director Numbers.

D. Appointment of Auditors

Management recommends the appointment of MNP LLP, Chartered Accountants (“MNP”), of Toronto, Ontario, as the auditor of the Corporation to hold office until the close of the next annual meeting of the Shareholders, or until their successor is appointed by the Board. MNP was appointed as the auditor of the Corporation on January 10, 2018, after the previous auditor, Wasserman Ramsay LLP, resigned.

In accordance with Part 4.11 of National Instrument 51-102Continuous Disclosure Obligations, a copy of the Corporation’s “Reporting Package”, which includes the Notice of Change of Auditor and letters from Wasserman Ramsay LLP, and MNP respecting the change of auditor, is attached hereto, and made a part hereof as Schedule “B”.

Common Shares represented by proxies in favour of the management nominees will be voted FOR the appointment of MNP LLP, Chartered Accountants, as the auditor of the Corporation and authorizing the directors of the Corporation to fix their remuneration, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting on the appointment of the auditor.

Audit Fees

The aggregate fees billed by the Corporation’s external auditors for professional services rendered for the audit of the consolidated financial statements of the Corporation and its subsidiaries were $2,000 in each of the fiscal years ended October 31, 2017, 2016 and 2015.

Audit Related Fees

The aggregate fees (including reimbursed expenses) billed by the Corporation’s external auditors for services related to the audit or review of the Corporation’s financial statements were $Nil in 2017, 2016 and 2015

 

9


Tax Fees

The aggregate fees (including reimbursed expenses) billed by the Corporation’s external auditors for the preparation of corporate tax returns, tax compliance, tax advice and tax planning services were $Nil in the fiscal year ended October 31, 2017, 2016 and 2015.

All Other Fees

The aggregate fees, including expenses reimbursed, billed by the Corporation’s external auditors for services rendered to the Corporation and its subsidiaries, other than the services described above, were $Nil in the fiscal year ended October 31, 2017, 2016 and 2015.

E. Ratification and Approval of the 10% Rolling Stock Option Plan

The Board is requesting shareholder approval and ratification of its new rolling stock option plan (the “Stock Option Plan”). The Board is authorized to grant options to purchase Common Shares (“Options”) for up to 10% of the issued and outstanding Common Shares from time to time.

The following information is intended to be a brief description of the Stock Option Plan and is qualified in its entirety by the full text of the Stock Option Plan, which is attached hereto as Schedule “C”.

The Stock Option Plan authorizes the Board to grant stock options to the officers, directors, employees, and consultants of the Corporation on the following terms:

 

1.

The number of Common Shares subject to each option is determined by the Board provided that the Stock Option Plan, together with all other previously established or proposed share compensation arrangements may not, during any 12 month period, result in:

 

  (a)

the number of Common Shares reserved for issuance pursuant to stock options granted to any one person or entity exceeding 5% of the issued Common Shares of the Corporation; or

 

  (b)

the issuance, within a one year period, to Insiders of the Corporation of a number of Common Shares exceeding 10%, or to one Insider of a number exceeding 5%, or to a consultant of a number exceeding 2%; or to employees or consultants (as defined by the Exchange on which the Common Shares are listed) who provides Investor Relations services of a number exceeding 1% (in the aggregate for all such employees or consultants) of the issued Common Shares of the Corporation.

 

2.

The aggregate number of shares which may be issued pursuant to options granted under the Stock Option Plan, may not exceed 10% of the issued and outstanding Common Shares of the Corporation as at the date of the grant.

 

3.

The exercise price of an option may not be lower than the greater of the closing market price of the Common Shares on the Canadian Securities Exchange on a) the trading day prior to the date of the grant of the stock options; and b) the date of grant of the stock options.

 

4.

The options may be exercisable for an exercise period determined by the Board in accordance with the rules and policies of the stock exchange on which the Common Shares are listed from time to time.

 

5.

The options are non-assignable, except in certain circumstances. The options can only be exercised by the optionee as long as the optionee remains an eligible optionee pursuant to the

 

10


 

Stock Option Plan or within a period of not more than 90 days (30 days for providers of investor relations services) after ceasing to be an eligible optionee or, if the optionee dies, within one year from the date of the optionee’s death.

 

6.

On the occurrence of a takeover bid, issuer bid or going private transaction, the Board will have the right to accelerate the date on which any option becomes exercisable.

As of the Record Date, the Corporation has 349,684,184 Common Shares issued and outstanding. This means that a total of 34,968,418 Options are currently available to be granted pursuant to the Stock Option Plan if the Stock Option Plan is approved by Shareholders at the Meeting. As of the date hereof, no Options had been granted pursuant to the Stock Option Plan and 34,968,418 Options were still available to be granted.

At the Meeting, Shareholders will be asked to pass an ordinary resolution as set out below. In order to be adopted, the resolution must be passed by a majority of the votes cast, in person or by proxy, at the Meeting:

BE IT RESOLVED, AS AN ORDINARY RESOLUTION, THAT:

 

  (a)

the rolling stock option plan (the “Stock Option Plan”) of Xanthic Biopharma Inc. (the “Corporation”) in the form set out as Schedule “C” to the Corporation’s management information circular dated January 11, 2018, is hereby ratified, confirmed and approved;

 

  (b)

the Corporation is authorized to grant stock options pursuant and subject to the terms and conditions of the Stock Option Plan, as amended, entitling all of the option holders in aggregate to purchase up to such number of Common Shares of the Corporation as is equal to ten percent (10%) of the number of Common Shares of the Corporation issued and outstanding on the applicable grant date; and

 

  (c)

any one officer or director of the Corporation is authorized and directed to perform all such acts, deeds and things and execute, under the seal of the Corporation or otherwise, all such documents and other writings, including treasury orders, stock exchange and securities commission forms, as may be required to give effect to the true intent of this resolution.”

Based on the foregoing, the Board unanimously recommends that Shareholders vote FOR the resolution to ratify and approve the Stock Option Plan.

Common Shares represented by proxies in favour of management nominees will be voted FOR the ratification and approval of the Stock Option Plan, unless a Shareholder has specified in his, her or its proxy that his, her or its Common Shares are to be voted against the ratification and approval of the Stock Option Plan.

F. Approval of Share Consolidation

The Corporation seeks Shareholder approval at the Meeting for a special resolution to consolidate all of the issued and outstanding Common Shares (the “Consolidation”) on the basis of one post-Consolidation Common Share for up to eight (8) pre-Consolidation Common Shares, or a ratio that is less at the discretion of the Board, with the Consolidation to be implemented by the Board at any time prior to the next annual meeting of the Shareholders. On completion of the Consolidation, on a 1:8 basis, the 349,684,184 Common Shares that are currently issued and outstanding would be consolidated into 43,710,523 post-Consolidation Common Shares. The Consolidation remains subject to all required regulatory approvals.

 

11


Reasons for the Consolidation

Management of the Corporation expects that the Consolidation will provide flexibility in the capital structure of the Corporation in order to facilitate raising capital in the future while keeping the Corporation’s capital structure manageable.

Effect on Common Shares

The Consolidation will not materially affect the percentage ownership in the Corporation by the Shareholders even though such ownership will be represented by a smaller number of Common Shares. The Consolidation will merely proportionately reduce the number of Common Shares held by the Shareholders.

Effect on Convertible Securities

The exercise or conversion price and/or the number of Common Shares issuable under any outstanding convertible securities, including under outstanding Options, warrants, rights, and any other similar securities will be proportionately adjusted upon the implementation of the Consolidation, in accordance with the terms of such securities, on the same basis as the consolidation of the Common Shares.

Fractional Common Shares

If, as a result of the Consolidation, a Shareholder would otherwise be entitled to a fraction of a Common Share in respect of the total aggregate number of pre-consolidation Common Shares held by such Shareholder, no such fractional Common Share will be awarded. The aggregate number of Common Shares that such Shareholder is entitled to will, if the fraction is less than one half of one share, be rounded down to the next closest whole number of Common Shares, and if the fraction is at least one half of one share, be rounded up to one whole Common Share. Except for any change resulting from the rounding described above, the change in the number of Common Shares outstanding that would result from the Consolidation will cause no change in the stated capital attributable to the Common Shares.

Certain Risks Associated with the Consolidation

There can be no assurance that the total market capitalization of the Corporation (the aggregate value of all Common Shares at the market price then in effect) immediately after the Consolidation will be equal to or greater than the total market capitalization immediately before the Consolidation.    

Notice of Consolidation and Letter of Transmittal

Prior to the completion of the Consolidation, the Corporation will provide Registered Shareholders with a letter of transmittal which will need to be duly completed and submitted by Registered Shareholders wishing to receive share certificates representing the post-Consolidation Common Shares to which he, she or it is entitled if the Corporation completes the Consolidation.

Procedure for Non-Registered Shareholders

Non-registered Shareholders holding the Common Shares through a bank, broker or other nominee should note that such banks, brokers or other nominees may have different procedures for processing the Consolidation than those that will be put in place by the Corporation for Registered Shareholders. If you hold the Common Shares with such bank, broker, or other nominee and if you have questions in this regard, you are encouraged to contact your nominee to obtain instructions for processing the Consolidation.

 

12


Shareholder Approval

In accordance with the OBCA, the resolution approving the Consolidation must be approved by a majority of not less than two-thirds (2/3) of the votes cast by the Shareholders represented at the Meeting in person or by proxy.

At the Meeting, the following special resolution, with or without variation, will be placed before the Shareholders in order to approve the Consolidation:

BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

  (a)

the Board be authorized, subject to approval of the applicable regulatory authorities, to take such actions as are necessary to consolidate, at any time following the date of this resolution but prior to the next annual meeting of shareholders of the Corporation, all of the issued and outstanding Common Shares on the basis that up to eight (8) pre-consolidation Common Shares, or a ratio that is less at the discretion of the Board, be consolidated into one post-consolidation Common Share;

 

  (b)

despite the foregoing authorization, the Board may, at its absolute discretion, determine when such consolidation will take place and may further, at its discretion, determine not to effect such consolidation of all of the issued and outstanding Common Shares, in each case without requirement for further approval, ratification or confirmation by the Shareholders;

 

  (c)

notwithstanding the foregoing, the Board is hereby authorized, without further approval of or notice to the Shareholders, to revoke this special resolution at any time before it is acted upon; and

 

  (d)

any one or more directors and officers of the Corporation be authorized to perform all such acts, deeds and things and execute all such documents and other writings, as may be required to give effect to this special resolution.”

The foregoing special resolution permits the directors of the Corporation, without further approval by the Shareholders, to proceed with the Consolidation at any time following the date of this Meeting but prior to the next annual meeting of the Shareholders. Alternatively, the directors of the Corporation may choose not to proceed with the Consolidation if the directors, in their discretion, deem that it is no longer desirable to do so.

Common Shares represented by proxies in favour of management nominees will be voted FOR the approval of the Consolidation as set out above, unless a Shareholder has specified in his, her or its proxy that his, her or its Common Shares are to be voted against the special resolution approving the Consolidation.

Effective Date

Subject to applicable regulatory requirements, the Consolidation will be effective on the date on which articles of amendment of the Corporation are filed and certified by the Ministry, on which the directors of the Corporation determine to carry out the Consolidation.

If the Consolidation is approved, no further action on the part of the Shareholders will be required in order for the Board to implement the Consolidation.

 

13


G. Approval of Name Change

The Board is recommending that the corporate name of Aurquest Resources Inc. be changed to Xanthic Biopharma Inc.” or such other name as may be determined by the Board (the “Name Change”). At the Meeting, Aurquest Shareholders will be asked to consider and, if deemed appropriate, to approve a special resolution approving the Name Change (the “Name Change Resolution”).

The Board has unanimously approved the Name Change Resolution and recommends that the Shareholders vote FOR the Name Change Resolution.

The Name Change Resolution must be approved by at least two-thirds of votes cast by the Shareholders present in person or represented by proxy at the Meeting. It is the intention of the persons named in the enclosed proxy, in the absence of instructions to the contrary, to vote the proxy FOR the Name Change Resolution.

“BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

(a)

The Corporation is hereby authorized to amend its articles to change the Corporation’s name to “Xanthic Biopharma Inc.” or such other such other similar name approved by the Board and acceptable to the applicable regulatory authorities;

 

(b)

the articles of the Corporation be amended to reflect the foregoing;

 

(c)

Notwithstanding that this resolution has been passed by the Shareholders of the Corporation, the directors of the Corporation are hereby authorized and empowered without further notice to, or approval of, the Shareholders of the Corporation to not proceed with the change of the Corporation’s name or otherwise give effect to this resolution at any time prior to the same becoming effective and may revoke this resolution without further approval of the Shareholders; and

 

(d)

any officer or director of the Corporation is hereby authorized and directed for and on behalf of the Corporation to execute, or to cause to be executed, whether under the corporate seal or otherwise, and to deliver or cause to be delivered all such other documents and instruments, and to do or cause to be done all such other acts and things as, in the opinion of such director or officer, may be necessary or desirable in order to carry out the intent of this resolution, the execution of any such document or the doing of any such other thing being conclusive evidence of such determination.”

Common Shares represented by proxies in favour of management nominees will be voted FOR the approval of the Name Change Resolution, unless a Shareholder has specified in his, her or its proxy that his, her or its Common Shares are to be voted against the special resolution approving the Name Change.

H. Change of Registered Office

Shareholders will be asked to consider, and if thought advisable, to pass with or without variation, a special resolution authorizing, confirming, and approving the change of the municipality in which the Corporation’s registered office is located from the Town of North York to the City of Toronto (the “Registered Office Change Resolution”). The registered office of the Corporation is currently located at 31 Sunset Trail, North York, Ontario M9M 1J4. If the Special Resolution is approved, the registered office of the Corporation will be changed to 77 King Street West, Suite 2905, Toronto, Ontario, M5K 1G8.

 

14


The Board has unanimously approved the Registered Office Change Resolution and recommends that the Shareholders vote FOR the Registered Office Change Resolution in order to facilitate the record keeping and day to day operations of the Corporation.

At the Meeting, the following special resolution, with or without variation, will be placed before the Shareholders in order to approve the Registered Office Change Resolution:

BE IT IS RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

  (a)

Aurquest Resources Inc. (the “Corporation”) is hereby authorized and directed to proceed with a change to the municipality in which the Corporation’s registered office is located from the Town of North York, Ontario to the City of Toronto, Ontario; and

 

  (b)

any one or more directors and officers of the Corporation be authorized to perform all such acts, deeds and things and execute all such documents and other writings, as may be required to give effect to this special resolution.”

The Registered Office Change Resolution must be approved by at least two-thirds of votes cast by the Shareholders present in person or represented by proxy at the Meeting. The Registered Office Change Resolution permits the directors of the Corporation, without further approval by the Shareholders, to proceed with the change of municipality of the registered office of the Corporation at any time following the date of the Meeting.    

Common Shares represented by proxies in favour of management nominees will be voted FOR the approval of the Registered Office Change Resolution, unless a Shareholder has specified in his proxy that his or her Common Shares are to be voted against the Registered Office Change Resolution.

I. Repeal and Replace the By-Law

The Corporation’s previous by-law no. 1 was adopted in 1999 and is out of date. On December 11, 2017, the Board adopted By-Law No. 1B of the Corporation (the “By-Law”) as set out in Schedule “D”, being a general operating by-law relating to the transaction of the business and affairs of the Corporation in compliance with the provisions of the OBCA and applicable securities laws and regulations, and repealed all previous by-laws of the Corporation.

The adoption of the By-Law became effective upon being approved by the Board; however, under the OBCA, the Board is required to submit a resolution (the “By-Law Resolution”) to the Shareholders approving such adoption at the Meeting, at which time the Shareholders may confirm, reject, or amend the By-Law Resolution. The Shareholders will be asked to consider and, if deemed advisable, confirm by ordinary resolution, the By-Law Resolution.

The Board has determined that the By-Law Resolution is in the best interests of the Shareholders and unanimously recommends that Shareholders vote FOR the By-Law Resolution. The By-Law Resolution requires the approval of a simple majority of the votes cast at the Meeting, in person or by proxy, in order to be adopted, failing which the amendment to the By-Laws will cease to be effective.    

Common Shares represented by proxies in favour of management nominees will be voted FOR the approval of the By-Law Resolution, unless a Shareholder has specified in his proxy that his or her Common Shares are to be voted against such resolution.

 

15


BE IT RESOLVED, AS AN ORDINARY RESOLUTION, THAT:

 

  (a)

By-Law No. 1B of the Corporation previously adopted by the board of directors of Aurquest Resources Inc. (the “Corporation”) on December 11, 2017, as set out in Schedule “D to the Corporation’s management information circular dated January 11, 2018, and repeal of all previous by-laws of the Corporation, is hereby confirmed and approved; and

 

  (b)

any officer or director of the Corporation is hereby authorized and directed for and on behalf of the Corporation to execute and deliver or cause to be executed and delivered, all such documents, agreements and instruments as are necessary or desirable to give effect to the foregoing resolution, and to perform or cause to be performed all such other acts and things as in such person’s opinion may be necessary or desirable to give full effect to the foregoing resolution and the matters authorized thereby, such determination to be conclusively evidenced by the execution and delivery of such document, agreement or instrument or doing any such act or thing.”

Based on the foregoing, the Board unanimously recommends that Shareholders vote FOR the By-Law Resolution.

Common Shares represented by proxies in favour of management nominees will be voted FOR the By-Law Resolution, unless a Shareholder has specified in his, her or its proxy that his, her or its shares are to be voted against the confirmation of the By-Law Resolution.

EXECUTIVE COMPENSATION

Securities laws require that a “Statement of Executive Compensation” in accordance with Form 51-102F6V (“the Form”) be included in this Information Circular. The Form prescribes the disclosure requirements in respect of the compensation of named executive officers and directors of reporting issuers.

The term “named executive officer” (“NEO”) means the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) of the Corporation and each of the three most highly compensated officers, other than the CEO and CFO, who were serving as at the most recently completed fiscal year and whose salary and bonus in the aggregate exceeded $150,000.

Based on these requirements, for the fiscal years ended October 31, 2017, 2016 and 2015, the only NEO of the Corporation for whom disclosure is required is Mr. Dominique Monardo, who served as the CEO and CFO of the Corporation.

In the last three fiscal years ended October 31, 2017, 2016 and 2015, the Corporation did not pay compensation, in any form, to Mr. Monardo, which was decided by the Board. Considerations included the lack of current operations and the lack of financial resources of the Corporation.    

The Board expects to convene a compensation committee following the Meeting, and expects that the Compensation Committee to review and set the objectives of the Corporation’s executive compensation arrangements, the Corporation’s executive compensation philosophy and the application of this philosophy to the Corporation’s executive compensation arrangements.

When determining the compensation arrangements for the executive officers of the Corporation, the Compensation Committee will consider the objectives of: (i) retaining an executive critical to the success of the Corporation and the enhancement of Shareholder values; (ii) providing fair and competitive

 

16


compensation; (iii) balancing the interests of management and Shareholders of the Corporation; and (iv) rewarding performance, both on an individual basis and with respect to the business in general.

The following table provides a summary of total compensation earned during each of the 12 month periods ended October 31, 2017, 2016 and 2015, respectively, by the Company’s CEO and CFO for services rendered in all capacities during such period.

 

SUMMARY COMPENSATION TABLE

Name and

Principal

Position of

Named

Executive

Officer

  

Twelve

Months

Ended Oct. 31

  

Salary

(CDN$)

  

Option-

Based
Awards
(CDN$)

  

Non-Equity

Incentive Plan

Compensation

  

All Other

Compensation
(CDN$)

  

Total

Compensation
(CDN$)

  

Annual
Incentive
Plans

(CDN$)

  

Long-Term
Incentive
Plans

(CDN$)

Dominique Monardo(1)

   2017    Nil    Nil    Nil    Nil    Nil    Nil

CEO & CFO

   2016    Nil    Nil    Nil    Nil    Nil    Nil
   2015    Nil    Nil    Nil    Nil    Nil    Nil

Notes:

 

(1)

Mr. Monardo was first appointed as a director of the Corporation on June 19, 1995.

Termination and Change of Control Benefits and Management Contracts

As at October 31, 2017 and during the fiscal year ended October 31, 2017, there were no contracts, agreements or plans of arrangement that provide for payment to an NEO at, following or in connection with any termination (whether voluntary, involuntary, or constructive), resignation, retirement, a change in control of the Corporation or a change in an NEO’s responsibilities.    

Compensation of Directors

The Corporation did not pay any fees or any other compensation to directors for serving on the Board (or any subcommittee) during the fiscal years ended October 31, 2017, 2016 and 2015. The Board expects that the Compensation Committee will review director compensation as part of its review of executive compensation arrangements following the Meeting.

Securities authorized for issuance under the Equity Compensation Plan

The Corporation did not have any equity compensation plan as at October 31, 2017.

STATEMENT OF CORPORATE GOVERNANCE MATTERS

Corporate Governance

Corporate governance relates to the activities of the Board, the members of which are elected by and are accountable to the Shareholders, and takes into account the role of the individual members of management who are appointed by the Board and who are charged with the day-to-day management of the Corporation. National Policy 58-201 - Corporate Governance Guidelines (“NP 58-201”) establishes corporate governance guidelines which apply to all public companies. These guidelines are not intended

 

17


to be prescriptive but to be used by issuers in developing their own corporate governance practices. The Board is committed to sound corporate governance practices, which are both in the interest of its Shareholders and contribute to effective and efficient decision making.

Pursuant to National Instrument 58-101 - Disclosure of Corporate Governance Practices (“NI 58-101”), the Corporation is required to disclose its corporate governance practices, as summarized below. The Board will continue to monitor such practices on an ongoing basis and, when necessary, implement such additional practices as it deems appropriate.

Board of Directors

On December 15, 2017, of the three previous directors of the Corporation, all three resigned, and the Board was reconstituted to be comprised of Mr. Tim Moore, Mr. Igor Galitsky, Dr. Shafik Dharamshi. Dr. Gunther Hintz, Carli Posner, David Lubotta and Peter Schwartz, the four new director nominees, are all independent of management within the meaning of NI 58-101.

NI 58-101 defines an “independent director” as a director who has no direct or indirect material relationship with the Corporation. A “material relationship” is in turn defined as a relationship which could, in the view of the Board, reasonably be expected to interfere with such member’s independent judgment.

Mr. Tim Moore is not considered “independent” as a result of his current position as CEO of the Corporation. Mr. Igor Galitsky is not considered “independent” as a result of his being the President of the Corporation. The remaining director, Dr. Shafik Dharamshi is considered to be an independent director since he is independent of management and free from any material relationship with the Corporation. Mr. Dharamshi has not been employed by the Corporation, received remuneration from the Corporation or had material contracts with or material interests in the Corporation which could interfere with his ability to act with a view to the best interests of the Corporation.

Other Reporting Issuer Directorships

None of the directors or director nominees of the Corporation currently hold directorships in other reporting issuers.

Orientation and Continuing Education

Each new director is given an outline of the nature of the business of the Corporation, its corporate strategy, and current issues within the Corporation. New directors are also required to meet with management of the Corporation to discuss and better understand the Corporation’s business and are given the opportunity to meet with counsel to the Corporation to discuss their legal obligations as directors of the Corporation.

In addition, management of the Corporation takes steps to ensure that its directors and officers are continually updated as to the latest corporate and securities policies which may affect the directors, officers, and committee members of the Corporation as a whole. The Corporation continually reviews the latest securities rules and policies. Any such changes or new requirements are then brought to the attention of the Corporation’s directors either by way of director or committee meetings or by direct communications from management to the directors.

Ethical Business Conduct

The Board has found that the fiduciary duties placed on individual directors by the Corporation’s governing corporate legislation and the common law and the restrictions placed by applicable corporate

 

18


legislation on an individual directors’ participation in the decision making of the Board in which the director has an interest as well as adherence to the standards contained in the Corporation’s Code of Business Conduct and Ethics have been sufficient to ensure that the Board operates independently of management and in the best interests of the Corporation. Further, the Corporation’s auditor has full and unrestricted access to the audit committee of the Corporation (the “Audit Committee”) at all times to discuss the annual audits of the Corporation’s financial statements and any related findings as to the integrity of the financial reporting process.

Nomination of Directors

The Board expects to meet at least annually in order to: (a) review the Board’s Corporate Governance guidelines and all Committee’s Charters to ensure that they are consistent with sound governance principles, and recommending any proposed changes to the Board for approval; (b) develop, and periodically update, a Code of Business Ethics (the “Code”), and ensure that management has established a system to disseminate and monitor compliance of the Code and is enforcing its application; (c) in consultation with the Audit Committee, monitor and review the Corporation’s policies and procedures relating to compliance with laws and regulations and its Code; (d) consider what competencies and skills the Board, as a whole, should possess and seeking individuals qualified to become Board members, including evaluating persons suggested by share owners or others; (e) recommend the director nominees for the next annual meeting of Shareholders; (f) review the composition of each Board committee; and (g) develop and perform an annual assessment process for the Board and each Committee of the Board.

Compensation

Currently, the Board oversees director and executive compensation. The Corporation anticipates convening a Compensation Committee after the Meeting. The Compensation Committee is expected to meet at least twice annually and is responsible for making recommendations to the Board regarding: (a) CEO compensation; (b) compensation of other executives; (c) incentive compensation plans; and (d) employment agreements, severance agreements, retirement agreements, change of control agreements and provisions, and any special or supplemental benefits for each officer of the Corporation. The Board then determines whether to adopt such recommendations as submitted or otherwise.

Other Board Committees

Board has an Audit Committee, the details of which are provided below.

Assessment of Board Performance

The Board monitors the adequacy of information given to directors, communication between the Board and management and the strategic direction and processes of the Board and committees.

AUDIT COMMITTEE INFORMATION

The Audit Committee is responsible for the Corporation’s financial reporting process and the quality of its financial reporting. In addition to its other duties, the Audit Committee reviews all financial statements, annual and interim, intended for circulation among Shareholders and reports upon these to the Board. In addition, the Board may refer to the Audit Committee other matters and questions relating to the financial position of the Corporation. In performing its duties, the Audit Committee maintains effective working relationships with the Board, management and the external auditors and monitors the independence of those auditors. The Audit Committee has formally adopted an Audit Committee charter, which sets forth purposes of the Audit Committee and guidelines for its practices. The full text of the Audit Committee Charter is annexed hereto as Schedule “A”.

 

19


The members of the Audit Committee will be: Messrs. Peter Schwartz (Chairman), David Lubotta and Igor Galitsky, all of whom are financially literate. As Mr. Igor Galitsky is the President of the Corporation, he is not independent of management within the meaning of NI 58-101. Each of Mr. Peter Schwartz and Mr. David Lubotta are independent of management within the meaning of NI 58-101.

The Corporation is relying on the exemption pursuant to Section 6.1 of National Instrument 52-110 “Audit Committees” (“NI 52-110”) (Venture Issuers). Thus, the composition of the Audit Committee complies with the requirements and the provisions of NI 52-110 of the Canadian Securities Administrators.

Composition of the Audit Committee

The following are the members or proposed members of the Audit Committee. Their biographies are set out under the heading “Matters to be Acted Upon at the Meeting – Election of Directors”.

 

Name

   Independent /Not Independent (1)
   Financial literacy (1)

Peter Schwartz (2)

  

Independent

  

Financially literate

David Lubotta

  

Independent

  

Financially literate

Igor Galitsky

  

Non-Independent

  

Financially literate

Notes:

 

(1)

Terms have their respective meanings ascribed in NI 52-110.

(2)

Mr. Schwartz will be appointed as the Chairman of the Audit Committee.

Audit Committee Member Information

The following table describes the education and experience of each current or proposed Audit Committee member that is relevant to the performance of his responsibilities as an Audit Committee member:

 

Peter Schwartz

  

Mr. Schwartz is currently business economics consultant with Anderson Economics Group within the firm’s Strategy and business valuations practice. Mr. Schwartz leads the firm’s coverage of the cannabis industry, and compiles reports for expert testimony. Mr. Schwartz has degrees with concentrations in law, and sports business management, from New York University. Prior to that he was a visiting student at Yale University and graduate of Upper Canada College.

David Lubotta

  

Mr. Lubotta has a solid track record of innovative and entrepreneurial accomplishments. With over 20 years of experience in business, Mr. Lubotta brings an admirable depth of leadership. Mr. Lubotta is a Principal in Red Team Wins (RTW is a leader in the agency sector of the vastly growing E-gaming/E-sports industry). Mr. Lubotta is also the founder and current Co-Chairman of CoolSafe Enterprises (an innovative product for the Resort and Hotel Industry). In addition to this Mr. Lubotta recently founded Block Rock Capital, a merchant bank focusing on investing, acquiring and partnering with companies in the BlockChain and Crypto currency industry. Mr. Lubotta is currently a special advisor to the

 

20


  

International WELL Building Institute (IWBI) and the Canadian partner of DELOS. Mr. Lubotta co-founded and remains a partner in Sygnus Ventures with Leonard Asper. Sygnus Ventures was established in 2011 in order to make investments in early stage technology and new media companies. Mr. Lubotta has recently been involved as a corporate advisor and partner to Creative Wealth Media (a film/content development and finance fund), RYU (a leader in the active wear and apparel industry), and Anthem Media (a specialty media company focusing on Sports and Entertainment). Mr. Lubotta also held the position of Executive Vice President of Northern Citadel Bancorp, where he oversaw the mortgage trust and investment operations of the organization. Preceding Northern Citadel, Mr. Lubotta held the position of Senior Corporate Advisor to the CEO of CanWest Global Communications Corp. He was also the Managing Director at Karl Prince von Thurn and Taxis LLC, a merchant bank based in New York and Central Europe. Mr. Lubotta brings with him an impressive background in the real estate industry where he worked some of North America’s most active developers in joint ventures, acquisitions of real estate assets. He holds a Masters of Business Administration from Kellogg at the University of Northwestern.

Igor Galitsky

  

Mr. Galitsky has been an entrepreneur and business owner for over a decade. He was one of the first applicants to receive a license under the Marijuana Medical Access Regulations for both personal and designated production in Canada.

INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS

Since the beginning of the last completed financial year and up to the date hereof, no director, executive officer or employee or former executive officer, director, or employee of the Corporation or any of its subsidiaries has been indebted to the Corporation.

INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS

No informed person, director, executive officer, nominee for director, any person who beneficially owns, directly or indirectly, Common Shares carrying more than 10% of the voting rights attached to all outstanding Common Shares of the Corporation, nor any associated or affiliate of such persons, has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any transaction or any proposed transaction which has materially affected or would materially affect the Corporation.

OTHER BUSINESS

Management of the Corporation knows of no matters to come before the Meeting other than the matters referred to in the Notice of Meeting. However, if matters not now known to management should come before the Meeting, Common Shares represented by proxies solicited by management will be voted on each such matter in accordance with the best judgment of the nominees voting same.

REGISTRAR AND TRANSFER AGENT

Capital Transfer Agency, at 920-390 Bay Street, Toronto, Ontario M5H 2Y2, is the registrar and transfer agent for the Corporation’s Common Shares.

ADDITIONAL INFORMATION

Additional information relating to the Corporation can be found on SEDAR at www.sedar.com. Financial information is provided in the Corporation’s comparative financial statements and management discussion

 

21


and analysis. Copies of the Corporation’s financial statements and management discussion and analysis may be obtained, without charge, upon request to the Corporate Secretary at Fogler, Rubinoff LLP, 77 King St. W, Suite 3000, Toronto, Ontario M5K 1G8.

APPROVAL OF DIRECTORS

The contents and the sending of this Information Circular have been approved by the directors of the Corporation.

DATED at Toronto, Ontario this 11th day of January 2018.

(signed) Tim Moore

Tim Moore

Chief Executive Officer

 

22


SCHEDULE “A”

AURQUEST RESOURCES INC.

(the “Corporation”)

AUDIT COMMITTEE CHARTER

 

1

Purpose

The audit committee (the “Committee”) will assist the Board of Directors of the Corporation (the “Board”) in fulfilling its responsibilities. The Committee will review the financial reporting process, the system of internal control and management of financial risks, the audit process, and the Corporation’s process for monitoring compliance with laws and regulations and its own code of business conduct as it relates to financial reporting and disclosure. In performing its duties, the Committee will maintain effective working relationships with the Board, management, and the external auditors and monitor the independence of those auditors. The Committee will also be responsible for reviewing the Corporation’s financial strategies, its financing plans and its use of the equity and debt markets.

To perform his or her role effectively, each Committee member will obtain an understanding of the responsibilities of committee membership as well as the Corporation’s business, operations, and risks.

 

2

Committee Membership

The Committee shall consist of no fewer than three members, a majority of whom shall not be officers or employees of the Corporation or any of its affiliates and who shall meet the independence requirements of Canadian securities laws and any stock exchange on which the Common Shares of the Corporation are listed from time to time. The members and chair of the Committee (the “Chair”) shall be appointed and removed by the Board.

 

3

Committee Meetings

The Committee shall meet quarterly each year. The Chairman will schedule regular meetings, and additional meetings may be held at the request of two or more members of the Committee, the CEO, or the Chairman of the Board. External auditors may convene a special meeting if they consider that it is necessary.

The Committee may invite such other persons (e.g. the CEO and/or CFO) to its meetings, as it deems appropriate. The external auditors should be present at each quarterly audit committee meeting and should be expected to comment on the financial statements in accordance with best practices.

The Committee shall keep adequate minutes of all its proceedings, and the Chair will report its actions to the next meeting of the Board. Committee members will be furnished with copies of the minutes of each Committee meeting and any action taken by unanimous consent.

 

4

Committee Authority and Responsibilities

In carrying out its responsibilities, the Committee will:

 

  4.1

Gain an understanding of whether internal control recommendations made by external auditors have been implemented by management.


  4.2

Gain an understanding of the current areas of greatest financial risk and whether management is managing these effectively.

 

  4.3

Review the Corporation’s strategic and financing plans to assist the Board’s understanding of the underlying financial risks and the financing alternatives.

 

  4.4

Review management’s plans to access the equity and debt markets and to provide the Board with advice and commentary.

 

  4.5

Review significant accounting and reporting issues, including recent professional and regulatory pronouncements, and understand their impact on the financial statements.

 

  4.6

Review any legal matters which could significantly impact the financial statements as reported on by the general counsel and meet with outside counsel whenever deemed appropriate.

 

  4.7

Review the annual and quarterly financial statements including Management’s Discussion and Analysis and determine whether they are complete and consistent with the information known to committee members; determine that the auditors are satisfied that the financial statements have been prepared in accordance with International Financial Reporting Standards, stock exchange requirements and governmental regulations.

 

  4.8

Pay particular attention to complex and/or unusual transactions such as those involving derivative instruments and consider the adequacy of disclosure thereof.

 

  4.9

Focus on judgmental areas, for example those involving valuation of assets and liabilities and other commitments and contingencies.

 

  4.10

Review audit issues related to the Corporation’s material associated and affiliated companies that may have a significant impact on the Corporation’s equity investment.

 

  4.11

Meet with management and the external auditors to review the annual financial statements and the results of the audit.

 

  4.12

Assess the fairness of the interim financial statements and disclosures, and obtain explanations from management on whether:

 

  a.

actual financial results for the interim period varied significantly from budgeted or projected results;

 

  b.

generally accepted accounting principles have been consistently applied;

 

  c.

there are any actual or proposed changes in accounting or financial reporting practices; and

 

  d.

there are any significant or unusual events or transactions which require disclosure and, if so, consider the adequacy of that disclosure.

 

  4.13

Review the external auditors’ proposed audit scope and approach and ensure no unjustifiable restriction or limitations have been placed on the scope.

 

  4.14

Review the performance of the external auditors and approve in advance provision of services other than auditing.


  4.15

Consider the independence of the external auditors, including reviewing the range of services provided in the context of all consulting services bought by the Corporation.

 

  4.16

Make recommendations to the Board regarding the reappointment of the external auditors.

 

  4.17

Meet separately with the external auditors to discuss any matters that the committee or auditors believe should be discussed privately.

 

  4.18

Endeavour to cause the receipt and discussion on a timely basis of any significant findings and recommendations made by the external auditors.

 

  4.19

Obtain regular updates from management and the Corporation’s legal counsel regarding compliance matters, as well as certificates from the CFO as to required statutory payments and bank covenant compliance and from senior operating personnel as to permit compliance.

 

  4.20

Ensure that the Board is aware of matters which may significantly impact the financial condition or affairs of the business.

 

  4.21

Perform other functions as requested by the full Board.

 

  4.22

If necessary, institute special investigations and, if appropriate, hire special counsel or experts to assist.

 

  4.23

Review and update the charter; receive approval of changes from the Board.


SCHEDULE “B”

AURQUEST RESOURCES INC.

(the “Corporation”)

NOTICE OF CHANGE OF AUDITORS


AURQUEST RESOURCES INC

 

 

Notice of Change of

Auditor

Pursuant to NI 51-102 (Part 4.11)

 

To:

Ontario Securities Commission

Alberta Securities Commission

British Columbia Securities Commission

Quebec Securities Commission

Nova Scotia Securities Commission

And to: Re:

WASSERMAN RAMSAY LLP

MNP LLP Notice of Change of Auditor

 

 

TAKE NOTICE THAT:

Pursuant to National Instrument 51-102 Continuous Disclosure Obligations, Aurquest Resources Inc. (the “Company”) advises that effective January 10 2018 (the “Effective Date”), Wasserman Ramsay LLP (the “Former Auditors”) have resigned, at the Company’s request, as the auditors of the Company, and that MNP, LLP (the “Successor Auditors”) have been appointed as the Company’s auditors in their place.

The resignation of the Former Auditors and the appointment of the Successor Auditor was approved by the Company’s Board of Directors. The Company will ask that the shareholders of the Company ratify the appointment of MNP, LLP at the next annual meeting of the shareholders of the Company.

There have been no reservations in the Former Auditor’s reports in connection with the audits of the two most recently completed fiscal years.

There are no reportable events, including disagreements, consultations or unresolved issues, as such terms are defined in National Instrument 51-102.

Dated this 10th day of January, 2018.

 

AURQUEST RESOURCES INC

/s/ Tim Moore

Name: Tim Moore
Title: Chief Executive Officer

77 King Street West, Suite 2905, Toronto-Dominion Centre,

Toronto, Ontario, Canada M5K 1G8


LOGO

January 12, 2018

Ontario Securities Commission

Alberta Securities Commission

British Columbia Securities Commission

Quebec Securities Commission

Nova Scotia Securities Commission

Dear Sirs/Mesdames:

 

Re:

Aurquest Resources Inc. (“Aurquest”)

 

Notice Pursuant to NI 51-102 - Change of Auditor

As required by the National Instrument 51-102 and in connection with our proposed engagement as auditor of Aurquest, we have reviewed the information contained in Aurquest’s Notice of Change in Auditor, dated January 10, 2018, and agree with the information contained therein, based upon our knowledge of the information relating to the said notice and of Aurquest at this time, except that we have no basis to agree or disagree with the statement that there have been no reportable events during the period that Wasserman Ramsay LLP has been auditor of Aurquest Resources Inc.

Yours truly,

 

LOGO

Chartered Professional Accountants

Licensed Public Accountants

 

LOGO


LOGO   

5140 Yonge Street, Suite 2250, Toronto, Ontario, Canada M2N 6L7

Tel. (416) 226-4631 Fax (416) 226-9562

email: wram@wassermanramsay.ca

January 11, 2018

Ontario Securities Commission

Alberta Securities Commission

British Columbia Securities Commission

Quebec Securities Commission

Nova Scotia Securities Commission

 

Re:

Aurquest Resources Inc. (the “Company”) - Notice Pursuant to National Instrument 51-102 Change of Auditor

We have read the Notice of Change of Auditor of the Company dated January 10, 2018 concerning our resignation as auditors of the Company.

In accordance with National Instrument 51-102, we advise that we are in agreement with the information contained in the above mentioned Notice.

Yours truly,

 

/s/ Wasserman Ramsay

WASSERMAN RAMSAY,

CHARTERED ACCOUNTANTS

 

cc.

Aurquest Resources Inc.


SCHEDULE “C”

AMENDED AND RESTATED ROLLING STOCK OPTION PLAN

XANTHIC BIOPHARMA INC.

(formerly Aurquest Resources Inc.)

ARTICLE 1

GENERAL

1.1 Purpose

The purpose of this amended and restated rolling stock option plan (this “Plan”) is to advance the interests of Xanthic Biopharma Inc. (the “Company”) and/or its Affiliates by:

 

(a)

providing Eligible Persons with additional performance incentives;

 

(b)

encouraging Share ownership by Eligible Persons;

 

(c)

increasing the proprietary interest of Eligible Persons in the success of the Company and/or its Affiliates;

 

(d)

encouraging Eligible Persons to remain with the Company and/or its Affiliates; and attracting new Directors, Officers, Employees and Consultants to the Company and/or its Affiliates.

1.2 Definitions

For the purposes of this Plan, the following terms have the respective meanings set forth below:

 

(a)

“Affiliate” has the meaning ascribed thereto in the CSE Policies;

 

(b)

Associate” has the meaning ascribed thereto in the CSE Policies;

 

(c)

“Blackout Period” means the time period, commonly referred to as the “blackout period”, determined by the Company in accordance with its trading policies pursuant to which directors, officers, employees and others are prohibited from trading in the securities of the Company (which may also include exercising options granted under the Plan) and, for greater certainty, Blackout Period shall not include any period in which there is a prohibition on trading in securities of the Company as a result of a cease trade or other order of any securities commission or regulatory authority;

 

(d)

“Board” means the board of directors of the Company;

 

(e)

“Change of Control” means the occurrence of any one or more of the following:

 

  i)

a consolidation, merger, amalgamation, arrangement or other reorganization or acquisition involving the Company or any of its Affiliates and another corporation or entity, as a result of which the holders of Shares prior to the completion of the transaction hold less than 50% of the outstanding shares or interests of the successor Legal Person after completion of the transaction;

 

  ii)

the sale, lease, exchange or other disposition, in a single transaction or a series of related transactions, of assets, rights or property of the Company and/or any of its subsidiaries which have an aggregate book value greater than 50% of the book value of the assets, rights and property of the Company and its subsidiaries on a consolidated basis to any other person or entity, other than a disposition to a wholly-owned subsidiary of the Company in the course of a reorganization of the assets of the Company and its subsidiaries;

 

  iii)

a resolution is adopted to wind up, dissolve or liquidate the Company;


  iv)

any person, entity or group of persons or entities acting jointly or in concert, other than an Insider (an “Acquiror”) acquires, or acquires control (including, without limitation, the right to vote or direct the voting of) of voting securities of the Company which, when added to the voting securities owned of record or beneficially by the Acquiror or which the Acquiror has the right to vote or in respect of which the Acquiror has the right to direct the voting, would entitle the Acquiror (or its Associates or Affiliates) to cast or to direct the casting of 50% or more of the votes attached to all of the Company’s outstanding voting securities which may be cast to elect directors of the Company or the successor corporation (regardless of whether a meeting has been called to elect directors); or

 

  v)

as a result of or in connection with

 

  (A)

a contested election of directors; or

 

  (B)

consolidation, merger, amalgamation, arrangement or other reorganization or acquisition involving the Company or any of its Affiliates and another corporation or entity,

the nominees named in the most recent management information circular of the Company for election to the Board shall not constitute a majority of the Board.

 

(f)

“Committee” has the meaning ascribed thereto in Section 2.1;

 

(g)

“Company” means Xanthic Biopharma Inc., a company incorporated under the Business Corporations Act (Ontario) and its successor corporations;

 

(h)

“Consultant” means an individual (other than an Employee or a Director of the Company) or Legal Person that:

 

  i)

is engaged to provide, on an ongoing bona fide basis, consulting, technical, management or other services to the Company or to an Affiliate of the Company, other than services provided in relation to a Distribution;

 

  ii)

provides legal services under a written contract between the Company or an Affiliate and the individual or the Legal Person, as the case may be;

 

  iii)

in the reasonable opinion of the Company, spends or will spend a significant amount of time and attention on the affairs and business of the Company or an Affiliate of the Company; and

 

  iv)

has a relationship with the Company or an Affiliate of the Company that enables the individual to be knowledgeable about the business and affairs of the Company;

 

(i)

“Consultant Company” means a Consultant that is a Legal Person;

 

(j)

“CSE” means the Canadian Securities Exchange or any successor thereto;

 

(k)

“CSE Policies” means the rules and policies of the CSE, as amended, supplemented or replaced from time to time;

 

(l)

“Director” means a member of the Board;

 

(m)

“Disinterested Shareholder Approval” means approval by a majority of the votes cast by all the Company’s shareholders at a duly constituted shareholders’ meeting, excluding votes attached to shares beneficially owned by Insiders to whom Options may be granted under this Plan and their Associates;

 

(n)

“Distribution” has the meaning ascribed thereto in the CSE Policies;

 

(o)

“Eligible Person” means:

 

  i)

a Director, Officer, Employee, or Consultant of the Company or of an Affiliate of the Company;


  ii)

a Management Company Employee;

 

  iii)

a company (other than a Consultant Company) wholly-owned by individuals who are Eligible Persons; and Consultant Companies;

 

(p)

“Employee” has the meaning ascribed thereto in the CSE Policies;

 

(q)

“Insider” means an insider as defined under the CSE Policies;

 

(r)

“Legal Person” unless specifically indicated otherwise, means a corporation, incorporated association or organization, body corporate, partnership, trust, association or other entity other than an individual;

 

(s)

“Investor Relations Activities” has the meaning ascribed thereto in the CSE Policies;

 

(t)

“Management Company Employee” means an individual employed by a person providing management services to the Company or an Affiliate of the Company, which are required for the ongoing successful operation of the Company or an Affiliate, but excluding a person engaged in Investor Relations Activities;

 

(u)

“Market Price” has the meaning ascribed thereto in the CSE Policies;

 

(v)

“Officer” means an officer of the Company or of an Affiliate of the Company;

 

(w)

“Option” means an option granted to an Eligible Person in accordance with the terms of this Plan to purchase Shares from the Company upon the exercise of the Option and upon payment of the exercise price;

 

(x)

“Option Agreement” means a written agreement between the Company and an Optionee that sets forth the terms, conditions and limitations applicable to an Option;

 

(y)

“Option Period” means the period during which an Option may be exercised;

 

(z)

“Optioned Shares” means the Shares for which an Option is or may become exercisable;

 

(aa)

“Optionee” means an Eligible Person to whom an Option has been granted under the terms of the Plan or who holds an Option that is otherwise subject to the terms of the Plan;

 

(bb)

“Outstanding Shares” means, at any particular time, the number of Shares then issued and outstanding, calculated on a non-diluted basis;

 

(cc)

“Plan” means this Amended and Restated Rolling Stock Option Plan of the Company, as amended, supplemented or replaced from time to time;

 

(dd)

“Retirement” means, in respect of an Employee, Officer or Consultant of the Company or its Affiliate, ceasing to be an Employee, Officer or Consultant of the Company or its Affiliate, as the case may be, after attaining a stipulated age in accordance with the Company’s retirement policy in effect from time to time or earlier with the Company’s consent;

 

(ee)

“Shares” means the common shares in the capital of the Company as constituted on the date hereof and any shares of the Company into which such common shares may be changed, reclassified, subdivided, consolidated or converted, whether by reason or an amalgamation, merger or other capital reorganization;

 

(ff)

“Take-over Bid” means a take-over bid, as defined in the Securities Act (Ontario), which is a “formal bid” as defined in the Securities Act (Ontario), and which is made:

 

  i)

for all of the issued and outstanding Shares of any one or more classes of shares in the capital of the Company; or

 

  ii)

for all of the issued and outstanding Shares of any one or more classes of Shares in the capital of the Company other than:


  (A)

those Shares in the capital of the Company which are then owned by the offeror under such Take-over Bid; and/or

 

  (B)

those Shares in the capital of the Company which the offeror under such Take-over Bid then otherwise has, directly or indirectly, the right to acquire; and

 

(gg)

“Termination” means:

 

  i)

in the case of an Employee, the termination of the employment of the Employee by the Company or its Affiliate or cessation of employment of the employee with the Company or its Affiliate as a result of resignation or otherwise (other than through the Retirement of the Employee);

 

  ii)

in the case of a Management Company Employee, the termination of the employment of the Management Company Employee by his or her employer or cessation of employment of the employee with his or his employer for any reason;

 

  iii)

in the case of an Officer, the removal of or failure to re-appoint the individual as an Officer of the Company or its Affiliate (other than through Retirement of an Officer); and

 

  iv)

in the case of a Consultant, the termination of the services of a Consultant by the Company or its Affiliate (other than through the Retirement of a Consultant).

ARTICLE 2

ADMINISTRATION

2.1 Establishment of Committee

The Plan will be administered by the Board or, if appointed, by a special committee consisting of two or more Directors appointed or designated from time to time by the Board (such committee, the “Committee”).

 

(a)

Power and Authority of Board or Committee

Subject to the provisions of the Plan, the Board or Committee shall have authority to, among other things,

 

  i)

grant Options to purchase Shares to Eligible Persons;

 

  ii)

determine the terms, including the limitations, restrictions and conditions, if any, upon such grants;

 

  iii)

construe and interpret the Plan and all Option Agreements entered into thereunder,

 

  iv)

define the terms used in the Plan and in all Option Agreements entered into thereunder, and

 

  v)

prescribe, amend and rescind rules and regulations relating to the Plan and to make all other determinations necessary or advisable for the administration of the Plan. All determinations and interpretations made by the Board or Committee shall be binding and conclusive on all parties, including, without limitation, all participants under the Plan and their heirs, successors, personal representatives and beneficiaries. No member of the Board or Committee shall be liable for anything done or omitted to be done by such member, by any other member of the Board or Committee or by any Officer of the Company, in connection with the performance of any duties under the Plan, except those which arise from willful misconduct or as expressly provided by statute.

 

(b)

Costs of Administration

The Company shall pay all administrative costs of the Plan.


ARTICLE 3

STOCK OPTION PLAN

3.1 Eligibility

 

(a)

Subject to the provisions of this Plan, the Board or Committee may from time to time grant Options to purchase Shares to Eligible Persons. The granting of Options is entirely at the discretion of the Board or Committee and nothing in this Plan shall be interpreted so as to give any person any right to participate in this Plan or to be granted Options hereunder. The granting of Options to any Eligible Person at any time does not guarantee such Eligible Person the right to receive additional Options in the future. The Board or Committee shall consider such factors as it deems pertinent in determining which Eligible Persons shall be entitled to participate in the Plan, to be granted Options hereunder and the amounts and terms of such Options;

 

(b)

For stock options granted to Employees, Consultants or Management Company Employees, the Company and the Optionee are responsible for ensuring and confirming that the Optionee is a bona fide Employee, Consultant or Management Company Employee, as the case may be; and

 

(c)

Subject to any applicable regulatory approvals, Options may also be granted under the Plan:

 

  i)

in exchange for outstanding Options granted by the Company or any predecessor Company thereof or any Affiliate thereof, whether such outstanding options were granted under the Plan, under any other stock option plan of the Company or any predecessor Company or any Affiliate thereof, or under any stock option agreement with the Company or any predecessor Company or Affiliate thereof; and

 

  ii)

in substitution for outstanding options of one or more other companies in connection with a plan of arrangement or exchange, amalgamation, merger, consolidation, acquisition of property or shares, or other reorganization between or involving such other companies and the Company or any of its Affiliates.

 

(d)

Number of Shares Reserved under the Plan:

 

  i)

The aggregate maximum number of Shares reserved for issuance under this Plan at any given time shall not exceed 10% of the Outstanding Shares as of the grant date of an Option hereunder, subject to adjustment in accordance with Section 3.3. If any Option granted pursuant to the Plan expires, is forfeited, terminated or otherwise lawfully cancelled for any reason whatsoever without having been exercised in full, the Optioned Shares that were issuable thereunder shall be returned to the Plan and will be available again for an Option grant under the Plan;

 

  ii)

The aggregate number of Shares reserved for issuance pursuant to Options granted to Insiders at any given time, or within a 12-month period, shall not exceed 10% of the Outstanding Shares, unless Disinterested Shareholder Approval is obtained. The aggregate number of Shares reserved for issuance pursuant to Options granted to any one person or entity within any 12-month period shall not exceed 5% of the Outstanding Shares, unless Disinterested Shareholder Approval is obtained;

 

  iii)

The aggregate number of Options granted to any one Consultant in any 12-month period must not exceed 2% of the Outstanding Shares, calculated at the date the Option is granted; and

 

  iv)

The aggregate number of Options granted to persons employed to provide Investor Relations Activities in any 12-month period must not exceed 1% of the Outstanding Shares, calculated at the date the Option is granted.

 

(e)

Adjustment in Shares Subject to the Plan

 

  i)

Following the date an Option is granted, the exercise price for and the number of Optioned Shares which are subject to an Option will be adjusted, with respect to the then unexercised portion thereof, by the Board or Committee from time to time (on the basis of such advice as the Board or


 

Committee considers appropriate, including, if considered appropriate by the Board or Committee, a certificate of the auditor of the Company) in the events and in accordance with the provisions and rules set out in this Section 3.3, with the intent that the rights of Optionees under their Options are, to the extent possible, preserved notwithstanding the occurrence of such events. The Board or Committee will conclusively determine any dispute that arises at any time with respect to any adjustment pursuant to such provisions and rules, and any such determination will be binding on the Company, the Optionee and all other affected parties.

 

  ii)

The number of Optioned Shares to be issued on the exercise of an Option shall be adjusted from time to time to account for each dividend of Shares (other than a dividend in lieu of cash dividends paid in the ordinary course), so that upon exercise of the Option for an Optioned Share the Optionee shall receive, in addition to such Optioned Share, an additional number of Shares (“Additional Shares”), at no further cost, to adjust for each such dividend of Shares. The adjustment shall take into account every dividend of Shares that occurs between the date of the grant of the Option and the date of exercise of the Option for such Optioned Share. If there has been more than one such dividend, the adjustment shall also take into account that the dividends that are later in time would have been distributed not only on the Optioned Share had it been outstanding, but also on all Additional Shares which would have been outstanding as a result of previous dividends.

 

  iii)

If the Shares are changed into or exchanged for a different number of Shares or into or for other securities of the Company or securities of another corporation or entity, whether through an arrangement, amalgamation or other similar procedure or otherwise, or a share recapitalization, subdivision or consolidation, then on each exercise of the Option which occurs following such events, for each Optioned Share for which the Option is exercised, the Optionee shall instead receive the number and kind of shares or other securities of the Company or other corporation or entity into which such Optioned Share would have been changed or for which such Optioned Share would have been exchanged if it had been outstanding on the date of such event.

 

  iv)

If the Shares are changed into or exchanged for a different number of Shares or into or for other securities of the Company or securities of another corporation or entity, in a manner other than as specified in Sections 3.3(b) or 3.3(c), then the Board or Committee, in its sole discretion, may make such adjustment to the securities to be issued pursuant to any exercise of the Option and the exercise price to be paid for each such security following such event as the Board or Committee in its sole and absolute discretion determines to be equitable to give effect to the principle described in Section 3.3(a), and such adjustments shall be effective and binding upon the Company and the Optionee for all purposes.

 

  v)

If the Company distributes, by way of a dividend or otherwise, to all or substantially all holders of Shares, property, evidences of indebtedness or shares or other securities of the Company (other than Shares) or rights, options or warrants to acquire Shares or securities convertible into or exchangeable for Shares or other securities or property of the Company, other than as a dividend in the ordinary course, then, if the Board or Committee, in its sole discretion, determines that such action equitably requires an adjustment in the exercise price under any outstanding Option or in the number(s) of Optioned Shares subject to any such Option, or both, such adjustment may be made by the Board or Committee and shall be effective and binding on the Company and the Optionee for all purposes.

 

  vi)

No adjustment or substitution provided for in this Section 3.3 shall require the Company to issue a fractional Share in respect of any Option, and the total adjustment with respect to each Option shall be limited accordingly.

 

  vii)

The grant or existence of an Option shall not in any way limit or restrict the right or power of the Company to effect adjustments, reclassifications, reorganizations, arrangements or changes of its capital or business structure, or to amalgamate, merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part of its business or assets.


ARTICLE 4

TERMS OF OPTIONS

4.1 Option Period

 

(a)

The Option Period for an Option shall be determined by the Board or Committee at the time the Option is granted and may be up to ten (10) years from the date the Option is granted. Any Option not exercised within the Option Period fixed for its exercise shall terminate and become void and of no effect.

 

(b)

Notwithstanding paragraph (a) above or anything else to the contrary in the Plan, but subject to the requirements of CSE Policies, if applicable, if the term of any Option granted under the Plan ends on a day occurring within a Blackout Period applicable to an Optionee, the term of such Option shall be automatically extended to (and such Option shall continue to be exercisable under the terms of the Plan up to) 5:00 p.m. (Toronto time) on the tenth business day following the expiry of such Blackout Period. This Section applies to all options outstanding under the Plan, regardless of the date of grant or issuance.

 

(c)

Vesting of Options

 

  i)

Subject to the provisions of this Plan, CSE Policies, the rules of any securities regulatory authority having jurisdiction over the Company and all applicable laws, the Board or Committee may determine when an Option will become exercisable and may determine that the Option will be exercisable immediately upon the date of grant, in installments or pursuant to a vesting schedule.

 

(d)

Exercise of Options

 

  i)

An Optionee may exercise, in whole or in part, any Option that has vested in accordance with its terms by delivering to the Company a notice of exercise, substantially in the form of Appendix “B” attached to this Plan. The exercise of any Option will be contingent upon receipt by the Company of payment in full for the exercise price of the Optioned Shares being purchased in cash by way of certified cheque, bank draft or electronic transfer of immediately available funds.

 

  ii)

If an Option is exercised for fewer than all of the Optioned Shares for which the Option has then vested, the Option shall remain in force and exercisable for the remaining Optioned Shares for which the Option has then vested, according to the terms of such Option.

 

  iii)

As soon as practicable following the receipt by the Company of the notice of exercise and payment in full for the Optioned Shares being acquired, the Company will, or will cause its transfer agent to, issue a certificate to the Optionee for the appropriate number of Optioned Shares acquired by such Optionee. If required by applicable securities laws or CSE Policies, such certificate will bear the legend referred to in Section 4.4(a)(ii).

 

(e)

Exercise Price

The Board or Committee shall establish the exercise price of an Option at the time each Option is granted, subject to the following conditions:

 

  i)

If the Shares are listed on the CSE, then the exercise price must not be lower than the greater of the closing market price of the underlying securities on (a) the trading day prior to the date of grant of the stock options; and (b) the date of grant of the stock options;

 

  ii)

If the Shares are listed on a stock exchange other than the CSE, the exercise price shall not be less than the minimum prevailing price permitted by the rules of the stock exchange on which the Shares are listed at the time the Option is granted.

 

(f)

Option Agreement

 

  i)

Upon the grant of an Option to an Optionee, the Company and the Optionee shall enter into an Option Agreement, substantially in the form attached to this Plan as Appendix “A”, setting out, among other things, the number of Optioned Shares subject to the Option, the exercise price per


 

Optioned Share, the Option Period and, if applicable, the vesting schedule for the Option, and incorporating the terms and conditions of the Plan and any other requirements of regulatory authorities and stock exchanges having jurisdiction over the securities of the Company, together with such other terms and conditions as the Board or Committee may determine in accordance with the Plan.

 

(g)

Termination, Retirement or Death

Unless otherwise determined by resolution of the Board or Committee, any Options granted under this Plan shall terminate and shall cease to be exercisable in the following circumstances:

 

  i)

in the case of an Optionee who is an Officer, Employee, Management Company Employee or Consultant of the Company or of an Affiliate of the Company, such Optionee:

 

  i)

is Terminated for cause, in which case all Options granted to such Optionee, whether vested or unvested, shall immediately terminate and cease to be exercisable on the effective date of such Optionee’s Termination; or

 

  ii)

is Terminated for any reason other than cause, Retirement or death, in which case such Optionee may exercise any Option granted hereunder, to the extent that such Option was exercisable and had vested on the date of Termination, until the date that is the earlier of (i) the expiry date of the Option and (ii) the date that is 90 days after the effective date of such Optionee’s Termination.

 

  (A)

in the case of an Optionee who is a Director of the Company or of an Affiliate of the Company, such Optionee:

 

  (1)

ceases to meet the qualifications for a director prescribed by the corporate legislation applicable to the Company, other than as a result of bankruptcy or mental incompetency;

 

  (2)

receives a formal request for resignation signed by a majority of the Board following a material breach of fiduciary duty by that Director; or

 

  (3)

is otherwise removed as a Director of the Company or of an Affiliate of the Company, and such Optionee:

 

  i.

does not otherwise continue to qualify as an Eligible Person in a different capacity with the Company, in which case all Options granted to such Optionee, whether vested or unvested, shall immediately terminate and cease to be exercisable on the effective date of such Optionee’s removal or failure to be re-elected; or

 

  ii.

resigns (other than in the situation referred to above) as a Director of the Company or of an Affiliate of the Company, in which case such Optionee may exercise any Option granted hereunder, to the extent that such Option was exercisable and had vested on the date of resignation, until the date that is the earlier of (i) the expiry date of the Option and (ii) the date that is 90 days after the effective date of such Optionee’s resignation.

 

  (B)

in the case of an Optionee who is an Officer, Employee or Consultant of the Company or of an Affiliate of the Company and,

 

  (1)

such Optionee Retires, such Optionee may exercise any Option granted hereunder, to the extent that such Option was exercisable and had vested on the date of Retirement, until the date that is the earlier of (i) the expiry date of the Option and (ii) the date that is 90 days after the effective date of such Optionee’s Retirement; or


  (2)

such Optionee dies, such Optionee’s legal personal representatives, heirs, executors or administrators may exercise any Option granted hereunder, to the extent that such Option was exercisable and had vested on the date of death, until the date that is the earlier of (i) the expiry date of the Option and (ii) the date that is twelve months after the date of death.

 

(h)

Acceleration of Term and Vesting

 

 

If:

 

  i)

the Company shall enter into an agreement providing for a Change of Control;

 

  ii)

the Board adopts a resolution to the effect that a Change of Control has occurred or is imminent; or

 

  iii)

a Take-over Bid shall be made, the Board may, at any time thereafter, in its sole and absolute discretion and if permitted by CSE Policies and applicable securities laws, determine by resolution (the “Board Determination”) that all outstanding Options shall (i) immediately become exercisable in full by the holders thereof, notwithstanding any vesting provisions or other restrictions or conditions that would otherwise attach to such Options, and (ii) expire on the date determined by the Board, provided however that the expiry date of any outstanding Option may not be extended beyond the 10-year maximum term prescribed by Section 4.1. For greater certainty and without limiting the generality of the foregoing, the Board may, in its sole and absolute discretion, determine by resolution that any Options that remain unexercised upon the occurrence of a Change of Control shall terminate and cease to be exercisable immediately, without payment of any consideration of any nature or kind to the holder(s) thereof. All determinations made by the Board pursuant to this Section 4.7 shall be binding for all purposes of the Plan and on all parties concerned.

Each Optionee shall have the right, on such terms and conditions as may be prescribed by the Board Determination, to elect to exercise up to the time that such Optionee’s option expires, after giving effect to the Board Determination, all options then held by such Optionee under the Plan in respect of up to all of the Shares which could have been purchased by such Optionee on a full exercise of all such options. Notwithstanding the foregoing:

 

  (A)

if such Optionee so elects to exercise such Optionee’s option;

 

  (B)

if such Optionee has not elected to exercise such Optionee’s option and subscribe for Shares in accordance with this Section; or

 

  (C)

if such Optionee has exercised such Optionee’s option but, following such exercise, such Optionee has not paid for the Shares which such Optionee has elected to subscribe for,

the Company shall have the right (which right may be exercised by the Company in its sole and absolute discretion) to pay to such Optionee cash in an amount equal to the result obtained by multiplying the amount, if any, by which the market price per Share on the date of completion of the Change of Control or Take-over Bid, as the case may be, exceeds the Option price, by the number of Shares then remaining unsubscribed for under all Options then held by such Optionee under the Plan which could have been purchased by such Optionee on a full exercise of all such Options (and, if such payment is made, any exercise made by such Optionee of his or her Options shall be deemed to have been not made and be null and void); and, if a Change of Control or Take-over Bid is completed, the market price for the purposes of calculating the amount of such cash payment to be made by the Company shall be the same as the value of the consideration paid per Share under the Change of Control or Take-over Bid, as applicable.

(i) Non-Assignability

Neither the Options nor the benefits and rights of any Optionee under any Option or under the Plan or any Option Agreement shall be assignable or otherwise transferable, except as specifically provided in Section 4.6(d) in the


event of the death of the Optionee. During the lifetime of the Optionee, all such Options, benefits and rights may only be exercised by the Optionee.

(j) Employment

Nothing contained in the Plan shall confer upon any Optionee, or any person employing a Management Company Employee, any right with respect to employment or continuance of employment with, or the provision of services to, the Company or any of its Affiliates, or interfere in any way with the right of the Company or any of its Affiliates to terminate the Optionee’s employment or the services of any such person at any time. Participation in the Plan by an Optionee is voluntary.

(k) No Rights as Shareholder

Nothing contained in this Plan, in any Option Agreement or in any Option granted hereunder shall be deemed to give any Optionee any interest in or title to any Shares or any rights as a shareholder of the Company or any other legal or equitable right against the Company whatsoever other than as set forth in this Plan and pursuant to the exercise of any Option in accordance with the provisions of the Plan and the applicable Option Agreement.

ARTICLE 5

AMENDMENT AND TERMINATION

5.1 Amendment or Termination of Plan

The Board or Committee reserves the right to amend or terminate the Plan at any time if and when it is deemed advisable in the absolute discretion of the Board or Committee; provided, however, that no such amendment or termination shall adversely affect any outstanding Options granted under the Plan without the consent of the affected Optionee(s). Any amendment to the Plan shall also be subject to acceptance of such amendment or amended Plan for filing by the CSE, if applicable, and, where required by the CSE, the approval of the shareholders of the Company.

ARTICLE 6

MISCELLANEOUS

6.1 Securities Regulation

 

(a)

Where necessary to enable the Company to rely on an exemption from the requirement to register the Optioned Shares or to file a prospectus or use a registered dealer to distribute the Optioned Shares under securities laws applicable to the securities of the Company in any jurisdiction, an Optionee, upon the acquisition of any Optioned Shares by the exercise of an Option and as a condition to such exercise, shall provide to the Board or Committee such evidence as the Board or Committee requires to demonstrate that the Optionee or recipient will acquire such Optioned Shares with investment intent (i.e., for investment purposes) and not with a view to their Distribution, including an undertaking to that effect in a form acceptable to the Board or Committee. The Board or Committee may cause a legend or legends to be placed upon any certificates for the Optioned Shares to make appropriate reference to applicable resale restrictions and the Optionee or recipient shall be bound by such restrictions. The Board or Committee may also take such other action or require such other action or agreement by such Optionee or proposed recipient as may from time to time be necessary to comply with applicable securities laws. This provision shall in no way obligate the Company to undertake the registration or qualification of any Options or the Optioned Shares under any securities laws applicable to the securities of the Company.

 

(b)

Issuance, transfer or delivery of certificates for Optioned Shares acquired pursuant to the Plan may be delayed, at the discretion of the Board or Committee, until the Board or Committee is satisfied that the requirements of applicable laws and regulations, and applicable rules of regulatory authorities, have been met.

6.2 Tax Withholding

 

(a)

Notwithstanding any other provisions of this Plan, the Company may, from time to time, implement such procedures and conditions as it determines appropriate with respect to the withholding and remittance of


taxes imposed under applicable law or the funding of related amounts for which liability may arise under such applicable law (collectively, the “Tax Obligations”). Without limiting the generality of the foregoing, an Optionee who wishes to exercise an option must, in addition to following the procedures set out in any stock option agreement and elsewhere in this Plan, and as a condition of exercise:

 

  i)

deliver a certified cheque, wire transfer or bank draft payable to the Company for the amount determined by the Company to be the appropriate amount on account of such Tax Obligations, or

 

  ii)

otherwise ensure, in a manner acceptable to the Company (if at all) in its sole and unfettered discretion, that such amount will be made available to the Company on a secure and timely basis, and must in all other respects follow any related procedures and conditions imposed by the Company, failing which the Company shall not be obliged to honour the purported Option exercise or issue certificates for Shares.

 

  iii)

Without limiting the generality of the foregoing or limiting the Company’s discretion under this Section 6.2, the Company may, at its option:

 

  (A)

accept the exercise of the options and withhold all or any number of Shares issued upon exercise of the options and deliver such number of Shares as it may determine to a broker or other selling agent for purposes of sale, or otherwise sell or transfer such Shares. In implementing any such sale or transfer, neither the Company nor any broker or selling agent shall be obligated to seek or obtain a minimum price or be liable for any loss arising out of any sale or transfer of such Shares (relating to the manner or timing of such sale or transfer, the terms or prices at which such Shares are sold or transferred, or otherwise). Any net proceeds derived therefrom shall in the first instance serve to satisfy the Tax Obligations and all related fees, interest or other obligations in respect thereof, and shall be available or made available to the Company for the purpose of satisfying the foregoing. Any shortfall in such net proceeds as required to satisfy such Tax Obligations and other amounts shall be to the account of the Optionee and (without limiting the Company’s remedies available under law) may be recovered by the Company from the Optionee by way of set-off against any other amount or property then or thereafter owing by the Company to the Optionee in any capacity (whether salary or other remuneration, Shares or remaining Shares issued on exercise of options then otherwise to be issued, or in any other manner). Any net proceeds derived from a sale or other transfer of such Shares in excess of the amount determined by the Company to be the amount required to satisfy the Tax Obligations and related fees, interest or other obligations shall, together with any remaining Shares not so sold or transferred, also be for the account of the Optionee; or

 

  (B)

accept the exercise of the options if and provided that the Optionee and the Company have agreed to procedures, acceptable to the Company in its sole discretion, whereby a sale of Shares sufficient to satisfy the Tax Obligations and related amounts (as determined by the Company in its sole discretion) has been coordinated through a broker or sales agent (including such broker or sales agent acting for the Optionee) on a basis that:

 

  (1)

obliges such broker or sales agent to retain and provide such amounts to the Company on a timely basis, and

 

  (2)

does not oblige the Company to issue such optioned Shares except against payment and delivery of such amounts (and the amount of the option exercise price if not separately paid under Section 4.3.


6.3 Regulatory Acceptances

 

(a)

Upon listing of the Shares on the CSE, the Plan is subject to the acceptance of the Plan for filing by the CSE, and the Board or Committee is authorized to amend the Plan from time to time in order to comply with any changes required from time to time by such applicable regulatory authorities, whether as conditions to the acceptance for filing of the Plan or otherwise, provided that no such amendment will in any way derogate from the rights held by Optionees holding Options (vested or unvested) at the time thereof without the consent of such Optionees; and

 

(b)

The obligation of the Company to issue and deliver Optioned Shares pursuant to the exercise of any Options granted under the Plan is subject to the acceptance of the Plan for filing by the CSE. If any Optioned Shares cannot be issued to any Optionee for any reason, including, without limitation, the failure to obtain such acceptance for filing, then the obligation of the Company to issue such Optioned Shares shall terminate and any amounts paid to the Company for such Optioned Shares shall be returned to the Optionee as soon as practicable without interest or deduction.

6.4 No Representation or Warranty

The Company makes no representation or warranty as to the future market value of Optioned Shares issued in accordance with the provisions of this Plan or to the effect of the Income Tax Act (Canada) or any other taxing statute governing the Options or the Optioned Shares issuable thereunder or the tax consequences to an Optionee. Compliance with applicable securities laws as to the disclosure and resale obligations of each Optionee is the responsibility of such Optionee and not the Company.

6.5 Other Compensation Arrangements

Nothing contained in the Plan shall prevent the Company or any of its Affiliates from adopting or continuing in effect other compensation arrangements (subject to shareholder approval if such approval is required by the CSE) and such arrangements may be either generally applicable or applicable only in specific cases.

6.6 Financial Assistance

The Company is authorized, in its sole discretion, to provide financial assistance to Optionees to purchase Optioned Shares under this Plan, subject to applicable laws and the rules and policies of any securities regulatory authority, stock exchange or quotation system with jurisdiction over the Company or a trade in securities of the Company. Any financial assistance so provided will be repayable with full recourse and the term of any such financial assistance shall not exceed the term of the Option to which the financial assistance applies.

6.7 Governing Law

The validity, construction and effect of the Plan, the grants of Options, the issue of Optioned Shares, any rules and regulations relating to the Plan or any Option Agreement, and all determinations made and actions taken pursuant to the Plan, shall be governed by and determined in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein.

6.8 Severability

If any provision of the Plan or any Option Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or as to any person or Option, or would disqualify the Plan or any Option under any law deemed applicable by the Board or Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Board or Committee, materially altering the intent of the Plan or the Option, such provision shall be stricken as to such jurisdiction, person or Option and the remainder of the Plan and any such Option Agreement shall remain in full force and effect.

6.9 Headings

Headings are given to the sections of the Plan solely as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof.


APPENDIX “A” to the Option Plan

Form of Option Agreement

XANTHIC BIOPHARMA INC.

________ [Date]

PERSONAL & CONFIDENTIAL

____________ [Name]

____________ [Address]

Dear ____________ [Name]:

The Company’s Amended and Restated Rolling Stock Option Plan (the “Plan”) permits the Board of Directors to grant options to officers, employees and others whose contribution to the Company is significant. In recognition of your contribution to the Company and in order to permit you to share in enhanced values that you will help to create, the Board is pleased to grant to you an option (the “Option”) to purchase Common Shares (the “Shares”) of the Company. The granting and exercise of the Options and the issuance of the Shares are subject to the terms and conditions of the Plan, all of which are incorporated into and form an integral part of this Option Agreement. This letter and the Plan are referred to collectively below as the “Option Documents”. All capitalized terms not otherwise defined shall have the meaning attributed to them in the Plan.

The total number of Shares that you may purchase pursuant to this Option is: __________________________________________

The Option exercise price per Share is: _________________________

Your rights to purchase Shares will vest and expire as follows:

 

  

• Vesting Date

  

• %

  

• Expiry Date

        

        

        

Subject to earlier expiration in accordance with the Option Documents, your rights to purchase Shares pursuant to this Option will expire with respect to any vested portion at 11:59 p.m. (Toronto time), on the expiry date set out above for such vested Options.

This Option may be exercised in whole or in part in respect of vested Options at any time prior to expiry of the relevant Options, by delivery of written notice to the Company’s head office to the attention of the Secretary of the Company, substantially in the form of Appendix “B” attached to the Plan, specifying the number of Shares to be purchased, accompanied by payment by bank draft or certified cheque of the total purchase price of the Shares.

By executing this Option Agreement, you confirm and acknowledge that you have not been induced to enter into this Option Agreement or acquire any Option by expectation of employment or continued employment with the Company. Nothing in the Option Documents will affect our right to terminate your services, responsibilities, duties and authority at any time for any reason whatsoever. Regardless of the reason for your termination, your Option rights will be restricted to those Option rights which have vested on or prior to your date of termination and, in any claim for wrongful dismissal or breach of contract, no consideration will be given to any Options that might have


vested during an appropriate notice period or as a result of additional compensation you may receive in place of that notice period.

All decisions made by the Board of Directors with regard to any questions arising in connection with the Option Documents, whether of interpretation or otherwise, will be binding and conclusive on all parties.

The Option rights granted to you are personal and may not be sold, pledged, transferred or encumbered in any way. There are restrictions on the transfer of Shares issued to you pursuant to the Plan. Complete details of the restrictions referred to in this letter are set out in the Plan.

The exercise of any Options pursuant to the Plan shall be subject to the Company’s right to take such steps as it considers necessary or appropriate for the deduction or withholding of any income taxes or other amounts which the Company or any affiliate of the Company is required by any law or regulation of any governmental authority whatsoever to deduct or withhold in connection with any Share issued pursuant to the Plan.

Please acknowledge acceptance of your Option rights on these terms by signing where indicated below on the enclosed copy of this letter and returning the signed copy to the Company to the attention of the Secretary. By signing and delivering this copy, you are acknowledging receipt of a copy of the Plan and are agreeing to be bound by all of the terms of the Option Documents.

Yours truly,

 

 

2.

 

    XANTHIC BIOPHARMA INC.

 

y:

 
 

 

 

    Authorized Signatory

I have read and agree to be bound by this letter and the Plan.

 

Name:

 
 

 

Signature

 
 

 

Address:

 
 

 

Witness Signature

 
 

 

Witness Name (printed):

 
 

 


APPENDIX “B” to the Option Plan

Notice of Election to Exercise Option

 

TO:

XANTHIC BIOPHARMA INC. (the “Company”)

Pursuant to the amended and restated rolling stock option plan (the “Plan”) adopted by the Company, the undersigned elects to purchase              common shares (the “Shares”) of the Company, which are subject to the options granted on              20    , and encloses a bank draft or personal cheque payable to the Company (or has otherwise arranged for electronic payment to the Company) in the aggregate amount of C$            , being C$             per Share. The undersigned requests that the Shares be issued as follows in his, her or its name as follows in accordance with the terms of the Plan:

DATED this          day of             , 20    .

 

Name of Optionee:

  

 

Signature:

  

 

Address:

  

 

Witness Signature:

  

 

Witness Name (Printed):

  

 

(Where the party exercising the Option is a trust, the trustee should execute this election)

(Where the party exercising the Option is a corporation, an officer or director should execute this election and the title should be entered)


SCHEDULE “D”

XANTHIC BIOPHARMA INC.

(the “Corporation”)

BY-LAW NO. 1B

a by-law relating generally to the

conduct of the business and affairs of

XANTHIC BIOPHARMA INC.

(hereinafter called the Corporation”)

BE IT ENACTED as a by-law of the Corporation as follows:

I. INTERPRETATION

1.01 In this by-law, unless the context otherwise clearly requires:

 

  (a)

“Act” means the Business Corporations Act (Ontario) and includes the Regulations made pursuant thereto;

 

  (b)

“Articles” means the Articles of Amalgamation of the Corporation as then in force;

 

  (c)

“board” means the board of directors of the Corporation, or if there shall only be one director of the Corporation at any particular time, such director, and all references herein to the directors or the board means the directors of the Corporation acting as such or any duly empowered committee of the board;

 

  (d)

“by-laws” means all by-laws, including special by-laws, of the Corporation as amended from time to time;

 

  (e)

“Corporation” means this Corporation;

 

  (f)

“person” includes an individual, sole proprietorship, partnership, unincorporated association, unincorporated syndicate, unincorporated organization, trust, corporation and a natural person in his capacity as trustee, executor, administrator or other legal representative.


1.02 In this by-law where the context permits words importing the singular include the plural and vice versa, and words importing gender include the masculine, feminine and neuter genders.

1.03 All words and terms appearing in this by-law which are defined by the Act as having a particular meaning shall be deemed to have the same meanings they are respectively thereby defined as having, unless the context otherwise reasonably requires.

II. DIRECTORS

2.01 Place of Meetings. Meetings of the board may be held at the place where the registered office of the Corporation is then located, or at any place within the City of Toronto; and may be held at any other place within or outside of Ontario with the written consent of all of the directors for the time being of the Corporation. Subject to the foregoing, a majority of the meetings of the board held in any financial year of the Corporation need not be held at places within Canada.

2.02 Calling of Meetings. Meetings of the board may be called for the transaction of any business by the Chairman, the President or a Vice-President who is a director, or any two directors, and the Secretary shall by written notice call meetings when directed or authorized by the Chairman, the President, any Vice-President who is a director, or any two directors. Written notice of the time and place for the holding of every meeting of the board specifying the general nature of the business to be transacted at the meeting shall be sent to every director of the Corporation not less than 48 hours (excluding Sundays and holidays) before the time when the meeting is to be held and need not be given on any longer notice.

2.03 Regular Meetings. The board may appoint a day or days in any month or months for regular meetings at a place and hour to be named. A copy of any resolution of the board fixing the place and time of regular meetings of the board shall be sent to each director forthwith after being passed, but no other notice shall be required for any such regular meeting.

2.04 Chairman. The chairman of any meeting of the board shall be the first-mentioned of such of the following officers as has then been appointed and who is then a director and is present at the meeting.

 

   

Chairman of the Board;

 

   

President;

 

   

A Vice-President who is then a director, if there shall be not more than one;

 

A-2


   

Vice-President who is a director; and

 

   

the most senior of those Vice-Presidents who are then directors, if more than one Vice-President is a director,

and if no such officer is present, the directors present shall choose one of their number to act as the chairman of the meeting.

2.05 Votes to Govern. At all meetings of the board, every question shall be decided by a majority of the votes cast on the question, and in the case of an equality of votes on any question at a meeting of the board, the chairman of the meeting shall not be entitled to a second or casting vote.

2.06 Remuneration. Any remuneration of the directors fixed by the board shall, in the absence of a provision to the contrary set forth in the resolution of the board fixing the same, be in addition to any salary or professional fees payable to a director who serves the Corporation in any other capacity. In addition, the directors shall be paid such sums as the board may from time to time determine in respect of their out-of-pocket expenses incurred in attending board, committee or shareholders’ meetings or otherwise in respect of the performance by them of their duties.

2.07 Limitation of Liability. No director or officer of the Corporation shall be liable as such for the acts, receipts, neglects or defaults of any other director or officer or employee, or for joining in any receipt or act for conformity, or for any loss, damage or expense happening to the Corporation through the insufficiency or deficiency of title to any property acquired for or on behalf of the Corporation, or for the insufficiency or deficiency of any security in or upon which any of the monies of the Corporation shall be invested, or for any loss or damage arising from the bankruptcy, insolvency or tortious act of any person with whom any of the monies, securities or effects of the Corporation shall be deposited, or for any loss occasioned by any error in judgment or oversight on his part, or for any other loss, damage or misfortune whatever which shall happen in the execution of the duties of his office or in relation thereto, unless the same are occasioned by his own willful neglect or default; provided that nothing herein shall relieve any director or officer from the duty to act in accordance with the Act or from liability for any breach thereof.

2.08 Indemnity of Directors and Officers. Except as provided in the Act, every director and officer of the Corporation, every former director and officer of the Corporation, and every person who acts or acted at the Corporation’s request as a director or officer of another corporation of which the Corporation is or was a shareholder or creditor, and his heirs and legal representatives, shall at all times be indemnified and saved harmless by the Corporation from and against all costs, charges and expenses,

 

A-3


including an amount paid to settle an action or satisfy a judgment, reasonably incurred by him in respect of any civil, criminal or administrative action or proceeding to which he is made a party by reason of or having been a director or officer of the Corporation or such other corporation if, (a) he acted honestly and in good faith with a view to the best interests of the Corporation; and (b) in case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, he had reasonable grounds for believing that his conduct was lawful.

2.09 Quorum At Meetings. The quorum at a meeting of the directors shall be as provided for in the Act.

III. OFFICERS

3.01 Term, Remuneration or Removal. The terms of employment and remuneration of all officers of the Corporation shall be determined from time to time by resolution of the board. The fact that any officer or employee is a director or shareholder of the Corporation shall not disqualify him from receiving such remuneration. All officers shall be subject to removal by resolution of the board at any time with or without cause.

3.02 Officers. Nothing contained in this section 3 shall be in limitation of the powers conferred upon the board by the Act to designate the offices of the Corporation, appoint officers, specify their duties and delegate them powers to manage the business and affairs of the Corporation. In the absence of any provision to the contrary contained in any resolution of the board, the persons appointed to the following respective offices shall have the following respective duties and powers, but, for certainty, the board may from time to time vary, add to, withhold, or limit the powers and duties of any officer or officers:

(a) Chairman of the Board - the Chairman of the Board, if one shall be appointed, shall be a director of the Corporation. The Chairman of the Board shall preside at each meeting of the board at which he is present and shall preside as Chairman of each meeting of the shareholders at which he is present. Unless his power as chief executive officer of the Corporation shall have been withheld by the board, the Chairman of the Board shall be the chief executive officer of the Corporation and as such shall be charged, subject to the authority of the board, with the general supervision of the business and affairs of the Corporation.

(b) President - the board shall at all times have elected or appointed a President. The President need not be a director of the Corporation. The President shall be the chief operating officer of the Corporation. As such, subject to the supervision, control and direction of the Chairman of the Board, so long as one shall have been elected and his authority as the chief executive officer of the Corporation

 

A-4


shall not have been withheld, and subject to the authority of the board, the President shall be charged with the general supervision of the day-to-day business and affairs of the Corporation, and subject as aforesaid the President shall have the power to appoint or remove any and all officers, employees and agents of the Corporation not elected or appointed directly by the board and to settle the terms of their employment and remuneration. The President shall exercise all of the powers and be charged with all of the duties of the office of Chairman of the Board during those respective periods of time during which such office shall be vacant. In the absence of the Chairman of the Board, if one has then been elected, the President shall preside as chairman of each meeting of the board at which he is present and acting as a director and as chairman of each meeting of the shareholders at which he is present. During the absence or inability of the Chairman of the Board, if one has then been elected, the President may perform the other duties and exercise the other powers of that office, if any, and if the President shall perform any of such duties or exercise any of such powers the absence or inability of the Chairman of the Board shall be presumed with respect thereto. If the authority of the Chairman of the Board to act as chief executive officer of the Corporation shall have been withheld by the board, the President shall also be the chief executive officer of the Corporation and as such charged, subject to the authority of the board, with the general supervision of the business and affairs of the Corporation.

(c) Secretary - the board shall at all times have elected or appointed a Secretary. The Secretary shall attend all meetings of the board and the shareholders and shall enter or cause to be entered in books kept for that purpose minutes of all proceedings at such meetings; he shall give, or cause to be given, when instructed, notices required to be given to shareholders, directors, auditors and others entitled to notices of meetings; he shall be the custodian of the corporate seal of the Corporation, if the Corporation has a corporate seal, and of all books, papers, records, documents or other instruments belonging to the Corporation; and he shall perform such other duties as may from time to time be prescribed by the board.

(d) Vice-President - the board may from time to time appoint one or more Vice-Presidents. The Vice-President, or if there are more than one, the Vice-Presidents in order of seniority (as determined by the board) shall be vested with all of the powers and shall perform all of the duties of the President in the absence or disability or refusal to act of the President, except that a Vice-President shall not preside at meetings of the board or of the shareholders except as may be specifically provided in the Corporation’s by-laws. If a Vice-President exercises any duty or power of the President, the absence or inability of the President shall be presumed with reference thereto. A Vice-President shall also perform such other duties and exercise such other powers as the President may from time to time delegate to him or the board may prescribe.

 

A-5


(e) Treasurer - the Treasurer, if one shall be appointed, shall keep, or cause to be kept, proper accounting records as required by the Act; he shall deposit or cause to be deposited all monies received by the Corporation in the Corporation’s bank account; he shall, under the direction of the chief executive officer of the Corporation and the board, supervise the safekeeping of securities and the disbursement of the funds of the Corporation; he shall render to the board, whenever required, an account of all his transactions as Treasurer and of the financial position of the Corporation; and he shall perform such other duties as may from time to time be prescribed by the board.

(f) Other Officers - the duties of all other officers of the Corporation shall be such as the terms of their engagement call for or the board requires of them. Any of the powers and duties of an officer to whom an assistant has been appointed may be exercised and performed by such assistant, unless the board otherwise directs.

3.03 Agents and Attorneys. The board shall have the power from time to time to appoint agents or attorneys for the Corporation within or outside of Ontario with such powers of management or otherwise (including the power to sub-delegate) as may be thought fit.

3.04 Fidelity Bonds. The board may require such officers, employees and agents of the Corporation as it deems advisable to furnish bonds for the faithful performance of their duties, in such form and with such surety as the board may from time to time prescribe.

IV. SHAREHOLDERS

4.01 Who is to Preside At Meetings. The Chairman of the Board or, in his absence, the President, or in his absence a Vice-President who is a director, shall preside as Chairman at any meeting of shareholders, but if there is no Chairman of the Board, the President or such Vice-President, or if at a meeting none of them is present within fifteen minutes after the time appointed for the holding of the meeting, the shareholders present shall choose a person from their number to be the Chairman.

4.02 Persons Entitled To Be Present. The only persons entitled to attend a meeting of shareholders shall be those entitled to vote thereat, the directors and the auditor of the Corporation and others who although not entitled to vote are entitled or required under any provision of the Act or the by-laws of the Corporation to be present at the meeting. Any other person may be admitted only on the invitation of the Chairman of the meeting or with the consent of the meeting.

 

A-6


4.03 Scrutineers. At each meeting of shareholders one or more scrutineers may be appointed by a resolution of the meeting or by the Chairman of the meeting with the consent of the meeting to act as scrutineers at the meeting. Such scrutineers need not be shareholders of the Corporation.

4.04 Quorum At Meetings. A quorum for the transaction of business at any meeting of shareholders shall be two persons present in person, each being a shareholder entitled to vote thereat or a duly appointed proxyholder for a shareholder so entitled, holding or representing in the aggregate not less than 10% of the issued and outstanding shares of the Corporation entitling the holders thereof to vote at such meeting. If a quorum is present at the opening of any meeting of shareholders, the shareholders present or represented may proceed with the business of the meeting notwithstanding that a quorum is not present throughout the meeting. If a quorum is not present at the time appointed for the meeting or within a reasonable time thereafter as the shareholders may determine, the shareholders present or represented may adjourn the meeting to a fixed time and place but may not transact any other business.

V. SHARES

5.01 Transfer Agent and Registrar. The Board may from time to time appoint a registrar to maintain any securities register and a transfer agent to maintain the register of transfers of such securities and may also appoint one or more branch registrars to maintain branch security registers and one or more branch transfer agents to maintain branch registers of transfers, and any one person may be appointed both registrar and transfer agent. The board may at any time terminate any such appointment.

VI. DIVIDENDS

6.01 Payment. A dividend payable in cash shall be paid by cheque drawn on the Corporation’s bankers or any one of them to the order of each registered holder of shares of the class in respect of which it has been declared, which cheque may be mailed by prepaid ordinary mail to such registered holder at his last address appearing on the records of the Corporation. In the case of joint holders the cheque shall, unless such joint holders otherwise direct, be made payable to the order of all of such joint holders and if more than one address appears in the books of the Corporation in respect of such joint holders the cheque shall be mailed to the first address so appearing. The mailing of such cheque as aforesaid shall satisfy and discharge all liability for the dividend to the extent of the sum represented thereby, unless such cheque shall not be paid on presentation. Upon proof being given to the Corporation of the non-receipt of any such cheque by the person to whom it was so sent, as aforesaid, and upon satisfactory indemnity being given to the Corporation in that regard, the Corporation shall issue to such person a replacement cheque for a like amount.

 

A-7


6.02 Purchase of Business as of Past Date. Where any business is purchased by the Corporation as from a past date (whether such date be before or after the incorporation of the Corporation) upon terms that the Corporation shall as from that date take the profits and bear the losses of the business, such profits or losses, as the case may be, shall, at the discretion of the directors, be credited or debited wholly or in part to revenue account and in that case the amount so credited or debited shall, for the purpose of ascertaining the funds available for dividends, be treated as a profit or loss arising from the business of the Corporation.

VII. FINANCIAL YEAR

7.01 Financial Year. The financial or fiscal year of the Corporation shall be as determined from time to time by the Board.

VIII. NOTICES

8.01 Omissions and Errors. The accidental omission to give any notice to any shareholder, director, officer or auditor or the non-receipt of any notice by any such person, or any error in any notice not affecting the substance thereof, shall not invalidate any action taken at any meeting held pursuant to such notice or otherwise founded thereon.

8.02 Notice to Joint Shareholders. All notices with respect to any shares registered in the name of more than one holder may if more than one address appears in the records of the Corporation in respect of such holders be given to such holders at the first address so appearing, and notice so given shall be sufficient notice to all of the holders of such shares.

8.03 Persons Entitled by Death or Operation of Law. Every person who by operation of law, by transfer, by the death of a shareholder, or otherwise, becomes entitled to shares, is bound by every notice in respect of such shares which has been duly given to the registered holder of such shares prior to the name and address of such person being entered on the records of the Corporation as the holder of such shares.

8.04 Signature to Notices. The signature to any notice to be given by the Corporation may be written, stamped, type-written or printed or partly written, stamped, type-written or printed.

 

A-8


IX. EXECUTION OF DOCUMENTS

9.01 Execution of Documents. Deeds, transfers, assignments, contracts and obligations of the Corporation may be signed as follows:

 

(i)

by any of the Chairman of the Board, the Chief Executive Officer, the Chief Financial Officer or the President; or

 

(ii)

by a Vice-President together with a director; or

 

(iii)

by any two directors.

Notwithstanding the foregoing, the board may at any time and from time to time direct the manner in which and the person or persons by whom any particular deed, transfer, contract or obligation or any class of deeds, transfers, contracts or obligations may be signed.

9.02 Seal. Any person authorized to sign any document may affix the corporate seal of the Corporation thereto, if the Corporation has a corporate seal.

X. REPEAL

10.01 Repeal. All previous by-laws of the Corporation are repealed upon the coming into force of this by-law but such repeal shall not affect the previous operation of any by-law. All officers and other persons acting under any by-law so repealed shall continue to act as if appointed under this by-law and all resolutions with continuing effect passed under any by-law so repealed shall continue in force until amended or repealed except to the extent inconsistent with this by-law.

XI. EFFECTIVE DATE

11.01 Effective Date. This by-law comes into force upon confirmation by the shareholders of the Corporation in accordance with the Act.

 

A-9

EX-3.11 16 d692201dex311.htm EX-3.11 EX-3.11

Exhibit 3.11

XANTHIC BIOPHARMA INC.

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

AND

MANAGEMENT INFORMATION CIRCULAR

IN RESPECT OF THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS OF XANTHIC

BIOPHARMA INC. TO BE HELD ON NOVEMBER 2, 2018

Dated as of October 12, 2018

Neither the Canadian Securities Exchange nor any securities commission has in any way passed upon the merits of

the transaction described herein and any representation to the contrary is an offence.


Dear Shareholders:

The directors of Xanthic Biopharma Inc. (“Xanthic” or the “Corporation”) cordially invite you to attend the annual and special meeting (the “Meeting”) of the shareholders of Xanthic (the “Shareholders”) to be held at the offices of Fogler, Rubinoff LLP at 77 King Street West, Suite 3000, TD Centre North Tower, Toronto, Ontario M5K 1G8 on Friday, November 2, 2018 at 10:00 a.m. (Toronto time).

At the Meeting, among other things, you will be asked to consider and, if thought appropriate, to pass, with or without variation, an ordinary resolution approving the business combination (the “Business Combination”) of Xanthic with Green Growth Brands Ltd. (“GGB”), pursuant to which a wholly-owned subsidiary of the Corporation, 2657013 Ontario Inc., will acquire all of the issued and outstanding securities of GGB by way of a three-cornered amalgamation transaction (the “Transaction”).

Following the completion of the Business Combination, current GGB Shareholders will hold approximately 86,537,687 Resulting Issuer Shares (excluding any Resulting Issuer Shares issuable upon conversion of the GGB Convertible Debentures), representing 85.7% of the Resulting Issuer Shares issued and outstanding on a non-diluted basis. A deemed value of C$0.36 per share has been placed on the Issuer Shares issued in connection with the Business Combination, resulting in total consideration paid to the holders of GGB Shares of approximately $125,000,000. Further details on the Transaction is set out in the Appendix “A” to the accompanying management information circular (the “Circular”).

At the Meeting, you will also be asked to consider and, if deemed appropriate, to pass, the following:

 

i.

the appointment of MNP LLP as the auditor of the Corporation and to authorize the directors to fix their remuneration;

 

ii.

a special resolution fixing the number of directors of the Corporation at seven (7), subject to the power of the directors to appoint up to one-third additional directors between annual meetings;

 

iii.

the election of directors of the Corporation;

 

iv.

an ordinary resolution approving the advance notice by-law for the Corporation;

 

v.

an ordinary resolution authorizing and approving the adoption of an equity incentive plan of the Corporation;

 

vi.

a special resolution approving the proposed consolidation of the common shares of the Corporation;

 

vii.

a special resolution approving an amendment of the Corporation’s articles of incorporation to change the name of the Corporation to “Green Growth Brands Ltd.”;

 

viii.

a special resolution approving an amendment of the Corporation’s articles of incorporation to eliminate the Corporation’s existing class of First Preferred Shares; and

 

ix.

a special resolution approving an amendment of Xanthic’s articles of incorporation to create a new class of Proportionate Voting Shares.

The foregoing resolutions are referred to herein as the “Xanthic Resolutions”.

The Board of Directors of the Corporation unanimously recommends that Shareholders vote in favour of the Xanthic Resolutions at the Meeting for the reasons set out in this Circular. You are urged to read this information carefully and, if you require assistance, to consult your own legal, tax, financial or other professional advisor.

We hope that we will have the opportunity to welcome you to this year’s Meeting.

Sincerely,

(Signed) “Tim Moore”

Tim Moore

Chief Executive Officer & Director

 

- 2 -


XANTHIC BIOPHARMA INC.

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that an annual and special meeting (the “Meeting”) of the shareholders (“Shareholders”) of Xanthic Biopharma Inc. (the “Corporation” or “Xanthic”) will be held at the offices of Fogler, Rubinoff LLP, 77 King Street West, Suite 3000, Toronto, Ontario M5K 1G8, on Friday, November 2, 2018, at 10:00 a.m. (Toronto time), for the following purposes:

 

1.

to receive and consider the audited financial statements of the Corporation as at and for the year ended June 30, 2018, together with the report of the auditors thereon;

 

2.

to appoint MNP LLP as the auditor of the Corporation for the ensuing year and to authorize the board of directors of the Corporation to fix the remuneration of the auditor;

 

3.

to consider, and if deemed advisable, to approve, with or without variation, a special resolution to fix the number of directors for the ensuing year at seven (7), subject to the power of the directors to appoint up to one-third additional directors between annual meetings;

 

4.

to elect the directors of the Corporation;

 

5.

to consider, and if deemed advisable, to approve, with or without variation, a special resolution the full text of which is set forth in the accompanying management information circular (the “Circular”), approving the Corporation’s proposed transaction with Green Growth Brands Ltd. (“GGB”), as more fully described therein (the “Transaction”);

 

6.

to consider, and if deemed advisable, to approve an ordinary resolution, the full text of which is set forth in the accompanying Circular, to confirm, ratify and approve the advance notice by-law of the Corporation;

 

7.

to consider, and if deemed advisable, to approve, with or without variation, an ordinary resolution, the full text of which is set forth in the Circular, approving the Corporation’s equity incentive plan;

 

8.

to consider, and if deemed advisable, to approve, with or without variation, a special resolution, the full text of which is set forth in the accompanying Circular, approving the proposed consolidation of the common shares of the Corporation;

 

9.

to consider, and if deemed advisable, to approve, with or without variation, a special resolution, the full text of which is set forth in the accompanying Circular, authorizing an amendment of the articles of the Corporation to change the name of the Corporation to “Green Growth Brands Ltd.” or such other name as may be determined by the board of directors;

 

10.

to consider, and if deemed advisable, to approve, with or without variation, a special resolution, the full text of which is set forth in the accompanying Circular, authorizing an amendment of the articles of the Corporation to eliminate the Corporation’s existing class of First Preferred Shares;

 

11.

to consider, and if deemed advisable, to approve, with or without variation, a special resolution, the full text of which is set forth in the accompanying Circular, authorizing an amendment of the articles of the Corporation providing for the creation of a new class of Proportionate Voting Shares; and

 

12.

to transact such other business as may properly come before the Meeting.

The specific details of the matters proposed to be put before the Meeting are set forth in the Circular, which accompanies this Notice of Meeting and forms part hereof.

A shareholder wishing to be represented by proxy at the Meeting or any adjournment thereof must have deposited his, her or its duly executed form of proxy not later than 10:00 a.m. (Toronto time) on October 31, 2018 or, if the Meeting is adjourned, not later than 48 hours, excluding Saturdays, Sundays and holidays, preceding the time of such adjourned Meeting, at the offices of Capital Transfer Agency ULC, 920-390 Bay Street, Toronto ON, M5H 2Y2; (2) by facsimile at (416) 350-5007; (3) via email to investor@capitaltransferagency.com

The participation of its shareholders is very important to the Corporation. Please ensure that the votes attached to your common shares will be exercised at the Meeting.


DATED at Toronto, Ontario as of the 12th day of October 2018.

BY ORDER OF THE BOARD OF DIRECTORS

(Signed) “Tim Moore”

Tim Moore

Chief Executive Officer & Director

 

- 2 -


XANTHIC BIOPHARMA INC.

MANAGEMENT INFORMATION CIRCULAR

ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Dated October 12, 2018, except where otherwise noted

Solicitation of Proxies

This management information circular (the “Circular”) is furnished in connection with the solicitation of proxies by the management of Xanthic Biopharma Inc. (“Xanthic” and/or the “Corporation”) for use at the annual and special meeting (the “Meeting”) of shareholders (the “Shareholders”) to be held on Friday, November 2, 2018 at the offices of Fogler, Rubinoff LLP, 77 King Street West, Suite 3000, Toronto, Ontario, at 10:00 a.m. (Toronto time) and at any adjournment(s) thereof. Solicitation of proxies will be primarily by mail, but may also be carried out by directors, officers, employees or agents of the Corporation personally, in writing, by telephone or by fax. All cost thereof will be borne by the Corporation. Management of the Corporation has therefore prepared this Circular and has sent it to those shareholders who are entitled to receive a notice of meeting.

Shareholders Entitled to Vote

Registered shareholders (“Registered Shareholders”) as at the close of business on October 3, 2018 (the “Record Date”), or the person or persons they appoint as their proxies, are entitled to attend and vote on all matters that may properly come before the Meeting in respect of which their vote is required. Each Shareholder of record at the close of business on the Record Date will be entitled to one vote for each common share of the Corporation (“Common Share”) held with respect to all matters proposed to come before the Meeting, or any adjournment or postponement thereof, and requiring a vote by Shareholders.

Registered Shareholders are entitled to vote at the Meeting, or any adjournment or postponement thereof, either in person or by proxy. Voting by proxy means that you are giving the person or persons named on your proxy form (your proxyholder) the authority to vote your Common Shares for you at the Meeting or any adjournment(s) or postponement(s) thereof.

Appointment of Proxies and Revocation of Proxies

The individuals named in the enclosed form of proxy will represent management of the Corporation at the Meeting. A Shareholder has the right to appoint a person or company (who need not be a Shareholder), other than the persons designated in the accompanying form of proxy, to represent the Shareholder at the Meeting. Such right may be exercised by inserting the name of such person or company in the blank space provided in the proxy or by completing another proper form of proxy. A Shareholder wishing to be represented by proxy at the Meeting or any adjournment thereof must, in all cases, deposit the completed proxy with Capital Transfer Agency ULC, 920-390 Bay Street, Toronto ON, M5H 2Y2 (“Capital Transfer”) by 10:00 a.m. (Toronto Time) on October 31, 2018 or, if the Meeting is adjourned or postponed, at least 48 hours, excluding Saturdays, Sundays and holidays, prior to any adjournment or postponement of the Meeting at which the proxy is to be used, or deliver it to the Chairman of the Meeting on the day of the Meeting or any adjournment thereof prior to the commencement of the Meeting. A proxy should be executed by the registered Shareholder or its attorney duly authorized in writing or, if the registered Shareholder is a corporation, by an officer or attorney thereof duly authorized. Failure to properly complete or deposit a proxy may result in its invalidation.

A Registered Shareholder who has submitted a proxy may revoke it at any time prior to the exercise thereof. If a Registered Shareholder who has given a proxy attends the Meeting in person at which such proxy is to be voted, such person may revoke the proxy and vote in person. In addition to any other manner permitted by law, a proxy may be revoked before it is exercised by an instrument in writing executed in the same manner as a proxy and deposited to the attention of the Chief Financial Officer of the Corporation at the registered office of the Corporation at any time up to and including the last business day preceding the day of the Meeting, or any adjournment thereof, at which the proxy is to be used or with the Chairman of the Meeting on the day of such Meeting or any adjournment thereof and thereupon the proxy is revoked.


A Registered Shareholder attending the Meeting has the right to vote in person and, if he or she does so, his or her proxy is nullified with respect to the matters such person votes upon and any subsequent matters thereafter to be voted upon at the Meeting or any adjournment thereof.

If you are not a Registered Shareholder, please refer to the section below entitled “Advice to Beneficial Holders of Common Shares”.

Advice to Beneficial Shareholders of Common Shares

The information set forth in this section is of significant importance to many Shareholders as a substantial number of Shareholders do not hold their Common Shares in their own name and thus are considered non-registered Shareholders (referred to as “Beneficial Shareholders”). Beneficial Shareholders should note that only proxies deposited by Shareholders whose names appear on the records of the Corporation as the registered holders of Common Shares can be recognized and acted upon at the Meeting. If Common Shares are listed in an account statement provided to Shareholders by a broker then, in almost all cases, those shares will not be registered in the Shareholder’s name on the records of the Corporation. Such Common Shares will more likely be registered under the name of the Shareholder’s broker or an agent of that broker or another similar entity (an “Intermediary”). Common Shares held in the name of an Intermediary can only be voted by the Intermediary (for or against resolutions or withheld) upon the instructions of the Beneficial Shareholder. Without specific instructions, Intermediaries are prohibited from voting shares.

If you are a Beneficial Shareholder:

Beneficial Shareholders should ensure that instructions respecting the voting of their Common Shares are communicated in a timely manner and in accordance with the instructions provided by their Intermediary. Applicable regulatory rules require Intermediaries to seek voting instructions from Beneficial Shareholders in advance of the Meeting. Every Intermediary has its own mailing procedures and provides its own return instructions to clients, which instructions should be carefully followed by Beneficial Shareholders in order to ensure that their Common Shares are voted at the Meeting.

Most brokers now delegate responsibility for obtaining instructions from clients to Broadridge Financial Solutions, Inc. (“Broadridge”) in the United States and in Canada. Broadridge mails a voting instruction form in lieu of a form of proxy provided by the Corporation. The voting instruction form will name the same persons as the Corporation’s form of proxy to represent you at the Meeting. You have the right to appoint a person (who need not be a shareholder of the Corporation), other than the persons designated in the voting instruction form, to represent you at the Meeting. To exercise this right, you should insert the name of the desired representative in the blank space provided in the voting instruction form. The completed voting instruction form must then be returned to Broadridge by mail or facsimile or given to Broadridge by phone or over the internet, in accordance with Broadridge’s instructions. Broadridge then tabulates the results of all instructions received and provides appropriate instructions respecting the voting of Common Shares to be represented at the Meeting. If you receive a voting instruction form from Broadridge, you cannot use it to vote Common Shares directly at the Meeting—the voting instruction form must be completed and returned to Broadridge, in accordance with its instructions, well in advance of the Meeting in order to have the Common Shares voted.

Although a Beneficial Shareholder may not be recognized directly at the Meeting for the purpose of voting Common Shares registered in the name of their Intermediary, a Beneficial Shareholder may attend at the Meeting as proxyholder for the Intermediary and vote the Common Shares in that capacity. Beneficial Shareholders who wish to attend the Meeting and indirectly vote their Common Shares as a proxyholder should enter their own names in the blank space on the form of proxy provided to them by their Intermediary and return the same to their Intermediary in accordance with the instructions provided by their Intermediary well in advance of the Meeting.

Non-registered holders who have not objected to their Intermediary disclosing certain ownership information about themselves to the Corporation are referred to as “non-objecting beneficial owners”. Those non-registered holders who have objected to their Intermediary disclosing ownership information about themselves to the Corporation are referred to as “objecting beneficial owners” (“OBOs”).

 

- 2 -


This Circular and applicable proxy-related materials are being sent directly to non-objecting beneficial owners pursuant to National Instrument 54-101.

The Corporation does not intend to pay for Intermediaries to deliver the Meeting materials and Form 54-101F7—Request for Voting Instructions Made by Intermediary to OBOs. As a result, OBOs will not receive the Meeting materials unless their Intermediary assumes the costs of delivery.

Interest of Certain Persons or Companies in Matters to Be Acted Upon

Other than as described herein, the Corporation is not aware of: (i) any person who has been a director or executive officer of the Corporation at any time since the beginning of the last financial year; (ii) a nominee for election as a director of the Corporation at the Meeting; or (iii) any associate or affiliate of any such director or executive officer or nominee, who has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Meeting.

Use of Discretionary Power Conferred By the Proxies

Common Shares represented by proxies in favour of management nominees will be voted in accordance with the instructions of the Shareholder on any ballot that may be called for and, if a Shareholder specifies a choice with respect to any matter to be acted upon at the Meeting, the shares represented by proxy shall be voted accordingly. Where no choice is specified, the proxy will confer discretionary authority and will be voted FOR all matters proposed by management at the Meeting. The enclosed form of proxy also confers discretionary authority upon the persons named therein to vote with respect to any amendments or variations to the matters identified in the notice with respect to this Meeting and with respect to any other matters which may properly come before the Meeting in such manner as the nominee in his judgment may determine. At the date hereof, management of the Corporation knows of no such amendments, variations or other matters to come before the Meeting.

Voting Securities and Principal Holders of Voting Securities

The authorized share capital of the Corporation consists of an unlimited number of Common Shares without par value. As at the date hereof, 57,746,547 Common Shares without par value are issued and outstanding. Each Common Share carries the right to one vote at any ballot taken at any meeting of the shareholders. Only shareholders of record of the Corporation at the close of business on the Record Date or their duly authorized agents are entitled to attend and vote at the Meeting.

To the knowledge of the directors and executive officers of the Corporation, no person beneficially owns, or controls or directs, directly or indirectly, Common Shares carrying in excess of 10% of the voting rights attached to all outstanding Common Shares as at the date of this Circular.

Currency

All references to dollars or $ are in Canadian dollars unless otherwise noted.

PARTICULARS OF MATTERS TO BE ACTED UPON

Financial Statements

The shareholders will receive and consider the audited financial statements of the Corporation for the year ended June 30, 2018, together with the auditor’s report hereon.

Appointment of Auditors

Management recommends the appointment of MNP LLP, Chartered Accountants (“MNP”), of Toronto, Ontario, as the auditor of the Corporation to hold office until the close of the next annual meeting of the Shareholders, or until their successor is appointed by the Board. MNP was appointed as the auditor of the Corporation on January 10, 2018, after the previous auditor, Wasserman Ramsay LLP, resigned.

 

- 3 -


Common Shares represented by proxies in favour of the management nominees will be voted FOR the appointment of MNP LLP, Chartered Accountants, as the auditor of the Corporation and authorizing the directors of the Corporation to fix their remuneration, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting on the appointment of the auditor.

Audit Fees

The aggregate fees billed by the Corporation’s external auditors for professional services rendered for the audit of the consolidated financial statements of the Corporation and its subsidiaries were $37,450 for the fiscal year ended June 30, 2018.

Audit Related Fees

The aggregate fees (including reimbursed expenses) billed by the Corporation’s external auditors for services related to the audit or review of the Corporation’s financial statements were $21,000 in 2018.

Tax Fees

The aggregate fees (including reimbursed expenses) billed by the Corporation’s external auditors for the preparation of corporate tax returns, tax compliance, tax advice and tax planning services were $Nil in the fiscal year ended June 30, 2018.

All Other Fees

The aggregate fees, including expenses reimbursed, billed by the Corporation’s external auditors for services rendered to the Corporation and its subsidiaries, other than the services described above, were $Nil in the fiscal year ended June 30, 2018.

Number of Directors

The articles of incorporation of the Corporation provide that the board of directors of the Corporation (the “Board”) shall consist of a minimum of one and a maximum of fifteen directors. Currently, the Board has seven directors. The Corporation wishes to fix the number of directors at seven, subject to the power of the directors to appoint up to one-third additional directors between annual meetings (the “Resolution Fixing the Number of Directors”).

From time to time, the Board identifies individuals who could make a valuable contribution to the Corporation as a director. By adopting the proposed Resolution Fixing the Number of Directors, this will allow the Board, prior to the next annual general meeting, to change the number of directors and appoint additional directors to augment the Board with different skills and expertise, with a view to enhancing value for the Shareholders.

At the Meeting, Shareholders will be asked to approve a special resolution fixing the number of directors at seven, subject to the power of the directors to appoint up to one-third additional directors between annual meetings, in the form set out below. The approval of the special resolution requires the affirmative vote of sixty-six and two-thirds percent (66 2/3%) of the votes cast by Shareholders present in person or represented by proxy at the Meeting.

“BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

  (a)

the number of directors of the Corporation be fixed at seven, subject to the power of the directors to appoint up to one-third additional directors between annual meetings; and

 

  (b)

any director or officer of the Corporation be and each of them is hereby authorized to do such things and to execute and deliver all such documents that such director or officer may, in his discretion, determine to be necessary or useful in order to give full effect to the intent and purpose of this resolution.”

 

- 4 -


Based on the foregoing, the Board unanimously recommends that Shareholders vote FOR the Resolution Fixing the Number of Directors set out above.

Common Shares represented by proxies in favour of management nominees will be voted FOR the Resolution Fixing the Number of Directors unless a Shareholder has specified in his, her or its proxy that such Common Shares are to be voted against such resolution.

Election of Directors

The articles of incorporation of the Corporation provide that the Board shall consist of a minimum of one and a maximum of fifteen directors. Provided that Shareholders shall have approved the Resolution Fixing the Number of Directors at the Meeting, the directors have determined that there will be seven persons elected to the Board at the Meeting.

 

1.

Management proposes that each of the persons named below be nominated at the Meeting for re-election or election, as the case may be, as directors of the Corporation to serve, until the next annual meeting of Shareholders or until his or her successor is elected or appointed. Management does not contemplate that any of the nominees will be unable to serve as a director. However, if a nominee should be unable to so serve for any reason prior to the Meeting, the persons named in the enclosed form of proxy reserve the right to vote for another nominee in their discretion. Common Shares represented by proxies in favour of management nominees will be voted FOR the election of all of the nominees whose names are set forth below, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting on the election of directors.

 

2.

The following table and the notes thereto state the names of all persons to be nominated for election as directors, all other positions or offices with the Corporation now held by them, their principal occupations of employment, the year in which they became directors for the Corporation, the approximate number of Common Shares beneficially owned, or controlled, directly or indirectly, by each of them, as of the date hereof.

Common Shares represented by proxies in favour of the management nominees will be voted FOR the appointment of each of the nominees as a director of the Corporation, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting for any or all of the nominees(1).

 

Name and Province of

Residence

  

Principal

occupation during

past five years

  

Year first became

director

  

Number of Common Shares
Beneficially Owned, or Controlled

Tim Moore

Chief Executive Officer and Director Unionville, ON

   CEO of Xanthic; Managing Director of Brita GmbH North America   

December 15, 2017

  

1,550,000

Igor Galitsky (1)

President and Director Thornhill, ON

   President of the Issuer; Entrepreneur and consultant to the cannabis industry   

July 11, 2018

  

3,828,332

Jean Schottenstein

Director Columbus, OH

   Trustee, Columbus Museum of Art; Founder, Beit Ohr Community Domestic Violence   

July 11, 2018

  

Nil

 

- 5 -


  

Program

     

Peter Horvath

Director New Albany, OH

  

CEO of GGB; CEO of Mission Essential Personnel

  

July 11, 2018

  

Nil

Steve Stoute (1)

Independent Director New York, NY

  

Founder and CEO of Translation

  

July 11, 2018

  

Nil

Carli Posner (1) (2) (3)

Independent Director Toronto, ON

  

Film producer at Notable Life

  

February 16, 2018

  

200,000

Marc Lehmann

Independent Director Miami, FLA

  

Managing Member of Flamingo Drive Partners, LLC; General Partner at Riverloft Capital Management

  

July 11, 2018

  

Nil

Notes:

(1)

Reference to Common Shares in this section refers to the post-consolidated shares of the Resulting Issuer.

(2)

Members of the Audit Committee.

(3)

Chair of the Audit Committee.

Biographies of Directors Nominees

Tim Moore (Age 60), Chief Executive Officer & Director

Mr. Moore has been the Chief Executive Officer of the Xanthic since December 2017. Mr. Moore has over 30 years of experience in various consumer products companies, including 18 years with The Clorox Company, a NYSE-listed company. Prior to working with The Clorox Company, Mr. Moore was the Managing Director, North America, for Brita GmbH, a privately held German manufacturer of water filters. Previous to Brita, Mr. Moore was the Chief Operating Officer for Synnex, a NYSE-listed electronics distribution company. Mr. Moore holds a Bachelor of Arts (Economics) from Western University and a Master of Business Administration from the Richard Ivey School of Business.

Igor Galitsky (Age 46), President & Director

Mr. Galitsky has been President of Xanthic since December 2017. Mr. Galitsky was one of the first applicants to receive a license under the Marijuana Medical Access Regulations for both personal and designated production in Canada. Mr. Galitsky has developed and refined over the last seven years the production and extraction processes for cannabis. In addition, Mr. Galitsky has been consulting varies licensed producers in Canada on scaling and refining their extraction and secondary processes.

Jean Schottenstein (Age 62), Director

Mrs. Schottenstein will serve as a director on Xanthic’s Board. Mrs. Schottenstein serves on the Board of Trustees of the Columbus Museum of Art, is Co-Chair of Congregation Torat Emet/Main Street Synagogue, and is Chair of “Defining Moments,” a group dedicated to leadership development. She is also on the Board of Trustees of Nishmat – the Jerusalem Center for Advanced Torah Study for Women and has co-chaired the recently completed Columbus

 

- 6 -


Community Mikvah Capital Campaign. She has previously served on the Boards of Trustees of Central Ohio State of Israel Bonds and Columbus Torah Academy; Chairperson of the Columbus Jewish Federation’s Women’s Division for their annual appeal; and the Board of Trustees of “I know I can”. Mrs. Schottenstein is deeply committed to issues relating to women’s health, education and increasing awareness of domestic violence. To that end, she created “Beit Ohr”, a community program designed to help meet the needs of victims of domestic violence within the Jewish community and serves as Honorary Chair of the National Council of Jewish Women’s “Women of Valor” program. Mrs. Schottenstein attended Indiana University and is a graduate of Ohio State University with a Bachelor of Science in Accounting and a Master of Science in Psychology from the University of Phoenix.

Peter Horvath (Age 61), Director

Mr. Horvath will serve as a director on Xanthic’s Board. Mr. Horvath currently serves as the Chief Executive Officer of Green Growth Brands LLC, doing business as Green Growth Brands Ltd., a lifestyle oriented, consumer products company that celebrates health, wellness and happiness. Mr. Horvath has 35 years of executive management experience with specialty brand retailers such as American Eagle Outfitters, DSW, and Victoria’s Secret Stores at L Brands. From 2012 to 2015, Mr. Horvath served as Chief Executive Officer of Mission Essential Personnel, a defense contractor focusing on intelligence solutions. Mr. Horvath received his Bachelor of Business Administration, Business, Management, Marketing, and Related Support Services from Boston University, School of Management.

Marc Lehmann (Age 46), Independent Director

Mr. Lehmann will serve as an independent director on Xanthic’s Board. Mr. Lehman is currently the Managing Member of Flamingo Drive Partners, LLC, an investment firm involved in public markets, real estate and start-up investing. Prior to that, Mr. Lehmann was the General Partner at Riverloft Capital Management from 2011 to 2016. From 2002 to 2010, Mr. Lehmann was a Partner and Director of Research at JANA Partners, a hedge fund. Earlier in his career, he was an Analyst at Appaloosa Management, from 1999 to 2002, sourcing and analyzing distressed special situations investments for the opportunistic hedge fund portfolio and began his career as an Analyst at Morgan Stanley and Lehman Brothers. Mr. Lehmann completed his Master of Business Administration at The Wharton Business at the University of Pennsylvania. Mr. Lehmann has a Bachelor of Science in Finance and International Business from New York University.

Steve Stoute (Age 48), Independent Director

Mr. Stoute will serve as an independent director on Xanthic’s Board. Mr. Stoute is the founder and Chief Executive Officer of Translation, a marketing agency. In 2017, Mr. Stoute joined United Masters, a data-driven digital distribution company helping music artist grow and manage their fan bases. In 2009 the American Advertising Federation inducted Mr. Stoute into the Advertising Hall of Achievement, and he was named “Executive of the Year” by Advertising Age in 2013.

Carli Posner (Age 35), Independent Director

 

- 7 -


Ms. Posner has served as an independent director on the Issuer Board since February 2018 and will continue to serve as an independent director on the Resulting Issuer Board. Ms. Posner is the Co-CEO and Principal of Notable Life, a media company that reaches over 1.2 million high-earning millennials across Canada. Prior to Notable, she was the executive producer of the hit show, Hockey Wives, overseeing many departments including premium sponsors and media strategy. Ms. Posner has spent a significant portion of her career in Los Angeles, working in film finance and production. She is the leading talent packager in our country and has worked with top stars including George Clooney, Coldplay, Drew Barrymore, Jamie Oliver and Wayne Gretzky, to name a few. During Ms. Posner’s career, she has generated over C$100 million dollars of sponsorships and endorsements in the Canadian marketplace with top brands including MasterCard®, Corvette®, Scotiabank®, BMW® and LG®.

Corporate Cease Trade Orders or Bankruptcies

No director or proposed director of the Corporation is, or has been within the past ten years, a director, chief executive officer or chief financial officer of any other corporation that, while such person was acting in that capacity:

was the subject of a cease trade order, an order similar to a cease trade order or an order that denied the Corporation access to any exemptions under securities legislation, and that was in effect for a period of more than 30 consecutive days; or

was the subject of a cease trade order, an order similar to a cease trade order or an order that denied the Corporation access to any exemptions under securities legislation, that was issued after that individual ceased to be a director or chief executive officer or chief financial officer and which resulted from an event that occurred while such person was acting in a capacity as a director, chief executive officer or chief financial officer.

No director or proposed director of the Corporation is, or has been within the past ten years, a director or executive officer of any other corporation that, while such person was acting in that capacity, or within a year of that individual ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

Individual Bankruptcies

No director or proposed director of the Corporation is or has, within the ten years prior to the date hereof, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold the assets of that individual.

Penalties or Sanctions

No director or proposed director of the Corporation has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority. No director or proposed director of the Corporation has been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable securityholder in deciding whether to vote for a proposed director.

Conflicts of Interest

To the best of GGB’s and the Issuer’s knowledge, there are no known existing or potential conflicts of interest among the Resulting Issuer, proposed directors, executive officers or other members of management of the Resulting Issuer as a result of their outside business interests other than the lease agreement dated as of July 10, 2018, as amended, between GGB and Schottenstein Property Group and certain product testing agreements with DSW®, except that certain proposed directors and officers may serve as directors and officers of other companies, and therefore it is possible that a conflict may arise between their duties to the Resulting Issuer and their duties as a director or officer of such other companies.

 

- 8 -


Transaction with Green Growth Brands Ltd.

In June 2018, representatives of the Corporation and Green Growth Brands Ltd. (“GGB”), a corporation incorporated pursuant to the laws of Ontario, discussed at arm’s length the merits of a potential business combination. Recognizing the potential benefit such a transaction would bring to its shareholders, management of the Corporation entered into a binding letter agreement (the “LOI”) with management of GGB on July 9, 2018. The LOI also provided for the acquisition by GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of the Corporation, of 95% of the issued and outstanding membership interests of Nevada Organic Remedies LLC (“NOR”), a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada, and the obligation to acquire the remaining 5% of the issued and outstanding membership interests for aggregate consideration of $56.75 million (the “NOR Acquisition”).

Business Combination Agreement

On July 13, 2018, the Corporation and GGB entered into an agreement (the “Business Combination Agreement”), to complete a business combination, pursuant to which a wholly-owned subsidiary of the Corporation (“Subco”), will acquire all of the issued and outstanding securities of GGB by way of a three-cornered amalgamation transaction (the “Transaction”). The completion of the Transaction will be effected pursuant to an amalgamation agreement (the “Amalgamation Agreement”) between GGB, Subco and the Corporation in the form of amalgamation agreement attached as Schedule “A” to the Business Combination Agreement.

On August 30, 2018, Xanthic and GGB entered into an amending agreement in order to amend the Business Combination Agreement in a number of ways, including:

 

  a)

to revise the Consolidation ratio from 4.07:1 to approximately 4.07:1;

 

  b)

to include and revise certain definitions in order to contemplate the issuance of the GGB Convertible Debentures pursuant to the terms of the GGB Convertible Debenture Indenture; and

 

  c)

to reference the GGB Shareholders Agreement, which shall terminate immediately upon completion of the Business Combination.

The Corporation and GGB intend to amend and restate the Business Combination Agreement and Amalgamation Agreement in order to, among other things, contemplate the exchange of GGB Proportionate Shares (as defined below) and GGB Proportionate Warrants (as defined below) from All Js Greenspace LLC (Greenspace”) for proportionate voting shares of Xanthic (Xanthic PVS”) and proportionate warrants of Xanthic (Xanthic PVS Warrants”), respectively.

GGB will acquire an aggregate principal amount of C$27,500,000 of its outstanding 12.00% unsecured convertible debentures (the GGB Convertible Debentures”) from Greenspace. The GGB Convertible Debentures were issued pursuant to the terms of a convertible debenture indenture dated August 30, 2018 between GGB and Capital Transfer Agency ULC and have a maturity date of March 1, 2019. In consideration for such acquisition, GGB will then issue to Greenspace C$27,500,000 aggregate principal amount of 12.00% unsecured convertible debentures of GGB (the GGB Greenspace Debentures”). On the closing date of the Transaction, each GGB Greenspace Debenture will be converted into units of GGB (the GGB Greenspace Units”), each GGB Greenspace Unit being comprised of one (1) proportionate voting share in the capital of GGB (the GGB Proportionate Shares”) and one-half (1/2) of one GGB proportionate share purchase warrant (the “GGB Proportionate Warrants”). The GGB Proportionate Shares and the GGB Proportionate Warrants will then be exchanged for Xanthic PVS and Xanthic PVS Warrants, respectively. The issuance of the GGB Greenspace Debentures is necessary in order to ensure the Corporation is able to meet the definition of “foreign private issuer”, as such term is defined in Rule 405 of Regulation C under the U.S. Securities Act of 1933.

 

- 9 -


NOR Transaction

Following the completion of its due diligence review, GGB Nevada entered into a purchase agreement dated July 13, 2018 (the “NOR Agreement”) with NOR and its members (the “NOR Members”), which has been filed by Xanthic with the Canadian securities regulatory authorities and is available at www.sedar.com.

To complete the NOR Acquisition, GGB Nevada was required to make a payment of a USD$2 million deposit (the “NOR Deposit”) upon the execution of the NOR Agreement and an initial cash payment of US$30 million (the “NOR Closing Payment”) on closing of the NOR Acquisition. To satisfy the NOR Deposit, Xanthic issued a promissory note in favour of GGB in the principal amount of USD$2 million (the “Deposit Promissory Note”). To satisfy the NOR Closing Payment, Xanthic and GGB entered into a loan agreement (the “Loan Agreement”) pursuant to which GGB loaned USD$30,347,500 to Xanthic (the “Loan”). In addition, on closing of the NOR Acquisition, GGB Nevada was required to deliver to the NOR Members a secured promissory note in the principal amount of US$21,565,000. The initial closing occurred on September 4, 2018, and is subject to GGB delivering to Andrew Jolley cash or an equivalent number of share consideration in Resulting Issuer Shares in the amount US$2,837,500.

Upon completion of the Transaction, the Corporation will carry on the business currently conducted by NOR. The Transaction constitutes a “Fundamental Change” under Policy 8 of the Canadian Securities Exchange (the “CSE”) and is therefore subject to approval by a majority of the votes cast by Shareholders eligible to vote on the resolution at the Meeting and CSE approval. The Corporation has submitted a draft listing statement (Form 2A) (the “Listing Statement”), attached hereto as Schedule “B”, in respect of the proposed Transaction to the CSE for review and completion of the Fundamental Change and the Transaction remains subject to receipt of CSE approval. Upon receipt of both CSE and Shareholder approval of the Transaction, the Corporation proposes to change its name to “Green Growth Brands Ltd.” or such other name as may be determined by the Board, subject to applicable regulatory approval.

For ease of reference, disclosure of the details of the Transaction, including details regarding the Corporation, GGB and the Resulting Issuer, are provided in Schedule “B” to this Circular.

The CSE will not approve a “Fundamental Change” or change of business proposed for an issuer that has been listed for a period of less than 12 months unless the issuer obtains approval from the majority of the minority of uninterested Shareholders (“Majority of Minority Approval”). This means that the following Shareholders are deemed to be interested persons and are excluded from voting on the Transaction Resolution (as defined below): (a) a Related Entity of the Corporation; (b) a partner, director or officer of the Corporation or Related Entity; (c) a promoter of or person who performs Investor Relations Activities for the Corporation or Related Entity; and (d) any person that beneficially owns, either directly or indirectly, or exercises voting control or direction over at least 10% of the total voting rights attached to all voting securities of the Corporation or Related Entity. Defined terms mentioned in this paragraph but not otherwise defined in this Circular have the meanings given to such terms in Policy 1 of the Exchange.

At the Meeting, Shareholders will be asked to consider and, if deemed advisable, to approve and authorize the following resolutions in respect of the Transaction (the “Transaction Resolution”):

“BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

  1.

the business combination transaction (the “Transaction”) between Green Growth Brands Ltd. (“GGB”) and the Corporation pursuant to the terms of a business combination agreement (the “Business Combination Agreement”) dated July 13, 2018 between GGB and the Corporation, as amended, and as described in the management information circular of the Corporation dated October 12, 2018 be and the same are hereby ratified and approved;

 

  2.

the amalgamation agreement (the “Amalgamation Agreement”) among the Corporation, Subco, and GGB, and the actions of the officers of the Corporation in executing and delivering the Amalgamation Agreement and any amendments thereto, are hereby ratified and approved;

 

- 10 -


  3.

notwithstanding that this resolution has been passed (and the Transaction adopted) by the shareholders of the Corporation, the directors of the Corporation are hereby authorized and empowered, without further notice to, or approval of, the shareholders of the Corporation:

 

  (a)

to amend the Business Combination Agreement or the Amalgamation Agreement to the extent permitted by the Amalgamation Agreement; or

 

  (b)

subject to the terms of the Amalgamation Agreement, not to proceed with the Amalgamation;

 

  4.

any one director or officer of the Corporation is hereby authorized and directed for and on behalf of the Corporation to execute, whether under corporate seal of the Corporation or otherwise, and to deliver such documents as are necessary or desirable to give effect to the Transaction; and

 

  5.

any one director or officer of the Corporation is hereby authorized, for and on behalf and in the name of the Corporation, to execute and deliver, whether under corporate seal of the Corporation or otherwise, all such agreements, forms, waivers, notices, certificates, confirmations and other documents and instruments and to do or cause to be done all such other acts and things as in the opinion of such director or officer may be necessary, desirable or useful for the purpose of giving effect to the foregoing resolutions and the Amalgamation Agreement, including:

 

  (a)

all actions required to be taken by or on behalf of the Corporation, and all necessary filings and obtaining the necessary approvals, consents and acceptances of appropriate regulatory authorities; and

 

  (b)

the signing of the certificates, consents and other documents or declarations required under the Amalgamation Agreement or otherwise to be entered into by the Corporation.”

The Board unanimously determined that the Transaction is fair to Shareholders, is in the best interests of the Corporation and the Shareholders and authorized the submission of the Transaction to Shareholders for approval.

The Board has unanimously approved the Transaction and recommends that Shareholders vote FOR the Transaction Resolution. In order to pass the above Transaction Resolution, a special majority consisting of at least sixty-six and two-thirds percent (6623%) of the votes cast by Shareholders, present in person or by proxy at the Meeting, is required. Unless the Shareholder has specified in the enclosed form of proxy that the Common Shares represented by such proxy are to be voted against the Transaction Resolution, the persons named in the enclosed form of proxy will vote FOR the Transaction Resolution.

Advance Notice By-Law

At the Meeting, Shareholders will be asked to pass an ordinary resolution approving the adoption by the Board on October 12, 2018 of an advance notice by-law of the Corporation (the “Advance Notice By-Law”) relating to the nomination of directors of the Corporation.

The Corporation believes that the Advance Notice By-Law will ensure that the directors and management of the Corporation and the Shareholders receive adequate notice of director nominations and sufficient information about the nominees to make an informed decision when electing directors at a general and annual meeting of Shareholders or a special meeting of Shareholders. The Advance Notice By-Law will also facilitate an orderly and efficient meeting process.

Among other things, the Advance Notice By-Law includes requirements for when a Shareholder must submit a notice of director nomination to the Corporate Secretary of the Corporation and what information with respect to the nominee must be included in the Notice of Nomination.

The Board may, in its sole discretion, waive any requirement in the Advance Notice By-Law.

 

- 11 -


The text of the resolution to approve the Advance Notice By-Law will be presented as follows, with or without modification (the “Advance Notice By-Law Resolution”):

“BE IT RESOLVED, AS AN ORDINARY RESOLUTION, THAT:

 

  a)

the advance notice by-law of the Corporation, in the form set forth in Schedule “E” to the management information circular of the Corporation dated October 12, 2018 (the “Advance Notice By-Law”), be and the same is hereby authorized and approved;

 

  b)

the board of directors of the Corporation be and is authorized to make any changes to the Advance Notice By-Law if required by any such stock exchange or market upon which the common shares of the Corporation may be listed from time to time; and

 

  c)

any director or officer of the Corporation is hereby authorized to do such things and to sign, execute and deliver all documents that such director or officer may, in their sole discretion, determine to be necessary in order to give full effect to the intent and purpose of this resolution.”

In the absence of contrary instructions, the persons named in the accompanying Form of Proxy intend to vote the Common Shares represented thereby in favour of the Advance Notice By-law Resolution.

Approval of Equity Incentive Plan

The Board is requesting shareholder approval and ratification of its new stock option plan (the “Equity Incentive Plan”). The Equity Incentive Plan provides flexibility to the Corporation to grant equity-based incentive awards in the form of options, deferred share units and restricted share units (as described in further detail below) to attract, retain and motivate qualified directors, officers, key employees and consultants of the Corporation and its subsidiaries.

Below is a summary of the key terms of the Equity Incentive Plan, which is qualified in its entirety by reference to the full text of the Equity Incentive Plan, attached hereto as Schedule “D”.

Common Shares Subject to the Equity Incentive Plan

Subject to the adjustment provisions provided for in the Equity Incentive Plan, the total number of Common Shares reserved for issuance pursuant to awards granted under the Equity Incentive Plan shall not exceed 10% of the issued and outstanding Common Shares from time to time.

Administration of the Equity Incentive Plan

The plan administrator of the Equity Incentive Plan (the “Plan Administrator”) will be determined by the Board, and will initially be the Board as a whole, but may in the future be delegated to a committee of the Board as may be established by the Board from time to time. The Plan Administrator will determine which employees, directors, officers or consultants are eligible to receive awards under the Equity Incentive Plan. In addition, the Plan Administrator will interpret the Equity Incentive Plan and may adopt administrative rules, regulations, procedures and guidelines governing the Equity Incentive Plan or any awards granted under the Equity Incentive Plan as it deems to be appropriate.

Types of Awards

The following types of awards may be made under the Equity Incentive Plan: stock options, restricted share units and deferred share units. All of the awards described below are subject to the conditions, limitations, restrictions, exercise price, vesting, settlement and forfeiture provisions determined by the Plan Administrator, in its sole discretion, subject to such limitations provided in the Equity Incentive Plan, and will generally be evidenced by an award agreement. In addition, subject to the limitations provided in the Equity Incentive Plan and in accordance

 

- 12 -


with applicable law, the Plan Administrator may accelerate or defer the vesting, settlement or payment of awards, cancel or modify outstanding awards, and waive any condition imposed with respect to awards or Common Shares issued pursuant to awards.

1. Stock Options

A stock option is a right to purchase Common Shares upon the payment of a specified exercise price as determined by the Plan Administrator at the time the stock option is granted. Subject to certain adjustments and whether the Common Shares are then trading on any stock exchange, the exercise price shall be not less than the volume weighted average closing price of the Common Shares for the five days immediately preceding the date of grant (the “Market Price”). The Plan Administrator shall have the authority to determine the vesting terms applicable to the grants of options. Subject to any accelerated termination as set forth in the Equity Incentive Plan, each stock option expires on the date that is the earlier of ten years from the date of grant or such earlier date as may be set out in the participant’s award agreement.

No Common Shares will be issued or transferred upon the exercise of stock options in accordance with the terms of the grant until full payment therefor has been received by the Corporation.

2. Restricted Share Units

A restricted share unit is a unit equivalent in value to a Common Share credited by means of a bookkeeping entry in the books of the Corporation which entitles the holder to receive one Common Share for each restricted share unit after a specified vesting period determined by the Plan Administrator. The number of restricted share units (including fractional restricted share units) granted at any particular time is determined by dividing (a) the aggregate dollar value of the applicable grant, by (b) the Market Price of a Common Share on the date of grant. Upon settlement, holders will receive (a) one fully paid and non-assessable Common Share in respect of each vested restricted share unit, or (b) subject to the approval of the Plan Administrator, a cash payment. The cash payment is determined by multiplying the number of restricted share units redeemed for cash by the Market Price of the Common Share on the date of settlement.

3. Deferred Share Units

A deferred share unit is a unit equivalent in value to a Common Share credited by means of a bookkeeping entry in the books of the Corporation which entitles the holder to receive one Common Share for each deferred share unit on a future date, generally upon termination of service to the Corporation. The number of deferred share units (including fractional deferred share units) granted at any particular time is determined by dividing (a) the aggregate dollar value of the applicable grant, by (b) the Market Price of a Common Share on the date of grant. Upon settlement, holders will receive (a) one fully paid and non-assessable Common Share in respect of each vested deferred share unit, or (b) subject to the approval of the Plan Administrator, a cash payment. The cash payment is determined with reference to the Market Price in the same manner as with the restricted share units.

4. Dividend Equivalents

Restricted share units and deferred share units shall be credited with dividend equivalents in the form of additional restricted share units and deferred share units, as applicable. Dividend equivalents shall vest in proportion to, and settle in the same manner as, the awards to which they relate. Such dividend equivalents shall be computed by dividing: (a) the amount obtained by multiplying the amount of the dividend declared and paid per Common Share by the number of restricted share units and deferred share units, as applicable, held by the participant on the record date for the payment of such dividend, by (b) the Market Price at the close of the first business day immediately following the dividend record date, with fractions computed to three decimal places.

Black-out Periods

 

- 13 -


If an award expires during, or within five business days after, a trading black-out period imposed by the Corporation to restrict trades in its securities, then, notwithstanding any other provision of the Equity Incentive Plan, unless the delayed expiration would result in tax penalties, the award shall expire ten business days after the trading black-out period is lifted by the Corporation.

Terminations

All awards granted under the Equity Incentive Plan will expire on the date set out in the applicable award agreement, subject to early expiry in certain circumstances, provided that in no circumstances will the duration of an award granted under the Equity Incentive Plan exceed 10 years from its date of grant.

Termination of Employment or Services

The following table describes the impact of certain events that may, unless otherwise determined by the Plan Administrator or as set forth in an award agreement, lead to the early expiry of awards granted under the Equity Incentive Plan:

 

Event    Provisions
For all Participants   

In the case of death or disability

  

Acceleration of vesting of all unvested

  

awards

Voluntary resignation

  

Forfeiture of all unvested awards

Termination for cause

  

Termination other than for cause

  

Acceleration of vesting of a prorated portion

  

of all unvested awards

  

Forfeiture of all other unvested awards

Non-Transferability of Awards

Subject to certain exceptions provided under the Equity Incentive Plan, and unless otherwise provided by the Plan Administrator, and to the extent that certain rights may pass to a beneficiary or legal representative upon death of a participant, by will or as required by law, no assignment or transfer of awards granted under the Equity Incentive Plan, whether voluntary, involuntary, by operation of law or otherwise, is permitted.

Resolution

Shareholders will be asked to consider and if deemed advisable, pass, with or without variation, an ordinary resolution to approve the Equity Incentive Plan (the “Equity Incentive Plan Resolution”).

The text of the Equity Incentive Plan Resolution to be considered at the Meeting will be substantially as follows:

“BE IT RESOLVED, AS AN ORDINARY RESOLUTION, THAT:

 

  1.

the stock option plan (the “Equity Incentive Plan”) of Xanthic Biopharma Inc. (the “Corporation”) in the form set out as Schedule “D” to the Corporation’s management information circular dated October 12, 2018 is hereby ratified, approved and adopted as the stock option plan of the Corporation;

 

- 14 -


  2.

the form of the Equity Incentive Plan may be amended in order to satisfy the requirements or requests of any regulatory authorities without requiring further approval of the shareholders of the Corporation;

 

  3.

the issued and outstanding stock options previously granted by the Corporation shall be continued under and governed by the Equity Incentive Plan;

 

  4.

the shareholders of the Corporation hereby expressly authorize the board of directors to revoke this resolution before it is acted upon without requiring further approval of the shareholders in that regard; and

 

  5.

any director or officer of the Corporation be and he or she is hereby authorized and directed, for and on behalf of the Corporation, to execute and deliver all such documents and to do all such other acts or things as he or she may determine to be necessary or advisable to give effect to this resolution, the execution of any such document or the doing of any such other act or thing being conclusive evidence of such determination.”

The Board recommends that shareholders vote in favour of the Equity Incentive Plan Resolution as set out above.

PROXIES RECEIVED IN FAVOUR OF MANAGEMENT WILL BE VOTED FOR THE APPROVAL OF THE EQUITY INCENTIVE PLAN RESOLUTION UNLESS A SHAREHOLDER HAS SPECIFIED IN THE PROXY THAT HIS, HER OR ITS COMMON SHARES ARE TO BE VOTED AGAINST SUCH RESOLUTION.

Share Consolidation

The Corporation seeks Shareholder approval at the Meeting for a special resolution to consolidate all of the issued and outstanding Common Shares (the “Consolidation”) on the basis of one post-Consolidation Common Share for approximately every four (4) pre-Consolidation Common Shares, or a ratio that is less at the discretion of the Board, with the Consolidation to be implemented by the Board at any time prior to the next annual meeting of the Shareholders (the “Consolidation Resolution”). On completion of the Consolidation, on an approximately 4:1 basis, the 57,746,547 Common Shares that are currently issued and outstanding would be consolidated into approximately 14,436,636 post-Consolidation Common Shares. The Consolidation remains subject to all required regulatory approvals.

Reasons for the Consolidation

Management of the Corporation expects that the Consolidation will provide flexibility in the capital structure of the Corporation in order to facilitate raising capital in the future while keeping the Corporation’s capital structure manageable.

Effect of Consolidation

If approved and implemented, the Consolidation will occur simultaneously for all of the Corporation’s issued and outstanding Common Shares and will occur immediately following the completion of the Transaction.

No fractional Common Shares of the Corporation will be issued if, as a result of the Consolidation, a Shareholder would otherwise be entitled to a fractional share. Instead, any fractional Common Shares resulting from the Consolidation will be rounded down to the nearest whole share if the fraction is less than one-half of a share and will be rounded up to the nearest whole share if the fraction is at least one-half or a share.

 

- 15 -


The implementation of the Consolidation would not affect the total Shareholders’ equity of the Corporation or any components of Shareholders’ equity as reflected on the Corporation’s financial statements except to change the number of issued and outstanding Common Shares to reflect the Consolidation.

Effect on Convertible Securities

The exercise or conversion price and/or the number of Common Shares issuable under any outstanding convertible securities, including under outstanding Options, warrants, rights, and any other similar securities will be proportionately adjusted upon the implementation of the Consolidation, in accordance with the terms of such securities, on the same basis as the consolidation of the Common Shares.

Certain Risks Associated with the Consolidation

There can be no assurance that the total market capitalization of the Corporation (the aggregate value of all Common Shares at the market price then in effect) immediately after the Consolidation will be equal to or greater than the total market capitalization immediately before the Consolidation.

Implementation

The Consolidation Resolution provides that the Board is authorized, in its sole discretion, to determine not to proceed with the proposed Consolidation without further approval of the Shareholders of the Corporation. The Board is authorized to revoke the Consolidation Resolution in its sole discretion without further approval of the Shareholders of the Corporation at any time prior to implementation of the Consolidation.

If the Consolidation Resolution does proceed, registered holders of Common Shares should complete the letter of transmittal accompanying this Circular providing instructions with respect to exchanging their certificates representing pre-Consolidation Common shares for post-Consolidation Common Shares. The Corporation will issue a news release after the Meeting to advise of the results of the Meeting and, if appropriate, the expected timing for the commencement of trading of the post-Consolidation Common Shares on the CSE.

Shareholder Approval

In accordance with the Business Corporations Act (Ontario), the resolution approving the Consolidation must be approved by a majority of not less than sixty-six and two-thirds percent (6623%) of the votes cast by the Shareholders represented at the Meeting in person or by proxy.

At the Meeting, Shareholders will be asked to consider and, if deemed advisable, to approve and authorize the following resolutions in respect of the Consolidation:

“BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

(a)

the Board be authorized, subject to approval of the applicable regulatory authorities, to take such actions as are necessary to consolidate, at any time following the date of this resolution but prior to the next annual meeting of shareholders of the Corporation, all of the issued and outstanding Common Shares on the basis that approximately four (4) pre-consolidation Common Shares, or a ratio that is less at the discretion of the Board, be consolidated into one (1) post-consolidation Common Share;

 

(b)

despite the foregoing authorization, the Board may, at its absolute discretion, determine when such consolidation will take place and may further, at its discretion, determine not to effect such consolidation of all of the issued and outstanding Common Shares, in each case without requirement for further approval, ratification or confirmation by the Shareholders;

 

(c)

notwithstanding the foregoing, the Board is hereby authorized, without further approval of or notice to the Shareholders, to revoke this special resolution at any time before it is acted upon; and

 

- 16 -


(d)

any one or more directors and officers of the Corporation be authorized to perform all such acts, deeds and things and execute all such documents and other writings, as may be required to give effect to this special resolution.”

The foregoing special resolution permits the directors of the Corporation, without further approval by the Shareholders, to proceed with the Consolidation Resolution at any time following the date of this Meeting but prior to the next annual meeting of the Shareholders. Alternatively, the directors of the Corporation may choose not to proceed with the Consolidation Resolution if the directors, in their discretion, deem that it is no longer desirable to do so.

Common Shares represented by proxies in favour of management nominees will be voted FOR the approval of the Consolidation Resolution as set out above, unless a Shareholder has specified in his, her or its proxy that his, her or its Common Shares are to be voted against the special resolution approving the Consolidation Resolution.

Effective Date

Subject to applicable regulatory requirements, the Consolidation Resolution will be effective on the date on which articles of amendment of the Corporation are filed and certified by the Ministry, on which the directors of the Corporation determine to carry out the Consolidation.

If the Consolidation is approved, no further action on the part of the Shareholders will be required in order for the Board to implement the Consolidation.

Name Change

In connection with the Transaction, Shareholders will be asked to consider and, if deemed advisable, pass a special resolution (the “Name Change Resolution”) authorizing the Corporation to change its name (the “Name Change”) from “Xanthic Biopharma Inc.” to “Green Growth Brands Ltd.”, or to such other name as the Board deems appropriate and as may be approved by applicable regulatory authorities. Management feels that the Name Change is in the best interests of the Corporation in order to reflect the change in its business activities. The Board may determine not to implement the Name Change Resolution at any time after the Meeting and after receipt of necessary regulatory approvals without further action on the part of the Shareholders. It is anticipated that the Name Change will be effected in the first quarter of 2019.

The Board has unanimously approved the Name Change Resolution and recommends that the Shareholders vote FOR the Name Change Resolution.

The Name Change Resolution must be approved by at least sixty-six and two-thirds percent (66 23%) of votes cast by the Shareholders present in person or represented by proxy at the Meeting. It is the intention of the persons named in the enclosed proxy, in the absence of instructions to the contrary, to vote the proxy FOR the Name Change Resolution.

“BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

a)

The Corporation is hereby authorized to amend its articles to change the Corporation’s name to “Green Growth Brands Ltd.” or such other such other similar name approved by the Board and acceptable to the applicable regulatory authorities;

 

b)

the articles of the Corporation be amended to reflect the foregoing;

 

c)

notwithstanding that this resolution has been passed by the Shareholders of the Corporation, the directors of the Corporation are hereby authorized and empowered without further notice to, or approval of, the Shareholders of the Corporation to not proceed with the change of the Corporation’s name or otherwise

 

- 17 -


 

give effect to this resolution at any time prior to the same becoming effective and may revoke this resolution without further approval of the Shareholders; and

 

d)

any officer or director of the Corporation is hereby authorized and directed for and on behalf of the Corporation to execute, or to cause to be executed, whether under the corporate seal or otherwise, and to deliver or cause to be delivered all such other documents and instruments, and to do or cause to be done all such other acts and things as, in the opinion of such director or officer, may be necessary or desirable in order to carry out the intent of this resolution, the execution of any such document or the doing of any such other thing being conclusive evidence of such determination.”

Common Shares represented by proxies in favour of management nominees will be voted FOR the approval of the Name Change Resolution, unless a Shareholder has specified in his, her or its proxy that his, her or its Common Shares are to be voted against the special resolution approving the Name Change.

Elimination of First Preferred Share Class

As there will be no First Preferred Shares issued and outstanding as at the date of the Meeting, and as the Corporation does not intend to further issue any such shares, the Corporation intends, in conjunction with the transactions set out below, to alter its authorized share structure by cancelling the First Preferred Shares and deleting the rights and restrictions attached to such shares, as set out in the Corporation’s articles.

Accordingly, at the Meeting, Shareholders will be asked to approve, with or without amendment, a special resolution (the “Amending Resolution”) under the Business Corporations Act (Ontario), to approve the alteration to the Corporation’s authorized share structure, and articles.

At the Meeting, Shareholders will be asked to consider and, if deemed advisable, to approve and authorize the following resolutions:

“BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:

 

a)

the Corporation’s authorized share structure, its notice of articles and its articles be altered by eliminating all of the Corporation’s First Preferred Shares, none of which shares are allotted or issued and deleting the rights and restrictions attached to the First Preferred Shares;

 

a)

any officer or director of the Corporation is hereby authorized and directed for and on behalf of the Corporation to execute and deliver all such documents and to do all such other acts and things as he or she may determine to be necessary or advisable to give effect to this special resolution including, without limitation, to determine the timing for delivery and effect the delivery of articles of amendment in the prescribed form to the Director appointed under the Business Corporations Act (Ontario), the execution of any such document or the doing of any such other act or thing being conclusive evidence of such determination; and

 

b)

notwithstanding that this special resolution has been passed by the shareholders of the Corporation, the board of directors be and is hereby authorized and empowered, without further approval of the shareholders of the Corporation, to revoke this resolution at any time before the certificate of amendment to be issued by the Director upon receipt of such articles of amendment becomes effective.”

The Board unanimously recommends that Shareholders vote in favour of the Amending Resolution. In order to pass the above Amending Resolution, a special majority consisting of at least sixty-six and two-thirds percent (66 23%) of the votes cast by Shareholders, present in person or by proxy at the Meeting, is required. Unless the Shareholder has specified in the enclosed form of proxy that the Common Shares represented by such proxy are to be voted against the Amending Resolution, the persons named in the enclosed form of proxy will vote FOR the Amending Resolution.

 

- 18 -


Addition of Proportionate Voting Share Class

At the Meeting, Shareholders will be asked to approve a special resolution to create a new class of Proportionate Voting Shares (the “Proportionate Voting Shares Resolution”). The Proportionate Voting Shares Resolution authorizes an amendment to the articles of incorporation of the Corporation, pursuant to section 168 of the Business Corporations Act (Ontario), to authorize the creation of the Proportionate Voting Shares and to attach special rights and restrictions to the Proportionate Voting Shares and Common Shares.

The creation of the Proportionate Voting Shares is a condition to the completion of the Transaction. The Proportionate Voting Shares are being created in order for the Corporation to meet the definition of “foreign private issuer”, as such term is defined in Rule 405 of Regulation C under the U.S. Securities Exchange Act of 1934. Provided that the Proportionate Voting Shares Resolution is approved at the Meeting, the Corporation will file a notice of amendment of the Corporation’s articles of incorporation to give effect to the creation of the Proportionate Voting Shares immediately prior to the completion of the Transaction.

Terms of the Proportionate Voting Shares

The following is a summary of the terms of the Proportionate Voting Shares and the special rights and restrictions that will attach to the Proportionate Voting Shares and Common Shares if the Proportionate Voting Shares are created. The following summary is subject to, and qualified in its entirety by, the full text of such terms and special rights and restrictions, which is attached as Schedule “A” to this Circular.

General

After the completion of the Transaction, the Corporation’s authorized share capital will consist of an unlimited number of Common Shares and an unlimited number of Proportionate Voting Shares.

Common Shares and Proportionate Voting Shares have the same rights, are equal in all respects and shall be treated as if they were shares of one class only.

Conversion Rights

Common Shares may at any time, at the option of the holder, be converted into Proportionate Voting Shares on the basis of 500 Common Shares for one Proportionate Voting Share.

Each issued and outstanding Proportionate Voting Share may at any time, at the option of the holder, be converted into 500 Common Shares.

Liquidation Entitlement

In the event of the liquidation, dissolution or winding-up of the Corporation or any other distribution of its assets among its shareholders for the purpose of winding-up its affairs, whether voluntarily or involuntarily, all the property and assets of the Corporation available for distribution to the holders of Common Shares and Proportionate Voting Shares will be paid or distributed on the basis that each Proportionate Voting Share will be entitled to 500 times the amount distributed per Common Share but otherwise there is no preference or distinction among or between the Common Shares and Proportionate Voting Shares.

Dividend Rights

Each Common Shares and Proportionate Voting Share is entitled to dividends if, as and when dividends are declared by the Corporation’s Board of Directors, on the basis, and otherwise without preference or distinction among or between such shares, that each Proportionate Voting Share will be entitled to 500 times the amount paid or distributed per Common Share.

Voting Rights

 

- 19 -


Common Shares carry one vote per share for all matters coming before shareholders and the Proportionate Voting Shares carry 500 votes per share for all matters coming before shareholders.

Unless a different majority is required by law or by Corporation’s articles, resolutions to be approved by holders of Common Shares and Proportionate Voting Shares require approval by a simple majority of the total number of votes of all Common Shares and Proportionate Voting Shares cast at a meeting of shareholders at which a quorum is present with holders of the Common Shares entitled to one vote per share and holders of Proportionate Voting Shares entitled to 500 votes per share.

Form of Resolution

The Proportionate Voting Shares Resolution will be in the following form, subject to amendment at the Meeting:

“BE IT RESOLVED AS A SPECIAL RESOLUTION, THAT:

 

a)

the Corporation’s articles of incorporation be amended pursuant to Section 168 of the Business Corporations Act (Ontario) (the “OBCA”):

 

  i.

to create a new class of authorized shares, unlimited in number and without par value, entitled “Proportionate Voting Shares”;

 

  ii.

by creating, defining and attaching to the Proportionate Voting Shares the special rights and restrictions set out in Schedule “A” to the information circular and proxy statement of the Corporation dated October 12, 2018.

 

b)

the foregoing amendment shall not take effect until:

 

  i.

this resolution has been deposited at the Corporation’s records office; and

 

  ii.

the notice of articles of the Corporation is altered to reflect the amendment as required under the OBCA;

 

c)

any officer or director of the Corporation is hereby authorized and directed for and on behalf of the Corporation to execute and deliver all such documents and to do all such other acts and things as he or she may determine to be necessary or advisable to give effect to this special resolution including, without limitation, to determine the timing for delivery and effect the delivery of articles of amendment in the prescribed form to the Director appointed under the OBCA, the execution of any such document or the doing of any such other act or thing being conclusive evidence of such determination; and

 

d)

notwithstanding that this special resolution has been passed by the shareholders of the Corporation, the board of directors be and is hereby authorized and empowered, without further approval of the shareholders of the Corporation, to revoke this resolution at any time before the certificate of amendment to be issued by the Director upon receipt of such articles of amendment becomes effective.”

The Board unanimously recommends that Shareholders vote in favour of the Proportionate Voting Share Resolution. In order to pass the above Proportionate Voting Share Resolution, a special majority consisting of at least sixty-six and two-thirds percent (66 23%) of the votes cast by Shareholders, present in person or by proxy at the Meeting, is required. Unless the Shareholder has specified in the enclosed form of proxy that the Common Shares represented by such proxy are to be voted against the Proportionate Voting Share Resolution, the persons named in the enclosed form of proxy will vote FOR the Proportionate Voting Share Resolution.

 

- 20 -


Other Matters to Be Acted Upon

As of the date of this Circular, management knows of no matters to come before the Meeting other than the matters referred to in the Notice of Meeting. However, if any other matters properly come before the Meeting, the accompanying proxy will be voted on such matters in the best judgment of the person or persons voting the proxy.

STATEMENT OF EXECUTIVE COMPENSATION

Securities laws require that a “Statement of Executive Compensation” in accordance with Form 51- 102F6V (“the Form”) be included in this Circular. The Form prescribes the disclosure requirements in respect of the compensation of named executive officers and directors of reporting issuers.

The term “named executive officer” (“NEO”) means the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) of the Corporation and each of the three most highly compensated officers, other than the CEO and CFO, who were serving as at the most recently completed fiscal year and whose salary and bonus in the aggregate exceeded $150,000.

Xanthic Compensation Discussion and Analysis

As of the date of this Circular, Xanthic did not, during the two most recently completed financial years, pay any fees to its current directors or named executive officers, except as disclosed below. The following is a compensation discussion and analysis in respect of the existing directors and NEOs of Xanthic.

Summary Compensation Table for Directors and Named Executive Officers:

 

     Table of compensation excluding compensation securities  

Name and position

   Year      Salary,
consulting
(C$)
     Bonus
(C$)
     Committee
or meeting
(C$)
     Value of
perquisites
(C$)
     Value of all
other
(C$)
     Total
compensation
(C$)
 

Tim Moore,

     2018        164,934        30,000        —          —          —          194,934  

Chief Executive Officer

     2017        —          —          —          —          —          —    

Igor Galitsky,

     2018        90,000        90,000        —          —          —          180,000  

President

     2017        —          —          —          —          —          —    

David Bhumgara,

     2018        126,009        30,000        —          —          —          156,009  

Chief Financial Officer

     2017        10,000        —          —          —          —          10,000  

Carli Posner,

     2018        —          —          —          —          —          —    

Director

     2017        —          —          —          —          —          —    

Peter Horvath,

     2018           —          —          —          —       

Director

     2017        —          —          —          —          —          —    

 

- 21 -


Jean Schottenstein,

     2018        —          —          —          —          —          —    

Director

     2017        —          —          —          —          —          —    

Steve Stoute,

     2018        —          —          —          —          —          —    

Director

     2017        —          —          —          —          —          —    

Marc Lehmann,

     2018        —          —          —          —          —          —    

Director

     2017        —          —          —          —          —          —    

Stock options and other compensation securities

The following table sets out all compensation securities, comprised of incentive shares, granted or issued to all directors and NEOs by Xanthic in the most recently completed financial year ended June 30, 2018, for services provided, directly or indirectly, to Xanthic. None of the compensation securities referenced below were exercised in the most recently completed financial year.

 

Compensation Securities

 

Name and position

   Type of
compensation
security
     Number of
compensation
securities,
number of
underlying
securities, and
percentage of
class
     Date of
issue or
grant
     Issue,
conversion
or
exercise
price
(C$)
     Closing price of
security or
underlying
security on date
of grant
(C$)
     Closing
price of
security or
underlying
security at
year end
(C$)
     Expiry
date
 

Tim Moore,
Chief Executive Officer

     Options        350,000        Feb 28/ 2018      $ 0.125      $ 0.125      $ 0.250        Feb 27 /2023  

Igor Galitsky,
President

     Options        358,000        Feb 28/ 2018      $ 0.125      $ 0.125      $ 0.250        Feb 27 /2023  

David Bhumgara,
Chief Financial Officer

     Options        350,000        Feb 28/ 2018      $ 0.125      $ 0.125      $ 0.250        Feb 27 /2023  

Carli Posner,
Director

     Options        200,000        Feb 28/ 2018      $ 0.125      $ 0.125      $ 0.250        Feb 27 /2023  

Peter Horvath,
Director

     N/A        N/A        N/A        N/A        N/A        N/A        N/A  

Jean Schottenstein,
Director

     N/A        N/A        N/A        N/A        N/A        N/A        N/A  

 

- 22 -


Steve Stoute,
Director

   N/A    N/A    N/A    N/A    N/A    N/A    N/A

Marc Lehmann,
Director

   N/A    N/A    N/A    N/A    N/A    N/A    N/A

No options were exercised by Xanthic NEOs or directors in the financial year ended June 30, 2018.

Stock Option Plans and Other Incentive Plans

Carli Posner received 200,000 Issuer Options for her board participation. As of June 30, 2018, 1/3 vested immediately, 1/3 vest 12 months from award date and 1/3 vest 24 months after the award date. On signing of the Business Combination Agreement, all unvested stock options vested immediately. Xanthic reimburses expenses incurred by such persons for acting as directors of Xanthic.

Employment, Consulting and Management Agreements

As Xanthic was still in its early stages of development, the Compensation & Governance Committee (the “C&G Committee”) determined that each of the Xanthic NEOs be retained on a consulting agreement basis. Mr. Tim Moore’s monthly compensation was C$15,000 per month while Mr. Igor Galitsky and Mr. David Bhumgara each received monthly compensation of C$10,000. In addition, the C&G Committee agreed to award a cash bonus of C$30,000 per Xanthic NEO for the successful completion and listing of the Issuer Common Shares on the CSE.

Additionally, as negotiated as part of the Business Combination, in lieu of change of control, if any Xanthic NEO is terminated without cause, such Xanthic NEO will be entitled to a one-time payment of C$200,000 in the case of Mr. Tim Moore and C$150,000 for each for Mr. Igor Galitsky and Mr. David Bhumgara.

Other than as described above, Xanthic does not intend to provide NEOs with any additional personal benefits, nor does Xanthic intend to provide any additional compensation to its NEOs for serving as directors.

Oversight and Description of Director and Named Executive Officer Compensation

The existing compensation of the Xanthic NEOs is determined by the board of directors of Xanthic. Compensation may be comprised of cash, equity awards, or a combination of both. Xanthic also reimburses expenses incurred by such persons for acting as officers of Xanthic. As at the date of this Circular, no element of compensation for NEOs is tied to performance criteria or goals.

Pension Plan Benefits

Xanthic does not currently provide any pension plan benefits to its named executive officers, directors, or employees.

Securities authorized for issuance under the Equity Compensation Plan

The Corporation did not have any equity compensation plan as at June 30, 2018.

STATEMENT OF CORPORATE GOVERNANCE MATTERS

Corporate Governance

Corporate governance relates to the activities of the Board, the members of which are elected by and are accountable to the Shareholders, and takes into account the role of the individual members of management who are appointed by

 

- 23 -


the Board and who are charged with the day-to-day management of the Corporation. National Policy 58-201—Corporate Governance Guidelines (“NP 58-201”) establishes corporate governance guidelines which apply to all public companies. These guidelines are not intended to be prescriptive but to be used by issuers in developing their own corporate governance practices. The Board is committed to sound corporate governance practices, which are both in the interest of its Shareholders and contribute to effective and efficient decision making.

Pursuant to National Instrument 58-101 - Disclosure of Corporate Governance Practices (“NI 58-101”), the Corporation is required to disclose its corporate governance practices, as summarized below. The Board will continue to monitor such practices on an ongoing basis and, when necessary, implement such additional practices as it deems appropriate.

Board of Directors

The Board is currently composed of composed of seven directors: Tim Moore, Igor Galitsky, Carli Posner, Jean Schottenstein, Peter Horvath, Steve Stoute and Marc Lehmann. It is proposed that all seven of these directors will be nominated at the Meeting.

NI 58-101 suggests that the board of directors of every listed company should be constituted with a majority of individuals who qualify as “independent” directors, within the meaning set out under National Instrument 52-110 Audit Committees (“NI 52-110”), which provides that a director is independent if he or she has no direct or indirect “material relationship” with the company. “Material relationship” is defined as a relationship which could, in the view of the company’s board of directors, be reasonably expected to interfere with the exercise of a director’s independent judgment.

Of the current directors, Tim Moore, Chief Executive Officer, and Igor Galitsky, President, are executive officers and accordingly are not considered to be “independent”. In addition, Peter Horvath, Chief Executive Officer of GGB, and Jean Schottenstein, Trustees of the trust that owns All Js Greenspace LLC, GGB’s largest shareholder, are also not considered to be “independent”. In assessing NI 58-101 and making the foregoing determinations, the circumstances of each director have been examined in relation to a number of factors. The remaining directors are considered to be independent directors since they are all independent of management and free from any material relationship with the Corporation. The basis for this determination is that, since the commencement of the Corporation’s fiscal year ended June 30, 2018, none of the current independent directors have worked for the Corporation, received remuneration from the Corporation (other than in their capacity as directors) or had material contracts with or material interests in the Corporation which could interfere with their ability to act with a view to the best interests of the Corporation.

The Board believes that it functions independently of management. To enhance its ability to act independently of management, the members of the Board may meet in the absence of members of management and the non-independent directors. In the event of a conflict of interest at a meeting of the Board, the conflicted director will, in accordance with corporate law and in accordance with his or her fiduciary obligations as a director of the Corporation, disclose the nature and extent of his interest to the meeting and abstain from voting on or against the approval of such participation. In addition, the members of the Board who are not members of management of the Corporation are encouraged by the management members of the Board to communicate and obtain advice from such advisors and legal counsel as they may deem necessary in order to reach a conclusion with respect to issues brought before the Board.

Other Reporting Issuer Directorships

None of the directors or director nominees of the Corporation currently hold directorships in other reporting issuers.

 

Name

  

Name of Reporting

Issuer

  

Name or Exchange

or Market

  

Position

  

From

  

To

Igor Galitsky

  

Platinex Inc.

  

CSE

  

Director

  

August 2, 2018

  

Current

 

- 24 -


Orientation and Continuing Education

Each new director is given an outline of the nature of the business of the Corporation, its corporate strategy, and current issues within the Corporation. New directors are also required to meet with management of the Corporation to discuss and better understand the Corporation’s business and are given the opportunity to meet with counsel to the Corporation to discuss their legal obligations as directors of the Corporation.

In addition, management of the Corporation takes steps to ensure that its directors and officers are continually updated as to the latest corporate and securities policies which may affect the directors, officers, and committee members of the Corporation as a whole. The Corporation continually reviews the latest securities rules and policies. Any such changes or new requirements are then brought to the attention of the Corporation’s directors either by way of director or committee meetings or by direct communications from management to the directors.

Ethical Business Conduct

The Board has found that the fiduciary duties placed on individual directors by the Corporation’s governing corporate legislation and the common law and the restrictions placed by applicable corporate legislation on an individual director’s participation in the decision making of the Board in which the director has an interest as well as adherence to the standards contained in the Corporation’s Code of Business Conduct and Ethics have been sufficient to ensure that the Board operates independently of management and in the best interests of the Corporation. Further, the Corporation’s auditor has full and unrestricted access to the audit committee of the Corporation (the “Audit Committee”) at all times to discuss the annual audits of the Corporation’s financial statements and any related findings as to the integrity of the financial reporting process.

Nomination of Directors

The Board expects to meet at least annually in order to: (a) review the Board’s Corporate Governance guidelines and all Committee’s Charters to ensure that they are consistent with sound governance principles, and recommending any proposed changes to the Board for approval; (b) develop, and periodically update, a Code of Business Ethics (the “Code”), and ensure that management has established a system to disseminate and monitor compliance of the Code and is enforcing its application; (c) in consultation with the Audit Committee, monitor and review the Corporation’s policies and procedures relating to compliance with laws and regulations and its Code; (d) consider what competencies and skills the Board, as a whole, should possess and seeking individuals qualified to become Board members, including evaluating persons suggested by share owners or others; (e) recommend the director nominees for the next annual meeting of Shareholders; (f) review the composition of each Board committee; and (g) develop and perform an annual assessment process for the Board and each Committee of the Board.

Compensation

Currently, the Board oversees director and executive compensation. The Compensation Committee is expected to meet at least twice annually and is responsible for making recommendations to the Board regarding: (a) CEO compensation; (b) compensation of other executives; (c) incentive compensation plans; and (d) employment agreements, severance agreements, retirement agreements, change of control agreements and provisions, and any special or supplemental benefits for each officer of the Corporation. The Board then determines whether to adopt such recommendations as submitted or otherwise.

Other Board Committees

The Board has an Audit Committee, the details of which are provided below.

Assessment of Board Performance

 

- 25 -


The Board monitors the adequacy of information given to directors, communication between the Board and management and the strategic direction and processes of the Board and committees.

AUDIT COMMITTEE INFORMATION

The Audit Committee is responsible for the Corporation’s financial reporting process and the quality of its financial reporting. In addition to its other duties, the Audit Committee reviews all financial statements, annual and interim, intended for circulation among Shareholders and reports upon these to the Board. In addition, the Board may refer to the Audit Committee other matters and questions relating to the financial position of the Corporation. In performing its duties, the Audit Committee maintains effective working relationships with the Board, management and the external auditors and monitors the independence of those auditors. The Audit Committee has formally adopted an Audit Committee charter, which sets forth purposes of the Audit Committee and guidelines for its practices. The full text of the Audit Committee Charter is annexed hereto as Schedule “C”.

The Audit Committee will consist of Carli Posner (Chair), Igor Galitsky and Steve Stoute, in compliance with the applicable requirements found under National Instrument 52-110Audit Committees (“NI 52-110”). Each of the Audit Committee members has an understanding of the accounting principles used to prepare the Resulting Issuer’s financial statements; experience preparing, auditing, analyzing or evaluating comparable financial statements; and experience as to the general application of relevant accounting principles, as well as an understanding of the internal controls and procedures necessary for financial reporting.

Composition of the Audit Committee

The following are the members or proposed members of the Audit Committee. Their biographies are set out under the heading “Matters to be Acted Upon at the Meeting – Election of Directors”.

 

Name

  

Independent/Not Independent (1)

  

Financial History (1)

Carli Posner (2)

  

Independent

  

Financially literate

Steve Stoute

  

Independent

  

Financially literate

Igor Galitsky

  

Not Independent (President)

  

Financially literate

Notes:

 

(1)

Terms have their respective meanings ascribed in NI 52-110.

(2)

Carli Posner will be appointed as the Chair of the Audit Committee.

Audit Committee Member Information

The following table describes the education and experience of each current or proposed Audit Committee member that is relevant to the performance of his responsibilities as an Audit Committee member:

 

Carli Posner

  

Ms. Posner has served as an independent director on the Board of the Corporation since February 2018 and is the Co-CEO and Principal of Notable Life, a media company that reaches over 1.2 million high-earning millennials across Canada. Prior to Notable, she was the executive producer of the hit show, Hockey Wives, overseeing many departments including premium sponsors and media strategy. Ms. Posner has spent a significant portion of her career in Los Angeles, working in film finance and production. She is the leading talent packager in Canada and has worked with top stars including George Clooney, Coldplay, Drew Barrymore, Jamie Oliver and Wayne Gretzky, to name a few. During Ms. Posner’s career, she has generated over C$100 million dollars of sponsorships and endorsements in the Canadian marketplace with top brands including MasterCard®, Corvette®, Scotiabank®, BMW® and LG®.

 

- 26 -


Steve Stoute   

Mr. Stoute will serve as an independent director on the Board of the Corporation and is the founder and Chief Executive Officer of Translation, a marketing agency. In 2017, Mr. Stoute joined United Masters, a data-driven digital distribution company helping music artist grow and manage their fan bases. In 2009 the American Advertising Federation inducted Mr. Stoute into the Advertising Hall of Achievement, and he was named “Executive of the Year” by Advertising Age in 2013.

Igor Galitsky   

Mr. Galitsky has been President of Xanthic since December 2017 and was one of the first applicants to receive a license under the Marijuana Medical Access Regulations for both personal and designated production in Canada. Mr. Galitsky has developed and refined over the last seven years the production and extraction processes for cannabis. In addition, Mr. Galitsky has been consulting varies licensed producers in Canada on scaling and refining their extraction and secondary processes.

Audit Committee Oversight

At no time since the commencement of the Corporation’s financial year ended June 30, 2018 was a recommendation of the audit committee to nominate or compensate an external auditor not adopted by the Board.

Reliance on Certain Exemptions

At no time since the commencement of the Corporation’s financial year ended June 30, 2018 has the Corporation relied on the exemption provided under section 2.4 of NI 52-110 (De Minimis Non-Audit Services) or an exemption from NI 52-110, in whole or in part, granted under Part 8 of NI 52-110.

Pre-Approval Policies and Procedures

The audit committee of the Corporation has adopted specific policies and procedures for the engagement of non-audit services as described in the audit committee’s charter attached hereto as Schedule “C”.

Assessments

The Board does not make regular formal assessments of the Board, its committees or its members. Rather, from time to time, the Board satisfies itself on an informal basis that its members and audit committee are performing effectively; in this respect, from time to time, the Board reviews and considers the size of the Board in relation to the needs of the Corporation, with a view of facilitating effective decision-making and identifying and selecting individuals qualified to become new Board members.

INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS

Since the beginning of the last completed financial year and up to the date hereof, no director, executive officer or employee or former executive officer, director, or employee of the Corporation or any of its subsidiaries has been indebted to the Corporation.

OTHER INFORMATION

Registrar and Transfer Agent

The registrar and transfer agent of the Corporation is Capital Transfer Agency, 920-390 Bay Street, Toronto ON, M5H 2Y2.

 

- 27 -


Interest of Informed Persons in Material Transactions

Except as disclosed in this Circular or the Schedules hereto, none of the informed persons of the Corporation (as defined in National Instrument 51-102), nor any of the Corporation’s principal holders of Common Shares, directors, senior officers, or any associate or affiliate of the foregoing persons, have any material interest, direct or indirect, in any transaction since the commencement of the Corporation’s most recently completed financial year or in any proposed transaction which, in either case, has or will materially affect the Corporation.

Interests of Certain Persons in Matters to be Acted Upon

Except as disclosed in this Circular or the Schedules hereto, none of the Corporation’s principal holders of Common Shares, directors, senior officers, or any associate or affiliate of the foregoing persons, have any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted on at the Meeting.

Other than in their capacity as Shareholders or as described above or elsewhere in this Circular, none of the Corporation’s principal holders of Common Shares, directors, senior officers, or any associate or affiliate of the foregoing are expected to benefit from the Transaction upon completion of the Transaction.

Reliance

GGB has provided the information contained in this Circular and the Listing Statement concerning GGB and its business, including it financial information and financial statements, which information has been relied upon by Xanthic in preparing this Circular. Xanthic assumes no responsibility for the accuracy or completeness of such information, nor for any omission on the part of GGB to disclose facts or events which may affect the accuracy of any such information.

Additional Information

Additional information relating to the Corporation is available through the internet on the Canadian System for Electronic Document Analysis and Retrieval (SEDAR) which can be accessed at www.sedar.com. Financial information on the Corporation is provided in the comparative financial statements and management discussion and analysis of the Corporation for its most recently completed financial year which can also be accessed at www.sedar.com or which may be obtained upon request to the Corporate Secretary at 77 King St. W., Suite 2905, Toronto, ON M5K 1A2.

APPROVAL OF DIRECTORS

The contents and sending of this Information Circular to the Shareholders of the Corporation have been approved by the Board.

DATED at Toronto, Ontario as of the 12th day of October 2018.

BY ORDER OF THE BOARD OF DIRECTORS

(Signed) “Tim Moore”

Tim Moore

Chief Executive Officer & Director

 

- 28 -


SCHEDULE “A”

RIGHTS AND RESTRICTIONS ATTACHED TO XANTHIC BIOPHARMA INC. COMMON SHARES AND PROPORTIONATE VOTING SHARES

Purpose

 

  (a)

To increase the authorized capital of the Corporation by the creation of an unlimited number of proportionate voting shares.

 

  (b)

After giving effect to the foregoing, the classes and maximum number of shares that the Corporation is authorized to issue shall be an unlimited number of common shares and an unlimited number of proportionate voting shares.

 

  (c)

To provide that the common shares and the proportionate voting shares of the Corporation shall have attached thereto the following rights, privileges, restrictions and conditions:

 

1.

COMMON SHARES

 

  (a)

Voting

 

  (i)

The holders of common shares (“Common Shares”) shall be entitled to receive notice of and to attend and vote at all meetings of shareholders of the Company except a meeting at which only the holders of another class or series of shares is entitled to vote. Each Common Share shall entitle the holder thereof to one vote at each such meeting.

 

  (b)

Alteration to Rights of Common Shares

 

  (i)

So long as any Common Shares remain outstanding, the Company will not, without the consent of the holders of Common Shares expressed by separate special resolution alter or amend these Articles if the result of such alteration or amendment would:

 

  (A)

prejudice or interfere with any right or special right attached to the Common Shares; or

 

  (B)

affect the rights or special rights of the holders of Common Shares and Proportionate Voting Shares on a per share basis which differs from the basis of one (1) per share in the case of the Common Shares, and five hundred (500) per share in the case of the Proportionate Voting Shares.

 

  (c)

Dividends

 

  (i)

Subject the holders of Common Shares shall be entitled to receive such dividends payable in cash or property of the Company as may be declared thereon by the directors from time to time. The directors may declare no dividend payable in cash or property on the Common Shares unless the directors simultaneously declare a dividend payable in cash or property on the Proportionate Voting Shares in an amount per Proportionate Voting Share equal to the amount of the dividend declared per Common Share, multiplied by five hundred (500), and each fraction of a Proportionate Voting Share will be entitled to the applicable fraction thereof.

 

  (ii)

The directors may declare a stock dividend payable in Common Shares on the Common Shares, but only if the directors simultaneously declare a stock dividend payable in:

 

- 1 -


  (A)

Proportionate Voting Shares on the Proportionate Voting Shares, in a number of shares per Proportionate Voting Share (or fraction thereof) having a value equal to the amount of the dividend declared per Common Share; or

 

  (B)

Common Shares on the Proportionate Voting Shares, in a number of shares per Proportionate Voting Share equal to the amount of the dividend declared per Common Share, multiplied by five hundred (500).

 

  (d)

Liquidation Rights

In the event of the liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or in the event of any other distribution of assets of the Company to its shareholders for the purposes of winding up its affairs, the holders of the Common Shares shall be entitled to participate pari passu with the holders of Proportionate Voting Shares, with the amount of such distribution per Proportionate Voting Share equal to the amount of such distribution per Common Share multiplied by five hundred (500), and each fraction of a Proportionate Voting Share will be entitled to the amount calculated by multiplying the fraction by the amount otherwise payable in respect of a whole Proportionate Voting Share.

 

  (e)

Subdivision or Consolidation

The Common Shares shall not be consolidated or subdivided unless the Proportionate Voting Shares are simultaneously consolidated or subdivided utilizing the same divisor or multiplier.

 

  (f)

Voluntary Conversion of Common Shares

Each Common Share shall be convertible at the option of the holder into such number of Proportionate Voting Shares as is determined by dividing the number of Common Shares being converted by five hundred (500), provided the directors have consented to such conversion.

Before any holder of Common Shares shall be entitled to voluntarily convert Common Shares into Proportionate Voting Shares in accordance with this Section II(f), the holder shall surrender the certificate or certificates representing the Common Shares to be converted at the head office of the Company, or the office of any transfer agent for the Common Shares, and shall give written notice to the Company at its head office of his or her election to convert such Common Shares and shall state therein the name or names in which the certificate or certificates representing the Proportionate Voting Shares are to be issued (a “Common Shares Conversion Notice”). The Company shall (or shall cause its transfer agent to) as soon as practicable thereafter, issue to such holder or his or her nominee, a certificate or certificates or direct registration statement representing the number of Proportionate Voting Shares to which such holder is entitled upon conversion. Such conversion shall be deemed to have taken place immediately prior to the close of business on the day on which the certificate or certificates representing the Common Shares to be converted is surrendered and the Common Shares Conversion Notice is delivered, and the person or persons entitled to receive the Proportionate Voting Shares issuable upon such conversion shall be treated for all purposes as the holder or holders of record of such Proportionate Voting Shares as of such date.

 

  (g)

Conversion of Common Shares Upon an Offer

In the event that an offer is made to purchase Proportionate Voting Shares, and such offer is:

 

  (i)

required, pursuant to applicable securities legislation or the rules of any stock exchange on which the Proportionate Voting Shares may then be listed, to be made to all or substantially all of the holders of Proportionate Voting Shares in a province or territory of Canada to which the requirement applies (such offer to purchase, an “Offer”); and

 

- 2 -


  (ii)

not made to the holders of Common Shares for consideration per Common Share equal to .002 of the consideration offered per Proportionate Voting Share;

each Common Share shall become convertible at the option of the holder into Proportionate Voting Shares on the basis of five hundred (500) Common Shares for one (1) Proportionate Voting Share, at any time while the Offer is in effect until one day after the time prescribed by applicable securities legislation or stock exchange rules for the offeror to take up and pay for such shares as are to be acquired pursuant to the Offer (the “Common Share Conversion Right”). For avoidance of doubt, fractions of Proportionate Voting Shares may be issued in respect of any amount of Common Shares in respect of which the Common Share Conversion Right is exercised which is less than five hundred (500).

The Common Share Conversion Right may only be exercised for the purpose of depositing the Proportionate Voting Shares acquired upon conversion under such Offer, and for no other reason. If the Common Share Conversion Right is exercised, the Company shall procure that the transfer agent for the Common Shares shall deposit under such Offer the Proportionate Voting Shares acquired upon conversion, on behalf of the holder.

To exercise the Common Share Conversion Right, a holder of Common Shares or his or her attorney, duly authorized in writing, shall:

 

  (iii)

give written notice of exercise of the Common Share Conversion Right to the transfer agent for the Common Shares, and of the number of Common Shares in respect of which the Common Share Conversion Right is being exercised;

 

  (iv)

deliver to the transfer agent for the Common Shares any share certificate or certificates representing the Common Shares in respect of which the Common Share Conversion Right is being exercised; and

 

  (v)

pay any applicable stamp tax or similar duty on or in respect of such conversion.

No certificates representing Proportionate Voting Shares acquired upon exercise of the Common Share Conversion Right will be delivered to the holders of Common Shares. If Proportionate Voting Shares issued upon such conversion and deposited under such Offer are withdrawn by such holder, or such Offer is abandoned, withdrawn or terminated by the offeror, or such Offer expires without the offeror taking up and paying for such Proportionate Voting Shares, such Proportionate Voting Shares and any fractions thereof issued shall automatically, without further action on the part of the holder thereof, be reconverted into Common Shares on the basis of one (1) Proportionate Voting Share for five hundred (500) Common Shares, and the Company will procure that the transfer agent for the Common Shares shall send to such holder a direct registration statement, certificate or certificates representing the Common Shares acquired upon such reconversion. If the offeror under such Offer takes up and pays for the Proportionate Voting Shares acquired upon exercise of the Common Share Conversion Right, the Company shall procure that the transfer agent for the Common Shares shall deliver to the holders of such Proportionate Voting Shares the consideration paid for such Proportionate Voting Shares by such Offeror.

 

II.

PROPORTIONATE VOTING SHARES

 

  (a)

Voting

The holders of Proportionate Voting Shares shall be entitled to receive notice of and to attend and vote at all meetings of shareholders of the Company at which holders of Common Shares are entitled to vote. Subject to Section II(b), each Proportionate Voting Share shall entitle the holder to five hundred (500) votes and each fraction of a Proportionate Voting Share shall entitle the

 

- 3 -


holder to the number of votes calculated by multiplying the fraction by five hundred (500) and rounding the product down to the nearest whole number, at each such meeting.

 

  (b)

Alteration to Rights of Proportionate Voting Shares

So long as any Proportionate Voting Shares remain outstanding, the Company will not, without the consent of the holders of Proportionate Voting Shares expressed by separate special resolution alter or amend these Articles if the result of such alteration or amendment would:

 

  (i)

prejudice or interfere with any right or special right attached to the Proportionate Voting Shares; or

 

  (ii)

affect the rights or special rights of the holders of Common Shares and Proportionate Voting Shares on a per share basis which differs from the basis of one (1) per share in the case of the Common Shares, and five hundred (500) per share in the case of the Proportionate Voting Shares.

At any meeting of holders of Proportionate Voting Shares called to consider such a separate special resolution, each Proportionate Voting Share shall entitle the holder to one (1) vote and each fraction of a Proportionate Voting Share will entitle the holder to the corresponding fraction of one (1) vote.

 

  (c)

Dividends

 

  (i)

The holders of Proportionate Voting Shares shall be entitled to receive such dividends payable in cash or property of the Company as may be declared by the directors from time to time. The directors may declare no dividend payable in cash or property on the Proportionate Voting Shares unless the directors simultaneously declare a dividend payable in cash or property on the Common Shares in an amount equal to the amount of the dividend declared per Proportionate Voting Share divided by five hundred (500).

 

  (ii)

The directors may declare a stock dividend payable in Proportionate Voting Shares on the Proportionate Voting Shares, but only if the directors simultaneously declare a stock dividend payable in Common Shares on the Common Shares, in a number of shares per Common Share having a value equal to the amount of the dividend declared per Proportionate Voting Share.

 

  (iii)

The directors may declare a stock dividend payable in Common Shares on the Proportionate Voting Shares, but only if the directors simultaneously declare a stock dividend payable in Common Shares on the Common Shares, in a number of shares per Common Share equal to the amount of the dividend declared per Proportionate Voting Share divided by five hundred (500).

 

  (iv)

Holders of fractional Proportionate Voting Shares shall be entitled to receive any dividend declared on the Proportionate Voting Shares, in an amount equal to the dividend per Proportionate Voting Share multiplied by the fraction thereof held by such holder.

 

  (d)

Liquidation Rights

In the event of the liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or in the event of any other distribution of assets of the Company to its shareholders for the purpose of winding up its affairs, the holders of the Proportionate Voting Shares shall be entitled to participate pari passu with the holders of Common Shares, with the amount of such

 

- 4 -


distribution per Proportionate Voting Share equal to the amount of such distribution per Common Share multiplied by five hundred (500), and each fraction of a Proportionate Voting Share will be entitled to the amount calculated by multiplying the fraction by the amount payable per whole Proportionate Voting Share.

 

  (e)

Subdivision or Consolidation

The Proportionate Voting Shares shall not be consolidated or subdivided unless the Common Shares are simultaneously consolidated or subdivided utilizing the same divisor or multiplier.

 

  (f)

Conversion

 

  (i)

Voluntary Conversion.

Subject to the Conversion Limitation set forth in this Article, holders of Proportionate Voting Shares shall have the following rights of conversion (the “Proportionate Share Conversion Right”):

 

  (A)

Right to Convert. Each Proportionate Voting Share shall be convertible at the option of the holder into such number of Common Shares as is determined by multiplying the number of Proportionate Voting Shares in respect of which the Proportionate Share Conversion Right is exercised by five hundred (500). Fractions of Proportionate Voting Shares may be converted into such number of Common Shares as is determined by multiplying the fraction by five hundred (500).

 

  (B)

Conversion Limitation. Unless already appointed, upon receipt of a PVS Conversion Notice (as defined below), the directors (or a committee thereof) shall designate an officer of the Company who shall determine whether the Conversion Limitation set forth in this Article shall apply to the conversion referred to therein (the “Conversion Limitation Officer”).

 

  (C)

Foreign Private Issuer Status. The Company shall use commercially reasonable efforts to maintain its status as a “foreign private issuer” (as determined in accordance with Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, the Company shall not give effect to any voluntary conversion of Proportionate Voting Shares pursuant to this Article or otherwise, and the Proportionate Share Conversion Right will not apply, to the extent that after giving effect to all permitted issuances after such conversion of Proportionate Voting Shares, the aggregate number of Common Shares and Proportionate Voting Shares (calculated on the basis that each Common Share and Proportionate Voting share is counted once, without regard to the number of votes carried by such share) held of record, directly or indirectly, by residents of the United States (as determined in accordance with Rules 3b-4 and 12g3-2(a) under the Exchange Act (“U.S. Residents”) would exceed forty percent (40%) (the “40% Threshold”) of the aggregate number of Common Shares and Proportionate Voting Shares (calculated on the same basis) issued and outstanding (the “FPI Restriction”) as calculated herein. The directors may by resolution increase the 40% Threshold to a number not to exceed fifty percent (50%), and if any such resolution is adopted, all references to the 40% Threshold herein shall refer instead to the amended percentage threshold set by the directors in such resolution.

 

  (D)

Conversion Limitation. In order to give effect to the FPI Restriction, the number of Common Shares issuable to a holder of Proportionate Voting Shares

 

- 5 -


upon exercise by such holder of the Proportionate Share Conversion Right will be subject to the 40% Threshold based on the number of Proportionate Voting Shares held by such holder as of the date of issuance of Proportionate Voting Shares to such holder, and thereafter at the end of each of the Company’s subsequent fiscal quarters (each, a “Determination Date”), calculated as follows:

X = [A x 40% - B] x (C/D)

Where, on the Determination Date:

X = Maximum Number of Common Shares which may be issued upon exercise of the Proportionate Share Conversion Right.

A = Aggregate number of Common Shares and Proportionate Voting Shares issued and outstanding.

B = Aggregate number of Common Shares and Proportionate Voting Shares held of record, directly or indirectly, by U.S. Residents.

C = Aggregate Number of Proportionate Voting Shares held by such holder.

D = Aggregate Number of All Proportionate Voting Shares.

The Conversion Limitation Officer shall determine as of each Determination Date, in his or her sole discretion acting reasonably, the aggregate number of Common Shares and Proportionate Voting Shares held of record, directly or indirectly, by U.S. Residents, the maximum number of Common Shares which may be issued upon exercise of the Proportionate Share Conversion Right, generally in accordance with the formula set forth immediately above. Upon request by a holder of Proportionate Voting Shares, the Company will provide each holder of Proportionate Voting Shares with notice of such maximum number as at the most recent Determination Date, or a more recent date as may be determined by the Conversion Limitation Officer in its discretion. To the extent that issuances of Common Shares on exercise of the Proportionate Share Conversion Right would result in the 40% Threshold being exceeded, the number of Common Shares to be issued will be pro-rated among each holder of Proportionate Voting Shares exercising the Proportionate Share Conversion Right.

Notwithstanding the provisions of this Section II(f)(i)(C) and (D), the directors may by resolution waive the application of the Conversion Restriction to any exercise or exercises of the Proportionate Share Conversion Right to which the Conversion Restriction would otherwise apply, or to future Conversion Restrictions generally, including with respect to a period of time.

 

  (E)

Disputes.

 

  (I)

Any holder of Proportionate Voting Shares who beneficially owns more than 5% of the issued and outstanding Proportionate Voting Shares may submit a written dispute as to the calculation of the 40% Threshold or the FPI Restriction by the Conversion Limitation Officer to the directors with the basis for the disputed calculations. The Company shall respond to the holder within 5 (five) business days of receipt of the notice of such dispute with a written calculation of the

 

- 6 -


40% Threshold or the FPI Restriction, as applicable. If the holder and the Company are unable to agree upon such calculation of the 40% Threshold or the FPI Restriction, as applicable, within 5 (five) business days of such response, then the Company and the holder shall, within 1 (one) business day thereafter submit the disputed calculation of the 40% Threshold or the FPI Restriction to the Company’s independent auditor. The Company, at the Company’s expense, shall cause the auditor to perform the calculations in dispute and notify the Company and the holder of the results no later than 5 (five) business days from the time it receives the disputed calculations. The auditor’s calculations shall be final and binding on all parties, absent demonstrable error.

 

  (II)

In the event of a dispute as to the number of Common Shares issuable to a holder of Proportionate Voting Shares in connection with a voluntary conversion of Proportionate Voting Shares, the Company shall issue to the holder of Proportionate Voting Shares the number of Common Shares not in dispute, and resolve such dispute in accordance with Section II(f)(i)(E)(I) above.

 

  (F)

Mechanics of Conversion. Before any holder of Proportionate Voting Shares shall be entitled to voluntarily convert Proportionate Voting Shares into Common Shares in accordance with Section II(f)(i), the holder shall surrender the certificate or certificates representing the Proportionate Voting Shares to be converted at the head office of the Company, or the office of any transfer agent for the Proportionate Voting Shares, and shall give written notice to the Company at its head office of his or her election to convert such Proportionate Voting Shares and shall state therein the name or names in which the certificate or certificates representing the Common Shares are to be issued (a “PVS Conversion Notice”). The Company shall (or shall cause its transfer agent to) as soon as practicable thereafter, issue to such holder or his or her nominee, a certificate or certificates or direct registration statement representing the number of Common Shares to which such holder is entitled upon conversion. Such conversion shall be deemed to have taken place immediately prior to the close of business on the day on which the certificate or certificates representing the Proportionate Voting Shares to be converted is surrendered and the PVS Conversion Notice is delivered, and the person or persons entitled to receive the Common Shares issuable upon such conversion shall be treated for all purposes as the holder or holders of record of such Common Shares as of such date.

 

  (ii)

Mandatory Conversion.

 

  (A)

The directors may at any time determine by resolution (a “Mandatory Conversion Resolution”) that it is no longer in the best interests of the Company that the Proportionate Voting Shares are maintained as a separate class of shares of the Company. If a Mandatory Conversion Resolution is adopted, then all issued and outstanding Proportionate Voting Shares will automatically, without any action on the part of the holder, be converted into Common Shares on the basis of one (1) Proportionate Voting Share for five hundred (500) Common Shares, and in the case of fractions of Proportionate Voting Shares, such number of Common Shares as is determined by multiplying the fraction by five hundred (500) as of a date to be specified in the Mandatory Conversion Resolution (the “Mandatory Conversion Record Date”). At least twenty (20) calendar days prior to the Mandatory Conversion Record Date, the Company will send, or cause its transfer agent to send, notice to all holders of

 

- 7 -


Proportionate Voting Shares of the adoption of a Mandatory Conversion Resolution (a “Mandatory Conversion Notice”) and specifying:

 

  (I)

the Mandatory Conversion Record Date;

 

  (II)

the number of Common Shares into which the Proportionate Voting Shares held by such holder are to be converted; and

 

  (III)

the address of record of such holder.

On the Mandatory Conversion Record Date, the Company shall issue or shall cause its transfer agent to issue to each holder of Proportionate Voting Shares certificates representing the number of Common Shares into which the Proportionate Voting Shares are converted, and each certificate representing Proportionate Voting Shares shall be null and void.

 

  (B)

From the date of the Mandatory Conversion Resolution, the directors shall no longer be entitled to issue any further Proportionate Voting Shares whatsoever.

 

  (iii)

Fractional Shares. No fractional Common Shares shall be issued upon the conversion of any Proportionate Voting Shares or fractions thereof, and the number of Common Shares to be issued shall be rounded down to the nearest whole number. In the event Common Shares are converted into Proportionate Voting Shares the number of applicable Proportionate Voting Shares shall be rounded down to two decimal places.

 

  (iv)

Effect of Conversion. All Proportionate Voting Shares which are converted as herein provided shall no longer be outstanding and all rights with respect to such shares shall immediately cease and terminate at the time of conversion, except only for the right of the holders thereof to receive Common Shares in exchange therefor.

 

(g)

Transfer

 

  (i)

Unless the directors have consented to such transfer, no Proportionate Voting Share may be transferred unless such transfer:

 

  (A)

is made to (A) an initial holder of Proportionate Voting Shares, or (B) an affiliate or person controlled, directly or indirectly, by an initial holder of Proportionate Voting Shares (each, a “Permitted Holder”); and

 

  (B)

complies with United States securities legislation.

 

  (ii)

subject to the Conversion Limitation, any Proportionate Voting Shares sold or transferred to a Person who is not a Permitted Holder shall be automatically converted to Common Shares, unless otherwise determined by the directors.

For purposes of this Section II(g):

 

  (i)

affiliate” means, with respect to any Person, any other person which is directly or indirectly through one or more intermediaries controlled by, or under common control with, such Person.

 

  (ii)

A Person is “controlled” by another person or other persons if: (i) in the case of a company or other body corporate wherever or however incorporated: (A) securities entitled to vote in the election of directors carrying in the aggregate at least a majority of the votes for the election of directors and representing in the aggregate at least a majority

 

- 8 -


of the participating (equity) securities are held, other than by way of security only, directly or indirectly, by or solely for the benefit of the other Person or Persons; and (B) the votes carried in the aggregate by such securities are entitled, if exercised, to elect a majority of the board of directors of such company or other body corporate; or (ii) in the case of a Person that is not an individual or a company or other body corporate, at least a majority of the participating (equity) and voting interests of such Person are held, directly or indirectly, by or solely for the benefit of the other Person or Persons; and “controls”, “controlling” and “under common control with” shall be interpreted accordingly.

 

  (iii)

Person” means any individual, partnership, corporation, company, association, trust, joint venture or limited liability company.

 

- 9 -


SCHEDULE “B”

INFORMATION PERTAINING TO THE CORPORATION’S

PROPOSED TRANSACTION WITH GREEN GROWTH BRANDS LTD.

See attached.

 

- 1 -


DRAFT – SUBJECT TO CSE REVIEW

OCTOBER 11, 2018

XANTHIC BIOPHARMA INC.

CSE FORM 2A LISTING STATEMENT

In connection with the listing of Xanthic Biopharma Inc., the entity formed upon the

Business Combination between Xanthic Biopharma Inc., Green Growth Brands Ltd. and

2657013 Ontario Inc.

OCTOBER [11], 2018


CAUTIONARY NOTE ON U.S. CANNABIS INVOLVEMENT

This Listing Statement describes the securities of an entity that is expected to continue to derive a significant portion of its revenues from the cannabis industry in certain states of the United States, which industry is illegal under United States federal law. Xanthic Biopharma Inc. (as the “Resulting Issuer”) will be indirectly involved (through its subsidiaries) in the cannabis industry in the United States where local state laws permit such activities. Currently, certain of the Issuer’s subsidiaries are directly engaged in the manufacture, possession, use, sale or distribution of cannabis in the recreational and medicinal cannabis marketplace. Xanthic’s subsidiaries are currently operating in the state of Nevada, Oregon and Washington. See Section 3 – Narrative Description Of The Business.

The United States federal government regulates drugs through the Controlled Substances Act (21 U.S.C. § 811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. Under United States federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. The United States Food and Drug Administration has not approved cannabis as a safe and effective drug for any indication.

In addition to the cultivation, production, and dispensing of cannabis, the Resulting Issuer further intends to derive a significant portion of its revenue from proprietary face-care, body-care, and ingestible articles containing cannabidiol (“CBD”) oil. CBD, though sometimes mistaken for marijuana, can be produced from marijuana, hemp plant or other natural substances, and, unless it contains tetrahydrocannabinol (“THC”), has no psychoactive effects. The United States Congress provided guidance regarding the legality of CBD through its enactment of HB 2642, the Agricultural Act of 2014 (the “2014 Farm Bill”).    It is the Resulting Issuer’s position that the 2014 Farm Bill created an exception to the Controlled Substances Act whereby states could develop pilot hemp programs to better understand the agricultural benefits of the plant, including its economic or commercial potential. The legality of CBD remains the subject of some confusion at both the state and federal level. Though many states have enacted these pilot hemp programs, not all have done so, leaving confusion as to the legality of hemp and its extracts in those states that have not taken advantage of the 2014 Farm Bill’s protections. In addition, inconsistent guidance from both the Drug Enforcement Administration and various state regulatory entities has only increased the confusion in the marketplace.

In the United States, cannabis is largely regulated at the state level. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal notwithstanding the Controlled Substances Act. Although certain states authorize medical or recreational cannabis production and distribution by licensed or registered entities, under U.S. federal law, the possession, use, cultivation, and transfer of cannabis and any related drug paraphernalia is illegal and any such acts are criminal acts under federal law. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and the federal laws made pursuant to it are paramount and in case of conflict between federal and state law, the federal law shall apply.

On January 4, 2018, U.S. Attorney General Jeff Sessions issued a memorandum to all U.S. Attorneys which rescinded previous guidance from the U.S. Department of Justice specific to

 

- 2 -


cannabis enforcement in the United States, including the Cole Memorandum (as defined herein). With the Cole Memorandum rescinded, U.S. federal prosecutors have been given discretion in determining whether to prosecute cannabis related violations of U.S. federal law.

There is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the United States Congress amends the Controlled Substances Act with respect to medical and/or adult-use cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may enforce current federal law. If the federal government begins to enforce federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing applicable state laws are repealed or curtailed, the Resulting Issuer’s business, results of operations, financial condition and prospects would be materially adversely affected. See Section 16Risk Factors for additional information on this risk.

In light of the political and regulatory uncertainty surrounding the treatment of U.S. cannabis-related activities, including the rescission of the Cole Memorandum discussed above, on February 8, 2018 the Canadian Securities Administrators published a staff notice (“Staff Notice 51-352”) setting out the Canadian Securities Administrator’s disclosure expectations for specific risks facing issuers with cannabis-related activities in the United States. Staff Notice 51-352 confirms that a disclosure-based approach remains appropriate for issuers with U.S. cannabis-related activities. Staff Notice 51-352 includes additional disclosure expectations that apply to all issuers with U.S. cannabis related activities, including those with direct and indirect involvement in the cultivation and distribution of cannabis, as well as issuers that provide goods and services to third parties involved in the U.S. cannabis industry.

See Section 2.4 – Trends, Commitments, Events or Uncertainties for further information on the material facts, risks and uncertainties related to issuers with marijuana-related activities.

 

- 3 -


TABLE OF CONTENTS

 

1.    CORPORATE STRUCTURE      15  
2.    GENERAL DEVELOPMENT OF THE BUSINESS      17  
3.    NARRATIVE DESCRIPTION OF THE BUSINESS      37  
4.    SELECTED CONSOLIDATED FINANCIAL INFORMATION      52  
5.    MANAGEMENT’S DISCUSSION AND ANALYSIS      54  
6.    MARKET FOR SECURITIES      54  
7.    CONSOLIDATED CAPITALIZATION      54  
8.    OPTIONS TO PURCHASE SECURITIES      55  
9.    DESCRIPTION OF THE SECURITIES      59  
10.    ESCROWED SECURITIES      64  
11.    PRINCIPAL SHAREHOLDERS      64  
12.    DIRECTORS AND OFFICERS OF THE RESULTING ISSUER      65  
13.    CAPITALIZATION      71  
14.    EXECUTIVE COMPENSATION      74  
15.    INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS      80  
16.    RISK FACTORS      80  
17.    PROMOTERS      97  
18.    LEGAL PROCEEDINGS      97  
19.    INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS      97  
20.    AUDITORS, TRANSFER AGENTS AND REGISTRARS      97  
21.    MATERIAL CONTRACTS      98  
22.    INTEREST OF EXPERTS      99  
23.    OTHER MATERIAL FACTS      99  
24.    FINANCIAL STATEMENTS      99  

 

- 4 -


SCHEDULE “A” – ISSUER FINANCIAL STATEMENTS      102  
SCHEDULE “B” – GGB FINANCIAL STATEMENTS      103  
SCHEDULE “C” – ISSUER MD&A      104  
SCHEDULE “D” – GGB MD&A      105  
SCHEDULE “E” – PRO FORMA FINANCIAL STATEMENTS      106  
SCHEDULE “F” – BUSINESS COMBINATION AGREEMENT      107  

 

- 5 -


GLOSSARY

“2014 Farm Bill” means the Agricultural Act of 2014;

“40% Threshold” has the meaning provided to such term in Section 9.1 – Description of the Securities;

“ABH” means ABH Pharma Inc.;

“ACMPR” means the Access to Cannabis for Medical Purposes Regulations (Canada);

“Advisory Agreements” means the advisory agreements dated April 10, 2018 between GGB and each of Chiron Ventures Inc. and All Js Greenspace LLC;

“affiliate” has the meaning specified in National Instrument 45-106Prospectus Exemptions;

“Agency Agreement” means the agency agreement dated August 30, 2018 between GGB and Canaccord;

“Amalco” means Green Growth Brands (Ontario) Ltd., the corporation resulting from the amalgamation of Subco and GGB;

“Amalco Shares” means the common shares in the capital of Amalco;

“Amalgamation” means the amalgamation of Subco and GGB;

“Amalgamation Agreement” means the amalgamation agreement dated the Closing Date between Subco and GGB;

“ATC” means alternative treatment centre;

“Aurquest” means Aurquest Resources Inc.;

“Business Combination” means the completion of the Amalgamation and the listing of the Resulting Issuer Common Shares on the CSE;

“Business Combination Agreement” means the business combination agreement dated July 13, 2018 between the Issuer and GGB, as amended;

“C&G Committee” means Compensation & Governance Committee;

“Cannabis Act” means the Cannabis Act (Canada);

“Canaccord” means Canaccord Genuity Corp.;

“CBD” means cannabidiol;

“CBP” means U.S. Customers and Border Protection;

“CDS” means CDS Clearing and Depository Services Inc.;

“CDSA” means the Controlled Drugs and Substances Act;

“CEO” means Chief Executive Officer;

 

- 6 -


“CFO” means Chief Financial Officer;

“Closing” means the completion of the Business Combination;

“Closing Date” means the date of Closing;

“Cole Memorandum” means the United States Department of Justice Memorandum drafted by former Deputy Attorney General James Michael Cole in 2013;

“company” unless specifically indicated otherwise, means a corporation, incorporated association or organization, body corporate, partnership, trust, association or other entity other than an individual;

“Consolidation” means the consolidation of the Resulting Issuer Shares on the basis of four (4) pre-consolidation Resulting Issuer Shares for one (1) post-consolidation Resulting Issuer Share;

“CSA” means the Controlled Substances Act of 1970;

“CSE” means the Canadian Securities Exchange;

“CTA” means Capital Transfer Agency ULC;

“Debenture Financing” means the concurrent brokered and non-brokered private placements of approximately 86,000 GGB Debentures at a price of C$1,000 per GGB Debenture, for gross proceeds of approximately C$86 million;

“Deposit Promissory Note” means the promissory note from the Issuer in favour of GGB in the principal amount of US$2 million used by the Issuer to satisfy the deposit under the NOR Agreement;

“Director” means the director appointed under Section 278 of the OBCA;

“DOT” means the Nevada Department of Taxation;

“Effective Date” means the date within five business days of the date upon which all of the conditions to completion of the Amalgamation as set forth in the Business Combination Agreement have been satisfied or waived and all documents agreed to be delivered have been delivered to the satisfaction of the Issuer and GGB, acting reasonably, which will be the date shown on the certificate of Amalgamation issued by the Director giving effect to the Amalgamation, or such earlier or later date as the Issuer and GGB may mutually agree in writing;

“EO6” means Executive Order No. 6 issued by New Jersey Governor Phil Murphy on January 23, 2018;

“Escrow Agreement” has the meaning ascribed to that term under Section 10—Escrowed Securities;

“Exchange Act” means the Securities Exchange Act of 1934;

“FDA” means the United States Food and Drug Administration;

“Financial Advisory Agreements” means the financial advisory agreements dated September 20, 2018 between GGB and each of All Js Greenspace LLC, Chiron Ventures Inc. and Hybrid Financial Ltd.;

“FinCEN Memorandum” means the memorandum issued by the Financial Crimes Enforcement Network of the Treasury Department in February 2014;

 

- 7 -


“Form 51-102F6V” means National Instrument Form 51-102F6V—Statement of Executive Compensation – Venture Issuers;

“Forward-Looking Information” has the meaning ascribed to that term under “Cautionary Note Regarding Forward-Looking Statements”;

“GAAP” means generally accepted accounting principles as set out in the Canadian Institute of Chartered Accountants Handbook – Accounting for an entity that prepares its financial statements in accordance with IFRS, at the relevant time, applied on a consistent basis;

“GGB” means Green Growth Brands Ltd.;

“GGB Beauty” means GGB Beauty LLC;

“GGB Common Shares” means the common shares in the capital of GGB;

“GGB Common Warrants” means the GGB Common Share purchase warrants;

“GGB Convertible Debentures” means the 12.00% unsecured convertible debentures of the Corporation with a maturity date of March 1, 2019 issued pursuant to the terms of the GGB Convertible Debenture Indenture;

“GGB Convertible Debenture Indenture” means the debenture indenture dated August 30, 2018 between GGB and CTA;

“GGB Greenspace Debentures” means the 12.00% unsecured convertible debentures of GGB issued to All Js Greenspace LLC;

“GGB Greenspace Units” means the units of GGB comprised of one (1) GGB Proportionate Share and one-half (1/2) one GGB Proportionate Warrant;

“GGB Licenses” means GGB Licenses LLC;

“GGB LLC” means Green Growth Brands LLC;

“GGB NEOs” has the meaning ascribed to that term under Section 14—Executive Compensation – GGB Executive Compensation;

“GGB Nevada” means GGB Nevada LLC;

“GGB New Jersey” means GGB New Jersey LLC;

“GGB Pahrump” means GGB Nevada Pahrump LLC;

“GGB Proportionate Shares” means the proportionate voting shares in the capital of GGB;

“GGB Proportionate Warrants” means the GGB Proportionate Share purchase warrants or the GGB Common Warrants, as applicable, pursuant to the terms of the warrant;

“GGB Shareholders” means the holders of GGB Shares;

 

- 8 -


GGB Shareholders Agreement” means the shareholders agreement dated April 10, 2018 among Chiron Ventures Inc., Cambridge Capital Ltd., and All JS Greenspace LLC as shareholders; Adam Arviv, Yoel Altman and JS Greenspace LLC as principals; and GGB;

GGB Shares” means, collectively, the GGB Common Shares and the GGB Proportionate Shares;

GGB Warrants” means, collectively, the GGB Common Warrants and the GGB Proportionate Warrants;

GMS” means Green Mile Solutions LLC;

GMP” means Good Manufacturing Practice;

HOR” means Henderson Organic Remedies LLC;

HOR Licensing Agreement” means the intellectual property licensing agreement between NOR and HOR dated September 4, 2018;

IFRS” means International Financial Reporting Standards;

Investor Rights Agreement” means the investor rights agreement to be entered into between GGB, Xanthic and All Js Greenspace LLC;

Issuer” or “Xanthic” means Xanthic Biopharma Inc., a corporation formed under the OBCA;

Issuer Board” means the board of directors of the Issuer;

Issuer Common Shares” means the common shares in the capital of the Issuer;

Issuer Common Warrants” means the Issuer Common Share purchase warrants;

Issuer Equity Incentive Plan” means the equity incentive plan of the Issuer;

Issuer Options” means options to acquire Issuer Shares pursuant to the Issuer Equity Incentive Plan;

Issuer Proportionate Shares” means the proportionate voting shares in the capital of the Issuer;

Issuer Proportionate Warrants” means the Issuer Proportionate Share purchase warrants or Issuer Common Warrants, as applicable, pursuant to the terms of the warrant;

Issuer Shares” means, collectively, the Issuer Common Shares and the Issuer Proportionate Shares;

Issuer Shareholders” mean the holders of Issuer Shares;

Issuer Units” means the units of the Issuer, with each Issuer Unit comprised of one (1) Issuer Common Share and one-half (12) of one Issuer Common Warrant;

Issuer Warrants” means, collectively, the Issuer Common Warrants and the Issuer Proportionate Warrants;

IT” means information technology;

 

- 9 -


Leahy Amendment” means the omnibus appropriations bill, SJ 1662 passed by United States Congress;

Lease” means the lease agreement dated as of July 10, 2018, as amended, between GGB and Schottenstein Property Group;

Listing Statement” means this listing statement of the Issuer including the schedules hereto;

Loan” means the loan of US$30,347,500 from GGB to the Issuer as evidenced by the Loan Agreement;

Loan Agreement” means the loan agreement dated August 30, 2018 between the Issuer and GGB pursuant to which GGB loaned US$30,347,500 to the Issuer to complete the NOR Acquisition;

Market Price” means the volume weighted average closing price of the Issuer Common Shares for the five days immediately preceding the date of grant;

MD&A” means management’s discussion and analysis;

Meeting” means the meeting of the Issuer Shareholders scheduled to take place on November 2, 2018;

MMP” means Medicinal Marijuana Program;

MMPR means the Marijuana for Medical Purposes Regulations;

NDS” means Nevada Dispensary Association;

NP 46-201” means National Policy 46-201Escrow for Initial Public Offerings;

NI 52-110” means National Instrument 52-110Audit Committees;

NJ DOH” means the New Jersey Department of Health;

NJCUMMA” means the New Jersey Compassionate Use Medical Marijuana Act;

Nomination Rights Agreement” means the nomination rights agreement dated August 30, 2018 between GGB, Xanthic, All Js Greenspace LLC, Chiron Ventures Inc. and WMB Resources LLC;

NOR” means Nevada Organic Remedies LLC, a company incorporated under the laws of Nevada;

NOR Acquisition” means the acquisition by GGB Nevada of substantially all of the issued and outstanding membership interests of NOR, pursuant to the NOR Agreement;

NOR Agreement” means the membership interest purchase agreement dated July 13, 2018 between NOR, as the company, the sellers set forth therein, as sellers, Andrew M. Jolley, as the representative of each seller, the Issuer, as parent, and GGB Nevada, as purchaser;

NOR Closing Payment” means the initial cash payment of US$30,347,500 made by GGB Nevada on closing of the NOR Acquisition;

NOR Deposit” means the US$2 million deposit payment made by GGB Nevada in connection with the NOR Acquisition;

NOR Members” means the members of NOR prior to the NOR Acquisition;

 

- 10 -


OBCA” means the Business Corporations Act (Ontario);

OTC” means over-the-counter;

Outside Date” means the deadline to complete the Business Combination, being December 1, 2018 unless the Issuer and GGB agree otherwise;

Participation Agreement” means the agreement dated August 30, 2018 between GGB and WMB Resources LLC;

person” means a Company or individual;

Plan Administrator” means the plan administrator of the Issuer Equity Incentive Plan;

Rampart Mercantile” means Rampart Mercantile Inc.;

Rampart Mines” means Rampart Mines Limited;

Rampart Resources” means Rampart Resources Limited;

Resulting Issuer” means the Issuer upon completion of the Business Combination;

Resulting Issuer Board” means the board of directors of the Resulting Issuer;

Resulting Issuer Common Shares” means the common shares in the capital of the Resulting Issuer;

Resulting Issuer Common Warrants” means the Resulting Issuer Common Share purchase warrants;

Resulting Issuer Equity Incentive Plan” means the equity incentive plan of the Resulting Issuer;

Resulting Issuer Options” means options to acquire Resulting Issuer Shares pursuant to the Resulting Issuer Equity Incentive Plan;

Resulting Issuer Proportionate Shares” means the proportionate voting shares in the capital of the Resulting Issuer;

Resulting Issuer Proportionate Warrants” means the Resulting Issuer Proportionate Share purchase warrants;

Resulting Issuer Shareholders” means the holders of Resulting Issuer Shares;

Resulting Issuer Shares” means, collectively, the Resulting Issuer Common Shares and Resulting Issuer Proportionate Shares;

Resulting Issuer Warrants” means, collectively, the Resulting Issuer Common Warrants and Resulting Issuer Proportionate Warrants;

Rohrabacher-Blumenauer Amendment” means the Rohrabacher Amendment Title: H.R.2578 — Commerce, Justice, Science, and Related Agencies Appropriations Act, 2016;

SEDAR” means System for Electronic Document Analysis and Retrieval;

 

- 11 -


Sessions Memorandum” means the United States Department of Justice Memorandum issued by Attorney General James Jeff Sessions on January 4, 2018 that rescinded the Cole Memorandum;

Staff Notice 51-352” means the Canadian Securities Administrators Staff Notice 51-352 (Revised) – Issuers with U.S. Marijuana-Related Activities;

Subco” means 2657013 Ontario Inc.;

Subco Shares” means the common shares in the capital of Subco;

THC” means tetrahydrocannabinol;

TMX MOU” means the memorandum of understanding among TMX Group, Aequitas NEO Exchange Inc., the CSE, the TSX and the TSX Venture Exchange;

Trans-Rampart” means Trans-Rampart Industries Ltd.;

TSX” means Toronto Stock Exchange;

Xanthic Beverages” means Xanthic Beverages USA, LLC; and

Xanthic Beverages Agreement” means the licensing and strategic partnership agreement dated March 22, 2018 between Xanthic and Xanthic Beverages.

 

- 12 -


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements contained in this listing statement (the “Listing Statement”) that are not historical facts are “forward-looking statements” or “forward-looking information” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation.

Forward-Looking Information includes, but is not limited to, statements relating to the timing, availability and amount of financings; expected use of proceeds; business objectives; results of operations; results of license applications; potential investments; the timing and costs of developing the Resulting Issuer’s products; success of the Resulting Issuer’s products and investments; requirements for additional capital; industry demand and developments in applicable legislation. In certain cases, Forward-Looking Information can be identified by the use of words such as “plans”, “expects”, or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intended”, “anticipates”, or “does not anticipate”, or “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”, or “be achieved”.

In providing the Forward-Looking Information in this Listing Statement, the Issuer and GGB have applied several material assumptions, including, but not limited to, the assumption that additional financings needed will be available on reasonable terms, that the objectives concerning its products and investments can be achieved, that general business, economic or regulatory conditions will not change in a materially adverse manner, and that all necessary governmental approvals for its current and future products will be obtained in a timely manner and on acceptable terms. Other assumptions are discussed throughout this Listing Statement and, in particular, in the “Risk Factors” found in this Listing Statement.

Forward-Looking Information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Resulting Issuer to be materially different from any future results, performance or achievements expressed or implied by the Forward-Looking Information. Such risks and other factors include, among others, risks set out below as well as those factors discussed in the “Risk Factors” found in this Listing Statement:

Although the Issuer and GGB have attempted to identify important factors that could affect the Resulting Issuer and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information.

The Forward Looking Information contained in this Listing Statement is current as of the date hereof and, unless so required by applicable law, the Issuer, GGB and the Resulting Issuer undertake no obligation to update publicly or revise any Forward Looking Information, whether as a result of new information future events or otherwise. The Forward Looking Information contained in this Listing Statement is expressly qualified by this cautionary statement.

 

- 13 -


NOTICE REGARDING INFORMATION

The information contained in this Listing Statement concerning GGB, including with respect to its directors, officers and affiliates, is based solely upon information provided to the Issuer by GGB or upon publicly available information. With respect to this information, the Issuer has relied exclusively upon GGB (which has reviewed the relevant parts of this Listing Statement), without independent verification by the Issuer.

The information contained in this Listing Statement concerning NOR is based solely upon information provided to the Issuer by NOR or upon publicly available information. With respect to this information, GGB and the Issuer have relied exclusively upon NOR (which has reviewed the relevant parts of this Listing Statement), without independent verification by GGB or the Issuer.

The information contained in this Listing Statement concerning the Issuer, including with respect to its directors, officers and affiliates, is based solely upon information provided by the Issuer or upon publicly available information. With respect to this information, GGB has relied exclusively upon the Issuer (which has reviewed the relevant parts of this Circular), without independent verification by GGB.

Information in this Listing Statement is given as at October 1, 2018 unless otherwise indicated and except for information contained in the documents incorporated herein by reference, which is given as at the respective dates stated therein. Financial amounts are expressed in Canadian dollars (C$) unless otherwise noted.

No person is authorized to give any information or make any representation not contained or incorporated by reference in this Listing Statement and, if given or made, such information or representation should not be relied upon as having been authorized. This Listing Statement does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities, or the solicitation of a proxy, by any person in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an offer or solicitation of an offer or proxy solicitation. Neither delivery of this Listing Statement nor any distribution of the securities referred to in this Listing Statement will, under any circumstances, create an implication that there has been no change in the information set forth herein since the date of this Listing Statement.

Any market data or industry forecasts used in this Listing Statement, unless otherwise specified, were obtained from publicly available sources. Although the Issuer and GGB believe these sources to be generally reliable, the accuracy and completeness of such information are not guaranteed and have not been independently verified.

Statistical information included in this Listing Statement and other data relating to the industry in which the Resulting Issuer intends to operate is derived from recognized industry reports published by industry analysts, industry associations and independent consulting and data compilation organizations.

 

- 14 -


1.

CORPORATE STRUCTURE

 

1.1

Corporate Name and Office

This Listing Statement has been prepared in connection with the Business Combination and proposed listing on the CSE of the common shares (the “Resulting Issuer Common Shares”) in the capital of Xanthic Biopharma Inc. (the “Resulting Issuer”).

The current registered office of Xanthic Biopharma Inc. (the “Issuer” or “Xanthic”) is 77 King St. W., Suite 2905, Toronto, ON M5K 1A2.

Upon completion of the Business Combination, the registered and head office of the Resulting Issuer will be 77 King St. W., Suite 2905, Toronto, ON M5K 1A2.

 

1.2

Jurisdiction of Incorporation

The Issuer was formed pursuant to a reverse takeover involving a publicly held British Columbia corporation, Aurquest Resources Inc. (“Aurquest”),1 and a privately held Ontario corporation, Xanthic Biopharma Limited, which was completed on December 15, 2017. On February 16, 2018, the Issuer completed a consolidation of the Issuer Common Shares on the basis of one post-consolidation Issuer Common Share for eight pre-consolidation Issuer Common Shares.

The Issuer has 11 wholly-owned subsidiaries:

 

   

Nevada Organic Remedies LLC (“NOR”), which was incorporated in Nevada on April 16, 2014;

 

   

Xanthic Biopharma Limited, which was incorporated under the Business Corporations Act (Ontario) (the “OBCA”) on March 15, 2017;

 

   

Xanthic Colorado LLC, which was incorporated in the state of Nevada on September 18, 2017;

 

   

Xanthic Biopharma Oregon LLC, which was incorporated in the state of Oregon on January 3, 2018;

 

   

Xanthic Biopharma US Hold Co., which was incorporated in the state of Nevada on March 13, 2018;

 

   

Xanthic Biopharma Nevada LLC, which was incorporated in Nevada on June 26, 2018;

 

   

Xanthic Biopharma California LLC, which was incorporated in California on June 27, 2018;

 

   

GGB Nevada LLC (“GGB Nevada”), which was incorporated in the state of Nevada on July 6, 2018;

 

   

GGB Nevada Pahrump LLC (“GGB Pahrump”), which was incorporated in the state of Nevada on August 13, 2018;

 

   

GGB New Jersey LLC (“GGB New Jersey”), which was incorporated in the state of New Jersey on August 17, 2018; and

 

1 

Aurquest Resources Inc. was formed pursuant to a Memorandum of Association, dated November 18, 1968, under the Business Corporations Act (British Columbia) under the name “Rampart Mines Limited” (“Rampart Mines”). On May 28, 1984, Rampart Mines changed its name to “Rampart Resources Limited” (“Rampart Resources”). On July 23, 1987, Rampart Resources changed its name to “Trans-Rampart Industries Ltd.” (“Trans-Rampart”). On May 3, 1993, Trans-Rampart changed its name to “Rampart Mercantile Inc.” (“Rampart Mercantile”) On October 6, 1999, Rampart Mercantile amended its Memorandum of Association, consolidating its outstanding capital on the basis of one (1) post-consolidated common share for each ten (10) pre-consolidated common shares and increasing its outstanding capital to 100,000,000 common shares. On November 24, 1999, Rampart Mercantile continued out of the province of British Columbia into the province of Ontario, increased its capital to an unlimited number of common shares and an unlimited number of first preferred shares, and adopted new by-laws. On November 1, 2000, Rampart Mercantile amalgamated with North American Store Finance Ltd. Finally, on April 14, 2011, Rampart Mercantile changed its name to Aurquest Resources Inc.

 

- 15 -


   

2657013 Ontario Inc. (“Subco”) which was incorporated under the OBCA on September 25, 2018.

Green Growth Brands Ltd (“GGB”) was incorporated under the OBCA on February 14, 2018 and has the following wholly-owned subsidiaries:

 

   

Green Growth Brands LLC (“GGB LLC”), which was incorporated in the state of Delaware on February 14, 2018;

 

   

GGB Licenses LLC (“GGB Licenses”), which was incorporated in the state of Delaware on July 25, 2018;

 

   

GGB Beauty LLC (“GGB Beauty”), which was incorporated in Delaware on July 25. 2018; and

 

   

GGB Nevada Land LLC, which was incorporated in the state of Nevada on August 13, 2018.

 

1.3

Intercorporate Relationships

Prior to the completion of the Business Combination, the corporate structure of the Issuer was as follows:

 

LOGO

 

- 16 -


Following the completion of the Business Combination, the corporate structure of the Resulting Issuer will be as follows:

 

LOGO

 

1.4

Fundamental Change

The Issuer, Subco and GGB will complete the Business Combination. Upon completion of the amalgamation of Subco and GGB (the “Amalgamation”), the Issuer will become the Resulting Issuer and have a direct wholly-owned subsidiary, being the resulting entity from the Amalgamation (“Amalco”), along with 15 other wholly-owned subsidiaries (as shown in the corporate structure diagram in Section 1.3Intercorporate Relationships above). In conjunction with the Business Combination, the Resulting Issuer will reorganize its share structure and consolidate all of the issued and outstanding shares (the “Resulting Issuer Shares”) on the basis of four (4) pre-consolidation Resulting Issuer Shares for one (1) post-consolidation Resulting Issuer Share (the “Consolidation”).

 

1.5

Non-Corporate Issuers and Issuers Incorporated Outside of Canada

Not applicable.

 

2.

GENERAL DEVELOPMENT OF THE BUSINESS

 

2.1

General Development of the Business of the Issuer Prior to the Business Combination

The Issuer Common Shares are currently listed for trading on the CSE under the trading symbol “xTHC”. The Issuer’s head and principal office is located at 77 King St. W., Suite 2905, Toronto, ON M5K 1A2.

On December 15, 2017, the Issuer was formed pursuant to a reverse takeover involving Aurquest and a privately held Ontario corporation, Xanthic Biopharma Limited. The Issuer was founded with the objective of becoming a leader in developing innovative, non-combustible alternative delivery methods for cannabis-infused products.

 

- 17 -


On January 16, 2018, the Issuer completed a non-brokered private placement of 96,000,000 Issuer Common Shares for gross proceeds of C$1,500,000.

On February 16, 2018, the Issuer consolidated the Issuer Common Shares on basis of one (1) post-consolidation Issuer Common Share for every eight (8) pre-consolidation Issuer Common Shares, resulting in a total of 55,710,547 Issuer Common Shares outstanding at the time of the consolidation. Concurrently, the Issuer changed its name from Aurquest Resources Inc. to Xanthic Biopharma Inc.

On March 22, 2018, the Issuer entered into a licensing and strategic partnership agreement (the “Xanthic Beverages Agreement”) with Xanthic Beverages USA, LLC (formerly Avitas CBD Water, LLC) (“Xanthic Beverages”), a company based in Portland, Oregon. Pursuant to the Xanthic Beverages Agreement, Xanthic Beverages agreed to produce CBD-infused water for distribution to over 500 retail locations, including grocery retailers and convenience stores, across Eastern Washington and Northeast Oregon. The Issuer also acquired a 45% ownership position in Xanthic Beverages in exchange for a cash payment of US$600,000 and the issuance of up to 600,000 Issuer Common Shares, with an aggregate value of US$300,000 at US$0.50 per Issuer Common Share, subject to certain performance milestones over the 12 months following the closing of the Xanthic Beverages Agreement.

On April 19, 2018, the Issuer Common Shares commenced trading on the CSE under the symbol “xTHC”. Concurrently, the Issuer completed a non-brokered private placement of 1,112,000 units (“Issuer Units”) at a price of $0.50 per Issuer Unit to raise aggregate gross proceeds of $556,000. Each Issuer Unit is comprised of one Issuer Common Share and one-half of one Issuer Common Warrant. Each Issuer Common Warrant entitles the holder thereof to purchase one Issuer Common Share at an exercise price of $0.75 per Issuer Common Share until April 19, 2020. In connection with the private placement, the Issuer paid an aggregate finder’s fee of C$18,000 and an aggregate of 24,000 compensation options.

On April 20, 2018, the Issuer signed a binding letter of intent with Green Mile Solutions LLC (“GMS”) to develop plans to manufacture and distribute Xanthic-branded cannabis-infused products in the states of Oregon, Nevada and Ohio. GMS facilitates the manufacturing of cannabis-infused powders in licensed facilities using the proprietary Xanthic process to create water soluble THC and CBD. GMS procures sales of the finished products into the local licensed dispensary networks through existing sales and distribution channels.

On May 7, 2018, the Issuer signed a binding letter of intent with Nutritional High International Inc. for the production and distribution of Xanthic-branded, water-soluble cannabis-infused powders in the state of California.

On June 11, 2018, the Issuer signed a letter of intent with ABH Pharma Inc. (“ABH”), a leading FDA-registered and GMP-certified manufacturer of in-house branded and private label dietary supplements in the United States. Through its partnership with the Issuer, ABH was to offer “Xanthic Powered” CBD-infused products to customers across its broad range of dietary supplements, which would be sold by various brick-and-mortar retailers and e-commerce websites. On July 3, 2018, the Issuer terminated its letter of intent with ABH due to the parties’ inability to reach agreement on key business terms.

On June 26, 2018, Dr. Gunther Hintz resigned from the Issuer Board.

On July 13, 2018, GGB Nevada entered into a membership interest purchase agreement (the “NOR Agreement”) with inter alios, Andrew Jolley and Stephen Byrne (together, the “NOR Sellers”), pursuant to which GGB Nevada, a wholly-owned subsidiary of Xanthic, acquired 95% of the issued and outstanding membership interests of NOR and the obligation to acquire the remaining 5% of the issued and outstanding membership interests of NOR (the “NOR Acquisition”) for a total purchase price of

 

- 18 -


US$56,750,000, plus all accrued interest pursuant to a secured promissory note for US$21,565,000 as payment of deferred purchase price consideration. The NOR Acquisition was completed on September 4, 2018. For the current fiscal year, the NOR Acquisition will be immediately accretive to Resulting Issuer’s net income. See Section 2.3 – The NOR Acquisition and the Business Combination for more information.

On July 13, 2018, the Issuer and GGB entered into a business combination agreement (the “Business Combination Agreement”), the terms of which are more fully described in Section 2.3 – The NOR Acquisition and the Business Combination.

On July 13, 2018, in connection with the Business Combination, the Issuer Board was reconstituted to include existing Issuer Board members Carli Posner as Chair, Tim Moore, Igor “Gary” Galitsky and new GGB nominees Jean Schottenstein, Peter Horvath, Steve Stoute and Marc Lehmann, subject to CSE approval.

On September 4, 2018, NOR, as an indirect subsidiary of the Issuer, entered into an intellectual property license agreement (the “HOR Licensing Agreement”) with Henderson Organic Remedies LLC (“HOR”), whereby NOR licensed certain of its intellectual property to HOR, allowing it to operate a retail marijuana store using “The Source” intangible property.

On September 17, 2018, NOR submitted an application for eight additional retail marijuana store facilities in Nevada. The Resulting Issuer anticipates that its Nevada operations will drive profitability in the near and long term. If NOR is successful in obtaining all eight of its license applications, it will operate nearly 30,000 square feet of medical and retail marijuana space.

In connection with the Business Combination, the Issuer will, subject to Issuer Shareholder approval, amend its articles in order to authorize the issuance of an unlimited number of proportionate voting shares (the “Issuer Proportionate Shares”) in the capital of the Issuer.

 

2.2

General Development of the Business of GGB Prior to the Business Combination

 

2.2.1

Background

GGB is a private company incorporated on February 14, 2018 under the laws of the Province of Ontario under the name “Schottenstein Arviv Group Inc.”. The head office of GGB is located at 4300 East Fifth Avenue, Columbus, Ohio 43219. The registered office of GGB is located at 199 Bay Street, Suite 5300, Commerce Court West, Toronto, Ontario M5L 1B9. GGB issued two GGB Common Shares on incorporation at a price of C$0.10 per GGB Common Share.

On July 12, 2018, GGB changed its name to “Green Growth Brands Ltd.”.

GGB LLC, a Delaware limited liability company, was formed on February 16, 2018 as “Schottenstein Arviv Group US LLC,” a wholly owned subsidiary of GGB. The entity changed its name to “Green Growth Brands LLC” on July 13, 2018. GGB LLC provides general and administrative support functions to GGB, including management support with significant and diverse retail experience. GGB LLC intends to leverage this vast management experience to create a new, unrivaled experience in the cannabis market for the cannabis retail segment and the CBD products segment utilizing brick-and-mortar as well as e-commerce retail options.

GGB Beauty, a Delaware limited liability company, was formed on July 25, 2018 as a wholly owned subsidiary of GGB LLC. GGB Beauty has developed and will market CBD-infused consumer products, including body care, face care, ingestible items, and other similar products focusing on health and

 

- 19 -


wellness benefits of CBD. GGB intends to distribute these items under several different brand names that it has developed for this purpose, as more fully described in Section 3.2.11 – Intangible Properties. Each of these marks is currently under review with the both the United States Patent and Trademark Office and the Canadian Intellectual Property Office pending final approval.

GGB Licenses, a Delaware limited liability company, was formed on July 25, 2018 as a wholly owned subsidiary of GGB LLC. GGB Licenses has applied for all trademarks currently used by GGB in its business. See Section 3.2.11 – Intangible Properties for a description of each of the trademarks.

GGB Nevada Land LLC, a Nevada limited liability company, was formed on August 13, 2018 as a wholly owned subsidiary of GGB LLC.

 

2.2.2

Development of the Business of GGB

On April 10, 2018, GGB issued an additional 92,000,000 GGB Common Shares at a price of C$0.10 per GGB Common Share for aggregate consideration C$9,200,000.

On April 10, 2018, a GGB also entered into advisory services fee agreements (the “Advisory Agreements”) with each of Chiron Ventures Inc. and All Js Greenspace LLC providing for the payment by GGB of 2,250,000 GGB Common Shares to each of Chiron Ventures Inc. and All Js Greenspace LLC in consideration for the provision and performance of certain advisory services.

On April 10, 2018, GGB also entered into a shareholders agreement (the “GGB Shareholders Agreement”) with Chiron Ventures Inc., Cambridge Capital Ltd., and All Js Greenspace LLC as shareholders; and Adam Arviv, Yoel Altman and JS Greenspace LLC as principals. The GGB Shareholders Agreement will terminate automatically upon completion of the Business Combination.

On July 16, 2018, GGB issued an additional 6,340,000 GGB Common Shares at a price of C$0.10 per GGB Common Share for aggregate consideration of C$634,000. GGB also issued 2,425,000 GGB Common Shares pursuant to restricted stock grants at a price of C$0.10 per GGB Common Share for aggregate consideration of C$242,500.

On August 30, 2018, GGB raised gross proceeds of C$63,998,000 from the first tranche of the concurrent brokered and non-brokered private placements (the “Debenture Financing”) of 12.00% unsecured convertible debentures of GGB (the “GGB Convertible Debentures”). Issue costs of the first tranche of the Debenture Financing included legal and other expenses of $660,200 The GGB Convertible Debentures were issued pursuant to the terms of a convertible debenture indenture (the “GGB Convertible Debenture Indenture”) dated August 30, 2018 between GGB and Capital Transfer Agency ULC (“CTA”). Each GGB Convertible Debenture is exchangeable for one unit of GGB (the “GGB Units”), with each GGB Unit being comprised of one (1) GGB Common Share and one-half (1/2) of one GGB Common Share purchase warrant (the “GGB Common Warrants”). Upon completion of the Business Combination, the GGB Common Shares will be exchanged for Resulting Issuer Common Shares and the GGB Common Warrants will be exchanged for Resulting Issuer Common Share purchase warrants (the “Resulting Issuer Common Warrants”) pursuant to the terms of the Business Combination Agreement. In connection with the Debenture Financing, GGB also entered into a warrant indenture (the “GGB Warrant Indenture”) with CTA, which sets out the terms of the GGB Common Warrants.

On August 30, 2018, GGB also entered into an agency agreement (the “Agency Agreement”) with Canaccord Genuity Corp. (“Canaccord”), as sole agent, in connection with to the brokered portion of the Debenture Financing. Commissions of C$97,300 in cash and C$2,738,000 in GGB Convertible

 

- 20 -


Debentures were paid to Canaccord pursuant to the Agency Agreement in connection with the first tranche of the Debenture Financing. GGB also paid to Haywood Securities Inc. (“Haywood”) a finder’s fee of C$33,460 in connection with the non-brokered portion of the first tranche of the Debenture Financing.

On August 30, 2018, GGB also entered into an agreement (the “Participation Agreement”) with WMB Resources LLC in connection with the Debenture Financing. A participation fee of C$378,000 in GGB Convertible Debentures was paid to WMB Resources LLC and certain of its affiliates pursuant to the Participation Agreement.

On August 30, 2018, GGB also entered into a nomination rights agreement (the “Nomination Rights Agreement”) with All Js Greenspace LLC, Chiron Ventures Inc., WMB Resources LLC and Xanthic Biopharma Inc. setting out certain director nomination rights of All JS Greenspace LLC, Chiron Ventures Inc., and WMB Resources LLC.

On August 31, 2018, pursuant to a Request for Applications issued by the New Jersey Department of Health, GGB New Jersey submitted a proposal to operate a single, fully integrated cannabis facility in New Jersey.

On September 5, 2018, GGB advanced US$30,347,500 of the net proceeds from the Debenture Financing to Xanthic pursuant to the terms of the Loan Agreement. The proceeds of the loan were subsequently advanced by Xanthic to GGB Nevada, which in turn used the proceeds to make the initial cash payment required pursuant to the NOR Agreement in order to close the NOR Acquisition. The Loan Agreement matures on March 4, 2019, bears interest at 12% per annum, and has been secured by a pledge over the shares of GGB Nevada. The Loan Agreement contains no prepayment privilege and includes customary events of default, which include the failure to complete the Business Combination prior to the maturity date of the Loan Agreement. As security for the amounts advanced pursuant to the Loan Agreement, GGB has been granted an irrevocable option from Xanthic to elect to satisfy Xanthic’s obligations under the Loan Agreement by acquiring GGB Nevada from Xanthic and assuming Xanthic and GGB Nevada’s obligations thereunder. The balance of US$2,837,500 owing to the NOR Members will be satisfied by the issuance of Resulting Issuer Common Shares following completion of the Business Combination.

On September 20, 2018, GGB entered into financial advisory consulting agreements (the “Financial Advisory Agreements”) with each of All Js Greenspace LLC, Chiron Ventures Inc. and Hybrid Financial Ltd., whereby GGB retained the consulting services of each of All Js Greenspace LLC, Chiron Ventures Inc. and Hybrid Financial Ltd. in exchange for the issue of an aggregate of C$3,260,000 in the form of GGB Convertible Debentures.

On September 20, 2018, GGB raised additional gross proceeds of C$22,129,000 pursuant to the second tranche of the Debenture Financing. Issue costs of the second tranche of the Debenture Financing included legal and other expenses of $11,650. Commissions of C$71,400 in cash and C$795,000 in GGB Convertible Debentures were paid to Canaccord pursuant to the Agency Agreement in connection with the second tranche of the Debenture Financing. GGB also paid to Haywood a finder’s fee of C$76,860 in connection with the non-brokered portion of the second tranche of the Debenture Financing.

In October 2018, GGB raised additional gross proceeds of approximately C$30,500,000 pursuant to a private placement of GGB Common Shares at a price of C$0.50 per GGB Common Share (C$2.00 on a post-Consolidation basis). GGB also issued GGB Common Warrants exercisable for an aggregate principal amount of approximately C$24,500,000 GGB Common Shares upon payment of C$0.50 per GGB Common Share (C$2.00 on a post-Consolidation basis). The GGB Common Warrants expire one day before the Closing Date with proceeds due no more than 30 days following the exercise date.

 

- 21 -


GGB also plans to enter into an investor rights agreement (the “Investor Rights Agreement”) with Xanthic and All Js Greenspace LLC, which will set out the registration rights and indemnification rights owed to All Js Greenspace.

Prior to Closing, GGB also intends to purchase from All Js Greenspace LLC all of its outstanding GGB Convertible Debentures. GGB will then issue to All Js Greenspace LLC C$27,500,000 aggregate principal amount of 12.00% unsecured convertible debentures of GGB (the “GGB Greenspace Debentures”). On the Closing Date, each GGB Greenspace Debenture will be converted into units of GGB (the “GGB Greenspace Units”), each GGB Greenspace Debenture being comprised of one (1) proportionate voting share in the capital of GGB (the “GGB Proportionate Shares”) and one-half (1/2) of one GGB Proportionate Share purchase warrant (the “GGB Proportionate Warrants”). The terms of the GGB Greenspace Debentures and GGB Proportionate Warrants will be set out in the certificates evidencing such securities.

In connection with the issuance of the GGB Greenspace Debentures and subject to GGB Shareholder approval, GGB intends to amend its articles of incorporation in order to authorize an unlimited number GGB Proportionate Shares for issuance. The Issuer and GGB also plan to amend the Business Combination Agreement and Amalgamation Agreement in order to, among other things, contemplate the exchange of GGB Proportionate Shares and GGB Proportionate Warrants for proportionate voting shares (the “Resulting Issuer Proportionate Shares”) in the capital of the Resulting Issuer and Resulting Issuer Proportionate purchase warrants (the “Resulting Issuer Proportionate Warrants”), respectively.

 

2.3

The NOR Acquisition and the Business Combination

 

2.3.1

Overview

In June 2018, representatives of Xanthic and GGB discussed at arm’s length the merits of a potential business combination. On July 13, 2018, GGB Nevada entered into the NOR Agreement with NOR and the NOR Members, which provided for the acquisition by GGB Nevada of substantially all of the outstanding membership interests of NOR, a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada, for aggregate consideration of US$56.75 million., which has been filed by the Issuer with the Canadian securities regulatory authorities and is available at www.sedar.com. Immediately following the execution of the NOR Agreement, the Issuer and GGB entered into the Business Combination Agreement.

To complete the NOR Acquisition, which occurred on September 4, 2018, GGB Nevada was required to deliver into escrow a US$2 million deposit (the “NOR Deposit”) upon the execution of the NOR Agreement and an initial cash payment of US$30 million (the “NOR Closing Payment”) on closing of the NOR Acquisition. To satisfy the NOR Deposit, the Issuer issued a promissory note in favour of GGB in the principal amount of US$2 million (the “Deposit Promissory Note”). To satisfy the NOR Closing Payment, the Issuer and GGB entered into a loan agreement (the “Loan Agreement”) pursuant to which GGB loaned US$30,347,500 to the Issuer (the “Loan”). The proceeds of the Loan were sourced from the Debenture Financing. In addition, on closing of the NOR Acquisition, GGB Nevada was required to deliver to the NOR Members a secured promissory note in the principal amount of US$21,565,000 and will be required to deliver cash or an equivalent number of share consideration in Resulting Issuer Common Shares in the amount US$2,837,500 to fulfill its payment obligations under the NOR Agreement.

Upon the completion of the Business Combination in accordance with the terms of the Business Combination Agreement, the Resulting Issuer will carry on the business of NOR, while retaining certain aspects of the Issuer’s current business. The CSE has conditionally accepted the Business Combination

 

- 22 -


subject to the Issuer fulfilling all of the requirements of the CSE. See Section 3.2 - General Business of the Resulting Issuer for more details.

The proposed Business Combination constitutes a significant acquisition for the Issuer. Under the Business Combination Agreement, a copy of which is attached hereto as Schedule “F” and is also available at www.sedar.com, the Issuer has agreed to combine its business with GGB by way of a three-cornered amalgamation of Subco and GGB, with Amalco becoming a wholly-owned subsidiary of the Resulting Issuer on Closing and the former GGB Shareholders becoming Resulting Issuer Shareholders. The Business Combination will constitute a reverse takeover under applicable securities legislation. The deadline to complete the Business Combination is December 1, 2018 (the “Outside Date”), unless the parties otherwise agree. Either the Issuer or GGB may terminate the Business Combination Agreement if the Business Combination has not been completed by the Outside Date subject to certain conditions or earlier in certain other circumstances.

 

2.3.2

Mechanics of the Business Combination

Subject to the receipt of all regulatory approvals, including the approval of the Issuer Shareholders to certain items of special business and the CSE, all of the issued and outstanding GGB Shares are to be acquired by the Issuer, and as consideration, the Issuer will issue to the GGB Shareholders, on a 3.394-for-one basis, 346,150,835 Issuer Shares in exchange for the then issued and outstanding GGB Shares (which for greater certainty excludes the GGB Shares and GGB Warrants issued in connection with the conversion of the GGB Convertible Debentures and GGB Greenspace Debentures). The shares of Subco (the “Subco Shares”) will be cancelled and replaced by shares of Amalco (the “Amalco Shares”) on the basis of one Amalco Share for each Subco Share. As consideration for the issuance of the Issuer Shares to GGB Shareholders to effect the Business Combination, Amalco will issue to its immediate shareholder, the Issuer, one Amalco Share for each Issuer Share so issued. Amalco will be a direct wholly-owned subsidiary of the Issuer upon the completion of the Business Combination.

In addition, the Resulting Issuer will reorganize its share structure and consolidate all of the issued and outstanding Resulting Issuer Shares on the basis of four (4) pre-Consolidation Resulting Issuer Shares for one (1) post-Consolidation Resulting Issuer Share.

Following the completion of the Business Combination, current GGB Shareholders will hold approximately 86,537,687 Resulting Issuer Shares (excluding any Resulting Issuer Shares and Resulting Issuer Warrants ultimately issuable upon conversion of the GGB Convertible Debentures and GGB Greenspace Debentures), representing 85.7% of the Resulting Issuer Shares issued and outstanding on a non-diluted basis. A deemed value of C$0.36 per share has been placed on the Issuer Shares issued in connection with the Business Combination, resulting in total consideration paid to the holders of GGB Shares of approximately C$125,000,000. The Issuer Shareholders that are insiders of the Issuer will own 1,513,333 Resulting Issuer Shares and the existing Issuer Shareholders that are not insiders of the Issuer will own 12,923,303 Resulting Issuer Shares, representing 0.87% and 7.45% of the Resulting Issuer Shares issued and outstanding, respectively, on a non-diluted basis.

Completion of the Business Combination is subject to, among other things, shareholder approval from GGB and the Issuer, all conditions precedent set forth in the Business Combination Agreement having been satisfied or waived by the appropriate party and the receipt of all necessary corporate, regulatory and third-party approvals including the approval of CSE, and compliance with all applicable regulatory requirements and conditions in connection with the Business Combination.

 

- 23 -


2.3.3

Summary of the Business Combination Agreement

The following summary of the Business Combination Agreement is qualified in its entirety by the text of the Business Combination Agreement, as amended, a copy of which is attached hereto as Schedule “F” and which has also been filed by the Issuer with the Canadian securities regulatory authorities and available at www.sedar.com.

Representations, Warranties and Covenants

The Business Combination Agreement contains customary representations and warranties made by each of the parties in respect of the respective assets, liabilities, financial position, business and operations of the Issuer and GGB. Both the Issuer and GGB also provided covenants in favour of each other in the Business Combination Agreement, which govern the conduct of the operations and affairs of each respective party prior to Closing.

Conditions to the Business Combination

The Business Combination Agreement contains certain conditions to the obligations of the Issuer and GGB to complete the Business Combination. Unless all of such conditions are satisfied or waived by the party or parties for whose benefit such conditions exist, the Business Combination will not be completed.

Mutual Conditions Precedent

The following is a summary of the significant mutual conditions precedent contained in the Business Combination Agreement:

 

1.

A special resolution approving the Amalgamation has been signed by written resolution by GGB Shareholders in lieu of a meeting.

 

2.

No law is in effect that makes the consummation of the Amalgamation illegal or otherwise prohibits or enjoins GGB or Subco from consummating the Amalgamation.

 

3.

Each regulatory approval necessary to consummate the Amalgamation, including all necessary approvals of the CSE, has been made, given or obtained on terms acceptable to GGB and the Issuer, each acting reasonably, and each such regulatory approval is in force and has not been modified.

 

4.

There shall not have occurred a Material Adverse Effect (as defined in the Business Combination) with respect to the Issuer, NOR or GGB.

 

5.

The NOR Acquisition shall have been completed.

 

6.

The Debenture Financing shall have been completed.

 

7.

The Loan Agreement shall have been executed.

 

8.

The Deposit Promissory Note shall have been executed.

 

9.

The latest available audited and unaudited financial statements of each of the Issuer, GGB and NOR, as required by the CSE policies for inclusion in a management information circular, shall

 

- 24 -


 

have been delivered and shall be true and correct and have been prepared in accordance with GAAP.

 

10.

There shall not be any pending or threatened litigation in any court or any proceeding or investigation by any governmental entity in which it is or may be sought to restrain or prohibit consummation of the Amalgamation and related transactions or to obtain divestiture, rescission or damages in connection with the Amalgamation and related transactions.

 

11.

All applicable securityholders shall have entered into the requisite escrow agreements and/or lock-up agreements required by the CSE.

Conditions Precedent for the Benefit of the Issuer

The following is a summary of the significant conditions precedent in favour of the Issuer contained in the Business Combination Agreement:

 

1.

The representations and warranties of GGB which are qualified by references to materiality or by Material Adverse Effect (as defined in the Business Combination Agreement) were true and correct as of the date of the Business Combination Agreement and are true and correct as of the Effective Date (as defined in the Business Combination Agreement), in all respects, and all other representations and warranties of GGB were true and correct as of the date of the Business Combination Agreement and are true and correct as of the Effective Date (as defined in the Business Combination Agreement), in all material respects, in each case except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of such specified date, and GGB shall have executed and delivered a certificate of an officer to that effect.

 

2.

GGB shall have fulfilled or complied, in all material respects, with all covenants contained in the Business Combination Agreement and the ancillary agreements (such as the Amalgamation Agreement) to be fulfilled or complied with by GGB at or prior to the Effective Date (as defined in the Business Combination Agreement), and GGB shall have executed and delivered a certificate to that effect.

 

3.

The Issuer shall have received all certificates, instruments and other deliverables required to be delivered from NOR under the NOR Agreement.

 

4.

The Issuer shall have received executed copies of the contractual lock-up agreements from the shareholders identified to the Issuer in writing.

Conditions Precedent for the Benefit of GGB

The following is a summary of the significant conditions precedent in favour of GGB contained in the Business Combination Agreement:

 

1.

The representations and warranties of the Issuer which are qualified by references to materiality and warranties were true and correct as of the date of the Business Combination Agreement and are true and correct as of the Effective Date (as defined in the Business Combination Agreement), in all respects, and all other representations and warranties of the Issuer were true and correct as of the date of the Business Combination Agreement and are true and correct as of the Effective Date (as defined in the Business Combination Agreement), in all material respects, in each case

 

- 25 -


 

except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of such specified date, and the Issuer shall have executed and delivered a certificate to that effect.

 

2.

The Issuer shall have fulfilled or complied, in all material respects, with all covenants contained in the Business Combination Agreement and any ancillary agreement (such as the Amalgamation Agreement) to be fulfilled or complied with by it at or prior to the Effective Date (as defined in the Business Combination Agreement), and the Issuer shall have executed and delivered a certificate to that effect.

 

3.

The Issuer shall have no liabilities or obligations (contingent or otherwise), exclusive of liabilities relating to the fees and disbursements of its legal counsel and auditors appointed in connection with the Amalgamation, and the Issuer shall have executed and delivered a certificate to that effect.

 

4.

The Issuer shall have cash of not less than C$400,000 (excluding proceeds from the Loan Agreement, the Deposit Promissory Note and net of expenses relating to the completion of the Amalgamation incurred by the Issuer) and the Issuer shall have executed and delivered a certificate to that effect, and any deviations from this amount must be previously approved in writing by GGB.

 

5.

Each of the required directors and officers of the Issuer and GGB Nevada shall have resigned from their respective positions, other than certain persons agreed to by the Issuer and GGB.

 

6.

Each of Tim Moore, David Bhumgara and Igor Galitsky shall have entered into employment agreements and restrictive covenant agreements with the Resulting Issuer on terms acceptable to GGB.

 

7.

GGB shall have received executed copies of the contractual lock-up agreements from the shareholders identified to the Issuer in writing.

Option to Assume the Rights and Obligations of the Issuer and GGB Nevada

Subject to compliance with the provisions of the NOR Agreement, in the event that any of the conditions precedent under the Business Combination Agreement fail to be satisfied by the Issuer, the Issuer grants (and shall cause GGB Nevada to grant) to GGB the exclusive and irrevocable option, in its sole and absolute discretion, to assume the rights and obligations of the Issuer and GGB Nevada under the NOR Agreement.

As security for amounts payable under the Loan Agreement and the Deposit Promissory Note, the Issuer shall provide GGB with the irrevocable right, subject to the NOR Agreement, to elect to satisfy the Issuer’s obligations under the Loan Agreement by acquiring GGB Nevada from the Issuer and assuming the Issuer’s and GGB Nevada’s obligations under the NOR Agreement. Upon the acquisition of GGB Nevada by GGB, all amounts owed by the Issuer to GGB under the Loan Agreement and the Deposit Promissory Note shall be released. In addition, subject to Nevada law, the Issuer shall pledge all of the shares of GGB Nevada to GGB.

Termination

The Business Combination Agreement may, by notice in writing given prior to the Effective Date (as defined in the Business Combination Agreement), be terminated:

 

- 26 -


  (a)

by mutual consent of GGB and the Issuer;

 

  (b)

by either GGB or the Issuer if:

 

  (i)

the approval of GGB Shareholders of the Amalgamation or the approval of the Issuer Shareholders of all matters to be considered at the Meeting, is not obtained, provided that a party may not terminate the Business Combination Agreement if the failure to obtain such approval has been caused by, or is a result of, a breach by such party of any of its representations or warranties or the failure of such party to perform any of its covenants or agreements under the Business Combination Agreement;

 

  (ii)

after the date of the Business Combination Agreement, any law is enacted, made, enforced or amended, as applicable, that makes the consummation of the Amalgamation illegal or otherwise permanently prohibits or enjoins GGB or the Issuer from consummating the Amalgamation, and such law has, if applicable, become final and non-appealable; or

 

  (iii)

the Effective Date (as defined in the Business Combination Agreement) does not occur on or prior to the Outside Date, provided that a party may not terminate the Business Combination Agreement if the failure of the Effective Date to so occur has been caused by, or is a result of, a breach by such party of any of its representations or warranties or the failure of such party to perform any of its covenants or agreements under the Business Combination Agreement.

 

  (c)

by GGB if a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the Issuer under the Business Combination Agreement occurs that would cause any condition in 1 or 2 not to be satisfied, and such breach or failure is incapable of being cured or is not cured on or prior to the Outside Date; provided that GGB is not then in breach of the Business Combination Agreement so as to cause any condition in 1 or 2 not to be satisfied.

 

  (d)

by the Issuer if a breach of any representation or warranty or failure to perform any covenant or agreement on the part of GGB under the Business Combination Agreement occurs that would cause any condition in 1 or 2 not to be satisfied, and such breach or failure is incapable of being cured or is not cured on or prior to the Outside Date; provided that the Issuer is not then in breach of the Business Combination Agreement so as to cause any condition in 1 or 2 not to be satisfied.

Expenses and Break Fee

Each party will pay for its own costs and expenses incurred in connection with the Business Combination Agreement and the transactions contemplated herein. Notwithstanding, in the event that GGB or the Issuer terminates this Agreement, other than as a result of a breach of a representation or warranty or non-performance by the Issuer, GGB shall: (i) pay the Issuer a break fee in the aggregate amount of C$250,000; and (ii) reimburse the Issuer for the full extent of its United States legal fees, up to C$150,000 of its Canadian legal fees, travel costs, and other reasonable expenses incurred in connection herewith.

 

- 27 -


Amendment to the Business Combination Agreement

On August 30, 2018, Xanthic and GGB entered into an amending agreement in order to amend the Business Combination Agreement in a number of ways, including:

 

  (a)

to revise the Consolidation ratio from 4.07:1 to approximately 4.07:1;

 

  (b)

to include and revise certain definitions in order to contemplate the issuance of the GGB Convertible Debentures pursuant to the terms of the GGB Convertible Debenture Indenture; and

 

  (c)

to reference the GGB Shareholders Agreement, which shall terminate immediately upon completion of the Business Combination.

 

2.4

Trends, Commitments, Events or Uncertainties

 

2.4.1

United States

In accordance with the Canadian Securities Administrators Staff Notice 51-352 (Revised) – Issuers with U.S. Marijuana-Related Activities (“Staff Notice 51-352”), below is a discussion of the federal and state-level United States regulatory regimes in those jurisdictions where the Resulting Issuer is currently directly engaged in the cultivation, extraction, possession, use, sale or distribution of cannabis. In accordance with Staff Notice 51-352, the Resulting Issuer will evaluate, monitor and reassess this disclosure, and any related risks, on an ongoing basis and the same will be supplemented and amended to investors in public filings, including in the event of government policy changes or the introduction of new or amended guidance, laws or regulations regarding marijuana regulation. Any non-compliance, citations or notices of violation which may have an impact on the Resulting Issuer’s license, business activities or operations will be promptly disclosed by the Resulting Issuer.

 

2.4.1.1

United States Federal Overview

The United States federal government regulates drugs through the Controlled Substances Act of 1970 (21 U.S.C § 811) (the “CSA”), which categorizes controlled substances, including cannabis, on schedules. Cannabis is currently classified as a Schedule I controlled substance. A Schedule I controlled substance is defined as a substance that has no currently accepted medical use in the United States, lacks safety for use under medical supervision and has a high potential for abuse.

Unlike in Canada, which has federal legislation uniformly governing the cultivation, distribution, sale and possession of cannabis, in the United States, cannabis is largely regulated at the state level. To the Resulting Issuer’s knowledge, to date 31 states, the District of Columbia, Puerto Rico and Guam have legalized cannabis in some form. Notwithstanding the permissive regulatory environment of medical cannabis at the state level, cannabis continues to be categorized as a Schedule I controlled substance under the CSA and, as such, violates federal law in the United States.

The Supreme Court of the United States has previously ruled that United States Congress has the power to regulate cannabis.

As a result of the conflicting views between state legislatures and the United States federal government, cannabis businesses in the United States are subject to inconsistent legislation and regulation. In response to this inconsistency, on August 29, 2013, then Deputy Attorney General, James Cole, authored a memorandum (the “Cole Memorandum”) addressed to all United States Attorneys (federal prosecutors)

 

- 28 -


acknowledging that notwithstanding the designation of cannabis as a controlled substance at the federal level in the United States, several states had enacted laws relating to cannabis for medical purposes.

The Cole Memorandum outlined certain priorities for the Department of Justice relating to the prosecution of cannabis offenses. In particular, the Cole Memorandum noted that in jurisdictions that have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. In light of limited investigative and prosecutorial resources, the Cole Memorandum concluded that the Department of Justice should be focused on addressing only the most significant threats related to cannabis. States where medical cannabis had been legalized were not characterized as a high priority. Notably, however, the Department of Justice never provided specific guidelines for what regulatory and enforcement systems it deemed sufficient under the Cole Memorandum standard.

Newly appointed Attorney General Jeff Sessions, while acknowledging that much of the Cole Memorandum had merit, disagreed the Cole Memorandum had been implemented effectively and, on January 4, 2018, he issued a memorandum (the “Sessions Memorandum”) that rescinded the Cole Memorandum. While this did not create a change in federal law, revoking the Cole Memorandum rescinded previous nationwide guidance specific to the prosecutorial authority of United States Attorneys relative to cannabis enforcement on the basis that they are unnecessary, given the well-established principles governing federal prosecution already in place. Those principals are included in chapter 9.27.000 of the United States Attorneys’ Manual and require federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community.

As a result of the Sessions Memorandum, federal prosecutors are free to utilize their prosecutorial discretion to decide whether to prosecute cannabis activities despite the existence of state-level laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memorandum as to the priority they should ascribe to such cannabis activities, and as a result it is uncertain how actively federal prosecutors will be in relation to such activities. Further, the Sessions Memorandum did not discuss the treatment of medical cannabis by federal prosecutors. Medical cannabis is currently protected against enforcement by enacted legislation from United States Congress in the form of the Rohrabacher-Blumenauer Amendment (also described as the Leahy Amendment, as defined herein), which prevents federal prosecutors from using federal funds to impede the implementation of medical cannabis laws enacted at the state level, subject to United States Congress restoring such funding. See Section 2.4.1.2 – United States Enforcement Proceedings. Due to ambiguity in the Sessions Memorandum in relation to medical cannabis, there can be no assurance that the United States federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law. See Section 16—Risk Factors for more details.

Federal law pre-empts state law in these circumstances, and therefore the federal government can assert criminal violations of federal law despite adherence to state law. The level of prosecutions of state-legal cannabis operations is entirely unknown. Nonetheless, the stated position of the current administration is hostile to legal cannabis, and furthermore may be changed at any time by the Department of Justice to become even more aggressive. The Sessions Memorandum lays the groundwork for United States Attorneys to take their cues on enforcement priority directly from Attorney General Jeff Sessions by referencing federal law enforcement priorities set by Attorney General Jeff Sessions. If the Department of Justice policy was to aggressively pursue financiers or equity owners of cannabis-related business, and United States Attorneys followed such Department of Justice policies through pursuing prosecutions, then the Resulting Issuer could face (i) seizure of its cash and other assets used to support or derived from its

 

- 29 -


cannabis operations, (ii) the arrest of its employees, directors, officers, managers and investors, and charges of ancillary criminal violations of the CSA for aiding and abetting and conspiring to violate the CSA by virtue of providing financial support to cannabis companies that service or provide goods to state-licensed or permitted cultivators, processors, distributors, and/or retailers of cannabis.

Additionally, under United States federal law it may potentially be a violation of federal anti-money laundering statutes for financial institutions to take any proceeds from cannabis sales or any other Schedule I controlled substance. Banks are similarly reluctant to transact with cannabis companies, due to the uncertain legal and regulatory framework of the industry at present. Banks and other financial institutions could be prosecuted and possibly convicted of money laundering for providing services to cannabis businesses. Under United States federal law, banks or other financial institutions that provide a cannabis business with a checking account, debit or credit card, small business loan, or any other service could be found guilty of money laundering or conspiracy. Despite these laws, in February 2014, the Financial Crimes Enforcement Network of the Treasury Department issued a memorandum (the “FinCEN Memorandum”) providing instructions to banks seeking to offer services to cannabis-related businesses. The FinCEN Memorandum states that in some circumstances, it is permissible for banks to provide services to cannabis-related businesses without risking prosecution for violation of federal anti-money laundering laws. The FinCEN Memorandum also refers to supplementary guidance that Deputy Attorney General Cole issued to federal prosecutors relating to the prosecution of money laundering offenses predicated on cannabis related violations of the CSA. It is unclear at this time whether the current administration will follow the guidelines of the FinCEN Memorandum.

As with cannabis, the legality of CBD production, possession, distribution, storage, or sale is not uniform throughout the United States. This lack of uniformity has resulted in confusion over not just the legality of CBD at both the Federal and state level, but the very nature of the compound. CBD can be produced from marijuana, hemp plants or other natural products. To derive CBD from marijuana, the CBD must be isolated from the THC also contained in marijuana which is the ingredient that provides the psychoactive effect common to the product. The hemp plant, grown for industrial processes, typically contains very low levels of THC.

The Controlled Substances Act defines marijuana broadly, and does not differentiate between the legality of marijuana and hemp in doing so. It was generally not possible to legally to grow hemp in the United States until the United States Congress enacted the 2014 Farm Bill. Section 7606 of the 2014 Farm Bill, entitled Legitimacy of Industrial Hemp Research, provided that “an institution of higher education” or state-level department of agriculture could grow and cultivate industrial hemp if it did so “for purposes of research conducted under an agricultural pilot program,” and, further, provided that the growing or cultivating of industrial hemp was allowed under the laws of the state where located. The legislation further authorized state departments of agriculture “to promulgate regulations to carry out the pilot program” in those states choosing to participate. The ultimate end use of the cultivated industrial hemp, therefore, was left to the discretion of the states.

The 2014 Farm Bill defines the term “industrial hemp” as “the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 (THC) concentration of not more than 0.3% on a dry weight basis.” This definition created a direct conflict with the definition of marijuana in the Controlled Substances Act, which definition specifically includes Cannabis sativa L.    To remove doubt regarding which law controls this program, Congress indicated in § 7606(a) that the states could implement these programs “[n]otwithstanding the Controlled Substances Act . . . or any other Federal law . . . .” Accordingly, it is believed that, if challenged, CBD sourced from producers who are otherwise legally operating within a state-run hemp or agricultural pilot program would not be considered illegal at the Federal level.

 

- 30 -


Despite congressional direction, the Drug Enforcement Administration has continued to maintain that CBD, which it considers a marijuana extract regardless of source, is illegal if it is derived from parts of the hemp plant that would otherwise fall within the definition of marijuana. The foundation for this belief was undercut in a recent decision from the United State Court of Appeals for the Ninth Circuit in Hemp Indust. Ass’n v. Drug Enforcement Admin., No. 17-70162 (9th Cir. April 30, 2018). Though the Court dismissed the petitioner’s claim on a procedural basis, it noted that “the Agricultural Act contemplates potential conflict between the Controlled Substances Act and pre-empts it.”

At the state level, numerous states have enacted versions of the hemp pilot program established by the 2014 Farm Bill. Some states have not done so, leaving legal questions about the legality of hemp-derived CBD production and sale unanswered.

The United States Congress is currently considering legislation that would renew the 2014 Farm Bill and that would specifically remove industrial hemp, including extracts from such hemp, from the definition of marijuana under the Controlled Substances Act. Those monitoring this legislation believe it could be enacted as soon as October 2018, though there can be no assurance that the legislation will ultimately become law.

For the reasons set forth above, the Resulting Issuer’s existing operations in the United States, and any future operations, may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, the Resulting Issuer may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Resulting Issuer’s ability to operate in the United States or any other jurisdiction. See Section 16 – Risk Factors for more details.

Government policy changes or public opinion may also result in a significant influence over the regulation of the cannabis industry in Canada, the United States or elsewhere. A negative shift in the public’s perception of cannabis in the United States or any other applicable jurisdiction could affect future legislation or regulation. Among other things, such a shift could cause state jurisdictions to abandon initiatives or proposals to legalize medical cannabis, thereby limiting the number of new state jurisdictions into which the Resulting Issuer could expand. Any inability to fully implement the Resulting Issuer’s expansion strategy may have a material adverse effect on the Resulting Issuer’s business, financial condition and results of operations. See Section 16 – Risk Factors for more details.

Further, violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, seizures, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on the Resulting Issuer, including its reputation and ability to conduct business, the listing of its securities on various stock exchanges, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for the Resulting Issuer to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. See Section 16 – Risk Factors for more details.

2.4.1.2   United States Enforcement Proceedings

The United States Congress has passed appropriations bills each of the previous three years that included the Rohrabacher Amendment Title: H.R.2578 — Commerce, Justice, Science, and Related Agencies Appropriations Act, 2016 (the “Rohrabacher-Blumenauer Amendment”), which by its terms does not

 

- 31 -


appropriate any federal funds to the United States Department of Justice for the prosecution of medical cannabis offenses of individuals who are in compliance with state medical cannabis laws. Subsequent to the issuance of the Sessions Memorandum, the United States Congress passed its omnibus appropriations bill, SJ 1662, which for the fourth consecutive year contained the Rohrabacher-Blumenauer Amendment language (referred to in 2018 as the “Leahy Amendment”) and continued the protections for the medical cannabis marketplace and its lawful participants from interference by the Department of Justice up and through the 2018 appropriations deadline of September 30, 2018. American courts have construed these appropriations bills to prevent the federal government from prosecuting individuals when those individuals comply with state law. However, because this conduct continues to violate federal law, American courts have observed that should United States Congress at any time choose to appropriate funds to fully prosecute the CSA, any individual or business—even those that have fully complied with state law—could be prosecuted for violations of federal law. If United States Congress restores funding, the United States government will have the authority to prosecute individuals for violations of the law before it lacked funding under the CSA’s five-year statute of limitations.

 

2.4.2

State-Level Overview

The following sections present an overview of market and regulatory conditions for the cannabis industry in those states in which the Resulting Issuer has an operating presence or an intention to operate, and is presented as of September 2018, unless otherwise indicated. Although the Resulting Issuer’s activities are compliant with applicable United States state and local law, strict compliance with state and local laws with respect to cannabis may neither absolve the Resulting Issuer of liability under United States federal law, nor provide a defense to any federal proceeding which may be brought against the Resulting Issuer.

2.4.2.1   Nevada

Legal History

Nevada legalized medical marijuana use through ballot question in the November 2000 general election. In 2013, the Nevada legislature passed SB374, which provided for state licensing of medical cannabis establishments, and began accepting medical cannabis business applications in 2014.

On November 8, 2016, Nevada voters passed NRS435D, allowing for the purchase, cultivation, possession, and consumption of marijuana by persons aged 21 or older, as well as the regulation and licensing of marijuana distributors, suppliers, and retailers. Legal possession and consumption of recreational cannabis began on January 1, 2017, and legal sales began on July 1, 2017.

Licensing Types

There are several types of retail marijuana establishment licenses, including retail store, medical cultivation, and medical production.

A retail store license permits the purchase of cannabis from cultivation facilities, cannabis products from product manufacturing facilities and cannabis from other retail stores, and allows the sale of cannabis and cannabis products to consumers.

A medical cultivation license permits acquiring, possessing, cultivating, delivering, transferring, having tested, transporting, supplying or selling cannabis and related supplies to medical cannabis dispensaries, facilities for the production of edible medical cannabis products and/or medical cannabis-infused products, or other medical cannabis cultivation facilities.

 

-32 -


A medical production manufacturing license permits acquiring, possessing, manufacturing, delivering, transferring, transporting, supplying, or selling edible cannabis products or cannabis-infused products to other medical cannabis production facilities or medical cannabis dispensaries.

Licensing

The Nevada Division of Public and Behavioral Health licensed medical cannabis establishments up to July 1, 2017, at which time the state’s medical cannabis program merged with adult-use cannabis enforcement under the Nevada Department of Taxation (the “DOT”). For the first 18 months, applications to the DOT for adult-use establishment licenses can only be accepted from existing medical cannabis establishments and existing liquor distributors for the adult-use distribution license. The DOT licenses cannabis cultivation facilities, product manufacturing facilities, distributors, retail stores and testing facilities.

All cannabis establishments must register with the DOT. When the DOT issues new licenses, it is done through a competitive application process, with the highest scoring applications receive provisional or conditional licenses. These are converted to final licenses after receiving local zoning approval and passing DOT inspection. Establishments that pass officer vetting are issued a medical cannabis establishment registration certificate. In a local governmental jurisdiction that issues business licenses, the issuance by the DOT of a medical cannabis establishment registration certificate is considered provisional until the local government has issued a business license for operation, and the establishment is in compliance with all applicable local governmental ordinances. Final registration certificates are valid for a period of one year and are subject to annual renewals contingent on payment of fees and good standing status of the business. Renewal requests are typically communicated through email from the DOT and include a renewal form. The renewal periods serve as an update for the DOT on the licensee’s status toward active licensure.

Residency is not required to own or invest in a Nevada medical cannabis business. In addition, vertical integration is neither required nor prohibited. Nevada’s medical law includes patient reciprocity, which permits medical patients from other states to purchase cannabis from Nevada dispensaries. Nevada also allows for dispensaries to deliver medical cannabis to patients.

2.4.2.2   New Jersey

Legal History

Medicinal marijuana use was legalized in New Jersey following the approval of N.J.A.C. 8:64 January 18, 2010 and implementation of the New Jersey Compassionate Use Medical Marijuana Act (“NJCUMMA”). In late 2010, the NJ Department of Health (“NJ DOH”) proposed new rules to implement the NJCUMMA and to establish the Medicinal Marijuana Program (“MMP”).

On January 23, 2018, New Jersey Governor Phil Murphy issued Executive Order No. 6 (“EO6”), in which he directed the NJ DOH and the Board of Medical Examiners to undertake a review of all aspects of MMP, with a focus on ways to expand access to marijuana for medical purposes. On March 23, 2018, NJ DOH Commissioner Shereef M. Elnahal issued the EO6 Report, in which he announced the results of the NJ DOH’s review of the MMP in accordance with EO6, identified ways to expand access to marijuana for medical purposes through programmatic and regulatory changes, and statutory amendments to the NJCUMMA.

On June 7, 2018, the New Jersey state Senate, via Senate Bill Nos. 2702 and 2703, introduced two separate bills that if passed, would legalize possession and personal use of cannabis for persons age 21

 

- 33 -


and over. The bills would also create a new agency responsible for cannabis enforcement and oversight, and they would implement new licensing requirements. Governor Phil Murphy has voiced his desire for the legislature to legalize marijuana, and has further requested that the legislature move to act by the end of 2018.

Licensing

The medicinal marijuana program is operated by the New Jersey Department of Health, which has currently issued six Alternative Treatment Center (“ATC”) permits to establish non-profit medical marijuana dispensaries under the Compassionate Use Medical Marijuana Act. ATCs are vertically integrated centers, required to cultivate, manufacture and dispense medical marijuana. Each ATC is required to submit an annual renewal application and the New Jersey Department of Health has established a permitting process to review thoroughly the financial and personal backgrounds of the principals associated with each ATC.

On June 16, 2018, the NJ DOH announced its request for applications to issue an additional six permits in a highly competitive and oversubscribed application process. Two permits would be issued to ATCs in each of the northern, southern and central regions of the state.

2.4.2.3   Compliance with Applicable State Law in the United States

The Resulting Issuer

The Resulting Issuer, through its wholly owned subsidiary, NOR, holds licenses that are in good standing to cultivate, produce, dispense and distribute marijuana in Nevada. NOR is fully in compliance with respect to its cannabis-related activities and has not received any notices of violation with respect to any of its cannabis-related activities by any Nevada regulatory authority. The Resulting Issuer will promptly disclose any non-compliance, citations or notices of violation which may have an impact on the Resulting Issuer’s license, business activities or operations.

While the Resulting Issuer’s business activities are compliant with applicable state and local law, such activities remain illegal under United States federal law. See Section 16 – Risk Factors for more details.

The Resulting Issuer, through NOR, has established a rigorous compliance program to ensure that it complies with all laws, regulations, and local rules applicable in the cannabis industry. Through its compliance department, NOR oversees, maintains, and implements the compliance program and personnel in conjunction with the Resulting Issuer’s in-house legal department. The compliance and legal departments are responsible for ensuring that operations do not endanger the health, safety, or welfare of the community and that NOR is compliant with state laws and regulations. In addition to the Resulting Issuer’s legal and compliance departments, the Resulting Issuer also has local regulatory and compliance counsel engaged in those jurisdictions in which it operates or is actively pursuing operations. The compliance department also works with applicable security employees and contractors to ensure that the operation and all employees are following and complying with the Resulting Issuer’s written security procedures.

Compliance begins with the proper training of employees. NOR offers a robust employee training plan for those individuals involved in the cultivation, production, dispensing, or distribution of cannabis. NOR is committed to providing employees and customers with training and up-to-date information that will help them better understand the legal and operational issues regarding the use of cannabis and cannabis-infused products pursuant to applicable law. Employees and volunteers

 

- 34 -


are trained before working in a facility and are required to complete mandatory on-going training and performance evaluations.

 

2.4.3

Canada Overview

On August 24, 2016, the Access to Cannabis for Medical Purposes Regulations (Canada) (the “ACMPR”) replaced the Marijuana for Medical Purposes Regulations (the “MMPR”) as the governing regulations in respect of the production, sale and distribution of medical cannabis and related oil extracts. The ACMPR effectively combines the regulations and requirements of the MMPR, the Marihuana Medical Access Regulations and the section 56 exemptions relating to cannabis oil under the Controlled Drugs and Substances Act (the “CDSA”) into one set of regulations.

On June 21, 2018, Bill C-45 received Royal Assent becoming the Cannabis Act (Canada) (the “Cannabis Act”), which is expected to come into force on October 17, 2018. The Cannabis Act regulates the production, distribution and sale of cannabis for unqualified adult use. The Cannabis Act also provides a licensing and permitting scheme for producing, testing, packaging, labelling, sending, delivering, transporting, selling, possessing and disposing of cannabis for non-medicinal (i.e. adult recreational) use, as implemented by regulations made under the Cannabis Act. On such date that the Cannabis Act comes into force, the CDSA shall no longer govern cannabis or cannabis products, which shall instead be governed under the Cannabis Act. Additionally, on that date, the ACMPR will be repealed.

Health Canada released the Cannabis Act Regulations on July 11, 2018, which included the Cannabis Regulations and the Industrial Hemp Regulations, which will come into effect concurrently with the Cannabis Act.

While the Cannabis Act provides for the regulation of the commercial production of cannabis for adult use purposes and related matters by the federal government, the Cannabis Act provides that the provinces and territories of Canada have the authority to regulate other aspects of adult use cannabis (similar to what is currently the case for liquor and tobacco products), such as sale and distribution, minimum age requirements, places where cannabis can be consumed, and a range of other matters.

To date, the Governments of each of the provinces and territories of Canada other than the territory of Nunavut and the provinces of Nova Scotia and Prince Edward Island have announced proposed regulatory regimes for the distribution and sale of recreational cannabis within their respective jurisdictions.

The Cannabis Act, 2017 (Ontario), will regulate the lawful use, sale and distribution of cannabis for adult use in Ontario (in addition to the Cannabis Act). The Cannabis Act, 2017 (Ontario) proposes to create a new provincial retailer (the Ontario Cannabis Store), overseen by the Liquor Control Board of Ontario, to manage the distribution of recreational cannabis and is to be the exclusive channel through which consumers in Ontario can legally purchase recreational cannabis. In addition, the Government of Ontario announced its intention to propose new legislation, which is projected to be enacted by April 1, 2019, that would allow for the private retail distribution of cannabis. Further details of the Province of Ontario’s approach to recreation cannabis will be set out in regulations to the Cannabis Act, 2017 (Ontario).

The Government of Manitoba has announced a “hybrid model” for cannabis distribution upon legalization. The supply of cannabis such a model is to be secured and tracked by the Manitoba Liquor and Lotteries Corp., however private retail stores will be permitted to sell recreational cannabis.

The Government of Alberta has announced a draft cannabis framework providing for the purchase of cannabis products from retailers that will receive their products from a government-regulated distributor.

 

- 35 -


Similar to the approach taken by the Province of Ontario, the Province of New Brunswick is to set up a network of government-controlled, stand-alone stores through the New Brunswick Liquor Corporation.

On November 16, 2017, the Government of Quebec announced that it is to create an agency to regulate sales as a parallel organization to its existing government-controlled alcohol sales regulator and chain of outlets commonly known in the province as the “SAQ”.

In November 2017, the Government of Newfoundland and Labrador announced that recreational cannabis will be sold through private stores, with a crown-owned liquor corporation overseeing the distribution to private sellers selling to consumers. The Government of Newfoundland and Labrador has stated that the Newfoundland and Labrador Liquor Corporation will control the possession, sale and delivery of cannabis, in addition to setting prices.

Similarly, the Government of Yukon has released a “starting point” policy which limits the distribution and sale of recreational cannabis to government outlets and government-run online stores, and allows for the later development of private retailer operations.

The Government of the Northwest Territories has also announced a proposed approach for the distribution and sale of recreational cannabis which relies on the N.W.T. Liquor Commission to control the importation and distribution of cannabis, whether through retail outlets or by mail order service. Communities in the Northwest Territories will be able to hold a plebiscite to prohibit cannabis, similar to the options currently available to restrict alcohol.

The Government of Saskatchewan announced that recreational cannabis will be sold by private companies.

The Government of British Columbia announced in December 2017 that recreational cannabis will be sold in that province through both public and privately operated stores, with the provincial Liquor Distribution Branch handling wholesale distribution.

On February 8, 2018, following discussions with the Canadian Securities Administrators and recognized Canadian securities exchanges, the TMX Group announced the signing of a Memorandum of Understanding (the “TMX MOU”) with Aequitas NEO Exchange Inc., the Canadian Securities Exchange, the Toronto Stock Exchange (the “TSX”) and the TSX Venture Exchange. The TMX MOU outlines the parties’ understanding of Canada’s regulatory framework applicable to the rules, procedures, and regulatory oversight of the exchanges and CDS as it relates to issuers with cannabis related activities in the United States. The TMX MOU confirms, with respect to the clearing of listed securities, that CDS Clearing and Depository Services Inc. (“CDS”) relies on the exchanges to review the conduct of listed issuers. As a result, there is no CDS ban on the clearing of securities of issuers with cannabis related activities in the United States. However, there can be no guarantee that this approach to regulation will continue in the future.

 

- 36 -


3.

NARRATIVE DESCRIPTION OF THE BUSINESS

 

3.1

General Business of the Issuer and NOR

Xanthic is a Canadian company based in Toronto, Ontario, which, prior to entering into the Business Combination Agreement, has provided valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis and cannabis-infused products. The Issuer has developed a patent-pending proprietary process to make THC and CBD, the two key active ingredients in cannabis, water soluble, and its operation will continue to be run by current management.

NOR, indirect, wholly-owned subsidiary of Xanthic, is a vertically-integrated cannabis company operating in the State of Nevada, which holds licenses for dispensing, cultivating, producing and distributing cannabis to both medical and retail marijuana customers. Through its cultivation and production operations, NOR produces high quality medical and retail marijuana products that are sold through its retail location and sold wholesale to various other dispensaries. NOR’s Las Vegas area dispensary is considered a premier dispensary, receiving top ratings by multiple local publications. NOR operates its dispensary under the brand “The Source” and offers a comprehensive line of medicinal and retail marijuana, edibles, concentrates, CBD, and topicals. Since July 1, 2017, with expanded legalization in Nevada, NOR’s customer base has expanded to include “adult-use” or retail customers, who do not require a prior medical diagnosis and applicable registration in order to legally purchase cannabis.

NOR also operates 12,000 square feet of cultivation and production space. NOR’s cultivation capabilities include the use of energy-efficient LED lights during cultivation, integrated pest management practices that reduce the need for pesticides, and use of CO2 as a more environmentally conscious extraction method. NOR also utilizes rockwool as a growing medium, providing a more efficient use of space and reducing the waste of thousands of pounds of soil and soil amendments in the cultivation process. A key component of Resulting Issuer’s strategic plan is to continue to expand and maximize its cultivation space in order to realize the vertical integration benefits of the NOR business.

Subject to completion of the Business Combination, Xanthic will combine its business with the businesses of GGB and NOR and thereafter will be engaged in the business of cultivation, processing, and retailing of cannabis and cannabis-infused products augmented by new and existing intellectual property.

 

3.2

General Business of the Resulting Issuer

 

3.2.1

General Business, Objectives and Milestones of the Resulting Issuer

Over the next twelve months, the Resulting Issuer intends to expand its retail and wholesale cannabis businesses, as well as its CBD consumer products businesses through a combination of strategic partnerships, merger and acquisition activity, and organic license capture. Its objectives are to establish retail cannabis locations, or otherwise apply for such licenses, in various states within that timeframe, pursuant to state laws. Such activity will focus on those certain states where cannabis has been legalized for medical and/or recreational use at the state level.

 

- 37 -


Retail Cannabis

Organic License Capture

The Resulting Issuer will target expansion into markets with open licensing application processes for dispensaries where it believes it can gain market share against local competition through superior retail experience.

On August 31, 2018, pursuant to a Request for Applications issued by the NJ DOH, the Resulting Issuer submitted a proposal to operate a single, fully integrated cannabis facility in New Jersey. Should the Resulting Issuer be awarded such license, it will be one of just 12 license holders in the state. The state is expected to make an award on or about November 1, 2018, and, if the Resulting Issuer is successful in being awarded a license, it is expected that operations would commence within 12 months thereafter.

On September 17, 2018, NOR submitted an application for eight retail marijuana store facilities in Nevada. The Resulting Issuer hopes to receive multiple retail marijuana store awards when State of Nevada makes its announcement in December 2018. Should the Resulting Issuer’s Nevada applications be successful, the build-out cost for each dispensary awarded is estimated at approximately US$1,500,000. Based on current experience and the number of licenses awarded to date, cultivation and processing capacity would need to be expanded in Nevada.

The Resulting Issuer has already incurred expenses for these license applications. Future expenses related to the captured licenses would be associated with dispensary build-outs as well as cultivation and processing build-outs. Should the Resulting Issuer’s New Jersey dispensary application be successful, estimated expenses to build a dispensary facility in New Jersey are approximately US$1,000,000, with an additional expected expense of approximately US$8,000,000 to US$10,000,000 in order to build out the cultivation and processing facility.

Mergers and Acquisitions

Management is continually evaluating acquisitions and strategic investments that are significant to the Resulting Issuer in both Canada and the United States. In identifying acquisition targets, companies that are well positioned in their markets and will enhance the Resulting Issuer’s portfolio of products are key targets. Given the increasingly competitive environment and the capital resources required to produce many of the product offerings, the Resulting Issuer will continue to seek out cannabis retailers, CBD manufacturers and cannabis cultivators and processors as prime targets for acquisition. The Resulting Issuer also is actively seeking strategic joint ventures and business relationships to position its current portfolio in existing distribution platforms.

The selection of states for acquisition activity is based upon the Resulting Issuer’s assessment of the regulatory market under the various state-level and local governments, profitability per location when compared to other cannabis-permissive states, and the perceived potential for medical-only states to move to recreational use in the near future. In selecting specific locations for expansion, the Resulting Issuer will continue to seek out real estate in premium locations with significant foot traffic and proximity to popular attractions, such as restaurants, malls, sports arenas and hotels. The Resulting Issuer focuses on retail spaces with a footprint of 3,500 to 5,000, square feet, depending on the market and available real estate.

 

- 38 -


Wholesale Cannabis

The Resulting Issuer, through NOR, its wholly owned subsidiary, owns a warehouse of approximately 12,000 square feet located in Clark County, Nevada, where cultivation, production, and distribution take place. NOR operates a perpetual harvest that ensures constant production of flower product.

The NOR and HOR dispensaries combined purchase flower each month from NOR cultivation and NOR production. NOR cultivation sells trim and flower each month to NOR Production for extraction. Additionally, NOR cultivates fresh frozen product each month that is sold wholesale to licensed production facilities in Nevada to produce additional concentrate and extraction products. NOR production sells wholesale vaporizer cartridges, disposable vaporizers, tinctures, capsules, and concentrates to licensed dispensaries in Nevada. When available, NOR production may wholesale oil to licensed production facilities in Nevada. NOR cultivation and production also employ a wholesale sales team to sell finished products to other dispensaries.

NOR cultivation and production also employ a wholesale sales team to sell finished products to other dispensaries. NOR has entered into supplier agreements to provide flower and disposable/cartridge units beginning September 2018 through the end of 2018. The remaining product is sold wholesale as available.

CBD Consumer Products

The Resulting Issuer anticipates a robust CBD consumer products industry in 2019. The Resulting Issuer will benefit from GGB’s previous investments of more than US$150,000 for research, development, and safety testing relating to proprietary CBD-infused products, including topical body care, face care, and ingestible agents. Research for body-care products is currently being finalized, with an expected limited launch of such products in the United States in October 2018. The Resulting Issuer expects to finalize research and development for proprietary face care and ingestible products in November 2018, with a launch of those products in the first quarter of 2019.

The Corporation will begin testing CBD consumer products in October 2018. The test results of consumer acceptance of the CBD consumer products will dictate the number of expanded distribution points throughout 2019. Expenses will be incurred in the production and manufacturing of the product, along with support associates in merchandising, planning and allocation. Further, the Resulting Issuer is currently exploring international opportunities in Canada and outside of North America, though the timeline for commercialization in these locations is unknown at this time.

In marketing its CBD consumer products, the Resulting Issuer intends to use consistent branding and messaging across all of its locations. The Resulting Issuer has dedicated merchandising and marketing teams, through whom it intends to provide a retail experience unmatched in the CBD space.

In addition, the Resulting Issuer intends to commercialize Xanthic’s existing, patent-pending powder process with partners in multiple states. The cost per new location would be approximately US$100,000, which includes equipment and make-ready items such as packaging artwork. To achieve this goal, Xanthic has executed a Letter of Intent with Pasaverde Labs LLC, based in California. The Resulting Issuer estimates that first production in California will occur in the fourth quarter of 2018. The NOR Acquisition, moreover, provides access to the Nevada market, with estimated first production in that state occurring in the fourth quarter of 2018.

 

- 39 -


Finally, Xanthic plans to exercise an option to acquire a further 6% of Xanthic Beverages, giving Xanthic control over this business. The cost of this exercise is US$300,000 in Issuer Common Shares at the 60 day average stock price at the time of exercise.

E-Commerce

The Resulting Issuer expects to create e-commerce-capable websites for its various brands by November 2018. Product sales are anticipated to begin in early 2019, and the Resulting Issuer expects to begin its product sales at that time. GGB’s e-commerce websites will sell proprietary CBD-infused consumer products, branded apparel, and proprietary branded accessory products.

The Resulting Issuer intends to use a third party provider to handle all orders, processing, packaging, unit storage, distribution, delivery, returns and customer-service call centers. No contract or estimated expenses are available at this time and will be dependent on the unit velocity and the terms of the applicable service agreements.

 

3.2.2

Available Funds

The Resulting Issuer is expected to have approximately US$110 million available to it on the closing of the Business Combination. The table below shows the breakdown of the estimated funds available:

 

Source of Funds
(expressed in United States Dollars)

      

Estimated working capital of the Issuer as at June 30, 2018

   $ 516,095  

Estimated working capital of GGB as at July 31, 2018

     3,558,339  

Estimated working capital of NOR as at June 30, 2018

     2,909,532  

GGB Debenture Financing

     65,070,314  

Private placement to close on Business Combination

     23,194,168  
  

 

 

 

Estimated funds available to the Resulting Issuer upon completion of the Business Combination

   $ 95,248,448  

Given the current laws regarding cannabis at the federal level in the United States, traditional bank financing is typically not available to cannabis companies in the United States. Specifically, the federal illegality of marijuana in the United States means that financial transactions involving proceeds generated by cannabis-related conduct can form the basis for prosecution under money laundering statutes, the unlicensed money transmitter statute and the Bank Secrecy Act. As a result, businesses involved in the cannabis industry often have difficulty finding a bank willing to accept their business. Banks who do accept deposits from cannabis-related businesses in the United States must do so in compliance with the Cole Memorandum and the FinCEN Memorandum.

GGB has, however, been successful at raising capital privately in the past and may choose to do so again in the future. Specifically, GGB intends to raise funds of up to C$50 million prior to the Business Combination through either an investment by a strategic partner or in connection with a subscription receipt financing.

 

3.2.3

Principal Purposes of Available Funds

The following table sets out information with respect to the Resulting Issuer’s intended uses of available funds on completion of the Business Combination over the next 12 months. The amounts shown in the table are estimates only and are based in United States dollars and on the information available to the Resulting Issuer as of the date of this Listing Statement.

 

- 40 -


Use of Available Funds
(expressed in United States Dollars)

   Amount  

NOR Acquisition

   $ 52,451,500  

General and Administrative Expenses, including salaries, consulting fees, rent, utilities, equipment costs, insurance, public company expenses, legal fees and auditor fees.

     22,335,000  

Acquisitions, license applications and capital expenditures

     13,250,000  

Estimated Business Combination Costs

     1,500,000  

Unallocated working capital

     5,711,948  
  

 

 

 

Estimated funds available to the Resulting Issuer upon completion of the Business Combination

   $ 95,248,448  

Notwithstanding the proposed uses of available funds as described above, there may be circumstances where, for sound business reasons, a reallocation of funds may be necessary. It is difficult, at this time, to definitively project the total funds necessary to effect the planned activities of the Resulting Issuer. For these reasons, management considers it to be in the best interests of the Resulting Issuer and the Resulting Issuer Shareholders to afford management a reasonable degree of flexibility as to how the funds are employed among the uses identified above, or for other purposes, as the need arises.

See Section 3.2.1 - General Business, Objectives and Milestones of the Resulting Issuer for a description of how the principal purposes of the funds available will be used to achieve the milestones of the Resulting Issuer.

 

3.2.4

Distribution Methods

Retail Cannabis

NOR operates a retail cannabis store in Las Vegas, Nevada called “The Source”. As of August 2018, this location served an average of over 900 customers per day. The Source also maintains impeccable reviews and ratings, and, in February 2018, was named “Best of the City” by NPR’s Desert Companion Magazine. According to the DOT figures released on August 28, 2018, medical and retail marijuana sales for the fiscal year 2017-2018 totaled approximately US$529,000,000 via 64 dispensary/retail stores. This equates to roughly US$8,200,000 per location. However, NOR’s location, “The Source”, outperformed the state average by over 200%.

This outstanding performance starts not just with quality product, but with a quality experience. NOR elected to take a customer-centric approach to designing its first store. A LEED-certified architect and a top national retail interior designer, specializing in high-traffic retail stores, were hired to create and implement the design. Elements from the most successful retailers in the country were incorporated into the store design, such as:

 

   

An open, spacious entrance with abundant natural light;

 

   

Modern, organic design that incorporates reclaimed wood, natural concrete floors, white walls, and special plants to warm up the environment;

 

   

Greeters stationed in the entrance to open the door and personally welcome customers;

 

   

Open ceilings with solar tubes to allow natural light to fill the entire retail area;

 

   

Secure, but unobtrusive, bulletproof safety glass surrounding areas with product or cash;

 

   

Open retail floor with highly trained roaming customer advisors to assist customers;

 

- 41 -


   

Highly efficient and flexible check-out process staffed with friendly cashiers and pick-up options;

 

   

Flexible customer experience with no lines where customers choose how to shop and with whom they interact;

 

   

Prompt service with very few lines and very little waiting;

 

   

Clean, uncluttered, minimalistic merchandising that focuses on education, experience, and the right product selection; and

 

   

Soft background music that appeals to customers from all walks of life.

NOR’s design was instantly accepted and appreciated by customers for an “everyday” approach to the marijuana retail experience. Through the many unique challenges of the industry, NOR focused on operating a compliant retail marijuana store while delivering a familiar and sought-after retail experience.

The size and layout of the proposed retail marijuana store is centered around creating the optimal customer experience. Unlike the vast majority of retail marijuana stores, customers dictate their shopping experience, rather than being assigned to a specific budtender.

When designing the space, NOR contemplated a myriad of operational considerations, including customer counts, shopper flow, product popularity, orders per hour, online orders/pickup, average wait times (i.e., queue monitoring), and employee roles. In order to deliver optimal customer experience, the store was designed to handle peak traffic flow, including variations in days of the week.

Like the brick-and-mortar retail experience, NOR’s online order and in-store pick up process has been designed around safety, convenience, and efficiency. NOR processes more than 100 orders per day through online order and pick up. As the marijuana market matures and customers become more familiar with the product offering, a growing number of customers choose to place orders online. NOR’s store layout has been designed to accommodate those customers.

Wholesale Cannabis

NOR is a vertically integrated, dual-licensed cannabis operator in Nevada. Through its cultivation, production, distribution, and dispensary licenses, NOR is able to control its entire supply chain, from growth and extraction, to transportation and customer sales.

For the two facilities that NOR directly supplies, it provides flower each month from NOR cultivation. Each month, the facilities also purchase units from NOR production. NOR cultivation sells trim and flower each month to NOR production for extraction. NOR produces fresh frozen product each month in addition to what it ultimately sells in its own retail locations. NOR sells this product wholesale to licensed production facilities in Nevada to produce additional concentrate and extraction products. NOR production also sells wholesale vaporizer cartridges, disposable vaporizers, tinctures, capsules, and concentrates to licensed dispensaries in Nevada. When available, NOR production may also wholesale oil to licensed production facilities in Nevada as well.

Additionally, NOR employs a wholesale sales team to sell finished products to other dispensaries. NOR has, for example, entered into supplier agreements to provide flower and disposable cartridge units beginning September 2018 through the end of the year. The remaining product is sold wholesale as available to other dispensaries in the state. NOR’s distribution license allows it deliver wholesale orders, a unique competitive advantage given that (1) the majority of licensees in the State of Nevada do not have distribution licenses, and (2) the state will shortly award an additional 60 recreational dispensary licenses.

 

- 42 -


CBD Consumer Products

The Resulting Issuer intends to distribute its CBD-infused personal care products to all jurisdictions where CBD sales comply with existing local law through (i) partnerships with specialty retailers; (ii) a robust e-commerce platform; (iii) the creation of kiosk establishments in targeted retail locations; and (iv) the creation of brick-and-mortar store locations.

Distribution of Xanthic’s CBD-infused water occurs through the licensing of intellectual property to licensed producers in specific, targeted jurisdictions. Production and distribution then follows pursuant to the granted license using the infrastructure of the licensee. At this time, the principal markets for Xanthic’s CBD-infused water are Oregon and Washington, with anticipated expansion to Nevada via the acquisition of NOR and potential expansion to other locations including California and Colorado.

E-Commerce

The Resulting Issuer expects to create e-commerce-capable websites for its various brands by November 2018. Product sales are anticipated to begin in early 2019, and the Resulting Issuer expects to begin its product sales at that time. The Resulting Issuer’s e-commerce websites will sell proprietary CBD-infused consumer products, branded apparel, and proprietary branded accessory products subject to governmental approvals, if necessary.

 

3.2.5

Category Revenues

NOR’s cultivation, manufacturing, and dispending operations generated the following revenue amounts for the years ending June 30, 2017 and June 30, 2018:

 

2018 YTD Revenue

   2017 Revenue  

US$ 18,991,307

   US$  5,644,805  

The Resulting Issuer’s CBD consumer products are non-revenue-generating at this time.

 

3.2.6

Development

The Resulting Issuer is finalizing research and development for proprietary formulations of face care, body care, and ingestible items, with an expected launch of CBD topical body-care products into select market segments in October 2018. The Resulting Issuer further anticipates completing research and development for additional proprietary formulations for CBD topical body-care, face-care, and ingestible products in November 2018. To date, the Resulting Issuer, through GGB, has invested approximately US$150,000 for research, development, and safety testing for these consumer products in 2018.

 

3.2.7

Production Methods

Cannabis

NOR’s cultivation facility grows cannabis through a hydroponic growing process. The product is then hung dry, bucket cured, and hand trimmed. The growing process uses rockwool grow cubes combined with high pressure sodium lighting, although LED and supplemental LED lighting is currently being tested.

 

- 43 -


NOR’s practices adhere to local, state and/or federal laws and regulations. Employees are required to follow the practices of exemplary health and safety sources, which include guidance from the following sources:

 

   

Environmental Protection Agency (EPA);

 

   

USDA Organic Standards (Dependent on state regulations);

 

   

Federal Insecticide, Fungicide and Rodenticide Act (FIFRA);

 

   

Organic Material Review Institute (OMRI);

 

   

Occupational, Safety and Health Act (OSHA);

 

   

State and Local Laws; and

 

   

Newly Adopted State and Local Laws

NOR does not treat or otherwise adulterate usable marijuana with any organic or nonorganic chemical or other compound whatsoever to alter the color, appearance, weight or smell of the usable marijuana. NOR’s cultivation facility will protect marijuana products from contamination by storing the products in a clean, dry location:

NOR’s production method uses a Waters CO2 extraction machine and distillation process to manufacture oil concentrates from flower and trim. Fresh frozen product is sent out for processing by production vendors that utilize a hydrocarbon extraction process. NOR’s cultivation process utilizes its distribution capabilities to wholesale flower, trim, and fresh frozen product to production licensees and flower to dispensary licensees in other locations within Nevada.

CBD Consumer Products

The Resulting Issuer’s CBD-infused water is produced under a co-packaging agreement with an independent bottler.

In producing its CBD-infused personal care products, the Resulting Issuer uses an independent research and development laboratory to create proprietary CBD formulations that meet its specifications and quality standards. These formulations are then tested for safety and stability by third-party laboratories. Once these tests are successfully concluded, the Resulting Issuer will provide the products to contract manufacturers with specific instructions to compound and fill its products. The Resulting Issuer also procures packaging components and provides them to the contract manufacturers, who fill the components and create the finished products.

Upon completion of the manufacturer’s work, and at such time as the Resulting Issuer begins shipping these products, they will either be shipped to a distribution or fulfillment center, or they will be shipped direct to the Resulting Issuer’s retail partner stores as required by business needs.

 

3.2.8

Real Estate

GGB entered into a lease agreement (the “Lease”) dated as of July 10, 2018 with Schottenstein Property Group with respect to its corporate office at 4300 East Fifth Avenue, Columbus, Ohio 43219. The term of the Lease is for a period of three years, commencing on May 1, 2018 and concluding on April 30, 2021. There are no options for renewal, and the Lease is in good standing. On August 13, 2018, the Lease was amended in order to generate a model for its brick-and-mortar retail stores. Pursuant to the terms of the Lease, GGB pays an annual rent of US$173,260. Schottenstein Property Group is owned by the Schottenstein family.

NOR has five material leases, all of which are in good standing and can be described as follows:

 

- 44 -


  a)

NOR has three leases for different areas at the 2550 S. Rainbow Blvd., Las Vegas, Nevada, 89146 location. This includes The Source dispensary, an employee breakroom, and an event space.

 

  i.

Dispensary: The term commenced on October 1, 2015, and concludes on September 30, 2025. There are two five-year extension options. Base annual rent is US$108,288, due monthly. There is a rent escalation of 3% starting in year three.

 

  ii.

Break Room: The term commenced on October 1, 2015, and concludes on September 30, 2025. There are two five-year extension options. Base annual rent is US$17,136, due monthly. There is a rent escalation of 3% starting in year three.

 

  iii.

Event Space: The term commenced on October 1, 2015, and concludes on September 30, 2025. There are two five-year extension options. Base annual rent is US$38,400, due monthly. There is a rent escalation of 3% starting in year three.

 

  b)

NOR has a lease for a cultivation, production, and distribution facility located at 3705 E. Post Rd., Las Vegas, NV 89120. The term commenced on March 1, 2015, and concludes on February 29, 2025. There are two five-year options. Base annual rent is US$312,000, due monthly. There is a rent escalation of 3% starting in year three.

 

  c)

NOR has a lease for its corporate offices located at 2009 E. Windmill Ln, Las Vegas, Nevada 89123. The term commenced on September 1, 2018, and concludes on August 31, 2021. Renewal options are to be determined at this time. Base annual rent is US$91,800, due monthly. There is a rent escalation of 3% annually.

 

3.2.9

Skill and Knowledge Requirements

The cannabis industry is one that requires management and employees with a broad range of skills and knowledge in order to be successful in the long-term. The Resulting Issuer will benefit from exceptional management teams from each of Xanthic, GGB and NOR.

Xanthic

Xanthic’s founders have the knowledge behind a patent-pending process to convert THC and CBD into water-soluble powder. Xanthic’s proprietary formulations are developed utilizing the most recent developments in cannabis science and are overseen by medical doctors and scientists. This knowledge is unique within the emerging CBD industry. With respect to Xanthic’s leadership, Igor Galitsky, who serves as President, has been a pioneer in the areas of cannabis extracts and products in Canada for over seven years. Mr. Galitsky is a board member of Platinex Inc., which focuses on development of an online community and portal by publishing timely and informative articles in respect of the cannabis industry.

GGB

GGB, through the vast experience of its leadership team, has immediate access to the retail skill and knowledge that comes with having worked at such household retail brand names as Victoria’s Secret®, American Eagle Outfitters®, Bath & Body Works®, Unilever®, and DSW®.

In particular, management experience derived from Bath & Body Works®, which is the #1 Beauty Products Specialty Retailer, means that GGB’s CBD-infused body-care and face-care products is expected to be a leader within this nascent market. The CBD consumer product market, which is

 

- 45 -


expected to grow significantly as the legal issues of CBD are resolved, will have access to the variety and quality of products that help make Bath & Body Works® a leader in the industry.

GGB’s leadership also brings with it significant experience in distribution strategy, merchandising, supply chain, and store management. This readily available knowledge differentiates GGB from other competitors in this space. The focus is not just on producing an outstanding product for the customer, but on an outstanding experience for the customer as well. GGB’s leadership team includes:

 

  1.

Peter Horvath: Mr. Horvath has been an established leader in the national retail industry for over 30 years, having executive positions in companies such as Victoria’s Secret®, American Eagle®, DSW® and the Limited Brands®.

 

  2.

Edward Kistner: During his 35-year tenure in speciality retail, Mr. Kistner held positions in finance, merchandise planning, operations and store management. He has held executive leadership roles with brands including Victoria’s Secret®, DSW®, Lane Bryant®, The Limited Brands®, Structure® and LSG® (Limited Brands Corporate) finance.

 

  3.

Fritz Hoefer: Mr. Hoefer has created and sourced consumer products from concept to market for some of the most successful retailers in the world, including Victoria’s Secret®, Avon Products®, Burt’s Bees®, L’Oreal Paris®, Dove®, Lancome®, Unilever®, Crabtree & Evelyn®, Abercrombie & Fitch®, and Johnson & Johnson®. Before initiating his own consulting company, Mr. Hoefer served as EVP General Merchandise Manager for Bath & Body Works® from 1995-2001.

 

  4.

Kevin Wadhams: With experience at Unilever® and Bath & Body Works®, Mr. Wadhams brings decades of merchandising, product development, branding, and design consulting experience to GGB. Additionally, he possesses thorough knowledge of FDA, OTC, and GMP requirements and best practices.

 

  5.

Tobin Anderson: Mr. Anderson brings experience from the consumer products industry, having held executive-level retail-merchandising positions with Bath & Body Works® and Lenscrafters®, having served as President of Sally Beauty®, and as retail executive with Yankee Candle Company®.

 

  6.

Patrick Peters: Mr. Peters comes to GGB with 32 years of experience at Unilever®, having held various senior executive positions, including Sr. VP Customer Management, Development, and Supply Chain.

NOR

NOR operates exclusively in the cannabis cultivation, production, and dispensing industries, where specialized knowledge and skill is a key to success. NOR, led by industry leader, Andrew Jolley has the specialized skill and knowledge required to succeed. Mr. Jolley holds the Americans for Safe Access Core Cannabis Training Certification and is a founding member and currently serves as President of the Nevada Dispensary Association (the “NDA”), which represents 95% of dispensaries in the State of Nevada, making it the state’s most prominent marijuana industry association. Further, Mr. Jolley played a key role in the implementation of Nevada’s medical and, later, its retail marijuana program. Through his role in the NDA, he has led efforts to influence responsible legislation, regulations, best practices, training, conferences, and dozens of events to help the marijuana industry be a productive and an engaged force for good in Nevada. He was instrumental in creating AB422 in the 2017 Legislative Session, which became known as the “medical preservation bill.” This bill improves access to medicines for medical

 

- 46 -


marijuana patients and ensures continued oversight from the Nevada Division of Pubic and Behavior Health as well as the DOT.

In the months leading up to the launch of retail sales in Nevada, Mr. Jolley served on Governor Sandoval’s marijuana task force retail committee. As an instrumental member of the committee, he provided key recommendations for the launch of retail sales and for the formation of regulations governing dispensary operations. The Early Start program was ultimately regarded as an enormous success, generating an extra US$40 million of tax revenue for the state.

In 2017, the Clark County Board of Commissioners appointed Mr. Jolley to serve on the Clark County Green Ribbon Panel to help create recommendations to the county regarding marijuana policies and programs. He continues to be an important member of the panel working with county and state officials as well as representatives from the medical community and gaming industry.

 

3.2.10

Product Sourcing

Retail Cannabis

NOR’s dispensary purchases finished products and wholesale accessories from a variety of production and cultivation licensees and other sources in the State of Nevada that are readily available and easy to source. It also purchases wholesale CBD products from a variety of sources whose availability has increased as CBD popularity has grown.

With respect to cultivation, the raw materials are as follows: nutrients, rockwool, packaging, CO2, and cocoa/peat. The nutrients, rockwool and cocoa/peat are purchased from an industry leader in commercial sales and large-scale grow design. These items are readily available. Pricing is very competitive for all products. Additional sources, should the need ever arise, are also readily available.

With respect to packaging, wholesale bags are purchased from a Las Vegas packaging supplier and are readily available and easy to source. Retail packaging is custom-made and available through multiple vendors.

CBD Consumer Products

The sources, pricing and availability of raw materials, component parts for the Resulting Issuer’s CBD finished products come from various suppliers, distributors and contract manufacturing companies based in the United States (under the 2014 Farm Bill), Europe and Asia. The Resulting Issuer has sourced raw materials and components from multiple distributors, and its contract manufacturer has several available manufacturing facilities. There are no material issues with the pricing or availability of any of the raw materials or component parts that comprise the finished CBD products.

 

3.2.11

Intangible Properties

Patents

Xanthic has filed a patent application for “Powdered Cannabis Products, Products Containing Powdered Cannabis, and Process of Making Same.” This process, once approved, will provide patent protection for Xanthic’s CBD-infused water products.

 

- 47 -


Trademarks

The Resulting Issuer’s current intangible properties include the various brands set out below. For the CAMP, Seventh Sense, Meri+Jayne and Green Lily marks, protection has been sought for each with the United States Patent and Trademark Office and the Canadian Intellectual Property Office. Additionally, the “The Source” mark has been submitted to the United States Patent and Trademark Office. In the case of the Xanthic Biopharma mark, protection has been sought only in the State of Oregon. The brands represent a vital part of the Resulting Issuer’s operation and serve as a differentiator among its competitors in terms of vision and customer experience. Through these brands, the Resulting Issuer intends to strategically market its cannabis and CBD-infused products.

 

CAMP

  LOGO   

CAMP is coming near you and will be a place where you and fellow CAMPers can gather, commune, be happy and share a love of great products, great information and great fun. It will also be a destination. Our planned BASE CAMP is a wellness center, grow facility, CAMPer experience, shopping village and events center where our CAMP programming and ideas are formed. It will be more than a place to gather; it’s a way of being. We can’t wait for you to come to CAMP.

Seventh Sense    

  LOGO   

This line of beautiful, efficacious, CBD infused beauty products will be available Nationally in the near future. From body oils, lotions and salves, to hair care, lip balm and sun products, 7th Sense is meant to awaken your body’s natural healing system, the CBD system (like a secondary nervous system in your body) to promote calm, better sleep, happiness and health.

Meri+Jayne

  LOGO   

We believe in friends, in music, in color of all kinds. We believe in good times, good health and creating a place where like-minded folks can come together, shop for the highest quality, curated CBD and Cannabis products and become friends. This will be your place. Welcome to Meri+Jayne.

Green Lily

  LOGO   

This is a brand that is designed to cater to her needs. Incredible botanically-led beauty products. Beautiful, inviting, comfortable interiors. A place she can feel at home because it was created specifically for her. We will focus on education of correct Cannabis and CBD consumption and make sure we are matching the right product to her specific needs. Green Lily will light up every sensibility of this underserved consumer.

The Source

  LOGO   

This mark has been approved by the DOT consistent with local requirements. The Source is a recognized name in the Nevada cannabis community, having been named by NPR’s Desert Companion Magazine as the Best Dispensary in Las Vegas in its February 2018 edition.

8/Fold

  LOGO   

8|Fold provides premium CO2-extracted cannabis products to the Nevada market, including disposable vaporizers, cartridges, and concentrates. Oil formulations include distillate, pure, and prismatic - ranging from high THC to high terpene.

 

8|Fold uses a proprietary method to capture strain specific terpenes that are reintroduced to the finished oil resulting in CO2 extracts

 

- 48 -


    

that taste and smell like the strains that produced them.

Xanthic Biopharma

  LOGO   

In an era where holistic medicine and modern health practices are converging, we are awakening to the diverse live improving, health benefits of cannabinoids. Our premium cannabinoid products are all natural, to fit all natural lives.

 

3.2.12

Cyclicality or Seasonality

Not applicable.

 

3.2.13

Business Affected and Dependant Contracts

Not applicable.

 

3.2.14

Environmental Protection Effects

Not applicable.

 

3.2.15

Employees

Xanthic

Xanthic currently has no employees. All management are performing pursuant to consultant contracts.

GGB

As of September 30, 2018, GGB had 20 employees. GGB is also a party to the Advisory Agreements with each of All Js Greenspace LLC and Chiron Ventures Inc. as well as the Financial Advisory Agreements with each of All Js Greenspace LLC, Chiron Ventures Inc. and Hybrid Financial Ltd.

NOR

As of August 31, 2018, NOR had 127 employees, split between its cultivation and dispensary locations.

 

3.2.16

Foreign Operation Risks

See Section 16 – Risk Factors.

 

3.2.17

Competitive Conditions

Retail Cannabis

Nevada has a heavily regulated and restricted retail and medical marijuana framework, where licenses are not only difficult to obtain, but are subject to a competitive application process that favors existing licensees such as NOR.

As one of the first five dispensaries to open in the State of Nevada, NOR opened its doors to medical patients on December 10, 2015 and began retail sales on July 1, 2017. During this time, NOR has distinguished itself as one of the leading dispensaries and retail cannabis stores in Nevada for customer service, compliance, and financial success.

 

- 49 -


Nevada’s competitive landscape is one of the healthiest among the states that have legalized cannabis in some form. There are more than sixty dispensaries in the entire state, although NOR, through its leadership, skill, and knowledge, has outperformed state revenue averages by approximately 200%. NOR, as discussed above, has recently submitted an application for an additional 8 recreational dispensary licenses in the State of Nevada. In all, the state is anticipating awarding 64 new recreational licenses as part of this application process. The market continues to grow, and NOR is in good position to further bolster its position as a leading cannabis retailer in the state.

Wholesale Cannabis

As to cultivation, the State of Nevada has issued approximately 200 such licenses, though only approximately 120 such licenses are currently active. Cultivators in the state are expanding. Pricing is competitive, with prices decreasing on medium-low quality product, while, for high quality product, the demand and pricing remains higher than average.

The State of Nevada issued approximately 100 production licenses, but only about 60 are currently active. Wholesale prices on edibles and cartridges are competitive and falling. CO2 concentrates are more competitively priced. Low-to-medium quality concentrates are competitive, and prices are falling. High quality concentrates and cartridges are maintaining higher prices and can be more difficult to find. Live resins and rosins are top of the market. Live resin cartridges are extremely popular with consumers and are difficult to keep in stock, even at higher prices.

CBD Consumer Products

The CBD consumer product market is nascent but will grow during the remainder of 2018 and through 2019 as legalization of CBD consumer products continues in the United States, Canada, and Europe. The Resulting Issuer anticipates establishing a footprint of operations in all United States locations where such sales are permitted, as well as in Canada and Europe.

At this time, the Resulting Issuer considers its primary competitors to be Charlotte’s Web and Mary’s Nutritionals. However, the Resulting Issuer’s management team, which includes leaders from face-care and body-care retailers such as Bath & Body Works®, places it at a competitive advantage with respect to quality, distribution, scale, and marketing when compared to these competitors.

 

3.2.18

Investment Policies

Not applicable.

 

3.2.19

Effects of Bankruptcy

Not applicable.

 

3.2.20

Material Restructuring

On December 15, 2017, Xanthic was formed pursuant to a reverse takeover involving Aurquest and a privately held Ontario corporation, Xanthic Biopharma Limited, with the objective of becoming a leader in developing innovative, non-combustible alternative delivery methods for cannabis-infused products.

 

3.2.21

Social or Environmental Policies

Not applicable.

 

- 50 -


3.3

Companies with Asset-backed Securities Outstanding

Not applicable.

 

3.4

Mineral Projects

Not applicable.

 

3.5

Issuers with Oil and Gas Operations

Not applicable.

 

- 51 -


4.

SELECTED CONSOLIDATED FINANCIAL INFORMATION

 

4.1

Financial Information

Issuer

The following table is a summary of selected financial information of the Issuer for the financial years ended June 30, 2018 and June 30, 2017:

 

Xanthic              
(Expressed in Canadian dollars)              
     June 30, 2018      June 30, 2017  

Total Revenue

   $ —        $ —    

Net Income (loss) from operations

     (2,829,225      (101,541

Net loss and Comprehensive loss

     (2,843,644      (101,541

Net Loss per common share (basic and fully diluted)

     0.08        0.04  
     

Total Assets

     2,809,504        36,524  

Total Long term financial liabilities

     0.00        0.00  

Dividends declared

   $ —        $ —    

A copy of the financial statements for the financial year ended June 30, 2018 previously filed with applicable securities commissions is available on the Issuer’s SEDAR profile at www.sedar.com and attached to Schedule “A” of this Listing Statement.

A copy of the pro forma consolidated statement of financial position of the Issuer as at June 30, 2018 is attached to Schedule “E” of this Listing Statement.

GGB

The following table is a summary of selected financial information of GGB for the periods ended July 31, 2017 and July 31, 2018:

 

GGB              
(Expressed in United States dollars)              
     July 31, 2018      July 31, 2017  

Total Revenue

   $ —        $ —    

Net Income (loss) from operations

     (3,945,120      —    

Net loss and Comprehensive loss

     (3,945,120      —    

Net Loss per common share (basic and fully diluted)

     0.06        —    
     

Total Assets

     4,383,959        —    

Total Long term financial liabilities

     0.00        —    

Dividends declared

   $ —        $ —    

A copy of the financial statements of GGB for the period ended July 31, 2018 is attached as Schedule “B” to this Listing Statement.

 

- 52 -


4.2

Quarterly Information

Issuer

The following information is in respect of the Issuer for the five quarters preceding the date of this Listing Statement:

 

(Expressed in Canadian dollars)                               
     June 30,
2018
    March 31,
2018
    December
31, 2017
    September
30, 2017
    June 30,
2017
 

Total Revenue

   $ —       $ —       $ —       $ —       $ —    

Net Income (loss) from operations

     (860,004     (566,047     (1,328,678     (74,496     (101,541

Net loss and Comprehensive loss

     (856,364     (582,416     (1,330,368     (74,496     (101,541

Net Loss per common share (basic and fully diluted)

     0.02       0.01       0.01       0.01       0.04  

Copies of the respective unaudited interim financial statements for the periods listed above for the Issuer are available on the Issuer’s SEDAR profile at www.sedar.com.

GGB

The following information is in respect of GGB for the two quarters since incorporation preceding the date of this Listing Statement:

 

(Expressed in United States dollars)              
     July 31,
2018
     April 30,
2018
 

Total Revenue

   $ —        $ —    

Net Income (loss) from operations

     (2,673,381      (821,739

Net loss and Comprehensive loss

     (2,673,381      (821,739

Net Loss per common share (basic and fully diluted)

     0.05        0.01  

 

4.3

Dividends

Neither the Issuer, GGB and NOR have paid any dividends on their shares since incorporation.

Other than statutory rules provided by the OBCA, there are no restrictions in the Resulting Issuer’s articles that prevent the declaration of dividends.

With respect to the Resulting Issuer, the payment of dividends, if any, will rest within the sole discretion of the directors of the Resulting Issuer. The decision to declare and pay dividends depends upon earnings, capital requirements and financial condition, as well as other relevant factors. Since incorporation, GGB has not declared any cash dividends and it intends to retain its earnings to finance the growth and expansion of its operations. As such, GGB and the Issuer do not anticipate that the Resulting Issuer will pay any dividends on the Resulting Issuer Shares or other securities in the foreseeable future.

 

- 53 -


4.4

Foreign GAAP

Not applicable.

 

5.

MANAGEMENT’S DISCUSSION AND ANALYSIS

The Issuer’s management’s discussion and analysis for the year ended June 30, 2018 is available on the Issuer’s SEDAR profile at www.sedar.com and is attached as Schedule “C” hereto.

GGB’s management’s discussion and analysis for the period ended July 31, 2018 is attached as Schedule “D” hereto.

 

6.

MARKET FOR SECURITIES

The Issuer Common Shares are listed on the CSE under the symbol “xTHC” and, subject to the final approval of the CSE, the Resulting Issuer Common Shares will be listed on the CSE under the trading symbol “GGB”. Listing on the CSE will be subject to the Resulting Issuer fulfilling all of the requirements of the CSE.

 

7.

CONSOLIDATED CAPITALIZATION

The following table sets out the capitalization of the Issuer as at June 30, 2018 and prior to giving effect to the Business Combination:

 

Designation of Security

  

Authorized Amount

  

Amount Outstanding as at
June 30, 2018

  

Amount Outstanding
prior to the Business
Combination

Issuer Common Shares    Unlimited    56,846,547    57,746,547
Issuer Options    10% of the issued and outstanding Issuer Common Shares    3,508,000    2,608,000
Issuer Common Warrants    Unlimited    568,000    568,000

 

- 54 -


The following table sets out the capitalization of the Resulting Issuer after giving effect to the Business Combination, and should be read with the unaudited pro forma consolidated financial statements of the Resulting Issuer included as Schedule “E” hereto:

 

Designation of Security

  

Authorized Amount

   Amount
Outstanding
as at June
30, 2018
Resulting Issuer Common Shares    Unlimited    163,843,785

Resulting Issuer Common Shares

reserved for issuance upon exercise of Resulting Issuer Common Warrants

   Unlimited    34,008,112

Resulting Issuer Common Shares

reserved upon exercise of Resulting

Issuer Broker Warrants

   Unlimited    1,226,736

Resulting Issuer Common Shares

reserved for issuance upon exercise of Resulting Issuer Options

   10% of the issued and outstanding Resulting Issuer Common Shares    652,000
Resulting Issuer Proportionate Shares    Unlimited    38,194

Resulting Issuer Proportionate Shares reserved for issuance upon exercise of

Resulting Issuer Proportionate Warrants

   Unlimited    19,097

 

8.

OPTIONS TO PURCHASE SECURITIES

 

8.1

Issuer Equity Incentive Plan

The Issuer has adopted the Issuer Equity Incentive Plan which provides flexibility to the Issuer to grant equity-based incentive awards in the form of options, deferred share units and restricted share units (as described in further detail below) to attract, retain and motivate qualified directors, officers, key employees and consultants of the Issuer and its subsidiaries.

The following is a summary of the key terms of the Issuer Equity Incentive Plan.

 

8.1.1

Issuer Common Shares Subject to the Issuer Equity Incentive Plan

Subject to the adjustment provisions provided for in the Issuer Equity Incentive Plan, the total number of Issuer Common Shares reserved for issuance pursuant to awards granted under the Issuer Equity Incentive Plan shall not exceed 10% of the issued and outstanding Issuer Common Shares from time to time.

 

8.1.2

Administration of the Issuer Equity Incentive Plan

The plan administrator of the Issuer Equity Incentive Plan (the “Plan Administrator”) will be determined by the Issuer Board, and will initially be the Issuer Board as a whole, but may in the future be delegated to a committee of the Issuer Board as may be established by the Issuer Board from time to time. The Plan Administrator will determine which employees, directors, officers or consultants are eligible to receive awards under the Issuer Equity Incentive Plan. In addition, the Plan Administrator will interpret the Issuer

 

- 55 -


Equity Incentive Plan and may adopt administrative rules, regulations, procedures and guidelines governing the Issuer Equity Incentive Plan or any awards granted under the Issuer Equity Incentive Plan as it deems to be appropriate.

 

8.1.3

Types of Awards

The following types of awards may be made under the Issuer Equity Incentive Plan: stock options, restricted share units and deferred share units. All of the awards described below are subject to the conditions, limitations, restrictions, exercise price, vesting, settlement and forfeiture provisions determined by the Plan Administrator, in its sole discretion, subject to such limitations provided in the Issuer Equity Incentive Plan, and will generally be evidenced by an award agreement. In addition, subject to the limitations provided in the Issuer Equity Incentive Plan and in accordance with applicable law, the Plan Administrator may accelerate or defer the vesting, settlement or payment of awards, cancel or modify outstanding awards, and waive any condition imposed with respect to awards or Issuer Common Shares issued pursuant to awards.

 

8.1.3.1  

Issuer Options

A stock option (“Issuer Option”) is a right to purchase Issuer Common Shares upon the payment of a specified exercise price as determined by the Plan Administrator at the time the stock option is granted. Subject to certain adjustments and whether the Issuer Common Shares are then trading on any stock exchange, the exercise price shall be not less than the volume weighted average closing price of the Issuer Common Shares for the five days immediately preceding the date of grant (the “Market Price”). The Plan Administrator shall have the authority to determine the vesting terms applicable to the grants of options. Subject to any accelerated termination as set forth in the Issuer Equity Incentive Plan, each stock option expires on the date that is the earlier of ten years from the date of grant or such earlier date as may be set out in the participant’s award agreement.

No Issuer Common Shares will be issued or transferred upon the exercise of stock options in accordance with the terms of the grant until full payment therefor has been received by the Issuer.

 

8.1.3.2  

Issuer Restricted Share Units

A restricted share unit is a unit equivalent in value to an Issuer Common Share credited by means of a bookkeeping entry in the books of the Issuer which entitles the holder to receive one Issuer Common Share for each restricted share unit after a specified vesting period determined by the Plan Administrator. The number of restricted share units (including fractional restricted share units) granted at any particular time is determined by dividing (a) the aggregate dollar value of the applicable grant, by (b) the Market Price of an Issuer Common Share on the date of grant. Upon settlement, holders will receive (a) one fully paid and non-assessable Issuer Common Share in respect of each vested restricted share unit, or (b) subject to the approval of the Plan Administrator, a cash payment. The cash payment is determined by multiplying the number of restricted share units redeemed for cash by the Market Price of the Issuer Common Share on the date of settlement.

 

8.1.3.3  

Issuer Deferred Share Units

A deferred share unit is a unit equivalent in value to an Issuer Common Share credited by means of a bookkeeping entry in the books of the Issuer which entitles the holder to receive one Issuer Common Share for each deferred share unit on a future date, generally upon termination of service to the Issuer. The number of deferred share units (including fractional deferred share units) granted at any particular time is determined by dividing (a) the aggregate dollar value of the applicable grant, by (b) the Market

 

- 56 -


Price of an Issuer Common Share on the date of grant. Upon settlement, holders will receive (a) one fully paid and non-assessable Issuer Common Share in respect of each vested deferred share unit, or (b) subject to the approval of the Plan Administrator, a cash payment. The cash payment is determined with reference to the Market Price in the same manner as with the restricted share units.

 

8.1.3.4.  

Dividend Equivalents

Restricted share units and deferred share units shall be credited with dividend equivalents in the form of additional restricted share units and deferred share units, as applicable. Dividend equivalents shall vest in proportion to, and settle in the same manner as, the awards to which they relate. Such dividend equivalents shall be computed by dividing: (a) the amount obtained by multiplying the amount of the dividend declared and paid per Issuer Common Share by the number of restricted share units and deferred share units, as applicable, held by the participant on the record date for the payment of such dividend, by (b) the Market Price at the close of the first business day immediately following the dividend record date, with fractions computed to three decimal places.

 

8.1.4

Black-out Periods

If an award expires during, or within five business days after, a trading black-out period imposed by the Issuer to restrict trades in its securities, then, notwithstanding any other provision of the Issuer Equity Incentive Plan, unless the delayed expiration would result in tax penalties, the award shall expire ten business days after the trading black-out period is lifted by the Issuer.

 

8.1.5

Terminations

All awards granted under the Issuer Equity Incentive Plan will expire on the date set out in the applicable award agreement, subject to early expiry in certain circumstances, provided that in no circumstances will the duration of an award granted under the Issuer Equity Incentive Plan exceed 10 years from its date of grant.

 

8.1.6

Termination of Employment or Services

The following table describes the impact of certain events that may, unless otherwise determined by the Plan Administrator or as set forth in an award agreement, lead to the early expiry of awards granted under the Issuer Equity Incentive Plan:

 

Event

  

Provisions

Death or disability    Acceleration of vesting of all unvested awards
Voluntary resignation    Forfeiture of all unvested awards
Termination for cause    Forfeiture of all unvested awards
Termination other than for cause    Acceleration of vesting of a prorated portion of all unvested awards and forfeiture of all other unvested awards

 

- 57 -


8.1.7

Non-Transferability of Awards

Subject to certain exceptions provided under the Issuer Equity Incentive Plan, and unless otherwise provided by the Plan Administrator, and to the extent that certain rights may pass to a beneficiary or legal representative upon death of a participant, by will or as required by law, no assignment or transfer of awards granted under the Issuer Equity Incentive Plan, whether voluntary, involuntary, by operation of law or otherwise, is permitted.

See Section 14 – Executive Compensation for a tabular description of Issuer Options outstanding.

 

8.3

Resulting Issuer Equity Incentive Plan

On completion of the Business Combination, the Resulting Issuer will continue the Issuer Equity Incentive Plan (the “Resulting Issuer Equity Incentive Plan”).

 

- 58 -


9.

DESCRIPTION OF THE SECURITIES

 

9.1

Description of the Securities

The authorized share capital of the Resulting Issuer will consist of: (i) an unlimited number of Resulting Issuer Common Shares, without par value and (ii) an unlimited number of Proportionate Voting Shares. Other securities to be outstanding include Resulting Issuer Common Warrants, Resulting Issuer Proportionate Warrants, Resulting Issuer Broker Warrants, and Resulting Issuer Options.

Resulting Issuer Common Shares

The holders of the Resulting Issuer Common Shares will be entitled to vote at meetings of the Resulting Issuer Shareholders, except meetings at which only holders of a specified class of shares are entitled to vote. Holders of Resulting Issuer Common Shares will not have cumulative voting rights. Subject to the rights, privileges and restrictions and conditions attaching to any other class of shares of the Resulting Issuer, the holders of the Resulting Issuer Common Shares will be entitled to share equally in the remaining property of the Resulting Issuer upon liquidation, dissolution or winding-up of the Resulting Issuer. Subject to the rights of the holders of Resulting Issuer Proportionate Shares, the holders of the Resulting Issuer Common Shares will be entitled to receive dividends if, as and when declared by the Resulting Issuer Board. Resulting Issuer Common Shares may at any time, at the option of the holder, be converted into Resulting Issuer Proportionate Shares on the basis of 500 Resulting Issuer Common Shares for one Resulting Issuer Proportionate Share. The Resulting Issuer Common Shares will not carry any pre-emptive, subscription or redemption rights, nor will they contain any sinking or purchase fund provisions.

At Closing, there will be 163,843,785 Resulting Issuer Common Shares issued and outstanding.

Resulting Issuer Proportionate Shares

Except as set out below, the Resulting Issuer Common Shares and Resulting Issuer Proportionate Shares shall have the same rights and be equal in all respects and shall be treated by the Resulting Issuer as if they were shares of one class only:

 

  a)

Liquidation Rights. In the event of the liquidation, dissolution or winding-up of the Resulting Issuer or any other distribution of its assets among the Resulting Issuer Shareholders for the purpose of winding-up its affairs, whether voluntarily or involuntarily, all the property and assets of the Resulting Issuer available for distribution to the holders of the Resulting Issuer Common Shares and Resulting Issuer Proportionate Shares will be paid or distributed on the basis that each Resulting Issuer Proportionate Share will be entitled to 500 times the amount distributed per Resulting Issuer Common Share, but otherwise there is no preference or distinction among or between the Resulting Issuer Common Shares and Resulting Issuer Proportionate Shares.

 

  b)

Dividend Rights. All dividends which are declared in the discretion of the directors on the Resulting Issuer Proportionate Shares shall be declared and paid on the Resulting Issuer Common Shares at the time outstanding, and vice versa, in the proportion hereinafter provided for. If, as and when dividends are declared by the directors, each Resulting Issuer Proportionate Share is entitled to 500 times the amount paid or distributed per Resulting Issuer Common Share.

 

  c)

Voting Rights. The holders of Resulting Issuer Proportionate Shares are entitled to receive notice of any meeting of Resulting Issuer Shareholders, and to attend and vote at those meetings, except

 

- 59 -


 

those meetings at which holders of a specific class of shares are entitled to vote separately as a class under the OBCA. The Resulting Issuer Proportionate Shares carry 500 votes per Resulting Issuer Proportionate Share for all matters coming before shareholders.

 

  d)

Conversion Rights.

 

  a.

Conversion Right. Each issued and outstanding Resulting Issuer Proportionate Share may at any time, at the option of the holder, be converted into 500 Resulting Issuer Common Shares.

 

  b.

Foreign Private Issuer Status. The Resulting Issuer shall use commercially reasonable efforts to maintain its status as a “foreign private issuer” (as determined in accordance with Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Accordingly, the Resulting Issuer shall not give effect to any voluntary conversion of Resulting Issuer Proportionate Shares and the Resulting Issuer Proportionate Share conversion right will not apply, to the extent that after giving effect to all permitted issuances after such conversion of Resulting Issuer Proportionate Shares, the aggregate number of Resulting Issuer Shares (calculated on the basis that each Resulting Issuer Common Share and Resulting Issuer Proportionate Share is counted once, without regard to the number of votes carried by such share) held of record, directly or indirectly, by residents of the United States (as determined in accordance with Rules 3b-4 and 12g3-2(a) under the Exchange Act would exceed forty percent (40%) (the “40% Threshold”) of the aggregate number of Resulting Issuer Shares (calculated on the same basis) issued and outstanding as calculated herein.

At Closing, there will be 38,194 Proportionate Voting Shares issued and outstanding.

Take-Over Bid Protection

Under applicable Canadian securities laws, an offer to purchase Resulting Issuer Proportionate Shares Shares would not necessarily require that an offer be made to purchase the Resulting Issuer Common Shares. The holders of all the outstanding Resulting Issuer Proportionate Shares will therefore enter into a customary coattail agreement with the Resulting Issuer and a trustee (the “Coattail Agreement”). The Coattail Agreement will contain provisions customary for dual class, listed corporations designed to prevent transactions that otherwise would deprive the holders of the Resulting Issuer Common Shares of rights under applicable provincial take-over bid legislation to which they would have been otherwise entitled.

The undertakings in the Coattail Agreement will not apply to prevent a sale by any holder of Resulting Issuer Proportionate Shares if concurrently an offer is made to purchase Resulting Issuer Common Shares that:

 

  a)

offers a price per Resulting Issuer Common Share (on an as converted basis) at least as high as the highest price per share paid pursuant to the take-over bid for the Resulting Issuer Proportionate Shares (on an as converted basis);

 

  b)

provides that the percentage of outstanding Resulting Issuer Common Shares to be taken up (exclusive of shares owned immediately prior to the offer by the offeror or persons acting jointly or in concert with the offeror) is at least as high as the percentage of Resulting Issuer Proportionate Shares to be sold (exclusive of Resulting Issuer Proportionate Shares owned

 

- 60 -


 

immediately prior to the offer by the offeror and persons acting jointly or in concert with the offeror);

 

  c)

has no condition attached other than the right not to take up and pay for Resulting Issuer Common Shares tendered if no shares are purchased pursuant to the offer for Resulting Issuer Proportionate Shares; and

 

  d)

is in all other material respects identical to the offer for Resulting Issuer Proportionate Shares.

Under the Coattail Agreement, any disposition of Resulting Issuer Proportionate Shares (including a transfer to a pledgee as security) by a holder of Resulting Issuer Proportionate Shares party to the agreement will be conditional upon the transferee or pledgee becoming a party to the Coattail Agreement, to the extent such transferred Resulting Issuer Proportionate Shares are not automatically converted into Resulting Issuer Common Shares in accordance with the articles of incorporation.

The Coattail Agreement will contain provisions for authorizing action by the trustee to enforce the rights under the Coattail Agreement on behalf of the holders of the Resulting Issuer Common Shares. The obligation of the trustee to take such action will be conditional on the Resulting Issuer or holders of the Resulting Issuer Common Shares, as the case may be, providing such funds and indemnity as the trustee may require. No holder of Resulting Issuer Common Shares, as the case may be, will have the right, other than through the trustee, to institute any action or proceeding or to exercise any other remedy to enforce any rights arising under the Coattail Agreement unless the trustee fails to act on a request authorized by holders of not less than 10% of the outstanding Resulting Issuer Common Shares, as the case may be, and reasonable funds and indemnity have been provided to the trustee. The Corporation will agree to pay the reasonable costs of any action that may be taken in good faith by holders of Resulting Issuer Common Shares, as the case may be, pursuant to the Coattail Agreement.

The Coattail Agreement will provide that it may not be amended, and no provision thereof may be waived, unless, prior to giving effect to such amendment or waiver, the following have been obtained: (a) the consent of any applicable securities regulatory authority in Canada, and (b) the approval of at least 66-2/3% of the votes cast by holders of Common Shares excluding votes attached to Common Shares, if any, held by holders of Resulting Issuer Proportionate Shares, their affiliates and any persons who have an agreement to purchase Resulting Issuer Proportionate Shares on terms which would constitute a sale or disposition for purposes of the Coattail Agreement other than as permitted thereby.

No provision of the Coattail Agreement will limit the rights of any holders of Resulting Issuer Common Shares under applicable law.

 

- 60 -


Resulting Issuer Common Warrants

At Closing, the Resulting Issuer will have the following Resulting Issuer Common Warrants outstanding:

 

(post 4:1 Consolidation)                     

Name

   #Warrants
O/S
     Exercise Price      Expiry Date  

Xanthic

     142,000      $ 3.00        April 18, 2020  

GGB Convertible Debenture Tranche 1

     3,124,305        1.80        August 29, 2020  

GGB Convertible Debenture Tranche 2

     18,512,847        1.80        September 20, 2020  

Private Placement

     12,228,960        2.00        Day before Closing Date 
  

 

 

       
     34,008,112        
  

 

 

       

Notes:

*

The GGB Common Warrants expire one day before the Closing Date with proceeds due no more than 30 days following the exercise date.

Resulting Issuer Proportionate Warrants

At Closing, the Resulting Issuer will have the following Resulting Issuer Proportionate Warrants outstanding:

 

(post 4:1 Consolidation)                     

Name

   #Warrants
O/S
     Exercise Price      Expiry Date  

GGB Convertible Debenture Tranche 1

     19,097        180.00        September 20, 2020  
  

 

 

       
     19,097        
  

 

 

       

Resulting Issuer Broker Warrants

At Closing, the Resulting Issuer will have the following Resulting Issuer Broker Warrants outstanding:

 

(post 4:1 Consolidation)                     

Name

   #Warrants
O/S
     Exercise Price      Expiry Date  

GGB Convertible Debenture

     1,226,736        1.80        September 20, 2020  
  

 

 

       
     1,226,736        
  

 

 

       

 

- 62 -


Resulting Issuer Options

Upon completion of the Business Combination, the Resulting Issuer will continue the Resulting Issuer Equity Incentive Plan. As at the date of this Listing Statement, the Issuer has 163,843,785 Issuer Common Shares issued and outstanding so that a maximum of 16,384,378 Issuer Common Shares would be available for issuance pursuant to Issuer Options granted under the Issuer Equity Incentive Plan. Currently there are 652,000 Issuer Options outstanding under the Issuer Equity Incentive Plan, leaving 15,732,378 Issuer Common Shares available for grant of further Issuer Options. See Section 8 – Options to Purchase Securities – Issuer Equity Incentive Plan for more details.

 

9.2

Debt Securities, Other Securities, Modification of Terms and Other Attributes

None of the matters set out in section 9.2 to 9.6 of this Listing Statement are applicable.

 

9.7

Prior Sales

Issuer

The following table summarizes the issuances of securities of the Issuer within 12 months prior to the date of this Listing Statement:

 

Date of Issue

   Description    Number of Securities   Price per Security
(C$)
   Total Issue Price
(C$)

November 7, 2017

   Private Placement    20,000,000 Issuer
Common Shares
  $0.02    $400,000

December 13, 2017

   Private Placement    10,252,000 Issuer
Common Shares
  $0.125    $1,281,500

January 17, 2018

   Private Placement    96,000,000 Issuer
Common Shares
  $0.015625    $1,500,000

April 19, 2018

   Private Placement    1,112,000 Units(1)   $0.50    $556,000

Notes:

(1)

Each Unit consisted of one Issuer Common Share and one-half of one common share purchase warrant. Each whole warrant (“Issuer Common Warrant”) entitles the holder thereof to purchase one Issuer Common Share at an exercise price of C$0.75 per Issuer Common Share for a period of 24 months from the date of closing, being April 19, 2018.

GGB

The following table summarizes the issuances of GGB Shares since incorporation up to the date of this Listing Statement:

 

Date of Issue

   Description    Number of
Shares
   Price per Share
(C$)
   Total Issue Price
(C$)

February 14, 2018

   GGB Common Shares    2    0.10    $0.20

April 10, 2018

   GGB Common Shares    92,000,000    0.10    $9,200,000

July 16, 2018

   GGB Common Shares    6,340,000    0.10    $634,000

July 16, 2018

   GGB Common Shares    2,425,000    0.10    $242,500

 

- 63 -


9.8

Stock Exchange Price

The Issuer Common Shares are listed and posted for trading on the CSE under the symbol “xTHC”. The following table sets forth the high and low sale prices and trading volumes of the Issuer Common Shares on the CSE for each of the months indicated.

 

Period

   High (C$)      Low (C$)      Volume  

July 2018(2)

     0.280        0.225        1,828,005  

June 2018

     0.300        0.180        10,220,140  

May 2018

     0.325        0.145        6,781,251  

April 2018(1)

     0.570        0.250        3,226,869  

Notes:

 

(1)

Trading of the Issuer Common Shares commenced on April 19, 2018.

 

(2)

Trading of the Issuer Common Shares was halted on July 13, 2018 pending the announcement of the Business Combination and will remain halted pending completion of the Business Combination.

 

10.

ESCROWED SECURITIES

The Resulting Issuer will be an exempt issuer pursuant to Section 3.2 of National Policy 46-201 – Escrow for Initial Public Offerings (“NP 46-201”) due to the fact that, following the Business Combination, the Resulting Issuer will have a market capitalization of over C$100 million. As a result, no Resulting Issuer Shares will be escrowed pursuant to NP 46-201.

Prior to the Closing Date, GGB intends to use commercially reasonable efforts to enter into voluntary lock-up agreements with certain current GGB Shareholders.

 

11.

PRINCIPAL SHAREHOLDERS

Following completion of the Business Combination, except as noted below, no person will beneficially own, directly or indirectly, or exercise control or direction over 10% or more of the Resulting Issuer Shares.

 

Name

   Type of Security    Number of
Securities
  Percentage of class
(undiluted /diluted)

All Js Greenspace LLC(1)

   Resulting Issuer
Common Shares
   37,464,236 (Basic)

38,011,111 (Fully Diluted)

  22.9% / 19.0%

All Js Greenspace LLC

   Resulting Issuer
Proportionate Shares
   38,194 (Basic)

57,291 (Fully Diluted)

  100% / 100%

Notes:

(1)

All Js Greenspace LLC is a company controlled by three individual family trusts.

 

- 64 -


12.

DIRECTORS AND OFFICERS OF THE RESULTING ISSUER

 

12.1

Directors and Executive Officers of the Resulting Issuer

Following completion of the Business Combination, the Resulting Issuer Board and its executive officers will consist of the individuals set out in the table below:

 

Name, place of
residence and
position with the
Resulting Issuer

  

Principal occupation
during past five years

   Periods During Which
Each Proposed
Director Has Served
as a Director
   Number of
Resulting Issuer
Common
Shares(1)
   Percentage of
Resulting
Issuer
Common
Shares

Tim Moore

Chief Executive Officer and Director

Unionville, ON

   CEO of the Issuer; Managing Director of Brita GmbH North America    December 15, 2017    387,500    0.19%

David Bhumgara

Chief Financial Officer

Toronto, ON

   CFO of the Issuer; CFO of Dundee Energy Limited    N/A    168,750    0.08%

Igor Galitsky

President and Director

Thornhill, ON

   President of the Issuer; Entrepreneur and consultant to the cannabis industry    December 15, 2017    957,083    0.48%

Jean Schottenstein

Director

Columbus, OH

   Trustee, Columbus Museum of Art; Founder, Beit Ohr Community Domestic Violence Program    July 11, 2018    Nil.    0%

Peter Horvath

Director

New Albany, OH

   CEO of GGB; CEO of Mission Essential Personnel    July 11, 2018    5,500,064    2.75%

Steve Stoute

Independent Director

New York, NY

   Founder and CEO of Translation    July 11, 2018    Nil.    0%

Carli Posner

Independent Director

Toronto, ON

   Film producer at Notable Life    February 16, 2018    50,000    0.03%

Marc Lehmann

Independent Director

Miami, FLA

   Managing Member of Flamingo Drive Partners, LLC; General Partner at Riverloft Capital Management    July 11, 2018    347,222    0.17%

 

- 65 -


Notes

 

(1)

No directors or executive officers of the Resulting Issuer will hold Resulting Issuer Proportionate Shares.

 

12.2

Period of Service of Directors

The term of each director will expire on the date of the next annual general meeting, unless his or her office is earlier vacated or he or she is removed in accordance with the Resulting Issuer’s articles and the OBCA.

 

12.3

Directors and Executive Officers Resulting Issuer Share Ownership

The proposed directors and executive officers of the Resulting Issuer as a group, directly or indirectly, will beneficially own or exercise control or direction over 7,410,619 Resulting Issuer Common Shares, representing approximately 3.7% of the issued and outstanding Resulting Issuer Common Shares. No directors or executive officers of the Resulting Issuer will beneficially own or exercise control over any Resulting Issuer Proportionate Shares.

 

12.4

Committees

Upon completion of the Business Combination, the Resulting Issuer Board proposes to establish two committees: the Audit Committee and the Compensation & Governance Committee (“C&G Committee”).

The Audit Committee will initially consist of Carli Posner (Chair), Igor Galitsky and Steve Stoute, in compliance with the requirements applicable to venture issuers under National Instrument 52-110Audit Committees (“NI 52-110”). Each of the Audit Committee members has an understanding of the accounting principles used to prepare the Resulting Issuer’s financial statements; experience preparing, auditing, analyzing or evaluating comparable financial statements; and experience as to the general application of relevant accounting principles, as well as an understanding of the internal controls and procedures necessary for financial reporting.

The Resulting Issuer Board proposes to adopt a written charter for the Audit Committee which sets out the Audit Committee’s responsibility in reviewing the financial statements of the Resulting Issuer and public disclosure documents containing financial information and reporting on such review to the Resulting Issuer Board, ensuring that adequate procedures are in place for the review of the Resulting Issuer’s public disclosure documents that contain financial information, overseeing the work and reviewing the independence of the external auditors and reviewing, evaluating and approving the internal control procedures that are implemented and maintained by management.

The C&G Committee will initially consist of Marc Lehmann (Chair), Carli Posner, and Steve Stoute. The C&G Committee will be charged with reviewing, overseeing and evaluating the governance and nominating policies and the compensation policies of the Resulting Issuer.

The Resulting Issuer Board may from time to time establish additional committees.

 

12.5

Principal Occupation of Directors and Executive Officers

Information on directors and executive officers’ principal occupation is set out in the table above.

 

- 66 -


12.6

Corporate Cease Trade Orders or Bankruptcies

No proposed director or executive officer of the Resulting Issuer or a shareholder that will hold a sufficient number of securities of the Resulting Issuer to affect materially the control of the Resulting Issuer, is, or within 10 years before the date of the Listing Statement has been, a director or officer of any other issuer that, while that person was acting in that capacity:

 

  a)

was the subject of a cease trade or similar order, or an order that denied the other issuer access to any exemptions under securities legislation, for a period of more than 30 consecutive days, except:

 

  b)

was subject to an event that resulted, after the director or executive officer ceased to be a director or executive officer, in the company being the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than 30 consecutive days, except:

 

  c)

became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets, except:

 

  d)

within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets, except:

 

12.7

Penalties or Sanctions

No proposed director or executive officer of the Resulting Issuer, or a shareholder that will hold a sufficient number of the Resulting Issuer’s securities to affect materially the control of the Resulting Issuer, has been subject to:

 

  a)

any penalties or sanctions imposed by a court relating to Canadian securities legislation or by a Canadian securities regulatory authority or has entered into a settlement agreement with a Canadian securities regulatory authority; or

 

  b)

any other penalties or sanctions imposed by a court or regulatory body that would be likely to be considered important to a reasonable investor making an investment decision.

 

12.8

Intentionally Deleted

 

12.9

Personal Bankruptcies

No proposed director or executive officer of the Resulting Issuer or a shareholder that will hold a sufficient number of securities of the Resulting Issuer to affect materially the control of the Resulting Issuer, or a personal holding company of any such persons has, within the 10 years before the date of the Listing Statement, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or been subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director or officer.

 

- 67 -


12.10      Conflicts

of Interest

The proposed directors of the Resulting Issuer will be required by law to act honestly and in good faith with a view to the best interests of the Resulting Issuer and to disclose any interests, which they may have in any project or opportunity of the Resulting Issuer. If a conflict of interest arises at a meeting of the Resulting Issuer Board, any director in a conflict will disclose his or her interest and abstain from voting on such matter.

To the best of GGB’s and the Issuer’s knowledge, there are no known existing or potential conflicts of interest among the Resulting Issuer, proposed directors, executive officers or other members of management of the Resulting Issuer as a result of their outside business interests other than the Lease and certain product testing agreements with DSW®, except that certain proposed directors and officers may serve as directors and officers of other companies, and therefore it is possible that a conflict may arise between their duties to the Resulting Issuer and their duties as a director or officer of such other companies. See Section 16 - Risk Factors for more details.

 

12.11      Management

Details

Details with respect to the proposed directors and management of the Resulting Issuer are set out below.

Tim Moore (Age 60), Chief Executive Officer & Director

Mr. Moore has been the Chief Executive Officer of the Issuer since December 2017 and will continue to serve as the Chief Executive Officer of the Resulting Issuer. Mr. Moore has over 30 years of experience in various consumer products companies, including 18 years with The Clorox Company, a NYSE-listed company. Prior to working with The Clorox Company, Mr. Moore was the Managing Director, North America, for Brita GmbH, a privately held German manufacturer of water filters. Previous to Brita, Mr. Moore was the Chief Operating Officer for Synnex, a NYSE-listed electronics distribution company. Mr. Moore holds a Bachelor of Arts (Economics) from Western University and a Master of Business Administration from the Richard Ivey School of Business. The Resulting Issuer intends to enter into a non-competition and non-disclosure agreement with Mr. Moore in the future.

Mr. Moore expects to devote 100% of his time to the affairs of the Resulting Issuer.

David Bhumgara (Age 49), Chief Financial Officer

Mr. Bhumgara has been the Chief Financial Officer of the Issuer since December 2017 and will continue to serve as the Chief Financial Officer of the Resulting Issuer. Mr. Bhumgara has over 20 years of finance experience across various industries and capacities. Prior to working with the Issuer, Mr. Bhumgara was the Chief Financial Officer of Dundee Energy Limited, a TSX-listed company, from September 2009 to December 2016. Previous to that, Mr. Bhumgara was a financial consultant from February 2009 to September 2009. From August 2007 to February 2009, Mr. Bhumgara was a corporate controller for Strategic Resource Acquisition Corporation, a TSX-listed mining company. Mr. Bhumgara is a Chartered Professional Accountant and holds a Bachelor of Commerce Honours degree in Accounting from the University of Ottawa. The Resulting Issuer intends to enter into a non-competition and non-disclosure agreement with Mr. Bhumgara in the future.

Mr. Bhumgara expects to devote 100% of his time to the affairs of the Resulting Issuer.

 

- 68 -


Igor Galitsky (Age 46), President & Director

Mr. Galitsky has been President of the Issuer since December 2017 and will continue as the President of the Resulting Issuer. Mr. Galitsky was one the of the first applicants to receive a license under the Marijuana Medical Access Regulations for both personal and designated production in Canada. Mr. Galitsky has developed and refined over the last seven years the production and extraction processes for cannabis. In addition, Mr. Galitsky has been consulting varies licensed producers in Canada on scaling and refining their extraction and secondary processes. The Resulting Issuer intends to enter into a non-competition and non-disclosure agreement with Mr. Galitsky in the future.

Mr. Galitsky expects to devote 40% of his time to the affairs of the Resulting Issuer.

Jean Schottenstein (Age 62), Director

Mrs. Schottenstein will serve as an independent director on the Resulting Issuer Board. Mrs. Schottenstein serves on the Board of Trustees of the Columbus Museum of Art, is Co-Chair of Congregation Torat Emet/Main Street Synagogue, and is Chair of “Defining Moments,” a group dedicated to leadership development. She is also on the Board of Trustees of Nishmat – the Jerusalem Center For Advanced Torah Study for Women and has co-chaired the recently completed Columbus Community Mikvah Capital Campaign. She has previously served on the Boards of Trustees of Central Ohio State of Israel Bonds and Columbus Torah Academy; Chairperson of the Columbus Jewish Federation’s Women’s Division for their annual appeal; and the Board of Trustees of “I know I can.” Mrs. Schottenstein is deeply committed to issues relating to women’s health, education and increasing awareness of domestic violence. To that end, she created “Beit Ohr,” a community program designed to help meet the needs of victims of domestic violence within the Jewish community and serves as Honorary Chair of the National Council of Jewish Women’s “Women of Valor” program. Mrs. Schottenstein attended Indiana University and is a graduate of The Ohio State University with a Bachelor of Science in Accounting and a Master of Science in Psychology from the University of Phoenix. Ms. Schottenstein is not party to any non-competition or non-disclosure agreement with the Resulting Issuer.

Peter Horvath (Age 61), Director

Mr. Horvath will serve as an independent director on the Resulting Issuer Board. Mr. Horvath currently serves as the chief executive officer of GGB LLC, doing business as Green Growth Brands Ltd., a lifestyle oriented, consumer products company that celebrates health, wellness and happiness. Mr. Horvath has 35 years of executive management experience with specialty brand retailers such as American Eagle Outfitters®, DSW®, and Victoria’s Secret® and L Brands®. From 2012 to 2015, Mr. Horvath served as Chief Executive Officer Mission Essential Personnel, a defense contractor focusing on intelligence solutions. Mr. Horvath received his Bachelor of Business Administration, Business, Management, Marketing, and Related Support Services from Boston University, School of Management. Mr. Horvath is party to a non-competition and non-disclosure agreement with the Resulting Issuer.

Marc Lehmann (Age 46), Independent Director

Mr. Lehmann will serve as an independent director on the Resulting Issuer Board. Mr. Lehman is currently the Managing Member of Flamingo Drive Partners, LLC, an investment firm involved in public markets, real estate and start-up investing. Prior to that, Mr. Lehmann was the General Partner at Riverloft Capital Management from 2011 to 2016. From 2002 to 2010, Mr. Lehmann was a Partner and Director of Research at JANA Partners, a hedge fund. Earlier in his career, he was an Analyst at Appaloosa Management, from 1999 to 2002, sourcing and analyzing distressed special situations investments for the opportunistic hedge fund portfolio and began his career as an Analyst at Morgan

 

- 69 -


Stanley and Lehman Brothers. Mr. Lehmann completed his Master of Business Administration at The Wharton Business at the University of Pennsylvania. Mr. Lehmann has a Bachelor of Science in Finance and International Business from New York University. Mr. Lehmann is not party to any non-competition or non-disclosure agreement with the Resulting Issuer.

Stephen Stoute (Age 48), Independent Director

Mr. Stoute will serve as an independent director on the Resulting Issuer Board. Mr. Stoute is the founder and Chief Executive Officer of Translation, a marketing agency. In 2017, Mr. Stoute joined United Masters, a data-driven digital distribution company helping music artist grow and manage their fan bases. As the author of The Tanning of America: How Hip-Hop Created a Culture That Rewrote the Rules of the New Economy. In 2009 the American Advertising Federation inducted Mr. Stoute into the Advertising Hall of Achievement, and he was named “Executive of the Year” by Advertising Age in 2013. Mr. Stoute is not party to any non-competition or non-disclosure agreement with the Resulting Issuer.

Carli Posner (Age 35), Independent Director

Ms. Posner has served as an independent director on the Issuer Board since February 2018 and will continue to serve as an independent director on the Resulting Issuer Board. Ms. Posner is the Co-CEO and Principal of Notable Life, a media company that reaches over 1.2 million high-earning millennials across Canada. Prior to Notable, she was the executive producer of the hit show, Hockey Wives, overseeing many departments including premium sponsors and media strategy. Ms. Posner has spent a significant portion of her career in Los Angeles, working in film finance and production. She is the leading talent packager in our country and has worked with top stars including George Clooney, Coldplay, Drew Barrymore, Jamie Oliver and Wayne Gretzky, to name a few. During Ms. Posner’s career, she has generated over C$100 million dollars of sponsorships and endorsements in the Canadian marketplace with top brands including Mastercard®, Corvette®, Scotiabank®, BMW® and LG®. Ms. Posner is not party to any non-competition or non-disclosure agreement with the Resulting Issuer.

 

- 70 -


13.

CAPITALIZATION

 

13.1

Resulting Issuer Capitalization

Issued Capital

 

     Number of
Securities
(non-diluted)
     Number of
Securities
(fully diluted)
     Percentage of
Issued
(non-diluted)
    Percentage of
Issued
(fully
diluted)
 

Total Outstanding (A)

     163,843,785        199,787,924        100     100

Held by Related Persons or employees of the Issuer or Related Person of the Issuer, or by persons or companies who beneficially own or control, directly or indirectly, more than a 5% voting position in the Issuer (or who would beneficially own or control, directly or indirectly, more than a 5% voting position in the Issuer upon exercise or conversion of other securities held) (B)

     56,080,028        57,639,889        34     29

Total Public Float (A-B)

     107,763,757        142,148,035        66     71

Freely-Tradeable Float

          

Number of outstanding securities subject to resale restrictions, including restrictions imposed by pooling or other arrangements or in a shareholder agreement and securities held by control block holders (C) (1)

     —          —          0     0

Total Tradeable Float (A-C)

     163,843,785        199,787,924        100     100

Notes:

 

(1)

Prior to the Closing Date, GGB intends to use commercially reasonable efforts to enter into voluntary lock-up agreements with certain current GGB Shareholders.

 

- 71 -


Public Securityholders (Registered)

The following table sets out the number of public securityholders (registered) of the Issuer prior to completion of the Business Combination:

 

Size of Holding

   Number of Holders    Total Number of Securities

1 – 99 securities

   281    1,888

100 -499 securities

   114    8,273

500 – 999 securities

   43    6,715

1,000 – 1,999 securities

   129    39,257

2,000 – 2,999 securities

   88    47,786

3,000 – 3,999 securities

   32    25,257

4,000 – 4,999 securities

   46    48,882

5,000 or more securities

   350    107,585,699

TOTAL

   1,083    107,763,757

Public Securityholders (Beneficial)

The following table sets out the number of public securityholders (beneficial)(1) of the Issuer prior to completion of the Business Combination:

 

Size of Holding

   Number of Holders    Total Number of Securities

1 – 99 securities

   281    1,888

100 -499 securities

   114    8,273

500 – 999 securities

   43    6,715

1,000 – 1,999 securities

   129    39,257

2,000 – 2,999 securities

   88    47,786

3,000 – 3,999 securities

   32    25,257

4,000 – 4,999 securities

   46    48,882

5,000 or more securities

   360    163,665,727

TOTAL

   1,093    163,843,785

Notes:

(1)

The amounts included in this table are based on the Resulting Issuer’s non-objecting beneficial owner’s list. The Resulting Issuer will have other beneficial holders of its securities that it is not aware of.

 

- 72 -


Non-Public Securityholders

The following table sets out the number of public securityholders (beneficial) of the Issuer prior to completion of the Business Combination:

 

Size of Holding

   Number of Holders    Total Number of Securities

1 – 99 securities

   Nil.    Nil.

100 -499 securities

   Nil.    Nil.

500 – 999 securities

   Nil.    Nil.

1,000 – 1,999 securities

   Nil.    Nil.

2,000 – 2,999 securities

   Nil.    Nil.

3,000 – 3,999 securities

   Nil.    Nil.

4,000 – 4,999 securities

   Nil.    Nil.

5,000 or more securities

   10    56,080,028

TOTAL

   10    56,080,028

 

13.2

Convertible Securities

The following are details for any securities convertible or exchangeable into Resulting Issuer Common Shares on completion of the Business Combination:

 

Description of Security

(conversion/exercise terms,

including exercise price)

   Number of convertible/exercisable
securities outstanding
   Number of listed securities
issuable upon conversion/exercise

Resulting Issuer Common Warrants

   34,008,112    34,008,112

Resulting Issuer Broker Warrants

   1,226,736    1,226,736

Resulting Issuer Options

   652,000    652,000

The following are details for any securities convertible or exchangeable into Resulting Issuer Proportionate Shares on completion of the Business Combination:

 

Description of Security

(conversion/exercise terms,

including exercise price)

   Number of convertible/exercisable
securities outstanding
   Number of listed securities
issuable upon conversion/exercise

Resulting Issuer Proportionate Warrants

   19,097    Nil.

Other than the Resulting Issuer Common Shares to be available for issuance under the Resulting Issuer Equity Incentive Plan, there are no listed securities that will be reserved for issuance that are not included in the table above.

 

- 73 -


13.3

Other Securities Reserved for Issuance

Not applicable.

 

14.

EXECUTIVE COMPENSATION

 

14.1

Xanthic Compensation Discussion and Analysis

As of the date of this Listing Statement, Xanthic did not, during the two most recently completed financial years, pay any fees to its current directors or named executive officers, except as disclosed below. The following is a compensation discussion and analysis in respect of the existing directors and named executive officers of Xanthic.

 

14.1.1

Xanthic Compensation Summary

The following table (presented in accordance with National Instrument Form 51-102F6V—Statement of Executive Compensation – Venture Issuers (“Form 51-102F6V”)) sets forth all compensation for services in all capacities to the Issuer for the financial years ended June 30, 2018 and June 30, 2017 in respect of:

 

  (a)

each individual who acted as Chief Executive Officer (“CEO”) or Chief Financial Officer (“CFO”) for all or any portion of the most recently completed financial year;

 

  (b)

the most highly compensated executive officer including any of its subsidiaries (other than the CEO and the CFO), whose total compensation was more than C$150,000 for the most recently completed financial year ended June 30, 2018; and

 

  (c)

any individual who would have satisfied these criteria but for the fact that the individual was neither an executive officer, nor acting in a similar capacity, at the end of June 30, 2018;

(collectively, the “Named Executive Officers” or “NEOs”).

 

- 74 -


Director and Named Executive Officer compensation, excluding compensation securities

 

Table of compensation excluding compensation securities

Name and
position

   Year    Salary,
consulting
(C$)
   Bonus
(C$)
   Committee
or meeting
(C$)
   Value of
perquisites
(C$)
   Value of all
other
(C$)
   Total
compensation
(C$)

Tim Moore,

   2018    164,934    30,000    —      —      —      194,934

Chief Executive Officer

   2017    —      —      —      —      —      —  

Igor Galitsky,

   2018    90,000    90,000    —      —      —      120,000

President

   2017    —      —      —      —      —      —  

David Bhumgara,

   2018    126,009    30,000    —      —      —      156,009

Chief Financial Officer

   2017    10,000    —      —      —      —      10,000

Carli Posner,

   2018    —      —      —      —      —      —  

Director

   2017    —      —      —      —      —      —  

Jean Schottenstein,

   2018    —      —      —      —      —      —  

Director

   2017    —      —      —      —      —      —  

Steve Stoute,

   2018    —      —      —      —      —      —  

Director

   2017    —      —      —      —      —      —  

Marc Lehmann,

   2018    —      —      —      —      —      —  

Director

   2017    —      —      —      —      —      —  

 

- 75 -


Stock options and other compensation securities

The following table sets out all compensation securities, comprised of incentive shares, granted or issued to all directors and NEOs by Xanthic in the most recently completed financial year ended June 30, 2018, for services provided, directly or indirectly, to Xanthic. None of the compensation securities referenced below were exercised in the most recently completed financial year.

 

            Compensation Securities                              

Name and
position

   Type of
compensation
security
     Number of
compensation
securities, number
of underlying
securities, and
percentage of
class
     Date of
issue or
grant
     Issue,
conversion
or
exercise
price

(C$)
     Closing price of
security or
underlying
security on date of
grant

(C$)
     Closing price
of security or
underlying
security at
year end

(C$)
     Expiry
date
 

Tim Moore,

Chief Executive Officer

     Options        350,000        Feb 28/ 2018      $ 0.125      $ 0.125      $ 0.250        Feb /2023  

Igor Galitsky,

President

     Options        358,000        Feb 28/ 2018      $ 0.125      $ 0.125      $ 0.250        Feb 27 /2023  

David Bhumgara,

Chief Financial Officer

     Options        350,000        Feb 28/ 2018      $ 0.125      $ 0.125      $ 0.250        Feb 27 /2023  

Carli Posner,

Director

     Options        200,000        Feb 28/ 2018      $ 0.125      $ 0.125      $ 0.250        Feb 27 /2023  

Jean Schottenstein,

Director

     N/A        N/A        N/A        N/A        N/A        N/A        N/A  

Steve Stoute,

Director

     N/A        N/A        N/A        N/A        N/A        N/A        N/A  

Marc Lehmann,

Director

     N/A        N/A        N/A        N/A        N/A        N/A        N/A  

No options were exercised by Xanthic NEOs or directors in the financial year ended June 30, 2018.

 

14.1.2

Equity Incentive Plans and Other Incentive Plans

Carli Posner received 200,000 Issuer Options for her board participation. As of June 30, 2018, 1/3 vested immediately, 1/3 vest 12 months from award date and 1/3 vest 24 months after the award date. On signing of the Business Combination Agreement, all unvested stock options vested immediately. Xanthic reimburses expenses incurred by such persons for acting as directors of Xanthic.

See Section 8 – Options to Purchase Securities for more details.

 

- 76 -


14.1.3

Employment, Consulting and Management Agreements

As Xanthic was still in its early stages of development, the C&G Committee determined that each of the Xanthic NEOs be retained on a consulting agreement basis. Mr. Tim Moore’s monthly compensation was C$15,000 per month while Mr. Igor Galitsky and Mr. David Bhumgara each received monthly compensation of C$10,000. In addition, the C&G Committee agreed to award a cash bonus of C$30,000 per Xanthic NEO for the successful completion and listing of the Issuer Common Shares on the CSE.

Additionally, as negotiated as part of the Business Combination, in lieu of change of control, if any Xanthic NEO is terminated without cause, such Xanthic NEO will be entitled to a one-time payment of C$200,000 in the case of Mr. Tim Moore and C$150,000 for each for Mr. Igor Galitsky and Mr. David Bhumgara.

Other than as described above, Xanthic does not intend to provide NEOs with any additional personal benefits, nor does Xanthic intend to provide any additional compensation to its NEOs for serving as directors.

 

14.1.4

Oversight and Description of Director and Named Executive Officer Compensation

The existing compensation of the Xanthic NEOs is determined by the board of directors of Xanthic. Compensation may be comprised of cash, equity awards, or a combination of both. Xanthic also reimburses expenses incurred by such persons for acting as officers of Xanthic. At the time of this Listing Statement, no element of compensation for NEOs is tied to performance criteria or goals.

 

14.1.5

Pension Plan Benefits

Xanthic does not currently provide any pension plan benefits to its named executive officers, directors, or employees.

 

14.2

GGB Compensation Discussion and Analysis

As of the date of this Listing Statement, GGB did not, during the most recently completed financial year, pay any fees to its current directors or named executive officers, except as disclosed below. The following is a compensation discussion and analysis in respect of the GGB NEOs and directors.

 

14.2.1

GGB Compensation Summary

The following table (presented in accordance with Form 51-102F6V) sets forth all compensation for services in all capacities to GGB for the period ended July 31, 2018 in respect of the GGB NEOs.

 

- 77 -


Director and Named Executive Officer compensation, excluding compensation securities

 

Table of compensation excluding compensation securities

        

Name and

position

   Year      Salary,
consulting
(US$)
     Bonus
(US$)
     Committee
or meeting
(US$)
     Value of
perquisites
(US$)
     Value of all
other
(US$)
     Total
compensation
(US$)
 

Peter Horvath,

     2018        266,667        —          —          —          —          266,667  

Chief Executive Officer

     2017        —          —          —          —          —          —    

Ian Fodie, Chief

     2018        130,000        —          —          —          —          130,000  

Financial Officer

     2017        —          —          —          —          —          —    

Stock options and other compensation securities

The following table sets out all compensation securities, comprised of incentive shares, granted or issued to all directors and NEOs by GGB in the period ended July 31, 2018, for services provided, directly or indirectly, to GGB.

 

Compensation Securities

Name and

position

   Type of
compensation
security
   Number of
compensation

securities, number
of underlying
securities, and
percentage of
class
   Date of
issue or
grant
   Issue,
conversion

or
exercise
price

(C$)
   Closing price of
security or
underlying
security on date of

grant
(C$)
   Closing price
of security or
underlying
security at
year end

(C$)
   Expiry
date

Peter Horvath,

Chief Executive Officer

   Deferred
Shares
   858,807    July 16/ 2018    $0.12    $0.12    $0.12    Nov 15/ 2020

Ian Fodie,

Chief Financial Officer

   Deferred
Shares
   85,880    July 16/ 2018    $0.12    $0.12    $0.12    Nov 15/ 2020

 

14.2.2

Equity Incentive Plans and Other Incentive Plans

See Section 8 – Options to Purchase Securities.

 

14.2.3

Employment, Consulting and Management Agreements

Not applicable.

 

14.2.4

Oversight and Description of Director and Named Executive Officer Compensation

See Section 14.3 – Resulting Issuer Compensation Discussion and Analysis.

 

- 78 -


14.2.5

Pension Plan Benefits

GGB does not currently provide any pension plan benefits to its named executive officers, directors, or employees.

 

14.3

Resulting Issuer Compensation Discussion and Analysis

 

14.3.1

Overview

The Resulting Issuer’s compensation practices will be designed to retain, motivate and reward its executive officers for their performance and contribution to the Resulting Issuer’s long-term success. The Resulting Issuer Board will seek to compensate the Resulting Issuer’s executive officers by combining short and long-term cash and equity incentives. It will also seek to reward the achievement of corporate and individual performance objectives, and to align executive officers’ incentives with shareholder value creation. The Resulting Issuer Board will seek to tie individual goals to the area of the executive officer’s primary responsibility. These goals may include the achievement of specific financial or business development goals. The Resulting Issuer Board will also seek to set company performance goals that reach across all business areas and include achievements in finance/business development and corporate development.

The independent directors of the Resulting Issuer will ratify and approve the executive compensation arrangements and the employment agreements for the Chief Executive Officer and the Chief Financial Officer.

 

14.3.2

Benchmarking

The executive team is expected to establish an appropriate comparator group for purposes of setting the future compensation of the Resulting Issuer NEOs.

 

14.3.3

Elements of Compensation

The compensation of the NEOs will include three major elements: (a) base salary, (b) an annual, discretionary cash bonus, and (c) long-term equity incentives, consisting of stock options granted under the Resulting Issuer Equity Incentive Plan and any other equity plan that may be approved by the Resulting Issuer Board. These three principal elements of compensation are described below.

Following the completion of the Business Combination, the Resulting Issuer Board is expected to establish an appropriate comparator group for purposes of setting the future compensation of the Named Executive Officers. The Named Executive Officers will not benefit from pension plan participation. Perquisites and personal benefits are not a significant element of compensation of the Named Executive Officers.

Base Salary

Base salaries are intended to provide an appropriate level of fixed compensation that will assist in employee retention and recruitment. Base salaries will be determined on an individual basis, taking into consideration the past, current and potential contribution to our success, the position and responsibilities of the Named Executive Officers and competitive industry pay practices for other medical marijuana investment companies of comparable size.

 

- 79 -


Annual Cash Bonus

Annual bonuses will be awarded based on qualitative and quantitative performance standards, and will reward performance of the named executive officer individually. The determination of a Named Executive Officer’s performance may vary from year to year depending on economic conditions and conditions in the cannabis industry, and may be based on measures such as stock price performance, the meeting of financial targets against budget (such as adjusted funds from operations), the meeting of acquisition objectives and balance sheet performance.

Resulting Issuer Equity Incentive Plan

The Resulting Issuer Equity Incentive Plan will be a rolling plan with the Resulting Issuer authorized to issue that number of options which is 10% of the issued and outstanding share capital at the date of the grant of shares, less the aggregate number of shares reserved for issuance or issuable under any share compensation arrangement.

See Section 8 – Options to Purchase Securities for more details.

Pension Plan Benefits

The Resulting Issuer does not intend to implement any deferred compensation plan or pension plan that provides for payments or benefits at, following or in connection with retirement.

 

15.

INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS

No proposed director, officer or promoter of the Resulting Issuer is or has been indebted to the Issuer or GGB in the most recently completed financial year, nor will they be indebted to the Resulting Issuer upon completion of the Business Combination.

 

16.

RISK FACTORS

Investing in shares of the Resulting Issuer involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information herein, including the financial statements and related notes included in this Listing Statement. Adverse developments such as those described in the following risk factors could materially and adversely harm the business, financial condition, results of operations or prospects of the Resulting Issuer, resulting in loss of all or part of your investment. You should consult your own independent advisors as to the tax, business and legal considerations regarding an investment in our securities.

Risks Specifically Related to Operating under the United States Regulatory System

The cannabis business in the United States is subject to additional risk

The Resulting Issuer will be engaged in the medical and adult-use marijuana industry in the United States in compliance with local and state law. While the cannabis industry in all markets is highly regulated and rapidly evolving, presenting challenges to management to operate effectively and accurately predict financial results contained in any forward looking statements, the Resulting Issuer is subject to additional risks in its United States operations. Investors are cautioned that in the United States, cannabis is illegal under United States federal law. Notwithstanding the more permissive regulatory environment of cannabis at the state level, cannabis continues to be categorized as a controlled substance under the CSA and as such, cultivation, distribution, sale and possession of cannabis violates federal law in the United States. To management’s knowledge, there are to date a total of 31 states, and the District of Columbia,

 

- 80 -


Puerto Rico, the U.S. Virgin Islands and Guam that have legalized cannabis in some form, including Nevada where the Resulting Issuer operates.

The United States Congress has passed appropriations bills each of the last four years that have expressly not appropriated funds for prosecution of cannabis offenses of persons who are in compliance with state medical cannabis laws. Courts in the United States have construed these appropriations bills to prevent the federal government from prosecuting persons when those persons comply with applicable state medical cannabis law. However, because this conduct continues to violate federal law, U.S. courts have observed that should United States Congress at any time choose to appropriate funds to fully prosecute the CSA, any individual or business—even those that have fully complied with state law—could be prosecuted for violations of federal law. If United States Congress restores funding, the government will have the authority to prosecute individuals for violations of the law during the time it lacked funding, subject to the CSA’s five-year statute of limitations.

Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, judgments or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, criminal convictions, disgorgement of profits, cessation of business activities, divestiture or civil asset forfeiture. This could have a material adverse effect on the Resulting Issuer, including its reputation and ability to conduct business, its holding (directly or indirectly) of medical and adult-use cannabis licenses in the United States, the listing of its securities on the CSE, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for management to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial.

Approach to the enforcement of cannabis laws is subject to change

As a result of the conflicting views between state legislatures and the federal government regarding cannabis, investments in cannabis businesses in the United States are subject to inconsistent legislation and regulation. The response to this inconsistency was addressed in the Cole Memorandum, acknowledging that notwithstanding the designation of cannabis as a controlled substance at the federal level in the United States, several states have enacted laws relating to cannabis for medical purposes.

The Cole Memorandum outlined certain priorities for the Department of Justice relating to the prosecution of cannabis offenses. In particular, the Cole Memorandum noted that in jurisdictions that have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. Notably, however, the Department of Justice did not provide specific guidelines for what regulatory and enforcement systems it deemed sufficient under the Cole Memorandum standard.

In light of limited investigative and prosecutorial resources, the Cole Memorandum concluded that the Department of Justice should be focused on addressing only the most significant threats related to cannabis. States where cannabis had been legalized were not characterized as a high priority. In March 2017, newly appointed Attorney General Jeff Sessions again noted limited federal resources and acknowledged that much of the Cole Memorandum had merit; however, he disagreed that it had been implemented effectively and, on January 4, 2018, Attorney General Jeff Sessions issued the Sessions Memorandum, which rescinded the Cole Memorandum. The Sessions Memorandum rescinded previous nationwide guidance specific to the prosecutorial authority of United States Attorneys relative to cannabis enforcement on the basis that they are unnecessary, given the well-established principles governing federal prosecution that are already in place. Those principals are included in chapter 9.27.000 of the United States Attorneys’ Manual and require federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney

 

- 81 -


General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community.

As a result of the Sessions Memorandum, federal prosecutors will now be free to utilize their prosecutorial discretion to decide whether to prosecute cannabis activities despite the existence of state-level laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memorandum as to the priority they should ascribe to such cannabis activities, and resultantly it is uncertain how active federal prosecutors will be in relation to such activities. Furthermore, the Sessions Memorandum did not discuss the treatment of medical cannabis by federal prosecutors. Medical cannabis is currently protected against enforcement by enacted legislation from United States Congress in the form of the Leahy Amendment to H.R.1625 – a vehicle for the Consolidated Appropriations Act of 2018 which similarly prevents federal prosecutors from using federal funds to impede the implementation of medical cannabis laws enacted at the state level, subject to United States Congress restoring such funding. Due to the ambiguity of the Sessions Memorandum, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law.

Such potential proceedings could involve significant restrictions being imposed upon the Resulting Issuer or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on the Resulting Issuer’s business, revenues, operating results and financial condition as well as the Resulting Issuer’s reputation and prospects, even if such proceedings were concluded successfully in favour of the Resulting Issuer. In the extreme case, such proceedings could ultimately involve the prosecution of key executives of the Resulting Issuer or the seizure of corporate assets.

The Leahy Amendment must be renewed to protect the medical cannabis industry

The Leahy Amendment, as discussed above, prohibits the Department of Justice from spending funds appropriated by United States Congress to enforce the tenets of the CSA against the medical cannabis industry in states which have legalized such activity. This amendment has historically been passed as an amendment to omnibus appropriations bills, which by their nature expire at the end of a fiscal year or other defined term. The Leahy Amendment will expire on September 30, 2018. At such time, it may or may not be included in the next omnibus appropriations package or a continuing budget resolution, and its inclusion or non-inclusion, as applicable, is subject to political changes.

Anti-money laundering laws and regulation

The Resulting Issuer will be subject to a variety of laws and regulations domestically and in the United States that involve money laundering, financial recordkeeping and proceeds of crime, including the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), Sections 1956 and 1957 of U.S.C. Title 18 (the Money Laundering Control Act), the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), as amended and the rules and regulations thereunder, the Criminal Code (Canada) and any related or similar rules, regulations or guidelines, issued, administered or enforced by governmental authorities in the United States and Canada.

Banks often refuse to provide banking services to businesses involved in the marijuana industry due to the present state of the laws and regulations governing financial institutions in the United States. The lack of banking and financial services presents unique and significant challenges to businesses in the marijuana industry. The potential lack of a secure place in which to deposit and store cash, the inability to pay creditors through the issuance of checks and the inability to secure traditional forms of operational financing, such as lines of credit, are some of the many challenges presented by the unavailability of traditional banking and financial services.

 

- 82 -


In February 2014, the Department of the Treasury Financial Crimes Enforcement Network issued a memo (the “FinCEN Memo”) providing instructions to banks seeking to provide services to cannabis-related businesses. The FinCEN Memo states that in some circumstances, it is permissible for banks to provide services to cannabis-related businesses without risking prosecution for violation of federal money laundering laws. It refers to supplementary guidance that former Deputy Attorney General James M. Cole issued to federal prosecutors relating to the prosecution of money laundering offenses predicated on cannabis-related violations of the CSA. While the FinCEN Memo has not been rescinded by the Department of Justice at this time, it remains unclear whether the current administration will follow its guidelines. Overall, the Department of Justice continues to have the right and power to prosecute crimes committed by banks and financial institutions, such as money laundering and violations of the Bank Secrecy Act, that occur in any state, including in states that have legalized the applicable conduct and the Department of Justice’s current enforcement priorities could change for any number of reasons, including a change in the opinions of the President of the United States or the United States Attorney General. A change in the Department of Justice’s enforcement priorities could result in the Department of Justice prosecuting banks and financial institutions for crimes that previously were not prosecuted.

In the event that any of the Resulting Issuer’s operations, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such operations in the United States were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under one or more of the statutes noted above or any other applicable legislation. This could restrict or otherwise jeopardize the ability of the Resulting Issuer to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada. Furthermore, while there are no current intentions to declare or pay dividends on the Resulting Issuer Shares in the foreseeable future, in the event that a determination was made that the Resulting Issuer’s proceeds from operations (or any future operations or investments in the United States) could reasonably be shown to constitute proceeds of crime, the Resulting Issuer may decide or be required to suspend declaring or paying dividends without advance notice for an indefinite period of time.

The illegality of cannabis in the United States presents additional legal and operational challenges

Because the use of cannabis is illegal under federal law, many judges and courts have denied cannabis businesses bankruptcy protections, enforcement of contracts, and protection of intellectual property – all of which may have a materially adversely effect on the Resulting Issuer’s results of operations and its investors return on investment. Without bankruptcy protections, it would be very difficult for lenders to recoup their investments in the cannabis industry in the event of a bankruptcy. In addition, there remains doubt and uncertainty that the Resulting Issuer will be able to legally enforce its contracts. The Resulting Issuer cannot be assured that it will have a remedy for breach of contract, which may have a material adverse effect on its business. Similarly, the benefit of federal laws and protections which are otherwise available to most businesses, such as federal trademark and patent protection regarding the intellectual property of a business, may not be available to the Resulting Issuer. The Resulting Issuer’s strategy is highly focused on creating brand equity and identity in its markets, by building strong brand awareness. The Resulting Issuer’s intellectual property may never be adequately or sufficiently protected against the use or misappropriation by third-parties. While many states do offer the ability to protect trademarks independent of the federal government, patent protection is wholly unavailable on a state level, and state-registered trademarks provide a lower degree of protection than would federally-registered marks. This position may prevent Resulting Issuer from effectively marketing and selling its cannabis-infused and CBD-infused consumable products using technology that management believes should otherwise be afforded patent protection. As a result of the United States regulatory position on cannabis businesses, the Resulting Issuer may not be able to effectively prevent competitors from using its technology to market similar products in the markets in which it operates.

 

- 83 -


Restriction of entry into the United States

In the past, U.S. Customs and Border Protection (“CBP”) was given the discretion to question Canadians entering the U.S. about their marijuana use and whether to use their response as a barrier to entry. Recently, the U.S. CBP has been focusing on the whole cannabis industry, including investors. Several highly publicized instances of U.S. CBP detaining and even banning Canadian investors from the United States have occurred in recent months. The restriction of travel to the United States of our executives and investors would seriously impair the ability of the Resulting Issuer to conduct business and could materially impact our results of operations.

Risks Related to the Cannabis Industry

Heightened scrutiny by regulatory authorities

For the reasons set forth above, the Resulting Issuer’s operations and investments in the United States may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, the Resulting Issuer may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Resulting Issuer’s ability to operate or invest in the United States or any other jurisdiction, in addition to those described herein.

It had been reported in Canada that the Canadian Depository for Securities Limited is considering a policy shift that would see its subsidiary, CDS, refuse to settle trades for cannabis issuers that have investments in the United States. CDS is Canada’s central securities depository, clearing and settling trades in the Canadian equity, fixed income and money markets. The TMX Group, the owner and operator of CDS, subsequently issued a statement on August 17, 2017 reaffirming that there is no CDS ban on the clearing of securities of issuers with cannabis-related activities in the United States, despite media reports to the contrary and that the TMX Group was working with regulators to arrive at a solution that will clarify this matter, which would be communicated at a later time.

On February 8, 2018, following discussions with the Canadian Securities Administrators and recognized Canadian securities exchanges, the TMX Group announced the signing of the TMX MOU. The TMX MOU outlines the parties’ understanding of Canada’s regulatory framework applicable to the rules, procedures, and regulatory oversight of the exchanges and CDS as it relates to issuers with cannabis-related activities in the United States. The TMX MOU confirms, with respect to the clearing of listed securities, that CDS relies on the exchanges to review the conduct of listed issuers. As a result, there is no CDS ban on the clearing of securities of issuers with cannabis-related activities in the United States. However, there can be no guarantee that this approach to regulation will continue in the future. If such a ban were to be implemented at a time when the Resulting Issuer Common Shares are listed on a stock exchange, it would have a material adverse effect on the ability of holders of Resulting Issuer Common Shares to make and settle trades. In particular, the Resulting Issuer Common Shares would become highly illiquid as until an alternative was implemented, investors would have no ability to effect a trade of the Resulting Issuer Common Shares through the facilities of the applicable stock exchange.

Risk of legal, regulatory or political change

The success of the business strategy of the Resulting Issuer depends on the legality of the marijuana industry. The political environment surrounding the marijuana industry in general can be volatile and the regulatory framework remains in flux. To management’s knowledge, there are to date a total of 31 states, and the District of Columbia, Puerto Rico, the U.S. Virgin Islands and Guam that have legalized cannabis in some form and additional states have pending legislation regarding the same; however, the risk remains that a shift in the regulatory or political realm could occur and have a drastic impact on the industry as a

 

- 84 -


whole, adversely impacting the Resulting Issuer’s business, results of operations, financial condition or prospects.

Delays in enactment of new state or federal regulations could restrict the ability of the Resulting Issuer to reach strategic growth targets and lower return on investor capital. The strategic growth strategy of the Resulting Issuer is reliant upon certain federal and state regulations being enacted to facilitate the legalization of medical and adult-use marijuana. If such regulations are not enacted, or enacted but subsequently repealed or amended, or enacted with prolonged phase-in periods, the growth targets of the Resulting Issuer, and thus, the effect on the return of investor capital, could be detrimental. Management is unable to predict with certainty when and how the outcome of these complex regulatory and legislative proceedings will affect its business and growth.

Further, there is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. If the federal government begins to enforce federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing applicable state laws are repealed or curtailed, the Resulting Issuer’s business, results of operations, financial condition and prospects would be materially adversely affected. It is also important to note that local and city ordinances may strictly limit and/or restrict disbursement of marijuana in a manner that will make it extremely difficult or impossible to transact business that is necessary for the continued operation of the marijuana industry. Federal actions against individuals or entities engaged in the marijuana industry or a repeal of applicable marijuana related legislation could adversely affect the Resulting Issuer and its business, results of operations, financial condition and prospects.

The Resulting Issuer is aware that multiple states are considering special taxes or fees on businesses in the marijuana industry. It is a potential yet unknown risk at this time that other states are in the process of reviewing such additional fees and taxation. This could have a material adverse effect upon the Resulting Issuer’s business, results of operations, financial condition or prospects.

Overall, the medical and adult-use marijuana industry is subject to significant regulatory change at both the state and federal level. The inability of the Resulting Issuer to respond to the changing regulatory landscape may cause it to not be successful in capturing significant market share and could otherwise harm its business, results of operations, financial condition or prospects.

Public opinion and perception

Government policy changes or public opinion may also result in a significant influence over the regulation of the cannabis industry in Canada, the United States or elsewhere. Public opinion and support for medical and adult-use marijuana has traditionally been inconsistent and varies from jurisdiction to jurisdiction. While public opinion and support appears to be rising for legalizing medical and adult-use marijuana, it remains a controversial issue subject to differing opinions surrounding the level of legalization (for example, legalization of medical marijuana as opposed to recreational use). A negative shift in the public’s perception of cannabis in the United States or any other applicable jurisdiction could affect future legislation or regulation. Among other things, such a shift could cause state jurisdictions to abandon initiatives or proposals to legalize medical and/or adult-use cannabis, thereby limiting the number of new state jurisdictions into which the Resulting Issuer could expand. Any inability to fully implement the Resulting Issuer’s expansion strategy may have a material adverse effect on the Resulting Issuer’s business, results of operations or prospects.

General regulatory risks; risks related to licensure

The Resulting Issuer’s business is subject to a variety of laws, regulations and guidelines relating to the manufacture, management, transportation, storage and disposal of marijuana, including laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. Achievement of the Resulting Issuer’s business objectives is contingent, in part, upon compliance with

 

- 85 -


applicable regulatory requirements and obtaining all requisite regulatory approvals. Changes to such laws, regulations and guidelines due to matters beyond the control of the Resulting Issuer may cause material adverse effects to the Resulting Issuer.

The Resulting Issuer is required to obtain or renew further government permits and licenses for its current and contemplated operations. Obtaining, amending or renewing the necessary governmental permits and licenses can be a time-consuming process potentially involving numerous regulatory agencies, involving public hearings and costly undertakings on the Resulting Issuer’s part. The duration and success of the Resulting Issuer’s efforts to obtain, amend and renew permits and licenses are contingent upon many variables not within its control, including the interpretation of applicable requirements implemented by the relevant permitting or licensing authority. The Resulting Issuer may not be able to obtain, amend or renew permits or licenses that are necessary to its operations. Any unexpected delays or costs associated with the permitting and licensing process could impede the ongoing or proposed operations of the Resulting Issuer. To the extent necessary permits or licenses are not obtained, amended or renewed, or are subsequently suspended or revoked, the Resulting Issuer may be curtailed or prohibited from proceeding with its ongoing operations or planned development and commercialization activities. Such curtailment or prohibition may result in a material adverse effect on the Resulting Issuer’s business, financial condition, results of operations or prospects.

In Nevada, all marijuana establishments must register with the DOT and be issued a medical marijuana or retail marijuana establishment registration certificate. In a local governmental jurisdiction that issues business licenses, the issuance by DOT of a medical marijuana or retail marijuana establishment registration certificate is considered provisional until the local government has issued a business license for operation and the establishment is in compliance with all applicable local governmental ordinances. Final registration certificates are valid for a period of one year and are subject to annual renewals after required fees are paid and the business remains in good standing. It is important to note provisional licenses do not permit the operation of any commercial or medical cannabis activity. Only after a provisional licensee has gone through necessary state and local inspections, if applicable, and has received a final registration certificate from DOT may an entity engage in cannabis business operation. There is no assurance that the Resulting Issuer will be issued final registration certificates in respect of any provisional licenses awarded in the future.

While the Resulting Issuer’s compliance controls have been developed to mitigate the risk of any material violations of any license it holds arising, there is no assurance that the Resulting Issuer’s licenses will be renewed by each applicable regulatory authority in the future in a timely manner. Any unexpected delays or costs associated with the licensing renewal process for any of the licenses held by the Resulting Issuer could impede the ongoing or planned operations of the Resulting Issuer and have a material adverse effect on the Resulting Issuer’s business, financial condition, results of operations or prospects.

The Resulting Issuer may become involved in a number of government or agency proceedings, investigations and audits. The outcome of any regulatory or agency proceedings, investigations, audits, and other contingencies could harm the Resulting Issuer’s reputation, require the Resulting Issuer to take, or refrain from taking, actions that could harm its operations or require the Resulting Issuer to pay substantial amounts of money, harming its financial condition. There can be no assurance that any pending or future regulatory or agency proceedings, investigations and audits will not result in substantial costs or a diversion of management’s attention and resources or have a material adverse impact on the Resulting Issuer’s business, financial condition, results of operations or prospects.

Environmental risk and regulation

The Resulting Issuer’s operations are subject to environmental regulation in the various jurisdictions in which it operates. These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility

 

- 86 -


for companies and their officers, directors (or the equivalent thereof) and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Resulting Issuer’s operations.

Government approvals and permits are currently, and may in the future, be required in connection with the Resulting Issuer’s operations. To the extent such approvals are required and not obtained, the Resulting Issuer may be curtailed or prohibited from proceeding with the development of its operations as currently proposed.

Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Resulting Issuer may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.

Amendments to current laws, regulations and permits governing the production of medical or retail marijuana, or more stringent implementation thereof, could have a material adverse impact on the Resulting Issuer and cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development.

Service providers

As a result of any adverse change to the approach in enforcement of United States cannabis laws, adverse regulatory or political change, additional scrutiny by regulatory authorities, adverse change in public perception in respect of the consumption of marijuana or otherwise, third party service providers to the Resulting Issuer could suspend or withdraw their services, which may have a material adverse effect on the Resulting Issuer’s business, revenues, operating results, financial condition or prospects.

Risks Related to the Resulting Issuer’s Business

Limited operating history

The Resulting Issuer, Green Growth Brands Ltd. and Xanthic Biopharma, Inc. have limited financial reporting history. Consequently, the Resulting Issuer’s financial results for 2018 are not comparable with prior years, and the financial information in this listing statement may not be indicative of its future performance. The Resulting Issuer does not have a history of profitability, with the exception of the NOR business. As such the Resulting Issuer has limited prospects of generating profit from its intended operations. The Resulting Issuer is therefore subject to many of the risks common to early-stage enterprises, including under-capitalization, cash shortages, limitations with respect to personnel, financial, and other resources and lack of revenues. There is no assurance that the Resulting Issuer will be successful in achieving a return on shareholders’ investment and the likelihood of success must be considered in light of the early stage of operations.

If the Resulting Issuer is unable to successfully execute any material part of its growth strategy, its future growth and ability to make profitable investments in its business would be harmed

The Resulting Issuer’s success depends on its ability to expand its business while maintaining profitability. The Resulting Issuer may not be able to sustain its growth or profitability on a quarterly or annual basis in future periods. The Resulting Issuer’s future growth and profitability will depend upon a number of factors, including, without limitation:

 

   

The level of competition in the cannabis industry;

 

   

The Resulting Issuer’s ability to identify, acquire and integrate strategic acquisitions;

 

- 87 -


   

The Resulting Issuer’s ability to win new licenses as cannabis is legalized at the state level;

 

   

The Resulting Issuer’s ability to achieve brand loyalty;

 

   

The Resulting Issuer’s ability to offer new products and to extend existing brands and products into new markets, both in the United States and internationally markets;

 

   

The Resulting Issuer’s ability to remain competitive in its pricing;

 

   

The Resulting Issuer’s ability to leverage its vertically integrated business model to increase profitability;

 

   

The Resulting Issuer’s ability to maintain efficient, timely and cost-effective production and delivery of its products;

 

   

The efficiency and effectiveness of the Resulting Issuer’s sales and marketing efforts in building product and brand awareness and cross-marketing its brands;

 

   

The Resulting Issuer’s ability to identify and respond successfully to emerging trends in the cannabis industry;

 

   

The level of consumer acceptance of the Resulting Issuer’s products; and

 

   

The general economic and political conditions and consumer confidence.

The Resulting Issuer may not be successful in executing its growth strategy, and even if the Resulting Issuer achieves targeted growth, it may not be able to sustain profitability. Failure to successfully execute any material part of the Resulting Issuer’s growth strategy would significantly impair the Resulting Issuer’s future growth and its ability to make profitable investments in its business.

Future acquisitions

The Resulting Issuer is continually evaluating acquisitions and strategic investments that are significant to its business both in the United States and internationally. Management may not be able to identify suitable acquisition candidates, or complete such acquisitions, joint ventures and strategic investments on acceptable terms and conditions, and these acquisitions, joint ventures and strategic investments may not be successfully integrated into the Resulting Issuer’s operations. The costs of unsuccessful acquisition, joint venture and strategic investment efforts may adversely affect results of operations, financial condition or prospects. Material acquisitions and other strategic transactions involve a number of risks, including: (i) potential disruption of the Resulting Issuer’s ongoing business; (ii) distraction of management; (iii) the Resulting Issuer may become financially leveraged; (iv) the anticipated benefits and cost savings of those transactions may not be realized fully or at all or may take longer to realize than expected; (v) increasing the scope and complexity of the Resulting Issuer’s operations; (vi) impairment of relationships with customers and (vii) loss or reduction of control over certain of the Resulting Issuer’s assets. Additionally, the Resulting Issuer may issue additional Resulting Issuer Shares in connection with such transactions, which would dilute a shareholder’s holdings in the Resulting Issuer.

The presence of one or more material liabilities of an acquired company that are unknown to the Resulting Issuer at the time of acquisition could have a material adverse effect on the business, results of operations, prospects and financial condition of the Resulting Issuer. A strategic transaction may result in a significant change in the nature of the Resulting Issuer’s business, operations and strategy. In addition, the Resulting Issuer may encounter unforeseen obstacles or costs in implementing a strategic transaction

 

- 88 -


or integrating any acquired business into the Resulting Issuer’s operations reducing its operating cash flow.

Well-capitalized entrants may develop large-scale operations

Currently, the marijuana industry generally is comprised of individuals and small to medium-sized entities, however, the risk remains that large conglomerates and companies who also recognize the potential for financial success through investment in this industry could strategically purchase or assume control of larger dispensaries and cultivation facilities. Larger companies in related business with similar customer bases may position themselves to enter into joint ventures and strategic partnerships in order to capitalize on their existing global distribution channels, which would restrict the Resulting Issuer’s ability to gain market penetration. In doing so, these larger competitors could establish price setting and cost controls which would effectively “price out” many of the individuals and small to medium-sized entities who currently make up the bulk of the participants in the varied businesses operating within and in support of the medical and adult-use marijuana industry. While the trend in most state laws and regulations seemingly deters this type of takeover, this industry remains quite nascent, so what the landscape will be in the future remains largely unknown, which in itself is a risk.

The Resulting Issuer’s proposed business plan is subject to all business risks associated with new business enterprises, including the absence of any significant operating history upon which to evaluate an investment. The likelihood of the Resulting Issuer’s success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with the formation of a new business, the development of new strategy and the competitive environment in which the Resulting Issuer will operate. It is possible that the Resulting Issuer will incur losses in the future. There is no guarantee that the Resulting Issuer will be profitable.

Competition

There is potential that the Resulting Issuer will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience than the Resulting Issuer. Increased competition by larger and better-financed competitors could materially and adversely affect the business, financial condition, results of operations or prospects of the Resulting Issuer.

Because of the early stage of the industry in which the Resulting Issuer operates, the Resulting Issuer expects to face additional competition from new entrants. To become and remain competitive, the Resulting Issuer will require research and development, marketing, sales and support. The Resulting Issuer may not have sufficient resources to maintain research and development, marketing, sales and support efforts on a competitive basis which could materially and adversely affect the business, financial condition, results of operations or prospects of the Resulting Issuer.

If the Business Combination’s benefits do not meet the expectations of investors or securities analysts, the market price of our securities may decline.

If the benefits of the Business Combination do not meet the expectations of investors or securities analysts, the market price of the Issuer Common Shares prior to the closing of the Business Combination may decline. Because the share exchange ratio will not be adjusted to reflect any changes in the market price of the Issuer Common Shares, the market value of the Resulting Issuer Common Shares issued in the Business Combination may be higher or lower than the values of the Issuer Common Shares on earlier dates. In addition, following the Business Combination, fluctuations in the price of the Resulting Issuer Shares could contribute to the loss of all or part of your investment. Prior to the Business Combination, trading in the Issuer Common Shares has not been active. Accordingly, the valuation ascribed to our common stock in the Business Combination may not be indicative of the price that will prevail in the trading market following the Business Combination. If an active market for our securities develops and continues, the trading price of our securities following the Business Combination could be

 

- 89 -


volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. In such circumstances, the trading price of our securities may not recover and may experience a further decline.

Warrants will become exercisable for Resulting Issuer Common Shares, which would increase the number of Resulting Issuer Common Shares eligible for future resale in the public market and result in dilution to our stockholders

Outstanding warrants to purchase an aggregate of 23,005,888 Resulting Issuer Shares will become exercisable for a like number of Resulting Issuer Shares in accordance with the terms of the warrant agreement governing those securities. To the extent Resulting Issuer Warrants are exercised, additional Resulting Issuer Shares will be issued, which will result in dilution to the Resulting Issuer Shareholders and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such Resulting Issuer Common Shares in the public market could adversely affect the market price of the Resulting Issuer Shares.

Additional Financing

The Resulting Issuer has obligations under the NOR transaction that will require future funding. There is also additional funding required to implement the strategic plan, including additional acquisitions. Therefore, Resulting Issuer may require equity or debt financing to support its strategic plan. There can be no assurance that additional financing will be available on acceptable terms when required. The Resulting Issuer’s inability to raise additional financing could severely limit its growth and ability to make strategic capital expenditures, both of which may have a material adverse effect on the Resulting Issuer’s business, results of operations, financial condition or prospects.

Conflicts of interest

Certain of the directors and officers of the Resulting Issuer are, or may become directors and officers of other companies, and conflicts of interest may arise between their duties as directors and officers of the Resulting Issuer and as directors and officers of such other companies.

Reliance on management

The success of the Resulting Issuer depends on its ability to attract, develop and retain talented employees, including executives and other key managers. The loss of certain key officers and employees, or the failure to attract and develop talented new executives and managers, could have an adverse effect on the Resulting Issuer’s business. The Resulting Issuer’s ability to attract and retain employees with the requisite experience and skills depends on several factors, including, but not limited to the Resulting Issuer’s ability to offer competitive wages, benefits and professional growth opportunities. Effective succession planning is also important to its long-term success. Failure to ensure effective transfer of knowledge and smooth transitions involving key employees could hinder the Resulting Issuer’s strategic planning and execution. The Resulting Issuer’s success is also dependent upon the ability, expertise, judgment, discretion and good faith of its senior management. Any loss of the services of key management could have a material adverse effect on the Resulting Issuer’s business, operating results, financial condition or prospects

Management of growth

The Resulting Issuer may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Resulting Issuer to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Resulting Issuer to deal with this growth may have a material adverse effect on the Resulting Issuer’s business, financial condition, results of operations or prospects.

 

- 90 -


Risks inherent in an agricultural business

Adult-use and medical marijuana are agricultural products. There are risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Although the products are usually grown indoors under climate-controlled conditions, with conditions monitored, there can be no assurance that natural elements will not have a material adverse effect on the production of the Resulting Issuer’s products.

Vulnerability to rising energy costs

Adult-use and medical marijuana growing operations consume considerable energy, making the Resulting Issuer potentially vulnerable to rising energy costs. Rising or volatile energy costs may adversely impact the business, results of operations, financial condition or prospects of the Resulting Issuer.

Unfavorable publicity or consumer perception

The Resulting Issuer believes the adult-use and medical marijuana industries are highly dependent upon consumer perception regarding the safety, efficacy and quality of the marijuana produced. Consumer perception can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of marijuana products. There can be no assurance that future scientific research or findings, regulatory investigations, litigation, media attention or other publicity will be favorable to the marijuana market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory investigations, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or other publicity could have a material adverse effect on the demand for adult-use or medical marijuana and on the business, results of operations, financial condition, cash flows or prospects of the Resulting Issuer. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of marijuana in general, or associating the consumption of adult-use and medical marijuana with illness or other negative effects or events, could have such a material adverse effect. There is no assurance that such adverse publicity reports or other media attention will not arise.

Results of future clinical research

Research in Canada, the U.S. and internationally regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in early stages. There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC). Although management believes that the articles, reports and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Given these risks, uncertainties and assumptions, prospective purchasers of Resulting Issuer Common Shares should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions to those stated in this Listing Statement or reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to cannabis, which could have a material adverse effect on the demand for the Resulting Issuer’s products with the potential to lead to a material adverse effect on the Resulting Issuer’s business, financial condition, results of operations or prospects.

Product liability

As a manufacturer and distributor of products designed to be ingested by humans, the Resulting Issuer faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury. In addition, the manufacture and sale of marijuana involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of

 

- 91 -


marijuana alone or in combination with other medications or substances could occur. As a manufacturer, distributor and retailer of adult-use and medical marijuana, or in its role as an investor in or service provider to an entity that is a manufacturer, distributor and/or retailer of adult-use or medical marijuana, the Resulting Issuer may be subject to various product liability claims, including, among others, that the marijuana product caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against the Resulting Issuer could result in increased costs, could adversely affect the Resulting Issuer’s reputation with its clients and consumers generally, and could have a material adverse effect on the business, results of operations, financial condition or prospects of the Resulting Issuer. There can be no assurances that the Resulting Issuer will be able to maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to maintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Resulting Issuer’s potential products or otherwise have a material adverse effect on the business, results of operations, financial condition or prospects of the Resulting Issuer.

Product recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. Such recalls cause unexpected expenses of the recall and any legal proceedings that might arise in connection with the recall. This can cause loss of a significant amount of sales. In addition, a product recall may require significant management attention. Although the Resulting Issuer has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if one of the Resulting Issuer’s brands were subject to recall, the image of that brand and the Resulting Issuer could be harmed. Additionally, product recalls can lead to increased scrutiny of operations by applicable regulatory agencies, requiring further management attention and potential legal fees and other expenses.

Reliance on key inputs

The marijuana business is dependent on a number of key inputs and their related costs including raw materials and supplies related to growing operations, as well as electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition, results of operations or prospects of the Resulting Issuer. Some of these inputs may only be available from a single supplier or a limited group of suppliers. If a sole source supplier was to go out of business, the Resulting Issuer might be unable to find a replacement for such source in a timely manner or at all. If a sole source supplier were to be acquired by a competitor, that competitor may elect not to sell to the Resulting Issuer in the future. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition, results of operations or prospects of the Resulting Issuer.

Dependence on suppliers and skilled labour

The ability of the Resulting Issuer to compete and grow will be dependent on it having access, at a reasonable cost and in a timely manner, to skilled labour, equipment, parts and components. No assurances can be given that the Resulting Issuer will be successful in maintaining its required supply of skilled labour, equipment, parts and components. It is also possible that the final costs of the major equipment contemplated by the Resulting Issuer’s capital expenditure plans may be significantly greater than anticipated by the Resulting Issuer’s management, and may be greater than funds available to the Resulting Issuer, in which circumstance the Resulting Issuer may curtail, or extend the timeframes for

 

- 92 -


completing, its capital expenditure plans. This could have an adverse effect on the business, financial condition, results of operations or prospects of the Resulting Issuer.

Co-investment risk

The Resulting Issuer may co-invest in one or more investments with certain strategic investors and/or other third parties through joint ventures or other entities, which parties in certain cases may have different interests or superior rights to those of the Resulting Issuer, although it is the general intent of the Resulting Issuer to retain superior rights associated with its investments. Although it is the Resulting Issuer’s intent to retain control and other superior rights over the Resulting Issuer’s investments, under certain circumstances it may be possible that the Resulting Issuer relinquishes such rights over certain of its investments and, therefore, may have a limited ability to protect its position therein. In addition, even when the Resulting Issuer does maintain a control position with respect to its investments, the Resulting Issuer’s investments may be subject to typical risks associated with third-party involvement, including the possibility that a third-party may have financial difficulties resulting in a negative impact on such investment, may have economic or business interests or goals that are inconsistent with those of the Resulting Issuer, or may be in a position to take (or block) action in a manner contrary to the Resulting Issuer’s objectives. The Resulting Issuer may also, in certain circumstances, be liable for the actions of its third-party partners or co-investors. Co-investments by third parties may or may not be on substantially the same terms and conditions as the Resulting Issuer, and such different terms may be disadvantageous to the Resulting Issuer.

Difficulty to forecast

The Resulting Issuer must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the industry. A failure in the demand for its products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations, financial condition or prospects of the Resulting Issuer.

Reliable data on the medical and adult-use marijuana industry is not available

As a result of recent and ongoing regulatory and policy changes in the medical and adult-use marijuana industry, the market data available is limited and unreliable. Federal and state laws prevent widespread participation and hinder market research. Therefore, market research and projections by management of estimated total retail sales, demographics, demand, and similar consumer research, are based on assumptions from limited and unreliable market data, and generally represent the personal opinions of the Resulting Issuer’s management team as of the date of this Listing Statement.

Litigation

The Resulting Issuer may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Resulting Issuer becomes involved be determined against the Resulting Issuer, such a decision could adversely affect the Resulting Issuer’s ability to continue operating and the market price for the Resulting Issuer Common Shares. Even if the Resulting Issuer is involved in litigation and wins, litigation can redirect significant company resources.

Intellectual property risks

The Resulting Issuer may have certain proprietary intellectual property, including but not limited to brands, trademarks, trade names, patents and proprietary processes. The Resulting Issuer will rely on this intellectual property, know-how and other proprietary information, and require employees, consultants and suppliers to sign confidentiality agreements. However, these confidentiality agreements may be breached, and the Resulting Issuer may not have adequate remedies for such breaches. Third parties may

 

- 93 -


independently develop substantially equivalent proprietary information without infringing upon any proprietary technology. Third parties may otherwise gain access to the Resulting Issuer’s proprietary information and adopt it in a competitive manner. Any loss of intellectual property protection may have a material adverse effect on the Resulting Issuer’s business, results of operations or prospects.

The risks associated with protecting intellectual property in the United States are discussed above.

Competition from synthetic production and technological advances

The pharmaceutical industry may attempt to dominate the marijuana industry, and in particular, legal marijuana, through the development and distribution of synthetic products which emulate the effects and treatment of organic marijuana. If they are successful, the widespread popularity of such synthetic products could change the demand, volume and profitability of the marijuana industry. This could adversely affect the ability of the Resulting Issuer to secure long-term profitability and success through the sustainable and profitable operation of its business. There may be unknown additional regulatory fees and taxes that may be assessed in the future.

Constraints on marketing products

The development of the Resulting Issuer’s business and operating results may be hindered by applicable restrictions on sales and marketing activities imposed by government regulatory bodies. The regulatory environment in the United States limits companies’ abilities to compete for market share in a manner similar to other industries. If the Resulting Issuer is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, the Resulting Issuer’s sales and results of operations could be adversely affected.

Fraudulent or illegal activity by employees, contractors and consultants

The Resulting Issuer is exposed to the risk that its employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to the Resulting Issuer that violates: (i) government regulations; (ii) manufacturing standards; (iii) federal and provincial healthcare fraud and abuse laws and regulations; or (iv) laws that require the true, complete and accurate reporting of financial information or data. It may not always be possible for the Resulting Issuer to identify and deter misconduct by its employees and other third parties, and the precautions taken by the Resulting Issuer to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting the Resulting Issuer from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against the Resulting Issuer, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on the Resulting Issuer’s business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of the Resulting Issuer’s operations, any of which could have a material adverse effect on the Resulting Issuer’s business, financial condition, results of operations or prospects.

Information technology systems and cyber-attacks

The Resulting Issuer’s operations depend, in part, on how well it and its suppliers protect networks, equipment, information technology (“IT”) systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism and theft. The Resulting Issuer’s operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, IT systems and software, as well as pre-emptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays and/or increase in capital

 

- 94 -


expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact the Resulting Issuer’s reputation and results of operations.

There can be no assurance that the Resulting Issuer will not incur material losses relating to cyber-attacks or other information security breaches in the future. The Resulting Issuer’s risk and exposure to these matters cannot be fully mitigated because of, among other things, the evolving nature of these threats. As a result, cyber security and the continued development and enhancement of controls, processes and practices designed to protect systems, computers, software, data and networks from attack, damage or unauthorized access is a priority. As cyber threats continue to evolve, the Resulting Issuer may be required to expend additional resources to continue to modify or enhance protective measures or to investigate and remediate any security vulnerabilities.

Security breaches

Given the nature of the Resulting Issuer’s product and its lack of legal availability outside of channels approved by the Government of the United States, as well as the concentration of inventory in its facilities, despite meeting or exceeding all legislative security requirements, there remains a risk of shrinkage as well as theft. A security breach at one of the Resulting Issuer’s facilities could expose the Resulting Issuer to additional liability and to potentially costly litigation, increase expenses relating to the resolution and future prevention of these breaches and may deter potential patients from choosing the Resulting Issuer’s products.

In addition, the Resulting Issuer collects and stores personal information about its patients and is responsible for protecting that information from privacy breaches. A privacy breach may occur through procedural or process failure, information technology malfunction, or deliberate unauthorized intrusions. Theft of data for competitive purposes, particularly patient lists and preferences, is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such theft or privacy breach would have a material adverse effect on the Resulting Issuer’s business, financial condition and results of operations.

Costs of being a public company

As a public issuer, the Resulting Issuer is subject to the reporting requirements and rules and regulations under the applicable Canadian securities laws and rules of any stock exchange on which the Resulting Issuer’s securities may be listed from time to time. Additional or new regulatory requirements may be adopted in the future. The requirements of existing and potential future rules and regulations will increase the Resulting Issuer’s legal, accounting and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on its personnel, systems and resources, which could adversely affect its business and financial condition.

In particular, the Resulting Issuer is subject to reporting and other obligations under applicable Canadian securities laws, including National Instrument 52-109Certification of Disclosure in Issuers’ Annual and Interim Filings, which requires annual management assessment of the effectiveness of the Resulting Issuer’s internal controls over financial reporting. Effective internal controls, including financial reporting and disclosure controls and procedures, are necessary for the Resulting Issuer to provide reliable financial reports, to effectively reduce the risk of fraud and to operate successfully as a public company. These reporting and other obligations place significant demands on the Resulting Issuer as well as on the Resulting Issuer’s management, administrative, operational and accounting resources.

Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Resulting Issuer’s results of operations or cause it to fail to meet its reporting obligations. If the Resulting Issuer or its auditors discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market’s confidence in the Resulting Issuer’s consolidated financial statements and materially adversely affect the trading price of the Resulting Issuer Common Shares.

 

- 95 -


Market price volatility risks

The market price of the Resulting Issuer Common Shares may be subject to wide fluctuations in response to many factors, including variations in the operating results of the Resulting Issuer, divergence in financial results from analysts’ expectations, changes in earnings estimates by stock market analysts, changes in the business prospects for the Resulting Issuer, general economic conditions, legislative changes, and other events and factors outside of the Resulting Issuer’s control. In addition, stock markets have from time to time experienced extreme price and volume fluctuations, which, as well as general economic and political conditions, could adversely affect the market price for the Resulting Issuer Common Shares.

Dividends

The Resulting Issuer has no earnings or dividend record, and does not anticipate paying any dividends on the Resulting Issuer Shares in the foreseeable future. Dividends paid by the Resulting Issuer would be subject to tax and, potentially, withholdings.

Limited market for securities

Notwithstanding that the Resulting Issuer Common Shares are listed on the CSE, there can be no assurance that an active and liquid market for the Resulting Issuer Common Shares will develop or be maintained and a Resulting Issuer Shareholder may find it difficult to resell any Resulting Issuer Shares.

Fluctuations in currency exchange rates could have an adverse effect on revenues and results of operations.

Resulting Issuer has operations in the United States, which is expected to account for approximately __% of Resulting Issuer’s operating expenses in 2018. As a result, Resulting Issuer generates a significant portion of its sales and incurs a significant portion of its expenses in currencies other than the Canadian dollar. To the extent that Resulting Issuer is unable to match revenues received in foreign currencies with costs paid in the same currency, exchange rate fluctuations in any such currency could have an adverse effect on Resulting Issuer’s financial results. Currency fluctuations between the Canadian dollar and the U.S. dollar affect Resulting Issuer’s results as reported in Canadian dollars. These fluctuations could adversely affect Resulting Issuer’s revenues and results of operations.

Global financial conditions

Following the onset of the credit crisis in 2008, global financial conditions were characterized by extreme volatility and several major financial institutions either went into bankruptcy or were rescued by governmental authorities. While global financial conditions subsequently stabilized, there remains considerable risk in the system given the extraordinary measures adopted by government authorities to achieve that stability. Global financial conditions could suddenly and rapidly destabilize in response to future economic shocks, as government authorities may have limited resources to respond to future crises.

Future economic shocks may be precipitated by a number of causes, including a rise in the price of oil, geopolitical instability and natural disasters. Any sudden or rapid destabilization of global economic conditions could impact the Resulting Issuer’s ability to obtain equity or debt financing in the future on terms favourable to the Resulting Issuer. Additionally, any such occurrence could cause decreases in asset values that are deemed to be other than temporary, which may result in impairment losses. Further, in such an event, the Resulting Issuer’s operations and financial condition could be adversely impacted.

Furthermore, general market, political and economic conditions, including, for example, inflation, interest and currency exchange rates, structural changes in the cannabis industry, supply and demand for commodities, political developments, legislative or regulatory changes, social or labour unrest and stock market trends will affect the Resulting Issuer’s operating environment and its operating costs, profit

 

- 96 -


margins and share price. Any negative events in the global economy could have a material adverse effect on the Resulting Issuer’s business, financial condition, results of operations or prospects

 

17.

PROMOTERS

 

17.1

Promoters

During the two years immediately preceding the date of this Listing Statement, the promoters of Xanthic, GGB and the Resulting Issuer have been and are as follows:

 

Name

  

Type of Securities

Held

   Number of Securities
Held
     % of Outstanding Class  

Igor Galitsky

  

Resulting Issuer

Common Shares

     957,083        0.58

All Js Greenspace LLC

  

Resulting Issuer

Common Shares

     37,464,236        22.87

Chiron Ventures Inc.

  

Resulting Issuer

Common Shares

     10,701,041        6.53

All Js Greenspace LLC

  

Resulting Issuer

Proportionate Shares

     38,194        100

 

18.

LEGAL PROCEEDINGS

Neither the Issuer, GGB nor any of their property is, was previously a party to, or was the subject of, any legal proceeding nor is the Resulting Issuer currently party to any material legal proceeding or contemplating any legal proceedings which are material to its business. Additionally, to the knowledge of the management of the Issuer, GGB and the Resulting Issuer, there are no such proceedings contemplated.

From time to time, however, the Resulting Issuer may be subject to various claims and legal actions arising in the ordinary course of business. Management of the Resulting Issuer is not currently aware of any legal proceedings contemplated against the Resulting Issuer.

 

19.

INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS

GGB is party to the Lease with an entity that is controlled by the Schottenstein family. See Section 3.2.8 – Real Estate for more details.

 

20.

AUDITORS, TRANSFER AGENTS AND REGISTRARS

 

20.1

Auditors

The auditors of the Issuer are MNP LLP, through its offices at 111 Richmond St. West, Suite 300, Toronto, ON M5H 2G4.

The auditors of GGB are MNP LLP, through its offices at 1155, boul. René-Lévesque O. 23e étage, Montréal, QC H3B 2K2.

The auditors of NOR are MNP LLP, through its offices at 111 Richmond St. West, Suite 300, Toronto, ON M5H 2G4.

 

- 97 -


It is anticipated that the auditor of the Resulting Issuer will be MNP LLP, through its offices at 111 Richmond St. West, Suite 300, Toronto, ON M5H 2G4.

 

20.2

Registrar and Transfer Agent

The current transfer agent and registrar of the Issuer is CTA, through its offices in Toronto, Ontario. CTA will remain the transfer agent and registrar of the Resulting Issuer following the Business Combination.

 

21.

MATERIAL CONTRACTS

Xanthic Material Contracts

Except for contracts entered into by Xanthic or its subsidiaries in the ordinary course of business, the only material contracts entered into by Xanthic or its subsidiaries in the previous two years are the following:

 

  (a)

Escrow agreement dated March 29, 2018;

 

  (b)

Services agreement, dated October 17, 2017 with CTA, and

 

  (c)

Definitive agreement dated December 13, 2017, among Aurquest, Xanthic and the Issuer Shareholders;

 

  (d)

The Business Combination Agreement; and

 

  (e)

The NOR Agreement.

GGB Material Contracts

Except for contracts entered into by GGB or its subsidiaries in the ordinary course of business, the only material contracts entered into by GGB or its subsidiaries since incorporation are the following:

 

  (a)

The Advisory Agreements;

 

  (b)

The Loan Agreement;

 

  (c)

The Business Combination Agreement;

 

  (d)

The Agency Agreement;

 

  (e)

The Participation Agreement;

 

  (f)

The GGB Convertible Debenture Indenture;

 

  (g)

The GGB Warrant Indenture;

 

  (h)

The Nomination Rights Agreement;

 

  (i)

The Financial Advisory Agreements; and

 

  (j)

The Investor Rights Agreement.

 

- 98 -


22.

INTEREST OF EXPERTS

Neither auditor has, and neither is entitled to receive, any registered or beneficial interest, direct or indirect, in the property of the Resulting Issuer and neither is expected to own any Resulting Issuer Shares or any associate, affiliate or Related Person (as defined by the policies of the CSE) of the Resulting Issuer.

 

23.

OTHER MATERIAL FACTS

There are no other material facts about the Resulting Issuer or the Resulting Issuer Shares that are not disclosed under any other Item of this Listing Statement and are necessary in order for this Listing Statement to contain full, true and plain disclosure of all material facts relating to the Resulting Issuer or the Resulting Issuer Shares.

 

24.

FINANCIAL STATEMENTS

 

24.1

Financial Statement of the Issuer

See Schedule “A”.

 

24.2

Financial Statement of GGB

See Schedule “B”.

 

- 99 -


CERTIFICATE OF THE ISSUER

Pursuant to a resolution duly passed by its Board of Directors, Xanthic Biopharma Inc. hereby applies for the listing of the above mentioned securities on the CSE. The foregoing contains full, true and plain disclosure of all material information relating to Xanthic Biopharma Inc. It contains no untrue statement of a material fact and does not omit to state a material fact that is required to be stated or that is necessary to prevent a statement that is made from being false or misleading in light of the circumstances in which it was made.

Dated at Toronto, Ontario this u day of u, 2018.

 

(signed) “Tim Moore”     (signed) “David Bhumgara”
Tim Moore     David Bhumgara
Chief Executive Officer and Director     Chief Financial Officer

ON BEHALF OF THE BOARD OF DIRECTORS

 

(signed) “Carli Posner”     (signed) “Igor Galitsky”
Carli Posner     Igor Galitsky
Director     Director


CERTIFICATE OF GGB

The foregoing contains full, true and plain disclosure of all material information relating to Green Growth Brands Ltd. It contains no untrue statement of a material fact and does not omit to state a material fact that is required to be stated or that is necessary to prevent a statement that is made from being false or misleading in light of the circumstances in which it was made.

Dated at Toronto, Ontario this u day of u, 2018.

 

(signed) “Peter Horvath”     (signed) “Ian Fodie”
Peter Horvath     Ian Fodie
Chief Executive Officer and Director     Chief Financial Officer

ON BEHALF OF THE BOARD OF DIRECTORS

 

(signed) “u     (signed) “u
u     u
Director     Director


SCHEDULE “A” – ISSUER FINANCIAL STATEMENTS

Please see attached.


LOGO

Xanthic Biopharma Inc.

Consolidated Financial Statements

For the year ended

June 30, 2018

(In Canadian Dollars)


MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL REPORTING

The accompanying consolidated financial statements of Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) are the responsibility of the management and Board of Directors of the Company.

The consolidated financial statements have been prepared by management, on behalf of the Board of Directors, in accordance with the accounting policies disclosed in the notes to the consolidated financial statements. Where necessary, management has made informed judgments and estimates in accounting for transactions which were not complete at the date of the consolidated statements of financial position. In the opinion of management, the consolidated financial statements have been prepared within acceptable limits of materiality and are in accordance with International Financial Reporting Standards using accounting policies consistent with International Financial Reporting Standards appropriate in the circumstances.

Management has established systems of internal control over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors is responsible for reviewing and approving the consolidated financial statements together with other financial information of the Company and for ensuring that management fulfills its financial reporting responsibilities. An Audit Committee assists the Board of Directors in fulfilling this responsibility. The Audit Committee meets with management to review the financial reporting process and the consolidated financial statements together with other financial information of the Company. The Audit Committee reports its findings to the Board of Directors for its consideration in approving the consolidated financial statements together with other financial information of the Company for issuance to the shareholders.

Management recognizes its responsibility for conducting the Company’s affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

 

“Tim Moore”    

“David Bhumgara”

Tim Moore     David Bhumgara
Chief Executive Officer     Chief Financial Officer


To the Board of Directors and Shareholders of Xanthic Biopharma Inc.:

We have audited the accompanying financial statements of Xanthic Biopharma Inc., which comprise the statement of financial position as at June 30, 2018 and 2017, and the consolidated statement of loss and comprehensive loss, changes in shareholders’ deficiency and cash flows for the year ended June 30, 2018 and the period from the date of incorporation March 15, 2017 to June 30, 2017, and a summary of significant accounting policies and other explanatory information.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Xanthic Biopharma Inc. as at June 30, 2018 and 2017, and its financial performance and its cash flows for the periods then ended in accordance with International Financial Reporting Standards.

Emphasis of Matter

Without qualifying our opinion, we draw attention to Note 1 in the financial statements which indicates the existence of a material uncertainty that may cast significant doubt on the ability of Xanthic Biopharma Inc, Inc. to continue as a going concern.

 

LOGO

 

Toronto, Ontario     Chartered Professional Accountants
September 13, 2018     Licensed Public Accountants


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Consolidated Statement of Financial Position

For the periods ended June 30, 2017 and June 30, 2018

 

(Expressed in Canadian dollars)                    
     Note      June 30, 2018     June 30, 2017  

Assets

       

Current Assets

       

Cash and cash equivalents

      $ 1,037,049     $ 24,096  

Prepaid expenses

        249,915       —    

Inventory

     5        181,096       —    

Other receivable

        157,982       12,428  
     

 

 

   

 

 

 
        1,626,042       36,524  

Non-Current Assets

       

Equipment

     6        56,597       —    

Equity investment in Xanthic Beverages USA, LLC

     7        1,126,865       —    
     

 

 

   

 

 

 
      $ 2,809,504     $ 36,524  
     

 

 

   

 

 

 

Liabilities

       

Current Liabilities

       

Accounts payable and accrued liabilities

     14        156,368       111,643  

Contingent consideration payable

     8        790,080       —    
     

 

 

   

 

 

 
        946,448       111,643  

Shareholders’ Equity (Deficiency)

       

Share capital

     9        4,236,395       26,422  

Reserve for share based payments

     11        385,542       —    

Reserve for warrants

     10        186,304       —    

Deficit

        (2,930,766     (101,541

Accumulated other comprehensive loss

        (14,419     —    
     

 

 

   

 

 

 
        1,863,056       (75,119
     

 

 

   

 

 

 
      $ 2,809,504     $ 36,524  
     

 

 

   

 

 

 

The comparative figures at June 30, 2017 represent those of Xanthic Biopharma Limited.

Nature of operations (note 1)

Subsequent events (note 18)

Approved on behalf of the Board of Directors:

 

“Tim Moore”      “Carli Posner”
CEO and Director      Director

The accompanying notes are an integral part of these consolidated financial statements.

 

1


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Consolidated Statements of Net Loss and Comprehensive Loss

For the periods ended June 30, 2018 and from the date of incorporation March 15, 2017 to June 30, 2017

 

(Expressed in Canadian dollars)                     
     Note      June 30, 2018      June 30, 2017  
  

 

 

    

 

 

    

 

 

 

Expenses

        

Consulting fees

     13      $ 827,658      $ 60,000  

Stock based compensaton

     11        385,542        —    

Advertising and promotion

        174,289        13,496  

Legal and professional fees

        375,023        27,968  

General and administration

        86,569        61  

Loss on equity investment in Xanthic Beverages USA, LLC

     7        58,255        —    

Interest and bank charges

        3,835        16  
     

 

 

    

 

 

 

Loss before transaction related expenses

        1,911,171        101,541  

Listing fees

     4        918,054        —    
     

 

 

    

 

 

 

Net loss from operations

      $ 2,829,225      $ 101,541  
     

 

 

    

 

 

 

Other comprehensive loss

        

Exchange loss on translating foreign operations

        14,419        —    
     

 

 

    

 

 

 

Comprehensive Loss for the period

      $ 2,843,644      $ 101,541  
     

 

 

    

 

 

 

Net Loss per Common Share

        

Basic and Diluted

      $ 0.08      $ 0.04  

Weighted average common shares outstanding

        34,472,257        2,373,953  
     

 

 

    

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Consolidated Statement of Changes in Shareholders’ Equity (Deficiency)

For the periods ended June 30, 2018 and from the date of incorporation March 15, 2017 to June 30, 2017

 

(Expressed in Canadian dollars)                                                     
     Note      Common
Shares
                               Accumulated
Other
Comprehensive
loss
       
     Reserves               
     Share
Capital
    Share based
Payments
     Warrants               
     Deficit     Total  

Balance at incorporation March 15, 2017

        —        $ —       $ —        $ —        $ —       $ —       $ —    

Shares issued for cash, net of issuance costs

        7,000,000        26,422       —          —          —         —         26,422  

Deficit

                   (101,541       (101,541
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at June 30, 2017

        7,000,000        26,422       —          —          (101,541     —         (75,119

Shares issued for cash, net of issuance costs

     9        43,388,000        3,588,962       —          —          —         —         3,588,962  

Issurance of shares on RTO

     4        6,458,547        807,315       —          —          —         —         807,315  

Warrants issued on private placement

     10        —          (186,304     —          186,304        —         —         —    

Stock based compensation

     11        —          —         385,542        —          —         —         385,542  

Deficit

        —          —         —          —          (2,829,225     —         (2,829,225

Exchange loss on translating foreign operations

        —          —         —          —          —         (14,419     (14,419
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at June 30, 2018

        56,846,547      $ 4,236,395     $ 385,542      $ 186,304      $ (2,930,766   $ (14,419   $ 1,863,056  
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 
   

The accompanying notes are an integral part of these consolidated financial statements.

 

3


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Consolidated Statement of Cashflow

For the periods ended June 30, 2018 and from the date of incorporation March 15, 2017 to June 30, 2017

 

(Expressed in Canadian dollars)                    
     Note      June 30, 2018     June 30, 2017  

Cashflow from Operating Activities

       

Net loss for the period

      $ (2,829,225   $ (101,541

Adjustments for:

       

Listing fees

     4        894,054       —    

Stock based compensation

     11        385,542       —    

Loss on equity investment in Xanthic Beverages USA, LLC

     7        58,255       —    

Changes in non-cash working capital balances

       

Other receivable

        (145,554     (12,428

Prepaid expenses

        (249,915     —    

Inventory

        (195,515     —    

Accounts payable and accrued liabilities

        (42,014     111,643  
     

 

 

   

 

 

 
        (2,124,372     (2,326

Cashflow from Investing Activities

       

Purchase of equipment

     6        (56,597     —    

Investment in Xanthic Beverages USA, LLC

     7        (395,040     —    
     

 

 

   

 

 

 
        (451,637     —    

Cashflow from Financing Activities

       

Private placement of shares, net of issuance costs

     9        3,588,962       26,422  
     

 

 

   

 

 

 
        3,588,962       26,422  

Increase in cash and cash equivalents

        1,012,953       24,096  

Cash and cash equivalents, beginning of period

        24,096       —    
     

 

 

   

 

 

 

Cash and cash equivalents, end of the period

      $ 1,037,049     $ 24,096  
     

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

1.

Nature of operations

Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Company”) was incorporated under Ontario Business Corporations Act. The Company was acquired by Xanthic Biopharma Limited (“Xanthic”) in a reverse takeover transaction (see Note 4) completed on December 15, 2017. The Company’s principal business activity is the licensing of non-combustible medical cannabis products. The Company is in the development stage and has not yet earned any revenues. As Xanthic has been identified as the accounting acquirer, these financial statements are considered a continuation of Xanthic and any comparative information provided prior to the reverse takeover are those of Xanthic.

 

2.

Basis of presentation and going concern

(a) Statement of compliance

The Company’s consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The accounting policies set out below were consistently applied to all periods presented unless otherwise noted.

These consolidated financial statements were reviewed, approved and authorized by the Company’s Board of Directors on September 13, 2018.

(b) Basis of measurement

These consolidated financial statements have been prepared in accordance with IFRS, on the historical cost basis except for certain financial instruments, which are measured at fair value, as explained in the accounting policies set out in Note 3.

(c) Basis of consolidation

These consolidated financial statements include the accounts of the Company and its subsidiaries, Xanthic Biopharma Limited, Xanthic US Hold Co., Xanthic Biopharma Oregon LLC, Xanthic Biopharma California LLC, Xanthic Biopharma Nevada LLC and Xanthic Colorado LLC. All significant intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement and has the ability to affect those returns through its power to direct the relevant activities of the entity.

(d) Functional and presentation currency

All figures presented in the consolidated financial statements are reflected in Canadian dollars, which is the functional currency of the Company. The functional currency of the Company’s wholly owned subsidiaries, Xanthic US Hold Co., Xanthic Biopharma Oregon LLC, Xanthic Biopharma California LLC, Xanthic Biopharma Nevada LLC and Xanthic Colorado LLC is United States dollars. Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. The assets and liabilities of foreign operations, are translated in Canadian dollars at year-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in equity.

 

5


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

(e) Use of estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant estimates include but are not limited to the following:

 

  (I)

Inputs when Black-Scholes valuation model

The estimates used in determining the stock option fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes valuation model. Inputs are subject to estimates include volatility, forfeiture rates, estimated lives and market rates.

 

  (II)

Functional and presentation currency

In determining the functional currency of the parent and its subsidiary companies, management considered the currency that mainly influences sales and the cost of providing goods and services in each jurisdiction in each the Company operates. The Company also considered secondary indicators including the currency in which each funds from financing activities are denominated, the currency in which funds are retained and whether the activities of the subsidiaries are carried out as an extension of the Company or if they are carried out with a degree of autonomy.

 

  (III)

Contingent Consideration

The valuation of the contingent consideration payable to former owners of Xanthic Beverages USA, LLC is subject to estimates surrounding the probability of milestones being made.

(f) Going Concern

These consolidated financial statements have been prepared using accounting principles applicable to a going concern. The going concern basis assumes that the Company will continue its operations for the foreseeable future, and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. As at June 30, 2018, the Company had working capital of $679,594 and during the year ended, it incurred a net loss from operations of $2,829,225. The uncertainty on the Company’s ability to raise additional finances to fund its operations casts significant doubt upon the Company’s ability to continue as a going concern and the ultimate appropriateness of using accounting principles applicable to a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is not able to continue as a going concern, the Company may be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in these consolidated financial statements. These differences could be material.

 

3.

Significant accounting policies

A summary of the significant accounting policies, which have been applied consistently to all periods presented in the accompanying consolidated financial statements are set out below:

Cash

Cash comprises bank balances held in Canadian chartered banks.

 

6


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

Inventory

Inventory is recorded at the lower of cost and net realizable value. Cost is determined using the standard cost method, which is updated regularly to reflect current conditions and approximate cost based on the weighted average formula. Cost of inventory includes cost of purchase (purchase price, transport, handling, and other costs directly attributable to the acquisition of inventories), cost of conversion, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

All inventories are reviewed for impairment due to slow moving and obsolete inventory. The provisions for obsolete, slow moving or defective inventories are recognized in profit or loss. Previous write downs to net realizable value are reversed to the extent there is a subsequent increase in the net realizable value of the inventory.

Capital assets

Capital assets are carried at cost less any residual value, accumulated depreciation and impairment losses. Cost includes the acquisition costs or construction costs, as well as the costs directly attributable to bringing the asset to the location and condition necessary for its use in operations. When capital assets include significant components with different useful lives, they are recorded and amortized separately. Depreciation is computed using the straight-line method based on the estimated useful life of the assets. The residual value, useful life and depreciation methods are reviewed at the end of each reporting period. Such a review takes into consideration the nature of the asset, the intended use and impact of technological changes. Where parts of an item of capital assets have different useful lives, they are accounted for as separate items of capital assets. Subsequent costs are included in the asset carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

Impairment of non-financial assets

At each date of the statement of financial position, the Company reviews the carrying amounts of its tangible assets to determine whether there is an indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash generating unit to which the assets belong. Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

If the recoverable amount of an asset (or cash generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in the statement of comprehensive loss.

Equity Accounted Investments

Equity accounted investments are investments over which the Company has significant influence, but not control. The financial results of the Company’s equity accounted investments are included in the Company’s consolidated financial statements using the equity method whereby the Company recognizes its proportionate share of income or loss and other comprehensive income or loss of the equity accounted investment in its own operations or comprehensive income or loss, as applicable.

Dilution gains and losses arising from changes in the Company’s interest in equity accounted investments are recognized in net operations. If the Company’s investment is reduced to zero, additional losses are not provided for, and a liability is not recognized, unless the Company has incurred legal or constructive obligations, or made payments on behalf of the equity accounted investment.

 

7


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

Financial instruments

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation specified in the contract is discharged, cancelled or expires.

A derivative is a financial instrument whose value changes in response to a specified variable, requires little or no net investment and is settled at a future date.

At initial recognition, the Company classifies its financial instruments in the following categories:

 

(i)

Financial assets and liabilities at fair value through profit or loss: a financial asset or liability is classified in this category if acquired principally for the purpose of selling or repurchasing in the short-term. Derivatives are also included in this category unless they are designated as hedges. Financial instruments in this category are recognized initially and subsequently at fair value. Gains and losses arising from changes in fair value are presented in the statements of net loss and comprehensive loss within other expense (income) in the period in which they arise. Cash and contingent consideration payable are included in this category.

 

(ii)

Loans and receivables: Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at the amount expected to be received, less, when material, a discount to reduce the loans and receivables to fair value. Subsequently, loans and receivables are measured at amortized cost using the effective interest method less a provision for impairment. Other receivable is included in this category.

 

(iii)

Available for sale financial assets: Available for sale assets are non-derivative financial assets that are designated as available for sale and are not categorized into any of the other categories described above. They are initially recognized at fair value including direct and incremental transaction costs. They are subsequently recognized at fair value. Gains and losses arising from changes in fair value are included as a separate component of equity until sale, when the cumulative gain or loss is transferred to the statements of loss and comprehensive loss. Interest is determined using the effective interest method, and impairment losses and translation differences on monetary items are recognized in the statements of net loss and comprehensive loss. The Company does not have any available for sale assets.

 

(iv)

Financial liabilities at amortized cost: Financial liabilities at amortized cost are composed of accounts payable and the promissory note payable. Trade payables, accrued liabilities and promissory note payable are initially recognized at the amount required to be paid, less, when material, a discount to reduce payables to fair value. Subsequently, accounts payables are measured at amortized cost using the effective interest method. These are classified as current liabilities if payment is due within 12 months. Otherwise, they are presented as non-current liabilities.

Impairment of financial assets carried at amortized cost

At each statement of financial position date, the Company assesses whether there is objective evidence a financial asset or group of financial assets is impaired. A financial asset or group of financial assets is impaired and impairment losses are incurred if, and only if, there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a loss event), and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

The amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows (excluding future credit losses) discounted at the financial asset’s original effective interest rate. The asset’s carrying amount is reduced and the amount of the loss is recognized in the statements of loss and comprehensive loss. If a loan has a variable interest rate, the discount rate for measuring any impairment loss is the

 

8


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

current effective interest rate determined under the contract. For practical reasons, the Company may measure impairment on the basis of an instrument’s fair value using an observable market price.

Stock based compensation

The Company issues stock based compensation awards to directors, employees and consultants. These arrangements include stock options. The Company expects that these stock based awards will be settled in equity of the Company. The Company uses a fair value method to account for stock based compensation. The fair value of stock based compensation, as at the date of grant, is measured using an option-pricing model and is recognized over the applicable vesting period as compensation expense, based on the number of stock based awards expected to vest, with a corresponding increase in contributed surplus. When stock options are exercised, the proceeds received, together with any amount in contributed surplus, are included in share capital. The expected number of stock based awards expected to vest is reviewed at least annually, with any impact being recognized immediately.

Share capital

In situations where the Company issues units, the value of units is bifurcated, and the value of warrants is included as a separate reserve of the Company’s equity. On expiry, the fair value of the warrants is transferred to share capital.

Share issuance costs

Costs incurred in connection with the issuance of share capital are netted against the proceeds received. Costs related to the issuance of share capital and incurred prior to issuance are recorded as deferred share issuance costs and subsequently netted against proceeds when they are received.

Loss per common share, basic and diluted

Basic loss per share is calculated by dividing the net loss for the period attributable to equity owners of the Company by the weighted average number of common shares outstanding during the period. Contingently issuable shares (including shares held in escrow) are not considered outstanding common shares and consequently are not included in the loss per share calculations.

Diluted loss per share is calculated by adjusting the weighted average number of common shares outstanding for dilutive instruments. The number of shares included with respect to options, warrants and similar instruments is computed using the treasury stock method.

For the periods presented, all options and warrants were anti-dilutive.

Income taxes

Income tax comprises current and deferred tax. Income tax is recognized in the statements of loss and comprehensive loss except to the extent that it relates to items recognized directly in shareholders’ equity, in which case the income tax is also recognized directly in shareholders’ equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect of previous years.

In general, deferred tax is recognized in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively enacted at the statements of financial position dates and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are recognized to the extent that it is probable the assets can be recovered.

Deferred income tax assets and liabilities are presented as non-current.

 

9


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

Provisions

A provision is recognized when the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable an outflow of economic benefits will be required to settle the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation.

New standards, amendments and interpretations not yet adopted

A number of new standards and amendments to standards and interpretations have been issued but have not yet been applied in preparing these consolidated financial statements, as set out below:

 

   

IFRS 9, Financial Instruments, addresses the classification, measurement and recognition of financial assets and financial liabilities. The complete version of IFRS 9 was issued in July 2014. It replaces the guidance in IAS 39 that relates to the classification and measurement of financial instruments. IFRS 9 retains but simplifies the mixed measurement model and establishes three primary measurement categories for financial assets: amortized cost, fair value through other comprehensive income (OCI) and fair value through profit or loss. The basis of classification depends on the entity’s business model and the contractual cash flow characteristics of the financial asset. Investments in equity instruments are required to be measured at fair value through profit or loss with the irrevocable option at inception to present changes in fair value in OCI not recycling. There is now a new expected credit losses model that replaces the incurred loss impairment model used in IAS 39. For financial liabilities, there were no changes to classification and measurement except for the recognition of changes in own credit risk in other comprehensive income, for liabilities designated at fair value through profit or loss. The standard is effective for accounting periods beginning on or after January 1, 2018 and earlier adoption is permitted. The Company does not expect this standard to have a significant impact on the Company’s financial statements at this time.

 

   

IFRS 15, Revenue from Contracts with Customers, deals with revenue recognition and establishes principles for reporting useful information to users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. Revenue is recognized when a customer obtains control of goods or services and thus has the ability to direct the use and obtain the benefits from the goods or services. The standard replaces IAS 18, Revenue, and IAS 11, Construction Contracts, and related interpretations. The standard is effective for annual periods beginning on or after January 1, 2018 and earlier adoption is permitted. The Company does not expect this standard to have a significant impact on the Company’s financial statements at this time.

 

   

In January 2016, the IASB issued IFRS 16, Leases, which will replace IAS 17, Leases. Under IFRS 16, a contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Under IAS 17, lessees were required to make a distinction between a finance lease and an operating lease. IFRS 16 now requires lessees to recognize a lease liability reflecting future lease payments and a right-of-use asset for virtually all lease contracts. There is an optional exemption for certain short-term leases and leases of low value assets; however, this exemption can only be applied by lessees. The standard is effective for annual periods beginning on or after January 1, 2019, with earlier application if IFRS 15 is also applied. The Company has yet to assess the impact of this standard.

 

   

IFRIC 22, Foreign Currency Transactions and Advance Consideration, was issued on December 8, 2016 and clarifies which date should be used for translation when a foreign currency transaction involves an advance payment or receipt and is applicable for annual periods beginning on or after January 1, 2018. The Company does not expect this standard to have a significant impact on the Company’s financial statements at this time.

 

   

IFRIC 23, Uncertainty over Income Tax Treatments, was issued in June 2017 and clarifies the accounting for uncertainties in income taxes. The interpretation committee concluded that an entity shall consider whether it is probable that a taxation authority will accept an uncertain tax treatment. If an entity concludes it is probable that the taxation authority will accept an uncertain tax treatment, then the entity shall determine

 

10


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

 

taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates consistently with the tax treatment used or planned to be used in its income tax filings. If an entity concludes it is not probable that the taxation authority will accept an uncertain tax treatment, the entity shall reflect the effect of uncertainty in determining the related taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates. IFRIC 23 is effective for annual periods beginning on or after January 1, 2019. Earlier adoption is permitted. The Company has yet to assess the impact of this standard.

 

4.

Xanthic’s Biopharma Limited Reverse Take Over (“RTO”)

On December 15, 2017, the Company entered into a definitive agreement with Xanthic Biopharma Limited (“Xanthic”). Pursuant to the definitive agreement the Company acquired all the issued and outstanding common shares of Xanthic (the “Xanthic Shares”) from the Xanthic shareholders. At the date of closing on the definitive agreement there were 37,252,000 Xanthic Shares issued and outstanding, inclusive of 10,252,000 Xanthic Shares issued at a price of $0.125 per Xanthic Share pursuant to a non-brokered private placement. In exchange for the Xanthic Shares, the Company issued 298,016,000 common shares in the Company at a ratio of eight Company shares for each Xanthic Share at a deemed price of $0.015625 per Company share, resulting in a reverse takeover of the Company by Xanthic shareholders.

The Company had 51,668,184 common shares outstanding prior to the completion of the RTO. On closing of the RTO there was 349,684,184 common shares outstanding of which 51,668,184 represented the original shareholders of the Company who retained 14.8% and Xanthic shareholders obtained 85.2% of the Company.

Since the Company did not meet the definition of a business under IFRS 3 – Business Combinations, the acquisition was accounted for as a purchase of the Company’s assets. The consideration paid was determined as equity-settled share based payments under IFRS 2, at the fair value of the equity of the Company retained by the shareholders of the Company based on the fair value of the Xanthic common shares on the date of closing of the RTO, which was determined to be $0.125 per common share based on the most recent equity raise completed just prior to the RTO. The Company recorded a listing fees of $918,054 in the consolidated financial statements of net loss and comprehensive loss. The details of the listing fees are as follows:

 

Fair value of consideration paid:

  

51,668,184 common shares of Xanthic at $0.015625 per share

   $ 807,315  

Net liabilities of Aurquest acquired by Xanthic

     86,739  
  

 

 

 
     894,054  

Other Transaction Costs:

  

Professional fees

     24,000  
  

 

 

 

Listing fees

   $ 918,054  
  

 

 

 

The net liabilities of the Company were included at their carrying value of $86,739, which approximates their fair value as follows:

 

Cash

   $ 2,141  

Prepaid expenses

     500  

Accounts payable and accrued liabilities

     (44,380

Shareholder loans

     (45,000
  

 

 

 
   $ (86,739
  

 

 

 

For accounting purposes, these consolidated financial statements reflect a continuation of the financial position, operating results and cash flows of the Company’s legal subsidiary, Xanthic Biopharma Limited.

 

11


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

5.

Inventory

As at June 30, 2018, the Company purchased certain raw materials which includes packaging, flavoring and other ingredients that will be resold to licensed producers who the Company has partnered with in each jurisdiction. Inventory is recorded at their carrying amount.

 

6.

Capital assets

As at June 30, 2018, the Company purchased certain equipment totaling $56,597 for use in the first jurisdiction it plans to license its technology. The equipment was not in use as at June 30, 2018 and was still undergoing testing and calibration. Once the equipment is in use it will be amortized using the declining balance method at rates from 25% to 40%.

 

7.

Equity investment in Xanthic Beverages USA, LLC (formerly Avitas CBD Water, LLC)

On March 22, 2018, the Company completed the investment in Xanthic Beverages USA, LLC (formerly Avitas CBD Water, LLC) (“Xanthic Beverages”). Xanthic Beverages is based in Portland, Oregon, and will be producing and distributing CBD-infused water, co-branded with the Company. Under the terms of the Agreement, the Company acquired a 45% ownership position in exchange for a cash payment of USD$300,000 and a contingent consideration payable of US$300,000 (see Note 8) on achieving certain performance milestones over the next 12 months.

Further, at the Company option, if Xanthic Beverages achieves certain milestones on sales, the Company may issue 600,000 common shares in the Company or a one time cash payment of up to USD$300,000.

Finally, at the Company’s option, the Company can acquire a further 6% interest in Xanthic Beverages for a one time payment in shares of US$300,000 at the then 60 day average price of the Company’s common shares.

 

For year ended June 30,

   2018  

Opening Investment in Xanthic Beverages USA, LLC

   $ —    

Initial investment

     1,185,120  

Xanthic share of operating loss

     (58,255
  

 

 

 

Closing balance in Xanthic Beverages USA, LLC

   $ 1,126,865  
  

 

 

 

The Company picks up its share of the loss of Xanthic Beverages USA, LLC for the period ended June 30, 2018 which was $58,255.

The following table summarizes certain financial information of Xanthic Beverages USA, LLC for the period noted below:

 

(Expressed in United States dollars)

      
     2018  

Total Current Assets

   $ 498,435  

Total Non-current assets

     —    

Total Current Liabilities

     —    

Revenue

     1,620  

Net loss from operations

   $ (101,665

 

12


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

8.

Contingent consideration payable

In connection with the Company’s equity investment in Xanthic Beverages, the Company has a contingent consideration payable of USD$300,000 (see Note 7) if Xanthic Beverages issues a second purchase order for a second production run over the next 12 months. The Company has assigned a 100% probability that Xanthic Beverages would be meet this performance milestone. The USD$300,000 payable on the second purchase order is subject to interest at the average US applicable federal rate of 1.76%.

In addition, the Company has accounted for the contingent consideration payable of paying up to USD$300,000 or issuing 600,000 common shares of the Company (see Note 7) if Xanthic Beverages achieves certain additional milestones. The Company has assigned a 100% probability that Xanthic Beverages would achieve either these milestones.

Subsequent to year end, on July 23, 2018, the Company paid the contingent payable of USD$300,000 along with accrued interest of USD$1,735.32 on the issuance of the second purchase order by Xanthic Beverages.

 

9.

Shareholders’ equity

Authorized share capital

Common Share – voting – unlimited

All historical references to share transactions or balances prior to this date have been recast on an eight for one basis unless otherwise stated.

Outstanding share capital

 

     Common Shares      Amount  

Outstanding at June 30, 2017

     7,000,000      $ 26,422  

Common Shares issued for cash

     43,388,000        3,551,196  

Issuance Costs

     —          (148,538

Issuance of shares in RTO

     6,458,547        807,315  
  

 

 

    

 

 

 

Outstanding at June 30, 2018

     56,846,547      $ 4,236,395  
  

 

 

    

 

 

 

On November 21, 2017, Xanthic completed a non-brokered private placement by issuing 160,000,000 (20,000,000 common shares before the share split of 1 for 8) common shares for gross proceeds of $400,000.

On December 13, 2017, prior to the completion of the RTO transaction noted above Xanthic completed a non-brokered private placement by issuing 82,016,000 (10,252,000 common shares before the share split of 1 for 8) common shares for net proceeds of $1,194,144 net of issue costs of $87,356.

On December 15, 2017, the Company completed the previously discussed (see Note 4) RTO by issuing 51,668,184 (6,458,547 common shares after the share consolidation of 8 for 1) common shares to Xanthic shareholders.

On January 16, 2018, the Company completed a non-brokered private placement by issuing 96,000,000 common (12,000,000 common shares after the consolidation of 8 for 1) shares for gross proceeds of $1,500,000.

On February 26, 2018, the Company completed an 8 for 1 consolidation of the common shares outstanding, after receiving shareholder approval at its annual general and special shareholder meeting.

 

13


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

On April 19, 2018, the Company closed a non-brokered private placement for gross proceeds of $556,000. The Company issued 1,112,000 units (the “Units”) at a price of $0.50 per Unit. Each Unit will be comprised of one common share in the Company and one-half of one (1/2) common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one common share at an exercise price of $0.75 per common share for a period of 24 months from the closing date of the private placement. The Company paid to certain finders an aggregate finder’s fee of $18,000 and 24,000 Units comprised of 24,000 common shares and 12,000 Warrants, having the same attributes as the Units.

10. Warrants

The following table reflects the continuity of warrants for the periods presented:

 

     Number of
Warrants
     Weighted
Average
Exercise Price
 

Balance outstanding, July 1, 2017

     —        $ —    

Issued

     568,000        0.750  

Expired

     —          —    
  

 

 

    

 

 

 

Balance outstanding, June 30, 2018

     568,000      $ 0.750  
  

 

 

    

 

 

 

On April 19, 2018, in conjunction with the non-brokered private placement, the Company issued 556,000 warrants at an exercise price of $0.75 per share, exercisable until April 18, 2020. There were 12,000 finders’ warrants granted in connection with this private placement.

The fair value of these warrants was valued using the Black-Scholes Option Pricing Model with the following assumptions:

 

     2018  

Risk free interest rate

     1.88

Expected divident yield

     0.00

Expected volatility1

     150

Expected life of the warrants

     2 years  

 

(1)

Expected volatility is based on historical volatility of comparable companies.

11. Stock based compensation

Stock Option Plan

The shareholders of the Company have approved a stock option plan (the “SOP”) pursuant to which the Company may issue up to 5,684,654 common shares of the Company to employees, directors and officers. The exercise price of each option issued pursuant to the terms of the SOP shall be established at the grant date by the directors of the Company and in all cases shall not be less than the closing price of the common shares of the Company on the trading day immediately preceding the grant date. Options are generally issued with a five year term from the date of grant and are subject to vesting conditions whereby one third of the options granted vest immediately, with the remaining two thirds vesting over a two-year period.

During the year ended June 30, 2018, the Company granted 4,208,000 stock option awards at an exercise prices ranging from $0.125 to $0.60 per option. The fair value of the options granted was estimated at the grant date using an option pricing model with the following assumptions:

 

14


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

     May 28,
2018
    April 19,
2018
    February 28,
2018
 

Number of options granted

     1,000,000       900,000       2,308,000  

Exercise price

   $ 0.160     $ 0.40 to $0.60     $ 0.125  

Risk free interest rate

     1.88     2.12     2.01

Expected divident yield

     0.00     0.00     0.00

Expected volatility1

     150     150     150

Expected life of the options

     1 year       1 to 5 years       3 to 5 years  

 

(1)

Expected volatility is based on historical volatility of comparable companies.

A summary of the status of the stock option component of the Company’s SOP as at and for the year ended June 30, 2018, is as follows:

 

     Stock
Options
     Weighted
Average
Exercise
Price
 

Options outstanding, July 1, 2017

     —        $ —    

Options granted

     4,208,000        0.189  

Forfeited

     (700,000      0.321  
  

 

 

    

 

 

 

Options outstanding, June 30, 2018

     3,508,000      $ 0.189  
  

 

 

    

 

 

 

Exercisable options

     1,702,661      $ 0.146  

 

Option price

   Options
Outstanding
     Weighted
Average
Exercise Price
     Weighted Ang
Remaining
Contractual
Life (Yrs.)
     Options
Exercisable
 

At $0.125

     2,108,000      $ 0.125        4.67        702,661  

At $0.16

     1,000,000      $ 0.160        0.91        1,000,000  

At $0.60

     400,000      $ 0.600        4.80        —    

During the year ended June 30, 2018, the Company recognized stock based compensation expense of $385,542 in respect of outstanding stock options.

A summary of the vesting schedule of stock options are as follows:

 

Vesting Schedule

      

Immediate

     1,702,661  

1 year

     400,000  

2 years

     1,405,339  

Subsequent to year end, 700,000 stock options were exercised.

 

15


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

12. Income taxes

The reconciliation of the combined Canadian federal and provincial corporate income taxes at a statutory rate 26.5% to the Company’s effective income tax expense is as follows:

 

For year ended June 30,

   2018     2017  

Loss before income taxes

   $ 2,829,225     $ 101,541  

Statutory rate

     26.5     26.5
  

 

 

   

 

 

 

Expected income tax recovery at combined basic federal and provincial tax rates

     749,745       26,908  

Effect on income taxes of:

    

Non-deductible expenses

     (417,608     —    

Changes in tax benefits not recognized

     (332,137     (26,908
  

 

 

   

 

 

 

Income tax recovery

   $ —       $ —    
  

 

 

   

 

 

 

Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities.

Deferred tax assets have not been recognized in respect of the following temporary differences:

 

     As at
June 30, 2018
     As at
June 30, 2017
 

Non-capital loss carryforward

   $ 2,930,766      $ 101,541  

Deductible share issuance costs

     157,117        8,578  

As at June 30, 2018, the Company had Canadian non-capital loss carry forwards which may be available to offset future year’s taxable income. The losses expire as follows:

 

     2018      2017  

2037

   $ 110,119      $ 110,119  

2038

     2,977,764        —    
  

 

 

    

 

 

 
   $ 3,087,883      $ 110,119  
  

 

 

    

 

 

 

13. Related parties

Related parties include the Board of Directors and key management, close family members and entities that are controlled by these individuals, as well as certain persons performing similar functions. At June 30, 2018 there was $25,366 indebtedness to shareholders of the Company.

 

16


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

Management compensation

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling activities of the entity, directly or indirectly including the Chief Executive Officer, President, and Chief Financial Officer and equivalent, and Directors. For the year ended June 30, 2018, the Company’s expenses included $470,942 respectively for salary or consulting fees paid to key management personnel, include in consulting fees. In addition, included in stock based compensation expense is $115,075 in connection with stock awards to management and Directors.

14. Capital management

The Company’s objective in managing capital is to ensure a sufficient liquidity position to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. In order to achieve this objective, the Company prepares budgets and capital requirements to manage its capital structure. The Company defines capital as equity and borrowings, comprised of issued share capital, share-based payments, accumulated deficit, as well as due to related parties.

Since inception, the Company has primarily financed its liquidity needs through issuance of shares.

The Company is not subject to externally imposed capital requirements.

15. Financial instruments and risk management

Financial instruments

The Company has classified its cash and contingent consideration payable as fair value through profit and loss (“FVTPL”), and other receivable as current assets, accounts payable and accrued liabilities and contingent consideration payable as current liabilities.

The carrying values of cash, other receivable, accounts payable and accrued liabilities and contingent consideration payable approximate their fair values due to their short periods to maturity.

Fair value hierarchy

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The hierarchy is summarized as follows:

Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities

Level 2 – inputs that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices) from observable market data

Level 3 – inputs for assets and liabilities not based upon observable market data

 

            Fair value as at June 30, 2018  
     Carrying value as at
June 30, 2018
     Quoted prices in
Active Markets for
Identical Assets
(Level 1)
     Significant Other
Observable Inputs
(Level 2)
     Significant
Unobservable Inputs
(Level 3)
 

Financial Assets

           

Cash

   $ 1,037,049      $ 1,037,049      $  —        $ —    

Financial Liabilities

           

Contingent consideration payable

     790,080        —          —          790,080  

 

17


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

Contingent consideration payable has a sensitivity of US$75,000 depending on the probability that Xanthic Beverages would achieve certain sales milestones (see Note 8).

Financial risk factors

The Company’s risk exposure and the impact on the Company’s financial instruments are summarized below:

 

(a)

Credit risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and other receivables. The Company’s cash is held at a major Canadian bank and in trust with lawyers. The Company’s other receivables is with Revenue Canada in connection with input tax credits. The Company regularly monitors the credit risk exposure and takes steps to mitigate the likelihood of these exposures resulting in actual loss.

 

(b)

Liquidity risk

The Company is exposed to liquidity risk or the risk of not meeting its financial obligations as they come due as discussed in Note 2 (e) above. The Company constantly monitors and manages its cash flows to assess the liquidity necessary to fund operations. All of the Company’s financial liabilities are due within one year.

 

(c)

Interest rate risk

The Company is not subject to any significant interest rate risk from its liabilities other than noted in connection with the promissory note (Note 8), which are all non-interest bearing instruments.

16. Accounts payable and accrued liabilities

 

     June 30, 2018      June 30, 2017  

Trade payables

   $ 63,303      $ 97,143  

Accrued liabilities

     93,065        14,500  
  

 

 

    

 

 

 
   $ 156,368      $ 111,643  
  

 

 

    

 

 

 

 

18


XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

Notes to the Consolidated Financial Statements

For the year ended June 30, 2018

 

17. Segmented information

The Company operates in one reportable operating segment, being the licensing of its technology and wholesale distribution of non-cannabis ingredients in North America. The Company is currently still in its development stage has no revenue for the fiscal year ended June 30, 2018.

18. Subsequent event

On July 16, 2018, the Company announced that they entered into an arm’s length business combination agreement (the “Definitive Agreement”) dated July 13, 2018 to combine Xanthic and Green Growth Brands (GGB”) by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

Following completion of the Business Combination, current shareholders of GGB will hold approximately 86% of the common shares (the “Resulting Issuer Shares”) of the resulting issuer (the “Resulting Issuer”). It is anticipated that the Resulting Issuer may operate under the name “Green Growth Brands Ltd.” after effecting a name change (the “Name Change”) with the Resulting Issuer Shares listed and posted for trading on the Canadian Securities Exchange (the “Exchange” or the “CSE”). Xanthic anticipates filing a management information circular or listing statement (the “Disclosure Document”) detailing certain matters relating to the Business Combination and other related matters to be mailed to Xanthic shareholders.

Xanthic and GGB also announced that GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic has entered into a purchase agreement (the “NOR Agreement”) dated July 13, 2018 with Nevada Organic Remedies LLC (“NOR”) and its members pursuant to which it will acquire (the “NOR Acquisition”) 100% of the outstanding membership interests of NOR for aggregate consideration of US$56,750,000 with 5% in common shares and the balance in cash. On July 17, 2018, GGB Nevada made a payment of US$2,000,000 to NOR as a deposit on the NOR Agreement. GGB Nevada secured such funds by signing a promissory note with GGB. NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada holding four Nevada marijuana licenses (dispensary, cultivation, production and distribution). Additionally, NOR produces a line of high quality medical and recreational products under the name 8|fold.

As of July 13, 2018, Xanthic had 57,046,547 Xanthic Shares outstanding together with Xanthic convertible securities entitling the holders thereof to acquire a further 3,876,000 Xanthic Shares. Based on the foregoing, Xanthic will, subject to the receipt of all regulatory approvals, including the approval of its shareholders to certain items of special business and the Exchange, (i) combine with GGB pursuant to the Definitive Agreement such that all of the issued and outstanding GGB Shares will be acquired, and as consideration, Xanthic will issue to holders of GGB Shares, on a 3.394-for-one basis, 346,150,835 Xanthic Shares (the “Consideration Shares”) , in exchange for the then issued and outstanding GGB Shares (which for greater certainty excludes the GGB Shares to be issued under the Subscription Receipt Private Placement and the Debenture Private Placement (as such terms are defined below)); and (ii) reorganize its share structure and consolidate all of the issued and outstanding Xanthic Shares (including the Consideration Shares) on the basis of approximately 4.07 pre-consolidation Xanthic Shares for one (1) post-consolidation Resulting Issuer Share (the “Consolidation”).

In the event that GGB terminates the Definitive Agreement, other than as a result of a breach of representation or warranty or non-performance by Xanthic, GGB shall pay Xanthic a break fee in the aggregate amount of $250,000 and reimburse Xanthic for the full extent of its US legal fees, a portion of its Canadian legal fees, travel costs and other reasonable expenses incurred in connection with the Business Combination.

Further, on September 5, 2018, the Company signed a loan agreement for US$30,347,500 with GGB in connection with the NOR Agreement which closed on the same day. The loan agreement is for a period of 180 days from September 5, 2018 and bears interest at 12% annum. The proceeds of the loan from GGB were used to make the initial payment on closing of the NOR Agreement. In addition, on closing of the NOR Acquisition, GGB Nevada provided to the NOR Members a secured promissory note in the principal amount of US$21,565,000.

 

19


SCHEDULE “B” – GGB FINANCIAL STATEMENTS

Please see attached.


LOGO

Green Growth Brands Ltd.

Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to

July 31, 2018

(In United States Dollars)


MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL REPORTING

The accompanying consolidated financial statements of Green Growth Brands Ltd. are the responsibility of the management and Board of Directors of the Company.

The consolidated financial statements have been prepared by management, on behalf of the Board of Directors, in accordance with the accounting policies disclosed in the notes to the consolidated financial statements. Where necessary, management has made informed judgments and estimates in accounting for transactions which were not complete at the date of the consolidated statements of financial position. In the opinion of management, the consolidated financial statements have been prepared within acceptable limits of materiality and are in accordance with International Financial Reporting Standards using accounting policies consistent with International Financial Reporting Standards appropriate in the circumstances.

Management has established systems of internal control over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors is responsible for reviewing and approving the consolidated financial statements together with other financial information of the Company and for ensuring that management fulfills its financial reporting responsibilities. Management assists the Board of Directors in fulfilling this responsibility. Management meets with the Board of Directors to review the financial reporting process and the consolidated financial statements together with other financial information of the Company. Management reports its findings to the Board of Directors for its consideration in approving the consolidated financial statements together with other financial information of the Company for issuance to the shareholders.

Management recognizes its responsibility for conducting the Company’s affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

 

(signed)

     

(signed)

Peter Horvath

     

Ian Fodie

Chief Executive Officer

     

Chief Financial Officer


LOGO

Independent Auditors’ Report

To the Board of Directors and Shareholders of Green Growth Brands Ltd.:

We have audited the accompanying financial statements of Green Growth Brands Ltd., which comprise the statement of financial position as at July 31, 2018, and the statement of loss and other comprehensive loss and cash flows from the commencement of operations on February 14, 2018 to July 31, 2018 and a summary of significant accounting policies and other explanatory information.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained in our audit is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of Green Growth Brands Ltd. as at July 31, 2018, and its financial performance and its cash flows from the commencement of operations on February 14, 2018 to July 31, 2018 in accordance with International Financial Reporting Standards.

 

Montréal, Québec

   LOGO

September 26, 2018

 

LOGO


GREEN GROWTH BRANDS LTD.

 

Consolidated Statement of Financial Position

 

(Expressed in United States dollars)              
     Note      July 31, 2018  

Assets

     

Current Assets

     

Cash

      $ 2,242,245  

Loan receivable

     4        2,000,000  

Other receivable

        141,714  
     

 

 

 
        4,383,959  
     

 

 

 
      $ 4,383,959  
     

 

 

 

Liabilities

     

Current Liabilities

     

Accrued liabilities

        825,620  

Shareholders’ Equity (Deficiency)

     

Share capital

     5        7,503,459  

Deficit

        (3,945,120
     

 

 

 
        3,558,339  
     

 

 

 
      $ 4,383,959  
     

 

 

 

Nature of operations (note 1)

Subsequent events (note 12)

Approved on behalf of the Board of Directors:

 

(signed)

   

(signed)

Director

   

Director

The accompanying notes are an integral part of these consolidated financial statements.


GREEN GROWTH BRANDS LTD.

 

Consolidated Statements of Net Loss and Comprehensive Loss

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

(Expressed in United States dollars)              
     Note      2018  

Expenses

     

Salaries

     7      $ 936,580  

Legal and professional fees

        2,233,548  

General and administration

        699,677  

Interest and bank charges

        1,165  

Exchange loss on translating foreign operations

        74,150  
     

 

 

 

Net Loss from operations

      $ 3,945,120  
     

 

 

 

Net Loss and Comprehensive Loss for the period

      $ 3,945,120  
     

 

 

 

Net Loss per Common Share

     

Basic and Diluted

      $ 0.06  

Weighted average common shares outstanding

        62,487,876  
     

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.


GREEN GROWTH BRANDS LTD.

 

Consolidated Statement of Changes in Shareholders’ Equity

For the period from commencement on February 14, 2018 to July 31, 2018

 

(Expressed in United States dollars)                                  
     Note                             
            Common
Shares
     Share
Capital
     Deficit     Total  

Balance at inception, February 14, 2018

        —        $ —        $ —       $ —    

Shares issued, net of issuance costs

     5        98,340,002        7,503,459        —         7,503,459  

Share based compensation

     5        2,425,000        —          —         —    

Deficit

        —          —          (3,945,120     (3,945,120
     

 

 

    

 

 

    

 

 

   

 

 

 

Balance at July 31, 2018

        100,765,002      $ 7,503,459      $ (3,945,120   $ 3,558,339  
     

 

 

    

 

 

    

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.


GREEN GROWTH BRANDS LTD.

 

Consolidated Statement of Cashflow

For the period from commencement on February 14, 2018 to July 31, 2018

 

(Expressed in United States dollars)              
     Note      July 31, 2018  

Cashflow from Operating Activities

     

Net loss for the period

      $ (3,945,120

Adjustments for:

     

Changes in non-cash working capital balances

     

Other receivable

        (141,714

Accounts payable and accrued liabilities

        825,620  
     

 

 

 
        (3,261,214

Cashflow from Investing Activities

     

Loan Receivable

     4        (2,000,000
     

 

 

 
        (2,000,000

Cashflow from Financing Activities

     

Private placement of shares, net of issuance costs

     5        7,503,459  
     

 

 

 
        7,503,459  

Increase in cash and cash equivalents

        2,242,245  

Cash and cash equivalents, beginning of period

        —    
     

 

 

 

Cash and cash equivalents, end of the period

      $ 2,242,245  
     

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

1.

Nature of operations

Green Growth Brands Ltd. (“Company”) was incorporated under Ontario Business Corporations Act on February 14, 2018. As such, the Company does not have any comparative information. The Corporation’s principal business activity is the development of lifestyle oriented, consumer products that celebrate health, wellness and happiness focused on the medicinal and recreational cannabis sectors in both the United States and Canada. The Company is in the development stage and has not yet earned any revenues. The Corporation’s registered office is 5300 Commerce Court West, 199 Bay Street, Toronto, ON, M5L 1B9 and its principal place of business is 4300 E. Fifth Avenue, Columbus, OH 43219.

 

2.

Basis of presentation and going concern

 

(a)

Statement of compliance

The Company’s consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The accounting policies set out below were consistently applied to all periods presented unless otherwise noted.

These consolidated financial statements were reviewed, approved and authorized by the Company’s Board of Directors on September 26, 2018.

 

(b)

Basis of measurement

These consolidated financial statements have been prepared in accordance with IFRS, on the historical cost basis except for certain financial instruments, which are measured at fair value, as explained in the accounting policies set out in Note 3.

 

(c)

Basis of consolidation

These consolidated financial statements include the accounts of the Company and its subsidiary, Green Growth Brands LLC. All significant intercompany balances and transactions were eliminated on consolidation. Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases.

 

(d)

Functional and presentation currency

All figures presented in the consolidated financial statements are reflected in United States dollars, which is the functional currency of both the Parent and Subsidiary entities as well as the presentation currency of the consolidated Company. Foreign currency transactions are translated into functional currency United States dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the statement of financial position date are translated to United States dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

(e)

Use of estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant estimates include but are not limited to the following:

 

  (I)

Inputs when Black-Scholes valuation model

The estimates used in determining the deferred share fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes valuation model. Inputs are subject to estimates include volatility of the underlying share price, the risk-free rate of return, and the estimated rate of forfeiture of shares granted.

 

  (II)

Functional and presentation currency

In determining the functional currency of the parent and its subsidiary companies, management considered the currency that mainly influences sales and the cost of providing goods and services in each jurisdiction in each the Company operates. The Company also considered secondary indicators including the currency in which each funds from financing activities are denominated, the currency in which funds are retained and whether the activities of the subsidiaries are carried out as an extension of the Company or if they are carried out with a degree of autonomy.

 

(f)

Going Concern

These consolidated financial statements have been prepared using accounting principles applicable to a going concern. The going concern basis assumes that the Company will continue its operations for the foreseeable future, and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. As at July 31, 2018, the Company had working capital of $3,558,339 and during the period ended, it incurred a net loss from operations of $3,945,120. The uncertainty on the Company’s ability to raise additional finances to fund its operations casts doubt upon the Company’s ability to continue as a going concern and the ultimate appropriateness of using accounting principles applicable to a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is not able to continue as a going concern, the Company may be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in these consolidated financial statements. These differences could be material.

 

3.

Significant accounting policies

A summary of the significant accounting policies, which have been applied consistently to all periods presented in the accompanying consolidated financial statements are set out below:

Cash

Cash comprises bank balances held in Canadian chartered banks and in United States state banks.


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

Impairment of non-financial assets

At each date of the statement of financial position, the Company reviews the carrying amounts of its tangible assets to determine whether there is an indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash generating unit to which the assets belong. Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

If the recoverable amount of an asset (or cash generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in the statement of comprehensive loss.

Financial instruments

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation specified in the contract is discharged, cancelled or expires. A derivative is a financial instrument whose value changes in response to a specified variable, requires little or no net investment and is settled at a future date.

Financial assets are classified and measured based on the business model in which assets are managed and their cash flow characteristics. The Company determines the classification of financial assets at initial recognition. Financial assets are classified and measured based on three categories: amortized cost, fair value through other comprehensive income (FVOCI) and fair value through profit and loss (FVTPL). Financial liabilities are classified and measured on two categories: amortized cost or FVTPL.    

The Company’s financial assets comprise cash, loan receivable and other receivable, which are classified and measured at amortized cost.

Such assets are carried at cost less any provision for impairment. Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default.

All financial assets except for those at fair value through profit or loss are subject to review for impairment at least at each reporting date. Financial assets are impaired when there is any objective evidence that a financial asset or a group of financial assets is impaired.

The Company’s financial liabilities are accounts payable and accrued liabilities which are classified and measured at amortized cost.

As at July 31, 2018, there are no amounts measured at fair value.

Impairment of financial assets carried at amortized cost

At each statement of financial position date, the Company assesses whether there is objective evidence a financial asset or group of financial assets is impaired. A financial asset or group of financial assets is impaired and impairment losses are incurred if, and only if, there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a loss event), and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

The amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows (excluding future credit losses) discounted at the financial asset’s original effective interest rate. The asset’s carrying amount is reduced and the amount of the loss is recognized in the statements of loss and comprehensive loss. If a loan has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. For practical reasons, the Company may measure impairment on the basis of an instrument’s fair value using an observable market price.

Deferred shares

The Company issues share based compensation awards to directors, employees and consultants. These arrangements include deferred shares granted to employees. The Company expects that these share-based awards will be settled in equity of the Company. The Company uses a fair value method to account for share based compensation. The fair value of share-based compensation, as at the date of grant, is measured using the value of the most recent financing.

Share capital

In situations where the Company issues units, the value of units is bifurcated, and the value of warrants is included as a separate reserve of the Company’s equity. On expiry, the fair value of the warrants is transferred to share capital.

Share issuance costs

Costs incurred in connection with the issuance of share capital are netted against the proceeds received. Costs related to the issuance of share capital and incurred prior to issuance are recorded as deferred share issuance costs and subsequently netted against proceeds when they are received.

Loss per common share, basic and diluted

Basic loss per share is calculated by dividing the net loss for the period attributable to equity owners of the Company by the weighted average number of common shares outstanding during the period. Contingently issuable shares (including shares held in escrow) are not considered outstanding common shares and consequently are not included in the loss per share calculations.

Diluted loss per share is calculated by adjusting the weighted average number of common shares outstanding for dilutive instruments. The number of shares included with respect to options, warrants and similar instruments is computed using the treasury stock method.

For the period presented, all deferred shares were anti-dilutive.


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

Income taxes

Income tax comprises current and deferred tax. Income tax is recognized in the statements of loss and comprehensive loss except to the extent that it relates to items recognized directly in shareholders’ equity, in which case the income tax is also recognized directly in shareholders’ equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect of previous years.

In general, deferred tax is recognized in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively enacted at the statements of financial position dates and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are recognized to the extent that it is probable the assets can be recovered.

Deferred income tax assets and liabilities are presented as non-current.

Provisions

A provision is recognized when the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable an outflow of economic benefits will be required to settle the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation.

New standards, amendments and interpretations not yet adopted

A number of new standards and amendments to standards and interpretations have been issued but have not yet been applied in preparing these consolidated financial statements, as set out below:

 

   

In January 2016, the IASB issued IFRS 16, Leases, which will replace IAS 17, Leases. Under IFRS 16, a contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Under IAS 17, lessees were required to make a distinction between a finance lease and an operating lease. IFRS 16 now requires lessees to recognize a lease liability reflecting future lease payments and a right-of-use asset for virtually all lease contracts. There is an optional exemption for certain short-term leases and leases of low value assets; however, this exemption can only be applied by lessees. The standard is effective for annual periods beginning on or after January 1, 2019, with earlier application if IFRS 15 is also applied. The Company has yet to assess the impact of this standard but based on the standard leases it currently has in place it does not expect this Standard to have a material impact on its financial statements.

 

   

IFRIC 22, Foreign Currency Transactions and Advance Consideration, was issued on December 8, 2016 and clarifies which date should be used for translation when a foreign currency transaction involves an advance payment or receipt and is applicable for annual periods beginning on or after January 1, 2018. The Company does not expect this standard to have a significant impact on the Company’s financial statements at this time given the operational nature of its current foreign currency transactions.

 

   

IFRIC 23, Uncertainty over Income Tax Treatments, was issued in June 2017 and clarifies the accounting for uncertainties in income taxes. The interpretation committee concluded that an entity shall consider whether it is probable that a taxation authority will accept an uncertain tax treatment. If an entity concludes it is probable that the taxation authority will accept an uncertain tax treatment, then the entity shall determine taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates consistently with the tax treatment used or planned to be used in its income tax filings. If an entity concludes it is not probable that the taxation authority will accept an uncertain tax treatment, the entity shall reflect the effect of uncertainty in determining the related taxable profit (tax loss), tax bases, unused tax losses and credits or tax rates. IFRIC 23 is effective


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

for annual periods beginning on or after January 1, 2019. Earlier adoption is permitted. The Company has yet to assess the impact of this standard but does not expect a material impact given there are no current uncertainty of income tax treatment of the Company’s transactions.

 

4.

Loan Receivable

On July 13, 2018, the Company entered into a definitive agreement with Xanthic Biopharma Limited (“Xanthic”). Pursuant to the definitive agreement Xanthic will acquire all the issued and outstanding common shares of the Company (the “GGB Shares”) from the Green Growth Brands Ltd. shareholders (see Note 12).

The Company also announced that GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic had entered into a purchase agreement (the “NOR Agreement”) dated July 13, 2018 with Nevada Organic Remedies LLC (“NOR”) and its members pursuant to which it will acquire 100% of the outstanding membership interests of NOR for aggregate consideration of $56.75 million (the “NOR Acquisition”). In connection with the NOR acquisition, the Company advanced to Xanthic $2,000,000 as a loan to facilitate the signing of the NOR agreement.

The Loan receivable is unsecured, is non-interest bearing, and is due on December 1, 2018.

 

5.

Shareholders’ equity

Authorized share capital

Common Share – voting – unlimited

Outstanding share capital

 

     Common Shares      Amount  

Outstanding at inception, February 14, 2018

     —        $ —    

Common Shares issued for cash

     87,500,002        6,786,628  

Issuance Costs

     —          (119,228

Shares issued for services

     10,840,000        836,059  

Shares issued for stock compensation

     2,425,000        —    
  

 

 

    

 

 

 

Outstanding at July 31, 2018

     100,765,002      $ 7,503,459  
  

 

 

    

 

 

 

On April 16, 2018, the Company completed a non-brokered private placement by issuing 87,500,002 common shares for gross proceeds of $6,786,628. Issue costs relating to this private placement were $119,228.

Concurrent with the April 12, 2018 financing, the Company issued 4,500,000 common shares valued at $349,020 for advisory fees.

On July 16, 2018, the Company issued 6,340,000 common shares valued at $487,039 in settlement for services provided to the Company.

On July 16, 2018, the Company issued 2,425,000 common shares valued at $61,543 to employees as deferred shares, which will vest over a period of 2 years following the completion of the acquisition of GGB shares by Xanthic. The Company used the Black-Scholes option pricing model to determine the fair value of the deferred stock granted using the following assumptions: risk-free rate of 1.75% on the date of grant; expected life of 2 years; volatility of 74% based on comparable companies; forfeiture rate of 25%; dividend yield of nil; and, the exercise price of the respective option. As such, an insignificant amount of share-based compensation was measured to July 31, 2018.


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

6.

Income taxes

The reconciliation of the combined Canadian federal and provincial corporate income taxes at a statutory rate 26.5% to the Company’s effective income tax expense is as follows:

 

For year period ending July 31,

   2018  

Loss before income taxes

   $ 3,945,120  

Statutory rate

     26.5
  

 

 

 

Expected income tax recovery at combined basic federal and provincial tax rates

     1,045,457  

Effect on income taxes of:

  

Non-deductible expenses

     (385

Changes in tax benefits not recognized

     (1,045,072
  

 

 

 

Income tax recovery

   $ —    
  

 

 

 

Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities.

Deferred tax assets have not been recognized in respect of the following temporary differences:

 

     As at
July 31, 2018
 

Non-capital loss carryforward

   $ 3,945,120  

As at July 31, 2018, the Company had Canadian and US non-capital loss carry forwards which may be available to

offset future year’s taxable income. The losses expire as follows:

 

     United States      Canada  

2038

        1,319,008  

Unlimited

     2,626,112     
  

 

 

    

 

 

 
     $2,626,112      $ 1,319,008  
  

 

 

    

 

 

 

 

7.

Related parties

Related parties include the Board of Directors and key management, close family members and entities that are controlled by these individuals, as well as certain persons performing similar functions. At July 31, 2018 there was no indebtedness to shareholders of the Company.

For the period ended July 31, 2018, the Company’s related party expenses included $945,594 respectively for salary and consulting fees paid to key management personnel, and advisory and consulting fees and services paid to Directors and entities controlled by these individuals.

 

8.

Capital management

The Company’s objective in managing capital is to ensure a sufficient liquidity position to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. In order to achieve this objective, the Company prepares budgets and capital requirements to manage its capital structure. The Company defines capital as equity and borrowings, comprised of issued share capital, share-based payments, accumulated deficit, as well as due to related parties.


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

Since inception, the Company has primarily financed its liquidity needs through issuance of shares.

The Company is not subject to externally imposed capital requirements.

 

9.

Financial instruments and risk management

Financial instruments

The Company has classified its cash as fair value through profit and loss (“FVTPL”), inventory, prepaids and other receivable as current assets, accounts payable and accrued liabilities and contingent consideration payable as current liabilities.

The carrying values of cash, inventory, prepaids, other receivable, accounts payable and accrued liabilities and contingent consideration payable approximate their fair values due to their short periods to maturity.

Fair value hierarchy

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The hierarchy is summarized as follows:

Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities

Level 2 – inputs that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices) from observable market data

Level 3 – inputs for assets and liabilities not based upon observable market data

Financial risk factors

The Company’s risk exposure and the impact on the Company’s financial instruments are summarized below:

 

(a)

Credit risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash. The Company’s cash is held at a major Canadian bank and in trust with lawyers. The Company regularly monitors the credit risk exposure and takes steps to mitigate the likelihood of these exposures resulting in actual loss.

 

(b)

Liquidity risk

The Company is exposed to liquidity risk or the risk of not meeting its financial obligations as they come due as discussed in Note 2 (e) above. The Company constantly monitors and manages its cash flows to assess the liquidity necessary to fund operations. All of the Company’s financial liabilities are due within one year.

 

(c)

Interest rate risk

The Company is not subject to any significant interest rate risk from its liabilities.

The Company is exposed to financial risks that arise from fluctuations in foreign exchange rates and the degree of volatility of these rates. The Company has balances denominated in Canadian dollars. The Company does not hold financial derivatives to manage the fluctuation of these risks.

The following presents the accounts that are exposed to foreign exchange volatility:

 

Item

   Canadian dollar balance      US denominated balance  

Cash

   $ 2,788,569      $ 2,142,252  


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

Accounts receivable

   $ 24,477      $ 18,951  

Accounts payable

   $ 20,777      $ 16,086  

A 1% increase or decrease in the USD/CAD exchange rates would not have a material impact on net loss or equity at July 31, 2018. The sensitivity analysis is based on the Company’s foreign currency financial instruments held at each reporting date. Exposure to foreign exchange rates varies during the period depending on the volume of foreign transactions. Nonetheless, the analysis above is considered to be representative of the Company’s exposure to exchange risk.

 

10.

Segmented information

The Company operates in one reportable operating segment, being the development of lifestyle-oriented consumer products North America. The Company is currently still in its development stage has no revenue for the fiscal period ended July 31, 2018.

 

11.

Commitments

As at July 31, 2018, the Company had the following commitments that have not been disclosed elsewhere in these consolidated financial statements:

 

     Not later than 1
year
     Later than 1
year and not
later than 5
years
     Later than 5
years
     Total

Rent of office space

   $ 169,750      $ 303,205      $ —        $472,955
  

 

 

    

 

 

    

 

 

    

 

 

12.

Subsequent event

On August 30, 2018, GGB raised gross proceeds of $49.3 million denominated in Canadian dollars (CAD$64 million) from a brokered and non-brokered private placement offering of 12% unsecured convertible debentures (the “Debenture Private Placement”) at a price of CAD$1,000 per Debenture. The brokered portion of the Debenture Private Placement was led by Canaccord Genuity as the sole agent for the offering. Commissions of $74,960 (CAD $97,300) were paid in cash and commissions and advisory fees of $2,425,990 (CAD $3,149,000) were paid in convertible debentures. Issue costs of the financing included legal and other expenses of $508,618 (CAD $660,200). US$30,347,500 of the proceeds were loaned to Xanthic for the NOR Acquisition and the balance of the net proceeds remain available to the Corporation for general corporate and working capital purposes and to finance potential acquisition activity.

On September 20, 2018, the Company raised gross proceeds of $17.1 million denominated in Canadian dollars (CAD$22.1 million) from a second tranche of the brokered and non-brokered private placement offering of Debentures, at a price of CAD$1,000 per Debenture. Commissions of $114,220 (CAD$148,260) were paid in cash and broker commissions and advisory fees of $710,309 (CAD$922,000) were paid in debentures. Issue costs of the financing included legal and other expenses of $8,975 (CAD$11,650).

Also on September 20, 2018, the Company issued 3,150 Debentures for financial advisory services received in the value of US$2,440,935 (CAD$3,150,000).

$30,347,500 of the net proceeds of the Debenture Financing were loaned to Xanthic Biopharma Inc. (“Xanthic) pursuant to a loan agreement (the “Loan Agreement”) dated August 30, 2018 among Xanthic, GGB Nevada LLC and the Company and the balance of the net proceeds remain available to the Company for general corporate and working capital purposes and to finance potential acquisition activity.

The Loan Agreement bears interest at 12% per annum and matures 180 days from September 5, 2018. The Loan Agreement contains no prepayment privilege and includes customary events of default, which include the failure to


GREEN GROWTH BRANDS LTD.

Notes to the Consolidated Financial Statements

For the period from commencement of operations on February 14, 2018 to July 31, 2018

 

complete the Business Combination prior to the maturity date of the Loan Agreement. As security for the amounts advanced pursuant to the Loan Agreement, the Company has been granted an irrevocable option from Xanthic to elect to satisfy Xanthic’s obligations under the Loan Agreement by acquiring GGB Nevada LLC from Xanthic and assuming Xanthic and GGB Nevada LLC’s obligations thereunder.

Each Debenture issued under the Debenture Private Placement entitles the holder thereof to a cash repayment of the principal amount thereof, plus accrued but unpaid interest thereon, on March 1, 2019 (the “Maturity Date”). In the event the Company and Xanthic complete a Business Combination prior to the Maturity Date, the Debentures shall automatically convert into units of the Company (“GGB Units”) at the conversion price resulting from application of the following formula: [Principal Amount of Debentures to be Converted / Issue Price] / The Exchange Ratio, with “Issue Price” meaning the lesser of: (i) CAD$0.36 and (ii) the issue price of the subscription receipts of the Company that may be offered and sold by the Company pursuant to a subscription receipt private placement, and “Exchange Ratio” meaning that number of Resulting Issuer Shares (defined below) that each holder of common shares of the Company shall receive pursuant to the Business Combination, which is currently expected to be 3.394:1, subject to adjustment in accordance with the terms of the Definitive Agreement, as amended on August 30, 2018. Immediately thereafter, in connection with the Business Combination, each GGB Unit will be exchanged for units of the resulting issuer (“Resulting Issuer Units”) at the Exchange Ratio. Each whole Resulting Issuer Unit shall be comprised of (i) one common share of the resulting issuer (a “Resulting Issuer Share”) and (ii) one half of one Resulting Issuer Share purchase warrant (each whole Resulting Issuer Share purchase warrant, a “Resulting Issuer Warrant”). Each Resulting Issuer Warrant entitles the holder to acquire, on payment of the Exercise Price (as defined below) plus 25% thereof (such exercise price not to exceed CAD$1.80 (on a post 4:1 consolidation basis) per Resulting Issuer Share), one Resulting Issuer Share. A Resulting Issuer Warrant may be exercised at any time during the two-year period starting on the date the Resulting Issuer Warrants are issued. The “Exercise Price” means the price that is equal to the lesser of: (i) CAD$1.44 per post-consolidation Resulting Issuer Share and (ii) the issue price of the subscription receipts that are anticipated to be offered and sold by the Company pursuant to a subscription receipt private placement.


SCHEDULE “C” – ISSUER MD&A

Please see attached.


LOGO

XANTHIC BIOPHARMA INC. (formerly Aurquest Resources Inc.)

MANAGEMENT DISCUSSION AND ANALYSIS

FOR THE YEAR ENDED JUNE 30, 2018


MANAGEMENT DISCUSSION AND ANALYSIS

Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company” or the “Corporation”) was incorporated under Ontario Business Corporations Act. Xanthic was acquired by Xanthic Biopharma Limited in a reverse takeover transaction completed on December 15, 2017. The Company’s principal business activity is the licensing of technology to produce non-combustible medical cannabis products. The Company is in the development stage and has not yet earned any revenues and is focused on developing innovative non-combustible alternative delivery methods of cannabis infused products. Xanthic is a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary methods. The Corporation’s registered office is 77 King St. West Suite 2905, Toronto, Ontario, M5K 1H1.

This Management’s Discussion and Analysis (“MD&A”) has been prepared with an effective date of September 13, 2018 and provides an update on matters discussed in, and should be read in conjunction with the Corporation’s audited financial statements, including the notes thereto, as at and for year ended June 30, 2018 (the “2018 Audited Consolidated Financial Statements”), which have been prepared using International Financial Reporting Standards (“IFRS”). All amounts are in Canadian dollars unless otherwise specified. Tabular dollar amounts, unless otherwise specified, are in dollars, except for per unit or per share amounts. This MD&A contains forward looking statements that are based on certain estimates and assumptions and involve risks and uncertainties. Actual results may vary materially from management’s expectations. See the “Caution Concerning Forward Looking Statements” section in this MD&A.

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements in this MD&A may contain “forward-looking information,” within the meaning of applicable securities laws, including the “safe harbour provisions” of the Securities Act (Ontario) with respect to the Company. Such statements include, but are not limited to, statements with respect to expectations, projections, or other characterizations of future events or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to our plans and objectives, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities. These statements are subject to certain risks, assumptions and uncertainties that could cause actual results to differ materially from those included in the forward-looking statements. The words “believe”, “plan”, “intend”, “estimate”, “expect”, or “anticipate”, and similar expressions, as well as future or conditional verbs such as “will”, “should”, “would”, and “could” often identify forward-looking statements. We have based these forward-looking statements on our current views with respect to future events and financial performance. With respect to forward looking statements contained in this MD&A, the Corporation has made assumptions and applied certain factors regarding, among other things: future product pricing; costs of inputs; its ability to market products successfully to its anticipated clients; reliance on key personnel; the regulatory requirements; the application of federal and state environmental laws; and the impact of increasing competition. These forward-looking statements are also subject to the risks and uncertainties discussed in the “Risks Factors” section of the CSE listing Statement as filed on SEDAR and elsewhere in this MD&A and other risks detailed from time to time in the publicly filed disclosure documents of the Corporation which are available at www.sedar.com. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which could cause actual results to differ materially from the conclusions, forecasts, or projections anticipated in these forward-looking statements. Because of these risks, uncertainties, and assumptions, the reader should not place undue reliance on these forward-looking statements. The Corporation’s forward-looking statements are made only as of the date of this MD&A, and except as required by applicable law, the Corporation undertakes no obligation to update or revise these forward-looking statements to reflect new information, future events or circumstances.


GOING CONCERN ASSUMPTION AND EARLY STAGE CORPORATION

The Corporation was incorporated March 15, 2017. The Corporation’s ability to continue as a going concern is dependent upon the ability to raise the necessary capital to finance development the Corporation’s business strategy of a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary non-combustible methods. The 2018 Audited Consolidated Financial Statements do not give effect to any adjustments which would be necessary should the Corporation be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business. The amounts the Corporation may realize on the disposition of its assets or the discharging of its liabilities in other than the normal course of its business may be significantly different than the carrying value of these assets and liabilities as reflected in the 2018 Audited Consolidated Financial Statements.

OVERVIEW OF THE CORPORATION

Description of Business

Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis and cannabis-infused products. Using a proprietary process, Xanthic empowers its strategic partners to deliver superior cannabinoid solubility, improved bioavailability, accurate micro-dosing, and greater consistency versus competitive infused products. Through its investment in Xanthic Beverages, Xanthic has access to non-cannabis derived CBD-infused products that qualify for distribution outside of the cannabis dispensary network and into mainstream retail. Both business streams are capital-light, utilizing the existing infrastructure of strategic partners to reduce the capital investment required by Xanthic.

Recent Developments

Subsequent to June 30, 2018, on July 16, 2018 Xanthic and Green Growth Brands Ltd. (“GGB”) announced they have entered into an arm’s length business combination agreement (as amended by agreement between Xanthic and GGB dated August 30, 2018, the “Definitive Agreement”) dated July 13, 2018 to combine Xanthic and GGB by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

GGB is a lifestyle oriented, consumer products company that celebrates health, wellness and happiness. GGB is focused on the medicinal and recreational cannabis sector in both the United States and Canada and is the parent company of the CAMP brand. GGB is led by the widely-renowned retailer Peter Horvath. The Business Combination represents the initial step in GGB’s strategy to grow its international footprint, through partnerships with cannabis cultivators and processors across Canada and the United States. While GGB’s principal focus will be to build a retail network, it will leverage Xanthic’s expertise in the science of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”), the two key active ingredients in cannabis.

Following completion of the Business Combination, current shareholders of GGB will hold approximately 86% of the common shares (the “Resulting Issuer Shares”) of the resulting issuer (the “Resulting Issuer”) (excluding any Resulting Issuer Shares that become issuable pursuant to the terms of GGB’s private placement of convertible debentures (the “Debenture Private Placement”) and any subsequent GGB private placement of subscription receipts (the “Subscription Receipt Private Placement”). It is anticipated that the Resulting Issuer may operate under the name “Green Growth Brands Ltd.” after effecting a name change (the “Name Change”) with the Resulting Issuer Shares listed and posted for trading on the Canadian Securities Exchange (the “Exchange” or the “CSE”). Xanthic anticipates filing a management information circular or listing statement (the “Disclosure Document”) detailing certain matters relating to the Business Combination and other related matters to be mailed to Xanthic shareholders. Trading in the common shares of Xanthic (the “Xanthic Shares”) will be halted as a result of this announcement and will remain halted until the resumption of trading is approved by the Exchange. If completed, the Business Combination will constitute a fundamental change of Xanthic (as such term is defined in the CSE’s policies and procedures manual).


Assuming the satisfaction of customary closing conditions, including the approval of Xanthic’s shareholders, the Business Combination is expected to close in the fourth quarter of this year.

Xanthic and GGB also announced that GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic has entered into a purchase agreement (the “NOR Agreement”) dated July 13, 2018 with Nevada Organic Remedies LLC (“NOR”) and its members (“NOR Members”) pursuant to which it will acquire (the “NOR Acquisition”) 100% of the outstanding membership interests of NOR for aggregate consideration of US$56,750,000 payable by a combination of cash and a promissory note. On July 16, 2018, Xanthic borrowed US$2,000,000 from GGB pursuant to a promissory note with a due date of December 1, 2018 and bears interest at a rate of 6% per annum and on July 17, 2018, Xanthic advanced the proceeds of the loan to GGB Nevada which in turn made a payment of US$2,000,000 to NOR as a deposit on the NOR Agreement. NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada holding four Nevada marijuana licenses (dispensary, cultivation, production and distribution). Additionally, NOR produces a line of high quality medical and recreational products under the name 8|fold.

Further, on September 5, 2018, Xanthic borrowed an additional US$30,347,500 from GGB pursuant to the terms of a loan agreement (the “Loan Agreement”) dated August 30, 2018. The proceeds of the loan were subsequently advanced by Xanthic to GGB Nevada, which in turn used the proceeds to make the initial cash payment required pursuant to the NOR Agreement in connection with the closing of the NOR Acquisition. In addition, on closing of the NOR Acquisition, GGB Nevada delivered to the NOR Members a secured promissory note (the “Purchase Note”) in the principal amount of US$21,565,000. The Purchase Note matures on March 3, 2019 and bears interest at 6% per annum and is fully secured by general security interest over the assets of NOR. The Loan Agreement matures on the date that is 180 days from September 5, 2018, bears interest at 12% per annum and has been secured by a pledge over the shares of GGB Nevada. The balance of US$2,715,000 owing to the NOR Members will be satisfied by the issuance of common shares of the resulting issuer following completion of the Business Combination.

The Business Combination

Subject to the terms of the Definitive Agreement, Subco and GGB will complete the Amalgamation and the amalgamated corporation (“Amalco”) will continue under the name “Green Growth Brands (Ontario) Ltd.”. Amalco will be a direct wholly-owned subsidiary of the Resulting Issuer. All of the property and assets of each of Subco and GGB will become the property and assets of Amalco and Amalco will be liable for all of the liabilities and obligations of each of Subco and GGB.

As of the July 16, 2018, Xanthic had 57,046,547 Xanthic Shares outstanding together with Xanthic convertible securities entitling the holders thereof to acquire a further 3,876,000 Xanthic Shares. As of the July 16, 2018, GGB had 92,000,002 GGB common shares (“GGB Shares”) outstanding and no outstanding convertible securities. Pursuant to the terms of the Definitive Agreement, GGB may issue up to an additional 9,200,000 GGB Shares (or convertible securities, or the equivalent) prior to closing of the Business Combination. Based on the foregoing, Xanthic will, subject to the receipt of all regulatory approvals, including the approval of its shareholders to certain items of special business and the Exchange, (i) combine with GGB pursuant to the Definitive Agreement such that all of the issued and outstanding GGB Shares will be acquired, and as consideration, Xanthic will issue to holders of GGB Shares, on a 3.394-for-one basis, 346,150,835 Xanthic Shares (the “Consideration Shares”) , in exchange for the then issued and outstanding GGB Shares (which for greater certainty excludes the GGB Shares to be issued under the Subscription Receipt Private Placement and the Debenture Private Placement (as such terms are defined below)); and (ii) reorganize its share structure and consolidate all of the issued and outstanding Xanthic Shares (including the Consideration Shares) on the basis of approximately 4.07 pre-consolidation Xanthic Shares for one (1) post-consolidation Resulting Issuer Share (the “Consolidation”).

In the event that GGB terminates the Definitive Agreement, other than as a result of a breach of representation or warranty or non-performance by Xanthic, GGB shall pay Xanthic a break fee in the aggregate amount of $250,000 and reimburse Xanthic for the full extent of its US legal fees, a portion of its Canadian legal fees, travel costs and other reasonable expenses incurred in connection with the Business Combination.


Resulting Issuer

The following table sets forth the pro forma capitalization of the Resulting Issuer after giving effect to the Business Combination and the Consolidation but prior to giving effect to the Subscription Receipt Private Placement and the Debenture Private Placement:

 

Equity
(Resulting Issuer Shares)
   Shares(1)
(#)
     Shares(2)
(%)
 

Held by current GGB Shareholders

     85,034,014        85.9

Held by current Xanthic Shareholders that are insiders of Xanthic

     1,487,036        1.5

Held by current Xanthic Shareholders that are not insiders of Xanthic

     12,526,788        12.6
  

 

 

    

 

 

 

Total

     99,047,838        100
  

 

 

    

 

 

 

 

(1)

Does not give effect to exercise and/or conversion of issued and outstanding Xanthic convertible securities.

(2)

Expressed on a non-diluted basis.

To the knowledge of the prospective directors and executive officers of the Resulting Issuer, no person or company beneficially will own, or control or direct, directly or indirectly, Resulting Issuer Shares carrying in excess of 10% of the voting rights attached to all outstanding Resulting Issuer Shares, other than All Js Greenspace LLC, a company controlled by three individual family trusts, which is expected to own 33,971,923 Resulting Issuer Shares, representing a 34.3% ownership stake in the Resulting Issuer prior to giving effect to the Subscription Receipt Private Placement and the Debenture Private Placement.

Board of Directors and Management

Subject to Exchange approval, the board of directors and management of Xanthic was reconstituted on July 16, 2018 with the following individuals:

 

   

Jean Schottenstein (Director)

 

   

Peter Horvath (Director)

 

   

Steve Stoute (Director)

 

   

Carli Posner (Director)

 

   

Marc Lehmann (Director)

 

   

Tim Moore (Director and Chief Executive Officer)

 

   

Gary Galitsky (Director and President)

 

   

David Bhumgara (Chief Financial Officer)

It is currently expected that the board of directors and management of the Resulting Issuer will be the aforementioned individuals.

Conditions of Completion

Completion of the Business Combination is subject to a number of conditions, including, but not limited to, Exchange acceptance. Where applicable, the Business Combination cannot close until the required shareholder approval is obtained. There can be no assurance that the Business Combination will be completed as proposed, or at all.

The remaining conditions to completion of the Business Combination include, but are not limited to:


   

The approval of GGB shareholders of the Amalgamation, the approval of Xanthic shareholders of the Amalgamation, the Name Change and the Consolidation, and other matters to be more fully described in the Disclosure Document, and the approval and acceptance of the Exchange;

 

   

Xanthic will have at least $400,000 of working capital (net of expenses relating to the completion of the Amalgamation); and

 

   

The Resulting Issuer being in compliance with the initial listing requirements of the Exchange.

Background

Aurquest Resources Inc. which was formed by an amalgamation of Rampart Mercantile Inc. and North American Store Finance Ltd. back in November 1, 2000. Previous to the amalgamation, the Corporation was initially incorporated in province of British Columbia on November 18, 1968, then continued into Ontario on November 24, 1999 prior to amalgamation with North American Store Finance Ltd. on November 1, 2000.

On December 15, 2017 Xanthic Biopharma Limited acquired via a reverse takeover transaction Aurquest Resources Inc. Pursuant to the Definitive Agreement, Aurquest acquired all of the issued and outstanding common shares of Xanthic Biopharma Limited from the Xanthic Shareholders. As of the date of closing, there was 37,252,000 issued and outstanding Xanthic Shares, inclusive of 10,252,000 Xanthic Shares issued at a price of $0.125 per share pursuant to a non-brokered private placement of Xanthic (the “Xanthic Private Placement”) which closed December 13, 2017. In exchange for the Xanthic Shares, Aurquest issued a total of 298,016,000 Aurquest Shares at a ratio of eight (8) Aurquest Shares for each one (1) Xanthic Share (the “Exchange Ratio”) at a deemed price of $0.01563 per Aurquest Share, resulting in a reverse take-over of Xanthic by Aurquest (the “RTO Transaction”). Aurquest had 51,668,184 shares outstanding. The RTO Transaction resulted in the Company having approximately 349,684,184 common shares. On closing of the RTO Transaction, the Aurquest shareholders had 51,668,184 shares (14.78%), the existing Xanthic shareholders hold 216,000,000 Aurquest shares (61.77%), and the purchasers in the Xanthic Private Placement hold 82,016,000 Aurquest shares (23.45%).

On February 16, 2018, the shareholders of Aurquest Resources Inc. voted in favour of the following: 1) consolidation of the common shares of the Corporation on an eight for one basis; 2) name change from Aurquest Resources Inc. to Xanthic Biopharma Inc.; 3) the election of directors, 4) appointment of auditors, 5) approving a 10% rolling stock option plan; and 6) adoption of new bylaws. The Corporation effected the name change and share consolidation on February 26, 2018, at which time the outstanding common shares were reduced to 55,710,547. Subsequent to the quarter end of March 31, 2018, on April 19, 2018 the Corporation’s common shares commenced trading on the Canadian Securities Exchange (“CSE”) under the stock ticker symbol XTHC.

On March 21, 2018, the Corporation completed its purchase of 45% interest in Xanthic Beverages USA LLC (previously Avitas CBD Water LLC “Xanthic Beverages”) for USD$600,000, USD$300,000 was due on signing and balance due when Xanthic Beverages issues its second purchase order for bottling with a co-packer. In addition, if Xanthic Beverages achieves a minimum market penetration of 100 retailers or sales throughput of 380,000 units, at the option of the Corporation, the Corporation has a contingent consideration payable of USD$150,000 or 600,000 common shares of the Corporation. The Corporation has assigned a 50% probability at June 30, 2018 that the contingent consideration payable will occur. Xanthic Beverages uses CBD isolate derived from non-hemp, non-cannabis source for use in water beverages sold both within and outside the licensed dispensary universe.

Further, the Corporation has an option for 24 months to acquire a further 6% interest in Xanthic Beverages bringing its ownership to 51% and therefore control for an additional $300,000 worth of shares in the Corporation based on the 60 day average price at the time of the exercise.

Corporate Outlook and Strategy

The Corporation is in its infancy, as previously noted, however the Corporation’s business strategy is to be a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary non-combustible methods.


The Corporation’s strategy will be focused initially in certain states in the United States where cannabis has been legalized for recreational or medical use. The Corporation will partner with local licensed cannabis producers in each state in order to facilitate its roll out and minimize capital needs.

The Corporation’s product offering will initially include cannabis infused powder beverage mixes such as a fruit drink, a rescue drink, an energy drink, hot chocolate and a protein drink, with first production planned in the third calendar quarter of 2018.

Through its equity investment in Xanthic Beverages, the Corporation plans to assist Xanthic Beverages with branding and distribution of the Xanthic CBD Water broadly through an extensive retail network using third party bottler’s distribution network, independent local grocery and other retail locations in the states of Oregon, Washington and California.

Overall Financial Performance

As previously discussed, the Corporation incorporated March 15, 2017 and has no revenue from operations. Below is a summary of the Corporation financial performance for the year ended June 30, 2018. During the year ended June 30, 2018 the Corporation had a net loss from operations of $2,829,225. Included in yearend results from operations are listing fees in connection with the RTO completed with Aurquest Resources Inc. of $918,054.

 

For the year ended

   June 30, 2018      June 30, 2017  

Revenue

   $ —        $ —    

Net loss from operations

     2,829,225        101,541  

Net Loss per share

   $ 0.08      $ 0.04  

RTO Transaction

On December 15, 2017, the Company entered into a definitive agreement with Xanthic Biopharma Limited (“Xanthic”). Pursuant to the definitive agreement the Company acquired all the issued and outstanding common shares of Xanthic (the “Xanthic Shares”) from the Xanthic shareholders. At the date of closing on the definitive agreement there were 37,252,000 Xanthic Shares issued and outstanding, inclusive of 10,252,000 Xanthic Shares issued at a price of $0.125 per Xanthic Share pursuant to a non-brokered private placement. In exchange for the Xanthic Shares, the Company issued 298,016,000 common shares in the Company at a ratio of eight Company shares for each Xanthic Share at a deemed price of $0.015625 per Company share, resulting in a reverse takeover of the Company by Xanthic shareholders.

The Company had 51,668,184 common shares outstanding prior to the completion of the RTO. On closing of the RTO there are 349,684,184 common shares outstanding of which 51,668,184 represented the original shareholders of the Company who retained 14.8% and Xanthic shareholders obtained 85.2% of the Company.

Since the Company did not meet the definition of a business under IFRS 3 – Business Combinations, the acquisition was accounted for as a purchase of the Company’s assets. The consideration paid was determined as equity-settled share based payments under IFRS 2, at the fair value of the equity of the Company retained by the shareholders of the Company based on the fair value of the Xanthic common shares on the date of closing of the RTO, which was determined to be $0.125 per common share based on the most recent equity raise completed just prior to the RTO.

The Company recorded listing fees of $918,054 in the 2018 Audited Consolidated Financial Statements of net loss and comprehensive loss. The details of the listing fees are as follows:


Fair value of consideration paid:

  

51,668,184 common shares of Xanthic at $0.015625 per share

   $ 807,315  

Net liabilities of Aurquest acquired by Xanthic

     86,739  
     894,054  
  

 

 

 

Other Transaction Costs:

  

Professional fees

     24,000  
  

 

 

 

Listing fees

   $ 918,054  
  

 

 

 

The net liabilities of the Company were included at their carrying value of $86,739, which approximates their fair value as follows:

 

Cash

   $ 2,141  

Prepaid expenses

     500  

Accounts payable and accrued liabilities

     (44,380

Shareholder loans

     (45,000
  

 

 

 
   $ (86,739
  

 

 

 

Review of Operations for the year ended June 30, 2018 compared to year ended June 30, 2017

During the year ended June 30, 2018 (“Fiscal 2018”), the Corporation incurred a net loss $2,829,225 or $0.08 per share, as compared to a net loss from operations of $101,541 or $0.04 per share for the year ended June 30, 2017 (“Fiscal 2017”). During Fiscal 2018 the Corporation completed three private placements which allowed the Corporation to commence execution on its business plan. In addition, the significant increase in net loss was primarily the result of first full year of operations compared to Fiscal 2017. The Corporation was formed March 2017 so Fiscal 2017 represented less than 4 months of activity.

During Fiscal 2018, the Corporation incurred management, consulting fees of $827,658, compared with $60,000 in Fiscal 2017. The increase is primarily due to the retaining of management and consultants to help establish and capitalize the Corporation. The Corporation also incurred $375,023 in legal costs in Fiscal 2018 compared with $27,968 in Fiscal 2017. The increase in legal costs reflects the increase in business activity and the establishment of agreements, patent filings, financing activities, general counsel and listing application fees with the CSE during Fiscal 2018. In addition, the Corporation incurred $174,289 in advertising and promotion compared with $13,496 in Fiscal 2017. The increase relates to web development, investor presentations, packaging and brand building in Fiscal 2018.

During Fiscal 2018, the Corporation adopted its share-based compensation plan and issued stock options which resulted in stock based compensation expense of $385,542 compared to nil in Fiscal 2017.

Review of Operations for the three months ended June 30, 2018 compared to three months ended June 30, 2017

 

For the quarter ended

   June 30, 2018      June 30, 2017  

Consulting fees

   $ 231,614      $ 60,000  

Stock based compensaton

     287,081        —    

Legal and professional fees

     181,297        27,968  

Advertising and promotion

     77,287        13,496  

Loss from equity accounted investment

     58,255        —    

General and administration

     47,761        61  

Interest and bank charges

     2,709        16  
  

 

 

    

 

 

 
     886,004        101,541  

Net Loss per share

   $ 0.02      $ 0.04  
  

 

 

    

 

 

 

During the three months ended June 30, 2018, the Corporation incurred $231,614 in consulting fees to senior management, accounting, corporate finance work and strategic advisory services compared to $60,000 in the same


period of the prior year. The Corporation consulting fees related to finance work to assist developing the business plan and strategy and product development. The Corporation had for the three months ended June 30, 2018 $181,297 in legal and professional fees associated with investor relations and legal activities this compares to $27,968 in the same period of the prior year. The increase in legal and professional relates to work to complete the CSE listing application with the Corporation first day of trading commencing April 19, 2018.

The Corporation incurred during the fourth quarter 2018 $77,287 in advertising and promotion compared to $13,496 in the same period of the prior year. The Corporation incurred expenses in developing its brand, packaging and artistic elements in anticipation of its product launch in later half of 2018.

The Corporation recorded a $58,255 loss on its share of its equity accounted investment in Xanthic Beverages. Xanthic Beverages commenced operations in March 2018 with the Corporations investment of the initial USD$300,000. The loss represents startup costs for Xanthic Beverages.

The Corporation incurred in the fourth quarter of 2018, $47,761 in general and administrative costs compared to $61 in the same period of the prior year. The increase represents the increased activity in the Corporation compared to the prior year.

On February 28, 2018, the Corporation’s board approved the stock option plan. As a result of grants during the year the Corporation incurred stock based compensation costs of $287,081 compared to nil in the same period of the prior year.

SELECTED QUATERLY FINANCIAL INFORMATION

 

For the three months ended,

   June 30, 2018      March 30, 2018      December 31, 2017      September 30, 2017      June 30, 2017  

Current Assets

   $ 1,626,042      $ 1,810,722      $ 1,236,139      $ 62,553      $ 36,524  

Current Liabilities

     650,168        804,766        314,663        138,168        111,643  

Net Loss from Operations

     860,004        566,047        1,328,678        74,496        101,541  

Net Loss per share

   $ 0.02      $ 0.01      $ 0.01      $ 0.01      $ 0.04  

 

   

The Corporation current assets represent cash, prepaids, inventory and HST receivable. Current assets at June 30, 2018 include cash of $1,037,049.

 

   

The Corporation’s current liabilities represent start up consulting fees, legal and audit fees since inception and include contingent consideration payable in connection with Xanthic Beverages purchase of $493,800 (see 2018 Audited Consolidated Financial Statements Note 8).

 

   

June 30, 2018 quarterly loss includes stock based compensation expense of $287,081.

 

   

December 31, 2017 net loss and comprehensive loss includes listing fees of $944,054.

LIQUIDITY AND CAPITAL RESOURCES

The Corporation has cash of $1,037,049, prepaids of $249,915, inventory of $181,096, and other receivable of $157,982 and current liabilities of $946,448 as at June 30, 2018. The Corporation therefore has a working capital of $679,594. Despite the positive working capital, the Corporation does not have sufficient liquidity and capital resources at June 30, 2018 to meet all its planned expenditures over the next twelve months.

The Corporation plans to complete further financings over the next twelve months in order to fund its ongoing expenditures and execute on its business plan to get to break even cashflow. However, there is no assurance that the Corporation will be successful in these endeavors.


Outstanding Share Data

At June 30, 2018, the Corporation had 56,846,547 common shares outstanding, 568,000 warrants outstanding and 3,508,000 stock options outstanding and on September 13, 2018, the Corporation had 57,546,547 common shares outstanding, 568,000 warrants outstanding and 2,808,000 stock options outstanding.


OFF BALANCE SHEET ARRANGEMENTS

In the normal course of business, the Corporation has entered into arrangements with several third-party goods and services providers. In certain instances, the Corporation, directly and through its subsidiaries, has provided indemnities and/or guarantees to these third parties for the payment of goods or services provided, or otherwise. Generally, there are no pre-determined amounts or limits included in these arrangements, and the occurrence of an event that would trigger the Corporation’s obligations pursuant to these arrangements is difficult to predict. Therefore, the Corporation’s potential future liability cannot be reasonably estimated.

COMMITMENT AND CONTINGENCIES

Commitments and contingencies are detailed in Note 8 to the 2018 Audited Consolidated Financial Statements. The following table summarizes payments due for the next five years and thereafter in respect of the Corporation’s contractual obligations and the obligations of its subsidiaries.

 

     Expected Payments Schedule  
     2019      2020 to 2021      2022 to 2023      Thereafter      Total  

Accounts payable and accured liabilities

   $ 156,368      $ —        $ —        $ —        $ 156,368  

Contingent consideration payable

     790,080        —          —          —          790,080  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 946,448      $ —        $ —        $ —        $ 946,448  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

RELATED PARTY TRANSACTIONS

The Corporation has not entered into any transactions with related parties, other than as disclosed in Note 13 to the 2018 Audited Consolidated Financial Statements.

ACCOUNTING POLICIES, CRITICAL JUDGMENTS AND ESTIMATES

The preparation of the Corporation’s financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and other items in net earnings or loss, and the related disclosure of contingent assets and liabilities, if any. Critical judgments and estimates represent estimates made by management that are, by their very nature, uncertain. The Corporation evaluates its estimates on an ongoing basis. Such estimates are based on historical experience and on various other assumptions that the Corporation believes are reasonable under the circumstances, and these estimates form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and other items in net earnings or loss that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Summaries of the significant accounting policies applied, and significant judgments, estimates and assumptions made by management in the preparation of its financial statements are provided in Notes 2 and 3 to the 2018 Audited Consolidated Financial Statements.

CONTROLS AND PROCEDURES

During 2018, the Chief Executive Officer and the Chief Financial Officer of the Corporation were responsible for establishing and maintaining disclosure controls and procedures and internal control over financial reporting, as defined in the Canadian Securities Administrators National Instrument 52-109,Certification of Disclosure in IssuersAnnual and Interim Filings”.

Internal Control over financial reporting (“ICFR”) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with applicable IFRS. Disclosure controls and procedures are designed to ensure that information required to be disclosed by the Corporation in the reports it files or submits under securities legislation is recorded, processed, summarized and reported on a timely basis and that such information is accumulated and reported to management, including the Corporation’s Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow required disclosures to be made in a timely fashion. Based on their evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that, as at June 30, 2018, the Corporation’s disclosure controls and procedures were effective.


BUSINESS RISKS

There are numerous and varied risks, known and unknown, that may prevent the Corporation from achieving its goals. If any of these risks occur, the Corporation’s business, financial condition or results of operation may be adversely affected. In such case, the trading price of the Corporation’s common shares could decline, and investors could lose all or part of their investment. The following is a summary of risks that could be applicable to the business of the Corporation:

The Company Relies on Securing and Maintaining Agreements with Licensed Partners

In most U.S. States, the Company is not eligible to obtain a license to grow, store and sell cannabis products. Accordingly, the Company must secure royalty agreements with Licensed Partners that have been able to obtain the requisite licenses with the appropriate regulatory authorities in the targeted jurisdictions. The failure of a Licensed Partner to comply with the requirements of their license or to maintain their license would have a material adverse impact on the business, financial condition and operating results of the Company. There can be no guarantee that the applicable licenses will be maintained by Licensed Operators or granted to other prospective Licensed Operators in the future.

Limited Operating History

Having been founded in late 2017, the Company has a limited operating history which can make it difficult for investors to evaluate the Company’s operations and prospects and may increase the risks associated with an investment in the Company. The Company will be subject to all of the business risks and uncertainties associated with any new business enterprise, such as under-capitalization, cash shortages, limitations with respect to personnel, financial and other resources, achieving market acceptance of existing and future solutions, competing against companies with greater financial and technical resources, and lack of revenues. There is no assurance that the Company will be successful in achieving a return for investors and the likelihood of success must be considered in light of the early stage of operations. Because the Company has a limited operating history in emerging area of business, investors should consider and evaluate its operating prospects in light of the risks and uncertainties frequently encountered by early-stage companies in rapidly evolving markets. These risks may include:

 

   

risks that it may not have sufficient capital to achieve its growth strategy;

 

   

risks that it may not develop its product and service offerings in a manner that enables it to be profitable and meet its customers’ requirements;

 

   

risks that its growth strategy may not be successful;

 

   

risks that fluctuations in its operating results will be significant relative to its revenues; and

 

   

risks relating to an evolving regulatory regime.

The Company’s future growth will depend substantially on its ability to address these and the other risks described in this section. If it does not successfully address these risks, its business may be significantly harmed.

Operating in the United States

The Company will initially focus its operations in the United States, specifically in states that have already passed legislation legalizing the recreational sale and use of cannabis. Currently, the states of California, Nevada, Massachusetts, Maine, Washington, Oregon, Colorado and Alaska, and the District of Columbia, have legalized the recreational use of cannabis. However, the U.S. federal government has not enacted similar legislation and the cultivation, sale and use of cannabis remains illegal under federal law pursuant to the U.S. Controlled Substance Act of 1970. While the Department of Justice under the previous U.S. presidential administration stated its intention not to enforce federal laws relating to cannabis where the conduct at issue is legal under applicable state law, pursuant to the Cole Memorandum, there can be no assurance that the current administration will not enforce such laws in the future. This risk is further compounded by the political and policy variability of the Donald Trump presidential administration, and the conservative, anti-cannabis stances of Attorney General Jeff Sessions. Mr. Trump’s positions regarding marijuana are difficult to discern; however, Attorney General Sessions has been a consistent opponent of marijuana legalization efforts throughout his political career. On January 4, 2018, Attorney General Sessions


rescinded the Cole Memorandum, shifting federal policy from a hands-off approach to unleashing federal prosecutors across the country to decide individually how to crack down on possession, distribution and cultivation of cannabis, including in states in which cannabis is legal. With the Cole Memorandum rescinded, U.S. federal prosecutors no longer have guidance relating to the exercise of their discretion in determining whether to prosecute cannabis related violations of U.S. federal law. It is possible that further developments could significantly adversely affect the business, financial condition and results of businesses involved in U.S. cannabis related activities and in the cannabis industry generally. There can be no assurance that the U.S. federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with applicable state law. If the federal government begins to enforce federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing state laws are repealed or curtailed, the Company would be materially and adversely affected notwithstanding the fact that the Company is not directly engaged in the sale or distribution of cannabis. The consequences of such enforcement would be materially adverse to the Company and the Company’s business and could result in the forfeiture or seizure of all or substantially all of the Company’s assets.

The Products Provided by the Company to Licensed Partners May Become Subject to Regulation Governing Food and Related Products

Should the U.S. federal government legalize cannabis for medical or recreational use nation-wide, there is a risk that the U.S. Food and Drug Administration (the “FDA”) would seek to regulate the products under the Food, Drug and Cosmetics Act of 1938. The FDA may issue rules and regulations including certified good manufacturing practices related to the growth, cultivation, harvesting and processing of cannabis and cannabis-infused products. Clinical trials may be needed to verify the efficacy and safety of cannabis. It is also possible that the FDA would require that facilities where cannabis is cultivated be registered with the applicable government agencies and comply with certain federal regulations. Compliance with such rules and regulations may be unduly costly and may have an adverse effect on the Company. If the Company or its Licensed Partners are unable to comply with the regulations prescribed by the FDA, the Company and/or its Licensed Partners may be unable to continue to operate.

Banking Regulation May Hinder the Company’s Ability to Establish and Maintain Bank Accounts

The U.S. federal prohibitions on the sale of cannabis may prevent the Company’s Licensed Partners from accessing the U.S. banking system and they may be unable to deposit funds in federally-insured and federally-licensed banking institutions. While the Company does not anticipate dealing with banking restrictions directly relating to its business, such restrictions could nevertheless be imposed due to the Company’s banking institutions not accepting payments from its Licensed Partners. Licensed Partners at times do not have deposit services and are at risk that any bank accounts they have could be closed at any time. Such risks increase costs to the Company and to its Licensed Partners. The inability of the Company’s Licensed Partners to access banking services can make it difficult to structure royalty agreements in a manner acceptable to the Company.

In the event financial service providers do not accept accounts or transactions related to the cannabis industry, it is possible that the Company’s Licensed Partners may seek alternative payment solutions, including but not limited to, cryptocurrencies such as Bitcoin. There are risks inherent in cryptocurrencies, most notably its volatility and security issues. If the industry was to move towards alternative payment solutions and accept payments in cryptocurrency the Company would have to adopt policies and protocols to manage its volatility and exchange rate risk exposures. The Company’s inability to manage such risks may adversely affect the Company’s operations and financial performance.

Managing Growth

In order to manage growth and change in strategy effectively, the Company must: (a) maintain adequate systems to meet customer demand; (b) expand sales and marketing, distribution capabilities and administrative functions; (c) expand the skills and capabilities of its current management team; and (d) attract and retain qualified employees. The inability of the Company to deal with this growth may have a material adverse effect on its business, financial condition, results of operations and prospects.


Competition

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience than the Company. Currently, the cannabis, nutraceuticals and pharmaceuticals industry generally is comprised of individuals and small to medium-sized entities, however, the risk remains that large conglomerates and companies that also recognize the potential for financial success through investment in this industry could strategically purchase or assume control of larger dispensaries and cultivation facilities. In doing so, these larger competitors could establish price setting and cost controls which would effectively “price out” many of the individuals and small to medium-sized entities that currently make up the bulk of the participants in the varied businesses operating within, and in support of, the medical and recreational cannabis industry. While most U.S. states seemingly deter this type of arrangement, the cannabis industry is still relatively new for public entities, so the future competitive environment remains largely unknown.

Because of the early stage of the industry in which the Company will operate, the Company expects to face additional competition from new entrants. To become and remain competitive, the Company will require research and development, marketing, sales and support. The Company may not have sufficient resources to maintain research and development, marketing, sales and support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of operations of the Company.

Retention, Acquisition and Integration of Skilled Personnel

The loss of any member of the Company’s management team could have a material adverse effect on its business and results of operations. In addition, the inability to hire new personnel and the increased costs of hiring new personnel could have a material adverse effect on the Company’s business and operating results. At present and for the near future, the Company will depend upon a relatively small number of employees to develop, market, sell and support its products. The expansion of marketing and sales of its products will require the Company to find, hire and retain additional capable employees who can understand, explain, market and sell its products. There is intense competition for capable personnel and the Company may not be successful in attracting, training, integrating, motivating, or retaining new personnel, vendors, or subcontractors for these required functions. New employees often require significant training and, in many cases, take significant time before they achieve full productivity. As a result, the Company may incur significant costs to attract and retain employees, including significant expenditures related to salaries and benefits and compensation expenses related to equity awards, and may lose new employees to its competitors or other companies before it realizes the benefit of its investment in recruiting and training them. In addition, as the Company moves into new jurisdictions, it will need to attract and recruit skilled employees in those areas.

Legal Proceedings

From time to time, the Company may be a party to legal and regulatory proceedings, including matters involving governmental agencies, entities with whom it does business and other proceedings arising in the ordinary course of business. The Company will evaluate its exposure to these legal and regulatory proceedings and establish reserves for the estimated liabilities in accordance with International Financial Reporting Standards. Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management’s evaluations or predictions and accompanying changes in established reserves, could have an adverse impact on the Company’s financial results.


Regulatory Compliance Risks

Achievement of the Company’s business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. The Company may not be able to obtain or maintain the necessary licenses, permits, authorizations or accreditations, or may only be able to do so at great cost, to operate its business. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by local governmental authorities. The impact of the compliance regime, any delays in obtaining, or failure to obtain or keep the regulatory approvals may significantly delay or impact the development of markets, products and sales initiatives and could have a material adverse effect on the business, results of operations and financial condition of the Company.

The Company will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company’s operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

Change of Cannabis Laws, Regulations and Guidelines

Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require the Company to incur substantial costs associated with compliance or alter certain aspects of its business plan. It is also possible that regulations may be enacted in the future that will be directly applicable to certain aspects of the Company’s businesses. The Company cannot predict the nature of any future laws, regulations, interpretations or applications, nor can it determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on the Company’s business. Management expects that the legislative and regulatory environment in the cannabis industry in Canada and internationally will continue to be dynamic and will require innovative solutions to try to comply with this changing legal landscape in this nascent industry for the foreseeable future. Compliance with any such legislation may have a material adverse effect on the Company’s business, financial condition and results of operations.

Unfavourable Publicity or Consumer Perception

Management of the Company believes the cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the cannabis produced. Consumer perception of the Company’s proposed products may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company’s proposed products and the business, results of operations, financial condition and cash flows of the Company. The Company’s dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for the Company’s proposed products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis in general, or the Company’s proposed products specifically, or associating the consumption of cannabis with illness or other negative effects or events, could have such a material adverse


effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers’ failure to consume such products appropriately or as directed.

Liability, Enforcement, Complaints, etc.

The Company’s participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by third parties, other companies and/or various governmental authorities against the Company. Litigation, complaints, and enforcement actions involving the Company could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on the Company’s future cash flows, earnings, results of operations and financial condition.

Product Liability

As a distributor of products designed to be ingested or inhaled by humans, the Company faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused damages, loss or injury. In addition, the sale of the Company’s products involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Adverse reactions resulting from human consumption of the Company’s products alone or in combination with other medications or substances could occur. The Company may be subject to various product liability claims, including, among others, that the Company’s products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning health risks, possible side effects or interactions with other substances. A product liability claims or regulatory action against the Company could: i) result in increased costs; ii) adversely affect the Company’s reputation with its Licensed Partners and consumers generally; and iii) have a material adverse effect on the results of operations and financial condition of the Company. There can be no assurances that the Company will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Company’s potential products.

Insurance Coverage

The Company’s production is, in general, subject to different risks and hazards, including adverse weather conditions, fires, plant diseases and pest infestations, other natural phenomena, industrial accidents, labour disputes, changes in the legal and regulatory framework applicable to the Company and environmental contingencies. Although management of the Company believes that the events and amounts of liability covered by its insurance policies will be reasonable, taking into account the risks relevant to its business, and the fact that agreements with users contain limitations of liability, there can be no assurance that such coverage will be available or sufficient to cover claims to which the Company may become subject. If insurance coverage is unavailable or insufficient to cover any such claims, the Company’s financial resources, results of operations and prospects could be adversely affected.

Product Recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of the Company’s products are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Company may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although the Company has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if the Company is subject to recall, the image of the Company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the Company’s products and could have a material adverse effect on the results of operations and financial condition of the Company. Additionally, product recalls may lead to


increased scrutiny of the Company’s operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses and potential legal fees and other expenses.

Limited Avenues to Market and Promote Products

To be successful, the Company’s business must be successfully marketed. The market for the Company’s products and services has and is expected to grow significantly and may require substantial sales and marketing capability. The Company will be dependent on independent parties to market its products and services. There can be no assurance that the Company can continue to market or can enter into satisfactory arrangements with third parties to continue to market its products and services in a manner that would assure its growth and acceptance in the market place.

Supply of Cannabis Extract

If for any reason the supply of cannabis extract from licensed producers is ceased or delayed, the Company would have to seek alternate suppliers and obtain all necessary authorization for the new cannabis extract. If replacement cannabis extract cannot be obtained at comparable prices, or at all, or if the necessary authorizations are not obtained, the Company’s business, financial condition and results of operations would be materially and adversely affected.

Global Economy

Financial markets are influenced by the economic and market conditions in other countries, including the United States and other global markets. Although economic conditions in these countries may differ significantly from economic conditions in Canada, investor reactions to developments in these other countries may substantially affect the capital flows into and the market value of securities of issuers with operations in the United States and Canada.

Consumer Acceptance of Premium Pricing

The Company branding, and pricing strategy is to offer a premium product at higher than existing market prices of competitive products. The Company assumes that it will be successful in establishing the brand as a premium brand and therefore is relying on pricing its products consistent with its brand image. There can be no assurance that the Company will be successful and that the marketplace will accept a premium price when there is no direct competitive, comparable product.

Access to Capital

In executing its business plan, the Company makes, and will continue to make, substantial investments and other expenditures related to acquisitions, research and development and marketing initiatives. Since its incorporation, the Company has financed these expenditures through offerings of its equity securities and debt financing. The Company will have further capital requirements and other expenditures as it proceeds to expand its business or take advantage of opportunities for acquisitions or other business opportunities that may be presented to it. The Company may incur major unanticipated liabilities or expenses. The Company can provide no assurance that it will be able to obtain financing to meet the growth needs of the Company.

Foreign Sales and Currency Risks

The Company’s functional currency is denominated in Canadian dollars. The Company currently expects that sales will be denominated in U.S. dollars and may, in the future, have sales denominated in the currencies of additional countries in which it establishes sales offices. In addition, the Company incurs the majority of its operating expenses in Canadian dollars. In the future, the proportion of the Company’s sales that are international may increase. Such sales may be subject to unexpected regulatory requirements and other barriers. Any fluctuation in the exchange rates of foreign currencies may negatively impact the Company’s business, financial condition and results of operations. The Company has not previously engaged in foreign currency hedging. If the Company decides to hedge its foreign currency exposure, it may not be able to hedge effectively due to lack of experience, unreasonable costs or illiquid


markets. In addition, those activities may be limited in the protection they provide the Company from foreign currency fluctuations and can themselves result in losses.

Estimates or Judgments Relating to Critical Accounting Policies

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided in the notes to the Company’s Financial Statements, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. The Company’s operating results may be adversely affected if the assumptions change or if actual circumstances differ from those in the assumptions, which could cause the Company’s operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the share price of the Company. Significant assumptions and estimates used in preparing the financial statements include those related to the credit quality of accounts receivable, income tax credits receivable, share based payments, impairment of non-financial assets, as well as revenue and cost recognition.

Tax Risks

The Company will operate and will be subject to income tax and other forms of taxation (which are not based upon income) in multiple tax jurisdictions. Taxation laws and rates which determine taxation expenses may vary significantly in different jurisdictions, and legislation governing taxation laws and rates is also subject to change. Therefore, the Company’s earnings may be impacted by changes in the proportion of earnings taxed in different jurisdictions, changes in taxation rates, changes in estimates of liabilities and changes in the amount of other forms of taxation. The Company may have exposure to greater than anticipated tax liabilities or expenses. The Company will be subject to income taxes and non-income taxes in a variety of jurisdictions and its tax structure is subject to review by both domestic and foreign taxation authorities and the determination of the Company’s provision for income taxes and other tax liabilities will require significant judgment.

Repatriation of Profits

As a holding company with no material assets other than the stock of the Company’s operating subsidiaries and intellectual property, nearly all of the Company’s funds generated from operations are generated by the Company’s operating subsidiaries. The Company’s subsidiaries are subject to requirements of various regulatory bodies, both domestically and internationally. Accordingly, if the Company’s operating subsidiaries are unable, due to regulatory restrictions or otherwise, to pay the Company’s dividends and make other payments to the Company when needed, the Company may be unable to satisfy the Company’s obligations when they arise.

Limited market for securities

There can be no assurance that an active and liquid market for the Company’s shares will develop or be maintained and an investor may find it difficult to resell any securities of the Company.

Stock Market Volatility

The market price of the Company’s Common Shares could be subject to significant fluctuations in response to various factors, many of which are beyond the Company’s control. In addition, the stock markets have experienced significant price and volume fluctuations that have particularly affected the market prices of equity securities of many companies and that often have been unrelated to the operating performance of such companies. These broad market fluctuations may adversely affect the market price of the Common Shares. There can be no assurance that the holders or purchasers of the Company’s Common Shares will be able to resell their shares at prices equal to or greater than their cost.

No History of Payment of Cash Dividends


The Company has never declared or paid cash dividends on its Common Shares. The Company intends to retain future earnings to finance the operation, development and expansion of the business. The Company does not anticipate paying cash dividends on its Common Shares in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of the Board and will depend on the Company’s financial condition, results of operations, contractual restrictions, capital requirements, business prospects and other factors that the Board considers relevant.

Analyst Coverage

The trading market for the Company’s Common Shares will, to some extent, depend on the research and reports that securities or industry analysts publish about the Company or its business. The Company will not have any control over these analysts. If one or more of the analysts who covers the Company should downgrade the Company’s Common Shares or change their opinion of the Company’s business prospects, the Company’s share price would likely decline. If one or more of these analysts ceases coverage of the Company or fails to regularly publish reports on the Company, the Company could lose visibility in the financial markets, which could cause the Company’s share price or trading volume to decline.

Tax Issues

There may be income tax consequences in relation to the Company’s Common Shares, which will vary according to circumstances of each investor. Prospective investors should seek independent advice from their own tax and legal advisers.

INFORMATION CONCERNING XANTHIC BIOPHARMA INC.

Additional information relating to the Corporation, may be accessed through the SEDAR website at www.sedar.com under Xanthic Biopharma Inc. and the Corporation’s website at www.xanthicbiopharma.com.

Toronto, Ontario

September 13, 2018


SCHEDULE “D” – GGB MD&A

Please see attached.


LOGO

GREEN GROWTH BRANDS LTD.

MANAGEMENT DISCUSSION AND ANALYSIS

FOR THE PERIOD FROM COMMENCEMENT OF OPERATIONS

ON FEBRUARY 14, 2028 TO JULY 31, 2018


MANAGEMENT DISCUSSION AND ANALYSIS

Green Growth Brands Ltd. (“GGB” or the “Corporation”) was incorporated under Ontario Business Corporations Act under the name Schottenstein Arviv Group Inc. on February 14, 2018. The name of the Corporation was changed to Green Growth Brands Ltd. on July 12, 2018. The Corporation’s principal business activity is the development of lifestyle oriented, consumer products that celebrate health, wellness and happiness focused on the medicinal and recreational cannabis sectors in both the United States and Canada. The Corporation is in the development stage and has not yet earned any revenues. The Corporation’s registered office is 5300 Commerce Court West, 199 Bay Street, Toronto, ON, M5L 1B9 and its principal place of business is 4300 E. Fifth Avenue, Columbus, OH 43219.

This Management’s Discussion and Analysis (“MD&A”) has been prepared with an effective date of September 26, 2018 and provides an update on matters discussed in, and should be read in conjunction with the Corporation’s audited financial statements, including the notes thereto, as at and for the period from commencement on February 14, 2018 to July 31, 2018 (the “2018 Audited Consolidated Financial Statements”), which have been prepared using International Financial Reporting Standards (“IFRS”). All amounts are in United States dollars unless otherwise specified. Tabular dollar amounts, unless otherwise specified, are in dollars, except for per unit or per share amounts. This MD&A contains forward looking statements that are based on certain estimates and assumptions and involve risks and uncertainties. Actual results may vary materially from management’s expectations. See the “Caution Concerning Forward Looking Statements” section in this MD&A.

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements in this MD&A may contain “forward-looking information,” within the meaning of applicable securities laws, including the “safe harbour provisions” of the Securities Act (Ontario) with respect to the Corporation. Such statements include, but are not limited to, statements with respect to expectations, projections, or other characterizations of future events or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to our plans and objectives, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities. These statements are subject to certain risks, assumptions and uncertainties that could cause actual results to differ materially from those included in the forward-looking statements. The words “believe”, “plan”, “intend”, “estimate”, “expect”, or “anticipate”, and similar expressions, as well as future or conditional verbs such as “will”, “should”, “would”, and “could” often identify forward-looking statements. We have based these forward-looking statements on our current views with respect to future events and financial performance. With respect to forward looking statements contained in this MD&A, the Corporation has made assumptions and applied certain factors regarding, among other things: future product pricing; costs of inputs; its ability to market products successfully to its anticipated clients; reliance on key personnel; the regulatory requirements; the application of federal and state environmental laws; and the impact of increasing competition. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which could cause actual results to differ materially from the conclusions, forecasts, or projections anticipated in these forward-looking statements. Because of these risks, uncertainties, and assumptions, the reader should not place undue reliance on these forward-looking statements. The Corporation’s forward-looking statements are made only as of the date of this MD&A, and except as required by applicable law, the Corporation undertakes no obligation to update or revise these forward-looking statements to reflect new information, future events or circumstances.


GOING CONCERN ASSUMPTION AND EARLY STAGE CORPORATION

The Corporation was incorporated on February 14, 2018. The Corporation’s ability to continue as a going concern is dependent upon the ability to raise the necessary capital to finance development of the Corporation’s business strategy of a premium cannabinoid brand offering scientifically proven relief through easy, innovative, and contemporary non-combustible methods. The 2018 Audited Consolidated Financial Statements do not give effect to any adjustments which would be necessary should the Corporation be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business. The amounts the Corporation may realize on the disposition of its assets or the discharging of its liabilities in other than the normal course of its business may be significantly different than the carrying value of these assets and liabilities as reflected in the 2018 Audited Consolidated Financial Statements.

OVERVIEW OF THE CORPORATION

Description of Business

The Corporation, through its wholly-owned subsidiary, Green Growth Brands LLC, develops lifestyle-oriented consumer products that celebrate health, wellness and happiness focused on the medicinal and recreational cannabis sectors in both the United States and Canada. Built on a foundation of retail-industry experts, the Corporation, via two separate business segments, expects to generate returns from world-class cannabis retail and CBD consumer products. Following completion of the Business Combination detailed below under Recent Developments, the Corporation will be a vertically integrated cannabis company, whose principal activities will include the cultivation, production/manufacturing, and dispensing of medicinal and recreational cannabis in the State of Nevada. The Company intends to provide access to all permissible forms of the cannabis plant, including dried cannabis, oils, tinctures, and edible products.

The Corporation’s vertically integrated cannabis facility, based in Las Vegas, Nevada, operates under the name “The Source.” Established in 2015, The Source is a recognized name in the Nevada cannabis community, having been named by NPR’s Desert Companion Magazine as the Best Dispensary in Las Vegas in its February 2018 edition.

Green Growth Brands LLC

Green Growth Brands LLC, a Delaware limited liability company, was formed on February 26, 2018 as Schottenstein Arviv Group US LLC, and is a wholly owned subsidiary of Schottenstein Arviv Group Ltd. (now Green Growth Brands Ltd.). The entity changed its name to Green Growth Brands LLC on July 13, 2018. Green Growth Brands LLC provides general and administrative support functions for the Corporation. Included within this general and administrative support function are executives and other management with significant and diverse retail experience. These officers have retail knowledge and experience stemming from executive-level positions at such well-known businesses and brands as Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, and DSW Shoe Warehouse. Green Growth Brands LLC intends to leverage this vast experience to create a new, unrivaled experience in the cannabis market for both the cannabis retail segment and the CBD products segment.

GGB Beauty LLC

GGB Beauty, a Delaware limited liability company, was formed on July 25, 2018 as a wholly owned subsidiary of Green Growth Brands LLC. GGB Beauty is developing and will market CBD-infused consumer products, including, without limitation, body care, face care, ingestible items, and other similar articles. The Corporation intends to distribute these items under several different brand names that it has developed for this purpose.

GGB Licenses LLC

GGB Licenses, a Delaware limited liability company, was formed on July 25, 2018 as a wholly owned subsidiary of Green Growth Brands LLC. GGB Licenses holds the trademarks used by the Corporation in operating its business.


Recent Developments

On July 17, 2018 GGB and Xanthic Biopharma Inc. (“Xanthic”) announced they entered into an arm’s length business combination agreement (as amended by agreement between GGB and Xanthic dated August 30, 2018, the “Definitive Agreement”) dated July 13, 2018 to combine GGB and Xanthic by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis and cannabis-infused products. Using a proprietary process, Xanthic empowers its strategic partners to deliver superior cannabinoid solubility, improved bioavailability, accurate micro-dosing, and greater consistency versus competitive infused products. Through its investment in Xanthic Beverages, Xanthic has access to non-cannabis derived CBD-infused products that qualify for distribution outside of the cannabis dispensary network and into mainstream retail. Both business streams are capital-light, utilizing the existing infrastructure of strategic partners to reduce the capital investment required by Xanthic. GGB will leverage Xanthic’s expertise in the science of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”), the two key active ingredients in cannabis.

As of July 31, 2018, GGB had 100,765,002 GGB common shares outstanding (the “GGB Shares”). As of July 31, 2018, Xanthic had 57,046,547 Xanthic Shares outstanding together with Xanthic convertible securities entitling the holders thereof to acquire a further 3,876,000 Xanthic Shares. Pursuant to the terms of the Definitive Agreement, GGB may issue up to an additional 435,000 GGB Shares (or convertible securities, or the equivalent) prior to closing of the Business Combination. Based on the foregoing, Xanthic will, subject to the receipt of all regulatory approvals, including the approval of its shareholders to certain items of special business and the Exchange, (i) combine with GGB pursuant to the Definitive Agreement such that all of the issued and outstanding GGB Shares will be acquired, and as consideration, Xanthic will issue to holders of GGB Shares, on a 3.394-for-one basis, 346,150,835 Xanthic Shares (the “Consideration Shares”) , in exchange for the then issued and outstanding GGB Shares (which for greater certainty excludes the GGB Shares to be issued under the Subscription Receipt Private Placement and the Debenture Private Placement (as such terms are defined below)); and (ii) reorganize its share structure and consolidate all of the issued and outstanding Xanthic Shares (including the Consideration Shares) on the basis of four (4) pre-consolidation Xanthic Shares for one (1) post-consolidation Resulting Issuer Share (the “Consolidation”).

Following completion of the Business Combination, current shareholders of GGB will hold approximately 86% of the common shares (the “Resulting Issuer Shares”) of the resulting issuer (the “Resulting Issuer”) (excluding any Resulting Issuer Shares that become issuable pursuant to the terms of GGB’s private placement of convertible debentures (the “Debenture Private Placement”) and any subsequent GGB private placement of subscription receipts (the “Subscription Receipt Private Placement”). It is anticipated that the Resulting Issuer may operate under the name “Green Growth Brands Ltd.” after effecting a name change (the “Name Change”) with the Resulting Issuer Shares listed and posted for trading on the Canadian Securities Exchange (the “Exchange” or the “CSE”). Xanthic anticipates filing a management information circular or listing statement (the “Disclosure Document”) detailing certain matters relating to the Business Combination and other related matters to be mailed to Xanthic shareholders. Trading in the common shares of Xanthic (the “Xanthic Shares”) was halted as a result of this announcement and will remain halted until the resumption of trading is approved by the Exchange. If completed, the Business Combination will constitute a fundamental change of Xanthic (as such term is defined in the CSE’s policies and procedures manual).

Assuming the satisfaction of customary closing conditions, including the approval of Xanthic’s shareholders, the Business Combination is expected to close in the fourth quarter of this year.

In the event that GGB terminates the Definitive Agreement, other than as a result of a breach of representation or warranty or non-performance by Xanthic, GGB shall pay Xanthic a break fee in the aggregate amount of $250,000 and reimburse Xanthic for the full extent of its US legal fees, a portion of its Canadian legal fees, travel costs and other reasonable expenses incurred in connection with the Business Combination.


Resulting Issuer

To the knowledge of the prospective directors and executive officers of the Resulting Issuer, no person or company beneficially will own, or control or direct, directly or indirectly, Resulting Issuer Shares carrying in excess of 10% of the voting rights attached to all outstanding Resulting Issuer Shares, other than All Js Greenspace LLC, a company controlled by three individual family trusts, which is expected to own 36,370,486 Resulting Issuer Shares, representing a 42.0% ownership stake in the Resulting Issuer prior to giving effect to the Subscription Receipt Private Placement and the Debenture Private Placement.

GGB and Xanthic also announced that GGB Nevada LLC (“GGB Nevada”), a wholly-owned subsidiary of Xanthic has entered into a purchase agreement (the “NOR Agreement”) dated July 13, 2018 with Nevada Organic Remedies LLC (“NOR”) and its members (“NOR Members”) pursuant to which it will acquire (the “NOR Acquisition”) 100% of the outstanding membership interests of NOR for aggregate consideration of US$56,750,000 payable by a combination of cash and a promissory note. On July 16, 2018, GGB loaned US$2,000,000 to Xanthic pursuant to an interest-free promissory note with a due date of December 1, 2018 and on July 17, 2018, Xanthic advanced the proceeds of the loan to GGB Nevada which in turn made a payment of US$2,000,000 to NOR as a deposit on the NOR Agreement. NOR is a vertically integrated medical and retail marijuana company based in Las Vegas, Nevada holding four Nevada marijuana licenses (dispensary, cultivation, production and distribution). Additionally, NOR produces a line of high quality medical and recreational products under the name 8|fold.

On August 30, 2018, GGB raised gross proceeds of US$49.3 million denominated in Canadian dollars (CAD$64 million) from a brokered and non-brokered private placement offering of 12% unsecured convertible debentures (the “Debenture Private Placement”) at a price of CAD$1,000 per Debenture. The brokered portion of the Debenture Private Placement was led by Canaccord Genuity as the sole agent for the offering. Commissions of $74,960 (CAD $97,300) were paid in cash and commissions and advisory fees of $2,425,990 (CAD $3,149,000) were paid in convertible debentures. Issue costs of the financing included legal and other expenses of $508,618 (CAD $660,200). US$30,347,500 of the proceeds were loaned to Xanthic for the NOR Acquisition and the balance of the net proceeds remain available to the Corporation for general corporate and working capital purposes and to finance potential acquisition activity.

On September 20, 2018, the Company raised gross proceeds of US$17.1 million denominated in Canadian dollars (CAD$22.1 million) from a second tranche of the brokered and non-brokered private placement offering of Debentures, at a price of CAD$1,000 per Debenture. Commissions of $114,220 (CAD$148,260) were paid in cash and broker commissions and advisory fees of $710,309 (CAD$922,000) were paid in debentures. Issue costs of the financing included legal and other expenses of $8,975 (CAD$11,650).

Also on September 20, 2018, the Company issued 3,150 Debentures for financial advisory services received in the value of US$2,440,935 (CAD$3,150,000).

On September 5, 2018, GGB advanced the US$30,347,500 to Xanthic pursuant to the terms of a loan agreement (the “Loan Agreement”) dated August 30, 2018. The proceeds of the loan were subsequently advanced by Xanthic to GGB Nevada, which in turn used the proceeds to make the initial cash payment required pursuant to the NOR Agreement in connection with the closing of the NOR Acquisition. In addition, on closing of the NOR Acquisition, GGB Nevada delivered to the NOR Members a secured promissory note (the “Purchase Note”) in the principal amount of US$21,565,000. The Purchase Note matures on March 3, 2019 and bears interest at 6% per annum and is fully secured by general security interest over the assets of NOR. The Loan Agreement matures on the date that is 180 days from September 5, 2018, bears interest at 12% per annum, and has been secured by a pledge over the shares of GGB Nevada. The balance of US$2,715,000 owing to the NOR Members will be satisfied by the issuance of common shares of the Resulting Issuer following completion of the Business Combination.

The Loan Agreement bears interest at 12% per annum and matures 180 days from September 5, 2018. The Loan Agreement contains no prepayment privilege and includes customary events of default, which include the failure to complete the Business Combination prior to the maturity date of the Loan Agreement. As security for the amounts advanced pursuant to the Loan Agreement, GGB has been granted an irrevocable option from Xanthic to elect to


satisfy Xanthic’s obligations under the Loan Agreement by acquiring GGB Nevada LLC from Xanthic and assuming Xanthic and GGB Nevada LLC’s obligations thereunder.

Each Debenture issued under the Debenture Private Placement entitles the holder thereof to a cash repayment of the principal amount thereof, plus accrued but unpaid interest thereon, on March 1, 2019 (the “Maturity Date”).

In the event GGB and Xanthic complete the Business Combination prior to the Maturity Date, the Debentures shall automatically convert into units of the Corporation (“GGB Units”) at the conversion price resulting from application of the following formula: [Principal Amount of Debentures to be Converted / Issue Price] / The Exchange Ratio, with “Issue Price” meaning the lesser of: (i) CAD$0.36 and (ii) the issue price of the subscription receipts of the Corporation that may be offered and sold by the Corporation pursuant to a subscription receipt private placement, and “Exchange Ratio” meaning that number of Resulting Issuer Shares (defined below) that each holder of common shares of the Corporation shall receive pursuant to the Business Combination, which is currently expected to be 3.394:1, subject to adjustment in accordance with the terms of the Definitive Agreement, as amended on August 30, 2018. Immediately thereafter, in connection with the Business Combination, each GGB Unit will be exchanged for units of the resulting issuer (“Resulting Issuer Units”) at the Exchange Ratio. Each whole Resulting Issuer Unit shall be comprised of (i) one common share of the resulting issuer (a “Resulting Issuer Share”) and (ii) one half of one Resulting Issuer Share purchase warrant (each whole Resulting Issuer Share purchase warrant, a “Resulting Issuer Warrant”). Each Resulting Issuer Warrant entitles the holder to acquire, on payment of the Exercise Price (as defined below) plus 25% thereof (such exercise price not to exceed CAD$1.80 (on a post 4:1 consolidation basis) per Resulting Issuer Share), one Resulting Issuer Share. A Resulting Issuer Warrant may be exercised at any time during the two-year period starting on the date the Resulting Issuer Warrants are issued. The “Exercise Price” means the price that is equal to the lesser of: (i) CAD$1.447 per post-consolidation Resulting Issuer Share and (ii) the issue price of the subscription receipts that are anticipated to be offered and sold by the Corporation pursuant to a subscription receipt private placement.

Board of Directors and Management

The board of directors and management of GGB are:

 

   

Ben Kraner (Director)

 

   

Joey Schottenstein (Director)

 

   

Adam Arviv (Director)

 

   

Shawn Dym (Director)

 

   

Peter Horvath (President and Chief Executive Officer)

 

   

Ian Fodie (Chief Financial Officer)

Corporate Outlook and Strategy

The Corporation is in its infancy, as previously noted, however the Corporation’s business strategy is multi-faceted, with an intent to develop facilities and product along two segments of the business: Cannabis Retail and CBD Consumer Products.

Cannabis Retail

The Corporation’s retail cannabis strategy, following the completion of the Business Combination identified above, is to continue its growth through a combination of merger & acquisition activity and organic license capture. Such activity will focus on those certain states where cannabis has been legalized for medical and/or recreational use at the state level. Having entered the competitive Nevada market via the acquisition process, the Corporation is strategically exploring similar options in Florida, Massachusetts, Michigan, and New Jersey. The selection of these states for acquisition activity is based upon the Corporation’s assessment of the regulatory market under the various state-level and local governments, profitability per location when compared to other cannabis-permissive states, and the perceived potential for medicinal-only states to move to recreational use in the near future.


The Corporation has also engaged in a strategically targeted license-capture approach in New Jersey and Nevada, detailed below, and is pursuing license application opportunities in other locations such as Florida and Michigan in the near future.

New Jersey

The Corporation, pursuant to a Request for Applications issued by the New Jersey Department of Health, submitted a proposal to operate a single, fully integrated Alternative Treatment Center in New Jersey. The Corporation, should it receive an award, will be one of just 12 current awardees in the state. The state is expected to make an award on or about November 1, 2018, and it is expected that operations will commence within 12 months of award.

At present, use in New Jersey is limited to medical use only. Pending legislation, which has the support of the current Governor, is expected to pass shortly that will move the state to recreational status in the next 12 months.

Nevada

On September 17, 2018, the Corporation submitted an application for eight recreational marijuana store facilities in Nevada through its affiliate, Nevada Organic Remedies LLC (“NOR”). With support from The Source, which will be owned by the Corporation following the Business Combination, the Corporation anticipates several recreational store awards when state makes its announcement in early December 2018.

CBD Consumer Products

The Corporation anticipates a robust CBD consumer products industry in 2019. To that end, it has invested more than $150,000 for research, development, and safety testing regarding proprietary CBD-infused products, including topical body care, face care, and ingestible agents. Research for body-care products is currently being finalized, with an expected limited launch of such products in the United States in October 2018. The Corporation expects to finalize research and development for proprietary face care and ingestible products in November 2018, with a launch of those products in the first quarter of 2019.

Overall Financial Performance

As previously discussed, the Corporation was incorporated on February 14, 2018 and has no revenue from operations. Below is a summary of the Corporation financial performance for the period from commencement of operations on February 14, 2018 to July 31, 2018. During the period ended July 31, 2018 the Corporation had a net loss from operations of $3,945,120.

 

For the period of commencement of operations on February 14, 2018 to July 31, 2018

   2018  

Revenues

   $ —    

Net loss from operations

   $ 3,945,120  

Net loss per share

   $ 0.06  

SELECTED QUARTERLY FINANCIAL INFORMATION

 

For the three months ended,

   July 31, 2018      April 30, 2018  

Current Assets

   $ 4,383,959      $ 5,892,275  

Current Liabilities

     825,620        88,597  

Net loss from operations

     2,673,381        821,739  

Net loss per share

   $ 0.05      $ 0.01  


   

The Corporation current assets represent cash, loan receivables and accounts receivable. Current assets at July 31, 2018 include cash of $2,242,245.

 

   

The Corporation’s current liabilities represent start up consulting, legal and audit fees, and general operating costs payable, since commencement.

LIQUIDITY AND CAPITAL RESOURCES

The Corporation has cash of $2,242,245, loan receivables of $2,000,000, and other receivables of $141,714 and current liabilities of $825,620 as at July 31, 2018. The Corporation therefore has a working capital of $3,558,339. Despite the positive working capital, the Corporation does not have sufficient liquidity and capital resources at July 31, 2018 to meet all its planned expenditures over the next twelve months.

The Corporation plans to complete further financings over the next twelve months in order to fund its ongoing expenditures and execute on its business plan to get to break even cashflow. However, there is no assurance that the Corporation will be successful in these endeavors.

Outstanding Share Data

At July 31, 2018 and September 26, 2018, the Corporation had 100,765,002 common shares outstanding.

OFF BALANCE SHEET ARRANGEMENTS

The Corporation has no off-balance sheet arrangements.

COMMITMENT AND CONTINGENCIES

Commitments are detailed in Note 11 to the 2018 Audited Consolidated Financial Statements. The following table summarizes payments due for the next five years and thereafter in respect of the Corporation’s contractual obligations and the obligations of its subsidiaries.

 

     Not later than 1
year
     Later than 1
year and not
later than 5
years
     Later than 5
years
     Total  

Rent of office space

   $ 169,750      $ 303,205      $ —        $ 472,955  

RELATED PARTY TRANSACTIONS

The Corporation has not entered into any transactions with related parties, other than as disclosed in Note 11 to the 2018 Audited Consolidated Financial Statements.

ACCOUNTING POLICIES, CRITICAL JUDGMENTS AND ESTIMATES

The preparation of the Corporation’s financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and other items in net earnings or loss, and the related disclosure of contingent assets and liabilities, if any. Critical judgments and estimates represent estimates made by management that are, by their very nature, uncertain. The Corporation evaluates its estimates on an ongoing basis. Such estimates are based on historical experience and on various other assumptions that the Corporation believes are reasonable under the circumstances, and these estimates form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and other items in net earnings or loss that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Summaries of the significant accounting policies applied, and significant judgments, estimates and assumptions made by management in the preparation of its financial statements are provided in Notes 2 and 3 to the 2018 Audited Consolidated Financial Statements.

BUSINESS RISKS


There are numerous and varied risks, known and unknown, that may prevent the Corporation from achieving its goals. If any of these risks occur, the Corporation’s business, financial condition or results of operation may be adversely affected. In such case, the trading price of the Corporation’s common shares could decline, and investors could lose all or part of their investment. The following is a summary of risks that could be applicable to the business of the Corporation:

The Corporation Relies on Securing and Maintaining Agreements with Licensed Partners

In most U.S. States, the Corporation is not eligible to obtain a license to grow, store and sell cannabis products. Accordingly, the Corporation must secure royalty agreements with Licensed Partners that have been able to obtain the requisite licenses with the appropriate regulatory authorities in the targeted jurisdictions. The failure of a Licensed Partner to comply with the requirements of their license or to maintain their license would have a material adverse impact on the business, financial condition and operating results of the Corporation. There can be no guarantee that the applicable licenses will be maintained by Licensed Operators or granted to other prospective Licensed Operators in the future.

Limited Operating History

Having been founded in early 2018, the Corporation has a limited operating history which can make it difficult for investors to evaluate the Corporation’s operations and prospects and may increase the risks associated with an investment in the Corporation. The Corporation will be subject to all of the business risks and uncertainties associated with any new business enterprise, such as under-capitalization, cash shortages, limitations with respect to personnel, financial and other resources, achieving market acceptance of existing and future solutions, competing against companies with greater financial and technical resources, and lack of revenues. There is no assurance that the Corporation will be successful in achieving a return for investors and the likelihood of success must be considered in light of the early stage of operations. Because the Corporation has a limited operating history in emerging area of business, investors should consider and evaluate its operating prospects in light of the risks and uncertainties frequently encountered by early-stage companies in rapidly evolving markets. These risks may include:

 

   

risks that it may not have sufficient capital to achieve its growth strategy;

 

   

risks that it may not develop its product and service offerings in a manner that enables it to be profitable and meet its customers’ requirements;

 

   

risks that its growth strategy may not be successful;

 

   

risks that fluctuations in its operating results will be significant relative to its revenues; and

 

   

risks relating to an evolving regulatory regime.

The Corporation’s future growth will depend substantially on its ability to address these and the other risks described in this section. If it does not successfully address these risks, its business may be significantly harmed.

Operating in the United States

The Corporation will initially focus its operations in the United States, specifically in states that have already passed legislation legalizing the recreational sale and use of cannabis. Currently, the states of California, Nevada, Massachusetts, Maine, Washington, Oregon, Colorado and Alaska, and the District of Columbia, have legalized the recreational use of cannabis. However, the U.S. federal government has not enacted similar legislation and the cultivation, sale and use of cannabis remains illegal under federal law pursuant to the U.S. Controlled Substance Act of 1970. While the Department of Justice under the previous U.S. presidential administration stated its intention not to enforce federal laws relating to cannabis where the conduct at issue is legal under applicable state law, pursuant to the Cole Memorandum, there can be no assurance that the current administration will not enforce such laws in the future. This risk is further compounded by the political and policy variability of the Donald Trump presidential administration, and the conservative, anti-cannabis stances of Attorney General Jeff Sessions. Mr. Trump’s positions regarding marijuana are difficult to discern; however, Attorney General Sessions has been a consistent opponent of marijuana legalization efforts throughout his political career. On January 4, 2018, Attorney General Sessions rescinded the Cole Memorandum, shifting federal policy from a hands-off approach to unleashing federal prosecutors across the


country to decide individually how to crack down on possession, distribution and cultivation of cannabis, including in states in which cannabis is legal. With the Cole Memorandum rescinded, U.S. federal prosecutors no longer have guidance relating to the exercise of their discretion in determining whether to prosecute cannabis related violations of U.S. federal law. It is possible that further developments could significantly adversely affect the business, financial condition and results of businesses involved in U.S. cannabis related activities and in the cannabis industry generally. There can be no assurance that the U.S. federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with applicable state law. If the federal government begins to enforce federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing state laws are repealed or curtailed, the Corporation would be materially and adversely affected notwithstanding the fact that the Corporation is not directly engaged in the sale or distribution of cannabis. The consequences of such enforcement would be materially adverse to the Corporation and the Corporation’s business and could result in the forfeiture or seizure of all or substantially all of the Corporation’s assets.

The Products Provided by the Corporation to Licensed Partners May Become Subject to Regulation Governing Food and Related Products

Should the U.S. federal government legalize cannabis for medical or recreational use nation-wide, there is a risk that the U.S. Food and Drug Administration (the “FDA”) would seek to regulate the products under the Food, Drug and Cosmetics Act of 1938. The FDA may issue rules and regulations including certified good manufacturing practices related to the growth, cultivation, harvesting and processing of cannabis and cannabis-infused products. Clinical trials may be needed to verify the efficacy and safety of cannabis. It is also possible that the FDA would require that facilities where cannabis is cultivated be registered with the applicable government agencies and comply with certain federal regulations. Compliance with such rules and regulations may be unduly costly and may have an adverse effect on the Corporation. If the Corporation or its Licensed Partners are unable to comply with the regulations prescribed by the FDA, the Corporation and/or its Licensed Partners may be unable to continue to operate.

Banking Regulation May Hinder the Corporation’s Ability to Establish and Maintain Bank Accounts

The U.S. federal prohibitions on the sale of cannabis may prevent the Corporation’s Licensed Partners from accessing the U.S. banking system and they may be unable to deposit funds in federally-insured and federally-licensed banking institutions. While the Corporation does not anticipate dealing with banking restrictions directly relating to its business, such restrictions could nevertheless be imposed due to the Corporation’s banking institutions not accepting payments from its Licensed Partners. Licensed Partners at times do not have deposit services and are at risk that any bank accounts they have could be closed at any time. Such risks increase costs to the Corporation and to its Licensed Partners. The inability of the Corporation’s Licensed Partners to access banking services can make it difficult to structure royalty agreements in a manner acceptable to the Corporation.

In the event financial service providers do not accept accounts or transactions related to the cannabis industry, it is possible that the Corporation’s Licensed Partners may seek alternative payment solutions, including but not limited to, cryptocurrencies such as Bitcoin. There are risks inherent in cryptocurrencies, most notably its volatility and security issues. If the industry was to move towards alternative payment solutions and accept payments in cryptocurrency the Corporation would have to adopt policies and protocols to manage its volatility and exchange rate risk exposures. The Corporation’s inability to manage such risks may adversely affect the Corporation’s operations and financial performance.

Managing Growth

In order to manage growth and change in strategy effectively, the Corporation must: (a) maintain adequate systems to meet customer demand; (b) expand sales and marketing, distribution capabilities and administrative functions; (c) expand the skills and capabilities of its current management team; and (d) attract and retain qualified employees. The inability of the Corporation to deal with this growth may have a material adverse effect on its business, financial condition, results of operations and prospects.

Competition


There is potential that the Corporation will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience than the Corporation. Currently, the cannabis, nutraceuticals and pharmaceuticals industry generally is comprised of individuals and small to medium-sized entities, however, the risk remains that large conglomerates and companies that also recognize the potential for financial success through investment in this industry could strategically purchase or assume control of larger dispensaries and cultivation facilities. In doing so, these larger competitors could establish price setting and cost controls which would effectively “price out” many of the individuals and small to medium-sized entities that currently make up the bulk of the participants in the varied businesses operating within, and in support of, the medical and recreational cannabis industry. While most U.S. states seemingly deter this type of arrangement, the cannabis industry is still relatively new for public entities, so the future competitive environment remains largely unknown.

Because of the early stage of the industry in which the Corporation will operate, the Corporation expects to face additional competition from new entrants. To become and remain competitive, the Corporation will require research and development, marketing, sales and support. The Corporation may not have sufficient resources to maintain research and development, marketing, sales and support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of operations of the Corporation.

Retention, Acquisition and Integration of Skilled Personnel

The loss of any member of the Corporation’s management team could have a material adverse effect on its business and results of operations. In addition, the inability to hire new personnel and the increased costs of hiring new personnel could have a material adverse effect on the Corporation’s business and operating results. At present and for the near future, the Corporation will depend upon a relatively small number of employees to develop, market, sell and support its products. The expansion of marketing and sales of its products will require the Corporation to find, hire and retain additional capable employees who can understand, explain, market and sell its products. There is intense competition for capable personnel and the Corporation may not be successful in attracting, training, integrating, motivating, or retaining new personnel, vendors, or subcontractors for these required functions. New employees often require significant training and, in many cases, take significant time before they achieve full productivity. As a result, the Corporation may incur significant costs to attract and retain employees, including significant expenditures related to salaries and benefits and compensation expenses related to equity awards, and may lose new employees to its competitors or other companies before it realizes the benefit of its investment in recruiting and training them. In addition, as the Corporation moves into new jurisdictions, it will need to attract and recruit skilled employees in those areas.

Legal Proceedings

From time to time, the Corporation may be a party to legal and regulatory proceedings, including matters involving governmental agencies, entities with whom it does business and other proceedings arising in the ordinary course of business. The Corporation will evaluate its exposure to these legal and regulatory proceedings and establish reserves for the estimated liabilities in accordance with International Financial Reporting Standards. Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management’s evaluations or predictions and accompanying changes in established reserves, could have an adverse impact on the Corporation’s financial results.

Regulatory Compliance Risks

Achievement of the Corporation’s business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. The Corporation may not be able to obtain or maintain the necessary licenses, permits, authorizations or accreditations, or may only be able to do so at great cost, to operate its business. The Corporation cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by local governmental authorities. The impact of the compliance regime, any delays in obtaining, or failure to obtain or keep the regulatory approvals may significantly delay or impact the


development of markets, products and sales initiatives and could have a material adverse effect on the business, results of operations and financial condition of the Corporation.

The Corporation will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Corporation may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Corporation’s operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Corporation.

Change of Cannabis Laws, Regulations and Guidelines

Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require the Corporation to incur substantial costs associated with compliance or alter certain aspects of its business plan. It is also possible that regulations may be enacted in the future that will be directly applicable to certain aspects of the Corporation’s businesses. The Corporation cannot predict the nature of any future laws, regulations, interpretations or applications, nor can it determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on the Corporation’s business. Management expects that the legislative and regulatory environment in the cannabis industry in Canada and internationally will continue to be dynamic and will require innovative solutions to try to comply with this changing legal landscape in this nascent industry for the foreseeable future. Compliance with any such legislation may have a material adverse effect on the Corporation’s business, financial condition and results of operations.

Unfavourable Publicity or Consumer Perception

Management of the Corporation believes the cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the cannabis produced. Consumer perception of the Corporation’s proposed products may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Corporation’s proposed products and the business, results of operations, financial condition and cash flows of the Corporation. The Corporation’s dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Corporation, the demand for the Corporation’s proposed products, and the business, results of operations, financial condition and cash flows of the Corporation. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis in general, or the Corporation’s proposed products specifically, or associating the consumption of cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers’ failure to consume such products appropriately or as directed.

Liability, Enforcement, Complaints, etc.

The Corporation’s participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by third parties, other companies and/or various governmental authorities against the Corporation. Litigation, complaints, and enforcement actions involving the Corporation could consume


considerable amounts of financial and other corporate resources, which could have an adverse effect on the Corporation’s future cash flows, earnings, results of operations and financial condition.

Product Liability

As a distributor of products designed to be ingested or inhaled by humans, the Corporation faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused damages, loss or injury. In addition, the sale of the Corporation’s products involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Adverse reactions resulting from human consumption of the Corporation’s products alone or in combination with other medications or substances could occur. The Corporation may be subject to various product liability claims, including, among others, that the Corporation’s products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning health risks, possible side effects or interactions with other substances. A product liability claims or regulatory action against the Corporation could: i) result in increased costs; ii) adversely affect the Corporation’s reputation with its Licensed Partners and consumers generally; and iii) have a material adverse effect on the results of operations and financial condition of the Corporation. There can be no assurances that the Corporation will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Corporation’s potential products.

Insurance Coverage

The Corporation’s production is, in general, subject to different risks and hazards, including adverse weather conditions, fires, plant diseases and pest infestations, other natural phenomena, industrial accidents, labour disputes, changes in the legal and regulatory framework applicable to the Corporation and environmental contingencies. Although management of the Corporation believes that the events and amounts of liability covered by its insurance policies will be reasonable, taking into account the risks relevant to its business, and the fact that agreements with users contain limitations of liability, there can be no assurance that such coverage will be available or sufficient to cover claims to which the Corporation may become subject. If insurance coverage is unavailable or insufficient to cover any such claims, the Corporation’s financial resources, results of operations and prospects could be adversely affected.

Product Recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of the Corporation’s products are recalled due to an alleged product defect or for any other reason, the Corporation could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Corporation may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although the Corporation has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if the Corporation is subject to recall, the image of the Corporation could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the Corporation’s products and could have a material adverse effect on the results of operations and financial condition of the Corporation. Additionally, product recalls may lead to increased scrutiny of the Corporation’s operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses and potential legal fees and other expenses.

Limited Avenues to Market and Promote Products


To be successful, the Corporation’s business must be successfully marketed. The market for the Corporation’s products and services has and is expected to grow significantly and may require substantial sales and marketing capability. The Corporation will be dependent on independent parties to market its products and services. There can be no assurance that the Corporation can continue to market or can enter into satisfactory arrangements with third parties to continue to market its products and services in a manner that would assure its growth and acceptance in the market place.

Supply of Cannabis Extract

If for any reason the supply of cannabis extract from licensed producers is ceased or delayed, the Corporation would have to seek alternate suppliers and obtain all necessary authorization for the new cannabis extract. If replacement cannabis extract cannot be obtained at comparable prices, or at all, or if the necessary authorizations are not obtained, the Corporation’s business, financial condition and results of operations would be materially and adversely affected.

Global Economy

Financial markets are influenced by the economic and market conditions in other countries, including the United States and other global markets. Although economic conditions in these countries may differ significantly from economic conditions in Canada, investor reactions to developments in these other countries may substantially affect the capital flows into and the market value of securities of issuers with operations in the United States and Canada.

Consumer Acceptance of Premium Pricing

The Corporation branding, and pricing strategy is to offer a premium product at higher than existing market prices of competitive products. The Corporation assumes that it will be successful in establishing the brand as a premium brand and therefore is relying on pricing its products consistent with its brand image. There can be no assurance that the Corporation will be successful and that the marketplace will accept a premium price when there is no direct competitive, comparable product.

Access to Capital

In executing its business plan, the Corporation makes, and will continue to make, substantial investments and other expenditures related to acquisitions, research and development and marketing initiatives. Since its incorporation, the Corporation has financed these expenditures through offerings of its equity securities and debt financing. The Corporation will have further capital requirements and other expenditures as it proceeds to expand its business or take advantage of opportunities for acquisitions or other business opportunities that may be presented to it. The Corporation may incur major unanticipated liabilities or expenses. The Corporation can provide no assurance that it will be able to obtain financing to meet the growth needs of the Corporation.

Foreign Sales and Currency Risks

The Corporation’s functional currency is denominated in US dollars. The Corporation currently expects that sales will be denominated in U.S. dollars and may, in the future, have sales denominated in the currencies of additional countries in which it establishes sales offices. In addition, the Corporation incurs the majority of its operating expenses in US dollars and has some expenses in Canadian dollars. In the future, the proportion of the Corporation’s sales that are international may increase. Such sales may be subject to unexpected regulatory requirements and other barriers. Any fluctuation in the exchange rates of foreign currencies may negatively impact the Corporation’s business, financial condition and results of operations. The Corporation has not previously engaged in foreign currency hedging. If the Corporation decides to hedge its foreign currency exposure, it may not be able to hedge effectively due to lack of experience, unreasonable costs or illiquid markets. In addition, those activities may be limited in the protection they provide the Corporation from foreign currency fluctuations and can themselves result in losses.

Estimates or Judgments Relating to Critical Accounting Policies


The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Corporation bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided in the notes to the Corporation’s Financial Statements, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. The Corporation’s operating results may be adversely affected if the assumptions change or if actual circumstances differ from those in the assumptions, which could cause the Corporation’s operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the share price of the Corporation. Significant assumptions and estimates used in preparing the financial statements include those related to the credit quality of accounts receivable, income tax credits receivable, share based payments, impairment of non-financial assets, as well as revenue and cost recognition. Significant judgements used in preparing the financial statements include the determination of the Corporation’s functional currency and the Corporation’s ability to continue operating as a going concern.

Tax Risks

The Corporation will operate and will be subject to income tax and other forms of taxation (which are not based upon income) in multiple tax jurisdictions. Taxation laws and rates which determine taxation expenses may vary significantly in different jurisdictions, and legislation governing taxation laws and rates is also subject to change. Therefore, the Corporation’s earnings may be impacted by changes in the proportion of earnings taxed in different jurisdictions, changes in taxation rates, changes in estimates of liabilities and changes in the amount of other forms of taxation. The Corporation may have exposure to greater than anticipated tax liabilities or expenses. The Corporation will be subject to income taxes and non-income taxes in a variety of jurisdictions and its tax structure is subject to review by both domestic and foreign taxation authorities and the determination of the Corporation’s provision for income taxes and other tax liabilities will require significant judgment.

Repatriation of Profits

As a holding company with no material assets other than the stock of the Corporation’s operating subsidiaries and intellectual property, nearly all of the Corporation’s funds generated from operations are generated by the Corporation’s operating subsidiaries. The Corporation’s subsidiaries are subject to requirements of various regulatory bodies, both domestically and internationally. Accordingly, if the Corporation’s operating subsidiaries are unable, due to regulatory restrictions or otherwise, to pay the Corporation’s dividends and make other payments to the Corporation when needed, the Corporation may be unable to satisfy the Corporation’s obligations when they arise.

Limited market for securities

There can be no assurance that an active and liquid market for the Corporation’s shares will develop or be maintained and an investor may find it difficult to resell any securities of the Corporation.

Stock Market Volatility

The market price of the Corporation’s Common Shares could be subject to significant fluctuations in response to various factors, many of which are beyond the Corporation’s control. In addition, the stock markets have experienced significant price and volume fluctuations that have particularly affected the market prices of equity securities of many companies and that often have been unrelated to the operating performance of such companies. These broad market fluctuations may adversely affect the market price of the Common Shares. There can be no assurance that the holders or purchasers of the Corporation’s Common Shares will be able to resell their shares at prices equal to or greater than their cost.

No History of Payment of Cash Dividends

The Corporation has never declared or paid cash dividends on its Common Shares. The Corporation intends to retain future earnings to finance the operation, development and expansion of the business. The Corporation does not anticipate paying cash dividends on its Common Shares in the foreseeable future. Payment of future cash dividends,


if any, will be at the discretion of the Board and will depend on the Corporation’s financial condition, results of operations, contractual restrictions, capital requirements, business prospects and other factors that the Board considers relevant.

Analyst Coverage

The trading market for the Corporation’s Common Shares will, to some extent, depend on the research and reports that securities or industry analysts publish about the Corporation or its business. The Corporation will not have any control over these analysts. If one or more of the analysts who covers the Corporation should downgrade the Corporation’s Common Shares or change their opinion of the Corporation’s business prospects, the Corporation’s share price would likely decline. If one or more of these analysts ceases coverage of the Corporation or fails to regularly publish reports on the Corporation, the Corporation could lose visibility in the financial markets, which could cause the Corporation’s share price or trading volume to decline.

Tax Issues

There may be income tax consequences in relation to the Corporation’s Common Shares, which will vary according to circumstances of each investor. Prospective investors should seek independent advice from their own tax and legal advisers.

INFORMATION CONCERNING GREEN GROWTH BRANDS LTD.

Additional information relating to the Corporation, may be accessed on the Corporation’s website at www.greengrowthbrands.com.

Toronto, Ontario

September 26, 2018


SCHEDULE “E” – PRO FORMA FINANCIAL STATEMENTS

Please see attached.


Green Growth Brands Ltd. (formerly Xanthic Biopharma Inc.)

Pro Forma Consolidated Financial statements of Resulting Issuer

As at June 30, 2018

(In United States Dollars)


INDEX TO PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS

 

  1.

Pro Forma Consolidated Statement of Financial Position

 

  2.

Pro Forma Consolidated Statement of Net Loss and Comprehensive Loss

 

  3.

Notes to Pro Forma Consolidated Financial Statements


GREEN GROWTH BRANDS LTD. (formerly Xanthic Biopharma Inc.)

Pro Forma Consolidated Statement of Financial Position

As at June 30, 2018

(unaudited)

 

     Business Acquisition of Nevada Organic Remedies LLC     Reverse Take Over by Green Growth Brands Ltd.  
     Xanthic
Biopharma Inc.
    Nevada Organic
Remedies LLC
     Notes      Pro forma
Adjustments
    Pro forma
Consolidated
    Green Growth
Brands Ltd.
    Notes      Pro forma
Adjustments
    Pro forma
Consolidated
 
     (CDN)     (USD)             (USD)     (USD)     (USD)            (USD)     (USD)  

Assets

                     

Current Assets

                     

Cash and cash equivalents

   $ 1,037,049     $ 601,010        2 c) d)      $ (145,457   $ 1,492,602     $ 2,242,245       2 e) f) g) h) m)      $ 37,733,489     $ 41,468,337  

Accounts receivable

     —         336,762           —         336,762            —         336,762  

Prepaids expenses

     249,915       124,418        2 c)        (60,125     314,208            —         314,208  

Inventory

     181,096       1,857,445        2 a) c)        (578,996     1,459,545            —         1,459,545  

Biological assets

     —         —          2 a)        379,170       379,170            —         379,170  

Loan receivable

     —         —             —         —       $ 2,000,000       2 g)        (2,000,000     —    

Other receivable

     157,982       212,467        2 c)        (38,008     332,441       141,714       2 e) f) g)        —         474,155  
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 
     1,626,042       3,132,102           (443,416     4,314,728       4,383,959          35,733,489       44,432,177  

Non-Current Assets

                     

Equipment

     56,597       390,003        2 b) c)        170,325       616,925       —            —         616,925  

Equity investment in Xanthic Beverages USA, LLC

     1,126,865       —          2 c)      (271,105     855,760       —            —         855,760  

Intangible assets

     —         2,100        2 b)        54,137,620       54,139,720       —         2 k)        21,717,966       75,857,686  
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 
   $ 2,809,504     $ 3,524,205         $ 53,593,424     $ 59,927,133     $ 4,383,959        $ 57,451,455     $ 121,762,548  
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Liabilities

                     

Current Liabilities

                     

Accounts payable and accrued liabilities

   $ 156,368     $ 939,424        2 c)      $ (37,620  ) $      1,058,172     $ 825,620       2 e) l)      $ 1,139,125     $ 3,022,917  

Notes payable

     —         85           —         85            —         85  

Due to GGB

     —         —          2 b)        32,347,500       32,347,500         2 g)      (32,347,500     —    

Loan Agreement

     —         —          2 b)        21,565,000       21,565,000         2 h)        (21,565,000     —    

Convertible Debenture

     —               —         —           2 e) f) i)        —         —    

Contingent consideration payable

     790,080       —          2 c)        (190,080     600,000       —            —         600,000  
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 
     946,448       939,509           53,684,800       55,570,757       825,620          (52,773,375     3,623,002  

Shareholders’ Deficiency

                     

Share Capital

     4,236,395       2,584,696        2 c) d)        (552,713     6,268,378       7,503,459       2 i) j) k) m)        91,515,470       105,287,307  

Reserve for share based payments

     385,542          2 c)        (82,776     302,766         2 j)        (302,766     —    

Reserve for warrants

     186,304          2 c)        (40,000     146,304         2 j)        16,586,380       16,732,684  

Deficit

     (2,930,766        2 a) b) c)        629,238       (2,301,528     (3,945,120     2 e) f) j) l)        2,366,202       (3,880,446

Accumulated other comprehensive loss

     (14,419        2 c)        (45,125     (59,544     —         2 j)        59,544       —    
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 
     1,863,056       2,584,696           (91,376     4,356,376       3,558,339          110,224,830       118,139,545  
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 
   $ 2,809,504     $ 3,524,205         $ 53,593,424     $ 59,927,133     $ 4,383,959        $ 57,451,455     $ 121,762,548  
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

The accompanying notes are an integral part of these pro forma consolidated financial statements.

 

3


GREEN GROWTH BRANDS LTD. (formerly Xanthic Biopharma Inc.)

Pro Forma Consolidated Statement of Net Income (Loss) and Comprehensive Income (Loss)

As at June 30, 2018

(unaudited)

 

     Business Acquisition of Nevada Organic Remedies LLC     Reverse Take Over by Green Growth Brands Ltd.  
     Xanthic
Biopharma Inc.
    Nevada Organic
Remedies LLC
    Notes      Pro forma
Adjustments
    Pro forma
Consolidated
    Green Growth
Brands Ltd.
    Notes      Pro forma
Adjustments
    Pro forma
Consolidated
 
     (CDN)     (USD)            (USD)     (USD)     (USD)            (USD)     (USD)  

Revenues

   $ —       $ 18,991,307          $ 18,991,307     $ —          $ —       $ 18,991,307  

Cost of goods sold

     —         9,533,001       2 a) b)        —         9,533,001       —            —         9,533,001  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Gross Profit

     —         9,458,306          —         9,458,306       —            —         9,458,306  

Expenses

                    

Consulting fees

     827,658       —            —         827,658       936,580          —         1,764,238  

Stock based compensation

     385,542       —            —         385,542       —            —         385,542  

Advertising and promotion

     174,289       334,215          —         508,504       —            —         508,504  

Legal and professional fees

     375,023       —            —         375,023       2,233,548       2 e) f)        3,152,577       5,761,148  

General and Adminstration

     86,569       4,504,593          —         4,591,162       699,677          —         5,290,839  

Depreciation

     —         26,126          —         26,126       —            —         26,126  

Loss on equity investment in Xanthic Bevearges USA, LLC

     58,255       —            —         58,255       —            —         58,255  

Exchange loss on translating foreign operations

     —         —            —         —         74,150          —         74,150  

Interest and bank charges

     3,835       34,737          —         38,572       1,165          —         39,737  

Other Income

     —         (3,856        —         (3,856     —            —         (3,856
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Income (Loss) before transaction related expenses

     (1,911,171     4,562,491          —         2,651,320       (3,945,120        (3,152,577     (4,446,377

Listing fees

     918,054       —         2 c)        (629,238     288,816       —         2 j) l)        (5,518,779     (5,229,963
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Net Income (Loss) from Operations

     (2,829,225     4,562,491          629,238       2,362,504       (3,945,120        2,366,202       783,586  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Other comprehensive Income (Loss)

                    

Exchange loss on translating foreign operations

     14,419       —         2 c)        45,125       59,544       —         2 j) k) l)        (59,544     —    
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Comprehensive Income (Loss) for the period

     (2,843,644     4,562,491          584,113       2,302,960       (3,945,120        2,425,746       783,586  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

The accompanying notes are an integral part of these pro forma consolidated financial statements.

 

4


GREEN GROWTH BRANDS LTD.

Notes to the Pro Forma Consolidated Financial Statements

1. Background and basis of presentation

Background

On July 16, 2018 Xanthic Biopharma Inc. (“Xanthic”) and Green Growth Brands Ltd. (“GGB”) announced they have entered into an arm’s length business combination agreement (as amended by agreement between Xanthic and GGB dated August 30, 2018, the “Definitive Agreement”) dated July 13, 2018 to combine Xanthic and GGB by way of amalgamation (the “Amalgamation”) between GGB and a wholly-owned subsidiary of Xanthic (“Subco”) to form one company as a wholly-owned subsidiary of Xanthic (the “Business Combination”).

Following completion of the Business Combination, current shareholders of GGB will hold approximately 86% of the common shares (the “Resulting Issuer Shares”) of the resulting issuer (the “Resulting Issuer”) (excluding any Resulting Issuer Shares that become issuable pursuant to the terms of GGB’s private placement of convertible debentures (the “Debenture Private Placement”) and any subsequent GGB private placement of subscription receipts (the “Subscription Receipt Private Placement”). It is anticipated that the Resulting Issuer may operate under the name “Green Growth Brands Ltd.” after effecting a name change (the “Name Change”) with the Resulting Issuer Shares listed and posted for trading on the Canadian Securities Exchange (the “Exchange” or the “CSE”).

As of the August 31, 2018, Xanthic had 57,546,547 Xanthic Shares outstanding together with Xanthic convertible securities entitling the holders thereof to acquire a further 3,376,000 Xanthic Shares. As of the August 31, 2018, GGB had 100,765,002 GGB common shares (“GGB Shares”) outstanding and no outstanding convertible securities. Based on the foregoing, Xanthic will, subject to the receipt of all regulatory approvals, including the approval of its shareholders to certain items of special business and the Exchange, (i) combine with GGB pursuant to the Definitive Agreement such that all of the issued and outstanding GGB Shares will be acquired, and as consideration, Xanthic will issue to holders of GGB Shares, on a 3.435-for-one basis, 346,150,835 Xanthic Shares (the “Consideration Shares”) , in exchange for the then issued and outstanding GGB Shares (which for greater certainty excludes the GGB Shares to be issued under the Subscription Receipt Private Placement and the Debenture Private Placement (as such terms are defined below)); and (ii) reorganize its share structure and consolidate all of the issued and outstanding Xanthic Shares (including the Consideration Shares) on the basis of approximately four (4) pre-consolidation Xanthic Shares for one (1) post-consolidation Resulting Issuer Share (the “Consolidation”).

On August 30, 2018, GGB raised gross proceeds of $49.3 million (CAD $64 million) from its previously announced brokered and non-brokered private placement offering of unsecured 12% convertible debentures (the “Debentures”) at a price of CAD $1,000 per Debenture. The brokered portion of the Debenture Financing was led by Canaccord Genuity as the sole agent for the offering. Each Debenture unit entitles the holder to 1 common share and 12 warrant with an exercise price of CAD $1.80 per share (post share consolidation) for a period of two years from the closing date.

On September 5, 2018 GGB Nevada LLC (“GGB Nevada”) completed the previously announced acquisition of Nevada Organic Remedies LLC (“NOR”) (the “NOR Acquisition”). The NOR Acquisition was completed in accordance with the terms of the membership interest purchase agreement (the “NOR Agreement”) dated July 13, 2018 among GGB Nevada, NOR and its members (the “NOR Members”) for aggregate consideration of US$56,750,000 (the “Purchase Price”). The Purchase Price was satisfied by GGB Nevada by payment of a US$2 million deposit on July 16, 2018 (the “NOR Deposit”), a closing cash payment of US$30,347,500 (the NOR Closing Payment”) and delivery of a secured promissory note (the “NOR Note”) in the principal amount of US$21,565,000. The balance of US$2,837,500 owing to the NOR Members will be satisfied by the issuance of common shares of the resulting issuer following completion of the Business Combination. The cash required by Xanthic to satisfy the NOR Deposit was loaned to Xanthic by GGB pursuant to a promissory note dated July 16, 2018 (the “Deposit Note”) and the cash required by Xanthic to satisfy the NOR Closing Payment was loaned to Xanthic pursuant to the Loan Agreement (see “Deposit Note and Loan Agreement” below).

 

5


GREEN GROWTH BRANDS LTD.

Notes to the Pro Forma Consolidated Financial Statements

 

On September 20, 2018, GGB closed the second tranche of the Debentures for gross proceeds of US$17.1 million (CAD $22.1 million) on same conditions as the earlier first tranche Debenture financing that closed August 30, 2018.

Prior to Closing, GGB also intends to purchase from All Js Greenspace LLC all 27,500 of its outstanding GGB Convertible Debentures. GGB will then issue to All Js Greenspace LLC 55 12.00% unsecured convertible debentures of GGB (the “GGB Greenspace Debentures”). On the Closing Date, each GGB Greenspace Debenture will be converted into units of GGB (the “GGB Greenspace Units”), each GGB Greenspace Debenture being comprised of one (1) proportionate voting share in the capital of GGB (the “GGB Proportionate Shares”) and one-half (1/2) of one GGB Proportionate Share purchase warrant (the “GGB Proportionate Warrants”). The terms of the GGB Greenspace Debentures and GGB Proportionate Warrants will be set out in the certificates evidencing such securities.

In October 2018, GGB raised additional gross proceeds of approximately CAD$30.5 million (US$23.2 million) pursuant to a private placement of GGB Shares at a price of CAD$0.50 per GGB Share (CAD$2.00 on a post-Consolidation basis). GGB also issued GGB warrants exercisable for an aggregate principal amount of approximately CAD$24.5 million (US$18.6 million) GGB Shares upon payment of C$0.50 per GGB Share (C$2.00 on a post-Consolidation basis). The GGB warrants expire one day before the close the Business Combination with proceeds due no more than 30 days following the exercise date.

GGB’s registered office is 5300 Commerce Court West, 199 Bay Street, Toronto, ON, M5L 1B9 and its principal place of business is 4300 E. Fifth Avenue, Columbus, OH 43219.

Basis of presentation

The accompanying unaudited pro forma consolidated financial statements of GGB have been prepared by management of GGB for illustrative purposes only, to show the effect of the proposed acquisition of GGB by Xanthic Biopharma Inc. ultimately constituting a reverse takeover of Xanthic by the shareholders of GGB including adjustments reflecting the NOR acquisition (the “Transaction”).

The NOR acquisition will be treated as a business combination for accounting purposes. The total purchase price of US$56,750,000 paid by US$32,347,500 cash, a promissory note in the amount of US$21,565,000 and common shares of the resulting issuer in the amount of US$2,837,500. The preliminary acquisition cost has been allocated as follows:

 

Cash and cash equivalents

   $ 32,347,500  

Promissory note

     21,565,000  

Common shares

     2,837,500  
  

 

 

 
     56,750,000  
  

 

 

 

Cash and cash equivalents

     601,010  

Accounts receivable

     336,762  

Inventory

     1,322,018  

Biological assets

     379,170  

Prepaid

     124,418  

Due to related parties

     212,467  

Equipment

     573,944  

Other assets

     2,100  

Intangible assets

     54,137,620  

Accounts payable

     (939,424

Notes Payable

     (85
  

 

 

 
   $ 56,750,000  
  

 

 

 

The reverse acquisition by GGB of Xanthic is accounted for as a continuation of the financial statements of GGB whose shareholders will hold approximately 86% of the voting shares of the Company immediately after the

 

6


GREEN GROWTH BRANDS LTD.

Notes to the Pro Forma Consolidated Financial Statements

 

Transaction, is treated as the acquirer for accounting purposes following the principles of IFRS 3. GGB has determined that Xanthic meets the definition of a business under IFRS 3, based on its patent registrations, supply agreements and letters of intent with licensed producers in numerous U.S. States. As a result, GGB will apply the acquisition method in which it has identified GGB as the acquirer and as such recognizing and measuring identifiable assets acquired, the liabilities assumed and recognizing and measuring intangible assets such as customer lists, licensing rights, patents, trademarks and goodwill. As the acquirer, the net assets of GGB are included in the consolidated statement of financial position at their carrying amounts. Any difference between the fair value of the post-consolidated shares of the resulting issuer over the net assets acquired is recognized as intangible assets.

These unaudited pro-forma consolidated financial statements have been compiled from and include:

An unaudited pro-forma consolidated statement of financial position giving effect to the Transaction as if it had occurred on June 30, 2018 combining

 

  (i)

the audited consolidated statement of financial position of Xanthic Biopharma Inc as at June 30, 2018; with

 

  (ii)

the audited U.S. GAAP statements of financial position of NOR as at June 30, 2018; with

 

  (iii)

the audited statement of financial position of GGB as at July 31, 2018.

The unaudited pro-forma consolidated financial statements have been compiled using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), as set out in the audited financial statements of Xanthic for the year ended June 30, 2018 unless otherwise indicated.

The unaudited pro-forma consolidated financial statements should be read in conjunction with the financial statements and notes thereto of Xanthic, NOR and GGB as described above. The unaudited pro-forma consolidated financial statements are not intended to reflect the results of operations or the financial position of the continuing entity, GGB, which would have actually resulted had the proposed transactions been effected on the dates indicated. Further, the unaudited pro-forma financial information is not necessarily indicative of the results of operations that may be obtained in the future. The pro-forma adjustments and allocations of the purchase price of Xanthic by GGB as a reverse takeover are based in part on estimates of the fair value of the assets acquired and liabilities assumed. The final purchase price allocation will be completed after asset and liability valuations are finalized. The final valuation will be based on the actual assets and liabilities of Xanthic that exist as of the date of completion of the acquisition on July 16, 2018.

 

2.

Pro Forma Adjustments and Assumptions

The unaudited pro forma consolidated financial statements incorporate the following pro forma assumptions:

 

  a)

The NOR audited financial statements are reflected in U.S. GAAP. IFRS requires biological assets which consist of cannabis plants to be valued in accordance with IAS 41 and be presented at their fair values less costs to sell up to the point of harvest. Fair values of the biological included making assumptions about how market participants assign fair values to these assets. These assumptions primarily relate to the level of effort required to bring the cannabis up to the point of harvest, costs to convert the harvested cannabis to finished goods, sales price, risk of loss, expected future yields from the cannabis plants and estimating values during the growth cycle. The average grow cycle of plants up to the point of harvest is approximately twelve weeks. NOR’s biological assets are adjusted to reflect their value and results in an adjustment to increase the value of the biological assets by US$379,170 and reduce inventory by US$535,427 and US$156,257 being recorded to cost of goods sold.

 

  b)

On September 5, 2018 GGB Nevada completed the acquisition of NOR. The NOR Acquisition was completed in accordance with the terms of the membership interest purchase agreement (the “NOR Agreement”) dated July 13, 2018 among GGB Nevada, NOR and its members (the “NOR Members”) for aggregate consideration of US$56.75 million. The Purchase Price was satisfied by GGB Nevada by

 

7


GREEN GROWTH BRANDS LTD.

Notes to the Pro Forma Consolidated Financial Statements

 

 

payment of a US$2 million deposit on July 16, 2018, a closing cash payment of US$30,347,500 and delivery of a secured promissory note in the principal amount of US$21,565,000. The balance of US$2,837,500 owing to the NOR Members will be satisfied by the issuance of common shares of the resulting issuer following completion of the Business Combination. GGB Nevada borrowed the funds to settle the deposit and closing cash payment by way of a loan with GGB for a combined $32,347,500. In addition, subsequent to June 30, 2018. NOR transferred in US$183,941 which was included in the purchase price of US$56.75 million. As a result, the unallocated intangible asset on the purchase price allocation was determined to be US$54,137,620. The Company has 12 months to identify and assign fair values to different components of the intangible assets which would include customer lists, licensing rights, patents, any trademarks and goodwill.

 

  c)

The functional currency of the new combined entity will be US dollars, as majority of operations will be derived from US sources. As such the Xanthic statement of financial position which is currently reported in Canadian dollars requires conversion into US dollars with the foreign exchange difference resulting in an accumulated other comprehensive loss of US$45,125.

 

  d)

Subsequent to June 30, 2018, 900,000 stock options of Xanthic that had vested were exercised by the option holders. This resulted in net cash proceeds of US$104,040 (C$137,000).

Reverse Takeover Adjustments:

 

  e)

On August 30, 2018, GGB raised gross proceeds of US$49,304,059 (CAD$63,998,000) via a brokered and non-brokered private placement offering of unsecured 12% convertible debentures (the “Debentures”) at a price of CAD $1,000 per Debenture. The brokered portion of the Debenture Financing was led by Canaccord Genuity as the sole agent for the offering. Issue costs in connection with this financing were US$583,578 (CAD $757,500).

 

  f)

On September 20, 2018, GGB completed a second closing on the brokered and non-brokered private placement offering for an additional gross proceeds US$17,147,762 (CAD$22,129,000). Issue costs in connection with this financing were US$2,568,999 (CAD$3,309,910).

 

  g)

On completion of the Business Combination proceeds loaned to Xanthic of US$32,347,500 are eliminate on consolidation.

 

  h)

On completion of the Business Combination, the promissory note in connection with the NOR agreement will be settled and repaid to the NOR Members for US$21,565,000.

 

  i)

On completion of the Business Combination, the convertible debenture financings referenced above will convert into common shares of the Resulting Issuer. GGB Greenspace Debentures will convert into GGB Proportionate Shares and GGB Proportionate Warrants. Further, as outlined in the listing statement, the Company will complete a 4:1 share consolidation on closing of the Business Combination.

 

  j)

The acquisition of GGB by Xanthic constitutes a reverse takeover transaction (“RTO”) and Xanthic is considered to meets the definition of a business, as defined in IFRS 3—Business Combinations due to its productive operating potential. Accordingly, as a result of the RTO, the pro forma consolidated statement of financial position has been adjusted for the elimination of Xanthic’s share capital of US$6,268,378, reserves for share based payments of US$302,766, reserves for warrants of US$146,304, accumulated deficit of US$2,301,528 and accumulated other comprehensive loss of US$59,514, within shareholders’ (deficiency) equity.

 

  k)

The Company has attributed a purchase price of US$23,132,802 for Xanthic, of which US$21,717,966 represents unallocated intangible assets once the net tangible assts of Xanthic of US$1,414,836 are deducted. The Company will identify and assign fair values to different components of the intangible assets which could include customer lists, licensing rights, patents, any trademarks and goodwill.

 

8


GREEN GROWTH BRANDS LTD.

Notes to the Pro Forma Consolidated Financial Statements

 

    l)

GGB has assumed US$1,139,125 (CAD$1,500,000) in transaction costs in connection with the Business Combination.

 

  m)

In October 2018, GGB raised additional gross proceeds of approximately CAD$30.5 million (US$23.2 million) pursuant to a private placement of GGB Shares at a price of CAD$0.50 per GGB Share (CAD$2.00 on a post-Consolidation basis). GGB also issued GGB warrants exercisable for an aggregate principal amount of approximately CAD$24.5 million (US$18.6 million) GGB Shares upon payment of CAD$0.50 per GGB Share (CAD$2.00 on a post-Consolidation basis). The GGB warrants expire one day before the close the Business Combination with proceeds due no more than 30 days following the exercise date.

 

9


GREEN GROWTH BRANDS LTD.

Notes to the Pro Forma Consolidated Financial Statements

 

3.

Pro Forma Shareholders’ equity

 

(Expressed in United States dollars)

                                           
    Note     Common
Shares
    Proportionate
Shares
    Share
Capital
    Reserves     Earnings
(Deficit)
    Accumulated
Other

Comprehensive
loss
    Total  
    Share based
Payments
    Warrants     Proportionate
Warrants
 
    #     $     #     $     #     $  

Xanthic’s Balance at incorporation June 30, 2018

      56,846,547       —       $ 4,236,395       3,508,000     $ 385,542       568,000     $ 186,304       —       $ —       $ (2,930,766   $ (14,419   $ 1,863,056  

Options Exercised subsequent to June 30, 2018

    2 d)       900,000       —         104,040       (900,000     —         —         —         —         —         —         —         104,040  

Foreign Exchange translation

    2 c)       —         —         (909,557     —         (82,776     —         (40,000     —         —         629,238       (45,125     (448,220

US GAAP to IFRS

    2 a)       —         —         —         —         —         —         —         —         —         (156,257     —         (156,257

NOR Consolidation

    2 b)       —         —         2,584,696       —         —         —         —         —         —         —         —         2,584,696  

NOR Acquisition

    2 b)       —         —         252,804       —         —         —         —         —         —         156,257       —         409,061  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance after NOR Acquisition

      57,746,547       —         6,268,378       2,608,000       302,766       568,000       146,304       —         —         (2,301,528     (59,544     4,356,376  

GGB Consolidation

    2 j)       346,150,835       —         7,503,459                   (3,945,120     —         3,558,339  

GGB 1st Tranche

    2 e)       101,383,333       152,778       38,486,559       —         —         50,691,666       11,401,078       76,389       —         (583,578     —         49,304,059  

GGB 2nd Tranche

    2 f)       81,527,777       —         15,210,788       —         —         40,763,889       4,505,973       —         —         (2,568,999     —         17,147,762  

NOR Acquisition

    2 h)       7,482,487       —         —         —         —         —         —         —         —         —         —         —    

Business Combination

    2 h) k)       —         —         15,449,588       —         (302,766     —         (146,304     —         —         6,657,904       59,544       21,717,966  

Private Placement

    2 m)       61,084,162       —         22,368,535       —         —         48,915,838       825,633       —         —         —         —         23,194,168  

Share Consolidation (4:1)

      (491,531,356     (114,584     —         (1,956,000     —         (105,704,545     —         (57,292     —         —         —         —    

Transaction Costs

    2 l)       —         —         —         —         —         —         —         —         —         (1,139,125     —         (1,139,125
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance post RTO

      163,843,785       38,194     $ 105,287,307       652,000     $ —         35,234,848     $ 16,732,684       19,097     $ —       $ (3,880,446   $ —       $ 118,139,545  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

10


GREEN GROWTH BRANDS LTD.

Notes to the Pro Forma Consolidated Financial Statements

 

4.

Income Taxes

The effective tax rate on a pro forma basis is nil given the history of losses.

 

11


SCHEDULE “F” – BUSINESS COMBINATION AGREEMENT

Please see attached.

 

- 101 -


Execution Version

XANTHIC BIOPHARMA INC.

as Xanthic

and

GREEN GROWTH BRANDS LTD.

as GGB

 

 

TRANSACTION AGREEMENT

July 13, 2018

 

 


Execution Version

 

TABLE OF CONTENTS

 

  ARTICLE 1   
  INTERPRETATION   
Section 1.1  

Defined Terms

     3  
Section 1.2  

Gender and Number

     8  
Section 1.3  

Headings, etc.

     8  
Section 1.4  

Currency

     8  
Section 1.5  

Certain Phrases, etc.

     8  
Section 1.6  

Knowledge

     9  
Section 1.7  

Accounting Terms

     9  
Section 1.8  

Schedules

     9  
Section 1.9  

References to Persons and Agreements

     9  
Section 1.10  

Statutes

     9  
Section 1.11  

Non-Business Days

     9  
  ARTICLE 2   
  AMALGAMATION   
Section 2.1  

Amalgamation

     9  
  ARTICLE 3   
  REPRESENTATIONS AND WARRANTIES OF GGB   
Section 3.1  

Representations and Warranties of GGB

     12  
  ARTICLE 4   
  REPRESENTATIONS AND WARRANTIES OF XANTHIC   
Section 4.1  

Representations and Warranties of Xanthic

     15  
  ARTICLE 5   
  COVENANTS OF THE PARTIES   
Section 5.1  

Conduct of Businesses of Xanthic and GGB

     20  
Section 5.2  

NOR Acquisition

     23  
Section 5.3  

Actions to Satisfy Conditions

     24  
Section 5.4  

No Shop

     24  
  ARTICLE 6   
  CONDITIONS   
Section 6.1  

Mutual Conditions Precedent

     24  
Section 6.2  

Conditions for the Benefit of Xanthic

     25  
Section 6.3  

Conditions for the Benefit of GGB

     26  

 


Execution Version

 

  ARTICLE 7   
  POST-CLOSING   
Section 7.1  

Share Consolidation

     27  
  ARTICLE 8   
  TERMINATION   
Section 8.1  

Term

     27  
Section 8.2  

Termination Rights

     27  
Section 8.3  

Effect of Termination

     28  
  ARTICLE 9   
  MISCELLANEOUS   
Section 9.1  

Notices

     29  
Section 9.2  

Time of the Essence

     29  
Section 9.3  

Announcements

     30  
Section 9.4  

Expenses

     30  
Section 9.5  

Amendments

     30  
Section 9.6  

Waiver

     30  
Section 9.7  

Entire Agreement

     30  
Section 9.8  

Successors and Assigns

     31  
Section 9.9  

Severability

     31  
Section 9.10  

Governing Law

     31  
Section 9.11  

Counterparts

     31  

SCHEDULE “A”

FORM OF AMALGAMATION AGREEMENT

 


Execution Version

 

TRANSACTION AGREEMENT

Transaction Agreement dated July 13, 2018 between Xanthic Biopharma Inc. (“Xanthic”) and Green Growth Brands Ltd. (“GGB”).

WHEREAS Xanthic intends to acquire all of the issued and outstanding common shares in the capital of GGB, which purchase will be effected pursuant to the Amalgamation as hereinafter set forth and on the terms and subject to the conditions set forth in the Amalgamation Agreement;

NOW THEREFORE in consideration of the foregoing, and the respective covenants, agreements, representations and warranties of the Parties contained herein, and for other good and valuable consideration (the receipt and adequacy of which are acknowledged), the Parties agree as follows:

ARTICLE 1

INTERPRETATION

Section 1.1 Defined Terms.

As used in this Agreement, the following terms have the following meanings:

Acquisition” means the acquisition by Xanthic Sub of all of the issued and outstanding membership interests of NOR, pursuant to the NOR SPA.

affiliate” has the meaning specified in National Instrument 45-106Prospectus Exemptions.

Agreement” means this transaction agreement, as such agreement may be amended, varied, modified or restated from time to time, together with all Schedules appended to the Agreement.

Amalco” means the company resulting from the Amalgamation, to be named “Xanthic Biopharma Corp.”.

Amalco Shares” means the common shares of Amalco.

Amalgamating Parties” means, collectively, Subco and GGB.

Amalgamation” means the amalgamation of Subco and GGB to the OBCA on the terms set forth in this Agreement and the Amalgamation Agreement.

Amalgamation Agreement” means the agreement to be entered into among Xanthic, GGB and Subco in respect of the Amalgamation, in substantially the form attached hereto as Schedule “A”.

Amalgamation Resolution” means the special resolution approving the Amalgamation signed by written resolution by all of the shareholders of GGB.

Ancillary Agreements” means all agreements, certificates and other instruments delivered or given pursuant to this Agreement, including without limitation, the Amalgamation Agreement.

 


Execution Version

 

Articles of Amalgamation” means the articles of amalgamation to be filed with the Ontario Ministry of Consumer and Business Services in order to effect the Amalgamation, substantially in the form agreed to between the Amalgamating Parties.

Assets” means all of the right, title, estate and interest in and to its property and assets, real and personal, moveable and immovable, of whatsoever nature and kind and wheresoever situated of GGB or Xanthic, as the case may be.

associate” has the meaning specified in the Securities Act (Ontario).

Authorization” means, with respect to any Person, any order, permit, approval, consent, waiver, licence or similar authorization of any Governmental Entity having jurisdiction over the Person.

Business Day” means any day of the year, other than a Saturday, Sunday or any day on which major banks are closed for business in Toronto, Ontario.

Certificate of Amalgamation” means the certificate of amalgamation to be issued by the Director, as date stamped on the Articles of Amalgamation, evidencing that the Articles of Amalgamation are effective.

Circular” means the notice of the Xanthic Meeting and accompanying management information circular or applicable listing statement, as the case may be, including all schedules and appendices attached thereto, to be sent to the Xanthic Shareholders in connection with the Xanthic Meeting.

Closing” means the completion of the Amalgamation on the terms and subject to the conditions set forth herein and in the Amalgamation Agreement.

Constating Documents” means, in respect of Xanthic or GGB, as the case may be, the articles of incorporation, amalgamation, or continuation arrangement, as applicable, by-laws and all amendments to such articles or by-laws.

Convertible Debenture Offering” means the non-brokered private placement offering of up to US$32 million extendible convertible debentures of GGB (the “Convertible Debentures”), whereby holders shall be entitled to receive, at their option, (A) cash equal to the principal amount thereof, plus accrued but unpaid interest thereon, on the maturity date, or (B) if certain conditions are satisfied prior to the maturity date, (i) cash equal to the principal amount thereof, plus accrued but unpaid interest thereon, on such earlier date, (ii) common shares of the Resulting Issuer, or (iii) some combination of (i) and (ii).

CSE” means the Canadian Securities Exchange.

Deposit Promissory Note” means the promissory note from Xanthic in favour of GGB in the principal amount of US$2 million to be used by Xanthic to satisfy the deposit under the NOR SPA.

Director” means the director appointed under Section 278 of the OBCA.

Effective Date” means the date within five Business Days of the date upon which all of the conditions to completion of the Amalgamation as set forth in this Agreement have been satisfied or waived and all documents agreed to be delivered hereunder have been delivered


Execution Version

 

to the satisfaction of the Parties, acting reasonably, which will be the date shown on the Certificate of Amalgamation issued by the Director giving effect to the Amalgamation, or such earlier or later date as the Parties may mutually agree in writing.

GAAP” means generally accepted accounting principles as set out in the Canadian Institute of Chartered Accountants Handbook – Accounting for an entity that prepares its financial statements in accordance with International Financial Reporting Standards, at the relevant time, applied on a consistent basis.

Governmental Entity” means (i) any international, multinational, national, federal, provincial, state, regional, municipal, local or other government, governmental or public department, central bank, court, tribunal, arbitral body, commission, board, bureau, ministry, agency or instrumentality, domestic or foreign, (ii) any subdivision or authority of any of the above, (iii) any quasi-governmental or private body exercising any regulatory, expropriation or taxing authority under or for the account of any of the foregoing or (iv) any stock exchange.

GGB” means Green Growth Brands Ltd., a corporation existing under the OBCA.

GGB Convertible Securities” means, collectively, all outstanding rights to acquire GGB Shares pursuant to GGB’s outstanding stock options, warrants, broker warrants, convertible debentures, rights of conversion or exchange privileges or other securities entitling the holder thereof to acquire any GGB Shares, including the Subscription Receipts and Convertible Debentures or any other rights, agreements or commitment of any character requiring the issuance, sale or transfer by GGB of any GGB Shares.

GGB Disclosure Letter” means the disclosure letter dated the date of this Agreement and delivered by GGB to Xanthic with this Agreement.

GGB Financial Statements” means the audited consolidated annual financial statements of GGB for the year ended June 30, 2018.

GGB Shareholders” means the holders of GGB Shares from time to time.

GGB Shares” means common shares in the capital of GGB as constituted on the date hereof.

Intellectual Property” means any licenses for or other rights to use, any inventions, patent applications, patents, trade-marks (both registered and unregistered), trade names, copyrights, trade secrets and other proprietary information.

Laws” means all laws, statutes, codes, ordinances, decrees, rules, regulations, by laws, statutory rules, principles of law, published policies, forms and guidelines, fee schedules, tariffs, judicial or arbitral or administrative or ministerial or departmental or regulatory judgments, orders, directives, decisions, rulings or awards, including general principles of common and civil law, and terms and conditions of any grant of approval, permission, authority or license of any Governmental Entity, statutory body or self-regulatory authority (including, but not limited to, the CSE), and the term “applicable” with respect to such Laws and in the context that refers to one or more Persons, means that such Laws apply to such Person or Persons or its or their business, undertaking, property or securities and emanate from a Governmental Entity (or any other Person) having jurisdiction over the aforesaid Person or Persons or its or their business, undertaking, property or securities.


Execution Version

 

Lien” means any mortgage, charge, pledge, hypothec, security interest, assignment, lien (statutory or otherwise), easement, title retention agreement or arrangement, conditional sale, deemed or statutory trust, restrictive covenant, adverse claim, exception, reservation, right of occupation, any matter capable of registration against title, right of pre-emption, privilege or other encumbrance of any nature or any other arrangement or condition which, in substance, secures payment or performance of an obligation.

Loan Agreement” means the proposed loan agreement between Xanthic and GGB pursuant to which GGB shall loan such amount as will be required by Xanthic to complete its financial obligation with respect to the Acquisition, with such amount expected to be approximately US$32 million (less the Deposit Promissory Note).

Material Adverse Effect” means any event or change that, individually or in the aggregate with other events or changes, is or would reasonably be expected to be, materially adverse to the business, operations, assets, condition (financial or otherwise) or liabilities, whether contractual or otherwise, of any Party, as the case may be; provided that a Material Adverse Effect shall not include an adverse effect resulting from a change (i) that arises out of a matter that has been publicly disclosed prior to the date of this Agreement or otherwise disclosed in writing by a Party to the other Party prior to the date of this Agreement; (ii) that results from conditions affecting the business of NOR, including changes in government policies or programs or taxes; (iii) that results from general economic, financial, currency exchange, interest rate or securities market conditions in Canada or the United States; (iv) that arises from a decline in the trading price of Xanthic Shares, or (v) that is a direct result of any matter permitted by this Agreement or consented to in writing by the applicable Party.

Material Contracts” has the meaning specified in Section 4.1(o).

Misrepresentation” means an untrue statement of a material fact or an omission to state a material fact required or necessary to make the statements contained therein not misleading in light of the circumstances in which they are made.

NOR” means Nevada Organic Remedies LLC.

NOR SPA” means the securities purchase agreement dated July 13, 2018 between NOR, as the company, the sellers set forth therein, as sellers, Andrew M. Jolley, as the representative of each seller, Xanthic, as parent, and Xanthic Sub, as purchaser.

Notice” has the meaning specified in Article 9.

OBCA” means the Business Corporations Act (Ontario).

Offerings” means, collectively, the Subscription Receipt Offering and the Convertible Debenture Offering.

Ordinary Course” means, with respect to an action taken by a Person, that such action is consistent with the past practices of the Person and is taken in the ordinary course of the normal day-to-day operations of the Person.

Outside Date” means December 1, 2018 or such later date as may be agreed to in writing by the Parties.


Execution Version

 

Parties” means, collectively, Xanthic and GGB, and any other Person who may become a party to this Agreement; and “Party” means any one of them.

Permitted Liens” means (i) Liens for Taxes not yet due and delinquent; and (ii) easements, encroachments and other minor imperfections of title which do not, individually or in the aggregate, materially detract from the value of or impair the use or marketability of any real property or interests in real property in any material respect.

Person” means a natural person, partnership, limited partnership, limited liability partnership, corporation, limited liability corporation, unlimited liability company, joint stock company, trust, unincorporated association, joint venture or other entity or Governmental Entity, and pronouns having a similarly extended meaning.

Public Statement” has the meaning ascribed thereto in Section 9.3 hereof.

Regulatory Approval” means any consent, waiver, permit, exemption, review, order, decision or approval of, or any registration and filing with, any Governmental Entity, or the expiry, waiver or termination of any waiting period imposed by Law or a Governmental Entity, in each case in connection with the Amalgamation, including any such approval from the CSE.

Securities Reports” has the meaning ascribed thereto in Section 4.1(w) hereof.

SEDAR” means the System for Electronic Document Analysis and Retrieval.

Subco” means a corporation to be incorporated under the OBCA and which shall be a wholly-owned Subsidiary of Xanthic.

Subscription Receipt Offering” means the brokered private placement offering of up to $60 million (less the amount of the Convertible Debenture Offering after deducting the amount required by GGB to satisfy its obligations to debenture holders that have elected the cash repayment option) subscription receipts of GGB (the “Subscription Receipts”), whereby each subscription receipt shall be exchangeable into common shares of the Resulting Issuer upon satisfaction of certain escrow release conditions.

Subsidiary” has the meaning specified in National Instrument 45-106—Prospectus Exemptions as in effect on the date of this Agreement.

Taxes” has the meaning specified in Section 4.1(l).

Xanthic” means Xanthic Biopharma Inc., a corporation existing under the OBCA.

Xanthic Board” means the board of directors of Xanthic.

Xanthic Convertible Securities” means, collectively, all outstanding rights to acquire Xanthic Shares pursuant to the Xanthic Options, Xanthic Warrants, and other warrants, broker warrants, convertible debentures, rights of conversion or exchange privileges or other securities entitling the holder thereof to acquire any Xanthic Shares, or any other rights, agreements or commitment of any character requiring the issuance, sale or transfer by Xanthic of any Xanthic Shares.


Execution Version

 

Xanthic Disclosure Letter” means the disclosure letter dated the date of this Agreement and delivered by Xanthic to GGB with this Agreement.

Xanthic Financial Statements” means the unaudited consolidated interim financial statements of Xanthic as at and for the three and nine months ended March 31, 2018.

Xanthic Meeting” means the special meeting of Xanthic Shareholders, including any adjournment or postponement of such special meeting in accordance with the terms of this Agreement to consider the matters set out in the notice to be provided to Xanthic Shareholders in connection with such meeting.

Xanthic Options” means the existing 3,308,000 incentive stock options of Xanthic exercisable to acquire an aggregate of 3,308,000 Xanthic Shares.

Xanthic Shareholders” means the holders of Xanthic Shares from time to time.

Xanthic Shares” means common shares in the capital of Xanthic as constituted on the date hereof.

Xanthic Sub” means GGB Nevada Acquisition LLC, a corporation incorporated under the laws of Nevada and a wholly-owned Subsidiary of Xanthic.

Xanthic Warrants” means the existing 568,000 common share purchase warrants of Xanthic exercisable to acquire an aggregate of 568,000 Xanthic Shares.

Section 1.2 Gender and Number.

Any reference in this Agreement or any Ancillary Agreement to gender includes all genders. Words importing the singular number only shall include the plural and vice versa.

Section 1.3 Headings, etc.

The provision of a Table of Contents, the division of this Agreement into Articles, Sections and Schedules and the insertion of headings are for convenient reference only and are not to affect its interpretation.

Section 1.4 Currency.

All references in this Agreement or any Ancillary Agreement to dollars, or to $ are expressed in Canadian currency unless otherwise specifically indicated.

Section 1.5 Certain Phrases, etc.

In this Agreement and any Ancillary Agreement (i) the words “including”, “includes” and “include” mean “including (or includes or include) without limitation”, and (ii) the phrase “the aggregate of”, “the total of”, “the sum of”, or a phrase of similar meaning means “the aggregate (or total or sum), without duplication, of”. In the computation of periods of time from a specified date to a later specified date, unless otherwise expressly stated, the word “from” means “from and including” and the words “to” and “until” each mean “to but excluding”.


Execution Version

 

Section 1.6 Knowledge.

Any reference herein to the knowledge of any Party will be deemed to mean the actual knowledge of the directors and executive officers of such Party after reasonable inquiry.

Section 1.7 Accounting Terms.

All accounting terms not specifically defined in this Agreement are to be interpreted in accordance with GAAP.

Section 1.8 Schedules.

The schedules attached to this Agreement form an integral part of this Agreement for all purposes of it.

Section 1.9 References to Persons and Agreements.

Any reference in this Agreement or any Ancillary Agreement to a Person includes such Person’s heirs, administrators, executors, legal personal representatives, successors and permitted assigns. Except as otherwise provided in this Agreement or any Ancillary Agreement, the term “Agreement” and any reference in this Agreement to this Agreement, any Ancillary Agreement or any other agreement or document includes, and is a reference to, this Agreement, such Ancillary Agreement or such other agreement or document as it may have been, or may from time to time be amended, restated, replaced, supplemented or novated and includes all schedules to it.

Section 1.10 Statutes.

Except as otherwise provided in this Agreement, any reference in this Agreement to a statute refers to such statute and all rules and regulations made under it, as it or they may have been or may from time to time be amended or re-enacted.

Section 1.11 Non-Business Days.

Whenever payments are to be made or an action is to be taken on or not later than a day which is not a Business Day, such payment shall be made or such action shall be taken on or not later than the next succeeding Business Day.

ARTICLE 2

AMALGAMATION

Section 2.1 Amalgamation.

 

(1)

Each of the Parties covenants to take all such actions as are within its power to control and use commercially reasonable efforts to cause other actions to be taken which are not within its power to control, so as to complete the Amalgamation as set forth in this Section 2.1 and otherwise on the terms, and subject to the conditions, set forth in this Agreement and subject to the approval of the CSE (if applicable).

 

(2)

Each Party hereby agrees, unless such steps have already been completed, that as soon as reasonably commercially practicable after the date hereof or at such other time as is specifically indicated below in this Section 2.1, and on the applicable terms, and subject to the


Execution Version

 

 

applicable conditions, set forth in this Agreement and the Amalgamation Agreement, it shall take the following steps:

 

  (a)

Preparation and Mailing of Circular. Xanthic shall use all commercially reasonable efforts to prepare and complete, in consultation with GGB, the Circular together with any other documents required by Law in connection with the Xanthic Meeting and the Amalgamation. Xanthic shall use their commercially reasonable efforts to cause the Circular and such other documents to be filed under the profile of Xanthic on SEDAR and sent to each Xanthic Shareholder and such other Persons as required by applicable Law as soon as practicable, and, in any event, no later than September 30, 2018 (or such later date as agreed to by the Parties in writing).

 

  (b)

Contents of Circular. The Parties shall ensure that the Circular complies in material respects with applicable Laws, does not contain any Misrepresentation (as it relates to the disclosure of such Party) and provides the Xanthic Shareholders with sufficient information to permit them to form a reasoned judgement concerning the matters to be placed before the Xanthic Meeting. The Parties shall give each other and their respective legal counsel a reasonable opportunity to review and comment on drafts of the Circular and other related documents, and shall give reasonable consideration to any comments made by the other Party and its counsel. GGB and Xanthic shall each provide all necessary information concerning them that is required by Law to be included by each of them in the Circular, and shall use their best efforts to ensure that information in the Circular (as it relates to the disclosure of such Party) does not contain any Misrepresentation. Each Party shall promptly notify the other Party if it becomes aware that the Circular contains any Misrepresentation (as it relates to the disclosure of such Party) or otherwise requires an amendment or supplement. The Circular shall provide for Xanthic: (i) amending its articles of incorporation or take such other actions as may be required under the OBCA to change its name to “Green Growth Brands Ltd.” (the “Resulting Issuer”) and (ii) effecting such other items of special business as may be mutually agreed upon by the Parties. The Parties shall cooperate in the preparation of any such amendment or supplement as required or appropriate, and the Parties shall, as required by applicable Laws, promptly file on SEDAR and mail or otherwise publicly disseminate any such amendment or supplement to the Xanthic Shareholders and, if required by Law, file the same with any other Governmental Entity as required.

 

  (c)

Xanthic Meeting. Xanthic will convene and conduct the Xanthic Meeting, on or before October 31, 2018 (or such later date as agreed to by the Parties in writing) and not adjourn, postpone or cancel (or propose the adjournment, postponement or cancellation of) the Xanthic Meeting without the prior written consent of GGB, except in the case of an adjournment, as required for quorum purposes.

 

  (d)

Filing of Articles of Amalgamation. Subject to obtaining the required approvals of the GGB Shareholders and the Xanthic Shareholders, and subject to the satisfaction or waiver of the applicable conditions of Closing as set forth in this Agreement, the Amalgamating Parties will submit the Articles of Amalgamation and such other documents as may be required under the OBCA in connection therewith to give effect to the Amalgamation.

 

  (e)

Amalgamation Agreement. The Parties hereby acknowledge that the form of Amalgamation Agreement attached as Schedule “A” complies with the requirements of the OBCA.


Execution Version

 

  (f)

Articles of Amalgamation. The Articles of Amalgamation shall, with such other matters as are necessary to effect the Amalgamation, and all as subject to the provisions of the Amalgamation Agreement, provide as follows:

 

  (i)

the Amalgamating Parties will amalgamate and continue as Amalco;

 

  (ii)

holders of GGB Shares shall receive 3.394 fully paid and non-assessable Xanthic Shares for each GGB Share held by such holder (the “Exchange Ratio”), amounting to 346,150,835 Xanthic Shares issued to such holders in the aggregate, and the GGB Shares shall thereafter be cancelled. Notwithstanding the foregoing, the Exchange Ratio shall be adjusted downward in the event GGB issues additional GGB Shares prior to the Amalgamation so that the applicable Exchange Ratio results, upon completion of the Amalgamation, in the aggregate issuance of 346,150,835 Xanthic Shares issued to GGB Shareholders (prior to giving effect to any issuance pursuant to the Offerings);

 

  (iii)

the shares of Subco will be cancelled and replaced by Amalco Shares on the basis of one Amalco Share for each share of Subco;

 

  (iv)

as consideration for the issuance of the Xanthic Shares to holders of GGB Shares to effect the Amalgamation, Amalco will issue to its immediate shareholder, Xanthic, one Amalco Share for each Xanthic Share so issued;

 

  (v)

Amalco will be a direct wholly-owned Subsidiary of Xanthic upon completion of the Amalgamation; and

 

  (vi)

all of the property, rights, privileges and assets of the Amalgamating Parties will continue as the property, rights, privileges and assets of Amalco, and Amalco will become liable for all of the liabilities and obligations of the Amalgamating Parties.

 

  (g)

U.S. Securities Law Matters.

 

  (i)

The Parties acknowledge that the GGB Shareholders will be issued Amalco Shares pursuant to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and the provisions of Rule 506 of Regulation D thereunder.

 

  (h)

Board of Directors and Management of Xanthic, Xanthic Sub and Resulting Issuer.

 

  (i)

Subject to CSE approval, immediately following the execution of this Agreement, the board of each of Xanthic and Xanthic Sub will consist of the following seven (7) individuals: Jean Schottenstein, Peter Horvath, Steve Stoute, Carli Posner, Tim Moore, Gary Galitsky and Marc Lehmann. Following completion of the transactions contemplated under this Agreement, the board of the Resulting Issuer and Xanthic Sub will consist of the same seven (7) individuals.

 

  (ii)

Immediately following the execution of this Agreement, the senior management of Xanthic shall be reconstituted as follows, subject to the policies of the CSE and Canadian securities Laws:


Execution Version

 

  (A)

Tim Moore – Chief Executive Officer;

 

  (B)

David Bhumgara – Chief Financial Officer; and

 

  (C)

Gary Galitsky – President.

 

  (iii)

Immediately following the execution of this Agreement, the senior management of Xanthic Sub shall be reconstituted as follows, subject to the policies of the CSE and Canadian securities Laws:

 

  (A)

Peter Horvath – Chief Executive Officer;

 

  (B)

Ian Fodie – Chief Financial Officer; and

 

  (C)

Andrew Jolley – President.

 

  (iv)

The senior management of the Resulting Issuer shall be reconstituted as follows, subject to the policies of the CSE and Canadian securities Laws, all on terms to be agreed to between GGB and the individuals below:

 

  (A)

Tim Moore – Chief Executive Officer;

 

  (B)

David Bhumgara – Chief Financial Officer; and

 

  (C)

Gary Galitsky – President.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES OF GGB

Section 3.1 Representations and Warranties of GGB.

GGB represents and warrants, as of the date of this Agreement, as follows to Xanthic and acknowledges and confirms that Xanthic is relying on such representations and warranties in connection with the transactions contemplated by this Agreement:

 

  (a)

GGB is a corporation duly incorporated and validly subsisting under the laws of the Province of Ontario and has the requisite corporate power and authority to carry on its business as it is now being conducted and to enter into this Agreement. GGB is duly registered to do business and is in good standing in each jurisdiction in which the character of its properties, owned or leased, or the nature of its activities make such registration necessary, except where the failure to be so registered or in good standing would not have a Material Adverse Effect on GGB.

 

  (b)

The execution and delivery of and performance by GGB of this Agreement and each of the Ancillary Agreements to which it is a party, and the consummation of the transactions contemplated by them have been duly authorized by all necessary corporate action on the part of GGB.

 

  (c)

The execution and delivery of and performance by GGB of this Agreement and each of the Ancillary Agreements to which it is a party:


Execution Version

 

  (i)

do not and will not (or would not with the giving of notice, the lapse of time or the happening of any other event or condition) constitute or result in a violation or breach of, or conflict with, or allow any other Person to exercise any rights under, any of the terms or provisions of its Constating Documents;

 

  (ii)

do not and will not (or would not with the giving of notice, the lapse of time or the happening or any other event or condition) constitute or result in a breach or violation of, or conflict with or allow any other Person to exercise any rights under, any of the terms or provisions of any material contracts to which it is a party; and

 

  (iii)

do not and will not result in the violation of any Law.

 

  (d)

This Agreement and each of the Ancillary Agreements to which GGB is a party have been duly executed and delivered by GGB and constitute legal, valid and binding agreements of GGB enforceable against it in accordance with their respective terms subject only to any limitation under applicable Laws relating to (i) bankruptcy, winding-up, insolvency, arrangement, fraudulent preference and conveyance, assignment and preference and other similar laws of general application affecting creditors’ rights, and (ii) the discretion that a court may exercise in the granting of equitable remedies such as specific performance and injunction.

 

  (e)

GGB has an authorized capital of an unlimited number of GGB Shares of which, as at the date hereof (and without giving effect to the Offerings), GGB has issued and outstanding (i) 100,765,002 GGB Shares. In addition, as of the date hereof (and without giving effect to the Offerings), GGB has no issued and outstanding GGB Convertible Securities, and will have, as of the Effective Date, GGB Convertible Securities entitling the holders thereof to acquire no more than 584,144,223 GGB Shares. Except as aforesaid, there are no outstanding shares of GGB or options, warrants, rights or conversion or exchange privileges or other securities entitling anyone to acquire any shares of GGB or any other rights, agreements or commitments of any character whatsoever requiring the issuance, sale or transfer by GGB of any shares of GGB (including GGB Shares) or any securities convertible into, exchangeable or exercisable for, or otherwise evidencing a right to acquire, any GGB Shares or other equity securities of GGB. All outstanding GGB Shares have been duly authorized and validly issued, and are fully paid and non-assessable and are not subject to, nor have they been issued in violation of any pre-emptive rights, and all GGB Shares issuable pursuant to agreements evidencing rights to acquire shares will, when issued in accordance with their respective terms, be duly authorized and validly issued, fully paid and non-assessable and not be subject to any pre-emptive rights.

 

  (f)

The ownership of the GGB Shares is as set forth in Section 3.1(f) of the GGB Disclosure Letter. The GGB Shareholders own such GGB Shares as the registered and beneficial owner with a good title, free and clear of all Liens other than those restrictions on transfer, if any, contained in the articles of GGB.

 

  (g)

The GGB Financial Statements have been prepared in accordance with GAAP applied on a basis consistent with prior periods and present fairly, in all material respects, the assets, liabilities (whether accrued, absolute, contingent or otherwise) and financial condition of GGB as at the respective dates of the GGB Financial


Execution Version

 

 

Statements and the sales, earnings and results of operations of GGB for the respective periods covered by the GGB Financial Statements.

 

  (h)

Since the date of the GGB Financial Statements, GGB has conducted its businesses only in the Ordinary Course. Since the date of the GGB Financial Statements, (i) there has been no Material Adverse Effect on GGB, or any condition, event or development involving a prospective change that would constitute a Material Adverse Effect on GGB, and (ii) no liability or obligation of any nature (whether absolute, accrued, contingent or otherwise) material to GGB has been incurred, other than in the Ordinary Course.

 

  (i)

There are no suits, actions or litigation or arbitration proceedings or governmental proceedings in progress pending or, to the best of the knowledge of GGB, contemplated or threatened, to which GGB is a party or to which the property of GGB is subject, except where such suit, action or litigation or arbitration proceeding or governmental proceeding would not result in a Material Adverse Effect to GGB taken as a whole. There is not presently outstanding against GGB any judgment, injunction, rule or order of any court, governmental department, commission, agency or arbitrator.

 

  (j)

GGB is not a party to any agreement which in any manner affects the voting control of any of the shares of GGB.

 

  (k)

Other than pursuant to the Loan Agreement and the Deposit Promissory Note, GGB is not subject to any obligation to make any investment in or to provide funds by way of loan, capital contribution or otherwise to any Persons.

 

  (l)

GGB is not a party to any written management contract or employment agreement which provides for a right of payment in the event of a change in control of GGB.

 

  (m)

GGB is not a “reporting issuer” within the meaning of the Securities Act (Ontario) and does not have a similar status in any other province or territory of Canada. No securities commission or similar regulatory authority has issued any order which is currently outstanding preventing or suspending trading in any securities of GGB, no such proceeding is, to the knowledge of GGB, pending, contemplated or threatened and GGB is not, to its knowledge, in default of any requirement of any securities laws, rules or policies applicable to GGB or its securities.

 

  (n)

Other than in connection with or in compliance with the provisions of applicable Laws, no filing or registration with, or authorization, consent or approval of any domestic or foreign public body or authority is necessary by GGB in connection with the consummation of the Amalgamation, except for such filings or registrations which, if not made, or for such authorizations, consents or approvals, which, if not received, would not have any Material Adverse Effect on the ability of GGB to consummate the transactions contemplated hereby.

 

  (o)

Except in connection with the Subscription Receipt Offering, GGB has not retained and will not retain any financial advisor, broker, agent or finder, or paid or agreed to pay any financial advisor, broker, agent or finder on account of this Agreement or the Amalgamation, any transaction contemplated hereby or any transaction presently ongoing or contemplated.


Execution Version

 

  (p)

Except with respect to the Regulatory Approvals and the requisite approvals in respect of the Amalgamation Resolution, there are no third party consents required to be obtained by GGB in order to complete the transactions contemplated hereby.

 

  (q)

Neither this Agreement nor any Ancillary Agreement to which GGB is a party (i) contains any untrue statement of a material fact in respect of GGB, the affairs, prospects, operations or condition of GGB or the Assets, or (ii) to the knowledge of GGB, omits any statement of a material fact necessary in order to make the statements in respect of GGB, the affairs, prospects, operations or condition of GGB or the Assets contained herein or therein not misleading.

 

  (r)

GGB owns (with good title) all of the properties and Assets that it purports to own including all the properties and Assets reflected as being owned by it in the GGB Financial Statements and does not own any other property or Assets. GGB has legal and beneficial ownership of its Assets free and clear of all Liens, except for Permitted Liens.

 

  (s)

The buildings, plants, structures, vehicles, equipment, technology and communications hardware and other tangible personal property of GGB are structurally sound, in good operating condition and repair having regard to their use and age and are adequate and suitable for the uses to which they are being put. None of such buildings, plants, structures, vehicles, equipment or other property are in need of maintenance or repairs except for routine maintenance and repairs in the Ordinary Course that are not material in nature or cost.

ARTICLE 4

REPRESENTATIONS AND WARRANTIES OF XANTHIC

Section 4.1 Representations and Warranties of Xanthic.

Xanthic represents and warrants as follows to GGB and acknowledges and confirms that GGB is relying on such representations and warranties in connection with the transactions contemplated by this Agreement:

 

  (a)

(i) Xanthic is a corporation incorporated and existing under the Province of Ontario, and (ii) has the corporate power and authority to enter into and perform its obligations under this Agreement and each of the Ancillary Agreements to which it is a party.

 

  (b)

The execution and delivery of and performance by Xanthic of this Agreement, and by Xanthic of each of the Ancillary Agreements to which it is a party, and the consummation of the transactions contemplated by them have been duly authorized by all necessary corporate action on the part of Xanthic.


Execution Version

 

  (c)

The execution and delivery of and performance by Xanthic of this Agreement, and by Xanthic of each of the Ancillary Agreements to which it is a party:

 

  (i)

do not and will not (or would not with the giving of notice, the lapse of time or the happening of any other event or condition) constitute or result in a violation or breach of, or conflict with, or allow any other Person to exercise any rights under, any of the terms or provisions of its Constating Documents;

 

  (ii)

do not and will not (or would not with the giving of notice, the lapse of time or the happening or any other event or condition) constitute or result in a breach or violation of, or conflict with or allow any other Person to exercise any rights under, any of the terms or provisions of any material contracts to which it is a party; and

 

  (iii)

do not and will not result in the violation of any Law.

 

  (d)

This Agreement and each of the Ancillary Agreements to which Xanthic is a party have been duly executed and delivered by Xanthic and constitute legal, valid and binding agreements of Xanthic enforceable against it in accordance with their respective terms subject only to any limitation under applicable Laws relating to (i) bankruptcy, winding-up, insolvency, arrangement, fraudulent preference and conveyance, assignment and preference and other similar laws of general application affecting creditors’ rights, and (ii) the discretion that a court may exercise in the granting of equitable remedies such as specific performance and injunction.

 

  (e)

Xanthic is authorized to issue an unlimited number of Xanthic Shares, of which 57,046,547 are outstanding as of the date hereof. Xanthic has issued and outstanding stock options and common share purchase warrants entitling the holders thereof to acquire, and is party to agreements evidencing rights to acquire, a further 568,000 Xanthic Shares and 3,308,000 Xanthic Shares, respectively. Except as aforesaid, there are no outstanding shares of Xanthic or options, warrants, rights or conversion or exchange privileges or other securities entitling anyone to acquire any shares of Xanthic or any other rights, agreements or commitments of any character whatsoever requiring the issuance, sale or transfer by Xanthic of any shares of Xanthic (including Xanthic Shares) or any securities convertible into, exchangeable or exercisable for, or otherwise evidencing a right to acquire, any Xanthic Shares or other equity securities of Xanthic. All outstanding Xanthic Shares have been duly authorized and validly issued, and are fully paid and non-assessable and are not subject to, nor have they been issued in violation of any pre-emptive rights, and all Xanthic Shares issuable upon exercise or conversion of outstanding Xanthic Convertible Securities or issuable pursuant to agreements evidencing rights to acquire shares will, when issued in accordance with their respective terms, be duly authorized and validly issued, fully paid and non-assessable and will not be subject to any pre-emptive rights.

 

  (f)

There are no suits, actions or litigation or arbitration proceedings or governmental proceedings in progress pending or, to the best of the knowledge of Xanthic, contemplated or threatened, to which Xanthic is a party or to which the property of Xanthic is subject. There is not presently outstanding against Xanthic any judgment, injunction, rule or order of any court, governmental department, commission, agency or arbitrator.


Execution Version

 

  (g)

Xanthic is a “reporting issuer” under the laws of British Columbia, Alberta, Ontario, Quebec and Nova Scotia and is not in default in any material respect of any requirements of applicable Canadian provincial securities Laws related thereto. Xanthic is not, as at the date hereof, included on the list of defaulting reporting issuers maintained by any of the applicable securities regulatory authorities.

 

  (h)

The Xanthic Financial Statements have been prepared in accordance with GAAP applied on a basis consistent with prior periods and present fairly, in all material respects, the assets, liabilities (whether accrued, absolute, contingent or otherwise) and financial condition of Xanthic as at the respective dates of the Xanthic Financial Statements and the sales, earnings and results of operations of Xanthic for the respective periods covered by the Xanthic Financial Statements.

 

  (i)

Since the date of the Xanthic Financial Statements, Xanthic has conducted its businesses only in the Ordinary Course. Since the date of the Xanthic Financial Statements, (i) there has been no Material Adverse Effect on Xanthic, or any condition, event or development involving a prospective change that would constitute a Material Adverse Effect on Xanthic, and (ii) no liability or obligation of any nature (whether absolute, accrued, contingent or otherwise) material to Xanthic has been incurred, other than in the Ordinary Course.

 

  (j)

The Assets include all rights and property necessary to enable Xanthic to conduct the business of Xanthic after the Closing (i) as reflected and disclosed in the Xanthic Financial Statements; and (ii) substantially in the same manner as it was conducted prior to the Closing. With the exception of inventory, motor vehicles and equipment in transit, all of the Assets are situate at the premises of Xanthic.

 

  (k)

Xanthic owns (with good title) all of the properties and Assets that it purports to own including all the properties and Assets reflected as being owned by it in the Xanthic Financial Statements and does not own any other property or Assets. Xanthic has legal and beneficial ownership of its Assets free and clear of all Liens, except for Permitted Liens.

 

  (l)

All taxes (including income tax, capital tax, payroll taxes, employer health tax, workers’ compensation payments, property taxes, custom and land transfer taxes), duties, royalties, levies, imposts, assessments, deductions, charges or withholdings and all liabilities with respect thereto including any penalty and interest payable with respect thereto (collectively, “Taxes”) due and payable by Xanthic have been paid except for where the failure to pay such taxes would not constitute an adverse material fact of Xanthic, or result in a Material Adverse Effect to Xanthic taken as a whole.

 

  (m)

Xanthic has conducted and is conducting its business in compliance in all material respects with all applicable Laws of each jurisdiction in which it carries on business and with all Laws, tariffs and directives material to its operation.

 

  (n)

Other than as provided for in Section 4.1(l) of the Xanthic Disclosure Letter, Xanthic is not subject to any obligation to make any investment in or to provide funds by way of loan, capital contribution or otherwise to any Persons.

 

  (o)

The material contracts of Xanthic previously disclosed in writing to GGB or its designee (the “Material Contracts”) are the only material documents and contracts


Execution Version

 

 

currently in effect. Each of the Material Contracts is in full force and effect and is unamended and there are no outstanding defaults or breaches under any of the Material Contracts on the part of

 

  (p)

Xanthic which would have a Material Adverse Effect. Xanthic is not a party to any agreement which in any manner affects the voting control of any of the shares of Xanthic.

 

  (q)

Other than as provided for in Section 4.1(n) of the Xanthic Disclosure Letter, there are no payments required to be made to directors, officers, consultants and employees of Xanthic as a result of this Agreement or the Amalgamation under all contract settlements, bonus plans, retention agreements, change of control agreements and severance obligations (whether resulting from termination, change of control or alteration of duties).

 

  (r)

No director, officer, consultant, insider or other non-arm’s length party to Xanthic (or any associate or affiliate thereof) has any right, title or interest in (or the right to acquire any right, title or interest in) any royalty interest, carried interest, participation interest or any other interest whatsoever which are based on revenue from or otherwise in respect of any Assets of Xanthic.

 

  (s)

Except for customary indemnity to its directors and officers, Xanthic is not a party to or bound by any agreement, guarantee, indemnification, or endorsement or like commitment respecting the obligations, liabilities (contingent or otherwise) or indebtedness of any Person, firm or corporation, other than as provided in the Ordinary Course, in transfer agency agreements, underwriting and agency agreements and agreements in connection with indebtedness of Xanthic outstanding on the date hereof.

 

  (t)

A correct and complete list of each independent contractor or consultant engaged by Xanthic has been provided to GGB which list includes their names, consulting fees, any other forms of compensation or benefits, and whether they are subject to a written contract. Current and complete copies of all such contracts have been delivered or made available to GGB. Each independent contractor or consultant who is disclosed on such list has been properly classified by Xanthic as an independent contractor and Xanthic has not received any notice from any Governmental Entity disputing such classification.

 

  (u)

Xanthic has not agreed to recognize any union or other collective bargaining representative, nor has any other union or other collective bargaining representative been certified as the exclusive bargaining representative of any Xanthic employees or consultants, and Xanthic is not a party to, or bound by, any collective bargaining agreement or any other labour contract applicable to any employees or consultants. To the knowledge of Xanthic, no union organizational campaign or representation petitions are currently pending with respect to any Xanthic employees or consultants. There is no labour strike or labour dispute, slowdown, lockout or stoppage actually pending or to the knowledge of Xanthic, threatened against or affecting Xanthic, and Xanthic has not experienced any labour strikes or labour disputes, slowdowns, lockouts or stoppages within the last three years.

 

  (v)

The common shares of Xanthic are listed and posted for trading solely on the CSE and other than as publicly disclosed, no order ceasing or suspending trading in any


Execution Version

 

 

securities of Xanthic is currently outstanding and no proceeding for such purpose are pending, or to the knowledge of Xanthic, threatened.

 

  (w)

Xanthic has filed all proxy circulars, reports and other continuous disclosure documents required to be filed by it by applicable Canadian provincial securities Laws (“Securities Reports”). Each Securities Report was, as of the date of filing, in compliance in all material respects with all applicable requirements under applicable Canadian provincial securities Laws and none of the Securities Reports, as of their respective filing dates, contained any Misrepresentation. No material change has occurred in relation to Xanthic which is not disclosed in the Securities Reports, and Xanthic has not filed any confidential material change reports which continue to remain confidential.

 

  (x)

Xanthic is not in any discussions and has not entered any outstanding proposals, letters of intent, agreements or any understandings with any Person (other than GGB) with respect to an amalgamation, merger, business combination or similar transaction.

 

  (y)

Xanthic is not a party to any lease, management or service agreement that cannot be immediately terminated without notice or penalty or both.

 

  (z)

Xanthic has made available to GGB all material information concerning Xanthic and all such information as made available to GGB is accurate, true and correct in all material respects.

 

  (aa)

Xanthic shall have cash of not less than $400,000 (excluding proceeds from the Loan Agreement, the Deposit Promissory Note and net of expenses relating to the completion of the Amalgamation incurred by Xanthic).

 

  (bb)

There is no action, suit, proceeding or claim pending or threatened by others challenging Xanthic’s rights in or to any Intellectual Property which is used for the conduct of Xanthic’s business as currently carried on.

 

  (cc)

Xanthic has not retained any financial advisor, broker, agent or finder, or paid or agreed to pay any financial advisor, broker, agent or finder on account of this Agreement or the Amalgamation, any transaction contemplated hereby or any transaction presently ongoing or contemplated.

 

  (dd)

None of the current directors, officers, consultants or employees of Xanthic or Xanthic Sub, any holder of more than 10% of any class of shares or equity interests, as applicable, of Xanthic or Xanthic Sub, or any known associate or affiliate of any of the foregoing Persons, has had or has any material interest, direct or indirect, in any transaction or proposed transaction involving Xanthic or Xanthic Sub which, as the case may be, materially affected, is material to or is reasonably expected to materially affect Xanthic or Xanthic Sub, on a consolidated basis.

 

  (ee)

To the knowledge of Xanthic, the representations and warranties of NOR contained in the NOR SPA are true and correct in all material respects, subject to the qualifications set out therein.

 

  (ff)

To the knowledge of Xanthic, there has been no (i) actual or alleged breach or default by any party of any provision of the NOR SPA and no event, condition, or


Execution Version

 

 

occurrence exists which after the notice or lapse of time (or both) would constitute a breach or default by any party to the NOR SPA; or (ii) dispute with respect to or termination, cancellation, amendment or renegotiation of the NOR SPA, and, to the knowledge of Xanthic, no state of facts giving rise to any of the foregoing exists.

ARTICLE 5

COVENANTS OF THE PARTIES

Section 5.1 Conduct of Businesses of Xanthic and GGB.

 

(1)

During the period between the date of this Agreement and the earlier of the Effective Date and the termination of this Agreement in accordance with its terms, except as otherwise expressly contemplated by this Agreement, Xanthic will conduct its business in the Ordinary Course.

 

(2)

Without limiting the generality of Section 5.1(1), Xanthic covenants as follows for the period between the date of this Agreement and the earlier of the Effective Date and the termination of this Agreement in accordance with its terms:

 

  (a)

Xanthic’s business shall be conducted only in the usual and Ordinary Course and Xanthic shall keep GGB apprised of all material developments relating thereto.

 

  (b)

Xanthic shall not directly or indirectly do or permit to occur any of the following: (i) amend its Constating Documents, other than as required to give effect to the Amalgamation and this Agreement; (ii) declare, set aside or pay any dividend or other distribution or payment (whether in cash, shares or property) in respect of its outstanding shares (other than salaries and expense reimbursements made in the Ordinary Course); (iii) issue (other than for issuance on exercise of currently outstanding Xanthic Convertible Securities or pursuant to the Amalgamation), grant, sell or pledge or agree to issue, grant, sell or pledge any shares of Xanthic, or securities convertible into or exchangeable or exercisable for, or otherwise evidencing a right to acquire, shares of Xanthic, without the prior written approval of GGB; (iv) redeem, purchase or otherwise acquire any of its outstanding shares or other securities, except as permitted hereunder; (v) split, combine or reclassify any of its shares and other than pursuant to the Amalgamation or as contemplated by this Agreement; (vi) reduce its stated capital; (vii) adopt a plan of liquidation or resolutions providing for the liquidation, dissolution, merger, consolidation or reorganization of Xanthic; (viii) take any action, or refrain from taking any action, permit any action to be taken or not taken, inconsistent with this Agreement, which might directly or indirectly interfere with or adversely affect the consummation of the Amalgamation; or (ix) enter into or modify any contract, agreement or commitment with respect to any of the foregoing.

 

  (c)

Xanthic shall not adopt or amend or make any contribution to any bonus, profit sharing, option, pension, retirement, deferred compensation, insurance, incentive compensation, other compensation or other similar plan, agreement, trust, fund or agreements for the benefit of employees or consultants, except as is necessary to comply with the law or with respect to existing provisions of any such plans, programs, or agreements.

 

  (d)

Xanthic shall make payment of all accounts payable as same become due and payable and shall collect all accounts receivable in the Ordinary Course.


Execution Version

 

  (e)

Xanthic shall not incur any debt, except in the Ordinary Course and pursuant to the Loan Agreement and the Deposit Promissory Note.

 

  (f)

Xanthic shall not incur any significant expenditure commitments, without the prior written approval of GGB.

 

  (a)

Xanthic shall operate and maintain its assets in strict compliance with regulations and with good and prudent industry standards and practices and all applicable Laws, licenses and permits and will keep all leases, agreements, licenses and permits comprising its assets or necessary for the operation thereof in good standing and ensure that, at the Effective Date, all property and assets necessary or desirable to enable Xanthic to conduct its business (on a consolidated basis) following Closing in substantially the same manner as it was conducted as of the date of this Agreement and that Xanthic (on a consolidated basis) owns, with good title, all of the properties and assets that it purports to own including the properties and assets reflected as being owned in Xanthic’s Financial Statements.

 

  (g)

Xanthic shall not grant any officer, director, employee or consultant an increase in compensation in any form or take any action with respect to the amendment or grant of any severance or termination pay policies for any directors, officers, employees or consultants, nor adopt or amend (other than to permit accelerated vesting of options) or make any contribution to any bonus, profit sharing, option, pension, retirement, deferred compensation, insurance, incentive compensation, other compensation or other similar plan from a trust fund for the benefit of directors, officers, employees or consultants, except as is necessary to comply with applicable local Law or with respect to existing provisions of any such plans, programs, arrangements or agreements.

 

  (h)

Xanthic shall use its reasonable commercial efforts to cause its current insurance (or re-insurance) policies not to be cancelled or terminated or any of the coverage thereunder to lapse, unless simultaneously with such termination, cancellation or lapse, replacement policies underwritten by insurance or re insurance companies of nationally recognized standing providing coverage equal to or greater than the coverage under the cancelled, terminated or lapsed policies for substantially similar premiums are in full force and effect.

 

  (i)

Xanthic shall promptly notify GGB in writing of any Material Adverse Effect on Xanthic or, upon the completion of the transactions contemplated by the NOR SPA, any Material Adverse Effect on NOR, or of any material breach by Xanthic of any representation or warranty provided by Xanthic in this Agreement with respect to itself.

 

  (j)

Xanthic shall not (and shall cause Xanthic Sub to not) take any action with respect to NOR (including, without limitation, the waiver of any conditions precedent to its obligations thereunder), consummate the transactions contemplated by the NOR SPA, amend, modify or supplement, or waive any right or grant consent under the NOR SPA or authorize, agree, resolve or otherwise commit, whether or not in writing, to do any of the foregoing, without the prior written consent of GGB, which consent may be withheld in its sole and absolute discretion. Subject to the foregoing, Xanthic shall use its commercially reasonable efforts to (and shall cause Xanthic Sub to) complete the acquisition of NOR in accordance with the terms of the NOR SPA,


Execution Version

 

 

including using commercially reasonable efforts to perform its covenants and satisfy the conditions precedent thereunder.

 

(3)

During the period between the date of this Agreement and the earlier of the Effective Date and the termination of this Agreement in accordance with its terms, except as otherwise expressly contemplated by this Agreement, GGB will conduct its business in the Ordinary Course.

 

(4)

Without limiting the generality of Section 5.1(3), GGB covenants as follows for the period between the date of this Agreement and the earlier of the Effective Date and the termination of this Agreement in accordance with its terms:

 

  (a)

GGB’s business shall be conducted only in the usual and Ordinary Course and GGB shall keep Xanthic apprised of all material developments relating thereto.

 

  (b)

GGB shall not directly or indirectly do or permit to occur any of the following: (i) amend its Constating Documents, other than as required to give effect to the Amalgamation; (ii) declare, set aside or pay any dividend or other distribution or payment (whether in cash, shares or property) in respect of its outstanding shares (other than salaries and expense reimbursements made in the Ordinary Course); (iii) issue (other than for the Offerings, pursuant to the Amalgamation or as provided in the last sentence hereof), grant, sell or pledge or agree to issue, grant, sell or pledge any shares of GGB, or securities convertible into or exchangeable or exercisable for, or otherwise evidencing a right to acquire, shares of GGB, without the prior written approval of Xanthic; (iv) redeem, purchase or otherwise acquire any of its outstanding shares or other securities, except as permitted hereunder; (v) split, combine or reclassify any of its shares and other than pursuant to the Amalgamation or as contemplated by this Agreement; (vi) reduce its stated capital; (vii) adopt a plan of liquidation or resolutions providing for the liquidation, dissolution, merger, consolidation or reorganization of GGB; (viii) take any action, or refrain from taking any action, permit any action to be taken or not taken, inconsistent with this Agreement, which might directly or indirectly interfere with or adversely affect the consummation of the Amalgamation; or (ix) enter into or modify any contract, agreement or commitment with respect to any of the foregoing. Notwithstanding the foregoing, GGB shall be permitted to issue up to 9,200,000 GGB Shares or options (or the economic equivalent pursuant to a phantom stock plan or other equity plan as determined by GGB in its sole discretion) to acquire GGB Shares in the aggregate to employees, consultants, officers and directors in consideration for services or inducement to accept employment with GGB.

 

  (c)

GGB shall not adopt or amend or make any contribution to any bonus, profit sharing, option, pension, retirement, deferred compensation, insurance, incentive compensation, other compensation or other similar plan, agreement, trust, fund or agreements for the benefit of employees, except as is necessary to comply with the law or with respect to existing provisions of any such plans, programs, or agreements.

 

  (d)

GGB shall make payment of all accounts payable as same become due and payable and shall collect all accounts receivable in the Ordinary Course.


Execution Version

 

  (e)

GGB shall not incur any debt, except in the Ordinary Course and pursuant to the Convertible Debenture Offering, provided that, GGB may incur debt to finance the completion of acquisition transactions as permitted pursuant to Section 5.1(4)(f).

 

  (f)

GGB shall not incur any significant expenditure commitments, without the prior written approval of Xanthic, provided that, GGB shall be permitted to complete up to $50 million of acquisition transactions, in the aggregate without the prior written consent of Xanthic.

 

  (g)

GGB shall operate and maintain its assets in strict compliance with regulations and with good and prudent industry standards and practices and all applicable Laws, licenses and permits and will keep all leases, agreements, licenses and permits comprising its Assets or necessary for the operation thereof in good standing.

 

  (h)

GGB shall not grant any officer, director, employee or consultant an increase in compensation in any form or take any action with respect to the amendment or grant of any severance or termination pay policies for any directors, officers, employees or consultants, nor adopt or amend (other than to permit accelerated vesting of options) or make any contribution to any bonus, profit sharing, option, pension, retirement, deferred compensation, insurance, incentive compensation, other compensation or other similar plan from a trust fund for the benefit of directors, officers, employees or consultants, except as is necessary to comply with applicable local Law or with respect to existing provisions of any such plans, programs, arrangements or agreements.

Section 5.2 NOR Acquisition.

 

(1)

Subject to compliance with the provisions of the NOR SPA, Xanthic grants (and shall cause Xanthic Sub to grant) to GGB the exclusive and irrevocable option, in its sole and absolute discretion, to assume the rights and obligations of Xanthic and Xanthic Sub under the NOR SPA in the event that (i) any of the conditions precedent under the NOR SPA fail to be, or are incapable of being, satisfied by Xanthic or Xanthic Sub, or (ii) any of the conditions precedent under this Agreement fail to be, or are incapable of being, satisfied by Xanthic. Upon exercise of such option by GGB, Xanthic shall (and shall cause Xanthic Sub to) take all necessary action, subject to compliance with the provisions of the NOR SPA, and execute and deliver all such documents, conveyances, transfers and other assurances as may be required to effectively transfer the rights and obligations of Xanthic and Xanthic Sub under the NOR SPA to GGB and carry out the intent of this Agreement.

 

(2)

GGB and Xanthic shall use commercially reasonable efforts to execute the Loan Agreement. GGB and Xanthic agree that as security for amounts payable under the Loan Agreement and the Deposit Promissory Note, Xanthic will provide GGB with the irrevocable right, subject to the NOR SPA, to elect to satisfy Xanthic’s obligations under the Loan Agreement by acquiring NOR from Xanthic and assuming Xanthic’s obligations under and resulting from the NOR SPA (including, for greater certainty, (a) the Note and (b) payment of the Parent Share Purchase Price, as such terms are defined in the NOR SPA) and covenants to do all things necessary and execute all documents directed to effect the option to transfer NOR back to GGB. Upon the acquisition of NOR by GGB in accordance with this provision, all amounts owed by Xanthic to GGB under the Loan Agreement and the Deposit Promissory Note shall be released and discharged and GGB shall execute and deliver such instruments as it be advised by Xanthic’s counsel are reasonably required to release Xanthic from such obligations. In addition, subject to Nevada law, GGB will be granted first priority security


Execution Version

 

 

over the shares and all assets of NOR and such security shall be provided for in the Loan Agreement and the agreements ancillary thereto.

 

(3)

In the event that the NOR SPA is terminated in accordance with its terms and in accordance with the terms of the Escrow Agreement (as such term is defined in the NOR SPA), and the Deposit (as such term is defined in the NOR SPA) is paid to the Representative (as such term is defined in the NOR SPA), and such failure is due, in whole or in part, to the action or inaction of GGB, including its inability to complete the Convertible Debenture Financing, the obligations of Xanthic under the Deposit Promissory Note shall be released and discharged as soon as permissible under applicable Nevada, United States law to transfer the ownership of the NOR license without any disruption in the operations of NOR and GGB shall execute and deliver such instruments as it be advised by Xanthic’s counsel are reasonably required to release Xanthic from such obligations.

 

(4)

Xanthic shall execute and deliver the Deposit Promissory Note within two Business Days of the execution of this Agreement, and GGB shall promptly thereafter wire transfer the principal amount of the Deposit Promissory Note as directed by Xanthic.

Section 5.3 Actions to Satisfy Conditions.

 

(1)

GGB shall take all such actions as are within its power to control and use commercially reasonable efforts to cause other actions to be taken which are not within its power to control, so as to ensure compliance with all of the applicable conditions precedent in favour of Xanthic as set forth in this Agreement and the Ancillary Agreements.

 

(2)

Xanthic shall take all such actions as are within its power to control and use commercially reasonable efforts to cause other actions to be taken which are not within its power to control, so as to ensure compliance with all of the applicable conditions precedent in favour of GGB as set forth in this Agreement and the Ancillary Agreements.

Section 5.4 No Shop.

The Parties and their respective agents will not, nor will they permit any of their respective directors, officers, employees, representatives or agents (including and without limitation, investment bankers, attorneys and accountants) directly or indirectly to, solicit or accept any offer for the purchase of outstanding securities of such Party or the business or the assets of such Party, whether as a primary or backup offer, or take any other action that would reasonably be expected to lead to any commitment or agreement to sell such Party or business or the assets of such Party. Notwithstanding the foregoing, nothing herein will restrict the Parties hereto and their respective directors, officers, employees, representatives or agents (including without limitation, investment bankers, attorneys and accountants) from taking such actions as may be required in order to discharge their obligations pursuant to applicable corporate and securities Laws.

ARTICLE 6

CONDITIONS

Section 6.1 Mutual Conditions Precedent.

The Parties are not required to complete the Amalgamation unless each of the following conditions is satisfied on or prior to the Effective Date, which conditions may only be waived, in whole or in part, by the mutual consent of each of the Parties:


Execution Version

 

(1)

The Amalgamation Resolution has been approved and adopted by the GGB Shareholders pursuant to a written resolution in lieu of a meeting.

 

(2)

No Law is in effect that makes the consummation of the Amalgamation illegal or otherwise prohibits or enjoins GGB or Subco from consummating the Amalgamation.

 

(3)

Each Regulatory Approval necessary to consummate the Amalgamation, including all necessary approvals of the CSE, has been made, given or obtained on terms acceptable to GGB and Xanthic, each acting reasonably, and each such Regulatory Approval is in force and has not been modified.

 

(4)

There shall not have occurred a Material Adverse Effect with respect to Xanthic, NOR or GGB.

 

(5)

The Offerings shall have been completed.

 

(6)

The Loan Agreement shall have been executed.

 

(7)

The Deposit Promissory Note shall have been executed.

 

(8)

The latest available audited and unaudited financial statements of each of the Parties and NOR, as required by the CSE policies for inclusion in the Circular, shall have been delivered and shall be true and correct and have been prepared in accordance with GAAP.

 

(9)

There shall not be any pending or threatened litigation in any court or any proceeding or investigation by any Governmental Entity in which it is or may be sought to restrain or prohibit consummation of the Amalgamation and related transactions or to obtain divestiture, rescission or damages in connection with the Amalgamation and related transactions.

 

(10)

All applicable securityholders shall have entered into the requisite escrow agreements and/or lock-up agreements required by the CSE.

Section 6.2 Conditions for the Benefit of Xanthic.

 

(1)

The completion of the transactions contemplated hereunder is subject to the following conditions being satisfied at or prior to the Effective Date, which conditions are for the exclusive benefit of Xanthic and may be waived, in whole or in part, by Xanthic in its sole discretion:

 

  (a)

The representations and warranties of GGB which are qualified by references to materiality or by the expression “Material Adverse Effect” were true and correct as of the date of this Agreement and are true and correct as of the Effective Date, in all respects, and all other representations and warranties of GGB were true and correct as of the date of this Agreement and are true and correct as of the Effective Date, in all material respects, in each case except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of such specified date, and GGB shall have executed and delivered a certificate of an officer to that effect.

 

  (b)

GGB shall have fulfilled or complied, in all material respects, with all covenants contained in this Agreement and the Ancillary Agreements to be fulfilled or


Execution Version

 

 

complied with by GGB at or prior to the Effective Date, and GGB shall have executed and delivered a certificate to that effect.

 

  (c)

Xanthic shall have received all certificates, instruments and other deliverables required to be delivered from NOR under the NOR SPA.

 

  (d)

Xanthic shall have received executed copies of the contractual lock-up agreements from the shareholders identified to Xanthic in writing.

 

(2)

GGB shall deliver or cause to be delivered to Xanthic at or prior to the Effective Date the following in form and substance satisfactory to Xanthic acting reasonably:

 

  (i)

a certified copy of the Amalgamation Resolution;

 

  (ii)

a certified copy of (A) all resolutions of the board of directors of GGB approving the entering into of this Agreement and the completion of the Amalgamation, and (B) a list of the directors and officers of GGB authorized to sign agreements together with their specimen signatures; and

 

  (iii)

a certificate of status, compliance, good standing or like certificate with respect to GGB issued by appropriate government officials of its jurisdiction of incorporation.

Section 6.3 Conditions for the Benefit of GGB.

 

(1)

The completion of the transactions contemplated hereunder is subject to the following conditions being satisfied at or prior to the Effective Date, which conditions are for the exclusive benefit of GGB and may be waived, in whole or in part, by GGB in its sole discretion:

 

  (a)

The representations and warranties of Xanthic which are qualified by references to materiality and warranties were true and correct as of the date of this Agreement and are true and correct as of the Effective Date, in all respects, and all other representations and warranties of Xanthic were true and correct as of the date of this Agreement and are true and correct as of the Effective Date, in all material respects, in each case except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of such specified date, and Xanthic shall have executed and delivered a certificate to that effect.

 

  (b)

Xanthic shall have fulfilled or complied, in all material respects, with all covenants contained in this Agreement and any Ancillary Agreement to be fulfilled or complied with by it at or prior to the Effective Date, and Xanthic shall have executed and delivered a certificate to that effect.

 

  (c)

Xanthic shall have no liabilities or obligations (contingent or otherwise), exclusive of liabilities relating to the fees and disbursements of its legal counsel and auditors appointed in connection with the Amalgamation, and Xanthic shall have executed and delivered a certificate to that effect.

 

  (d)

Xanthic shall have cash of not less than $400,000 (excluding proceeds from the Loan Agreement, the Deposit Promissory Note and net of expenses relating to the completion of the Amalgamation incurred by Xanthic) and Xanthic shall have


Execution Version

 

 

 

executed and delivered a certificate to that effect, and any deviations from this amount must be previously approved in writing by GGB.

 

  (e)

Each of the required directors and officers of Xanthic and Xanthic Sub shall have resigned from their respective positions, other than those persons identified in Section 2.1(2)(h).

 

  (f)

Each of Tim Moore, David Bhumgara and Gary Galitsky shall have entered into employment agreements and restrictive covenant agreements with the Resulting Issuer on terms acceptable to GGB.

 

  (g)

Each of Tim Moore, David Bhumgara and Gary Galitsky shall have executed an acknowledgement and waiver in respect of certain provisions of their existing consulting agreements with Xanthic on terms acceptable to GGB.

 

  (h)

GGB shall have received executed copies of the contractual lock-up agreements from the shareholders identified to Xanthic in writing.

 

  (i)

The Acquisition shall have been completed.

 

(2)

Xanthic shall deliver or cause to be delivered to GGB at or prior to the Effective Date the following in form and substance satisfactory to GGB acting reasonably:

 

  (a)

a certified copy of (A) all resolutions of the board of directors of such entity approving the entering into of this Agreement and the completion of the Amalgamation, (B) all resolutions of the Xanthic Shareholders passed in connection with the Xanthic Meeting and (C) a list of the directors and officers authorized to sign agreements together with their specimen signatures; and

 

  (b)

a certificate of status, compliance, good standing or like certificate with respect to Xanthic issued by appropriate government officials of their respective jurisdictions of incorporation.

ARTICLE 7

POST-CLOSING

Section 7.1 Share Consolidation.

Immediately following the Closing, the Resulting Issuer shall effect a 4.07:1 share consolidation.

ARTICLE 8

TERMINATION

Section 8.1 Term.

This Agreement shall be effective from the date hereof until the earlier of the Effective Date and the termination of this Agreement in accordance with its terms.

Section 8.2 Termination Rights.

This Agreement may, by Notice in writing given prior to the Effective Date, be terminated:


Execution Version

 

  (a)

by mutual consent of GGB and Xanthic;

 

  (b)

either GGB or Xanthic if:

 

  (i)

the approval of GGB Shareholders of the Amalgamation or the approval of Xanthic Shareholders of all matters to be considered at the Xanthic Meeting, is not obtained, provided that a Party may not terminate this Agreement pursuant to this Section 8.2(b)(i) if the failure to obtain such approval has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants or agreements under this Agreement;

 

  (ii)

after the date of this Agreement, any Law is enacted, made, enforced or amended, as applicable, that makes the consummation of the Amalgamation illegal or otherwise permanently prohibits or enjoins GGB or Xanthic from consummating the Amalgamation, and such Law has, if applicable, become final and non-appealable; or

 

  (iii)

the Effective Date does not occur on or prior to the Outside Date, provided that a Party may not terminate this Agreement pursuant to this Section 8.2(b)(iii) if the failure of the Effective Date to so occur has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants or agreements under this Agreement.

 

  (c)

by GGB if a breach of any representation or warranty or failure to perform any covenant or agreement on the part of Xanthic under this Agreement occurs that would cause any condition in Section 6.3(1)(a) or Section 6.3(1)(b) not to be satisfied, and such breach or failure is incapable of being cured or is not cured on or prior to the Outside Date; provided that GGB is not then in breach of this Agreement so as to cause any condition in Section 6.2(1)(a) or Section 6.2(1)(b) not to be satisfied.

 

  (d)

by Xanthic if a breach of any representation or warranty or failure to perform any covenant or agreement on the part of GGB under this Agreement occurs that would cause any condition in Section 6.2(1)(a) or Section 6.2(1)(b) not to be satisfied, and such breach or failure is incapable of being cured or is not cured on or prior to the Outside Date; provided that Xanthic is not then in breach of this Agreement so as to cause any condition in Section 6.3(1)(a) or Section 6.3(1)(b) not to be satisfied.

Section 8.3 Effect of Termination.

 

(1)

If a Party waives compliance with any of the conditions, obligations or covenants contained in this Agreement, the waiver will be without prejudice to any of its rights of termination in the event of non-fulfilment, non-observance or non-performance of any other condition, obligation or covenant in whole or in part.

 

(2)

If this Agreement is terminated, the Parties are released from all of their respective obligations under this Agreement except that each Party’s obligations under Section 9.3 and Section 9.4 will survive.


Execution Version

 

ARTICLE 9

MISCELLANEOUS

Section 9.1 Notices.

Any notice, direction or other communication (each a “Notice”) given regarding the matters contemplated by this Agreement or any Ancillary Agreement must be in writing, sent by personal delivery, courier or facsimile (but not by electronic mail) and addressed:

 

  (a)

to Xanthic at:

77 King Street West, Suite 2905

Toronto, Ontario, Canada

M5K 1A2

Attention:         Tim Moore, Chief Executive Officer

Email Address: timm@xanthicbiopharma.com

 

  (b)

to GGB at:

Suite 5300, Commerce Court West

199 Bay Street

Toronto, ON, M5L 1B9

Attention:          Peter Horvath, Chief Executive Officer

Email Address: PHorvath@greengrowthbrands.com

with a copy (which shall not constitute notice) to:

4300 E. 5th Avenue

Columbus, Ohio 43219

Attention:         Tod Friedman

Email Address: tod.friedman@spgroup.com

A Notice is deemed to be delivered and received (i) if sent by personal delivery, on the date of delivery if it is a Business Day and the delivery was made prior to 4:00 p.m. (local time in place of receipt) and otherwise on the next Business Day, (ii) if sent by same-day service courier, on the date of delivery if sent on a Business Day and delivery was made prior to 4:00 p.m. (local time in place of receipt) and otherwise on the next Business Day, (iii) if sent by overnight courier, on the next Business Day, or (iv) if sent by e-mail or facsimile, on the Business Day following the date of confirmation of transmission by the originating facsimile. A Party may change its address for service from time to time by providing a Notice in accordance with the foregoing. Any subsequent Notice must be sent to the Party at its changed address. Any element of a Party’s address that is not specifically changed in a Notice will be assumed not to be changed. Sending a copy of a Notice to a Party’s legal counsel as contemplated above is for information purposes only and does not constitute delivery of the Notice to that Party. The failure to send a copy of a Notice to legal counsel does not invalidate delivery of that Notice to a Party.

Section 9.2 Time of the Essence.

Time is of the essence in this Agreement.


Execution Version

 

Section 9.3 Announcements.

The Parties agree that Xanthic shall issue a press release with respect to Amalgamation immediately following the execution of this Agreement, which press release shall be jointly approved by the Parties. No other press release, public statement or announcement or other public disclosure (a “Public Statement”) with respect to this Agreement or the transactions contemplated in this Agreement may be made except with the prior written consent and joint approval of Xanthic and GGB, or if required by Law or a Governmental Entity. Where the Public Statement is required by Law or a Governmental Entity, the Party required to make the Public Statement will use commercially reasonable efforts to obtain the approval of the other Party as to the form, nature and extent of the disclosure.

Section 9.4 Expenses.

Each Party will pay for its own costs and expenses incurred in connection with this Agreement and the transactions contemplated herein. Notwithstanding the foregoing, in the event that GGB or Xanthic terminates this Agreement pursuant to Section 8.2, other than as a result of a breach of a representation or warranty or non-performance by Xanthic, GGB shall: (i) pay Xanthic a break fee in the aggregate amount of $250,000; and (ii) reimburse Xanthic for the full extent of its US legal fees, up to $150,000 of its Canadian legal fees, travel costs, and other reasonable expenses incurred in connection herewith.

Section 9.5 Amendments.

This Agreement may only be amended, supplemented or otherwise modified by written agreement signed by the Parties.

Section 9.6 Waiver.

No waiver of any of the provisions of this Agreement or any Ancillary Agreement will constitute a waiver of any other provision (whether or not similar). No waiver will be binding unless executed in writing by the Party to be bound by the waiver. A Party’s failure or delay in exercising any right under this Agreement will not operate as a waiver of that right. A single or partial exercise of any right will not preclude a Party from any other or further exercise of that right or the exercise of any other right.

Section 9.7 Entire Agreement.

This Agreement, together with the Ancillary Agreements, constitutes the entire agreement between the Parties with respect to the transactions contemplated by this Agreement and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties. There are no representations, warranties, covenants, conditions or other agreements, express or implied, collateral, statutory or otherwise, between the Parties in connection with the subject matter of this Agreement, except as specifically set forth in this Agreement or any Ancillary Agreement. The Parties have not relied and are not relying on any other information, discussion or understanding in entering into and completing the transactions contemplated by this Agreement and the Ancillary Agreements. If there is any conflict or inconsistency between the provisions of this Agreement and the provisions of any Ancillary Agreement, the provisions of this Agreement shall govern.


Execution Version

 

Section 9.8 Successors and Assigns.

 

(1)

This Agreement becomes effective only when executed by Xanthic and GGB. After that time, it will be binding upon and enure to the benefit of Xanthic and GGB and their respective successors and permitted assigns.

 

(2)

Neither this Agreement nor any of the rights or obligations under this Agreement are assignable or transferable by any Party without the prior written consent of the other Parties.

Section 9.9 Severability.

If any provision of this Agreement is determined to be illegal, invalid or unenforceable by an arbitrator or any court of competent jurisdiction, that provision will be severed from this Agreement and the remaining provisions shall remain in full force and effect.

Section 9.10 Governing Law.

 

(1)

This Agreement will be governed by and interpreted and enforced in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein.

 

(2)

Each Party irrevocably attorns and submits to the non-exclusive jurisdiction of the Ontario courts situated in the City of Toronto and waives objection to the venue of any proceeding in such court or that such court provides an inconvenient forum.

Section 9.11 Counterparts.

This Agreement may be executed in any number of counterparts (including counterparts by facsimile) and all such counterparts taken together shall be deemed to constitute one and the same instrument.

[Remainder of page intentionally left blank]


IN WITNESS WHEREOF the Parties have executed this Transaction Agreement.

 

XANTHIC BIOPHARMA INC.

By: 

  LOGO
  Authorized Signatory

 

GREEN GROWTH BRANDS LTD.

By: 

   
  Authorized Signatory

Business Combination Agreement


IN WITNESS WHEREOF the Parties have executed this Transaction Agreement.

 

XANTHIC BIOPHARMA INC.

By: 

   
  Authorized Signatory

 

GREEN GROWTH BRANDS LTD.

By: 

  LOGO
  Authorized Signatory

Business Combination Agreement


SCHEDULE “A”

FORM OF AMALGAMATION AGREEMENT

See attached.


SCHEDULE “A”

FORM OF AMALGAMATION AGREEMENT

THIS AGREEMENT is dated as of the [●] day of [●], 2018,

BY AND A M O N G:

GREEN GROWTH BRANDS LTD., a corporation existing under the laws of the Province of Ontario

(hereinafter referred to as “GGB”)

OF THE FIRST PART;

- and -

●, a corporation existing under the laws of the Province of Ontario

(hereinafter referred to as “Subco”)

OF THE SECOND PART;

- and -

XANTHIC BIOPHARMA INC., a corporation existing under the laws of the Province of Ontario

(hereinafter referred to as “Xanthic”)

OF THE THIRD PART.

WHEREAS GGB and Subco wish to amalgamate and continue as one corporation to be known as “Xanthic Biopharma Corp.” in accordance with the terms and conditions hereof;

AND WHEREAS Subco is a wholly-owned subsidiary of Xanthic and has not carried on active business;

AND WHEREAS Xanthic and GGB are parties to the Transaction Agreement which contemplates such amalgamation;

AND WHEREAS the parties have entered into this Agreement to provide for the matters referred to in the foregoing recitals and for other matters relating to the proposed amalgamation;

 

A-1


NOW THEREFORE THIS AGREEMENT WITNESSES that for and in consideration of the mutual covenants and agreements herein contained and other lawful and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.

Definitions. In this Agreement (including the recitals hereto):

 

  (a)

Act” means the Business Corporations Act (Ontario) as from time to time amended or re-enacted;

 

  (b)

Agreement” means this amalgamation agreement;

 

  (c)

Amalco” means the continuing corporation constituted upon the amalgamation of the Amalgamating Parties pursuant to the Amalgamation;

 

  (d)

Amalco Shares” means the common shares in the capital of Amalco;

 

  (e)

Amalgamating Parties” means, collectively, GGB and Subco;

 

  (f)

Amalgamation” means the amalgamation of GGB and Subco on the terms and conditions set forth in this Agreement;

 

  (g)

Articles of Amalgamation” means the articles of amalgamation to be filed with the Ministry in order to effect the Amalgamation, substantially in the form agreed to between the Amalgamating Parties;

 

  (h)

Business Combination” means the business combination between Xanthic and GGB wherein Xanthic will acquire 100% of the issued and outstanding shares of GGB by way of the Amalgamation;

 

  (i)

Business Combination Date” means the date the Business Combination is completed, as evidenced by the issuance of the Certificate of Amalgamation giving effect to the Amalgamation;

 

  (j)

Business Day” means a day other than a Saturday, Sunday or a civic or statutory holiday in the City of Toronto, Ontario;

 

  (k)

Certificate of Amalgamation” means the certificate of amalgamation to be issued by the Director, as date stamped on the Articles of Amalgamation, evidencing that the Articles of Amalgamation are effective;

 

  (l)

Consolidation” means the consolidation of the Xanthic Shares, the Xanthic Options and the Xanthic Warrants, on a 4.07 to 1 basis, as further set out in Section 13(g);

 

  (m)

CSE” means the Canadian Securities Exchange;

 
 

 

A-2


  (n)

Debenture Offering” means a private placement offering of up to 32,000 GGB Debentures;

 

  (o)

Director” means the Director appointed under Section 278 of the Act;

 

  (p)

Effective Time” means 12:01 a.m. (Toronto time) on the Business Combination Date;

 

  (q)

Exchange Ratio” means 3.394;

 

  (r)

Ministry” means the Ontario Ministry of Consumer and Business Services;

 

  (s)

Paid-up Capital” has the meaning assigned to the term “paid-up capital” in subsection 89(1) of the Income Tax Act (Canada));

 

  (t)

GGB Securityholder” means a registered holder owning GGB Shares immediately prior to the filing of the Articles of Amalgamation;

 

  (u)

GGB Shares” means the common shares in the capital of GGB, as presently constituted on the date hereof;

 

  (v)

GGB Debentures” means the up to $32 million extendible convertible debentures of GGB to be issued in connection with the Debenture Offering;

 

  (w)

GGB Subscription Receipts” means the up to $● million subscription receipts of GGB to be issued in connection with the Subscription Receipt Offering;

 

  (x)

Subscription Receipt Offering” means a private placement offering of up to ● GGB Subscription Receipts, pursuant to the terms of an agency agreement to be entered into between GGB, Xanthic and ●;

 

  (y)

Subco Shares” means the common shares in the capital of Subco;

 

  (z)

Transaction Agreement” means the transaction agreement dated July 13, 2018 among Xanthic and GGB governing the terms and conditions of the Business Combination, as amended from time to time;

 

  (aa)

Xanthic Convertible Securities” means, collectively, all outstanding rights to acquire Xanthic Shares pursuant to the Xanthic Options, the Xanthic Warrants and other warrants, broker warrants, convertible debentures, rights of conversion or exchange privileges or other securities entitling the holder thereof to acquire any Xanthic Shares, or any other rights, agreements or commitment of any character requiring the issuance, sale or transfer by Xanthic of any Xanthic Shares;

 

  (bb)

Xanthic Options” means the 3,308,000 existing stock options of Xanthic, each entitling the holder to purchase one Xanthic Share, in accordance with their terms;

 

A-3


  (cc)

Xanthic Replacement Options” has the meaning ascribed to such term in Section 13(g)(ii);

 

  (dd)

Xanthic Replacement Warrants” has the meaning ascribed to such term in Section 13(g)(iii);

 

  (ee)

Xanthic Shares” means the common shares in the capital of Xanthic, as presently constituted on the date hereof; and

 

  (ff)

Xanthic Warrants” means the 568,000 common share purchase warrants to purchase Xanthic Shares at $0.75, expiring April 18, 2020.

 

2.

Amalgamation. In accordance with the Transaction Agreement, the Amalgamating Parties hereby agree to amalgamate and continue as one corporation under the provisions of the Act upon the terms and conditions hereinafter set out.

 

3.

Certain Phrases, etc. In this Agreement (i) the words “including”, “includes” and “include” mean “including (or includes or include) without limitation”, and (ii) the phrase “the aggregate of”, “the total of”, “the sum of”, or a phrase of similar meaning means “the aggregate (or total or sum), without duplication, of”. In the computation of periods of time from a specified date to a later specified date, unless otherwise expressly stated, the word “from” means “from and including” and the words “to” and “until” each mean “to but excluding”.

 

4.

Effect of Amalgamation. At the Effective Time, subject to the Act:

 

  (a)

the amalgamation of the Amalgamating Parties and their continuance as one corporation, Amalco, under the terms and conditions prescribed in this Agreement shall be effective;

 

  (b)

the property, rights and interests of each of the Amalgamating Parties shall continue to be the property of Amalco;

 

  (c)

Amalco will be a wholly-owned subsidiary of Xanthic;

 

  (d)

Amalco shall continue to be liable for the obligations of each of the Amalgamating Parties;

 

  (e)

any existing cause of action, claim or liability to prosecution with respect to either or both of the Amalgamating Parties shall be unaffected;

 

  (f)

a legal proceeding prosecuted or pending by or against any of the Amalgamating Parties may be prosecuted, or its prosecution may be continued, as the case may be, by or against Amalco;

 

  (g)

any conviction against, or ruling, order or judgment in favour of or against, any of the Amalgamating Parties may be enforced by or against Amalco; and

 

A-4


  (h)

the Articles of Amalgamation shall be deemed to be the articles of incorporation of Amalco and the Certificate of Amalgamation shall be deemed to be the certificate of incorporation of Amalco.

 

5.

Name. The name of Amalco shall be “Xanthic Biopharma Corp.”.

 

6.

Registered Office. The registered office of Amalco shall be located at [Address].

 

7.

Authorized Capital. The authorized capital of Amalco shall consist of an unlimited number of Amalco Shares, which shares shall have the rights, privileges, restrictions and conditions as set out in the Act.

 

8.

Restrictions on Business. There shall be no restrictions on the business which Amalco is authorized to carry on.

 

9.

Transfer Restrictions. The right to transfer securities of Amalco shall be restricted. Securities of Amalco, other than non-convertible debt securities, may not be transferred unless:

 

  (a)

(i) the consent of the directors of Amalco is obtained; or (ii) the consent of shareholders holding more than 66 2/3% of the shares entitled to vote at such time is obtained; or

 

  (b)

in the case of securities, other than shares which are subject to restrictions on transfer contained in a securityholders’ agreement, such restrictions on transfer are complied with.

The consent of the directors or the shareholders for the purposes of this section is evidenced by a resolution of the directors or shareholders, as the case may be, or by an instrument or instruments in writing signed by a majority of the directors, or by all of the shareholders.

 

10.

Number of Directors. The minimum number of directors of Amalco shall be one (1) and the maximum number of directors of Amalco shall be ten (10).

 

11.

By-laws. The by-laws of GGB shall, so far as applicable, be the by-laws of Amalco until repealed or amended in the normal manner provided for in the Act. Prior to the Effective Time, a copy of such by-laws may be examined at the registered address of GGB at any time during regular business hours.

 

12.

First Directors. The first directors of Amalco, at least one of whom is resident Canadian, shall be the Persons whose names and addresses are set out below, who shall hold office until the first annual meeting of shareholders of Amalco or until their successors are duly elected or appointed and will be responsible for the subsequent management and operation of Amalco:

 

A-5


Name

  

Address

Jean Schottenstein

  

Peter Horvath

  

Steve Stoute

  

Carli Posner

  

Tim Moore

  

Gary Galitsky

  

Mark Lehmann

  

 

13.

Treatment of Issued Capital. On the Effective Time:

 

  (a)

each issued and outstanding Subco Share will be cancelled and replaced by one issued and fully paid Amalco Share for each Subco Share held by Xanthic;

 

  (b)

the GGB Subscription Receipts shall be deemed to be automatically exercised into GGB Shares in accordance with their terms;

 

  (c)

the GGB Debentures of which holders thereof have elected to convert into GGB Shares, shall be deemed to be automatically exercised into GGB Shares in accordance with their terms;

 

  (d)

holders of issued and outstanding GGB Shares shall receive from Xanthic such number of fully paid Xanthic Shares as is equal to the number of GGB Shares so held multiplied by the Exchange Ratio;

 

  (e)

GGB Shares replaced by issued and fully paid Xanthic Shares in accordance with the provisions of Section 13(d) hereof will be cancelled;

 

  (f)

in consideration of the issuance by Xanthic of the Xanthic Shares pursuant to Section 13(d), Amalco shall issue to Xanthic one fully paid and non-assessable Amalco Share for each Xanthic Share issued to former holders of GGB Shares; and

 

  (g)

immediately after the Amalgamation, the Consolidation shall occur, such that:

 

  (i)

each of the issued and outstanding Xanthic Shares (including the Xanthic Shares issued pursuant to Section 13(d)) are consolidated on the basis of 4.07 pre-consolidation Xanthic Shares for one (1) post-consolidation Xanthic Share;

 

  (ii)

each of the issued and outstanding Xanthic Options are consolidated such that each holder thereof is entitled to purchase that number of Xanthic Shares (rounded down to the next nearest whole Xanthic Share) as is equal to the number of Xanthic Shares issuable pursuant to the Xanthic Options immediately prior to the Consolidation divided by 4.07 at an

 

A-6


 

exercise price per share (rounded up to the nearest whole cent) equal to the original exercise price per share of each such Xanthic Option multiplied by 4.07 (the “Xanthic Replacement Options”); and

 

  (iii)

each of the issued and outstanding Xanthic Warrants are consolidated such that each holder thereof is entitled to purchase that number of Xanthic Shares (rounded down to the next nearest whole Xanthic Share) as is equal to the number of Xanthic Shares issuable pursuant to the Xanthic Warrants immediately prior to the Consolidation divided by 4.07 at an exercise price per share (rounded up to the nearest whole cent) equal to the original exercise price per share of each such Xanthic Warrant multiplied by 4.07 (the “Xanthic Replacement Warrants”).

 

14.

No Fractional Shares or Securities upon Conversion. Notwithstanding Section 13 of this Agreement, but subject to the Act, no GGB Securityholder shall be entitled to, and Xanthic will not issue, fractions of Xanthic Shares and no cash amount will be payable by Xanthic in lieu thereof. To the extent any GGB Securityholder is entitled to receive a fractional Xanthic Share such fraction shall be rounded down to the closest whole number of the applicable security.

 

15.

Certificates. On the Business Combination Date:

 

  (a)

the registered holders of GGB Shares (the “Original Securities”) shall be deemed to be the registered holders of the Xanthic Shares (the “Replacement Securities”) to which they are entitled hereunder, and upon surrender to Xanthic of the certificates representing the issued and outstanding Original Securities, such GGB Securityholders shall be entitled, in exchange, to receive certificates representing the Replacement Securities, as the case may be, as set forth in Section 13 hereof;

 

  (b)

Xanthic, as the registered holder of the Subco Shares, shall be deemed to be the registered holder of the Amalco Shares to which it is entitled hereunder and, upon surrender of the certificates representing such Subco Shares to Amalco, Xanthic shall be entitled to receive a share certificate representing the number of Amalco Shares to which it is entitled as set forth in Section 13 hereof;

 

  (c)

share certificates evidencing GGB Shares and certificates representing the other Original Securities shall cease to represent any claim upon or interest in GGB or Amalco other than the right of the holder to receive, pursuant to the terms hereof and the Amalgamation, the applicable Replacement Securities in accordance with Section 13 hereof;

 

  (d)

upon the delivery and surrender by a GGB Securityholder to Xanthic of certificates representing all of the Original Securities owned by such GGB Securityholder which have been exchanged for Replacement Securities and in accordance with the provisions of Sections 13(d) and (f) hereof, Xanthic shall on the later of: (i) the third Business Day following the Business Combination Date;

 

A-7


 

and (ii) the date of receipt by Xanthic of the certificates referred to above, issue to each such GGB Securityholder certificates representing the number of Replacement Securities to which such holder is entitled;

 

  (e)

Upon delivery and surrender by a holder of Xanthic Options to Xanthic of certificates representing all of the Xanthic Options owned by such holder, Xanthic shall on the later of: (i) the third Business Day following the Business Combination Date; and (ii) the date of receipt by Xanthic of the certificates referred to above, issue to such holder of Xanthic Options certificates representing the number of Xanthic Replacement Options to which such holder is entitled; and

 

  (f)

Upon delivery and surrender by a holder of Xanthic Warrants to Xanthic of certificates representing all of the Xanthic Warrants owned by such holder, Xanthic shall on the later of: (i) the third Business Day following the Business Combination Date; and (ii) the date of receipt by Xanthic of the certificates referred to above, issue to such holder of Xanthic Warrants certificates representing the number of Xanthic Replacement Warrants to which such holder is entitled.

 

16.

Lost Certificates. In the event any certificate which immediately prior to the Effective Time represented one or more outstanding Original Securities that were exchanged pursuant to Section 13 shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the holder of such Original Security claiming such certificate to be lost, stolen or destroyed, Xanthic will issue in exchange for such lost, stolen or destroyed certificate, one or more certificates representing the applicable Replacement Security pursuant to Section 13. The holder to whom certificates representing Replacement Securities are to be issued shall, as a condition precedent to the issuance thereof, give a bond satisfactory to Xanthic in such sum as Xanthic may direct or otherwise indemnify Xanthic in a manner satisfactory to Xanthic against any claim that may be made against Xanthic with respect to the certificate alleged to have been lost, stolen or destroyed.

 

17.

Amalco Stated Capital. The amount to be added to the stated capital account maintained in respect of the Amalco Shares in connection with the issue of Amalco Shares under Section 13 hereof on the Business Combination Date shall be the amount which is the sum of (i) the Paid-up Capital, determined immediately before the Effective Time, of all the issued and outstanding GGB Shares and (ii) the Paid-up Capital, determined immediately before the Effective Time, of the issued and outstanding Subco Shares converted into Amalco Shares.

 

18.

Xanthic Stated Capital. Xanthic shall add an amount to the stated capital maintained in respect of the Xanthic Shares an amount equal to the Paid-Up Capital of the GGB Shares, determined immediately prior to the Effective Time.

 

A-8


19.

Covenants of GGB. GGB covenants and agrees with Subco and Xanthic that it will:

 

  (a)

use reasonable commercial efforts to obtain a resolution of the holders of GGB Shares approving the Amalgamation, this Agreement and the transactions contemplated hereby in accordance with the Act;

 

  (b)

use reasonable efforts to cause each of the conditions precedent set forth in Sections 26 and 27 hereof to be complied with; and

 

  (c)

subject to the approval of the shareholders of each of GGB and Subco being obtained for the completion of the Amalgamation and subject to all applicable regulatory approvals being obtained (including that of the CSE), thereafter jointly with Subco file with the Ministry the Articles of Amalgamation and such other documents as may be required to give effect to the Amalgamation upon and subject to the terms and conditions of this Agreement.

 

20.

Covenants of Xanthic. Xanthic covenants and agrees with GGB that it will:

 

  (a)

sign a resolution as sole shareholder of Subco in favour of the approval of the Amalgamation, this Agreement and the transactions contemplated hereby in accordance with the Act;

 

  (b)

use reasonable efforts to cause each of the conditions precedent set forth in Sections 26 and 28 hereof to be complied with; and

 

  (c)

subject to the approval of the holders of GGB Shares being obtained for the completion of the Amalgamation, and the obtaining of all applicable regulatory approvals (including that of the CSE) and the issuance of the Certificate of Amalgamation, issue that number of Xanthic Shares and Replacement Securities as required by Sections 13 (d) and (g) hereof.

 

21.

Covenants of Subco. Subco covenants and agrees with GGB and Xanthic that it will not from the date of execution hereof to the Business Combination Date, except with the prior written consent of GGB and Xanthic, conduct any business which would prevent Subco or Amalco from performing any of their respective obligations hereunder.

 

22.

Further Covenants of Subco. Subco further covenants and agrees with GGB that it will:

 

  (a)

use its best efforts to cause each of the conditions precedent set forth in Section 26 hereof to be complied with; and

 

  (b)

subject to the approval of the holders of GGB Shares and the sole shareholder of Subco being obtained and subject to the obtaining of all applicable regulatory approvals, thereafter jointly with GGB file with the Ministry the Articles of Amalgamation and such other documents as may be required to give effect to the Amalgamation upon and subject to the terms and conditions of this Agreement.

 

A-9


23.

Representation and Warranty of Xanthic. Xanthic hereby represents and warrants to and in favour of GGB and Subco and acknowledges that GGB and Subco are relying upon such representation and warranty, that Xanthic is duly authorized to execute and deliver this Agreement and this Agreement is a valid and binding agreement, enforceable against Xanthic in accordance with its terms.

 

24.

Representation and Warranty of GGB. GGB hereby represents and warrants to and in favour of Xanthic and Subco, and acknowledges that Xanthic and Subco are relying upon such representation and warranty, that GGB is duly authorized to execute and deliver this Agreement and this Agreement is a valid and binding agreement, enforceable against GGB in accordance with its terms.

 

25.

Representation and Warranty of Subco. Subco represents and warrants to and in favour of GGB and Xanthic, and acknowledges that GGB and Xanthic are relying upon such representations and warranty, that Subco is duly authorized to execute and deliver this Agreement and this Agreement is a valid and binding agreement, enforceable against Subco in accordance with its terms.

 

26.

General Conditions Precedent. The respective obligations of the parties hereto to consummate the transactions contemplated hereby, and in particular the Amalgamation, are subject to the satisfaction, on or before the Business Combination Date, of the following conditions, any of which may be waived by the consent of each of the parties without prejudice to their rights to rely on any other or others of such conditions:

 

  (a)

this Agreement and the transactions contemplated hereby, including, in particular, the Amalgamation, shall be approved by the sole shareholder of Subco and by the holders of GGB Shares in accordance with the Act;

 

  (b)

all the conditions required to close the Business Combination set out herein and in the Transaction Agreement being met or waived; and

 

  (c)

there shall not be in force any order or decree restraining or enjoining the consummation of the transactions contemplated by this Agreement, including, without limitation, the Amalgamation.

 

27.

Conditions to Obligations of Xanthic and Subco. The obligations of Xanthic and Subco to consummate the transactions contemplated hereby and in particular the issue of the Xanthic Shares and Replacement Securities and the Amalgamation, as the case may be, are subject to the satisfaction, on or before the Business Combination Date, of the conditions for the benefit of Xanthic set forth in the Transaction Agreement governing the terms and conditions of the Business Combination and of the following conditions:

 

  (a)

the acts of GGB to be performed on or before the Business Combination Date pursuant to the terms of this Agreement shall have been duly performed by it and there shall have been no material adverse change in the financial condition or business of GGB, taken as a whole, from and after the date hereof; and

 

A-10


  (b)

Xanthic and Subco shall have received a certificate from a senior officer of GGB confirming that the conditions set forth in Sections 26 and 27(a) hereof have been satisfied.

The conditions described above are for the exclusive benefit of Xanthic and Subco and may be asserted by Xanthic and Subco regardless of the circumstances or may be waived by Xanthic and Subco in their sole discretion, in whole or in part, at any time and from time to time without prejudice to any other rights which Xanthic and Subco may have.

 

28.

Conditions to Obligations of GGB. The obligations of GGB to consummate the transactions contemplated hereby and in particular the Amalgamation are subject to the satisfaction, on or before the Business Combination Date, of the conditions for the benefit of GGB set forth in the Transaction Agreement governing the terms and conditions of the Business Combination and of the following conditions:

 

  (a)

each of the acts of Xanthic and Subco to be performed on or before the Business Combination Date pursuant to the terms of this Agreement shall have been duly performed by them and there shall have been no material adverse change in the financial condition or business of Xanthic and Subco, taken as a whole, from and after the date hereof; and

 

  (b)

GGB shall have received a certificate from a senior officer of each of Xanthic and Subco confirming that the conditions set forth in Sections 26 and 28(a) hereof have been satisfied.

The conditions described above are for the exclusive benefit of GGB and may be asserted by GGB regardless of the circumstances or may be waived by GGB in its sole discretion, in whole or in part, at any time and from time to time without prejudice to any other rights which GGB may have.

 

29.

Amendment. This Agreement may at any time and from time to time be amended by written agreement of the parties hereto without, subject to applicable law, further notice to or authorization on the part of their respective shareholders and any such amendment may, without limitation:

 

  (a)

change the time for performance of any of the obligations or acts of the parties hereto;

 

  (b)

waive any inaccuracies or modify any representation or warranty contained herein or in any document delivered pursuant hereto;

 

  (c)

waive compliance with or modify any of the covenants contained herein and waive or modify performance of any of the obligations of the parties hereto; or

 

  (d)

waive compliance with or modify any other conditions precedent contained herein;

 

A-11


provided that no such amendment shall change the provisions hereof regarding the consideration to be received by GGB Securityholders in exchange for their GGB Shares without approval by the GGB Securityholders given in the same manner as required for the approval of the Amalgamation.

 

30.

Termination. This Agreement may, prior to the issuance of the Certificate of Amalgamation, be terminated by mutual agreement of the respective boards of directors of the parties hereto, without further action on the part of the shareholders of GGB or Subco. This Agreement shall also terminate without further notice or agreement if:

 

  (a)

the Amalgamation is not approved by the shareholders of GGB entitled to vote in accordance with the Act; or

 

  (b)

the Transaction Agreement is terminated.

 

31.

Binding Effect. This Agreement shall be binding upon and enure to the benefit of the parties hereto and their successors and permitted assigns.

 

32.

Assignment. No party to this Agreement may assign any of its rights or obligations under this Agreement without the prior written consent of each of the other parties.

 

33.

Further Assurances. Each of the parties hereto agrees to execute and deliver such further instruments and to do such further reasonable acts and things as may be necessary or appropriate to carry out the intent of this Agreement.

 

34.

Notice. Any notice which a party may desire to give or serve upon another party shall be in writing and may be delivered, mailed by prepaid registered mail, return receipt requested or sent by telecopy transmission to the following addresses:

 

  (a)

GGB:

Suite 5300, Commerce Court West

199 Bay Street

Toronto, ON M5L 1B9

Attention:      Joey Schottenstein, Chairman

Fax Number: (614) 388-8410

Email:            joey.schottenstein@spgroup.com

 

  (b)

Xanthic and Subco:

77 King Street West, Suite 2905

Toronto, Ontario M5K 1A2

Attention:      Tim Moore, Chief Executive Officer

Fax Number: (416) 765-0029

Email:            timm@xanthicbiopharma.com

 

A-12


or to such other address as the party to or upon whom notice is to be given or served has communicated to the other parties by notice given or served in the manner provided for in this Section. In the case of delivery or telecopy transmission, notice shall be deemed to be given on the date of delivery and in the case of mailing, notice shall be deemed to be given on the third Business Day after such mailing.

 

35.

Time of Essence. Time shall be of the essence of this Agreement.

 

36.

Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the Province of Ontario and the federal Laws of Canada applicable therein.

[Remainder of page intentionally left blank.]

 

A-13


IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the date first above written.

 

GREEN GROWTH BRANDS LTD.

Per:

   
 

Name:

 

Title:

 

Per:

   
 

Name:

 

Title:

 

XANTHIC BIOPHARMA INC.

Per:

   
 

Name:

 

Title:


Execution Version

XANTHIC BIOPHARMA INC.

as Xanthic

and

GREEN GROWTH BRANDS LTD.

as GGB

 

 

AMENDING AGREEMENT TO THE TRANSACTION AGREEMENT

August 30, 2018

 

 


Execution Version

 

AMENDING AGREEMENT

Amending agreement (the “Amending Agreement”) dated August 30, 2018 between Xanthic Biopharma Inc. (“Xanthic”) and Green Growth Brands Ltd. (“GGB”).

 

  RECITALS:

 

  (a)

Xanthic and GGB have entered into a transaction agreement dated July 13, 2018 (the “Transaction Agreement”); and

 

  (b)

Xanthic and GGB wish to amend the Transaction Agreement as provided in this Amending Agreement.

In consideration of the above and for other good and valuable consideration, the parties agree as follows:

Section 1 Defined Terms.

Capitalized terms used in this Amending Agreement that are not defined in it have the meanings given to them in the Transaction Agreement.

Section 2 Amendments to Article 1 of the Transaction Agreement.

Section 1.1 “Defined Terms” of the Transaction Agreement is amended as of the date of this amending agreement, as follows:

 

  (a)

The definition of “Convertible Debenture Offering” in Section 1.1 of the Transaction Agreement is deleted and replaced by the following:

““Convertible Debenture Offering” means the contemplated brokered and non-brokered private placement offering of a minimum of $55 million of Debentures to be created and issued pursuant to the Debenture Indenture.”;

 

  (b)

Following the definition of “CSE” and before the definition of “Deposit Promissory Note” in Section 1.1 of the Transaction Agreement, the following definitions are added:

““Debentures” means the 12.00% unsecured convertible debentures of GGB at $1,000 per Debenture issued in connection with the Convertible Debenture Offering that shall, in the event certain conditions are satisfied prior to the maturity date of such Debentures, be automatically converted into GGB Units pursuant to and in accordance with the terms of the Debenture Indenture.”; and

““Debenture Indenture” means the debenture indenture to be entered into between GGB and Capital Transfer Agency ULC, as debenture trustee pursuant to which the Debentures will be created and issued.”;


  (c)

Following the definition of “GGB Shareholders” and before the definition of “GGB Shares” in Section 1.1 of the Transaction Agreement, the following definition is added:

““GGB Shareholders Agreement” mean shareholders agreement of GGB dated April 10, 2018 by and among, inter alia, GGB, Chiron Ventures Inc., Cambridge Capital Ltd. And All JS Greenspace LLC.”;

 

  (d)

Following the definition of “GGB Shares” and before the definition of “Intellectual Property” in Section 1.1 of the Transaction Agreement, the following definitions are added:

““GGB Units” mean units of GGB with each whole unit comprised of one GGB Share and 12 of a GGB Warrant.”; and

““GGB Warrants” means common share purchase warrants of GGB to be issued and created pursuant to a warrant indenture to be entered into among GGB, Xanthic and Capital Transfer Agency ULC, as warrant trustee.”; and

 

  (e)

The definition of “Subscription Receipt Offering” in Section 1.1 of the Transaction Agreement is deleted and replaced by the following:

““Subscription Receipt Offering” means the brokered private placement offering of subscription receipts of GGB (the “Subscription Receipts”), whereby each subscription receipt shall be exchangeable into GGB Shares upon satisfaction of certain escrow release conditions.”.

Section 3 Amendments to Article 2 of the Transaction Agreement.

Section 2.1”Amalgamtion” of the Transaction Agreement is amended as of the date of this amending agreement, as follows:

 

  (a)

Following Section 2.1(2)(f)(ii) and before Section 2.1(2)(f)(iii) of the Transaction Agreement, the following new Section 2.1(2)(f)(iii) and Section 2.1(2)(f)(iv) are inserted and Section 2.1(2)(f)(iii) – (vi) will become Section 2.1(2)(f)(v) – (viii):

“(iii) holders of GGB Shares issued to holders upon exchange of Subscription Receipts for GGB Shares shall receive that number of fully paid and non-assessable Xanthic Shares for each GGB Share held by such holder as is equal to the number of GGB Shares held by such holder (without duplication pursuant to Section 2.1(2)(f)(ii) above) as is equal to the number of GGB Shares held multiplied by “Exchange Ratio””.

“(iv) holders of GGB Warrants shall receive replacement warrants of Xanthic to purchase from Xanthic that number of fully paid and non-assessable Xanthic Shares for each whole GGB Warrant held by such holder as is equal

 

- 2 -


to the number of whole GGB Warrants held multiplied by “Exchange Ratio” in accordance with and pursuant to the term of the Warrant Indenture”.

Section 4 Amendments to Article 3 “Representations and Warranties” of the Transaction Agreement.

Section 3.1 “Representations and Warranties of GGB” of the Transaction Agreement is amended to read as follows:

 

  (a)

Section 3.1(f) is deleted and replaced with the following:

“The ownership of the GGB Shares is as set forth in Section 3.1(f) of the GGB Disclosure Letter. The GGB Shareholders own such GGB Shares as the registered and beneficial owner with a good title, free and clear of all Liens other than those restrictions on transfer, if any, contained in the articles of GGB and the GGB Shareholders Agreement.”

 

  (b)

Section 3.1(j) is deleted and replaced with the following:

“Other than the GGB Shareholders Agreement, GGB is not a party to any agreement which in any manner affects the voting control of any of the shares of GGB.”

 

  (c)

Section 3.1(o) is deleted and replaced with the following:

“Except in connection with the Offerings, GGB has not retained and will not retain any financial advisor, broker, agent or finder, or paid or agreed to pay any financial advisor, broker, agent or finder on account of this Agreement or the Amalgamation, any transaction contemplated hereby or any transaction presently ongoing or contemplated.”

Section 5 Amendments to Article 5 “Covenants of the Parties” of the Transaction Agreement.

 

  (a)

Section 5.1(4) of the Transaction Agreement is amended to read as follows:

“Except pursuant to the Offerings and without limiting the generality of Section 5.1(3), GGB covenants as follows for the period between the date of this Agreement and the earlier of the Effective Date and the termination of this Agreement in accordance with its terms: …”

 

  (b)

Part (ix) of Section 5.1(4)(c) of the Transaction Agreement is amended to read as follows:

“except in connection with the issuance of GGB Shares pursuant to part (ix) of Section 5.1(4)(b), GGB shall not adopt or amend or make any contribution to any bonus, profit sharing, option, pension, retirement, deferred compensation, insurance, incentive compensation, other compensation or other similar plan, agreement, trust, fund or agreements for the benefit of

 

- 3 -


employees, except as is necessary to comply with the law or with respect to existing provisions of any such plans, programs, or agreements:

Section 6 Amendments to Article 7 “Post-Closing” to the Transaction Agreement

The reference to “4.07” in Section 7.1 of the Transaction Agreement shall be deleted and replaced with a reference to “approximately 4.07”.

Section 7 Amendments to Schedules to the Transaction Agreement.

Schedule “A” to the Transaction Agreement is deleted and replaced with the form of Schedule attached as Schedule “A to this amending agreement.

Section 8 Reference to and Effect on the Transaction Agreement.

On and after the date of this Amending Agreement, any reference to “this Agreement” in the Transaction Agreement and any reference to the Transaction Agreement in any other agreements will mean the Transaction Agreement as amended by this Amending Agreement. Except as specifically amended by this Amending Agreement, the provisions of the Transaction Agreement remain in full force and effect.

Section 9 Successors and Assigns.

This Amending Agreement becomes effective when executed by Xanthic and GGB. After that time, it will be binding upon and enure to the benefit of Xanthic and GGB and their respective successors and permitted assigns.

Section 10 Governing Law.

This Amending Agreement is governed by, and will be interpreted and construed in accordance with, the laws of the Province of Ontario and the federal laws of Canada applicable therein.

Section 11 Counterparts.

This Amending Agreement may be executed in any number of counterparts, each of which is deemed to be an original, and such counterparts together constitute one and the same instrument. Transmission of an executed signature page by facsimile, email or other electronic means is as effective as a manually executed counterpart of this Amending Agreement.

[Remainder of this page intentionally left blank.]

 

- 4 -


The parties have executed this Amending Agreement.

 

XANTHIC BIOPHARMA INC.

By:

  LOGO
 

Name: David Bhumgara

Title: Chief Financial Officer

 

GREEN GROWTH BRANDS LTD.

By:

   
 

Name:

Title:


The parties have executed this Amending Agreement.

 

XANTHIC BIOPHARMA INC.

By:

   
 

Name:

Title:

 

GREEN GROWTH BRANDS LTD.

By: 

 

LOGO

 

Name: IAN FODIE

Title: CFO


SCHEDULE “C”

XANTHIC BIOPHARMA INC.

(the “Corporation”)

AUDIT COMMITTEE CHARTER

 

1.

PURPOSE

The audit committee (the “Committee”) will assist the Board of Directors of the Corporation (the “Board”) in fulfilling its responsibilities. The Committee will review the financial reporting process, the system of internal control and management of financial risks, the audit process, and the Corporation’s process for monitoring compliance with laws and regulations and its own code of business conduct as it relates to financial reporting and disclosure. In performing its duties, the Committee will maintain effective working relationships with the Board, management, and the external auditors and monitor the independence of those auditors. The Committee will also be responsible for reviewing the Corporation’s financial strategies, its financing plans and its use of the equity and debt markets.

To perform his or her role effectively, each Committee member will obtain an understanding of the responsibilities of committee membership as well as the Corporation’s business, operations, and risks.

 

2.

COMMITTEE MEMBERSHIP

The Committee shall consist of no fewer than three members, a majority of whom shall not be officers or employees of the Corporation or any of its affiliates and who shall meet the independence requirements of Canadian securities laws and any stock exchange on which the Common Shares of the Corporation are listed from time to time. The members and chair of the Committee (the “Chair”) shall be appointed and removed by the Board.

 

3.

COMMITTEE MEETINGS

The Committee shall meet quarterly each year. The Chairman will schedule regular meetings, and additional meetings may be held at the request of two or more members of the Committee, the CEO, or the Chairman of the Board. External auditors may convene a special meeting if they consider that it is necessary.

The Committee may invite such other persons (e.g. the CEO and/or CFO) to its meetings, as it deems appropriate. The external auditors should be present at each quarterly audit committee meeting and should be expected to comment on the financial statements in accordance with best practices.

The Committee shall keep adequate minutes of all its proceedings, and the Chair will report its actions to the next meeting of the Board. Committee members will be furnished with copies of the minutes of each Committee meeting and any action taken by unanimous consent.

 

4.

COMMITTEE AUTHORITY AND RESPONSIBILITIES

In carrying out its responsibilities, the Committee will:

4.01 Gain an understanding of whether internal control recommendations made by external auditors have been implemented by management.

4.02 Gain an understanding of the current areas of greatest financial risk and whether management is managing these effectively.

4.03 Review the Corporation’s strategic and financing plans to assist the Board’s understanding of the underlying financial risks and the financing alternatives.

 

- 1 -


4.04 Review management’s plans to access the equity and debt markets and to provide the Board with advice and commentary.

4.05 Review significant accounting and reporting issues, including recent professional and regulatory pronouncements, and understand their impact on the financial statements.

4.06 Review any legal matters which could significantly impact the financial statements as reported on by the general counsel and meet with outside counsel whenever deemed appropriate.

4.07 Review the annual and quarterly financial statements including Management’s Discussion and Analysis and determine whether they are complete and consistent with the information known to committee members; determine that the auditors are satisfied that the financial statements have been prepared in accordance with International Financial Reporting Standards, stock exchange requirements and governmental regulations.

4.08 Pay particular attention to complex and/or unusual transactions such as those involving derivative instruments and consider the adequacy of disclosure thereof.

4.09 Focus on judgmental areas, for example those involving valuation of assets and liabilities and other commitments and contingencies.

4.10 Review audit issues related to the Corporation’s material associated and affiliated companies that may have a significant impact on the Corporation’s equity investment.

4.11 Meet with management and the external auditors to review the annual financial statements and the results of the audit.

4.12 Assess the fairness of the interim financial statements and disclosures, and obtain explanations from management on whether:

 

  (a)

actual financial results for the interim period varied significantly from budgeted or projected results;

 

  (b)

generally accepted accounting principles have been consistently applied;

 

  (c)

there are any actual or proposed changes in accounting or financial reporting practices; and

 

  (d)

there are any significant or unusual events or transactions which require disclosure and, if so, consider the adequacy of that disclosure.

4.13 Review the external auditors’ proposed audit scope and approach and ensure no unjustifiable restriction or limitations have been placed on the scope.

4.14 Review the performance of the external auditors and approve in advance provision of services other than auditing.

4.15 Consider the independence of the external auditors, including reviewing the range of services provided in the context of all consulting services bought by the Corporation.

4.16 Make recommendations to the Board regarding the reappointment of the external auditors.

4.17 Meet separately with the external auditors to discuss any matters that the committee or auditors believe should be discussed privately.

4.18 Endeavour to cause the receipt and discussion on a timely basis of any significant findings and recommendations made by the external auditors.

 

- 2 -


4.19 Obtain regular updates from management and the Corporation’s legal counsel regarding compliance matters, as well as certificates from the CFO as to required statutory payments and bank covenant compliance and from senior operating personnel as to permit compliance.

4.20 Ensure that the Board is aware of matters which may significantly impact the financial condition or affairs of the business.

4.21 Perform other functions as requested by the full Board.

4.22 If necessary, institute special investigations and, if appropriate, hire special counsel or experts to assist.

4.23 Review and update the charter; receive approval of changes from the Board.

 

- 3 -


SCHEDULE “D”

EQUITY INCENTIVE PLAN

XANTHIC BIOPHARMA INC.

ARTICLE 1

PURPOSE

 

1.1

Purpose

The purpose of this Plan is to provide the Corporation with a share-related mechanism to attract, retain and motivate qualified Directors, Employees and Consultants of the Corporation and its subsidiaries, to reward such of those Directors, Employees and Consultants as may be granted Awards under this Plan by the Board from time to time for their contributions toward the long term goals and success of the Corporation, and to enable and encourage such Directors, Employees and Consultants to acquire Shares as long term investments and proprietary interests in the Corporation. This Plan is also intended to replace the Prior Plan (as defined below) as of the Effective Date and with respect to future grants and awards following such date.

ARTICLE 2

DEFINITIONS

 

2.1

Definitions

When used herein, unless the context otherwise requires, the following terms have the indicated meanings, respectively:

Affiliate” means, with respect to any Person, (i) any Person directly or indirectly controlling, controlled by or under common control with such Person, (ii) any Person directly or indirectly owning or controlling 10% or more of any class of outstanding equity securities of such Person;

Award” means any Option, Restricted Share Unit or Deferred Share Unit granted under this Plan;

Award Agreement” means a signed, written agreement between a Participant and the Corporation, in the form or any one of the forms approved by the Plan Administrator, evidencing the terms and conditions on which an Award has been granted under this Plan and which need not be identical to any other such agreements;

Board” means the board of directors of the Corporation;

Business Day” means a day, other than a Saturday or Sunday, on which the principal commercial banks in the City of Toronto are open for commercial business during normal banking hours;

Cash Fees” has the meaning set forth in Subsection 6.1(a);

Cause” means, with respect to a particular Employee:

 

  (a)

cause” as such term is defined in the employment or other written agreement between the Corporation or a Designated Affiliate and the Employee; or

 

  (b)

in the event there is no written or other applicable employment agreement between the Corporation or a Designated Affiliate or “cause” is not defined in such agreement, “cause” as such term is defined in the Award Agreement; or

 

  (c)

in the event neither (a) nor (b) apply, then “cause” as such term is defined by applicable law or, if not so defined, such term shall refer to circumstances where an employer can terminate an individual’s employment without notice or pay in lieu thereof;

 

- 1 -


Change in Control” means the occurrence of any one or more of the following events:

 

  (a)

any transaction at any time and by whatever means pursuant to which any Person or any group of two or more Persons acting jointly or in concert (other than the Corporation or a wholly-owned subsidiary of the Corporation) hereafter acquires the direct or indirect “beneficial ownership” (as defined in the Securities Act (Ontario)) of, or acquires the right to exercise control or direction over, securities of the Corporation representing more than 50% of the then issued and outstanding voting securities of the Corporation, including, without limitation, as a result of a take-over bid, an Exchange of securities, an amalgamation of the Corporation with any other entity, an arrangement, a capital reorganization or any other business combination or reorganization;

 

  (b)

the sale, assignment or other transfer of all or substantially all of the assets of the Corporation to a Person other than a wholly-owned subsidiary of the Corporation;

 

  (c)

the dissolution or liquidation of the Corporation, other than in connection with the distribution of assets of the Corporation to one or more Persons which were wholly- owned subsidiaries of the Corporation prior to such event;

 

  (d)

the occurrence of a transaction requiring approval of the Corporation’s shareholders whereby the Corporation is acquired through consolidation, merger, Exchange of securities, purchase of assets, amalgamation, statutory arrangement or otherwise by any other Person (other than a short form amalgamation or Exchange of securities with a wholly-owned subsidiary of the Corporation); or

 

  (e)

individuals who comprise the Board as of the last annual meeting of shareholders of the Corporation (the “Incumbent Board”) for any reason cease to constitute at least a majority of the members of the Board, unless the election, or nomination for election by the Corporation’s shareholders, of any new director was approved by a vote of at least a majority of the Incumbent Board, and in that case such new director shall be considered as a member of the Incumbent Board;

provided that, notwithstanding clause (a), (b), (c) and (d) above, a Change in Control shall be deemed not to have occurred if immediately following the transaction set forth in clause (a), (b), (c) or (d) above: (A) the holders of securities of the Corporation that immediately prior to the consummation of such transaction represented more than 50% of the combined voting power of the then outstanding securities eligible to vote for the election of directors of the Corporation hold (x) securities of the entity resulting from such transaction (the “Surviving Entity”) that represent more than 50% of the combined voting power of the then outstanding securities eligible to vote for the election of directors or trustees (“voting power”) of the Surviving Entity, or (y) if applicable, securities of the entity that directly or indirectly has beneficial ownership of 100% of the securities eligible to elect directors or trustees of the Surviving Entity (the “Parent Entity”) that represent more than 50% of the combined voting power of the then outstanding securities eligible to vote for the election of directors or trustees of the Parent Entity, and (B) no Person or group of two or more Persons, acting jointly or in concert, is the beneficial owner, directly or indirectly, of more than 50% of the voting power of the Parent Entity (or, if there is no Parent Entity, the Surviving Entity) (any such transaction which satisfies all of the criteria specified in clauses

(A) and (B) above being referred to as a “Non-Qualifying Transaction” and, following the Non-Qualifying Transaction, references in this definition of “Change in Control” to the “Corporation” shall mean and refer to the Parent Entity (or, if there is no Parent Entity, the Surviving Entity) and, if such entity is a company or a trust, references to the “Board” shall mean and refer to the board of directors or trustees, as applicable, of such entity). Notwithstanding the foregoing, for purposes of any Award that constitutes “deferred compensation” (within the meaning of Section 409A of the Code), the payment of which would be accelerated upon a Change in Control, a transaction will not be deemed a Change in Control for Awards granted to any Participant who is a U.S. Taxpayer unless the transaction qualifies as “a change in control event” within the meaning of Section 409A of the Code.

Code” means the United States Internal Revenue Code of 1986, as amended from time to time;

 

- 2 -


Committee” has the meaning set forth in Section 3.2;

Consultant” means an individual consultant or an employee or director of a consultant entity, other than an Employee Participant, who:

 

  (a)

is engaged to provide services on a bona fide basis to the Corporation or a Designated Affiliate, other than services provided in relation to a distribution of securities of the Corporation or a Designated Affiliate;

 

  (b)

provides the services under a written contract with the Corporation or a Designated Affiliate;

 

  (c)

spends or will spend a significant amount of time and attention on the affairs and business of the Corporation or a Designated Affiliate;

Control” means the relationship whereby a Person is considered to be “controlled” by a Person if:

 

  (a)

in the case of a Person,

 

  (i)

voting securities of the first-mentioned Person carrying more than 50% of the votes for the election of directors are held, directly or indirectly, otherwise than by way of security only, by or for the benefit of the other Person;

 

  (ii)

the votes carried by the securities are entitled, if exercised, to elect a majority of the directors of the first-mentioned Person;

 

  (iii)

in the case of a partnership that does not have directors, other than a limited partnership, the second-mentioned Person holds more than 50% of the interests in the partnership; or

 

  (b)

in the case of a limited partnership, the general partner is the second-mentioned Person.

Corporation” means Xanthic Biopharma Inc.;

Date of Grant” means, for any Award, the date specified by the Plan Administrator at the time it grants the Award (which, for greater certainty, shall be no earlier than the date on which the Board meets or otherwise acts for the purpose of granting such Award) or if no such date is specified, the date upon which the Award was granted;

Deferred Share Unit” or “DSU” means a unit equivalent in value to a Share, credited by means of a bookkeeping entry in the books of the Corporation in accordance with Article 6;

Designated Affiliate” means each Affiliate of the Corporation as designated by the Plan Administrator for purposes of the Plan from time to time;

Director” means a director of the Corporation who is not an employee of the Corporation or an Affiliate of the Corporation;

Director Fees” means the total compensation (including annual retainer and meeting fees, if any) paid by the Corporation to a Director in a calendar year for service on the Board;

Disabled” or “Disability” means the permanent and total incapacity of a Participant as determined in accordance with procedures established by the Plan Administrator for purposes of this Plan;

Effective Date” means the effective date of this Plan, being October 12, 2018;

Elected Amount” has the meaning set forth in Subsection 6.1(a);

 

- 3 -


Electing Person” means a Participant who is, on the applicable Election Date, a Director;

Election Date” means the date on which the Electing Person files an Election Notice in accordance with Subsection 6.1(b);

Election Notice” has the meaning set forth in Subsection 6.1(b);

Employee” means an individual who:

 

  (a)

is considered an employee of the Corporation or an Affiliate of the Corporation for purposes of source deductions under applicable tax or social welfare legislation; or

 

  (b)

works full-time or part-time on a regular weekly basis for the Corporation or an Affiliate of the Corporation providing services normally provided by an employee and who is subject to the same control and direction by the Corporation or an Affiliate of the Corporation over the details and methods of work as an employee of the Corporation.

Exchange” means the Canadian Securities Exchange and any other exchange on which the Shares are or may be listed from time to time;

Exercise Notice” means a notice in writing, signed by a Participant and stating the Participant’s intention to exercise a particular Option;

Exercise Price” means the price at which an Option Share may be purchased pursuant to the exercise of an Option;

Expiry Date” means the expiry date specified in the Award Agreement (which shall not be later than the tenth anniversary of the Date of Grant) or, if not so specified, means the tenth anniversary of the Date of Grant;

Insider” means an “insider” as defined by the Exchange from time to time in its rules and regulations governing Security Based Compensation Arrangements and other related matters;

Market Price” at any date in respect of the Shares shall be the volume weighted average closing price of Shares on the Exchange, for the five trading days immediately preceding the Date of Grant (or, if such Shares are not then listed and posted for trading on the Exchange, on such stock exchange on which the Shares are listed and posted for trading as may be selected for such purpose by the Board). In the event that such Shares are not listed and posted for trading on any exchange, the Market Price shall be the fair market value of such Shares as determined by the Board in its sole discretion.

NI 45-106” means National Instrument 45-106 – Prospectus Exemptions of the Canadian Securities Administrators, as amended from time to time;

Option” means a right to purchase Shares under this Plan that is non-assignable and non- transferable unless otherwise approved by the Plan Administrator;

Option Shares” means Shares issuable by the Corporation upon the exercise of outstanding Options;

Participant” means an Employee, Consultant or Director to whom an Award has been granted under this Plan;

Participant’s Employer” means with respect to a Participant that is or was an Employee, the Corporation or such Affiliate of the Corporation as is or, if the Participant has ceased to be employed by the Corporation or such Affiliate of the Corporation, was the Participant’s Employer;

Performance Goals” means performance goals expressed in terms of attaining a specified level of the particular criteria or the attainment of a percentage increase or decrease in the particular criteria, and may be applied to one or more of the Corporation, Affiliate of the Corporation, a division of the Corporation or Affiliate of the Corporation,

 

- 4 -


or an individual, or may be applied to the performance of the Corporation or an Affiliate of the Corporation relative to a market index, a group of other companies or a combination thereof, or on any other basis, all as determined by the Plan Administrator;

Person” includes an individual, sole proprietorship, partnership, unincorporated association, unincorporated syndicate, unincorporated organization, trust, body corporate, and a natural person in his or her capacity as trustee, executor, administrator or other legal representative;

Plan” means this Equity Incentive Plan, as may be amended from time to time;

Plan Administrator” means the Board, or if the administration of this Plan has been delegated by the Board to the Committee pursuant to Section 3.2, the Committee;

Prior Plan” means the Corporation’s current Stock Option Plan;

Restricted Share Unit” or “RSU” means a unit equivalent in value to a Share, credited by means of a bookkeeping entry in the books of the Corporation in accordance with Article 5;

Securities Laws” means securities legislation, securities regulation and securities rules, as amended, and the policies, notices, instruments and blanket orders in force from time to time that govern or are applicable to the Corporation or to which it is subject;

Security Based Compensation Arrangement” means an option to purchase Shares, or a plan in respect thereof, or any other compensation or incentive mechanism involving the issuance or potential issuance of Shares to Directors, Consultant or Employees of the Corporation or its subsidiaries including any Share purchase from treasury which is financially assisted by the Corporation by way of a loan, guarantee or otherwise;

Share” means one common share in the capital of the Corporation as constituted on the Effective Date or after an adjustment contemplated by Article 9, such other shares or securities to which the holder of an Award may be entitled as a result of such adjustment;

Termination Date” means:

 

  (a)

in the case of an Employee whose employment with the Corporation or a Designated Affiliate terminates, (i) the date designated by the Employee and the Corporation or a Designated Affiliate in a written employment agreement, or other written agreement between the Employee and Corporation or a Designated Affiliate, or (ii) if no written employment agreement exists, the date designated by the Corporation or a Designated Affiliate, as the case may be, on which an Employee ceases to be an employee of the Corporation or the Designated Affiliate, as the case may be, provided that, in the case of termination of employment by voluntary resignation by the Participant, such date shall not be earlier than the date notice of resignation was given, and “Termination Date” specifically does not mean the date of termination of any period of reasonable notice that the Corporation or the Designated Affiliate (as the case may be) may be required by law to provide to the Participant;

 

  (b)

in the case of a Consultant whose consulting agreement or arrangement with the Corporation or a Designated Affiliate, as the case may be, terminates, the date that is designated by the Corporation or the Designated Affiliate (as the case may be), as the date on which the Participant’s consulting agreement or arrangement is terminated, provided that in the case of voluntary termination by the Participant of the Participant’s consulting agreement or other written arrangement, such date shall not be earlier than the date notice of voluntary termination was given, and “Termination Date” specifically does not mean the date on which any period of notice of termination that the Corporation or the Designated Affiliate (as the case may be) may be required to provide to the Participant under the terms of the consulting agreement or arrangement expires; or

 

- 5 -


  (c)

in the case of a U.S. Taxpayer, a Participant’s “Termination Date” will be the date the Participant “separates from service” with the Corporation or a Designated Affiliate within the meaning of Section 409A of the Code;

U.S.” means the United States of America; and

U.S. Taxpayer” shall mean a Participant who, with respect to an Award, is subject to taxation under the applicable U.S. tax laws.

 

2.2

Interpretation

 

  (a)

Whenever the Plan Administrator exercises discretion in the administration of this Plan, the term “discretion” means the sole and absolute discretion of the Plan Administrator.

 

  (b)

As used herein, the terms “Article”, “Section”, “Subsection” and “clause” mean and refer to the specified Article, Section, Subsection and clause of this Plan, respectively.

 

  (c)

Words importing the singular include the plural and vice versa and words importing any gender include any other gender.

 

  (d)

Unless otherwise specified, time periods within or following which any payment is to be made or act is to be done shall be calculated by excluding the day on which the period begins, including the day on which the period ends, and abridging the period to the immediately preceding Business Day in the event that the last day of the period is not a Business Day. In the event an action is required to be taken or a payment is required to be made on a day which is not a Business Day, such action shall be taken or such payment shall be made by the immediately preceding Business Day.

 

  (e)

Unless otherwise specified, all references to money amounts are to Canadian currency.

 

  (f)

The headings used herein are for convenience only and are not to affect the interpretation of this Plan.

ARTICLE 3

ADMINISTRATION

 

3.1

Administration

This Plan will be administered by the Plan Administrator and the Plan Administrator has sole and complete authority, in its discretion, to:

 

  (a)

determine the individuals to whom grants under the Plan may be made;

 

  (b)

make grants of Awards under the Plan relating to the issuance of Shares (including any combination of Options, Restricted Share Units or Deferred Share Units) in such amounts, to such Persons and, subject to the provisions of this Plan, on such terms and conditions as it determines including without limitation:

 

  (i)

the time or times at which Awards may be granted; (ii) the conditions under which:

 

  (A)

Awards may be granted to Participants; or

 

  (B)

Awards may be forfeited to the Corporation, including any conditions relating to the attainment of specified Performance Goals;

 

- 6 -


  (ii)

the number of Shares to be covered by any Award;

 

  (iii)

the price, if any, to be paid by a Participant in connection with the purchase of Shares covered by any Awards;

 

  (iv)

whether restrictions or limitations are to be imposed on the Shares issuable pursuant to grants of any Award, and the nature of such restrictions or limitations, if any; and

 

  (v)

any acceleration of exercisability or vesting, or waiver of termination regarding any Award, based on such factors as the Plan Administrator may determine;

 

  (c)

establish the form or forms of Award Agreements;

 

  (d)

cancel, amend, adjust or otherwise change any Award under such circumstances as the Plan Administrator may consider appropriate in accordance with the provisions of this Plan;

 

  (e)

construe and interpret this Plan and all Award Agreements;

 

  (f)

adopt, amend, prescribe and rescind administrative guidelines and other rules and regulations relating to this Plan, including rules and regulations relating to sub- plans established for the purpose of satisfying applicable foreign laws or for qualifying for favorable tax treatment under applicable foreign laws; and

 

  (g)

make all other determinations and take all other actions necessary or advisable for the implementation and administration of this Plan.

 

3.2

Delegation to Committee

 

  (a)

The initial Plan Administrator shall be the Board.

 

  (b)

To the extent permitted by applicable law, the Board may, from time to time, delegate to a committee of the Board (the “Committee”) all or any of the powers conferred on the Plan Administrator pursuant to this Plan, including the power to sub-delegate to any specified officer(s) of the Corporation or its subsidiaries all or any of the powers delegated by the Board. In such event, the Committee or any sub-delegate will exercise the powers delegated to it in the manner and on the terms authorized by the delegating party. Any decision made or action taken by the Committee or any sub-delegate arising out of or in connection with the administration or interpretation of this Plan in this context is final and conclusive and binding on the Corporation and all Affiliates of the Corporation, all Participants and all other Persons.

 

3.3

Determinations Binding

Any decision made or action taken by the Board, the Committee or any sub-delegate to whom authority has been delegated pursuant to Section 3.2 arising out of or in connection with the administration or interpretation of this Plan is final, conclusive and binding on the Corporation, the affected Participant(s), their legal and personal representatives and all other Persons.

 

3.4

Eligibility

All Employees, Consultants and Directors are eligible to participate in the Plan, subject to Section 8.1(d). Participation in the Plan is voluntary and eligibility to participate does not confer upon any Employee, Consultant or Director any right to receive any grant of an Award pursuant to the Plan. The extent to which any Employee, Consultant or Director is entitled to receive a grant of an Award pursuant to the Plan will be determined in the sole and absolute discretion of the Plan Administrator.

 

- 7 -


3.5

Board Requirements

Any Award granted under this Plan shall be subject to the requirement that, if at any time the Corporation shall determine that the listing, registration or qualification of the Shares issuable pursuant to such Award upon any securities exchange or under any Securities Laws of any jurisdiction, or the consent or approval of the Exchange and any securities commissions or similar securities regulatory bodies having jurisdiction over the Corporation is necessary as a condition of, or in connection with, the grant or exercise of such Award or the issuance or purchase of Shares thereunder, such Award may not be accepted or exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained on conditions acceptable to the Board. Nothing herein shall be deemed to require the Corporation to apply for or to obtain such listing, registration, qualification, consent or approval. Participants shall, to the extent applicable, cooperate with the Corporation in complying with such legislation, rules, regulations and policies.

 

3.6

Total Shares Subject to Awards

 

  (a)

Subject to adjustment as provided for in Article 9 and any subsequent amendment to the Plan, the aggregate number of Shares reserved for issuance pursuant to Awards granted under the Plan and the Prior Plan shall not exceed 10% of the Shares issued and outstanding from time to time. The Plan is considered an “evergreen” plan, since the shares covered by Awards which have been exercised or terminated shall be available for subsequent grants under the Plan and the number of Awards available to grant increases as the number of issued and outstanding units increases.

 

  (b)

To the extent any (i) Awards (or portion(s) thereof) under the Plan or (ii) awards (or portion(s) thereof) under the Prior Plan terminate or are cancelled for any reason prior to exercise in full, or are surrendered to the Corporation by the Participant, except surrenders relating to the payment of the purchase price of any such award or the satisfaction of the tax withholding obligations related to any such award, the Shares subject to such awards (or portion(s) thereof) shall be added back to the number of Shares reserved for issuance under this Plan and will again become available for issuance pursuant to the exercise of Awards granted under this Plan.

 

  (c)

Any Shares issued by the Corporation through the assumption or substitution of outstanding stock options or other equity-based awards from an acquired company shall not reduce the number of Shares available for issuance pursuant to the exercise of Awards granted under this Plan.

 

3.7

Limits on Grants of Awards

Notwithstanding anything in this Plan:

 

  (a)

the aggregate number of Shares:

 

  (i)

issuable to Insiders at any time, under all of the Corporation’s Security Based Compensation Arrangements, shall not exceed 10% of the issued and outstanding Shares;

 

  (ii)

issued to Insiders within any one year period, under all of the Corporation’s Security Based Compensation Arrangements, shall not exceed 10% of the issued and outstanding Shares (on a non-diluted basis);

 

  (iii)

issued to persons or Consultants employed in Investor Relations Activities (as defined in the policies of the Exchange) shall vest in stages over 12 months with no more than 14 of the Options vesting in any three month period;

 

  (iv)

issued to any one Participant and such Participant’s associates under all of the Corporation’s Security Based Compensation Arrangements in any 12 month period shall

 

- 8 -


 

be 5% of the issued and outstanding Shares at the date of the issuance (on a non-diluted basis);

 

  (v)

issued to persons employed in Investor Relations Activities under the Plan or under all of the Corporation’s Security Based Compensation Arrangements, in any 12 month period shall not exceed 2% of the Shares outstanding at the date of grant (on a non-diluted basis); and

 

  (vi)

issued to any one person employed as a Consultant under the Plan or any other Share Compensation Arrangement in any 12 month period shall not exceed 2% of the Shares outstanding at the date of the grant (on a non-diluted basis).

 

  (a)

provided that the acquisition of Shares by the Corporation for cancellation shall not constitute non-compliance with this Section 3.7 for any Awards outstanding prior to such purchase of Shares for cancellation.

 

3.8

Award Agreements

Each Award under this Plan will be evidenced by an Award Agreement. Each Award Agreement will be subject to the applicable provisions of this Plan and will contain such provisions as are required by this Plan and any other provisions that the Plan Administrator may direct. Any one officer of the Corporation is authorized and empowered to execute and deliver, for and on behalf of the Corporation, an Award Agreement to each Participant granted an Award pursuant to this Plan.

 

3.9

Non-transferability of Awards

Except as permitted by the Plan Administrator, and to the extent that certain rights may pass to a beneficiary or legal representative upon death of a Participant, by will or as required by law, no assignment or transfer of Awards, whether voluntary, involuntary, by operation of law or otherwise, vests any interest or right in such Awards whatsoever in any assignee or transferee and immediately upon any assignment or transfer, or any attempt to make the same, such Awards will terminate and be of no further force or effect.

ARTICLE 4

OPTIONS

 

4.1

Grant of Options

The Plan Administrator may, from time to time, subject to the provisions of this Plan and such other terms and conditions as the Plan Administrator may prescribe, grant Options to any Participant. The terms and conditions of each Option grant shall be evidenced by an Award Agreement.

 

4.2

Exercise Price

The Plan Administrator will establish the Exercise Price at the time each Option is granted, which Exercise Price must in all cases be not less than the Market Price on the Date of Grant.

 

4.3

Term of Options

Subject to any accelerated termination as set forth in this Plan, each Option expires on its Expiry Date.

 

4.4

Vesting and Exercisability

 

  (a)

The Plan Administrator shall have the authority to determine the vesting terms applicable to grants of Options.

 

- 9 -


  (b)

Once an instalment becomes vested, it shall remain vested and shall be exercisable until expiration or termination of the Option, unless otherwise specified by the Plan Administrator, or as may be otherwise set forth in any written employment agreement, or other written agreement between the Corporation or a Designated Affiliate and the Participant. Each Option or instalment may be exercised at any time or from time to time, in whole or in part, for up to the total number of Option Shares with respect to which it is then exercisable. The Plan Administrator has the right to accelerate the date upon which any instalment of any Option becomes exercisable.

 

  (c)

Subject to the provisions of this Plan and any Award Agreement, Options shall be exercised by means of a fully completed Exercise Notice delivered to the Corporation.

 

  (d)

The Plan Administrator may provide at the time of granting an Option that the exercise of that Option is subject to restrictions, in addition to those specified in Section 4.4, such as performance-based vesting conditions.

 

4.5

Payment of Exercise Price

 

  (a)

Unless otherwise specified by the Plan Administrator at the time of granting an Option, the Exercise Notice must be accompanied by payment in full of the purchase price for the Option Shares to be purchased. The Exercise Price must be fully paid by certified cheque, bank draft or money order payable to the Corporation or by such other means as might be specified from time to time by the Plan Administrator, which may include (i) through an arrangement with a broker approved by the Corporation (or through an arrangement directly with the Corporation) whereby payment of the exercise price is accomplished with the proceeds of the sale of Shares deliverable upon the exercise of the Option, (ii) through the cashless exercise process set out in Section 4.5(b), or (iii) such other consideration and method of payment for the issuance of Shares to the extent permitted by the Securities Laws, or any combination of the foregoing methods of payment.

 

  (b)

Subject to the approval of the Plan Administrator, a Participant may elect to receive upon the exercise of an Option in accordance with the terms of this Plan (instead of payment of the exercise price and receipt of Shares issuable upon payment of the exercise price) the number of Shares equal to:

 

  (i)

the Market Price of the Shares issuable on the exercise of such Option (or portion thereof) as of the date such Option (or portion thereof) is exercised, less

 

  (ii)

the aggregate Exercise Price of the Option (or portion thereof) surrendered relating to such Shares, divided by

 

  (iii)

the Market Price per Share, as of the date such Option (or portion thereof) is exercised.

 

  (c)

No Shares will be issued or transferred until full payment therefor has been received by the Corporation.

ARTICLE 5

RESTRICTED SHARE UNITS

 

5.1

Granting of RSUs

 

  (a)

The Plan Administrator may, from time to time, subject to the provisions of this Plan and such other terms and conditions as the Plan Administrator may prescribe, grant RSUs to any Participant.

 

  (b)

The number of RSUs (including fractional RSUs) granted at any particular time pursuant to this Article 5 will be calculated by dividing (i) the amount of any compensation that is to be paid in

 

- 10 -


 

RSUs, as determined by the Plan Administrator, by (ii) the Market Price of a Share on the Date of Grant.

 

5.2

RSU Account

All RSUs received by a Participant shall be credited to an account maintained for the Participant on the books of the Corporation, as of the Date of Grant. The terms and conditions of each RSU grant shall be evidenced by an Award Agreement.

 

5.3

Vesting of RSUs

The Plan Administrator shall have the authority to determine any vesting terms applicable to the grant of RSUs.

 

5.4

Settlement of RSUs

 

  (a)

The Plan Administrator shall have the authority to determine the settlement terms applicable to the grant of RSUs. Subject to Section 10.6(d) below, on the settlement date for any RSU, the Participant shall redeem each vested RSU for:

 

  (i)

one fully paid and non-assessable Share issued from treasury to the Participant or as the Participant may direct; or

 

  (ii)

subject to the approval of the Plan Administrator, a cash payment.

 

  (b)

Any cash payments made under this Section 5.4 by the Corporation to a Participant in respect of RSUs to be redeemed for cash shall be calculated by multiplying the number of RSUs to be redeemed for cash by the Market Price per Share as at the settlement date.

 

  (c)

Payment of cash to Participants on the redemption of vested RSUs may be made through the Corporation’s payroll in the pay period that the settlement date falls within.

ARTICLE 6

DEFERRED SHARE UNITS

 

6.1

Granting of DSUs

 

  (a)

The Board may fix from time to time a portion of the Director Fees that is to be payable in the form of DSUs. In addition, each Electing Person is given, subject to the conditions stated herein, the right to elect in accordance with Section 6.1(b) to participate in the grant of additional DSUs pursuant to this Article 6. An Electing Person who elects to participate in the grant of additional DSUs pursuant to this Article 6 shall receive their Elected Amount (as that term is defined below) in the form of DSUs in lieu of cash. The “Elected Amount” shall be an amount, as elected by the Director, in accordance with applicable tax law, between 0% and 100% of any Director Fees that are otherwise intended to be paid in cash (the “Cash Fees”).

 

  (b)

Each Electing Person who elects to receive their Elected Amount in the form of DSUs in lieu of cash will be required to file a notice of election in the form of Schedule A hereto (the “Election Notice”) with the Chief Financial Officer of the Corporation: (i) in the case of an existing Electing Person, by December 31st in the year prior to the year to which such election is to apply (other than for Director Fees payable for the 2018 financial year, in which case any Electing Person who is not a U.S. Taxpayer as of the date of this Plan shall file the Election Notice by the date that is 30 days from the effective date of the Plan with respect to compensation paid for services to be performed after such date); and (ii) in the case of a newly appointed Electing Person who is not a

 

- 11 -


 

U.S. Taxpayer, within 30 days of such appointment with respect to compensation paid for services to be performed after such date. In the case of an existing Electing Person who is a U.S. Taxpayer as of the Effective Date of this Plan, an initial Election Notice may be filed by the date that is 30 days from the Effective Date only with respect to compensation paid for services to be performed after the Election Date; and, in the case of a newly appointed Electing Person who is a U.S. Taxpayer, an Election Notice may be filed within 30 days of such appointment only with respect to compensation paid for services to be performed after the Election Date. If no election is made within the foregoing time frames, the Electing Person shall be deemed to have elected to be paid the entire amount of his or her Cash Fees in cash.

 

  (c)

Subject to Subsection 6.1(d), the election of an Electing Person under Subsection 6.1(b) shall be deemed to apply to all Cash Fees paid subsequent to the filing of the Election Notice, and such Electing Person is not required to file another Election Notice for subsequent calendar years

 

  (d)

Each Electing Person who is not a U.S. Taxpayer is entitled once per calendar year to terminate his or her election to receive DSUs in lieu of Cash Fees by filing with the Chief Financial Officer of the Corporation a notice in the form of Appendix A hereto. Such termination shall be effective immediately upon receipt of such notice, provided that the Corporation has not imposed a “blackout” on trading. Thereafter, any portion of such Electing Person’s Cash Fees payable or paid in the same calendar year and, subject to complying with Subsection 6.1(b), all subsequent calendar years shall be paid in cash. For greater certainty, to the extent an Electing Person terminates his or her participation in the grant of DSUs pursuant to this Article 6, he or she shall not be entitled to elect to receive the Elected Amount, or any other amount of his or her Cash Fees in DSUs in lieu of cash again until the calendar year following the year in which the termination notice is delivered. An election by a U.S. Taxpayer to receive the Elected Amount in DSUs in lieu of cash for any calendar year is irrevocable for that calendar year after the expiration of the election period for that year and any termination of the election will not take effect until the first day of the calendar year following the calendar year in which the termination notice in the form of Appendix C is delivered.

 

  (e)

Any DSUs granted pursuant to this Article 6 prior to the delivery of a termination notice pursuant to Section 6.1(d) shall remain in the Plan following such termination and will be redeemable only in accordance with the terms of the Plan.

 

  (f)

The number of DSUs (including fractional DSUs) granted at any particular time pursuant to this Article 6 will be calculated by dividing (i) the amount of any Director Fees that are to be paid in DSUs (including any Elected Amount), by (ii) the Market Price of a Share on the Date of Grant.

 

  (g)

In addition to the foregoing, the Plan Administrator may, from time to time, subject to the provisions of this Plan and such other terms and conditions as the Plan Administrator may prescribe, grant DSUs to any Participant.

 

6.2

DSU Account

All DSUs received by a Participant (which, for greater certainty includes Electing Persons) shall be credited to an account maintained for the Participant on the books of the Corporation, as of the Date of Grant. The terms and conditions of each DSU grant shall be evidenced by an Award Agreement.

 

6.3

Vesting of DSUs

Except as otherwise determined by the Plan Administrator, DSUs shall vest immediately upon grant.

 

6.4

Settlement of DSUs

 

- 12 -


  (a)

DSUs shall be settled on the date established in the Award Agreement; provided, however that in no event shall a DSU Award be settled prior to, or, subject to the discretion of the Plan Administrator, later than one year following, the date of the applicable Participant’s separation from service. In no event shall a DSU Award be settled later than three years following the date of the applicable Participant’s separation from service. If the Award Agreement does not establish a date for the settlement of the DSUs, then the settlement date shall be the date of separation from service, subject to the delay that may be required under Section 10.6(d) below. Subject to 10.6(d) below, on the settlement date for any DSU, the Participant shall redeem each vested DSU for:

 

  (i)

one fully paid and non-assessable Share issued from treasury to the Participant or as the Participant may direct; or

 

  (ii)

subject to the approval of the Plan Administrator, a cash payment.

 

  (b)

Any cash payments made under this Section 6.4 by the Corporation to a Participant in respect of DSUs to be redeemed for cash shall be calculated by multiplying the number of DSUs to be redeemed for cash by the Market Price per Share as at the settlement date.

 

  (c)

Payment of cash to Participants on the redemption of vested DSUs may be made through the Corporation’s payroll in the pay period that the settlement date falls within.

ARTICLE 7

ADDITIONAL AWARD TERMS

 

7.1

Dividend Equivalents

 

  (a)

Unless otherwise determined by the Plan Administrator and set forth in the particular Award Agreement, RSUs and DSUs shall be credited with dividend equivalents in the form of additional RSUs and DSUs, respectively, as of each dividend payment date in respect of which normal cash dividends are paid on Shares. Such dividend equivalents shall be computed by dividing: (a) the amount obtained by multiplying the amount of the dividend declared and paid per Share by the number of RSUs and DSUs, as applicable, held by the Participant on the record date for the payment of such dividend, by (b) the Market Price at the close of the first business day immediately following the dividend record date, with fractions computed to three decimal places.

 

  (b)

Dividend equivalents credited to a Participant’s accounts shall vest in proportion to the RSUs and DSUs to which they relate, and shall be settled in accordance with Subsections 5.4 and 6.4, respectively.

 

  (c)

The foregoing does not obligate the Corporation to declare or pay dividends on Shares and nothing in this Plan shall be interpreted as creating such an obligation.

 

7.2

Black-out Period

If an Award expires during, or within five business days after, a routine or special trading black- out period imposed by the Corporation to restrict trades in the Corporation’s securities, then, notwithstanding any other provision of this Plan, unless the delayed expiration would result in tax penalties, the Award shall expire ten business days after the trading black-out period is lifted by the Corporation.

 

7.3

Withholding Taxes

The granting or vesting of each Award under this Plan is subject to the condition that if at any time the Plan Administrator determines, in its discretion, that the satisfaction of withholding tax or other withholding liabilities is necessary or desirable in respect of such grant or vesting, such action is not effective unless such withholding has been effected to the satisfaction of the Plan Administrator. In such circumstances, the Plan Administrator may

 

- 13 -


require that a Participant pay to the Corporation the minimum amount as the Corporation or an Affiliate of the Corporation is obliged to remit to the relevant taxing authority in respect of the granting or vesting of the Award. Any such additional payment is due no later than the date on which such amount with respect to the Award is required to be remitted to the relevant tax authority by the Corporation or an Affiliate of the Corporation, as the case may be. Alternatively, and subject to any requirements or limitations under applicable law, the Corporation may (a) withhold such amount from any remuneration or other amount payable by the Corporation or any Designated Affiliate to the Participant, (b) require the sale of a number of Shares issued upon exercise, vesting, or settlement of such Award and the remittance to the Corporation of the net proceeds from such sale sufficient to satisfy such amount or (c) enter into any other suitable arrangements for the receipt of such amount.

 

7.4

Recoupment

Notwithstanding any other terms of this Plan, Awards may be subject to potential cancellation, recoupment, rescission, payback or other action in accordance with the terms of any clawback, recoupment or similar policy adopted by the Corporation or an Affiliate of the Corporation and in effect at the Date of Grant of the Award, or as otherwise required by law or the rules of the Exchange. The Plan Administrator may at any time waive the application of this Section 7.4 to any Participant or category of Participants.

ARTICLE 8

TERMINATION OF EMPLOYMENT OR SERVICES

 

8.1

Termination of Employment, Services or Director

Subject to Section 8.2, unless otherwise determined by the Plan Administrator or as set forth in an Award Agreement:

 

  (a)

where a Participant’s employment, consulting agreement or arrangement is terminated or the Participant ceases to hold office or his or her position, as applicable, by reason of voluntary resignation by the Participant or termination by the Corporation or a Designated Affiliate for Cause, then any Option or other Award held by the Participant that has not vested as of the Termination Date is immediately forfeited and cancelled as of the Termination Date;

 

  (b)

where a Participant’s employment, consulting agreement or arrangement is terminated by the Corporation or a Designated Affiliate without Cause (whether such termination occurs with or without any or adequate reasonable notice, or with or without any or adequate compensation in lieu of such reasonable notice); then:

 

  (i)

a portion of any Options or other Awards not yet vested shall immediately vest, such portion to be equal to the number of unvested Options or other Awards multiplied by a fraction the numerator of which is the number of days between the Date of Grant and the Termination Date and the denominator of which is the number of days between the Date of Grant and the date the unvested Options or other Awards were originally scheduled to vest. For clarity and by way of example, if a participant’s employment is terminated 400 days following the Date of Grant and unvested Awards were originally scheduled to vest 600 days from the Date of Grant, two-thirds of the unvested Options or other Awards will immediately vest. In such a scenario the Plan Administrator reserves the right to defer settlement to the originally scheduled settlement date provided any related taxes can also be deferred and provided the timing of the settlement for U.S. Taxpayers complies with the requirements of Section 409A of the Code; and

 

  (ii)

subject to Subsection 8.1(b)(i), any Options or other Awards held by the Participant that are not yet vested at the Termination Date shall be immediately forfeited to the Corporation;

 

- 14 -


  (c)

where a Participant’s employment is terminated by reason of the death of the Participant or the Participant becomes Disabled, then each Option or other Award held by the Participant that has not vested as of the date of the death or Disability, as applicable, of such Participant shall vest on such date;

 

  (d)

a Participant’s eligibility to receive further grants of Options or other Awards under this Plan ceases as of:

 

  (i)

the date that the Corporation or a Designated Affiliate, as the case may be, provides the Participant with written notification that the Participant’s employment, consulting agreement or arrangement is terminated in the circumstances contemplated by this Section 8.1, notwithstanding that such date may be prior to the Termination Date; or

 

  (ii)

the date of the death or Disability of the Participant; and

 

  (e)

notwithstanding Subsection 8.1(b), unless the Plan Administrator, in its discretion, otherwise determines, at any time and from time to time, Options or Awards are not affected by a change of employment agreement or arrangement, or directorship within or among the Corporation or a Designated Affiliate for so long as the Participant continues to be a Director, Employee or Consultant, as applicable, of the Corporation or a Designated Affiliate.

 

8.2

Discretion to Permit Acceleration

Notwithstanding the provisions of Section 8.1, the Plan Administrator may, in its discretion, at any time prior to, or following the events contemplated in such Section, or in an employment agreement or other written agreement between the Corporation or a Designated Affiliate and the Participant, permit the acceleration of vesting of any or all Awards, all in the manner and on the terms as may be authorized by the Plan Administrator.

 

8.3

Participants’ Entitlement

Except as otherwise provided in this Plan, Awards previously granted under this Plan are not affected by any change in the relationship between, or ownership of, the Corporation and an Affiliate of the Corporation. For greater certainty, all grants of Awards remain outstanding and are not affected by reason only that, at any time, an Affiliate of the Corporation ceases to be an Affiliate of the Corporation.

ARTICLE 9

EVENTS AFFECTING THE CORPORATION

 

9.1

General

The existence of any Awards does not affect in any way the right or power of the Corporation or its shareholders to make, authorize or determine any adjustment, recapitalization, reorganization or any other change in the Corporation’s capital structure or its business, or any amalgamation, combination, arrangement, merger or consolidation involving the Corporation, to create or issue any bonds, debentures, Shares or other securities of the Corporation or to determine the rights and conditions attaching thereto, to effect the dissolution or liquidation of the Corporation or any sale or transfer of all or any part of its assets or business, or to affect any other corporate act or proceeding, whether of a similar character or otherwise, whether or not any such action referred to in this Article 9 would have an adverse effect on this Plan or on any Award granted hereunder.

 

9.2

Change in Control

Except as may be set forth in an employment agreement, or other written agreement between the Corporation or a Designated Affiliate and the Participant:

 

- 15 -


  (a)

Notwithstanding anything else in this Plan or any Award Agreement, the Plan Administrator may, without the consent of any Participant, take such steps as it deems necessary or desirable, including to cause (i) the conversion or Exchange of any outstanding Awards into or for, rights or other securities of substantially equivalent value (or greater value), as determined by the Plan Administrator in its discretion, in any entity participating in or resulting from a Change in Control; (ii) outstanding Awards to vest and become exercisable, realizable, or payable, or restrictions applicable to an Award to lapse, in whole or in part prior to or upon consummation of such merger or Change in Control, and, to the extent the Plan Administrator determines, terminate upon or immediately prior to the effectiveness of such merger or Change in Control; (iii) the termination of an Award in Exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise or settlement of such Award or realization of the Participant’s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Plan Administrator determines in good faith that no amount would have been attained upon the exercise or settlement of such Award or realization of the Participant’s rights, then such Award may be terminated by the Corporation without payment); (iv) the replacement of such Award with other rights or property selected by the Board of Directors in its sole discretion; or (v) any combination of the foregoing. In taking any of the actions permitted under this subparagraph (a), the Plan Administrator will not be required to treat all Awards similarly in the transaction.

 

  (b)

Notwithstanding Section 9.2(a), and unless otherwise determined by the Plan Administrator, if, as a result of a Change in Control, the Shares will cease trading on an Exchange, then the Corporation may terminate all of the Options granted under this Plan at the time of and subject to the completion of the Change in Control transaction by paying to each holder at or within a reasonable period of time following completion of such Change in Control transaction an amount for each Option equal to the fair market value of the Option held by such Participant as determined by the Plan Administrator, acting reasonably.

 

  (c)

Notwithstanding Section 8.1, and except as otherwise provided in an employment agreement, consulting agreement or arrangement, or other written agreement between the Corporation or a Designated Affiliate and a Participant, if within 12 months following the completion of a transaction resulting in a Change in Control, an Participant’s employment, consulting agreement or arrangement is terminated by the Corporation or a Designated Affiliate without Cause, without any action by the Plan Administrator, the vesting of all Awards held by such Employee shall immediately accelerate, and all Options shall be exercisable notwithstanding Section 4.4 until the earlier of: (i) the Expiry Date of such Award; and (ii) the date that is 90 days after the Termination Date.

 

  (d)

It is intended that any actions taken under this Section 9.2 will comply with the requirements of Section 409A of the Code with respect to Awards granted to U.S. Taxpayers.

 

9.3

Reorganization of Corporation’s Capital

Should the Corporation effect a subdivision or consolidation of Shares or any similar capital reorganization or a payment of a stock dividend (other than a stock dividend that is in lieu of a cash dividend), or should any other change be made in the capitalization of the Corporation that does not constitute a Change in Control and that would warrant the amendment or replacement of any existing Awards in order to adjust the number of Shares that may be acquired on the vesting of outstanding Awards and/or the terms of any Award in order to preserve proportionately the rights and obligations of the Participants holding such Awards, the Plan Administrator will, subject to the prior approval of the Exchange, authorize such steps to be taken as it may consider to be equitable and appropriate to that end.

 

9.4

Other Events Affecting the Corporation

In the event of an amalgamation, combination, arrangement, merger or other transaction or reorganization involving the Corporation and occurring by Exchange of Shares, by sale or lease of assets or otherwise, that does not constitute

 

- 16 -


a Change in Control and that warrants the amendment or replacement of any existing Awards in order to adjust the number of Shares that may be acquired on the vesting of outstanding Awards and/or the terms of any Award in order to preserve proportionately the rights and obligations of the Participants holding such Awards, the Plan Administrator will, subject to the prior approval of the Exchange (if required), authorize such steps to be taken as it may consider to be equitable and appropriate to that end.

 

9.5

Immediate Acceleration of Awards

Where the Plan Administrator determines that the steps provided in Sections 9.3 and 9.4 would not preserve proportionately the rights, value and obligations of the Participants holding such Awards in the circumstances or otherwise determines that it is appropriate, the Plan Administrator may, but is not required, to permit the immediate vesting of any unvested Awards.

 

9.6

Issue by Corporation of Additional Shares

Except as expressly provided in this Article 9, neither the issue by the Corporation of shares of any class or securities convertible into or exchangeable for shares of any class, nor the conversion or exchange of such shares or securities, affects, and no adjustment by reason thereof is to be made with respect to the number of Shares that may be acquired as a result of a grant of Awards.

 

9.7

Fractions

No fractional Shares will be issued pursuant to an Award. Accordingly, if, as a result of any adjustment under this Article 9 or a dividend equivalent, a Participant would become entitled to a fractional Share, the Participant has the right to acquire only the adjusted number of full Shares and no payment or other adjustment will be made with respect to the fractional Shares, which shall be disregarded.

ARTICLE 10

U.S. TAXPAYERS

 

10.1

Provisions for U.S. Taxpayers

Awards granted under this Plan to U.S. Taxpayers may be non-qualified stock options or incentive stock options qualifying under Section 422 of the Code (“ISOs”). Each Award shall be designated in the Award Agreement as either an ISO or a non-qualified stock option.

 

10.2

ISOs

Subject to any limitations in Section 3.6, the aggregate number of Shares reserved for issuance as an ISO shall not exceed 10% of the Shares issued and outstanding from time to time, and the terms and conditions of any ISOs granted to a U.S. Taxpayer on the Date of Grant hereunder, including the eligible recipients of ISOs, shall be subject to the provisions of Section 422 of the Code, and the terms, conditions, limitations and administrative procedures established by the Plan Administrator from time to time in accordance with this Plan. At the discretion of the Plan Administrator, ISOs may be granted to any employee of the Corporation, its parent or any subsidiary of the Corporation, as such terms are defined in Sections 424(e) and (f) of the Code.

 

10.3

ISO Grants to 10% Shareholders

Notwithstanding anything to the contrary in this Plan, if an ISO is granted to a U.S. Taxpayer who owns shares representing more than 10% of the voting power of all classes of shares of the Corporation or of a subsidiary or parent, as such terms are defined in Section 424(e) and (f) of the Code, on the Date of Grant, the term of the Option 18 shall not exceed five years from the time of grant of such Option and the Exercise Price shall be at least 110% of the Market Price of the Shares subject to the Option.

 

10.4

$100,000 Per Year Limitation for ISOs Granted to U.S. Taxpayers

 

- 17 -


To the extent the aggregate Market Price as at the Date of Grant of the Shares for which ISOs are exercisable for the first time by any U.S. Taxpayer during any calendar year (under all plans of the Corporation) exceeds $100,000, such excess ISOs shall be treated as non-qualified stock options.

 

10.5

Disqualifying Dispositions

Each U.S. Taxpayer awarded an ISO under this Plan shall notify the Corporation in writing immediately after the date he or she makes a disposition of any Shares acquired pursuant to the exercise of such ISO. The Corporation may, if determined by the Plan Administrator and in accordance with procedures established by it, retain possession of any Shares acquired pursuant to the exercise of an ISO as agent for the applicable person until the end of the period described in the preceding sentence, subject to complying with any instructions from such person as to the sale of such Share.

 

10.6

Section 409A of the Code

 

  (a)

This Plan will be construed and interpreted to be exempt from, or where not so exempt, to comply with Section 409A of the Code to the extent required to preserve the intended tax consequences of this Plan. To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Section 409A of the Code, the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Section 409A of the Code, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A of the Code. The Corporation reserves the right to amend this Plan to the extent it reasonably determines is necessary in order to preserve the intended tax consequences of this Plan in fight of Section 409A of the Code and any regulations or guidance under that section. In no event will the Corporation be responsible if Awards under this Plan result in adverse tax consequences to a U.S. Taxpayer under Section 409A of the Code.

 

  (b)

All terms of the Plan that are undefined or ambiguous must be interpreted in a manner that complies with Section 409A of the Code if necessary to comply with Section 409A of the Code.

 

  (c)

The Plan Administrator, in its sole discretion, may permit the acceleration of the time or schedule of payment of a U.S. Taxpayer’s vested Awards in the Plan under circumstances that constitute permissible acceleration events under Section 409A of the Code.

 

  (d)

Notwithstanding any provisions of the Plan to the contrary, in the case of any “specified employee” within the meaning of Section 409A of the Code who is a U.S. Taxpayer, distributions of non-qualified deferred compensation under Section 409A of the Code made in connection with a “separation from service” within the meaning set forth in Section 409A of the Code may not be made prior to the date which is 6 months after the date of separation from service (or, if earlier, the date of death of the U.S. Taxpayer). Any amounts subject to a delay in payment pursuant to the preceding sentence shall be paid as soon practicable following such 6-month anniversary of such separation from service.

ARTICLE 11

AMENDMENT, SUSPENSION OR TERMINATION OF THE PLAN

 

11.1

Amendment, Suspension, or Termination of the Plan

The Plan Administrator may from time to time, without notice and without approval of the holders of voting shares of the Corporation, amend, modify, change, suspend or terminate the Plan or any Awards granted pursuant to the Plan as it, in its discretion determines appropriate, provided, however, that:

 

  (a)

no such amendment, modification, change, suspension or termination of the Plan or any Awards granted hereunder may materially impair any rights of a Participant or materially increase any obligations of a Participant under the Plan without the consent of the Participant, unless the Plan

 

- 18 -


Administrator determines such adjustment is required or desirable in order to comply with any applicable Securities Laws or Exchange requirements; and

 

  (b)

any amendment that would cause an Award held by a U.S. Taxpayer be subject to the additional tax penalty under Section 409A(1)(b)(i)(II) of the Code shall be null and void ab initio with respect to the U.S. Taxpayer unless the consent of the U.S. Taxpayer is obtained.

 

11.2

Shareholder Approval

Notwithstanding Section 11.1 and subject to any rules of the Exchange, approval of the holders of the Shares shall be required for any amendment, modification or change that:

 

  (a)

increases the percentage of Shares reserved for issuance under the Plan, except pursuant to the provisions in the Plan which permit the Plan Administrator to make equitable adjustments in the event of transactions affecting the Corporation or its capital;

 

  (b)

increases or removes the 10% limits on Shares issuable or issued to insiders as set forth in Subsection 3.7(a);

 

  (c)

reduces the exercise price of an Award (for this purpose, a cancellation or termination of an Award of a Participant prior to its Expiry Date for the purpose of reissuing an Award to the same Participant with a lower exercise price shall be treated as an amendment to reduce the exercise price of an Award) except pursuant to the provisions in the Plan which permit the Plan Administrator to make equitable adjustments in the event of transactions affecting the Corporation or its capital;

 

  (d)

extends the term of an Award beyond the original Expiry Date (except where an Expiry Date would have fallen within a blackout period applicable to the Participant or within 5 business days following the expiry of such a blackout period);

 

  (e)

permits an Award to be exercisable beyond 10 years from its Date of Grant (except where an Expiry Date would have fallen within a blackout period of the Corporation);

 

  (f)

increases or removes the limits on the participation of Directors;

 

  (g)

permits Awards to be transferred to a Person; or

 

  (h)

deletes or reduces the range of amendments which require approval of shareholders under this Section 11.2.

 

11.3

Permitted Amendments

Without limiting the generality of Section 11.1, but subject to Section 11.2, the Plan Administrator may, without shareholder approval, at any time or from time to time, amend the Plan for the purposes of:

 

  (a)

making any amendments to the general vesting provisions of each Award;

 

  (b)

making any amendments to the provisions set out in Article 8;

 

  (c)

making any amendments to add covenants of the Corporation for the protection of Participants, as the case may be, provided that the Plan Administrator shall be of the good faith opinion that such additions will not be prejudicial to the rights or interests of the Participants, as the case may be;

 

- 19 -


  (d)

making any amendments not inconsistent with the Plan as may be necessary or desirable with respect to matters or questions which, in the good faith opinion of the Plan Administrator, having in mind the best interests of the Participants, it may be expedient to make, including amendments that are desirable as a result of changes in law in any jurisdiction where a Participant resides,

 

  (e)

provided that the Plan Administrator shall be of the opinion that such amendments and modifications will not be prejudicial to the interests of the Participants and Directors; or

 

  (f)

making such changes or corrections which, on the advice of counsel to the Corporation, are required for the purpose of curing or correcting any ambiguity or defect or inconsistent provision or clerical omission or mistake or manifest error, provided that the Plan Administrator shall be of the opinion that such changes or corrections will not be prejudicial to the rights and interests of the Participants.

ARTICLE 12

MISCELLANEOUS

 

12.1

Legal Requirement

The Corporation is not obligated to grant any Awards, issue any Shares or other securities, make any payments or take any other action if, in the opinion of the Plan Administrator, in its sole discretion, such action would constitute a violation by a Participant or the Corporation of any provision of any applicable statutory or regulatory enactment of any government or government agency or the requirements of any Exchange upon which the Shares may then be listed.

 

12.2

No Other Benefit

No amount will be paid to, or in respect of, a Participant under the Plan to compensate for a downward fluctuation in the price of a Share, nor will any other form of benefit be conferred upon, or in respect of, a Participant for such purpose.

 

12.3

Rights of Participant

No Participant has any claim or right to be granted an Award and the granting of any Award is not to be construed as giving a Participant a right to remain as an employee, consultant or director of the Corporation or an Affiliate of the Corporation. No Participant has any rights as a shareholder of the Corporation in respect of Shares issuable pursuant to any Award until the allotment and issuance to such Participant, or as such Participant may direct, of certificates representing such Shares.

 

12.4

Corporate Action

Nothing contained in this Plan or in an Award shall be construed so as to prevent the Corporation from taking corporate action which is deemed by the Corporation to be appropriate or in its best interest, whether or not such action would have an adverse effect on this Plan or any Award.

 

12.5

Conflict

In the event of any conflict between the provisions of this Plan and an Award Agreement, the provisions of this Plan shall govern. In the event of any conflict between or among the provisions of this Plan, an Award Agreement and (i) an employment agreement or other written agreement between the Corporation or a Designated Affiliate and a Participant which has been approved by the Chief Executive Officer of the Corporation (or where the Participant is the Chief Executive Officer, approved by a Director), the provisions of the employment agreement or other written agreement shall govern and (ii) any other employment agreement or other written agreement between the Corporation or a Designated Affiliate and a Participant, the provisions of this Plan shall govern.

 

- 20 -


12.6

Anti-Hedging Policy

By accepting the Option or Award each Participant acknowledges that he or she is restricted from purchasing financial instruments such as prepaid variable forward contracts, equity swaps, collars, or units of Exchange funds that are designed to hedge or offset a decrease in market value of Options or Awards.

 

12.7

Participant Information

Each Participant shall provide the Corporation with all information (including personal information) required by the Corporation in order to administer to the Plan. Each Participant acknowledges that information required by the Corporation in order to administer the Plan may be disclosed to any custodian appointed in respect of the Plan and other third parties, and may be disclosed to such persons (including persons located in jurisdictions other than the Participant’s jurisdiction of residence), in connection with the administration of the Plan. Each Participant consents to such disclosure and authorizes the Corporation to make such disclosure on the Participant’s behalf.

 

12.8

Participation in the Plan

The participation of any Participant in the Plan is entirely voluntary and not obligatory and shall not be interpreted as conferring upon such Participant any rights or privileges other than those rights and privileges expressly provided in the Plan. In particular, participation in the Plan does not constitute a condition of employment or engagement nor a commitment on the part of the Corporation to ensure the continued employment or engagement of such Participant. The Plan does not provide any guarantee against any loss which may result from fluctuations in the market value of the Shares. The Corporation does not assume responsibility for the income or other tax consequences for the Participants and Directors and they are advised to consult with their own tax advisors.

 

12.9

International Participants

With respect to Participants who reside or work outside Canada and the United States, the Plan Administrator may, in its sole discretion, amend, or otherwise modify, without shareholder approval, the terms of the Plan or Awards with respect to such Participants in order to conform such terms with the provisions of local law, and the Plan Administrator may, where appropriate, establish one or more sub-plans to reflect such amended or otherwise modified provisions.

 

12.10

Successors and Assigns

The Plan shall be binding on all successors and assigns of the Corporation and its Designated Affiliates.

 

12.11

General Restrictions and Assignment

Except as required by law, the rights of a Participant under the Plan are not capable of being assigned, transferred, alienated, sold, encumbered, pledged, mortgaged or charged and are not capable of being subject to attachment or legal process for the payment of any debts or obligations of the Participant unless otherwise approved by the Plan Administrator.

 

12.12

Severability

The invalidity or unenforceability of any provision of the Plan shall not affect the validity or enforceability of any other provision and any invalid or unenforceable provision shall be severed from the Plan.

 

12.13

Notices

All written notices to be given by the Participant to the Corporation shall be delivered personally, e-mail or mail, postage prepaid, addressed as follows:

 

- 21 -


  (b)

Xanthic Biopharma Inc.

   

77 King Street West, Suite 2905

   

Toronto, Ontario, Canada

   

M5K 1A2

 

  (c)

Attention:           Tim Moore, Chief Executive Officer

   

E-mail Address: timm@xanthicbiopharma.com

All notices to the Participant will be addressed to the principal address of the Participant on file with the Corporation. Either the Corporation or the Participant may designate a different address by written notice to the other. Such notices are deemed to be received, if delivered personally or by e-mail, on the date of delivery, and if sent by mail, on the fifth business day following the date of mailing. Any notice given by either the Participant or the Corporation is not binding on the recipient thereof until received.

 

12.14

Effective Date

This Plan becomes effective on a date to be determined by the Plan Administrator, subject to the approval of the shareholders of the Corporation.

 

12.15

Governing Law

This Plan and all matters to which reference is made herein shall be governed by and interpreted in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein.

 

12.16

Submission to Jurisdiction

The Corporation and each Participant irrevocably submits to the exclusive jurisdiction of the courts of competent jurisdiction in the Province of Ontario in respect of any action or proceeding relating in any way to the Plan, including with respect to the grant of Awards and any issuance of Shares made in accordance with the Plan.

 

- 22 -


APPENDIX A

XANTHIC BIOPHARMA INC.

EQUITY INCENTIVE PLAN (THE “PLAN”)

ELECTION NOTICE

All capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Plan.

Pursuant to the Plan, I hereby elect to participate in the grant of DSUs pursuant to Article 6 of the Plan and to receive     % of my Cash Fees in the form of DSUs in lieu of cash.

I confirm that:

 

  (a)

I have received and reviewed a copy of the terms of the Plan and agreed to be bound by them.

 

  (b)

I recognize that when DSUs credited pursuant to this election are redeemed in accordance with the terms of the Plan, income tax and other withholdings as required will arise at that time. Upon redemption of the DSUs, the Corporation will make all appropriate withholdings as required by law at that time.

 

  (c)

The value of DSUs is based on the value of the Shares of the Corporation and therefore is not guaranteed.

 

  (d)

To the extent I am a U.S. taxpayer, I understand that this election is irrevocable for the calendar year to which it applies and that any revocation or termination of this election after the expiration of the election period will not take effect until the first day of the calendar year following the year in which I file the revocation or termination notice with the Corporation.

The foregoing is only a brief outline of certain key provisions of the Plan. For more complete information, reference should be made to the Plan’s text.

 

Date:                                                                        

(Name of Participant)

      (Signature of Participant)

 

- 1 -


APPENDIX B

XANTHIC BIOPHARMA INC.

EQUITY INCENTIVE PLAN (THE “PLAN”)

ELECTION TO TERMINATE RECEIPT OF ADDITIONAL DSUs

All capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Plan.

Notwithstanding my previous election in the form of Appendix A to the Plan, I hereby elect that no portion of the Cash Fees accrued after the date hereof shall be paid in DSUs in accordance with Article 6 of the Plan.

I understand that the DSUs already granted under the Plan cannot be redeemed except in accordance with the Plan.

I confirm that I have received and reviewed a copy of the terms of the Plan and agree to be bound by them.

 

Date:                                                                        

(Name of Participant)

      (Signature of Participant)

Note: An election to terminate receipt of additional DSUs can only be made by a Participant once in a calendar year.

 

Date:                                                                        

(Name of Participant)

      (Signature of Participant)

 

- 2 -


APPENDIX C

XANTHIC BIOPHARMA INC.

Equity Incentive Plan (THE “PLAN”)

ELECTION TO TERMINATE RECEIPT OF ADDITIONAL DSUs

(U.S. TAXPAYERS)

All capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Plan.

Notwithstanding my previous election in the form of Appendix A to the Plan, I hereby elect that no portion of the Cash Fees accrued after the effective date of this termination notice shall be paid in DSUs in accordance with Article 6 of the Plan.

I understand that this election to terminate receipt of additional DSUs will not take effect until the first day of the calendar year following the year in which I file this termination notice with the Corporation.

I understand that the DSUs already granted under the Plan cannot be redeemed except in accordance with the Plan.

I confirm that I have received and reviewed a copy of the terms of the Plan and agree to be bound by them.

 

Date:                                                                        

(Name of Participant)

      (Signature of Participant)

Note: An election to terminate receipt of additional DSUs can only be made by a Participant once in a calendar year.

 

Date:                                                                        

(Name of Participant)

      (Signature of Participant)

 

- 3 -


SCHEDULE “E”

ADVANCE NOTICE BY-LAW

XANTHIC BIOPHARMA INC.

ADVANCE NOTICE BY-LAW

(Adopted by the board of directors, with immediate effect, on October 1, 2018)

The purpose of this Advance Notice By-law (this “By-law”) is to provide shareholders, directors and management of the Corporation with guidance on the nomination of directors (and certain other advance notice requirements). This By-law is the framework by which a deadline is fixed for shareholders to submit director nominations prior to any annual or special meeting of shareholders and sets forth the information that a shareholder must include in the notice for it to be in proper written form.

It is the belief of the Board that this By-law is beneficial to the Corporation and its shareholders. This By-law will be subject to periodic review and, subject to the Act, will reflect changes as required by securities regulatory or stock exchange requirements and, at the discretion of the Board, amendments necessary to meet evolving industry standards.

 

1.

INTERPRETATION

 

1.01

Definitions

In this By-law:

 

  (a)

Act” means the Business Corporations Act (Ontario) or any statute which may be substituted therefor, including the regulations thereunder, as amended from time to time;

 

  (b)

Applicable Securities Laws” means the applicable securities legislation of each relevant province of Canada, as amended from time to time, the rules, regulations and forms made or promulgated under any such legislation and the published national instruments, multilateral instruments, policies, bulletins and notices of the securities commission and similar regulatory authority of each relevant province of Canada;

 

  (c)

Articles” means the articles of the Corporation, as defined in the Act, and includes any amendments thereto;

 

  (d)

Board” means the board of directors of the Corporation;

 

  (e)

Corporation” means Xanthic Biopharma Inc.;

 

  (f)

Director” means a director of the Corporation as defined in the Act;

 

  (g)

Nominating Shareholder” has the meaning given to it in Section 2.1;

 

  (h)

Person” means a natural person, partnership, limited partnership, limited liability partnership, corporation, limited liability company, unlimited liability company, joint stock company, trust, unincorporated association, joint venture or other entity or governmental or regulatory entity, and pronouns have a similarly extended meaning;

 

  (i)

Public Announcement” means disclosure in a press release reported by a national news service in Canada or in a document publicly filed by the Corporation under its profile on the System for Electronic Document Analysis and Retrieval at www.sedar.com; and

 

-1-


  (j)

Shareholders’ Meeting” means any annual meeting of shareholders of the Corporation or special meeting of shareholders of the Corporation.

 

1.02

Interpretation

In this By-law:

 

  (a)

words importing the singular include the plural and vice versa, and words importing gender include all genders; and

 

  (b)

all terms used in this By-law that are defined in the Act have the meaning given to such terms in the Act.

The headings used throughout this By-law are inserted for convenience only and are not to be used as an aid in the interpretation of this By-law.

This By-law is subject to, and should be read in conjunction with, the Act and the Articles. If there is any conflict or inconsistency between any provision of the Act or the Articles and any provision of this By-law, the provision of the Act or the Articles will govern.

 

2.

ADVANCE NOTICE

 

2.01

Nomination of Directors

Subject only to the Act, Applicable Securities Laws and the Articles, only persons who are nominated in accordance with the provisions of this section shall be eligible for election as Directors. Nominations of persons for election to the Board may be made at any Shareholders’ Meeting, but only if one of the purposes for which such Shareholders’ Meeting was called was the election of Directors. Such nominations may be made in the following manner:

 

  (a)

by or at the direction of the Board, including pursuant to a notice of meeting;

 

  (b)

by or at the direction or request of one or more shareholders of the Corporation pursuant to a proposal made in accordance with the provisions of the Act, or a requisition for a Shareholders’ Meeting made in accordance with the provisions of the Act; or

 

  (c)

by any Person (a “Nominating Shareholder”) who:

 

  (i)

at the close of business on the date of the giving of the notice provided below in this section and on the record date for notice of such Shareholders’ Meeting, is entered in the securities register of the Corporation as a holder of one or more shares in the capital of the Corporation carrying the right to vote at such Shareholders’ Meeting or who beneficially owns shares in the capital of the Corporation that are entitled to be voted at such Shareholders’ Meeting; and

 

  (ii)

has given timely notice in proper written form in accordance with the procedures set forth below in this section.

For the avoidance of doubt, this section shall be the exclusive means for any Person to bring nominations for election to the Board before any Shareholders’ Meeting.

 

2.02

Timely Notice; Proper Written Form

 

  (a)

In addition to any other applicable requirements, for a nomination to be made by a Nominating Shareholder, the Nominating Shareholder must have given timely notice thereof in proper written

 

-2-


 

form to the Corporate Secretary of the Corporation at the principal executive offices of the Corporation.

 

  (b)

To be timely, a Nominating Shareholder’s notice to the Corporate Secretary of the Corporation must be made:

 

  (i)

in the case of an annual Shareholders’ Meeting, not less than 30 days prior to the date of such annual Shareholders’ Meeting; provided, however, that if such annual Shareholders’ Meeting is to be held on a date that is less than 50 days after the date on which the first Public Announcement (the “Notice Date”) of the date of such annual Shareholders’ Meeting was made, notice by the Nominating Shareholder may be made not later than the close of business on the 10th day following the Notice Date; or

 

  (ii)

in the case of a special Shareholders’ Meeting (which is not also an annual Shareholders’ Meeting) called for the purpose of electing Directors (whether or not called for other purposes), not later than the close of business on the 15th day following the day on which the first Public Announcement of the date of such special Shareholders’ Meeting was made;

provided that, in either instance, if notice-and-access (as defined in National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer) is used for delivery of proxy related materials in respect of a Shareholders’ Meeting and the Notice Date in respect of the Shareholders’ Meeting is not less than 50 days prior to the date of the Shareholders’ Meeting, the notice must be received not later than the close of business on the 40th day before the Shareholders’ Meeting (but, in any event, not prior to the Notice Date); provided further, however, that in the event that the Shareholders’ Meeting is to be held on a date that is less than 50 days after the Notice Date, notice by the Nominating Shareholder shall be made, in the case of an annual Shareholders’ Meeting, not later than the close of business on the 10th day following the Notice Date and, in the case of a special Shareholders’ Meeting (which is not also an annual Shareholders’ Meeting), not later than the close of business on the 15th day following the Notice Date.

 

  (c)

To be in proper written form, a Nominating Shareholder’s notice to the Corporate Secretary of the Corporation must be in writing and must set forth:

 

  (i)

as to each person whom the Nominating Shareholder proposes to nominate for election as a Director (each, a “Proposed Nominee”):

 

  (A)

the name, age, business address and residential address of the Proposed Nominee;

 

  (B)

the principal occupation, business or employment of the Proposed Nominee;

 

  (C)

whether the Proposed Nominee is a resident Canadian within the meaning of the Act;

 

  (D)

the class or series and number of shares in the capital of the Corporation which are controlled or which are owned beneficially or of record by the Proposed Nominee as of the record date for the applicable Shareholders’ Meeting (if such date shall then have been made publicly available and shall have occurred) and as of the date of such notice;

 

  (E)

a description of any relationship, agreement, arrangement or understanding (whether financial, compensatory, indemnity related or otherwise) between the Nominating Shareholder and the Proposed Nominee, or any affiliates or associates of, or any Person acting jointly or in concert with the Nominating

 

-3-


 

Shareholder or the Proposed Nominee, in connection with the Proposed Nominee’s nomination and election as a Director;

 

  (F)

whether the Proposed Nominee is party to any existing or proposed relationship, agreement, arrangement or understanding with any competitor of the Corporation or its affiliates or any other third party which may give rise to a real or perceived conflict of interest between the interests of the Corporation and the interests of the Proposed Nominee; and

 

  (G)

any other information relating to the Proposed Nominee that would be required to be disclosed in a dissident’s information circular or other filings required to be made in connection with solicitations of proxies for the election of Directors pursuant to the Act or Applicable Securities Laws; and

 

  (ii)

as to each Nominating Shareholder:

 

  (A)

the name, business and, if applicable, residential address of such Nominating Shareholder;

 

  (B)

the number of securities of each class of voting securities of the Corporation or any of its subsidiaries beneficially owned, or controlled or directed, directly or indirectly, by such Nominating Shareholder or any other Person with whom such Nominating Shareholder is acting jointly or in concert with respect to the Corporation or any of its securities, as of the record date for the applicable Shareholders’ Meeting (if such date shall then have been made publicly available and shall have occurred) and as of the date of such notice;

 

  (C)

the interests in, or rights or obligations associated with, any agreement, arrangement or understanding, the purpose or effect of which may be to alter, directly or indirectly, such Nominating Shareholder’s economic interest in a security of the Corporation or such Nominating Shareholder’s economic exposure to the Corporation;

 

  (D)

full particulars regarding any proxy, contract, arrangement, agreement, understanding or relationship pursuant to which such Nominating Shareholder, or any of its affiliates or associates, has any interests, rights or obligations relating to the voting of any securities of the Corporation or the nomination of Directors to the Board; and

 

  (E)

any other information relating to such Nominating Shareholder that would be required to be disclosed in a dissident’s information circular or other filings required to be made in connection with solicitations of proxies for election of Directors pursuant to the Act or any Applicable Securities Laws.

Reference to “Nominating Shareholder” in this section shall be deemed to refer to each shareholder that nominates or seeks to nominate a person for election as a Director in the case of a nomination proposal where more than one shareholder is involved in making the nomination proposal.

The Corporation may require any Proposed Nominee to furnish such other information as may reasonably be requested by the Corporation to determine the eligibility of such Proposed Nominee to serve as an “independent” Director or that could be material to a shareholder’s understanding of such “independence”, or the lack thereof, of such Proposed Nominee. In addition, the Corporate Secretary of the Corporation may request and require that the Nominating Shareholder provide to the Corporation from a Proposed Nominee a declaration as to the Proposed Nominee’s status as a “resident Canadian” for purposes of the Act and the Proposed Nominee’s written consent to act as a Director.

 

-4-


  (d)

No person shall be eligible for election as a Director unless nominated in accordance with the provisions of this section; provided, however, that nothing in this section shall be deemed to preclude discussion by a shareholder of the Corporation (as distinct from the nomination of Directors) at a Shareholders’ Meeting of any matter in respect of which it would have been entitled to submit a proposal pursuant to the provisions of the Act.

 

  (e)

The chairman of a Shareholders’ Meeting shall have the power and duty to determine whether a nomination has been made in accordance with the procedures set forth in the foregoing provisions of this section at such Shareholders’ Meeting and, if any proposed nomination is not in compliance with such foregoing provisions, to declare that such defective nomination shall be disregarded.

 

  (f)

Notwithstanding any other provision of this section, notice given to the Corporate Secretary of the Corporation may only be given by personal delivery or by e-mail (at such e-mail address as stipulated from time to time by the Corporate Secretary of the Corporation for the purpose of any such notice), and shall be deemed to have been given and made only at the time it is so served by personal delivery or e-mail to the Corporate Secretary of the Corporation at the address of the principal executive offices of the Corporation; provided, however, that if any such delivery or electronic communication is made on a day which is not a business day in the City of Toronto, Canada or later than 5:00 p.m. (Eastern Standard time) on a day which is a business day in the City of Toronto, Canada, then such delivery or electronic communication shall be deemed to have been made on the next subsequent day that is a business day in the City of Toronto, Canada.

 

  (g)

To be considered timely and in proper form, a Nominating Shareholder’s notice shall be promptly updated and supplemented if necessary, so that the information provided or required to be provided in such notice shall be true and correct as of the record date for the applicable Shareholders’ Meeting.

 

3.

TRANSACTION OF BUSINESS AT SHAREHOLDERS’ MEETINGS

 

3.01

Proper Meeting Business

No business may be transacted at Shareholders’ Meeting other than business that is either (i) specified in the Corporation’s notice of meeting (or any supplement thereto) given by or at the direction of the Board, (ii) otherwise properly brought before the Shareholders’ Meeting by or at the direction of the Board, or (iii) otherwise properly brought before the Shareholders’ Meeting by any shareholder of the Corporation who complies with the proposal procedures set forth in Section 3.2 below.

 

3.02

Submission of Proposals

For business to be properly brought before a Shareholder’s Meeting by a shareholder of the Corporation, such shareholder must submit a proposal to the Corporation for inclusion in the Corporation’s management information circular in accordance with the requirements of the Act; provided that any proposal that includes nominations for the election of Directors shall also comply with the other applicable requirements of this By-Law.

 

4.

MISCELLANEOUS

 

4.01

Board Discretion

The Board may, in its sole discretion, waive any requirement in this By-law.

 

4.02

Effective Date

This By-law comes into force with immediate effect on October 1, 2018, being the date it was approved by the Board.

 

-5-

EX-4.1 17 d692201dex41.htm EX-4.1 EX-4.1

Exhibit 4.1

 

LOGO

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form F-10 of Green Growth Brands Inc. (the “Registration Statement”) of our report dated September 13, 2018 relating to the audited consolidated financial statements of Xanthic Biopharma Inc. for the year ended June 30, 2018 and related notes. We also consent to the reference to us under the heading “Experts” in the offer to purchase and takeover bid circular dated January 22, 2019 made by Green Growth Brands Inc. to the holders of Aphria Shares, which is part of the Registration Statement.

(signed) “MNP LLP”

MNP LLP

January 22, 2019

 

LOGO    LOGO
EX-4.2 18 d692201dex42.htm EX-4.2 EX-4.2

Exhibit 4.2

 

LOGO

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form F-10 of Green Growth Brands Inc. (the “Registration Statement”) of our report dated September 26, 2018 relating to the audited consolidated financial statements for the period from commencement of operations on February 14, 2018 to July 31, 2018 and related notes. We also consent to the reference to us under the heading “Experts” in the offer to purchase and takeover bid circular dated January 22, 2019 made by Green Growth Brands Inc. to the holder of Aphria Shares, which is part of the Registration Statement.

(signed) “MNP SENCRL, srl”

MNP SENCRL, srl

Montreal, Quebec

January 22, 2019

 

LOGO    LOGO
EX-4.3 19 d692201dex43.htm EX-4.3 EX-4.3

Exhibit 4.3

CONSENT OF NORTON ROSE FULBRIGHT CANADA LLP

TO: The Directors of the Offeror

We hereby consent to the reference to our opinion contained under “Certain Canadian Federal Income Tax Considerations” in the Circular accompanying the Offer to Purchase dated January 22, 2019 made by the Offeror to the holders of Aphria Shares.

DATED: January 22, 2019

(signed) “NORTON ROSE FULBRIGHT CANADA LLP”

GRAPHIC 20 g624548dsp1.jpg GRAPHIC begin 644 g624548dsp1.jpg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end GRAPHIC 21 g624548dsp3.jpg GRAPHIC begin 644 g624548dsp3.jpg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end GRAPHIC 22 g624564g50z14.jpg GRAPHIC begin 644 g624564g50z14.jpg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g624569g75m00.jpg GRAPHIC begin 644 g624569g75m00.jpg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�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end GRAPHIC 24 g624573dsp001.jpg GRAPHIC begin 644 g624573dsp001.jpg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g624585b.jpg GRAPHIC begin 644 g624585b.jpg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end GRAPHIC 26 g6245891.jpg GRAPHIC begin 644 g6245891.jpg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end GRAPHIC 27 g624593a.jpg GRAPHIC begin 644 g624593a.jpg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end GRAPHIC 28 g624601dsp07.jpg GRAPHIC begin 644 g624601dsp07.jpg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g624601dsp5b.jpg GRAPHIC begin 644 g624601dsp5b.jpg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g624601g0111104736430.jpg GRAPHIC begin 644 g624601g0111104736430.jpg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g624601g0111104736601.jpg GRAPHIC begin 644 g624601g0111104736601.jpg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end GRAPHIC 32 g624673dsp31a.jpg GRAPHIC begin 644 g624673dsp31a.jpg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g624673dsp31b.jpg GRAPHIC begin 644 g624673dsp31b.jpg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end GRAPHIC 34 g624673dsp31c.jpg GRAPHIC begin 644 g624673dsp31c.jpg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end GRAPHIC 35 g624673dsp32a.jpg GRAPHIC begin 644 g624673dsp32a.jpg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end GRAPHIC 36 g6246781.jpg GRAPHIC begin 644 g6246781.jpg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end GRAPHIC 37 g62467810.jpg GRAPHIC begin 644 g62467810.jpg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g62467811.jpg GRAPHIC begin 644 g62467811.jpg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�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

8E4HS'*N1>35!R36<'7:E9F?5&$X\M*1*R32B3[1 M],@UM"619H\2"=;6>BJ;WJJ"B/60=@,(@CG1LLTR),B2AQME:7-T-!).Z=OA M;YMLOS5!N(.E.,^(P3>K=2:HQ^3Q>!G1LDJ.UB$Q7%IBNI4YNOB8YT=F2[O' M<5=-TFP-ZM:0719[S=]S5Y)J+Z[_8?,_) M4OX.Y6-@+\Q.%?DEQQZG0VO(7O)GW)'DBM?#[]@<'\CP_@S=;O*N/HO*V-[O MCB9,9%AM5",)=H(" D?0\AY3I P" D61*8/$-9R6$RHZX MZ_:K21W+\A[QVBEVK-/1=6Z9G::FG=CS8KC6\.5"E)(0XG]\VO=6D\RD@U!F M.\ARV2.*MADK3TIW^M4O(./LFLP'[(SR-0H^7K%L!0FQ?+3D9&/%\@'B M72 M1@$0, BCCR%2,:I3G\NE"DK\=((5ZI%QVB*@>G-1R]3<)I,G*[-0Q8,N)-3S MIF1$.,2+]@+6CI4]E#B2"0;U('&/V;\!_(UC3U-A];\=Z/8]Q1Y(J1<+?FTT M]\BPO@S=3EI94[H2^#WLWUG\>\[?/WDW37A_>"?'<_"KJH.!/S:1?E#*_I:= M1::=*M^A-YK_ )B%?E5P!\^N.]->8]Y?[1O\(FJBXX_L KY6Q/Z4AT66G2K= MK\$Q2[=0@&X@4-Q -S#Z #?TB.BO"0.6OW17M+110IXH*4.4O+80* "=AQ[, M80 ZC?@79B=1MO2;H( ;^G8 #W--D7TE*[C7DFJDTB .*^L+<[>(^#/UR8] MVCV_,[_;Z5ZA5O58:G].O_:^2*^0_6^^D%G_ !XWP1BMKV^\D8BF(3-G#SD% M/H4_&'):+@S5^^.CH)-:%EBIN%'%1FG3ER)6S1J\643*=14R:1E&Z::AR$4, M$8R8(NVAEDMC"0>L"[^!S!XZW.:3S256:2VXWS*"P >\>2I!D^H MUQICS7&\0,;.QH/WM]$E"$N(YE;J[*3<:6+N5.'30#6G3&92XM"C8H-P56YCW.S70>L.J5 MGG.-V+XKZ,5'1B'LW$GS8;B@AR,M+[;\DM*2-QU"E!:@D;J@HE*=Y-B/'%WM MKS-FGW!6L9$(-4Y$!2 M2 5#HKB"R@AY($4PQ>F9D.6O)2DH4XA2U-MI/*HD[I)V6M?O=NMO"[JKZDTE MQ)RO%S5"8\G(,2YLC&06W >D><4X6''W39ML +\%-U%*[+44[FZJMZW=H[N$ MW>UV>Z3]&I[F=MUAFK/,N/RB5[9:5GI%S*2"@=2PCTF=.C;;B/AIA7IC4+JU M.N-(+BE$GPQRDW/-7,N;ZF_6&S^9EYW(1("ITV2Z^X?.V=KCJU.+/+SJ4:^U M1[+7+=W-MAR:XQQBBB-C>^;->)BZQ4FA"Q*.ZKURBP9'*+APFW(82@JJ@B [ M"=0I=QUDUI/+J5_6.C99YU%0-AS[.YWJ]PW4!'*4K(-$B%7 *X.D=8@="A=),U*CNNM0H)O!BM[B3]D?KE=\CO MU!>LGKK2F.?S-:I^09OX!=**YC<24 MXN-34Y/\?2')'LBG(;,6/@,4P-D@$I@&P;E,4? 0'Q ="_0TID>$,=U49 MO(^59&HH%J=K-#K(('=H$ZQ,80!(U(:R&32[&(7&8;4" ML>U*UE/@@\AL$W-M@N*AV%U+B.)O%N-F=)NIFZ7TYC);:YC7A1W9D]<<>;LN MCP'NB8CEQU394E)<;3+1(%0 MCB1IES6&ALGIZ.=V<_&46%;/8+;H6V1S%)%24]>-8YF[D'JR; M9FP:KO';A4P$20:M4CKKK*',(%*FDD03"(^ &E!(2"I6P 5)WWFHS*Y#Z@E MEM)4HGD"4BY)[0 O0P\,FCA; L#=Y!(R*;;:7*%*>-MU:G:Q( M%.4#E,RGHMU%N@,4=P,'DNC>&M;S8>96RKVJTD'OBU->:4+3/0M4QQR8Q19;=$24](LX6'99LH57_!RSQ*;QZNW M9$?WJCK1CM%,3>8X7B' E 3".[#)<;@2GNE4E$>0T5 D@#I$BQ%SSJ3NGM[I MKG+5N1QW#K5>;;RLAB)IK5&(>D-K=6EIM.3B,="^V%*(2%RHI8<2";K7'?#_/.#ZE@>&KMJS'BZMS\9?\YHR4'/7ZK1,O'JJ9VR2X32>QK^ M50>-5#H+$.4%"%$2& 0\! =,6*G0FX00X\TE8<0T3?Z3G&_^_["_P#B M?2OY:TX_&./_ ->S]VGV:M'_ #1X:?WAPG]NC?TM#3R S3C+.+W&7'?$-WK& M3+C=L8-!RG6TH]F5PHFJY=O4P2 M*;81!NG3(\PMP(JTN.K=03ND*W4(4%*)(V#DL.R358\0];Z6UV_B^'&CI\7* M9J=EH3[XBNH?3%A0Y+JH.-;C^/TI%U.T'51L)F8$^0ENY48 MK#Z1)-D[5!ME:W5)%[I;.P\E$+7\A4*V0L;9*S=*M/P$RT1?14Q$ST8^CG[- M<@*).&KINY.DJF"UDL7.B2 M,>\@+;<;=0I"TG:"E04016S7M%9;(K.7-B@F[=NF=9=PO+QZ2*"*91.HJLJH MX*1--,H")C&$ /3K(NM@7*DV[HI4YE<6T@NNR8Z6T@DDN( '*22; #G)H/ M^/=[K-LN_+3D0TF8Y#$#^R5FN0%Y:E0 5S$-I\)5^Q^YJ@/^GSC=_=?-?V9SV*D M&%XQ=RFML4HNNXSY65^,0 1C8-:^Q,>B !L ),H^1;MDP /H%#6Q.+S[8W6 MVI:4]@%8'J!0J3P>&76?QD9,/'8S5;$1 LE#?G*$ =@)2H #N"MK^0#NC?T- MYA_QSDK^6-9?%VHOL)OW;G\:E?ZA=:W\2UA]U+_C4OR =T;^AO,/^..8>5Q6J9,0\J'1)<0>?:E1(Y=O)3%_0' MYI?JQ9D_J7*?^GK#XER_XL]]S4<_Z?.-O]U\U_9G/8H_>V%Q'Y.8OYJXGNN0 M\%9+IM2B6UU+)V*P5A_'1+$SVFS;)H#EXN0J20N':Y$R;C]414LP92D7(MEF4A&R+5!ZP?LW*9DG#1XS0U]>I,:--CKB3&T.Q74E*T+2%(6E0L4J M2H$*21L((((V&HN_1]P)_8PO]2U]PGV*/\NN'W_ L-_8HW]%4EPT)#5V. M;0]?B(R"B&9/+9Q<,P:1D249,NXQ@ZEX4C]. M'DUVB"K^+3E$T49(D>[.0R[0K])NF58$S%!0I"@;< #6)0@J"R 5"]CSB_+; MNTE=A0WY34UYIM8A&047'PT<5P\=E81C1!BS(YD7:S]^N1LV(FB15X^4K<0D)3O+45K.ZD 74I14H\ZB2=I MK-=-6SYJY9/$$G3-X@LU=M7"954'+9PF9)=!9(X"11)9(XE,40$! =AUZ0% MI.T&MSK33[2F'TA;*TE*DD7"DD6((.P@C81SBO#%BRBV3.-C6C9A'1[5NQ8, M6:*;9HR9M$B(-6C5NB4B2#=N@F4A"% "E* ;!H "0$I%D@6%>1V&(K"(L9 M"6XS: E"4@)2E*19*4@; -@ L*RM>UMI:**UL7#1,&W6:0T8PB6J[Y]) M+-HYH@S05D)1TJ^DGQT6Y$TS.G[U9:D M,KCOI2MAQ)2I*@"E25"Q20=A!!L0=A%?C)FTCF;2/CVR#)@P;(,V3-JD1!JT M:-4B(-FS9!(I4T4$$2%(0A0 I2@ &V@ ) 2D62*\899C,HCQTI1';2$I2D M)2E(LE( V ; *R=>UMIGW/'U$R-'-XB_TVKW:*:NROVL=:H*,GV3=Z5) M1 KM!M*-G**3@$5CDZR@!NDPAOL.M3S#,A.X^A*T@WLH CZM,V;T[@-2QDP] M0PHLZ(A>^E#[2'4A5B-X)6E0"K$BXVV)%.6/8,8IBRBXQFVCXV.:MV,>P9() MMF;)DT2(@U:-6R)2)(-VZ*92$(4 *4H !L&MB4I2D)2+) L!3G'CL1(Z(L5 M"6XS2 E"$@)2E*19*4@; -@&P5EZ]K=4(/>,_'62>.Y&0P7B1Z_D'3A\ M^>NL?59=T\>.UCN'3MRNI%F47<.5U#'.?%N._P!0S]PGV*U?Y4\,?[O87^Q1_P"CJ0:9C+'&.4G:./Z%3J2F M_,4SXM4K_3$W%,78Q;-J9SY>X]/6)NG?PUO9C1XX(80A /+N@#UJD6$T MOIK325HT[CX4%+GM_-V6V=ZW)O=&E.];FO>U/C6ZGVO"B::R:B*R9%4E2&35 M24*4Z:B9RB4Z:A# )3D.41 0$! 0'1R[#R5BI*5I*%@%!%B#M!!Y01S@T'TS MV^^%-@E'TU+<:<5.9*2<'=/7!*ZFT*LNH.YU ;,E6[5+J'Q$"$*&_N::%X'# M.+*UQFBH_O:IR9U>>",^4Y-E:9Q2I+JBI1#6Z"3RG=24I'> K7I=N?@VBJFL MGQCQ6"B1R*$$T&P@-Q&:OW*3IZM_ M"@ ML:7Q5P;_ ,F3]0JL>X:+%*GU1"J#1$:W!HTHT(M6AJ:46S3KHUYPS/'KP@Q! M$08C%KL5#)'0Z/+,F82B @(Z=0TT&NA"4]#:V[;9;DM;DMVJMM.&Q",1\0(B ML#!] 6?-PVD,]"4E!:Z.VYT922DIM8@D$4X];* GRAPHIC 39 g62467812.jpg GRAPHIC begin 644 g62467812.jpg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end GRAPHIC 40 g62467813.jpg GRAPHIC begin 644 g62467813.jpg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end GRAPHIC 41 g62467814.jpg GRAPHIC begin 644 g62467814.jpg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g62467815.jpg GRAPHIC begin 644 g62467815.jpg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end GRAPHIC 43 g62467816.jpg GRAPHIC begin 644 g62467816.jpg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g62467817.jpg GRAPHIC begin 644 g62467817.jpg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end GRAPHIC 45 g62467818.jpg GRAPHIC begin 644 g62467818.jpg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end GRAPHIC 46 g62467819.jpg GRAPHIC begin 644 g62467819.jpg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g62467820.jpg GRAPHIC begin 644 g62467820.jpg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g6246782n.jpg GRAPHIC begin 644 g6246782n.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@!,0)3 P$1 (1 0,1 ?_$ . 0 !!0$! 0$ M &! 4'" D# @$* 0$ P$! 0 @,$ 04&$ !@( M P,#"1(+!@0#!P4! @,$!08 !Q$2"!,6"2$4%3%3E-256'B8V$%1(C14-55U MM=4V=I:VUCBX.6$R4I+2(S-TM%87<=%"LK/3@7(DY9%B6\M86+IBUET\5_4\OL?J/W#:==-I3<[ZWM:368BFZ+VQNF5DET*.@M.O M9%ZCK0&++7ZSX=/LGJ6]J8B M.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX M=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM M3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_ M6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ M6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S> M+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I] MD]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B M.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX M=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM M3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_ M6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ M6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S> M+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I] MD]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B M.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX M=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM M3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_ M6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ M6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S> M+7ZSX=/LGJ6]J8B.;Q:_6?#I]D]2WM3$1S>+7ZSX=/LGJ6]J8B.;Q:_6?#I] MD]2WM3$1S>+7ZSX=/LGJ6]J8B8*ZG>H#Q2.E;I[W%U'W"L] EKJVDZ%/;&L- M:K.:2;IJDD.8I5DRJ 4W"NB B4#_;VG[%P'N[(_ MHYB([>T_8N ]W9']',1';VG[%P'N[(_HYB([>T_8N ]W9']',1';VG[%P'N[ M(_HYB([>T_8N ]W9']',1';VG[%P'N[(_HYB(:24F,J2,DF#%N9:/E$&KEHW525(XC& D$PO"B40$WJ#QX>3$2_XB,1&(C$1B(Q$8B,1&(C$1B( MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$3F]XP?[K?KU M^#!M;\VW>(F^/Z'XB:6=6?ZV'A\8/]UOUZ_!@VM^;;O$3?']#\1-+.K/];#PN/A/[Q_8.ZK,1.@>(C$1B M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$LUB$ MK\Z(B $-)B(B/ &2_$1$?( !B)4Q/UJC/M>R_PR>(G,>:T]U\U^]6J4UK M?X U;MNZTK;$$L]^DYHM!U.A+.Q7UJG S-9>LY%*4.^E9H7R:PN6RTNSB@*= ME$-5DZJQ:O&2IC^.$MW-USN0BE==?P3A=V#W""[X)(EUC5/?9:!Z6[84=,;2 M3:^,_P":=F4Z(NX)UQ/*1Z=.M>5=LUY+>4\[EXAK6Y""L25R@FD>VFJLC?I$ MOI.J-M@V8QE@2N&&34 #:PL)_+O4JD#0JQMXUCL/#0)<*\Y(R "0]=CQ2-,>;+-735! M(J/8'4)7RUILH1*0VU6R+VBQR;IHFC' V?%:,98AW+DSYN<$S*V;KGD@2OQC1.G(A]*GR>0632C8H _:!8,WL#+L)'@V M[&F"<[K"'>R.#B''N],CPXAQ$/24"'$ ]7AQ'*\'KX3LD6(C$1B(Q$8B,1&( MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$Y MO>,'^ZWZ]?@P;6_-MWB)OC^A^(FEG5G^MAX7'PG]X_L'=5F(G0/$1B(Q$8B, M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$IW+MJR2,N\ZLJZ^HF, MRRDWX\/)Y&$:J[>&\OSB9Z=?R'YU:N]>+>$\V0JO\S #],R/\R^7H=INKW>0 M8$_4,F4JVU((2%/%0=]L'.( 48BA6H$1$?4$'TI&1D<)?X06X!\W)K\CY0.+ M[>+3^_?5G^569OT2!^8TXS6ES_NUO^L@#],^S7&XN2%-%:KL0 <.)%+!/4^% M2\OJ"J1C.3T@B7_:WYP_DYP?+OEZ'%_.IT_W:6N?HRB*?YL>V=/*Y3#\/C6? MQ,B_J9C^B?!7.WWH (1&NJ\!O7IVQVM0G\)DD8*I)G'^ %>'\(^KG2G_ $_7 M_FB(!Q;UFBL&AR#\ MT".K'+VH#!_M2SOYSY+6N*N$[MYV7,?T5K5^N<['S!CE^0JCR2L#]+%_U3]4 MUL+PY5):_P"R9+@("*:5G+741'YH"2H,*Z82#\X3#G%^<]L8HXG#3VFON'_Z MK60>!O.;;^0W\>W_ !9;)[4NO?0DTL[KJ.<_U_YN!BJXU#_P -5J_^VJSO^F<$G+UAS^V6?_$3,FQ 6)BRE *$022MN.0-K/N M]H--JKI@@XL9&UZ$;NH$OI-(RMXRI:K^5;ZFLU&",U*ZZ$9SC(SF8/TW ]7% M2NKI':\V&R:F#5K$0HL,6%L@EP5 "D#&XM#(4.4VKD=#O M(3N9.#E Q8U 88!"&)W";I9EEL8B,1,%;=U#3MNRD QL\4S=OX&)GI*M2:Y' M';Q$@L\@D' IJLG3)Z#1^@ )N")+)',0 $IR*$(U*BW,XC(!^XC)F&(F,G3K--V@JA$U#F!L^A+E5IF FG$&^!,P(NG2$ MB;B4R:A2+$.0OT'+^?,X%W+4/QK#Z;JTKZ^*O3:CH'7Q537X$$J03Y=/RP#- M=!*VIU1V?Z"MB,K;3X$AO(@$$2^C%GA5"C9R;JJ'D4YI6O7RR;$JB8)>7F!1 M3TK+LT. _P!H]BFR8?--P U;'M3^UA[V0"3F$BUI]AY[3]W6&79@/(+E,-?6)%-4./%%1P1-=-9N3?Q>6[+Y_A- M_L?VYER3KVU&QQ,ELF ?IAPY4I?7H&./#UQ>(M<0'E_^5,,I/+^1N,-P[4/F ME_\ 8]3?KE@H^8J=.0C#]JK^U77]4]1+M]N/D4UM*@ _-0M%?$P?^#BS<@_S MLCG_ *??PYE?TUV?V5SO_P"47QX[?0Z_VO/@9S:[8W!QKZJ/TPX?UD-L1V9< MWS^#68I$4D7^#BX'_P ,E^6^1./1R[T/[?'&/K2YC_=G.]\R7XJ*F'[-I_4U M8_7/8MRM:11,]U3;R@ <3#&S%!D #^$"*V]@X.'_ )4Q-_!D#\NX+'%7.X_\ M27K_ /M,/TR7YKD@9?C6_0U9_P!L&4R>T6P*BD]HVSXX2_QE%*-*R20?/X*U M_P!,D. ?_+QRP_)'V[JN5PG_ /653]5FR1'S%GD+_ .F3_AW3W4VU16X\ M'LC*Q?S_ $S4[?# 7_SC*P3,"?\ CPR ^0_-'_I(C_N6U/\ X7,Z?F7#7XV9 M?WD=?UJ)[-=M:N>G[-OL2E&6#AQ;J6:'0QFH:4+S1DM&2)1#B!F+]J[+P'U! MXMU5 X9Y]O&Y%!Q=6Z']I2/UB:4NJLUK96'L(/ZI<\IED8B,1&(C$1B(Q$8B M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$3F]XP?[K?KU^#!M;\VW>(F^/Z'XB M:6=6?ZV'A(<,TTT O*)R\@T.N-#T.O@Q5P%V?$<=;"N@ZGIIXC MJ.51?$)Z@WM#U1>8-.ESDX.C^DR^_P"G3,U=7DNIJ>WE-S=:V(OKY"(=SDNQ M:U96$,NW;1IA5AUB+#)E42[-$-7)XWRCBWW%N6[JENS97Q[&VH>&W([I:PTY M4-T;5&2FT#U$M7@XO(^8$FZ59=,;6JK)EH:Z6&0KU=*61G)S=E.G;"]T)6VK:2*W>/*4TJ[ MF2>*(G--Q+%\T6?B=JDZ<9/DG_I_Y>]P*\WD5TW7U+86KKKM6JBFX\@[$N(K M0.[%U)0K@8+ ;IU'YIRT0C\O3;=3384&YVJ+WW4]KU.@-CLJ(%< [R<$ ^GI M=TV76Q=1&FZOL8=OSQU)4CQE-FJU0IM:8IS\:[5;RR$,H\0O95X5!R'(U63? M.#G0 O;'*X!4A-/(Y/RWAN!1P:V0@X-MECD@,4)85M6N=RGH"IZJ60JQIJKY M=Y=;>0RV(V&"*B@$JK@ L')PK+DY!SD$*P*C/1-7PZJ8DE[#?I[G#^L](7JR MM4E/G\[."?PT>)1#U2]D!1^=F<_.^0ISQZN+5^[163];J[?IS+Q\NJ(Q:]S^ M^QA^A2H_1/9AJ76<.0,(^J//Q'(V_/ MOG5PVMRK@GDK%1]2X'Z)U/EGR]#D4UD^9 8_69))_3-BHB#" >P8E5D)*,1&(C$1B)9[# M]8)S[3R?^"7Q$J(GZU1GVO9?X9/$2X8B8/ZCVER?::MS6AHRCFQ*+5@?-H0S MDLRY@4[A *W!O%^9*(O#R"]0(^(D1(Y5%#B!2B B&56KN-8R0O?IR0,X'=3) M(/5 -7'VD##QEU)K'<-@)'Y>[ ! )8U.$ )T#%L!3X'!FEU>U)UR1[I!6*OD MK5 1-")74)K8,;L%MLBY0\J[[QWNO(VR%LQ] M7^OG6"Z[;:UCFL66.!Z^XS X])7\9 MZU"$E5VGLUOH-RE@"=O<;XI-$\0U.PU"K3-W=1.L8K7FM(*RV>;M&N;9LF=L M\-,Q"]XFBRC>CIM4Y"P1P239906G 6IFBJ!TG8J]C.QNXEAQAL#8!ITXEPPQ M'GR>QO(P='*':T65D<('AH:/EFT"\D7-:;J)6!R_? MNK,@L[9G19"!#74E-Y9\:I;G0],C:%QA=7[+5Z;EK3D!R2ZXGR,DOV?Z.]=@ M!U^,$%LG)VT]];#\!=J-B@J2.E&41&(D>6_"N/\ Q>F?NE!8B>=BKI)HK9VT M='BI^+,HK"S2! 459J* 7MFSI$3%(_B7P)E*Y;'$"J% #%$BI$U";>'S#QBU M=BBSB/HZ'H0.A!^RZ]58=.ARI(-%] M 93MN7X6\O8?,'Q'C[" 1Y5ZQ*22K MF(EVI8JSQ9"&DHP#F4;KH',)$9>&L_P.&7Z<9]LY=PN+[UP;65F0P M?_VJ_,BB[[+B(BDVM5>09N4>4/(4[MC(*"'\8PCY1K\MY%-Y^Z3VK/=LLP&/LK=X_ M/&K_ )NIZ_:!O3WY7) _>59-XB=Q;UL_;@H )DQ6:J M*D*H4!#B41 P?-#/-Y'&Y/$L[7*K>NSR92I^HXFRJZJ]=]+*Z>8((_1+IE$L MC$1B)2NF+)Z3LWC-J[)ZG(Z;I+D_FJD.&32VRLYK9E/L)'ZI%D1QAP"/:,R* MO-;Z\D.(OJ+3W9A_XUZU#**@/SRJF9BH4W\(" YOK^TA)6<@C@(>H)30\FQ$O#YG#AP MS2?^HOG+#;9=O7]M4?\ QJTJ_P!*X .4KVG]EF7_ D2H4UE% '!C9=AQG#^ M)YOL&UNRD'AP\B*= L+7F%CMG8)>(_0)R*-&ED"!PX=['/7X>0I_>K!_PLL\01W.W.(^?Z MQED@X5ZO8XDP#P-Z;HEZADRC_"O)UQJV, ?/ XA_#D MO_\ /_,S_3%-G[E]+_H6PG]$Y_J?$'QFQ?WJ[%_25 G+U?KFL[G9VW-4GZA- M),VB'6!3]3PFQ81A66W^D6H+%TWJ[;\YL$3/6^<92,\&PH4U6-*R8(,QDGYD MP:I*D2;AEX_R+YY;Q*FLX]XL-O.#6"MFK(HI2RD#&@#NY^V6=*V"G<0RSN^: M_+ZN9:B.C5BCB,B%P'S=<:[2>A.U<, %]+,A92H:8MHG7IU,[5I%8LM7LVJX M^_6.QN=6+ZO?,86,9,(N/Z70WF_ZD#34K+.I" B'LP@;S-&3YH%NQ=MT71Q6 M*=FT[]!Y%!L;C\6Q M.1;7F0C+@+99Q>ZAJ6T@K94S*P((<*^K^&FUT5< M#:Q5G!]01.AN42Z,1&(C$1B(Q$8B,1&(C$1B)S>\8/\ =;]>OP8-K?FV[Q$W MQ_0_$32SJS_6P\+CX3^\?V#NJS$3H HH1),ZJA@(FF0RBAS#P*0A $QC"/S M*4..(D?):X=0A%$_2ITU"%43.2NV$Q#IG*!R'(8(L0,0Y1 0$/((#B)]=Z(G M^3+_ ).6+[U8B.]$3_)E_P G+%]ZL1'>B)_DR_Y.6+[U8B.]$3_)E_RFNN!!4[!N+J/2\ MX7[,HFY"'R^;8:N'59;8!DA%+8'F< X'M.DJNOHXZ[[W5%\V M('U9ZR/--XZ\DVAWL(YM%B0((AS5S7FP9P#B''R)FC:PX(S]Q'8?6%(_3*9OMY>2=HL8C6&S55G1 MCD9+3L&PIK-V=-!5RHFF:U2T6^*J5N@<_(9N!Q*41 !X"&/]*XM?]?G<0'R4 MV6'^Y65_O1^=N;^EQKR/,[%']Y@?T2\GEMLO #S&ETZ) 1#BI/7:08J[:O1*3@#?R MQ<%: N8X_/$PCF>WYO\ -;QB[DWLI\#8Q'U9Q+DX/"K.:Z:P?,*,_7B3$I2E M "E "E* !2@ !Z@ >0 #/.)SJ>LU2CDHV.F&#N*EV#*5C'Z"C5]'235! M\P>ME0Y56[MFZ35;N4%"CP,0Y3%$/5#.$!AAAD?]VH^HSH)4Y4X,L;&C4J+/ M"*1E/JT?CQR6XYW M9.XKMS[!T'N'ETD=JXQ@8SGZ?/W^V5L96*U"D[.&KT'$IA)/9D$XR)8,">EY M(BB2]<#R&=<=)TG))/4G) M]I\SYGVRMBXJ+A&*$7"QK"(C&O:>;1T6S;Q[%OVRRCA;L&C1-)NCVJZICFY2 MAS',(CY1$<[DG'L 'T 8 ]P&@\A'M\2<_2>LK\1&(C$1B(Q$8B,1&(E!*M5' MT7),DA(55XP>-4S'$0(51PW42()Q*!C 0#'#CP 1X8B6-DO9FK-HV- ,#F;M MD$#&+/B!3&22(F)B\8GCRB)?)QQ$LBUNLJM@1KL568YZX:D(\L3DUA$K6#9+ M)F,S;JG)$&%69E!^B0;@'T*!3*J&(44@5VKQ O$;F<@E5.E8\78'U'V(OVF\ M6PH!.[;G:\F\45#)&KGP4>'\1\!Y9)QIF2>?67_+S'W?_P#:?67_+S'W?_P#:<1'GUE_R\Q]W_P#VG$1Y]9?\O,?=_P#]IQ$M M3"TRDD\EX]M!M//H)VDSDFJTT=!9(SALD\:.4RGB0[9B\;J\4EB\2',0Y?(8 MARA?;QKJ:Z[G [5JDJ0<@X)!'L8$:@ZC(/0@RM+4L9D7XT."/HR#[B.A]_B# M+BS1EW,VE)2#!JP0;13QD0J,B9\JLJ[=QZ_'E\R;%333(R'B/$1$3!Y,HEDD MV(D,Q?@N<*WBIZE''@X^IAZE)&<1HO+DTVC;R%&H\"/O+YJ?K!T/ MME>8)IC$2$3&NJA,NSRBD5Z,FSB)AL%==.ZY/B?Y@JR\(NQ>NR!P\J:YU4C! MY#%$!$!]+C_-_F''K% ??QA_EV 6)]".& ]X /D9DMX/%M;N%=MOWE)5OYEP M3[CD2U^AMD0/,:$M$;<&8&3[.*NS,L;)$2*' R:-JK;,J?'AZ@N(IRH8?XRG MJCFC\S\GY6G)H?CV?>I.Y<^VJP_X;5'D)7VN?3_2L6U?*P8/\ZC]:$^V!V2E M$@45 L4 +]!@W*/#B>138#Y?XN/\ 1FY&ORRZ MGDY^R#LL_P#;LVEC[*R_OC\^*O\ FZWJ]I&Y/YER /W@LGD;*QDRT3?P\BPE M6*W'LGL:[;OFBG#AQ[-PV452/PX_,'/*NHOXUAJY"-7:.H8%3]1P9LKLKM7? M4P9#X@@CZQ*_*I.8SDMSZBAIV[5>5V;1(^RZVJD;>MA5]U:H5&:I%-F3R)(B MSVJ,.\![ PDJ>(= V<.2)IKB@?D$W*.0[B%'M!!KK=48^"N_P(?)F^RO4^ D MMC=Q*L?B6*S*/%E4@,P_94D GH/$R-M.I?I]?#0RM-S:X6-L\SXE *6V1 &M M2L8_7B9!"**9R45'#.8:JLE$S[:CMG[ MJ.>BL1$:KO'PBS9_'N"[??N95QYLHZL,RJD[?U9LEO#.Z!L*H7%O86$Y*0:E M#PB0335D=/0O\ W2S$T;J-!\[E&% KL-*OT6C9]*UYH:N2KUM'E4+'-GP:2K_P!*X%'ZW3VQ(OYQ6VRKRZ2+\[D;2\[) MM2%#^24@%_@Q_KG*;^M5Q']_'I!^M$4_IG/]-I']-[U]UMA_0S$3Q>TZ2AV+ MU^AM#8;5!BT<.U06&HS12HMD3K*#RRM3=N53 0@\ [4!$?FYS_5..W]7A<1O M=W4/]VT#]$[^2M7X.1>/?L;_ !(3^F1A!/:J/!5M9[$]34 %$R3E!I#D.4Y0 M,4##"6VMG'R#\\!R9YWR9QA^"5/[%[C_ !K9.#C\]>G)!_>K4_X2LKE);7:(=&X_P#TLY^1^5O_ $^=6/WZKE_PHX_3._F>8OQ\9OX7K/ZV63-C:Y!X MU2?Y2L_\R!^_P!E,LCO M$\_RE9_YD#]_L1'>)Y_E*S_S('[_ &(GLRL'G4@E&N(>8BW"[5T[;FD4V'9+ MI,U&B3DI#L9!Z)5$S/4QX' H" CP$> XB<__ !@_W6_7K\&#:WYMN\1-\?T/ MQ$TLZL_UL/"X^$_O']@[JLQ$WTE?K7)?W!Y_AU,1/*#^LL/]JX__ B.(ETQ M$YZ;JZV9'4^T[Q02UJN.NZ\85.&BI"2E4[-/.U:.QO"]^DD631PK7M/5]H[< M(/9=)E))E5AY IU6ZR2*#B-!%RMZD4]S;DG"UCN45E[C]G/>W(#M#( =^K!) MV 5*&VNP[>[ &6L)%Q"5#[1_"PQ&2"XRF &;'-9\0N>G-HUR@-*M2[%$R.NK M[8GUH@9HZ23RQ4HF[C"YKK!.4G5Y.E.W.G@;!(-?/V)C2)%//BF[%NXS\ODG MC\+E\M$;-'#%RJVA)[:V;7P"5SE@,@:IA386 DZ*A;SN/Q&8;+.2E;L-$UXP4>R4=P IOA*"HF:E]"]:JU-B$FI5M9B1@H*F='W* M,GT-58'(R,]LKN6P,,U7==C60-Y-03&2'-PW)AN@W*U94'!R;%.#40:BY>*[ M2V\9=TJ%KN1E)F.UM#["I,G:IQA6ZG)L+3&RR , @33M?",?1K$JZ MCR5/*H,B=@Y,&5['(QH'6ZM&'B-Z,Y ^)UVLNP=?BSM!Q@R+UV JQTVY]"1LP ME+PJJS=LX23,5^9!9 Y#&;K)&)VB@?19IMH-=*\FL_@V66H!G7%; 9., AE9 M2#IKD8TR31%<%5B=LRKT5V@HK6"53*8G.F0Y3$:-^8IGC@.0!!,BRB7H\+BU,AYO, MR.$AQ@:&QNHK7];-T1=>I4-EY%SAAQZ,'D,,^Q1]X_V#[1TZ D7B @6-=CB1 M[+M51,JJZ>OG1P6D)61I)\2?\ Y:2]9FEL8B,1&(C$ M3'ER9.XEXSOT*W5O\NLKOK;Y5R2!5: